PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bradding, P; Richardson, M; Hinks, TSC; Howarth, PH; Choy, DF; Arron, JR; Wenzel, SE; Siddiqui, S				Bradding, Peter; Richardson, Matthew; Hinks, Timothy S. C.; Howarth, Peter H.; Choy, David F.; Arron, Joseph R.; Wenzel, Sally E.; Siddiqui, Salman			ACE2, TMPRSS2, andfuringeneexpression in the airways of people with asthma-implications for COVID-19	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Bradding, Peter; Richardson, Matthew; Siddiqui, Salman] Univ Leicester, Natl Inst Hlth Res NIHR, Leicester Biomed Res Ctr Resp Theme, Leicester, Leics, England; [Bradding, Peter; Richardson, Matthew; Siddiqui, Salman] Univ Leicester, Coll Life Sci, Leicester, Leics, England; [Hinks, Timothy S. C.] Univ Oxford, Resp Med Unit, Oxford, England; [Hinks, Timothy S. C.] Univ Oxford, Natl Inst Hlth Res NIHR, Oxford Biomed Res Ctr BRC, Oxford, England; [Howarth, Peter H.] Univ Southampton, Fac Med, Clin & Expt Sci, Southampton, Hants, England; [Howarth, Peter H.] Univ Hosp Southampton NHS Fdn Trust, Natl Inst Hlth Res NIHR, Southampton Biomed Res Ctr, Southampton, Hants, England; [Choy, David F.; Arron, Joseph R.] Genentech Inc, San Francisco, CA 94080 USA; [Wenzel, Sally E.] Univ Pittsburgh, Asthma Inst, UPMC UPSOM, Pittsburgh, PA USA	University of Leicester; University of Leicester; University of Oxford; University of Oxford; University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust; Roche Holding; Genentech; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Bradding, P (corresponding author), Univ Leicester, Natl Inst Hlth Res NIHR, Leicester Biomed Res Ctr Resp Theme, Leicester, Leics, England.; Bradding, P (corresponding author), Univ Leicester, Coll Life Sci, Leicester, Leics, England.	pb46@le.ac.uk		Howarth, Peter/0000-0003-0619-7927; Wenzel, Sally/0000-0002-4242-0164	National Institute for Health Research (NIHR) Leicester Biomedical Research Centre (Respiratory theme); Wellcome Trust [088365/z/09/z]	National Institute for Health Research (NIHR) Leicester Biomedical Research Centre (Respiratory theme); Wellcome Trust(Wellcome TrustEuropean Commission)	This analysis was supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre (Respiratory theme) and the Wellcome Trust (088365/z/09/z). The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health.	Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; Jackson DJ, 2020, J ALLERGY CLIN IMMUN, V146, P203, DOI 10.1016/j.jaci.2020.04.009; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Lokugamage K.G., 2020, J VIROL, V2020, DOI [10.1101/2020.03.07.982264, DOI 10.1101/2020.03.07.982264]; Lukassen S, 2020, EMBO J, V39, DOI 10.15252/embj.20105114; Modena BD, 2017, AM J RESP CRIT CARE, V195, P1449, DOI 10.1164/rccm.201607-1407OC; Pescarmona R, 2019, CYTOKINE, V113, P446, DOI 10.1016/j.cyto.2018.10.023; Singhania A, 2018, AM J RESP CELL MOL, V58, P261, DOI 10.1165/rcmb.2017-0162OC; Singhania A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168680; Sodhi CP, 2019, J IMMUNOL, V203, P3000, DOI 10.4049/jimmunol.1900579; Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	12	60	62	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					208	+		10.1016/j.jaci.2020.05.013	http://dx.doi.org/10.1016/j.jaci.2020.05.013			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB	32450087	Green Published, hybrid, Green Submitted			2022-12-18	WOS:000579170500031
J	Bunyavanich, S; Berin, MC				Bunyavanich, Supinda; Berin, M. Cecilia			Food allergy and the microbiome: Current understandings and future directions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; microbiome; microbiota; dysbiosis; prebiotic; probiotic; symbiotic; regulatory T cells; short-chain fatty acids	COWS MILK ALLERGY; INFANT GUT MICROBIOTA; ORAL TOLERANCE; GERM-FREE; WIDE ASSOCIATION; EARLY-LIFE; T-REG; EUROPEAN ACADEMY; AMERICAN ACADEMY; FECAL MICROBIOTA	Growing evidence points to an important role for the commensal microbiota in susceptibility to food allergy. Epidemiologic studies demonstrate associations between exposures known to modify the microbiome and risk of food allergy. Direct profiling of the gut microbiome in human cohort studies has demonstrated that individuals with food allergy have distinct gut microbiomes compared to healthy control subjects, and dysbiosis precedes the development of food allergy. Mechanistic studies in mouse models of food allergy have confirmed that the composition of the intestinal microbiota can imprint susceptibility or resistance to food allergy on the host and have identified a unique population of microbially responsive RORgt-positive FOXp3-positive regulatory T cells as critical for the maintenance of tolerance to foods. Armed with this new understanding of the role of the microbiota in food allergy and tolerance, therapeutics aimed at modifying the gastrointestinal microbiota are in development. In this article we review key milestones in the development of our current understanding of how the gastrointestinal microbiota contributes to food allergy and discuss our vision for the future of the field.	[Bunyavanich, Supinda; Berin, M. Cecilia] Icahn Sch Med Mt Sinai, Dept Pediat, Div Allergy & Immunol, New York, NY 10029 USA; [Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Berin, M. Cecilia] Icahn Sch Med Mt Sinai, PRIISM Precis Immunol Inst, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Bunyavanich, S; Berin, MC (corresponding author), Icahn Sch Med Mt Sinai, 1425 Madison Ave,Box 1189, New York, NY 10029 USA.	supinda@post.harvard.edu; cecilia.berin@mssm.edu		berin, cecilia/0000-0002-9051-9249	National Institutes of Health (NIH) [R01AI147028, R01AI118833, U19AI136053]; NIH [U19AI136053, U24AI118644]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI118833, R01AI147028, U19AI136053, U24AI118644] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	S.B. is funded by National Institutes of Health (NIH) grants R01AI147028, R01AI118833, and U19AI136053. M.C.B. is funded by NIH grants U24AI118644 and U19AI136053.	Abdel-Gadir A, 2019, NAT MED, V25, P1164, DOI 10.1038/s41591-019-0461-z; Agus A, 2018, CELL HOST MICROBE, V23, P716, DOI 10.1016/j.chom.2018.05.003; Aichbhaumik N, 2008, CLIN EXP ALLERGY, V38, P1787, DOI 10.1111/j.1365-2222.2008.03079.x; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Asai Y, 2018, J ALLERGY CLIN IMMUN, V141, P991, DOI 10.1016/j.jaci.2017.09.015; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Azad MB, 2015, CLIN EXP ALLERGY, V45, P632, DOI 10.1111/cea.12487; Bager P, 2008, CLIN EXP ALLERGY, V38, P634, DOI 10.1111/j.1365-2222.2008.02939.x; Barcik W, 2017, CURR OPIN IMMUNOL, V48, P108, DOI 10.1016/j.coi.2017.08.011; Barcik W, 2016, J ALLERGY CLIN IMMUN, V138, P1491, DOI 10.1016/j.jaci.2016.05.049; Bashir MEH, 2004, J IMMUNOL, V172, P6978, DOI 10.4049/jimmunol.172.11.6978; Berni Canani R, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bunyavanich S, 2019, NAT REV GASTRO HEPAT, V16, P200, DOI 10.1038/s41575-019-0123-0; Bunyavanich S, 2016, J ALLERGY CLIN IMMUN, V138, P1122, DOI 10.1016/j.jaci.2016.03.041; Bunyavanich S, 2015, J ALLERGY CLIN IMMUN, V135, P31, DOI 10.1016/j.jaci.2014.10.015; Burks AW, 2015, PEDIAT ALLERG IMM-UK, V26, P316, DOI 10.1111/pai.12390; Cahenzli J, 2013, CELL HOST MICROBE, V14, P559, DOI 10.1016/j.chom.2013.10.004; Canani RB, 2017, J ALLERGY CLIN IMMUN, V139, P1906, DOI 10.1016/j.jaci.2016.10.050; Canani RB, 2016, ISME J, V10, P742, DOI 10.1038/ismej.2015.151; Canani RB, 2012, J ALLERGY CLIN IMMUN, V129, P580, DOI 10.1016/j.jaci.2011.10.004; Cuello-Garcia CA, 2015, J ALLERGY CLIN IMMUN, V136, P952, DOI [10.1016/j.jaci.2015.07.021, 10.1016/j.jaci.2015.04.031]; Eggesbo M, 2003, J ALLERGY CLIN IMMUN, V112, P420, DOI 10.1067/mai.2003.1610; Faith JJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008051; Fazlollahi M, 2018, ALLERGY, V73, P1515, DOI 10.1111/all.13389; Feehley T, 2019, NAT MED, V25, P448, DOI 10.1038/s41591-018-0324-z; Ferretti P, 2018, CELL HOST MICROBE, V24, P133, DOI 10.1016/j.chom.2018.06.005; Fiocchi A, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0055-2; Fox A, 2019, WORLD ALLERGY ORGAN, V12, DOI 10.1016/j.waojou.2019.100034; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Gilbert JA, 2016, NATURE, V535, P94, DOI 10.1038/nature18850; Grimshaw K, 2017, ARCH DIS CHILD, V102, P179, DOI 10.1136/archdischild-2015-309770; Hanski I, 2012, P NATL ACAD SCI USA, V109, P8334, DOI 10.1073/pnas.1205624109; Hazebrouck S, 2009, INT ARCH ALLERGY IMM, V148, P65, DOI 10.1159/000151507; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Ho HE, 2019, CURR ALLERGY ASTHM R, V19, DOI 10.1007/s11882-019-0859-1; Ho HE, 2018, CURR ALLERGY ASTHM R, V18, DOI 10.1007/s11882-018-0780-z; Hol J, 2008, J ALLERGY CLIN IMMUN, V121, P1448, DOI 10.1016/j.jaci.2008.03.018; Hong XM, 2016, J ALLERGY CLIN IMMUN, V138, P908, DOI 10.1016/j.jaci.2016.01.056; Hong XM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7304; Hsiao KC, 2017, LANCET CHILD ADOLESC, V1, P97, DOI 10.1016/S2352-4642(17)30041-X; Huang YJ, 2017, J ALLERGY CLIN IMMUN, V139, P1099, DOI 10.1016/j.jaci.2017.02.007; Hussain M, 2019, J ALLERGY CLIN IMMUN, V144, P157, DOI 10.1016/j.jaci.2019.01.043; Kim H, 2019, CURR ALLERGY ASTHM R, V19, DOI 10.1007/s11882-019-0851-9; Knight R, 2017, ANNU REV GENOM HUM G, V18, P65, DOI 10.1146/annurev-genom-083115-022438; Kong J, 2015, ALLERGY, V70, P495, DOI 10.1111/all.12579; Koplin JJ, 2012, ALLERGY, V67, P1415, DOI 10.1111/all.12015; Lambrecht BN, 2017, NAT IMMUNOL, V18, P1076, DOI 10.1038/ni.3829; Lee-Sarwar K, 2018, J ALLERGY CLIN IMMUN, V142, P335, DOI 10.1016/j.jaci.2018.04.016; Levan SR, 2019, NAT MICROBIOL, V4, P1851, DOI 10.1038/s41564-019-0498-2; Lloyd-Price J, 2017, NATURE, V550, P61, DOI 10.1038/nature23889; Maeda Y, 2001, IMMUNOBIOLOGY, V204, P442, DOI 10.1078/0171-2985-00054; Marenholz I, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01220-0; Martino D, 2014, EPIGENETICS-US, V9, P998, DOI 10.4161/epi.28945; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Metsala J, 2010, AM J EPIDEMIOL, V171, P1310, DOI 10.1093/aje/kwq074; Ohnmacht C, 2015, SCIENCE, V349, P989, DOI 10.1126/science.aac4263; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Osborn DA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005090.pub2; Osborn DA, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006474.pub3; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880; Rivas MN, 2015, IMMUNITY, V42, P512, DOI 10.1016/j.immuni.2015.02.004; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Rodriguez B, 2012, FEMS MICROBIOL ECOL, V79, P192, DOI 10.1111/j.1574-6941.2011.01207.x; Rodriguez B, 2011, FEMS MICROBIOL ECOL, V76, P133, DOI 10.1111/j.1574-6941.2010.01035.x; Roduit C, 2019, ALLERGY, V74, P799, DOI 10.1111/all.13660; Rook GAW, 2012, CLIN REV ALLERG IMMU, V42, P5, DOI 10.1007/s12016-011-8285-8; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Savage JH, 2018, ALLERGY, V73, P145, DOI 10.1111/all.13232; Schulz VJ, 2011, TOXICOL SCI, V123, P491, DOI 10.1093/toxsci/kfr175; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; Steinke JW, 2016, J ALLERGY CLIN IMMUN, V138, P1465, DOI 10.1016/j.jaci.2016.05.021; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Sudo N, 1997, J IMMUNOL, V159, P1739; Tan J, 2016, CELL REP, V15, P2809, DOI 10.1016/j.celrep.2016.05.047; Tanaka M, 2017, FEMS MICROBIOL ECOL, V93, DOI 10.1093/femsec/fix099; Tang MLK, 2015, J ALLERGY CLIN IMMUN, V135, P737, DOI 10.1016/j.jaci.2014.11.034; Tessler M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06665-3; Thompson-Chagoyan OC, 2010, PEDIAT ALLERG IMM-UK, V21, pE394, DOI 10.1111/j.1399-3038.2009.00961.x; Tordesillas L, 2017, IMMUNITY, V47, P32, DOI 10.1016/j.immuni.2017.07.004; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010; WANNEMUEHLER MJ, 1982, J IMMUNOL, V129, P959; Watson CT, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02188-7; Wopereis H, 2018, J ALLERGY CLIN IMMUN, V141, P1334, DOI 10.1016/j.jaci.2017.05.054; Yassour M, 2018, CELL HOST MICROBE, V24, P146, DOI 10.1016/j.chom.2018.06.007; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Young VB, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j831; Youngster I, 2014, JAMA-J AM MED ASSOC, V312, P1772, DOI 10.1001/jama.2014.13875; Zhao W, 2019, ANN ALLERG ASTHMA IM, V122, P276, DOI 10.1016/j.anai.2018.12.012	93	60	62	17	65	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2019	144	6					1468	1477		10.1016/j.jaci.2019.10.019	http://dx.doi.org/10.1016/j.jaci.2019.10.019			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT0NR	31812181	Green Accepted, Bronze			2022-12-18	WOS:000500694900002
J	Ottman, N; Ruokolainen, L; Suomalainen, A; Sinkko, H; Karisola, P; Lehtimaki, J; Lehto, M; Hanski, I; Alenius, H; Fyhrquist, N				Ottman, Noora; Ruokolainen, Lasse; Suomalainen, Alina; Sinkko, Hanna; Karisola, Piia; Lehtimaki, Jenni; Lehto, Maili; Hanski, Ilkka; Alenius, Harri; Fyhrquist, Nanna			Soil exposure modifies the gut microbiota and supports immune tolerance in a mouse model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Gut microbiota; biodiversity; immunity; living environment; gut-lung axis; mouse asthma model	SEGMENTED FILAMENTOUS BACTERIA; ENVIRONMENTAL BIODIVERSITY; HOUSE-DUST; ALLERGY; ASTHMA; INFLAMMATION; HEALTH; FARM; A20; SENSITIZATION	Background: Sufficient exposure to natural environments, in particular soil and its microbes, has been suggested to be protective against allergies. Objective: We aim at gaining more direct evidence of the environment-microbiota-health axis by studying the colonization of gut microbiota in mice after exposure to soil and by examining immune status in both a steady-state situation and during allergic inflammation. Methods: The gastrointestinal microbiota of mice housed on clean bedding or in contact with soil was analyzed by using 16S rRNA gene sequencing, and the data were combined with immune parameters measured in the gut mucosa, lung tissue, and serum samples. Results: We observed marked differences in the small intestinal and fecal microbiota composition between mice housed on clean bedding or in contact with soil, with a higher proportion of Bacteroidetes relative to Firmicutes in the soil group. The housing environment also influenced mouse intestinal gene expression, as shown by upregulated expression of the immunoregulatory markers IL-10, forkhead box P3, and cytotoxic T lymphocyte-associated protein 4 in the soil group. Importantly, using the murine asthma model, we found that exposure to soil polarizes the immune system toward T(H)1 and a higher level of anti-inflammatory signaling, alleviating T(H)2-ype allergic responses. The inflammatory status of the mice had a marked influence on the composition of the gut microbiota, suggesting bidirectional communication along the gut-lung axis. Conclusion: Our results provide evidence of the role of environmentally acquired microbes in alleviating against T(H)2-driven inflammation, which relates to allergic diseases.	[Ottman, Noora; Ruokolainen, Lasse; Lehtimaki, Jenni; Hanski, Ilkka] Univ Helsinki, Dept Biosci, Helsinki, Finland; [Suomalainen, Alina; Karisola, Piia; Alenius, Harri; Fyhrquist, Nanna] Univ Helsinki, Dept Bacteriol & Immunol, Helsinki, Finland; [Sinkko, Hanna] Univ Helsinki, Fac Vet Med, Dept Equine & Small Anim Med, Helsinki, Finland; [Ottman, Noora; Alenius, Harri; Fyhrquist, Nanna] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Lehto, Maili] Finnish Inst Occupat Hlth, Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Karolinska Institutet; Finnish Institute of Occupational Health	Fyhrquist, N (corresponding author), Karolinska Inst, Inst Environm Med, Nobels Vag 13, Solna, Sweden.	nanna.fyhrquist@ki.se	Lehtimäki, Jenni/HDM-7952-2022; Ottman, Noora/C-2225-2018	Lehtimäki, Jenni/0000-0001-7220-1985; Suomalainen, Alina/0000-0003-1531-6932; Karisola, Piia/0000-0003-0635-2704; Alenius, Harri/0000-0003-0106-8923; Ruokolainen, Lasse/0000-0003-0951-9100; Ottman, Noora/0000-0001-5011-9294	Jane & Aatos Erkko Foundation [261366]; Svenska Kulturfonden - Academy of Finland [286405]	Jane & Aatos Erkko Foundation; Svenska Kulturfonden - Academy of Finland(Academy of Finland)	Supported by the Jane & Aatos Erkko Foundation and FP7/2007-2013 (grant 261366), and funded in part by Svenska Kulturfonden (to N.F.). L.R. was funded by the Academy of Finland (286405).	Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Borton MA, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0264-8; Bowcutt R, 2014, WORLD J GASTROENTERO, V20, P15216, DOI 10.3748/wjg.v20.i41.15216; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Budden KF, 2017, NAT REV MICROBIOL, V15, P55, DOI 10.1038/nrmicro.2016.142; Carding Simon, 2015, Microbial Ecology in Health and Disease, V26, P26191, DOI 10.3402/mehd.v26.26191; Dickson RP, 2016, ANNU REV PHYSIOL, V78, P481, DOI 10.1146/annurev-physiol-021115-105238; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; EDWARDS U, 1989, NUCLEIC ACIDS RES, V17, P7843, DOI 10.1093/nar/17.19.7843; Fierer N, 2017, NAT REV MICROBIOL, V15, P579, DOI 10.1038/nrmicro.2017.87; Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111; Fyhrquist N, 2014, J ALLERGY CLIN IMMUN, V134, P1301, DOI 10.1016/j.jaci.2014.07.059; Gilbert JA, 2016, NATURE, V535, P94, DOI 10.1038/nature18850; Graf Daniela, 2015, Microbial Ecology in Health and Disease, V26, P26164, DOI 10.3402/mehd.v26.26164; Grigg JB, 2017, J IMMUNOL, V198, P564, DOI 10.4049/jimmunol.1601621; Haahtela T, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-3; Hanski I, 2012, P NATL ACAD SCI USA, V109, P8334, DOI 10.1073/pnas.1205624109; Harley ITW, 2013, MOL METAB, V2, P171, DOI 10.1016/j.molmet.2013.04.004; Ho JTK, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0083-2; Hosseini E, 2011, NUTR REV, V69, P245, DOI 10.1111/j.1753-4887.2011.00388.x; Johansson MEV, 2015, CELL HOST MICROBE, V18, P582, DOI 10.1016/j.chom.2015.10.007; Kang NI, 2009, J IMMUNOL, V183, P1488, DOI 10.4049/jimmunol.0900163; Kuramae EE, 2012, FEMS MICROBIOL ECOL, V79, P12, DOI 10.1111/j.1574-6941.2011.01192.x; Lane DJ, 1991, NUCL ACID TECHNIQUES, P115, DOI DOI 10.4135/9781446279281.N7; Lathrop SK, 2011, NATURE, V478, P250, DOI 10.1038/nature10434; Lederbogen F, 2011, NATURE, V474, P498, DOI 10.1038/nature10190; Lehtimaki J, 2017, SCI REP-UK, V7, DOI 10.1038/srep45651; Liu LM, 1999, J IMMUNOL, V163, P2284; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Martin M., 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; Meehan CJ, 2014, GENOME BIOL EVOL, V6, P703, DOI 10.1093/gbe/evu050; Mulder IE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028279; Oksanen J, 2008, VEGAN COMMUNITY ECOL; Ormerod KL, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0181-2; Pamp SJ, 2012, GENOME RES, V22, P1107, DOI 10.1101/gr.131482.111; Paulson JN, 2013, NAT METHODS, V10, P1200, DOI [10.1038/NMETH.2658, 10.1038/nmeth.2658]; Pinheiro J., 2014, NLME LINEAR NONLINEA, V3, P1; Powell N, 2017, NAT REV GASTRO HEPAT, V14, P143, DOI 10.1038/nrgastro.2016.191; Prakash T, 2011, CELL HOST MICROBE, V10, P273, DOI 10.1016/j.chom.2011.08.007; Price MN, 2009, MOL BIOL EVOL, V26, P1641, DOI 10.1093/molbev/msp077; Quast Christian, 2013, Nucleic Acids Res, V41, pD590, DOI 10.1093/nar/gks1219; R Development Core Team, 2018, R LANG ENV STAT COMP; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Rehman A, 2016, GUT, V65, P238, DOI 10.1136/gutjnl-2014-308341; Reynolds LA, 2017, NAT REV IMMUNOL, V17, P518, DOI 10.1038/nri.2017.39; Richards JL, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.29; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Rognes T, 2016, PEERJ, V4, DOI 10.7717/peerj.2584; Rook GAW, 2010, CLIN EXP IMMUNOL, V160, P70, DOI 10.1111/j.1365-2249.2010.04133.x; Rubtsov YP, 2008, IMMUNITY, V28, P546, DOI 10.1016/j.immuni.2008.02.017; Ruokolainen L, 2017, CLIN EXP ALLERGY, V47, P665, DOI 10.1111/cea.12895; Ruokolainen L, 2015, ALLERGY, V70, P195, DOI 10.1111/all.12545; Ruokolainen L, 2017, ANN ZOOL FENN, V54, P39, DOI 10.5735/086.054.0106; Ruokolainen L, 2016, CURR OPIN ALLERGY CL, V16, P421, DOI 10.1097/ACI.0000000000000304; Sallis JF, 2016, LANCET, V387, P2207, DOI 10.1016/S0140-6736(15)01284-2; Sandifer PA, 2015, ECOSYST SERV, V12, P1, DOI 10.1016/j.ecoser.2014.12.007; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Schmidt Bettina, 2011, PLoS One, V6, pe28284, DOI 10.1371/journal.pone.0028284; Schnupf P, 2015, NATURE, V520, P99, DOI 10.1038/nature14027; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Seedorf H, 2014, CELL, V159, P253, DOI 10.1016/j.cell.2014.09.008; Sonnenburg JL, 2016, NATURE, V535, P56, DOI 10.1038/nature18846; Sundin OH, 2017, BMC MICROBIOL, V17, DOI 10.1186/s12866-017-1059-6; Suzuki K, 2004, P NATL ACAD SCI USA, V101, P1981, DOI 10.1073/pnas.0307317101; Suzuki TA, 2014, BIOL LETTERS, V10, DOI 10.1098/rsbl.2013.1037; Sze MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111228; Thorburn AN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8320; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Vereecke L, 2009, TRENDS IMMUNOL, V30, P383, DOI 10.1016/j.it.2009.05.007; Vital M, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/892568; von Hertzen L, 2006, J ALLERGY CLIN IMMUN, V117, P334, DOI 10.1016/j.jaci.2005.11.013; von Hertzen L, 2011, EMBO REP, V12, P1089, DOI 10.1038/embor.2011.195; von Mutius E, 2016, J ALLERGY CLIN IMMUN, V137, P680, DOI 10.1016/j.jaci.2015.12.1301; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Vos M, 2013, FEMS MICROBIOL REV, V37, P936, DOI 10.1111/1574-6976.12023; Wall DH, 2015, NATURE, V528, P69, DOI 10.1038/nature15744; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Wang W, 2014, J CLIN MICROBIOL, V52, P398, DOI 10.1128/JCM.01500-13; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Yin YS, 2013, ISME J, V7, P615, DOI 10.1038/ismej.2012.128; Yu ZT, 2004, BIOTECHNIQUES, V36, P808, DOI 10.2144/04365ST04; Zhou DR, 2016, ENVIRON MICROBIOL, V18, P1326, DOI 10.1111/1462-2920.12895	83	60	60	3	41	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					1198	+		10.1016/j.jaci.2018.06.024	http://dx.doi.org/10.1016/j.jaci.2018.06.024			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30097187	Bronze, Green Accepted			2022-12-18	WOS:000460272900039
J	Wang, H; Li, ZY; Jiang, WX; Liao, B; Zhai, GT; Wang, N; Zhen, Z; Ruan, JW; Long, XB; Wang, H; Liu, WH; Liang, GT; Xu, WM; Kato, A; Liu, Z				Wang, Hai; Li, Zhi-Yong; Jiang, Wen-Xiu; Liao, Bo; Zhai, Guan-Ting; Wang, Nan; Zhen, Zhen; Ruan, Jian-wen; Long, Xiao-Bo; Wang, Heng; Liu, Wei-Hong; Liang, Geng-Tian; Xu, Wei-Min; Kato, Atsushi; Liu, Zheng			The activation and function of IL-36 gamma in neutrophilic inflammation in chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Activate; chronic rhinosinusitis; elastase; IL-17; IL-36; nasal polyps; neutrophil	EOSINOPHILIC CHRONIC RHINOSINUSITIS; IL-36 RECEPTOR ANTAGONIST; THYMIC STROMAL LYMPHOPOIETIN; NF-KAPPA-B; NASAL POLYPS; EPITHELIAL BARRIER; MAST-CELLS; T-CELLS; FAMILY; IL-1F8	Background: Although increased accumulation of neutrophils has been noted in chronic rhinosinusitis (CRS), the function and regulation of neutrophils in CRS are largely unknown. IL-36 family cytokines may play an important role in neutrophilic inflammation. Objective: This study sought to investigate the expression and function of IL-36 cytokines in CRS. Methods: Quantitative RT-PCR, immunohistochemistry, immunofluorescence, and ELISA were used to investigate the expression of IL-36 cytokines and IL-36 receptor (IL-36R) in sinonasal mucosa. The expression of IL-36R on neutrophils in polyps and blood was measured by flow cytometry. Purified blood neutrophils were cultured to investigate the regulation of IL-36R expression. The cleavage of IL-36g was detected by Western blotting. Dispersed nasal polyp cells were treated with IL-36g with or without elastase inhibitor and dexamethasone. Results: Neutrophil infiltration and expression of IL-36 cytokines and IL-36R were upregulated in both CRS with and without nasal polyps. IL-36g gamma was the most abundant isoform and mainly expressed by epithelial cells in CRS. Neutrophils were the principal IL-36R(+) cell type in polyps. IL-36R expression was almost absent in blood neutrophils and upregulated by IL-6, IL-1 beta, and Dermatophagoides pteronyssinus group 1. Elastase activity was increased in polyps and degraded full-length IL-36 gamma. Consistently, the levels of cleaved IL-36 gamma were increased in polyps. Full-length IL-36 gamma promoted the production of matrix metalloproteinase 9; IL-17A; and chemokine (C-X-C motif) ligands 1, 2, and 8 from dispersed nasal polyp cells, which was abolished by elastase inhibitor. The proinflammatory effect of IL-36 gamma was not suppressed by dexamethasone. Conclusions: Increased production and activation of IL-36 gamma may act on neutrophils and further exaggerate neutrophilic inflammation in CRS.	[Wang, Hai; Li, Zhi-Yong; Jiang, Wen-Xiu; Liao, Bo; Zhai, Guan-Ting; Wang, Nan; Ruan, Jian-wen; Long, Xiao-Bo; Wang, Heng; Liu, Zheng] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Otolaryngol Head & Neck Surg, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China; [Liu, Wei-Hong] Wuhan 1 Hosp, Dept Otolaryngol Head & Neck Surg, Wuhan, Hubei, Peoples R China; [Liang, Geng-Tian] Wuhan 3 Hosp, Dept Otolaryngol Head & Neck Surg, Wuhan, Hubei, Peoples R China; [Xu, Wei-Min] Wuhan Puai Hosp, Dept Otolaryngol Head & Neck Surg, Wuhan, Hubei, Peoples R China; [Zhen, Zhen] Peking Univ, Dept Otolaryngol Head & Neck Surg, Hosp 1, Beijing, Peoples R China; [Kato, Atsushi] Northwestern Univ, Dept Med, Div Allergy & Immunol, Feinberg Sch Med, Chicago, IL 60611 USA	Huazhong University of Science & Technology; Peking University; Northwestern University; Feinberg School of Medicine	Liu, Z (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Otolaryngol Head & Neck Surg, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.	zhengliuent@hotmail.com	Xu, Wei ******/C-4408-2019; Xu, Wei/AAE-2967-2020; xu, wei/HHD-2891-2022	Xu, Wei ******/0000-0003-0816-6016; Kato, Atsushi/0000-0001-9144-3138	National Natural Science Foundation of China [81325006, 81570899, 81630024, 81200733, 81400448]; Hubei Province Natural Science Foundation [2017CFA016]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hubei Province Natural Science Foundation(Natural Science Foundation of Hubei Province)	This study was supported by National Natural Science Foundation of China grants 81325006, 81570899, and 81630024 (Z.L.), 81200733 (H.W.), and 81400448 (X.B.L.), and Hubei Province Natural Science Foundation grant 2017CFA016 (Z.L.).	Bachert C, 2016, J ALLERGY CLIN IMMUN, V138, P1277, DOI 10.1016/j.jaci.2016.09.008; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Boraschi D, 2013, SEMIN IMMUNOL, V25, P394, DOI 10.1016/j.smim.2013.10.023; Borregaard N, 2010, IMMUNITY, V33, P657, DOI 10.1016/j.immuni.2010.11.011; Bozoyan L, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0392-7; Brodlie M, 2011, EUR RESPIR J, V37, P1378, DOI 10.1183/09031936.00067110; Calzetti F, 2017, J ALLERGY CLIN IMMUN, V139, P352, DOI 10.1016/j.jaci.2016.06.025; Cao PP, 2014, CLIN EXP ALLERGY, V44, P690, DOI 10.1111/cea.12304; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Carrier Y, 2011, J INVEST DERMATOL, V131, P2428, DOI 10.1038/jid.2011.234; Cho HJ, 2012, J ALLERGY CLIN IMMUN, V129, P529, DOI 10.1016/j.jaci.2011.11.024; Chustz RT, 2011, AM J RESP CELL MOL, V45, P145, DOI 10.1165/rcmb.2010-0075OC; Davidson CE, 2013, CLIN EXP ALLERGY, V43, P1274, DOI 10.1111/cea.12185; de Borja F, 2014, PLOS ONE, V9; Debets R, 2001, J IMMUNOL, V167, P1440, DOI 10.4049/jimmunol.167.3.1440; Dietrich D, 2016, CYTOKINE, V84, P88, DOI 10.1016/j.cyto.2016.05.012; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Foster AM, 2014, J IMMUNOL, V192, P6053, DOI 10.4049/jimmunol.1301481; Frey S, 2013, ANN RHEUM DIS, V72, P1569, DOI 10.1136/annrheumdis-2012-202264; Gabay C, 2015, J LEUKOCYTE BIOL, V97, P645, DOI 10.1189/jlb.3RI1014-495R; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Gevaert E, 2017, J ALLERGY CLIN IMMUN, V139, P1849, DOI 10.1016/j.jaci.2017.01.019; Gould BR, 2017, METHODS MOL BIOL, V1641, P399, DOI 10.1007/978-1-4939-7172-5_22; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Gresnigt MS, 2013, SEMIN IMMUNOL, V25, P458, DOI 10.1016/j.smim.2013.11.003; Henry CM, 2016, CELL REP, V14, P708, DOI 10.1016/j.celrep.2015.12.072; Johnston A, 2017, J ALLERGY CLIN IMMUN, V140, P109, DOI 10.1016/j.jaci.2016.08.056; Keijsers RRMC, 2014, J INVEST DERMATOL, V134, P1276, DOI 10.1038/jid.2013.526; Lee NR, 2016, IMMUNOL RES, V64, P123, DOI 10.1007/s12026-015-8730-5; Liao B, 2015, ALLERGY, V70, P1169, DOI 10.1111/all.12667; Lin AM, 2011, J IMMUNOL, V187, P490, DOI 10.4049/jimmunol.1100123; Lu XA, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-28; Ma J, 2016, CLIN EXP ALLERGY, V46, P1162, DOI 10.1111/cea.12758; Macleod T, 2016, SCI REP-UK, V6, DOI 10.1038/srep24880; Magne D, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1946; Medina-Contreras O, 2016, J IMMUNOL, V196, P34, DOI 10.4049/jimmunol.1501312; Mutamba S, 2012, EUR J IMMUNOL, V42, P607, DOI 10.1002/eji.201142035; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005; Orlandi RR, 2016, INT FORUM ALLERGY RH, V6, pS22, DOI 10.1002/alr.21695; Peters AT, 2010, J ALLERGY CLIN IMMUN, V125, P397, DOI 10.1016/j.jaci.2009.10.072; Pothoven KL, 2016, J ALLERGY CLIN IMMUN, V139; Ramadas RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045784; Ramadas RA, 2011, AM J RESP CELL MOL, V44, P134, DOI 10.1165/rcmb.2009-0315OC; Schleimer RP, 2017, ANNU REV PATHOL-MECH, V12, P331, DOI 10.1146/annurev-pathol-052016-100401; Seshadri S, 2013, J ALLERGY CLIN IMMUN, V132, P1227, DOI 10.1016/j.jaci.2013.05.042; Shaik Y, 2013, INT J IMMUNOPATH PH, V26, P27, DOI 10.1177/039463201302600103; Shi LL, 2013, ALLERGY, V68, P101, DOI 10.1111/all.12064; Shi LL, 2014, AM J RESP CRIT CARE, V190, P628, DOI 10.1164/rccm.201402-0234OC; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Stevens WW, 2015, J ALLERGY CLIN IMMUN, V136, P1442, DOI 10.1016/j.jaci.2015.10.009; Taylor PR, 2014, NAT IMMUNOL, V15, P143, DOI 10.1038/ni.2797; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Towne JE, 2004, J BIOL CHEM, V279, P13677, DOI 10.1074/jbc.M400117200; Towne JE, 2011, J BIOL CHEM, V286, P42594, DOI 10.1074/jbc.M111.267922; Van Crombruggen K, 2011, J ALLERGY CLIN IMMUN, V128, P728, DOI 10.1016/j.jaci.2011.07.049; van de Veerdonk FL, 2012, P NATL ACAD SCI USA, V109, P3001, DOI 10.1073/pnas.1121534109; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Vigne S, 2011, BLOOD, V118, P5813, DOI 10.1182/blood-2011-05-356873; Wang BF, 2016, INT FORUM ALLERGY RH, V6, P1013, DOI 10.1002/alr.21799; Wang PL, 2005, CYTOKINE, V29, P245, DOI 10.1016/j.cyto.2004.12.002; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041; Wen WP, 2012, J ALLERGY CLIN IMMUN, V129, P1522, DOI 10.1016/j.jaci.2012.01.079; Xu J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161013; Yamada Y, 2017, INT ARCH ALLERGY IMM, V173, P84, DOI 10.1159/000473700; Zhang XH, 2012, AM J RESP CRIT CARE, V185, P140, DOI 10.1164/rccm.201103-0456OC; Zhang YN, 2016, J ALLERGY CLIN IMMUN, V137, P462, DOI 10.1016/j.jaci.2015.07.025	66	60	70	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1646	1658		10.1016/j.jaci.2017.12.972	http://dx.doi.org/10.1016/j.jaci.2017.12.972			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29274415	Bronze			2022-12-18	WOS:000432148200012
J	Gold, DR; Adamkiewicz, G; Arshad, SH; Celedon, JC; Chapman, MD; Chew, GL; Cook, DN; Custovic, A; Gehring, U; Gern, JE; Johnson, CC; Kennedy, S; Koutrakis, P; Leaderer, B; Mitchell, H; Litonjua, AA; Mueller, GA; O'Connor, GT; Ownby, D; Phipatanakul, W; Persky, V; Perzanowski, MS; Ramsey, CD; Salo, PM; Schwaninger, JM; Sordillo, JE; Spira, A; Suglia, SF; Togias, A; Zeldin, DC; Matsui, EC				Gold, Diane R.; Adamkiewicz, Gary; Arshad, Syed Hasan; Celedon, Juan C.; Chapman, Martin D.; Chew, Ginger L.; Cook, Donald N.; Custovic, Adnan; Gehring, Ulrike; Gern, James E.; Johnson, Christine C.; Kennedy, Suzanne; Koutrakis, Petros; Leaderer, Brian; Mitchell, Herman; Litonjua, Augusto A.; Mueller, Geoffrey A.; O'Connor, George T.; Ownby, Dennis; Phipatanakul, Wanda; Persky, Victoria; Perzanowski, Matthew S.; Ramsey, Clare D.; Salo, Paivi M.; Schwaninger, Julie M.; Sordillo, Joanne E.; Spira, Avrum; Suglia, Shakira F.; Togias, Alkis; Zeldin, Darryl C.; Matsui, Elizabeth C.			NIAID, NIEHS, NHLBI, and MCAN Workshop Report: The indoor environment and childhood asthma-implications for home environmental intervention in asthma prevention and management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergy; child health; indoor allergens; pollutants; environmental intervention; clinical trials	DUST-MITE ALLERGEN; FLUORESCENT MULTIPLEX ARRAY; INNER-CITY CHILDREN; EARLY-LIFE EXPOSURE; HOUSE-DUST; CONTROLLED-TRIAL; UNITED-STATES; VITAMIN-D; BACTERIAL COMMUNITIES; LONGITUDINAL ANALYSIS	Environmental exposures have been recognized as critical in the initiation and exacerbation of asthma, one of the most common chronic childhood diseases. The National Institute of Allergy and Infectious Diseases; National Institute of Environmental Health Sciences; National Heart, Lung, and Blood Institute; and Merck Childhood Asthma Network sponsored a joint workshop to discuss the current state of science with respect to the indoor environment and its effects on the development and morbidity of childhood asthma. The workshop included US and international experts with backgrounds in allergy/allergens, immunology, asthma, environmental health, environmental exposures and pollutants, epidemiology, public health, and bioinformatics. Workshop participants provided new insights into the biologic properties of indoor exposures, indoor exposure assessment, and exposure reduction techniques. This informed a primary focus of the workshop: to critically review trials and research relevant to the prevention or control of asthma through environmental intervention. The participants identified important limitations and gaps in scientific methodologies and knowledge and proposed and prioritized areas for future research. The group reviewed socioeconomic and structural challenges to changing environmental exposure and offered recommendations for creative study design to overcome these challenges in trials to improve asthma management. The recommendations of this workshop can serve as guidance for future research in the study of the indoor environment and on environmental interventions as they pertain to the prevention and management of asthma and airway allergies.	[Gold, Diane R.; Litonjua, Augusto A.; Sordillo, Joanne E.] Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA USA; [Adamkiewicz, Gary; Koutrakis, Petros] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Arshad, Syed Hasan] David Hide Asthma & Allergy Res Ctr, Isle Of Wight, England; [Arshad, Syed Hasan] Univ Southampton, Fac Med, Clin & Expt Sci, Southampton, Hants, England; [Celedon, Juan C.] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Div Pulm Med Allergy & Immunol, Pittsburgh, PA USA; [Chapman, Martin D.] Indoor Biotechnol, Charlottesville, VA USA; [Chew, Ginger L.] Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Ctr Dis Control & Prevent CDC, Atlanta, GA USA; [Cook, Donald N.] NIEHS, Immun Inflammat & Dis Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA; [Mueller, Geoffrey A.] NIEHS, Genome Integr & Struct Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA; [Salo, Paivi M.; Zeldin, Darryl C.] NIEHS, Div Intramural Res, NIH, POB 12233, Res Triangle Pk, NC 27709 USA; [Custovic, Adnan] Imperial Coll London, Sect Paediat, London, England; [Custovic, Adnan] Imperial Coll London, MRC & Asthma UK Ctr Allerg Mech Asthma, London, England; [Gehring, Ulrike] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; [Gern, James E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53706 USA; [Gern, James E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA; [Johnson, Christine C.] Henry Ford Hosp & Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA; [Kennedy, Suzanne] Univ N Carolina, Dept Pediat, NC Childrens Hosp, Chapel Hill, NC USA; [Leaderer, Brian] Yale Sch Med, Yale Sch Forestry & Environm Studies, Yale Sch Publ Hlth, Ctr Perinatal Pediat & Environm Epidemiol CPPEE, New Haven, CT USA; [Mitchell, Herman] Rho Inc, Rho Fed Syst Div, Chapel Hill, NC USA; [O'Connor, George T.] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA; [Ownby, Dennis] Augusta Univ, Dept Pediat, Div Allergy Immunol & Rheumatol, Augusta, GA USA; [Phipatanakul, Wanda] Harvard Med Sch, Boston Childrens Hosp, Asthma Allergy & Immunol, Boston, MA USA; [Persky, Victoria] Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL USA; [Perzanowski, Matthew S.] Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY USA; [Ramsey, Clare D.] Univ Manitoba, Rady Fac Hlth Sci, Dept Med, Winnipeg, MB, Canada; [Ramsey, Clare D.] Univ Manitoba, Rady Fac Hlth Sci, Dept Community Hlth Sci, Winnipeg, MB, Canada; [Schwaninger, Julie M.; Togias, Alkis] NIAID, Div Allergy Immunol & Transplantat, NIH, Rockville, MD USA; [Spira, Avrum] Boston Univ, Dept Med, Div Computat Biomed, Boston, MA USA; [Suglia, Shakira F.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA; [Matsui, Elizabeth C.] Johns Hopkins Univ, Div Pediat Allergy Immunol, Baltimore, MD USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; University of Southampton; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; INDOOR Biotechnologies; Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Imperial College London; Imperial College London; University of London; King's College London; Utrecht University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Henry Ford Health System; University of North Carolina; University of North Carolina Chapel Hill; Yale University; Rho; Boston University; University System of Georgia; Augusta University; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Columbia University; University of Manitoba; University of Manitoba; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Boston University; Emory University; Rollins School Public Health; Johns Hopkins University	Gold, DR (corresponding author), Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.	diane.gold@channing.harvard.edu	Zeldin, Darryl C/Y-7091-2018; Mueller, Geoffrey A/I-2909-2017; Custovic, Adnan/A-2435-2012; Cook, Donald/E-5079-2019	Zeldin, Darryl C/0000-0002-2087-7307; Mueller, Geoffrey A/0000-0001-8361-5323; Custovic, Adnan/0000-0001-5218-7071; Cook, Donald/0000-0002-0052-3755; Matsui, Elizabeth/0000-0001-8134-5593; Chapman, Martin/0000-0002-0845-3632; Gehring, Ulrike/0000-0003-3612-5780	Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases; Division of Lung Diseases, National Heart, Lung, and Blood Institute; Division of Intramural Research, National Institute of Environmental Health Sciences; Merck Childhood Asthma Network; MRC [MR/K002449/2] Funding Source: UKRI; Medical Research Council [G1000758B, MR/K002449/2, G1000758] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre, MRC-Asthma UK Centre] Funding Source: researchfish; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [T42OH008672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI089473] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES025041, ZIAES102906, P30ES020957] Funding Source: NIH RePORTER	Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Division of Lung Diseases, National Heart, Lung, and Blood Institute; Division of Intramural Research, National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Merck Childhood Asthma Network; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This workshop was supported by funds from the Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases; the Division of Lung Diseases, National Heart, Lung, and Blood Institute; the Division of Intramural Research, National Institute of Environmental Health Sciences; and the Merck Childhood Asthma Network. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the official position of any of the above-referenced National Institutes of Health institutes or the US Centers for Disease Control and Prevention.	Adams RI, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0078866, 10.1371/journal.pone.0067861]; Alwis KU, 2006, AM J IND MED, V49, P296, DOI 10.1002/ajim.20264; Amend AS, 2010, P NATL ACAD SCI USA, V107, P13748, DOI 10.1073/pnas.1000454107; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Arshad SH, 2007, J ALLERGY CLIN IMMUN, V119, P307, DOI 10.1016/j.jaci.2006.12.621; Azad MB, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-15; Baxi SN, 2013, PEDIAT ALLERG IMM-UK, V24, P697, DOI 10.1111/pai.12127; Behbod B, 2015, CLIN EXP ALLERGY, V45, P154, DOI 10.1111/cea.12401; Bousquet J, 2014, J ALLERGY CLIN IMMUN, V133, P1535, DOI 10.1016/j.jaci.2014.01.018; Breysse J, 2014, AM J PUBLIC HEALTH, V104, pE57, DOI 10.2105/AJPH.2013.301402; Breysse J, 2011, PUBLIC HEALTH REP, V126, P64, DOI 10.1177/00333549111260S110; Bryant-Stephens Tyra, 2009, Am J Public Health, V99 Suppl 3, pS657, DOI 10.2105/AJPH.2009.165423; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Butz AM, 2011, ARCH PEDIAT ADOL MED, V165, P741, DOI 10.1001/archpediatrics.2011.111; Cacioppo JT, 1998, ANN NY ACAD SCI, V840, P664, DOI 10.1111/j.1749-6632.1998.tb09605.x; Carter MC, 2001, J ALLERGY CLIN IMMUN, V108, P732, DOI 10.1067/mai.2001.119155; Cayrol C, 2014, CURR OPIN IMMUNOL, V31, P31, DOI 10.1016/j.coi.2014.09.004; Celedon Juan C, 2014, Ann Am Thorac Soc, V11, P473, DOI 10.1513/AnnalsATS.201402-059PS; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657, DOI 10.1001/archpedi.154.7.657; Chan-Yeung M, 2007, J ALLERGY CLIN IMMUN, V120, P1221, DOI 10.1016/j.jaci.2007.08.025; Chapman MD, 2007, CURR ALLERGY ASTHM R, V7, P363, DOI 10.1007/s11882-007-0055-6; Chapman MD, 2012, CURR ALLERGY ASTHM R, V12, P478, DOI 10.1007/s11882-012-0282-3; Chen W, 2013, AM J RESP CRIT CARE, V187, P584, DOI 10.1164/rccm.201210-1789OC; Chew GL, 2006, ENVIRON HEALTH PERSP, V114, P1883, DOI 10.1289/ehp.9258; Chew GL, 2016, J ALLER CL IMM-PRACT, V4, P417, DOI 10.1016/j.jaip.2016.01.013; Colton MD, 2015, AM J PUBLIC HEALTH, V105, P2482, DOI 10.2105/AJPH.2015.302793; Colton MD, 2014, ENVIRON SCI TECHNOL, V48, P7833, DOI 10.1021/es501489u; Corver K, 2006, PEDIAT ALLERG IMM-UK, V17, P329, DOI 10.1111/j.1399-3038.2006.00410.x; Crocker DD, 2011, AM J PREV MED, V41, pS5, DOI [10.1016/j.amepre.2011.04.011, 10.1016/j.amepre.2011.05.012]; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Da Silva CA, 2010, AM J RESP CRIT CARE, V182, P1482, DOI 10.1164/rccm.200912-1877OC; Dickey BF, 2007, NEW ENGL J MED, V357, P2082, DOI 10.1056/NEJMe0706634; DiMango E, 2016, J ALLER CL IMM-PRACT, V4, P671, DOI 10.1016/j.jaip.2016.01.016; Earle CD, 2007, J ALLERGY CLIN IMMUN, V119, P428, DOI 10.1016/j.jaci.2006.11.004; Eggleston PA, 2005, ANN ALLERG ASTHMA IM, V95, P518, DOI 10.1016/S1081-1206(10)61012-5; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; Faino L, 2015, MBIO, V6, DOI 10.1128/mBio.00936-15; Fenaille F, 2009, J PROTEOME RES, V8, P4014, DOI 10.1021/pr900359p; Filep S, 2012, ALLERGY, V67, P235, DOI 10.1111/j.1398-9995.2011.02750.x; Fuchs O, 2017, LANCET RESP MED, V5, P224, DOI 10.1016/S2213-2600(16)30187-4; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111; Fujimura KE, 2012, J MICROBIOL METH, V91, P231, DOI 10.1016/j.mimet.2012.08.016; Fujimura KE, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.042; Garland E, 2013, PROG COMM HLTH PARTN, V7, P29, DOI 10.1353/cpr.2013.0010; Gehring U, 2012, ALLERGY, V67, P248, DOI 10.1111/j.1398-9995.2011.02739.x; Gore RB, 2002, CLIN EXP ALLERGY, V32, P856, DOI 10.1046/j.1365-2222.2002.01403.x; Graham JAH, 2000, ANN ALLERG ASTHMA IM, V84, P599, DOI 10.1016/S1081-1206(10)62410-6; Habre R, 2014, J EXPO SCI ENV EPID, V24, P380, DOI 10.1038/jes.2014.21; Habre R, 2014, J EXPO SCI ENV EPID, V24, P269, DOI 10.1038/jes.2013.74; Hanson B, 2016, ENVIRON SCI-PROC IMP, V18, P713, DOI [10.1039/c5em00639b, 10.1039/C5EM00639B]; Hoppe KA, 2012, INDOOR AIR, V22, P446, DOI 10.1111/j.1600-0668.2012.00785.x; Howden-Chapman P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1411; Jacobs DE, 2015, J PUBLIC HEALTH MAN, V21, P345, DOI 10.1097/PHH.0000000000000047; Jhun I, 2017, J ALLER CL IMM-PRACT, V5, P154, DOI 10.1016/j.jaip.2016.07.018; Johnson CC, 2017, TRANSL RES, V179, P60, DOI 10.1016/j.trsl.2016.06.010; Karp CL, 2010, J ALLERGY CLIN IMMUN, V125, P955, DOI 10.1016/j.jaci.2010.03.002; Kattan M, 2005, J ALLERGY CLIN IMMUN, V116, P1058, DOI 10.1016/j.jaci.2005.07.032; Keet CA, 2014, J ALLERGY CLIN IMMUN, V133, P399, DOI 10.1016/j.jaci.2013.09.042; Kembel SW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087093; Kercsmar CM, 2006, ENVIRON HEALTH PERSP, V114, P1574, DOI 10.1289/ehp.8742; Kim D, 2012, IEEE T MAGN, V48, P3266, DOI 10.1109/TMAG.2012.2195163; King EM, 2013, J IMMUNOL METHODS, V387, P89, DOI 10.1016/j.jim.2012.09.015; Konya T, 2014, ENVIRON RES, V131, P25, DOI 10.1016/j.envres.2014.02.005; Koopman LP, 2002, AM J RESP CRIT CARE, V166, P307, DOI 10.1164/rccm.2106026; Korkalainen M, 2017, INDOOR AIR, V27, P13, DOI 10.1111/ina.12282; Krieger J, 2010, PEDIAT ALLER IMM PUL, V23, P139, DOI 10.1089/ped.2010.0022; Krieger JW, 2005, AM J PUBLIC HEALTH, V95, P652, DOI 10.2105/AJPH.2004.042994; Kurita R, 2013, BIOSENS BIOELECTRON, V48, P43, DOI 10.1016/j.bios.2013.04.010; Lai PS, 2015, J ALLERGY CLIN IMMUN, V136, P1120, DOI 10.1016/j.jaci.2015.04.032; Lambrecht BN, 2014, J ALLERGY CLIN IMMUN, V134, P499, DOI 10.1016/j.jaci.2014.06.036; Lambrecht BN, 2013, EUR J IMMUNOL, V43, P3125, DOI 10.1002/eji.201343730; Lanphear BP, 2011, PEDIATRICS, V127, P93, DOI 10.1542/peds.2009-2312; Lax S, 2014, SCIENCE, V345, P1048, DOI 10.1126/science.1254529; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419, DOI 10.1289/ehp.02110419; Lee WC, 2015, ENVIRON SCI TECHNOL, V49, P9592, DOI 10.1021/acs.est.5b03126; Levin AM, 2016, SCI REP-UK, V6, DOI 10.1038/srep31775; Lichtveld M, 2016, AM J PUBLIC HEALTH, V106, P1235, DOI 10.2105/AJPH.2016.303169; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Litonjua AA, 2016, JAMA-J AM MED ASSOC, V315, P362, DOI 10.1001/jama.2015.18589; Litonjua AA, 2014, CONTEMP CLIN TRIALS, V38, P37, DOI 10.1016/j.cct.2014.02.006; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Maas T, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006480.pub2; Mack Ines, 2015, Mol Cell Pediatr, V2, P3, DOI 10.1186/s40348-015-0014-6; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; Matsui EC, 2014, ALLERGY, V69, P553, DOI 10.1111/all.12361; Matsui EC, 2017, JAMA-J AM MED ASSOC, V317, P1027, DOI 10.1001/jama.2016.21048; Matsui EC, 2013, AM J RESP CRIT CARE, V188, P1210, DOI 10.1164/rccm.201305-0889OC; McEvoy CT, 2014, JAMA-J AM MED ASSOC, V311, P2074, DOI 10.1001/jama.2014.5217; Meadow JF, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-7; MILTON DK, 1992, ENVIRON RES, V57, P212, DOI 10.1016/S0013-9351(05)80081-7; Mitchell H, 2012, ENVIRON HEALTH PERSP, V120, P1607, DOI 10.1289/ehp.1104242; Monaci L, 2014, J CHROMATOGR A, V1358, P136, DOI 10.1016/j.chroma.2014.06.092; Moreno-Macias H, 2014, J ALLERGY CLIN IMMUN, V133, P1237, DOI 10.1016/j.jaci.2014.03.020; Moreno-Macias H, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-14; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; National Institute of Biomedical Imaging and Bioengineering, PED RES US INT SENS; National Institutes of Health, ENV INFL CHILD HLTH; Nurmatov U, 2011, J ALLERGY CLIN IMMUN, V127, P724, DOI 10.1016/j.jaci.2010.11.001; Okupa AY, 2013, J ALLERGY CLIN IMMUN, V131, DOI 10.1016/j.jaci.2012.08.015; Olmedo O, 2011, J ALLERGY CLIN IMMUN, V128, P284, DOI 10.1016/j.jaci.2011.02.044; Ownby DR, 2016, J ALLERGY CLIN IMMUN, V138, P1591, DOI 10.1016/j.jaci.2016.08.021; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Park JH, 2004, APPL ENVIRON MICROB, V70, P262, DOI 10.1128/aEM.70.1.262-267.2004; Paulin LM, 2014, INDOOR AIR, V24, P416, DOI 10.1111/ina.12085; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Perzanowski MS, 2013, J ALLERGY CLIN IMMUN, V131, P886, DOI 10.1016/j.jaci.2012.12.666; Phipatanakul W, 2004, ANN ALLERG ASTHMA IM, V92, P420, DOI 10.1016/S1081-1206(10)61777-2; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V105, pS503, DOI 10.1016/S0091-6749(00)90051-4; Pongracic JA, 2008, ANN ALLERG ASTHMA IM, V101, P35, DOI 10.1016/S1081-1206(10)60832-0; Pongracic JA, 2010, J ALLERGY CLIN IMMUN, V125, P593, DOI 10.1016/j.jaci.2009.10.036; Poole A, 2014, J ALLERGY CLIN IMMUN, V133, P670, DOI 10.1016/j.jaci.2013.11.025; Rabito FA, 2017, J ALLERGY CLIN IMMUN, V140, P565, DOI [10.1016/j.jaci.2016.10.019, 10.1016/j.jaci.2016.12.221]; Renstrom A, 2002, CLIN EXP ALLERGY, V32, P1769, DOI 10.1046/j.1365-2222.2002.01545.x; Salo PM, 2008, J ALLERGY CLIN IMMUN, V121, P678, DOI 10.1016/j.jaci.2007.12.1164; Salo PM, 2014, J ALLERGY CLIN IMMUN, V134, P350, DOI 10.1016/j.jaci.2013.12.1071; Sauni Riitta, 2013, Evid Based Child Health, V8, P944, DOI 10.1002/ebch.1914; Schloss PD, 2016, PEERJ, V4, DOI 10.7717/peerj.1869; Scott M, 2012, THORAX, V67, P1046, DOI 10.1136/thoraxjnl-2012-202150; Sever ML, 2007, J ALLERGY CLIN IMMUN, V120, P849, DOI 10.1016/j.jaci.2007.07.003; Sewell DA, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-173; SHETH JS, 2017, AM J RESP CRIT CARE, V195; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Simpson A, 2009, CURR ALLERGY ASTHM R, V9, P363, DOI 10.1007/s11882-009-0053-y; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Song SJ, 2013, ELIFE, V2, DOI 10.7554/eLife.00458; Sordillo JE, 2011, ENVIRON HEALTH PERSP, V119, P189, DOI 10.1289/ehp.1002004; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Sternthal MJ, 2010, EUR RESPIR J, V36, P1400, DOI 10.1183/09031936.00003010; Suglia SF, 2009, ARCH PEDIAT ADOL MED, V163, P244, DOI 10.1001/archpediatrics.2008.555; Sun XL, 2012, J AGR FOOD CHEM, V60, P10979, DOI 10.1021/jf3027233; Szentpetery SE, 2016, J ALLERGY CLIN IMMUN, V138, P1556, DOI 10.1016/j.jaci.2016.08.047; Taubel M, 2009, J ALLERGY CLIN IMMUN, V124, P834, DOI 10.1016/j.jaci.2009.07.045; Tovey ER, 2008, J ALLERGY CLIN IMMUN, V122, P114, DOI 10.1016/j.jaci.2008.05.010; Tovey ER, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069900; Tringe SG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001862; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Tsai JJ, 2011, INT J NANOMED, V6, P1201, DOI 10.2147/IJN.S20757; Tsay A., 2002, Clinical and Experimental Allergy, V32, P1596, DOI 10.1046/j.1365-2222.2002.01533.x; Turyk M, 2013, J ASTHMA, V50, P729, DOI 10.3109/02770903.2013.796971; van Strien RT, 2003, CLIN EXP ALLERGY, V33, P490, DOI 10.1046/j.1365-2222.2003.01626.x; Whitehead GS, 2014, ENVIRON HEALTH PERSP, V122, P34, DOI 10.1289/ehp.1307280; Wilson RH, 2012, NAT MED, V18, P1705, DOI 10.1038/nm.2920; Winn AK, 2016, J ASTHMA, V53, P133, DOI 10.3109/02770903.2015.1072721; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; Yo JY, 2015, J HAZARD MATER, V289, P184, DOI 10.1016/j.jhazmat.2015.02.038; Zhang XL, 2013, SCI WORLD J, DOI 10.1155/2013/951416; Zhang XL, 2010, PHYSIOL GENOMICS, V41, P1, DOI 10.1152/physiolgenomics.00167.2009	151	60	60	0	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					933	949		10.1016/j.jaci.2017.04.024	http://dx.doi.org/10.1016/j.jaci.2017.04.024			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	FI7JL	28502823	Green Accepted, Bronze			2022-12-18	WOS:000412172900004
J	Takagi, M; Ogata, S; Ueno, H; Yoshida, K; Yeh, T; Hoshino, A; Piao, J; Yamashita, M; Nanya, M; Okano, T; Kajiwara, M; Kanegane, H; Muramatsu, H; Okuno, Y; Shiraishi, Y; Chiba, K; Tanaka, H; Bando, Y; Kato, M; Hayashi, Y; Miyano, S; Imai, K; Ogawa, S; Kojima, S; Morio, T				Takagi, Masatoshi; Ogata, Shohei; Ueno, Hiroo; Yoshida, Kenichi; Yeh, Tzuwen; Hoshino, Akihiro; Piao, Jinhua; Yamashita, Motoy; Nanya, Mai; Okano, Tsubasa; Kajiwara, Michiko; Kanegane, Hirokazu; Muramatsu, Hideki; Okuno, Yusuke; Shiraishi, Yuichi; Chiba, Kenichi; Tanaka, Hiroko; Bando, Yuki; Kato, Motohiro; Hayashi, Yasuhide; Miyano, Satoru; Imai, Kohsuke; Ogawa, Seishi; Kojima, Seiji; Morio, Tomohiro			Haploinsufficiency of TNFAIP3 (A20) by germline mutation is involved in autoimmune lymphoproliferative syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autoimmune lymphoproliferative syndrome; TNFAIP3 (A20)	LOSS-OF-FUNCTION; NF-KAPPA-B; IMMUNE DYSREGULATION; INFECTION	Background: Autoimmune diseases in children are rare and can be difficult to diagnose. Autoimmune lymphoproliferative syndrome (ALPS) is a well-characterized pediatric autoimmune disease caused by mutations in genes associated with the FAS-dependent apoptosis pathway. In addition, various genetic alterations are associated with the ALPS-like phenotype. Objective: The aim of the present study was to elucidate the genetic cause of the ALPS-like phenotype. Methods: Candidate genes associated with the ALPS-like phenotype were screened by using whole-exome sequencing. The functional effect of the identified mutations was examined by analyzing the activity of related signaling pathways. Results: A de novo heterozygous frameshift mutation of TNF-alpha-induced protein 3 (TNFAIP3, A20), a negative regulator of the nuclear factor kappa B pathway, was identified in one of the patients exhibiting the ALPS-like phenotype. Increased activity of the nuclear factor kappa B pathway was associated with haploinsufficiency of TNFAIP3 (A20). Conclusion: Haploinsufficiency of TNFAIP3 (A20) by a germline heterozygous mutation leads to the ALPS phenotype.	[Takagi, Masatoshi; Yeh, Tzuwen; Hoshino, Akihiro; Piao, Jinhua; Yamashita, Motoy; Nanya, Mai; Okano, Tsubasa; Kanegane, Hirokazu; Imai, Kohsuke; Morio, Tomohiro] Tokyo Med & Dent Univ, Dept Pediat & Dev Biol, Tokyo, Japan; [Kajiwara, Michiko] Tokyo Med & Dent Univ, Dept Transfus Med, Tokyo, Japan; [Ogata, Shohei] Kitasato Univ, Dept Pediat, Sagamihara, Kanagawa, Japan; [Ueno, Hiroo; Yoshida, Kenichi; Ogawa, Seishi] Kyoto Univ, Dept Pathol & Tumor Biol, Kyoto, Japan; [Muramatsu, Hideki; Okuno, Yusuke; Kojima, Seiji] Nagoya Univ, Dept Pediat, Nagoya, Aichi, Japan; [Shiraishi, Yuichi; Chiba, Kenichi; Miyano, Satoru] Univ Tokyo, Lab DNA Informat Anal, Tokyo, Japan; [Tanaka, Hiroko; Miyano, Satoru] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Sequence Anal, Tokyo, Japan; [Bando, Yuki] Kitasato Univ, Med Ctr, Dept Pediat, Saitama, Japan; [Kato, Motohiro] Natl Ctr Child Hlth & Dev, Dept Pediat Hematol & Oncol Res, Tokyo, Japan; [Hayashi, Yasuhide] Gunma Childrens Med Ctr, Shibukawa, Gunma, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Kitasato University; Kyoto University; Nagoya University; University of Tokyo; University of Tokyo; Kitasato University; National Center for Child Health & Development - Japan; Gunma Children's Medical Centre	Takagi, M (corresponding author), Tokyo Med & Dent Univ, Dept Pediat & Dev Biol, Grad Sch, Bunkyo Ku, Yushima 1-5-45, Tokyo 1138519, Japan.	m.takagi.ped@tmd.ac.jp	Ueno, Hiroo/AAJ-7175-2020; Muramatsu, Hideki/I-3763-2012; Okuno, Yusuke/C-9082-2009; Ogawa, Seishi/AAE-7088-2019; 岡野, 翼/AAU-8246-2021; Muramatsu, Hideki/ABA-3376-2021; Imai, Kohsuke/Q-2602-2015	Okuno, Yusuke/0000-0003-3139-9272; Muramatsu, Hideki/0000-0002-8801-0021; Imai, Kohsuke/0000-0003-2132-8403; Takagi, Masatoshi/0000-0002-7580-9184; Kato, Motohiro/0000-0001-5145-1774; Morio, Tomohiro/0000-0002-9259-1025; Yoshida, Kenichi/0000-0003-4612-2778; Miyano, Satoru/0000-0002-1753-6616	Japan Agency for Medical Research and Development (AMED) [27280301, 26070201]; Grants-in-Aid for Scientific Research [15K09640, 26461570] Funding Source: KAKEN	Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by a Grant-in-Aid for Research on Measures for Intractable Diseases from the Japan Agency for Medical Research and Development (AMED), 27280301 and 26070201.	Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Catrysse L, 2014, TRENDS IMMUNOL, V35, P22, DOI 10.1016/j.it.2013.10.005; Elkaim E, 2016, J ALLERGY CLIN IMMUN, V138, P210, DOI 10.1016/j.jaci.2016.03.022; Flanagan SE, 2014, NAT GENET, V46, P812, DOI 10.1038/ng.3040; Fleisher TA, 2001, CLIN REV ALLERG IMMU, V20, P109, DOI 10.1385/CRIAI:20:1:109; Janda A, 2011, SCAND J IMMUNOL, V74, P518, DOI 10.1111/j.1365-3083.2011.02597.x; Kato M, 2009, NATURE, V459, P712, DOI 10.1038/nature07969; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Kuehn HS, 2013, BLOOD, V121, P3117, DOI 10.1182/blood-2012-12-469544; Kunishima S, 2013, AM J HUM GENET, V92, P431, DOI 10.1016/j.ajhg.2013.01.015; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lo B, 2015, SCIENCE, V349, P436, DOI 10.1126/science.aaa1663; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Milner JD, 2015, BLOOD, V125, P591, DOI 10.1182/blood-2014-09-602763; Neven B, 2014, BLOOD, V124, P1597, DOI 10.1182/blood-2014-02-553834; Niemela JE, 2011, BLOOD, V117, P2883, DOI 10.1182/blood-2010-07-295501; Oliveira JB, 2010, BLOOD, V116, pE35, DOI 10.1182/blood-2010-04-280347; Patuzzo G, 2016, AUTOIMMUN REV, V15, P877, DOI 10.1016/j.autrev.2016.07.011; Pujari R, 2013, IMMUNOL RES, V57, P166, DOI 10.1007/s12026-013-8463-2; Rao VK, 2011, BLOOD, V118, P5741, DOI 10.1182/blood-2011-07-325217; Rensing-Ehl A, 2014, BLOOD, V124, P851, DOI 10.1182/blood-2014-03-564286; Saitoh Y, 2016, LEUKEMIA, V30, P716, DOI 10.1038/leu.2015.267; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Skaug B, 2011, MOL CELL, V44, P559, DOI 10.1016/j.molcel.2011.09.015; Takagi M, 2011, BLOOD, V117, P2887, DOI 10.1182/blood-2010-08-301515; Zhou Q, 2016, NAT GENET, V48, P67, DOI 10.1038/ng.3459	27	60	62	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1914	1922		10.1016/j.jaci.2016.09.038	http://dx.doi.org/10.1016/j.jaci.2016.09.038			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	27845235	Bronze			2022-12-18	WOS:000402724600022
J	Fergeson, JE; Patel, SS; Lockey, RF				Fergeson, Jennifer E.; Patel, Shiven S.; Lockey, Richard F.			Acute asthma, prognosis, and treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma flare; acute asthma; asthma attack; wheezing; acute asthma diagnosis; acute asthma management	EMERGENCY-DEPARTMENT; ADULTS; CORTICOSTEROIDS; EXACERBATIONS; CHILDREN	Asthma affects about 300 million people globally and accounts for 1 in every 250 deaths in the world. Approximately 12 million people in the United States each year experience an acute exacerbation of their asthma, a quarter of which require hospitalization. Acute asthma should be differentiated from poor asthma control. Patients with acute asthma will exhibit increasing shortness of breath, chest tightness, coughing, and/or wheezing. In contrast, poor asthma control typically presents with a diurnal variability in airflow and is a characteristic that is usually not seen during an acute exacerbation. The history should include a review of comorbidities, adherence to medications, previous episodes of near-fatal asthma, and whether the patient has experienced multiple emergency department visits or hospitalizations, particularly those requiring admission to an intensive care unit involving respiratory failure, intubation, and mechanical ventilation. Patient education is important to ensure that the patient understands that asthma is mostly a chronic disease and necessitates the avoidance of allergens, prevention of infections, adherence with routine vaccinations, management of comorbid conditions, and adherence to treatment regimens. This article is a structured review of the available literature regarding the diagnosis and management of acute asthma.	[Fergeson, Jennifer E.; Patel, Shiven S.; Lockey, Richard F.] Univ S Florida, Dept Internal Med, Div Allergy & Immunol, Tampa, FL 33620 USA	State University System of Florida; University of South Florida	Fergeson, JE (corresponding author), 13000 Bruce B Downs Blvd 111D, Tampa, FL 33612 USA.	jfergeso@health.usf.edu			Merck; AstraZeneca	Merck(Merck & Company); AstraZeneca(AstraZeneca)	R. F. Lockey is a board member for the Journal of Allergy and Clinical Immunology-In Practice and Allergy, Asthma & Immunology Research, has consultant arrangements with Merck and AstraZeneca, is employed by the University of South Florida College of Medicine, has received payment for lectures from Merck and AstraZeneca, has received royalties from Informa Publishing, and has received travel support from national and international congresses for presentations. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2014, THORAX, V69, P1; Beckhaus AA, 2014, PEDIATR PULM, V49, P326, DOI 10.1002/ppul.22846; Blake K, 2013, CURR OPIN PULM MED, V19, P24, DOI 10.1097/MCP.0b013e32835b582b; Bloom BM, 2014, EUR J EMERG MED, V21, P81, DOI 10.1097/MEJ.0b013e32836437cf; Camargo CA, 2009, ASTHMA AND COPD: BASIC MECHANISMS AND CLINICAL MANAGEMENT, 2ND EDITION, P775, DOI 10.1016/B978-0-12-374001-4.00064-X; Camargo Carlos A Jr, 2009, Proc Am Thorac Soc, V6, P357, DOI 10.1513/pats.P09ST2; Camargo Jr CA, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001115, 10.1002/14651858.CD001115]; Cates CJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000052.pub2; Chaudhry RQ, 2010, J ALLERGY CLIN IMMUN, V125, pAB69, DOI 10.1016/j.jaci.2009.12.270; Gibson PG, 2003, COCHRANE DATABASE SY, pCD001496, DOI DOI 10.1002/14651858.CD001496; Gibson PG, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001117], 10.1002/14651858.CD001117]; Goodacre S, 2014, EMERG MED J, V31, pE40, DOI 10.1136/emermed-2013-203046; Hasegawa K, 2014, J ALLER CL IMM-PRACT, V2, P733, DOI 10.1016/j.jaip.2014.06.012; Hasegawa K, 2014, J ALLERGY CLIN IMMUN, V133, pAB173, DOI 10.1016/j.jaci.2013.12.621; Holguin F, 2011, J ALLERGY CLIN IMMUN, V127, P1486, DOI 10.1016/j.jaci.2011.03.036; Kang MG, 2013, ALLERGY ASTHMA IMMUN, V5, P357, DOI 10.4168/aair.2013.5.6.357; Krishnan JA, 2009, J ALLERGY CLIN IMMUN, V124, pS29, DOI 10.1016/j.jaci.2009.05.007; Ledford DK, 2013, CURR OPIN ALLERGY CL, V13, P78, DOI 10.1097/ACI.0b013e32835c16b6; Lim WJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004360.pub4; Lockey RF, 2014, ASTHMA COMORBIDITIES, P231; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; Oborne J, 2009, AM J RESP CRIT CARE, V180, P598, DOI 10.1164/rccm.200904-0616OC; Patel M, 2014, J ALLER CL IMM-PRACT, V2, P751, DOI 10.1016/j.jaip.2014.06.001; Rodrigo GJ, 2005, THORAX, V60, P740, DOI 10.1136/thx.2005.040444; Rodrigo GJ, 2005, EMERG MED J, V22, P404, DOI 10.1136/emj.2003.012039; Schatz M, 2014, J ALLER CL IMM-PRACT, V2, P645, DOI 10.1016/j.jaip.2014.09.004; Thomas AO, 2014, PEDIAT ALLERG IMM-UK, V25, P122, DOI 10.1111/pai.12147; Waseem M, 2015, J ALLERGY CLIN IMMUN, V3	29	60	66	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					438	447		10.1016/j.jaci.2016.06.054	http://dx.doi.org/10.1016/j.jaci.2016.06.054			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27554811				2022-12-18	WOS:000397002400008
J	Everaere, L; Ait-Yahia, S; Molendi-Coste, O; Vorng, H; Quemener, S; LeVu, P; Fleury, S; Bouchaert, E; Fan, Y; Duez, C; de Nadai, P; Staels, B; Dombrowicz, D; Tsicopoulos, A				Everaere, Laetitia; Ait-Yahia, Saliha; Molendi-Coste, Olivier; Vorng, Han; Quemener, Sandrine; LeVu, Pauline; Fleury, Sebastien; Bouchaert, Emmanuel; Fan, Ying; Duez, Catherine; de Nadai, Patricia; Staels, Bart; Dombrowicz, David; Tsicopoulos, Anne			Innate lymphoid cells contribute to allergic airway disease exacerbation by obesity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Innate lymphoid cells; T(H)2; T(H)17; allergy; asthma; house dust mite; obesity; high-fat diet	TYPE-2 IMMUNE-RESPONSE; ADIPOSE-TISSUE; LUNG INFLAMMATION; ASTHMA; MICE; HYPERRESPONSIVENESS; EOSINOPHILIA; SENSITIZATION; ATOPY; HYPERREACTIVITY	Background: Epidemiologic and clinical observations identify obesity as an important risk factor for asthma exacerbation, but the underlying mechanisms remain poorly understood. Type 2 innate lymphoid cells (ILC2s) and type 3 innate lymphoid cells (ILC3s) have been implicated, respectively, in asthma and adipose tissue homeostasis and in obesity-associated airway hyperresponsiveness (AHR). Objective: We sought to determine the potential involvement of innate lymphoid cells (ILCs) in allergic airway disease exacerbation caused by high-fat diet (HFD)-induced obesity. Methods: Obesity was induced by means of HFD feeding, and allergic airway inflammation was subsequently induced by means of intranasal administration of house dust mite (HDM) extract. AHR, lung and visceral adipose tissue inflammation, humoral response, cytokines, and innate and adaptive lymphoid populations were analyzed in the presence or absence of ILCs. Results: HFD feeding exacerbated allergic airway disease features, including humoral response, airway and tissue eosinophilia, AHR, and T(H)2 and T(H)17 pulmonary profiles. Notably, nonsensitized obese mice already exhibited increased lung ILC counts and tissue eosinophil infiltration compared with values in lean mice in the absence of AHR. The numbers of total and cytokine-expressing lung ILC2s and ILC3s further increased in HDM-challenged obese mice compared with those in HDM-challenged lean mice, and this was accompanied by high IL-33 and IL-1 beta levels and decreased ILC markers in visceral adipose tissue. Furthermore, depletion of ILCs with an anti-CD90 antibody, followed by T-cell reconstitution, led to a profound decrease in allergic airway inflammatory features in obese mice, including T(H)2 and T(H)17 infiltration. Conclusion: These results indicate that HFD-induced obesity might exacerbate allergic airway inflammation through mechanisms involving ILC2s and ILC3s.	[Everaere, Laetitia; Ait-Yahia, Saliha; Vorng, Han; Fan, Ying; Duez, Catherine; de Nadai, Patricia; Tsicopoulos, Anne] INSERM, U1019, Lille, France; [Everaere, Laetitia; Ait-Yahia, Saliha; Vorng, Han; Fan, Ying; Duez, Catherine; de Nadai, Patricia; Tsicopoulos, Anne] Ctr Infect & Immun Lille, CNRS UMR 8204, Pulm Immun Team, Lille, France; [Everaere, Laetitia; Ait-Yahia, Saliha; Molendi-Coste, Olivier; Vorng, Han; Quemener, Sandrine; LeVu, Pauline; Fleury, Sebastien; Bouchaert, Emmanuel; Fan, Ying; Duez, Catherine; de Nadai, Patricia; Staels, Bart; Dombrowicz, David; Tsicopoulos, Anne] Inst Pasteur, Lille, France; [Everaere, Laetitia; Ait-Yahia, Saliha; Molendi-Coste, Olivier; Vorng, Han; Quemener, Sandrine; LeVu, Pauline; Fleury, Sebastien; Bouchaert, Emmanuel; Fan, Ying; Duez, Catherine; de Nadai, Patricia; Staels, Bart; Dombrowicz, David; Tsicopoulos, Anne] Univ Lille, Lille, France; [Everaere, Laetitia; Molendi-Coste, Olivier; Quemener, Sandrine; LeVu, Pauline; Fleury, Sebastien; Bouchaert, Emmanuel; Staels, Bart; Dombrowicz, David] INSERM, U1011, Lille, France; [Everaere, Laetitia; Molendi-Coste, Olivier; Quemener, Sandrine; LeVu, Pauline; Fleury, Sebastien; Bouchaert, Emmanuel; Staels, Bart; Dombrowicz, David] European Genom Inst Diabet, Lille, France; [Dombrowicz, David] Clin Malad Resp, Lille, France; Ctr Hosp Reg & Univ Lille, Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; CHU Lille	Dombrowicz, D (corresponding author), Inst Pasteur, Lille, France.; Dombrowicz, D (corresponding author), Univ Lille, Lille, France.; Dombrowicz, D (corresponding author), INSERM, U1011, Lille, France.; Dombrowicz, D (corresponding author), European Genom Inst Diabet, Lille, France.; Tsicopoulos, A (corresponding author), Inst Pasteur, Ctr Infect & Immun Lille, Pulm Immun U1019, 1 Rue Prof Calmette, F-59019 Lille, France.; Dombrowicz, D (corresponding author), Inst Pasteur, Nucl Receptors Immunoinflammat & Cardiovasc Dis U, 1 Rue Prof Calmette, F-59019 Lille, France.	david.dombrowicz@pasteur-lille.fr; anne.tsicopoulos@pasteur-lille.fr	BOUCHAERT, Emmanuel/AFU-7112-2022; Dombrowicz, David/F-7044-2013; Staels, Bart/N-9497-2016; Quemener, Sandrine/AAC-2788-2021; TSICOPOULOS, Anne/C-2260-2019; Duez, Catherine/B-8425-2018	BOUCHAERT, Emmanuel/0000-0003-2558-9862; Dombrowicz, David/0000-0002-0485-8923; Staels, Bart/0000-0002-3784-1503; Quemener, Sandrine/0000-0001-6369-3906; TSICOPOULOS, Anne/0000-0002-1579-2763; Fleury, Sebastien/0000-0002-0679-3086; Duez, Catherine/0000-0002-2327-1095; de NADAI, Patricia/0000-0001-6084-7447; Molendi-Coste, Olivier/0000-0002-0498-9456; LE VU, Pauline/0000-0002-2788-5019; SALIHA, AIT YAHIA/0000-0003-1108-4222	ITMO IHP Inserm; Region Nord Pas de Calais; Santelys; Institut Pasteur de Lille; European Genomic Institute for Diabetes (EGID) [ANR-10-LABX-46]; European Commission	ITMO IHP Inserm; Region Nord Pas de Calais(Region Hauts-de-France); Santelys; Institut Pasteur de Lille; European Genomic Institute for Diabetes (EGID); European Commission(European CommissionEuropean Commission Joint Research Centre)	Supported by grants from ITMO IHP Inserm, Region Nord Pas de Calais, Santelys, Institut Pasteur de Lille, the European Genomic Institute for Diabetes (EGID; ANR-10-LABX-46), and the European Commission.	Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Bossard C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044787; Buonocore S, 2010, NATURE, V464, P1371, DOI 10.1038/nature08949; Calixto MC, 2010, BRIT J PHARMACOL, V159, P617, DOI 10.1111/j.1476-5381.2009.00560.x; Coccia M, 2012, J EXP MED, V209, P1595, DOI 10.1084/jem.20111453; de Vries A, 2009, CLIN EXP ALLERGY, V39, P731, DOI 10.1111/j.1365-2222.2008.03179.x; Desai D, 2013, AM J RESP CRIT CARE, V188, P657, DOI 10.1164/rccm.201208-1470OC; Dietze J, 2012, ALLERGY, V67, P1519, DOI 10.1111/all.12031; Dixon AE, 2011, J ALLERGY CLIN IMMUN, V128, P508, DOI 10.1016/j.jaci.2011.06.009; Drake LY, 2014, ALLERGY, V69, P1300, DOI 10.1111/all.12446; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Forno E, 2014, J ALLERGY CLIN IMMUN, V133, P1308, DOI 10.1016/j.jaci.2013.09.041; Ge XN, 2013, EXP LUNG RES, V39, P365, DOI 10.3109/01902148.2013.829537; Gold MJ, 2014, J ALLERGY CLIN IMMUN, V133, P1142, DOI 10.1016/j.jaci.2014.02.033; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hams E, 2013, J IMMUNOL, V191, P5349, DOI 10.4049/jimmunol.1301176; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; Hepworth MR, 2013, NATURE, V498, P113, DOI 10.1038/nature12240; Jartti T, 2009, ALLERGY, V64, P770, DOI 10.1111/j.1398-9995.2008.01872.x; Kim HY, 2014, NAT MED, V20, P54, DOI 10.1038/nm.3423; Kim SH, 2014, ALLERGY ASTHMA IMMUN, V6, P189, DOI 10.4168/aair.2014.6.3.189; Lloyd CM, 2013, NAT MED, V19, P976, DOI 10.1038/nm.3296; Lu FL, 2006, AM J PHYSIOL-LUNG C, V290, pL856, DOI 10.1152/ajplung.00386.2005; Ma J, 2010, ALLERGY, V65, P1455, DOI 10.1111/j.1398-9995.2010.02402.x; Makki Kassem, 2013, ISRN Inflamm, V2013, P139239, DOI 10.1155/2013/139239; Makki K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092684; Mionnet C, 2010, NAT MED, V16, P1305, DOI 10.1038/nm.2253; Mirchandani AS, 2014, J IMMUNOL, V192, P2442, DOI 10.4049/jimmunol.1300974; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Molofsky AB, 2013, J EXP MED, V210, P535, DOI 10.1084/jem.20121964; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Nussbaum JC, 2013, NATURE, V502, P245, DOI 10.1038/nature12526; Oliphant CJ, 2014, IMMUNITY, V41, P283, DOI 10.1016/j.immuni.2014.06.016; Peters MC, 2013, AM J RESP CRIT CARE, V188, P633, DOI 10.1164/rccm.201307-1360ED; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Quinto KB, 2011, J ALLERGY CLIN IMMUN, V128, P964, DOI 10.1016/j.jaci.2011.06.031; Rasmussen F, 2014, CURR OPIN ALLERGY CL, V14, P35, DOI 10.1097/ACI.0000000000000024; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Scott HA, 2013, CLIN EXP ALLERGY, V43, P36, DOI 10.1111/cea.12004; Scott HA, 2011, EUR RESPIR J, V38, P594, DOI 10.1183/09031936.00139810; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Shore SA, 2006, J ALLERGY CLIN IMMUN, V118, P389, DOI 10.1016/j.jaci.2006.04.021; Shore SA, 2010, J APPL PHYSIOL, V108, P735, DOI 10.1152/japplphysiol.00749.2009; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Staumont-Salle D, 2014, J EXP MED, V211, P1185, DOI 10.1084/jem.20121350; Sutherland TJT, 2008, AM J RESP CRIT CARE, V178, P469, DOI 10.1164/rccm.200802-301OC; Sutherland TJT, 2009, ANN ALLERG ASTHMA IM, V103, P101, DOI 10.1016/S1081-1206(10)60161-5; Takeda K, 2001, AM J PHYSIOL-LUNG C, V281, pL394, DOI 10.1152/ajplung.2001.281.2.L394; Telenga ED, 2012, ALLERGY, V67, P1060, DOI 10.1111/j.1398-9995.2012.02855.x; von Burg N, 2014, P NATL ACAD SCI USA, V111, P12835, DOI 10.1073/pnas.1406908111; Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691; Winer S, 2009, EUR J IMMUNOL, V39, P2629, DOI 10.1002/eji.200838893; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Wood IS, 2009, BIOCHEM BIOPH RES CO, V384, P105, DOI 10.1016/j.bbrc.2009.04.081; Yahia SA, 2014, AM J RESP CRIT CARE, V189, P899, DOI 10.1164/rccm.201310-1827OC; Zeyda M, 2013, INT J OBESITY, V37, P658, DOI 10.1038/ijo.2012.118	60	60	65	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1309	+		10.1016/j.jaci.2016.03.019	http://dx.doi.org/10.1016/j.jaci.2016.03.019			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27177781				2022-12-18	WOS:000389542700009
J	Malinovschi, A; Janson, C; Borres, M; Alving, K				Malinovschi, Andrei; Janson, Christer; Borres, Magnus; Alving, Kjell			Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Exhaled nitric oxide; blood eosinophil count; asthma control; lung function; bronchial responsiveness	LUNG-FUNCTION TESTS; REFERENCE VALUES; REGRESSION EQUATIONS; UNCONTROLLED ASTHMA; PERSISTENT ASTHMA; IGE SENSITIZATION; SMOKING VARIABLES; STEROID TREATMENT; CHILDHOOD ASTHMA; MEPOLIZUMAB	Background: We have previously described that fraction of exhaled nitric oxide (FENO) levels and blood eosinophil counts offer additive information in relation to asthma and asthma exacerbations when analyzing data from a large population study. Objective: We sought to investigate increased FENO levels and blood eosinophil counts in relation to lung function, bronchial hyperresponsiveness (BHR), and asthma control in a cohort of young asthmatic patients. Methods: Measurements of FENO levels and blood eosinophil counts were available in 406 subjects (208 women) aged 10 to 35 years. Asthma control was assessed through the Asthma Control Test. Moderate-to-severe BHR was defined as a cumulative dose of methacholine of less than 0.3 mg causing an FEV1 decrease of 20%. Results: Subjects with simultaneously increased FENO levels (>= 20-25 ppb) and blood eosinophil counts (>= 0.3 x 10(9)/L) had a higher prevalence of uncontrolled asthma (Asthma Control Test score, < 20) than subjects with singly increased blood eosinophil counts (40.5% vs 21.1%, P = .01). This difference remained significant (P = .006), and a significant difference was also found between subjects with both increased FENO levels and blood eosinophil counts and subjects with normal FENO levels and blood eosinophil counts (P = .02) after adjusting for confounders. Having increased FENO levels and blood eosinophil counts related to a higher prevalence of moderate-to-severe BHR than having normal FENO levels and blood eosinophil counts or singly increased FENO levels or blood eosinophil counts (85.7% vs 35.8% or 63.3% or 60%, P < .05 all comparisons). Conclusion: We have shown that simultaneously increased local (FENO) and systemic (blood eosinophil) markers of type 2 inflammation related to a higher likelihood of BHR and uncontrolled asthma in a large cohort of young asthmatic patients.	[Malinovschi, Andrei] Uppsala Univ, Dept Med Sci, Clin Physiol, S-75105 Uppsala, Sweden; [Janson, Christer] Uppsala Univ, Dept Med Sci, Respiratory Med & Allergol, S-75105 Uppsala, Sweden; [Borres, Magnus; Alving, Kjell] Uppsala Univ, Dept Womens & Childrens Hlth, S-75105 Uppsala, Sweden	Uppsala University; Uppsala University; Uppsala University	Malinovschi, A (corresponding author), Uppsala Univ, Dept Med Sci, Clin Physiol, S-75105 Uppsala, Sweden.; Malinovschi, A (corresponding author), Uppsala Univ, Akad Sjukhuset, Dept Med Sci, Clin Physiol, Ing 35,1 Tr, S-75185 Uppsala, Sweden.	Andrei.Malinovschi@medsci.uu.se			Uppsala University Hospital; Swedish Heart and Lung Foundation; Bror Hjerpstedt's Foundation; Asthma and Allergy Foundation	Uppsala University Hospital; Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation); Bror Hjerpstedt's Foundation; Asthma and Allergy Foundation	The MIDAS study was performed within an industry-academy collaboration framework initiated by the Swedish Governmental Agency for Innovation Systems (VINNOVA, SAMBIO program), where Aerocrine AB (producer of exhaled NO devices) and Thermo Fisher Scientific, Immunodiagnostics (producer of allergy tests), were partners and cofinanced the program. A.M. had support from Uppsala University Hospital, the Swedish Heart and Lung Foundation, Bror Hjerpstedt's Foundation, and the Asthma and Allergy Foundation.	Alving K, 2010, EUR RESPIR MONOGR, P1, DOI 10.1183/1025448x.00028509; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P912; Bel EH, 2011, THORAX, V66, P910, DOI 10.1136/thx.2010.153643; Bjermer L, 2014, RESP MED, V108, P830, DOI 10.1016/j.rmed.2014.02.005; Burney P, 1996, EUR RESPIR J, V9, P687; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Cowan DC, 2015, J ALLERGY CLIN IMMUN, V135, P877, DOI 10.1016/j.jaci.2014.10.026; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Gotlib J, 2011, AM J HEMATOL, V86, P678, DOI 10.1002/ajh.22062; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; HEDENSTROM H, 1986, UPSALA J MED SCI, V91, P299, DOI 10.3109/03009738609178670; HEDENSTROM H, 1985, B EUR PHYSIOPATH RES, V21, P551; Heijkenskjold-Rentzhog C, 2014, ALLERGY, V69, P1102, DOI 10.1111/all.12430; Kato M, 2010, INT ARCH ALLERGY IMM, V152, P62, DOI 10.1159/000312127; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Koh YI, 2002, RESP MED, V96, P120, DOI 10.1053/rmed.2001.1238; Malinovschi A, 2014, NITRIC OXIDE-BIOL CH, V40, P110, DOI 10.1016/j.niox.2014.06.009; Malinovschi A, 2013, J ALLERGY CLIN IMMUN, V132, P821, DOI 10.1016/j.jaci.2013.06.007; MARTIN TR, 1987, J APPL PHYSIOL, V63, P2042, DOI 10.1152/jappl.1987.63.5.2042; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Patelis A, 2014, ALLERGY, V69, P380, DOI 10.1111/all.12345; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Rabinovitch N, 2010, J ALLERGY CLIN IMMUN, V126, pe1; Rabinovitch N, 2010, J ALLERGY CLIN IMMUN, V126, P545, DOI 10.1016/j.jaci.2010.07.008; Roos AB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090018; Schleich FN, 2014, EUR RESPIR J, V44, P1098, DOI [10.1183/09031936.00201813, 10.1183/09031936.00118014]; Schulze J, 2009, RESP MED, V103, P1898, DOI 10.1016/j.rmed.2009.06.007; SIMMONS A, 1974, J CLIN PATHOL, V27, P55, DOI 10.1136/jcp.27.1.55; SOLYMAR L, 1980, EUR J RESPIR DIS, V61, P275; Sverrild A, 2010, J ALLERGY CLIN IMMUN, V126, P952, DOI 10.1016/j.jaci.2010.08.028; Syk J, 2009, CLIN RESPIR J, V3, P143, DOI 10.1111/j.1752-699X.2008.00124.x; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; Tran TN, 2014, ANN ALLERG ASTHMA IM, V113, P19, DOI 10.1016/j.anai.2014.04.011; Vidal C, 2005, J INVEST ALLERG CLIN, V15, P124; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wos M, 2008, AM J RESP CRIT CARE, V177, P1082, DOI 10.1164/rccm.200607-973OC; Zeiger RS, 2014, J ALLER CL IMM-PRACT, V2, P741, DOI 10.1016/j.jaip.2014.06.005; Zeiger RS, 2011, J ALLERGY CLIN IMMUN, V128, P412, DOI 10.1016/j.jaci.2011.06.008; Zeiger RS, 2011, J ASTHMA, V48, P8, DOI 10.3109/02770903.2010.539295	42	60	62	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1301	+		10.1016/j.jaci.2016.01.044	http://dx.doi.org/10.1016/j.jaci.2016.01.044			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27113848	Bronze			2022-12-18	WOS:000389542700008
J	Berry, A; Busse, WW				Berry, Alalia; Busse, William W.			Biomarkers in asthmatic patients: Has their time come to direct treatment?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; biomarkers; eosinophil; IgE; periostin; nitric oxide	EXHALED NITRIC-OXIDE; EOSINOPHILIC AIRWAY INFLAMMATION; E ANTIBODY OMALIZUMAB; INCREASED EXPRESSION; INDUCED SPUTUM; IGE ANTIBODY; DOUBLE-BLIND; PERIOSTIN; CHILDREN; MEPOLIZUMAB	Asthma is a heterogeneous disease with multiple phenotypes that have variable risk factors and responses to therapeutics. Mild-to-moderate asthma often responds to traditional medications, whereas severe disease can be refractory to inhaled corticosteroids, long-acting beta-agonists, and leukotriene receptor antagonists. There is robust research into the variable phenotypes of asthma. Biomarkers help define the specific pathophysiology of different asthma phenotypes and identify potential therapeutic targets. The following review will discuss the current use of biomarkers for the diagnosis of asthma, triaging the severity of a patient's disease, and the potential efficacy of treatments. This information can be used to define certain patient populations that are more likely to respond to inhaled corticosteroids or biologics. As knowledge of patient phenotypes and endotypes and biological agents to target specific classes of asthma emerge, the ability to provide personalized care to asthmatic patients will follow.	[Berry, Alalia; Busse, William W.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Sect Allergy Pulm & Crit Care Med, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Busse, WW (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med Allergy Pulm & Crit Care Med, K4-910 CSC,MC9988,600 Highland Ave, Madison, WI 53792 USA.	wwb@medicine.wisc.edu			AstraZeneca	AstraZeneca(AstraZeneca)	W. W. Busse reports personal fees from AstraZeneca during the conduct of the study and personal fees from Novartis, GlaxoSmithKline, Genentech, Roche, Pfizer, Merck, Boehringer Ingelheim, Sanofi, Gilead, Teva, Takeda, Aerocrine, Boston Scientific, Circassia, and ICON outside the submitted work. A. Berry declares no relevant conflicts of interest.	Agrawal S, 2014, EXPERT OPIN BIOL TH, V14, P165, DOI 10.1517/14712598.2014.859673; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Bjermer L, 2014, RESP MED, V108, P830, DOI 10.1016/j.rmed.2014.02.005; Bousquet J, 2004, CHEST, V125, P1378, DOI 10.1378/chest.125.4.1378; Brightling CE, 2003, THORAX, V58, P528, DOI 10.1136/thorax.58.6.528; Brumme Z, 2009, CLIN INFECT DIS, V49, P956, DOI 10.1086/605503; Brusselle GG, 2013, NAT MED, V19, P977, DOI 10.1038/nm.3300; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; BURROWS B, 1995, AM J RESP CRIT CARE, V152, P1497, DOI 10.1164/ajrccm.152.5.7582283; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Chang TS, 2014, J ALLERGY CLIN IMMUN, V133, P363, DOI 10.1016/j.jaci.2013.09.002; Contie S, 2011, INT J CANCER, V128, P352, DOI 10.1002/ijc.25591; Conway SJ, 2014, CELL MOL LIFE SCI, V71, P1279, DOI 10.1007/s00018-013-1494-y; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Darveaux J, 2015, J ALLER CL IMM-PRACT, V3, P152, DOI 10.1016/j.jaip.2014.09.014; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Dressel H, 2008, RESP MED, V102, P962, DOI 10.1016/j.rmed.2008.02.012; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Frank R, 2003, NAT REV DRUG DISCOV, V2, P566, DOI 10.1038/nrd1130; Gauthier M, 2015, AM J RESP CRIT CARE, V192, P660, DOI 10.1164/rccm.201504-0763PP; Gerald JK, 2015, J ALLER CL IMM-PRACT, V3, P540, DOI 10.1016/j.jaip.2015.01.023; GLEICH GJ, 1993, ANNU REV MED, V44, P85, DOI 10.1146/annurev.me.44.020193.000505; Gratziou C, 1999, EUR RESPIR J, V14, P897, DOI 10.1034/j.1399-3003.1999.14d28.x; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; GULBENKIAN AR, 1992, AM REV RESPIR DIS, V146, P263, DOI 10.1164/ajrccm/146.1.263; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Humbert M, 2014, J ALLER CL IMM-PRACT, V2, P525, DOI 10.1016/j.jaip.2014.03.010; Jacobsen EA, 2007, J ALLERGY CLIN IMMUN, V119, P1313, DOI 10.1016/j.jaci.2007.03.043; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Komakula S, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-32; Kostikas K, 2011, CURR MED CHEM, V18, P1423, DOI 10.2174/092986711795328436; Lapraz Jean-Claude, 2013, Glob Adv Health Med, V2, P32, DOI 10.7453/gahmj.2013.013; Laviolette M, 2013, J ALLERGY CLIN IMMUN, V132, P1086, DOI 10.1016/j.jaci.2013.05.020; Lim KG, 2008, CHEST, V133, P1232, DOI 10.1378/chest.07-1712; Lyons TJ, 2012, TRANSL RES, V159, P303, DOI 10.1016/j.trsl.2012.01.009; Majid H, 2010, CURR OPIN PULM MED, V16, P42, DOI 10.1097/MCP.0b013e328332ca46; Malinovschi A, 2013, J ALLERGY CLIN IMMUN, V132, P821, DOI 10.1016/j.jaci.2013.06.007; Malmberg LP, 2006, PEDIATR PULM, V41, P635, DOI 10.1002/ppul.20417; Marcus P, 2006, CHEST, V129, P466, DOI 10.1378/chest.129.2.466; Mikheev AM, 2015, NEURO-ONCOLOGY, V17, P372, DOI 10.1093/neuonc/nou161; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Olin AC, 2007, CHEST, V131, P1852, DOI 10.1378/chest.06-2928; Ortega Hector, 2014, Ann Am Thorac Soc, V11, P1011, DOI 10.1513/AnnalsATS.201312-454OC; Pavord ID, 2013, J ALLERGY CLIN IMMUN, V132, P828, DOI 10.1016/j.jaci.2013.07.045; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pijnenburg MW, 2005, THORAX, V60, P215, DOI 10.1136/thx.2004.023374; Pijnenburg MWH, 2005, CLIN EXP ALLERGY, V35, P920, DOI 10.1111/j.1365-2222.2005.02279.x; Pizzichini E, 1997, J ALLERGY CLIN IMMUN, V99, P539, DOI 10.1016/S0091-6749(97)70082-4; Schulman ES, 2001, AM J RESP CRIT CARE, V164, pS6, DOI 10.1164/ajrccm.164.supplement_1.2103025; Shikotra A, 2012, J ALLERGY CLIN IMMUN, V129, P104, DOI 10.1016/j.jaci.2011.08.031; Silkoff PE, 1998, J ASTHMA, V35, P473, DOI 10.3109/02770909809071000; Simpson A, 2005, J ALLERGY CLIN IMMUN, V116, P744, DOI 10.1016/j.jaci.2005.06.032; Strimbu K, 2010, CURR OPIN HIV AIDS, V5, P463, DOI 10.1097/COH.0b013e32833ed177; Szefler SJ, 2012, J ALLERGY CLIN IMMUN, V129, pS9, DOI 10.1016/j.jaci.2011.12.979; Taylor DR, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-82; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107, DOI 10.1164/ajrccm.164.11.2006165; Wadsworth SJ, 2013, CURR ALLERGY ASTHM R, V13, P118, DOI 10.1007/s11882-012-0325-9; Wickman M, 2003, PEDIATR ALLERGY IMMU, V14, P441, DOI 10.1046/j.0905-6157.2003.00079.x; Williams PB, 2001, ANN ALLERG ASTHMA IM, V86, P196, DOI 10.1016/S1081-1206(10)62691-9; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC	72	60	63	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1317	1324		10.1016/j.jaci.2016.03.009	http://dx.doi.org/10.1016/j.jaci.2016.03.009			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	27155028	Bronze			2022-12-18	WOS:000376180200003
J	Sato, S; Utsunomiya, T; Imai, T; Yanagida, N; Asaumi, T; Ogura, K; Koike, Y; Hayashi, N; Okada, Y; Shukuya, A; Ebisawa, M				Sato, Sakura; Utsunomiya, Tomohiro; Imai, Takanori; Yanagida, Noriyuki; Asaumi, Tomoyuki; Ogura, Kiyotake; Koike, Yumi; Hayashi, Noriko; Okada, Yu; Shukuya, Akinori; Ebisawa, Motohiro			Wheat oral immunotherapy for wheat-induced anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							TOLERANCE INDUCTION; CHILDREN		[Sato, Sakura; Utsunomiya, Tomohiro; Imai, Takanori; Ogura, Kiyotake; Koike, Yumi; Hayashi, Noriko; Shukuya, Akinori; Ebisawa, Motohiro] Sagamihara Natl Hosp, Dept Allergy, Clin Res Ctr Allergol & Rheumatol, Sagamihara, Kanagawa, Japan; [Utsunomiya, Tomohiro] Takasaki Natl Hosp, Dept Pediat, Gunma, Japan; [Imai, Takanori] Showa Univ, Dept Pediat, Tokyo, Japan; [Yanagida, Noriyuki; Asaumi, Tomoyuki; Okada, Yu] Sagamihara Natl Hosp, Dept Pediat, Sagamihara, Kanagawa, Japan	Showa University	Sato, S (corresponding author), Sagamihara Natl Hosp, Dept Allergy, Clin Res Ctr Allergol & Rheumatol, Sagamihara, Kanagawa, Japan.	m-ebisawa@sagamihara-hosp.gr.jp	Yanagida, Noriyuki/ABF-3471-2021	Yanagida, Noriyuki/0000-0001-9643-744X; Ebisawa, Motohiro/0000-0003-4117-558X				Ebisawa M, 2001, ADV FOOD NUTR RES, V62, P140; Itoh Naoka, 2010, Allergology International, V59, P43, DOI 10.2332/allergolint.09-OA-0107; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; del Rio PR, 2014, J INVEST ALLERG CLIN, V24, P240; Sato S, 2014, INT ARCH ALLERGY IMM, V164, P1, DOI 10.1159/000361025; Takahashi M, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-3; Vetander M, 2011, PEDIAT ALLERG IMM-UK, V22, P369, DOI 10.1111/j.1399-3038.2010.01115.x	9	60	63	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					1131	+		10.1016/j.jaci.2015.07.019	http://dx.doi.org/10.1016/j.jaci.2015.07.019			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	26319801	Bronze			2022-12-18	WOS:000362976300046
J	Adamko, DJ; Nair, P; Mayers, I; Tsuyuki, RT; Regush, S; Rowe, BH				Adamko, Darryl J.; Nair, Parameswaran; Mayers, Irvin; Tsuyuki, Ross T.; Regush, Shana; Rowe, Brian H.			Metabolomic profiling of asthma and chronic obstructive pulmonary disease: A pilot study differentiating diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Metabolomics; asthma; chronic obstructive pulmonary disease; biomarkers; urine; nuclear magnetic resonance spectroscopy	N-METHYLHISTAMINE; NITRIC-OXIDE; HISTAMINE-RELEASE; URINARY-EXCRETION; OXIDATIVE STRESS; AMINO-ACIDS; EXACERBATIONS; FLUIDS; INFLAMMATION; NICOTINAMIDE	Background: Differentiating asthma from other causes of chronic airflow limitation, such as chronic obstructive pulmonary disease (COPD), can be difficult in a typical outpatient setting. The inflammation of asthma typically is different than that of COPD, and the degree of inflammation and cellular damage varies with asthma severity. Metabolomics is the study of molecules created by cellular metabolic pathways. Objectives: We hypothesized that the metabolic activity of adults with asthma would differ from that of adults with COPD. Furthermore, we hypothesized that nuclear magnetic resonance spectroscopy (NMR) would measure such differences in urine samples. Methods: Clinical and urine-based NMR data were collected on adults meeting the criteria of asthma and COPD before and after an exacerbation (n = 133 and 38, respectively) and from patients with stable asthma or COPD (n = 54 and 23, respectively). Partial least-squares discriminant analysis was performed on the NMR data to create models of separation (86 metabolites were measured per urine sample). Some subjects' metabolomic data were withheld from modeling to be run blindly to determine diagnostic accuracy. Results: Partial least-squares discriminant analysis of the urine NMR data found unique differences in select metabolites between patients with asthma and those with COPD seen in the emergency department and even in follow-up after exacerbation. By using these select metabolomic profiles, the model could correctly diagnose blinded asthma and COPD with greater than 90% accuracy. Conclusion: This is the first report showing that metabolomic analysis of human urine samples could become a useful clinical tool to differentiate asthma from COPD.	[Adamko, Darryl J.; Regush, Shana] Univ Alberta, Dept Pediat, Sch Publ Hlth, Edmonton, AB, Canada; [Adamko, Darryl J.; Mayers, Irvin; Tsuyuki, Ross T.] Univ Alberta, Dept Med, Sch Publ Hlth, Edmonton, AB, Canada; [Rowe, Brian H.] Univ Alberta, Dept Emergency Med, Sch Publ Hlth, Edmonton, AB, Canada; [Adamko, Darryl J.] Univ Saskatchewan, Dept Pediat, Saskatoon, SK S7N OW8, Canada; [Nair, Parameswaran] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Nair, Parameswaran] St Josephs Healthcare, Hamilton, ON, Canada	University of Alberta; University of Alberta; University of Alberta; University of Saskatchewan; McMaster University	Adamko, DJ (corresponding author), Univ Saskatchewan, Royal Univ Hosp 2742, Coll Med, Dept Pediat, Saskatoon, SK S7N OW8, Canada.	darryl.adamko@usask.ca	Tsuyuki, Ross T/E-2462-2016	Tsuyuki, Ross T/0000-0002-3724-598X	AllerGen; Canadian Institutes of Health Research (CIHR); Genome Prairie; Genome Canada; AHFMR; Natural Science and Engineering Research Council of Canada (NSERC); University of Alberta Hospital Foundation; Alberta Science and Research Authority (ASRA); Tier I Canada Research Chair in Evidence-based Emergency Medicine from the CIHR through the Government of Canada (Ottawa, Ontario, Canada); Canada Research Chair in Airway Inflammometry through the Government of Canada (Ottawa, Ontario, Canada)	AllerGen; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Genome Prairie; Genome Canada(Genome Canada); AHFMR(Alberta Heritage Foundation for Medical Research); Natural Science and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); University of Alberta Hospital Foundation(University of Alberta); Alberta Science and Research Authority (ASRA); Tier I Canada Research Chair in Evidence-based Emergency Medicine from the CIHR through the Government of Canada (Ottawa, Ontario, Canada); Canada Research Chair in Airway Inflammometry through the Government of Canada (Ottawa, Ontario, Canada)	Supported by AllerGen, the Canadian Institutes of Health Research (CIHR), Genome Prairie, Genome Canada, an establishment grant from AHFMR, the Natural Science and Engineering Research Council of Canada (NSERC), the University of Alberta Hospital Foundation, and the Alberta Science and Research Authority (ASRA). B.H.R.'s research is supported by a Tier I Canada Research Chair in Evidence-based Emergency Medicine from the CIHR through the Government of Canada (Ottawa, Ontario, Canada). P.N. is supported by a Canada Research Chair in Airway Inflammometry through the Government of Canada (Ottawa, Ontario, Canada).	Ahmad T, 2010, AM J RESP CELL MOL, V42, P3, DOI 10.1165/rcmb.2009-0137RC; Azmi J, 2005, BIOMARKERS, V10, P401, DOI 10.1080/13547500500309259; Beckwith-Hall BM, 1998, CHEM RES TOXICOL, V11, P260, DOI 10.1021/tx9700679; BEKIER E, 1974, INT ARCH ALLER A IMM, V47, P737, DOI 10.1159/000231265; BERGLUND T, 1994, FEBS LETT, V351, P145, DOI 10.1016/0014-5793(94)00850-7; Boger RH, 2004, J NUTR, V134, p2842S, DOI 10.1093/jn/134.10.2842S; Brightling Christopher E, 2005, Treat Respir Med, V4, P309, DOI 10.2165/00151829-200504050-00002; Cowan DC, 2015, J ALLERGY CLIN IMMUN, V135, P877, DOI 10.1016/j.jaci.2014.10.026; Dillon PF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015130; Esther CR, 2011, INHAL TOXICOL, V23, P324, DOI 10.3109/08958378.2011.572096; FIELD H, 1946, ARCH BIOCHEM, V9, P45; Forsythe Ian J, 2009, Curr Protoc Bioinformatics, VChapter 14, DOI 10.1002/0471250953.bi1408s25; Gallos G, 2012, AM J PHYSIOL-LUNG C, V302, pL248, DOI 10.1152/ajplung.00131.2011; Garrel D, 2003, CRIT CARE MED, V31, P2444, DOI 10.1097/01.CCM.0000084848.63691.1E; Gebicki J, 2003, POL J PHARMACOL, V55, P109; Gowda GAN, 2008, EXPERT REV MOL DIAGN, V8, P617, DOI 10.1586/14737159.8.5.617; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Hall KL, 2012, NUTRIENTS, V4, P1554, DOI 10.3390/nu4111554; Han YY, 2013, LANCET RESP MED, V1, P813, DOI 10.1016/S2213-2600(13)70126-7; Hofford JM, 1997, AM J RESP CRIT CARE, V155, P432, DOI 10.1164/ajrccm.155.2.9032174; Holguin Fernando, 2013, J Allergy (Cairo), V2013, P714595, DOI 10.1155/2013/714595; Holguin F, 2013, AM J RESP CRIT CARE, V187, P153, DOI 10.1164/rccm.201207-1270OC; Hunninghake GM, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-17; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Jung J, 2013, CLIN EXP ALLERGY, V43, P425, DOI 10.1111/cea.12089; Koller DY, 1999, CLIN EXP ALLERGY, V29, P786; Koskela HO, 2013, CLIN RESPIR J, V7, P382, DOI 10.1111/crj.12020; Lenz EM, 2004, J PHARMACEUT BIOMED, V36, P841, DOI 10.1016/j.jpba.2004.08.002; Lever M, 2010, CLIN BIOCHEM, V43, P732, DOI 10.1016/j.clinbiochem.2010.03.009; Maarsingh H, 2006, EUR J PHARMACOL, V546, P171, DOI 10.1016/j.ejphar.2006.07.041; Marcinkiewicz J, 2014, AMINO ACIDS, V46, P7, DOI 10.1007/s00726-012-1361-4; McClay JL, 2010, J PROTEOME RES, V9, P3083, DOI 10.1021/pr1000048; Menezes AMB, 2014, CHEST, V145, P297, DOI 10.1378/chest.13-0622; Mirrakhimov AE, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-132; Mock NI, 1997, AM J CLIN NUTR, V65, P951, DOI 10.1093/ajcn/65.4.951; Nair P, 2013, CAN RESPIR J, V20, P117, DOI 10.1155/2013/602936; Nishiwaki F, 2000, BIOMED CHROMATOGR, V14, P184, DOI 10.1002/1099-0801(200005)14:3<184::AID-BMC970>3.0.CO;2-2; Nural S, 2013, INFLAMMATION, V36, P66, DOI 10.1007/s10753-012-9520-z; Ohtsu H, 2012, INT ARCH ALLERGY IMM, V158, P2, DOI 10.1159/000337735; Pendharkar S, 2008, CAN RESPIR J, V15, P99, DOI 10.1155/2008/463762; Pouw EM, 1998, AM J RESP CRIT CARE, V158, P797, DOI 10.1164/ajrccm.158.3.9708097; Puente-Maestu L, 2009, EUR RESPIR J, V33, P1045, DOI 10.1183/09031936.00112408; Rossman MJ, 2013, AM J PHYSIOL-REG I, V305, pR1163, DOI 10.1152/ajpregu.00360.2013; Saude EJ, 2007, METABOLOMICS, V3, P439, DOI 10.1007/s11306-007-0091-1; Saude EJ, 2007, METABOLOMICS, V3, P19, DOI 10.1007/s11306-006-0042-2; Saude EJ, 2006, METABOLOMICS, V2, P113, DOI 10.1007/s11306-006-0023-5; Saude EJ, 2011, J ALLERGY CLIN IMMUN, V127, P757, DOI 10.1016/j.jaci.2010.12.1077; Saude EJ, 2009, AM J RESP CRIT CARE, V179, P25, DOI 10.1164/rccm.200711-1716OC; Schock BC, 2003, PEDIATR RES, V53, P375, DOI 10.1203/01.PDR.0000049625.51462.D1; Sethi S, 2012, AM J MED, V125, P1162, DOI 10.1016/j.amjmed.2012.06.024; Severien C, 2000, EUR RESPIR J, V16, P588, DOI 10.1034/j.1399-3003.2000.16d03.x; Sharma S, 2014, J ALLERGY CLIN IMMUN, V133, P1246, DOI 10.1016/j.jaci.2013.10.039; Shockcor John P., 2002, Current Topics in Medicinal Chemistry, V2, P35, DOI 10.2174/1568026023394498; STEPHAN V, 1990, J ALLERGY CLIN IMMUN, V86, P862, DOI 10.1016/S0091-6749(05)80147-2; Takei S, 1997, ANN ALLERG ASTHMA IM, V78, P492, DOI 10.1016/S1081-1206(10)63237-1; Takenaka S, 2014, BIOCHEM BIOPH RES CO, V445, P597, DOI 10.1016/j.bbrc.2014.02.052; Vulimiri SV, 2009, CHEM RES TOXICOL, V22, P492, DOI 10.1021/tx8003246; WAGENMAKERS AJM, 1985, INT J BIOCHEM, V17, P957, DOI 10.1016/0020-711X(85)90240-X; Wang L, 2014, PSYCHOL MED, V44, P1417, DOI 10.1017/S0033291713002031; Wedes SH, 2011, J PEDIATR-US, V159, P248, DOI 10.1016/j.jpeds.2011.01.029; Xu EY, 2009, CURR OPIN DRUG DISC, V12, P40; YUYAMA S, 1991, ADV EXP MED BIOL, V294, P475; Zuo L, 2014, ANN ALLERG ASTHMA IM, V112, P18, DOI 10.1016/j.anai.2013.10.007	63	60	65	1	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					571	+		10.1016/j.jaci.2015.05.022	http://dx.doi.org/10.1016/j.jaci.2015.05.022			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	26152317				2022-12-18	WOS:000360913300006
J	Martino, D; Dang, T; Sexton-Oates, A; Prescott, S; Tang, MLK; Dharmage, S; Gurrin, L; Koplin, J; Ponsonby, AL; Allen, KJ; Saffery, R				Martino, David; Dang, Thanh; Sexton-Oates, Alexandra; Prescott, Susan; Tang, Mimi L. K.; Dharmage, Shyamali; Gurrin, Lyle; Koplin, Jennifer; Ponsonby, Anne-Louise; Allen, Katrina J.; Saffery, Richard		HealthNuts Study Investigators	Blood DNA methylation biomarkers predict clinical reactivity in food-sensitized infants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; epigenetics; DNA methylation profiling; Infinium; methylation profiling; epigenetic epidemiology; allergy epigenetics; biomarkers; shrunken centroids	PEANUT ALLERGY; EXPRESSION; DIAGNOSIS; CRITERIA; DISEASES; LIFE; AGE; EGG	Background: The diagnosis of food allergy (FA) can be challenging because approximately half of food-sensitized patients are asymptomatic. Current diagnostic tests are excellent makers of sensitization but poor predictors of clinical reactivity. Thus oral food challenges (OFCs) are required to determine a patient's risk of reactivity. Objective: We sought to discover genomic biomarkers of clinical FA with utility for predicting food challenge outcomes. Methods: Genome-wide DNA methylation (DNAm) profiling was performed on blood mononuclear cells from volunteers who had undergone objective OFCs, concurrent skin prick tests, and specific IgE tests. Fifty-eight food-sensitized patients (aged 11-15 months) were assessed, half of whom were clinically reactive. Thirteen nonallergic control subjects were also assessed. Reproducibility was assessed in an additional 48 samples by using methylation data from an independent population of patients with clinical FA. Results: Using a supervised learning approach, we discovered a DNAm signature of 96 CpG sites that predict clinical outcomes. Diagnostic scores were derived from these 96 methylation sites, and cutoffs were determined in a sensitivity analysis. Methylation biomarkers outperformed allergen-specific IgE and skin prick tests for predicting OFC outcomes. FA status was correctly predicted in the replication cohort with an accuracy of 79.2%. Conclusion: DNAm biomarkers with clinical utility for predicting food challenge outcomes are readily detectable in blood. The development of this technology in detailed follow-up studies will yield highly innovative diagnostic assays.	[Martino, David; Dang, Thanh; Prescott, Susan; Tang, Mimi L. K.; Dharmage, Shyamali; Gurrin, Lyle; Koplin, Jennifer; Ponsonby, Anne-Louise; Allen, Katrina J.] Murdoch Childrens Res Inst, Ctr Food & Allergy Res, Parkville, Vic, Australia; [Martino, David; Dang, Thanh; Sexton-Oates, Alexandra; Tang, Mimi L. K.; Dharmage, Shyamali; Gurrin, Lyle; Koplin, Jennifer; Ponsonby, Anne-Louise; Allen, Katrina J.; Saffery, Richard] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Prescott, Susan] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia; [Martino, David; Tang, Mimi L. K.; Ponsonby, Anne-Louise; Allen, Katrina J.; Saffery, Richard] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia; [Tang, Mimi L. K.] Royal Childrens Hosp, Dept Allergy & Immunol, Parkville, Vic 3052, Australia; [Dharmage, Shyamali; Gurrin, Lyle; Koplin, Jennifer] Univ Melbourne, Sch Populat & Global Hlth, Melbourne, Vic 3010, Australia; [Allen, Katrina J.] Univ Manchester, Inst Inflammat & Repair, Manchester M13 9PL, Lancs, England	Murdoch Children's Research Institute; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Western Australia; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne; University of Manchester	Allen, KJ (corresponding author), Murdoch Childrens Res Inst, Gastro & Food Allergy, Flemington Rd, Melbourne, Vic, Australia.	Katie.Allen@rch.org.au	Tang, Mimi/ABD-8350-2020; Saffery, Richard/GLS-1976-2022; Martino, DJ/X-1753-2019; Allen, Katrina/I-4361-2018; Ponsonby, Anne-Louise/AAE-4351-2019; Dang, Thanh/AAK-1608-2021	Tang, Mimi/0000-0002-3839-5293; Saffery, Richard/0000-0002-9510-4181; Martino, DJ/0000-0001-6823-4696; Allen, Katrina/0000-0002-1921-4493; Dang, Thanh/0000-0003-2010-5582; Gurrin, Lyle/0000-0001-7052-1969; Koplin, Jennifer/0000-0002-7576-5142; Ponsonby, Anne-Louise/0000-0002-6581-3657	CASS Foundation [SM/11/3647/RMR:DSA]; DHB Foundation [CT21242]; NHMRC [1072752]	CASS Foundation; DHB Foundation; NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	Supported by the CASS Foundation (SM/11/3647/RMR:DSA), the DHB Foundation (CT21242), and the NHMRC (1072752).	Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049; Bair E, 2004, PLOS BIOL, V2, P511, DOI 10.1371/journal.pbio.0020108; Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470; Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; Ho MHK, 2008, J ALLERGY CLIN IMMUN, V121, P731, DOI 10.1016/j.jaci.2007.11.024; Ito K, 2013, ASIA PAC ALLERGY, V3, P59, DOI 10.5415/apallergy.2013.3.1.59; Koplin JJ, 2012, J ALLERGY CLIN IMMUN, V129, P1145, DOI 10.1016/j.jaci.2011.09.044; Martino D, 2014, J REPROD IMMUNOL, V104, P43, DOI 10.1016/j.jri.2014.05.003; Martino D, 2014, EPIGENETICS-US, V9, P998, DOI 10.4161/epi.28945; Martino D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-5-r42; McCarthy JJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005785; Novakovic B, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-529; Oh JE, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2012.130; Osborne NJ, 2010, CLIN EXP ALLERGY, V40, P1516, DOI 10.1111/j.1365-2222.2010.03562.x; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Peters RL, 2014, J ALLERGY CLIN IMMUN, V133, P485, DOI 10.1016/j.jaci.2013.11.032; Peters RL, 2013, J ALLERGY CLIN IMMUN, V132, P874, DOI 10.1016/j.jaci.2013.05.038; Prescott S, 2011, PEDIAT ALLERG IMM-UK, V22, P155, DOI 10.1111/j.1399-3038.2011.01145.x; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Rakyan VK, 2011, NAT REV GENET, V12, P529, DOI 10.1038/nrg3000; Santos AF, 2012, PEDIAT ALLERG IMM-UK, V23, P698, DOI 10.1111/pai.12025; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299	26	60	64	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1319	U345		10.1016/j.jaci.2014.12.1933	http://dx.doi.org/10.1016/j.jaci.2014.12.1933			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25678091	Bronze			2022-12-18	WOS:000353980700026
J	Mahdavinia, M; Carter, RG; Ocampo, CJ; Stevens, W; Kato, A; Tan, BK; Kern, RC; Conley, DB; Chandra, R; Hulse, KE; Suh, LA; Norton, JE; Peters, AT; Grammer, LC; Schwartz, LB; Schleimer, RP				Mahdavinia, Mahboobeh; Carter, Roderick G.; Ocampo, Christopher J.; Stevens, Whitney; Kato, Atsushi; Tan, Bruce K.; Kern, Robert C.; Conley, David B.; Chandra, Rakesh; Hulse, Kathryn E.; Suh, Lydia A.; Norton, James E.; Peters, Anju T.; Grammer, Leslie C., III; Schwartz, Lawrence B.; Schleimer, Robert P.			Basophils are elevated in nasal polyps of patients with chronic rhinosinusitis without aspirin sensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CELL-ADHESION MOLECULE-1; IL-4 MESSENGER-RNA; MAST-CELLS; EOSINOPHILS; EXPRESSION; DISTINCT; INFILTRATION; RECRUITMENT; IMMUNITY; DISEASE		[Mahdavinia, Mahboobeh; Carter, Roderick G.; Ocampo, Christopher J.; Stevens, Whitney; Kato, Atsushi; Hulse, Kathryn E.; Suh, Lydia A.; Norton, James E.; Peters, Anju T.; Grammer, Leslie C., III; Schleimer, Robert P.] Northwestern Univ, Dept Med, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60611 USA; [Tan, Bruce K.; Kern, Robert C.; Conley, David B.; Chandra, Rakesh; Schleimer, Robert P.] Northwestern Univ, Dept Otolaryngol, Chicago, IL 60611 USA; [Schwartz, Lawrence B.] Virginia Commonwealth Univ, Dept Med, Div Rheumatol Allergy & Immunol, Richmond, VA 23298 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Virginia Commonwealth University	Mahdavinia, M (corresponding author), Northwestern Univ, Dept Med, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60611 USA.	rpschleimer@northwestern.edu		Grammer, Leslie/0000-0001-6860-2014; Mahdavinia, mahboobeh/0000-0003-4004-203X; Kato, Atsushi/0000-0001-9144-3138; Hulse, Kathryn/0000-0003-0969-999X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD055884] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068546, R21HL113913, R01HL078860, R37HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072570, P01AI106683, T32AI083216, R01AI104733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K23DC012067] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL078860, R01 HL068546, R37 HL068546, R21 HL113913] Funding Source: Medline; NIAID NIH HHS [P01 AI106683, T32 AI083216, R01 AI104733, R01 AI072570] Funding Source: Medline; NICHD NIH HHS [K12 HD055884] Funding Source: Medline; NIDCD NIH HHS [K23 DC012067] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bochner BS, 2001, IMMUNOL REV, V179, P5, DOI 10.1034/j.1600-065X.2001.790101.x; Gauvreau GM, 2000, AM J RESP CRIT CARE, V161, P1473, DOI 10.1164/ajrccm.161.5.9908090; HASTIE R, 1979, LAB INVEST, V40, P554; Irani AMA, 1998, J ALLERGY CLIN IMMUN, V101, P354, DOI 10.1016/S0091-6749(98)70248-9; JAHNSEN FL, 1995, AM J RESP CELL MOL, V12, P624, DOI 10.1165/ajrcmb.12.6.7539273; Lantz CS, 1998, NATURE, V392, P90, DOI 10.1038/32190; Macfarlane AJ, 2000, J ALLERGY CLIN IMMUN, V105, P99, DOI 10.1016/S0091-6749(00)90184-2; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005; Nouri-Aria KT, 2001, J ALLERGY CLIN IMMUN, V108, P205, DOI 10.1067/mai.2001.117175; Payne SC, 2011, LARYNGOSCOPE, V121, P2262, DOI 10.1002/lary.21969; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Plager DA, 2006, J ALLERGY CLIN IMMUN, V117, P626, DOI 10.1016/j.jaci.2005.10.023; Rudack C, 1998, AM J RHINOL, V12, P383, DOI 10.2500/105065898780708008; Schroeder JT, 2011, IMMUNOL REV, V242, P144, DOI 10.1111/j.1600-065X.2011.01023.x; Seshadri S, 2012, ALLERGY, V67, P920, DOI 10.1111/j.1398-9995.2012.02848.x; SIRAGANIAN RP, 1977, J IMMUNOL, V119, P2078; Suzukawa M, 2008, J IMMUNOL, V181, P5981, DOI 10.4049/jimmunol.181.9.5981; Takabayashi T, 2012, J ALLERGY CLIN IMMUN, V130, P410, DOI 10.1016/j.jaci.2012.02.046; Wilson DR, 2001, CLIN EXP ALLERGY, V31, P1705, DOI 10.1046/j.1365-2222.2001.01231.x; Ying S, 1997, J IMMUNOL, V158, P5050; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008	22	60	61	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1759	1763		10.1016/j.jaci.2013.12.1092	http://dx.doi.org/10.1016/j.jaci.2013.12.1092			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24636088	Green Accepted, Bronze			2022-12-18	WOS:000336672500033
J	Patel, P; Holdich, T; von Weikersthal-Drachenberg, KJF; Huber, B				Patel, Piyush; Holdich, Tom; von Weikersthal-Drachenberg, Karl J. Fischer; Huber, Birgit			Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinoconjunctivitis; specific immunotherapy; ragweed; ultrashort course; environmental exposure chamber	MONOPHOSPHORYL-LIPID-A; SUBLINGUAL IMMUNOTHERAPY; GRASS-POLLEN; FOLLOW-UP; POSTMARKETING SURVEILLANCE; RHINITIS; ASTHMA; SAFETY; CHILDREN; ADJUVANT	Background: Specific immunotherapy acts to modify the underlying cause of allergic rhinoconjunctivitis. Addition of adjuvants, such as monophosphoryl lipid A (MPL), might allow for efficacious and safe treatment with only 4 injections administered preseasonally, which is in contrast to most available schedules requiring long injection courses. Objective: The primary objective was to assess the clinical efficacy of Ragweed MATA MPL (short ragweed pollen allergoid adsorbed to L-Tyrosine + MPL) versus placebo in reducing allergic rhinoconjunctivitis symptoms caused by ragweed pollen in an environmental exposure chamber (EEC) 3 weeks after treatment. Methods: This was a randomized, double-blind, placebo-controlled phase IIb study to evaluate the clinical efficacy and safety of Ragweed MATA MPL compared with placebo by using controlled ragweed pollen exposure in an EEC. Two hundred twenty-eight patients with a history of ragweed allergy and positive skin prick test responses to ragweed were randomized and received 4 weekly injections of active treatment or placebo. Total nasal and nonnasal symptom scores were obtained in the EEC before and after treatment. Results: Mean improvement in total symptom scores in the Ragweed MATA MPL group was statistically significantly greater than in the placebo group (relative mean improvement of active vs placebo, 48%; P < .05; median improvement, 82%). The majority of adverse events (AEs) experienced by subjects were mild injection-site reactions. No severe systemic AEs or serious AEs occurred during the study. Conclusion: This study demonstrated that an ultrashort course of Ragweed MATA MPL is efficacious in reducing allergy symptoms in patients with seasonal allergic rhinitis and that it is well tolerated.	[Patel, Piyush] Allied Res Int, Mississauga, ON, Canada; [Holdich, Tom] Allergy Therapeut, Worthing, W Sussex, England; [von Weikersthal-Drachenberg, Karl J. Fischer; Huber, Birgit] Bencard Allergie, Munich, Germany		Patel, P (corresponding author), Inflamax Res, 3121 Univ Dr, Mississauga, ON L4X 2E2, Canada.	PPatel@inflamaxresearch.com			Allergy Therapeutics (UK) Ltd, West Sussex, United Kingdom	Allergy Therapeutics (UK) Ltd, West Sussex, United Kingdom	Supported by Allergy Therapeutics (UK) Ltd, West Sussex, United Kingdom. The company was responsible for protocol development, study coordination, and data analysis and for supporting the development of this article.	Akdis CA, 2000, ALLERGY, V55, P522, DOI 10.1034/j.1398-9995.2000.00120.x; Akerlund Anders, 2005, J Allergy Clin Immunol, V115, pS460, DOI 10.1016/j.jaci.2004.12.016; [Anonymous], 2000, ALL RHIN CLIN DEV PR; Baldrick P, 2004, J APPL TOXICOL, V24, P261, DOI 10.1002/jat.981; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Blaiss M, 2011, J ALLERGY CLIN IMMUN, V127, P64, DOI 10.1016/j.jaci.2010.11.034; Bousquet J, 2005, B WORLD HEALTH ORGAN, V83, P548; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Calderon MA, 2011, ALLERGY, V66, P1345, DOI 10.1111/j.1398-9995.2011.02669.x; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, pS25, DOI 10.1016/j.jaci.2007.06.019; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Day J. H., 2006, Clinical and Experimental Allergy Reviews, V6, P31, DOI 10.1111/j.1365-2222.2005.00099.x; Devillier P, 2011, ALLERGY, V66, P163, DOI 10.1111/j.1398-9995.2010.02473.x; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Drachenberg K J, 2003, Allergol Immunopathol (Madr), V31, P270; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; DuBuske LH, 2011, ALLERGY ASTHMA PROC, V32, P239, DOI 10.2500/aap.2011.32.3453; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Garn H, 2007, IMMUNOBIOLOGY, V212, P441, DOI 10.1016/j.imbio.2007.03.006; Gupta R, 2004, CLIN EXP ALLERGY, V34, P520, DOI 10.1111/j.1365-2222.2004.1935.x; Hamilton RG, 1992, MANUAL CLIN LABORATO, P702; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Kaiser HB, 2009, J ALLERGY CLIN IMMUN, V123, P731, DOI 10.1016/j.jaci.2009.01.034; Lehnigk U, 2011, ALLERGO J S, V20, pS11; MARSH DG, 1970, IMMUNOLOGY, V18, P705; Matricardi PM, 2011, J ALLERGY CLIN IMMUN, V128, P791, DOI 10.1016/j.jaci.2011.03.049; Meltzer EO, 2009, J ALLERGY CLIN IMMUN, V124, pS43, DOI 10.1016/j.jaci.2009.05.013; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, P72, DOI 10.1016/j.jaci.2010.11.035; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Patel P, 2006, EXPERT REV VACCINES, V5, P617, DOI 10.1586/14760584.5.5.617; Reed SD, 2004, PHARMACOECONOMICS, V22, P345, DOI 10.2165/00019053-200422060-00002; Rosewich M, 2010, PEDIAT ALLERG IMM-UK, V21, pE185, DOI 10.1111/j.1399-3038.2009.00953.x; Salapatek A, 2012, J ALLERGY CLIN IMMUN, V129, pAB207, DOI 10.1016/j.jaci.2011.12.195; Sauve H, 2006, 25 C EUR AC ALL CLIN; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Verlato G, 2003, J ALLERGY CLIN IMMUN, V111, P1232, DOI 10.1067/mai.2003.1484; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009; WHEELER AW, 1982, INT ARCH ALLER A IMM, V69, P113, DOI 10.1159/000233157; Zielen S, 2007, ALLERGOLOGIE, V30, pS1	46	60	63	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					121	+		10.1016/j.jaci.2013.05.032	http://dx.doi.org/10.1016/j.jaci.2013.05.032			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	23870670				2022-12-18	WOS:000329105700017
J	Gomez, E; Campo, P; Rondon, C; Barrionuevo, E; Blanca-Lopez, N; Torres, MJ; Herrera, R; Galindo, L; Mayorga, C; Blanca, M				Gomez, Enrique; Campo, Paloma; Rondon, Carmen; Barrionuevo, Esther; Blanca-Lopez, Natalia; Jose Torres, Maria; Herrera, Rocio; Galindo, Luisa; Mayorga, Cristobalina; Blanca, Miguel			Role of the basophil activation test in the diagnosis of local allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DISEASE; ENTOPY; IGE		[Gomez, Enrique; Mayorga, Cristobalina] Hosp Reg Univ Malaga, Allergy Res Lab, Malaga, Spain; [Campo, Paloma; Rondon, Carmen; Barrionuevo, Esther; Jose Torres, Maria; Herrera, Rocio; Galindo, Luisa; Blanca, Miguel] Hosp Reg Univ Malaga, UGC Allergy, Inst Biomed Malaga IBIMA, Malaga, Spain; [Blanca-Lopez, Natalia] Infanta Leonor Hosp, Allergy Serv, Madrid, Spain	Universidad de Malaga; Hospital Universitario Infanta Leonor	Gomez, E (corresponding author), Hosp Reg Univ Malaga, Allergy Res Lab, Malaga, Spain.	campomozo@yahoo.com	Torres, María José/T-3518-2017; Mayorga, Lina/FBO-7730-2022; Torres, Maria/GVU-3391-2022; Mayorga, Cristobalina/D-7167-2018	Torres, María José/0000-0001-5228-471X; Mayorga, Cristobalina/0000-0001-8852-8077; Gomez Alcaide, Enrique/0000-0003-0542-303X; RONDON SEGOVIA, CARMEN/0000-0003-0976-3402				Dullaers M, 2012, J ALLERGY CLIN IMMUN, V129, P635, DOI 10.1016/j.jaci.2011.10.029; HUGGINS KG, 1975, LANCET, V2, P148; Kleine-Tebbe J, 2006, INT ARCH ALLERGY IMM, V141, P79, DOI 10.1159/000094495; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Molgaard E, 2007, ALLERGY, V62, P1033, DOI 10.1111/j.1398-9995.2007.01355.x; Powe DG, 2010, CLIN EXP ALLERGY, V40, P987, DOI 10.1111/j.1365-2222.2010.03536.x; Powe DG, 2003, CLIN EXP ALLERGY, V33, P1374, DOI 10.1046/j.1365-2222.2003.01737.x; Rondon C, 2012, ALLERGY, V67, P1282, DOI 10.1111/all.12002; Rondon C, 2012, J ALLERGY CLIN IMMUN, V129, P1460, DOI 10.1016/j.jaci.2012.02.032	9	60	63	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					975	976		10.1016/j.jaci.2013.07.016	http://dx.doi.org/10.1016/j.jaci.2013.07.016			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	24001803				2022-12-18	WOS:000325096500027
J	Jin, GH; Hamaguchi, Y; Matsushita, T; Hasegawa, M; Le Huu, D; Ishiura, N; Naka, K; Hirao, A; Takehara, K; Fujimoto, M				Jin, Guihua; Hamaguchi, Yasuhito; Matsushita, Takashi; Hasegawa, Minoru; Le Huu, Doanh; Ishiura, Nobuko; Naka, Kazuhito; Hirao, Atsushi; Takehara, Kazuhiko; Fujimoto, Manabu			B-cell linker protein expression contributes to controlling allergic and autoimmune diseases by mediating IL-10 production in regulatory B cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B10 cell; IL-10; B-cell linker protein; signal transducer and activator of transcription 3	BRUTONS TYROSINE KINASE; B10 CELLS; LUPUS MICE; ACTIVATION; LYMPHOCYTES; DEFICIENT; SUBSET; INFLAMMATION; ARTHRITIS; RESPONSES	Background: Regulatory B cells that exhibit the cell-surface CD1d(hi)CD5(+) phenotype and produce IL-10 are termed B10 cells. Although B10 cells exert potent suppressive functions in patients with various allergic and autoimmunity disorders, the precise signaling mechanisms required for B10 cell functions remain unknown. B-cell linker protein (BLNK) is an essential component of the B-cell antigen receptor signaling pathway and is required for optimal B-cell development. Objective: We sought to elucidate the signaling pathways that are responsible for IL-10 production in B10 cells and in vivo mechanisms of how impaired B10 cell functions influence allergic and autoimmune responses. Method: For in vitro assays, splenic CD1d(hi)CD5(+) B cells from BLNK-deficient (BLNK-/-) mice were analyzed for intracellular signaling pathways and cytokine production. Contact hypersensitivity (CHS) and experimental autoimmune encephalomyelitis were examined by using BLNK-/- mice. Results: Although the CD1d(hi)CD5(+) B-cell population was present in BLNK-/- mice, IL-10 production was impaired both in vitro and in vivo. BLNK-/- mice had exaggerated CHS and experimental autoimmune encephalomyelitis responses, which were normalized by adoptive transfer of splenic CD1d(hi)CD5(+) B cells from wild-type mice. In mice with CHS, BLNK-/- mice exhibited decreased B-cell and regulatory T-cell percentages and increased CD8(+) T-cell percentages in the skin and lymph nodes. In vitro BLNK was required for LPS-induced signal transducer and activator of transcription 3 phosphorylation in CD1d(hi)CD5(+) B cells. Finally, secreted IL-10 leads to autocrine expansion of IL-10-producing B cells. Conclusion: BLNK serves as a critical signaling component for B10 cell function by mediating IL-10 production.	[Jin, Guihua; Hamaguchi, Yasuhito; Matsushita, Takashi; Hasegawa, Minoru; Le Huu, Doanh; Takehara, Kazuhiko; Fujimoto, Manabu] Kanazawa Univ, Fac Med, Inst Med Pharmaceut & Hlth Sci, Dept Dermatol, Kanazawa, Ishikawa 9208641, Japan; [Jin, Guihua] Yanbian Univ, Coll Med, Dept Immunol & Pathogen Biol, Yanji, Jilin, Peoples R China; [Ishiura, Nobuko] Natl Ctr Global Hlth & Med, Div Dermatol, Tokyo, Japan; [Naka, Kazuhito] Kanazawa Univ, Canc Res Inst, Exploratory Project Canc Stem Cells, Kanazawa, Ishikawa 9208641, Japan; [Hirao, Atsushi] Kanazawa Univ, Canc Res Inst, Div Mol Genet, Kanazawa, Ishikawa 9208641, Japan	Kanazawa University; Yanbian University; National Center for Global Health & Medicine - Japan; Kanazawa University; Kanazawa University	Fujimoto, M (corresponding author), Kanazawa Univ, Fac Med, Inst Med Pharmaceut & Hlth Sci, Dept Dermatol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.	fujimoto-m@umin.ac.jp	Matsushita, Takashi/C-4750-2015; Naka, Kazuhito/X-3756-2019	Matsushita, Takashi/0000-0002-1617-086X; Naka, Kazuhito/0000-0001-6646-6004; Le Huu, Doanh/0000-0002-9982-9905; Fujimoto, Manabu/0000-0002-3062-4872; Hasegawa, Minoru/0000-0003-3738-2682	Ministry of Education, Science, and Culture of Japan	Ministry of Education, Science, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	Supported by a Grant-in-Aid from the Ministry of Education, Science, and Culture of Japan.	Amu S, 2010, J ALLERGY CLIN IMMUN, V125, P1114, DOI 10.1016/j.jaci.2010.01.018; Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009; Brummel R, 2005, J IMMUNOL, V174, P2429, DOI 10.4049/jimmunol.174.4.2429; DiLillo DJ, 2010, ANN NY ACAD SCI, V1183, P38, DOI 10.1111/j.1749-6632.2009.05137.x; Ding Q, 2011, J CLIN INVEST, V121, P3645, DOI 10.1172/JCI46274; Evans JG, 2007, J IMMUNOL, V178, P7868, DOI 10.4049/jimmunol.178.12.7868; Fillatreau S, 2002, NAT IMMUNOL, V3, P944, DOI 10.1038/ni833; Fruman DA, 2000, IMMUNITY, V13, P1, DOI 10.1016/S1074-7613(00)00002-9; Fujimoto M, 2010, J DERMATOL SCI, V60, P1, DOI 10.1016/j.jdermsci.2010.08.010; Gray M, 2007, P NATL ACAD SCI USA, V104, P14080, DOI 10.1073/pnas.0700326104; Hayashi K, 2000, P NATL ACAD SCI USA, V97, P2755, DOI 10.1073/pnas.040575697; Horwood NJ, 2006, J IMMUNOL, V176, P3635, DOI 10.4049/jimmunol.176.6.3635; Horwood NJ, 2003, J EXP MED, V197, P1603, DOI 10.1084/jem.20021845; Iwata Y, 2011, BLOOD, V117, P530, DOI 10.1182/blood-2010-07-294249; Jumaa H, 1999, IMMUNITY, V11, P547, DOI 10.1016/S1074-7613(00)80130-2; Koretzky GA, 2006, NAT REV IMMUNOL, V6, P67, DOI 10.1038/nri1750; Kubo T, 2009, J EXP MED, V206, P1971, DOI 10.1084/jem.20082392; Kurosaki T, 2002, NAT REV IMMUNOL, V2, P354, DOI 10.1038/nri801; Kurosaki T, 2009, IMMUNOL REV, V228, P132, DOI 10.1111/j.1600-065X.2008.00748.x; Lampropoulou V, 2008, J IMMUNOL, V180, P4763, DOI 10.4049/jimmunol.180.7.4763; LeBien TW, 2008, BLOOD, V112, P1570, DOI 10.1182/blood-2008-02-078071; Lee KG, 2008, J BIOL CHEM, V283, P11189, DOI 10.1074/jbc.M708516200; Lenert P, 2005, J CLIN IMMUNOL, V25, P29, DOI 10.1007/s10875-005-0355-6; Matsumoto M, 2011, IMMUNITY, V34, P703, DOI 10.1016/j.immuni.2011.03.016; Matsushita T, 2008, J CLIN INVEST, V118, P3420, DOI 10.1172/JCI36030; Mauri C, 2003, J EXP MED, V197, P489, DOI 10.1084/jem.20021293; Mauri C, 2012, ANNU REV IMMUNOL, V30, P221, DOI 10.1146/annurev-immunol-020711-074934; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Mizoguchi A, 2002, IMMUNITY, V16, P219, DOI 10.1016/S1074-7613(02)00274-1; Nakashima H, 2010, J IMMUNOL, V184, P4637, DOI 10.4049/jimmunol.0901719; Nakayama J, 2009, BLOOD, V113, P1483, DOI 10.1182/blood-2008-07-166355; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Poe JC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022464; Saharinen P, 1997, BLOOD, V90, P4341; Scapini P, 2011, P NATL ACAD SCI USA, V108, pE823, DOI 10.1073/pnas.1107913108; Schmidt NW, 2006, J IMMUNOL, V177, P7203, DOI 10.4049/jimmunol.177.10.7203; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Watanabe R, 2010, J IMMUNOL, V184, P4801, DOI 10.4049/jimmunol.0902385; Yanaba K, 2008, IMMUNITY, V28, P639, DOI 10.1016/j.immuni.2008.03.017; Yanaba K, 2011, AM J PATHOL, V178, P735, DOI 10.1016/j.ajpath.2010.10.022; Yanaba K, 2009, J IMMUNOL, V182, P7459, DOI 10.4049/jimmunol.0900270	41	60	66	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1674	+		10.1016/j.jaci.2013.01.044	http://dx.doi.org/10.1016/j.jaci.2013.01.044			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23534976	Bronze			2022-12-18	WOS:000320532800028
J	Wahn, U; Klimek, L; Ploszczuk, A; Adelt, T; Sandner, B; Trebas-Pietras, E; Eberle, P; Bufe, A				Wahn, Ulrich; Klimek, Ludger; Ploszczuk, Anna; Adelt, Thomas; Sandner, Bernhard; Trebas-Pietras, Ewa; Eberle, Peter; Bufe, Albrecht		SLIT Study Grp	High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: A double-blind, placebo-controlled study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sublingual immunotherapy; single-dose; high-dose; pre-/co-seasonal treatment; allergic rhinitis/rhinoconjunctivitis; children; double-blind placebo-controlled trial; efficacy; safety; grass polle	ALLERGEN-SPECIFIC IMMUNOTHERAPY; CLINICAL-TRIALS; RESPIRATORY-DISEASES; EFFICACY; STATEMENT; RHINITIS; TABLET; ASTHMA; RHINOCONJUNCTIVITIS; METAANALYSES	Background: Sublingual allergen-specific immunotherapy is a viable alternative to subcutaneous immunotherapy particularly attractive for use in children. Objective: This study investigated efficacy and safety of high-dose sublingual immunotherapy (SLIT) in children allergic to grass pollen in a randomized, double-blind, placebo-controlled trial. Methods: After a baseline seasonal observation, 207 children aged 4 to 12 years with grass pollen-allergic rhinitis/rhinoconjunctivitis with/without bronchial asthma (Global Initiative for Asthma I/II) received either high-dose grass pollen SLIT or placebo daily for 1 pre-/co-seasonal period. The primary end point was the change of the area under the curve of the symptom-medication score (SMS) from the baseline season to the first season after start of treatment. Secondary outcomes were well days, responders, immunologic changes, and safety. Results: Mean changes in the area under the curve of the SMS from the baseline to the first grass pollen season after the start of treatment were -212.5 for the active group and -97.8 for the placebo group (P = .0040). Rhinoconjunctivitis SMS (P = .0020) and separated symptom and medication scores were also statistically different between the 2 groups (P = .0121 and P = .0226, respectively). The number of well days and the percentage of responders were greater in the active group. Changes in allergen-specific IgE and IgG levels indicated a significant immunologic effect. The treatment was well tolerated, and no serious treatment-related events were reported. Conclusions: This study confirmed that this SLIT preparation significantly reduced symptoms and medication use in children with grass pollen-allergic rhinoconjunctivitis. The preparation showed significant effects on allergen-specific antibodies, was well tolerated, and appeared to be a valid therapeutic option in children allergic to grass pollen. This trial was registered at www.clinicaltrials.gov as NCT00841256. (J Allergy Clin Immunol 2012; 130:886-93.)	[Wahn, Ulrich] Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; [Klimek, Ludger] Ctr Rhinol & Allergol, Wiesbaden, Germany; [Ploszczuk, Anna] Univ Childrens Hosp, Dept Allergol, Bialystok, Poland; [Adelt, Thomas] Pediat Ctr, Bramsche, England; [Adelt, Thomas; Sandner, Bernhard; Bufe, Albrecht] NETSTAP eV, Network Pediatricians Clin Studies, Bochum, Germany; [Sandner, Bernhard] Pediat Ctr, Aschaffenburg, England; [Trebas-Pietras, Ewa] Hlth Care Ctr Allergol, Lublin, Poland; [Eberle, Peter] Pediat Ctr, Kassel, Germany; [Bufe, Albrecht] Ruhr Univ Bochum, Bochum, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruhr University Bochum	Wahn, U (corresponding author), Charite, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.	ulrich.wahn@charite.de		Bufe, Albrecht/0000-0001-7335-9362; Kuna, Piotr/0000-0003-2401-0070	Allergopharma; ALK-Abello; HAL; Novartis; GlaxoSmithKline	Allergopharma; ALK-Abello; HAL(Horticulture Australia Limited); Novartis(Novartis); GlaxoSmithKline(GlaxoSmithKline)	U. Wahn has received research support from Allergopharma. L. Klimek has received research support from Allergopharma, ALK-Abello, HAL, Novartis, and GlaxoSmithKline and has consultant arrangements with Boehringer Ingelheim. A. Bufe has consultant arrangements with ALK-Abello, Bitop AG, and NETSTAP Forschungs GmbH and has received lecture fees from ALK-Abello and Allergopharma. The rest of the authors declare that they have no relevant conflicts of interest.	Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Blaiss M, 2011, J ALLERGY CLIN IMMUN, V127, P64, DOI 10.1016/j.jaci.2010.11.034; Bousquet J, 2011, ALLERGY, V66, P765, DOI 10.1111/j.1398-9995.2011.02590.x; Bousquet PJ, 2009, ALLERGY, V64, P1737, DOI 10.1111/j.1398-9995.2009.02232.x; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Calderon MA, 2011, ALLERGY, V66, P1345, DOI 10.1111/j.1398-9995.2011.02669.x; Calderon MA, 2012, PEDIAT ALLERG IMM-UK, V23, P300, DOI 10.1111/j.1399-3038.2012.01313.x; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Casale TB, 2009, J ALLERGY CLIN IMMUN, V124, P665, DOI 10.1016/j.jaci.2009.07.054; Cox L, 2007, CURR ALLERGY ASTHM R, V7, P410, DOI 10.1007/s11882-007-0063-6; Dahl R, 2008, J ALLERGY CLIN IMMUN, V121, P512, DOI 10.1016/j.jaci.2007.10.039; Di Bona D, 2010, J ALLERGY CLIN IMMUN, V126, P558, DOI 10.1016/j.jaci.2010.06.013; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; *EMA PDCO, 2010, EMAPDCO7376052009; European Medicines Agency, 2008, CHMPEWP185042006 EUR; Hafner D, 2011, ALLERGY, V66, P629, DOI 10.1111/j.1398-9995.2010.02531.x; Larenas-Linnemann DE, 2007, ALLERGY, V62, P704, DOI 10.1111/j.1398-9995.2007.01335.x; Larenas-Linnemann D, 2009, PEDIAT ALLERG IMM-UK, V20, P399, DOI 10.1111/j.1399-3038.2008.00809.x; Larenas-Linnemann D, 2009, CURR OPIN ALLERGY CL, V9, P168, DOI 10.1097/ACI.0b013e328329a2a9; Lombardi C, 2009, ALLERGY, V64, P849, DOI 10.1111/j.1398-9995.2009.02063.x; Nieto A, 2009, J ALLERGY CLIN IMMUN, V124, P157, DOI 10.1016/j.jaci.2009.04.015; Novak N, 2011, ALLERGY, V66, P733, DOI 10.1111/j.1398-9995.2010.02535.x; Passalacqua G, 2011, IMMUNOL ALLERGY CLIN, V31, P265, DOI 10.1016/j.iac.2011.03.002; Pfaar O, 2011, IMMUNOL ALLERGY CLIN, V31, P289, DOI 10.1016/j.iac.2011.02.004; Radulovic S, 2011, ALLERGY, V66, P740, DOI 10.1111/j.1398-9995.2011.02583.x; Sander I, 2009, ALLERGY, V64, P1486, DOI 10.1111/j.1398-9995.2009.02040.x; Senna G, 2010, J ALLERGY CLIN IMMUN, V126, P668, DOI 10.1016/j.jaci.2010.06.045; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Worm M, 2006, Eur Ann Allergy Clin Immunol, V38, P355	34	60	62	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					886	+		10.1016/j.jaci.2012.06.047	http://dx.doi.org/10.1016/j.jaci.2012.06.047			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22939758				2022-12-18	WOS:000309594800007
J	Fuchs, O; Genuneit, J; Latzin, P; Buchele, G; Horak, E; Loss, G; Sozanska, B; Weber, J; Boznanski, A; Heederik, D; Braun-Fahrlander, C; Frey, U; von Mutius, E				Fuchs, Oliver; Genuneit, Jon; Latzin, Philipp; Buechele, Gisela; Horak, Elisabeth; Loss, Georg; Sozanska, Barbara; Weber, Juliane; Boznanski, Andrzej; Heederik, Dick; Braun-Fahrlaender, Charlotte; Frey, Urs; von Mutius, Erika		GABRIELA Study Grp	Farming environments and childhood atopy, wheeze, lung function, and exhaled nitric oxide	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; atopy; children; exhaled nitric oxide; farming; hay fever; protection; protective environments; pulmonary function test; wheeze	1ST 6 YEARS; NONATOPIC WHEEZE; EARLY-LIFE; ASTHMA; EXPOSURE; INFECTIONS; CHILDREN	Background: Previous studies have demonstrated that children raised on farms are protected from asthma and allergies. It is unknown whether the farming effect is solely mediated by atopy or also affects nonatopic wheeze phenotypes. Objective: We sought to study the farm effect on wheeze phenotypes and objective markers, such as lung function and exhaled nitric oxide, and their interrelation with atopy in children. Methods: The GABRIEL Advanced Studies are cross-sectional, multiphase, population-based surveys of the farm effect on asthma and allergic disease in children aged 6 to 12 years. Detailed data on wheeze, farming exposure, and IgE levels were collected from a random sample of 8023 children stratified for farm exposure. Of those, another random subsample of 858 children was invited for spirometry, including bronchodilator tests and exhaled nitric oxide measurements. Results: We found effects of exposure to farming environments on the prevalence and degree of atopy, on the prevalence of transient wheeze (adjusted odds ratio, 0.78; 95% CI, 0.64-0.96), and on the prevalence of current wheeze among nonatopic subjects (adjusted odds ratio, 0.45; 95% CI, 0.32-0.63). There was no farm effect on lung function and exhaled nitric oxide levels in the general study population. Conclusions: Children living on farms are protected against wheeze independently of atopy. This farm effect is not attributable to improved airway size and lung mechanics. These findings imply as yet unknown protective mechanisms. They might include alterations of immune response and susceptibility to triggers of wheeze, such as viral infections. (J Allergy Clin Immunol 2012;130:382-8.)	[Fuchs, Oliver; Frey, Urs] Univ Basel, Univ Childrens Hosp UKBB, CH-4056 Basel, Switzerland; [Fuchs, Oliver; Latzin, Philipp; Frey, Urs] Univ Bern, Inselspital, Dept Pediat, Div Resp Med, CH-3012 Bern, Switzerland; [Genuneit, Jon; Buechele, Gisela] Univ Ulm, Inst Epidemiol & Med Biometry, D-89069 Ulm, Germany; [Horak, Elisabeth] Innsbruck Med Univ, Div Cardiol & Pulmonol, Dept Pediat & Adolescents, Innsbruck, Austria; [Loss, Georg; Braun-Fahrlaender, Charlotte] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Loss, Georg; Braun-Fahrlaender, Charlotte] Univ Basel, CH-4056 Basel, Switzerland; [Sozanska, Barbara; Boznanski, Andrzej] Wroclaw Med Univ, Dept Pediat Allergol & Cardiol 1, Wroclaw, Poland; [Weber, Juliane; von Mutius, Erika] Univ Munich, Univ Childrens Hosp, Munich, Germany; [Heederik, Dick] Univ Utrecht, IRAS, Div Environm Epidemiol, NL-3508 TC Utrecht, Netherlands	University of Basel; University of Bern; University Hospital of Bern; Ulm University; Medical University of Innsbruck; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Wroclaw Medical University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Utrecht University	Frey, U (corresponding author), Univ Basel, Univ Childrens Hosp UKBB, Spitalstr 33, CH-4056 Basel, Switzerland.	urs.frey@ukbb.ch	Genuneit, Jon/I-9323-2012; Loss, Georg/F-1557-2013; Loss, Georg/AAE-7296-2019; Ege, Markus/C-1962-2012; Latzin, Philipp/F-2206-2017	Genuneit, Jon/0000-0001-5764-1528; Loss, Georg/0000-0003-1090-812X; Ege, Markus/0000-0001-6643-3923; von Mutius, Erika/0000-0002-8893-4515; Heederik, Dick/0000-0002-4550-1437; Frey, Urs/0000-0003-3773-2822; Latzin, Philipp/0000-0002-5239-1571	European Commission, GABRIEL [018996, LSH-2004-1.2.5-1]; European Respiratory Society [675]; Austrian, German and Swiss Pediatric Respiratory Society; InfectoPharm; European Commission (EU); European Commission; Deutsche Forschungsgemeinschaft (DFG); Roxall; GlaxoSmithKline; Novartis; Sanofi Aventis; Allergopharma; AstraZeneca GmbH; BMBF; EU	European Commission, GABRIEL(European Commission); European Respiratory Society; Austrian, German and Swiss Pediatric Respiratory Society; InfectoPharm; European Commission (EU)(European CommissionEuropean Commission Joint Research Centre); European Commission(European CommissionEuropean Commission Joint Research Centre); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Roxall; GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); Sanofi Aventis(Sanofi-Aventis); Allergopharma; AstraZeneca GmbH(AstraZeneca); BMBF(Federal Ministry of Education & Research (BMBF)); EU(European Commission)	Supported by the European Commission as part of GABRIEL (a multidisciplinary study to identify the genetic and environmental causes of asthma in the European Community), contract no. 018996, under the FP6-LIFESCIHEALTH Integrated Program LSH-2004-1.2.5-1. O.F. is the recipient of a Long-Term Research Fellowship by the European Respiratory Society (no. 675) and a Training Scholarship by the Austrian, German and Swiss Pediatric Respiratory Society.; E. von Mutius is a consultant for Novartis, GlaxoSmithKline, ALK-Abello, and Protectimmun; has received speaker's fees from InfectoPharm; and is a member of the expert panel for the UK Research Excellence Framework. B. Sozanska, J. Weber, D. Heederik, H. Danielewicz, M. Depner, C. StrunzLehner, and I. Wouters have received research support from the European Commission (EU). M. Ege has received research support from the European Commission and the Deutsche Forschungsgemeinschaft (DFG). M. Kabesch has received research support from Roxall, GlaxoSmithKline, Novartis, Sanofi Aventis, Allergo-pharma, AstraZeneca GmbH, DFG, BMBF, and the EU. The rest of the authors declare that they have no relevant conflicts of interest.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Beydon N, 2007, AM J RESP CRIT CARE, V175, P1304, DOI 10.1164/rccm.200605-642ST; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Bush Andrew, 2009, Proc Am Thorac Soc, V6, P712, DOI 10.1513/pats.200906-046DP; Court CS, 2002, THORAX, V57, P951, DOI 10.1136/thorax.57.11.951; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ege MJ, 2011, J ALLERGY CLIN IMMUN, V127, P138, DOI 10.1016/j.jaci.2010.09.041; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563, DOI 10.1164/ajrccm.161.5.9908119; Fuchs O, 2009, EUR RESP J S53, V34, p758s; Garcia-Marcos L, 2005, PEDIAT ALLERG IMM-UK, V16, P471, DOI 10.1111/j.1399-3038.2005.00318.x; Genuneit J, 2009, EUR RESP J S53, V4, p758s; Genuneit J, 2011, PAEDIATR PERINAT EP, V25, P436, DOI 10.1111/j.1365-3016.2011.01223.x; Gern JE, 2009, CURR OPIN ALLERGY CL, V9, P73, DOI 10.1097/ACI.0b013e32831f8f1b; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; Kurukulaaratchy RJ, 2004, THORAX, V59, P563, DOI 10.1136/thx.2003.010462; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Merchant JA, 2005, ENVIRON HEALTH PERSP, V113, P350, DOI 10.1289/ehp.7240; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Sly PD, 2010, J ALLERGY CLIN IMMUN, V125, P1202, DOI 10.1016/j.jaci.2010.01.024; Stanojevic S, 2008, AM J RESP CRIT CARE, V177, P253, DOI 10.1164/rccm.200708-1248OC; Tse K, 2008, SEMIN IMMUNOPATHOL, V30, P53, DOI 10.1007/s00281-007-0098-8; Turato G, 2008, AM J RESP CRIT CARE, V178, P476, DOI 10.1164/rccm.200712-1818OC; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010; von Mutius E, 2007, IMMUNOBIOLOGY, V212, P433, DOI 10.1016/j.imbio.2007.03.002; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8	31	60	60	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					382	+		10.1016/j.jaci.2012.04.049	http://dx.doi.org/10.1016/j.jaci.2012.04.049			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22748700	Green Submitted			2022-12-18	WOS:000307002200017
J	Holbreich, M; Genuneit, J; Weber, J; Braun-Fahrlander, C; Waser, M; von Mutius, E				Holbreich, Mark; Genuneit, Jon; Weber, Juliane; Braun-Fahrlaender, Charlotte; Waser, Marco; von Mutius, Erika			Amish children living in northern Indiana have a very low prevalence of allergic sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDHOOD ASTHMA		[Holbreich, Mark] Allergy & Asthma Consultants, Indianapolis, IN USA; [Genuneit, Jon] Univ Ulm, Inst Epidemiol & Med Biometry, Ulm, Germany; [Weber, Juliane; von Mutius, Erika] Univ Childrens Hosp, Munich, Germany; [Braun-Fahrlaender, Charlotte; Waser, Marco] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Waser, Marco] Univ Basel, Basel, Switzerland	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; University of Basel; Swiss Tropical & Public Health Institute; University of Basel	Holbreich, M (corresponding author), Allergy & Asthma Consultants, Indianapolis, IN USA.	mholbreich@comcast.net	Genuneit, Jon/I-9323-2012	Genuneit, Jon/0000-0001-5764-1528; von Mutius, Erika/0000-0002-8893-4515				Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Genuneit J, 2011, PAEDIATR PERINAT EP, V25, P436, DOI 10.1111/j.1365-3016.2011.01223.x; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Weinmayr G, 2010, ALLERGY, V65, P766, DOI 10.1111/j.1398-9995.2009.02283.x; Wong GWK, 2004, BMJ-BRIT MED J, V329, P486, DOI 10.1136/bmj.329.7464.486; Zekveld C, 2006, EUR RESPIR J, V28, P82, DOI 10.1183/09031936.06.00021305	9	60	60	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1671	1673		10.1016/j.jaci.2012.03.016	http://dx.doi.org/10.1016/j.jaci.2012.03.016			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22513133				2022-12-18	WOS:000304764600031
J	Nunez, R; Carballada, F; Gonzalez-Quintela, A; Gomez-Rial, J; Boquete, M; Vidal, C				Nunez, Ramon; Carballada, Francisco; Gonzalez-Quintela, Arturo; Gomez-Rial, Jose; Boquete, Manuel; Vidal, Carmen			Delayed mammalian meat-induced anaphylaxis due to galactose-alpha-1,3-galactose in 5 European patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IGE; RELEVANCE		[Nunez, Ramon; Carballada, Francisco; Boquete, Manuel] Hosp Lucus Augusti, Dept Allergy, Lugo, Spain; [Gonzalez-Quintela, Arturo] Hosp Clin Univ, Dept Med, Santiago De Compostela, Spain; [Vidal, Carmen] Hosp Clin Univ, Dept Allergy, Santiago De Compostela, Spain; [Gomez-Rial, Jose] Hosp Clin Univ, Immunol Lab, Santiago De Compostela, Spain	Hospital Universitario Lucus Augusti-Lugo; Complexo Hospitalario Universitario de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela	Nunez, R (corresponding author), Hosp Lucus Augusti, Dept Allergy, Lugo, Spain.	carmen.vidal.pan@sergas.es		Gomez Rial, Jose/0000-0002-3173-8484; Gonzalez-Quintela, Arturo/0000-0002-6909-1807; Rodriguez-Tenreiro Sanchez, Carmen/0000-0003-1142-2818				Arkestal K, 2011, J ALLERGY CLIN IMMUN, V127, P1024, DOI 10.1016/j.jaci.2011.01.033; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Commins SP, 2010, CURR ALLERGY ASTHM R, V10, P29, DOI 10.1007/s11882-009-0079-1; Commins SP, 2009, J ALLERGY CLIN IMMUN, V124, P652, DOI 10.1016/j.jaci.2009.08.026; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Gronlund H, 2009, J ALLERGY CLIN IMMUN, V123, P1189, DOI 10.1016/j.jaci.2009.03.011; Jacquenet S, 2009, J ALLERGY CLIN IMMUN, V124, P603, DOI 10.1016/j.jaci.2009.06.014; Marcher BA, 2008, BIOCHIM BIOPHYS ACTA, V1780, P75; Vazquez L, 2011, EXP APPL ACAROL, V53, P399, DOI 10.1007/s10493-010-9403-7	10	60	60	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1122	1124		10.1016/j.jaci.2011.07.020	http://dx.doi.org/10.1016/j.jaci.2011.07.020			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21835442				2022-12-18	WOS:000296578200034
J	Korosec, P; Valenta, R; Mittermann, I; Celesnik, N; Erzen, R; Zidarn, M; Kosnik, M				Korosec, Peter; Valenta, Rudolf; Mittermann, Irene; Celesnik, Nina; Erzen, Renato; Zidarn, Mihaela; Kosnik, Mitja			Low sensitivity of commercially available rApi m 1 for diagnosis of honeybee venom allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANXIETY DISORDERS; DOUBLE POSITIVITY; MENTAL-DISORDERS; ADOLESCENTS; IGE; BEE; COMORBIDITY; RELIABILITY; PREVALENCE; VALIDATION		[Korosec, Peter; Celesnik, Nina; Erzen, Renato; Zidarn, Mihaela; Kosnik, Mitja] Univ Clin Resp & Allerg Dis, Golnik, Slovenia; [Valenta, Rudolf; Mittermann, Irene] Med Univ Vienna, Christian Doppler Lab Allergy Res, Ctr Physiol & Pathophysiol, Dept Pathophysiol,Div Immunopathol, Vienna, Austria	Medical University of Vienna	Korosec, P (corresponding author), Univ Clin Resp & Allerg Dis, Golnik, Slovenia.	peter.korosec@klinika-golnik.si	Košnik, Mitja/AAI-2295-2019	Košnik, Mitja/0000-0002-4701-7374; Mittermann, Irene/0000-0002-6240-6730; Zidarn, Mihaela/0000-0003-0515-5207; Valenta, Rudolf/0000-0001-5944-3365; Korosec, Peter/0000-0002-0835-1599				American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Angold A, 2002, ARCH GEN PSYCHIAT, V59, P893, DOI 10.1001/archpsyc.59.10.893; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Blum S, 2011, ALLERGY, V66, P222, DOI 10.1111/j.1398-9995.2010.02470.x; Costello EJ, 2006, J CHILD PSYCHOL PSYC, V47, P1263, DOI 10.1111/j.1469-7610.2006.01682.x; Hemmer W, 2001, J ALLERGY CLIN IMMUN, V108, P1045, DOI 10.1067/mai.2001.120013; Hofmann SC, 2011, J ALLERGY CLIN IMMUN, V127, P265, DOI 10.1016/j.jaci.2010.06.042; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; KOVACS M, 1985, PSYCHOPHARMACOL BULL, V21, P995; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Lewinsohn PM, 1998, CLIN PSYCHOL REV, V18, P765, DOI 10.1016/S0272-7358(98)00010-5; Lewinsohn PM, 1997, J ANXIETY DISORD, V11, P377, DOI 10.1016/S0887-6185(97)00017-0; Lewinsohn PM, 1998, J ABNORM PSYCHOL, V107, P109, DOI 10.1037/0021-843X.107.1.109; LEWISJONES MS, 1995, BRIT J DERMATOL, V132, P942; March JS, 1997, J AM ACAD CHILD PSY, V36, P554, DOI 10.1097/00004583-199704000-00019; Martin RJ, 2002, AM J RESP CRIT CARE, V165, P1377, DOI 10.1164/rccm.2105013; Merikangas KR, 2010, J AM ACAD CHILD PSY, V49, P980, DOI 10.1016/j.jaac.2010.05.017; Mittermann I, 2010, J ALLERGY CLIN IMMUN, V125, P1300, DOI 10.1016/j.jaci.2010.03.017; Muller UR, 2009, ALLERGY, V64, P543, DOI 10.1111/j.1398-9995.2008.01794.x; Muller U, 1997, CLIN EXP ALLERGY, V27, P915, DOI 10.1111/j.1365-2222.1997.tb01233.x; MULLER UR, 1995, J ALLERGY CLIN IMMUN, V96, P395, DOI 10.1016/S0091-6749(95)70059-5; SOBOTKA AK, 1976, J ALLERGY CLIN IMMUN, V57, P29, DOI 10.1016/0091-6749(76)90076-2; Soldatova LN, 1998, J ALLERGY CLIN IMMUN, V101, P691, DOI 10.1016/S0091-6749(98)70179-4; Sturm GJ, 2007, ALLERGY, V62, P884, DOI 10.1111/j.1398-9995.2007.01413.x; TANNER JM, 1981, NUTR REV, V39, P43, DOI 10.1111/j.1753-4887.1981.tb06734.x	25	60	60	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					671	673		10.1016/j.jaci.2011.03.012	http://dx.doi.org/10.1016/j.jaci.2011.03.012			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21481443				2022-12-18	WOS:000294283400031
J	Kuna, P; Kaczmarek, J; Kupczyk, M				Kuna, Piotr; Kaczmarek, Jadwiga; Kupczyk, Maciej			Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Specific immunotherapy; Alternaria alternata; molds; rhinoconjunctivitis treatment; asthma treatment	SKIN-TEST RESPONSES; QUALITY-OF-LIFE; DOUBLE-BLIND; POLLEN IMMUNOTHERAPY; RESPIRATORY ALLERGY; CLINICAL-EFFICACY; MOLD ALLERGY; RHINITIS; ASTHMA; CLADOSPORIUM	Background: The safety and efficacy of specific immunotherapy for mold allergy are not known in children and adolescents. Objective: We evaluated the efficacy and safety of specific immunotherapy with a standardized allergen extract in a randomized, double-blind, placebo-controlled, 3-year prospective study of patients who were allergic to only Alternaria alternata. Methods: Fifty children and adolescents (25 girls; 5-18 years of age) with A alternata-induced seasonal allergic rhinoconjunctivitis and/or bronchial asthma were randomly assigned to groups given treatment (Novo-Helisen Depot, A alternata 100%) or placebo. The primary end point was the combined symptom medication score. Secondary end points included safety, quality of life, and sensitivity to allergen-specific nasal challenge. Results: Forty-five children completed the 3-year study. Although there was no significant change in year 1, the combined symptom medication score decreased in years 2 and 3 of the study (by 38.7% and 63.5%, respectively; P < .001 for each). The reduction in symptoms was associated with a significant improvement in quality of life (P < .05) and decrease in sensitivity after allergen-specific nasal challenge. Side effects were observed in 7 patients; the most common (edema at the site of injection) occurred after 11 injections. Conclusions: Allergen-specific immunotherapy with standardized A alternata extract reduces symptoms of asthma and rhinoconjunctivitis in children and adolescents without serious side effects. (J Allergy Clin Immunol 2011;127:502-8.)	[Kuna, Piotr; Kaczmarek, Jadwiga; Kupczyk, Maciej] Med Univ Lodz, Barlicki Univ Hosp, Dept Internal Med Asthma & Allergy, Lodz, Poland	Medical University Lodz	Kupczyk, M (corresponding author), Med Univ Lodz, Dept Internal Med Asthma & Allergy, Kopcinskiego 22, PL-90153 Lodz, Poland.	matiska@wp.pl	Kupczyk, Maciej/S-9677-2016	Kupczyk, Maciej/0000-0003-0800-7867; Kuna, Piotr/0000-0003-2401-0070				Aden E, 1999, J ALLERGY CLIN IMMUN, V104, P128, DOI 10.1016/S0091-6749(99)70124-7; Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bousquet PJ, 2007, ALLERGY, V62, P367, DOI 10.1111/j.1398-9995.2006.01276.x; Bousquet PJ, 2007, ALLERGY, V62, P301, DOI 10.1111/j.1398-9995.2006.01293.x; Bousquet PJ, 2009, ALLERGY, V64, P1737, DOI 10.1111/j.1398-9995.2009.02232.x; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Calabria CW, 2007, ALLERGY ASTHMA PROC, V28, P442, DOI 10.2500/aap.2007.28.3016; Calabria CW, 2007, ANN ALLERG ASTHMA IM, V99, P161, DOI 10.1016/S1081-1206(10)60640-0; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; CANTANI A, 1988, ALLERGOL IMMUNOPATH, V16, P1; Clark J, 2007, ALLERGY, V62, P1023, DOI 10.1111/j.1398-9995.2007.01469.x; Corden J.M., 2001, AEROBIOLOGIA, V17, P127, DOI [10.1023/A, DOI 10.1023/A:1010876917512, 10.1023/A:1010876917512]; Corrigan CJ, 2005, ALLERGY, V60, P801, DOI 10.1111/j.1398-9995.2005.00790.x; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, pS25, DOI 10.1016/j.jaci.2007.06.019; DAmato G, 1997, ALLERGY, V52, P711, DOI 10.1111/j.1398-9995.1997.tb01227.x; DAMATO G, 1995, ALLERGY, V50, P870, DOI 10.1111/j.1398-9995.1995.tb02492.x; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Eng PA, 2002, ALLERGY, V57, P306, DOI 10.1034/j.1398-9995.2002.1o3264.x; Esch RE, 2004, J ALLERGY CLIN IMMUN, V113, P210, DOI 10.1016/j.jaci.2003.11.024; *GINA, 1995, 023659 NIH; Hardy CL, 2004, CLIN EXP ALLERGY, V34, P510, DOI 10.1111/j.1365-2222.2004.1943.x; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V101, P163, DOI 10.1016/S0091-6749(98)70380-X; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; KAAD PH, 1982, CLIN ALLERGY, V12, P317, DOI 10.1111/j.1365-2222.1982.tb02534.x; Mabry RL, 1997, OTOLARYNG HEAD NECK, V117, P367, DOI 10.1016/S0194-5998(97)70128-1; MALLING HJ, 1986, ALLERGY, V41, P507, DOI 10.1111/j.1398-9995.1986.tb00336.x; Mari A, 2003, CLIN EXP ALLERGY, V33, P1429, DOI 10.1046/j.1365-2222.2003.01783.x; Miller FG, 2006, J CLIN EPIDEMIOL, V59, P331, DOI 10.1016/j.jclinepi.2005.12.001; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; OHOLLAREN MT, 1999, NEW ENGL J MED, V324, P359; Passalacqua G, 2007, J ALLERGY CLIN IMMUN, V119, P881, DOI 10.1016/j.jaci.2007.01.045; Position paper: immunotherapy. (EAACI), 1993, ALLERGY S, V48, P7; Randriamanantany ZA, 2010, ALLERGY, V65, P368, DOI 10.1111/j.1398-9995.2009.02210.x; Reijula K, 2003, ANN ALLERG ASTHMA IM, V91, P280, DOI 10.1016/S1081-1206(10)63531-4; Roeder E, 2008, PEDIAT ALLERG IMM-UK, V19, P197, DOI 10.1111/j.1399-3038.2007.00648.x; Salo PM, 2006, J ALLERGY CLIN IMMUN, V118, P892, DOI 10.1016/j.jaci.2006.07.037; Tabar AI, 2000, J INVEST ALLERG CLIN, V10, P327; Tabar AI, 2008, PEDIAT ALLERG IMM-UK, V19, P67, DOI 10.1111/j.1399-3038.2007.00589.x; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; Lizaso MT, 2008, PEDIAT ALLERG IMM-UK, V19, P76, DOI 10.1111/j.1399-3038.2007.00587.x; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	46	60	68	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					502	U1832		10.1016/j.jaci.2010.11.036	http://dx.doi.org/10.1016/j.jaci.2010.11.036			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21281874				2022-12-18	WOS:000286808000026
J	Arnoldussen, DL; Linehan, M; Sheikh, A				Arnoldussen, Denise L.; Linehan, Mary; Sheikh, Aziz			BCG vaccination and allergy: A systematic review and meta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Allergy; asthma; atopy; BCG vaccination; meta-analysis; systematic review	PERTUSSIS VACCINATION; TUBERCULIN REACTIVITY; PRESCHOOL-CHILDREN; ATOPIC DISEASES; HAY-FEVER; ASTHMA; PREVALENCE; INFECTION; DISORDERS; RHINITIS	Background: There is conflicting evidence on whether BCG vaccination might represent an effective primary preventative strategy against the development of allergic sensitization and disease. Objectives: We sought to systematically review the relationship between BCG vaccination and the risk of sensitization, eczema/atopic dermatitis, allergic rhinoconjunctivitis, asthma, and other allergic conditions, such as food allergy and anaphylaxis. Methods: Four international databases were searched for published epidemiologic or interventional studies. Additional online study databases were searched and vaccine manufacturers and a panel of international experts were contacted in an attempt to locate unpublished or ongoing studies. Quality assessment was undertaken by using internationally established criteria. Meta-analyses were undertaken by using fixed-or random-effects modeling. Funnel plots were used to assess for the risk of publication bias. Results: We identified 767 articles, of which 17 satisfied our inclusion criteria; there was only 1 randomized controlled trial, with the remaining studies being epidemiologic investigations. Meta-analyses did not show any protective effect of vaccination against the risk of sensitization, as judged by specific IgE tests (odds ratio [OR], 1.31; 95% CI, 1.07-1.60) or skin prick testing (OR, 0.87; 95% CI, 0.67-1.13); the risk of atopic eczema/dermatitis (OR, 0.84; 95% CI, 0.64-1.09); or the risk of allergic rhinoconjunctivitis (OR, 1.07; 95% CI, 0.89-1.28). BCG vaccination was associated with a protective effect against the risk of asthma (OR, 0.73; 95% CI, 0.56-0.95), although this might be explained by publication bias. Conclusions: BCG vaccination is unlikely to be associated with protection against the risk of allergic sensitization and disease. The observed possible benefit in relation to the development of asthma is unlikely to be due to allergic sensitization. (J Allergy Clin Immunol 2011;127:246-53.)	[Arnoldussen, Denise L.; Sheikh, Aziz] Univ Edinburgh, Allergy & Resp Res Grp, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland; [Linehan, Mary] Univ Manchester, Resp Med Res Grp, Sch Translat Med, Manchester, Lancs, England	University of Edinburgh; University of Manchester	Sheikh, A (corresponding author), Univ Edinburgh, Allergy & Resp Res Grp, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland.	Aziz.Sheikh@ed.ac.uk	Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056	Socrates Studentship	Socrates Studentship	D. L. A. was supported by a Socrates Studentship.	Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x; Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Annus T, 2004, ALLERGY, V59, P1068, DOI 10.1111/j.1398-9995.2004.00557.x; Austin JB, 1999, ARCH DIS CHILD, V81, P225, DOI 10.1136/adc.81.3.225; Balicer RD, 2007, PEDIATRICS, V120, pE1269, DOI 10.1542/peds.2006-3569; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; Bremner SA, 2005, ARCH DIS CHILD, V90, P567, DOI 10.1136/adc.2004.051714; da Cunha SS, 2004, ALLERGY, V59, P857; El-Zein M, 2010, INT J EPIDEMIOL, V39, P469, DOI 10.1093/ije/dyp307; Garcia-Marcosa L, 2005, INT ARCH ALLERGY IMM, V137, P303, DOI 10.1159/000086461; Gruber C, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e36; Gruber C, 2002, PEDIAT ALLERG IMM-UK, V13, P177, DOI 10.1034/j.1399-3038.2002.01006.x; Gupta R, 2004, CLIN EXP ALLERGY, V34, P520, DOI 10.1111/j.1365-2222.2004.1935.x; Holt PG, 2010, CLIN EXP IMMUNOL, V160, P22, DOI 10.1111/j.1365-2249.2010.04129.x; Krause TG, 2003, JAMA-J AM MED ASSOC, V289, P1012, DOI 10.1001/jama.289.8.1012; Linehan MF, 2007, J ALLERGY CLIN IMMUN, V119, P1079, DOI 10.1016/j.jaci.2006.12.672; Linehan MF, 2006, INVESTIGATION PREVAL; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Marks GB, 2003, J ALLERGY CLIN IMMUN, V111, P541, DOI 10.1067/mai.2003.171; Miyake Y, 2008, CLIN EXP ALLERGY, V38, P486, DOI 10.1111/j.1365-2222.2007.02869.x; Mohrenschlager M, 2007, PEDIAT ALLERG IMM-UK, V18, P5, DOI 10.1111/j.1399-3038.2006.00485.x; Mommers M, 2004, PEDIATR PULM, V38, P329, DOI 10.1002/ppul.20089; Obihara CC, 2007, PEDIAT ALLERG IMM-UK, V18, P551, DOI 10.1111/j.1399-3038.2007.00569.x; ODENT MR, 1994, JAMA-J AM MED ASSOC, V272, P592, DOI 10.1001/jama.1994.03520080034035; Pahari A, 2002, Indian Pediatr, V39, P254; Punekar YS, 2009, CLIN EXP ALLERGY, V39, P1209, DOI 10.1111/j.1365-2222.2009.03248.x; Romagnani S, 2007, J ALLERGY CLIN IMMUN, V119, P1511, DOI 10.1016/j.jaci.2007.04.005; Rook GAW, 2007, IMMUNOBIOLOGY, V212, P461, DOI 10.1016/j.imbio.2007.03.003; Rousseau MC, 2008, PEDIAT ALLERG IMM-UK, V19, P438, DOI 10.1111/j.1399-3038.2007.00669.x; Sheikh Aziz, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P232, DOI 10.1097/01.moo.0000122311.13359.30; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Sironi M, 2010, MICROBES INFECT, V12, P421, DOI 10.1016/j.micinf.2010.02.002; Steenhuis TJ, 2008, CLIN EXP ALLERGY, V38, P79, DOI 10.1111/j.1365-2222.2007.02859.x; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]; Walker S, 2007, J ALLERGY CLIN IMMUN, V120, P381, DOI 10.1016/j.jaci.2007.03.034; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	37	60	65	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					246	U404		10.1016/j.jaci.2010.07.039	http://dx.doi.org/10.1016/j.jaci.2010.07.039			29	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	20933258				2022-12-18	WOS:000285917300035
J	Lieberman, P; Nicklas, RA; Oppenheimer, J; Kemp, SF; Lang, DM; Bernstein, DI; Bernstein, JA; Burks, AW; Feldweg, AM; Fink, JN; Greenberger, PA; Golden, DBK; James, JM; Ledford, DK; Sheffer, AL; Blessing-Moore, J; Cox, L; Khan, DA; Lang, D; Portnoy, JM; Randolph, C; Schuller, DE; Spector, SL; Tilles, S; Wallace, D				Lieberman, Phillip; Nicklas, Richard A.; Oppenheimer, John; Kemp, Stephen F.; Lang, David M.; Bernstein, David I.; Bernstein, Jonathan A.; Burks, A. Wesley; Feldweg, Anna M.; Fink, Jordan N.; Greenberger, Paul A.; Golden, David B. K.; James, John M.; Ledford, Dennis K.; Sheffer, Albert L.; Blessing-Moore, Joann; Cox, Linda; Khan, David A.; Lang, David; Portnoy, Jay M.; Randolph, Christopher; Schuller, Diane E.; Spector, Sheldon L.; Tilles, Stephen; Wallace, Dana			The diagnosis and management of anaphylaxis practice parameter: 2010 Update	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							EXERCISE-INDUCED ANAPHYLAXIS; LARGE LOCAL REACTIONS; RADIOGRAPHIC CONTRAST-MEDIA; HUMAN SEMINAL PLASMA; INSECT STING ANAPHYLAXIS; FOOD-INDUCED ANAPHYLAXIS; MUSCLE-RELAXANT DRUGS; INTRADERMAL SKIN-TEST; MAST-CELL TRYPTASE; HYPERSENSITIVITY REACTIONS	These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology; the American College of Allergy, Asthma and Immunology; and the Joint Council of Allergy, Asthma and Immunology. The American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI) have jointly accepted responsibility for establishing "The Diagnosis and Management of Anaphylaxis Practice Parameter: 2010 Update.'' This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, or the Joint Council of Allergy, Asthma and Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.	[Lieberman, Phillip] Univ Tennessee, Dept Med, Coll Med, Memphis, TN 38104 USA; [Lieberman, Phillip] Univ Tennessee, Coll Med, Dept Pediat, Memphis, TN 38104 USA; [Nicklas, Richard A.] George Washington Med Ctr, Dept Med, Washington, DC USA; [Oppenheimer, John] Univ Med & Dent New Jersey, Dept Internal Med, Morristown, NJ USA; [Kemp, Stephen F.] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA; [Kemp, Stephen F.] Univ Mississippi, Med Ctr, Dept Pediat, Jackson, MS 39216 USA; [Lang, David M.] Cleveland Clin Fdn, Div Med, Resp Inst, Allergy Immunol Sect, Cleveland, OH 44195 USA; [Bernstein, David I.] Univ Cincinnati, Coll Med, Div Immunol, Dept Clin Med, Cincinnati, OH USA; [Bernstein, Jonathan A.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Immunol, Cincinnati, OH USA; [Burks, A. Wesley] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; [Feldweg, Anna M.] Brigham & Womens Hosp, Div Rheumatol Allergy Immunol, Chestnut Hill, MA USA; [Fink, Jordan N.] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; [Fink, Jordan N.] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; [Golden, David B. K.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA; [Greenberger, Paul A.] Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Chicago, IL 60611 USA; [James, John M.] Allergy Ctr PC, Ft Collins, CO USA; [James, John M.] Asthma Ctr PC, Ft Collins, CO USA; [Ledford, Dennis K.] Univ S Florida, Coll Med, Dept Med, Tampa, FL 33612 USA; [Ledford, Dennis K.] James A Haley VA Hosp, Tampa, FL USA; [Sheffer, Albert L.] Brigham & Womens Hosp, Dept Med, Div Rhemetol Immunol & Asthma, Boston, MA 02115 USA; [Blessing-Moore, Joann] Stanford Univ, Med Ctr, Dept Immunol, Palo Alto, CA 94304 USA; [Cox, Linda; Wallace, Dana] Nova SE Univ, Dept Med, Davie, FL USA; [Khan, David A.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Portnoy, Jay M.] Univ Missouri, Childrens Mercy Hosp, Sect Allergy Asthma & Immunol, Kansas City Sch Med, Kansas City, MO 64108 USA; [Randolph, Christopher] Waterbury Hosp & Hlth Ctr, Yale Affliated Programs, Ctr Allergy Asthma & Immunol, Waterbury, CT USA; [Schuller, Diane E.] Penn State Univ, Milton S Hershey Med Coll, Dept Pediat, Hershey, PA USA; [Spector, Sheldon L.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA; [Tilles, Stephen] Univ Washington, Sch Med, Dept Med, Redmond, WA USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; George Washington University; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center; Cleveland Clinic Foundation; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Duke University; Harvard University; Brigham & Women's Hospital; Medical College of Wisconsin; Medical College of Wisconsin; Johns Hopkins University; Northwestern University; Feinberg School of Medicine; State University System of Florida; University of South Florida; Harvard University; Brigham & Women's Hospital; Stanford University; Nova Southeastern University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Pennsylvania; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Washington	Lieberman, P (corresponding author), Joint Council Allergy Asthma & Immunol, 50 N Brockway St,3-3, Palatine, IL 60067 USA.		Cox, Linda/AAP-1697-2021	Cox, Linda/0000-0002-5258-6870				AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; ADOURIAN U, 1993, ANESTHESIOLOGY, V78, P368, DOI 10.1097/00000542-199302000-00024; Aihara Y, 2001, J ALLERGY CLIN IMMUN, V108, P1035, DOI 10.1067/mai.2001.119914; Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; ALENIUS H, 1994, J LAB CLIN MED, V123, P712; Alonso MAT, 2002, ANN ALLERG ASTHMA IM, V88, P313, DOI 10.1016/S1081-1206(10)62014-5; *AM AC ALL IMM BOA, 1994, J ALLERGY CLIN IMMUN, V94, P666; American Heart Association, 2005, CIRCULATION, V112, P58; Amin HS, 2006, J ALLERGY CLIN IMMUN, V117, P169, DOI 10.1016/j.jaci.2005.10.010; ANNE S, 1994, ANN ALLERGY, V73, P402; [Anonymous], 1999, Ann Allergy Asthma Immunol, V83, P665; [Anonymous], 1994, J Allergy Clin Immunol, V93, P811; [Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Atanaskovic-Markovic M, 2009, J ALLERGY CLIN IMMUN, V124, P167, DOI 10.1016/j.jaci.2009.02.031; AUSDENMOORE R W, 1991, Pediatric Asthma Allergy and Immunology, V5, P21, DOI 10.1089/pai.1991.5.21; AWAI LE, 1984, ANN ALLERGY, V53, P48; BALDO BA, 1983, MOL IMMUNOL, V20, P1393, DOI 10.1016/0161-5890(83)90171-2; BALDO BA, 1983, NATURE, V306, P262, DOI 10.1038/306262a0; BALDO BA, 1993, ANN FR ANESTH, V12, P131, DOI 10.1016/S0750-7658(05)81022-6; BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BENITAH E, 1986, THERAPIE, V41, P139; BERKELMAN RL, 1986, ANN INTERN MED, V104, P134, DOI 10.7326/0003-4819-104-1-134_1; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; BERNSTEIN IL, 1981, ANN INTERN MED, V94, P459, DOI 10.7326/0003-4819-94-4-459; Bernstein JA, 1997, ANN ALLERG ASTHMA IM, V78, P54, DOI 10.1016/S1081-1206(10)63372-8; BERNSTEIN JA, 1994, ANN ALLERGY, V73, P423; Bernstein JA, 2003, OBSTET GYNECOL, V101, P93, DOI 10.1016/S0029-7844(02)02318-9; BERNSTEIN JA, 1993, OBSTET GYNECOL, V82, P667; BETTMANN MA, 1990, RADIOLOGY, V175, P616, DOI 10.1148/radiology.175.3.2343105; BIRNBAUM J, 1994, CLIN EXP ALLERGY, V24, P915, DOI 10.1111/j.1365-2222.1994.tb02722.x; BIRNBAUM J, 1993, CLIN EXP ALLERGY, V23, P226, DOI 10.1111/j.1365-2222.1993.tb00886.x; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; Bousquet J, 1998, ANN ALLERG ASTHMA IM, V81, P401, DOI 10.1016/S1081-1206(10)63136-5; BOVET D, 1972, SYNTHETIC INHIBITORS; Braganza SC, 2006, ARCH DIS CHILD, V91, P159, DOI 10.1136/adc.2004.069914; Brown AFT, 1998, J ACCID EMERG MED, V15, P89; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; Brown SGA, 2004, EMERG MED J, V21, P149, DOI 10.1136/emj.2003.009449; Brown SGA, 2003, LANCET, V361, P1001, DOI 10.1016/S0140-6736(03)12827-9; Brown Simon G A, 2004, Emerg Med Australas, V16, P120, DOI 10.1111/j.1742-6723.2004.00562.x; Buck ML, 2007, ANN PHARMACOTHER, V41, P1679, DOI 10.1345/aph.1K168; BUSH WH, 1991, AM J ROENTGENOL, V157, P1153, DOI 10.2214/ajr.157.6.1950858; BUSH WH, 1990, UROLOGY, V35, P145, DOI 10.1016/0090-4295(90)80064-T; Calabria CW, 2009, J ALLERGY CLIN IMMUN, V124, P739, DOI 10.1016/j.jaci.2009.07.048; Campbell RL, 2008, ANN ALLERG ASTHMA IM, V101, P631, DOI 10.1016/S1081-1206(10)60227-X; CAPELLIER G, 1989, PRESSE MED, V18, P181; CASALE TB, 1986, JAMA-J AM MED ASSOC, V255, P2049, DOI 10.1001/jama.255.15.2049; Castells MC, 2008, J ALLERGY CLIN IMMUN, V122, P574, DOI 10.1016/j.jaci.2008.02.044; Caughey GH, 2006, J ALLERGY CLIN IMMUN, V117, P1411, DOI 10.1016/j.jaci.2006.02.026; Cesario David A, 2002, Rev Cardiovasc Med, V3, P14; Choi J, 2004, ANN ALLERG ASTHMA IM, V93, P137, DOI 10.1016/S1081-1206(10)61465-2; Chowdhury BA, 2002, J ALLERGY CLIN IMMUN, V109, P720, DOI 10.1067/mai.2002.123252; Choy AC, 1995, J ALLERGY CLIN IMMUN, V96, P893, DOI 10.1016/S0091-6749(95)70225-3; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Cianferoni A, 2001, ANN ALLERG ASTHMA IM, V87, P27, DOI 10.1016/S1081-1206(10)62318-6; Clark S, 2005, J ALLERGY CLIN IMMUN, V116, P643, DOI 10.1016/j.jaci.2005.06.026; Cogen FC, 2002, ANN ALLERG ASTHMA IM, V88, P61, DOI 10.1016/S1081-1206(10)63594-6; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; COOK FV, 1978, ANN INTERN MED, V88, P813, DOI 10.7326/0003-4819-88-6-813; CORNAILLE G, 1985, PRESSE MED, V14, P790; COULDWELL WT, 1993, NEUROSURGERY, V33, P1116; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, P1373, DOI 10.1016/j.jaci.2007.09.032; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, pS25, DOI 10.1016/j.jaci.2007.06.019; CROMWELL TA, 1974, PLAST RECONSTR SURG, V54, P224, DOI 10.1097/00006534-197407001-00026; CURRIE M, 1993, ANAESTH INTENS CARE, V21, P621, DOI 10.1177/0310057X9302100522; Daulat S, 2004, J ALLERGY CLIN IMMUN, V113, P1220, DOI 10.1016/j.jaci.2004.03.023; De Souza RL, 2004, ANAESTH INTENS CARE, V32, P580, DOI 10.1177/0310057X0403200419; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; DeCuyper C, 1996, J ALLERGY CLIN IMMUN, V97, P1427, DOI 10.1016/S0091-6749(96)70219-1; Derby CJ, 2005, PEDIAT ALLERG IMM-UK, V16, P171, DOI 10.1111/j.1399-3038.2005.00232.x; DESOTO H, 1989, ANESTH ANALG, V69, P264; Dibs SD, 1997, PEDIATRICS, V99, pE71; Dieterich HJ, 1998, ANESTH ANALG, V86, P1123, DOI 10.1097/00000539-199805000-00041; Ditto AM, 1996, ANN ALLERG ASTHMA IM, V77, P285, DOI 10.1016/S1081-1206(10)63322-4; DOHI M, 1991, J ALLERGY CLIN IMMUN, V87, P34, DOI 10.1016/0091-6749(91)90210-F; DOLOVICH J, 1980, CAN MED ASSOC J, V123, P292; DYKEWICZ MS, 1994, J ALLERGY CLIN IMMUN, V93, P117, DOI 10.1016/0091-6749(94)90240-2; Edston E, 2003, FORENSIC SCI INT, V131, P8, DOI 10.1016/S0379-0738(02)00383-3; Edston E, 1999, CLIN EXP ALLERGY, V29, P1648, DOI 10.1046/j.1365-2222.1999.00679.x; Elberink JNGO, 2002, J ALLERGY CLIN IMMUN, V109, P162, DOI 10.1067/mai.2002.120552; Ellis AK, 2007, ANN ALLERG ASTHMA IM, V98, P64, DOI 10.1016/S1081-1206(10)60861-7; Empedrad R, 2003, J ALLERGY CLIN IMMUN, V112, P629, DOI 10.1067/mai.2003.1690; ENRIGHT T, 1989, ANN ALLERGY, V62, P302; Estelle F, 2006, J ALLERGY CLIN IMMUN, V117, P367, DOI 10.1016/j.jaci.2005.12.002; Evora PRB, 2007, ANN ALLERG ASTHMA IM, V99, P306, DOI 10.1016/S1081-1206(10)60545-5; FAHMY NR, 1981, ANESTHESIOLOGY, V55, P329, DOI 10.1097/00000542-198109000-00028; Fiocchi A, 2001, J ALLERGY CLIN IMMUN, V108, P298, DOI 10.1067/mai.2001.116985; Fisher MM, 2000, ANAESTH INTENS CARE, V28, P167, DOI 10.1177/0310057X0002800207; FISHER MM, 1993, ANN FR ANESTH, V12, P97, DOI 10.1016/S0750-7658(05)81016-0; FRANKEN HH, 1994, J ALLERGY CLIN IMMUN, V93, P431, DOI 10.1016/0091-6749(94)90351-4; FREEMAN TM, 1992, J ALLERGY CLIN IMMUN, V90, P210, DOI 10.1016/0091-6749(92)90073-B; FREW AJ, 1993, BRIT MED J, V307, P919, DOI 10.1136/bmj.307.6909.919; FRIEDMAN SA, 1984, JAMA-J AM MED ASSOC, V251, P2684, DOI 10.1001/jama.251.20.2684; FUJITA Y, 1994, ANESTH ANALG, V79, P811; GADDE J, 1993, JAMA-J AM MED ASSOC, V270, P2456, DOI 10.1001/jama.270.20.2456; Gangur V, 2005, ANN ALLERG ASTHMA IM, V95, P4, DOI 10.1016/S1081-1206(10)61181-7; GARRIGA MM, 1988, J ALLERGY CLIN IMMUN, V82, P425, DOI 10.1016/0091-6749(88)90015-2; Gavalas M, 1998, J ACCID EMERG MED, V15, P96; Goldberg A, 1997, J ALLERGY CLIN IMMUN, V100, P182, DOI 10.1016/S0091-6749(97)70222-7; Golden DBK, 2006, J ALLERGY CLIN IMMUN, V117, P670, DOI 10.1016/j.jaci.2005.12.1313; Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; Golden DBK, 1997, J ALLERGY CLIN IMMUN, V100, P760, DOI 10.1016/S0091-6749(97)70270-7; GOLDEN DBK, 1981, JAMA-J AM MED ASSOC, V246, P2460, DOI 10.1001/jama.246.21.2460; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; Goldenhersh MJ, 1989, ANN ALLERGY, V2, P256; Goodman EJ, 2001, J CLIN ANESTH, V13, P561, DOI 10.1016/S0952-8180(01)00329-4; GRAFT DF, 1984, J PEDIATR-US, V104, P664, DOI 10.1016/S0022-3476(84)80940-3; Graif Y, 2006, ANN ALLERG ASTHMA IM, V96, P24, DOI 10.1016/S1081-1206(10)61035-6; Grammer LC, 2000, ANN ALLERG ASTHMA IM, V85, P368, DOI 10.1016/S1081-1206(10)62547-1; GRANADY LC, 1995, IMMUNOL ALLERGY CLIN, V15, P21; GREEN AW, 1980, J ALLERGY CLIN IMMUN, V66, P186, DOI 10.1016/0091-6749(80)90037-8; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; GREEN RL, 1985, JAMA-J AM MED ASSOC, V254, P531, DOI 10.1001/jama.254.4.531; GREENBERGER PA, 1986, J ALLERGY CLIN IMMUN, V77, P630, DOI 10.1016/0091-6749(86)90357-X; GREENBERGER PA, 1994, J ALLERGY CLIN IMMUN, V93, P302; GREENBERGER PA, 1989, AM J MED SCI, V298, P104, DOI 10.1097/00000441-198908000-00006; Greenberger PA, 2007, IMMUNOL ALLERGY CLIN, V27, P273, DOI 10.1016/j.iac.2007.03.009; Greenberger PA, 2007, ANN ALLERG ASTHMA IM, V98, P252, DOI 10.1016/S1081-1206(10)60714-4; Gueant J.-L., 1998, Clinical and Experimental Allergy, V28, P65; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; HAMILTON G, 1985, CAN MED ASSOC J, V133, P122; Hamilton RG, 2002, J ALLERGY CLIN IMMUN, V110, pS47, DOI 10.1067/mai.2002.125334; Hamilton RG, 2001, ANN ALLERG ASTHMA IM, V86, P353, DOI 10.1016/S1081-1206(10)62477-5; Hamilton RG, 2004, CURR OPIN ALLERGY CL, V4, P297, DOI 10.1097/01.all.0000136755.13077.b5; Harada S, 2001, BRIT J DERMATOL, V145, P336, DOI 10.1046/j.1365-2133.2001.04329.x; HARLE DG, 1989, ANESTHESIOLOGY, V71, P489, DOI 10.1097/00000542-198910000-00003; HARLE DG, 1986, CLIN ALLERGY, V16, P493, DOI 10.1111/j.1365-2222.1986.tb01984.x; Hawkins C, 2003, ALLERGY, V58, P688, DOI 10.1034/j.1398-9995.2003.00190.x; HEPNER MJ, 1990, J ALLERGY CLIN IMMUN, V86, P407, DOI 10.1016/S0091-6749(05)80105-8; HIATT WR, 1985, CLIN PHARMACOL THER, V37, P2, DOI 10.1038/clpt.1985.2; HIRSHMAN CA, 1985, ANESTHESIOLOGY, V63, P353, DOI 10.1097/00000542-198510000-00002; Hoffman B, 1990, GOODMAN GILMANS PHAR, P209; HOFFMAN DR, 1991, ANN ALLERGY, V66, P29; HOFFMAN DR, 2004, HYMENOPTERA VENOMSED; Hogendijk S, 1997, ALLERGY, V52, P1145, DOI 10.1111/j.1398-9995.1997.tb00193.x; Horrow JC, 1996, ANESTH ANALG, V82, P386, DOI 10.1097/00000539-199602000-00031; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; Jarvinen KM, 2008, J ALLERGY CLIN IMMUN, V122, P133, DOI 10.1016/j.jaci.2008.04.031; Jerath MR, 2009, J ALLERGY CLIN IMMUN, V123, P260, DOI 10.1016/j.jaci.2008.09.046; Jochberger S, 2005, CURR OPIN ANESTHESIO, V18, P396, DOI 10.1097/01.aco.0000174963.35877.81; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; *JOINT TASK FORC P, 1998, J ALLERGY CLIN IMMUN, V101, pS465; JONES WR, 1991, AUST NZ J OBSTET GYN, V31, P137, DOI 10.1111/j.1479-828X.1991.tb01802.x; JUJI F, 1994, ANN ALLERGY, V72, P452; KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; Kemp SF, 2001, IMMUNOL ALLERGY CLIN, V21, P611, DOI 10.1016/S0889-8561(15)30004-7; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; Kill C, 2004, INT ARCH ALLERGY IMM, V134, P260, DOI 10.1159/000078775; Kimmel SE, 1998, J AM COLL CARDIOL, V32, P1916, DOI 10.1016/S0735-1097(98)00484-7; Kindler CH, 1996, ANESTHESIOLOGY, V85, P1209, DOI 10.1097/00000542-199611000-00037; KINT B, 1994, CONTACT DERMATITIS, V30, P7, DOI 10.1111/j.1600-0536.1994.tb00720.x; Kishimoto TK, 2008, NEW ENGL J MED, V358, P2457, DOI 10.1056/NEJMoa0803200; KIVITY S, 1990, J ALLERGY CLIN IMMUN, V85, P669, DOI 10.1016/0091-6749(90)90111-G; Kleine-Tebbe J, 2002, J ALLERGY CLIN IMMUN, V110, P797, DOI 10.1067/mai.2002.128946; Korenblat P, 1999, ALLERGY ASTHMA PROC, V20, P383, DOI 10.2500/108854199778251834; KREIMEIER U, 1995, LANCET, V346, P49, DOI 10.1016/S0140-6736(95)92677-1; LANG DM, 1991, ANN INTERN MED, V115, P270, DOI 10.7326/0003-4819-115-4-270; LANG DM, 1995, DRUG SAFETY, V12, P299, DOI 10.2165/00002018-199512050-00002; LANG DM, 1993, ARCH INTERN MED, V153, P2033, DOI 10.1001/archinte.153.17.2033; LAROCHE D, 1992, BRIT J ANAESTH, V69, P611, DOI 10.1093/bja/69.6.611; LAROCHE D, 1991, ANESTHESIOLOGY, V75, P945, DOI 10.1097/00000542-199112000-00004; LAXENAIRE M C, 1984, Annales Francaises d'Anesthesie et de Reanimation, V3, P453, DOI 10.1016/S0750-7658(84)80146-X; LAXENAIRE MC, 1982, KLIN WOCHENSCHR, V60, P1006, DOI 10.1007/BF01716963; LAXENAIRE MC, 1993, ANN FR ANESTH, V12, P91, DOI 10.1016/S0750-7658(05)81015-9; LAXENAIRE MC, 1985, INT ANESTHESIOL CLIN, V23, P145, DOI 10.1097/00004311-198511000-00010; LAXENAIRE MC, 1988, LANCET, V2, P739; Lee C, 2009, ANN ALLERG ASTHMA IM, V102, P179, DOI 10.1016/S1081-1206(10)60078-6; Lehane L, 2000, MED J AUSTRALIA, V173, P149, DOI 10.5694/j.1326-5377.2000.tb125575.x; LEVINE BB, 1973, NEW ENGL J MED, V288, P894, DOI 10.1056/NEJM197304262881707; LEVY J, 1992, ANAPHYLACTIC REACTIO, P83; LEWIS J, 1981, J ALLERGY CLIN IMMUN, V68, P432, DOI 10.1016/0091-6749(81)90197-4; LEYNADIER F, 1991, INT ARCH ALLER A IMM, V94, P349, DOI 10.1159/000235400; LEYNADIER F, 1987, BRIT J ANAESTH, V59, P683, DOI 10.1093/bja/59.6.683; Lieberman P, 2005, ANN ALLERG ASTHMA IM, V95, P217, DOI 10.1016/S1081-1206(10)61217-3; Lieberman P, 2001, IMMUNOL ALLERGY CLIN, V21, P813; LIEBERMAN P, 1991, CLIN REV ALLERG, V9, P319; LIEBERMAN P, 2003, MIDDLETONS ALLERGY P, P1497; LIEBERMAN P, 2005, J ALLERGY CLIN IMMUN, V115, P483, DOI DOI 10.1016/j.jaci.2005.01.010; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; Lieberman P, 2007, ANN ALLERG ASTHMA IM, V98, P519, DOI 10.1016/S1081-1206(10)60729-6; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; LIGHT WC, 1977, J ALLERGY CLIN IMMUN, V59, P391, DOI 10.1016/0091-6749(77)90024-0; Limb SL, 2007, J ALLERGY CLIN IMMUN, V120, P1378, DOI 10.1016/j.jaci.2007.09.022; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Lin RY, 2000, J ALLERGY CLIN IMMUN, V106, P65, DOI 10.1067/mai.2000.107600; Lin RY, 2000, ANN EMERG MED, V36, P462, DOI 10.1067/mem.2000.109445; Lindner KH, 1997, LANCET, V349, P535, DOI 10.1016/S0140-6736(97)80087-6; LOCKEY RF, 1988, J ALLERGY CLIN IMMUN, V82, P370, DOI 10.1016/0091-6749(88)90008-5; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Lockey RF, 2001, ANN ALLERG ASTHMA IM, V87, P47, DOI 10.1016/S1081-1206(10)62195-3; MADOWITZ JS, 1979, JAMA-J AM MED ASSOC, V241, P2813, DOI 10.1001/jama.241.26.2813; MADOWITZ JS, 1979, JAMA-J AM MED ASSOC, V29, P2813; Malinovsky JM, 2008, ACTA ANAESTH SCAND, V52, P175, DOI 10.1111/j.1399-6576.2007.01489.x; Markman M, 2003, J CLIN ONCOL, V21, P4611, DOI 10.1200/JCO.2003.05.539; MATHIAS CGT, 1980, ARCH DERMATOL, V116, P209, DOI 10.1001/archderm.116.2.209; MATLOFF SM, 1993, J ALLERGY CLIN IMMUN, V91, P1230, DOI 10.1016/0091-6749(93)90328-D; MATSSON P, 1991, AGENTS ACTIONS, V33, P218, DOI 10.1007/BF01993172; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; MAURIELLO PM, 1984, J ALLERGY CLIN IMMUN, V74, P494, DOI 10.1016/0091-6749(84)90384-1; MAYUMI H, 1987, ANN ALLERGY, V58, P447; Mehl A, 2005, ALLERGY, V60, P1440, DOI 10.1111/j.1398-9995.2005.00909.x; MENDELSON LM, 1984, J ALLERGY CLIN IMMUN, V73, P76, DOI 10.1016/0091-6749(84)90487-1; Mertes PM, 2003, ANESTHESIOLOGY, V99, P536, DOI 10.1097/00000542-200309000-00007; MITTMAN RJ, 1990, J ALLERGY CLIN IMMUN, V86, P954, DOI 10.1016/S0091-6749(05)80159-9; Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046; Moreno-Ancillo A, 2003, Allergol Immunopathol (Madr), V31, P342, DOI 10.1157/13055214; MOSCICKI RA, 1990, J ALLERGY CLIN IMMUN, V86, P325, DOI 10.1016/S0091-6749(05)80095-8; MOTULSKY HJ, 1982, NEW ENGL J MED, V307, P18, DOI 10.1056/NEJM198207013070104; Mueller UR, 2007, CURR OPIN ALLERGY CL, V7, P337, DOI 10.1097/ACI.0b013e328259c328; MULLER U, 1979, ALLERGY, V34, P369, DOI 10.1111/j.1398-9995.1979.tb02006.x; Muller UR, 2005, J ALLERGY CLIN IMMUN, V115, P606, DOI [10.1016/j.jaci.2004.11.012, 10.1016/j.jsci.2004.11.012]; MUMFORD DM, 1978, ANN ALLERGY, V40, P40; MYERS G, 1981, J ALLERGY CLIN IMMUN, V67, P305, DOI 10.1016/0091-6749(81)90026-9; NEWFIELD P, 1979, ANN INTERN MED, V91, P581, DOI 10.7326/0003-4819-91-4-581; NEWMAN BR, 1981, ANN ALLERGY, V47, P35; NICKLAS RA, 1998, J ALLERGY CLIN IMM S, V101, P472; Nugent JS, 2003, ANN ALLERG ASTHMA IM, V90, P398, DOI 10.1016/S1081-1206(10)61823-6; Nusam D, 1999, ALLERGY, V54, P765, DOI 10.1034/j.1398-9995.1999.00215.x; OHMAN JL, 1990, J ALLERGY CLIN IMMUN, V85, P103, DOI 10.1016/0091-6749(90)90230-2; Oren E, 2007, ANN ALLERG ASTHMA IM, V99, P429, DOI 10.1016/S1081-1206(10)60568-6; Park JW, 1999, ALLERGY, V54, P990, DOI 10.1034/j.1398-9995.1999.00129.x; Park M, 2006, ANN ALLERG ASTHMA IM, V97, P681, DOI 10.1016/S1081-1206(10)61100-3; Patel DD, 2006, ONCOLOGY-NY, V20, P1373; PEPYS J, 1994, ANAESTHESIA, V49, P470, DOI 10.1111/j.1365-2044.1994.tb03515.x; PEREZ C, 1995, J ALLERGY CLIN IMMUN, V95, P368; Pollack Chalres V. Jr., 1993, Journal of Emergency Medicine, V11, P195; Porri F, 1999, CLIN EXP ALLERGY, V29, P72, DOI 10.1046/j.1365-2222.1999.00453.x; Porsche R, 1999, HEART LUNG, V28, P418, DOI 10.1016/S0147-9563(99)70031-2; Poulos LM, 2007, J ALLERGY CLIN IMMUN, V120, P878, DOI 10.1016/j.jaci.2007.07.040; PRESTI ME, 1989, ANN ALLERGY, V63, P477; PSATY BM, 1990, JAMA-J AM MED ASSOC, V263, P1653, DOI 10.1001/jama.263.12.1653; Pumphrey RSH, 1999, LANCET, V353, P1157, DOI 10.1016/S0140-6736(99)00449-3; Ragusa FV, 1997, J INVEST ALLERG CLIN, V7, P151; RANDALL B, 1995, J FORENSIC SCI, V40, P208; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V91, P1100, DOI 10.1016/0091-6749(93)90227-7; REISMAN RE, 1989, J ALLERGY CLIN IMMUN, V84, P331, DOI 10.1016/0091-6749(89)90417-X; Renz CL, 1998, ANESTHESIOLOGY, V89, P620, DOI 10.1097/00000542-199809000-00010; Renz CL, 1999, CRIT CARE MED, V27, P1732, DOI 10.1097/00003246-199909000-00006; Resnick DJ, 2004, AM J REPROD IMMUNOL, V52, P42, DOI 10.1111/j.1600-0897.2004.00180.x; Rezvani M, 2007, IMMUNOL ALLERGY CLIN, V27, P295, DOI 10.1016/j.iac.2007.03.010; Ricci G, 1999, BJU INT, V84, P1058; RING J, 1985, INT ANESTHESIOL CLIN, V23, P67; Romano A, 2006, NEW ENGL J MED, V354, P2835, DOI 10.1056/NEJMc053529; Romano A, 2001, INT ARCH ALLERGY IMM, V125, P264, DOI 10.1159/000053825; Rose M, 2001, BRIT J ANAESTH, V86, P678, DOI 10.1093/bja/86.5.678; ROSOW CE, 1982, ANESTHESIOLOGY, V56, P93, DOI 10.1097/00000542-198202000-00003; Ross MP, 2008, J ALLERGY CLIN IMMUN, V121, P166, DOI 10.1016/j.jaci.2007.10.012; ROTHSCHILD P, 1966, JAMA-J AM MED ASSOC, V206, P130; Roy SR, 2007, ANN ALLERG ASTHMA IM, V99, P82, DOI 10.1016/S1081-1206(10)60626-6; Rueff F, 1996, ALLERGY, V51, P216, DOI 10.1111/j.1398-9995.1996.tb04596.x; Rueff F, 2009, J ALLERGY CLIN IMMUN, V124, P1047, DOI 10.1016/j.jaci.2009.08.027; RUNGE JW, 1992, ANN EMERG MED, V21, P237, DOI 10.1016/S0196-0644(05)80881-9; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; SAXON A, 1984, J INFECT DIS, V149, P16, DOI 10.1093/infdis/149.1.16; SAXON A, 1988, J ALLERGY CLIN IMMUN, V82, P213, DOI 10.1016/0091-6749(88)91001-9; SCHOLAND JF, 1968, J AMER MED ASSOC, V206, P130, DOI 10.1001/jama.206.1.130; Scholl L, 2005, AM J CLIN NUTR, V81, P154; SCHUBERTH KC, 1982, J PEDIATR-US, V100, P546, DOI 10.1016/S0022-3476(82)80750-6; SCHWARTZ HJ, 1995, J ALLERGY CLIN IMMUN, V95, P917, DOI 10.1016/S0091-6749(95)70139-7; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; Shadick NA, 1999, J ALLERGY CLIN IMMUN, V104, P123, DOI 10.1016/S0091-6749(99)70123-5; Shanmugam G, 2006, J ALLERGY CLIN IMMUN, V117, P950, DOI 10.1016/j.jaci.2005.12.1356; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P479, DOI 10.1016/S0091-6749(85)80021-X; SHEFFER AL, 1984, J ALLERGY CLIN IMMUN, V73, P699, DOI 10.1016/0091-6749(84)90309-9; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; SHEFFER AL, 1983, J ALLERGY CLIN IMMUN, V71, P311, DOI 10.1016/0091-6749(83)90085-4; SHEHADI WH, 1980, RADIOLOGY, V137, P299, DOI 10.1148/radiology.137.2.7433658; Shek LPC, 2004, CURR OPIN ALLERGY CL, V4, P325, DOI 10.1097/01.all.0000136761.51195.01; Shen YW, 2009, FORENSIC SCI INT, V186, P1, DOI 10.1016/j.forsciint.2008.12.007; SHERMAN MS, 1988, J ALLERGY CLIN IMMUN, V81, P908, DOI 10.1016/0091-6749(88)90949-9; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Simon MR, 2008, INT ARCH ALLERGY IMM, V146, P89, DOI 10.1159/000112508; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; SIMONS FER, 1994, CAN MED ASSOC J, V150, P337; Sinkiewicz Wladyslaw, 2008, Cardiol J, V15, P220; SOGN DD, 1992, ARCH INTERN MED, V152, P1025, DOI 10.1001/archinte.152.5.1025; Solensky R, 2003, CLIN REV ALLERG IMMU, V24, P201, DOI 10.1385/CRIAI:24:3:201; SOREIDE E, 1988, ACTA ANAESTH SCAND, V32, P339; SPECKEN, 1958, Ned Tijdschr Verloskd Gynaecol, V58, P314; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; Stecher D, 2009, PEDIATRICS, V124, P65, DOI 10.1542/peds.2008-3388; Stevenson DD, 2004, IMMUNOL ALLERGY CLIN, V24, P491, DOI 10.1016/j.iac.2004.03.001; Sticherling M, 1999, CLIN DERMATOL, V17, P417, DOI 10.1016/S0738-081X(99)00027-9; Stiell IG, 2001, LANCET, V358, P105, DOI 10.1016/S0140-6736(01)05328-4; Stumpf JL, 2006, ANN PHARMACOTHER, V40, P699, DOI 10.1345/aph.1G295; Summers CW, 2008, J ALLERGY CLIN IMMUN, V121, P632, DOI 10.1016/j.jaci.2007.12.003; Sussman GL, 2002, J ALLERGY CLIN IMMUN, V110, pS33, DOI 10.1067/mai.2002.124969; Takenoshita M, 1996, ANESTHESIOLOGY, V84, P233, DOI 10.1097/00000542-199601000-00030; Tankersley MS, 2002, J ALLERGY CLIN IMMUN, V109, P556, DOI 10.1067/mai.2002.121956; TANUS T, 1994, ANN EMERG MED, V24, P104, DOI 10.1016/S0196-0644(94)70169-5; TenBrook JA, 2004, J ALLERGY CLIN IMMUN, V113, P977, DOI 10.1016/j.jaci.2004.02.043; Thomas M, 2005, EMERG MED J, V22, P272, DOI 10.1136/emj.2005.023507; Thong BYH, 2004, ANN ALLERG ASTHMA IM, V92, P619, DOI 10.1016/S1081-1206(10)61427-5; THRALL J, 1990, ADVERSE REACTIONS CO; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; TOOGOOD JH, 1987, CMAJ, V1, P929; Triggiani M, 2008, CLIN EXP IMMUNOL, V153, P7, DOI 10.1111/j.1365-2249.2008.03714.x; Untersmayr E, 2005, FASEB J, V19, P656, DOI 10.1096/fj.04-3170fje; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI [10.1016/S0091-6749(03)01719-6, 10.1016/mai.2003.1681]; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Valabhji J, 2000, J ROY SOC MED, V93, P141, DOI 10.1177/014107680009300309; VALENTINE MD, 1990, NEW ENGL J MED; Vander Zanden JA, 2001, ANN PHARMACOTHER, V35, P1633, DOI 10.1345/1542-6270(2001)035<1633:SAEOOB>2.0.CO;2; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889; VINER NA, 1975, J UROLOGY, V113, P108, DOI 10.1016/S0022-5347(17)59419-7; Von Hoff DD, 2008, AM J EMERG MED, V26, P31, DOI 10.1016/j.ajem.2007.03.024; Wade J P, 1989, Prog Clin Biol Res, V297, P175; Wang JL, 2007, CLIN EXP ALLERGY, V37, P651, DOI 10.1111/j.1365-2222.2007.02682.x; Wenzel V, 2004, NEW ENGL J MED, V350, P105, DOI 10.1056/NEJMoa025431; Westfall T.C., 2006, ADRENERGIC AGONISTS; Wiggins CA, 1991, IMMUN ALLERGY PRACT, V13, P313; Williams SR, 2004, CAN J ANAESTH, V51, P169, DOI 10.1007/BF03018778; WILLIAMSON J, 1990, ANAESTH INTENS CARE, V18, P277; WONG S, 1991, ANN INTERN MED, V114, P133, DOI 10.7326/0003-4819-114-2-133; Worster Andrew, 2004, ACP J Club, V141, P2; YAKEL DL, 1992, CRIT CARE MED, V20, P307, DOI 10.1097/00003246-199202000-00020; YARBROUGH JA, 1989, ANN ALLERGY, V63, P235; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; YOCUM MW, 1994, MAYO CLIN PROC, V69, P16, DOI 10.1016/S0025-6196(12)61606-1; YUNGINGER JW, 1991, J FORENSIC SCI, V36, P857; ZALOGA GP, 1986, ANN INTERN MED, V105, P65, DOI 10.7326/0003-4819-105-1-65; 1973, PEDIATRICS, V51, P136	328	60	60	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3												42	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF					2022-12-18	WOS:000281512500010
J	Peters, M; Kauth, M; Scherner, O; Gehlhar, K; Steffen, I; Wentker, P; von Mutius, E; Holst, O; Bufe, A				Peters, Marcus; Kauth, Marion; Scherner, Olaf; Gehlhar, Kirsten; Steffen, Imke; Wentker, Pia; von Mutius, Erika; Holst, Otto; Bufe, Albrecht			Arabinogalactan isolated from cowshed dust extract protects mice from allergic airway inflammation and sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic airway inflammation; sensitization; immunomodulation; arabinogalactan	IMMUNE-RESPONSES; DC-SIGN; ASTHMA; POLLEN; EOSINOPHILIA; EXPOSURE; HYPERRESPONSIVENESS; POLYSACCHARIDES; PHYTOPROSTANES; CHILDREN	Background: Extract from cowshed dust (CDE) is a source of immunomodulating substances. We have previously shown that such substances protect from experimental allergic disorders in a mouse model of asthma. Objective: The objective of this study was to identify immunomodulatory molecules in extracts of dust from an allergy protective farming environment. Methods: Polysaccharides were isolated from CDE and plants by chromatography and precipitation with specific reagents. Polysaccharides were then characterized by nuclear magnetic resonance spectroscopy. Subsequently, the allergy-protective potential of isolated polysaccharides was tested in a mouse model of asthma. Results: The authors demonstrate that plant arabinogalactans are contained in CDE in high concentrations. The source of this arabinogalactan is fodder, in particular a prevalent grass species known as Alopecurus pratensis. Treatment of murine dendritic cells with grass arabinogalactan resulted in autocrine IL-10 production. Interestingly, these dendritic cells were not able to induce an allergic immune response. Furthermore, intranasal application of grass arabinogalactan protected mice from developing atopic sensitization, allergic airway inflammation and airway hyperreactivity in a mouse model of allergic asthma. This allergy-protective effect is specific for grass arabinogalactan because control experiments with arabinogalactan from gum arabic and larch revealed that these molecules do not show allergy-protective properties. This is likely because of structural differences because we were able to show by nuclear magnetic resonance spectroscopy that although they are predominantly composed of arabinose and galactose, the molecules differ in structure. Conclusions: The authors conclude that grass arabinogalactans are important immunomodulatory substances that contribute to the protection from allergic airway inflammation, airway hyperresponsiveness, and atopic sensitization in a mouse model of asthma. (J Allergy Clin Immunol 2010;126:648-56.)	[Peters, Marcus; Kauth, Marion; Gehlhar, Kirsten; Steffen, Imke; Wentker, Pia; Bufe, Albrecht] Ruhr Univ Bochum, Dept Expt Pneumol, D-44789 Bochum, Germany; [Kauth, Marion; Scherner, Olaf] Protectimmun GmbH, Bochum, Germany; [von Mutius, Erika] Dr Hauner Childrens Hosp, Munich, Germany; [Holst, Otto] Res Ctr Borstel, Dept Struct Biochem, Borstel, Germany	Ruhr University Bochum; University of Munich; Forschungszentrum Borstel	Peters, M (corresponding author), Ruhr Univ Bochum, Dept Expt Pneumol, Burkle Camp Pl 1, D-44789 Bochum, Germany.	marcus.peters@rub.de	Peters, Marcus/J-3955-2019; Steffen, Imke/AAY-3266-2020	Peters, Marcus/0000-0003-1850-2845; Bufe, Albrecht/0000-0001-7335-9362; von Mutius, Erika/0000-0002-8893-4515; Steffen, Imke/0000-0001-6592-0332				Adler A, 2005, J ALLERGY CLIN IMMUN, V115, P67, DOI 10.1016/j.jaci.2004.10.008; Appelmelk BJ, 2008, CELL MICROBIOL, V10, P930, DOI 10.1111/j.1462-5822.2007.01097.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brecker L, 2005, CARBOHYD RES, V340, P657, DOI 10.1016/j.carres.2005.01.006; Broide D, 1998, J IMMUNOL, V161, P7054; Chandrasekaran R, 2002, CARBOHYD RES, V337, P2211, DOI 10.1016/S0008-6215(02)00223-9; Chen ZS, 2009, J IMMUNOL, V182, P3503, DOI 10.4049/jimmunol.0802567; Chieppa M, 2003, J IMMUNOL, V171, P4552, DOI 10.4049/jimmunol.171.9.4552; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Currier NL, 2003, PHYTOMEDICINE, V10, P145, DOI 10.1078/094471103321659852; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; FINCHER GB, 1983, ANNU REV PLANT PHYS, V34, P47, DOI 10.1146/annurev.pp.34.060183.000403; Gerhold K, 2002, J ALLERGY CLIN IMMUN, V110, P110, DOI 10.1067/mai.2002.125831; Glaab T, 2004, J APPL PHYSIOL, V97, P1104, DOI 10.1152/japplphysiol.01182.2003; Gorelik L, 2008, INNATE IMMUN-LONDON, V14, P345, DOI 10.1177/1753425908098006; Gringhuis SI, 2007, IMMUNITY, V26, P605, DOI 10.1016/j.immuni.2007.03.012; Gutermuth J, 2007, J ALLERGY CLIN IMMUN, V120, P293, DOI 10.1016/j.jaci.2007.03.017; Hanuszkiewicz A, 2008, EUR J ORG CHEM, V2008, P6183, DOI 10.1002/ejoc.200800887; Hopfenspirger MT, 2002, J IMMUNOL, V168, P2516, DOI 10.4049/jimmunol.168.5.2516; Kelly G S, 1999, Altern Med Rev, V4, P96; Kohl J, 2006, J CLIN INVEST, V116, P783, DOI 10.1172/JCI26582; Koppel EA, 2004, IMMUNOBIOLOGY, V209, P117, DOI 10.1016/j.imbio.2004.03.003; Nergard CS, 2006, BIOMACROMOLECULES, V7, P71, DOI 10.1021/bm050355g; ODONMAZIG P, 1994, CARBOHYD RES, V252, P317, DOI 10.1016/0008-6215(94)90028-0; Peters M, 2006, THORAX, V61, P134, DOI 10.1136/thx.2005.049403; QI W, 1991, PLANT PHYSIOL, V96, P848, DOI 10.1104/pp.96.3.848; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Roy SR, 2003, J ALLERGY CLIN IMMUN, V112, P571, DOI 10.1067/mai.2003.1711; Saito K, 2003, J BIOL CHEM, V278, P38571, DOI 10.1074/jbc.M304948200; Schepetkin IA, 2005, INT IMMUNOPHARMACOL, V5, P1783, DOI 10.1016/j.intimp.2005.05.009; Sudre B, 2009, ALLERGY, V64, P1068, DOI 10.1111/j.1398-9995.2009.01958.x; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; YARIV J, 1967, BIOCHEM J, V105, pC1, DOI 10.1042/bj1050001C; Zhang X, 2009, J IMMUNOL, V182, P5123, DOI 10.4049/jimmunol.0804276; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	37	60	64	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					648	U9		10.1016/j.jaci.2010.05.011	http://dx.doi.org/10.1016/j.jaci.2010.05.011			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20621350				2022-12-18	WOS:000281512500036
J	Kulkarni, NS; Hollins, F; Sutcliffe, A; Saunders, R; Shah, S; Siddiqui, S; Gupta, S; Haldar, P; Green, R; Pavord, I; Wardlaw, A; Brightling, CE				Kulkarni, Neeta S.; Hollins, Fay; Sutcliffe, Amanda; Saunders, Ruth; Shah, Sachil; Siddiqui, Salman; Gupta, Sumit; Haldar, Pranab; Green, Ruth; Pavord, Ian; Wardlaw, Andrew; Brightling, Christopher E.			Eosinophil protein in airway macrophages: A novel biomarker of eosinophilic inflammation in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; macrophage; eosinophil; computer-assisted image analysis; induced sputum	INDUCED SPUTUM; INHALED CORTICOSTEROIDS; EXACERBATIONS; BRONCHITIS; IDENTIFICATION; MEPOLIZUMAB; EXPRESSION; GUIDELINES; RESOLUTION; APOPTOSIS	Background: Noneosinophilic asthma is common across asthma severities. However, in patients with moderate-to-severe disease, the absence of sputum eosinophilia cannot distinguish between asthmatic subjects with eosinophilic inflammation controlled by corticosteroids versus those in whom eosinophilic inflammation is not a component of the disease. Objectives: We sought to develop a method to quantify eosinophil proteins in airway macrophages as a novel biomarker of eosinophilic airway inflammation. Methods: Eosinophil proteins in airway macrophages were assessed by means of flow cytometry, immunofluorescence, and cytoplasmic hue change after ingestion of apoptotic eosinophils. Airway macrophage median percentage of red-hued area in stained sputum cytospin preparations was assessed by means of image analysis from (1) subjects with mild-to-severe asthma, subjects with nonasthmatic eosinophilic bronchitis, and healthy control subjects; (2) subjects with eosinophilic severe asthma after treatment with prednisolone; and (3) subject with noneosinophilic asthma before corticosteroid withdrawal. Results: Eosinophil proteins were detected in airway macrophages, and cytoplasmic red hue increased after ingestion of apoptotic eosinophils. Airway macrophage percentage red-hued area was increased in subjects with moderate-to-severe asthma compared with that seen in subjects with mild asthma and healthy control subjects, was similar in those with or without a sputum eosinophilia, and was increased after corticosteroid therapy. In asthmatic subjects without sputum eosinophilia, the airway macrophage percentage red-hued area was increased in subjects who did versus those who did not have sputum eosinophilia after corticosteroid withdrawal. Conclusions: Eosinophil proteins can be reliably measured in airway macrophages. In combination with sputum eosinophilia, the macrophage eosinophil protein content might further define the asthma phenotype and provide an additional tool to direct therapy. (J Allergy Clin Immunol 2010;126:61-9.)	[Kulkarni, Neeta S.; Hollins, Fay; Sutcliffe, Amanda; Saunders, Ruth; Shah, Sachil; Siddiqui, Salman; Gupta, Sumit; Haldar, Pranab; Green, Ruth; Pavord, Ian; Wardlaw, Andrew; Brightling, Christopher E.] Glenfield Hosp, Inst Lung Hlth, Leicester LE3 9QP, Leics, England; [Kulkarni, Neeta S.; Hollins, Fay; Sutcliffe, Amanda; Saunders, Ruth; Shah, Sachil; Siddiqui, Salman; Gupta, Sumit; Haldar, Pranab; Green, Ruth; Pavord, Ian; Wardlaw, Andrew; Brightling, Christopher E.] Univ Leicester, Leicester, Leics, England; [Kulkarni, Neeta S.] Leicester City NHS Primary Care Trust, Childrens Community Hlth Serv, Leicester, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; University of Leicester	Kulkarni, NS (corresponding author), Glenfield Hosp, Inst Lung Hlth, Groby Rd, Leicester LE3 9QP, Leics, England.	nsk4@le.ac.uk		Haldar, Pranabashis/0000-0002-1572-5421; brightling, chris/0000-0002-9345-4903; Pavord, Ian/0000-0002-4288-5973; Siddiqui, Salman/0000-0003-3770-7870; Saunders, Ruth Mary/0000-0001-8893-6687; Gupta, Sumit/0000-0002-7123-6139; Wardlaw, Andrew/0000-0001-6583-0791	Midland Allergy and Asthma Association; Asthma UK; Trent NHS RD; Wellcome Senior Fellowship; GlaxoSmithKline; AstraZeneca; National Institute for Health Research [CL-2008-11-005] Funding Source: researchfish	Midland Allergy and Asthma Association; Asthma UK; Trent NHS RD; Wellcome Senior Fellowship; GlaxoSmithKline(GlaxoSmithKline); AstraZeneca(AstraZeneca); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by the Midland Allergy and Asthma Association, Asthma UK, Trent NHS R&D, Wellcome Senior Fellowship (CB), GlaxoSmithKline (Severe Asthma Study funding), and AstraZeneca (THP-1 Cells).	Berry MA, 2004, J ALLERGY CLIN IMMUN, V114, P1106, DOI 10.1016/j.jaci.2004.08.032; Berry M, 2007, THORAX, V62, P1043, DOI 10.1136/thx.2006.073429; Brightling CE, 2006, CHEST, V129, p116S, DOI 10.1378/chest.129.1_suppl.116S; Brightling CE, 2003, THORAX, V58, P528, DOI 10.1136/thorax.58.6.528; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Day CE, 2009, J IMMUNOL METHODS, V342, P91, DOI 10.1016/j.jim.2008.12.001; Dewson G, 2001, BLOOD, V98, P2239, DOI 10.1182/blood.V98.7.2239; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; DVORAK AM, 1990, LAB INVEST, V62, P590; Fahy John V, 2009, Proc Am Thorac Soc, V6, P256, DOI 10.1513/pats.200808-087RM; *GLOB IN ASTHM, 2008, GLOB STRAT ASTHM MAN; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Gupta S, 2009, CHEST, V136, P1521, DOI 10.1378/chest.09-0174; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; in't Veen JCCM, 1999, AM J RESP CRIT CARE, V160, P93; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64, DOI 10.1164/ajrccm.161.1.9809100; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Leuppi JD, 2001, AM J RESP CRIT CARE, V163, P406, DOI 10.1164/ajrccm.163.2.9912091; Lex C, 2007, PEDIATR PULM, V42, P298, DOI 10.1002/ppul.20570; Matsumoto K, 2007, INT ARCH ALLERGY IMM, V143, P60, DOI 10.1159/000101407; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Pavord ID, 2009, J ALLERGY CLIN IMMUN, V123, P1083, DOI 10.1016/j.jaci.2009.02.034; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Walsh GM, 1999, BLOOD, V94, P2827, DOI 10.1182/blood.V94.8.2827.420a04_2827_2835; Woolley KL, 1996, AM J RESP CRIT CARE, V154, P237, DOI 10.1164/ajrccm.154.1.8680686	28	60	65	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					61	69		10.1016/j.jaci.2010.03.026	http://dx.doi.org/10.1016/j.jaci.2010.03.026			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20639010	Green Accepted			2022-12-18	WOS:000280061800012
J	Singh, M; Lee, SH; Porter, P; Xu, CA; Ohno, A; Atmar, RL; Greenberg, SB; Bandi, V; Gern, J; Amineva, S; Aminev, A; Skern, T; Smithwick, P; Perusich, S; Barrow, N; Roberts, L; Corry, DB; Kheradmand, F				Singh, Manisha; Lee, Seung-Hyo; Porter, Paul; Xu, Chuang; Ohno, Ayako; Atmar, Robert L.; Greenberg, Stephen B.; Bandi, Venkata; Gern, Jim; Amineva, Svetlana; Aminev, Alex; Skern, Tim; Smithwick, Pamela; Perusich, Sarah; Barrow, Nadia; Roberts, Luz; Corry, David B.; Kheradmand, Farrah			Human rhinovirus proteinase 2A induces T(H)1 and T(H)2 immunity in patients with chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)1/T(H)2 cells; chronic obstructive pulmonary disease; proteinase; lung inflammation	NONTYPABLE HAEMOPHILUS-INFLUENZAE; ALLERGIC AIRWAY INFLAMMATION; RESPIRATORY VIRUSES; EXPERIMENTAL ASTHMA; VIRAL-INFECTIONS; CELL EGRESSION; LUNG-DISEASE; EXACERBATIONS; INTERLEUKIN-5; POLARIZATION	Background: Tobacco-related lung diseases, including chronic obstructive pulmonary disease (COPD), are major causes of lung-related disability and death worldwide. Acute exacerbation of COPD (AE-COPD) is commonly associated with upper and lower respiratory tract viral infections and can result in respiratory failure in those with advanced lung disease. Objective: We sought to determine the mechanism underlying COPD exacerbation and host response to pathogen-derived factors. Methods: Over a 24-month period, we assessed the viral causes for upper and lower respiratory tract infections in patients with COPD (n = 155) and control subjects (n = 103). We collected nasal and bronchoalveolar lavage fluid and peripheral blood under baseline and exacerbated conditions. We determined the effect of human rhinovirus (HRV) proteinases on T-cell activation in human subjects and mice. Results: HRVs are isolated from nasal and lung fluid from subjects with AE-COPD. Bronchoalveolar lavage fluid and CD4 T cells from patients with COPD exhibited a T(H)1 and T(H)2 cell cytokine phenotype during acute infection. HRV-encoded proteinase 2A activated monocyte-derived dendritic cells in vitro and induced strong T(H)1 and T(H)2 immune responses from CD4 T cells. Intranasal administration of recombinant rhinovirus proteinase 2A in mice resulted in an increase in airway hyperreactivity, lung inflammation, and IL-4 and IFN-gamma production from CD4 T cells. Conclusion: Our findings suggest that patients with severe COPD show T(H)1- and T(H)2-biased responses during AE-COPD. HRV-encoded proteinase 2A, like other microbial proteinases, could provide a T(H)1- and T(H)2-biasing adjuvant factor during upper and lower respiratory tract infection in patients with severe COPD. Alteration of the immune response to secreted viral proteinases might contribute to worsening of dyspnea and respiratory failure in patients with COPD. (J Allergy Clin Immunol 2010;125:1369-78.)	[Singh, Manisha; Porter, Paul; Xu, Chuang; Bandi, Venkata; Smithwick, Pamela; Perusich, Sarah; Barrow, Nadia; Roberts, Luz; Corry, David B.; Kheradmand, Farrah] Baylor Coll Med, Dept Med, Div Pulm & Crit Care, Houston, TX 77030 USA; [Lee, Seung-Hyo] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Taejon 305701, South Korea; [Ohno, Ayako; Corry, David B.; Kheradmand, Farrah] Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; [Atmar, Robert L.; Greenberg, Stephen B.] Baylor Coll Med, Div Infect Dis, Houston, TX 77030 USA; [Gern, Jim; Amineva, Svetlana] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Aminev, Alex] Univ Wisconsin, Inst Mol Virol, Madison, WI 53706 USA; [Skern, Tim] Med Univ Vienna, Max F Perutz Labs, Vienna, Austria; [Kheradmand, Farrah] Michael E DeBakey VA, Houston, TX USA	Baylor College of Medicine; Korea Advanced Institute of Science & Technology (KAIST); Baylor College of Medicine; Baylor College of Medicine; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Kheradmand, F (corresponding author), 1 Baylor Plaza,Suite 512E, Houston, TX 77030 USA.	farrahk@bcm.edu	Atmar, Robert/AFQ-5392-2022; Skern, Tim/AAC-1732-2022; Singh, Manisha/HCJ-0070-2022; Lee, Seung-Hyo/B-9922-2015	Atmar, Robert/0000-0001-9989-6772; Skern, Tim/0000-0001-8865-5500; Singh, Manisha/0000-0002-4640-8453; Lee, Seung-Hyo/0000-0003-0010-4072	National Institutes of Health (NIH) [M01-RR00188]; NIH [AI65298]; American Heart Association; Alphal-AT foundation; Austrian Science Fund;  [HL082487];  [HL72419];  [HL075243];  [AI057696];  [AI070973]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000188] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082487, R01HL072419, K02HL075243] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070503, N01AI065298, U19AI070973, R01AI057696] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Alphal-AT foundation; Austrian Science Fund(Austrian Science Fund (FWF)); ; ; ; ; ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants to F.K. (HL082487 and HL72419) and D.B.C. (HL075243, AI057696, and AI070973), National Institutes of Health (NIH) grant M01-RR00188, the General Clinical Research Center by contract N01-AI65298 from the NIH, an American Heart Association Fellowship to S.-H.L., and an Alphal-AT foundation fellowship grant to M.S.; Disclosure of potential conflict of interest: T. Skem has received research support front the Austrian Science Fund. The rest of the authors have declared that they have no conflict of interest.	Amineva SP, 2004, J GEN VIROL, V85, P2969, DOI 10.1099/vir.0.80164-0; Bandi V, 2003, FEMS IMMUNOL MED MIC, V37, P69, DOI 10.1016/S0928-8244(03)00100-7; Bandi V, 2001, AM J RESP CRIT CARE, V164, P2114, DOI 10.1164/ajrccm.164.11.2104093; Bermingham Alison, 2007, Antivir Ther, V12, P671; Connors AF, 1996, AM J RESP CRIT CARE, V154, P959, DOI 10.1164/ajrccm.154.4.8887592; Corry David B, 2002, Am J Respir Med, V1, P185; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Corry DB, 2006, J ALLERGY CLIN IMMUN, V117, pS461, DOI 10.1016/j.jaci.2005.09.001; Corry DB, 2004, FASEB J, V18, P995, DOI 10.1096/fj.03-1412fje; Corry DB, 2002, NAT IMMUNOL, V3, P347, DOI 10.1038/ni773; COYLE AJ, 1995, J EXP MED, V181, P1229, DOI 10.1084/jem.181.3.1229; Crowder S, 2005, NAT GENET, V37, P701, DOI 10.1038/ng1583; Croxton TL, 2003, AM J RESP CRIT CARE, V167, P1142, DOI 10.1164/rccm.200207-756WS; Deszcz L, 2006, J VIROL, V80, P9619, DOI 10.1128/JVI.00612-06; Friedlander SL, 2005, J ALLERGY CLIN IMMUN, V116, P267, DOI 10.1016/j.jaci.2005.06.003; Goswami S, 2009, NAT IMMUNOL, V10, P496, DOI 10.1038/ni.1719; Gough L, 2003, CLIN EXP ALLERGY, V33, P1159, DOI 10.1046/j.1365-2222.2003.01716.x; Greenberg SB, 2000, AM J RESP CRIT CARE, V162, P167, DOI 10.1164/ajrccm.162.1.9911019; Greenberg SB, 2007, SEMIN RESP CRIT CARE, V28, P182, DOI 10.1055/s-2007-976490; Grumelli S, 2004, PLOS MED, V1, P75, DOI 10.1371/journal.pmed.0010008; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; KERSTJENS HAM, 1995, AM J RESP CRIT CARE, V151, P360, DOI 10.1164/ajrccm.151.2.7842192; Kheradmand F, 2002, ENVIRON HEALTH PERSP, V110, P553, DOI 10.1289/ehp.02110s4553; Kheradmand F, 2002, J IMMUNOL, V169, P5904, DOI 10.4049/jimmunol.169.10.5904; Kim CH, 2001, J CLIN INVEST, V108, P1331, DOI 10.1172/JCI200113543; Kiss A, 2007, J ALLERGY CLIN IMMUN, V120, P334, DOI 10.1016/j.jaci.2007.04.025; Lamhamedi-Cherradi SE, 2008, J IMMUNOL, V180, P6000, DOI 10.4049/jimmunol.180.9.6000; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Niewoehner DE, 1999, NEW ENGL J MED, V340, P1941, DOI 10.1056/NEJM199906243402502; Nolte FS, 2007, J CLIN MICROBIOL, V45, P2779, DOI 10.1128/JCM.00669-07; Papi A, 2006, AM J RESP CRIT CARE, V173, P1114, DOI 10.1164/rccm.200506-859OC; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Porter P, 2009, MUCOSAL IMMUNOL, V2, P504, DOI 10.1038/mi.2009.102; Seemungal TAR, 2003, CURR OPIN PULM MED, V9, P111, DOI 10.1097/00063198-200303000-00004; Senior RM, 2000, CHEST, V117, p320S, DOI 10.1378/chest.117.5_suppl_1.320S-a; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; STAMPFLI MR, 2007, NAT REV IMMUNOL, V9, P377; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; Wedzicha Jadwiga A, 2003, Respir Care, V48, P1204; Ying S, 2008, J IMMUNOL, V181, P2790, DOI 10.4049/jimmunol.181.4.2790	41	60	67	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1369	1378		10.1016/j.jaci.2010.02.035	http://dx.doi.org/10.1016/j.jaci.2010.02.035			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20430426	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000278831000027
J	Caminha, I; Fleisher, TA; Hornung, RL; Dale, JK; Niemela, JE; Price, S; Davis, J; Perkins, K; Dowdell, KC; Brown, MR; Rao, VK; Oliveira, JB				Caminha, Iusta; Fleisher, Thomas A.; Hornung, Ronald L.; Dale, Janet K.; Niemela, Julie E.; Price, Susan; Davis, Joie; Perkins, Katie; Dowdell, Kennichi C.; Brown, Margaret R.; Rao, V. Koneti; Oliveira, Joao Bosco			Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DISEASE		[Caminha, Iusta; Fleisher, Thomas A.; Niemela, Julie E.; Brown, Margaret R.; Oliveira, Joao Bosco] NIAID, Dept Lab Med, Ctr Clin, NIH, Bethesda, MD 20892 USA; [Dale, Janet K.] NIAID, Off Clin Res, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD 20892 USA; [Price, Susan; Davis, Joie; Rao, V. Koneti] NIAID, ALPS Unit, NIH, Bethesda, MD 20892 USA; [Dowdell, Kennichi C.] NIAID, Med Virol Sect, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; [Hornung, Ronald L.] NCI, Clin Serv Program, SAIC Frederick Inc, Frederick, MD 21701 USA; [Perkins, Katie] NCI, Clin Monitoring Res Program, SAIC Frederick Inc, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Caminha, I (corresponding author), NIAID, Dept Lab Med, Ctr Clin, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	oliveirajb@cc.nih.gov	Oliveira, Joao Bosco/AAC-9947-2021; Oliveira, João/GXN-3304-2022; Rao, V. Koneti/AAR-2171-2020	Oliveira, Joao Bosco/0000-0001-9388-8173; Rao, V. Koneti/0000-0002-7881-6902; Niemela, Julie/0000-0003-4197-3792	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000732] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL010287] Funding Source: NIH RePORTER; CCR NIH HHS [HHSN261200800001C] Funding Source: Medline; Intramural NIH HHS [Z01 CL010287-12, Z01 CL010287-11] Funding Source: Medline; NCI NIH HHS [HHSN261200800001E] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER; CCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bidere N, 2006, ANNU REV IMMUNOL, V24, P321, DOI 10.1146/annurev.immunol.24.021605.090513; Bleesing JJH, 2001, BLOOD, V98, P2466, DOI 10.1182/blood.V98.8.2466; Fuss IJ, 1997, J IMMUNOL, V158, P1912; Lopatin U, 2001, BLOOD, V97, P3161, DOI 10.1182/blood.V97.10.3161; Magerus-Chatinet A, 2009, BLOOD, V113, P3027, DOI 10.1182/blood-2008-09-179630; Oliveira JB, 2007, P NATL ACAD SCI USA, V104, P8953, DOI 10.1073/pnas.0702975104; SNELLER MC, 1992, J CLIN INVEST, V90, P334, DOI 10.1172/JCI115867	7	60	62	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					946	949		10.1016/j.jaci.2009.12.983	http://dx.doi.org/10.1016/j.jaci.2009.12.983			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20227752	Green Accepted			2022-12-18	WOS:000276787900026
J	Hoffman, HM				Hoffman, Hal M.			Therapy of autoinflammatory syndromes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Autoinflammatory; IL-1; inflammasome	FAMILIAL MEDITERRANEAN FEVER; MUCKLE-WELLS-SYNDROME; ONSET STILLS-DISEASE; INTERLEUKIN-1 RECEPTOR ANTAGONIST; TUMOR-NECROSIS-FACTOR; JUVENILE IDIOPATHIC ARTHRITIS; PERIODIC SYNDROME TRAPS; PROPHYLACTIC COLCHICINE THERAPY; NALP3 INFLAMMASOME; SCHNITZLERS-SYNDROME	The therapy of autoinflammatory syndromes is an excellent example of the power of translational research. Recent advances in our understanding of the molecular and immunologic basis of this newly identified classification of disease have allowed for the application of novel, effective, targeted treatments with life-changing effects on patients. Although colchicine and TNF-alpha inhibitors are important therapies for specific autoinflammatory syndromes, the novel IL-1-targeted drugs are particularly effective for many of these diseases. Recently, the pharmaceutical industry has adopted a strategy of confirming the efficacy of new targeted drugs in often-ignored patients with orphan diseases, and US Food and Drug Administration policies have allowed for accelerated approval of these drugs, creating a win-win situation for patients and industry. This article reviews the general approach to the therapy of autoinflammatory diseases, focusing on current approved therapies and novel approaches that might be used in the future. (J Allergy Clin Immunoll 2009;124:1129-38.)	[Hoffman, Hal M.] Univ Calif San Diego, Sch Med, Div Allergy Immunol & Rheumatol, Dept Pediat, La Jolla, CA 92093 USA; [Hoffman, Hal M.] Univ Calif San Diego, Dept Med, Div Allergy Immunol & Rheumatol, La Jolla, CA 92093 USA; [Hoffman, Hal M.] Rady Childrens Hosp San Diego, La Jolla, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego	Hoffman, HM (corresponding author), Univ Calif San Diego, Sch Med, Div Allergy Immunol & Rheumatol, Dept Pediat, 9500 Gilman Dr, La Jolla, CA 92093 USA.	hahoffman@ucsd.edu			NIAID NIH HHS [R01 AI052430] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052430] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aganna E, 2002, ARTHRITIS RHEUM-US, V46, P2445, DOI 10.1002/art.10509; Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Aksentijevich I, 2009, NEW ENGL J MED, V360, P2426, DOI 10.1056/NEJMoa0807865; Alexander T, 2005, ANN RHEUM DIS, V64, P1245, DOI 10.1136/ard.2004.032060; Announ N, 2009, JOINT BONE SPINE, V76, P424, DOI 10.1016/j.jbspin.2009.01.001; Arostegui JI, 2007, ARTHRITIS RHEUM-US, V56, P3805, DOI 10.1002/art.22966; Belkhir R, 2007, ANN INTERN MED, V146, P825, DOI 10.7326/0003-4819-146-11-200706050-00023; Ben-Chetrit E, 1998, SEMIN ARTHRITIS RHEU, V28, P48, DOI 10.1016/S0049-0172(98)80028-0; Ben-Chetrit E, 2001, ANN RHEUM DIS, V60, P146, DOI 10.1136/ard.60.2.146; Bertin J, 2000, CELL DEATH DIFFER, V7, P1273, DOI 10.1038/sj.cdd.4400774; Bodar EJ, 2005, NETH J MED, V63, P260; Botsios C, 2005, AUTOIMMUN REV, V4, P162, DOI 10.1016/j.autrev.2004.09.001; Brenner M, 2009, BRIT J DERMATOL, V161, P1199, DOI 10.1111/j.1365-2133.2009.09404.x; Brydges S, 2006, CURR TOP MICROBIOL, V305, P127, DOI 10.1007/3-540-29714-6_7; Cailliez M, 2006, J INHERIT METAB DIS, V29, P763, DOI 10.1007/s10545-006-0408-7; Cassel SL, 2008, P NATL ACAD SCI USA, V105, P9035, DOI 10.1073/pnas.0803933105; Church LD, 2009, CURR OPIN MOL THER, V11, P81; de Koning HD, 2006, ANN RHEUM DIS, V65, P542, DOI 10.1136/ard.2005.045245; Devlin Lisa A, 2008, Cases J, V1, P348, DOI 10.1186/1757-1626-1-348; Dierselhuis MP, 2005, RHEUMATOLOGY, V44, P406, DOI 10.1093/rheumatology/keh479; DINARELLO CA, 1974, NEW ENGL J MED, V291, P934, DOI 10.1056/NEJM197410312911804; DINARELLO CA, 1976, ARTHRITIS RHEUM-US, V19, P618, DOI 10.1002/art.1780190315; Dinarello CA, 2002, CLIN EXP RHEUMATOL, V20, pS1; DINARELLO CA, 1974, J EXP MED, V139, P1369, DOI 10.1084/jem.139.6.1369; Dinarello CA, 2005, J EXP MED, V201, P1355, DOI 10.1084/jem.20050640; Dode C, 2003, J NEPHROL, V16, P435; Dode C, 2002, AM J HUM GENET, V70, P1498, DOI 10.1086/340786; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Drewe E, 2007, RHEUMATOLOGY, V46, P1865, DOI 10.1093/rheumatology/kem231; Drewe E, 2003, RHEUMATOLOGY, V42, P235, DOI 10.1093/rheumatology/keg070; Duncan JA, 2007, P NATL ACAD SCI USA, V104, P8041, DOI 10.1073/pnas.0611496104; Dybowski F, 2008, CLIN EXP RHEUMATOL, V26, P354; ELISABETH E, 2007, J AM ACAD DERMATOL, V57, P361; Feldmann J, 2002, AM J HUM GENET, V71, P198, DOI 10.1086/341357; Fitzgerald AA, 2005, ARTHRITIS RHEUM-US, V52, P1794, DOI 10.1002/art.21061; Frenkel J, 2004, ARTHRITIS RHEUM-US, V50, P3738, DOI 10.1002/art.20497; Frischmeyer-Guerrerio PA, 2008, ANN ALLERG ASTHMA IM, V100, P617, DOI 10.1016/S1081-1206(10)60064-6; Gattorno M, 2008, ARTHRITIS RHEUM, V58, P1516, DOI 10.1002/art.23475; Gattorno M, 2008, ARTHRITIS RHEUM, V58, P1505, DOI 10.1002/art.23437; Gattringer R, 2007, EUR J CLIN INVEST, V37, P912, DOI 10.1111/j.1365-2362.2007.01868.x; Gilson M, 2007, CLIN EXP RHEUMATOL, V25, P931; Godinho FMV, 2005, ANN RHEUM DIS, V64, P647, DOI 10.1136/ard.2004.026617; Goldbach-Mansky R, 2008, ARTHRITIS RHEUM-US, V58, P2432, DOI 10.1002/art.23620; Goldbach-Mansky R, 2006, NEW ENGL J MED, V355, P581, DOI 10.1056/NEJMoa055137; GOLDFINGER SE, 1972, NEW ENGL J MED, V287, P1302; GOLDSTEIN RC, 1974, ANN INTERN MED, V81, P792, DOI 10.7326/0003-4819-81-6-792; Harton JA, 2002, J IMMUNOL, V169, P4088, DOI 10.4049/jimmunol.169.8.4088; Hawkins PN, 2004, ARTHRITIS RHEUM-US, V50, P607, DOI 10.1002/art.20033; Hawkins PN, 2003, NEW ENGL J MED, V348, P2583, DOI 10.1056/NEJM200306193482523; Hoffman HM, 2008, CURR MED RES OPIN, V24, P2531, DOI [10.1185/03007990802297495, 10.1185/03007990802297495 ]; Hoffman HM, 2008, ARTHRITIS RHEUM, V58, P2443, DOI 10.1002/art.23687; Hoffman HM, 2009, NAT REV RHEUMATOL, V5, P249, DOI 10.1038/nrrheum.2009.40; Hoffman HM, 2009, EXPERT OPIN BIOL TH, V9, P519, DOI [10.1517/14712590902875518, 10.1517/14712590902875518 ]; Hoffman HM, 2004, LANCET, V364, P1779, DOI 10.1016/S0140-6736(04)17401-1; Hoffman HM, 2004, ARTHRITIS RHEUM-US, V50, P345, DOI 10.1002/art.20032; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hull KM, 2002, ARTHRITIS RHEUM-US, V46, pS378; Kalliolias GD, 2007, ANN RHEUM DIS, V66, P842, DOI 10.1136/ard.2006.066381; Kotter I, 2007, SEMIN ARTHRITIS RHEU, V37, P189, DOI 10.1016/j.semarthrit.2007.04.002; Kuijk LM, 2007, ANN RHEUM DIS, V66, P1545, DOI 10.1136/ard.2007.071498; Lachmann HJ, 2009, NEW ENGL J MED, V360, P2416, DOI 10.1056/NEJMoa0810787; Lachmann HJ, 2009, J EXP MED, V206, P1029, DOI 10.1084/jem.20082481; Lequerre T, 2008, ANN RHEUM DIS, V67, P302, DOI 10.1136/ard.2007.076034; Leslie KS, 2006, ARCH DERMATOL, V142, P1591, DOI 10.1001/archderm.142.12.1591; Maier J, 2008, J RHEUMATOL, V35, P939; MAJEED HA, 1990, J PEDIATR-US, V116, P997, DOI 10.1016/S0022-3476(05)80667-5; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martin TM, 2009, ARTHRITIS RHEUM, V60, P611, DOI 10.1002/art.24222; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masters SL, 2009, ANNU REV IMMUNOL, V27, P621, DOI 10.1146/annurev.immunol.25.022106.141627; Matsubara T, 2006, ARTHRITIS RHEUM-US, V54, P2314, DOI 10.1002/art.21965; Mayor A, 2007, NAT IMMUNOL, V8, P497, DOI 10.1038/ni1459; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; McDermott MF, 2002, CURR OPIN ALLERGY CL, V2, P511, DOI 10.1097/00130832-200212000-00006; McGonagle D, 2007, ANN RHEUM DIS, V66, P1683, DOI 10.1136/ard.2007.073759; McGonagle D, 2008, ARTHRITIS RHEUM-US, V58, P631, DOI 10.1002/art.23119; Mertens M, 2009, J RHEUMATOL, V36, P1118, DOI 10.3899/jrheum.090074; Mitroulis I, 2008, NETH J MED, V66, P489; Molad Yair, 2002, Curr Rheumatol Rep, V4, P252, DOI 10.1007/s11926-002-0073-2; Moser C, 2009, NEPHROL DIAL TRANSPL, V24, P676, DOI 10.1093/ndt/gfn646; Nedjai B, 2009, ARTHRITIS RHEUM-US, V60, P619, DOI 10.1002/art.24294; Ohlsson V, 2008, RHEUMATOLOGY, V47, P555, DOI 10.1093/rheumatology/ken030; Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195; Priori R, 2008, CLIN EXP RHEUMATOL, V26, P933; Reddy S, 2009, NEW ENGL J MED, V360, P2438, DOI 10.1056/NEJMoa0809568; Rigante D, 2006, RHEUMATOL INT, V27, P97, DOI 10.1007/s00296-006-0164-x; Roldan R, 2008, JOINT BONE SPINE, V75, P504, DOI 10.1016/j.jbspin.2008.04.001; Ross JB, 2008, J CUTAN MED SURG, V12, P8, DOI 10.2310/7750.2008.07050; Rudinskaya A, 2003, JCR-J CLIN RHEUMATOL, V9, P330, DOI 10.1097/01.rhu.0000089966.48691.7f; Rynne M, 2006, ANN RHEUM DIS, V65, P533, DOI 10.1136/ard.2005.038091; Sacre K, 2008, J RHEUMATOL, V35, P357; Simon A, 2004, AM J MED, V117, P208, DOI 10.1016/j.amjmed.2004.02.039; So A, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2143; Stack JH, 2005, J IMMUNOL, V175, P2630, DOI 10.4049/jimmunol.175.4.2630; STEFAN WS, 2007, J AM ACAD DERMATOL S, V56, pS120; Terkeltaub R, 2009, ANN RHEUM DIS, V68, P1613, DOI 10.1136/ard.2009.108936; Thornton BD, 2007, AM J KIDNEY DIS, V49, P477, DOI 10.1053/j.ajkd.2006.10.026; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; van der Poll T, 1999, INFECT DIS CLIN N AM, V13, P413, DOI 10.1016/S0891-5520(05)70083-0; Youssef J, 2008, J RHEUMATOL, V35, P2453, DOI 10.3899/jrheum.080150; ZEMER D, 1974, NEW ENGL J MED, V291, P932, DOI 10.1056/NEJM197410312911803; ZEMER D, 1991, ARTHRITIS RHEUM-US, V34, P973, DOI 10.1002/art.1780340806	106	60	63	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1129	1138		10.1016/j.jaci.2009.11.001	http://dx.doi.org/10.1016/j.jaci.2009.11.001			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	20004774	Green Accepted			2022-12-18	WOS:000273071500001
J	Hyde, DM; Hamid, Q; Irvin, CG				Hyde, Dallas M.; Hamid, Qutayba; Irvin, Charles G.			Anatomy, pathology, and physiology of the tracheobronchial tree: Emphasis on the distal airways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anatomy; pathology; histology; physiology; airways; small airways	OBSTRUCTIVE PULMONARY-DISEASE; MESSENGER-RNA EXPRESSION; PERIPHERAL AIRWAYS; NOCTURNAL ASTHMA; RHESUS-MONKEYS; FREQUENCY DEPENDENCE; ALVEOLAR TISSUE; SMOOTH-MUSCLE; LUNG DISEASE; INFLAMMATION	This article covers the airway tree with respect to anatomy, pathology, and physiology. The anatomic portion discusses various primate groups so as to help investigators understand similarities and differences between animal models. An emphasis is on distal airway findings. The pathology section focuses on the inflammatory responses that occur in proximal and distal airways. The physiologic review brings together the anatomic and pathologic components to the functional state and proposes ways to evaluate the small airways in patients with asthma. (J Allergy Clin Immunol 2009;124:S72-7.)	[Hyde, Dallas M.] Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA; [Hamid, Qutayba] McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada; [Irvin, Charles G.] Univ Vermont, Dept Med, Burlington, VT USA	University of California System; University of California Davis; McGill University; University of Vermont	Hyde, DM (corresponding author), Care of Martin RJ, Natl Jewish Hlth, 1400 Jackson St, Denver, CO 80206 USA.				Teva Respiratory, LLC	Teva Respiratory, LLC	Supported by an unrestricted grant from Teva Respiratory, LLC.	Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Bergeron C, 2005, J ALLERGY CLIN IMMUN, V116, P983, DOI 10.1016/j.jaci.2005.07.029; BHANSALI PV, 1979, J APPL PHYSIOL, V47, P161, DOI 10.1152/jappl.1979.47.1.161; Brown RH, 2006, J APPL PHYSIOL, V101, P30, DOI 10.1152/japplphysiol.01190.2005; Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292; Chou DL, 2005, AM J RESP CELL MOL, V33, P1, DOI 10.1165/rcmb.2004-0236RC; Christodoulopoulos P, 2000, J ALLERGY CLIN IMMUN, V106, P479; COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303; DESPAS PJ, 1972, J CLIN INVEST, V51, P3235, DOI 10.1172/JCI107150; DSILVA JL, 1961, J PHYSIOL-LONDON, V157, P611, DOI 10.1113/jphysiol.1961.sp006747; Faul JL, 1997, EUR RESPIR J, V10, P301, DOI 10.1183/09031936.97.10020301; GREEN M, 1964, HOSP GAZETTE, V62, P136; GRIMBY G, 1968, J CLIN INVEST, V47, P1455, DOI 10.1172/JCI105837; Haley KJ, 1998, AM J RESP CRIT CARE, V158, P565, DOI 10.1164/ajrccm.158.2.9705036; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; Irvin CG, 2003, EUR RESPIR J, V22, P3, DOI 10.1183/09031936.03.00035703; Irvin CG, 2006, J APPL PHYSIOL, V101, P7, DOI 10.1152/japplphysiol.00294.2006; KAMINSKY DA, 1995, AM J RESP CRIT CARE, V152, P1784, DOI 10.1164/ajrccm.152.6.8520737; Kaminsky DA, 2008, J APPL PHYSIOL, V104, P10, DOI 10.1152/japplphysiol.00519.2007; Kraft M, 1999, J ALLERGY CLIN IMMUN, V103, P66, DOI 10.1016/S0091-6749(99)70527-0; Kraft M, 1999, AM J RESP CRIT CARE, V159, P228, DOI 10.1164/ajrccm.159.1.9804033; Kraft M, 2001, AM J RESP CRIT CARE, V163, P1551, DOI 10.1164/ajrccm.163.7.2008013; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Kraft M, 2006, CHEST, V130, P1726, DOI 10.1378/chest.130.6.1726; Leone N, 2009, AM J RESP CRIT CARE, V179, P509, DOI 10.1164/rccm.200807-1195OC; LEVINE G, 1970, NEW ENGL J MED, V282, P1277, DOI 10.1056/NEJM197006042822301; Macklem PT, 1998, AM J RESP CRIT CARE, V157, pS181, DOI 10.1164/ajrccm.157.5.rsaa-2; MACKLEM PT, 1970, RESP PHYSIOL, V8, P191, DOI 10.1016/0034-5687(70)90015-0; MACKLEM PT, 1967, J APPL PHYSIOL, V22, P395, DOI 10.1152/jappl.1967.22.3.395; MARIASSY A, 1992, TREATISE PULMONARY T, P63; MCBRIDE JT, 1992, TREATISE PULMONARY T, P49; MEAD J, 1970, NEW ENGL J MED, V282, P1318, DOI 10.1056/NEJM197006042822311; Miller LA, 2005, CLIN EXP ALLERGY, V35, P894, DOI 10.1111/j.1365-2222.2005.02271.x; Minshall EM, 1998, J ALLERGY CLIN IMMUN, V101, P386, DOI 10.1016/S0091-6749(98)70252-0; NADEL JA, 1964, J APPL PHYSIOL, V19, P387, DOI 10.1152/jappl.1964.19.3.387; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; OHRUI T, 1992, AM REV RESPIR DIS, V146, P88, DOI 10.1164/ajrccm/146.1.88; Plopper C. G., 1992, TREATISE PULMONARY T, P85; Schelegle ES, 2003, TOXICOL APPL PHARM, V191, P74, DOI 10.1016/S0041-008X(03)00218-7; Schelegle ES, 2001, AM J PATHOL, V158, P333, DOI 10.1016/S0002-9440(10)63973-9; Sutherland ER, 2004, J ALLERGY CLIN IMMUN, V113, P1046, DOI 10.1016/j.jaci.2004.03.016; Taha RA, 1999, J ALLERGY CLIN IMMUN, V103, P476, DOI 10.1016/S0091-6749(99)70474-4; TYLER WS, 1992, TREATISE PULMONARY T, P37; Wagers S, 2004, J APPL PHYSIOL, V96, P2019, DOI 10.1152/japplphysiol.00924.2003; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; Weibel E.R., 1963, MORPHOMETRY HUMAN LU, DOI DOI 10.1007/978-3-642-87553-3; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; WOOLCOCK AJ, 1969, J CLIN INVEST, V48, P1097, DOI 10.1172/JCI106066	50	60	68	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					S72	S77		10.1016/j.jaci.2009.08.048	http://dx.doi.org/10.1016/j.jaci.2009.08.048			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VJ	19962039	Bronze			2022-12-18	WOS:000273071700002
J	Valet, RS; Perry, TT; Hartert, TV				Valet, Robert S.; Perry, Tamara T.; Hartert, Tina V.			Rural health disparities in asthma care and outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; rural health disparities; hygiene hypothesis	HAY-FEVER; EARLY-CHILDHOOD; PREVALENCE; CHILDREN; RISK; SENSITIZATION; ENDOTOXIN; EXPOSURE; DISTANCE; ECZEMA	Fifty-nine million Americans (21% of the US population) live in rural areas of the United States. Compared with persons living in urban areas of the United States, rural populations have lower income, a higher rate of government versus private insurance, and decreased access to health care. Although there are reports of lower asthma prevalence in rural areas, the majority of these data have been published on international populations, with few available studies looking at American urban versus rural asthma prevalence on a national scale or comparing rural with nearby urban cohorts in the United States. A large body of literature, mainly generated from studies of rural Europe, suggests that lower prevalence might be due to beneficial effects of exposure to farm environments, but the extent to which this applies to the rural United States, where a smaller proportion of the population engages in farming, is unclear. The United States has the additional covariate of having a higher proportion of African Americans, who have a greater asthma burden than whites independent of socioeconomic status, clustered in cities. There are data indicating that rural patients have increased difficulty obtaining health care in general and limited data suggesting that they receive inferior care for asthma. Future work is needed to more clearly define asthma prevalence and morbidity among residents of the rural United States, as well as to identify interventions effective in this population. (J Allergy Clin Immunol 2009;123:1220-5.)	[Hartert, Tina V.] Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Div Allergy Pulm & Crit Care Med,Dept Med, Nashville, TN 37232 USA; [Valet, Robert S.; Hartert, Tina V.] Vanderbilt Univ, Sch Med, Inst Med & Publ Hlth, Nashville, TN 37232 USA; [Perry, Tamara T.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Perry, Tamara T.] Arkansas Childrens Hosp, Inst Res, Little Rock, AR 72202 USA	Vanderbilt University; Vanderbilt University; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital	Hartert, TV (corresponding author), Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Div Allergy Pulm & Crit Care Med,Dept Med, 6107 MCE, Nashville, TN 37232 USA.	tina.hartert@vanderbilt.edu			National Institutes of Health: NIH [U01 HL 072471, K24 At 077930]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI077930] Funding Source: NIH RePORTER	National Institutes of Health: NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by research grants from that National Institutes of Health: NIH U01 HL 072471 (T.V.H.). NIH K24 At 077930 (T.V.H.).	American Lung Association. American Lung Association, 2007, TRENDS ASTHM MORB MO; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Boudreaux ED, 2003, CHEST, V124, P803, DOI 10.1378/chest.124.3.803; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Casey MM, 2001, AM J PREV MED, V21, P182, DOI 10.1016/S0749-3797(01)00349-X; *CDCP, 2003, NAT ASTHM SURV; Chang Jei-Wen, 2006, Journal of Microbiology Immunology and Infection, V39, P316; Chrischilles E, 2004, J ALLERGY CLIN IMMUN, V113, P66, DOI 10.1016/j.jaci.2003.09.037; Doescher MP, 2006, J RURAL HEALTH, V22, P112, DOI 10.1111/j.1748-0361.2006.00018.x; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563, DOI 10.1164/ajrccm.161.5.9908119; *EUR EUR UN GOV, 2006, AGR STAT MAIN RES, P30; Higgins PS, 2005, CHEST, V128, P3846, DOI 10.1378/chest.128.6.3846; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; JACKSON JE, 2007, NATL STUDY LIFETIME; Jones AP, 1999, INT J EPIDEMIOL, V28, P101, DOI 10.1093/ije/28.1.101; *KAIS COMM MED UN, KEY FACTS UN RUR AM; *KAIS COMM MED UN, 2003, HLTH INS COV RUR AM; KEELEY DJ, 1991, THORAX, V46, P549, DOI 10.1136/thx.46.8.549; Kozyrskyj A. L., 2004, Journal of Allergy and Clinical Immunology, V113, pS306, DOI 10.1016/j.jaci.2004.01.596; Kramer U, 1999, LANCET, V353, P1969, DOI 10.1016/S0140-6736(05)77177-4; Le Moual N, 2008, AM J RESP CRIT CARE, V177, P4, DOI 10.1164/rccm.200703-415PP; Lemanske RF, 2006, J ALLERGY CLIN IMMUN, V117, pS456, DOI 10.1016/j.jaci.2005.07.006; Lum Elaine Y, 2007, Can J Clin Pharmacol, V14, pe275; Lynd LD, 2004, CHEST, V126, P1161, DOI 10.1378/chest.126.4.1161; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; Miller JE, 2000, AM J PUBLIC HEALTH, V90, P428, DOI 10.2105/AJPH.90.3.428; Nelson DA, 1997, ANN ALLERG ASTHMA IM, V78, P21, DOI 10.1016/S1081-1206(10)63365-0; Nicholl J, 2007, EMERG MED J, V24, P665, DOI 10.1136/emj.2007.047654; *ORG EC COOP DEV, 2003, FARM HOUS INC ISS PO, P17; Panettieri RA, 2008, J ALLERGY CLIN IMMUN, V121, P607, DOI 10.1016/j.jaci.2008.01.006; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Peden DB, 2005, J ALLERGY CLIN IMMUN, V115, P213, DOI 10.1016/j.jaci.2004.12.003; Perry TT, 2008, ANN ALLERG ASTHMA IM, V101, P375, DOI 10.1016/S1081-1206(10)60313-4; Perzanowski MS, 2006, J ALLERGY CLIN IMMUN, V117, P1082, DOI 10.1016/j.jaci.2005.12.1348; Phipatanakul W, 2004, PEDIATRICS, V114, P13, DOI 10.1542/peds.114.1.13; Piette JD, 1996, HEALTH SERV RES, V31, P573; Probst JC, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-40; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Schram-Bijkerk D, 2006, ALLERGY, V61, P640, DOI 10.1111/j.1398-9995.2006.01079.x; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Singh AM, 2007, AM J RESP CRIT CARE, V175, P108, DOI 10.1164/rccm.200603-435PP; Smith SR, 2007, PEDIATR PULM, V42, P1041, DOI 10.1002/ppul.20694; Sole D, 2007, ALLERGOL IMMUNOPATH, V35, P248, DOI 10.1157/13112991; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strachan DP, 1996, BRIT MED J, V312, P1195; Strauss K, 2006, J GEN INTERN MED, V21, P378, DOI 10.1111/j.1525-1497.2006.00386.x; Taksey J, 2001, J Am Osteopath Assoc, V101, pS4; *TN DEP HLTH, BURD ASTHM TENN, P53; Tong S, 1999, Aust J Rural Health, V7, P18, DOI 10.1046/j.1440-1584.1999.00195.x; U.S. Census Bureau; American Community Survey (ACS), AM FACT FIND; U.S. Department of Agriculture Economic Research Service, FARM HOUS EC WELL BE; [United States Department of Agriculture (USDA) National Agricultural Statistics Service (NASS)], 2002 CENS AGR; US Census Bureau, CENS 2000 URB RUR CL; US Census Bureau, 2011, METR MICR STAT AR; US Department of Agriculture Economic Research Service Rural-Urban Commuting Areas (RUCA), RUR DEF DAT DOC METH; *USDA, RUR LAB ED NONM ED; *USDA, 2008, PROF HIR FARMW; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; Withy K, 2008, ETHNIC DIS, V18, P247; Wright RJ, 2007, CHEST, V132, p757S, DOI 10.1378/chest.07-1904; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	66	60	60	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1220	1225		10.1016/j.jaci.2008.12.1131	http://dx.doi.org/10.1016/j.jaci.2008.12.1131			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	455WO	19233453	Green Accepted			2022-12-18	WOS:000266799100009
J	Matangkasombut, P; Marigowda, G; Ervine, A; Idris, L; Pichavant, M; Kim, HY; Yasumi, T; Wilson, SB; DeKruyff, RH; Faul, JL; Israel, E; Akbari, O; Umetsu, DT				Matangkasombut, Ponpan; Marigowda, Gautham; Ervine, Aaron; Idris, Luaie; Pichavant, Muriel; Kim, Hye Young; Yasumi, Takahiro; Wilson, S. Brian; DeKruyff, Rosemarie H.; Faul, John L.; Israel, Elliot; Akbari, Omid; Umetsu, Dale T.			Natural killer T cells in the lungs of patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AIRWAY HYPERREACTIVITY; BRONCHIAL-ASTHMA; ACTIVATION; DISEASE; MODEL		[Matangkasombut, Ponpan; Pichavant, Muriel; Kim, Hye Young; Yasumi, Takahiro; DeKruyff, Rosemarie H.; Akbari, Omid; Umetsu, Dale T.] Harvard Univ, Sch Med, Dept Pediat, Div Immunol & Allergy,Childrens Hosp Boston, Boston, MA 02115 USA; [Marigowda, Gautham; Israel, Elliot] Harvard Univ, Sch Med, Div Pulm & Crit Care,Dept Med, Brigham & Womens Hosp, Boston, MA 02115 USA; [Ervine, Aaron; Idris, Luaie; Faul, John L.] Connolly Hosp Blanchardstown, Resp Dept, Dublin, Ireland; [Matangkasombut, Ponpan] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; [Wilson, S. Brian] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Diabet Unit, Cambridge, MA 02138 USA; [Akbari, Omid] Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; University of Southern California	Matangkasombut, P (corresponding author), Harvard Univ, Sch Med, Dept Pediat, Div Immunol & Allergy,Childrens Hosp Boston, Boston, MA 02115 USA.	dale.umetsu@childrens.harvard.edu	Pichavant, Muriel/B-9036-2018; Kim, Hye Young/AAF-7609-2020	Pichavant, Muriel/0000-0002-1315-4397; Kim, Hye Young/0000-0001-5978-512X; Yasumi, Takahiro/0000-0003-3257-5071	NHLBI NIH HHS [R01 HL062348-09, HL63248, R01 HL062348] Funding Source: Medline; NIAID NIH HHS [AI066020, R01 AI066020, R01 AI026322-17, AI026322, P01 AI042288, R01 AI026322, P01 AI042288-11] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI066020, P01AI042288, R01AI026322] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Lisbonne M, 2003, J IMMUNOL, V171, P1637, DOI 10.4049/jimmunol.171.4.1637; Matangkasombut P, 2008, J ALLERGY CLIN IMMUN, V121, P1287, DOI 10.1016/j.jaci.2008.02.006; Meyer EH, 2006, P NATL ACAD SCI USA, V103, P2782, DOI 10.1073/pnas.0510282103; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Mutalithas K, 2007, J ALLERGY CLIN IMMUN, V119, P1274, DOI 10.1016/j.jaci.2007.02.021; Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507; Thomas SY, 2006, NEW ENGL J MED, V354, P2613; Vijayanand P, 2007, NEW ENGL J MED, V356, P1410, DOI 10.1056/NEJMoa064691	11	60	61	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1181	1185		10.1016/j.jaci.2009.02.013	http://dx.doi.org/10.1016/j.jaci.2009.02.013			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19356791	Green Accepted, Bronze			2022-12-18	WOS:000266309400033
J	Goplen, N; Karim, Z; Liang, QL; Gorska, MM; Rozario, S; Guo, L; Alam, R				Goplen, Nicholas; Karim, Zunayet; Liang, Qiaoling; Gorska, Magdalena M.; Rozario, Sadee; Guo, Lei; Alam, Rafeul			Combined sensitization of mice to extracts of dust mite, ragweed, and Aspergillus species breaks through tolerance and establishes chronic features of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic asthma; mouse; inflammation; airway hyperreactivity; tolerance; dendritic cells	COLONY-STIMULATING FACTOR; REGULATORY T-CELLS; MOUSE BONE-MARROW; AIRWAY INFLAMMATION; DENDRITIC CELLS; MURINE MODEL; ALLERGEN CHALLENGE; MAST-CELLS; HYPERREACTIVITY; EXPOSURE	Background: Existing asthma models develop tolerance when chronically exposed to the same allergen. Objective: We sought to establish a chronic model that sustains features of asthma long after discontinuation of allergen exposure. Methods: We immunized and exposed mice to a combination of single, double, or triple allergens (dust mite, ragweed, and Aspergillus species) intranasally for 8 weeks. Airway hyperreactivity (AHR) and morphologic features of asthma were studied 3 weeks after allergen exposure. Signaling effects of the allergens were studied on dendritic cells. Results: Sensitization and repeated exposure to a single allergen induced tolerance. Sensitization to double and especially triple allergens broke through tolerance and established AHR, eosinophilic inflammation, mast cell and smooth muscle hyperplasia, mucus production, and airway remodeling that persisted at least 3 weeks after allergen exposure. Mucosal exposure to triple allergens in the absence of an adjuvant was sufficient to induce chronic airway inflammation. Anti-IL-5 and anti-IL-13 antibodies inhibited inflammation and AHR in the acute asthma model but not in the chronic triple-allergen model. Multiple allergens produce a synergy in p38 mitogen-activated protein kinase signaling and maturation of dendritic cells, which provides heightened T-cell costimulation at a level that cannot be achieved with a single allergen. Conclusions: Sensitivity to multiple allergens leads to chronic asthma in mice. Multiple allergens synergize in dendritic cell signaling and T-cell stimulation that allows escape from the single allergen-associated tolerance development. (J Allergy Clin Immunol 2009;123:925-32.)	[Alam, Rafeul] Natl Jewish Hlth, Dept Med, Div Allergy & Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Alam, R (corresponding author), Natl Jewish Hlth, Dept Med, Div Allergy & Immunol, 1400 Jackson St, Denver, CO 80206 USA.	alamr@njc.org			National Institutes of Health [RO1 AI059719, AI68088, PPG HL 36577, N01 HHSN272200700048C]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068088, R01AI059719, R01AI091614] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants RO1 AI059719 and AI68088, PPG HL 36577, and N01 HHSN272200700048C.	Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Bates JHT, 2006, ANN BIOMED ENG, V34, P384, DOI 10.1007/s10439-005-9056-6; BERETA J, 1993, CELL IMMUNOL, V147, P313, DOI 10.1006/cimm.1993.1072; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; Cui ZH, 2003, AM J RESP CRIT CARE, V168, P1324, DOI 10.1164/rccm.200305-634OC.R1; Escors D, 2008, BLOOD, V111, P3050, DOI 10.1182/blood-2007-11-122408; Fattouh R, 2005, AM J RESP CRIT CARE, V172, P314, DOI 10.1164/rccm.200502-198OC; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Garlisi CG, 1999, AM J RESP CELL MOL, V20, P248, DOI 10.1165/ajrcmb.20.2.3327; Hadeiba H, 2003, J IMMUNOL, V170, P5502, DOI 10.4049/jimmunol.170.11.5502; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Kheradmand F, 2002, J IMMUNOL, V169, P5904, DOI 10.4049/jimmunol.169.10.5904; Koya T, 2006, AM J RESP CRIT CARE, V173, P42, DOI 10.1164/rccm.200505-783OC; Kumar RK, 2004, CLIN EXP ALLERGY, V34, P1796, DOI 10.1111/j.1365-2222.2004.02097.x; Kumar RK, 2004, AM J RESP CRIT CARE, V170, P1043, DOI 10.1164/rccm.200405-681OC; Lamhamedi-Cherradi SE, 2008, J IMMUNOL, V180, P6000, DOI 10.4049/jimmunol.180.9.6000; Lommatzsch M, 2006, J ALLERGY CLIN IMMUN, V118, P91, DOI 10.1016/j.jaci.2006.02.034; Luft T, 2006, BLOOD, V107, P4763, DOI 10.1182/blood-2005-04-1501; Masuda T, 2003, CLIN EXP ALLERGY, V33, P705, DOI 10.1046/j.1365-2222.2003.01588.x; Reed CE, 2004, J ALLERGY CLIN IMMUN, V114, P997, DOI 10.1016/j.jaci.2004.07.060; Sarpong SB, 2003, INT ARCH ALLERGY IMM, V132, P346, DOI 10.1159/000074902; SCHEICHER C, 1992, J IMMUNOL METHODS, V154, P253, DOI 10.1016/0022-1759(92)90199-4; Siegle JS, 2006, AM J RESP CELL MOL, V35, P565, DOI 10.1165/rcmb.2006-0135OC; Takabayashi K, 2003, J IMMUNOL, V170, P3898, DOI 10.4049/jimmunol.170.7.3898; Taube C, 2004, INT ARCH ALLERGY IMM, V135, P173, DOI 10.1159/000080899; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482; Tomioka S, 2002, J APPL PHYSIOL, V93, P263, DOI 10.1152/japplphysiol.01129.2001; Van Hove CL, 2007, AM J RESP CELL MOL, V36, P573, DOI 10.1165/rcmb.2006-0385OC; Wegmann M, 2005, CLIN EXP ALLERGY, V35, P1263, DOI 10.1111/j.1365-2222.2005.02306.x; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Whitehead GS, 2003, AM J PHYSIOL-LUNG C, V285, pL32, DOI 10.1152/ajplung.00390.2002; Yu M, 2006, J CLIN INVEST, V116, P1633, DOI 10.1172/JCI25702	35	60	63	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					925	932		10.1016/j.jaci.2009.02.009	http://dx.doi.org/10.1016/j.jaci.2009.02.009			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19348928	Green Accepted			2022-12-18	WOS:000265058600022
J	Miller, GE; Gaudin, A; Zysk, E; Chen, E				Miller, Gregory E.; Gaudin, Alexandra; Zysk, Eva; Chen, Edith			Parental support and cytokine activity in childhood asthma: The role of glucocorticoid sensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PSYCHOLOGICAL STRESS; PSYCHOSOCIAL STRESS; CORTISOL RESPONSES; EARLY-LIFE; CHILDREN; EXPRESSION; DYSREGULATION; INFLAMMATION; PREDICTORS; SEVERITY	Background: Stress is known to worsen the course of asthma, but the underlying mechanisms are poorly understood. This problem is especially difficult because stress elicits secretion of cortisol, a hormone that dampens airway inflammation and ameliorates asthma symptoms. Objective: This article proposes that stress affects asthma by inducing resistance to the anti-inflammatory properties of glucocorticoids. To evaluate this hypothesis, we examine whether a particular kind of stress in children's lives, not feeling supported or understood by parents, is associated with in vitro measures of lymphocyte resistance to glucocorticoids and indices of eosinophil mobilization and activation. Methods: Children with asthma (n = 67) and medically healthy children (n = 76) completed standardized questionnaires about support from their parents. PBMCs were collected and incubated with a mitogen cocktail in the presence of physiologic concentrations of hydrocortisone. Production of IL-5, IL-13, and tFN-gamma was measured by means of ELISA. Circulating eosinophils were enumerated with a hematology analyzer, and the extent of their activation was indexed by means of ELISA for eosinophil cationic protein. Results: To the extent that children with asthma perceived low support from their parents, children were more resistant to hydrocortisone's anti-inflammatory effects on IL-5 and IFN-gamma production and had higher circulating levels of eosinophil cationic protein. These associations were independent of socioeconomic conditions, cigarette exposure, disease severity, and medication use. Conclusions: These patterns suggest the hypothesis that strained parent-child relations, and perhaps stress more generally, brings about adverse outcomes in asthma by diminishing cortisol's ability to regulate cytokine activity and subsequent airway inflammation. (J Allergy Clin Immunol 2009;123:824-30.)	[Miller, Gregory E.; Gaudin, Alexandra; Zysk, Eva; Chen, Edith] Univ British Columbia, Dept Psychol, Vancouver, BC, Canada	University of British Columbia	Miller, GE (corresponding author), 2136 W Mall Ave, Vancouver, BC V6T 1Z4, Canada.	gemiller@psych.ubc.ca	Zysk, Eva/C-1265-2013	Zysk, Eva/0000-0002-7715-5874	Michael Smith Foundation; National Heart, Lung, and Blood Institute; National Institute of Child Health and Human Development; Canadian Institutes of Health Research; William T. Grant Foundation	Michael Smith Foundation(Michael Smith Foundation for Health Research); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); William T. Grant Foundation	Supported by grants from the Michael Smith Foundation; the National Heart, Lung, and Blood Institute; the National Institute of Child Health and Human Development; the Canadian Institutes of Health Research; and the William T. Grant Foundation.	Aiken L.S., 1991, MULTIPLE REGRESSION; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Barnes Peter J, 2004, Proc Am Thorac Soc, V1, P264, DOI 10.1513/pats.200402-014MS; Bloomberg GR, 2005, IMMUNOL ALLERGY CLIN, V25, P83, DOI 10.1016/j.iac.2004.09.001; Buske-Kirschbaum A, 2003, PSYCHOSOM MED, V65, P806, DOI 10.1097/01.PSY.0000095916.25975.4F; Chen E, 2007, BRAIN BEHAV IMMUN, V21, P993, DOI 10.1016/j.bbi.2007.03.009; Chen E, 2007, AM J RESP CRIT CARE, V176, P644, DOI 10.1164/rccm.200610-1473OC; Chen E, 2006, J ALLERGY CLIN IMMUN, V117, P1014, DOI 10.1016/j.jaci.2006.01.036; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Chida Y, 2007, AM J RESP CRIT CARE, V175, P316, DOI 10.1164/rccm.200607-898OC; Cohen S, 1999, PSYCHOSOM MED, V61, P175, DOI 10.1097/00006842-199903000-00009; Cole SW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r189; Dickerson SS, 2004, PSYCHOL BULL, V130, P355, DOI 10.1037/0033-2909.130.3.355; FRENCH TM, 1941, PSYCHOSOMATIC MED 1, V4; Goleva E, 2008, J ALLERGY CLIN IMMUN, V122, P550, DOI 10.1016/j.jaci.2008.07.007; Harter, 1985, MANUAL SOCIAL SUPPOR; Holtzman MJ, 2003, CHEST, V123, p377S, DOI 10.1378/chest.123.3_suppl.377S-a; Holtzman MJ, 2003, J ALLERGY CLIN IMMUN, V111, P244, DOI 10.1067/mai.2003.141; Kaugars AS, 2004, J PEDIATR PSYCHOL, V29, P475, DOI 10.1093/jpepsy/jsh051; Klinnert MD, 2002, AM J PUBLIC HEALTH, V92, P792, DOI 10.2105/AJPH.92.5.792; Klinnert MD, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.4.e69; Konstantinos AP, 2001, RESP PHYSIOL, V128, P71, DOI 10.1016/S0034-5687(01)00266-3; Kozyrskyj AL, 2008, AM J RESP CRIT CARE, V177, P142, DOI 10.1164/rccm.200703-381OC; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; Liu LY, 2002, AM J RESP CRIT CARE, V165, P1062, DOI 10.1164/ajrccm.165.8.2109065; Marshall GD, 2007, PSYCHONEUROIMMUNOLOGY, VOLS I AND II, 4TH EDITION, P799; Marshall GD, 2004, ANN ALLERG ASTHMA IM, V93, pS11, DOI 10.1016/S1081-1206(10)61482-2; Marshall GD, 1998, BRAIN BEHAV IMMUN, V12, P297, DOI 10.1006/brbi.1998.0537; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; Miller GE, 2006, P NATL ACAD SCI USA, V103, P5496, DOI 10.1073/pnas.0506312103; Miller GE, 2002, HEALTH PSYCHOL, V21, P531, DOI 10.1037//0278-6133.21.6.531; Miller GE, 2008, BIOL PSYCHIAT, V64, P266, DOI 10.1016/j.biopsych.2008.03.017; Miller GE, 2007, PSYCHOL BULL, V133, P25, DOI 10.1037/0033-2909.133.1.25; Mrazek DA, 1999, PEDIATR PULM, V27, P85, DOI 10.1002/(SICI)1099-0496(199902)27:2<85::AID-PPUL4>3.0.CO;2-B; Muntner S, 1968, Dis Chest, V54, P128; Rosenkranz MA, 2005, P NATL ACAD SCI USA, V102, P13319, DOI 10.1073/pnas.0504365102; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; Sandel M, 2006, ARCH DIS CHILD, V91, P942, DOI 10.1136/adc.2006.098376; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; von Weiss RT, 2002, J PEDIATR PSYCHOL, V27, P155, DOI 10.1093/jpepsy/27.2.155; Webster JI, 2002, ANNU REV IMMUNOL, V20, P125, DOI 10.1146/annurev.immunol.20.082401.104914; Wolf JM, 2008, BRAIN BEHAV IMMUN, V22, P433, DOI 10.1016/j.bbi.2007.10.016; Wright RJ, 2005, CURR OPIN ALLERGY CL, V5, P23, DOI 10.1097/00130832-200502000-00006; Wright RJ, 1998, THORAX, V53, P1066, DOI 10.1136/thx.53.12.1066; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016; Wright RJ, 2007, PAEDIATR PERINAT EP, V21, P8, DOI 10.1111/j.1365-3016.2007.00879.x	47	60	62	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					824	830		10.1016/j.jaci.2008.12.019	http://dx.doi.org/10.1016/j.jaci.2008.12.019			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19181373	Bronze			2022-12-18	WOS:000265058600006
J	Baroody, FM; Mucha, SM; De Tineo, M; Naclerio, RM				Baroody, Fuad M.; Mucha, Samantha M.; De Tineo, Marcy; Naclerio, Robert M.			Nasal challenge with allergen leads to maxillary sinus inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; chronic rhinosinusitis; allergen challenge; eosinophils; maxillary sinus; reflex	VASOACTIVE-INTESTINAL-PEPTIDE; CHRONIC RHINOSINUSITIS; SUBSTANCE-P; CYTOKINE EXPRESSION; PARANASAL SINUSES; MUCOSA; RHINITIS; HISTAMINE; CHILDREN; RELEASE	Background: Allergic rhinitis and chronic rhinosinusitis are both characterized by chronic inflammation. Objective: We sought to investigate the effect of nasal allergen challenge on the maxillary sinus and study the effect of premedication with loratadine. Methods: We performed a double blind, crossover, randomized, placebo-controlled study in 20 allergic subjects out of season. After treatment with either placebo or loratadine (10 mg PO daily) for I week, a catheter was inserted into one maxillary sinus and used to lavage the cavity. The subjects then underwent nasal challenge with diluent for the allergen extract, followed by 3 concentrations of grass or ragweed. Nasal and ipsilateral sinus lavages were performed after each challenge and then hourly for 8 hours. Sneezes and symptoms were recorded, and the lavage specimens were evaluated for eosinophils and levels of eosinophil cationic protein, albumin, and histamine. Eleven of the subjects underwent a similar challenge with lactated Ringer's solution. Results: Compared with the lactated Ringer's solution challenge, allergen challenge resulted in significant increases in most early- and late-phase nasal parameters. Allergen challenge of the nose also led to a significant increase compared with control values in maxillary sinus eosinophils and the levels of albumin, eosinophil cationic protein, and histamine during the late response. Loratadine resulted in significant inhibition of the nasal early response compared with that seen with placebo (P <.05). Conclusion: These findings suggest that a neural reflex or systemic allergic inflammation is responsible for the sinus inflammatory response and that this inflammatory response might play a role in the development of rhinosinusitis in allergic subjects.	[Baroody, Fuad M.; Mucha, Samantha M.; De Tineo, Marcy; Naclerio, Robert M.] Univ Chicago, Pritzker Sch Med, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA	University of Chicago	Baroody, FM (corresponding author), Univ Chicago, Pritzker Sch Med, Sect Otolaryngol Head & Neck Surg, 5841 S Maryland Ave MC 1035, Chicago, IL 60637 USA.	fbaroody@surgery.bsd.uchicago.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045583] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 45583] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adkins TN, 1998, ANN ALLERG ASTHMA IM, V81, P181, DOI 10.1016/S1081-1206(10)62807-4; BARANIUK JN, 1991, AM J RESP CELL MOL, V4, P228, DOI 10.1165/ajrcmb/4.3.228; BARANIUK JN, 1990, J CLIN INVEST, V86, P825, DOI 10.1172/JCI114780; BAROODY FM, 1994, AM J RESP CRIT CARE, V149, P1457, DOI 10.1164/ajrccm.149.6.7516250; Baroody FM, 1999, J APPL PHYSIOL, V87, P1038, DOI 10.1152/jappl.1999.87.3.1038; BAROODY FM, 1993, J APPL PHYSIOL, V74, P2661, DOI 10.1152/jappl.1993.74.6.2661; Blair C, 2001, J ALLERGY CLIN IMMUN, V108, P424, DOI 10.1067/mai.2001.117793; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051, DOI 10.1164/ajrccm.161.6.9906121; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; Chen Chien-Fu, 2001, Journal of Microbiology Immunology and Infection, V34, P57; Chung JH, 1997, ANN ALLERG ASTHMA IM, V78, P307, DOI 10.1016/S1081-1206(10)63187-0; CONNER BL, 1989, ANN ALLERGY, V62, P457; Cunningham MJ, 2000, ARCH OTOLARYNGOL, V126, P1363, DOI 10.1001/archotol.126.11.1363; FURUKAWA CT, 1992, J ALLERGY CLIN IMMUN, V90, P515, DOI 10.1016/0091-6749(92)90177-4; GRANEY DO, 1998, OTOLARYNGOLOGY HEAD, P1060; Gutman M, 2004, OTOLARYNG HEAD NECK, V130, P545, DOI 10.1016/j.otohns.2004.02.007; Gwaltney JM, 2000, CLIN INFECT DIS, V30, P387, DOI 10.1086/313661; HAIGHT JS, 1919, J OTOLARYNGOL, V28, P197; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; Kramer MF, 2000, LARYNGOSCOPE, V110, P1056, DOI 10.1097/00005537-200006000-00031; LAITINEN LA, 1987, AM REV RESPIR DIS, V136, pS59, DOI 10.1164/ajrccm/136.6_Pt_2.S59; LIU CM, 1993, AM J RHINOL, V7, P111, DOI 10.2500/105065893781976410; MATHEW RC, 1992, J IMMUNOL, V148, P3572; Metson RB, 2000, LARYNGOSCOPE, V110, P24, DOI 10.1097/00005537-200003002-00007; MOSIMANN BL, 1993, J ALLERGY CLIN IMMUN, V92, P95, DOI 10.1016/0091-6749(93)90043-F; Murphy MP, 2002, OTOLARYNG HEAD NECK, V127, P367, DOI 10.1067/mhn.2002.129815; Naclerio RM, 1997, ARCH OTOLARYNGOL, V123, P193; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; OKAMOTO Y, 1993, J IMMUNOL, V151, P4391; PHILIP G, 1994, J ALLERGY CLIN IMMUN, V94, P1035, DOI 10.1016/0091-6749(94)90122-8; PHILIP G, 1993, AM REV RESPIR DIS, V148, P1616, DOI 10.1164/ajrccm/148.6_Pt_1.1616; Ponikau JU, 2003, J ALLERGY CLIN IMMUN, V112, P877, DOI 10.1016/j.jaci.2003.08.009; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; Slavin RG, 2000, ANN ALLERG ASTHMA IM, V85, P275, DOI 10.1016/S1081-1206(10)62529-X; Suzuki M, 1999, AM J OTOLARYNG, V20, P143, DOI 10.1016/S0196-0709(99)90061-3	35	60	64	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1126	1132		10.1016/j.jaci.2008.02.010	http://dx.doi.org/10.1016/j.jaci.2008.02.010			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18367240				2022-12-18	WOS:000255961700008
J	Reefer, AJ; Satinover, SM; Solga, MD; Lannigan, JA; Nguyen, JT; Wilson, BB; Woodfolk, JA				Reefer, Amanda J.; Satinover, Shama M.; Solga, Michael D.; Lannigan, Joanne A.; Nguyen, Jennifer T.; Wilson, Barbara B.; Woodfolk, Judith A.			Analysis of CD25(hi)CD(4+) "regulatory" T-cell subtypes in atopic dermatitis reveals a novel T(H)2-like population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human regulatory T cells; T(H)2 cytokines; CCR4; CLA; CCR6; CD25; foxp3; bacterial superantigen; allergen avoidance	GAMMA PRODUCTION; EXPRESSION; CCR4; LYMPHOCYTES; INDUCTION; MAJORITY; ALLERGEN; FOXP3	Background: It is unresolved whether circulating CD25(hi) CD4+ T cells in patients with atopic dermatitis who have elevated IgE (IgE high) are regulatory or effector in nature. Objective: To analyze the properties of CD25(hi) T-cell subtypes in IgE high atopic dermatitis. Methods: The phenotype of circulating CD25(hi) T cells was analyzed by flow cytometry using PBMCs from patients with atopic dermatitis (total IgE > 250 IU/mL). Cytokines induced in CD25hi subtypes were analyzed after activation with anti-CD3 mAb (+/- IL-2) and in the presence of activated autologous effector T cells (CD25(neg)CD(4+)). Reactivity to bacterial superantigen derived from the skin-colonizing organism Staphylococcus aureus was also evaluated. Results: CD25(hi) T cells expressing regulatory T-cell markers (Foxp3, CCR4, cutaneous lymphocyte-associated antigen) were increased in atopic dermatitis compared with IgE(low) controls. This phenomenon was linked to disease severity. Two subtypes of CD25(hi) T cells were identified on the basis of differential expression of the chemokine receptor CCR6. Although the ratio of CCR6(+) and CCR6(neg) subtypes within the CD25(hi) subset was unaltered in atopic dermatitis, each subtype proliferated spontaneously ex vivo, suggesting in vivo activation. Activated CCR6(neg) cells secreted T(H)2 cytokines, and coculture with effector T cells selectively enhanced IL-5 production. Moreover, induction of a T(H)2-dominated cytokine profile on activation with bacterial superantigen was restricted to the CCR6(neg) subtype. Conclusion: Despite a regulatory phenotype, activated CD25(hi) T cells that lack expression of CCR6 promote TH2 responses.	[Reefer, Amanda J.; Satinover, Shama M.; Nguyen, Jennifer T.; Woodfolk, Judith A.] Univ Virginia Hlth Syst, Div Allergy, Asthma & Allergy Dis Ctr, Charlottesville, VA 22908 USA; [Solga, Michael D.; Lannigan, Joanne A.] Univ Virginia Hlth Syst, Flow Cytometry Core Facil, Dept Microbiol, Charlottesville, VA 22908 USA; [Wilson, Barbara B.] Univ Virginia Hlth Syst, Dept Dermatol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Woodfolk, JA (corresponding author), Univ Virginia Hlth Syst, Div Allergy, Asthma & Allergy Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	jaw4m@virginia.edu	Nguyen, Jennifer/GVS-4347-2022	Lannigan, Joanne/0000-0002-3981-8681	NCRR NIH HHS [5 M01RR00847] Funding Source: Medline; NIAID NIH HHS [AI-052196, AI-020565] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, R01AI052196, R37AI020565] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis M, 2003, FASEB J, V17, P1026, DOI 10.1096/fj.02-1070com; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Baekkevold ES, 2005, J EXP MED, V201, P1045, DOI 10.1084/jem.20041059; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Caproni M, 2006, J CLIN IMMUNOL, V26, P370, DOI 10.1007/s10875-006-9034-2; Cardona ID, 2006, J ALLERGY CLIN IMMUN, V117, P688, DOI 10.1016/j.jaci.2005.11.037; Carneiro R, 2004, J INVEST DERMATOL, V122, P927, DOI 10.1111/j.0022-202X.2004.22407.x; Clark RA, 2007, BLOOD, V109, P194, DOI 10.1182/blood-2006-02-002873; Clark RA, 2006, J IMMUNOL, V176, P4431, DOI 10.4049/jimmunol.176.7.4431; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hirahara K, 2006, J IMMUNOL, V177, P4488, DOI 10.4049/jimmunol.177.7.4488; Iellem A, 2003, EUR J IMMUNOL, V33, P1488, DOI 10.1002/eji.200323658; Katsunuma T, 2004, INT ARCH ALLERGY IMM, V134, P240, DOI 10.1159/000078772; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Nagato T, 2007, J IMMUNOL, V178, P1189, DOI 10.4049/jimmunol.178.2.1189; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Reefer AJ, 2007, J ALLERGY CLIN IMMUN, V120, P156, DOI 10.1016/j.jaci.2007.03.042; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Shimojo N, 1996, CLIN EXP IMMUNOL, V106, P62, DOI 10.1046/j.1365-2249.1996.d01-816.x; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Verhagen J, 2006, J ALLERGY CLIN IMMUN, V117, P176, DOI 10.1016/j.jaci.2005.10.040; Walker MR, 2005, P NATL ACAD SCI USA, V102, P4103, DOI 10.1073/pnas.0407691102; Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441; Woodfolk JA, 2007, J ALLERGY CLIN IMMUN, V119, P280, DOI 10.1016/j.jaci.2006.11.008	28	60	66	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					415	422		10.1016/j.jaci.2007.11.003	http://dx.doi.org/10.1016/j.jaci.2007.11.003			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18177697				2022-12-18	WOS:000253337800021
J	Horvath, G; Mendes, ES; Schmid, N; Schmid, A; Conner, GE; Salathe, M; Wanner, A				Horvath, Gabor; Mendes, Eliana S.; Schmid, Nathalie; Schmid, Andreas; Conner, Gregory E.; Salathe, Matthias; Wanner, Adam			The effect of corticosteroids on the disposal of long-acting beta(2)-agonists by airway smooth muscle cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchial smooth muscle; organic cation transporter; corticosteroids; budesonide; fluticasone; nongenomic; long-acting; beta(2)-agonists; formoterol; salmeterol	ORGANIC CATION TRANSPORTERS; HUMAN BRONCHIAL ARTERIAL; INHALED CORTICOSTEROIDS; ASTHMA; GLUCOCORTICOSTEROIDS; ACETYLCHOLINE; FLUTICASONE; EPITHELIUM; RECEPTORS	Background: Organic cation transporters (OCTs) have an important role in tissue distribution and elimination of cationic drugs. Carrier-mediated disposal of cationic bronchodilators in the airway tissue, however, is incompletely understood. Objectives: We sought to assess the uptake of long-acting beta(2)-agonist bronchodilators by bronchial and vascular smooth muscle cells. Methods: Human airway cells and tissues obtained from organ donors were evaluated for cationic drug transporter expression by means of quantitative RT-PCR and immunofluorescence. For in vitro functional studies, tritiated formoterol and tritiated salmeterol uptake by bronchial and vascular smooth muscle cells was measured. Results: Quantitative RT-PCR analysis revealed high mRNA levels for the corticosteroid-sensitive OCT3 in bronchial and vascular smooth muscle cells. Immunofluorescence staining of airway sections confirmed OCT3 expression in these cells. In bronchial smooth muscle cells, uptake of the cationic formoterol was inhibited with OCT inhibitors. Corticosteroids also inhibited formoterol uptake through a rapid (within 15 minutes) nongenomic action, with the following rank order for inhibitory potency: corticosterone > budesonide > fluticasone. The corticosteroid-induced inhibition was significantly higher in vascular than bronchial smooth muscle cells. In comparison with formoterol, uptake of the noncharged lipophilic salmeterol was approximately 10-fold higher and insensitive to all OCT inhibitors and corticosteroids. Conclusions: Our findings suggest that corticosteroids, through OCT3 inhibition, rapidly interfere with the disposal of cationic drugs by smooth muscle cells in the airway. Clinical implications: This novel immediate interaction between corticosteroids and cationic beta(2)-agonist bronchodilators supports the use of such combinations in the pharmacotherapy of asthma.	Univ Miami, Miller Sch Med, Div Pulm & Crit Care Med, Miami, FL 33101 USA; Semmelweis Univ, Sch Med, Dept Pulmonol, Budapest, Hungary	University of Miami; Semmelweis University	Wanner, A (corresponding author), Univ Miami, Miller Sch Med, Div Pulm & Crit Care Med, POB 016960 R-47, Miami, FL 33101 USA.	ghorvath.mail@gmail.com; awanner@miami.edu	Horvath, Gabor/A-1201-2008; Conner, Gregory/AAI-1285-2021	Conner, Gregory/0000-0003-2217-2252; Salathe, Matthias/0000-0001-9092-4861	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066125, R01HL060644] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-66125, R01 HL060644, R01 HL060644-09A1, HL-60644, R01 HL066125] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARAMORI G, 2006, DRUG DISCOV TODAY, V3, P261; Ehrhardt C, 2005, PULM PHARMACOL THER, V18, P165, DOI 10.1016/j.pupt.2004.11.007; Frost AE, 1997, CLIN CHEST MED, V18, P231, DOI 10.1016/S0272-5231(05)70374-9; Gasser PJ, 2006, J NEUROSCI, V26, P8758, DOI 10.1523/JNEUROSCI.0570-06.2006; Hayer-Zillgen M, 2002, BRIT J PHARMACOL, V136, P829, DOI 10.1038/sj.bjp.0704785; Horvath G, 2006, EUR RESPIR J, V27, P172, DOI 10.1183/09031936.06.00048605; Horvath G, 2003, AM J PHYSIOL-LUNG C, V285, pL829, DOI 10.1152/ajplung.00054.2003; Horvath G, 2001, AM J RESP CELL MOL, V25, P500, DOI 10.1165/ajrcmb.25.4.4559; Horvath G, 2007, PULM PHARMACOL THER, V20, P157, DOI 10.1016/j.pupt.2006.03.009; Horvath G, 2007, AM J RESP CELL MOL, V36, P53, DOI 10.1165/rcmb.2006-0230OC; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; IVERSEN LL, 1970, BRIT J PHARMACOL, V40, P528, DOI 10.1111/j.1476-5381.1970.tb10637.x; Johnston L, 2002, SOC COGNITION, V20, P18, DOI 10.1521/soco.20.1.18.20944; Ketchell RI, 2002, J ALLERGY CLIN IMMUN, V110, P603, DOI 10.1067/mai.2002.128486; Koepsell H, 2004, TRENDS PHARMACOL SCI, V25, P375, DOI 10.1016/j.tips.2004.05.005; Kumar SD, 2000, AM J RESP CRIT CARE, V161, P918, DOI 10.1164/ajrccm.161.3.9904106; Kummer W, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-65; Lips KS, 2005, AM J RESP CELL MOL, V33, P79, DOI 10.1165/rcmb.2004-0363OC; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; MAK JCW, 1995, J CLIN INVEST, V96, P99, DOI 10.1172/JCI118084; MAK JCW, 1995, AM J PHYSIOL-LUNG C, V268, pL41, DOI 10.1152/ajplung.1995.268.1.L41; Mendes ES, 2003, EUR RESPIR J, V21, P989, DOI 10.1183/09031936.03.00072402; Miller-Larsson A, 2006, CURR PHARM DESIGN, V12, P3261, DOI 10.2174/138161206778194187; Norman AW, 2004, NAT REV DRUG DISCOV, V3, P27, DOI 10.1038/nrd1283; Patton John S, 2004, Proc Am Thorac Soc, V1, P338, DOI 10.1513/pats.200409-049TA; Rodrigo G, 1998, AM J RESP CRIT CARE, V157, P698, DOI 10.1164/ajrccm.157.3.9704022; Rodrigo GJ, 2006, CHEST, V130, P1301, DOI 10.1378/chest.130.5.1301; Schmid A, 2006, J CELL SCI, V119, P4176, DOI 10.1242/jcs.03181; Urbach V, 2006, STEROIDS, V71, P323, DOI 10.1016/j.steroids.2005.09.014	29	60	61	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1103	1109		10.1016/j.jaci.2007.08.034	http://dx.doi.org/10.1016/j.jaci.2007.08.034			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17920670				2022-12-18	WOS:000250973400019
J	Chen, CM; Rzehak, P; Zutavern, A; Fahlbusch, B; Bischof, W; Herbarth, O; Borte, M; Lehmann, I; Behrendt, H; Kramer, U; Wichmann, HE; Heinrich, J				Chen, Chih-Mei; Rzehak, Peter; Zutavern, Anne; Fahlbusch, Baerbel; Bischof, Wolfgang; Herbarth, Olf; Borte, Michael; Lehmann, Irina; Behrendt, Heidrun; Kraemer, Ursula; Wichmann, H.-Erich; Heinrich, Joachim		LISA Study Grp	Longitudinal study on cat allergen exposure and the development of allergy in young children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; cats; children; cohort study; house dust; ownership; sensitization	IN-HOUSE DUST; BIRTH COHORT; ATOPIC SENSITIZATION; ENDOTOXIN EXPOSURE; RISK ENVIRONMENT; PET OWNERSHIP; GERMAN HOMES; ASTHMA; LIFE; SCHOOL	Background: The influence of cat allergen exposure in early childhood on the development of sensitization and allergic diseases is complex. Little is known about the natural course of the sensitization development within individuals. Objective: We investigated the association between cat allergen exposure in infancy and cat ownership and cat contact during childhood and the development of cat sensitization and allergic diseases up to age 6 years using a longitudinal analysis approach. Methods: Overall, 2166 children from an ongoing birth cohort study were included in the analysis. House dust samples were collected 3 months after birth. Cat allergen levels were extracted. Blood samples were collected when the children were 2 and 6 years old. Information on the allergic symptoms of children and doctor-diagnosed allergic disease were collected at each follow-up using questionnaires. Results: Cat allergen exposure in infancy was positively associated with sensitization at age 2 years but not at age 6 years. No associations existed between cat allergen exposure in infancy and allergic symptoms and diseases up to age 6 years. Cumulative allergen exposure from cat ownership and regular cat contact increased the risk of cat sensitization up to age 6 years. Conclusion: Cat allergen exposure in infancy increases the risk of sensitization development in early childhood but not in school-age children. Cumulative allergen exposure from cat ownership and regular cat contact during childhood contribute to sensitization development up to school age. Clinical implications: Cat allergen avoidance at home alone might be not effective to prevent the development of allergic sensitization in young children.	GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, D-85764 Neuherberg, Germany; Univ Munich, Inst Med Data Management Biometr & Epidemiol, Munich, Germany; Univ Munich, Childrens Hosp, D-8000 Munich, Germany; Univ Jena, Dept Indoor Climatol Ark, Inst Clin Immunol, D-6900 Jena, Germany; Univ Jena, Dept Indoor Climatol Ark, Inst Occupat Social & Environm Med, D-6900 Jena, Germany; UFZ Helmholtz Ctr Environm Res, Ctr Environm Res Leipzig, Dept Human Exposure Res & Epidemiol, Leipzig, Germany; Univ Leipzig, Akad Lehrkrankhaus, St Klinikum St Georg Leipzig, Klin Kinder & Jugendmed, D-7010 Leipzig, Germany; Univ Leipzig, Dept Pediat, D-7010 Leipzig, Germany; UFZ Helmholtz Ctr Environm Res, Dept Environm Immunol, Leipzig, Germany; Tech Univ Munich, GSF, Natl Res Ctr Environm & Hlth, Div Environm Dermatol & Allergol, D-8000 Munich, Germany; IUF, Dusseldorf, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Leipzig University; Leipzig University; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Munich; Leibniz Institut fur Umweltmedizinische Forschung (IUF)	Heinrich, J (corresponding author), GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.	joachim.heinrich@gsf.de	Wichmann, Heinz Erich/AAA-5695-2022; Heinrich, Joachim/N-1720-2013	Heinrich, Joachim/0000-0002-9620-1629; Lehmann, Irina/0000-0001-8875-5587				Ahrens W., 1998, MESSUNG SOZIODEMOGRA; Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Almqvist C, 2003, J ALLERGY CLIN IMMUN, V111, P800, DOI 10.1067/mai.2003.1334; Antens CJM, 2006, CLIN EXP ALLERGY, V36, P1525, DOI 10.1111/j.1365-2222.2006.02603.x; Anyo G, 2002, CLIN EXP ALLERGY, V32, P361, DOI 10.1046/j.1365-2222.2002.01254.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brussee JE, 2005, J ALLERGY CLIN IMMUN, V115, P946, DOI 10.1016/j.jaci.2005.02.035; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348, DOI 10.1164/ajrccm.162.4.9909118; Fahlbusch B, 2002, J INVEST ALLERG CLIN, V12, P12; Gehring U, 2004, INDOOR AIR, V14, P284, DOI 10.1111/j.1600-0668.2004.00244.x; Gehring U, 2004, ENVIRON HEALTH PERSP, V112, P834, DOI 10.1289/ehp.6685; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gross I, 1997, ALLERGOLOGIE, V20, P449; Gross I, 2000, CLIN EXP ALLERGY, V30, P376, DOI 10.1046/j.1365-2222.2000.00780.x; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; Heinrich J, 2002, EUR RESPIR J, V20, P617, DOI 10.1183/09031936.02.02322001; Heissenhuber A, 2003, ALLERGY, V58, P154, DOI 10.1034/j.1398-9995.2003.00037.x; Hesselmar B, 2003, CLIN EXP ALLERGY, V33, P1681, DOI 10.1111/j.1365-2222.2003.01821.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Holscher B, 2002, PEDIAT ALLERG IMM-UK, V13, P334, DOI 10.1034/j.1399-3038.2002.02063.x; Ichikawa K, 1999, CLIN EXP ALLERGY, V29, P754; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Lau S, 2005, ALLERGY, V60, P766, DOI 10.1111/j.1398-9995.2005.00781.x; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Torrent M, 2006, J ALLERGY CLIN IMMUN, V118, P742, DOI 10.1016/j.jaci.2006.04.059; Wijga A, 2001, CLIN EXP ALLERGY, V31, P576, DOI 10.1046/j.1365-2222.2001.01072.x; Zutavern A, 2006, PEDIATRICS, V117, P401, DOI 10.1542/peds.2004-2521	34	60	61	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1148	1155		10.1016/j.jaci.2007.02.017	http://dx.doi.org/10.1016/j.jaci.2007.02.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17399781	Bronze			2022-12-18	WOS:000246427200015
J	Kurz, T; Hoffjan, S; Hayes, MG; Schneider, D; Nicolae, R; Heinzmann, A; Jerkic, SP; Parry, R; Cox, NJ; Deichmann, KA; Ober, C				Kurz, Thorsten; Hoffjan, Sabine; Hayes, M. Geoffrey; Schneider, Dan; Nicolae, Raluca; Heinzmann, Andrea; Jerkic, Sylvija P.; Parry, Rod; Cox, Nancy J.; Deichmann, Klaus A.; Ober, Carole			Fine mapping and positional candidate studies on chromosome 5p13 identify multiple asthma susceptibility loci	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; linkage; founder population	INHIBITORY FACTOR LIF; QUANTITATIVE TRAITS; COMPLEX TRAITS; GENE; LINKAGE; IDENTIFICATION; ASSOCIATION; ENVIRONMENT; POPULATION; RECEPTOR	Background: Genome-wide linkage scans to identify asthma susceptibility loci have revealed many linked regions, including a broad region on chromosome 5p. Objective: To identify a 5p-linked asthma or bronchial hyperresponsiveness (BHR) locus. Methods: We performed fine mapping and positional candidate studies of this region in the Hutterites and an outbred case-control sample from Germany by genotyping 89 single nucleotide polymorphisms (SNPs) in 22 genes. SNP and haplotype analyses were performed. Results: Three genes in a distal region (zinc finger RNA binding protein [ZFR], natriuretic peptide receptor C, and a disintegrin and metalloproteinase domain with thrombospondin type 1 motif [ADAMTS12]) were associated with BHR, whereas 4 genes in a proximal region (prolactin receptor, IL-7 receptor [IL7R], leukemia inhibitory factor receptor [LIFR], and prostaglandin E4 receptor [PTGER4]) were associated with asthma symptoms in the Hutterites. Furthermore, nearly the entire original linkage signal in the Hutterites was generated by individuals who had the risk-associated alleles in ZFR3, natriuretic peptide receptor C, ADAMTS12, LIFR, and PTGER4. Variation in ADAMTS12, IL7R, and PTGER4 were also associated with asthma in the outbred Germans, and the frequencies of long-range haplotypes composed of SNPs at ZFR, ADAMTS12, IL7R, LIFR, and PTGER4 were significantly different between both the German and Hutterite cases and controls. There is little linkage disequilbrium between alleles in these 2 regions in either population. Conclusion: These results suggest that a broad region on 5p, separated by > 9 Mb, harbors at least 2 and possibly 5 asthma or BHR susceptibility loci. These findings are consistent with the hypothesis that regions providing evidence for linkage in multiple populations may, in fact, house more than 1 susceptibility locus, as appears to be the case for the linked region on 5p. Clinical implications: Identifying asthma or BHR genes could lead to novel therapeutic approaches.	Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Freiburg, Dept Pediat, D-7800 Freiburg, Germany; Univ S Dakota, Sch Med, Dept Med, Vermillion, SD 57069 USA	University of Chicago; University of Chicago; University of Freiburg; University of South Dakota	Ober, C (corresponding author), Univ Chicago, Dept Human Genet, 920 E 58th St,CLSC 507C, Chicago, IL 60637 USA.	c-ober@genetics.uchicago.edu		Ober, Carole/0000-0003-4626-9809; Hayes, M Geoffrey/0000-0002-4617-3981	NHLBI NIH HHS [P50 HL056399, R01 HL066533, T32 HL 007605, R01 HL072414, HL 66533] Funding Source: Medline; NIDDK NIH HHS [DK 55889] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066533, P50HL056399, T32HL007605, R01HL072414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055889] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abney M, 2000, AM J HUM GENET, V66, P629, DOI 10.1086/302759; Addington AM, 2004, BIOL PSYCHIAT, V55, P976, DOI 10.1016/j.biopsych.2004.01.024; Akaogi J, 2004, J LEUKOCYTE BIOL, V76, P227, DOI 10.1189/jlb.1203627; Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Barnes KC, 1999, J ALLERGY CLIN IMMUN, V104, P485, DOI 10.1016/S0091-6749(99)70398-2; Beasley R, 2002, J ALLERGY CLIN IMMUN, V109, pS482, DOI 10.1067/mai.2002.122716; Becker T, 2004, AM J HUM GENET, V75, P561, DOI 10.1086/424390; Becker T, 2004, GENET EPIDEMIOL, V27, P21, DOI 10.1002/gepi.10323; Bourgain C, 2004, GENETICS, V168, P2349, DOI 10.1534/genetics.104.031617; Bourgain C, 2003, AM J HUM GENET, V73, P612, DOI 10.1086/378208; Chan A, 2006, GENES IMMUN, V7, P169, DOI 10.1038/sj.gene.6364287; Chen XN, 1999, GENOME RES, V9, P492; Crane J, 2002, ALLERGY, V57, P663, DOI 10.1034/j.1398-9995.2002.25004.x; CURTIS D, 1995, AM J HUM GENET, V57, P703; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812, DOI 10.1164/ajrccm.162.5.2002113; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; HOSTETLER JA, 1985, AM J MED GENET, V22, P453, DOI 10.1002/ajmg.1320220303; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Kleeberger SR, 2005, ANNU REV MED, V56, P383, DOI 10.1146/annurev.med.56.062904.144908; Knight DA, 1999, AM J RESP CELL MOL, V20, P834, DOI 10.1165/ajrcmb.20.4.3429; Knight DA, 2000, BRIT J PHARMACOL, V130, P975, DOI 10.1038/sj.bjp.0703415; Kraan TCTMV, 1999, GENES IMMUN, V1, P61, DOI 10.1038/sj.gene.6363630; Kurz T, 2000, J ALLERGY CLIN IMMUN, V106, P925, DOI 10.1067/mai.2000.110557; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; Marsh DG, 1997, NAT GENET, V15, P389; MEYERS DA, 1992, GENETIC BASIS COMMON, P130; Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551; Moffatt MF, 2001, EUR J HUM GENET, V9, P341, DOI 10.1038/sj.ejhg.5200636; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; Noguchi E, 2005, AM J RESP CRIT CARE, V172, P183, DOI 10.1164/rccm.200409-1223OC; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Ober C, 2005, CURR OPIN IMMUNOL, V17, P670, DOI 10.1016/j.coi.2005.09.009; Ober C, 2001, AM J HUM GENET, V69, P1068, DOI 10.1086/324025; Oefner P. J., 1995, American Journal of Human Genetics, V57, pA266; Raby BA, 2003, HUM MOL GENET, V12, P1973, DOI 10.1093/hmg/ddg208; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; Roberts SB, 1999, AM J HUM GENET, V65, P876, DOI 10.1086/302528; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; Singh J, 2005, J ALLERGY CLIN IMMUN, V115, P330, DOI 10.1016/j.jaci.2004.11.021; Sun L, 2002, AM J HUM GENET, V70, P399, DOI 10.1086/338660; Upham JW, 2005, CURR OPIN ALLERGY CL, V5, P167, DOI 10.1097/01.all.0000162310.79555.ed; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Ying S, 2004, J ALLERGY CLIN IMMUN, V114, P1309, DOI 10.1016/j.jaci.2004.08.034; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166	52	60	62	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					396	402		10.1016/j.jaci.2006.04.036	http://dx.doi.org/10.1016/j.jaci.2006.04.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890764				2022-12-18	WOS:000239877700015
J	Loke, TK; Mallett, KH; Ratoff, J; O'Connor, BJ; Ying, S; Meng, Q; Soh, C; Lee, TH; Corrigan, CJ				Loke, Tuck-Kay; Mallett, Kirsty H.; Ratoff, Jonathan; O'Connor, Brian J.; Ying, Sun; Meng, Qiu; Soh, Cecilia; Lee, Tak H.; Corrigan, Chris J.			Systemic glucocorticoid reduces bronchial mucosal activation of activator protein 1 components in glucocorticoid-sensitive but not glucocorticoid-resistant asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; glucocorticoid; activator protein 1; therapy; resistance	N-TERMINAL KINASE; C-FOS; GENE-EXPRESSION; RECEPTOR; BINDING; CELLS; TRANSCRIPTION; PHOSPHORYLATION; PROLIFERATION; INTERLEUKIN-5	Background: Overexpression of the transcriptional regulatory factor activator protein 1 might contribute to T-cell glucocorticoid (GC) refractoriness in GC-resistant asthma. Objective: We sought to address the hypothesis that clinically GC-resistant asthma is accompanied by failure of systemic GCs to inhibit phosphorylation of c-jun and c-jun N-terminal kinase (JNK) in bronchial mucosal cells. Methods: We performed enumeration of total (CD45+) leukocytes and cells expressing e-fos and total and phosphorylated c-jun and JNK in bronchial biopsy sections from 9 GC-sensitive and 17 GC-resistant asthmatic patients taken before and after oral prednisolone (40 mg/1.72 m(2) body surface area daily for 14 days) using specific antibodies, immunohistochemistry, and image analysis. Results: At baseline, mean total (CD45(+)) mucosal leukocytes, total cells expressing phosphorylated c-jun and JNK, and mean percentages of cells in which these molecules were phosphorylated were similar in both groups, whereas mean total numbers of c-fos-immunoreactive cells were increased in the GC-resistant asthmatic subjects (P = .04). After prednisolone, the mean total cells expressing phosphorylated c-jun and JNK and the mean percentages of cells in which these molecules were phosphorylated were significantly reduced in the GC-sensitive (P < .02) but not the GC-resistant asthmatic subjects. Mean total CD45(+) leukocytes and c-fos-immunoreactive cells were not significantly altered in either group. Conclusion: Clinical GC responsiveness in asthma is accompanied by reduced phosphorylation of bronchial mucosal c-jun and JNK, a phenomenon not seen in resistant patients. Clinical implications: Dysregulation of activator protein 1 activation leading to clinical GC resistance might reflect identifiable environmental influences and is a target for future therapy.	Guys Hosp, Dept Asthma Allergy & Resp Sci, London SE1 9RT, England; Kings Coll London, MRC, London WC2R 2LS, England; Asthma UK Ctr Allerg Mech Asthma, Div Asthma Allergy & Lung Biol, London, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London	Corrigan, CJ (corresponding author), Guys Hosp, Dept Asthma Allergy & Resp Sci, 5th Floor,Thomas Guy House, London SE1 9RT, England.	chris.corrigan@kcl.ac.uk	Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059; Corrigan, Chris/0000-0002-0706-6534; Loke, Tuck-Kay/0000-0002-4608-2756	Medical Research Council [G9805965] Funding Source: Medline; MRC [G9805965] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ADCOCK IM, 1995, J EXP MED, V182, P1951, DOI 10.1084/jem.182.6.1951; ADCOCK IM, 1995, J IMMUNOL, V154, P3500; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Cabral ALB, 2001, MOL CELL ENDOCRINOL, V175, P67, DOI 10.1016/S0303-7207(01)00396-3; Corrigan C, 2005, J ALLERGY CLIN IMMUN, V115, P316, DOI 10.1016/j.jaci.2004.10.051; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016, DOI 10.1164/ajrccm/144.5.1016; CURRAN T, 1985, CANCER SURV, V4, P655; deGroot RP, 1997, J BIOL CHEM, V272, P2319; DEMOLY P, 1992, AM J RESP CELL MOL, V7, P128, DOI 10.1165/ajrcmb/7.2.128; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Gonzalez MV, 2000, J CELL BIOL, V150, P1199, DOI 10.1083/jcb.150.5.1199; HACZKU A, 1994, J ALLERGY CLIN IMMUN, V93, P510, DOI 10.1016/0091-6749(94)90361-1; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI200112466; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; Itoh M, 2002, MOL ENDOCRINOL, V16, P2382, DOI 10.1210/me.2002-0144; Johnson CM, 1997, J NEUROSCI, V17, P6189; KAM JC, 1993, J IMMUNOL, V151, P3460; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Lane SJ, 1998, J CLIN INVEST, V102, P2156, DOI 10.1172/JCI2680; LEE TH, 1996, AM J RESP CRIT CAR S, V154, pS51; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; Li LB, 2004, J ALLERGY CLIN IMMUN, V114, P1059, DOI 10.1016/j.jaci.2004.08.005; Livingston E, 2005, DRUGS, V65, P1521, DOI 10.2165/00003495-200565110-00005; Matthews JG, 2004, J ALLERGY CLIN IMMUN, V113, P1100, DOI 10.1016/j.jaci.2004.03.018; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; Sousa AR, 1999, J ALLERGY CLIN IMMUN, V104, P565, DOI 10.1016/S0091-6749(99)70325-8; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153	32	60	66	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					368	375		10.1016/j.jaci.2006.04.055	http://dx.doi.org/10.1016/j.jaci.2006.04.055			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890760				2022-12-18	WOS:000239877700011
J	Kanda, N; Koike, S; Watanabe, S				Kanda, N; Koike, S; Watanabe, S			IL-17 suppresses TNF-alpha-induced CCL27 production through induction of COX-2 in human keratinocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-17; TNF-alpha; CCL27; prostaglandin E-2; COX-2	NECROSIS-FACTOR-ALPHA; INTERFERON-GAMMA; CYCLOOXYGENASE-2 EXPRESSION; CHEMOKINE PRODUCTION; MESSENGER-RNA; T-LYMPHOCYTES; UP-REGULATION; INTERLEUKIN-17; CELLS; ACTIVATION	Background: The chemokine CCL27 attracts skin-homing T cells. CCL27 production by keratinocytes is dependent on nuclear factor kappa B (NF-kappa B) activity and enhanced in lesions of patients with atopic dermatitis, psoriasis vulgaris, or allergic contact dermatitis. IL-17 is released from activated memory T cells and modulates skin inflammation. Objective: We examined the in vitro effects of IL-17 on TNF-alpha-induced CCL27 production in human keratinocytes. Methods: Keratinocytes were incubated with TNF-alpha, IL-17, or both. CCL27 secretion and mRNA levels were analyzed by means of ELISA and RT-PCR, respectively. COX-2 promoter and NF-kappa B activities were analyzed by using luciferase assays. COX-2 protein levels were analyzed by means of Western blotting. Results: IL-17 suppressed TNF-alpha-induced CCL27 secretion and mRNA expression and NF-kappa B activity in keratinocytes. The COX-2 inhibitor NS398 counteracted the effects of IL-17, and prostaglandin E-2 prevented counteraction by NS398. IL-17 alone or synergistically with TNF-alpha increased prostaglandin E2 release from keratinocytes, and the increase was suppressed by NS398. IL-17 alone or synergistically with TNF-alpha increased COX-2 mRNA and protein levels, promoter activity, and mRNA stability. The stimulatory effects of IL-17 on COX-2 expression were suppressed by inhibitors of p38 mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) kinase. IL-17 alone or synergistically with TNF-a induced dual phosphorylation of p38 MAPK and ERK. Conclusion: IL-17 might suppress TNF-alpha-induced CCL27 production by inhibiting NF-kappa B through induction of COX-2. The induction of COX-2 might be mediated by activation of p38 MAPK and ERK. T cell-derived IL-17 might alleviate T-cell skin infiltration through inhibition of CCL27 production.	Teikyo Univ, Sch Med, Dept Dermatol, Itabashi Ku, Tokyo 1738605, Japan	Teikyo University	Kanda, N (corresponding author), Teikyo Univ, Sch Med, Dept Dermatol, Itabashi Ku, 11-1,Kaga 2, Tokyo 1738605, Japan.	nmk@med.teikyo-u.ac.jp	Kanda, Naoko/AAD-1808-2020	Kanda, Naoko/0000-0003-4389-2312				Albanesi C, 2000, J INVEST DERMATOL, V115, P81, DOI 10.1046/j.1523-1747.2000.00041.x; Albanesi C, 1999, J IMMUNOL, V162, P494; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chen L, 2004, CLIN EXP IMMUNOL, V138, P375, DOI 10.1111/j.1365-2249.2004.02649.x; Dean JLE, 2003, J BIOL CHEM, V278, P39470, DOI 10.1074/jbc.M306345200; Faour WH, 2003, J BIOL CHEM, V278, P26897, DOI 10.1074/jbc.M212790200; Fornai M, 2005, GUT, V54, P608, DOI 10.1136/gut.2004.053322; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Hsieh HG, 2002, CYTOKINE, V19, P159, DOI 10.1006/cyto.2002.1952; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Kanda N, 2004, J ALLERGY CLIN IMMUN, V114, P1403, DOI 10.1016/j.jaci.2004.08.041; Kanda N, 2002, J INVEST DERMATOL, V119, P174, DOI 10.1046/j.1523-1747.2002.01804.x; Kawaguchi M, 2004, J ALLERGY CLIN IMMUN, V114, P1265, DOI 10.1016/j.jaci.2004.10.019; KAWAGUCHI M, 1999, J ALLERGY CLIN IMMUN, V162, P494; Maertzdorf J, 2002, J IMMUNOL, V169, P5897, DOI 10.4049/jimmunol.169.10.5897; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Mestre JR, 2001, J BIOL CHEM, V276, P3977, DOI 10.1074/jbc.M005077200; Meyer F, 2003, J IMMUNOL, V171, P3913, DOI 10.4049/jimmunol.171.8.3913; Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470; Morteau O, 2000, J CLIN INVEST, V105, P469, DOI 10.1172/JCI6899; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Ogawa A, 2004, CLIN IMMUNOL, V110, P55, DOI 10.1016/j.clim.2003.09.013; Ohnaka K, 2000, HYPERTENSION, V35, P68, DOI 10.1161/01.HYP.35.1.68; Pathak SK, 2004, J BIOL CHEM, V279, P55127, DOI 10.1074/jbc.M409885200; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; Ruddy MJ, 2004, J BIOL CHEM, V279, P2559, DOI 10.1074/jbc.M308809200; Schwandner R, 2000, J EXP MED, V191, P1233, DOI 10.1084/jem.191.7.1233; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V116, P153, DOI 10.1016/j.jaci.2005.03.017; Stamp LK, 2004, J RHEUMATOL, V31, P1246; STRASSMANN G, 1994, J EXP MED, V180, P2365, DOI 10.1084/jem.180.6.2365; Teunissen MBM, 1998, J INVEST DERMATOL, V111, P645, DOI 10.1046/j.1523-1747.1998.00347.x; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; UYEMURA K, 1993, J INVEST DERMATOL, V101, P701, DOI 10.1111/1523-1747.ep12371679; Witowski J, 2004, CELL MOL LIFE SCI, V61, P567, DOI 10.1007/s00018-003-3228-z; Zhang ZB, 2005, J GASTROEN HEPATOL, V20, P619, DOI 10.1111/j.1440-1746.2004.03748.x	36	60	62	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1144	1150		10.1016/j.jaci.2005.08.014	http://dx.doi.org/10.1016/j.jaci.2005.08.014			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275389				2022-12-18	WOS:000235686700030
J	de Blic, J; Tillie-Leblond, I; Ernond, S; Mahut, B; Duy, TLD; Scheinmann, P				de Blic, J; Tillie-Leblond, I; Ernond, S; Mahut, B; Duy, TLD; Scheinmann, P			High-resolution computed tomography scan and airway remodeling in children with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; nitrous oxide; HRCT scan; bronchial wall thickening; reticular basement membrane; remodeling; airway inflammation; ECP; IFN-gamma; IL-4	WALL THICKNESS; NITRIC-OXIDE; DIFFICULT ASTHMA; INFLAMMATION; EOSINOPHILS; DISEASE; CT	Background: Children with severe asthma have a significantly higher bronchial wall thickness (BWT) on high-resolution computed tomography scan than control children. Objective: We sought to determine whether a BWT score correlates with markers of airway remodeling and inflammation. Methods: In 37 children with severe asthma, we determined reticular basement membrane thickness; number of intraepithelial neutrophils and eosinophils on bronchial biopsy; IFN-gamma, IL-4, IL-5, and eosinophil cationic protein levels and IFN-gamma/IL-4 ratio on bronchoalveolar lavage specimen; and alveolar nitric oxide (NO) concentration and the maximum airway wall NO flux. Results: The BWT score significantly correlated with reticular basement membrane thickening (r = 0.34; P =.04) and NO production by the airway wall (r = 0.45; P =.02). The correlation with the eosinophil cationic protein level was just significant (r = 0.40; P =.05), whereas there was no correlation with IFN-gamma/IL-4 ratio (r = -0.31; P = .08). The BWT score did not correlate with FEV1 or forced expiratory flow at 25% to 75% of forced vital capacity. Conclusion: High-resolution computed tomography scan is a noninvasive technique that might be valuable for quantifying airway remodeling in children with severe asthma. The new generations of multislice computed tomography scanners will allow higher definition and lower radiation exposure and probably give a better assessment of airway remodeling and efficacy of treatment in children with asthma.	Univ Paris 05, Serv Pneumol & Allergol Pediat, Hop Necker Enfants Malad, F-75015 Paris, France; Inst Pasteur, INSERM, U416, F-59019 Lille, France; Hop Necker Enfants Malad, Serv Radiol, F-75015 Paris, France; Hop Europeen Georges Pompidou, Lab Explorat Fonct Resp Radio Isotope, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	de Blic, J (corresponding author), Univ Paris 05, Serv Pneumol & Allergol Pediat, Hop Necker Enfants Malad, 149 Rue Sevres, F-75015 Paris, France.	j.deblic@nck.aphp.fr						[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Awadh N, 1998, THORAX, V53, P248, DOI 10.1136/thx.53.4.248; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; de Blic J, 2004, J ALLERGY CLIN IMMUN, V113, P94, DOI 10.1016/j.jaci.2003.10.045; de Blic J, 2000, EUR RESPIR J, V15, P217; Hamad AM, 1999, AM J PHYSIOL-LUNG C, V277, pL910, DOI 10.1152/ajplung.1999.277.5.L910; Harmanci E, 2002, RESPIRATION, V69, P420, DOI 10.1159/000064018; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; James AL, 2002, AM J RESP CRIT CARE, V166, P1590, DOI 10.1164/rccm.2108069; Kasahara K, 2002, THORAX, V57, P242, DOI 10.1136/thorax.57.3.242; Ketai L, 2001, ACAD RADIOL, V8, P257, DOI 10.1016/S1076-6332(03)80535-4; Lemjabbar H, 1999, AM J RESP CRIT CARE, V159, P1298, DOI 10.1164/ajrccm.159.4.9708080; Little SA, 2002, THORAX, V57, P247, DOI 10.1136/thorax.57.3.247; Mahut B, 2004, CHEST, V125, P1012, DOI 10.1378/chest.125.3.1012; Mahut B, 2004, J ALLERGY CLIN IMMUN, V113, P252, DOI 10.1016/j.jaci.2003.10.038; Marchac V, 2002, AM J ROENTGENOL, V179, P1245, DOI 10.2214/ajr.179.5.1791245; Mitsunobu F, 2005, CURR OPIN ALLERGY CL, V5, P85, DOI 10.1097/00130832-200502000-00015; Nakano Y, 2002, CHEST, V122, p271S, DOI 10.1378/chest.122.6_suppl.271S-a; Niimi A, 2000, AM J RESP CRIT CARE, V162, P1518, DOI 10.1164/ajrccm.162.4.9909044; Niimi A, 2003, AM J RESP CRIT CARE, V168, P983, DOI 10.1164/rccm.200211-1268OC; PAGANIN F, 1992, AM REV RESPIR DIS, V146, P1084, DOI 10.1164/ajrccm/146.4.1084; Park JW, 1997, J INVEST ALLERG CLIN, V7, P186; Patel HJ, 1999, FASEB J, V13, P1810, DOI 10.1096/fasebj.13.13.1810; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; Pifferi M, 2002, J PEDIATR-US, V141, P104, DOI 10.1067/mpd.2002.125006; Ricciardolo FLM, 2004, PHYSIOL REV, V84, P731, DOI 10.1152/physrev.00034.2003; ROCHE WR, 1989, LANCET, V1, P520; Saetta M, 1998, EUR RESPIR J, V11, p20S; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P653, DOI 10.1152/jappl.1998.85.2.653; Vignola AM, 2004, EUR RESPIR J, V24, P910, DOI 10.1183/09031936.04.00032603; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040; Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP; Zagai U, 2004, CLIN EXP IMMUNOL, V135, P427, DOI 10.1111/j.1365-2249.2004.02396.x; 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/ajrccm/136.1.225	36	60	61	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					750	754		10.1016/j.jaci.2005.07.009	http://dx.doi.org/10.1016/j.jaci.2005.07.009			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210046				2022-12-18	WOS:000235686600005
J	Agertoft, L; Pedersen, S				Agertoft, L; Pedersen, S			Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; ciclesonide; knemometry; lower-leg growth rate	FLUTICASONE PROPIONATE; INHALED GLUCOCORTICOSTEROIDS; ASTHMATIC-CHILDREN; LINEAR GROWTH; BUDESONIDE	Background: Measurement of short-term lower-leg growth rate in children by means of knemometry has become established as an integral part of the available measures of systemic activity of topical steroids in children. Objective: We sought to determine the effects of clinically effective doses of the novel inhaled corticosteroid ciclesonide on lower-leg growth rate and hypothalamic-pituitary-adrenal axis function in children with asthma. Methods: In a double-blind, placebo-controlled, 4-period crossover study, 24 children aged 6 to 12 years sequentially received ciclesonide (40, 80, and 160 mu g) in randomized order once daily in the evening. Each 2-week treatment period was followed by a 2-week washout period. Knemometry was performed at the beginning and end of each treatment period. Cortisol levels in 12-hour overnight urine were measured at the end of each treatment period. Results: No statistically significant differences were seen in lower-leg growth rates between any of the ciclesonide treatments and placebo. Lower-leg growth rates were 0.412 mm/wk for placebo, 0.425 mm/wk for 40 mu g of ciclesonide, 0.397 mm/wk for 80 pig of ciclesonide, and 0.370 mm/wk for 160 mu g of ciclesonide. There was no statistically significant dose-response effect. Likewise, no statistically significant differences or dose-response effects were found for urinary cortisol adjusted for creatinine. Conclusion: Short-term lower-leg growth rate and hypothalamic-pituitary-adrenal axis function are not affected by treatment with ciclesonide in doses intended for clinical use in children.	Univ So Denmark, Dept Pediat, Kolding Hosp, DK-6000 Kolding, Denmark	Kolding Hospital; University of Southern Denmark	Agertoft, L (corresponding author), Univ So Denmark, Dept Pediat, Kolding Hosp, DK-6000 Kolding, Denmark.	Lone_Agertoft@dadlnet.dk		Agertoft, Lone/0000-0001-6840-7921				Agertoft L, 1999, J ALLERGY CLIN IMMUN, V104, P948, DOI 10.1016/S0091-6749(99)70073-4; Agertoft L, 1997, EUR RESPIR J, V10, P1507, DOI 10.1183/09031936.97.10071507; BISGAARD H, 1988, J ALLERGY CLIN IMMUN, V81, P1088, DOI 10.1016/0091-6749(88)90874-3; Bisgaard H, 2004, PEDIATRICS, V113, P87; BUHL R, 2004, AM J RESP CRIT CARE, V169, pA91; Chapman KR, 2005, ALLERGY, V60, P330, DOI 10.1111/j.1398-9995.2004.00750.x; Dent Gordon, 2002, Curr Opin Investig Drugs, V3, P78; Dietzel K, 2001, PROG R RES, V31, P91; DROLLMANN A, 11 ANN EUR RESP SOC; ENGELSTATTER R, 2003, AM J RESP CRIT CARE, V167, pA771; GROVE A, 1994, BRIT J CLIN PHARMACO, V38, P527, DOI 10.1111/j.1365-2125.1994.tb04394.x; HANSEL T, 2003, EUR RESP J S45, V22, pS410; JENNINGS BH, 1990, EUR J CLIN PHARMACOL, V39, P127, DOI 10.1007/BF00280045; Mealy NE, 2001, DRUG FUTURE, V26, P1033, DOI 10.1358/dof.2001.026.11.642072; Nave R, 2004, CLIN PHARMACOKINET, V43, P479, DOI 10.2165/00003088-200443070-00004; Pedersen S., 2003, Journal of Allergy and Clinical Immunology, V111, pS269, DOI 10.1016/S0091-6749(03)80966-1; Pedersen S, 2001, J ALLERGY CLIN IMMUN, V108, pS40, DOI 10.1067/mai.2001.115565; Pedersen S, 2001, AM J RESP CRIT CARE, V164, P521, DOI 10.1164/ajrccm.164.4.2101050; PEDERSEN S, 2004, P 23 ANN C EUR AC AL; Postma DS, 2001, EUR RESPIR J, V17, P1083, DOI 10.1183/09031936.01.00099701; Rohatagi S, 2004, J CLIN PHARMACOL, V44, P37, DOI 10.1177/0091270003260334; Stoeck M, 2004, J PHARMACOL EXP THER, V309, P249, DOI 10.1124/jpet.103.059592; VALK IM, 1983, GROWTH, V47, P53; Wilson AM, 1999, THORAX, V54, P20, DOI 10.1136/thx.54.1.20; WOLTHERS OD, 1995, RESP MED, V89, P347, DOI 10.1016/0954-6111(95)90006-3; WOLTHERS OD, 1993, ARCH DIS CHILD, V68, P673, DOI 10.1136/adc.68.5.673; WOLTHERS OD, 1992, PEDIATRICS, V89, P839; WOLTHERS OD, 1990, BRIT MED J, V301, P145, DOI 10.1136/bmj.301.6744.145	28	60	64	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					940	945		10.1016/j.jaci.2005.01.066	http://dx.doi.org/10.1016/j.jaci.2005.01.066			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867849	Bronze			2022-12-18	WOS:000229055100007
J	Weerkamp, F; de Haas, EFE; Naber, BAE; Comans-Bitter, WM; Bogers, AJJC; van Dongen, JJM; Staal, FJT				Weerkamp, F; de Haas, EFE; Naber, BAE; Comans-Bitter, WM; Bogers, AJJC; van Dongen, JJM; Staal, FJT			Age-related changes in the cellular composition of the thymus in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						thymus; thymocyte development; childhood; T lymphocytes; B lymphocytes; NK cells; Down syndrome; Williams syndrome	BONE-MARROW; NATURAL-KILLER; DOWNS-SYNDROME; HUMAN ADULT; B-CELLS; HUMAN T; LYMPHOCYTES; INVOLUTION; ONTOGENY; LYMPHOPOIESIS	Background: T-cell development in the thymus is an extensively studied subject, mainly in mice. Nevertheless, the normal composition and cell numbers of the noninvoluted human thymus are largely unknown. Objective: We aimed to gain insight into age-related changes in different thymic subpopulations and to provide reference values for the distribution of thymocyte subsets. The composition of the normal thymus may serve as a reference for thymi in pathological conditions and may aid diagnoses of immunodeficiency diseases. Methods: Thymic lobes of 70 children (58 immunologically normal and 12 diseased), ranging in age from 8 days to 8 years old, were studied by 4-color flow-cytometric analysis. Detailed staining and gating strategies allowed us to dissect small subsets, including immature CD4(-)CD8(-) populations and thymic B, natural killer, and T-cell receptor gamma delta(+) cells. Results: We demonstrate that distribution of thymocyte subsets changes with age and correlates with age-related fluctuations of T-lymphocyte counts in peripheral blood. Thymi of children 3 to 6 months old appear to be the most active: they have high numbers of total thymocytes, the highest percentage of double-positive cells, and large numbers of CD34(+) progenitors in their thymi. Furthermore, we show that the human thymus is a site for B-cell development, because all B-cell progenitor stages that can be found in the bone marrow are also present in the thymus. Conclusion: We conclude that T-cell development in children is a dynamic process, answering the demands of a maturing and expanding immune system.	Univ Rotterdam Hosp, Ctr Med, Erasmus MC, Dept Immunol, NL-3015 GE Rotterdam, Netherlands; Univ Rotterdam Hosp, Ctr Med, Erasmus MC, Dept Cardiothorac Surg, NL-3015 GE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Staal, FJT (corresponding author), Univ Rotterdam Hosp, Ctr Med, Erasmus MC, Dept Immunol, Dr Molewaterplein 50, NL-3015 GE Rotterdam, Netherlands.	f.staal@erasmusmc.nl	van Dongen, Jacques J.M./F-8537-2015	van Dongen, Jacques J.M./0000-0001-7686-0021; Bogers, Ad/0000-0001-6200-1998; van Dongen, Jacques J.M./0000-0002-3650-7087; Naber, Brigitta/0000-0002-0031-6086				Akashi K, 2000, J IMMUNOL, V164, P5221, DOI 10.4049/jimmunol.164.10.5221; Anderson G, 2001, NAT REV IMMUNOL, V1, P31, DOI 10.1038/35095500; Bertho JM, 1997, CELL IMMUNOL, V179, P30, DOI 10.1006/cimm.1997.1148; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Dadi HK, 2003, NEW ENGL J MED, V349, P1821, DOI 10.1056/NEJMoa031178; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; DUNNWALTERS DK, 1995, EUR J IMMUNOL, V25, P513, DOI 10.1002/eji.1830250231; Dunon D, 1997, J EXP MED, V186, P977, DOI 10.1084/jem.186.7.977; Guy-Grand D, 2003, J EXP MED, V197, P333, DOI 10.1084/jem.20021639; Hazenberg MD, 2000, NAT MED, V6, P1036, DOI 10.1038/79549; Ikawa T, 1999, J EXP MED, V190, P1617, DOI 10.1084/jem.190.11.1617; Jamieson BD, 1999, IMMUNITY, V10, P569, DOI 10.1016/S1074-7613(00)80056-4; LEVIN S, 1979, PEDIATRICS, V63, P80; LOBACH DF, 1987, J CLIN IMMUNOL, V7, P81, DOI 10.1007/BF00916002; MacDonald HR, 2001, CURR OPIN IMMUNOL, V13, P219, DOI 10.1016/S0952-7915(00)00207-7; Marusic M, 1998, CLIN EXP IMMUNOL, V111, P450; MURPHY M, 1990, CLIN IMMUNOL IMMUNOP, V55, P453, DOI 10.1016/0090-1229(90)90131-9; Noordzij JG, 2002, PEDIATR RES, V51, P159, DOI 10.1203/00006450-200202000-00007; Paz-Miguel JE, 1999, J IMMUNOL, V163, P5399; Poulin JF, 1999, J EXP MED, V190, P479, DOI 10.1084/jem.190.4.479; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; SPENCER J, 1992, IMMUNOLOGY, V75, P596; Spits H, 1998, IMMUNOL REV, V165, P75, DOI 10.1111/j.1600-065X.1998.tb01231.x; STEINMANN GG, 1985, SCAND J IMMUNOL, V22, P563, DOI 10.1111/j.1365-3083.1985.tb01916.x; TERSTAPPEN LWMM, 1992, BLOOD, V79, P666; van Lochem EG, 2000, LEUKEMIA, V14, P688, DOI 10.1038/sj.leu.2401749; VANBAARLEN J, 1988, HUM PATHOL, V19, P1155, DOI 10.1016/S0046-8177(88)80146-1; Varas A, 2000, J IMMUNOL, V164, P6260, DOI 10.4049/jimmunol.164.12.6260	28	60	62	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					834	840		10.1016/j.jaci.2004.10.031	http://dx.doi.org/10.1016/j.jaci.2004.10.031			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15806007				2022-12-18	WOS:000228373400026
J	Wei, HM; Zhang, J; Xiao, W; Feng, JB; Sun, R; Tian, ZG				Wei, HM; Zhang, J; Xiao, W; Feng, JB; Sun, R; Tian, ZG			Involvement of human natural killer cells in asthma pathogenesis: Natural killer 2 cells in type 2 cytokine predominance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						natural killer cells; cytokine; predominance; asthma	T-CELLS; BRONCHIAL HYPERRESPONSIVENESS; PERIPHERAL-BLOOD; GENE-EXPRESSION; DENDRITIC CELLS; IN-VITRO; INTERLEUKIN-4; DIFFERENTIATION; POLARIZATION; SUBSETS	Background: T(H)2 cells play a pivotal role in the pathogenesis of human asthma. Natural killer (NK) cells are also thought to divide into NK1 and NK2 subsets. Objective: Whether NK1 or NK2 cells are involved in asthma remains unclear. Methods: Triple-color flow cytometry for detecting intracellular cytokine and NK cell surface phenotype from asthmatic patients was used. The NK cell cloning and analysis with RT-PCR for cytokine expression and Western blotting for signal transducer and activator of transcription activation were performed. Results: For the first time, we observed that the ratio of IL-(4+)CD56(+) NK2 cells in PBMCs of 8 asthmatic patients were higher than in healthy individuals. NK cell clones were then obtained by means of limited dilution, and the average mean of the relative intensity of PCR products for type 2 cytokines significantly increased in the asthmatic patients. Signal transducer and activator of transcription 6, a key transcript factor of type 2 phenotype, was constitutively activated in NK2 clones from asthmatic patients. We cocultured freshly purified NK cells from asthmatic patients with IFN-gamma and anti-IL-4 antibody in the presence of IL-15 and found that the content of IL-4(+) NK2 cells significantly decreased after treatment. Interestingly, NK2-biased status in asthmatic patients was reversed when patients recovered from regular therapy. Conclusion: The results suggest that the NK2 cell subset is involved in the pathogenesis of asthma.	Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; Shandong Univ, Sch Pharm, Jinan 250100, Peoples R China; Shandong Univ, Qilu Hosp, Jinan 250100, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Shandong University; Shandong University	Tian, ZG (corresponding author), Univ Sci & Technol China, Sch Life Sci, 443 Huangshan Rd, Hefei 230027, Anhui, Peoples R China.	srtzg@yahoo.com	Tian, Zhigang/J-3512-2013; Wei, Haiming/G-7703-2018	Wei, Haiming/0000-0002-1675-6502				Agarwal SK, 2001, J INTERF CYTOK RES, V21, P147, DOI 10.1089/107999001750133159; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Altfeld M, 2000, J ACQ IMMUN DEF SYND, V23, P287; Amayasu H, 2000, ANN ALLERG ASTHMA IM, V84, P594, DOI 10.1016/S1081-1206(10)62409-X; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Asselin S, 1998, EUR J IMMUNOL, V28, P532, DOI 10.1002/(SICI)1521-4141(199802)28:02<532::AID-IMMU532>3.0.CO;2-U; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Bertorelli G, 2000, ALLERGY, V55, P449, DOI 10.1034/j.1398-9995.2000.055005449.x; Brand U, 1999, J ALLERGY CLIN IMMUN, V104, P1052, DOI 10.1016/S0091-6749(99)70088-6; Briard D, 2002, J IMMUNOL, V168, P4326, DOI 10.4049/jimmunol.168.9.4326; Carson WE, 1997, J CLIN INVEST, V99, P937, DOI 10.1172/JCI119258; Chakir H, 2000, J IMMUNOL, V165, P4985, DOI 10.4049/jimmunol.165.9.4985; Chan SC, 1996, J INVEST DERMATOL, V106, P1131, DOI 10.1111/1523-1747.ep12340181; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Cooper MA, 2001, BLOOD, V97, P3146, DOI 10.1182/blood.V97.10.3146; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54, DOI 10.1165/ajrcmb.13.1.7598937; Dabbagh K, 1999, J IMMUNOL, V162, P6233; DAHER S, 1995, J INVEST ALLERG CLIN, V5, P251; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Deniz G, 2002, EUR J IMMUNOL, V32, P879, DOI 10.1002/1521-4141(200203)32:3<879::AID-IMMU879>3.0.CO;2-2; Hamelmann E, 2001, IMMUNOL REV, V179, P182, DOI 10.1034/j.1600-065X.2001.790118.x; Henderson WR, 2000, J IMMUNOL, V164, P1086, DOI 10.4049/jimmunol.164.2.1086; Jaffe A, 2001, PEDIATR PULM, V31, P464, DOI 10.1002/ppul.1076; Kemeny DM, 1999, AM J RESP CRIT CARE, V160, pS33, DOI 10.1164/ajrccm.160.supplement_1.10; Leonard C, 1997, AM J RESP CELL MOL, V17, P368, DOI 10.1165/ajrcmb.17.3.2797; Lim CS, 2001, NEPHROL DIAL TRANSPL, V16, P269, DOI 10.1093/ndt/16.2.269; Liu YJ, 2000, CURR TOP MICROBIOL, V251, P149; Loza MJ, 2002, BLOOD, V99, P1273, DOI 10.1182/blood.V99.4.1273; MIYATAKE H, 1991, CHEST, V99, P670, DOI 10.1378/chest.99.3.670; Mrozek E, 1996, BLOOD, V87, P2632, DOI 10.1182/blood.V87.7.2632.bloodjournal8772632; Neurath MF, 2002, NAT MED, V8, P567, DOI 10.1038/nm0602-567; PARRONCHI P, 1992, EUR J IMMUNOL, V22, P1615, DOI 10.1002/eji.1830220640; Pernis AB, 2002, J CLIN INVEST, V109, P1279, DOI 10.1172/JCI200215786; Piccinni MP, 1996, EUR J IMMUNOL, V26, P2293, DOI 10.1002/eji.1830261004; Renz H, 1996, INT ARCH ALLERGY IMM, V109, P167, DOI 10.1159/000237216; Rosmaraki EE, 2001, EUR J IMMUNOL, V31, P1900, DOI 10.1002/1521-4141(200106)31:6<1900::AID-IMMU1900>3.0.CO;2-M; Steinke JW, 2001, RESP RES, V2, P66, DOI 10.1186/rr40; Tian ZG, 1998, STEM CELLS, V16, P193, DOI 10.1002/stem.160193; Tian ZG, 2000, J IMMUNOL, V165, P3959, DOI 10.4049/jimmunol.165.7.3959; Todate A, 2000, AM J RESP CRIT CARE, V162, P148, DOI 10.1164/ajrccm.162.1.9907015; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; Vukmanovic-Stejic M, 2000, BLOOD, V95, P231; WALKER C, 1994, AM J RESP CRIT CARE, V150, P1038, DOI 10.1164/ajrccm.150.4.7921434; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; Zalewska-Kaszubska J, 2001, PHARMACOL RES, V44, P451, DOI 10.1006/phrs.2001.0884	47	60	73	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					841	847		10.1016/j.jaci.2004.11.026	http://dx.doi.org/10.1016/j.jaci.2004.11.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15806008				2022-12-18	WOS:000228373400027
J	Sicherer, SH; Teuber, S				Sicherer, SH; Teuber, S		Adverse Reactions Foods Comm	Current approach to the diagnosis and management of adverse reactions to foods	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy	ALLERGY; ANAPHYLAXIS; EPINEPHRINE		Mt Sinai Med Ctr, Dept Pediat, Div Immunol, Mt Sinai Sch Med, New York, NY 10029 USA; Jaffe Food Allergy Inst, New York, NY USA; Univ Calif Davis, Sch Med, Davis, CA 95616 USA	Icahn School of Medicine at Mount Sinai; University of California System; University of California Davis	Sicherer, SH (corresponding author), Mt Sinai Med Ctr, Dept Pediat, Div Immunol, Mt Sinai Sch Med, 1 Gustav L Levy Pl,Box 1198, New York, NY 10029 USA.	Scott.Sicherer@mssn.edu						[Anonymous], 1998, J Allergy Clin Immunol, V102, P173; [Anonymous], 1998, J Allergy Clin Immunol, V101, pS465; Bernstein IL, 1995, ANN ALLERG ASTHMA IM, V75, P543; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Li XM, 2003, J ALLERGY CLIN IMMUN, V111, P1140, DOI 10.1067/mai.2003.1494; Sampson HA, 2003, PEDIATRICS, V111, P1601; Sampson HA, 2001, GASTROENTEROLOGY, V120, P1026, DOI 10.1053/gast.2001.23031; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Sicherer SH, 2002, LANCET, V360, P701, DOI 10.1016/S0140-6736(02)09831-8; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P837, DOI 10.1016/j.jaci.2004.01.079; Simons FER, 2001, J ALLERGY CLIN IMMUN, V108, P1040, DOI 10.1067/mai.2001.119916; Simons FER, 2002, J ALLERGY CLIN IMMUN, V109, P171, DOI 10.1067/mai.2002.120758; Vadas P, 2003, J ALLERGY CLIN IMMUN, V112, P175, DOI 10.1067/mai.2003.1480; Zeiger RS, 2002, J ALLERGY CLIN IMMUN, V110, P834, DOI 10.1067/mai.2002.129372	14	60	64	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1146	1150		10.1016/j.jaci.2004.07.034	http://dx.doi.org/10.1016/j.jaci.2004.07.034			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536423	Bronze			2022-12-18	WOS:000225047800023
J	Duez, C; Dakhama, A; Tomkinson, A; Marquillies, P; Balhorn, A; Tonnel, AB; Bratton, DL; Gelfand, EW				Duez, C; Dakhama, A; Tomkinson, A; Marquillies, P; Balhorn, A; Tonnel, AB; Bratton, DL; Gelfand, EW			Migration and accumulation of eosinophils toward regional lymph nodes after airway allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; airway challenge; allergic inflammation; lymph node; MHC class II	ANTIGEN-PRESENTATION; HLA-DR; CELLS; HYPERRESPONSIVENESS; MICE; EXPRESSION; ASTHMA	Background: Eosinophils play a major role in allergic airway inflammation because of their ability to release toxic mediators. In addition, they are able to migrate toward draining thoracic lymph nodes (TLNs) after intratracheal administration, where they can function as antigen-presenting cells. Objective: In this study, we evaluated in vivo eosinophil migration toward the TLN after allergen sensitization and analyzed expression of molecules involved in antigen presentation. Methods: Mice were sensitized by intraperitoneal injection of ovalbumin on days 1 and 10 and challenged once intranasally with ovalbumin on day 20. The kinetics of eosinophilia was evaluated in blood, lung tissue homogenate, bronchoalveolar lavage fluid, and TLN. Cell surface staining was analyzed by flow cytometry. Results: The kinetics of eosinophil recruitment was similar in TLN, lung tissue, and blood, beginning at 12 hours and peaking at 48 hours after allergen challenge. Approximately 70% of TLN eosinophils expressed MHC class II molecules, compared with less than 25% in blood and lungs. Moreover, TLN eosinophils expressed higher levels of MHC class II and CD86 compared with blood and lung eosinophils. Most eosinophils expressed CD80 and CD54, whereas only a few eosinophils expressed CD40. Eosinophils in lungs and TLN appeared to be activated with lower CD62-ligand expression compared with blood eosinophils. Conclusion: The presence of eosinophils with a different phenotype in the TLN at early time points after allergen challenge of sensitized mice supports their capacity to serve as antigen-presenting cells, sustaining allergic/inflammatory responses in the airways.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA; Inst Pasteur, INSERM, U416, F-59019 Lille, France	National Jewish Health; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Gelfand, EW (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, 1400 Jackson St, Denver, CO 80206 USA.	gelfande@njc.org	Duez, Catherine/B-8425-2018	Duez, Catherine/0000-0002-2327-1095	NHLBI NIH HHS [HL-61005, HL-36577] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577, R01HL061005] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Celestin J, 2001, J IMMUNOL, V167, P6097, DOI 10.4049/jimmunol.167.11.6097; DELPOZO V, 1992, EUR J IMMUNOL, V22, P1919; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; Dombrowicz D, 2001, CURR OPIN IMMUNOL, V13, P716, DOI 10.1016/S0952-7915(01)00284-9; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; HANSEL TT, 1992, J IMMUNOL, V149, P2130; HANSEL TT, 1991, CLIN EXP IMMUNOL, V86, P271; Hogan MB, 2003, J IMMUNOL, V171, P2644, DOI 10.4049/jimmunol.171.5.2644; Humbles AA, 2002, P NATL ACAD SCI USA, V99, P1479, DOI 10.1073/pnas.261462598; KUNG TT, 1994, J ALLERGY CLIN IMMUN, V94, P1217, DOI 10.1016/0091-6749(94)90335-2; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; MacKenzie JR, 2001, J IMMUNOL, V167, P3146, DOI 10.4049/jimmunol.167.6.3146; MAWHORTER SD, 1994, IMMUNOLOGY, V81, P584; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; Shi HZ, 2000, J CLIN INVEST, V105, P945, DOI 10.1172/JCI8945; Shinagawa K, 2000, J IMMUNOL METHODS, V237, P65, DOI 10.1016/S0022-1759(00)00134-4; Tamura N, 1996, SCAND J IMMUNOL, V44, P229, DOI 10.1046/j.1365-3083.1996.d01-303.x; TILNEY NL, 1971, J ANAT, V109, P369; Tomkinson A, 2001, AM J RESP CRIT CARE, V163, P721, DOI 10.1164/ajrccm.163.3.2005010; van Rijt LS, 2003, J IMMUNOL, V171, P3372, DOI 10.4049/jimmunol.171.7.3372; WELLER PF, 1993, J IMMUNOL, V150, P2554	21	60	61	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					820	825		10.1016/j.jaci.2004.08.011	http://dx.doi.org/10.1016/j.jaci.2004.08.011			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480321				2022-12-18	WOS:000224439100015
J	Winningham, KM; Fitch, CD; Schmidt, M; Hoffman, DR				Winningham, KM; Fitch, CD; Schmidt, M; Hoffman, DR			Hymenoptera venom protease allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						honeybee; venom; protease; allergen; CUB domain; paper wasp; bumblebee	AMINO-ACID-SEQUENCES; YELLOW JACKET VENOM; SOL-I-II; BEE VENOM; MAJOR ALLERGENS; IDENTIFICATION; HONEYBEE; PROTEINS; CLONING; BINDING	Background: Recent studies have shown the presence of additional allergenic proteins in honeybee and paper wasp venoms. Both venoms contain serine protease enzymes. Objective: We isolated and obtained complete sequences of honeybee and Mediterranean paper wasp venom proteases, both of which have significant IgE binding activity. The structures are compared with bumblebee venom protease. Methods: Venom proteases were chromatographically isolated from venoms and partial amino acid sequences determined. RT-PCR and rapid amplification of cDNA ends methods were used to clone cDNA, and complete sequences were determined for honeybee and a paper wasp venom protease. Results: The venom proteases are all serine proteases of the trypsin type. The honeybee protease contains a complement, embryonic sea urchin protein, bone morphogenetic protein interaction domain as well as a linker and propeptide sequence, and a unique methionine residue near the active site. It has IgE binding activity. The paper wasp protease is a single trypsin domain and is an important allergen. The framework residues are poorly conserved among honeybee, bumblebee, and paper wasp enzymes. Conclusions: The 3 venom serine proteases have significant IgE binding activities. The structures are poorly conserved even among the Apidae, suggesting little cross-reactivity among the protein portions. The paper wasp venom proteases are important allergens.	E Carolina Univ, Brody Sch Med, Dept Pathol & Lab Med, Greenville, NC 27858 USA; E Carolina Univ, Dept Biol, Greenville, NC 27858 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	Hoffman, DR (corresponding author), E Carolina Univ, Brody Sch Med, Dept Pathol & Lab Med, Greenville, NC 27858 USA.	hoffmand@mail.ecu.edu						Barrett A. J, 2012, HDB PROTEOLYTIC ENZY; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BORRIELLO F, 1990, NUCLEIC ACIDS RES, V18, P5481, DOI 10.1093/nar/18.18.5481; Fitch CD, 2001, J ALLERGY CLIN IMMUN, V107, pS221; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hemmer W, 2004, CLIN EXP ALLERGY, V34, P460, DOI 10.1111/j.1365-2222.2004.01897.x; Hemmer W, 2001, J ALLERGY CLIN IMMUN, V108, P1045, DOI 10.1067/mai.2001.120013; Hoffman D., 2003, MONOGRAPH INSECT ALL, P37; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V92, P707, DOI 10.1016/0091-6749(93)90014-7; HOFFMAN DR, 1987, J ALLERGY CLIN IMMUN, V80, P307, DOI 10.1016/0091-6749(87)90036-4; Hoffman DR, 1998, J ALLERGY CLIN IMMUN, V101, pS33; HOFFMAN DR, 1976, J ALLERGY CLIN IMMUN, V58, P551, DOI 10.1016/0091-6749(76)90201-3; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P364, DOI 10.1016/0091-6749(77)90019-7; Hoffman DR, 2001, J ALLERGY CLIN IMMUN, V108, P855, DOI 10.1067/mai.2001.119029; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P147, DOI 10.1016/0091-6749(77)90217-2; Hoffman DR, 1996, J ALLERGY CLIN IMMUN, V97, P812, DOI 10.1016/S0091-6749(96)80159-X; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P599, DOI 10.1016/0091-6749(85)90036-3; HOFFMAN DR, 1979, ANN ALLERGY, V42, P224; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V91, P71, DOI 10.1016/0091-6749(93)90298-T; Kettner A, 1999, CLIN EXP ALLERGY, V29, P394, DOI 10.1046/j.1365-2222.1999.00492.x; KING TP, 1984, ARCH BIOCHEM BIOPHYS, V230, P1, DOI 10.1016/0003-9861(84)90080-8; King TP, 2000, INT ARCH ALLERGY IMM, V123, P99, DOI 10.1159/000024440; McNairy MM, 2000, J ALLERGY CLIN IMMUN, V105, pS57, DOI 10.1016/S0091-6749(00)90602-X; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pantera B, 2003, BBA-GEN SUBJECTS, V1623, P72, DOI 10.1016/j.bbagen.2003.07.001; SANCHEZ F, 1995, CLIN EXP ALLERGY, V25, P281, DOI 10.1111/j.1365-2222.1995.tb01041.x; Schmidt M, 2003, ALLERGY, V58, P342, DOI 10.1034/j.1398-9995.2003.00085.x; SCHMIDT M, 1993, FEBS LETT, V319, P138, DOI 10.1016/0014-5793(93)80053-W; Winningham KM, 2001, J ALLERGY CLIN IMMUN, V107, pS221	29	60	67	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					928	933		10.1016/j.jaci.2004.07.043	http://dx.doi.org/10.1016/j.jaci.2004.07.043			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480337	Bronze			2022-12-18	WOS:000224439100031
J	Chaudhuri, R; McMahon, AD; Thomson, LJ; MacLeod, KJ; McSharry, CP; Livingston, E; McKay, A; Thomson, NC				Chaudhuri, R; McMahon, AD; Thomson, LJ; MacLeod, KJ; McSharry, CP; Livingston, E; McKay, A; Thomson, NC			Effect of inhaled corticosteroids on symptom severity and sputum mediator levels in chronic persistent cough	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic persistent cough; inflammation; mediators; inhaled corticosteroids	CHRONIC NONPRODUCTIVE COUGH; RANDOMIZED CONTROLLED-TRIAL; INCREASED CARBON-MONOXIDE; AIRWAY INFLAMMATION; NITRIC-OXIDE; EXHALED AIR; EOSINOPHILIC INFLAMMATION; DIAGNOSTIC PROTOCOL; ASTHMATIC-PATIENTS; MILD ASTHMA	Background: Chronic cough often lasts for more than I year and is associated with airway inflammation. The effect of inhaled corticosteroids on symptom severity and inflammatory mediator levels in these patients is unknown. Objective: We sought to determine whether inhaled corticosteroids reduce cough severity and sputum mediator concentrations in patients with chronic persistent cough. Methods: We performed a double-blind, randomized, placebo-controlled crossover study with inhaled fluticasone, 500 mug twice daily, and placebo for 14 days in 88 patients with cough for more than 1 year, with normal chest radiography and spirometry results. Outcome measures were a daily cough visual analogue scale and induced sputum concentrations of eosinophilic cationic protein (ECP), myeloperoxidase, leukotriene B-4 (LTB4), leukotrienes C-4/D-4/E-4 (cysteinyl leukotrienes [Cys-LTs]), prostaglandin E-2 (PGE(2)), IL-8, and TNF-alpha. Sputum cell counts, exhaled nitric oxide levels, and carbon monoxide levels were also measured. Results: There was a significant improvement in the cough visual analogue scale after inhaled fluticasone compared with placebo (mean difference, 1.0; 95% CI, 0.4-1.5; P < .001). LTB4, Cys-LT, and PGE(2) levels were increased in all causes of cough. Sputum ECP counts, exhaled nitric oxide levels, and carbon monoxide levels decreased significantly after inhaled fluticasone. There was no change in sputum cell counts and other mediator concentrations. Conclusion: Cough severity and sputum ECP levels are modestly reduced by inhaled corticosteroids; in patients with chronic cough persisting for more than 1 year. LTB4, Cys-LT, PGE(2), IL-8, myeloperoxidase, and TNF-alpha levels are unaltered by this therapy. This raises the possibility that drugs targeted to reduce the effects of these mediators might be of benefit in chronic persistent cough.	Univ Glasgow, Dept Resp Med, Div Immunol Infect & Inflammat, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, Dept Immunol, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow	Thomson, NC (corresponding author), Univ Glasgow, Dept Resp Med, Div Immunol Infect & Inflammat, Glasgow G11 6NT, Lanark, Scotland.	n.c.thomson@clinmed.gla.ac.uk	McMahon, Alex D/C-4304-2008	McSharry, Charles/0000-0003-4758-9038; Thomson, Neil/0000-0003-1632-6630				Aziz I, 2000, CHEST, V118, P1049, DOI 10.1378/chest.118.4.1049; Birring SS, 2004, AM J RESP CRIT CARE, V169, P15, DOI 10.1164/rccm.200308-1092OC; BOULET LP, 1994, AM J RESP CRIT CARE, V149, P482, DOI 10.1164/ajrccm.149.2.8306050; Brichtling CE, 2000, AM J RESP CRIT CARE, V162, P878, DOI 10.1164/ajrccm.162.3.9909064; Brightling CE, 2000, LANCET, V356, P1480, DOI 10.1016/S0140-6736(00)02872-5; Chalmers GW, 2001, CHEST, V120, P1917, DOI 10.1378/chest.120.6.1917; CHOUDRY NB, 1989, AM REV RESPIR DIS, V140, P137, DOI 10.1164/ajrccm/140.1.137; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CRAPO RO, 1987, AM REV RESPIR DIS, V135, P1221; DAHINDEN CA, 1989, J EXP MED, V170, P1787, DOI 10.1084/jem.170.5.1787; Davies MJ, 1999, ARCH DIS CHILD, V81, P38, DOI 10.1136/adc.81.1.38; Fujimoto K, 1999, CHEST, V115, P697, DOI 10.1378/chest.115.3.697; GIBSON PG, 1989, LANCET, V1, P1346; Gibson PG, 1998, J ALLERGY CLIN IMMUN, V101, P320, DOI 10.1016/S0091-6749(98)70242-8; GIBSON PG, 1995, CLIN EXP ALLERGY, V25, P127, DOI 10.1111/j.1365-2222.1995.tb01017.x; IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640, DOI 10.1164/ajrccm/141.3.640; Irwin RS, 1998, CHEST, V114, p133S, DOI 10.1378/chest.114.2_Supplement.133S; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234; Jatakanon A, 1999, THORAX, V54, P234, DOI 10.1136/thx.54.3.234; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542, DOI 10.1164/ajrccm.155.2.9032192; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Little SA, 2000, THORAX, V55, P232, DOI 10.1136/thorax.55.3.232; McGarvey LPA, 1998, THORAX, V53, P738, DOI 10.1136/thx.53.9.738; McGarvey LPA, 1999, EUR RESPIR J, V13, P59; Meijer RJ, 2002, CLIN EXP ALLERGY, V32, P1096, DOI 10.1046/j.1365-2222.2002.01412.x; Niimi A, 1998, EUR RESPIR J, V11, P1064, DOI 10.1183/09031936.98.11051064; O'Connell F, 1998, THORAX, V53, P723, DOI 10.1136/thx.53.9.723; OCONNELL F, 1994, AM J RESP CRIT CARE, V150, P374, DOI 10.1164/ajrccm.150.2.8049818; OSHAUGHNESSY KM, 1993, AM REV RESPIR DIS, V147, P1472, DOI 10.1164/ajrccm/147.6_Pt_1.1472; Paredi P, 1999, THORAX, V54, P917, DOI 10.1136/thx.54.10.917; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; PEDE CD, 1991, CHEST, V99, P916; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1998, AM J RESP CRIT CARE, V158, P1511, DOI 10.1164/ajrccm.158.5.9804028; Pizzichini M M, 1999, Can Respir J, V6, P323; POE RH, 1989, CHEST, V95, P723, DOI 10.1378/chest.95.4.723; POPOV T, 1994, CLIN EXP ALLERGY, V24, P778, DOI 10.1111/j.1365-2222.1994.tb00990.x; PRATTER MR, 1993, ANN INTERN MED, V119, P977, DOI 10.7326/0003-4819-119-10-199311150-00003; Sampson AP, 2000, CLIN EXP ALLERGY, V30, P22; Spanevello A, 2000, AM J RESP CRIT CARE, V162, P1172, DOI 10.1164/ajrccm.162.3.9908057; WHITE MV, 1989, IMMUNOL LETT, V22, P151, DOI 10.1016/0165-2478(89)90182-X; WYNDER EL, 1965, AM REV RESPIR DIS, V91, P679; Zayasu K, 1997, AM J RESP CRIT CARE, V156, P1140, DOI 10.1164/ajrccm.156.4.96-08056	46	60	68	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1063	1070		10.1016/j.jaci.2004.03.019	http://dx.doi.org/10.1016/j.jaci.2004.03.019			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208586	Green Published			2022-12-18	WOS:000222091000010
J	Frossard, CP; Tropia, L; Hauser, C; Eigenmann, PA				Frossard, CP; Tropia, L; Hauser, C; Eigenmann, PA			Lymphocytes in Peyer patches regulate clinical tolerance in a murine model of food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food hypersensitivity; anaphylaxis; tolerance; T-lymphocytes; beta-lactoglobulin; IL-10	PEANUT-INDUCED ANAPHYLAXIS; BETA-LACTOGLOBULIN; ORAL IMMUNIZATION; T-CELLS; ANTIGEN; IGE; RESPONSES; PROTEIN; OVALBUMIN; EPITOPES	Background: Food allergy can lead to severe, potentially life-threatening anaphylactic reactions. To generate efficient strategies aimed at an active cure, a better understanding of the pathogenic mechanisms is strongly needed. Objective: To investigate T-cell-related mechanisms of food allergy and tolerance to beta-lactoglobulin (BLG) in gut-associated lymphoid structures. Methods: beta-Lactoglobulin-specific IgG1, IgG2a, and IgE in serum from mice anaphylactic to BLG were analyzed by ELISA and compared with those obtained in mice actively tolerized to BLG. The number of Ab-secreting cells in the spleen and in Peyer patches was determined by ELISPOT. The numbers of cytokine-producing cells after antigen-specific activation were measured by the same method. Furthermore, mesenteric lymph node cells and Peyer patches cells were transferred to naive mice, and Ab production as well as Ab-secreting cells were measured. Results: Serum IgG1 and IgE Ab titers as well as IL-4-producing cell numbers were strongly increased in anaphylactic mice. IL-10 was found in Peyer patch cells from tolerant mice after BLG activation but not in anaphylactic mice. Peyer patch cells, in contrast to mesenteric lymph node cells, proliferated weakly in anaphylactic mice after antigen activation, and activation of Peyer patches was partially inhibited by tolerization. Conclusions: Our data suggest a specific role for lymphocytes in Peyer patches in tolerance to BLG. Low IL-10 production in Peyer patches may favor symptoms of food allergy.	Univ Hosp Geneva, Dept Pediat, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Dept Med, Div Immunol & Allergy, Geneva, Switzerland	University of Geneva; University of Geneva	Eigenmann, PA (corresponding author), Univ Hosp Geneva, Dept Pediat, 6 Rue Willy Donze, CH-1211 Geneva 14, Switzerland.		Eigenmann, Philippe/A-6569-2017	Eigenmann, Philippe/0000-0003-1738-1826				Adel-Patient K, 2000, J IMMUNOL METHODS, V235, P21, DOI 10.1016/S0022-1759(99)00210-0; Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, P688, DOI 10.1067/mai.2002.123235; DEL PG, 1993, J IMMUNOL, V150, P353; EIGENMANN PA, 1996, PEDIATR ALLERGY IMMU, V715, P612; Frossard CP, 2001, PEDIATR RES, V49, P417, DOI 10.1203/00006450-200103000-00018; Groux H, 1996, J EXP MED, V184, P19, DOI 10.1084/jem.184.1.19; Holen E, 2001, CLIN EXP ALLERGY, V31, P952, DOI 10.1046/j.1365-2222.2001.01102.x; Holen E, 1996, CLIN EXP ALLERGY, V26, P1080, DOI 10.1046/j.1365-2222.1996.d01-412.x; HOYNE GF, 1993, IMMUNOLOGY, V78, P534; JACKSON RJ, 1993, INFECT IMMUN, V61, P4272, DOI 10.1128/IAI.61.10.4272-4279.1993; Kato C, 1999, J ALLERGY CLIN IMMUN, V104, P870, DOI 10.1016/S0091-6749(99)70301-5; LAMONT AG, 1989, IMMUNOLOGY, V66, P595; Lee SY, 2001, CLIN IMMUNOL, V101, P220, DOI 10.1006/clim.2001.5122; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Li XM, 2003, J IMMUNOL, V170, P3289, DOI 10.4049/jimmunol.170.6.3289; Li XM, 2001, J ALLERGY CLIN IMMUN, V108, P639, DOI 10.1067/mai.2001.118787; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; Mora JR, 2003, NATURE, V424, P88, DOI 10.1038/nature01726; NGAN J, 1978, J IMMUNOL, V120, P861; Pecquet S, 1999, IMMUNOLOGY, V96, P278, DOI 10.1046/j.1365-2567.1999.00678.x; PENG HJ, 1989, IMMUNOLOGY, V67, P425; Reekers R, 1996, BRIT J DERMATOL, V135, P935, DOI 10.1046/j.1365-2133.1996.d01-1098.x; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; SNIDER DP, 1994, J IMMUNOL, V153, P647; XUAMANO JC, 1993, J EXP MED, V178, P1309, DOI 10.1084/jem.178.4.1309	26	60	61	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					958	964		10.1016/j.jaci.2003.12.017	http://dx.doi.org/10.1016/j.jaci.2003.12.017			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131580				2022-12-18	WOS:000221269000020
J	Diaz-Perales, A; Blanco, C; Sanchez-Monge, R; Varela, J; Carrillo, T; Salcedo, G				Diaz-Perales, A; Blanco, C; Sanchez-Monge, R; Varela, J; Carrillo, T; Salcedo, G			Analysis of avocado allergen (Prs a 1) IgE-binding peptides generated by simulated gastric fluid digestion	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen digestion; simulated gastric fluid; food allergy; Prs a 1; hevein-like domain; latex-fruit syndrome	LIPID-TRANSFER PROTEIN; HEVEIN-LIKE DOMAIN; CLASS-I CHITINASES; CROSS-REACTIVITY; FOOD ALLERGENS; LATEX; IDENTIFICATION; CLONING; FRUIT; DIGESTIBILITY	Background: Resistance to pepsin digestion has been claimed to be a characteristic of food allergens that can induce severe adverse reactions. Moreover, pepsin treatment is included in protocols to evaluate the potential allergenicity of transgenic foods. Allergenic plant class I chitinases, such as avocado Prs a 1, are the panallergens involved in the latex-fruit syndrome. Previous reports indicated their susceptibility to simulated gastric fluid (SGF) digestion. Objective: We sought to evaluate the IgE-binding capacity and the in vivo reactivity of the SGF products of the avocado allergen Prs a 1. Methods: Patients with a clinical history of latex-fruit allergy syndrome, a positive skin prick test (SPT) response to Prs a 1, and specific IgE to avocado were selected. Untreated and SGF-digested Prs a 1 samples were analyzed by means of IgE and IgG immunoblotting, IgE immunoblotting and ELISA-inhibition assays, and SPTs. Peptides from SGF-digested samples were fractionated by means of HPLC, characterized by N-terminal amino acid sequencing and matrix-assisted laser desorption/ionization analysis, and tested for in vivo reactivity with SPTs. Results: Neither protein staining nor IgE immunoblotting with a pool of sera from allergic patients resulted in the detection of any band after SDS-PAGE separation of an SGF-digested sample of Prs a 1. However, this sample showed a similar inhibitory potency to that of untreated Prs a 1 in both immunoblot- and ELISA-inhibition assays (up to 70% inhibition of the IgE binding to crude avocado extract) and induced positive SPT responses in 5 of 8 allergic patients. Peptides from SGF-digested Prs a 1 were separated by means of HPLC, and 4 of them reached more than 50% inhibition values when using avocado extract as the solid phase in ELISA-inhibition assays. Reactive peptides were located both in the N-terminal hevein-like domain and in the catalytic domain of Prs a 1. Those corresponding to the hevein-like domain (approximately 5100 d) produced positive SPT responses in 5 of 8 allergic patients, whereas 2 peptides located in the catalytic domain (approximately 1400 and 2500 d) were reactive in 2 or 3 of the 8 patients. Conclusion: Prs a 1 was extensively degradated when subjected to SGF digestion. However, the resulting peptides, particularly those corresponding to the hevein-like domain, were clearly reactive both in vitro and in vivo.	UPM, ETS Ingn Agron, Dept Biotechnol, Madrid, Spain; Hosp Gran Canaria Dr Negrin, Secc Algeria, Las Palmas Gran Canaria, Spain; CSIC, Serv Quim Proteinas, Ctr Invest Biol, Madrid, Spain	Universidad Politecnica de Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Salcedo, G (corresponding author), Ciudad Univ, Unidad Bioquim, Dept Biotechnol, ETS Ingn Agron, Madrid 28040, Spain.		Blanco, Carlos/B-3895-2012; Díaz-Perales, Araceli/D-8433-2016	Blanco, Carlos/0000-0002-2893-6594; Díaz-Perales, Araceli/0000-0002-1093-3627				Asero R, 2000, INT ARCH ALLERGY IMM, V122, P20, DOI 10.1159/000024355; Asturias JA, 1998, MOL IMMUNOL, V35, P469, DOI 10.1016/S0161-5890(98)00036-4; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; Bannon G.A., 2002, COMMENTS TOXICOL, V8, P271, DOI [10.2307/2528490, DOI 10.2307/2528490]; BLANCO C, 1994, ANN ALLERGY, V73, P309; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen ZP, 1997, J ALLERGY CLIN IMMUN, V99, P402, DOI 10.1016/S0091-6749(97)70059-9; Chen ZP, 1998, J ALLERGY CLIN IMMUN, V102, P476, DOI 10.1016/S0091-6749(98)70138-1; Diaz-Perales A, 1999, J ALLERGY CLIN IMMUN, V104, P681, DOI 10.1016/S0091-6749(99)70342-8; Diaz-Perales A, 1998, J ALLERGY CLIN IMMUN, V102, P127, DOI 10.1016/S0091-6749(98)70063-6; Diaz-Perales A, 2002, CLIN EXP ALLERGY, V32, P448, DOI 10.1046/j.1365-2222.2002.01306.x; Diaz-Perales A, 2002, CLIN EXP ALLERGY, V32, P87, DOI 10.1046/j.0022-0477.2001.01257.x; FAO/WHO  Codex Alimentarius Commission, 2001, 1012A FAOWHO ALINORM; Fu TT, 2002, J AGR FOOD CHEM, V50, P7154, DOI 10.1021/jf020599h; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maleki SJ, 2000, J IMMUNOL, V164, P5844, DOI 10.4049/jimmunol.164.11.5844; Mikkola JH, 1998, J ALLERGY CLIN IMMUN, V102, P1005, DOI 10.1016/S0091-6749(98)70339-2; Posch A, 1999, CLIN EXP ALLERGY, V29, P667, DOI 10.1046/j.1365-2222.1999.00502.x; Rodriguez-Perez R, 2003, J ALLERGY CLIN IMMUN, V111, P634, DOI 10.1067/mai.2003.74; Salcedo G, 2001, CURR OPIN ALLERGY CL, V1, P177, DOI 10.1097/00130832-200104000-00010; Sanchez-Monge R, 1999, CLIN EXP ALLERGY, V29, P673, DOI 10.1046/j.1365-2222.1999.00526.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sowka S, 1998, J BIOL CHEM, V273, P28091, DOI 10.1074/jbc.273.43.28091; Taylor SL, 2002, ANNU REV PHARMACOL, V42, P99, DOI 10.1146/annurev.pharmtox.42.082401.130208; van Ree R, 2002, BIOCHEM SOC T, V30, P910, DOI 10.1042/BST0300910; Yagami T, 2000, J ALLERGY CLIN IMMUN, V106, P752, DOI 10.1067/mai.2000.109171	26	60	65	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					1002	1007		10.1016/j.jaci.2003.07.006	http://dx.doi.org/10.1016/j.jaci.2003.07.006			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610495	Bronze			2022-12-18	WOS:000186553300026
J	Sengler, C; Heinzmann, A; Jerkic, SP; Haider, A; Sommerfeld, C; Niggemann, B; Lau, S; Forster, J; Schuster, A; Kamin, W; Bauer, C; Laing, I; LeSouef, P; Wahn, U; Deichmann, K; Nickel, R				Sengler, C; Heinzmann, A; Jerkic, SP; Haider, A; Sommerfeld, C; Niggemann, B; Lau, S; Forster, J; Schuster, A; Kamin, W; Bauer, C; Laing, I; LeSouef, P; Wahn, U; Deichmann, K; Nickel, R			Clara cell protein 16 (CC16) gene polymorphism influences the degree of airway responsiveness in asthmatic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						genetics; Clara cell protein; CC16; asthma; bronchial hyperreactivity	CELL 10-KDA PROTEIN; DEFICIENT; SERUM	Background: Several studies have indicated linkage of chromosome 11q12-13 to asthma and associated traits. Among other candidate genes, the Clara cell protein 16 (CC16) gene maps to this region. CC16 is expressed in the bronchial epithelium and exhibits potent anti-inflammatory properties. A single-nucleotide polymorphism (SNP) in the CC16 gene (A38G) was previously associated with asthma. Objective: We evaluated the role of the CC16 SNP in pediatric asthma and asthma severity in 2 German study populations. Methods: The German Multicenter Allergy Study (MAS) cohort (n = 872, 94 asthmatic patients) and 112 allergic asthmatic children recruited in Freiburg, Germany, were included in the present study. Histamine provocations were performed at the age of 7 years in the MAS cohort to determine bronchial hyperreactivity; in the Freiburg study population a standardized exercise-induced decrease in FEV1 was evaluated. For genotyping, melting-curve analysis and restriction enzyme digestion were applied. Results: No association of the CC16*38A allele with asthma could be observed in either study population. However, in asthmatic subjects (MAS cohort) PC20FEV1 values were significantly lower in individuals homozygous or heterozygous for the CC16*38A allele compared with those in subjects with the CC16*38GG genotype (P <.05 and P <.03, respectively). Similarly, allergic asthmatic patients in the Freiburg cohort showed a significantly greater decrease in FEV1 after exercise when homozygous for the CC16*38A allele compared with that seen in asthmatic patients with the *38AG or *38GG genotype (P < .04 and P =.006, respectively). Conclusion: We conclude that the CC16*A38G SNP influences bronchial hyperreactivity and might be a genetic determinant of asthma severity in German children. (J Allergy Clin Immunol 2003;111:515-9.).	Humboldt Univ, Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; Univ Freiburg, Univ Childrens Hosp, Dept Pediat, Freiburg, Germany; Univ Dusseldorf, Univ Childrens Hosp, Dept Pediat Cardiol & Pneumol, Dusseldorf, Germany; Johannes Gutenberg Univ Mainz, Univ Childrens Hosp, Dept Pediat, Mainz, Germany; Univ Munich, Dr Von Haunersches Childrens Hosp, Munich, Germany; Univ Western Australia, Childrens Hosp, Med Care Ctr, Dept Paediat, Perth, WA, Australia	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Freiburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Heinrich Heine University Dusseldorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Johannes Gutenberg University of Mainz; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; University of Western Australia	Nickel, R (corresponding author), Humboldt Univ, Charite, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.		Laing, Ingrid/I-7092-2013; Le Souef, Peter N/H-5256-2014	Laing, Ingrid/0000-0002-1641-9899; Le Souef, Peter/0000-0003-0930-1654				BERNARD A, 1992, EUR RESPIR J, V5, P1231; Chen LC, 2001, J IMMUNOL, V167, P3025, DOI 10.4049/jimmunol.167.6.3025; COOKSON WOCM, 1989, LANCET, V1, P1292; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; DIERYNCK I, 1995, AM J RESP CELL MOL, V12, P205, DOI 10.1165/ajrcmb.12.2.7865218; Johnston CJ, 1997, AM J RESP CELL MOL, V17, P147, DOI 10.1165/ajrcmb.17.2.2676; KLEINETEBBE J, 1992, CLIN EXP ALLERGY, V22, P475, DOI 10.1111/j.1365-2222.1992.tb00150.x; Laing IA, 1998, J MED GENET, V35, P463, DOI 10.1136/jmg.35.6.463; Laing IA, 2000, AM J RESP CRIT CARE, V161, P124, DOI 10.1164/ajrccm.161.1.9904073; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lau Susanne, 2002, Paediatr Respir Rev, V3, P265, DOI 10.1016/S1526-0542(02)00189-6; Mango GW, 1998, AM J PHYSIOL-LUNG C, V275, pL348, DOI 10.1152/ajplung.1998.275.2.L348; MANTILE G, 1993, J BIOL CHEM, V268, P20343; Nickel R, 2002, CLIN EXP ALLERGY, V32, P1274, DOI 10.1046/j.1365-2745.2002.01482.x; Niggemann B, 2001, EUR RESPIR J, V17, P246, DOI 10.1183/09031936.01.17202460; SAWAYA PL, 1993, MOL CELL BIOL, V13, P3860, DOI 10.1128/MCB.13.7.3860; Shijubo N, 1999, LUNG, V177, P45, DOI 10.1007/PL00007626; Singh G, 1997, AM J RESP CELL MOL, V17, P141, DOI 10.1165/ajrcmb.17.2.f138; STRIPP BR, 1992, J BIOL CHEM, V267, P14703; VANVYVE T, 1995, J ALLERGY CLIN IMMUN, V95, P60, DOI 10.1016/S0091-6749(95)70153-2	20	60	61	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					515	519		10.1067/mai.2003.180	http://dx.doi.org/10.1067/mai.2003.180			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642831	Bronze			2022-12-18	WOS:000181639500012
J	Rullo, VEV; Rizzo, MC; Arruda, LK; Sole, D; Naspitz, CK				Rullo, VEV; Rizzo, MC; Arruda, LK; Sole, D; Naspitz, CK			Daycare centers and schools as sources of exposure to mites, cockroach, and endotoxin in the city of Sao Paulo, Brazil	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergens; endotoxin; schools; daycare; mites; cat; dog; cockroach	HOUSE-DUST MITE; FEL-D-I; DAY-CARE-CENTERS; DER-P-I; CAT ALLERGEN; F-I; MONOCLONAL-ANTIBODIES; ASTHMATIC-CHILDREN; IMMUNE-RESPONSES; PUBLIC PLACES	Background: Public places, including schools, have been identified as sources of exposure to allergens derived from mites, cockroach, cat, and dog and to endotoxin. Objectives: The purposes of this study were to assess and compare exposure to allergens and endotoxin in 4 types of public child-care facilities in Brazil and to investigate whether the presence of children and the performance of cleaning procedures could have an influence on allergen and endotoxin levels. Methods: We have analyzed dust from bedding, floors, chairs, and tables of daycare centers (DCs), preschools, kindergartens, and elementary schools (ESs). Major allergens from mites, cockroach, cat, and dog were quantitated by means of ELISA, and endotoxin content was determined by using the Limulus Amebocyte Lysate assay. Results: Group 1 mite allergens were greater than 2 mug/g in 67% of DC and preschool samples and in 8.9% and 2.2% of kindergarten and ES samples, respectively. The presence of bedding in DCs and preschools accounted for increased levels of mite allergens in these settings. Levels of Bla g I were higher in ES floors compared with those found in DC and preschool floors. Low levels (<1 mug/g) of Fel d 1 e Can f 1 were found in most samples. Levels of endotoxin in DCs and preschools were 3 times higher than in ESs. Conclusions: DCs and schools in Brazil should be considered as important sources of exposure to dust mites and cockroach allergens and to endotoxin. Recommendations for mite allergen avoidance should include appropriate care of bedding in DCs and preschools.	Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Pediat, Div Rheumatol Allergy & Immunol, BR-14049900 Ribeirao Preto, SP, Brazil; Univ Fed Sao Paulo, Paulista Sch Med, Dept Pediat, Div Rheumatol Allergy & Clin Immunol, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP)	Arruda, LK (corresponding author), Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Pediat, Div Rheumatol Allergy & Immunol, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.		Rizzo, Maria/HGD-6576-2022; Solé, Dirceu/D-7789-2013; Arruda, L. Karla/D-5845-2013; Rullo, Vera/G-8952-2018	Arruda, L. Karla/0000-0002-7505-210X; Rullo, Vera/0000-0002-4754-6612				Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Almqvist C, 2001, AM J RESP CRIT CARE, V163, P694, DOI 10.1164/ajrccm.163.3.2006114; ARRUDA LK, 1991, CLIN EXP ALLERGY, V21, P433, DOI 10.1111/j.1365-2222.1991.tb01683.x; Arruda LK, 2001, J ALLERGY CLIN IMMUN, V107, P419, DOI 10.1067/mai.2001.112854; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Berge M, 1998, PEDIATR ALLERGY IMMU, V9, P25, DOI 10.1111/j.1399-3038.1998.tb00296.x; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHAPMAN MD, 1995, PEDIAT ALLERG IMM-UK, V6, P8, DOI 10.1111/j.1399-3038.1995.tb00378.x; Custovic A, 1998, THORAX, V53, P33, DOI 10.1136/thx.53.1.33; Custovic A, 1999, ALLERGY, V54, P612, DOI 10.1034/j.1398-9995.1999.00062.x; CUSTOVIC A, 1994, CLIN EXP ALLERGY, V24, P1164, DOI 10.1111/j.1365-2222.1994.tb03323.x; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1111/j.1365-2222.1996.tb00521.x; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; DEANDRADE AD, 1995, J ALLERGY CLIN IMMUN, V95, P1158, DOI 10.1016/S0091-6749(95)70071-4; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Fernandez-Caldas E, 2001, ANN ALLERG ASTHMA IM, V87, P196, DOI 10.1016/S1081-1206(10)62225-9; Finn PW, 2000, J ALLERGY CLIN IMMUN, V105, P933, DOI 10.1067/mai.2000.106546; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; MUNIR AKM, 1995, CLIN EXP ALLERGY, V25, P119, DOI 10.1111/j.1365-2222.1995.tb01016.x; OVSYANNIKOVA IG, 1994, J ALLERGY CLIN IMMUN, V94, P537, DOI 10.1016/0091-6749(94)90211-9; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Perzanowski M, 1999, J ALLERGY CLIN IMMUN, V103, pS22; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V105, pS503, DOI 10.1016/S0091-6749(00)90051-4; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; REMILLARD JF, 1987, DETECTION BACTERIAL, P197; Rizzo MC, 1997, PEDIAT ALLERG IMM-UK, V8, P121; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; Sarpong SB, 1997, J ALLERGY CLIN IMMUN, V99, P486, DOI 10.1016/S0091-6749(97)70074-5; SCHOU C, 1991, J ALLERGY CLIN IMMUN, V88, P847, DOI 10.1016/0091-6749(91)90240-O; Silva JRL, 2000, TOXICOLOGY, V152, P31; Sopelete MC, 2000, INT ARCH ALLERGY IMM, V122, P257, DOI 10.1159/000024407; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Wahn U, 2001, J ALLERGY CLIN IMMUN, V107, P567, DOI 10.1067/mai.2001.112943; Wickens K, 1997, J ALLERGY CLIN IMMUN, V99, P587, DOI 10.1016/S0091-6749(97)70017-4	52	60	61	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2002	110	4					582	588		10.1067/mai.2002.127511	http://dx.doi.org/10.1067/mai.2002.127511			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	602JJ	12373265	Bronze			2022-12-18	WOS:000178501900007
J	Stempel, DA; O'Donnell, JC; Meyer, JW				Stempel, DA; O'Donnell, JC; Meyer, JW			Inhaled corticosteroids plus salmeterol or montelukast: Effects on resource utilization and costs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	57th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 16-21, 2001	NEW ORLEANS, LOUISIANA	Amer Acad Asthma & Immunol		dual-controller therapy; asthma; inhaled corticosteroids; leukotriene modifiers; montelkast; fluticasone; salmeterol; pharmacoeconomic evaluation	FLUTICASONE PROPIONATE; PERSISTENT ASTHMA; ORAL ZAFIRLUKAST	Background: Experimental clinical studies have demonstrated that the addition of salmeterol to inhaled corticosteroids (ICSs) is superior to the addition of montelukast to ICSs. Observational research from real-world clinical practice is needed to confirm these results. Objective: The present study was designed to assess, in clinical practice, the comparative impact on health care utilization and cost of 2 dual-controller therapies, ICS + salmeterol and ICS + montelukast. Methods: This study involved the use of a 24-month pre/post retrospective design in patients continuously enrolled in any of 14 United HealthCare plans. Outcomes assessed were postindex pharmacy costs, rates of emergency department visits and hospitalizations, numbers of filled prescriptions for short-acting beta-agonists (SABAs), total asthma costs, and total health care costs. Results: Subjects in the ICS + salmeterol group had 35% fewer post-index SABA claims than subjects in the montelukast add-on group (P less than or equal to .05). Subjects using ICS + montelukast were 2.5 times more likely to have an asthma-related hospitalization than subjects using ICS + salmeterol (P less than or equal to .065). Total adjusted asthma costs were 63% higher for the patients receiving ICS + montelukast than for the patients receiving ICS + salmeterol (P less than or equal to .0001). In addition, total health care costs were 25% lower in the ICS + salmeterol group. (P less than or equal to .0004). Additional reductions in hospitalization and emergency department visits were observed when the patients on FP + salmeterol were studied separately. Conclusion: In comparison with the use of montelukast and ICS, the use of salmeterol and ICS was associated with a significant reduction in SABA use, decreased hospital event rates, and significantly lower total asthma care costs.	Virginia Mason Clin, Seattle, WA 98101 USA; GlaxoSmithKline, Res Triangle Pk, NC USA; Ingenix Pharmaceut Serv, Eden Prairie, MN USA	Virginia Mason Medical Center; GlaxoSmithKline	Stempel, DA (corresponding author), Virginia Mason Clin, 1100 9th Ave, Seattle, WA 98101 USA.							Belsley D. A., 1981, REGRESSION DIAGNOSTI; Bleecker ER, 2000, J ALLERGY CLIN IMMUN, V105, P1123, DOI 10.1067/mai.2000.106043; Busse W, 1999, J ALLERGY CLIN IMMUN, V103, P1075, DOI 10.1016/S0091-6749(99)70182-X; Busse W, 2001, J ALLERGY CLIN IMMUN, V107, P461, DOI 10.1067/mai.2001.114657; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P1002; Condemi JJ, 1997, J ALLERGY CLIN IMMUN, V100, P467, DOI 10.1016/S0091-6749(97)70137-4; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; DUAN N, 1983, J AM STAT ASSOC, V78, P605, DOI 10.2307/2288126; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; Fish JE, 2001, CHEST, V120, P423, DOI 10.1378/chest.120.2.423; *GLAX WELLC, ASTHM AM EX SUMM; Goldman M, 2000, J ALLERGY CLIN IMMUN, V105, P71, DOI 10.1016/S0091-6749(00)90180-5; GREENE WH, 1997, ECONOMETRIC ANAL, P552; *NAT ASTHM ED PROG, 1997, NIH PUBL, V4051; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V106, P1088, DOI 10.1067/mai.2000.110920; *NIH NATL HEART LU, 2000, DAT FACT SHEET ASTHM; OCONNOR R, IN PRESS CHEST; Radford MJ, 2001, JAMA-J AM MED ASSOC, V286, P1228, DOI 10.1001/jama.286.10.1228; Raphael GD, 1999, J ALLERGY CLIN IMMUN, V103, P796, DOI 10.1016/S0091-6749(99)70422-7; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Stempel DA, 2001, RESP MED, V95, P992, DOI 10.1053/rmed.2001.1185; Stempel DA, 2001, J ALLERGY CLIN IMMUN, V107, P94, DOI 10.1067/mai.2001.112029; Stempel DA, 2001, RESP MED, V95, P227, DOI 10.1053/rmed.2000.1027; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504	24	60	60	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					433	439		10.1067/mai.2002.121953	http://dx.doi.org/10.1067/mai.2002.121953			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11897987				2022-12-18	WOS:000174586400008
J	Saary, MJ; Kanani, A; Alghadeer, H; Holness, DL; Tarlo, SM				Saary, MJ; Kanani, A; Alghadeer, H; Holness, DL; Tarlo, SM			Changes in rates of natural rubber latex sensitivity among dental school students and staff members after changes in latex gloves	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; occupational rhinitis; asthma; urticaria	OCCUPATIONAL ASTHMA; ALLERGY; PREVALENCE; PERSONNEL	Background: A high rate of sensitization and clinical allergy to natural rubber latex (NRL) gloves has been reported in dental students and staff members. Objective: The purpose of this study was to determine whether a change in glove use from high-protein/powdered to low-protein/powder-free latex gloves at a previously surveyed dental school reduced the prevalence of NRL sensitivity among students and staff members. Methods: A cross-sectional study was performed through use of a questionnaire and skin prick testing to low ammoniated NRL extract; the method was similar to that used in a study conducted in 1995. Analyses were performed on the entire groups as well as on a subset of senior students. Results: A total of 97 subjects (61 students and 36 staff members) completed the questionnaire and underwent skin prick testing; this compared with 131 subjects in 1995. Percentages of subjects reporting asthma symptoms, rhinitis or conjunctivitis, urticaria, or pruritis within minutes of NRL exposure were 4%, 7%, 6%, and 8%, respectively; the corresponding percentages in the 1995 survey were 7% (P = not significant), 13% (P = not significant), 20% (P = .004), and 22% (P = .005). Results were similar for the subset of senior students, but in addition there were also significantly fewer complaints of rhinoconjunctivitis in 2000 than in 1995 (0% and 12%, respectively; P = .007). Of 97 subjects who underwent skin prick testing, 3 (3%) had positive skin prick test responses of 2+ or greater to NRL; this compared with 13 (10%) of 131 subjects in 1995 (P = .03). There were 3 positive skin test responses among staff members in 2000; there were none among students. Conclusions: Our results suggest a preventive effect on NRL allergy in dental students from the change to low-protein/powder-free NRL gloves in the dental school.	Univ Toronto, St Michaels Hosp, Gage Occupat & Environm Hlth Unit, Toronto, ON M5B 1W8, Canada; Univ Toronto, Toronto Western Hosp, Gage Occupat & Environm Hlth Unit, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Tarlo, SM (corresponding author), Gage Occupat & Environm Hlth Unit, 223 Coll St, Toronto, ON M9R 2S8, Canada.			Tarlo, Susan/0000-0002-4746-5310				BERKY ZT, 1992, JAMA-J AM MED ASSOC, V268, P2695; BEZHOLD D, 1992, GUTHRIE J, V61, P77; Brehler R, 1997, EUR J SURG, V163, P23; Field EA, 1999, OCCUP MED-OXFORD, V49, P103, DOI 10.1093/occmed/49.2.103; Hadjiliadis D, 1996, J ALLERGY CLIN IMMUN, V97, P1202, DOI 10.1016/S0091-6749(96)70185-9; Hamann CP, 1998, J AM DENT ASSOC, V129, P43, DOI 10.14219/jada.archive.1998.0021; HEESE A, 1991, J AM ACAD DERMATOL, V25, P831, DOI 10.1016/S0190-9622(08)80977-2; Katelaris CH, 1996, MED J AUSTRALIA, V164, P711, DOI 10.5694/j.1326-5377.1996.tb122267.x; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; Levy DA, 1999, JAMA-J AM MED ASSOC, V281, P988, DOI 10.1001/jama.281.11.988; Lindberg M, 2000, CONTACT DERMATITIS, V43, P4, DOI 10.1034/j.1600-0536.2000.043001004.x; Liss GM, 2001, AM J IND MED, V40, P347, DOI 10.1002/ajim.1108; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; Smedley J, 1999, OCCUP ENVIRON MED, V56, P833, DOI 10.1136/oem.56.12.833; Tarlo SM, 1997, J ALLERGY CLIN IMMUN, V99, P396, DOI 10.1016/S0091-6749(97)70058-7; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; Tarlo SM, 2001, J ALLERGY CLIN IMMUN, V108, P628, DOI 10.1067/mai.2001.118792; Turjanmaa K, 2000, J ALLERGY CLIN IMMUN, V105, pS373, DOI 10.1016/S0091-6749(00)91520-3; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; Vandenplas O, 1999, ASTHMA WORKPLACE, P425; WRANGSJO K, 1994, CONTACT DERMATITIS, V30, P102, DOI 10.1111/j.1600-0536.1994.tb00572.x	21	60	62	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					131	135		10.1067/mai.2002.120557	http://dx.doi.org/10.1067/mai.2002.120557			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799379				2022-12-18	WOS:000173739300022
J	Vignola, AM; Chiappara, G; Siena, L; Bruno, A; Gagliardo, R; Merendino, AM; Polla, BS; Arrigo, AP; Bonsignore, G; Bousquet, J; Chanez, P				Vignola, AM; Chiappara, G; Siena, L; Bruno, A; Gagliardo, R; Merendino, AM; Polla, BS; Arrigo, AP; Bonsignore, G; Bousquet, J; Chanez, P			Proliferation and activation of bronchial epithelial cells in corticosteroid-dependent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; apoptosis; proliferation; corticosteroids; inflammation	FACTOR-KAPPA-B; CD40 LIGATION; BCL-2; INFLAMMATION; APOPTOSIS; DIFFERENTIATION; LYMPHOCYTES; EXPRESSION; BIOPSIES; IL-4	Background: Structural and functional characteristics of bronchial epithelial cells in corticosteroid-dependent asthma are unknown. Objective: In bronchial biopsy specimens from 16 control, 9 untreated asthmatic, 9 inhaled corticosteroid-treated asthmatic, and 19 corticosteroid-dependent asthmatic subjects, we evaluated epithelium morphology and patterns of cell apoptosis, proliferation, and activation. Methods: We used the terminal deoxynucleotidyl-mediated dUTP nick end labeling (TUNEL) technique to study apoptosis. Immunohistochemistry was used to evaluate the expression of molecules related to apoptosis (such as Bcl-2 and P53), cell proliferation (PCNA), and cell activation (NF kappaB and CD40/CD40-L). Results: Epithelium thickness was higher in corticosteroid-dependent asthmatic and control subjects than in inhaled corticosteroid-treated and untreated asthmatic subjects (P <.0001 and P <.0003). Very few TUNEL-positive epithelial cells were found in the 4 groups. Bcl-2 expression was higher in all groups of asthmatic subjects than in controls (P <.001). In corticosteroid-dependent asthmatic subjects, PCNA, NF<kappa>B, and CD40-L expression was higher than in inhaled corticosteroid-treated asthmatic (P <.001), untreated asthmatic (P <.001 and P <.04), and control (P <.01) subjects. CD40 expression was greater in corticosteroid-dependent asthmatic and untreated asthmatic subjects than in inhaled corticosteroid-treated asthmatic subjects (P <.0001 and P <.0006) and controls (P <.02 and P <.03). In corticosteroid-dependent asthma, PCNA expression was correlated with the epithelium thickness (P <.007). Conclusion: This study shows that in bronchial epithelial cells of corticosteroid-dependent asthma, markers of cell survival and proliferation are coexpressed with markers of cell activation, suggesting that in this disease epithelium repair is associated with a persistent activation state of epithelial cells.	CNR, Ist Fisiopatol Resp, I-90146 Palermo, Italy; Univ Palermo, Clin Pneumol, Palermo, Italy; Univ Paris 05, UFR Cochin Port Royal, Physiol Resp Lab, Paris, France; Univ Lyon 1, CGMC, Lab Stress Cellulaire, CNRS,UMR 5534, F-69365 Lyon, France; Hop Arnaud de Villeneuve, Clin Malad Resp, Montpellier, France; Hop Arnaud de Villeneuve, INSERM, U454, Montpellier, France	Consiglio Nazionale delle Ricerche (CNR); University of Palermo; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Vignola, AM (corresponding author), CNR, Ist Fisiopatol Resp, Via Trabucco 180, I-90146 Palermo, Italy.		Bruno, Andreina/AAX-8151-2020; Bousquet, Jean/O-4221-2019; Gagliardo, Rosalia/AAX-7244-2020	chanez, pascal/0000-0003-4059-0917; SIENA, LIBORIA/0000-0002-3182-9503; CHIAPPARA, GIUSEPPINA/0000-0002-7226-5660				Barnes PJ, 1998, EUR RESPIR J, V12, P221, DOI 10.1183/09031936.98.12010221; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CAMPBELL AM, 1993, AM REV RESPIR DIS, V147, P529, DOI 10.1164/ajrccm/147.3.529; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; DAWSON CW, 1995, ONCOGENE, V10, P69; DEMOLY P, 1994, AM J RESP CRIT CARE, V150, P214, DOI 10.1164/ajrccm.150.1.7912988; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Hart L, 2000, AM J RESP CRIT CARE, V161, P224, DOI 10.1164/ajrccm.161.1.9809019; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; HAWKINS CJ, 1994, IMMUNOL REV, V142, P127, DOI 10.1111/j.1600-065X.1994.tb00886.x; Holgate ST, 1999, CLIN EXP ALLERGY, V29, P90, DOI 10.1046/j.1365-2222.1999.00016.x; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Jeppson JD, 1998, J IMMUNOL, V161, P1738; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Laliberte F, 2000, ALLERGY, V55, P718, DOI 10.1034/j.1398-9995.2000.00649.x; Laman JD, 1997, IMMUNOL TODAY, V18, P272, DOI 10.1016/S0167-5699(97)80022-9; Lazaar AL, 1998, J IMMUNOL, V161, P3120; PeguetNavarro J, 1997, J IMMUNOL, V158, P144; SOUSA AR, 1993, AM REV RESPIR DIS, V147, P1557, DOI 10.1164/ajrccm/147.6_Pt_1.1557; Vachier I, 1998, AM J RESP CRIT CARE, V158, P963, DOI 10.1164/ajrccm.158.3.9710085; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040; Vignola AM, 1999, J ALLERGY CLIN IMMUN, V103, P563, DOI 10.1016/S0091-6749(99)70225-3; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; Worm MM, 1998, EUR J IMMUNOL, V28, P901, DOI 10.1002/(SICI)1521-4141(199803)28:03<901::AID-IMMU901>3.0.CO;2-S; Young LS, 1998, IMMUNOL TODAY, V19, P502, DOI 10.1016/S0167-5699(98)01340-1; [No title captured]	29	60	68	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					738	746		10.1067/mai.2001.119160	http://dx.doi.org/10.1067/mai.2001.119160			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692098	Bronze			2022-12-18	WOS:000172523800013
J	Vonakis, BM; Gibbons, S; Sora, R; Langdon, JM; MacDonald, SM				Vonakis, BM; Gibbons, S; Sora, R; Langdon, JM; MacDonald, SM			Src homology 2 domain-containing inositol 5 ' phosphatase is negatively associated with histamine release to human recombinant histamine-releasing factor in human basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophil; cytokines; cellular activation; signal transduction	FC-EPSILON-RI; AFFINITY IGE RECEPTOR; NONRELEASING HUMAN BASOPHILS; POLYPHOSPHATE 5-PHOSPHATASE; MESSENGER-RNA; TARGETED DISRUPTION; TYROSINE KINASES; IMMUNE-SYSTEM; BETA-SUBUNIT; GAMMA-RIIB	Background: The human recombinant histamine-releasing factor (HrHRF) acts as a complete stimulus for histamine release and IL-4 secretion from a subpopulation of highly allergic donor basophils, termed IgE(+) basophils. Additionally, IgE(+) basophils release histamine to other secretogues, IL-3, and deuterium oxide. We hypothesized that IgE(+) basophils were hyperreleasable. Objective: Deficiencies in early signal transduction events associated with Fc epsilon RI lead to a nonreleasable phenotype, whereas the Src homology 2 domain-containing inositol 5' phosphatase (SHIP) knockout mice have hyperreleasable mast cells. The purpose of this study was to ascertain whether a difference in intracellular signaling molecules could explain the hyperreleasable phenotype of human IgE(+) basophils. Methods: Basophils were purified by means of double Percoll gradients and negative selection with magnetic beads. Cell lysates were Western blotted for the tyrosine kinases Lyn and Syk and the phosphatase SHIP. Additionally, histamine release to HrHRF was performed in addition to real-time RT-PCR to investigate mRNA for SHIP. Results: We show a striking negative correlation between the amount of SHIP protein per cell equivalent, but not Lyn or Syk, and maximum histamine release to HrHRF. This deficiency of SHIP was observed in basophils, but not lymphocytes or monocytes, of these IgE(+) donors. Additionally, levels of mRNA for SHIP did not differ between IgE(+) and IgE(-) donor basophils, which is consistent with a posttranscriptional mechanism of protein regulation. SHIP and phosphatidylinositol 3-kinase reciprocally regulate phosphatidylinositol (3,4,5) triphosphate levels. We also demonstrated that Ly294002, the phosphatidylinositol 3 kinase inhibitor, prevented HrHRF-induced histamine release in IgE(+) donor basophils. Conclusion: Taken together, these data suggest that the hyper-releasability of IgE(+) donors is associated with low levels of SHIP and implicate SHIP as an additional regulator of secretion in human basophils.	Johns Hopkins Sch Med, Div Clin Immunol & Allergy, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine	MacDonald, SM (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.		Vonakis, Becky/GSN-7958-2022	Vonakis, Becky/0000-0003-4174-6514	PHS HHS [R01 A132651] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adachi T, 1999, J IMMUNOL, V162, P1496; Allerson CR, 1999, J BIOL CHEM, V274, P26439, DOI 10.1074/jbc.274.37.26439; Bheekha-Escura R, 2000, BLOOD, V96, P2191; Bheekha-Escura R, 1999, J ALLERGY CLIN IMMUN, V103, P937, DOI 10.1016/S0091-6749(99)70442-2; Cazzola M, 1997, BLOOD, V90, P814, DOI 10.1182/blood.V90.2.814.814_814_821; Coggeshall KM, 1998, CURR OPIN IMMUNOL, V10, P306, DOI 10.1016/S0952-7915(98)80169-6; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; Gibbs BF, 1999, J LEUKOCYTE BIOL, V65, P883, DOI 10.1002/jlb.65.6.883; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Huber M, 1998, EMBO J, V17, P7311, DOI 10.1093/emboj/17.24.7311; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kepley CL, 2000, J IMMUNOL, V165, P5913, DOI 10.4049/jimmunol.165.10.5913; Kepley CL, 1999, J ALLERGY CLIN IMMUN, V104, P279, DOI 10.1016/S0091-6749(99)70367-2; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Kimura T, 1997, J BIOL CHEM, V272, P13991, DOI 10.1074/jbc.272.21.13991; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; Lavens-Phillips SE, 2000, AM J RESP CELL MOL, V23, P566, DOI 10.1165/ajrcmb.23.4.4123; LICHTENSTEIN LM, 1986, J ALLERGY CLIN IMMUN, V77, P291, DOI 10.1016/S0091-6749(86)80106-3; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu QR, 1998, BLOOD, V91, P2753, DOI 10.1182/blood.V91.8.2753.2753_2753_2759; MACDONALD SM, 1989, J IMMUNOL, V142, P3527; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MACDONALD SM, 1995, SCIENCE, V269, P688, DOI 10.1126/science.7542803; MACDONALD SM, 1991, CLIN EXP ALLERGY, V21, P133, DOI 10.1111/j.1365-2222.1991.tb00815.x; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MAEYAMA K, 1986, J BIOL CHEM, V261, P2583; Mano H, 1999, CYTOKINE GROWTH F R, V10, P267, DOI 10.1016/S1359-6101(99)00019-2; MARONE G, 1994, J ALLERGY CLIN IMMUN, V94, P1293, DOI 10.1016/0091-6749(94)90345-X; MARONE G, 1986, J ALLERGY CLIN IMMUN, V77, P377, DOI 10.1016/S0091-6749(86)80121-X; MARONE G, 1986, J IMMUNOL, V137, P3588; Miura K, 2000, BLOOD, V96, P2199, DOI 10.1182/blood.V96.6.2199.h8002199_2199_2205; Miura K, 2000, J IMMUNOL, V164, P3026, DOI 10.4049/jimmunol.164.6.3026; NGUYEN KL, 1990, J ALLERGY CLIN IMMUN, V85, P1020, DOI 10.1016/0091-6749(90)90046-7; OKAZAKI H, 1999, ALLERGY CLIN IMMUNOL, V11, P86; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Putney JW, 1999, BIOESSAYS, V21, P38; Sattler M, 1999, MOL CELL BIOL, V19, P7473; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SCHLEIMER RP, 1982, J IMMUNOL, V129, P1632; Schroeder JT, 1997, J IMMUNOL, V159, P447; Schroeder JT, 1996, J EXP MED, V183, P1265, DOI 10.1084/jem.183.3.1265; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; Thomson AM, 1999, INT J BIOCHEM CELL B, V31, P1139, DOI 10.1016/S1357-2725(99)00080-1; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wantke F, 1999, J ALLERGY CLIN IMMUN, V103, P642, DOI 10.1016/S0091-6749(99)70237-X; Wofsy C, 1997, J IMMUNOL, V159, P5984; Wofsy C, 1999, P NATL ACAD SCI USA, V96, P8615, DOI 10.1073/pnas.96.15.8615; Wolf I, 2000, GENOMICS, V69, P104, DOI 10.1006/geno.2000.6324; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	54	60	65	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					822	831		10.1067/mai.2001.119159	http://dx.doi.org/10.1067/mai.2001.119159			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692111				2022-12-18	WOS:000172523800026
J	Addo-Yobo, EOD; Custovic, A; Taggart, SCO; Craven, M; Bonnie, B; Woodcock, A				Addo-Yobo, EOD; Custovic, A; Taggart, SCO; Craven, M; Bonnie, B; Woodcock, A			Risk factors for asthma in urban Ghana	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; risk factors; allergens; Africa	CHILDHOOD ASTHMA; ALLERGENS; EXPOSURE; CHILDREN; PREVALENCE; SENSITIZATION; DUST	Background: Asthma is increasing in prevalence and severity in Africa. Previous studies have suggested that the prevalence of atopy in West Africa was low. Objective: We sought to investigate the risk factors for asthma in Ghanaian school children. Methods: Fifty children (age range, 9-16 years) with a physician diagnosis of asthma and asthma symptoms within the previous 12 months and 50 age- and sex-matched healthy control subjects were randomly selected and evaluated by means of questionnaire, skin testing, total and specific IgE measurements, and allergen level measurements from bed dust samples (mite, cat, dog, and cockroach). Results: Asthmatic children were exposed to higher levels of mite allergens than were control children (geometric mean, 19 mug/g (95% CI, 13.6-26.5] vs 11.2 mug/g [7.4-15.7]; P < .05). Cat and dog allergen levels were low. There was a marked dissociation between skin test responses and the presence of specific IgE to cat and dog (CAP method). However, 84% of subjects, with positive cat dander-specific IgE levels in cat CAP tests and negative skin test responses did not have Fel d I-specific IgE (chimeric ELISA). In the univariate analysis significant associations with the patient group were found for sensitization to mite (odds ratio [OR], 9.3; 95% CI, 3.7-23.4) and cockroach (OR, 3.9; 95% CI, 1.3-11.6), inner-city residence (OR, 3.5; 95% CI, 1.4-8.9), asthma in family member (OR, 3.5; 95% CI, 1.4-9.0), low (<5) position in sibship (OR, 3.6; 95% CI, 1.2-11), presence of smoker in home (OR, 3.7; 95 % CI, 1.2-11.9), small household size (OR, 0.57; 95% CI, 0.35-0.93), and use of electricity as domestic fuel (OR, 0.34; 95% Cl, 0.12-0.97). In the multivariate analysis sensitization to mites remained the strongest risk factor associated with the asthmatic group (OR, 10.4; 95% CI, 3.5-30.9). The other significant associations were inner-city residence (OR, 4.8; 95 % CI, 1.5-5.2), sensitization to cockroach (OR, 4.9; 95% CI, 1.3-18.6), and position in sibship of less than 5 (OR, 6.3; 95 % CI, 1.3-29.4). Conclusion: Sensitization to dust mite and cockroach allergens, inner-city residence, and low position in sibship were independent risk factors for asthma in Ghanaian children.	Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England; Komfo Anokye Teaching Hosp, Dept Child Hlth, Kumasi, Ghana	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Kwame Nkrumah University Science & Technology	Custovic, A (corresponding author), Wythenshawe Hosp, NW Lung Ctr, Southmoor Rd, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578				ABDURRAHMAN MB, 1982, CLIN ALLERGY, V12, P379, DOI 10.1111/j.1365-2222.1982.tb02542.x; AWOTEDU AA, 1992, E AFR MED J, V69, P631; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; COOKSON J B, 1975, Clinical Allergy, V5, P375, DOI 10.1111/j.1365-2222.1975.tb01876.x; deBlay F, 1997, J ALLERGY CLIN IMMUN, V99, P107, DOI 10.1016/S0091-6749(97)70307-5; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681, DOI 10.1164/ajrccm.154.3.8810605; FRASER BN, 1979, S AFR MED J, V55, P637; HADDOCK DRW, 1977, T ROY SOC TROP MED H, V71, P32, DOI 10.1016/0035-9203(77)90203-6; Ichikawa K, 1999, CLIN EXP ALLERGY, V29, P754; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; KEELEY DJ, 1991, THORAX, V46, P549, DOI 10.1136/thx.46.8.549; LAN JL, 1988, J ALLERGY CLIN IMMUN, V82, P736, DOI 10.1016/0091-6749(88)90072-3; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Leung R, 1997, J ALLERGY CLIN IMMUN, V99, P594, DOI 10.1016/S0091-6749(97)70018-6; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; NG'Ang'A LW, 1997, E AFR MED J, V74, P694; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; PRITCHARD DI, 1990, PARASITOLOGY, V100, P317, DOI 10.1017/S0031182000061333; REES PH, 1974, E AFR MED J, V51, P729; Rona RJ, 1999, J EPIDEMIOL COMMUN H, V53, P15, DOI 10.1136/jech.53.1.15; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WARRELL DA, 1975, Q J MED, V44, P325; Yobo EODA, 1997, THORAX, V52, P161, DOI 10.1136/thx.52.2.161	26	60	61	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					363	368		10.1067/mai.2001.117464	http://dx.doi.org/10.1067/mai.2001.117464			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544454				2022-12-18	WOS:000171215400006
J	Shodell, M; Siegal, FP				Shodell, M; Siegal, FP			Corticosteroids depress IFN-alpha-producing plasmacytoid dendritic cells in human blood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IFN-producing cells; dendritic cells; plasmacytoid; corticosteroids; steroid effects; pDC; immunosuppression; T(H)1 immunity; flow cytometry	GLUCOCORTICOIDS; INTERFERON; MATURATION	Glucocorticoids are strongly immunosuppressive and are associated with reactivation of some intracellular infections. The plasmacytoid dendritic cell is a rare blood mononuclear cell detected through its production of IFN-alpha in response to herpes simplex virus and by surface immunophenotyping. We here report that steroid administration results in a decrease of IFN-alpha generation of approximately 25-fold, accompanied by reduction in circulating plasmacytoid dendritic cell numbers. Both parameters return to normal within days after steroid cessation.	St Vincent Hosp & Med Ctr, Dept Med, Sect HIV Med, New York, NY USA; Long Isl Univ, Brookville, NY USA	Saint Vincents Hospital Manhattan	Siegal, FP (corresponding author), St Vincents Catholic Med Ctr, Dept Med, NR 1425,153 W 11th St, New York, NY 10011 USA.							Cella M, 2000, NAT IMMUNOL, V1, P305, DOI 10.1038/79747; Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360; DISONATO JA, 1996, AM J RESP CRIT CAR 2, V154, pS11; Franchimont D, 2000, J IMMUNOL, V164, P1768, DOI 10.4049/jimmunol.164.4.1768; Matyszak MK, 2000, EUR J IMMUNOL, V30, P1233, DOI 10.1002/(SICI)1521-4141(200004)30:4<1233::AID-IMMU1233>3.0.CO;2-F; Piemonti L, 1999, J IMMUNOL, V162, P6473; Reissland P, 1999, IMMUNOBIOLOGY, V200, P227, DOI 10.1016/S0171-2985(99)80072-2; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; SIEGAL FP, 1986, J CLIN INVEST, V78, P115, DOI 10.1172/JCI112539; SIEGAL FP, IN PRESS AIDS	10	60	63	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					446	448		10.1067/mai.2001.117928	http://dx.doi.org/10.1067/mai.2001.117928			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544466				2022-12-18	WOS:000171215400018
J	Vandenplas, O; Binard-Van Cangh, F; Brumagne, A; Caroyer, JM; Thimpont, J; Sohy, C; Larbanois, A; Jamart, J				Vandenplas, O; Binard-Van Cangh, F; Brumagne, A; Caroyer, JM; Thimpont, J; Sohy, C; Larbanois, A; Jamart, J			Occupational asthma in symptomatic workers exposed to natural rubber latex: Evaluation of diagnostic procedures	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; bronchial provocation tests; occupational disease; natural rubber latex	IGE SENSITIZATION; HISTORY; AGENTS	Background: Natural rubber latex (NRL) has been increasingly identified as a cause of occupational asthma (OA). Objective: We sought to examine the accuracy of the clinical history, immunologic tests, and assessment of nonspecific bronchial hyperresponsiveness in diagnosing OA caused by latex compared with that of the specific inhalation challenge (SIC). Methods: Forty-five consecutive patients referred for investigation of possible OA caused by latex underwent a diagnostic protocol, including an open medical questionnaire, skin prick testing against latex, measurement of bronchial responsiveness to histamine,and inhalation challenge with latex gloves. Recorded clinical history was judged retrospectively by 4 physicians who mere blinded for the results of other objective tests. Results: The clinical history, skin prick testing against NRL, and assessment of nonspecific bronchial hyperresponsiveness showed a high sensitivity (87%, 100%, and 90%, respectively) but a low specificity (14%, 21%, and 7%, respectively) when compared with the results of the SIG. Logistic regression analysis showed that combining the results of skin prick tests against latex with the clinical history enhanced the negative predictive value from 50% to 71%, whereas the positive predictive value remained virtually unchanged (75% vs 76%). Conclusion: The clinical history and immunologic tests were the most useful procedures in diagnosing NRL-induced asthma, although combining the 2 procedures remained less accurate than SIC. Further examination of the predictive values of available tests is warranted to recommend diagnostic strategies that are specific to the various agents causing OA.	Catholic Univ Louvain, Clin Univ Mt Godinne, Serv Pneumol, B-5530 Yvoir, Belgium; Catholic Univ Louvain, Clin Univ Mt Godinne, Ctr Biostat & Documentat Med, B-5530 Yvoir, Belgium; Fonds Malad Profess, Brussels, Belgium	Universite Catholique Louvain; Universite Catholique Louvain Hospital; Universite Catholique Louvain; Universite Catholique Louvain Hospital	Vandenplas, O (corresponding author), Catholic Univ Louvain, Clin Univ Mt Godinne, Serv Pneumol, B-5530 Yvoir, Belgium.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; BARDY JD, 1987, AM REV RESPIR DIS, V135, P1033; Baur X, 1998, AM J IND MED, V33, P114; Bernstein David I., 1993, P103; Bernstein IL, 1999, ASTHMA WORKPLACE, P279; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P823, DOI 10.1016/0091-6749(89)90346-1; CARTIER A, 1986, J ALLERGY CLIN IMMUN, V78, P344, DOI 10.1016/S0091-6749(86)80087-2; CHANYEUNG M, 1995, CHEST, V108, P1084, DOI 10.1378/chest.108.4.1084; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; *EUR COMM COAL STE, 1983, B EUR PHYSIOPATHO S5, V19, P7; Johnson A., 1999, ASTHMA WORKPLACE, P173; JONES RT, 1994, ANN ALLERGY, V73, P321; Lemiere C, 1996, AM J RESP CRIT CARE, V154, P329, DOI 10.1164/ajrccm.154.2.8756802; MAESTRELLI P, 1992, CLIN EXP ALLERGY, V22, P103; MALO JL, 1991, AM REV RESPIR DIS, V143, P528, DOI 10.1164/ajrccm/143.3.528; MERGET R, 1993, J ALLERGY CLIN IMMUN, V92, P264, DOI 10.1016/0091-6749(93)90170-K; Ross DJ, 1998, OCCUP MED-OXFORD, V48, P481, DOI 10.1093/occmed/48.8.481; SMITH AB, 1990, CHEST, V98, P398, DOI 10.1378/chest.98.2.398; Tarlo S M, 1998, Can Respir J, V5, P289; Vandenplas O, 1996, THORAX, V51, P472, DOI 10.1136/thx.51.5.472; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; Vandenplas O, 1997, ALLERGY, V52, P1147, DOI 10.1111/j.1398-9995.1997.tb00195.x; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P887	23	60	62	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					542	547		10.1067/mai.2001.113519	http://dx.doi.org/10.1067/mai.2001.113519			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240958	Bronze			2022-12-18	WOS:000167793300019
J	Nelson, HS				Nelson, HS			Advair: Combination treatment with fluticasone propionate/salmeterol in the treatment of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; Advair; salmeterol; fluticasone propionate; combination therapy; Seretide; leukotriene modifiers; exacerbations; Serevent; Flovent	LONG-TERM TREATMENT; ACTING INHALED BETA(2)-AGONISTS; AIRWAY SMOOTH-MUSCLE; LUNG MAST-CELLS; DOUBLE-BLIND; BECLOMETHASONE DIPROPIONATE; PROPIONATE POWDER; SALMETEROL XINAFOATE; SYSTEMIC ACTIVITY; MEDIATOR RELEASE	Several classes of medications are available for the treatment of asthma, and often they must be taken concurrently to achieve asthma control. Based on the understanding of asthma as an inflammatory disease, the National Heart Lung and Blood Institute guidelines provide a stepwise approach to pharmacologic therapy. Corticosteroid therapy, principally inhaled corticosteroid (ICS) therapy, is considered the most effective antiinflammatory treatment. In cases of moderate-to-severe persistent asthma, the addition of a second long-term control medication to ICS therapy is one recommended treatment option. A combination-product inhaler (Advair, Seretide) was developed to treat both the inflammatory and bronchoconstrictive components of asthma by delivering a dose of the ICS, fluticasone propionate, and a dose of the long-acting beta (2)-adrenergic (LABA) bronchodilator, salmeterol. The Advair Diskus is available in 3 strengths of fluticasone propionate (100, 250, and 500 mug) and a fixed dose (50 mug) of salmeterol, Combination treatment with both ICS and LABA provides greater asthma control than increasing the ICS dose alone, while at the same time reducing the frequency and perhaps the severity of exacerbations. Furthermore, salmeterol added to ICS therapy provides superior asthma control compared with the addition of leukotriene modifiers or theophylline. The superior control is likely a consequence of the complementary actions of the drugs when taken together, including the activation of the glucocorticoid receptor by salmeterol, By combining anti-inflammatory treatment with a long-acting beta (2)-agonist in a single inhaler (1 inhalation twice daily), physicians can provide coverage for both the inflammatory and bronchoconstrictive aspects of asthma without introducing any new or unexpected adverse consequences, The most common drug-related adverse events were those known to be attributable to the constituent medications (ICS therapy and/or LABA therapy). Although the benefits of combined ICS plus LABA therapy can be achieved with separate inhalers, the convenience of the combination product may improve patient adherence and may therefore reduce the morbidity of asthma.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	National Jewish Health	Nelson, HS (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.							Allen DB, 1998, J PEDIATR-US, V132, P472, DOI 10.1016/S0022-3476(98)70023-X; Anderson GP, 2000, AM J RESP CRIT CARE, V161, pS188, DOI 10.1164/ajrccm.161.supplement_2.a1q4-9; Anenden V., 1998, European Respiratory Journal, V12, p157S; Aubier M, 1999, RESP MED, V93, P876, DOI 10.1016/S0954-6111(99)90053-7; Baraniuk J, 1999, CHEST, V116, P625, DOI 10.1378/chest.116.3.625; Baraniuk JN, 1997, AM J RESP CRIT CARE, V155, P704, DOI 10.1164/ajrccm.155.2.9032216; Barnes N, 1998, J ALLERGY CLIN IMMUN, V101, pS460, DOI 10.1016/S0091-6749(98)70160-5; Barnes NC, 1998, RESP MED, V92, P95, DOI 10.1016/S0954-6111(98)90039-7; Barnes PJ, 1998, J ALLERGY CLIN IMMUN, V101, pS427, DOI 10.1016/S0091-6749(98)70154-X; BENNETT JA, 1994, THORAX, V49, P771, DOI 10.1136/thx.49.8.771; Bissonnette EY, 1997, J ALLERGY CLIN IMMUN, V100, P825, DOI 10.1016/S0091-6749(97)70280-X; Bjermer L, 2000, RESP MED, V94, P612, DOI 10.1053/rmed.2000.0806; Bleecker ER, 2000, J ALLERGY CLIN IMMUN, V105, P1123, DOI 10.1067/mai.2000.106043; Booth H, 1996, THORAX, V51, P1100, DOI 10.1136/thx.51.11.1100; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRITTON MG, 1992, EUR RESPIR J, V5, P1062; BRONSKY EA, 1994, CHEST, V105, P1032, DOI 10.1378/chest.105.4.1032; Busse W, 1999, J ALLERGY CLIN IMMUN, V103, P1075, DOI 10.1016/S0091-6749(99)70182-X; BUTCHERS PR, 1991, BRIT J PHARMACOL, V104, P672, DOI 10.1111/j.1476-5381.1991.tb12487.x; Chapman K R, 1999, Can Respir J, V6, P45; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; Chong LK, 1998, BRIT J PHARMACOL, V123, P1009, DOI 10.1038/sj.bjp.0701703; Condemi JJ, 1997, J ALLERGY CLIN IMMUN, V100, P467, DOI 10.1016/S0091-6749(97)70137-4; Condemi JJ, 1999, ANN ALLERG ASTHMA IM, V82, P383, DOI 10.1016/S1081-1206(10)63288-7; DALONZO GE, 1994, JAMA-J AM MED ASSOC, V271, P1412, DOI 10.1001/jama.271.18.1412; Davies B, 1998, RESP MED, V92, P256, DOI 10.1016/S0954-6111(98)90105-6; DOMPELING E, 1993, ANN INTERN MED, V118, P770, DOI 10.7326/0003-4819-118-10-199305150-00003; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; Dowling RB, 1997, AM J RESP CRIT CARE, V155, P327, DOI 10.1164/ajrccm.155.1.9001332; Dowling RB, 1998, EUR RESPIR J, V11, P86, DOI 10.1183/09031936.98.11010086; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; ERNST P, 1992, JAMA-J AM MED ASSOC, V268, P3462, DOI 10.1001/jama.268.24.3462; Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002; FAURSCHOU P, 1994, ALLERGY, V49, P827, DOI 10.1111/j.1398-9995.1994.tb00782.x; Galant SP, 1996, ANN ALLERG ASTHMA IM, V77, P112, DOI 10.1016/S1081-1206(10)63496-5; Galant SP, 1999, ANN ALLERG ASTHMA IM, V82, P273, DOI 10.1016/S1081-1206(10)62608-7; GARDINER PV, 1994, AM J RESP CRIT CARE, V150, P1006, DOI 10.1164/ajrccm.150.4.7921429; Gerdtham UG, 1996, MED CARE, V34, P1188, DOI 10.1097/00005650-199612000-00004; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Gross GN, 1998, AM J MANAG CARE, V4, P233; Guhan AR, 2000, THORAX, V55, P650, DOI 10.1136/thorax.55.8.650; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; Kalra S, 1996, CHEST, V109, P953, DOI 10.1378/chest.109.4.953; Kamada Alan K., 1997, Current Opinion in Pediatrics, V9, P585, DOI 10.1097/00008480-199712000-00007; Kavuru M, 2000, J ALLERGY CLIN IMMUN, V105, P1108, DOI 10.1067/mai.2000.105711; Kelloway JS, 2000, ANN ALLERG ASTHMA IM, V84, P324, DOI 10.1016/S1081-1206(10)62781-0; Kelsen SG, 1999, J ASTHMA, V36, P703, DOI 10.3109/02770909909055422; Kemp JP, 1999, J ALLERGY CLIN IMMUN, V104, P1189, DOI 10.1016/S0091-6749(99)70012-6; Kips JC, 2000, AM J RESP CRIT CARE, V161, P996, DOI 10.1164/ajrccm.161.3.9812056; Kraft M, 1997, CHEST, V111, P1249, DOI 10.1378/chest.111.5.1249; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; Lanes SF, 1998, AM J RESP CRIT CARE, V158, P857, DOI 10.1164/ajrccm.158.3.9803047; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Li JTC, 1999, J ALLERGY CLIN IMMUN, V103, P1062, DOI 10.1016/S0091-6749(99)70180-6; LOTVALL J, 1992, ALLERGY, V47, P477, DOI 10.1111/j.1398-9995.1992.tb00668.x; LUNDBACK B, 1993, THORAX, V48, P148, DOI 10.1136/thx.48.2.148; MAK JCW, 1995, J CLIN INVEST, V96, P99, DOI 10.1172/JCI118084; MAK JCW, 1995, AM J PHYSIOL-LUNG C, V268, pL41, DOI 10.1152/ajplung.1995.268.1.L41; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Mann RD, 1996, J CLIN EPIDEMIOL, V49, P247, DOI 10.1016/0895-4356(95)00555-2; Matz J, 2000, J ALLERGY CLIN IMMUN, V105, pS162, DOI 10.1016/S0091-6749(00)90923-0; McIvor RA, 1998, AM J RESP CRIT CARE, V158, P924; Meier CR, 1997, THORAX, V52, P612, DOI 10.1136/thx.52.7.612; Moore RH, 1998, CHEST, V113, P1095, DOI 10.1378/chest.113.4.1095; Murray JJ, 1999, ALLERGY ASTHMA PROC, V20, P173, DOI 10.2500/108854199778553028; *NAT ASTHM ED PREV, 1997, NIH PUBL; Nayak AS, 1998, J ALLERGY CLIN IMMUN, V101, pS233; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V106, P1088, DOI 10.1067/mai.2000.110920; Nelson HS, 1999, AM J RESP CRIT CARE, V159, P1556, DOI 10.1164/ajrccm.159.5.9807128; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V103, P267, DOI 10.1016/S0091-6749(99)70501-4; NIALS AT, 1994, EUR J PHARMACOL, V251, P127, DOI 10.1016/0014-2999(94)90392-1; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467, DOI 10.1164/ajrccm.152.5.7582278; Oddera S, 1998, RESPIRATION, V65, P199, DOI 10.1159/000029260; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; Overbeek SE, 1996, CHEST, V110, P35, DOI 10.1378/chest.110.1.35; Pang LH, 2000, AM J RESP CELL MOL, V23, P79, DOI 10.1165/ajrcmb.23.1.3985; PANG LH, 1999, RESP MED S3, V54, pA6; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pauwels RA, 1998, AM J RESP CRIT CARE, V157, P827, DOI 10.1164/ajrccm.157.3.9610009; Pearlman DS, 1999, ANN ALLERG ASTHMA IM, V82, P257, DOI 10.1016/S1081-1206(10)62606-3; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; Price JF, 1997, PEDIATR PULM, V24, P178; Proud D, 1998, CLIN EXP ALLERGY, V28, P868; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; Rao R, 1999, EUR RESPIR J, V13, P87; Raphael GD, 1999, J ALLERGY CLIN IMMUN, V103, P796, DOI 10.1016/S0091-6749(99)70422-7; Redington AE, 1998, INT J CLIN PRACT, V52, P482; Reed CE, 1998, J ALLERGY CLIN IMMUN, V101, P14, DOI 10.1016/S0091-6749(98)70187-3; Rosenthal RR, 1999, CHEST, V116, P595, DOI 10.1378/chest.116.3.595; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Shapiro G, 2000, AM J RESP CRIT CARE, V161, P527, DOI 10.1164/ajrccm.161.2.9905091; Sheffer AL, 1996, J FAM PRACTICE, V42, P369; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Simons FER, 1997, PEDIATRICS, V99, P655, DOI 10.1542/peds.99.5.655; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Sorkness CA, 1998, J ALLERGY CLIN IMMUN, V102, pS52, DOI 10.1016/S0091-6749(98)70005-3; Spilker B, 1991, PATIENT COMPLIANCE M, P3; SUECHU M, 1999, EUR RESPIR J, V14, pS124; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Szefler SJ, 1999, J ALLERGY CLIN IMMUN, V103, P780, DOI 10.1016/S0091-6749(99)70420-3; Tattersfield AE, 1999, AM J RESP CRIT CARE, V160, P594, DOI 10.1164/ajrccm.160.2.9811100; Taylor DR, 1998, THORAX, V53, P744, DOI 10.1136/thx.53.9.744; Ukena D, 1997, EUR RESPIR J, V10, P2754, DOI 10.1183/09031936.97.10122754; Van den Berg NJ, 2000, PEDIATR PULM, V30, P97, DOI 10.1002/1099-0496(200008)30:2<97::AID-PPUL4>3.0.CO;2-P; van Noord JA, 1999, THORAX, V54, P207, DOI 10.1136/thx.54.3.207; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040; Wallin A, 1999, AM J RESP CRIT CARE, V159, P79, DOI 10.1164/ajrccm.159.1.9801007; Weersink EJM, 1997, AM J RESP CRIT CARE, V155, P1241, DOI 10.1164/ajrccm.155.4.9105061; Wennergren G, 1996, J ALLERGY CLIN IMMUN, V97, P742, DOI 10.1016/S0091-6749(96)80150-3; Wilding P, 1997, BRIT MED J, V314, P1441, DOI 10.1136/bmj.314.7092.1441; Wolfe JD, 1996, CLIN THER, V18, P635, DOI 10.1016/S0149-2918(96)80214-1; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; Yates DH, 1997, AM J RESP CRIT CARE, V156, P988, DOI 10.1164/ajrccm.156.3.9610051	120	60	62	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					397	416		10.1067/mai.2001.112939	http://dx.doi.org/10.1067/mai.2001.112939			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174215	Bronze			2022-12-18	WOS:000167071400034
J	Leach, C				Leach, C			Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						beclomethasone; lung deposition	ASTHMA	Chlorofluorocarbon metered dose inhalers (MDIs) and dry ponder inhalers currently deliver drug that deposits primarily in the oropharynx and secondarily in the large central airways. Chlorofluorocarbon-beclomethasone dipropionate (CFC-BDP) MDIs deliver more than 90% of the drug in the oropharynx and less than 10% in the lungs. The elimination of chlorofluorocarbons from MDIs provided the opportunity to more optimally target corticosteroids directly to all inflammatory sites, Hydrofluoroalkane-BDP (HFA-BDP) MDIs (QVAR(TM)) deliver 50% to 60% of the drug to the lungs with approximately 30% delivered to the mouth. Additionally, the amount of drug delivered to the Lungs is distributed throughout the large, intermediate, and small airways. Radiolabeled deposition studies have shown that the HFA-BDP MDI is a "forgiving" aerosol in that even the extreme discoordinated use of the press and breathe MDI still resulted in more than 30% lung deposition The breath-actuated Autohaler inhaler provided the same lung deposition as an optimally used press and breathe MDI. The dose delivered from either the press and breathe HFA-BDP MDI or the Autohaler was consistent across a wide range of inspiratory flows (eg, flows of 26-137 L/min), Clinical studies have shown that the improvements in lung deposition of HFA-BDP result in equivalent efficacy at approximately one half of the total daily dose compared with current CFC-BDP products.	3M Pharmaceut, 3M Ctr, St Paul, MN 55144 USA	3M	Leach, C (corresponding author), 3M Pharmaceut, 3M Ctr, Bldg 270-3S-05, St Paul, MN 55144 USA.							BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Leach CL, 1998, EUR RESPIR J, V12, P1346, DOI 10.1183/09031936.98.12061346; LEACH CL, 1995, BR J CLIN PRACT S, V79, P10; LEACH CL, 1996, RESP DRUG DEL 5 P, P133; United Nations Environmental Programme (Ozone Secretariat), 1996, HDB INT TREAT PROT O; 1997, FED REG         0306, V62, P10242; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	8	60	64	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					S250	S252		10.1016/S0091-6749(99)70041-2	http://dx.doi.org/10.1016/S0091-6749(99)70041-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10588985				2022-12-18	WOS:000084289200041
J	Jahn-Schmid, B; Wiedermann, U; Bohle, BA; Repa, A; Kraft, D; Ebner, C				Jahn-Schmid, B; Wiedermann, U; Bohle, BA; Repa, A; Kraft, D; Ebner, C			Oligodeoxynucleotides containing CpG motifs modulate the allergic T-H2 response of BALB/c mice to Bet v 1, the major birch pollen allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CpG oligodeoxynucleotides; immunomodulation; type I allergy; T-H1/T-H2; Bet v 1; BALB/c mice	T-CELL RESPONSES; BACTERIAL-DNA; IMMUNE-RESPONSE; IMMUNOSTIMULATORY DNA; CUTTING EDGE; B-CELL; AIRWAY HYPERRESPONSIVENESS; INTERFERON-GAMMA; IMMUNOGLOBULIN-E; POTENTIAL USE	Background: The use of adequate adjuvants to modulate the allergic T-H2-type immune response is a promising concept for future immunotherapy of type I allergy Bacterial DNA or oligodeoxynucleotides containing CpG motifs (CpG-ODNs) have been demonstrated to foster T-H1-type immune responses, Objective: We investigated the adjuvanticity of CpG-ODNs and their capability to modulate the allergic T-H2 response in a mouse model, Methods: BALB/c mice were treated with CpG-ODNs and Bet v 1, the major birch pollen allergen, in different experimental setups, Allergen-specific antibody responses, T-H cytokines, and eosinophilic infiltration of the airways were investigated, Results: Intraperitoneal administration of Bet v 1 together with aluminium hydroxide led to a typical T-H2 response, In contrast, coadminstration of CpG-ODNs with Bet v 1 in aluminium hydroxide resulted in markedly increased T-H1 activities (high IgG2a levels) and subsequently to reduced airway inflammation, The T-H1-like immune response indicated by these humoral findings was also reflected by decreased IL-5 and increased IFN-gamma levels in cell cultures. CpG-ODNs as sole adjuvants with Bet v 1 did not lead to measureable Ig responses after subcutaneous or intraperitoneal immunizations; after intranasal application, 3 of 10 mice reacted. Nevertheless, a prophylactic effect was obtained with all routes tested; that is, mice treated subsequently with an established aerosol sensitization protocol display ed altered immune responses characterized by drastically elevated levels of Bet v 1-specific IgG2a, indicating a T-H1/T-H0-like immunity, Application of CpG-ODNs after aerosol sensitization also induced IgG2a, Conclusion: By inducing T-H1/T-H0-biased immune responses to allergens, the use of CpG-ODNs as adjuvants may have important impacts for new forms of specific immunotherapy in type I hypersensitivity.	Univ Vienna, Inst Gen & Expt Pathol, Div Immunopathol, A-1090 Vienna, Austria; Univ Agr Sci, Ludwig Boltzmann Inst Mol Nanotechnol, Vienna, Austria; Univ Agr Sci, Ctr Ultrastruct Res, Vienna, Austria	University of Vienna; Ludwig Boltzmann Institute; University of Natural Resources & Life Sciences, Vienna; University of Natural Resources & Life Sciences, Vienna	Ebner, C (corresponding author), Univ Vienna, Inst Gen & Expt Pathol, Div Immunopathol, AKH-EBO 3Q,Wahringer Gurtel 18-20, A-1090 Vienna, Austria.			Wiedermann, Ursula/0000-0002-1302-3223; Bohle, Barbara/0000-0002-5105-7985				ANDRI L, 1995, CLIN EXP ALLERGY, V25, P1092, DOI 10.1111/j.1365-2222.1995.tb03256.x; Ballas ZK, 1996, J IMMUNOL, V157, P1840; Bauer L, 1997, CLIN EXP IMMUNOL, V107, P536, DOI 10.1046/j.1365-2249.1997.d01-953.x; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bohle B, 1999, EUR J IMMUNOL, V29, P2344, DOI 10.1002/(SICI)1521-4141(199907)29:07<2344::AID-IMMU2344>3.0.CO;2-R; BOUSQUET J, 1998, ALLERGY, V53, P6; Broide D, 1998, J IMMUNOL, V161, P7054; Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623; Davis HL, 1998, J IMMUNOL, V160, P870; Ebner C, 1998, CLIN EXP ALLERGY, V28, P781; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; Hartl A, 1999, J ALLERGY CLIN IMMUN, V103, P107, DOI 10.1016/S0091-6749(99)70533-6; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; ISHIZAKA K, 1984, ANNU REV IMMUNOL, V2, P159, DOI 10.1146/annurev.immunol.2.1.159; Jahn-Schmid B, 1997, INT IMMUNOL, V9, P1867, DOI 10.1093/intimm/9.12.1867; Kline JN, 1998, J IMMUNOL, V160, P2555; Klinman DM, 1998, ANTISENSE NUCLEIC A, V8, P181, DOI 10.1089/oli.1.1998.8.181; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 1998, J IMMUNOL, V161, P2428; Lipford GB, 1997, EUR J IMMUNOL, V27, P3420, DOI 10.1002/eji.1830271242; Lipford GB, 1997, EUR J IMMUNOL, V27, P2340, DOI 10.1002/eji.1830270931; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; McCluskie MJ, 1998, J IMMUNOL, V161, P4463; Moldoveanu Z, 1998, VACCINE, V16, P1216, DOI 10.1016/S0264-410X(98)80122-9; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; ROMAGNANI S, 1994, CURR OPIN IMMUNOL, V6, P838, DOI 10.1016/0952-7915(94)90002-7; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; Sacks T, 1997, CELL IMMUNOL, V177, P162, DOI 10.1006/cimm.1997.1114; Schwartz DA, 1997, J CLIN INVEST, V100, P68, DOI 10.1172/JCI119523; Segal BM, 1997, J IMMUNOL, V158, P5087; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; Sun SQ, 1998, J EXP MED, V187, P1145, DOI 10.1084/jem.187.7.1145; TAYLOR B, 1982, CLIN ALLERGY, V12, P499, DOI 10.1111/j.1365-2222.1982.tb01648.x; WALKER RI, 1994, VACCINE, V12, P387, DOI 10.1016/0264-410X(94)90112-0; Weiner GJ, 1997, P NATL ACAD SCI USA, V94, P10833, DOI 10.1073/pnas.94.20.10833; Wiedermann U, 1998, CLIN EXP IMMUNOL, V111, P144; Wiedermann U, 1999, INT IMMUNOL, V11, P1131, DOI 10.1093/intimm/11.7.1131; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149, DOI 10.1159/000236836; Yi AK, 1998, J IMMUNOL, V161, P4493; Yi AK, 1996, J IMMUNOL, V156, P558; Zimmermann S, 1998, J IMMUNOL, V160, P3627	48	60	70	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					1015	1023		10.1016/S0091-6749(99)70083-7	http://dx.doi.org/10.1016/S0091-6749(99)70083-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550747				2022-12-18	WOS:000083778400025
J	Arlian, LG; Neal, JS; Vyszenski-Moher, DL				Arlian, LG; Neal, JS; Vyszenski-Moher, DL			Reducing relative humidity to control the house dust mite Dermatophagoides farinae	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dust mites; relative humidity; Dermatophagoides farinae; control; population	PTERONYSSINUS ACARI; PYROGLYPHIDAE; POPULATION; PREVALENCE; FECUNDITY; HOMES	Background: Indoor relative humidity (RH) is the key factor that determines the survival and population development of the house dust mite Dermatophagoides farinae. Maintaining RH below 50% is one recommendation in a comprehensive plan to reduce house dust mites and mite allergen levels in homes, Even when mean daily RH is reduced below 50%, RH may rise above 50% intermittently for brief periods because of activities in the home (eg, cooking, bathing, and ventilation). Objective: The purpose of this study was to determine how brief daily periods of moist air alternating with long spells of low ambient RH (0% of 35%) influence population survival and gros th of D farinae. Methods: Population growth was determined for D farinae at daily RH regimens of 2, 4, 6, and 8 hours at 75% or 85% RH alternating with 22, 20, 18, and 16 hours at 0% or 35% RH. Results: D farinae populations declined at daily regimens of 2 hours at 75% or 85% RH alternating with 22 hours at 0% or 35% RH, Daily regimens of 4, 6, and 8 hours at 75% RH alternating with 20, 18, and 16 hours, respectively, at 35% RH provided sufficient moisture for small growths in population size. These growths after 10 weeks were reduced by 98.2%, 98.0%, and 97.3% for daily regimens of 4, 6, and 8 hours, respectively, at 75% RH (with the remainder of the day at 35% RH) compared with the growth of populations continuously exposed to 75% RH. Continuous exposure to 85% RH inhibited population growth, but alternating daily regimens of 16, 18, and 20 hours at 35% RH allowed small populations to develop, although they were reduced by 99.4%, 98.8%, and 99.1% compared with population growth at a continuous 75% RH. Conclusion: This study indicates that maintaining mean daily RH below 50%, even when RH rises above 50% for 2 to 8 hours daily, effectively restricts population growth of these mites and thus the production of allergen. To completely prevent population growth of D farinae, RH must be maintained below 35% for at least 22 hours per day when the daily RH is 75% or 85% for the remainder of the day.	Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA	University System of Ohio; Wright State University Dayton	Arlian, LG (corresponding author), Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA.							ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; Arlian LG, 1998, J MED ENTOMOL, V35, P46, DOI 10.1093/jmedent/35.1.46; ARLIAN LG, 1981, J MED ENTOMOL, V18, P351, DOI 10.1093/jmedent/18.4.351; ARLIAN LG, 1990, J MED ENTOMOL, V27, P1035, DOI 10.1093/jmedent/27.6.1035; ARLIAN LG, 1981, PHYSIOL ZOOL, V54, P393, DOI 10.1086/physzool.54.4.30155831; ARLIAN LG, 1983, J MED ENTOMOL, V20, P99, DOI 10.1093/jmedent/20.1.99; Arlian LG, 1999, J MED ENTOMOL, V36, P457, DOI 10.1093/jmedent/36.4.457; Arlian LG, 1998, J MED ENTOMOL, V35, P962, DOI 10.1093/jmedent/35.6.962; Arlian LG, 1996, J MED ENTOMOL, V33, P257, DOI 10.1093/jmedent/33.2.257; BRONSWIJK JEM, 1971, RES POPUL ECOL, V13, P67; De Boer R, 1998, J MED ENTOMOL, V35, P905, DOI 10.1093/jmedent/35.6.905; deBoer R, 1997, ALLERGY, V52, P299; Matsumoto K., 1986, Japanese Journal of Sanitary Zoology, V37, P79; MURRAY AB, 1979, J ALLERGY CLIN IMMUN, V64, P266, DOI 10.1016/0091-6749(79)90142-8; Sakaki I., 1991, Japanese Journal of Sanitary Zoology, V42, P93; SPIEKSMA FM, 1967, ACAROLOGIA, V1, P226; Suto C., 1990, Japanese Journal of Sanitary Zoology, V41, P375; [No title captured]; 1997, 974051 NAT I HLTH PU	20	60	63	1	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				852	856		10.1016/S0091-6749(99)70298-8	http://dx.doi.org/10.1016/S0091-6749(99)70298-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518832				2022-12-18	WOS:000083281200019
J	Nathan, RA; Bernstein, JA; Bielory, L; Bonuccelli, CM; Calhoun, WJ; Galant, SP; Hanby, LA; Kemp, JP; Kylstra, JW; Nayak, AS; O'Connor, JP; Schwartz, HJ; Southern, DL; Spector, SL; Williams, PV				Nathan, RA; Bernstein, JA; Bielory, L; Bonuccelli, CM; Calhoun, WJ; Galant, SP; Hanby, LA; Kemp, JP; Kylstra, JW; Nayak, AS; O'Connor, JP; Schwartz, HJ; Southern, DL; Spector, SL; Williams, PV		ACCOLATE Trialists Grp	Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							OF-LIFE; CLINICAL-TRIALS; 5-LIPOXYGENASE INHIBITOR; RECEPTOR ANTAGONIST; ALLERGIC RHINITIS; LEUKOTRIENE; ICI-204,219; QUESTIONNAIRE	Background: Previous trials demonstrated the effectiveness of the leukotriene receptor antagonist zafirlukast in patients with mild-to-moderate asthma. Objectives: We sought to assess the efficacy and safety of zafirlukast and its effect on patients' quality of life (QOL) during a 13-week, double-blind, placebo-controlled, multicenter trial in adults and adolescents with moderate reversible airflow obstruction. Methods: Patients (age range, 12 to 68 years) with total daytime asthma symptoms scores of 10 or greater over 7 consecutive days (maximum, 21/wk), FEV1 45% or greater but less than or equal to 80% of predicted value (greater than or equal to 6 hours after beta(2)-agonist), and reversible airway disease were randomized to 20 mg zafirlukast twice daily (n(Z) = 231) or placebo twice daily (n(P) = 223). Efficacy was assessed from changes in daytime and nocturnal symptoms, beta(2)-agonist use, nasal congestion score, and pulmonary function. QOL was evaluated with a disease-specific Asthma Quality of Life Questionnaire. Safety was determined from adverse event information and clinical laboratory test results. Results: Zafirlukast was significantly (P < .001) more effective than placebo, with reductions from baseline in the daytime asthma symptoms score (-23%), nighttime awakenings with asthma (-19%), and beta(2)-agonist use (-24%) and improvements from baseline in morning (+25 L/min) and evening (+18 L/min) peak expiratory flow rates. Compared with placebo, zafirlukast significantly (P less than or equal to .018) improved scores for QOL domains (activity limitations, symptoms, emotional function, and exposure to environmental stimuli) and overall QOL, with a significantly greater proportion of zafirlukast-treated patients demonstrating clinically meaningful improvements (greater than or equal to 0.5-unit change from baseline; P less than or equal to .037). The safety profile of zafirlukast was clinically indistinguishable from that of placebo. Conclusions: Zafirlukast is effective and well tolerated and improves QOL in the long-term treatment of patients with moderate reversible airflow obstruction.	Asthma & Allergy Associates PC, Colorado Springs, CO 80907 USA; Bernstein Clin Res Ctr, Cincinnati, OH USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; Zeneca Pharmaceut, Wilmington, DE USA; Univ Pittsburgh, Pittsburgh, PA USA; Asthma & Allergy Res Ctr, Orange, CA USA; Allergy & Asthma Med Grp & Res Ctr PC, San Diego, CA USA; Asthma & Allergy Res Associates PA, Normal, IL USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Princeton Allergy & Asthma Associates PA, Princeton, NJ USA; Allergy Res Fdn Inc, Los Angeles, CA USA; NW Asthma & Allergy Ctr, Mt Vernon, IA USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Jefferson University; University Hospitals of Cleveland	Nathan, RA (corresponding author), Asthma & Allergy Associates PC, 2709 N Tejon, Colorado Springs, CO 80907 USA.			Calhoun, William/0000-0001-7075-712X; Bernstein, Jonathan/0000-0002-3476-1196; Williams, Paul/0000-0003-3300-1328				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; BROWN HK, 1994, STAT MED, V13, P1601, DOI 10.1002/sim.4780131602; DONNELLY AL, 1995, AM J RESP CRIT CARE, V151, P1734, DOI 10.1164/ajrccm.151.6.7767514; Fish JE, 1997, CLIN THER, V19, P675, DOI 10.1016/S0149-2918(97)80092-6; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; HENDERSON WR, 1994, ANN ALLERGY, V72, P272; Israel E, 1996, JAMA-J AM MED ASSOC, V275, P931, DOI 10.1001/jama.275.12.931; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V102, P16, DOI 10.1016/S0091-6749(98)70048-X; JUNIPER EF, 1995, AM J RESP CRIT CARE, V151, P66, DOI 10.1164/ajrccm.151.1.7812574; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; LYDICK E, 1993, QUAL LIFE RES, V2, P221, DOI 10.1007/BF00435226; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; Munoz NM, 1997, AM J RESP CRIT CARE, V155, P1398, DOI 10.1164/ajrccm.155.4.9105085; *NAT ASTHM ED PREV, 1997, NIH PUBL; OKUDA M, 1988, ANN ALLERGY, V60, P537; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; SMITH LJ, 1993, CLIN PHARMACOL THER, V54, P430, DOI 10.1038/clpt.1993.170; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; ULRIK CS, 1995, CLIN EXP ALLERGY, V25, P820, DOI 10.1111/j.1365-2222.1995.tb00024.x; Underwood DC, 1996, AM J RESP CRIT CARE, V154, P850, DOI 10.1164/ajrccm.154.4.8887574	22	60	62	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				935	942		10.1016/S0091-6749(98)70331-8	http://dx.doi.org/10.1016/S0091-6749(98)70331-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847434				2022-12-18	WOS:000077690700011
J	Lummus, ZL; Alam, R; Bernstein, JA; Bernstein, DI				Lummus, ZL; Alam, R; Bernstein, JA; Bernstein, DI			Diisocyanate antigen-enhanced production of monocyte chemoattractant protein-1, IL-8, and tumor necrosis factor-alpha by peripheral mononuclear cells of workers with occupational asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chemokines; occupational asthma; diisocyanate; monocyte chemoattractant protein-1; TNF-alpha	HISTAMINE-RELEASING FACTORS; TOLUENE DIISOCYANATE; AIRWAY INFLAMMATION; BRONCHIAL-MUCOSA; CHEMOKINES; BLOOD; EOSINOPHILS; RECRUITMENT; EXPRESSION; MIGRATION	Background: Previous studies have shown a significant association between confirmed diisocyanate-induced asthma (DOA) and in vitro production of diisocyanate antigen-stimulated histamine-releasing factors by PBMCs. Chemokines found in PBMC supernatants are known to express histamine-releasing factor activity. Objective: PBMCs of diisocyanate-exposed workers were tested in vitro for diisocyanate antigen-specific enhancement of monocyte chemoattractant protein-1 (MCP-1), monocyte chemoattractant protein-3 (MCP-3), macrophage inflammatory protein-1 alpha, RANTES, IL-8, and T-cell cytokines that could play a regulatory role in chemokine synthesis (IL-4, IL-5, IFN-gamma, and TNF-alpha). Methods: Secretion of chemokines and cytokines was determined by quantitative immunochemical assays of PBMC supernatants. Synthesis of mRNA for beta-chemokines was determined by reverse transcription-polymerase chain reaction. Results: PBMCs of workers with DOA showed significantly enhanced secretion for MCP-1 compared with diisocyanate-exposed asymptomatic workers (P <.05). In vitro induction of antigen-stimulated MCP-1 mRNA synthesis in cultured PBMCs was demonstrated by reverse-transcription polymerase chain reaction. Quantitation of cytokines in supernatants showed increased mean production of IL-8 and TNF-alpha. IFN-gamma, IL-4, and IL-5 were not enhanced in subjects with DOA. Conclusion: Antigen stimulation of MCP-1 and TNF-alpha suggest that diisocyanate-specific cellular immune reactions result in activation of macrophages, which may be important in the pathogenesis of DOA.	Univ Cincinnati, Coll Med, Dept Internal Med, Div Immunol, Cincinnati, OH 45267 USA; Univ Texas, Med Branch, Dept Internal Med, Div Allergy, Galveston, TX 77550 USA	University System of Ohio; University of Cincinnati; University of Texas System; University of Texas Medical Branch Galveston	Lummus, ZL (corresponding author), Univ Cincinnati, Coll Med, Dept Internal Med, Div Immunol, 231 Bethesda Ave, Cincinnati, OH 45267 USA.			Bernstein, Jonathan/0000-0002-3476-1196				Alam R, 1997, J ALLERGY CLIN IMMUN, V99, P273, DOI 10.1016/S0091-6749(97)70042-3; Alam R, 1996, AM J RESP CRIT CARE, V153, P1398, DOI 10.1164/ajrccm.153.4.8616572; AVERY SB, 1969, CLIN EXP IMMUNOL, V4, P585; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; BERNSTEIN DI, 1993, ALLERGY PRINCIPLES P, P1369; Bernstein JA, 1997, J ALLERGY CLIN IMMUN, V99, P245, DOI 10.1016/S0091-6749(97)70104-0; Cai JP, 1996, CELL IMMUNOL, V167, P269, DOI 10.1006/cimm.1996.0035; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; EBISAWA M, 1994, J IMMUNOL, V153, P2153; FINOTTO S, 1991, BRIT J IND MED, V48, P116; GALLAGHER JS, 1981, J OCCUP ENVIRON MED, V23, P610, DOI 10.1097/00043764-198109000-00009; GRUSS HJ, 1994, J IMMUNOL, V153, P4907; HERD ZL, 1994, AM J RESP CRIT CARE, V150, P988, DOI 10.1164/ajrccm.150.4.7522854; Hornbeck P, 1991, CURRENT PROTOCOLS IM; Karpus WJ, 1997, J IMMUNOL, V158, P4129; KIPS JC, 1992, AM REV RESPIR DIS, V145, P332, DOI 10.1164/ajrccm/145.2_Pt_1.332; LUKACS NW, 1995, EUR J IMMUNOL, V25, P245, DOI 10.1002/eji.1830250140; Lukacs NW, 1997, J IMMUNOL, V158, P4398; LUKACS NW, 1995, J IMMUNOL, V154, P5411; Lummus ZL, 1996, TOXICOLOGY, V111, P191, DOI 10.1016/0300-483X(96)03376-8; MAESTRELLI P, 1994, SCAND J WORK ENV HEA, V20, P376, DOI 10.5271/sjweh.1383; Marsh CB, 1997, J IMMUNOL, V158, P1078; MING WJ, 1987, J IMMUNOL, V138, P1469; MOIRA CY, 1986, AM REV RESPIR DIS, V133, P686; MOLLER DR, 1986, CHEST, V90, P494, DOI 10.1378/chest.90.4.494; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SAETTA M, 1992, AM REV RESPIR DIS, V145, P169, DOI 10.1164/ajrccm/145.1.169; SIRACUSA A, 1992, AM REV RESPIR DIS, V146, P408, DOI 10.1164/ajrccm/146.2.408; Taub DD, 1996, J IMMUNOL, V156, P2095; WHEELER AP, 1990, J APPL PHYSIOL, V68, P2542, DOI 10.1152/jappl.1990.68.6.2542; YOSHIMURA T, 1989, J IMMUNOL, V142, P1956; ZAMMITTABONA M, 1983, AM REV RESPIR DIS, V128, P226	35	60	63	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					265	274		10.1016/S0091-6749(98)70095-8	http://dx.doi.org/10.1016/S0091-6749(98)70095-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723671	Bronze			2022-12-18	WOS:000075537100020
J	Aziz, I; Hall, IP; McFarlane, LC; Lipworth, BJ				Aziz, I; Hall, IP; McFarlane, LC; Lipworth, BJ			beta(2)-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						desensitization; beta(2)-adrenoceptor; asthma; formoterol; albuterol	SUBSENSITIVITY; EFORMOTEROL	Objective: We have previously found that beta(2)-adrenoceptor downregulation and bronchodilator desensitization to albuterol occurred at 36 hours after stopping regular treatment with twice daily salmeterol. In this study we have evaluated these same effects with formoterol given once or twice daily on a regular basis. Methods: In a randomized, placebo-controlled, double-blind, double-dummy crossover study, 16 subjects with mild-to-moderate stable asthma (mean [SD] age, 32.5 [15.3] years; mean [SD] FEV1, 73.2 [12.1] percent predicted) receiving regular inhaled corticosteroid therapy received 1 week of treatment with formoterol dry powder (24 mu g twice daily [8 AM/8 PM]), formoterol (24 mu g once daily [8 PM]), or identical placebo. Lymphocyte beta(2)-adrenoceptor parameters and a dose-response curve to inhaled albuterol (200 to 1600 mu g) were evaluated at 36 hours after the last dose of each treatment period. Results: There were no significant differences in the mean values for albuterol dose-response effects among the three treatment regimens. Comparison of maximal bronchodilator responses between treatments (mean and SEM as change from baseline) revealed no significant differences between treatments for FEV1 (0.47 L [0.06 L] for placebo vs 0.48 L [0.07 L] for 24 mu g once daily formoterol vs 0.51 L [0.08 L] for 24 mu g twice daily formoterol) or for forced expiratory flow, mid-expiratory phase (FEF25-75) (0.80 L/sec [0.12 L/sec] for placebo vs 0.80 L/sec [0.16 L/sec] for 24 mu g once daily formoterol vs 0.89 L/sec [0.14 L/sec] for 24 mu g twice daily formoterol). Formoterol also had no significant effect on mean lymphocyte Pz-adrenoceptor density. However, in five of seven patients with the homozygous Gly-16 polymorphism, beta(2)-adrenoceptor density was downregulated by twice daily formoterol, whereas only two such cases exhibited a reduction in maximal FEV, response to albuterol. Conclusions: The results of this study showed that for patients taking inhaled corticosteroids, overall beta(2)-adrenoceptor regulation and associated bronchodilator sensitivity to inhaled albuterol were unaltered at 36 hours after stopping regular treatment with formoterol. However, in a subset of patients who were Gly-16 homozygous, there was a tendency towards downregulation but not desensitization. Further studies in subjects with more severe asthma are required to assess the clinical relevance of these findings.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut & Resp Med, Dundee DD1 9SY, Scotland; Univ Nottingham Hosp, Dept Med, Div Therapeut, Nottingham NG7 2UH, England	University of Dundee; University of Nottingham	Lipworth, BJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut & Resp Med, Dundee DD1 9SY, Scotland.			Hall, Ian/0000-0001-9933-3216				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; Green SA, 1995, PULM PHARMACOL, V8, P1, DOI 10.1006/pulp.1995.1001; GROVE A, 1995, LANCET, V346, P201, DOI 10.1016/S0140-6736(95)91265-7; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; LENFANT C, 1995, NATL I HLTH PUBLICAT; NEWNHAM DM, 1995, THORAX, V50, P497, DOI 10.1136/thx.50.5.497; NEWNHAM DM, 1993, EUR J CLIN PHARMACOL, V45, P535, DOI 10.1007/BF00315310; NEWNHAM DM, 1994, AM J MED, V97, P29, DOI 10.1016/0002-9343(94)90045-0; Tan KS, 1996, BRIT J CLIN PHARMACO, V42, pP654; Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X	11	60	63	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					337	341		10.1016/S0091-6749(98)70245-3	http://dx.doi.org/10.1016/S0091-6749(98)70245-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525449				2022-12-18	WOS:000072593900010
J	Zeiler, T; Taivainen, A; Rytkonen, M; Rautiainen, J; Karjalainen, H; Mantyjarvi, R; Tuomisto, L; Virtanen, T				Zeiler, T; Taivainen, A; Rytkonen, M; Rautiainen, J; Karjalainen, H; Mantyjarvi, R; Tuomisto, L; Virtanen, T			Recombinant allergen fragments as candidate preparations for allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						recombinant allergen; fragment; cow; allergic asthma; immunotherapy	BIRCH POLLEN ALLERGEN; MAJOR BOVINE ALLERGEN; FEL-D-I; T-CELL; ANTIBODY-RESPONSES; ESCHERICHIA-COLI; PURIFICATION; PROTEINS; PEPTIDES; PERFORMANCE	Background: Lately, renewed interest has arisen in the new forms of allergen immunotherapy because they may offer alternatives for drug treatment. Objective: The purpose of this study was to develop a well-characterized preparation of the main respiratory cow dander allergen, Bos d 2, with attenuated allergenic activity. Methods: The immunologic characteristics of Bos d 2 preparations were studied by indirect IgE ELISA, ELISA inhibition, Western blotting, histamine release, skin prick tests, and the proliferation tests of allergen-specific T-cell clones. Results: The complete recombinant Bos d 2 was observed to bind effectively, IgE of cow-allergic patients in indirect ELISA. In other experiments, the IgE-binding capacity of recombinant Bos d 2 proved to be lower compared with native Bos d 2. When the two overlapping recombinant fragments of Bos d 2 (corresponding amino acids 1-131 and 81-172, respectively) covering the whole molecule were compared with the complete recombinant Bos d 2 with several methods, only a low level of residual reactivity was observed. For example, recombinant fragments could not bind antibody at all in ELISA inhibition tests retaining, however, some reactivity in skin prick tests. In contrast, the fragments were able to stimulate vigorously Bos d 2-specific T-cell clones. Conclusion: The approach rye have taken may offer a simple and reproducible way to produce hypoallergenic preparations for immunotherapy, circumventing simultaneously some of the problems of other experimental methods such as individual T-cell epitope recognition in peptide-based immunotherapy.	Univ Kuopio, Dept Clin Microbiol, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, Dept Pulm Dis, FIN-70210 Kuopio, Finland; Univ Kuopio, Dept Pharmacol & Toxicol, FIN-70211 Kuopio, Finland	University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland	Virtanen, T (corresponding author), Univ Kuopio, Dept Clin Microbiol, POB 1627, FIN-70211 Kuopio, Finland.			Rytkonen-Nissinen, Marja/0000-0002-2014-8315				BATANERO E, 1994, MOL IMMUNOL, V31, P31, DOI 10.1016/0161-5890(94)90135-X; BOND JF, 1993, MOL IMMUNOL, V30, P1529, DOI 10.1016/0161-5890(93)90461-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; CROMWELL O, 1986, HDB EXPT IMMUNOLOGY, P1271; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; EBNER C, 1993, EUR J IMMUNOL, V23, P1523, DOI 10.1002/eji.1830230719; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; FRANCESCHI G, 1989, J ANTIMICROB CHEMOTH, V23, P1; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; KING TP, 1995, J IMMUNOL, V154, P577; Liebers V, 1996, CLIN EXP ALLERGY, V26, P494, DOI 10.1111/j.1365-2222.1996.tb00570.x; Mantyjarvi R, 1996, J ALLERGY CLIN IMMUN, V97, P1297, DOI 10.1016/S0091-6749(96)70198-7; MAPP CE, 1994, EUR RESPIR J, V7, P544, DOI 10.1183/09031936.94.07030544; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; OHMAN JL, 1991, CLIN IMMUNOLOGIC RES, P209; Oshiba A, 1996, AM J RESP CRIT CARE, V153, P102, DOI 10.1164/ajrccm.153.1.8542101; ROGERS BL, 1994, MOL IMMUNOL, V31, P955, DOI 10.1016/0161-5890(94)90090-6; ROMAGNANI S, 1994, CURR OPIN IMMUNOL, V6, P838, DOI 10.1016/0952-7915(94)90002-7; Sambrook J, 1989, MOL CLONING LAB MANU, VII; SCHEINER O, 1995, ALLERGY, V50, P384, DOI 10.1111/j.1398-9995.1995.tb01167.x; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; SLUNT JB, 1995, J ALLERGY CLIN IMMUN, V95, P1221, DOI 10.1016/S0091-6749(95)70079-X; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VIRTANEN T, 1995, J ALLERGY CLIN IMMUN, V96, P411, DOI 10.1016/S0091-6749(95)70061-7; Virtanen T, 1996, CLIN EXP ALLERGY, V26, P188, DOI 10.1111/j.1365-2222.1996.tb00079.x; YAMATODANI A, 1985, J CHROMATOGR, V344, P115, DOI 10.1016/S0378-4347(00)82012-5; YLONEN J, 1992, CLIN EXP ALLERGY, V22, P83, DOI 10.1111/j.1365-2222.1992.tb00118.x; YLONEN J, 1994, ALLERGY, V49, P707, DOI 10.1111/j.1398-9995.1994.tb02091.x; YLONEN J, 1992, INT ARCH ALLERGY IMM, V99, P112, DOI 10.1159/000236343; YLONEN J, 1994, J ALLERGY CLIN IMMUN, V93, P851, DOI 10.1016/0091-6749(94)90377-8	32	60	68	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				721	727		10.1016/S0091-6749(97)70264-1	http://dx.doi.org/10.1016/S0091-6749(97)70264-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438477				2022-12-18	WOS:000071353600001
J	Apter, AJ; Affleck, G; Reisine, ST; Tennen, HA; Barrows, E; Wells, M; Willard, A; ZuWallack, RL				Apter, AJ; Affleck, G; Reisine, ST; Tennen, HA; Barrows, E; Wells, M; Willard, A; ZuWallack, RL			Perception of airway obstruction in asthma: Sequential daily analyses of symptoms, peak expiratory flow rate, and mood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; peak expiratory flow rate; symptom; mood; perception	INDIVIDUAL-DIFFERENCES; ADULT ASTHMATICS; DAILY STRESS; PANIC-FEAR; BREATHLESSNESS; SYMPTOMATOLOGY; VARIABILITY; SEVERITY; DYSPNEA	Background and objective: Studies have demonstrated a weak correlation between the degree of airways obstruction and the severity of asthma symptoms. Although the causes for this disparity are probably multiple, mood has been hypothesized to modulate symptoms. This investigation was designed to evaluate the effect of mood and other patient characteristics on the perception of airways obstruction, Methods: We compared mood variables, symptom severity, albuterol use, and peak expiratory Bow rate (PEFR) measured three times daily over a 21-day period in 21 adults with moderate to severe asthma, Electronic equipment was used for data collection. Analyses included both individual patient assessments and a within-subjects, time series, pooled regression of concurrent and time-lag data. Results: After pooling 1323 observations, there was a weak concurrent relationship between symptoms and PEFR (beta = -0.17, p < 0.001), Only five patients (24%) were accurate perceivers, defined by a statistically significant relationship between symptoms and PEFR across time. Higher forced expiratory flow at 25% to 75% of capacity predicted perception accuracy (p = 0.004); active mood was marginally associated with accuracy (p = 0.06). These two variables together explained 41% of the variation in perception accuracy (p = 0.004). Mood did not independently predict symptoms, but conversely, increased symptoms predicted less pleasant mood (beta = 0.08, p < 0.001), less active mood (beta = -0.11, p < 0.001), and less active-pleasant mood (beta = -0.06, p < 0.001). PEFR did not predict mood, and only pleasant mood independently predicted higher PEFR (beta = 0.04, p < 0.05). Symptoms, but not PEFR, were concurrently associated with albuterol use (beta = 0.23, p < 0.001). Conclusion: The relationship between changes in PEPR and symptoms over time was generally poor, Those patients with lower FEF25.75 values tended to be less accurate perceivers. Mood states were influenced by asthma symptoms, but the converse was not true.	UNIV CONNECTICUT,CTR HLTH,DEPT COMMUNITY MED & HLTH CARE,FARMINGTON,CT 06030; UNIV CONNECTICUT,CTR HLTH,GEN CLIN RES CTR,FARMINGTON,CT 06030; UNIV CONNECTICUT,CTR HLTH,DEPT BEHAV SCI & COMMUNITY HLTH,FARMINGTON,CT 06030; ST FRANCIS HOSP & MED CTR,DEPT MED,HARTFORD,CT 06105	University of Connecticut; University of Connecticut; University of Connecticut; Saint Francis Hospital & Medical Center	Apter, AJ (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT MED,FARMINGTON,CT 06030, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR006192] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR06192] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AFFLECK G, 1994, J PERS SOC PSYCHOL, V66, P329, DOI 10.1037/0022-3514.66.2.329; AFFLECK G, 1992, J CONSULT CLIN PSYCH, V60, P119, DOI 10.1037/0022-006X.60.1.119; AFFLECK G, IN PRESS ANN BEHAV M; *AM THOR SOC, 1987, AM REV RESPIR DIS, V130, P1296; APTER AJ, 1994, J ALLERGY CLIN IMMUN, V94, P732, DOI 10.1016/0091-6749(94)90181-3; Atherton HA, 1996, EUR RESPIR J, V9, P232, DOI 10.1183/09031936.96.09020232; BOULET LP, 1994, THORAX, V49, P965, DOI 10.1136/thx.49.10.965; Brantley Phillip J., 1993, Annals of Behavioral Medicine, V15, P17; BURDON JGW, 1982, AM REV RESPIR DIS, V126, P825; BURKI NK, 1978, AM REV RESPIR DIS, V117, P71; DALES RE, 1989, AM REV RESPIR DIS, V139, P1459, DOI 10.1164/ajrccm/139.6.1459; DIRKS JF, 1978, PSYCHOSOM MED, V40, P5, DOI 10.1097/00006842-197802000-00003; DIRKS JF, 1977, PSYCHOSOM MED, V39, P120, DOI 10.1097/00006842-197703000-00006; HYLAND ME, 1993, BRIT MED J, V306, P487, DOI 10.1136/bmj.306.6876.487; HYLAND ME, 1990, BRIT J MED PSYCHOL, V63, P379, DOI 10.1111/j.2044-8341.1990.tb01633.x; HYLAND ME, 1992, BRIT J GEN PRACT, V42, P395; HYLAND ME, 1992, LANCET, V339, P118; Jaccard James, 1993, Annals of Behavioral Medicine, V15, P41; JANSONBJERKLIE S, 1992, HEART LUNG, V21, P265; Johnston J., 1984, ECONOMETRIC METHODS; KENDRICK AH, 1993, BRIT MED J, V307, P422, DOI 10.1136/bmj.307.6901.422; KIKUCHI Y, 1994, NEW ENGL J MED, V330, P1329, DOI 10.1056/NEJM199405123301901; KINSMAN RA, 1973, PSYCHOSOM MED, V35, P250, DOI 10.1097/00006842-197305000-00008; KLEIGER JH, 1980, PSYCHOTHER PSYCHOSOM, V34, P25, DOI 10.1159/000287443; Klein RB, 1995, PEDIATR PULM, V20, P372, DOI 10.1002/ppul.1950200607; LARSEN RJ, 1992, EMOTION; LEHRER PM, 1993, J ASTHMA, V30, P5, DOI 10.3109/02770909309066375; Li JTC, 1996, ANN ALLERG ASTHMA IM, V76, P1, DOI 10.1016/S1081-1206(10)63400-X; MARCO CA, 1993, J PERS SOC PSYCHOL, V64, P1053, DOI 10.1037/0022-3514.64.6.1053; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; PEIFFER C, 1989, CLIN SCI, V77, P237, DOI 10.1042/cs0770237; PENNER LA, 1994, J PERS SOC PSYCHOL, V66, P712, DOI 10.1037/0022-3514.66.4.712; *PHS, 1991, PHS NAT I HLTH PUBL; RUBINFELD AR, 1976, LANCET, V1, P882; Shiffman Saul, 1994, Annals of Behavioral Medicine, V16, P203; STEINER H, 1987, PSYCHOSOM MED, V49, P35, DOI 10.1097/00006842-198701000-00003; STEPTOE A, 1985, BRIT J MED PSYCHOL, V58, P87, DOI 10.1111/j.2044-8341.1985.tb02619.x; STONE AA, 1995, MESURING STRESS GUID, P149; Stone Arthur A., 1994, Annals of Behavioral Medicine, V16, P228; SULS J, 1994, HEALTH PSYCHOL, V13, P103, DOI 10.1037/0278-6133.13.2.103; TOTTERDELL P, 1992, BEHAV RES METH INSTR, V24, P545, DOI 10.3758/BF03203603; TOTTERDELL P, 1993, SLEEP, V17, P466	42	60	62	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1997	99	5					605	612		10.1016/S0091-6749(97)70020-4	http://dx.doi.org/10.1016/S0091-6749(97)70020-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	WY600	9155825	Bronze			2022-12-18	WOS:A1997WY60000006
J	WUTHRICH, B; JOHANSSON, SGO				WUTHRICH, B; JOHANSSON, SGO			ALLERGY TO CHEESE PRODUCED FROM SHEEPS AND GOATS MILK BUT NOT TO CHEESE PRODUCED FROM COWS MILK	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									KAROLINSKA HOSP,DEPT CLIN IMMUNOL,S-10401 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital	WUTHRICH, B (corresponding author), UNIV ZURICH HOSP,DEPT DERMATOL,ALLERGY UNIT,GLORIASTR 31,CH-8091 ZURICH,SWITZERLAND.							JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; JOST R, 1988, FOOD ALLERGY, V17, P199; KALVERAM CM, 1991, 14 INT C ALL CLIN IM; LORENZ F, 1988, NESTLE NUTRITION WOR, V17, P215; SAVLIATHI E, 1981, ALLERGY, V36, P73; STOGER P, 1993, INT ARCH ALLERGY IMM, V102, P399, DOI 10.1159/000236589	6	60	62	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					270	273		10.1016/S0091-6749(95)70021-8	http://dx.doi.org/10.1016/S0091-6749(95)70021-8			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7636068				2022-12-18	WOS:A1995RQ00100021
J	GRESELE, P; DOTTORINI, M; SELLI, ML; IANNACCI, L; CANINO, S; TODISCO, T; ROMANO, S; CROOK, P; PAGE, CP; NENCI, GG				GRESELE, P; DOTTORINI, M; SELLI, ML; IANNACCI, L; CANINO, S; TODISCO, T; ROMANO, S; CROOK, P; PAGE, CP; NENCI, GG			ALTERED PLATELET-FUNCTION ASSOCIATED WITH THE BRONCHIAL HYPERRESPONSIVENESS ACCOMPANYING NOCTURNAL ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PLATELET FUNCTION; BRONCHIAL HYPERRESPONSIVENESS; NOCTURNAL ASTHMA	ACTIVATION; OBSTRUCTION	Background: Nocturnal awakening is a common feature of bronchial asthma, and vet the mechanisms underlying this phenomenon are poorly understood. We investigated whether nocturnal awakening is associated with changes in platelet function with the use of a variety of markers of platelet activation. Methods: Ten patients with a history of nocturnal asthma and 10 age- and sex-matched healthy control subjects were studied at 10:00 PM, 4:00 AM, and 10:00 AM on 2 consecutive days. The following parameters were tested: forced expiratory volume in 1 second (FEV1), log dose of methacholine inducing a 20% fall in FEV1, platelet count and volume, platelet aggregation induced by collagen or activating factor, and plasma and intraplatelet levels of beta-thromboglobulin and platelet factor 4. Results: We have demonstrated that altered platelet function and platelet activation occurs at 4:00 AM in patients with nocturnal asthma and is associated with the maximum increases in bronchial reactivity. Such changes were not observed in 10 control subjects. Platelet dysfunction has been detected as a reduced aggregatory response of platelets to collagen and platelet activating factor such that up to 5 times more platelet activating factor and 1.5 times more collagen were required to elicit a threshold aggregatory response in asthmatic subjects when compared with control subjects; this difference was evident at all time points tested. Furthermore, at 4:00 AM there were significantly lower levels of intraplatelet beta-thromboglobulin corresponding to the maximum reduction in peak expiratory flow and to the maximal increase in bronchial responses to inhaled methacholine. Conclusions: These results suggest that platelet activation accompanies nocturnal asthma and further suggest that platelets may play a role in this common clinical condition.	UNIV LONDON,KINGS COLL,DEPT PHARMACOL,MANRESA RD,LONDON SW3 6LX,ENGLAND; UNIV PERUGIA,MONTELUCE POLICLIN,INT INTERUNIV CTR THROMBOSIS & HAEMOSTASIS,I-06100 PERUGIA,ITALY; UNIV PERUGIA,MONTELUCE POLICLIN,IST MED INTERNA & MED VASC,I-06100 PERUGIA,ITALY; UNIV FLORENCE,DEPT PHYSIOPATHOL,I-50121 FLORENCE,ITALY	University of London; King's College London; University of Perugia; University of Perugia; University of Florence			Gresele, Paolo/F-6775-2013; gresele, paolo/AAG-8019-2019	Gresele, Paolo/0000-0001-5365-8445; 				BARNES PJ, 1983, NEW ENGL J MED, V303, P263; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHIHARA J, 1988, AM REV RESPIR DIS, V137, pA421; COYLE AJ, 1990, AM REV RESPIR DIS, V142, P587, DOI 10.1164/ajrccm/142.3.587; GRESELE P, 1984, LANCET, V1, P991; Gresele P., 1991, PLATELET HLTH DISEAS, P132; GRESELE P, 1987, AGENTS ACTIONS, V521, P119; HALBERG F, 1967, CELLULAR ASPECTS BIO, P210; HAYDU SP, 1976, LANCET, V2, P1225; HENSON PM, 1977, J IMMUNOL, V119, P29; HETZL MR, 1984, ROYAL SOC MED INT C, V73, P59; IANNACCI L, 1990, AM REV RESPIR DIS, V141, pA447; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KAPLAN KL, 1981, BLOOD, V57, P199; Keppel G., 1973, DESIGN ANAL RES HDB; LALAUKERALY C, 1982, BRIT J HAEMATOL, V51, P313; LELLOUCHTUBIANA A, 1988, AM REV RESPIR DIS, V137, P948, DOI 10.1164/ajrccm/137.4.948; LUPINETTI MD, 1989, AM REV RESPIR DIS, V140, P932, DOI 10.1164/ajrccm/140.4.932; Martin J F, 1987, Agents Actions Suppl, V21, P37; METZGER W J, 1990, Journal of Allergy and Clinical Immunology, V85, P262; MOHIUDDIN AA, 1990, AM REV RESPIR DIS, V142, P1153, DOI 10.1164/ajrccm/142.5.1153; MORRISON JFJ, 1991, THORAX, V46, P197, DOI 10.1136/thx.46.3.197; NENCI GG, 1981, THROMB HAEMOSTASIS, V46, P572; OBRIEN JR, 1978, LANCET, V2, P1316; PAGE CP, 1989, PULMON PHARM, V2, P13; REINBERG A, 1963, J ALLERGY, V34, P1153; RYAN G, 1982, THORAX, V37, P420; SLATER D, 1985, LANCET, V1, P110; Sothern R., 1972, PHYSIOL TEACH, V1, P1; STRAZZULLA G, 1990, CHRONOBIOLOGIA, V17, P149; TAYTARD A, 1986, AM REV RESPIR DIS, V134, P983, DOI 10.1164/arrd.1986.134.5.983; THOMPSON P J, 1984, American Review of Respiratory Disease, V129, pA3; TODISCO T, 1983, LANCET, V1, P650; TODISCO T, 1984, B EUR PHYSIOPATHOL R, V23, P533; VANRENTERGHEM Y, 1985, LANCET, V1, P999, DOI 10.1016/S0140-6736(85)91610-1; 1975, B EUR PHYSIOPATHO S5, V19, P7	37	60	63	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1993	91	4					894	902		10.1016/0091-6749(93)90347-I	http://dx.doi.org/10.1016/0091-6749(93)90347-I			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KY251	8473678	Bronze			2022-12-18	WOS:A1993KY25100010
J	CHARPIN, D; BIRNBAUM, J; LANTEAUME, A; VERVLOET, D				CHARPIN, D; BIRNBAUM, J; LANTEAUME, A; VERVLOET, D			PREVALENCE OF ALLERGY TO HYMENOPTERA STINGS IN DIFFERENT SAMPLES OF THE GENERAL-POPULATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HYMENOPTERA; ALLERGY; ANAPHYLAXIS; SYSTEMIC REACTION; OCCURRENCE; EPIDEMIOLOGY	BEE	To get figures of prevalence of systemic reactions (SRs) to hymenoptera sting in adults between the ages of 18 to 65 years, we performed three different surveys using the same questionnaire from 1984 to 1988. The first one was a door-to-door survey in Southeast France, which included 8271 adults and used a questionnaire. The second one, which included 2067 adults, was performed in a health care center and comprised the same questionnaire and venom skin tests in subjects reporting a history of SRs. The third survey was a national poll performed through a home-based national computer network. The percentage of SRs ranged from 0.66% in the second survey including skin tests to 3.3% in the poll survey. The higher prevalence figure in this latter survey may be related to a false-positive history. There was no urban-rural difference in prevalence of SR.			CHARPIN, D (corresponding author), HOP ST MARGUERITE,DEPT MALAD RESP,SERV PNEUMOALLERGOL,BP 29,F-13277 MARSEILLE 9,FRANCE.							ABRISHAMI MA, 1971, ACTA ALLERGOL, V26, P117; CHAFEE FH, 1970, ACTA ALLERGOL, V25, P292, DOI 10.1111/j.1398-9995.1970.tb01265.x; CHARPIN P, 1989, EUR J COMBIN, V10, P1; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; SAVLIWALA M, 1987, J ALLERGY CLIN IMMUN, V79, pA127; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; SETTIPANE GA, 1979, CLIN ALLERGY, V9, P385, DOI 10.1111/j.1365-2222.1979.tb02497.x; SETTIPANE GA, 1972, J ALLERGY CLIN IMMUN, V50, P146, DOI 10.1016/0091-6749(72)90045-0; STUCKEY M, 1982, LANCET, V2, P41	9	60	60	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	1				331	334		10.1016/S0091-6749(05)80011-9	http://dx.doi.org/10.1016/S0091-6749(05)80011-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP520	1527317				2022-12-18	WOS:A1992JP52000009
J	BONINI, S; BONINI, S; SCHIAVONE, M; CENTOFANTI, M; ALLANSMITH, MR; BUCCI, MG				BONINI, S; BONINI, S; SCHIAVONE, M; CENTOFANTI, M; ALLANSMITH, MR; BUCCI, MG			CONJUNCTIVAL HYPERRESPONSIVENESS TO OCULAR HISTAMINE CHALLENGE IN PATIENTS WITH VERNAL CONJUNCTIVITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						VERNAL CONJUNCTIVITIS; HYPERREACTIVITY; OCULAR ALLERGY	BRONCHIAL RESPONSIVENESS; AIRWAY INFLAMMATION; ASTHMA; HISTAMINE; REACTIVITY; MEDIATORS	We compared the conjunctival responsiveness to histamine diphosphate in patients with vernal conjunctivitis and in healthy control subjects. Fourteen asymptomatic patients with vernal conjunctivitis and 10 healthy volunteers were challenged in one eye with 10-mu-l of increasing doses (0.01, 0.05, 0.5, and 1 mg/ml in phosphate-buffered saline) of histamine diphosphate. The contralateral eye was challenged with the diluent only. Photographs of each eye were taken for evaluation of conjunctival redness by two masked investigators. Both patients with vernal conjunctivitis and control subjects reacted to histamine with a dose-dependent conjunctival redness 2 to 5 minutes after ocular challenge. Conjunctival redness was more intense in patients with vernal conjunctivitis than in control subjects after ocular challenge with 0.01 and 0.05 mg/ml of histamine diphosphate solution (p < 0.05). Moreover, the threshold concentration of histamine diphosphate, extrapolated from each individual dose-response curve, was significantly (p < 0.02) lower in patients with vernal conjunctivitis than in control subjects. Our findings suggest that patients with vernal conjunctivitis demonstrate conjunctival hyperresponsiveness to a nonspecific challenging agent. Nonspecific conjunctival hyperreactivity, novel concept in allergic eye disease, may be relevant for a better understanding of the pathogenesis and clinical variability of vernal conjunctivitis.	UNIV ROME TOR VERGATA,DEPT OPHTHALMOL,ROME,ITALY; UNIV ROME LA SAPIENZA,ANDREA CESALPINO FDN,I-00185 ROME,ITALY; HARVARD UNIV,SCH MED,BOSTON,MA 02115; EYE RES INST,BOSTON,MA	University of Rome Tor Vergata; Sapienza University Rome; Harvard University; Harvard Medical School			Bonini, Sergio/T-6594-2019; Bonini, Stefano/A-2250-2012	Bonini, Sergio/0000-0003-0079-3031; Bonini, Stefano/0000-0002-7787-2144				ABELSON MB, 1979, IMMUNOLOGY IMMUNOPAT, P362; Allansmith M.R., 1982, EYE IMMUNOLOGY; ANDERSON SD, 1975, BRIT J DIS CHEST, V69, P1; BALLOW M, 1983, AM J OPHTHALMOL, V95, P161, DOI 10.1016/0002-9394(83)90009-0; BEIGELMAN MN, 1950, VERNAL CONJUNCTIVITI, P252; BONINI S, 1988, J ALLERGY CLIN IMMUN, V82, P462, DOI 10.1016/0091-6749(88)90020-6; BONINI S, 1990, CONGIUNTIVITI ALLERG, P47; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1985, ANN ALLERGY, V55, P527; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEVRIES K, 1987, BRONCHIAL HYPERESPON, P359; Frankland A W, 1971, Trans Ophthalmol Soc U K, V91, P479; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HARGREAVE FE, 1980, AIRWAY REACTIVITY ME, P145; HOLLANDER M, 1973, NONPARAMETRIC STAT, P71; JOSEPHS LK, 1989, AM REV RESPIR DIS, V140, P350, DOI 10.1164/ajrccm/140.2.350; KONNO A, 1987, J ALLERGY CLIN IMMUN, V79, P620, DOI 10.1016/S0091-6749(87)80158-6; MAGNUSSEN H, 1989, RESPIRATION, V55, P65; PAUWELS R, 1987, BRONCHIAL HYPERRESPO, P342; TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113; WOODWARD DF, 1986, INVEST OPHTH VIS SCI, V27, P1495; WOOLCOCK AJ, 1986, EUR J RESPIR DIS, V69, P166; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	23	60	60	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	1				103	107		10.1016/S0091-6749(05)80046-6	http://dx.doi.org/10.1016/S0091-6749(05)80046-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ908	1730830	Bronze			2022-12-18	WOS:A1992GZ90800012
J	MURRAY, AB; MORRISON, BJ				MURRAY, AB; MORRISON, BJ			IT IS CHILDREN WITH ATOPIC-DERMATITIS WHO DEVELOP ASTHMA MORE FREQUENTLY IF THE MOTHER SMOKES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV BRITISH COLUMBIA,DEPT PEDIAT,VANCOUVER V6T 1W5,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia; University of British Columbia								BURCHFIEL CM, 1986, AM REV RESPIR DIS, V133, P966; BURNEY PGJ, 1989, INT J EPIDEMIOL, V18, P165, DOI 10.1093/ije/18.1.165; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1118, DOI 10.1136/adc.64.8.1118; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COULTAS DB, 1988, AM REV RESPIR DIS, V137, P810, DOI 10.1164/ajrccm/137.4.810; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HARGREAVE FE, 1985, CHEST, V87, P325; HASSELBLAD V, 1981, AM REV RESPIR DIS, V123, P479; HURWITZ D, 1981, CLIN PEDIATRIC DERMA, P39; JARVIS MJ, 1985, BRIT MED J, V291, P927, DOI 10.1136/bmj.291.6500.927; JARVIS MJ, 1986, THORAX, V41, P886, DOI 10.1136/thx.41.11.886; JARVIS MJ, 1980, BRIT MED J, V281, P484, DOI 10.1136/bmj.281.6238.484; JONES DT, 1987, BRIT J DIS CHEST, V81, P332, DOI 10.1016/0007-0971(87)90181-1; JOSSA D, 1985, H3966 MIN NAT HLTH W, P26; KELLY WJW, 1987, BRIT MED J, V294, P1059, DOI 10.1136/bmj.294.6579.1059; LETWITTER FI, 1984, AM J EPIDEMIOL, V120, P518; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518, DOI 10.1164/ajrccm/138.3.518; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; MURRAY AB, 1983, CAN MED ASSOC J, V129, P828; MURRAY AB, 1988, CHEST, V94, P701, DOI 10.1378/chest.94.4.701; MURRAY AB, 1981, J ALLERGY CLIN IMMUN, V68, P119, DOI 10.1016/0091-6749(81)90169-X; MURRAY AB, 1989, PEDIATRICS, V84, P451; PASTERNACK B, 1965, J PEDIATR-US, V66, P164; TAYLOR B, 1987, ARCH DIS CHILD, V62, P786, DOI 10.1136/adc.62.8.786; VEDAL S, 1984, AM REV RESPIR DIS, V130, P187; WARE JH, 1984, AM REV RESPIR DIS, V129, P366; WEISS ST, 1980, AM REV RESPIR DIS, V122, P697, DOI 10.1164/arrd.1980.122.5.697	28	60	60	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1990	86	5					732	739		10.1016/S0091-6749(05)80177-0	http://dx.doi.org/10.1016/S0091-6749(05)80177-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EJ631	2229839				2022-12-18	WOS:A1990EJ63100005
J	REISMAN, RE; LIVINGSTON, A				REISMAN, RE; LIVINGSTON, A			LATE-ONSET ALLERGIC REACTIONS, INCLUDING SERUM SICKNESS, AFTER INSECT STINGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											REISMAN, RE (corresponding author), SUNY BUFFALO,BUFFALO GEN HOSP,DEPT MED,ALLERGY RES LAB,100 HIGH ST,BUFFALO,NY 14203, USA.							CHABANE MH, 1988, ANN ALLERGY, V61, P216; COCHRANE CG, 1973, ADV IMMUNOL, P16; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P39; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; LAWLEY TJ, 1984, NEW ENGL J MED, V311, P1407, DOI 10.1056/NEJM198411293112204; LICHTENSTEIN LM, 1983, HOSP PRACT, V18, P36; LIGHT WC, 1977, J ALLERGY CLIN IMMUN, V59, P247, DOI 10.1016/0091-6749(77)90158-0; LIGHT WC, 1977, J ALLERGY CLIN IMMUN, V59, P391, DOI 10.1016/0091-6749(77)90024-0; LOCKEY RF, 1988, J ALLERGY CLIN IMMUN, V82, P370, DOI 10.1016/0091-6749(88)90008-5; NICKLAS RA, 1988, J ALLERGY CLIN IMMUN, V81, P237, DOI 10.1016/0091-6749(88)90512-X; REISMAN RE, 1961, J ALLERGY, V32, P531, DOI 10.1016/0021-8707(61)90008-9; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; UMETSU DT, 1985, J ALLERGY CLIN IMMUN, V76, P113; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X	15	60	62	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1989	84	3					331	337		10.1016/0091-6749(89)90417-X	http://dx.doi.org/10.1016/0091-6749(89)90417-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AR199	2778239				2022-12-18	WOS:A1989AR19900010
J	WIGGINS, CA; DYKEWICZ, MS; PATTERSON, R				WIGGINS, CA; DYKEWICZ, MS; PATTERSON, R			IDIOPATHIC ANAPHYLAXIS - CLASSIFICATION, EVALUATION, AND TREATMENT OF 123 PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACAL E, 1978, CLIN ALLERGY, V8, P295, DOI 10.1111/j.1365-2222.1978.tb03227.x; BOXER M, 1987, ARCH INTERN MED, V147, P269, DOI 10.1001/archinte.147.2.269; GREENBERGER PA, 1984, AM J MED, V76, P553, DOI 10.1016/0002-9343(84)90681-8; GREENBERGER PA, 1986, CLIN RES, V24, P940; HENDRIX S, 1981, J ALLERGY CLIN IMMUN, V67, P8, DOI 10.1016/0091-6749(81)90038-5; KALINER M, 1984, INVEST RADIOL, V19, P116, DOI 10.1097/00004424-198403000-00007; KALINER MA, 1983, NER ALLERGY P, V5, P324; LIEBERMAN P, 1979, ARCH INTERN MED, V139, P1032, DOI 10.1001/archinte.139.9.1032; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; MCGRATH KG, 1984, IMMUNOL ALLERGY PRAC, V6, P41; MEGGS WJ, 1985, J ALLERGY CLIN IMMUN, V76, P840, DOI 10.1016/0091-6749(85)90758-4; MEYERS G, 1981, J ALLERGY CLIN IMMUN, V67, P305; NOVEY HS, 1983, J ALLERGY CLIN IMMUN, V71, P498, DOI 10.1016/0091-6749(83)90468-2; PATTERSON R, 1974, CLIN ALLERGY, V4, P307, DOI 10.1111/j.1365-2222.1974.tb01390.x; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; SONIN L, 1985, J ALLERGY CLIN IMMUN, V75, P67, DOI 10.1016/0091-6749(85)90014-4; SONIN L, 1985, PSEUDOALLERGIC REACT, V4, P47; STRICKER WE, 1986, J ALLERGY CLIN IMMUN, V77, P516, DOI 10.1016/0091-6749(86)90188-0; 1979, NIH79387 PUBL, P3	19	60	61	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				849	855		10.1016/0091-6749(88)90089-9	http://dx.doi.org/10.1016/0091-6749(88)90089-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	3192868				2022-12-18	WOS:A1988R170800020
J	TRENTIN, L; MARCER, G; CHILOSI, M; MA, CS; ZAMBELLO, R; AGOSTINI, C; MASCIARELLI, M; BIZZOTTO, R; GEMIGNANI, C; CIPRIANI, A; DIVITTORIO, G; SEMENZATO, G				TRENTIN, L; MARCER, G; CHILOSI, M; MA, CS; ZAMBELLO, R; AGOSTINI, C; MASCIARELLI, M; BIZZOTTO, R; GEMIGNANI, C; CIPRIANI, A; DIVITTORIO, G; SEMENZATO, G			LONGITUDINAL-STUDY OF ALVEOLITIS IN HYPERSENSITIVITY PNEUMONITIS PATIENTS - AN IMMUNOLOGICAL EVALUATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									PADUA UNIV,SCH MED,MED CLIN 1,IST MED CLIN,VIA GIUSTINIANI 2,I-35128 PADOVA,ITALY; PADUA UNIV,SCH MED,DEPT CLIN MED,I-35128 PADOVA,ITALY; PADUA UNIV,SCH MED,CLIN IMMUNOL BRANCH,I-35128 PADOVA,ITALY; PADUA UNIV,SCH MED,DEPT OCCUPAT MED,I-35128 PADOVA,ITALY; UNIV VERONA,DEPT PATHOL,I-37100 VERONA,ITALY; PADUA HOSP,DEPT PNEUMOL,PADUA,ITALY	University of Padua; University of Padua; University of Padua; University of Padua; University of Verona; University of Padua; Azienda Ospedaliera - Universita di Padova			CHILOSI, MARCO/ABB-8028-2021; Zambello, Renato/AAB-5280-2022; TRENTIN, LIVIO/J-7676-2016; TRENTIN, LIVIO/L-6678-2019; SEMENZATO, GIANPIETRO C/J-7727-2016; Agostini, Carlo/J-3103-2012	Zambello, Renato/0000-0002-8799-5324; TRENTIN, LIVIO/0000-0003-1222-6149; TRENTIN, LIVIO/0000-0003-1222-6149; SEMENZATO, GIANPIETRO C/0000-0002-6061-4595; Agostini, Carlo/0000-0001-7786-3574				ABO T, 1981, J IMMUNOL, V127, P1024; AGOSTINI C, 1984, Immunologia Clinica e Sperimentale, V3, P283; BASSET F, 1987, American Review of Respiratory Disease, V135, pA374; BERNARDO J, 1979, AM REV RESPIR DIS, V120, P985; CAMPBELL JM, 1932, BMJ-BRIT MED J, V2, P1142; CHILOSI M, 1981, AM J CLIN PATHOL, V76, P729; CHILOSI M, 1983, BRIT J CANCER, V48, P763, DOI 10.1038/bjc.1983.265; COCHRAN WG, 1957, EXPT DESIGNS, P100; CORMIER Y, 1987, AM REV RESPIR DIS, V135, P692; CORMIER Y, 1986, ANN NY ACAD SCI, V465, P370, DOI 10.1111/j.1749-6632.1986.tb18512.x; CORMIER Y, 1986, BRIT J IND MED, V43, P401; COSTABEL U, 1987, American Review of Respiratory Disease, V135, pA373; COSTABEL U, 1984, CHEST, V85, P514, DOI 10.1378/chest.85.4.514; CRYSTAL RG, 1981, AM J MED, V70, P542, DOI 10.1016/0002-9343(81)90577-5; FINK JN, 1984, J ALLERGY CLIN IMMUN, V74, P1, DOI 10.1016/0091-6749(84)90077-0; FOURNIER E, 1985, CHEST, V88, P563, DOI 10.1378/chest.88.4.563; GATENBY PA, 1982, J IMMUNOL, V129, P1997; HASLAM PL, 1987, AM REV RESPIR DIS, V135, P35; LEATHERMAN MD, 1984, ANN INTERN MED, V100, P390; LEBLANC P, 1986, ARCH INTERN MED, V146, P153, DOI 10.1001/archinte.146.1.153; LEBLANC P, 1984, CHEST, V84, P323; MONKARE S, 1987, CLIN ALLERGY, V17, P143, DOI 10.1111/j.1365-2222.1987.tb02332.x; REINHERZ EL, 1986, LEUCOCYTE TYPING, V2; REYES CN, 1982, CHEST, V81, P142, DOI 10.1378/chest.81.2.142; REYNOLDS HY, 1982, CHEST, V81, P745, DOI 10.1016/S0012-3692(16)57764-2; REYNOLDS HY, 1977, J CLIN INVEST, V59, P165, DOI 10.1172/JCI108615; RICHERSON HB, 1981, J ALLERGY CLIN IMMUN, V68, P226, DOI 10.1016/0091-6749(81)90188-3; ROBERTS RC, 1977, AM REV RESPIR DIS, V116, P1075; SALVAGGIO JE, 1979, CHEST, V75, P270, DOI 10.1378/chest.75.2.270; SALVAGGIO JE, 1986, CHEST, V190, P89; SCHUYLER MR, 1983, AM REV RESPIR DIS, V128, P1071; SEMENZATO G, 1985, AM REV RESPIR DIS, V132, P400; SEMENZATO G, 1986, J IMMUNOL, V137, P1164; VANDENBOSCH JMM, 1986, RESPIRATION, V49, P45, DOI 10.1159/000194858; WILSON BD, 1984, J ALLERGY CLIN IMMUN, V74, P180, DOI 10.1016/0091-6749(84)90283-5	35	60	61	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					577	585		10.1016/0091-6749(88)90967-0	http://dx.doi.org/10.1016/0091-6749(88)90967-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	2971707				2022-12-18	WOS:A1988Q639900007
J	GLEICH, GJ; MOTOJIMA, S; FRIGAS, E; KEPHART, GM; FUJISAWA, T; KRAVIS, LP				GLEICH, GJ; MOTOJIMA, S; FRIGAS, E; KEPHART, GM; FUJISAWA, T; KRAVIS, LP			THE EOSINOPHILIC LEUKOCYTE AND THE PATHOLOGY OF FATAL BRONCHIAL-ASTHMA - EVIDENCE FOR PATHOLOGICAL HETEROGENEITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN, DEPT INTERNAL MED, ROCHESTER, MN 55905 USA; UNIV PENN, CHILDRENS HOSP, SCH MED, DEPT PEDIAT, PHILADELPHIA, PA 19104 USA	Mayo Clinic; University of Pennsylvania; Childrens Hospital of Philadelphia	GLEICH, GJ (corresponding author), MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55905 USA.				NIAID NIH HHS [AI 11483, AI 09728, AI 15231] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015231, R37AI009728, R01AI009728, P50AI011483, R37AI015231] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUTTERWORTH AE, 1975, NATURE, V256, P727, DOI 10.1038/256727a0; BUTTERWORTH AE, 1979, J IMMUNOL, V122, P221; DUNNILL MS, 1978, ALLERGY PRINCIPLES P, P678; Ellis AG, 1908, AM J MED SCI, V136, P407, DOI 10.1097/00000441-190809000-00009; FILLEY WV, 1982, LANCET, V2, P11; FRIGAS E, 1980, LAB INVEST, V42, P35; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; FUJISAWA T, 1987, J ALLERGY CLIN IMMUN, V79, P262; GLEICH GJ, 1974, J EXP MED, V140, P313, DOI 10.1084/jem.140.2.313; GLEICH GJ, 1973, J EXP MED, V137, P1459, DOI 10.1084/jem.137.6.1459; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GLEICH GJ, 1976, J CLIN INVEST, V57, P633, DOI 10.1172/JCI108319; HARLIN SL, UNPUB CLIN PATHOLOGI; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; Huber HL, 1922, ARCH INTERN MED, V30, P689, DOI 10.1001/archinte.1922.00110120002001; KALLOS P, 1984, INT ARCH ALLER A IMM, V73, P77, DOI 10.1159/000233441; KRAVIS LP, 1985, AM J DIS CHILD, V139, P558, DOI 10.1001/archpedi.1985.02140080028026; LEWIS DM, 1978, J CELL BIOL, V77, P702, DOI 10.1083/jcb.77.3.702; MOTOJIMA S, 1986, FASEB J, V45, P994; NAYLOR BERNARD, 1962, THORAX, V17, P69, DOI 10.1136/thx.17.1.69; PETERS MS, 1986, LAB INVEST, V54, P656; PORTER R, 1971, CIBA F STUDY GROUP, V38	22	60	60	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			412	415		10.1016/0091-6749(87)90063-7	http://dx.doi.org/10.1016/0091-6749(87)90063-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037	3624694				2022-12-18	WOS:A1987K103700014
J	CARTIER, A; MALO, JL; GHEZZO, H; MCCANTS, M; LEHRER, SB				CARTIER, A; MALO, JL; GHEZZO, H; MCCANTS, M; LEHRER, SB			IGE SENSITIZATION IN SNOW CRAB PROCESSING WORKERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV, SCH MED, DEPT MED, NEW ORLEANS, LA 70112 USA	Tulane University	CARTIER, A (corresponding author), HOP SACRE COEUR, DEPT CHEST MED, 5400 W GOUIN, MONTREAL H4J 1C5, QUEBEC, CANADA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019266] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-19266] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUTCHER BT, 1980, J ALLERGY CLIN IMMUN, V66, P213, DOI 10.1016/0091-6749(80)90041-X; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; GADDIE J, 1980, LANCET, V2, P1350; HOWE W, 1983, J ALLERGY CLIN IMMUN, V71, P5, DOI 10.1016/0091-6749(83)90539-0; JYO T, 1974, ALLERG IMMUNOL, V21, P425; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LONGBOTTOM JL, 1984, CLIN IMMUNOL ALLERGY, V4, P19; MILLER R, 1982, BIOMETRICS, V38, P1011, DOI 10.2307/2529881; ORFORD RR, 1976, THESIS U WASHINGTON; PEPYS J, 1973, CLIN ALLERGY, V3, P491, DOI 10.1111/j.1365-2222.1973.tb03057.x; PEPYS J, 1973, P ROY SOC MED, V66, P930, DOI 10.1177/003591577306600950; PEPYS J, 1984, CLIN IMMUNOL ALLERGY, V4, P131; SACKETT DL, 1985, CLIN EPIDEMIOLOGY BA, P232; TSE KS, 1982, CLIN ALLERGY, V12, P249, DOI 10.1111/j.1365-2222.1982.tb02525.x	15	60	63	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1986	78	2					344	348		10.1016/S0091-6749(86)80087-2	http://dx.doi.org/10.1016/S0091-6749(86)80087-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D7261	3734286				2022-12-18	WOS:A1986D726100017
J	ANDERSON, MC; BAER, H; OHMAN, JL				ANDERSON, MC; BAER, H; OHMAN, JL			A COMPARATIVE-STUDY OF THE ALLERGENS OF CAT URINE, SERUM, SALIVA, AND PELT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									US FDA,NATL CTR DRUGS & BIOL,OFF BIOL RES & REVIEW,8800 ROCKVILLE PIKE,BETHESDA,MD 20205; VET ADM OUTPATIENT CLIN,MED SERV,BOSTON,MA 02108	US Food & Drug Administration (FDA)								ANDERSON MC, 1981, J IMMUNOL, V127, P972; AXELSEN NH, 1983, SCAND J IMMUNOL S10, V17; BARSELA S, 1983, J ALLERGY CLIN IMMUN, V72, P690, DOI 10.1016/0091-6749(83)90631-0; BARTHOLOME K, 1984, Journal of Allergy and Clinical Immunology, V73, P160; FINDLAY SR, 1983, ANN REV RESPIR DIS, V123, P1008; OHMAN JL, 1976, CLIN ALLERGY, V6, P419, DOI 10.1111/j.1365-2222.1976.tb01926.x; OHMAN JL, 1974, J IMMUNOL, V113, P1668; OHMAN JL, 1983, J ALLERGY CLIN IMMUN, V72, P288, DOI 10.1016/0091-6749(83)90033-7; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; RICHMAN PG, UNPUB NINHYDRIN ASSA; VARGA JM, 1972, J ALLERGY CLIN IMMUN, V49, P274, DOI 10.1016/0091-6749(72)90095-4	11	60	61	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	4					563	569		10.1016/0091-6749(85)90776-6	http://dx.doi.org/10.1016/0091-6749(85)90776-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ATH66	4056244				2022-12-18	WOS:A1985ATH6600007
J	WIHL, JA; PETERSEN, BN; PETERSEN, LN; GUNDERSEN, G; BRESSON, K; MYGIND, N				WIHL, JA; PETERSEN, BN; PETERSEN, LN; GUNDERSEN, G; BRESSON, K; MYGIND, N			EFFECT OF THE NONSEDATIVE H1-RECEPTOR ANTAGONIST ASTEMIZOLE IN PERENNIAL ALLERGIC AND NONALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GENTOFTE HOSP,DEPT LUNG DIS,DK-2900 COPENHAGEN,DENMARK; RIGSHOSP,DEPT OTORHINOLARYNGOL,OTOPATHOL LAB,DK-2100 COPENHAGEN O,DENMARK	University of Copenhagen; Herlev & Gentofte Hospital; Rigshospitalet	WIHL, JA (corresponding author), MALMO GEN HOSP,DEPT OTORHINOLARYNGOL,S-21401 MALMO,SWEDEN.							AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; AWOUTERS FHL, 1983, ARZNEIMITTEL-FORSCH, V33-1, P381; BORUM P, 1980, J ALLERGY CLIN IMMUN, V66, P25, DOI 10.1016/0091-6749(80)90134-7; CALLIER J, 1981, CURR THER RES CLIN E, V29, P24; CALLIER J, 1980, R43512006 JANSS PHAR; CARPENTER GB, 1983, J ALLERGY CLIN IMMUN, V71, P412, DOI 10.1016/0091-6749(83)90071-4; CHALMAGNE J, 1982, R4351229 JANSS PHARM; CLARYSSE J, 1981, R43512013 JANSS PHAR; CONNELL JT, 1979, ANN ALLERGY, V42, P278; EMANUEL MB, 1983, N31963 JANSS PHARM C; GARCELON D, 1981, R4351221 JANSS PHARM; GRONBORG H, ACTA OTOLARYNGOL STO; KIRKEGAARD J, 1982, ALLERGY, V37, P203, DOI 10.1111/j.1398-9995.1982.tb01897.x; KIRKEGAARD J, 1983, BRIT J DIS CHEST, V77, P113, DOI 10.1016/0007-0971(83)90017-7; LADURON PM, 1982, MOL PHARMACOL, V21, P294; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; MUNCH EP, 1983, ALLERGY, V38, P517, DOI 10.1111/j.1398-9995.1983.tb02361.x; MYGIND N, 1983, EUR J RESPIR DIS, V64, P167; MYGIND N, 1978, CLIN OTOLARYNGOL, V3, P189, DOI 10.1111/j.1365-2273.1978.tb00681.x; MYGIND N, 1982, CLIN OTOLARYNGOL, V7, P343, DOI 10.1111/j.1365-2273.1982.tb01918.x; Mygind N., 1979, NASAL ALLERGY; NACLERIO RM, 1983, EUR J RESPIR DIS, V64, P26; NICHOLSON AN, 1983, LANCET, V2, P211; SCHWARTZ JC, 1981, TRENDS PHARM SCI, V2, P12; SECHER C, 1982, J ALLERGY CLIN IMMUN, V70, P211, DOI 10.1016/0091-6749(82)90044-6; TRZECIAKOWSKI JP, 1983, ALLERGY PRINCIPLES P, P575; WILSON JD, 1982, CLIN ALLERGY, V12, P131; WONG L, 1981, J ALLERGY CLIN IMMUN, V67, P223, DOI 10.1016/0091-6749(81)90065-8	28	60	60	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	6					720	727		10.1016/0091-6749(85)90100-9	http://dx.doi.org/10.1016/0091-6749(85)90100-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ALA84	2861220	Bronze			2022-12-18	WOS:A1985ALA8400015
J	HOWARTH, PH; PAO, GJK; CHURCH, MK; HOLGATE, ST				HOWARTH, PH; PAO, GJK; CHURCH, MK; HOLGATE, ST			EXERCISE AND ISOCAPNIC HYPERVENTILATION-INDUCED BRONCHOCONSTRICTION IN ASTHMA - RELEVANCE OF CIRCULATING BASOPHILS TO MEASUREMENTS OF PLASMA HISTAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											HOWARTH, PH (corresponding author), SOUTHAMPTON GEN HOSP, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND.			Howarth, Peter/0000-0003-0619-7927				ANDERSON SD, 1981, THORAX, V36, P259, DOI 10.1136/thx.36.4.259; ANDERTON RC, 1979, J ALLERGY CLIN IMMUN, V63, P315, DOI 10.1016/0091-6749(79)90125-8; BARNES PJ, 1981, CLIN SCI, V61, P159, DOI 10.1042/cs0610159; BARNES PJ, 1982, CLIN SCI, V62, P661, DOI 10.1042/cs0620661; BAROR O, 1977, J ALLERGY CLIN IMMUN, V60, P163, DOI 10.1016/0091-6749(77)90119-1; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; BROWN MJ, 1980, ANAL BIOCHEM, V109, P142, DOI 10.1016/0003-2697(80)90022-6; BRUCE C, 1976, THORAX, V31, P724, DOI 10.1136/thx.31.6.724; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHARLES TJ, 1979, CLIN SCI, V57, P39, DOI 10.1042/cs0570039; CHURCH MK, 1982, J IMMUNOL, V129, P2116; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; DURER H, 1958, SCAND J CLIN LAB INV, V10, P394; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V66, P295, DOI 10.1016/0091-6749(80)90024-X; HARRIES MG, 1979, CLIN ALLERGY, V9, P437, DOI 10.1111/j.1365-2222.1979.tb02506.x; HARTLEY JPR, 1981, CLIN SCI, V61, P151, DOI 10.1042/cs0610151; IND PW, 1982, AGENTS ACTIONS, V12, P12, DOI 10.1007/BF01965099; IND PW, 1983, BRIT J CLIN PHARMACO, V15, pP145; IZHIZAKA T, 1972, J IMMUNOL, V108, P1000; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; KAY AB, 1982, J ALLERGY CLIN IMMUN, V70, P317, DOI 10.1016/0091-6749(82)90019-7; KIVILOOG J, 1973, SCAND J RESPIR DIS, V54, P347; KIVITY S, 1980, EUR J RESPIR DIS, V61, P342; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; MAY CD, 1982, CLIN ALLERGY, V12, P229, DOI 10.1111/j.1365-2222.1982.tb02523.x; MORGAN DJR, 1982, THORAX, V37, P788; MORGAN DJR, 1982, CLIN ALLERGY, V12, P29; NEIJENS HJ, 1982, CLIN ALLERGY, V12, P577, DOI 10.1111/j.1365-2222.1982.tb02556.x; NEIJENS HJ, 1980, CLIN ALLERGY, V10, P535, DOI 10.1111/j.1365-2222.1980.tb02134.x; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SIMON RA, 1977, J ALLERGY CLIN IMMUN, V60, P312, DOI 10.1016/0091-6749(77)90111-7; SNYDER SH, 1966, J PHARMACOL EXP THER, V153, P544; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; SOUHRADA M, 1981, RESP PHYSIOL, V44, P311, DOI 10.1016/0034-5687(81)90026-8; STRAUSS RH, 1978, J CLIN INVEST, V61, P433, DOI 10.1172/JCI108954; WEINSTEIN RE, 1976, J ALLERGY CLIN IMMUN, V57, P250; ZEBALLOS RJ, 1978, AM REV RESPIR DIS, V118, P877	45	60	60	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	3					391	399		10.1016/0091-6749(84)90414-7	http://dx.doi.org/10.1016/0091-6749(84)90414-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SK155	6199398				2022-12-18	WOS:A1984SK15500015
J	MORNEX, JF; CORDIER, G; PAGES, J; VERGNON, JM; LEFEBVRE, R; BRUNE, J; REVILLARD, JP				MORNEX, JF; CORDIER, G; PAGES, J; VERGNON, JM; LEFEBVRE, R; BRUNE, J; REVILLARD, JP			ACTIVATED LUNG LYMPHOCYTES IN HYPERSENSITIVITY PNEUMONITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP EDOUARD HERRIOT,UER BIOL,CTR CYTOFLUOROMETRIE,F-69374 LYON 08,FRANCE; HOP LOUIS PRADEL,SERV PNEUMOL,LYON,FRANCE; HOP EDOUARD HERRIOT,CNRS,ERA 782,INSERM,U80,F-69003 LYON,FRANCE	CHU Lyon; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)								BEACHAM CH, 1982, CELL IMMUNOL, V74, P284, DOI 10.1016/0008-8749(82)90029-6; BICE DE, 1978, J ALLERGY CLIN IMMUN, V58, P250; BURNS GF, 1982, CELL IMMUNOL, V71, P12, DOI 10.1016/0008-8749(82)90492-0; CALDWELL JR, 1973, J ALLERGY CLIN IMMUN, V52, P225, DOI 10.1016/0091-6749(73)90060-2; CALVANICO NJ, 1980, J LAB CLIN MED, V96, P129; CANONICA GW, 1982, CLIN IMMUNOL IMMUNOP, V23, P616, DOI 10.1016/0090-1229(82)90324-5; CHARLES J, 1976, THORAX, V31, P127, DOI 10.1136/thx.31.2.127; CHARRON DJ, 1981, IMMUNOL COMMUN, V10, P293, DOI 10.3109/08820138109093462; COLLSTE L, 1979, J HISTOCHEM CYTOCHEM, V27, P390, DOI 10.1177/27.1.86568; CORTE G, 1981, EUR J IMMUNOL, V11, P162, DOI 10.1002/eji.1830110220; CRYSTAL RG, 1981, AM J MED, V70, P542, DOI 10.1016/0002-9343(81)90577-5; DAVIS GS, 1978, AM REV RESPIR DIS, V118, P7; FINK JN, 1975, INT ARCH ALLER A IMM, V49, P831, DOI 10.1159/000231466; GODARD P, 1981, CHEST, V80, P447, DOI 10.1378/chest.80.4.447; HANSEN PJ, 1974, INT ARCH ALLER A IMM, V47, P498, DOI 10.1159/000231244; HIRATA T, 1982, CHEST, V82, P232; HOFFMAN RA, 1980, P NATL ACAD SCI USA, V77, P4814; KAWANAMI O, 1983, AM J PATHOL, V110, P275; KELLER RH, 1982, J CLIN IMMUNOL, V2, P46, DOI 10.1007/BF00915978; KELLER RH, 1982, J IMMUNOL, V128, P116; KRENSKY AM, 1982, J IMMUNOL, V129, P2001; KUNG PC, 1979, SCIENCE, V206, P347, DOI 10.1126/science.314668; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LANIER LL, 1981, J IMMUNOL METHODS, V47, P25, DOI 10.1016/0022-1759(81)90253-2; LAVIOLETTE M, 1983, Revue Francaise des Maladies Respiratoires, V11, P485; LOKEN MR, 1982, J IMMUNOL METHODS, V50, pR85, DOI 10.1016/0022-1759(82)90161-2; LOPEZ M, 1976, ANNU REV MED, V27, P453, DOI 10.1146/annurev.me.27.020176.002321; MOORE VL, 1980, J ALLERGY CLIN IMMUN, V65, P365, DOI 10.1016/0091-6749(80)90214-6; MOORE VL, 1974, J ALLERGY CLIN IMMUN, V53, P319, DOI 10.1016/0091-6749(74)90115-8; MORNEX JF, 1983, MONOGR ALLERGY, V18, P178; PACHECO Y, 1982, AM J MED, V73, P82, DOI 10.1016/0002-9343(82)90930-5; PACHECO Y, 1981, NOUV PRESSE MED, V10, P1503; PESANDO JM, 1981, HUM IMMUNOL, V3, P67, DOI 10.1016/0198-8859(81)90044-6; REED CE, 1982, JAMA-J AM MED ASSOC, V248, P2683, DOI 10.1001/jama.248.20.2683; REINHERZ EL, 1979, J EXP MED, V150, P1472, DOI 10.1084/jem.150.6.1472; REINHERZ EL, 1980, NEW ENGL J MED, V303, P370, DOI 10.1056/NEJM198008143030704; REYES CN, 1982, CHEST, V81, P142, DOI 10.1378/chest.81.2.142; REYNOLDS HY, 1977, J CLIN INVEST, V59, P165, DOI 10.1172/JCI108615; SALVAGGIO JE, 1979, CHEST, V75, P270, DOI 10.1378/chest.75.2.270; SCHATZ M, 1977, J ALLERGY CLIN IMMUN, V60, P27, DOI 10.1016/0091-6749(77)90079-3; SCHATZ M, 1976, CLIN ALLERGY, V6, P7, DOI 10.1111/j.1365-2222.1976.tb01407.x; SCHWARTZ D, 1980, METHODES STATISTIQUE, P151; SHUYLER MR, 1978, ANN INTERN MED, V88, P355; STANKUS RP, 1978, J IMMUNOL, V120, P685; THOMAS Y, 1981, J EXP MED, V154, P459, DOI 10.1084/jem.154.2.459; TODD RF, 1981, J IMMUNOL, V126, P1435; TOOGOOD JH, 1980, CLIN ALLERGY, V10, P547, DOI 10.1111/j.1365-2222.1980.tb02136.x; WIESENDANGER T, 1982, PHYSIOPATHOLOGIE CAR, P363; WINTERBAUER RH, 1982, UPDATE PULMONARY DIS, P225; YONISHROUACH E, 1983, PROTIDES BIOL FLUIDS, V30, P487	50	60	60	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	5					719	727		10.1016/0091-6749(84)90236-7	http://dx.doi.org/10.1016/0091-6749(84)90236-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TT169	6209321				2022-12-18	WOS:A1984TT16900011
J	GRIFFIN, MP; MACDONALD, N; MCFADDEN, ER				GRIFFIN, MP; MACDONALD, N; MCFADDEN, ER			SHORT-TERM AND LONG-TERM EFFECTS OF CROMOLYN SODIUM ON THE AIRWAY REACTIVITY OF ASTHMATICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BRIGHAM & WOMENS HOSP, SHIPLEY INST MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NHLBI NIH HHS [HL 17382, HL 17873, HL 27432] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTOUNYAN REC, 1980, CLIN ALLERGY, V10, P481, DOI 10.1111/j.1365-2222.1980.tb02162.x; ARKINS JA, 1968, J ALLERGY, V41, P209, DOI 10.1016/0021-8707(68)90043-9; BRESLIN FJ, 1980, AM REV RESPIR DIS, V122, P11; BUTCHER BT, 1979, J ALLERGY CLIN IMMUN, V64, P146, DOI 10.1016/0091-6749(79)90049-6; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; DICKSON W, 1970, DISODIUM CROMOGLYCAT, P105; EASTON JG, 1981, J ALLERGY CLIN IMMUN, V67, P388, DOI 10.1016/0091-6749(81)90084-1; ENGSTROM I, 1977, SCAND J RESPIR DIS, P49; GODFREY S, 1976, THORAX, V31, P137, DOI 10.1136/thx.31.2.137; GODFREY S, 1975, ACTA ALLERGOL, V30, P51, DOI 10.1111/j.1398-9995.1975.tb02307.x; GRIFFIN MD, J APPL PHYSL; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HARRIES MG, 1981, LANCET, V1, P5; HYDE JS, 1973, CHEST, V63, P875, DOI 10.1378/chest.63.6.875; JUNIPER E F, 1980, American Review of Respiratory Disease, V121, P76; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KANG B, 1976, BMJ-BRIT MED J, V1, P867, DOI 10.1136/bmj.1.6014.867; KERR JW, 1970, BMJ-BRIT MED J, V2, P139, DOI 10.1136/bmj.2.5702.139; KONIG P, 1974, J ALLERGY CLIN IMMUN, V54, P14, DOI 10.1016/S0091-6749(74)80003-5; MASCIA AV, 1976, ANN ALLERGY, V37, P1; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; MCLEAN WL, 1973, AM J DIS CHILD, V125, P332, DOI 10.1001/archpedi.1973.04160030014003; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; ROSSING TH, 1982, J APPL PHYSIOL, V52, P1119, DOI 10.1152/jappl.1982.52.5.1119; RYO UY, 1976, JAMA-J AM MED ASSOC, V236, P927; SHEPPARD D, 1981, AM REV RESPIR DIS, V124, P257; SILVERMAN M, 1973, THORAX, V28, P574, DOI 10.1136/thx.28.5.574; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; WOENNE R, 1979, AM REV RESPIR DIS, V119, P927; WOLFE JD, 1979, J ALLERGY CLIN IMMUN, V63, P162	34	60	60	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	3					331	338		10.1016/0091-6749(83)90088-X	http://dx.doi.org/10.1016/0091-6749(83)90088-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH188	6402540				2022-12-18	WOS:A1983QH18800010
J	SHAPIRO, GG; FURUKAWA, CT; PIERSON, WE; BIERMAN, CW				SHAPIRO, GG; FURUKAWA, CT; PIERSON, WE; BIERMAN, CW			METHACHOLINE BRONCHIAL CHALLENGE IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON, SCH MED, DEPT PEDIAT, SEATTLE, WA 98195 USA; CHILDRENS ORTHOPED HOSP & MED CTR, DIV ALLERGY, SEATTLE, WA 98105 USA	University of Washington; University of Washington Seattle								BIERMAN CW, 1975, PEDIATRICS 2, V56; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CORRAO WM, 1979, NEW ENGL J MED, V300, P633, DOI 10.1056/NEJM197903223001201; EGGLESTON PA, 1976, J ALLERGY CLIN IMMUN, V58, P414, DOI 10.1016/0091-6749(76)90122-6; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; HARGREAVE FE, 1980, AIRWAY REACTIVITY ME; KIVILOOG J, 1973, SCAND J RESPIR DIS, V54, P359; MAKINO S, 1966, J ALLERGY, V38, P127, DOI 10.1016/0021-8707(66)90036-0; MELLIS CM, 1978, AM REV RESPIR DIS, V117, P911; MUITTARI A, 1968, Annales Medicinae Internae Fenniae, V57, P197; MYERS JR, 1981, JAMA-J AM MED ASSOC, V246, P225, DOI 10.1001/jama.246.3.225; OREHEK J, 1977, AM REV RESPIR DIS, V115, P937; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; Polgar G, 1971, PULMONARY FUNCTION T; TIFFENEAU R, 1956, PRESSE MED, V64, P719; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5	17	60	60	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	4					365	369		10.1016/0091-6749(82)90147-6	http://dx.doi.org/10.1016/0091-6749(82)90147-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL280	6802893	Bronze			2022-12-18	WOS:A1982NL28000006
J	PETERSON, AP; ALTMAN, LC; HILL, JS; GOSNEY, K; KADIN, ME				PETERSON, AP; ALTMAN, LC; HILL, JS; GOSNEY, K; KADIN, ME			GLUCOCORTICOID RECEPTORS IN NORMAL HUMAN EOSINOPHILS - COMPARISON WITH NEUTROPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON,DEPT MED,DIV ALLERGY & INFECT DIS,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT LAB MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT OBSTET & GYNECOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195; VIRGINIA MASON CLIN,SEATTLE,WA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Virginia Mason Medical Center					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE002600] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-02600] Funding Source: Medline; NIGMS NIH HHS [GM-24990] Funding Source: Medline; PHS HHS [A-107763] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTMAN LC, 1981, J CLIN INVEST, V67, P28, DOI 10.1172/JCI110024; BAXTER JD, 1970, P NATL ACAD SCI USA, V65, P709, DOI 10.1073/pnas.65.3.709; BEESON PB, 1977, EOSINOPHIL, P147; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CLARK RAF, 1979, BLOOD, V53, P633; CRABTREE GR, 1979, NATURE, V279, P338, DOI 10.1038/279338a0; CRABTREE GR, 1978, CANCER RES, V38, P4268; DAY RP, 1970, IMMUNOLOGY, V18, P955; GEUSKENS M, 1977, VIRCHOWS ARCH B, V24, P67; Goldstein I M, 1976, Inflammation, V1, P305, DOI 10.1007/BF00917870; GORDON AS, 1955, ANN NY ACAD SCI, V59, P907, DOI 10.1111/j.1749-6632.1955.tb45990.x; HAMMERSCHMIDT DE, 1979, J CLIN INVEST, V63, P798, DOI 10.1172/JCI109365; HILLS AG, 1948, BLOOD, V3, P755, DOI 10.1182/blood.V3.7.755.755; LIAO S, 1975, INT REV CYTOL, V41, P87, DOI 10.1016/S0074-7696(08)60967-5; LIPPMAN ME, 1978, CANCER RES, V38, P4251; LIPPMAN ME, 1977, GLUCOCORTICOID HORMO, P390; LIPPMAN ME, 1976, HORMONE RECEPTOR INT, P221; Munck A., 1977, RECEPTORS MECHANIS 2, P311; MURAKAMI T, 1979, ENDOCRINOLOGY, V104, P500, DOI 10.1210/endo-104-2-500; MURAKAMI T, 1979, J STEROID BIOCHEM, V10, P475, DOI 10.1016/0022-4731(79)90207-3; NEIFELD JP, 1977, J BIOL CHEM, V252, P2972; RAUCH HC, 1961, ENDOCRINOLOGY, V68, P375, DOI 10.1210/endo-68-3-375; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIMONSSON B, 1976, ACTA PHYSIOL SCAND, V98, P131, DOI 10.1111/j.1748-1716.1976.tb00232.x; SIMONSSON B, 1972, ACTA PHYSIOL SCAND, V86, P398, DOI 10.1111/j.1748-1716.1972.tb05345.x; SPRY C, 1976, YALE J BIOL MED, V49, P411; TCHERNITCHIN A, 1976, DIFFERENTIATION, V5, P145, DOI 10.1111/j.1432-0436.1976.tb00905.x; TCHERNITCHIN A, 1976, EXPERIENTIA, V32, P1240, DOI 10.1007/BF01953070; WERB F, 1978, J EXP MED, V47, P1684; [No title captured]	30	60	61	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	3					212	217		10.1016/0091-6749(81)90186-X	http://dx.doi.org/10.1016/0091-6749(81)90186-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG544	7264103	Bronze			2022-12-18	WOS:A1981MG54400008
J	ROSENTHAL, RR				ROSENTHAL, RR			EMERGING ROLE OF BRONCHOPROVOCATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ROSENTHAL, RR (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,DIV ALLERGY & IMMUNOL,BALTIMORE,MD 21239, USA.							ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; BLEECKER ER, 1979, AM REV RESPIR DIS, V119, P60; BOUSHEY H, 1977, CHEST, V72, P3; BRUCE CA, 1974, J ALLERGY CLIN IMMUN, V53, P230, DOI 10.1016/0091-6749(74)90085-2; BRUCE CA, 1975, J ALLERGY CLIN IMMUN, V56, P331, DOI 10.1016/0091-6749(75)90126-8; CASE RL, 1979, J ALLERGY CLIN IMMUN, V63, P161; CASTERLINE CL, 1976, J ALLERGY CLIN IMMUN, V58, P607, DOI 10.1016/0091-6749(76)90207-4; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; FISH JE, 1977, AM REV RESPIR DIS, V115, P371; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; FORD L, 1979, J ALLERGY CLIN IMMUN, V63, P160; KATCHER ML, 1979, J ALLERGY CLIN IMMUN, V63, P160; LAUBE BL, UNPUBLISHED; PERMUTT S, 1977, ASTHMA, V2, P265; REED CE, 1979, J ALLERGY CLIN IMMUN, V63, P164; ROSENBERG GL, 1975, J ALLERGY CLIN IMMUN, V55, P2; ROSENTHAL R R, 1977, American Review of Respiratory Disease, V115, P72; ROSENTHAL R R, 1978, American Review of Respiratory Disease, V117, P76; ROSENTHAL RR, 1977, J APPL PHYSIOL, V42, P600, DOI 10.1152/jappl.1977.42.4.600; ROSENTHAL RR, 1978, J ALLERGY CLIN IMMUN, V61, P139, DOI 10.1016/0091-6749(78)90275-0; ROSENTHAL RR, 1976, J ALLERGY CLIN IMMUN, V57, P223; ROSENTHAL RR, 1978, CHEST              S, V73, pS977; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; WOENNE R, 1978, J ALLERGY CLIN IMMUN, V62, P119, DOI 10.1016/0091-6749(78)90089-1	24	60	60	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					564	568		10.1016/0091-6749(79)90013-7	http://dx.doi.org/10.1016/0091-6749(79)90013-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX843	512246				2022-12-18	WOS:A1979HX84300001
J	TOOGOOD, JH; LEFCOE, NM; HAINES, DSM; CHUANG, L; JENNINGS, B; ERRINGTON, N; BAKSH, L; CAUCHI, M				TOOGOOD, JH; LEFCOE, NM; HAINES, DSM; CHUANG, L; JENNINGS, B; ERRINGTON, N; BAKSH, L; CAUCHI, M			MINIMUM DOSE REQUIREMENTS OF STEROID-DEPENDENT ASTHMATIC-PATIENTS FOR AEROSOL BECLOMETHASONE AND ORAL PREDNISONE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WESTERN ONTARIO, SCH MED, DEPT MED, LONDON N6A 3K7, ONTARIO, CANADA; UNIV WESTERN ONTARIO, SCH MED, DEPT PATHOL CHEM, LONDON N6A 3K7, ONTARIO, CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario)	TOOGOOD, JH (corresponding author), VICTORIA HOSP, ALLERGY CLIN, LONDON NA6 4G5, ONTARIO, CANADA.							BOE J, 1975, CURR THER RES CLIN E, V17, P460; BONDAREVSKY E, 1976, JAMA-J AM MED ASSOC, V236, P1969; BULOW KB, 1974, CURR THER RES CLIN E, V16, P1110; CAMERON SJ, 1973, BRIT MED J, V4, P205, DOI 10.1136/bmj.4.5886.205; CHAMPION P, 1975, CAN MED ASSOC J, V113, P213; COSTELLO JF, 1974, THORAX, V29, P571, DOI 10.1136/thx.29.5.571; DAVIES G, 1977, ANN INTERN MED, V86, P549, DOI 10.7326/0003-4819-86-5-549; GADDIE J, 1973, LANCET, V2, P280; GODFREY S, 1973, ARCH DIS CHILD, V48, P665, DOI 10.1136/adc.48.9.665; GRANT IWB, 1975, POSTGRAD MED J, V51, P57; HARGREAVE FE, 1969, BMJ-BRIT MED J, V1, P443, DOI 10.1136/bmj.1.5641.443-b; HARVEY LL, 1976, CHEST, V70, P345, DOI 10.1378/chest.70.3.345; KASS I, 1977, CHEST, V71, P703, DOI 10.1378/chest.71.6.703; KEHLET H, 1973, BRIT J ANAESTH, V45, P1043, DOI 10.1093/bja/45.10.1043; KERIGAN AT, 1977, CAN MED ASSOC J, V116, P867; LAL S, 1972, BMJ-BRIT MED J, V3, P314, DOI 10.1136/bmj.3.5822.314; LEEHONG E, 1977, ANN ALLERGY, V38, P242; LIEBERMAN P, 1972, J ALLERGY CLIN IMMUN, V49, P329, DOI 10.1016/0091-6749(72)90131-5; LOVERA J, 1976, J ALLERGY CLIN IMMUN, V57, P112, DOI 10.1016/0091-6749(76)90030-0; MABERLY DJ, 1973, BRIT MED J, V1, P778, DOI 10.1136/bmj.1.5856.778; MACDONALD JB, 1976, BRIT MED J, V1, P1493, DOI 10.1136/bmj.1.6024.1493; MAUNSELL K, 1968, BMJ-BRIT MED J, V1, P661, DOI 10.1136/bmj.1.5593.661; MCALISTER NH, 1974, COMPUT BIOMED RES, V7, P496, DOI 10.1016/0010-4809(74)90028-7; MELLIS CM, 1977, THORAX, V32, P29, DOI 10.1136/thx.32.1.29; MELLIS CM, 1976, MED J AUSTRALIA, V1, P957, DOI 10.5694/j.1326-5377.1976.tb141209.x; MESSERLI C, 1975, PNEUMONOLOGIE, V153, P29, DOI 10.1007/BF02096333; MORRIS HG, 1974, J PEDIATR-US, V85, P248, DOI 10.1016/S0022-3476(74)80406-3; Morrow-Brown H., 1972, BRIT MED J, V1, P585; MORROWBROWN H, 1973, BRIT MED J, V3, P161; MORROWBROWN H, 1975, POSTGRAD MED J    S4, V51, P59; MURPHY BEP, 1967, J CLIN ENDOCR METAB, V27, P973, DOI 10.1210/jcem-27-7-973; PLUMPTON FS, 1969, ANAESTHESIA, V24, P3, DOI 10.1111/j.1365-2044.1969.tb02798.x; REES HA, 1962, BMJ-BRIT MED J, P1575, DOI 10.1136/bmj.1.5292.1575; ROTSTEIN J, 1957, ARCH INTERN MED, V99, P545, DOI 10.1001/archinte.1957.00260040045005; SMYLLIE HC, 1968, THORAX, V23, P571, DOI 10.1136/thx.23.6.571; TOOGOOD J, 1974, ACTA ALLERGOL, P50; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V60, P367, DOI 10.1016/0091-6749(77)90068-9; TOOGOOD JH, 1973, CHEST, V63, P881, DOI 10.1378/chest.63.6.881; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; TOOGOOD JH, UNPUBLISHED; TOOGOOD JH, 1977, MEDINFO 77, P401; VANDENBERG R, 1975, MED J AUSTRALIA, V1, P189, DOI 10.5694/j.1326-5377.1975.tb111324.x; VOGT F, 1976, J ALLERGY CLIN IMMUN, V58, P316, DOI 10.1016/0091-6749(76)90137-8; WILLEY RF, 1976, BRIT J DIS CHEST, V70, P32, DOI 10.1016/0007-0971(76)90004-8; 1976, BRIT J DIS CHEST, V70, P95; 1976, PHYSICIANS INFORMATI, P13; 1969, STANDARDS EPIDEMOLOG	47	60	60	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	6					355	364		10.1016/0091-6749(78)90114-8	http://dx.doi.org/10.1016/0091-6749(78)90114-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC593	659727	Bronze			2022-12-18	WOS:A1978FC59300003
J	YUNGINGER, JW; JONES, RT; LEIFERMAN, KM; PAULL, BR; WELSH, PW; GLEICH, GJ				YUNGINGER, JW; JONES, RT; LEIFERMAN, KM; PAULL, BR; WELSH, PW; GLEICH, GJ			IMMUNOLOGICAL AND BIOCHEMICAL STUDIES IN BEEKEEPERS AND THEIR FAMILY MEMBERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN, DEPT INTERNAL MED, ROCHESTER, MN 55901 USA; MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55901 USA; MAYO CLIN & MAYO FDN, DEPT PEDIAT, ROCHESTER, MN 55901 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	YUNGINGER, JW (corresponding author), MAYO CLIN & MAYO FDN, SCH MED, ALLERG DIS RES LAB, ROCHESTER, MN 55901 USA.							BARKER SA, 1967, CLIN CHIM ACTA, V17, P119, DOI 10.1016/0009-8981(67)90105-2; BARKER SA, 1966, CLIN CHIM ACTA, V13, P582, DOI 10.1016/0009-8981(66)90162-8; BENTON AV, 1973, REV FRANC DAPICULT, V31, P399; BERNTON HS, 1965, J ALLERGY, V36, P315, DOI 10.1016/0021-8707(65)90038-9; BUSSE WW, 1975, JAMA-J AM MED ASSOC, V231, P1154, DOI 10.1001/jama.231.11.1154; DIXON WJ, 1969, INTRO STATISTICAL AN, P114; ELLIS RV, 1931, J ALLERGY, V3, P247; GLEICH GJ, 1969, IMMUNOCHEMISTRY, V6, P85, DOI 10.1016/0019-2791(69)90181-5; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; KABAT EA, 1967, EXPT IMMUNOCHEMISTRY, P559; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; Lichtenstein LM, 1974, NEW ENGL J MED, V290, P1123; LIGHT W C, 1975, Clinical Allergy, V5, P389, DOI 10.1111/j.1365-2222.1975.tb01878.x; LIGHT WC, 1977, J ALLERGY CLIN IMMUN, V59, P247, DOI 10.1016/0091-6749(77)90158-0; LOVELESS MARY HEWITT, 1956, ANN ALLERGY, V14, P347; MOHAMMED AH, 1961, NATURE, V189, P837, DOI 10.1038/189837b0; SCHWARTZ HJ, 1965, J AMER MED ASSOC, V194, P703, DOI 10.1001/jama.194.7.703; STEIGERW.F, 1966, IND MED SURG, V35, P1045; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	21	60	60	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	2					93	101		10.1016/0091-6749(78)90231-2	http://dx.doi.org/10.1016/0091-6749(78)90231-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EL413	621349				2022-12-18	WOS:A1978EL41300005
J	SETTIPANE, GA; CHAFEE, FH; POSTMAN, IM; LEVINE, MI; SAKER, JH; BARRICK, RH; NICHOLAS, SS; SCHWARTZ, HJ; HONSINGER, RW; KLEIN, DE				SETTIPANE, GA; CHAFEE, FH; POSTMAN, IM; LEVINE, MI; SAKER, JH; BARRICK, RH; NICHOLAS, SS; SCHWARTZ, HJ; HONSINGER, RW; KLEIN, DE			SIGNIFICANCE OF TARTRAZINE SENSITIVITY IN CHRONIC URTICARIA OF UNKNOWN ETIOLOGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BRUNN E, 1950, ACTA ALLERGOL, V3, P281; CHAFEE FH, 1967, J ALLERGY, V40, P65, DOI 10.1016/0021-8707(67)90099-8; CHAFEE FH, 1974, J ALLERGY CLIN IMMUN, V53, P193, DOI 10.1016/0091-6749(74)90080-3; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; COOKE RA, 1947, ALLERGY THEORY PRACT, P301; FLOWER RJ, 1973, AM HEART J, V86, P844, DOI 10.1016/0002-8703(73)90292-5; GREEN GR, 1965, ANN ALLERGY, V23, P30; HAGY GW, 1971, J ALLERGY CLIN IMMUN, V48, P200, DOI 10.1016/0091-6749(71)90066-2; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; HELLGREN L, 1964, ACTA ALLERGOL, V19, P406, DOI 10.1111/j.1398-9995.1964.tb03269.x; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; JUHLIN L, 1972, J ALLERGY CLIN IMMUN, V50, P92, DOI 10.1016/0091-6749(72)90004-8; LOCKEY STEPHEN D., 1959, ANN ALLERGY, V17, P719; MICHAELS.G, 1969, ACTA DERM-VENEREOL, V49, P404; MICHAELSSON G, 1973, BRIT J DERMATOL, V88, P525, DOI 10.1111/j.1365-2133.1973.tb08014.x; MOOREROB.M, 1967, BRIT MED J, V4, P262, DOI 10.1136/bmj.4.5574.262; PLUMBE S, 1837, PRACTICAL TREATISE D, P197; RACKEMANN FM, 1931, CLINICAL ALLERGY PAR, P526; ROBERT A, 1967, AM J DIG DIS, V12, P1073, DOI 10.1007/BF02233268; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; SETTIPANE GA, 1974, J ALLERGY CLIN IMMUN, V53, P200, DOI 10.1016/0091-6749(74)90081-5; SETTIPANE GA, 1975, J ALLERGY CLIN IMMUN, V56, P215, DOI 10.1016/0091-6749(75)90092-5; SPEER F, 1958, MANAGEMENT CHILDHOOD, P23; WARIN RP, 1960, BRIT J DERMATOL, V72, P350, DOI 10.1111/j.1365-2133.1960.tb13817.x; WYNVEEN WB, 1974, CLIN RES, V22, pA745; 1971, FOOD COLORS	26	60	60	1	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	6					541	546		10.1016/0091-6749(76)90004-X	http://dx.doi.org/10.1016/0091-6749(76)90004-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BV054	777074				2022-12-18	WOS:A1976BV05400004
J	GLEICH, GJ; JONES, RT				GLEICH, GJ; JONES, RT			MEASUREMENT OF IGE ANTIBODIES BY RADIOALLERGOSORBENT TEST .1. TECHNICAL CONSIDERATIONS IN PERFORMANCE OF TEST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,MED SCH,ROCHESTER,MN; MAYO CLIN & MAYO FDN,DEPT MED,ALLERGIC DIS RES LAB,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT MICROBIOL,ROCHESTER,NY; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic								AAS K, 1971, J ALLERGY CLIN IMMUN, V48, P134, DOI 10.1016/0091-6749(71)90008-X; BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; BERG T, 1971, INT ARCH ALLER A IMM, V41, P452, DOI 10.1159/000230539; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CESKA M, 1972, EUR J IMMUNOL, V2, P58, DOI 10.1002/eji.1830020112; EVANS R, 1972, J ALLERGY CLIN IMMUN, V49, P285, DOI 10.1016/0091-6749(72)90096-6; FAGERBERG E, 1970, INT ARCH ALLER A IMM, V39, P301, DOI 10.1159/000230356; FOUCARD T, 1973, J ALLERGY CLIN IMMUN, V51, P39, DOI 10.1016/0091-6749(73)90007-9; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GLEICH GJ, 1973, J MED, V26, P39; GLEICH GJ, UNPUBLISHED OBSERVAT; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HOLFORDSTREVENS V, 1970, CLIN EXP IMMUNOL, V6, P49; HULDT G, 1973, ARCH ENVIRON HEALTH, V26, P36, DOI 10.1080/00039896.1973.10666216; Johansson S G, 1972, Prog Clin Immunol, V1, P157; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; REISMAN RE, 1973, INT ARCH ALLER A IMM, V44, P161, DOI 10.1159/000230925; SARSFIELD JK, 1973, CLIN EXP IMMUNOL, V13, P619; STENIUS B, 1969, LANCET, V2, P455; WIDE L, 1971, Clinical Allergy, V1, P171, DOI 10.1111/j.1365-2222.1971.tb03016.x; WIDE L, 1967, LANCET, V2, P1105; YALOW RS, 1969, EXCERPTA MEDICA  161, P605; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P326, DOI 10.1016/0091-6749(72)90036-X; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	26	60	60	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	5					334	345		10.1016/0091-6749(75)90005-6	http://dx.doi.org/10.1016/0091-6749(75)90005-6			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AB754	1168214	Bronze			2022-12-18	WOS:A1975AB75400005
J	YUNGINGER, JW; GLEICH, GJ				YUNGINGER, JW; GLEICH, GJ			MEASUREMENT OF RAGWEED ANTIGEN E BY DOUBLE ANTIBODY RADIOIMMUNOASSAY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ANDERSON LB, 1970, J ALLERGY, V45, P310, DOI 10.1016/0021-8707(70)90037-7; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; FEIGEN GA, 1967, INT ARCH ALLER A IMM, V32, P174, DOI 10.1159/000229926; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HUNTER WM, 1967, HDB EXPT IMMUNOLOGY, P647; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; LICHTENSTEIN LM, 1966, J ALLERGY, V38, P174, DOI 10.1016/0021-8707(66)90040-2; MACY NE, 1968, P SOC EXP BIOL MED, V128, P1098; MALLEY A, 1964, J IMMUNOL, V93, P420; MIDGLEY AR, 1969, ACTA ENDOCRINOL-COP, VS 63, P163; PAYNE WILLARD W., 1964, J ARNOLD ARBORETUM HARVARD UNIV, V45, P401; Scheff?, 1970, J AM STAT ASSOC, V65, P1501, DOI DOI 10.1080/01621459.1970.10481179; SHELDON JM, 1967, MANUAL CLINICAL ALLE, P511; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P109, DOI 10.1016/0091-6749(72)90006-1	15	60	60	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	6					326	+		10.1016/0091-6749(72)90036-X	http://dx.doi.org/10.1016/0091-6749(72)90036-X			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	O2043	4628905				2022-12-18	WOS:A1972O204300002
J	Risma, KA; Edwards, KM; Hummell, DS; Little, FF; Norton, AE; Stallings, A; Wood, RA; Milner, JD				Risma, Kimberly A.; Edwards, Kathryn M.; Hummell, Donna S.; Little, Frederic F.; Norton, Allison E.; Stallings, Amy; Wood, Robert A.; Milner, Joshua D.			Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; adults; prevalence; food allergy COVID-19 vaccine; mRNA vaccine; anaphylaxis; allergy; polyethylene glycol; PEGylated liposome; lipid nanoparticle; mast cells	PEGYLATED LIPOSOMAL DOXORUBICIN; POLYETHYLENE-GLYCOL; ACTIVATION; PEG; COMPLEMENT; ANTIBODIES; HYPERSENSITIVITY; MASTOCYTOSIS; IGG	Anaphylaxis to vaccines is historically a rare event. The coronavirus disease 2019 pandemic drove the need for rapid vaccine production applying a novel antigen delivery system: messenger RNA vaccines packaged in lipid nanoparticles. Unexpectedly, public vaccine administration led to a small number of severe allergic reactions, with resultant substantial public concern, especially within atopic individuals. We reviewed the constituents of the messenger RNA lipid nanoparticle vaccine and considered several contributors to these reactions: (1) contact system activation by nucleic acid, (2) complement recognition of the vaccine-activating allergic effector cells, (3) preexisting antibody recognition of polyethylene glycol, a lipid nanoparticle surface hydrophilic polymer, and (4) direct mast cell activation, coupled with potential genetic or environmental predispositions to hypersensitivity. Unfortunately, measurement of antipolyethylene glycol antibodies in vitro is not clinically available, and the predictive value of skin testing to polyethylene glycol components as a coronavirus disease 2019 messenger RNA vaccine-specific anaphylaxis marker is unknown. Even less is known regarding the applicability of vaccine use for testing (in vitro/vivo) to ascertain pathogenesis or predict reactivity risk. Expedient and thorough research-based evaluation of patients who have suffered anaphylactic vaccine reactions and prospective clinical trials in putative at-risk individuals are needed to address these concerns during a public health crisis.	[Risma, Kimberly A.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Edwards, Kathryn M.] Vanderbilt Univ, Med Ctr, Dept Pediat, Div Infect Dis, 221 Kirkland Hall, Nashville, TN 37232 USA; [Hummell, Donna S.; Norton, Allison E.] Vanderbilt Univ, Sch Med, Monroe Carell Jr Childrens Hosp Vanderbilt, Div Pediat Allergy Immunol & Pulm Med,Dept Pediat, Nashville, TN 37212 USA; [Little, Frederic F.] Boston Univ, Sch Med, Dept Pediat, Div Pulm Allergy Sleep & Crit Care Med, Boston, MA 02118 USA; [Stallings, Amy] Duke Univ, Med Ctr, Div Pediat Allergy & Immunol, Durham, NC 27706 USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Div Pediat Allergy & Immunol, Baltimore, MD USA; [Milner, Joshua D.] Columbia Univ, Dept Pediat, Irving Med Ctr, New York, NY 10027 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Vanderbilt University; Vanderbilt University; Boston University; Duke University; Johns Hopkins University; Columbia University; NewYork-Presbyterian Hospital	Risma, KA (corresponding author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Kimberly.Risma@cchmc.org						Akin C, 2010, J ALLERGY CLIN IMMUN, V126, P1099, DOI 10.1016/j.jaci.2010.08.035; Alberts DS, 1997, DRUGS, V54, P30, DOI 10.2165/00003495-199700544-00007; Alysandratos KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048934; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bahri R, 2018, J ALLERGY CLIN IMMUN, V142, P485, DOI 10.1016/j.jaci.2018.01.043; Balbino B, 2020, J CLIN INVEST, V130, P1330, DOI 10.1172/JCI129697; Banerji A, 2021, J ALLER CL IMM-PRACT, V9, P1423, DOI 10.1016/j.jaip.2020.12.047; Barenholz Y, 2012, J CONTROL RELEASE, V160, P117, DOI 10.1016/j.jconrel.2012.03.020; Bender L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01115; Beutier H, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aan5997; Bonadonna P, 2010, CURR OPIN ALLERGY CL, V10, P347, DOI 10.1097/ACI.0b013e32833b280c; Chanan-Khan A, 2003, ANN ONCOL, V14, P1430, DOI 10.1093/annonc/mdg374; Corbett KS, 2020, NATURE, V586, P567, DOI 10.1038/s41586-020-2622-0; Cullis PR, 2017, MOL THER, V25, P1467, DOI 10.1016/j.ymthe.2017.03.013; Duguay BA, 2018, J LEUKOCYTE BIOL, V104, P587, DOI 10.1002/JLB.3TA0517-192R; Fan Z, 2019, ALLERGOL IMMUNOPATH, V47, P506, DOI 10.1016/j.aller.2019.03.001; Finkelman FD, 2016, J ALLERGY CLIN IMMUN, V137, P1674, DOI 10.1016/j.jaci.2016.02.015; Ganson NJ, 2016, J ALLERGY CLIN IMMUN, V137, P1610, DOI 10.1016/j.jaci.2015.10.034; Ganson NJ, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1861; Garay RP, 2012, EXPERT OPIN DRUG DEL, V9, P1319, DOI 10.1517/17425247.2012.720969; Garcia-Rodriguez KM, 2020, IMMUN INFLAMM DIS, V8, P198, DOI 10.1002/iid3.295; Giangrande N, 2019, ANN ALLERG ASTHMA IM, V123, P302, DOI 10.1016/j.anai.2019.07.002; Greiner G, 2021, BLOOD, V137, P238, DOI 10.1182/blood.2020006157; Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033; Hox V, 2015, J ALLERGY CLIN IMMUN, V135, P729, DOI 10.1016/j.jaci.2014.11.003; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jonsson F, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat1479; Cerda VJ, 2019, ALLERGY ASTHMA CL IM, V15, DOI 10.1186/s13223-019-0327-4; Khalil A, 2022, HAEMATOLOGICA, V107, P49, DOI 10.3324/haematol.2020.258525; Kozma GT, 2020, ADV DRUG DELIVER REV, V154, P163, DOI 10.1016/j.addr.2020.07.024; Krantz MS, 2020, J ALLER CL IMM-PRACT, V8, P1416, DOI 10.1016/j.jaip.2019.12.041; Laczko D, 2020, IMMUNITY, V53, P724, DOI 10.1016/j.immuni.2020.07.019; Liu YW, 2019, J CLIN ONCOL, V37, P2051, DOI 10.1200/JCO.18.02439; Lu IN, 2020, J ALLER CL IMM-PRACT, V8, P3194, DOI 10.1016/j.jaip.2020.04.057; Lyons JJ, 2021, J ALLERGY CLIN IMMUN, V147, P622, DOI 10.1016/j.jaci.2020.06.035; Lyons JJ, 2016, NAT GENET, V48, P1564, DOI 10.1038/ng.3696; McNeil MM, 2018, J ALLERGY CLIN IMMUN, V141, P463, DOI 10.1016/j.jaci.2017.12.971; Moghimi SM, 2010, J CONTROL RELEASE, V146, P175, DOI 10.1016/j.jconrel.2010.04.003; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Norton AE, 2019, ANN ALLERG ASTHMA IM, V122, P148, DOI 10.1016/j.anai.2018.11.014; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Picard M, 2013, CLIN THER, V35, P548, DOI 10.1016/j.clinthera.2013.04.001; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Povsic TJ, 2016, J ALLERGY CLIN IMMUN, V138, P1712, DOI 10.1016/j.jaci.2016.04.058; Preissner KT, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.619221; Rama TA, 2021, J ALLERGY CLIN IMMUN, V147, P877, DOI 10.1016/j.jaci.2021.01.004; Ribo P, 2021, J ALLERGY CLIN IMMUN, V147, P1855, DOI 10.1016/j.jaci.2020.12.637; Sala-Cunill A, 2015, J ALLERGY CLIN IMMUN, V135, P1031, DOI 10.1016/j.jaci.2014.07.057; Santos AF, 2021, ALLERGY, V76, P2420, DOI 10.1111/all.14747; Santos AF, 2018, J ALLERGY CLIN IMMUN, V142, P689, DOI 10.1016/j.jaci.2018.03.011; Sellaturay P, 2021, J ALLER CL IMM-PRACT, V9, P670, DOI 10.1016/j.jaip.2020.09.029; Shimabukuro T, 2021, MMWR-MORBID MORTAL W, V70, P125, DOI [10.15585/mmwr.mm7004e1, 10.1111/ajt.16517, 10.15585/mmwr.mm7004e1externalicon]; Shimabukuro T, 2021, JAMA-J AM MED ASSOC, V325, P780, DOI 10.1001/jama.2021.0600; Stone CA, 2019, BRIT J CLIN PHARMACO, V85, P2694, DOI 10.1111/bcp.14112; Stone CA, 2019, J ALLER CL IMM-PRACT, V7, P1533, DOI 10.1016/j.jaip.2018.12.003; Szebeni J, 2011, ADV DRUG DELIVER REV, V63, P1020, DOI 10.1016/j.addr.2011.06.017; Theoharides TC, 2020, ANN ALLERG ASTHMA IM, V125, P388, DOI 10.1016/j.anai.2020.07.007; Trigunaite A, 2015, CELL IMMUNOL, V294, P87, DOI 10.1016/j.cellimm.2015.02.004; Vasiadi M, 2006, INT J IMMUNOPATH PH, V19, P787, DOI 10.1177/039463200601900408; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wenande E, 2016, CLIN EXP ALLERGY, V46, P907, DOI 10.1111/cea.12760; Jimenez-Rodriguez TW, 2018, J ASTHMA ALLERGY, V11, P121, DOI 10.2147/JAA.S159411; Woolhiser MR, 2001, EUR J IMMUNOL, V31, P3298, DOI 10.1002/1521-4141(200111)31:11<3298::AID-IMMU3298>3.0.CO;2-U; Wylon K, 2016, ALLERGY ASTHMA CL IM, V12, DOI 10.1186/s13223-016-0172-7; Yang Q, 2016, ANAL CHEM, V88, P11804, DOI 10.1021/acs.analchem.6b03437; Yang Q, 2015, WIRES NANOMED NANOBI, V7, P655, DOI 10.1002/wnan.1339; Zhou ZH, 2021, J ALLER CL IMM-PRACT, V9, P1731, DOI 10.1016/j.jaip.2020.11.011	67	59	60	6	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2021	147	6					2075	+		10.1016/j.jaci.2021.04.002	http://dx.doi.org/10.1016/j.jaci.2021.04.002		JUN 2021	10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM7YB	33857566	Bronze, Green Published			2022-12-18	WOS:000657814800013
J	Krueger, JG; Wharton, KA; Schlitt, T; Suprun, M; Torene, RI; Jiang, XY; Wang, CQ; Fuentes-Duculan, J; Hartmann, N; Peters, T; Koroleva, I; Hillenbrand, R; Letzkus, M; Yu, XJ; Li, Y; Glueck, A; Hasselberg, A; Flannery, B; Suarez-Farinas, M; Hueber, W				Krueger, James G.; Wharton, Keith A., Jr.; Schlitt, Thomas; Suprun, Maria; Torene, Rebecca I.; Jiang, Xiaoyu; Wang, Claire Q.; Fuentes-Duculan, Judilyn; Hartmann, Nicole; Peters, Thomas; Koroleva, Irina; Hillenbrand, Rainer; Letzkus, Martin; Yu, Xiaojing; Li, Yue; Glueck, Anton; Hasselberg, Anke; Flannery, Brian; Suarez-Farinas, Mayte; Hueber, Wolfgang			IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Secukinumab; IL-17A; plaque psoriasis; transcriptomics	DOUBLE-BLIND; EXPRESSION; COMORBIDITIES; TRANSCRIPTOME; INFLAMMATION; CYTOKINES; ARTHRITIS; RESPONSES; PATHWAYS; IMMUNITY	Background: Hyperactivity of the IL-23/IL-17 axis is central to plaque psoriasis pathogenesis. Secukinumab, a fully human mAb that selectively inhibits IL-17A, is approved for treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis. Secukinumab improves the complete spectrum of psoriasis manifestations, with durable clinical responses beyond 5 years of treatment. In the feed-forward model of plaque chronicity, IL-17A has been hypothesized as the key driver of pathogenic gene expression by lesional keratinocytes, but in vivo evidence in human subjects is lacking. Methods: We performed a randomized, double-blind, placebo controlled study (NCT01537432) of patients receiving secukinumab at the clinically approved dose up to 12 weeks. We then correlated plaque and nonlesional skin transcriptomic profiles with histopathologic and clinical measures of efficacy. Results: After 12 weeks of treatment, secukinumab reversed plaque histopathology in the majority of patients and modulated thousands of transcripts. Suppression of the IL-23/IL-17 axis by secukinumab was evident at week 1 and continued through week 12, including reductions in levels of the upstream cytokine IL-23, the drug target IL-17A, and downstream targets, including 13-defensin 2. Suppression of the IL-23/IL-17 axis by secukinumab at week 4 was associated with clinical and histologic responses at week 12. Secukinumab did not affect ex vivo T-cell activation, which is consistent with its favorable long-term safety profile. Conclusion: Our data suggest that IL-17A is the critical node within the multidimensional pathogenic immune circuits that maintain psoriasis plaques and that early reduction of IL-17A dependent feed-forward transcripts synthesized by hyperplastic keratinocytes favors plaque resolution.	[Krueger, James G.; Wang, Claire Q.; Fuentes-Duculan, Judilyn; Suarez-Farinas, Mayte] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10065 USA; [Wharton, Keith A., Jr.; Torene, Rebecca I.; Jiang, Xiaoyu; Koroleva, Irina] Novartis Inst Biomed Res, Cambridge, MA USA; [Schlitt, Thomas; Hartmann, Nicole; Peters, Thomas; Hillenbrand, Rainer; Letzkus, Martin; Glueck, Anton; Hueber, Wolfgang] Novartis Inst Biomed Res, Basel, Switzerland; [Suprun, Maria; Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, Dept Genet & Genom Sci, New York, NY 10029 USA; [Yu, Xiaojing] Novartis Inst Biomed Res, Shanghai, Peoples R China; [Li, Yue; Hasselberg, Anke] Novartis Pharmaceut AG, Basel, Switzerland; [Flannery, Brian] Novartis Inst Biomed Res, E Hanover, NJ USA	Rockefeller University; Novartis; Novartis; Icahn School of Medicine at Mount Sinai; Novartis; Novartis; Novartis	Krueger, JG (corresponding author), Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10065 USA.	jgk@rockefeller.edu	Peters, Thomas/GQB-3622-2022; Suprun, Maria/AAE-5507-2022; Suprun, Maria/ABE-8323-2020; Schlitt, Thomas/GWQ-8928-2022	Suprun, Maria/0000-0001-9161-4021; Wang, Qiufan/0000-0002-7331-070X; Schlitt, Thomas/0000-0002-0508-3971	Novartis Pharma AG, Basel, Switzerland; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM062754] Funding Source: NIH RePORTER	Novartis Pharma AG, Basel, Switzerland; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Jackie L. Johnson, PhD; Evelyn Altemeyer, PhD; and Rowan Higgs, PhD, of Novartis Ireland for providing medical writing support/editorial support, which was funded by Novartis Pharma AG, Basel, Switzerland, in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).We also thank the site investigators (listed in this article's Online Repository at www.jacionline.org) and, from the NIBR, Doug Selinger PhD, Preclinical Safety, for help with Spotfire. Finally, we thank Drs Christian Seemayer, Christoph Wanke, Martin Kaul, and Christian Loesche for guidance with study design and management.	Amatya N, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aat4617; Bachelez H, 2019, NEW ENGL J MED, V380, P981, DOI 10.1056/NEJMc1811317; Baeten D, 2015, NEW ENGL J MED, V373, P2534, DOI 10.1056/NEJMoa1505066; Baumer Y, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.97179; Boutet MA, 2016, CLIN EXP IMMUNOL, V184, P159, DOI 10.1111/cei.12761; Brembilla NC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01682; Chang SH, 2011, IMMUNITY, V35, P611, DOI 10.1016/j.immuni.2011.09.010; Chiricozzi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090284; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Chyou S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032828; Di Meglio P, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a015354; ELLIS CN, 1986, JAMA-J AM MED ASSOC, V256, P3110, DOI 10.1001/jama.256.22.3110; Fuentes-Duculan J, 2010, J INVEST DERMATOL, V130, P2412, DOI 10.1038/jid.2010.165; Gelfand JM, 2018, J AM ACAD DERMATOL, V79, P69, DOI 10.1016/j.jaad.2018.03.046; Golden JB, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0738-z; Gudjonsson JE, 2010, J INVEST DERMATOL, V130, P1829, DOI 10.1038/jid.2010.36; Gudjonsson JE, 2009, J INVEST DERMATOL, V129, P2795, DOI 10.1038/jid.2009.173; Guttman-Yassky E, 2008, J INVEST DERMATOL, V128, P1182, DOI 10.1038/jid.2008.4; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Haider AS, 2008, J IMMUNOL, V180, P1913, DOI 10.4049/jimmunol.180.3.1913; Hawkes JE, 2018, J IMMUNOL, V201, P1605, DOI 10.4049/jimmunol.1800013; Hawkes JE, 2017, J ALLERGY CLIN IMMUN, V140, P645, DOI 10.1016/j.jaci.2017.07.004; Kim J, 2015, DERMATOL CLIN, V33, P13, DOI 10.1016/j.det.2014.09.002; Kimball AB, 2008, J AM ACAD DERMATOL, V58, P1031, DOI 10.1016/j.jaad.2008.01.006; Krueger J, 2016, J ALLERGY CLIN IMMUN, V137, P1079, DOI 10.1016/j.jaci.2015.12.1318; Krueger JG, 2012, J ALLERGY CLIN IMMUN, V130, P145, DOI 10.1016/j.jaci.2012.04.024; Lande R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6621; Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Lynde CW, 2014, J AM ACAD DERMATOL, V71, P141, DOI 10.1016/j.jaad.2013.12.036; McInnes IB, 2015, LANCET, V386, P1137, DOI 10.1016/S0140-6736(15)61134-5; Mee JB, 2007, AM J PATHOL, V171, P32, DOI 10.2353/ajpath.2007.061067; Monin L, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028522; Moseley TA, 2003, CYTOKINE GROWTH F R, V14, P155, DOI 10.1016/S1359-6101(03)00002-9; Moustou AE, 2014, AN BRAS DERMATOL, V89, P891, DOI 10.1590/abd1806-4841.20143210; Muller A, 2018, P NATL ACAD SCI USA, V115, P10088, DOI 10.1073/pnas.1801377115; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Papp KA, 2017, NEW ENGL J MED, V376, P1551, DOI 10.1056/NEJMoa1607017; Pergolizzi S, 1998, ARCH DERMATOL RES, V290, P483, DOI 10.1007/s004030050340; Pfohler C, 2013, CURR RHEUMATOL REV, V9, P2, DOI 10.2174/1573397111309010002; Pfoertner S, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r54; Reich K, 2015, EXP DERMATOL, V24, P529, DOI 10.1111/exd.12710; Russell CB, 2014, J IMMUNOL, V192, P3828, DOI 10.4049/jimmunol.1301737; Ryan C, 2015, DERMATOL CLIN, V33, P41, DOI 10.1016/j.det.2014.09.004; Sa SM, 2007, J IMMUNOL, V178, P2229, DOI 10.4049/jimmunol.178.4.2229; Sofen H, 2014, J ALLERGY CLIN IMMUN, V133, P1032, DOI 10.1016/j.jaci.2014.01.025; Swindell WR, 2014, PHYSIOL GENOMICS, V46, P533, DOI 10.1152/physiolgenomics.00022.2014; Swindell WR, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-27; Swindell WR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034594; Thaci D, 2015, J AM ACAD DERMATOL, V73, P400, DOI 10.1016/j.jaad.2015.05.013; Varshney P, 2016, SCI REP-UK, V6, DOI 10.1038/srep19295; Wang CQF, 2014, J INVEST DERMATOL, V134, P2990, DOI 10.1038/jid.2014.268; Yao YH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002737; Zaba LC, 2007, J EXP MED, V204, P3183, DOI 10.1084/jem.20071094; Zaba LC, 2009, J ALLERGY CLIN IMMUN, V124, P1022, DOI 10.1016/j.jaci.2009.08.046	55	59	65	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2019	144	3					750	763		10.1016/j.jaci.2019.04.029	http://dx.doi.org/10.1016/j.jaci.2019.04.029			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IW8CV	31129129	hybrid			2022-12-18	WOS:000485222300020
J	Ding, Y; Zhou, LN; Xia, Y; Wang, W; Wang, Y; Li, L; Qi, ZX; Zhong, LQ; Sun, JQ; Tang, WJ; Liang, FF; Xiao, HJ; Qin, T; Luo, Y; Zhao, XZ; Shu, Z; Ru, Y; Dai, RX; Wang, H; Wang, YP; Zhang, YJ; Zhang, SQ; Gao, C; Du, HQ; Zhang, X; Chen, ZL; Wang, XC; Song, HM; Yang, J; Zhao, XD				Ding, Yuan; Zhou, Lina; Xia, Yu; Wang, Wei; Wang, Ying; Li, Li; Qi, Zhongxiang; Zhong, Linqing; Sun, Jinqiao; Tang, Wenjing; Liang, Fangfang; Xiao, Haijuan; Qin, Tao; Luo, Ying; Zhao, Xuezhen; Shu, Zhou; Ru, Ying; Dai, Rongxin; Wang, Hong; Wang, Yanping; Zhang, Yongjie; Zhang, Suqian; Gao, Cong; Du, Hongqiang; Zhang, Xuan; Chen, Zhaolong; Wang, Xiaochuan; Song, Hongmei; Yang, Jun; Zhao, Xiaodong			Reference values for peripheral blood lymphocyte subsets of healthy children in China	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							AGE		[Ding, Yuan; Zhou, Lina; Li, Li; Tang, Wenjing; Qin, Tao; Shu, Zhou; Dai, Rongxin; Wang, Yanping; Zhang, Yongjie; Zhang, Suqian; Gao, Cong; Du, Hongqiang; Zhang, Xuan; Chen, Zhaolong; Zhao, Xiaodong] Chongqing Med Univ, Childrens Hosp, Key Lab Child Dev & Disorders, Minist Educ, Chongqing, Peoples R China; [Xia, Yu; Qi, Zhongxiang; Liang, Fangfang; Luo, Ying; Yang, Jun] Shenzhen Childrens Hosp, Dept Immunol, Shenzhen, Peoples R China; [Wang, Wei; Zhong, Linqing; Xiao, Haijuan; Zhao, Xuezhen; Ru, Ying; Wang, Hong; Song, Hongmei] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pediat, Beijing, Peoples R China; [Wang, Wei; Zhong, Linqing; Xiao, Haijuan; Zhao, Xuezhen; Ru, Ying; Wang, Hong; Song, Hongmei] Peking Union Med Coll, Beijing, Peoples R China; [Wang, Ying; Sun, Jinqiao; Wang, Xiaochuan] Fudan Univ, Childrens Hosp, Dept Clin Immunol, Shanghai, Peoples R China	Chongqing Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Fudan University	Zhao, XD (corresponding author), Chongqing Med Univ, Childrens Hosp, Key Lab Child Dev & Disorders, Minist Educ, Chongqing, Peoples R China.; Yang, J (corresponding author), Shenzhen Childrens Hosp, Dept Immunol, Shenzhen, Peoples R China.; Song, HM (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pediat, Beijing, Peoples R China.; Song, HM (corresponding author), Peking Union Med Coll, Beijing, Peoples R China.; Wang, XC (corresponding author), Fudan Univ, Childrens Hosp, Dept Clin Immunol, Shanghai, Peoples R China.	xchwang@shmu.edu.cn; songhm1021@hotmail.com; rogasanz@163.com; zhaoxd530@aliyun.com			Public Welfare Scientific Research Project of China [201402012]	Public Welfare Scientific Research Project of China	This study was supported by grants from the Public Welfare Scientific Research Project of China (grant no. 201402012).	Aranburu A, 2017, EUR J IMMUNOL, V47, P327, DOI 10.1002/eji.201646642; Berrington JE, 2005, CLIN EXP IMMUNOL, V140, P289, DOI 10.1111/j.1365-2249.2005.02767.x; Huenecke S, 2008, EUR J HAEMATOL, V80, P532, DOI 10.1111/j.1600-0609.2008.01052.x; Jia LT, 2015, CYTOM PART A, V87A, P1116, DOI 10.1002/cyto.a.22716; Sack U, 2007, TRANSFUS MED HEMOTH, V34, P176, DOI 10.1159/000101357; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Tosato F, 2015, CYTOM PART A, V87A, P81, DOI 10.1002/cyto.a.22520; van Gent R, 2009, CLIN IMMUNOL, V133, P95, DOI 10.1016/j.clim.2009.05.020; Wu M, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/2932531	9	59	77	2	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					970	973		10.1016/j.jaci.2018.04.022	http://dx.doi.org/10.1016/j.jaci.2018.04.022			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29746882	Bronze			2022-12-18	WOS:000443726500028
J	Sehmi, R; Lim, HF; Mukherjee, M; Huang, C; Radford, K; Newbold, P; Boulet, LP; Dorscheid, D; Martin, JG; Nair, P				Sehmi, Roma; Lim, Hui Fang; Mukherjee, Manali; Huang, Chynna; Radford, Katherine; Newbold, Paul; Boulet, Louis-Philippe; Dorscheid, Delbert; Martin, James G.; Nair, Parameswaran			Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CELL		[Sehmi, Roma; Lim, Hui Fang; Mukherjee, Manali; Huang, Chynna; Radford, Katherine; Nair, Parameswaran] McMaster Univ, Div Respirol, Hamilton, ON, Canada; [Newbold, Paul] MedImmune LLC, Gaithersburg, MD USA; [Boulet, Louis-Philippe] Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada; [Dorscheid, Delbert] Univ British Columbia, Vancouver, BC, Canada; [Martin, James G.] McGill Univ Hlth Ctr, Res Inst, Meakins Christie Labs, Montreal, PQ, Canada	McMaster University; AstraZeneca; Medimmune; University of British Columbia; McGill University	Nair, P (corresponding author), McMaster Univ, Div Respirol, Hamilton, ON, Canada.	parames@mcmaster.ca	Mukherjee, Manali/AAE-2778-2020	Mukherjee, Manali/0000-0002-7924-7211; Martin, James/0000-0001-7574-5363; Lim, Hui Fang/0000-0002-9464-0476	AstraZeneca; AllerGen NCE	AstraZeneca(AstraZeneca); AllerGen NCE	This substudy was funded by AstraZeneca and AllerGen NCE. AstraZeneca and AllerGen NCE did not have any role in the design and conduct of the substudy, interpretation of data, or preparation of the early drafts of the manuscript. Editorial support, including editing and submission of the manuscript, was funded by AstraZeneca. All authors had full access to all data in the study and had final responsibility for the decision to submit for publication.	Dasgupta A, 2013, EUR RESPIR J, V42, P1003, DOI 10.1183/09031936.00075712; Holgate ST, 2010, DISCOV MED, V9, P439; Kolbeck R, 2010, J ALLERGY CLIN IMMUN, V125, P1344, DOI 10.1016/j.jaci.2010.04.004; Mukherjee M, 2018, AM J RESP CRIT CARE, V197, P38, DOI 10.1164/rccm.201707-1323OC; Nair P, 2017, NEW ENGL J MED, V376, P2448, DOI 10.1056/NEJMoa1703501; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Salter BM, 2017, CHEST, V152, P410, DOI 10.1016/j.chest.2017.01.021; Sehmi R, 2016, CLIN EXP ALLERGY, V46, P793, DOI 10.1111/cea.12695; Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037; Pham TH, 2016, RESP MED, V111, P21, DOI 10.1016/j.rmed.2016.01.003	10	59	60	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1529	+		10.1016/j.jaci.2018.01.008	http://dx.doi.org/10.1016/j.jaci.2018.01.008			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	29382593	Bronze			2022-12-18	WOS:000429197800050
J	Alroqi, FJ; Charbonnier, LM; Baris, S; Kiykim, A; Chou, J; Platt, CD; Algassim, A; Keles, S; Al Saud, BK; Alkuraya, FS; Jordan, M; Geha, RS; Chatila, TA				Alroqi, Fayhan J.; Charbonnier, Louis-Marie; Baris, Safa; Kiykim, Ayca; Chou, Janet; Platt, Craig D.; Algassim, Abdulrahman; Keles, Sevgi; Al Saud, Bandar K.; Alkuraya, Fowzan S.; Jordan, Michael; Geha, Raif S.; Chatila, Talal A.			Exaggerated follicular helper T-cell responses in patients with LRBA deficiency caused by failure of CTLA4-mediated regulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autoantibodies; LPS-responsive beige-like anchor; cytotoxic T lymphocyte-associated antigen 4; regulatory T cells; follicular helper T cells; follicular regulatory T cells	SYSTEMIC-LUPUS-ERYTHEMATOSUS; IMMUNE DYSREGULATION; MUTATIONS; AUTOIMMUNITY; CTLA-4; DIFFERENTIATION; DISEASE; PHENOTYPE; EXPANSION; PROMOTE	Background: LPS-responsive beige-like anchor protein (LRBA) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) deficiencies give rise to overlapping phenotypes of immune dysregulation and autoimmunity, with dramatically increased frequencies of circulating follicular helper T (cTFH) cells. Objective: We sought to determine the mechanisms of cTFH cell dysregulation in patients with LRBA deficiency and the utility of monitoring cTFH cells as a correlate of clinical response to CTLA4-Ig therapy. Methods: cTFH cells and other lymphocyte subpopulations were characterized. Functional analyses included in vitro follicular helper T (TFH) cell differentiation and cTFH naive B-cell cocultures. Serum soluble IL-2 receptor a chain levels and in vitro immunoglobulin production by cultured B cells were quantified by using ELISA. Results: cTFH cell frequencies in patients with LRBA or CTLA4 deficiency sharply decreased with CTLA4-Ig therapy in parallel with other markers of immune dysregulation, including soluble IL-2 receptor a chain, CD45RO(+)CD4(+) effector T cells, and autoantibodies, and this was predictive of favorable clinical responses. cTFH cells in patients with LRBA deficiency were biased toward a TH1-like cell phenotype, which was partially reversed by CTLA4-Ig therapy. LRBA-sufficient but not LRBA-deficient regulatory T cells suppressed in vitro TFH cell differentiation in a CTLA4-dependent manner. LRBA-deficient TFH cells supported in vitro antibody production by naive LRBA-sufficient B cells. Conclusions: cTFH cell dysregulation in patients with LRBA deficiency reflects impaired control of TFH cell differentiation because of profoundly decreased CTLA4 expression on regulatory T cells and probably contributes to autoimmunity in patients with this disease. Serial monitoring of cTFH cell frequencies is highly useful in gauging the clinical response of LRBA-deficient patients to CTLA4-Ig therapy.	[Alroqi, Fayhan J.; Charbonnier, Louis-Marie; Chou, Janet; Platt, Craig D.; Algassim, Abdulrahman; Keles, Sevgi; Geha, Raif S.; Chatila, Talal A.] Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Alroqi, Fayhan J.; Charbonnier, Louis-Marie; Chou, Janet; Platt, Craig D.; Algassim, Abdulrahman; Keles, Sevgi; Geha, Raif S.; Chatila, Talal A.] Harvard Med Sch, Dept Pediat, Boston, MA USA; [Baris, Safa; Kiykim, Ayca] Marmara Univ, Div Pediat Allergy Immunol, Istanbul, Turkey; [Keles, Sevgi] Necmettin Erbakan Univ, Meram Med Fac, Div Pediat Allergy & Immunol, Konya, Turkey; [Al Saud, Bandar K.] King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Riyadh, Saudi Arabia; [Alkuraya, Fowzan S.] King Faisal Specialist Hosp & Res Ctr, Dept Genet, Riyadh, Saudi Arabia; [Jordan, Michael] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH 45221 USA; [Jordan, Michael] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Immunobiol, Cincinnati, OH 45221 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Marmara University; Necmettin Erbakan University; Selcuk University; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Chatila, TA (corresponding author), Boston Childrens Hosp, Div Immunol, One Blackfan Circle, Boston, MA 02115 USA.	talal.chatila@childrens.harvard.edu	Baris, Safa/AAH-1932-2019; KIYKIM, Ayca/J-6400-2017; Kiykim, Ayca/AAJ-7089-2021	Baris, Safa/0000-0002-4730-9422; KIYKIM, Ayca/0000-0001-5821-3963; Kiykim, Ayca/0000-0001-5821-3963; Algassim, Abdulrahman/0000-0001-7834-520X; Chatila, Talal/0000-0001-7439-2762; Charbonnier, Louis-Marie/0000-0002-4594-7893	National Institutes of Health [5R01AI065617, 4R01AI100315]; Scientific and Technological Research Council of Turkey [1059B191300622]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI085090, R01AI065617, R01AI100315] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Scientific and Technological Research Council of Turkey(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants 5R01AI065617 (to T.A.C.) and 4R01AI100315 (to R.S.G.) and a grant from the Scientific and Technological Research Council of Turkey (1059B191300622; to S.K.).	Alangari A, 2012, J ALLERGY CLIN IMMUN, V130, P481, DOI 10.1016/j.jaci.2012.05.043; Alkhairy OK, 2016, J CLIN IMMUNOL, V36, P33, DOI 10.1007/s10875-015-0224-7; Borriello F, 1997, IMMUNITY, V6, P303, DOI 10.1016/S1074-7613(00)80333-7; Charbonnier LM, 2015, J ALLERGY CLIN IMMUN, V135, P217, DOI 10.1016/j.jaci.2014.10.019; Choi JY, 2015, ARTHRITIS RHEUMATOL, V67, P988, DOI 10.1002/art.39020; Chung Y, 2011, NAT MED, V17, P983, DOI 10.1038/nm.2426; Craft JE, 2012, NAT REV RHEUMATOL, V8, P337, DOI 10.1038/nrrheum.2012.58; Cubas RA, 2013, NAT MED, V19, P494, DOI 10.1038/nm.3109; Gamez-Diaz L, 2016, J ALLERGY CLIN IMMUN, V137, P223, DOI 10.1016/j.jaci.2015.09.025; He J, 2013, IMMUNITY, V39, P770, DOI 10.1016/j.immuni.2013.09.007; Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870; Kawamoto S, 2012, SCIENCE, V336, P485, DOI 10.1126/science.1217718; Kim YU, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120294; Klocke K, 2016, P NATL ACAD SCI USA, V113, pE2383, DOI 10.1073/pnas.1603892113; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Li QZ, 2007, CLIN EXP IMMUNOL, V147, P60, DOI 10.1111/j.1365-2249.2006.03251.x; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Linterman MA, 2009, J EXP MED, V206, P561, DOI 10.1084/jem.20081886; Liu R, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4100; Lo B, 2015, SCIENCE, V349, P436, DOI 10.1126/science.aaa1663; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Ma CS, 2015, J ALLERGY CLIN IMMUN, V136, P993, DOI 10.1016/j.jaci.2015.05.036; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Odegard JM, 2008, J EXP MED, V205, P2873, DOI 10.1084/jem.20080840; Rolf J, 2010, J IMMUNOL, V185, P4042, DOI 10.4049/jimmunol.1001730; Sabouri Z, 2014, P NATL ACAD SCI USA, V111, pE2567, DOI 10.1073/pnas.1406974111; Sage PT, 2016, IMMUNOL REV, V271, P246, DOI 10.1111/imr.12411; Sage PT, 2014, IMMUNITY, V41, P1026, DOI 10.1016/j.immuni.2014.12.005; Schaerli P, 2000, J EXP MED, V192, P1553, DOI 10.1084/jem.192.11.1553; Schmitt N, 2014, NAT IMMUNOL, V15, P856, DOI 10.1038/ni.2947; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Simpson N, 2010, ARTHRITIS RHEUM-US, V62, P234, DOI 10.1002/art.25032; Sweet RA, 2011, P NATL ACAD SCI USA, V108, P7932, DOI 10.1073/pnas.1018571108; Ueno H, 2015, NAT IMMUNOL, V16, P142, DOI 10.1038/ni.3054; Vinuesa CG, 2016, ANNU REV IMMUNOL, V34, P335, DOI 10.1146/annurev-immunol-041015-055605; Wang CJ, 2015, P NATL ACAD SCI USA, V112, P524, DOI 10.1073/pnas.1414576112; Wing JB, 2014, IMMUNITY, V41, P1013, DOI 10.1016/j.immuni.2014.12.006; Zhu CL, 2012, J CLIN ENDOCR METAB, V97, P943, DOI 10.1210/jc.2011-2003	38	59	59	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					1050	+		10.1016/j.jaci.2017.05.022	http://dx.doi.org/10.1016/j.jaci.2017.05.022			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	28601686	Green Accepted, Bronze			2022-12-18	WOS:000426974800025
J	Davies, EG; Cheung, M; Gilmour, K; Maimaris, J; Curry, J; Furmanski, A; Sebire, N; Halliday, N; Mengrelis, K; Adams, S; Bernatoniene, J; Bremner, R; Browning, M; Devlin, B; Erichsen, HC; Gaspar, HB; Hutchison, L; Ip, W; Ifversen, M; Leahy, TR; McCarthy, E; Moshous, D; Neuling, K; Pac, M; Papadopol, A; Parsley, KL; Poliani, L; Ricciardelli, I; Sansom, DM; Voor, T; Worth, A; Crompton, T; Markert, ML; Thrasher, AJ				Davies, E. Graham; Cheung, Melissa; Gilmour, Kimberly; Maimaris, Jesmeen; Curry, Joe; Furmanski, Anna; Sebire, Neil; Halliday, Neil; Mengrelis, Konstantinos; Adams, Stuart; Bernatoniene, Jolanta; Bremner, Ronald; Browning, Michael; Devlin, Blythe; Erichsen, Hans Christian; Gaspar, H. Bobby; Hutchison, Lizzie; Ip, Winnie; Ifversen, Marianne; Leahy, T. Ronan; McCarthy, Elizabeth; Moshous, Despina; Neuling, Kim; Pac, Malgorzata; Papadopol, Alina; Parsley, Kathryn L.; Poliani, Luigi; Ricciardelli, Ida; Sansom, David M.; Voor, Tiia; Worth, Austen; Crompton, Tessa; Markert, M. Louise; Thrasher, Adrian J.			Thymus transplantation for complete DiGeorge syndrome: European experience	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DiGeorge syndrome; athymia; thymus transplantation	T-CELLS; AUTOIMMUNE REGULATOR; RECONSTITUTION	Background: Thymus transplantation is a promising strategy for the treatment of athymic complete DiGeorge syndrome (cDGS). Methods: Twelve patients with cDGS underwent transplantation with allogeneic cultured thymus. Objective: We sought to confirm and extend the results previously obtained in a single center. Results: Two patients died of pre-existing viral infections without having thymopoiesis, and 1 late death occurred from autoimmune thrombocytopenia. One infant had septic shock shortly after transplantation, resulting in graft loss and the need for a second transplant. Evidence of thymopoiesis developed from 5 to 6 months after transplantation in 10 patients. Median circulating naive CD4 counts were 44 x 10(6)/L (range, 11-440 x 10(6)/L) and 200 x 10(6)/L (range, 5-310 x 10(6)/L) at 12 and 24 months after transplantation and T-cell receptor excision circles were 2,238/10(6) T cells (range, 320-8,807/10(6) T cells) and 4,184/10(6) T cells (range, 1,582-24,596/10(6) T cells). Counts did not usually reach normal levels for age, but patients were able to clear pre-existing infections and those acquired later. At a median of 49 months (range, 22-80 months), 8 have ceased prophylactic antimicrobials, and 5 have ceased immunoglobulin replacement. Histologic confirmation of thymopoiesis was seen in 7 of 11 patients undergoing biopsy of transplanted tissue, including 5 showing full maturation through to the terminal stage of Hassall body formation. Autoimmune regulator expression was also demonstrated. Autoimmune complications were seen in 7 of 12 patients. In 2 patients early transient autoimmune hemolysis settled after treatment and did not recur. The other 5 experienced ongoing autoimmune problems, including thyroiditis (3), hemolysis (1), thrombocytopenia (4), and neutropenia (1). Conclusions: This study confirms the previous reports that thymus transplantation can reconstitute T cells in patients with cDGS but with frequent autoimmune complications in survivors.	[Davies, E. Graham; Cheung, Melissa; Maimaris, Jesmeen; Furmanski, Anna; Mengrelis, Konstantinos; Gaspar, H. Bobby; Ip, Winnie; Parsley, Kathryn L.; Ricciardelli, Ida; Worth, Austen; Crompton, Tessa; Thrasher, Adrian J.] UCL Great Ormond St Inst Child Hlth, Infect Immun & Inflammat Theme, London, England; [Davies, E. Graham; Gilmour, Kimberly; Curry, Joe; Sebire, Neil; Adams, Stuart; Gaspar, H. Bobby; Ip, Winnie; Parsley, Kathryn L.; Worth, Austen] Great Ormond St Hosp Sick Children, Dept Immunol, London, England; [Furmanski, Anna] Univ Bedfordshire, Sch Life Sci, Luton, Beds, England; [Halliday, Neil; Sansom, David M.] UCL, Inst Immun & Transplantat, Sch Life & Med Sci, Div Infect & Immun,Royal Free Hosp, London, England; [Bernatoniene, Jolanta; Hutchison, Lizzie] Bristol Childrens Hosp, Dept Paediat Immunol & Infect Dis, Bristol, Avon, England; [Bremner, Ronald] Birmingham Childrens Hosp, Dept Gastroenterol, Birmingham, W Midlands, England; [Browning, Michael; Markert, M. Louise] Leicester Royal Infirm, Dept Immunol, Leicester, Leics, England; [Devlin, Blythe; McCarthy, Elizabeth] Duke Univ, Div Allergy & Immunol, Dept Pediat, Med Ctr, Durham, NC 27706 USA; [Erichsen, Hans Christian] Oslo Univ Hosp, Div Paediat & Adolescent Med, Sect Paediat Med & Transplantat, Oslo, Norway; [Ifversen, Marianne] Copenhagen Univ Hosp, Rigshosp, Paediat Clin 2, Copenhagen, Denmark; [Leahy, T. Ronan] Our Ladys Childrens Hosp, Dept Paediat Immunol & Infect Dis, Dublin, Ireland; [Moshous, Despina] Hop Necker Enfants Malad, Paediat Immunol Haematol & Rheumatol Unit, Paris, France; [Neuling, Kim] Univ Hosp, Dept Paediat, Coventry, W Midlands, England; [Pac, Malgorzata] Childrens Mem Hlth Inst, Dept Immunol, Warsaw, Poland; [Papadopol, Alina] Polyclin Regina Maria Baneasa, Paediat Clin, Bucharest, Romania; [Poliani, Luigi] Univ Brescia, Inst Immun & Translat Med, Brescia, Italy; [Voor, Tiia] Tartu Univ Hosp, Childrens Clin, Tartu, Estonia	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Bedfordshire; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Bristol Royal Hospital For Children; University of Birmingham; University of Leicester; Duke University; University of Oslo; Rigshospitalet; University of Copenhagen; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Warwick; Children's Memorial Health Institute; University of Brescia	Davies, EG (corresponding author), Great Ormond St Hosp Sick Children, Great Ormond St, London WC1N 3JH, England.	Graham.Davies@gosh.nhs.uk	Leahy, Ronan/AAL-5008-2021; Furmanski, Anna/AAF-3721-2020; Ifversen, Marianne/AAN-4016-2021; Ricciardelli, Ida/ABC-8937-2020; Moshous, Despina/B-7507-2017; POLIANI, Pietro Luigi/E-8145-2010	Leahy, Ronan/0000-0001-6419-9328; Furmanski, Anna/0000-0001-6126-8770; Ifversen, Marianne/0000-0002-2558-1935; Moshous, Despina/0000-0001-6719-3693; Crompton, Tessa/0000-0002-8973-4021; Thrasher, Adrian/0000-0002-6097-6115; Sansom, David/0000-0001-6506-3115; , Jesmeen/0000-0003-4169-8209; Sebire, Neil/0000-0001-5348-9063; Halliday, Neil/0000-0001-8220-9139; POLIANI, Pietro Luigi/0000-0002-5662-8978; Pac, Malgorzata/0000-0003-2071-3297	European Union Seventh Framework Programme [261387]; Great Ormond Street Hospital Children's Charity; Mason Medical Research Trust; Wellcome Trust; National Institute for Health Research [NF-SI-0513-10046] Funding Source: researchfish; Wellcome Trust [104807/Z/14/Z] Funding Source: researchfish; Great Ormond Street Hospital Childrens Charity [W1110, V1297] Funding Source: researchfish; Asthma UK [AUK-SPD-2012-171] Funding Source: researchfish	European Union Seventh Framework Programme(European Commission); Great Ormond Street Hospital Children's Charity; Mason Medical Research Trust; Wellcome Trust(Wellcome TrustEuropean Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Wellcome Trust(Wellcome TrustEuropean Commission); Great Ormond Street Hospital Childrens Charity; Asthma UK	The research leading to these results has received funding from the European Union Seventh Framework Programme ([FP7/2007-2013] [FP7/2007-2011]) under grant agreement no. 261387, the Great Ormond Street Hospital Children's Charity, the Mason Medical Research Trust, and the Wellcome Trust. All research at Great Ormond Street Hospital and UCL Great Ormond Street Institute of Child Health was made possible by the National Institute for Health Research and the Great Ormond Street Hospital Biomedical Research Centre. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health. A.J.T. is a Wellcome Trust Principal Research Fellow.	Amrolia PJ, 2006, BLOOD, V108, P1797, DOI 10.1182/blood-2006-02-001909; Anderson G, 2001, NAT REV IMMUNOL, V1, P31, DOI 10.1038/35095500; Davies EG, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00322; Furmanski AL, 2013, J INVEST DERMATOL, V133, P1221, DOI 10.1038/jid.2012.492; Hassan A, 2014, J ALLERGY CLIN IMMUN, V133, P1660, DOI 10.1016/j.jaci.2014.02.042; Heino M, 1999, BIOCHEM BIOPH RES CO, V257, P821, DOI 10.1006/bbrc.1999.0308; Janda A, 2010, BLOOD, V116, P2229, DOI 10.1182/blood-2010-03-275966; King C, 2004, CELL, V117, P265, DOI 10.1016/S0092-8674(04)00335-6; Markert ML, 2008, AM J TRANSPLANT, V8, P1729, DOI 10.1111/j.1600-6143.2008.02301.x; Markert ML, 2008, J IMMUNOL, V180, P6354, DOI 10.4049/jimmunol.180.9.6354; Markert ML, 2007, BLOOD, V109, P4539, DOI 10.1182/blood-2006-10-048652; Markert ML, 2010, CLIN IMMUNOL, V135, P236, DOI 10.1016/j.clim.2010.02.007; Markert ML, 2004, J ALLERGY CLIN IMMUN, V113, P734, DOI 10.1016/j.jaci.2004.01.766; Markert ML, 1997, J IMMUNOL, V158, P998; McGhee SA, 2009, IMMUNOL RES, V45, P37, DOI 10.1007/s12026-009-8108-7; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; Poliani PL, 2010, AM J PATHOL, V176, P1104, DOI 10.2353/ajpath.2010.090956; Rucci F, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00015; Ryan AK, 1997, J MED GENET, V34, P798, DOI 10.1136/jmg.34.10.798; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Yang J, 2000, BLOOD, V96, P4055	22	59	61	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1660	+		10.1016/j.jaci.2017.03.020	http://dx.doi.org/10.1016/j.jaci.2017.03.020			27	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28400115	Green Published, hybrid, Green Accepted			2022-12-18	WOS:000417206000021
J	Chen, CC; Kobayashi, T; Iijima, K; Hsu, FC; Kita, H				Chen, Chien-Chang; Kobayashi, Takao; Iijima, Koji; Hsu, Fan-Chi; Kita, Hirohito			IL-33 dysregulates regulatory T cells and impairs established immunologic tolerance in the lungs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Regulatory T cells; T(H)2 cells; IL-33; allergy; asthma; lung	INNATE LYMPHOID-CELLS; DENDRITIC CELLS; ALLERGIC-ASTHMA; TH2 DIFFERENTIATION; PERIPHERAL-BLOOD; AIRWAY TOLERANCE; GENE-EXPRESSION; TYPE-2 IMMUNITY; INFLAMMATION; CYTOKINE	Background: Airway exposure to environmental antigens generally leads to immunologic tolerance. A fundamental question remains: Why is airway tolerance compromised in patients with allergic airway diseases? IL-33 promotes innate and adaptive type 2 immunity and might provide the answer to this question. Objective: The goal of this study was to investigate the roles played by IL-33 in altering regulatory T (Treg) cells in the lungs and in affecting previously established airway immunologic tolerance. Methods: We analyzed CD4(+) forkhead box P3 (Foxp3)(+) Treg cells that were isolated from the lungs of naive BALB/c mice and those treated with IL-33. Airway tolerance and allergen-induced airway inflammation models in mice were used to investigate how IL-33 affects established immunologic tolerance in vivo. Results: CD4(+) Foxp3(+) Treg cells in the lungs expressed the IL-33 receptor ST2. When exposed to IL-33, Treg cells upregulated their expression of the canonical T(H)2 transcription factor GATA3, as well as ST2, and produced type 2 cytokines. Treg cells lost their ability to suppress effector T cells in the presence of IL-33. Airway administration of IL-33 with an antigen impaired immunologic tolerance in the lungs that had been established by prior exposure to the antigen. Dysregulated Foxp3(+) Treg cells with distinct characteristics of T(H)2 cells increased in the lungs of mice undergoing IL-33-dependent allergen-driven airway inflammation. Conclusions: IL-33 dysregulated lung Treg cells and impaired immunologic tolerance to inhaled antigens. Established airway tolerance might not be sustained in the presence of an innate immunologic stimulus, such as IL-33.	[Chen, Chien-Chang; Hsu, Fan-Chi; Kita, Hirohito] Mayo Clin Rochester, Dept Immunol, 200 First St SW, Rochester, MN 55905 USA; [Kobayashi, Takao; Iijima, Koji; Kita, Hirohito] Mayo Clin Rochester, Dept Med, Rochester, MN USA	Mayo Clinic; Mayo Clinic	Kita, H (corresponding author), Mayo Clin Rochester, Dept Immunol, 200 First St SW, Rochester, MN 55905 USA.; Kita, H (corresponding author), Mayo Clin Rochester, Dept Med, Div Allerg Dis, 200 First St SW, Rochester, MN 55905 USA.	kita.hirohito@mayo.edu			National Institutes of Health [R01 HL117823]; Mayo Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL117823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI128729, R01AI071106] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from the National Institutes of Health (R01 HL117823) and the Mayo Foundation.	Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Akdis CA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7390; Arpaia N, 2015, CELL, V162, P1078, DOI 10.1016/j.cell.2015.08.021; Bartemes KR, 2012, CLIN IMMUNOL, V143, P222, DOI 10.1016/j.clim.2012.03.001; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Bohm L, 2015, J IMMUNOL, V194, P887, DOI 10.4049/jimmunol.1401612; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Burzyn D, 2013, CELL, V155, P1282, DOI 10.1016/j.cell.2013.10.054; Burzyn D, 2013, NAT IMMUNOL, V14, P1007, DOI 10.1038/ni.2683; Chaudhry A, 2009, SCIENCE, V326, P986, DOI 10.1126/science.1172702; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Cook KD, 2010, J IMMUNOL, V185, P3209, DOI 10.4049/jimmunol.0902544; D'Amato G, 2005, CLIN EXP ALLERGY, V35, P1113, DOI 10.1111/j.1365-2222.2005.02328.x; Duan W, 2008, J IMMUNOL, V181, P8650, DOI 10.4049/jimmunol.181.12.8650; Endo Y, 2015, IMMUNITY, V42, P294, DOI 10.1016/j.immuni.2015.01.016; Guo LY, 2009, P NATL ACAD SCI USA, V106, P13463, DOI 10.1073/pnas.0906988106; Holgate ST, 2008, CLIN EXP ALLERGY, V38, P872, DOI 10.1111/j.1365-2222.2008.02971.x; Iijima K, 2014, J IMMUNOL, V193, P1549, DOI 10.4049/jimmunol.1302984; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; Kobayashi T, 2013, AM J RESP CELL MOL, V49, P989, DOI 10.1165/rcmb.2012-0444OC; Kobayashi T, 2009, J IMMUNOL, V182, P2502, DOI 10.4049/jimmunol.0802773; Koch MA, 2009, NAT IMMUNOL, V10, P595, DOI 10.1038/ni.1731; Kuswanto W, 2016, IMMUNITY, V44, P355, DOI 10.1016/j.immuni.2016.01.009; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lloyd CM, 2009, IMMUNITY, V31, P438, DOI 10.1016/j.immuni.2009.08.007; MacDonald KG, 2015, J ALLERGY CLIN IMMUN, V135, P946, DOI 10.1016/j.jaci.2014.12.1932; Makrinioti H, 2014, LANCET RESP MED, V2, P226, DOI 10.1016/S2213-2600(13)70261-3; Maneechotesuwan K, 2007, J IMMUNOL, V178, P2491, DOI 10.4049/jimmunol.178.4.2491; Matta BM, 2014, J IMMUNOL, V193, P4010, DOI 10.4049/jimmunol.1400481; Mehta AK, 2016, J ALLERGY CLIN IMMUN, V137, P278, DOI 10.1016/j.jaci.2015.05.007; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Molofsky AB, 2015, IMMUNITY, V43, P161, DOI 10.1016/j.immuni.2015.05.019; Murdoch JR, 2010, MUTAT RES-FUND MOL M, V690, P24, DOI 10.1016/j.mrfmmm.2009.09.005; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Ohno T, 2012, ALLERGY, V67, P1203, DOI 10.1111/all.12004; Pant H, 2014, AM J RHINOL ALLERGY, V28, pE83, DOI 10.2500/ajra.2013.28.4014; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; Rivas MN, 2015, IMMUNITY, V42, P512, DOI 10.1016/j.immuni.2015.02.004; Rudra D, 2012, NAT IMMUNOL, V13, P1010, DOI 10.1038/ni.2402; Ruprecht CR, 2005, J EXP MED, V201, P1793, DOI 10.1084/jem.20050085; Sakaguchi S, 2013, NAT REV IMMUNOL, V13, P461, DOI 10.1038/nri3464; Saruta M, 2007, CLIN IMMUNOL, V125, P281, DOI 10.1016/j.clim.2007.08.003; Schiering C, 2014, NATURE, V513, P564, DOI 10.1038/nature13577; Sharma S, 2012, AM J RHINOL ALLERGY, V26, P371, DOI 10.2500/ajra.2012.26.3800; Sharma S, 2014, J ALLERGY CLIN IMMUN, V134, P1153, DOI 10.1016/j.jaci.2014.04.011; Smyth LJC, 2007, CHEST, V132, P156, DOI 10.1378/chest.07-0083; Soroosh P, 2013, J EXP MED, V210, P775, DOI 10.1084/jem.20121849; Stellato C, 2011, J IMMUNOL, V187, P441, DOI 10.4049/jimmunol.1001881; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; van Amelsfort JMR, 2004, ARTHRITIS RHEUM, V50, P2775, DOI 10.1002/art.20499; Vasanthakumar A, 2015, NAT IMMUNOL, V16, P276, DOI 10.1038/ni.3085; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wang YQ, 2011, IMMUNITY, V35, P337, DOI 10.1016/j.immuni.2011.08.012; Wenzel SE, 2016, AM J RESP CELL MOL, V55, P1, DOI 10.1165/rcmb.2016-0141PS; Wohlfert EA, 2011, J CLIN INVEST, V121, P4503, DOI 10.1172/JCI57456; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Yagi RJ, 2014, IMMUNITY, V40, P378, DOI 10.1016/j.immuni.2014.01.012; Yamashita M, 2005, J BIOL CHEM, V280, P29409, DOI 10.1074/jbc.M502333200; Yang XO, 2008, IMMUNITY, V29, P44, DOI 10.1016/j.immuni.2008.05.007; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878	64	59	61	2	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2017	140	5					1351	+		10.1016/j.jaci.2017.01.015	http://dx.doi.org/10.1016/j.jaci.2017.01.015			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL5RV	28196763	Green Accepted, Bronze			2022-12-18	WOS:000414304300015
J	Litosh, VA; Rochman, M; Rymer, JK; Porollo, A; Kottyan, LC; Rothenberg, ME				Litosh, Vladislav A.; Rochman, Mark; Rymer, Jeffrey K.; Porollo, Aleksey; Kottyan, Leah C.; Rothenberg, Marc E.			Calpain-14 and its association with eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Calpains; calpain-14; calpainopathy; IL-13; desmoglein-1; epithelial barrier; enzymes; food allergy; genetics; eosinophils; eosinophilic esophagitis; limb-girdle muscular dystrophy; myositis	INTERLEUKIN-4 RECEPTOR-ALPHA; MUSCULAR-DYSTROPHY TYPE-2A; MUSCLE-SPECIFIC CALPAIN; KAPPA-B PATHWAY; SKELETAL-MUSCLE; CRYSTAL-STRUCTURE; ANTIMICROBIAL PEPTIDES; PROTEOLYTIC ACTIVITY; PROVIDES INSIGHT; EPITHELIAL-CELLS	Calpains are a family of intracellular, calcium-dependent cysteine proteases involved in a variety of regulatory processes, including cytoskeletal dynamics, cell-cycle progression, signal transduction, gene expression, and apoptosis. These enzymes have been implicated in a number of disease processes, notably for this review involving eosinophilic tissue inflammation, such as eosinophilic esophagitis (EoE), a chronic inflammatory disorder triggered by allergic hypersensitivity to food and associated with genetic variants in calpain 14 (CAPN14). Herein we review the genetic, structural, and biochemical properties of CAPN14 and its gene product CAPN14, and its emerging role in patients with EoE. The CAPN14 gene is localized at chromosome 2p23.1-p21 and is most homologous to CAPN13 (36% sequence identity), which is located 365 kb downstream of CAPN14. Structurally, CAPN14 has classical calpain motifs, including a cysteine protease core. In comparison with other human calpains, CAPN14 has a unique expression pattern, with the highest levels in the upper gastrointestinal tract, particularly in the squamous epithelium of the esophagus. The CAPN14 gene is positioned in an epigenetic hotspot regulated by IL-13, a T(H)2 cytokine with increased levels in patients with EoE that has been shown to be a mediator of the disease. CAPN14 induces disruptive effects on the esophageal epithelium by impairing epithelial barrier function in association with loss of desmoglein-1 expression and has a regulatory role in repairing epithelial changes induced by IL-13. Thus CAPN14 is a unique protease with distinct tissue-specific expression and function in patients with EoE and is a potential therapeutic target for EoE and related eosinophilic and allergic diseases.	[Litosh, Vladislav A.; Rochman, Mark; Rymer, Jeffrey K.; Rothenberg, Marc E.] Univ Cincinnati, Div Allergy & Immunol, Coll Med, Cincinnati, OH 45221 USA; [Porollo, Aleksey; Kottyan, Leah C.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Coll Med, Cincinnati, OH 45221 USA; [Rymer, Jeffrey K.] Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Coll Med, Cincinnati, OH 45221 USA; [Rothenberg, Marc E.] Univ Cincinnati, Dept Pediat, Coll Med, Cincinnati, OH 45221 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, MLC 7028,3333 Burnet Ave, Cincinnati, OH 45229 USA.	marc.rothenberg@cchmc.org	Kottyan, Leah C./H-3050-2019	Kottyan, Leah C./0000-0003-3979-2220; Litosh, Vladislav/0000-0002-7183-9597; Porollo, Alexey/0000-0002-3202-5099; Rochman, Mark/0000-0002-0818-927X	National Institutes of Health (NIH) [U19 AI070235, NIH R01 AI124355, NIH R01 DK107502, NIH P30 AR070549, R37 A1045898]; Campaign Urging Research for Eosinophilic Disease (CURED) Foundation; Buckeye Foundation; American Partnership for Eosinophilic Disorders (APFED) [e10078]; Sunshine Charitable Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI124355, U19AI070235, R37AI045898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR047363, P30AR070549] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK107502] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Campaign Urging Research for Eosinophilic Disease (CURED) Foundation; Buckeye Foundation; American Partnership for Eosinophilic Disorders (APFED); Sunshine Charitable Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported in part by National Institutes of Health (NIH) U19 AI070235, NIH R01 AI124355, NIH R01 DK107502, NIH P30 AR070549, R37 A1045898, the Campaign Urging Research for Eosinophilic Disease (CURED) Foundation, the Buckeye Foundation, the American Partnership for Eosinophilic Disorders (APFED; e10078), and the Sunshine Charitable Foundation and its supporters, Denise A. Bunning and David G. Bunning.	Abe K, 2007, NEURON, V53, P387, DOI 10.1016/j.neuron.2007.01.016; [Anonymous], HUM PROT COD GEN CAP; Beckmann JS, 2008, NEUROMUSCULAR DISORD, V18, P913, DOI 10.1016/j.nmd.2008.08.005; Benayoun B, 2008, FASEB J, V22, P1521, DOI 10.1096/fj.07-8701com; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Cianferoni A, 2015, CURR OPIN ALLERGY CL, V15, P417, DOI 10.1097/ACI.0000000000000200; CONG JY, 1989, J BIOL CHEM, V264, P10096; Davis BP, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86355; Dear TN, 2001, GENE, V274, P245, DOI 10.1016/S0378-1119(01)00599-6; Ghosh CC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119577; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Hashimoto R, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.110; Hornickel IN, 2011, ACTA HISTOCHEM, V113, P175, DOI 10.1016/j.acthis.2009.09.008; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Huang YC, 2008, HUM MOL GENET, V17, P1855, DOI 10.1093/hmg/ddn081; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053; Kottyan LC, 2014, NAT GENET, V46, P895, DOI 10.1038/ng.3033; Krahn M, 2007, NEUROMUSCULAR DISORD, V17, P791, DOI 10.1016/j.nmd.2007.06.107; Kramerova I, 2009, HUM MOL GENET, V18, P3194, DOI 10.1093/hmg/ddp257; Laure L, 2010, FEBS J, V277, P4322, DOI 10.1111/j.1742-4658.2010.07820.x; Low KE, 2014, BBA-GEN SUBJECTS, V1840, P3367, DOI 10.1016/j.bbagen.2014.08.014; Macqueen DJ, 2014, OPEN BIOL, V4, DOI 10.1098/rsob.130219; Marchler-Bauer A, 2015, NUCLEIC ACIDS RES, V43, pD222, DOI 10.1093/nar/gku1221; Meyer W, 2014, ACTA HISTOCHEM, V116, P235, DOI 10.1016/j.acthis.2013.07.008; Moldoveanu T, 2003, NAT STRUCT BIOL, V10, P371, DOI 10.1038/nsb917; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Moldoveanu T, 2008, NATURE, V456, P404, DOI 10.1038/nature07353; Murata K, 2003, EUR J NEUROL, V10, P35, DOI 10.1046/j.1468-1331.2003.00481.x; Oflazer PS, 2009, NEUROMUSCULAR DISORD, V19, P261, DOI 10.1016/j.nmd.2009.01.010; Ono Y, 2004, J BIOL CHEM, V279, P2761, DOI 10.1074/jbc.M308789200; Ono Y, 1998, J BIOL CHEM, V273, P17073, DOI 10.1074/jbc.273.27.17073; Ono Y, 2012, BBA-PROTEINS PROTEOM, V1824, P224, DOI 10.1016/j.bbapap.2011.08.005; Oyoshi MK, 2015, CURR OPIN PEDIATR, V27, P741, DOI 10.1097/MOP.0000000000000284; Paco S, 2012, J NEUROPATH EXP NEUR, V71, P894, DOI 10.1097/NEN.0b013e31826c6f7b; Partha SK, 2014, FEBS J, V281, P3138, DOI 10.1111/febs.12849; Peschel A, 2006, NAT REV MICROBIOL, V4, P529, DOI 10.1038/nrmicro1441; Porollo AA, 2004, BIOINFORMATICS, V20, P2460, DOI 10.1093/bioinformatics/bth248; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Richard I, 2000, J CELL BIOL, V151, P1583, DOI 10.1083/jcb.151.7.1583; Rothenberg ME, 2015, GASTROENTEROLOGY, V148, P1143, DOI 10.1053/j.gastro.2015.02.002; Samuelov L, 2013, NAT GENET, V45, P1244, DOI 10.1038/ng.2739; Selva-O'Callaghan A, 2014, AUTOIMMUN REV, V13, P375, DOI 10.1016/j.autrev.2014.01.018; Shea TB, 1997, J NEUROSCI RES, V48, P543, DOI 10.1002/(SICI)1097-4547(19970615)48:6<543::AID-JNR7>3.0.CO;2-A; Sherrill JD, 2014, GENES IMMUN, V15, P361, DOI 10.1038/gene.2014.27; Sherrill JD, 2014, MUCOSAL IMMUNOL, V7, P718, DOI 10.1038/mi.2013.90; Sherrill JD, 2011, J ALLERGY CLIN IMMUN, V128, P23, DOI 10.1016/j.jaci.2011.03.046; Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75; Sleiman PMA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6593; Smith MA, 2012, CARDIOVASC RES, V96, P32, DOI 10.1093/cvr/cvs163; Sorimachi H, 2011, P JPN ACAD B-PHYS, V87, P287, DOI 10.2183/pjab.87.287; Steubesand N, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-36; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Sugihara R, 2001, MUSCLE NERVE, V24, P1627, DOI 10.1002/mus.1198; Ueta M, 2011, JPN J OPHTHALMOL, V55, P405, DOI 10.1007/s10384-011-0030-6; Ueta M, 2010, BRIT J OPHTHALMOL, V94, P1239, DOI 10.1136/bjo.2009.173419; van Esch E, 2012, J COMP PATHOL, V147, P248, DOI 10.1016/j.jcpa.2011.11.201; Veeranna, 2004, AM J PATHOL, V165, P795, DOI 10.1016/S0002-9440(10)63342-1; VERNET T, 1995, J BIOL CHEM, V270, P16645, DOI 10.1074/jbc.270.28.16645; Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142; YOSHIZAWA T, 1995, FEBS LETT, V358, P101, DOI 10.1016/0014-5793(94)01401-L; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	63	59	61	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1762	+		10.1016/j.jaci.2016.09.027	http://dx.doi.org/10.1016/j.jaci.2016.09.027			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	28131390	Green Accepted			2022-12-18	WOS:000402724600004
J	Maniscalco, M; Paris, D; Melck, DJ; D'Amato, M; Zedda, A; Sofia, M; Stellato, C; Motta, A				Maniscalco, Mauro; Paris, Debora; Melck, Dominique J.; D'Amato, Maria; Zedda, Anna; Sofia, Matteo; Stellato, Cristiana; Motta, Andrea			Coexistence of obesity and asthma determines a distinct respiratory metabolic phenotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Obesity; asthma; phenotype; nuclear magnetic resonance; metabolomics; profiling; exhaled breath condensate; biomarkers	EXHALED BREATH CONDENSATE; RESONANCE-BASED METABOLOMICS; GUT MICROBIOTA; BODY-MASS; INFLAMMATION; METHANE; SPECTROSCOPY; ASSOCIATION; GLUCOSE; ADULTS	Background: Epidemiologic and clinical evidence supports the existence of an obesity-related asthma phenotype. No distinct pathophysiologic elements or specific biomarkers have been identified thus far, but increased oxidative stress has been reported. Objective: We aimed at verifying whether metabolomics of exhaled breath condensate from obese asthmatic (OA) patients, lean asthmatic (LA) patients, and obese nonasthmatic (ONA) subjects could recognize specific and statistically validated biomarkers for a separate "asthma-obesity'' respiratory metabolic phenotype, here defined as "metabotype.'' Methods: Twenty-five OA patients, 30 ONA subjects, and 30 mild-to-moderate LA age-matched patients participated in a cross-sectional study. Nuclear magnetic resonance (NMR) profiles were analyzed by using partial least-squares discriminant analysis, and the results were validated with an independent patient set. Results: From NMR profiles, we obtained strong regression models that distinguished OA patients from ONA subjects (quality parameters: goodness-of-fit parameter [R-2] = 0.81 and goodness-of-prediction parameter [Q(2)] = 0.79), as well as OA patients from LA patients (R-2 = 0.91 and Q(2) = 0.89). The allclasses comparison (R-2 = 0.86 and Q(2) = 0.83) indicated that OA patients possess a respiratory metabolic profile fully divergent from those obtained in the other patient groups. We also identified specific biomarkers for between-class separation, which are independent from clinical bias. They are involved in the methane, pyruvate, and glyoxylate and dicarboxylate metabolic pathways. Conclusions: NMR-based metabolomics indicates that OA patients are characterized by a respiratory metabolic fingerprint fully different from that of patients independently affected by asthma or obesity. Such a phenotypic difference strongly suggests unique pathophysiologic pathways involved in the pathogenesis of asthma in adult obese subjects. Furthermore, the OA metabotype could define a strategy for patient stratification based on unbiased biomarkers, with important diagnostic and therapeutic implications.	[Maniscalco, Mauro; Zedda, Anna] S Maria della Pieta Hosp, Sect Resp Med, Naples, Italy; [Maniscalco, Mauro] IRCCS Salvatore Maugeri Fdn, Lab Resp Inflammat, Telese Terme, Benevento, Italy; [Paris, Debora; Melck, Dominique J.; Motta, Andrea] CNR, Inst Biomol Chem, Naples, Italy; [D'Amato, Maria; Sofia, Matteo] Univ Naples Federico II, AO Colli, Dept Resp Med, Naples, Italy; [Stellato, Cristiana] Univ Salerno, Dept Med Surg & Dent Scuola Med Salernitana, Fisciano, SA, Italy	Istituti Clinici Scientifici Maugeri IRCCS; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Salerno	Motta, A (corresponding author), CNR, Ist Chim Biomol, Comprensorio Olivetti, Edificio A,Via Campi Flegrei 34, I-80078 Pozzuoli, NA, Italy.; Maniscalco, M (corresponding author), Presidio Osped S Maria della Pieta, Via S Rocco 9, I-80026 Casoria, NA, Italy.	mauromaniscalco@hotmail.com; andrea.motta@icb.cnr.it	Paris, Debora/ABI-2224-2020; Stellato, Cristiana/P-3001-2015; Maniscalco, Mauro/B-1915-2018; Paris, Debora/P-1624-2018; D'AMATO, Maria/H-3074-2012	Paris, Debora/0000-0003-4526-8353; Stellato, Cristiana/0000-0002-1294-8355; Maniscalco, Mauro/0000-0001-6751-9921; Paris, Debora/0000-0003-4526-8353; Motta, Andrea/0000-0002-8643-658X; D'AMATO, Maria/0000-0002-5906-5701	National Research Council [PON01_02740, FARB-ORSA132313]	National Research Council	Supported in part by the National Research Council, PON01_02740 (project SIBAFEQ), and FARB-ORSA132313.	Baker EH, 2007, J APPL PHYSIOL, V102, P1969, DOI 10.1152/japplphysiol.01425.2006; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Bush A, 2011, PAEDIATR RESPIR REV, V12, P177, DOI 10.1016/j.prrv.2011.01.003; Calvani R, 2010, INT J OBESITY, V34, P1095, DOI 10.1038/ijo.2010.44; Cano KE, 2011, J PROTEOME RES, V10, P2873, DOI 10.1021/pr200200y; Carraro S, 2007, AM J RESP CRIT CARE, V175, P986, DOI 10.1164/rccm.200606-769OC; Cesario V, 2013, GASTROENTEROLOGY, V144, pS564; Chen Y, 2006, CHEST, V130, P890, DOI 10.1378/chest.130.3.890; de Laurentiis G, 2008, EUR RESPIR J, V32, P1175, DOI 10.1183/09031936.00072408; de Laurentiis G, 2013, J PROTEOME RES, V12, P1502, DOI 10.1021/pr301171p; Dixon AE, 2011, J ALLERGY CLIN IMMUN, V128, P508, DOI 10.1016/j.jaci.2011.06.009; Dixon JB, 2011, DIABETIC MED, V28, P628, DOI 10.1111/j.1464-5491.2011.03306.x; Eriksson L., 2006, MULTI MEGAVARIATE 1; Fitzpatrick AM, 2014, J ALLERGY CLIN IMMUN, V133, P258, DOI 10.1016/j.jaci.2013.10.012; Garrett R.H., 2012, BIOCHEMISTRY; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HAKALA K, 1995, INT J OBESITY, V19, P343; Holguin F, 2011, J ALLERGY CLIN IMMUN, V127, P1486, DOI 10.1016/j.jaci.2011.03.036; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kim HY, 2014, NAT MED, V20, P54, DOI 10.1038/nm.3423; Kovacic P, 2009, REV ENVIRON CONTAM T, V201, P41, DOI 10.1007/978-1-4419-0032-6_2; Kupczyk M, 2014, ALLERGY, V69, P1198, DOI 10.1111/all.12445; LIEBER CS, 1994, GASTROENTEROLOGY, V106, P1085, DOI 10.1016/0016-5085(94)90772-2; Lino-dos-Santos-Franco A, 2011, TOXICOL LETT, V207, P278, DOI 10.1016/j.toxlet.2011.09.026; Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275; Marieb EN, 2013, HUMAN ANATOMY PHYSL, P804; Mathur R, 2013, J CLIN ENDOCR METAB, V98, pE698, DOI 10.1210/jc.2012-3144; MILLER TL, 1985, ARCH MICROBIOL, V141, P116, DOI 10.1007/BF00423270; Milner JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097238; Montuschi P, 2014, AM J RESP CRIT CARE, V190, P229, DOI 10.1164/rccm.201402-0249LE; Montuschi P, 2012, THORAX, V67, P222, DOI 10.1136/thoraxjnl-2011-200072; Motta A, 2012, EUR RESPIR J, V39, P498, DOI 10.1183/09031936.00036411; Motta A, 2014, J PROTEOME RES, V13, P6107, DOI 10.1021/pr5010407; Munoz X, 2015, INT ARCH ALLERGY IMM, V166, P1, DOI 10.1159/000371849; Paris D, 2015, METABOLOMICS, V11, P1934, DOI 10.1007/s11306-015-0805-8; Persoz C, 2012, TOXICOL LETT, V211, P159, DOI 10.1016/j.toxlet.2012.03.799; Philips BJ, 2005, THORAX, V60, P761, DOI 10.1136/thx.2004.035766; Pike LS, 2011, BBA-BIOENERGETICS, V1807, P726, DOI 10.1016/j.bbabio.2010.10.022; Ray A, 2015, AM J PHYSIOL-LUNG C, V308, pL130, DOI 10.1152/ajplung.00070.2014; Rui LY, 2014, COMPR PHYSIOL, V4, P177, DOI 10.1002/cphy.c130024; Scott HA, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-10; Sofia M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/403260; Stanley AH, 2005, J ASTHMA, V42, P97, DOI 10.1081/JAS-51338; Sutherland ER, 2008, AM J RESP CRIT CARE, V178, P682, DOI 10.1164/rccm.200801-076OC; Sutherland ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036631; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999; Vinolo MAR, 2011, J NUTR BIOCHEM, V22, P849, DOI 10.1016/j.jnutbio.2010.07.009; Weiss ST, 2005, NAT IMMUNOL, V6, P537, DOI 10.1038/ni0605-537; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Whiteson Katrine L, 2014, ISME J, V8, P1247, DOI 10.1038/ismej.2013.229; Wolak JE, 2009, BIOMARKERS, V14, P55, DOI 10.1080/13547500802688194; Wold S, 1998, CHEMOMETR INTELL LAB, V44, P175, DOI 10.1016/S0169-7439(98)00109-9; Xia JG, 2015, NUCLEIC ACIDS RES, V43, pW251, DOI 10.1093/nar/gkv380; Zhang HS, 2009, P NATL ACAD SCI USA, V106, P2365, DOI 10.1073/pnas.0812600106; Zheng H, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/537157	57	59	61	1	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1536	+		10.1016/j.jaci.2016.08.038	http://dx.doi.org/10.1016/j.jaci.2016.08.038			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27746236				2022-12-18	WOS:000400465300014
J	Krause, K; Tsianakas, A; Wagner, N; Fischer, J; Weller, K; Metz, M; Church, MK; Maurer, M				Krause, Karoline; Tsianakas, Athanasios; Wagner, Nicola; Fischer, Joerg; Weller, Karsten; Metz, Martin; Church, Martin K.; Maurer, Marcus			Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autoinflammatory; canakinumab; IL-1; Schnitzler syndrome; urticaria	JUVENILE IDIOPATHIC ARTHRITIS; OPEN-LABEL; PERIODIC SYNDROMES; CHRONIC URTICARIA; FOLLOW-UP; INTERLEUKIN-1-BETA; S100A12; INFLAMMASOME; ANAKINRA; DISEASE	Background: Schnitzler syndrome is an adult-onset autoinflammatory disease characterized by urticarial exanthema and monoclonal gammopathy accompanied by systemic symptoms such as fever, bone, and muscle pain. Up to now, approved treatment options are not available. Objective: We assessed effects of the anti-IL-1 beta mAb canakinumab on the clinical signs and symptoms of Schnitzler syndrome. Methods: In this phase II, randomized placebo-controlled multicenter study, 20 patients with active disease enrolled in 4 German study centers. Patients were randomly assigned to receive single subcutaneous canakinumab 150 mg or placebo injections for 7 days, followed by a 16-week open-label phase with canakinumab injections on confirmed relapse of symptoms. The primary end point was the proportion of patients with complete clinical response evaluated by physician global assessment at day 7. Key secondary end points included changes in patient-reported disease activity (Schnitzler activity score), inflammation markers (C-reactive protein and serum amyloid A), and quality-of-life assessments (Dermatology Life Quality Index and 36-item short form health survey). Results: The proportion of patients with complete clinical response at day 7 was significantly higher (P = .001) in the canakinumab-treated group (n = 5 of 7) than in the placebo group (n = 0 of 13). Levels of inflammation markers C-reactive protein and serum amyloid A and quality-of-life scores were significantly reduced in canakinumab-treated but not in placebo-treated individuals. Positive effects continued up to 16 weeks. Adverse events were manageable and included respiratory tract infections, gastrointestinal symptoms, and hypertension. Conclusions: In this first placebo-controlled study, canakinumab was effective in patients with Schnitzler syndrome, and thus canakinumab may be further evaluated as a therapeutic option for this rare disease.	[Krause, Karoline; Weller, Karsten; Metz, Martin; Church, Martin K.; Maurer, Marcus] Charite, Dept Dermatol & Allergy, Charitepl 1, D-10117 Berlin, Germany; [Krause, Karoline; Maurer, Marcus] Charite, Autoinflammat Reference Ctr Charite, Berlin, Germany; [Tsianakas, Athanasios] Univ Klinikum Munster, Dept Dermatol, Munster, Germany; [Wagner, Nicola] Klinikum Darmstadt, Dept Dermatol, Darmstadt, Germany; [Fischer, Joerg] Univ Klin Tubingen, Dept Dermatol & Allergy, Tubingen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munster; Klinikum Darmstadt; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Krause, K (corresponding author), Charite, Dept Dermatol & Allergy, Charitepl 1, D-10117 Berlin, Germany.	karoline.krause@charite.de	Krause, Karoline/G-5218-2018; Metz, Martin/B-8799-2009; Maurer, Marcus/ABG-2174-2020	Krause, Karoline/0000-0001-9711-9654; Metz, Martin/0000-0002-4070-9976; Maurer, Marcus/0000-0002-4121-481X; Weller, Karsten/0000-0003-4437-0313	Novartis Pharma GmbH	Novartis Pharma GmbH	This study was financially supported by Novartis Pharma GmbH and intramural grants.	Besada E, 2010, CLIN RHEUMATOL, V29, P567, DOI 10.1007/s10067-010-1375-9; de Koning HD, 2015, BRIT J DERMATOL, V173, P448, DOI 10.1111/bjd.13857; de Koning HD, 2007, SEMIN ARTHRITIS RHEU, V37, P137, DOI 10.1016/j.semarthrit.2007.04.001; de Koning HD, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0696-0; de Koning HD, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-41; de Koning HD, 2013, ANN RHEUM DIS, V72, P1634, DOI 10.1136/annrheumdis-2012-202192; Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800; Hoffman HM, 2003, HUM GENET, V112, P209, DOI 10.1007/s00439-002-0860-x; Kallinich T, 2010, ANN RHEUM DIS, V69, P677, DOI 10.1136/ard.2009.114363; Krause K, 2012, ALLERGY, V67, P943, DOI 10.1111/j.1398-9995.2012.02843.x; Krause K, 2013, J ALLERGY CLIN IMMUN, V132, P751, DOI 10.1016/j.jaci.2013.04.008; Kuemmerle-Deschner JB, 2011, ANN RHEUM DIS, V70, P2095, DOI 10.1136/ard.2011.152728; Lachmann HJ, 2007, NEW ENGL J MED, V356, P2361, DOI 10.1056/NEJMoa070265; Lachmann HJ, 2009, NEW ENGL J MED, V360, P2416, DOI 10.1056/NEJMoa0810787; Lachmann HJ, 2009, J EXP MED, V206, P1029, DOI 10.1084/jem.20082481; Launay D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059327; Lewis V, 2004, J INVEST DERM SYMP P, V9, P169, DOI 10.1111/j.1087-0024.2004.09113.x; Lipsker D, 2001, MEDICINE, V80, P37, DOI 10.1097/00005792-200101000-00004; Martinez-Taboada VM, 2005, ARTHRITIS RHEUM, V52, P2226, DOI 10.1002/art.21101; Nakamura Y, 2009, J EXP MED, V206, P1037, DOI 10.1084/jem.20082179; Neel A, 2014, AUTOIMMUN REV, V13, P1035, DOI 10.1016/j.autrev.2014.08.031; Pizzirani C, 2009, RHEUMATOLOGY, V48, P1304, DOI 10.1093/rheumatology/kep222; Rizzi R, 2008, ACTA HAEMATOL-BASEL, V120, P1, DOI 10.1159/000143499; Ruperto N, 2012, NEW ENGL J MED, V367, P2396, DOI 10.1056/NEJMoa1205099; Ryan JG, 2008, J ALLERGY CLIN IMMUN, V121, P260, DOI 10.1016/j.jaci.2007.09.021; Schlesinger N, 2012, ANN RHEUM DIS, V71, P1839, DOI 10.1136/annrheumdis-2011-200908; SCHNITZLER L, 1974, B SOC FR DERMATOL SY, V81, P363; Schnitzler L, 1972, LESIONS URTICARIENNE; Simon A, 2013, ALLERGY, V68, P562, DOI 10.1111/all.12129; Wittkowski H, 2011, ANN RHEUM DIS, V70, P2075, DOI 10.1136/ard.2011.152496; Wittkowski H, 2008, ARTHRITIS RHEUM-US, V58, P3924, DOI 10.1002/art.24137; Yang Z, 2007, J ALLERGY CLIN IMMUN, V119, P106, DOI 10.1016/j.jaci.2006.08.021	32	59	61	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1311	1320		10.1016/j.jaci.2016.07.041	http://dx.doi.org/10.1016/j.jaci.2016.07.041			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27658762	Bronze			2022-12-18	WOS:000398771800026
J	Pirmohamed, M; Ostrov, DA; Park, BK				Pirmohamed, Munir; Ostrov, David A.; Park, B. Kevin			New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Drug hypersensitivity; HLA; genetic polymorphisms; mechanisms; crystallography	STEVENS-JOHNSON-SYNDROME; CLOZAPINE-INDUCED AGRANULOCYTOSIS; COST-EFFECTIVENESS ANALYSIS; TOXIC EPIDERMAL NECROLYSIS; INDUCED LIVER-INJURY; T-CELL RESPONSES; HLA-B LOCUS; ABACAVIR HYPERSENSITIVITY; NITROSO SULFAMETHOXAZOLE; HLA-B-ASTERISK-1502 ALLELE	Drug hypersensitivity reactions are an important clinical problem for both health care and industry. Recent advances in genetics have identified a number of HLA alleles associated with a range of these adverse reactions predominantly affecting the skin but also other organs, such as the liver. The associations between abacavir hypersensitivity and HLA-B*57:01 and carbamazepine-induced Stevens-Johnson syndrome and HLA-B*15: 02 have been implemented in clinical practice. There are many different mechanisms proposed in the pathogenesis of drug hypersensitivity reactions, including the hapten hypothesis, direct binding to T-cell receptors (the pharmacologic interaction hypothesis), and peptide-binding displacement. A problem with all the hypotheses is that they are largely based on in vitro findings, with little direct in vivo evidence. Although most studies have focused on individual mechanisms, it is perhaps more important to consider them all as being complementary, potentially occurring at the same time with the same drug in the same patient. This might at least partly account for the heterogeneity of the immune response seen in different patients. There is a need to develop novel methodologies to evaluate how the in vitro mechanisms relate to the in vivo situation and how the highly consistent genetic findings with different HLA alleles can be more consistently used for both prediction and prevention of these serious adverse reactions.	[Pirmohamed, Munir; Park, B. Kevin] Univ Liverpool, Dept Mol & Clin Pharmacol, Ctr Drug Safety Sci, MRC, Liverpool L69 3GL, Merseyside, England; [Ostrov, David A.] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL USA	University of Liverpool; State University System of Florida; University of Florida	Pirmohamed, M (corresponding author), Univ Liverpool, Dept Mol & Clin Pharmacol, Ctr Drug Safety Sci, Liverpool L69 3GL, Merseyside, England.	munirp@liverpool.ac.uk	Pirmohamed, Munir/H-6004-2011	Pirmohamed, Munir/0000-0002-7534-7266	MRC through the MRC Centre for Drug Safety Science; National Institutes of Health/National Institute of Allergy and Infectious Diseases [5R01AI103348-02]; MRC [MR/L006758/1] Funding Source: UKRI; Medical Research Council [MR/L006758/1] Funding Source: researchfish; National Institute for Health Research [II-LB-0313-20008, NF-SI-0512-10064] Funding Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI103348] Funding Source: NIH RePORTER	MRC through the MRC Centre for Drug Safety Science(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Both M.P. and B.K.P. wish to thank the MRC for their support through the MRC Centre for Drug Safety Science. M.P. is a NIHR Senior Investigator. D.A.O. is supported through National Institutes of Health/National Institute of Allergy and Infectious Diseases grant 5R01AI103348-02.	Adam J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095339; Adam J, 2011, BRIT J CLIN PHARMACO, V71, P701, DOI 10.1111/j.1365-2125.2010.03764.x; Aithal GP, 2004, HEPATOLOGY, V39, P1430, DOI 10.1002/hep.20205; Alfirevic A, 2006, PHARMACOGENOMICS, V7, P813, DOI 10.2217/14622416.7.6.813; Alfirevic A, 2009, PHARMACOGENOMICS, V10, P531, DOI 10.2217/PGS.09.6; Andrews E, 2008, TOXICOLOGY, V254, P158, DOI 10.1016/j.tox.2008.08.009; BATCHELO.FR, 1965, NATURE, V206, P362, DOI 10.1038/206362a0; BRANDER C, 1995, J IMMUNOL, V155, P2670; Burkhart C, 2001, BRIT J PHARMACOL, V132, P623, DOI 10.1038/sj.bjp.0703845; Callan HE, 2009, CHEM RES TOXICOL, V22, P937, DOI 10.1021/tx900034r; Carey MA, 2005, TOXICOLOGY, V216, P41, DOI 10.1016/j.tox.2005.07.015; Castrejon JL, 2010, J ALLERGY CLIN IMMUN, V125, P411, DOI 10.1016/j.jaci.2009.10.031; Chen P, 2011, NEW ENGL J MED, V364, P1126, DOI 10.1056/NEJMoa1009717; Chen ZB, 2014, NEUROLOGY, V83, P2077, DOI 10.1212/WNL.0000000000001034; CHRISTIE G, 1988, BRIT J CLIN PHARMACO, V25, P381, DOI 10.1111/j.1365-2125.1988.tb03317.x; Chung WH, 2014, JAMA-J AM MED ASSOC, V312, P525, DOI 10.1001/jama.2014.7859; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Clay PG, 2002, CLIN THER, V24, P1502, DOI 10.1016/S0149-2918(02)80057-1; Daly AK, 2009, NAT GENET, V41, P816, DOI 10.1038/ng.379; Ding WY, 2010, INT J DERMATOL, V49, P834, DOI 10.1111/j.1365-4632.2010.04481.x; Easterbrook P J, 2003, HIV Med, V4, P321, DOI 10.1046/j.1468-1293.2003.00166.x; El-Ghaiesh S, 2012, J PHARMACOL EXP THER, V341, P597, DOI 10.1124/jpet.111.190900; Eliasson E, 1996, MOL PHARMACOL, V50, P573; Elsheikh A, 2010, J IMMUNOL, V185, P6448, DOI 10.4049/jimmunol.1000889; Esser PR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041340; Faulkner L, 2012, TOXICOL SCI, V127, P150, DOI 10.1093/toxsci/kfs080; FRIEDMANN PS, 1983, CLIN EXP IMMUNOL, V53, P709; Genin E, 2014, PHARMACOGENOMICS J, V14, P281, DOI 10.1038/tpj.2013.40; Gibson A, 2014, J IMMUNOL, V192, P2611, DOI 10.4049/jimmunol.1302720; Gill HJ, 1996, BRIT J CLIN PHARMACO, V42, P347, DOI 10.1046/j.1365-2125.1996.40110.x; Goldstein JI, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5757; Gueant JL, 2015, J ALLERGY CLIN IMMUN, V135, P253, DOI 10.1016/j.jaci.2014.07.047; Hardy KD, 2014, DRUG METAB DISPOS, V42, P162, DOI 10.1124/dmd.113.054817; Hebbring SJ, 2013, GENES IMMUN, V14, P187, DOI 10.1038/gene.2013.2; Hetherington S, 2002, LANCET, V359, P1121, DOI 10.1016/S0140-6736(02)08158-8; Hughes DA, 2004, PHARMACOGENETICS, V14, P335, DOI 10.1097/00008571-200406000-00002; Hung SL, 2006, PHARMACOGENET GENOM, V16, P297, DOI 10.1097/01.fpc.0000199500.46842.4a; Ikeda H, 2010, EPILEPSIA, V51, P297, DOI 10.1111/j.1528-1167.2009.02269.x; Illing PT, 2012, NATURE, V486, P554, DOI 10.1038/nature11147; Jenkins RE, 2009, PROTEOM CLIN APPL, V3, P720, DOI 10.1002/prca.200800222; Jensen PE, 2007, NAT IMMUNOL, V8, P1041, DOI 10.1038/ni1516; Kaniwa N, 2008, PHARMACOGENOMICS, V9, P1617, DOI 10.2217/14622416.9.11.1617; Kauf TL, 2010, PHARMACOECONOMICS, V28, P1025, DOI 10.2165/11535540-000000000-00000; Landsteiner K, 1935, J EXP MED, V61, P643, DOI 10.1084/jem.61.5.643; LEVINE BB, 1961, J EXP MED, V114, P875, DOI 10.1084/jem.114.6.875; LEY AB, 1958, SCIENCE, V127, P1118, DOI 10.1126/science.127.3306.1118; Lichtenfels M, 2014, CHEM RES TOXICOL, V27, P175, DOI 10.1021/tx400460w; Locharernkul C, 2008, EPILEPSIA, V49, P2087, DOI 10.1111/j.1528-1167.2008.01719.x; Lonjou C, 2006, PHARMACOGENOMICS J, V6, P265, DOI 10.1038/sj.tpj.6500356; Lonjou C, 2008, PHARMACOGENET GENOM, V18, P99, DOI 10.1097/FPC.0b013e3282f3ef9c; Lucena MI, 2011, GASTROENTEROLOGY, V141, P338, DOI 10.1053/j.gastro.2011.04.001; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; Mammen AL, 2012, ARTHRIT CARE RES, V64, P1233, DOI 10.1002/acr.21671; Man CBL, 2007, EPILEPSIA, V48, P1015, DOI 10.1111/j.1528-1167.2007.01022.x; McCormack Mark, 2011, N Engl J Med, V364, P1134, DOI 10.1056/NEJMoa1013297; Mehta TY, 2009, INDIAN J DERMATOL VE, V75, P579, DOI 10.4103/0378-6323.57718; Meng XL, 2014, CHEM RES TOXICOL, V27, P524, DOI 10.1021/tx400406p; Meng XL, 2011, J PHARMACOL EXP THER, V338, P841, DOI 10.1124/jpet.111.183871; Metushi IG, 2014, HEPATOLOGY, V59, P1084, DOI 10.1002/hep.26564; Naisbitt DJ, 1996, BIOORG MED CHEM LETT, V6, P1511, DOI 10.1016/S0960-894X(96)00260-0; Naisbitt DJ, 1999, BRIT J PHARMACOL, V126, P1393, DOI 10.1038/sj.bjp.0702453; Naisbitt DJ, 2002, MOL PHARMACOL, V62, P628, DOI 10.1124/mol.62.3.628; Naisbitt DJ, 2001, BRIT J PHARMACOL, V133, P295, DOI 10.1038/sj.bjp.0704074; Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047; Neefjes J, 2013, NAT CHEM BIOL, V9, P769, DOI [10.1038/NCHEMBIO.1391, 10.1038/nchembio.1391]; Calatrava DN, 2010, ENFERM INFEC MICR CL, V28, P590, DOI 10.1016/j.eimc.2009.09.010; Ogese MO, 2015, CHEM RES TOXICOL, V28, P144, DOI 10.1021/tx500458k; Ostrov DA, 2012, P NATL ACAD SCI USA, V109, P9959, DOI 10.1073/pnas.1207934109; Ozeki T, 2011, HUM MOL GENET, V20, P1034, DOI 10.1093/hmg/ddq537; Park BK, 2011, NAT REV DRUG DISCOV, V10, P292, DOI 10.1038/nrd3408; Park BE, 1998, CHEM RES TOXICOL, V11, P969, DOI 10.1021/tx980058f; Pavlos R, 2015, ANNU REV MED, V66, P439, DOI 10.1146/annurev-med-050913-022745; Phillips EJ, 2002, AIDS, V16, P2223, DOI 10.1097/00002030-200211080-00017; Pichler Werner J., 2014, Current Immunology Reviews, V10, P7, DOI 10.2174/1573395510666140407212357; Pichler WJ, 2011, J ALLERGY CLIN IMMUN, V127, pS74, DOI 10.1016/j.jaci.2010.11.048; Pichler WJ, 2003, ANN INTERN MED, V139, P683, DOI 10.7326/0003-4819-139-8-200310210-00012; Pickard C, 2007, J INVEST DERMATOL, V127, P630, DOI 10.1038/sj.jid.5700581; Pickard C, 2009, J IMMUNOL, V183, P7576, DOI 10.4049/jimmunol.0901064; Pirmohamed M, 1997, CNS DRUGS, V7, P139, DOI 10.2165/00023210-199707020-00005; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; Pirmohamed M, 2014, ANNU REV GENOM HUM G, V15, P349, DOI 10.1146/annurev-genom-090413-025419; Pirmohamed M, 2012, CHEM IMMUNOL ALLERGY, V97, P18, DOI 10.1159/000335613; Plumpton CO, 2015, EPILEPSIA, V56, P556, DOI 10.1111/epi.12937; Rauch A, 2006, CLIN INFECT DIS, V43, P99, DOI 10.1086/504874; Sanderson JP, 2007, J IMMUNOL, V178, P5533, DOI 10.4049/jimmunol.178.9.5533; Schackman BR, 2008, AIDS, V22, P2025, DOI 10.1097/QAD.0b013e3283103ce6; Schnyder B, 2000, J IMMUNOL, V164, P6647, DOI 10.4049/jimmunol.164.12.6647; Singer JB, 2010, NAT GENET, V42, P711, DOI 10.1038/ng.632; Tassaneeyakul W, 2010, EPILEPSIA, V51, P926, DOI 10.1111/j.1528-1167.2010.02533.x; Uetrecht J, 2013, PHARMACOL REV, V65, P779, DOI 10.1124/pr.113.007450; Waters LJ, 2007, AIDS, V21, P2533, DOI 10.1097/QAD.0b013e328273bc07; Whitaker P, 2011, J IMMUNOL, V187, P200, DOI 10.4049/jimmunol.1100647; White KD, 2015, J ALLERGY CLIN IMMUN, V136, P219, DOI 10.1016/j.jaci.2015.05.050; WILSON JT, 1978, BRIT MED J, V1, P1583, DOI 10.1136/bmj.1.6127.1583; Wong ICK, 1999, ANN PHARMACOTHER, V33, P1037, DOI 10.1345/aph.18422; Yip VL, 2012, CLIN PHARMACOL THER, V92, P757, DOI 10.1038/clpt.2012.189; YUEN AWC, 1992, BRIT J CLIN PHARMACO, V33, P511, DOI 10.1111/j.1365-2125.1992.tb04079.x; Yun J, 2012, ALLERGY, V67, P1338, DOI 10.1111/all.12008; Zucman D, 2007, JAIDS-J ACQ IMM DEF, V45, P1, DOI 10.1097/QAI.0b013e318046ea31	100	59	64	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					236	244		10.1016/j.jaci.2015.06.022	http://dx.doi.org/10.1016/j.jaci.2015.06.022			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	26254050	Green Published, hybrid			2022-12-18	WOS:000359004900002
J	Czarnowicki, T; Malajian, D; Shemer, A; Fuentes-Duculan, J; Gonzalez, J; Suarez-Farinas, M; Krueger, JG; Guttman-Yassky, E				Czarnowicki, Tali; Malajian, Dana; Shemer, Avner; Fuentes-Duculan, Judilyn; Gonzalez, Juana; Suarez-Farinas, Mayte; Krueger, James G.; Guttman-Yassky, Emma			Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							REGULATORY CELLS; BLOOD		[Czarnowicki, Tali; Malajian, Dana; Fuentes-Duculan, Judilyn; Suarez-Farinas, Mayte; Krueger, James G.] Rockefeller Univ, Lab Invest Dermatol, New York, NY 10021 USA; [Gonzalez, Juana] Rockefeller Univ, Translat Technol Core Lab, New York, NY 10021 USA; [Suarez-Farinas, Mayte] Rockefeller Univ, Ctr Clin & Translat Sci, New York, NY 10021 USA; [Malajian, Dana] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Shemer, Avner] Tel Hashomer Hosp, Dept Dermatol, Tel Aviv, Israel; [Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA	Rockefeller University; Rockefeller University; Rockefeller University; Columbia University; Icahn School of Medicine at Mount Sinai	Czarnowicki, T (corresponding author), Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA.	tczarnowic01@rockefeller.edu						Bauquet AT, 2009, NAT IMMUNOL, V10, P167, DOI 10.1038/ni.1690; Gorski K, 2010, J IMMUNOL, V184; Martin P, 2010, MOL CELL BIOL, V30, P4877, DOI 10.1128/MCB.00456-10; Martin P, 2010, J ALLERGY CLIN IMMUN, V126, P355, DOI 10.1016/j.jaci.2010.05.010; McHugh RS, 2002, J ALLERGY CLIN IMMUN, V110, P693, DOI 10.1067/mai.2002.129339; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Samochocki Z, 2012, ARCH DERMATOL RES, V304, P795, DOI 10.1007/s00403-012-1290-9; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Soler DC, 2011, J INVEST DERMATOL, V131, P1785, DOI 10.1038/jid.2011.200; Stelmaszczyk-Emmel A, 2013, INT ARCH ALLERGY IMM, V162, P16, DOI 10.1159/000350769; Sugiyama H, 2005, J IMMUNOL, V174, P164, DOI 10.4049/jimmunol.174.1.164	11	59	63	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					208	211		10.1016/j.jaci.2015.03.032	http://dx.doi.org/10.1016/j.jaci.2015.03.032			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	25936564				2022-12-18	WOS:000357542200029
J	Berkowska, MA; Heeringa, JJ; Hajdarbegovic, E; van der Burg, M; Thio, HB; van Hagen, PM; Boon, L; Orfao, A; van Dongen, JJM; van Zelm, MC				Berkowska, Magdalena A.; Heeringa, Jorn J.; Hajdarbegovic, Enes; van der Burg, Mirjam; Thio, H. Bing; van Hagen, P. Martin; Boon, Louis; Orfao, Alberto; van Dongen, Jacques J. M.; van Zelm, Menno C.			Human IgE(+) B cells are derived from T cell-dependent and T cell-independent pathways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CLASS-SWITCH RECOMBINATION; IMMUNOGLOBULIN-E SYNTHESIS; PLASMA-CELLS; NASAL-MUCOSA; PERIPHERAL-BLOOD; BRONCHIAL MUCOSE; HUMAN NAIVE; IN-VIVO; EXPRESSION; MEMORY	Background: The prevalence of IgE-mediated diseases has been increasing worldwide, yet IgE-expressing B cells are poorly characterized, mainly because of their scarcity and low membrane IgE levels. Objective: We sought to study the immunobiology of human IgE-expressing B cells in healthy subjects and patients with allergic disease. Methods: We used a stepwise approach for flow cytometric detection and purification of human IgE-expressing B cells in control subjects, CD40 ligand-deficient patients, and patients with atopic dermatitis. Molecular analysis of replication histories, somatic hypermutation (SHM), and immunoglobulin class-switching was performed. Results: Using multicolor flow cytometry, we reliably detected IgE-expressing plasma cells and 2 IgE-expressing memory B-cell subsets. These IgE-expressing cells showed molecular and phenotypic signs of antigen responses. The replication history and SHM levels of IgE(+) plasma cells and CD27(+)IgE(+) memory B cells fitted with a germinal center (GC)-dependent pathway, often through an IgG intermediate, as evidenced from S gamma remnants in S mu-S epsilon switch regions. CD27(-)IgE(+) cells showed limited proliferation and SHM and were present in CD40 ligand-deficient patients, indicating a GC-independent origin. Patients with atopic dermatitis had normal numbers of blood IgE(+) plasma cells and CD27(+)IgE(+) memory B cells but increased numbers of CD27(-)IgE(+) memory B cells with high SHM loads compared with those seen in healthy control subjects and patients with psoriasis. Conclusions: We delineated GC-dependent and GC-independent IgE(+) B-cell responses in healthy subjects and indicated involvement of the GC-independent pathway in a human IgE-mediated disease. These findings provide new insights into the pathogenesis of IgE-mediated diseases and might contribute to accurate monitoring of IgE(+) B cells in patients with severe disease undergoing anti-IgE treatment.	[Berkowska, Magdalena A.; Heeringa, Jorn J.; van der Burg, Mirjam; van Hagen, P. Martin; van Dongen, Jacques J. M.; van Zelm, Menno C.] Erasmus MC, Univ Med Ctr, Dept Immunol, NL-3015 CN Rotterdam, Netherlands; [Heeringa, Jorn J.] Erasmus MC, Univ Med Ctr, Dept Pediat, NL-3015 CN Rotterdam, Netherlands; [Hajdarbegovic, Enes; Thio, H. Bing] Erasmus MC, Univ Med Ctr, Dept Dermatol, NL-3015 CN Rotterdam, Netherlands; [van der Burg, Mirjam] Erasmus MC, Univ Med Ctr, Dept Internal Med, NL-3015 CN Rotterdam, Netherlands; [Boon, Louis] Bioceros BV, Utrecht, Netherlands; [Orfao, Alberto] Ctr Invest Canc IBMCC CSIC USAL Nucleus IBSAL, Salamanca, Spain; [Orfao, Alberto] Univ Salamanca, Dept Med, Serv Cytometry, E-37008 Salamanca, Spain	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Bioceros B.V.; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	van Zelm, MC (corresponding author), Erasmus MC, Univ Med Ctr, Dept Immunol, Unit Mol Immunol, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands.	m.vanzelm@erasmusmc.nl	van Dongen, Jacques J.M./F-8537-2015; Boon, Laurence/HCI-3629-2022; van Zelm, Menno C/O-4404-2015; Orfao, Alberto/B-5801-2017	van Dongen, Jacques J.M./0000-0001-7686-0021; van Zelm, Menno C/0000-0003-4161-1919; Boon, Louis/0000-0002-0937-9171; van Dongen, Jacques J.M./0000-0002-3650-7087	Sophia Children's Hospital Fund (SKF) [S698]	Sophia Children's Hospital Fund (SKF)	Supported by grant S698 from the Sophia Children's Hospital Fund (SKF) to J.J.H., J.J.M.v.D., and M.C.v.Z.	Acharya M, 2010, CLIN EXP IMMUNOL, V162, P12, DOI 10.1111/j.1365-2249.2010.04210.x; Agematsu K, 1997, EUR J IMMUNOL, V27, P2073, DOI 10.1002/eji.1830270835; AKINBAMI LJ, 2011, NATL HLTH STAT REPOR, V32, P1; Berkowska MA, 2011, BLOOD, V118, P2150, DOI 10.1182/blood-2011-04-345579; Cameron LA, 1998, J ALLERGY CLIN IMMUN, V101, P330, DOI 10.1016/S0091-6749(98)70244-1; Caraux A, 2010, HAEMATOL-HEMATOL J, V95, P1016, DOI 10.3324/haematol.2009.018689; Davies JM, 2013, J ALLERGY CLIN IMMUN, V131, P972, DOI 10.1016/j.jaci.2012.12.1569; Devereux G, 2006, NAT REV IMMUNOL, V6, P869, DOI 10.1038/nri1958; DONOHOE PJ, 1995, J ALLERGY CLIN IMMUN, V95, P587, DOI 10.1016/S0091-6749(95)70321-7; Dullaers M, 2012, J ALLERGY CLIN IMMUN, V129, P635, DOI 10.1016/j.jaci.2011.10.029; Erazo A, 2007, IMMUNITY, V26, P191, DOI 10.1016/j.immuni.2006.12.006; Ettinger R, 2005, J IMMUNOL, V175, P7867, DOI 10.4049/jimmunol.175.12.7867; Fagarasan S, 2001, NATURE, V413, P639, DOI 10.1038/35098100; Fecteau JF, 2006, J IMMUNOL, V177, P3728, DOI 10.4049/jimmunol.177.6.3728; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Good KL, 2009, J IMMUNOL, V182, P890, DOI 10.4049/jimmunol.182.2.890; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; He B, 2007, IMMUNITY, V26, P812, DOI 10.1016/j.immuni.2007.04.014; Hibbert RG, 2005, J EXP MED, V202, P751, DOI 10.1084/jem.20050811; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Isnardi I, 2010, BLOOD, V115, P5026, DOI 10.1182/blood-2009-09-243071; Jeannin P, 1997, J BIOL CHEM, V272, P15613, DOI 10.1074/jbc.272.25.15613; JUNG S, 1994, J EXP MED, V179, P2023, DOI 10.1084/jem.179.6.2023; Karnowski A, 2006, EUR J IMMUNOL, V36, P1917, DOI 10.1002/eji.200535495; KIKUTANI H, 1986, J EXP MED, V164, P1455, DOI 10.1084/jem.164.5.1455; Kobayashi S, 2009, HUM IMMUNOL, V70, P35, DOI 10.1016/j.humimm.2008.10.021; KUMAGAI K, 1975, J IMMUNOL, V115, P982; LAFAILLE JJ, 2012, NAT IMMUNOL, V13, P623; Lefranc MP, 2009, NUCLEIC ACIDS RES, V37, pD1006, DOI 10.1093/nar/gkn838; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Longo NS, 2009, BLOOD, V113, P3706, DOI 10.1182/blood-2008-10-183632; Lowe PJ, 2011, BRIT J CLIN PHARMACO, V72, P306, DOI 10.1111/j.1365-2125.2011.03962.x; McCoy KD, 2006, IMMUNITY, V24, P329, DOI 10.1016/j.immuni.2006.01.013; Medina F, 2002, BLOOD, V99, P2154, DOI 10.1182/blood.V99.6.2154; Niederberger V, 2007, INT ARCH ALLERGY IMM, V142, P133, DOI 10.1159/000096439; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P252, DOI 10.1067/mai.2003.1595; Pawankar R, 2011, WAO WHITE BOOK ALLER; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Ramesh S, 2008, CLIN REV ALLERG IMMU, V34, P217, DOI 10.1007/s12016-007-8034-1; SHAPIRA SK, 1991, P NATL ACAD SCI USA, V88, P7528, DOI 10.1073/pnas.88.17.7528; SHAPIRA SK, 1992, J EXP MED, V175, P289, DOI 10.1084/jem.175.1.289; Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017; Takahama H, 1997, CELL IMMUNOL, V176, P34, DOI 10.1006/cimm.1996.1065; Takhar P, 2005, J IMMUNOL, V174, P5024, DOI 10.4049/jimmunol.174.8.5024; Takhar P, 2007, J ALLERGY CLIN IMMUN, V119, P213, DOI 10.1016/j.jaci.2006.09.045; Talay O, 2012, NAT IMMUNOL, V13, P396, DOI 10.1038/ni.2256; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; van Zelm MC, 2014, J ALLERGY CLIN IMMUN; van Zelm MC, 2007, J EXP MED, V204, P645, DOI 10.1084/jem.20060964; Weller S, 2004, BLOOD, V104, P3647, DOI 10.1182/blood-2004-01-0346; Wesemann DR, 2011, J EXP MED, V208, P2733, DOI 10.1084/jem.20111155; Wu YCB, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00081; Xiong HZ, 2012, J EXP MED, V209, P353, DOI 10.1084/jem.20111941; Yang ZY, 2012, IMMUNITY, V36, P857, DOI 10.1016/j.immuni.2012.02.009; Ying S, 2001, J ALLERGY CLIN IMMUN, V107, P686, DOI 10.1067/mai.2001.114339	56	59	61	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					688	+		10.1016/j.jaci.2014.03.036	http://dx.doi.org/10.1016/j.jaci.2014.03.036			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24835500	Bronze			2022-12-18	WOS:000341372400023
J	Saffari, H; Hoffman, LH; Peterson, KA; Fang, JC; Leiferman, KM; Pease, LF; Gleich, GJ				Saffari, Hedieh; Hoffman, Laura H.; Peterson, Kathryn A.; Fang, John C.; Leiferman, Kristin M.; Pease, Leonard F., III; Gleich, Gerald J.			Electron microscopy elucidates eosinophil degranulation patterns in patients with eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; eosinophils; activation; piecemeal degranulation; electron microscopy; cytolysis	MAJOR BASIC-PROTEIN; CONSENSUS RECOMMENDATIONS; ATOPIC-DERMATITIS; GRANULE PROTEINS; LOCALIZATION; DEPOSITION; CHILDREN; IMMUNOFLUORESCENCE; IDENTIFICATION; RELEASE	Background: In patients with eosinophilic esophagitis (EoE), eosinophils accumulate and release granule proteins onto esophageal epithelium. However, little is understood about the mechanism of eosinophil degranulation. Objective: To determine and quantify eosinophil degranulation patterns, we studied esophageal biopsy specimens from both the proximal and distal esophagi of 9 randomly selected patients with EoE. Methods: The specimens were fixed in glutaraldehyde, embedded, sectioned, and imaged by means of transmission electron microscopy. Eosinophils and their granules were identified by their distinctive morphology, and all eosinophils and granules were imaged. A total of 1672 images from 18 esophageal specimens were evaluated and graded. Eosinophils were categorized based on membrane integrity and by cytoplasmic vesiculation as evidence of piecemeal degranulation. Granules were categorized based on reversal of staining (eosinophil granule core lightening) and localization within and outside the cells. Results: The results revealed that greater than 98% of eosinophils infiltrating the esophagus in patients with EoE demonstrate morphologic abnormalities ranging from granule changes with reversal of staining to marked cytoplasmic vesiculation to loss of cellular membrane integrity with cytolytic disruption and release of intact membrane-bound granules into the tissues. Approximately 81% of eosinophils showed membrane disruption. Extracellular granules were abundant in at least 70% of the images, and approximately 50% of these granules showed reversal of staining. On the basis of the prominence of tubulovesicular development, piecemeal degranulation appears closely related to the other morphologic changes seen in patients with EoE. Conclusion: These findings reveal that eosinophils in esophageal biopsy specimens from patients with EoE are abnormal, with greater than 80% showing cytolysis, and therefore that evaluation by means of light microscopy after hematoxylin and eosin staining might not accurately reflect eosinophil involvement.	[Saffari, Hedieh] Univ Utah, Dept Chem Engn, Salt Lake City, UT 84112 USA; [Hoffman, Laura H.] Univ Utah, Microscopy Core Facil, Salt Lake City, UT 84112 USA; [Peterson, Kathryn A.; Fang, John C.; Pease, Leonard F., III] Univ Utah, Dept Internal Med, Div Gastroenterol, Salt Lake City, UT 84112 USA; [Leiferman, Kristin M.; Gleich, Gerald J.] Univ Utah, Dept Dermatol, Salt Lake City, UT 84112 USA; [Pease, Leonard F., III] Univ Utah, Dept Chem Engn, Div Gastroenterol, Salt Lake City, UT 84112 USA; [Pease, Leonard F., III] Univ Utah, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA; [Gleich, Gerald J.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Saffari, H (corresponding author), Univ Utah, 3290 MEB,50 S Cent Campus, Salt Lake City, UT 84112 USA.	Hedieh.Saffari@utah.edu			US National Science Foundation [NSF CBET-1125490]; University of Utah	US National Science Foundation(National Science Foundation (NSF)); University of Utah	Supported by the US National Science Foundation (NSF CBET-1125490) and University of Utah startup funds.	Cheng JF, 1997, J ALLERGY CLIN IMMUN, V99, P683, DOI 10.1016/S0091-6749(97)70031-9; DVORAK AM, 1990, LAB INVEST, V62, P590; DVORAK AM, 1980, J IMMUNOL, V125, P460; Erjefalt JS, 1999, AM J RESP CRIT CARE, V160, P304, DOI 10.1164/ajrccm.160.1.9809048; FILLEY WV, 1982, LANCET, V2, P11; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GLEICH GJ, 1984, NEW ENGL J MED, V310, P1621, DOI 10.1056/NEJM198406213102501; Gleich GJ, 2003, ATLAS BLOOD CELLS FU, P299; HAMANN KJ, 1989, AM J TROP MED HYG, V40, P291, DOI 10.4269/ajtmh.1989.40.291; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; Justinich CJ, 1997, J PEDIATR GASTR NUTR, V25, P194, DOI 10.1097/00005176-199708000-00011; Kephart GM, 2010, AM J GASTROENTEROL, V105, P298, DOI 10.1038/ajg.2009.584; KEPHART GM, 1984, LAB INVEST, V50, P51; KEPHART GM, 1988, AM J PATHOL, V133, P389; LEIFERMAN KM, 1990, LAB INVEST, V62, P579; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Melo RCN, 2009, LAB INVEST, V89, P769, DOI 10.1038/labinvest.2009.40; Neves JS, 2008, P NATL ACAD SCI USA, V105, P18478, DOI 10.1073/pnas.0804547105; NOGUCHI H, 1992, AM J PATHOL, V140, P521; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; PETERS MS, 1986, LAB INVEST, V54, P656; PETERS MS, 1983, BRIT J DERMATOL, V109, P141, DOI 10.1111/j.1365-2133.1983.tb07074.x; Protheroe C, 2009, CLIN GASTROENTEROL H, V7, P749, DOI 10.1016/j.cgh.2009.03.022; SONGSIRIDEJ V, 1985, ANN INTERN MED, V103, P503, DOI 10.7326/0003-4819-103-4-503; Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/j.gastro.2003.09.024; TAI PC, 1987, LANCET, V1, P643	29	59	61	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1728	+		10.1016/j.jaci.2013.11.024	http://dx.doi.org/10.1016/j.jaci.2013.11.024			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24439077				2022-12-18	WOS:000336672500027
J	Zhang, Y; Leung, DYM; Goleva, E				Zhang, Yong; Leung, Donald Y. M.; Goleva, Elena			Anti-inflammatory and corticosteroid-enhancing actions of vitamin D in monocytes of patients with steroid-resistant and those with steroid-sensitive asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; steroid resistance; corticosteroids; vitamin D	GLUCOCORTICOID-RECEPTOR-BETA; HEALTH-CARE UTILIZATION; MAP KINASE; CELLS; PHOSPHORYLATION; INDUCTION; CHILDREN; MEDIATOR; INNATE; D-3	Background: Vitamin D is known for its anti-inflammatory effects. Objective: Vitamin D regulation of responses in patients with steroid-resistant (SR) versus steroid-sensitive (SS) asthma has not been studied. Methods: Peripheral blood cells from 11 patients with SR asthma and 8 patients with SS asthma were preincubated with 1,25-dihydroxyvitamin D(1,25[OH](2)D [VitD]), followed by dexamethasone (DEX) treatment and LPS stimulation. LPS-induced phosphorylated p38 mitogen-activated protein kinase (p-p38) in monocytes was examined by means of flow cytometry. Mitogen-activated protein kinase phosphatase-1 (MKP-1) mRNA expression, which inhibits p-p38, was analyzed by means of real-time PCR. Glucocorticoid receptor (GR) binding and histone H4 acetylation in the glucocorticoid response element of the MKP-1 promoter in monocytes were analyzed by means of chromatin immunoprecipitation. Results: DEX significantly inhibited LPS-induced p-p38 in monocytes from patients with SS asthma but not those from patients with SR asthma (P<.01). VitD inhibited LPS-induced p-p38 in monocytes from both patient groups (P<.01) but enhanced DEX suppression of LPS-induced p-p38 only in monocytes from patients with SS asthma (P<.01). VitD induced MKP-1 expression and enhanced DEX induction of MKP-1 in both patients with SS asthma and patients with SR asthma. VitD/DEX-induced MKP-1 mRNA levels remained significantly lower in monocytes from patients with SR asthma (P<.05). DEX-stimulated recruitment of GR and histone H4 acetylation at the glucocorticoid response element 4.6 kbp upstream of the MKP-1 gene were significantly lower in monocytes from patients with SR asthma compared with those from patients with SS asthma. VitD pretreatment enhanced DEX-induced GR binding and histone acetylation in monocytes from both patient groups. However, GR binding and histone H4 acetylation remained significantly lower in monocytes from patients with SR asthma. Conclusion: VitD demonstrated anti-inflammatory and corticosteroid-enhancing effects in monocytes of patients with SR asthma and patients with SS asthma. However, the responses to corticosteroids in patients with SR asthma remained significantly lower than those in patients with SS asthma.	[Zhang, Yong; Leung, Donald Y. M.; Goleva, Elena] Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA; [Leung, Donald Y. M.] Univ Colorado Denver, Dept Pediat, Aurora, CO USA	National Jewish Health; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Goleva, E (corresponding author), Natl Jewish Hlth, 1400 Jackson St,K1016A, Denver, CO 80206 USA.	golevae@njhealth.org			National Institutes of Health [AI070140, 2R56AI070140, HL37260]; NIH/NCATS Colorado CTSI [UL1 TR001082]; Edelstein Family Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037260, R37HL037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI070140, R01AI070140] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCATS Colorado CTSI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Edelstein Family Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants AI070140, 2R56AI070140, and HL37260 and NIH/NCATS Colorado CTSI grant no. UL1 TR001082. This work was also supported by the Edelstein Family Foundation.	Adams JS, 2008, NAT CLIN PRACT ENDOC, V4, P80, DOI 10.1038/ncpendmet0716; Akinbami LJ, 2012, J ALLERGY CLIN IMMUN, V129, pS49, DOI 10.1016/j.jaci.2011.12.984; Barnes PJ, 2013, J ALLERGY CLIN IMMUN, V131, P636, DOI 10.1016/j.jaci.2012.12.1564; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4; Chen WW, 2008, MOL ENDOCRINOL, V22, P1754, DOI 10.1210/me.2007-0219; Clark AR, 2003, J ENDOCRINOL, V178, P5, DOI 10.1677/joe.0.1780005; Drazen JM, 2012, J ALLERGY CLIN IMMUN, V129, P1200, DOI 10.1016/j.jaci.2012.03.026; Ginde AA, 2009, ARCH INTERN MED, V169, P626, DOI 10.1001/archinternmed.2008.604; Goleva E, 2006, AM J RESP CRIT CARE, V173, P607, DOI 10.1164/rccm.200507-1046OC; Goleva E, 2008, J ALLERGY CLIN IMMUN, V122, P550, DOI 10.1016/j.jaci.2008.07.007; Goleva E, 2007, J ALLERGY CLIN IMMUN, V120, P1065, DOI 10.1016/j.jaci.2007.07.042; Goleva E, 2012, J ALLERGY CLIN IMMUN, V129, P1243, DOI 10.1016/j.jaci.2012.01.044; Goleva E, 2012, J ALLERGY CLIN IMMUN, V129, P687, DOI 10.1016/j.jaci.2011.12.001; Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600, DOI 10.1164/ajrccm.159.5.9804131; Hauk PJ, 1999, J ALLERGY CLIN IMMUN, V104, P37, DOI 10.1016/S0091-6749(99)70111-9; Hewison M, 2011, NAT REV ENDOCRINOL, V7, P336, DOI 10.1038/nrendo.2010.226; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Hossein-nezhad A, 2013, MAYO CLIN PROC, V88, P720, DOI 10.1016/j.mayocp.2013.05.011; Institute of Medicine, 2010, DIET REF INT VIT D C, P1; Ismaili N, 2004, ANN NY ACAD SCI, V1024, P86, DOI 10.1196/annals.1321.007; Jeffery LE, 2012, J IMMUNOL, V189, P5155, DOI 10.4049/jimmunol.1200786; Jones G, 2008, AM J CLIN NUTR, V88, p582S, DOI 10.1093/ajcn/88.2.582S; Juniper EF, 2000, AM J RESP CRIT CARE, V162, P1330, DOI 10.1164/ajrccm.162.4.9912138; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Kim S, 2005, J BONE MINER RES, V20, P305, DOI 10.1359/JBMR.041112; Kumar R, 2005, J STEROID BIOCHEM, V94, P383, DOI 10.1016/j.jsbmb.2004.12.046; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Nanzer AM, 2013, J ALLERGY CLIN IMMUN, V132, P297, DOI 10.1016/j.jaci.2013.03.037; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Ramamoorthy S, 2013, ENDOCR DEV, V24, P41, DOI 10.1159/000342502; Searing DA, 2010, J ALLERGY CLIN IMMUN, V125, P995, DOI 10.1016/j.jaci.2010.03.008; Sutherland ER, 2010, AM J RESP CRIT CARE, V181, P699, DOI 10.1164/rccm.200911-1710OC; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Tchen CR, 2010, J BIOL CHEM, V285, P2642, DOI 10.1074/jbc.M109.037309; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Weigel NL, 2007, MOL ENDOCRINOL, V21, P2311, DOI 10.1210/me.2007-0101; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; Zhang Y, 2013, J BIOL CHEM, V288, P14544, DOI 10.1074/jbc.M112.427054; Zhang Y, 2012, J IMMUNOL, V188, P2127, DOI 10.4049/jimmunol.1102412; Zhang Y, 2009, J BIOL CHEM, V284, P24542, DOI 10.1074/jbc.M109.021469; 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/ajrccm/136.1.225	48	59	63	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1744	+		10.1016/j.jaci.2013.12.004	http://dx.doi.org/10.1016/j.jaci.2013.12.004			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24418482	Green Accepted			2022-12-18	WOS:000336672500029
J	Fitzpatrick, AM; Park, Y; Brown, LAS; Jones, DP				Fitzpatrick, Anne M.; Park, Youngja; Brown, Lou Ann S.; Jones, Dean P.			Children with severe asthma have unique oxidative stress-associated metabolomic profiles	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Fitzpatrick, Anne M.; Brown, Lou Ann S.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; [Fitzpatrick, Anne M.; Brown, Lou Ann S.] Childrens Healthcare Atlanta, Ctr Dev Lung Biol, Atlanta, GA USA; [Park, Youngja; Jones, Dean P.] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA; [Park, Youngja] Korea Univ, Coll Pharm, Seong, South Korea	Emory University; Children's Healthcare of Atlanta (CHOA); Emory University; Korea University	Fitzpatrick, AM (corresponding author), Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA.	anne.fitzpatrick@emory.edu		Park, Youngja/0000-0002-1310-148X; Fitzpatrick, Anne/0000-0002-2933-5926	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR012021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG038746] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR000454] Funding Source: Medline; NIA NIH HHS [R01 AG038746] Funding Source: Medline; NINR NIH HHS [R01 NR012021] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Barnes PJ, 2013, J ALLERGY CLIN IMMUN, V131, P636, DOI 10.1016/j.jaci.2012.12.1564; Berdyshev EV, 2001, BIOCHEM J, V360, P67, DOI 10.1042/0264-6021:3600067; Bossley CJ, 2009, EUR RESPIR J, V34, P1052, DOI 10.1183/09031936.00186508; Brown SD, 2012, J ALLERGY CLIN IMMUN, V129, P388, DOI 10.1016/j.jaci.2011.11.037; Duncan RS, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-50; Fitzpatrick AM, 2012, ANTIOXID REDOX SIGN, V17, P375, DOI 10.1089/ars.2011.4198; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P1604, DOI 10.1016/j.jaci.2011.03.031; Fitzpatrick AM, 2011, PEDIATR RES, V69, P154, DOI 10.1203/PDR.0b013e3182026370; Fitzpatrick AM, 2009, J ALLERGY CLIN IMMUN, V123, P146, DOI 10.1016/j.jaci.2008.10.047; Ueda N, 2010, BBA-MOL CELL BIOL L, V1801, P1274, DOI 10.1016/j.bbalip.2010.08.010	10	59	61	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					258	261		10.1016/j.jaci.2013.10.012	http://dx.doi.org/10.1016/j.jaci.2013.10.012			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24369802	Green Accepted			2022-12-18	WOS:000329105700035
J	James, KM; Gebretsadik, T; Escobar, GJ; Wu, PS; Carroll, KN; Li, SX; Walsh, EM; Mitchel, EF; Sloan, C; Hartert, TV				James, Kristina M.; Gebretsadik, Tebeb; Escobar, Gabriel J.; Wu, Pingsheng; Carroll, Kecia N.; Li, Sherian Xu; Walsh, Eileen M.; Mitchel, Edward F.; Sloan, Chantel; Hartert, Tina V.			Risk of childhood asthma following infant bronchiolitis during the respiratory syncytial virus season	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RSV BRONCHIOLITIS; EARLY-LIFE; INFECTION; CHILDREN; ATOPY; AGE		[James, Kristina M.; Wu, Pingsheng; Sloan, Chantel; Hartert, Tina V.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; [Gebretsadik, Tebeb; Wu, Pingsheng] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA; [Carroll, Kecia N.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA; [Mitchel, Edward F.] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA; [James, Kristina M.; Gebretsadik, Tebeb; Wu, Pingsheng; Carroll, Kecia N.; Sloan, Chantel; Hartert, Tina V.] Vanderbilt Univ, Sch Med, Ctr Asthma & Environm Sci Res, Nashville, TN 37212 USA; [Escobar, Gabriel J.] Kaiser Permanente Med Care Program, Oakland, CA USA; [Escobar, Gabriel J.; Li, Sherian Xu; Walsh, Eileen M.] Kaiser Permanente Med Care Program, Div Res, Perinatal Res Unit, Oakland, CA 94611 USA; [Escobar, Gabriel J.] Kaiser Permanente Med Ctr, Dept Inpatient Pediat, Walnut Creek, CA USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Kaiser Permanente; Kaiser Permanente; Kaiser Permanente	James, KM (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA.	tina.hartert@vanderbilt.edu	Sloan-Aagard, Chantel/GWC-7572-2022		AHRQ HHS [R01 HS018454] Funding Source: Medline; NIAID NIH HHS [U19 AI095227, K24 AI077930, K24 AI77839] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI077930, U19AI095227] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P964, DOI 10.1016/j.jaci.2008.12.011; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; Hartert TV, 2003, AM J OBSTET GYNECOL, V189, P1705, DOI 10.1016/S0002-9378(03)00857-3; Henderson J, 2005, PEDIAT ALLERG IMM-UK, V16, P386, DOI 10.1111/j.1399-3038.2005.00298.x; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Krishnamoorthy N, 2012, NAT MED, V18, P1525, DOI 10.1038/nm.2896; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Stempel HE, 2009, ACTA PAEDIATR, V98, P123, DOI 10.1111/j.1651-2227.2008.01023.x; Subbarao P, 2009, CAN MED ASSOC J, V181, pE181, DOI 10.1503/cmaj.080612; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC	14	59	60	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					227	229		10.1016/j.jaci.2013.01.009	http://dx.doi.org/10.1016/j.jaci.2013.01.009			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23419541	Green Accepted			2022-12-18	WOS:000321052300033
J	Rank, MA; Hagan, JB; Park, MA; Podjasek, JC; Samant, SA; Volcheck, GW; Erwin, PJ; West, CP				Rank, Matthew A.; Hagan, John B.; Park, Miguel A.; Podjasek, Jenna C.; Samant, Shefali A.; Volcheck, Gerald W.; Erwin, Patricia J.; West, Colin P.			The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; antiasthma agents; glucocorticoids; clinical trial; step down; withdraw; discontinue; decrease; wean; cessation	STEP-DOWN THERAPY; PERSISTENT ASTHMA; FLUTICASONE PROPIONATE/SALMETEROL; COMBINATION THERAPY; SINGLE INHALER; DOUBLE-BLIND; BECLOMETHASONE; BUDESONIDE; STRATEGIES; CHILDREN	Background: Current asthma guidelines suggest that patients and their providers consider decreasing or stopping controller medications when asthma is stable. Objective: We sought to estimate the risk of asthma exacerbation in patients who stop low-dose inhaled corticosteroids (ICSs) compared with those who continue ICSs in randomized controlled trials. Methods: We identified relevant trials from a systematic review of English-language and non-English-language articles using MEDLINE, EMBASE, and CENTRAL (inception to January 21, 2012). Articles were screened at the abstract and full-text level by 2 independent reviewers. We included randomized controlled trials with a stable asthma run-in period of 4 weeks or more, an intervention to stop or continue ICSs, and a follow-up period of at least 3 months. We pooled results using a random-effects meta-analysis. Results: The search strategy identified 1798 potential articles, of which 172 were reviewed at the full-text level and 7 met the criteria for inclusion. The relative risk for an asthma exacerbation in patients who stopped ICSs compared with those who continued use was 2.35 (95% CI, 1.88-2.92; P < .001; I-2 = 0%), as determined by using data pooled from trials with a mean follow-up of 27 weeks. The pooled absolute risk difference for an asthma exacerbation was 0.23 (95% CI, 0.16-0.30; P < .001; I-2 = 44%). Patients who discontinued ICSs also had a decreased FEV1 of 130 mL (95% CI, 40-210 mL; P 5.003; I-2 = 53%), a decreased mean morning peak expiratory flow of 18 L/min (95% CI, 6-29 L/min; P = .004; I-2 = 82%), and an increased mean standardized asthma symptom score of 0.43 SDs (95% CI, 0.28-0.58 SDs; P < .001; I-2 = 0%). Conclusion: Patients with well-controlled asthma who stop regular use of low-dose ICSs have an increased risk of an asthma exacerbation compared with those who continue ICSs. (J Allergy Clin Immunol 2013;131:724-9.)	[Rank, Matthew A.; Hagan, John B.; Park, Miguel A.; Podjasek, Jenna C.; Samant, Shefali A.; Volcheck, Gerald W.] Mayo Clin, Div Allerg Dis, Rochester, MN 55905 USA; [Erwin, Patricia J.] Mayo Clin, Mayo Med Lib, Rochester, MN 55905 USA; [West, Colin P.] Mayo Clin, Div Gen Internal Med, Rochester, MN 55905 USA; [West, Colin P.] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Rank, MA (corresponding author), Mayo Clin, Div Allerg Dis, 200 1st St SW, Rochester, MN 55905 USA.	rank.matthew@mayo.edu			Mayo Foundation; National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, MedImmune	Mayo Foundation; National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, MedImmune(AstraZenecaMedimmune)	Supported by the Mayo Foundation.; M. A. Rank is employed by the Mayo Clinic. J. B. Hagan is the Dyac Chairman of Adjudication panel for KALBITOR; has received research support from the National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, MedImmune, and the Mayo Foundation; is inventor of technology to assess asthma therapy adherence; and previously owned stock in Johnson & Johnson and Teva. The rest of the authors declare that they have no relevant conflicts of interest.	Bateman ED, 2006, J ALLERGY CLIN IMMUN, V117, P563, DOI 10.1016/j.jaci.2005.11.036; Berger WE, 2010, ALLERGY ASTHMA PROC, V31, P49, DOI 10.2500/aap.2010.31.3309; Busse WW, 2012, J ALLERGY CLIN IMMUN, V129, pS1, DOI 10.1016/j.jaci.2011.12.985; Condemi JJ, 1997, J ALLERGY CLIN IMMUN, V100, P467, DOI 10.1016/S0091-6749(97)70137-4; Deykin A, 2007, AM J RESP CRIT CARE, V175, P228, DOI 10.1164/rccm.200601-112OC; Drummond MB, 2011, J ASTHMA, V48, P1051, DOI 10.3109/02770903.2011.627488; Fowler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P929, DOI 10.1067/mai.2002.123869; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Godard P, 2008, RESP MED, V102, P1124, DOI 10.1016/j.rmed.2008.03.014; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Koenig SM, 2008, J ASTHMA, V45, P681, DOI 10.1080/02770900802168695; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Martinez FD, 2011, LANCET, V377, P650, DOI 10.1016/S0140-6736(10)62145-9; Moher David, 2009, Ann Intern Med, V151, P264, DOI [10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007]; National Institutes of Health, FACTB FISC YEAR 2011; Papi A, 2007, NEW ENGL J MED, V356, P2040, DOI 10.1056/NEJMoa063861; Peters SP, 2007, NEW ENGL J MED, V356, P2027; Reddel HK, 2010, RESP MED, V104, P1110, DOI 10.1016/j.rmed.2010.04.003; WAALKENS HJ, 1993, AM REV RESPIR DIS, V148, P1252, DOI 10.1164/ajrccm/148.5.1252	20	59	66	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					724	+		10.1016/j.jaci.2012.11.038	http://dx.doi.org/10.1016/j.jaci.2012.11.038			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23321206				2022-12-18	WOS:000315587800013
J	Krishnan, JA; Lemanske, RF; Canino, GJ; Elward, KS; Kattan, M; Matsui, EC; Mitchell, H; Sutherland, ER; Minnicozzi, M				Krishnan, Jerry A.; Lemanske, Robert F., Jr.; Canino, Glorisa J.; Elward, Kurtis S.; Kattan, Meyer; Matsui, Elizabeth C.; Mitchell, Herman; Sutherland, E. Rand; Minnicozzi, Michael			Asthma outcomes: Symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma Symptom Utility Index; Asthma Symptom Diary Scales; Pediatric Asthma Caregiver Diary	LEUKOTRIENE RECEPTOR ANTAGONIST; PRESCHOOL-CHILDREN; ALLERGIC RHINITIS; CHILDHOOD ASTHMA; EXACERBATIONS; MONTELUKAST; VALIDATION; SEVERITY; MODERATE; DIARY	Background: Respiratory symptoms are commonly used to assess the impact of patient-centered interventions. Objective: At the request of National Institutes of Health (NIH) institutes and other federal agencies, an expert group was convened to propose which measurements of asthma symptoms should be used as a standardized measure in future clinical research studies. Methods: Asthma symptom instruments were classified as daily diaries (prospectively recording symptoms between research visits) or retrospective questionnaires (completed at research visits). We conducted a systematic search in PubMed and a search for articles that cited key studies describing development of instruments. We classified outcome instruments as either core (required in future studies), supplemental (used according to study aims and standardized), or emerging (requiring validation and standardization). This work was discussed at an NIH-organized workshop in March 2010 and finalized in September 2011. Results: Four instruments (3 daily diaries, 1 for adults and 2 for children; and 1 retrospective questionnaire for adults) were identified. Minimal clinically important differences have not been established for these instruments, and validation studies were only conducted in a limited number of patient populations. Validity of existing instruments may not be generalizable across racial-ethnic or other subgroups. Conclusions: An evaluation of symptoms should be a core asthma outcome measure in clinical research. However, available instruments have limitations that preclude selection of a core instrument. The working group participants propose validation studies in diverse populations, comparisons of diaries versus retrospective questionnaires, and evaluations of symptom assessment alone versus composite scores of asthma control. (J Allergy Clin Immunol 2012; 129: S124-35.)	[Minnicozzi, Michael] NIAID, DAIT, NIH, Bethesda, MD 20892 USA; [Krishnan, Jerry A.] Univ Illinois, Chicago, IL USA; [Lemanske, Robert F., Jr.] Univ Wisconsin, Madison, WI 53706 USA; [Canino, Glorisa J.] Univ Puerto Rico, San Juan, PR 00936 USA; [Elward, Kurtis S.] Family Med Albermarle, Charlottesville, VA USA; [Kattan, Meyer] Columbia Univ, Med Ctr, New York, NY USA; [Matsui, Elizabeth C.] Johns Hopkins Univ, Baltimore, MD USA; [Mitchell, Herman] Rho Fed Syst Div Inc, Chapel Hill, NC USA; [Sutherland, E. Rand] Natl Jewish Hlth, Denver, CO USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Wisconsin System; University of Wisconsin Madison; University of Puerto Rico; Columbia University; Johns Hopkins University; National Jewish Health	Minnicozzi, M (corresponding author), NIAID, DAIT, NIH, 6610 Rockledge Dr, Bethesda, MD 20892 USA.	minnicozzmi@niaid.nih.gov		Matsui, Elizabeth/0000-0001-8134-5593	National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Environmental Health Sciences; Agency for Healthcare Research and Quality; Merck Childhood Asthma Network; Robert Wood Johnson Foundation; US Environmental Protection Agency; National Asthma Control Initiative; NIH-NIAID	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Merck Childhood Asthma Network; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); US Environmental Protection Agency(United States Environmental Protection Agency); National Asthma Control Initiative; NIH-NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The Asthma Outcomes workshop was funded by contributions from the National Institute of Allergy and Infectious Diseases; the National Heart, Lung, and Blood Institute; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Environmental Health Sciences; the Agency for Healthcare Research and Quality; and the Merck Childhood Asthma Network, as well as by a grant from the Robert Wood Johnson Foundation. Contributions from the National Heart, Lung, and Blood Institute; the National Institute of Allergy and Infectious Diseases; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Environmental Health Sciences, and the US Environmental Protection Agency funded the publication of this article and all other articles in this supplement.; Disclosure of potential conflict of interest: R. F. Lemanske, Jr, is a speaker for Merck and AstraZeneca and has consulted for AstraZeneca, Map Pharmaceuticals, Gray Consulting, Smith Research Inc, Merck Childhood Asthma Network, Novartis, Quintiles/Innovax, RC Horowitz & Co Inc. Scienomics, Scientific Therapeutics, Cognimed Inc, SA Boney and Associates, GlaxoSmithKline, and Double Helix Development Inc. K. S. Elward is a speaker on guidelines implementation for Merck; has received research support from the National Asthma Control Initiative; is a member of the Virginia Asthma Coalition; and is a member of the National Asthma Education and Prevention Program Coordination Committee. M. Kattan has received research support from the NIH-NIAID. The rest of the authors declare that they have no relevant conflicts of interest.	Bacharier LB, 2008, J ALLERGY CLIN IMMUN, V122, pe8; Bacharier LB, 2007, J ALLERGY CLIN IMMUN, V119, P604, DOI 10.1016/j.jaci.2006.12.607; Bacharier LB, 2008, J ALLERGY CLIN IMMUN, V122, P1127, DOI 10.1016/j.jaci.2008.09.029; Banks JL, 2007, STROKE, V38, P1091, DOI 10.1161/01.STR.0000258355.23810.c6; Bijl-Hofland ID, 1999, THORAX, V54, P15, DOI 10.1136/thx.54.1.15; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Castro M, 2001, NEW ENGL J MED, V345, P1529, DOI 10.1056/NEJMoa011961; Cote J, 1998, CHEST, V113, P968, DOI 10.1378/chest.113.4.968; Covar RA, 2008, J ALLERGY CLIN IMMUN, V122, P741, DOI 10.1016/j.jaci.2008.08.021; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; Davis SQ, 2009, ANN ALLERG ASTHMA IM, V102, P455; Dixon AE, 2006, J ASTHMA, V43, P553, DOI 10.1080/02770900600859123; Dixon AE, 2006, CHEST, V130, P429, DOI 10.1378/chest.130.2.429; Flood EM, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-51; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hanania NA, 2009, NEW ENGL J MED, V360, P1487, DOI 10.1056/NEJMoa0806290; Hanania NA, 2004, J ALLERGY CLIN IMMUN, V113, P717, DOI 10.1016/j.jaci.2003.12.584; Hardie GE, 2000, CHEST, V117, P935, DOI 10.1378/chest.117.4.935; Irvin CG, 2007, AM J RESP CRIT CARE, V175, P235, DOI 10.1164/rccm.200603-416OC; Johnston SL, 2006, NEW ENGL J MED, V354, P1589, DOI 10.1056/NEJMoa044080; Juniper EF, 2000, AM J RESP CRIT CARE, V162, P1330, DOI 10.1164/ajrccm.162.4.9912138; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Knorr B, 2001, J CLIN PHARMACOL, V41, P612, DOI 10.1177/00912700122010492; Lima JJ, 2006, J ASTHMA, V43, P185, DOI 10.1080/02770900600566611; Mattke S, 2009, PEDIATRICS, V123, pS199, DOI 10.1542/peds.2008-2233K; MCFADDEN ER, 1986, J ALLERGY CLIN IMMUN, V77, P1, DOI 10.1016/0091-6749(86)90313-1; McKenzie L, 2001, HEALTH POLICY, V57, P193, DOI 10.1016/S0168-8510(01)00128-2; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Motomura C, 2009, ANN ALLERG ASTHMA IM, V102, P121, DOI 10.1016/S1081-1206(10)60241-4; Mougey EB, 2009, PHARMACOGENET GENOM, V19, P129, DOI 10.1097/FPC.0b013e32831bd98c; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Nogueira-Silva L, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-52; Peters SP, 2007, NEW ENGL J MED, V356, P2027; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Reddel HK, 2002, BRIT MED J, V324, P146, DOI 10.1136/bmj.324.7330.146; Revicki DA, 1998, CHEST, V114, P998, DOI 10.1378/chest.114.4.998; Reznik M, 2005, J ADOLESCENT HEALTH, V36, P537, DOI 10.1016/j.jadohealth.2004.05.009; Santanello NC, 1997, EUR RESPIR J, V10, P646; Santanello NC, 2000, J ALLERGY CLIN IMMUN, V106, P861, DOI 10.1067/mai.2000.110478; Santanello NC, 1999, ARCH DIS CHILD, V80, P414, DOI 10.1136/adc.80.5.414; Sharek PJ, 2002, PEDIATRICS, V110, P797, DOI 10.1542/peds.110.4.797; Shih YCT, 2007, PHARMACOECONOMICS, V25, P577, DOI 10.2165/00019053-200725070-00004; Skoner DP, 2005, PEDIATR PULM, V40, P477, DOI 10.1002/ppul.20288; Smith LJ, 2004, J ASTHMA, V41, P833, DOI 10.1081/JAS-200038447; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Stone AA, 2002, BMJ-BRIT MED J, V324, P1193, DOI 10.1136/bmj.324.7347.1193; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Tamaoki J, 2008, ALLERGY ASTHMA PROC, V29, P189, DOI 10.2500/aap.2008.29.3100; Wildfire JJ, 2012, J ALLERGY CLIN IMMUN; Wise RA, 2009, J ALLERGY CLIN IMMUN, V124, P436, DOI 10.1016/j.jaci.2009.05.041; Yawn BP, 2006, PEDIATRICS, V118, P322, DOI 10.1542/peds.2005-2576; Zeidler MR, 2006, EUR RESPIR J, V27, P307, DOI 10.1183/09031936.06.00005605	53	59	59	3	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3		S			S124	S135		10.1016/j.jaci.2011.12.981	http://dx.doi.org/10.1016/j.jaci.2011.12.981			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	901OL	22386505	Green Accepted			2022-12-18	WOS:000300976600008
J	Verbsky, J; Thakar, M; Routes, J				Verbsky, James; Thakar, Monica; Routes, John			The Wisconsin approach to newborn screening for severe combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe combined immunodeficiency; T-cell receptor excision circle; lymphopenia; newborn screening		Severe combined immunodeficiency (SCID) is a life-threatening disease of infants that is curable with hematopoietic cell transplantation if detected early. Population-based screening for SCID using the T-cell receptor excision circle (TREC) assay began in Wisconsin in 2008; 5 infants with SCID or other forms of severe T-cell lymphopenia (TCL) have been detected, and no infants with SCID have been missed. This review will provide an overview of the TREC screening assay and an update of the findings from Wisconsin on all infants screened from January 1, 2008, until December 31, 2010. Importantly, we give practical recommendations regarding newborn population-based screening using the TREC assay, including the evaluation and care of infants detected. (J Allergy Clin Immunol 2012; 129: 622-7.)	[Verbsky, James] Med Coll Wisconsin, Div Rheumatol, Dept Pediat, Childrens Res Inst, Milwaukee, WI 53226 USA; [Thakar, Monica] Med Coll Wisconsin, Div Allergy Clin Immunol, Dept Pediat, Childrens Res Inst, Milwaukee, WI 53226 USA; [Routes, John] Med Coll Wisconsin, Childrens Hosp Wisconsin, Div Hematol Oncol Transplant, Dept Pediat,Childrens Res Inst, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; Children's Hospital of Wisconsin; Medical College of Wisconsin	Routes, J (corresponding author), Med Coll Wisconsin, Childrens Hosp Wisconsin, Div Hematol Oncol Transplant, Dept Pediat,Childrens Res Inst, 9000 W Wisconsin Ave, Milwaukee, WI 53226 USA.	jroutes@mcw.edu	Routes, john/AAA-4833-2021	Routes, john/0000-0001-8378-3773	Children's Hospital of Wisconsin; Jeffrey Modell Foundation; Wisconsin State Laboratory of Hygiene; Centers for Disease Control and Prevention [U01 EH000365]; National Institutes of Health; NATIONAL CENTER FOR ENVIRONMENTAL HEALTH [U01EH000365] Funding Source: NIH RePORTER	Children's Hospital of Wisconsin; Jeffrey Modell Foundation; Wisconsin State Laboratory of Hygiene; Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ENVIRONMENTAL HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Supported by the Children's Hospital of Wisconsin, the Jeffrey Modell Foundation, the Wisconsin State Laboratory of Hygiene, and the Centers for Disease Control and Prevention (U01 EH000365).; J. Verbsky has received honoraria from Baxter, Illumina, and the Jeffrey Modell Foundation. M. Thakar declares that she has no relevant conflicts of interest. J. Routes has received research support from the National Institutes of Health.	Accetta D, 2011, J ALLERGY CLIN IMMUN, V127, P535, DOI 10.1016/j.jaci.2010.10.013; Accetta DJ, 2011, J CLIN IMMUNOL, V31, P962, DOI 10.1007/s10875-011-9591-x; Al-Herz W, 2012, FRONT IMMUN IN PRESS; Baker MW, 2009, J ALLERGY CLIN IMMUN, V124, P522, DOI 10.1016/j.jaci.2009.04.007; Brown L, 2011, BLOOD, V117, P3243, DOI 10.1182/blood-2010-08-300384; Chabra S, 1998, BIOL NEONATE, V74, P200, DOI 10.1159/000014025; Chan K, 2005, J ALLERGY CLIN IMMUN, V115, P391, DOI 10.1016/j.jaci.2004.10.012; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Griffith LM, 2009, J ALLERGY CLIN IMMUN, V124, P1152, DOI 10.1016/j.jaci.2009.10.022; HOLODNIY M, 1991, J CLIN MICROBIOL, V29, P676, DOI 10.1128/JCM.29.4.676-679.1991; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; Pickering LK, 2009, RED BOOK 2009 REPORT, P72; Routes JM, 2009, JAMA-J AM MED ASSOC, V302, P2465, DOI 10.1001/jama.2009.1806; Verbsky JW, 2011, J CLIN IMMUNOL; Verschuren MCM, 1997, J IMMUNOL, V158, P1208; Wilson JM, 1968, WHO PUBLIC HLTH PAPE, V34, P7; Worthey EA, 2011, GENET MED, V13, P255, DOI 10.1097/GIM.0b013e3182088158	17	59	65	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					622	627		10.1016/j.jaci.2011.12.004	http://dx.doi.org/10.1016/j.jaci.2011.12.004			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22244594				2022-12-18	WOS:000301189300004
J	Arias, K; Chu, DK; Flader, K; Botelho, F; Walker, T; Arias, N; Humbles, AA; Coyle, AJ; Oettgen, HC; Chang, HD; Van Rooijen, N; Waserman, S; Jordana, M				Arias, Katherine; Chu, Derek K.; Flader, Kristin; Botelho, Fernando; Walker, Tina; Arias, Natalia; Humbles, Alison A.; Coyle, Anthony J.; Oettgen, Hans C.; Chang, Hyun-Dong; Van Rooijen, Nico; Waserman, Susan; Jordana, Manel			Distinct immune effector pathways contribute to the full expression of peanut-induced anaphylactic reactions in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; anaphylaxis; mast cells; macrophages; basophils; IgE; IgG1; Fc epsilon RI; Fc gamma RIII; Kit(W-sh)/(W-sh)	MAST-CELL DEGRANULATION; ANTI-IGE THERAPY; FC-GAMMA RIII; CARDIOPULMONARY CHANGES; ACTIVE ANAPHYLAXIS; NATURAL-HISTORY; IN-VIVO; FOOD; DEFICIENT; EMERGENCY	Background: Food-induced anaphylaxis is often a severe allergic reaction characterized by multiorgan dysfunction and a potentially fatal outcome. Objectives: We sought to investigate the relative contribution of immunoglobulin-dependent effector pathways to anaphylactic responses to food (ie, peanut). Methods: Wild-type and various mutant mice were sensitized with peanut protein and cholera toxin by means of oral gavage weekly for 4 weeks. Mice were subjected to different cellular depletion and Fc receptor blocking strategies before challenge with peanut 1 week after the last sensitization. Results: Our data indicate that pathways other than the classical mast cell (MC)-IgE pathway contribute to the full spectrum of anaphylactic reactions to peanut. We show that the single deletion of MCs, basophils, or phagocytes (ie, macrophages) prevents the most significant clinical outcome: death. Remarkably, the combined deficiency of MCs and phagocytes, but not MCs and basophils, averted nearly all clinical and physiological signs of anaphylaxis. Furthermore, blockade of both IgE and IgG1 signaling was necessary to abolish anaphylactic responses to peanut. Although MC responses occurred through IgE and IgG1, phagocyte responses were fully mediated through IgG1. Conclusions: Peanut-induced anaphylaxis is a process that involves the concerted action of multiple immune effector pathways, and thus interventions targeting a single pathway (eg, MC-IgE) might not be sufficient to fully prevent anaphylactic responses. (J Allergy Clin Immunol 2011;127:1552-61.)	[Arias, Katherine; Chu, Derek K.; Flader, Kristin; Botelho, Fernando; Walker, Tina; Arias, Natalia; Coyle, Anthony J.; Jordana, Manel] McMaster Univ, Dept Pathol & Mol Med, Ctr Gene Therapeut, Hamilton, ON L8N 3Z5, Canada; [Humbles, Alison A.; Coyle, Anthony J.] MedImmune LLC, Dept Resp Inflammat & Autoimmun, Gaithersburg, MD USA; [Oettgen, Hans C.] Harvard Univ, Sch Med, Div Immunol, Boston, MA USA; [Chang, Hyun-Dong] Deutsch Rheuma Forschungszentrum Berlin DRFZ, Berlin, Germany; [Van Rooijen, Nico] Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol, Amsterdam, Netherlands; [Waserman, Susan] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada	McMaster University; AstraZeneca; Medimmune; Harvard University; Harvard Medical School; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; McMaster University	Jordana, M (corresponding author), McMaster Univ, Dept Pathol & Mol Med, Ctr Gene Therapeut, MDCL Room 4013,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	jordanam@mcmaster.ca	Van Rooijen, Nico/Z-1578-2019; Chang, Hyun-Dong/T-3697-2017	Chang, Hyun-Dong/0000-0002-7341-4533; Chu, Derek/0000-0001-8269-4496	Anaphylaxis Canada; Food Allergy Initiative organization (New York, NY); MedImmune, LLC; AllerGen NCE; Ontario Graduate Scholarship (OGS); Canadian Institutes for Health Research (CIHR); AllerGen Canadian Allergy & Immune Diseases Advanced Training Initiative (CAIDATI); Food Allergy Initiative	Anaphylaxis Canada; Food Allergy Initiative organization (New York, NY); MedImmune, LLC(AstraZenecaMedimmune); AllerGen NCE; Ontario Graduate Scholarship (OGS)(Ontario Graduate Scholarship); Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); AllerGen Canadian Allergy & Immune Diseases Advanced Training Initiative (CAIDATI); Food Allergy Initiative	Supported by Anaphylaxis Canada; the Food Allergy Initiative organization (New York, NY); MedImmune, LLC; and AllerGen NCE. M.J. holds a Senior Canada Research Chair on the Immunobiology of Respiratory Diseases and Allergy. K. A. was supported by an Ontario Graduate Scholarship (OGS) and currently holds an AllerGen Canadian Allergy & Immune Diseases Advanced Training Initiative (CAIDATI) award. D. K. C. holds a Canadian Institutes for Health Research (CIHR) award.; A. A. Humbles is employed by and owns shares of MedImmune, LLC. A.J. Coyle is employed by Pfizer. M. Jordana receives research support from Anaphylaxis Canada, the Food Allergy Initiative, Allergen NCE, and MedImmune, LLC. The rest of the authors have declared that they have no conflict of interest.	Arias K, 2009, J ALLERGY CLIN IMMUN, V124, P307, DOI 10.1016/j.jaci.2009.03.012; Berin MC, 2009, MUCOSAL IMMUNOL, V2, P24, DOI 10.1038/mi.2008.72; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; Dirks CG, 2005, J ALLERGY CLIN IMMUN, V115, P1321, DOI 10.1016/j.jaci.2005.03.027; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; JUNG S, 1994, J EXP MED, V179, P2023, DOI 10.1084/jem.179.6.2023; Khodoun M, 2009, J ALLERGY CLIN IMMUN, V123, P342, DOI 10.1016/j.jaci.2008.11.004; Kojima T, 2007, J IMMUNOL, V179, P7093, DOI 10.4049/jimmunol.179.10.7093; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Lopez-Exposito I, 2009, J ALLERGY CLIN IMMUN, V124, P1039, DOI 10.1016/j.jaci.2009.08.024; LORENZ M, 1995, SCIENCE, V267, P1825, DOI 10.1126/science.7892607; Maloney JM, 2008, J ALLERGY CLIN IMMUN, V122, P145, DOI 10.1016/j.jaci.2008.04.014; Mancardi DA, 2008, J CLIN INVEST, V118, P3738, DOI 10.1172/JCI36452; Mathias CB, 2011, J ALLERGY CLIN IMMUN, V127, P795, DOI 10.1016/j.jaci.2010.11.009; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; Nicklas RA, 2003, ANN ALLERG ASTHMA IM, V91, P119, DOI 10.1016/S1081-1206(10)62163-1; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; Osterfeld H, 2010, J ALLERGY CLIN IMMUN, V125, P469, DOI 10.1016/j.jaci.2009.09.054; Robbie-Ryan M, 2003, J IMMUNOL, V170, P1630, DOI 10.4049/jimmunol.170.4.1630; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Sampson HA, 2003, PEDIATRICS, V111, P1601; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P717, DOI 10.1016/j.jaci.2007.07.027; Scott-Taylor TH, 2010, PEDIAT ALLERG IMM-UK, V21, P935, DOI 10.1111/j.1399-3038.2010.01025.x; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Smit DV, 2005, J EMERG MED, V28, P381, DOI 10.1016/j.jemermed.2004.11.028; Srivastava KD, 2005, J ALLERGY CLIN IMMUN, V115, P171, DOI 10.1016/j.jaci.2004.10.003; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Sun JF, 2007, J IMMUNOL, V179, P6696, DOI 10.4049/jimmunol.179.10.6696; TAKEISHI T, 1991, J CLIN INVEST, V88, P598, DOI 10.1172/JCI115344; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83	40	59	61	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1552	U359		10.1016/j.jaci.2011.03.044	http://dx.doi.org/10.1016/j.jaci.2011.03.044			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21624619				2022-12-18	WOS:000291048500036
J	Accetta, D; Syverson, G; Bonacci, B; Reddy, S; Bengtson, C; Surfus, J; Harbeck, R; Huttenlocher, A; Grossman, W; Routes, J; Verbsky, J				Accetta, Deborah; Syverson, Grant; Bonacci, Benedetta; Reddy, Sreelatha; Bengtson, Christine; Surfus, Jill; Harbeck, Ronald; Huttenlocher, Anna; Grossman, William; Routes, John; Verbsky, James			Human phagocyte defect caused by a Rac2 mutation detected by means of neonatal screening for T-cell lymphopenia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RHO GTPASES; IMMUNODEFICIENCY; DEFICIENCY		[Accetta, Deborah; Syverson, Grant; Bonacci, Benedetta; Reddy, Sreelatha; Bengtson, Christine; Routes, John; Verbsky, James] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; [Routes, John; Verbsky, James] Med Coll Wisconsin, Dept Microbiol & Med Genet, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Childrens Res Inst, Milwaukee, WI 53226 USA; [Surfus, Jill; Huttenlocher, Anna] Univ Wisconsin, Dept Pediat, Madison, WI USA; [Surfus, Jill; Huttenlocher, Anna] Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI 53706 USA; [Harbeck, Ronald] Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA; [Harbeck, Ronald] Univ Colorado, Hlth Sci Ctr, Denver, CO USA; [Grossman, William] Baxter Pharmaceut, Deerfield, IL USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Accetta, D (corresponding author), Med Coll Wisconsin, Dept Pediat, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	jverbsky@mcw.edu	Routes, john/AAA-4833-2021	Routes, john/0000-0001-8378-3773				Ambruso DR, 2000, P NATL ACAD SCI USA, V97, P4654, DOI 10.1073/pnas.080074897; Cancelas JA, 2009, CURR OPIN HEMATOL, V16, P249, DOI 10.1097/MOH.0b013e32832c4b80; Chan K, 2005, J ALLERGY CLIN IMMUN, V115, P391, DOI 10.1016/j.jaci.2004.10.012; Gu Y, 2001, J BIOL CHEM, V276, P15929, DOI 10.1074/jbc.M010445200; Guo F, 2008, BLOOD, V112, P1767, DOI 10.1182/blood-2008-01-132068; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Routes JM, 2009, JAMA-J AM MED ASSOC, V302, P2465, DOI 10.1001/jama.2009.1806; Sato Y, 2009, IMMUNOL LETT, V124, P27, DOI 10.1016/j.imlet.2009.03.014; Selvatici R, 2006, EUR J PHARMACOL, V534, P1, DOI 10.1016/j.ejphar.2006.01.034; Svensson L, 2009, NAT MED, V15, P306, DOI 10.1038/nm.1931; Williams DA, 2000, BLOOD, V96, P1646	12	59	62	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					535	538		10.1016/j.jaci.2010.10.013	http://dx.doi.org/10.1016/j.jaci.2010.10.013			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21167572				2022-12-18	WOS:000286808000035
J	Wu, WH; Park, CO; Oh, SH; Kim, HJ; Kwon, YS; Bae, BG; Noh, JY; Lee, KH				Wu, Wen Hao; Park, Chang Ook; Oh, Sang Ho; Kim, Hee Jung; Kwon, Yeon Sook; Bae, Byung Gi; Noh, Ji Yeon; Lee, Kwang Hoon			Thymic stromal lymphopoietin-activated invariant natural killer T cells trigger an innate allergic immune response in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; invariant natural killer T cells; NKT cells; thymic stromal lymphopoietin; dendritic cells	HUMAN EPITHELIAL-CELLS; NKT CELLS; IL-4 PRODUCTION; DENDRITIC CELL; AIRWAY HYPERREACTIVITY; SEVERITY INDEX; ECZEMA AREA; INFLAMMATION; SKIN; RECOGNITION	Background: Although invariant natural killer T (iNKT) cells have been shown to play a critical role in the pathogenesis of asthma, the role of iNKT cells in atopic dermatitis (AD) has not been well evaluated. Objective: We investigated whether iNKT cells in patients with AD increased and whether iNKT cells were activated by thymic stromal lymphopoietin (TSLP), which is highly expressed in keratinocytes of AD. Methods: We assessed the population of iNKT cells in PBMCs of patients with AD and healthy controls (HCs) using flow cytometry. Immunohistochemistry was used to evaluate iNKT cells and TSLP expression in AD and HC skin. We also evaluated whether iNKT cells expressed the TSLP receptor, the effects of TSLP on iNKT cells, and iNKT cell-dendritic cell interactions in a TSLP-rich environment. Results: There were more iNKT cells among PBMCs of patients with moderate to severe AD than mild AD (P < .05) and HC (P < .001). The number of iNKT cells was significantly larger in severe AD skin lesions than in mild (P < .001) or moderate AD skin lesions (P < .05). TSLP expression increased in lesional skin (P < .001) but not in the sera of patients with AD (P = .729) compared with HC. iNKT cells expressed TSLP receptor protein and mRNA. TSLP directly activated iNKT cells to secrete IL-4 and IL-13, and the concurrent addition of dendritic cells further activated IFN-gamma expression. Conclusion: Increased iNKT cells activated by TSLP, especially in patients with severe AD, might play an essential role in the innate allergic immune response in AD. (J Allergy Clin Immunol 2010;126:290-9.)	[Wu, Wen Hao; Park, Chang Ook; Oh, Sang Ho; Kim, Hee Jung; Kwon, Yeon Sook; Bae, Byung Gi; Noh, Ji Yeon; Lee, Kwang Hoon] Yonsei Univ, Coll Med, Dept Dermatol, Seoul 120752, South Korea; [Wu, Wen Hao; Park, Chang Ook; Oh, Sang Ho; Kim, Hee Jung; Kwon, Yeon Sook; Bae, Byung Gi; Noh, Ji Yeon; Lee, Kwang Hoon] Yonsei Univ, Coll Med, Cutaneous Biol Res Inst, Seoul 120752, South Korea; [Wu, Wen Hao; Noh, Ji Yeon; Lee, Kwang Hoon] Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Lee, KH (corresponding author), Yonsei Univ, Coll Med, Dept Dermatol, 134 Shinchon Dong, Seoul 120752, South Korea.	kwanglee@yuhs.ac		Oh, Sang Ho/0000-0002-4477-1400; Noh, ji yeon/0000-0002-4158-9443; Park, Chang Ook/0000-0003-3856-1201	Ministry of Health and Welfare, Republic of Korea [A080892]	Ministry of Health and Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	Supported by a grant of the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (A080892).	Agea E, 2005, J EXP MED, V202, P295, DOI 10.1084/jem.20050773; Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Balato A, 2009, J INVEST DERMATOL, V129, P1628, DOI 10.1038/jid.2009.30; Barbier N, 2004, BRIT J DERMATOL, V150, P96, DOI 10.1111/j.1365-2133.2004.05696.x; Bendelac A, 2007, ANNU REV IMMUNOL, V25, P297, DOI 10.1146/annurev.immunol.25.022106.141711; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Campos RA, 2003, J EXP MED, V198, P1785, DOI 10.1084/jem.20021562; Demehri S, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000067; Elkhal A, 2006, J ALLERGY CLIN IMMUN, V118, P1363, DOI 10.1016/j.jaci.2006.08.010; Gober MD, 2008, J INVEST DERMATOL, V128, P1460, DOI 10.1038/sj.jid.5701199; Hameg A, 1999, J IMMUNOL, V162, P7067; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Ilhan Fulya, 2007, Skinmed, V6, P218, DOI 10.1111/j.1540-9740.2007.06458.x; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Kronenberg M, 2005, ANNU REV IMMUNOL, V23, P877, DOI 10.1146/annurev.immunol.23.021704.115742; Lee HJ, 2009, EXP DERMATOL, V18, P199, DOI 10.1111/j.1600-0625.2008.00781.x; Leite-De-Moraes MC, 2001, J IMMUNOL, V166, P945, DOI 10.4049/jimmunol.166.2.945; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Lind SM, 2009, EUR J IMMUNOL, V39, P2293, DOI 10.1002/eji.200839195; Liu YJ, 2009, ADV IMMUNOL, V101, P1, DOI 10.1016/S0065-2776(08)01001-8; Magnan A, 2000, ALLERGY, V55, P286, DOI 10.1034/j.1398-9995.2000.00425.x; Matangkasombut P, 2009, J ALLERGY CLIN IMMUN, V123, P1181, DOI 10.1016/j.jaci.2009.02.013; Metelitsa LS, 2004, CLIN IMMUNOL, V110, P267, DOI 10.1016/j.clim.2003.11.005; Meyer EH, 2008, ANNU REV MED, V59, P281, DOI 10.1146/annurev.med.59.061506.154139; Milner JD, 1999, J IMMUNOL, V163, P2522; Nagarajan NA, 2007, J IMMUNOL, V178, P2706, DOI 10.4049/jimmunol.178.5.2706; Nagata Y, 2007, INT ARCH ALLERGY IMM, V144, P305, DOI 10.1159/000106319; Nakamura K, 2008, J DERMATOL, V35, P546, DOI 10.1111/j.1346-8138.2008.00518.x; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P252, DOI 10.1067/mai.2003.1595; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Oishi Y, 2000, CLIN EXP IMMUNOL, V119, P404, DOI 10.1046/j.1365-2249.2000.01157.x; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Oyoshi MK, 2009, ADV IMMUNOL, V102, P135, DOI 10.1016/S0065-2776(09)01203-6; Pandey A, 2000, NAT IMMUNOL, V1, P59, DOI 10.1038/76923; Park CO, 2008, EXP DERMATOL, V17, P24, DOI 10.1111/j.1600-0625.2007.00634.x; Prell C, 2003, IMMUNOBIOLOGY, V208, P367, DOI 10.1078/0171-2985-00284; Russano AM, 2006, J ALLERGY CLIN IMMUN, V117, P1178, DOI 10.1016/j.jaci.2006.01.001; Simon D, 2009, ALLERGY, V64, P1681, DOI 10.1111/j.1398-9995.2009.02097.x; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Takahashi T, 2003, HUM IMMUNOL, V64, P586, DOI 10.1016/S0198-8859(03)00066-1; Tupin E, 2007, NAT REV MICROBIOL, V5, P405, DOI 10.1038/nrmicro1657; Van Kaer L, 2005, NAT REV IMMUNOL, V5, P31, DOI 10.1038/nri1531; Werfel T, 2009, J INVEST DERMATOL, V129, P1878, DOI 10.1038/jid.2009.71; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zhou DP, 2004, SCIENCE, V306, P1786, DOI 10.1126/science.1103440	50	59	60	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					290	U31		10.1016/j.jaci.2010.05.024	http://dx.doi.org/10.1016/j.jaci.2010.05.024			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20624642				2022-12-18	WOS:000281203800014
J	Simon, D; Wardlaw, A; Rothenberg, ME				Simon, Dagmar; Wardlaw, Andrew; Rothenberg, Marc E.			Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; cutaneous; dermatitis; eosinophilia; esophagitis; intestine; lung; respiratory; skin	ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; RANDOMIZED CONTROLLED-TRIAL; CHURG-STRAUSS-SYNDROME; HUMANIZED MONOCLONAL-ANTIBODY; MAJOR BASIC-PROTEIN; TERM-FOLLOW-UP; ATOPIC-DERMATITIS; T-CELLS; HYPEREOSINOPHILIC SYNDROME; FUNGAL SENSITIZATION	Eosinophils are multifunctional leukocytes that increase in various tissues in patients with a variety of disorders. Locally, they can be involved in the initiation and propagation of diverse inflammatory responses. In this review the clinical association of eosinophils with diseases of the skin, lung, and gastrointestinal tract is summarized. An approach to determining the causal role of eosinophils in these diseases is presented. Recent findings concerning molecular diagnosis, cause, and treatment are discussed. (J Allergy Clin Immunol 2010;126:3-13.)	[Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol,Dept Pediat, Cincinnati, OH 45229 USA; [Simon, Dagmar] Univ Bern, Inselspital, Univ Hosp Bern, Dept Dermatol, CH-3010 Bern, Switzerland; [Wardlaw, Andrew] Univ Leicester, Dept Infect Immun & Inflammat, Inst Lung Hlth, Leicester LE1 7RH, Leics, England	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of Bern; University Hospital of Bern; University of Leicester	Rothenberg, ME (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol,Dept Pediat, 3333 Burnet Ave,MLC 7028, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org		Wardlaw, Andrew/0000-0001-6583-0791	National Institutes of Health National Institute of Allergy and Infectious Diseases; Food Allergy and Anaphylaxis Network; Food Allergy Project; CURED Foundation; Buckeye Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR008084] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL076383] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070235, U01AI088806, R01AI057803, R01AI053479, R01AI045898, R01AI042242, R01AI083450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076893] Funding Source: NIH RePORTER	National Institutes of Health National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Food Allergy and Anaphylaxis Network; Food Allergy Project; CURED Foundation; Buckeye Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported in part by the National Institutes of Health National Institute of Allergy and Infectious Diseases, the Food Allergy and Anaphylaxis Network, the Food Allergy Project, the CURED Foundation, and the Buckeye Foundation (to M. E. R.).	Aceves SS, 2007, AM J GASTROENTEROL, V102, P2271, DOI 10.1111/j.1572-0241.2007.01379.x; Akdis CA, 1999, J INVEST DERMATOL, V113, P628, DOI 10.1046/j.1523-1747.1999.00720.x; Akei HS, 2005, GASTROENTEROLOGY, V129, P985, DOI 10.1053/j.gastro.2005.06.027; Amerio P, 2001, ACTA DERM-VENEREOL, V81, P92, DOI 10.1080/00015550152384191; Amerio P, 2000, BRIT J DERMATOL, V143, P974, DOI 10.1046/j.1365-2133.2000.03765.x; Assa'ad A., 2008, GASTROINTEST ENDOSC, V18, px; Assa'ad AH, 2007, J ALLERGY CLIN IMMUN, V119, P731, DOI 10.1016/j.jaci.2006.10.044; Berry M, 2007, THORAX, V62, P1043, DOI 10.1136/thx.2006.073429; Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, P707, DOI 10.1067/mai.2002.122503; Bhattacharya B, 2007, HUM PATHOL, V38, P1744, DOI 10.1016/j.humpath.2007.05.008; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2005, CLIN EXP ALLERGY, V35, P1096, DOI 10.1111/j.1365-2222.2005.02299.x; Blanchard Carine, 2008, Gastrointest Endosc Clin N Am, V18, P133, DOI 10.1016/j.giec.2007.09.016; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Blanchard C, 2006, J ALLERGY CLIN IMMUN, V118, P1054, DOI 10.1016/j.jaci.2006.07.038; Bochner BS, 2010, J ALLERGY CLIN IMMUN, V126, P16, DOI 10.1016/j.jaci.2010.02.026; Bocquet H, 1996, SEMIN CUTAN MED SURG, V15, P250, DOI 10.1016/S1085-5629(96)80038-1; Borrego L, 1996, AM J PATHOL, V148, P897; Brightling CE, 2000, LANCET, V356, P1480, DOI 10.1016/S0140-6736(00)02872-5; Brightling CE, 1999, AM J RESP CRIT CARE, V160, P406, DOI 10.1164/ajrccm.160.2.9810100; BUTTERFIELD JH, 1992, BLOOD, V79, P688; Chang JW, 2002, J PEDIATR GASTR NUTR, V35, P387, DOI 10.1097/00005176-200209000-00031; Chehade M, 2006, J PEDIATR GASTR NUTR, V42, P516, DOI 10.1097/01.mpg.0000221903.61157.4e; Cheng JF, 1997, J ALLERGY CLIN IMMUN, V99, P683, DOI 10.1016/S0091-6749(97)70031-9; Chitkara RK, 2006, SEMIN RESP CRIT CARE, V27, P171, DOI 10.1055/s-2006-939520; Collins, 2008, GASTROINTEST ENDOSC, V18, pviii; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Costello RW, 1997, AM J PHYSIOL-LUNG C, V273, pL93, DOI 10.1152/ajplung.1997.273.1.L93; CZECH W, 1992, BRIT J DERMATOL, V126, P351, DOI 10.1111/j.1365-2133.1992.tb00677.x; DeBrosse CW, 2006, PEDIATR DEVEL PATHOL, V9, P210, DOI 10.2350/11-05-0130.1; Denning DW, 2009, AM J RESP CRIT CARE, V179, P11, DOI 10.1164/rccm.200805-737OC; Di Zenzo Giovanni, 2007, Adv Dermatol, V23, P257, DOI 10.1016/j.yadr.2007.07.013; Dougherty RH, 2009, CLIN EXP ALLERGY, V39, P193, DOI 10.1111/j.1365-2222.2008.03157.x; FILLEY WV, 1982, LANCET, V2, P11; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Foroughi S, 2005, CURR ALLERGY ASTHM R, V5, P259, DOI 10.1007/s11882-005-0062-4; Foster PS, 2001, IMMUNOL REV, V179, P173, DOI 10.1034/j.1600-065X.2001.790117.x; Fukakusa M, 2005, J ALLERGY CLIN IMMUN, V115, P280, DOI 10.1016/j.jaci.2004.10.036; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; GIBSON PG, 1989, LANCET, V1, P1346; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Greenberger PA, 2002, J ALLERGY CLIN IMMUN, V110, P685, DOI 10.1067/mai.2002.130179; Guillevin L, 1999, MEDICINE, V78, P26, DOI 10.1097/00005792-199901000-00003; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hargreave FE, 2009, CLIN EXP ALLERGY, V39, P1652, DOI 10.1111/j.1365-2222.2009.03321.x; Hart TK, 2001, J ALLERGY CLIN IMMUN, V108, P250, DOI 10.1067/mai.2001.116576; Hellmich B, 2003, CLIN EXP RHEUMATOL, V21, pS69; Higgins BG, 2003, THORAX, V58, P98, DOI 10.1136/thorax.58.2.98; Ionescu MA, 2005, J AM ACAD DERMATOL, V52, P32, DOI 10.1016/j.jaad.2004.03.003; JAFFE JS, 1994, J CLIN IMMUNOL, V14, P299, DOI 10.1007/BF01540983; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Jundt F, 1999, BLOOD, V94, P2065, DOI 10.1182/blood.V94.6.2065.418k15_2065_2071; KAGI MK, 1994, INT ARCH ALLERGY IMM, V103, P332, DOI 10.1159/000236651; KANNOURAKIS G, 1994, BRIT J CANCER, V70, pS37; Kiehl P, 2001, BRIT J DERMATOL, V145, P720, DOI 10.1046/j.1365-2133.2001.04456.x; Klein NC, 1970, MEDICINE, V2, P215; Konikoff MR, 2006, GASTROENTEROLOGY, V131, P1381, DOI 10.1053/j.gastro.2006.08.033; Lake AM, 2000, J PEDIATR GASTR NUTR, V30, pS58, DOI 10.1097/00005176-200001001-00009; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; Liacouras CA, 2005, CLIN GASTROENTEROL H, V3, P1198, DOI 10.1016/S1542-3565(05)00885-2; LIU LX, 1995, LANCET, V346, P410, DOI 10.1016/S0140-6736(95)92782-4; Mallia P, 2006, CHEST, V130, P1203, DOI 10.1378/chest.130.4.1203; MASSEY W, 1993, J IMMUNOL, V150, P1084; Mikami Chikage, 1999, Journal of Dermatology (Tokyo), V26, P633; Mishra A, 2003, GASTROENTEROLOGY, V125, P1419, DOI 10.1016/j.gastro.2003.07.007; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Mishra A, 2002, J IMMUNOL, V168, P2464, DOI 10.4049/jimmunol.168.5.2464; Moossavi M, 2003, INT J DERMATOL, V42, P62, DOI 10.1046/j.1365-4362.2003.01705.x; Muessel MJ, 2008, J IMMUNOL, V180, P8354, DOI 10.4049/jimmunol.180.12.8354; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nathani N, 2008, THORAX, V63, P883, DOI 10.1136/thx.2007.093955; Nervi SJ, 2006, J AM ACAD DERMATOL, V55, P285, DOI 10.1016/j.jaad.2006.02.034; Newman B, 2007, J AM ACAD DERMATOL, V56, P302, DOI 10.1016/j.jaad.2006.06.010; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; O'Byrne PM, 2001, J ALLERGY CLIN IMMUN, V108, P503, DOI 10.1067/mai.2001.119149; O'Driscoll BR, 2009, CLIN EXP ALLERGY, V39, P1677, DOI 10.1111/j.1365-2222.2009.03339.x; Ogbogu PU, 2009, J ALLERGY CLIN IMMUN, V124, P1319, DOI 10.1016/j.jaci.2009.09.022; Oldhoff JM, 2005, ALLERGY, V60, P693, DOI 10.1111/j.1398-9995.2005.00791.x; Pavord ID, 2010, CLIN EXP ALLERGY, V40, P62, DOI 10.1111/j.1365-2222.2009.03410.x; Pearlman E, 1999, J INFECT DIS, V180, P1394, DOI 10.1086/315041; Plotz S, 2003, NEW ENGL J MED, V349, P2334, DOI 10.1056/NEJMoa031261; Quack I, 2005, BMC GASTROENTEROL, V5, DOI 10.1186/1471-230X-5-24; Ramdial PK, 2009, J CLIN PATHOL, V62, P493, DOI 10.1136/jcp.2008.058289; Rico MJ, 1999, BRIT J DERMATOL, V140, P1079; Rothenberg MA, 2001, J ALLERGY CLIN IMMUN, V108, P891, DOI 10.1067/mai.2001.120095; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Rothenberg ME, 2009, GASTROENTEROLOGY, V137, P1238, DOI 10.1053/j.gastro.2009.07.007; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Scott KA, 2006, SEMIN RESP CRIT CARE, V27, P128, DOI 10.1055/s-2006-939515; SEMINARIO MC, 1994, CURR OPIN IMMUNOL, V6, P860, DOI 10.1016/0952-7915(94)90005-1; Simon D, 2007, J ALLERGY CLIN IMMUN, V119, P1291, DOI 10.1016/j.jaci.2007.02.010; Simon HU, 1999, NEW ENGL J MED, V341, P1112, DOI 10.1056/NEJM199910073411503; Simon HU, 2001, INT ARCH ALLERGY IMM, V124, P242, DOI 10.1159/000053723; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Stevens DA, 2000, NEW ENGL J MED, V342, P756, DOI 10.1056/NEJM200003163421102; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Tillie-Leblond I, 2005, ALLERGY, V60, P1004, DOI 10.1111/j.1398-9995.2005.00887.x; VANSICKLE GJ, 1985, GASTROENTEROLOGY, V88, P1915, DOI 10.1016/0016-5085(85)90019-8; Viallard JF, 2001, J RHEUMATOL, V28, P75; VOWELS BR, 1994, J INVEST DERMATOL, V103, P669, DOI 10.1111/1523-1747.ep12398454; Wakugawa M, 2000, BRIT J DERMATOL, V143, P112, DOI 10.1046/j.1365-2133.2000.03599.x; Wardlaw AJ, 1999, J ALLERGY CLIN IMMUN, V104, P917, DOI 10.1016/S0091-6749(99)70069-2; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; Wark PAB, 2003, J ALLERGY CLIN IMMUN, V111, P952, DOI 10.1067/mai.2003.1388; Wechsler ME, 2007, IMMUNOL ALLERGY CLIN, V27, P477, DOI 10.1016/j.iac.2007.07.005; Wehner J H, 1997, Semin Respir Infect, V12, P122; Yagi H, 1997, BRIT J DERMATOL, V136, P918, DOI 10.1111/j.1365-2133.1997.tb03934.x; Yawalkar N, 2000, J ALLERGY CLIN IMMUN, V106, P1171, DOI 10.1067/mai.2000.110922; Yawalkar N, 1999, J INVEST DERMATOL, V113, P43, DOI 10.1046/j.1523-1747.1999.00619.x; Ying S, 2002, J ALLERGY CLIN IMMUN, V109, P694, DOI 10.1067/mai.2002.123236	116	59	64	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					3	13		10.1016/j.jaci.2010.01.055	http://dx.doi.org/10.1016/j.jaci.2010.01.055			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20392477	Green Accepted			2022-12-18	WOS:000280061800002
J	Gern, JE				Gern, James E.			The Urban Environment and Childhood Asthma Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; children; environment; immune development; cytokines	RHINOVIRUS ILLNESSES; ATOPIC SENSITIZATION; INFANCY; RISK; IDENTIFICATION; INFECTIONS; PREVALENCE; CHILDREN; GENE	Childhood asthma is not distributed evenly throughout the population, and children who grow up in crowded urban neighborhoods have higher rates of asthma and experience greater morbidity because of asthma. There are several environmental and lifestyle factors associated with urban living that are suspected to promote the development of asthma, particularly in the first few years of life. Collectively, this information suggests the hypothesis that exposure in early life to adverse environmental and lifestyle factors associated with disadvantaged urban environments modifies immune development to increase the risk for allergic diseases and asthma. The Urban Environment and Childhood Asthma (URECA) birth cohort study was initiated in 2004 to test this hypothesis. The study population was recruited prenatally and consisted of 560 families from 4 urban areas who were at high risk for allergies and/or asthma on the basis of parental histories, along with an additional 49 families without atopic parents. Immune development, respiratory illnesses, and exposure to stress, indoor pollutants, microbial products, and allergens were measured prospectively, and the major study outcomes are recurrent wheeze at 3 years of age and asthma at age 7 years. This review summarizes the study design, methods, and early findings of the URECA study. (J Allergy Clin Immunol 2010;125:545-9.)	Univ Wisconsin, Dept Pediat & Med, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Gern, JE (corresponding author), Univ Wisconsin, Dept Pediat & Med, K4-918 CSC,600 Highland Ave, Madison, WI 53792 USA.	gern@medicine.wisc.edu			National Institute of Allergy and Infectious Diseases, National Institutes of Health [NO1-AI-25496, NO1-AI-25482]; National Center for Research Resources, National Institutes of Health [RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, 5UL1RR024992-02]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025771, UL1RR024156, M01RR000533, UL1RR024992, M01RR000052, M01RR000071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025496] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in whole or in part by federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under contract nos. NO1-AI-25496 and NO1-AI-25482, and from the National Center for Research Resources, National Institutes of Health, under grants RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, and 5UL1RR024992-02.	Adler A, 2005, J ALLERGY CLIN IMMUN, V115, P67, DOI 10.1016/j.jaci.2004.10.008; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Dillie KTS, 2008, CLIN EXP ALLERGY, V38, P298, DOI 10.1111/j.1365-2222.2007.02891.x; Gern James E, 2009, BMC Pulm Med, V9, P17, DOI 10.1186/1471-2466-9-17; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Gold DR, 2009, J ALLERGY CLIN IMMUN, V124, P1078, DOI 10.1016/j.jaci.2009.08.021; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lee WM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000966; Lee WM, 2007, J CLIN MICROBIOL, V45, P2626, DOI 10.1128/JCM.02501-06; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lucas SR, 2005, J ALLERGY CLIN IMMUN, V115, P928, DOI 10.1016/j.jaci.2005.01.033; Ly Ngoc P, 2009, Clin Mol Allergy, V7, P8, DOI 10.1186/1476-7961-7-8; Moore YF, 2004, IMMUNOGENETICS, V56, P1, DOI 10.1007/s00251-004-0661-6; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Pfefferle PI, 2010, J ALLERGY CLIN IMMUN, V125, P108, DOI 10.1016/j.jaci.2009.09.019; Prescott SL, 2003, CURR OPIN ALLERGY CL, V3, P125, DOI 10.1097/01.all.0000064776.57552.32; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; Shreffler WG, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-29; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; von Mutius E, 2007, IMMUNOBIOLOGY, V212, P433, DOI 10.1016/j.imbio.2007.03.002; Weinmayr G, 2007, AM J RESP CRIT CARE, V176, P565, DOI 10.1164/rccm.200607-994OC; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC	26	59	61	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					545	549		10.1016/j.jaci.2010.01.037	http://dx.doi.org/10.1016/j.jaci.2010.01.037			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20226291	Green Accepted			2022-12-18	WOS:000275883200006
J	Hollams, EM; Deverell, M; Serralha, M; Suriyaarachchi, D; Parsons, F; Zhang, GC; de Klerk, N; Holt, BJ; Ladyman, C; Sadowska, A; Rowe, J; Loh, R; Sly, PD; Holt, PG				Hollams, Elysia M.; Deverell, Marie; Serralha, Michael; Suriyaarachchi, Devinda; Parsons, Faith; Zhang, Guicheng; de Klerk, Nicholas; Holt, Barbara J.; Ladyman, Claire; Sadowska, Agata; Rowe, Julie; Loh, Richard; Sly, Peter D.; Holt, Patrick G.			Elucidation of asthma phenotypes in atopic teenagers through parallel immunophenotypic and clinical profiling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; atopy; bronchial hyperresponsiveness; IgE; eosinophils; neutrophils; teenagers; cytokines; immunoepidemiology	T-CELL RESPONSE; RESPIRATORY-INFECTIONS; HOSPITAL ADMISSIONS; AIRWAY EPITHELIUM; VIRUS-INFECTION; FOLLOW-UP; CHILDREN; SENSITIZATION; ASSOCIATION; CHILDHOOD	Background: Current treatment strategies for asthma in teenagers derive primarily from information on chronic disease in adults. More detailed understanding of risk factors related to teenage asthma might aid in the development of improved preventive and treatment strategies for this age group. Objective: We sought to identify biomarkers associated with asthma phenotypes in teenagers, particularly atopic asthma, and to identify markers that aid in discriminating between atopic subjects at high versus low risk of asthma. Methods: We studied 1380 unselected 14-year-olds and collected data on clinical history, allergic sensitization, and respiratory and immunoinflammatory function. The latter comprised measurements of circulating inflammatory markers and in vitro innate and adaptive immune functions, including house dust mite T-cell responses. We integrated the data into regression models to identify variables most strongly associated with asthma risk and severity among atopic subjects. Results: Eight hundred twenty-seven subjects were atopic, 140 subjects were asthmatic, and 81% of asthmatic subjects were also atopic. We identified asthma risk variables related to atopy intensity, including specific IgE and eosinophil levels, plus an additional series external to the T(H)2 cascade but that modified risk only in atopic subjects, including IFN-gamma, IL-10, and IL-12 responses and neutrophil numbers in blood. Moreover, bronchial hyperresponsiveness was associated strongly with atopic but not nonatopic asthma, and the bronchial hyperresponsiveness risk profile was itself dominated by atopy-associated variables. Conclusions: Asthma in teenagers is predominantly driven by atopy acting in concert with a second tier of T(H)2-independent immunoinflammatory mechanisms, which contribute to pathogenesis only against the background of pre-existing inhalant allergy. (J Allergy Clin Immunol 2009;124:463-70.)	[Deverell, Marie; Sly, Peter D.] Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Div Clin Sci, Perth, WA 6009, Australia; [de Klerk, Nicholas] Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Div Populat Sci, Perth, WA 6009, Australia; [Loh, Richard] Princess Margaret Hosp Children, Perth, WA, Australia; [Hollams, Elysia M.; Serralha, Michael; Suriyaarachchi, Devinda; Parsons, Faith; Zhang, Guicheng; Holt, Barbara J.; Ladyman, Claire; Sadowska, Agata; Rowe, Julie; Holt, Patrick G.] Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Div Cell Biol, Perth, WA 6009, Australia	Telethon Kids Institute; University of Western Australia; Telethon Kids Institute; University of Western Australia; University of Western Australia; Telethon Kids Institute; University of Western Australia	Holt, PG (corresponding author), Telethon Inst Child Hlth Res, Div Cell Biol, POB 855, Perth, WA 6872, Australia.	patrick@ichr.uwa.edu.au	de Klerk, Nicholas H/D-8388-2016; Study, Raine/K-4517-2013; Holt, Patrick G/H-1548-2011; Serralha, Michael/CAA-0940-2022; Zhang, Brad/AAF-8719-2021; Sly, Peter D/F-1486-2010	de Klerk, Nicholas H/0000-0001-9223-0767; Holt, Patrick G/0000-0003-1193-0935; Sly, Peter D/0000-0001-6305-2201; Zhang, Guicheng/0000-0001-9888-5385; Hollams, Elysia/0000-0002-3481-6396; Deverell, Marie/0000-0002-0048-8013; Serralha, Michael/0000-0002-0121-2879	National Health and Medical Research Council of Australia; Stanley Trust (UK); Raine Medical Research Foundation of the University of Western Australia	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Stanley Trust (UK); Raine Medical Research Foundation of the University of Western Australia	Supported by the National Health and Medical Research Council of Australia, the Stanley Trust (UK), and the Raine Medical Research Foundation of the University of Western Australia. Reagents for antibody and eosinophil protein X arrays were provided gratis by Phadia AB.	Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Beeh KM, 2006, CLIN EXP ALLERGY, V36, P142, DOI 10.1111/j.1365-2222.2006.02418.x; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Blanco-Quiros A, 1999, PEDIATR PULM, V28, P175, DOI 10.1002/(SICI)1099-0496(199909)28:3<175::AID-PPUL3>3.0.CO;2-U; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CALHOUN W J, 1992, American Review of Respiratory Disease, V145, pA638; Colavita AM, 2000, J ALLERGY CLIN IMMUN, V106, P880, DOI 10.1067/mai.2000.110475; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; Eriksson U, 2005, J IMMUNOL, V175, P2715, DOI 10.4049/jimmunol.175.4.2715; Grembiale RD, 2000, AM J RESP CRIT CARE, V162, P2048, DOI 10.1164/ajrccm.162.6.9909087; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P1117, DOI 10.1067/mai.2000.105804; Holt PG, 2004, NAT IMMUNOL, V5, P695, DOI 10.1038/ni0704-695; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; McWilliam AS, 1997, J VIROL, V71, P226, DOI 10.1128/JVI.71.1.226-236.1997; McWilliam AS, 1996, J EXP MED, V184, P2429, DOI 10.1084/jem.184.6.2429; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; NEWNHAM JP, 1993, LANCET, V342, P887, DOI 10.1016/0140-6736(93)91944-H; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176, DOI 10.1164/ajrccm.165.2.2104032; Rothman KJ., 1986, MODERN EPIDEMIOLOGY; Salvi SS, 2001, AM J RESP CRIT CARE, V164, P1343, DOI 10.1164/ajrccm.164.8.2103080; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Smart JM, 2002, CLIN EXP ALLERGY, V32, P796, DOI 10.1046/j.1365-2222.2002.01391.x; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6	33	59	59	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					463	U118		10.1016/j.jaci.2009.06.019	http://dx.doi.org/10.1016/j.jaci.2009.06.019			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19733295	Bronze			2022-12-18	WOS:000274315900010
J	Jin, HL; Kumar, L; Mathias, C; Zurakowski, D; Oettgen, H; Gorelik, L; Geha, R				Jin, Haoli; Kumar, Lalit; Mathias, Clinton; Zurakowski, David; Oettgen, Hans; Gorelik, Leonid; Geha, Raif			Toll-like receptor 2 is important for the T(H)1 response to cutaneous sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Toll-like receptor 2; atopic dermatitis; contact hypersensitivity; oxazolone	EOSINOPHIL-DERIVED NEUROTOXIN; ATOPIC-DERMATITIS; DENDRITIC CELLS; CYTOKINE/CHEMOKINE PRODUCTION; INTERFERON-GAMMA; CUTTING EDGE; MOUSE MODEL; IFN-GAMMA; KAPPA-B; TLR2	Background: Atopic dermatitis and allergic contact dermatitis are skin disorders triggered by epicutaneous sensitization with protein antigens and contact sensitization with haptens, respectively. Skin is colonized with bacteria, which are a source of Toll-like receptor (TLR) 2 ligands. Objective: We sought to examine the role of TLR2 in marine models of atopic dermatitis and allergic contact dermatitis. Methods: TLR2(-/-) mice and wild-type littermates were epicutaneously sensitized with ovalbumin (OVA) or contact sensitized with oxazolone (OX). Skin histology was assessed by means of hematoxylin and eosin staining and immunohistochemistry. Ear swelling was measured with a micrometer. Cytokine mRNA expression was examined by means of quantitative RT-PCR. Antibody levels and splenocyte secretion of cytokines in response to OVA stimulation were measured by means of ELISA. Dendritic cells were examined for their ability to polarize T-cell receptor/OVA transgenic naive T cells to T(H)1 and T(H)2. Results: In response to OVA sensitization, TLR2(-/-) mice experienced skin infiltration with eosinophils and CD4(+) cells, as well as upregulation of T(H)2 cytokine mRNAs that was comparable with that seen in wild-type littermates. In contrast, epidermal thickening, IFN-gamma expression in the skin, IFN-gamma production by splenocytes, and IgG2a anti-OVA antibody levels were impaired in TLR2(-/-) mice. After OX ear challenge, contact sensitized TLR2(-/-) mice exhibited defective ear swelling with impaired cellular infiltration, decreased epidermal thickening and local IFN-gamma expression, and impaired OX-specific IgG2a responses. Dendritic cells from TLR2(-/-) mice induced significantly lower production of IFN-gamma but normal IL-4 and IL-13 production in naive T cells. Conclusions: These results indicate that TLR2 promotes the IFN-gamma response to cutaneously introduced antigens. (J Allergy Clin Immunol 2009;123:875-82.)	[Jin, Haoli; Kumar, Lalit; Mathias, Clinton; Oettgen, Hans; Geha, Raif] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Jin, Haoli; Kumar, Lalit; Mathias, Clinton; Oettgen, Hans; Geha, Raif] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Zurakowski, David] Childrens Hosp, Dept Anesthesia & Surg, Boston, MA 02115 USA; [Gorelik, Leonid] Biogen Idec Inc, Cambridge, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Biogen	Geha, R (corresponding author), Childrens Hosp, Div Immunol, Room 10210,Karp Family Res Bldg,1 Blackfan Circle, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu		Mathias, Clinton/0000-0002-0223-4842	Atopic Dermatitis and Vaccinia Immunization Network; National Institutes of Health/National Institute of Allergy and Infectious Diseases [NO1 (AI 40030)]; US Public Health Service [AR-047417]; American Heart Association; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047417] Funding Source: NIH RePORTER	Atopic Dermatitis and Vaccinia Immunization Network(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); American Heart Association(American Heart Association); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by the Atopic Dermatitis and Vaccinia Immunization Network; National Institutes of Health/National Institute of Allergy and Infectious Diseases contract NO1 (AI 40030); and a US Public Health Service grant AR-047417 to R.G.H.J. has received a postdoctoral fellowship from the American Heart Association.	Abeck D, 1998, BRIT J DERMATOL, V139, P13; Ahmad-Nejad P, 2004, J ALLERGY CLIN IMMUN, V113, P565, DOI 10.1016/j.jaci.2003.12.583; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Baker BS, 2003, BRIT J DERMATOL, V148, P670, DOI 10.1046/j.1365-2133.2003.05287.x; Breuer K, 2002, BRIT J DERMATOL, V147, P55, DOI 10.1046/j.1365-2133.2002.04872.x; Carroll JM, 1997, J INVEST DERMATOL, V108, P412, DOI 10.1111/1523-1747.ep12289702; Cheng JF, 1997, J ALLERGY CLIN IMMUN, V99, P683, DOI 10.1016/S0091-6749(97)70031-9; Cheng N, 2008, J IMMUNOL, V181, P22, DOI 10.4049/jimmunol.181.1.22; Chisholm D, 2004, J ALLERGY CLIN IMMUN, V113, P448, DOI 10.1016/j.jaci.2003.12.011; Daehnel K, 2007, PARASITE IMMUNOL, V29, P455, DOI 10.1111/j.1365-3024.2007.00962.x; Fricke I, 2006, J IMMUNOL, V176, P5173, DOI 10.4049/jimmunol.176.9.5173; GOEBELER M, 1995, J IMMUNOL, V155, P2459; Hasannejad H, 2007, J ALLERGY CLIN IMMUN, V120, P69, DOI 10.1016/j.jaci.2007.04.010; Hisbergues M, 2007, CLIN EXP ALLERGY, V37, P1286, DOI 10.1111/j.1365-2222.2007.02792.x; Imanishi T, 2007, J IMMUNOL, V178, P6715, DOI 10.4049/jimmunol.178.11.6715; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Johnson CM, 2007, J BIOL CHEM, V282, P31197, DOI 10.1074/jbc.M705151200; Karimipour DJ, 2005, J AM ACAD DERMATOL, V52, P215, DOI 10.1016/j.jaad.2004.10.008; Khan AQ, 2005, INFECT IMMUN, V73, P298, DOI 10.1128/IAI.73.1.298-307.2005; Lin YT, 2007, CLIN REV ALLERG IMMU, V33, P167, DOI 10.1007/s12016-007-0044-5; Marshall JS, 2003, INT ARCH ALLERGY IMM, V132, P87, DOI 10.1159/000073709; Patel M, 2005, J IMMUNOL, V174, P7558, DOI 10.4049/jimmunol.174.12.7558; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Re F, 2001, J BIOL CHEM, V276, P37692, DOI 10.1074/jbc.M105927200; Robert C, 1999, NEW ENGL J MED, V341, P1817, DOI 10.1056/NEJM199912093412407; Sawaki J, 2007, INT IMMUNOL, V19, P311, DOI 10.1093/intimm/dxl148; Schaefer L, 2005, J CLIN INVEST, V115, P2223, DOI 10.1172/JCI23755; Schmidtko A, 2007, PAIN, V127, P287, DOI 10.1016/j.pain.2006.11.002; Shimada M, 2008, DEVELOPMENT, V135, P2001, DOI 10.1242/dev.020461; Sieling PA, 2003, J IMMUNOL, V170, P194, DOI 10.4049/jimmunol.170.1.194; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; Sumikawa Y, 2006, MICROBES INFECT, V8, P1513, DOI 10.1016/j.micinf.2006.01.008; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tamura T, 2004, BRIT J DERMATOL, V151, P1133, DOI 10.1111/j.1365-2133.2004.06172.x; Taniuchi S, 2001, J DERMATOL SCI, V26, P79, DOI 10.1016/S0923-1811(00)00151-1; THOMSON JA, 1993, IMMUNOLOGY, V78, P185; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Weigt H, 2005, AM J RESP CRIT CARE, V172, P566, DOI 10.1164/rccm.200411-1490OC; Weigt H, 2003, IMMUNOBIOLOGY, V207, P223, DOI 10.1078/0171-2985-00234; Woodward AL, 2001, J ALLERGY CLIN IMMUN, V107, P359, DOI 10.1067/mai.2001.112695; Wu Q, 2007, AM J PHYSIOL-LUNG C, V292, pL1064, DOI 10.1152/ajplung.00301.2006; Yang D, 2008, J EXP MED, V205, P79, DOI 10.1084/jem.20062027	44	59	59	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					875	882		10.1016/j.jaci.2009.02.007	http://dx.doi.org/10.1016/j.jaci.2009.02.007			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19348925	Green Accepted			2022-12-18	WOS:000265058600014
J	Shiraishi, Y; Takeda, K; Thurmond, RL; Gelfand, EW				Shiraishi, Y.; Takeda, K.; Thurmond, R. L.; Gelfand, E. W.			The Critical Role of Histamine H4 Receptor in the Development of Allergic Rhinitis in Mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	65th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 13-17, 2009	Washington, DC	Amer Acad Allergy, Asthma & Immunol					[Shiraishi, Y.; Takeda, K.; Gelfand, E. W.] Natl Jewish Hlth, Denver, CO USA; [Thurmond, R. L.] Johnson & Johnson Pharmaceut Res & Dev, San Diego, CA USA	National Jewish Health; Johnson & Johnson; Johnson & Johnson USA				Ueki, Shigeharu/0000-0002-3537-7735; Sasaki, Takehiko/0000-0003-1837-3748					0	59	71	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2				202	S56	S56		10.1016/j.jaci.2008.12.183	http://dx.doi.org/10.1016/j.jaci.2008.12.183			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	410RR	19232703	Bronze			2022-12-18	WOS:000263596300215
J	Dakhama, A; Lee, YM; Ohnishi, H; Jing, X; Balhorn, A; Takeda, K; Gelfand, EW				Dakhama, Azzeddine; Lee, Young-Mok; Ohnishi, Hiroshi; Jing, Xia; Balhorn, Annette; Takeda, Katsuyuki; Gelfand, Erwin W.			Virus-specific IgE enhances airway responsiveness on reinfection with respiratory syncytial virus in newborn mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Virus; IgE; airway hyperresponsiveness; wheezing; asthma	FC-EPSILON-RI; EPIDERMAL LANGERHANS CELLS; HIGH-AFFINITY RECEPTOR; MEDIATED ALLERGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; BLOOD DENDRITIC CELLS; IMMUNOGLOBULIN-E; HISTAMINE-RECEPTOR; INFECTION DETERMINES; CHILDHOOD ASTHMA	Background: Respiratory syncytial virus (RSV)-specific IgE is a component of the host response to RSV infection, but its role in the subsequent enhancement of altered airway responsiveness is unknown. Objective: To define the role of RSV-specific IgE in the enhancement of airway responsiveness on reinfection of newborn mice. Methods: Mice were infected as newborns with RSV and were reinfected 5 weeks later. The role of IgE was determined by documenting RSV-specific IgE response after neonatal infection, and by assessing airway responsiveness on reinfection. Results: After neonatal infection, wild-type (WT) mice developed an RSV-specific IgE response. On reinfection, these mice developed enhanced airway hyperresponsiveness (AHR), airway eosinophilia, and mucus hyperproduction, and their T-cell cytokine response was skewed toward a T(H)2 phenotype. None of these altered responses developed on reinfection of IL4(-/-)/IL-13(-/-) mice, and no RSV-specific IgE could be detected after neonatal infection of these mice. Fc epsilon RI(-/-) mice did not develop the enhanced AHR on reinfection, and airway eosinophilia and mucus production were significantly attenuated. These responses could be restored in deficient mice reconstituted with WT mast cells. In RSV-infected newborn WT mice, administration of anti-IgE prevented the enhancement of AHR and attenuated eosinophilia and mucus hyperproduction on reinfection, an effect that was associated with diminished T(H)2 cytokine production and increased IFN-gamma production. Conclusion: Respiratory syncytial virus-specific IgE enhances the development of T(H)2-biased airway responsiveness on reinfection of mice initially infected as newborns. (J Allergy Clin Immunol 2009;123:138-45.)	[Dakhama, Azzeddine; Lee, Young-Mok; Ohnishi, Hiroshi; Jing, Xia; Balhorn, Annette; Takeda, Katsuyuki; Gelfand, Erwin W.] Natl Jewish Hlth, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA	National Jewish Health	Dakhama, A (corresponding author), Natl Jewish Hlth, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.	DakhamaA@njhealth.org		Lee, Young Mok/0000-0003-4039-0456; Ohnishi, Hiroshi/0000-0002-7863-4519	National Institutes of Health [HD-053557, HL-61005, HL-36577]; Novartis; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD053557] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061005, P01HL036577] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Novartis(Novartis); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grants HD-053557 (A.D.) HL-61005 (E.W.G.), and HL-36577 (E.W.G.) and a grant from Novartis (E.W.G.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases, or the National Institutes of Health.	Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ALEXEYEV OA, 1994, CLIN DIAGN LAB IMMUN, V1, P269, DOI 10.1128/CDLI.1.3.269-272.1994; ARRANG JM, 1983, NATURE, V302, P832, DOI 10.1038/302832a0; Bacharier LB, 2000, J ALLERGY CLIN IMMUN, V105, pS547, DOI 10.1016/S0091-6749(00)90059-9; BIEBER T, 1989, J INVEST DERMATOL, V93, P215, DOI 10.1111/1523-1747.ep12277574; Bieber T, 1997, INT ARCH ALLERGY IMM, V113, P30, DOI 10.1159/000237500; Bieber T, 1996, J DERMATOL SCI, V13, P71, DOI 10.1016/0923-1811(95)00504-8; Bieber T, 2007, IMMUNOBIOLOGY, V212, P499, DOI 10.1016/j.imbio.2007.03.001; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; Bradding P, 2003, CURR OPIN ALLERGY CL, V3, P45, DOI 10.1097/01.all.0000053267.39029.fd; Brown JM, 2008, CLIN EXP ALLERGY, V38, P4, DOI 10.1111/j.1365-2222.2007.02886.x; CALENOFF E, 1995, ARCH OTOLARYNGOL, V121, P861; Caron G, 2001, J IMMUNOL, V167, P3682, DOI 10.4049/jimmunol.167.7.3682; Culley FJ, 2002, J EXP MED, V196, P1381, DOI 10.1084/jem.20020943; Dakhama A, 2005, J IMMUNOL, V175, P1876, DOI 10.4049/jimmunol.175.3.1876; Dakhama A, 2004, AM J RESP CRIT CARE, V170, P952, DOI 10.1164/rccm.200311-1610oc; Dakhama A, 2002, AM J RESP CRIT CARE, V165, P1137, DOI 10.1164/ajrccm.165.8.2109058; DAKHAMA A, 2005, PEDIATR INFECT DIS J, V24, pS66; Dakhama Azzeddine, 2005, Pediatr Infect Dis J, V24, pS159, DOI 10.1097/01.inf.0000188155.46381.15; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; Dunford PJ, 2006, J IMMUNOL, V176, P7062, DOI 10.4049/jimmunol.176.11.7062; Geiger E, 2000, J ALLERGY CLIN IMMUN, V105, P150, DOI 10.1016/S0091-6749(00)90190-8; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Gutzmer R, 2005, J IMMUNOL, V174, P5224, DOI 10.4049/jimmunol.174.9.5224; Holloway JA, 2001, J ALLERGY CLIN IMMUN, V107, P1009, DOI 10.1067/mai.2001.115039; Koraka P, 2003, J MED VIROL, V70, P91, DOI 10.1002/jmv.10358; Lee YM, 2008, AM J RESP CRIT CARE, V177, P208, DOI 10.1164/rccm.200612-1890OC; LEUNG DYM, 1987, CLIN IMMUNOL IMMUNOP, V42, P328, DOI 10.1016/0090-1229(87)90021-3; Liu CL, 2001, MOL PHARMACOL, V59, P420, DOI 10.1124/mol.59.3.420; Martinez FD, 2003, PEDIATR INFECT DIS J, V22, pS76, DOI 10.1097/00006454-200302001-00011; Maurer D, 1996, J IMMUNOL, V157, P607; Maurer D, 1998, J IMMUNOL, V161, P2731; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI200113930; McKenna DB, 2001, BRIT J DERMATOL, V144, P459, DOI 10.1046/j.1365-2133.2001.04068.x; McKenzie GJ, 1999, J EXP MED, V189, P1565, DOI 10.1084/jem.189.10.1565; Oda T, 2000, J BIOL CHEM, V275, P36781, DOI 10.1074/jbc.M006480200; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; Perez-Yarza EG, 2007, PEDIATR INFECT DIS J, V26, P733, DOI 10.1097/INF.0b013e3180618c42; Singh AM, 2007, AM J RESP CRIT CARE, V175, P108, DOI 10.1164/rccm.200603-435PP; Small CB, 1998, ANN ALLERG ASTHMA IM, V81, P75, DOI 10.1016/S1081-1206(10)63112-2; Stingl G, 1997, INT ARCH ALLERGY IMM, V113, P24, DOI 10.1159/000237499; TunonDeLara JM, 1996, CLIN EXP ALLERGY, V26, P648, DOI 10.1046/j.1365-2222.1996.1095481.x; Votava M, 1996, ACTA VIROL, V40, P99; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WOLLENBERG A, 1995, LANCET, V346, P1626, DOI 10.1016/S0140-6736(95)91958-9	45	59	61	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					138	145		10.1016/j.jaci.2008.10.012	http://dx.doi.org/10.1016/j.jaci.2008.10.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19056111				2022-12-18	WOS:000262793900023
J	Jung, T; Stingl, G				Jung, Thomas; Stingl, Georg			Atopic dermatitis: Therapeutic concepts evolving from new pathophysiologic insights	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; skin barrier function; innate immune system; adaptive immune system; filaggrin; T(H)2 cells; T(H)17 cells; immunotherapy; proof-of-concept trial	PLACEBO-CONTROLLED TRIAL; FC-EPSILON-RI; MYCOBACTERIUM-VACCAE SUSPENSION; ANTI-CD20 RITUXIMAB TREATMENT; ANTI-IGE THERAPY; DOUBLE-BLIND; DENDRITIC CELLS; ANTIMICROBIAL PEPTIDES; T-CELLS; MYCOPHENOLATE-MOFETIL	Recent insights into the relevance of the epidermal barrier function and its interaction with components of the innate and adaptive immune responses in patients with atopic dermatitis (AD) give rise to a number of novel potential treatment options. In particular, the identification of loss-of-function mutations in the barrier protein filaggrin and of a diminished expression of certain antimicrobial peptides in AD skin stimulates new concepts to think beyond the T(H)1/T(H)2 paradigm. This review will focus on these most recent discoveries and will discuss new and corresponding proof-of-concept trials in patients with AD. It will further speculate on novel ways to restore the homeostasis among the 3 major components in AD skin suspected to be clinically relevant. (J Allergy Clin Immunol 2008;122:1074-81.)	[Jung, Thomas] Novartis Pharma Dev Immunol & Infect Dis Franchis, CH-4056 Basel, Switzerland; [Stingl, Georg] Med Univ Vienna, Dept Dermatol, Div Immunol, Vienna, Austria; [Stingl, Georg] Med Univ Vienna, Dept Dermatol, Div Allergy & Infect Dis, Vienna, Austria	Novartis; Medical University of Vienna; Medical University of Vienna	Jung, T (corresponding author), Novartis Pharma Dev Immunol & Infect Dis Franchis, WSJ-27-4-071, CH-4056 Basel, Switzerland.	thomas.jung@novartis.com						Aberg KM, 2008, J INVEST DERMATOL, V128, P917, DOI 10.1038/sj.jid.5701099; Arkwright PD, 2003, BRIT J DERMATOL, V149, P1029, DOI 10.1111/j.1365-2133.2003.05557.x; Arkwright PD, 2001, J ALLERGY CLIN IMMUN, V107, P531, DOI 10.1067/mai.2001.113081; Arshad SH, 2007, J ALLERGY CLIN IMMUN, V119, P307, DOI 10.1016/j.jaci.2006.12.621; Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Beck LA, 2006, J AM ACAD DERMATOL, V55, P540, DOI 10.1016/j.jaad.2006.01.037; Belloni B, 2007, J ALLERGY CLIN IMMUN, V120, P1223, DOI 10.1016/j.jaci.2007.08.060; Berth-Jones J, 2006, CLIN EXP ALLERGY, V36, P1115, DOI 10.1111/j.1365-2222.2006.02558.x; Berth-Jones J, 2002, BRIT J DERMATOL, V147, P324, DOI 10.1046/j.1365-2133.2002.04989.x; Betsi GL, 2008, AM J CLIN DERMATOL, V9, P93, DOI 10.2165/00128071-200809020-00002; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; Buechau AS, 2008, J INVEST DERMATOL, V128, P2646, DOI 10.1038/jid.2008.135; Buka RL, 2005, J AM ACAD DERMATOL, V53, P358, DOI 10.1016/j.jaad.2005.03.013; Bussmann C, 2007, CLIN EXP ALLERGY, V37, P1277, DOI 10.1111/j.1365-2222.2007.02783.x; Bussmann C, 2006, J ALLERGY CLIN IMMUN, V118, P1292, DOI 10.1016/j.jaci.2006.07.054; Buttner C, 2003, EUR RESPIR J, V21, P799, DOI 10.1183/09031936.03.00027302; Cao W, 2007, CURR OPIN IMMUNOL, V19, P24, DOI 10.1016/j.coi.2006.11.004; Chamlin SL, 2002, J AM ACAD DERMATOL, V47, P198, DOI 10.1067/mjd.2002.124617; Chinen J, 2008, J ALLERGY CLIN IMMUN, V122, P36, DOI 10.1016/j.jaci.2008.04.035; Descargues P, 2005, NAT GENET, V37, P56, DOI 10.1038/ng1493; DI ML, 2008, INT J IMMUNOPATH PH, V21, P137; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Farshidi Arta, 2006, J Drugs Dermatol, V5, P994; Friedmann PS, 2007, CLIN EXP ALLERGY, V37, P1536, DOI 10.1111/j.1365-2222.2007.02811.x; Gilliet M, 2003, J EXP MED, V197, P1059, DOI 10.1084/jem.20030240; Gruber C, 2007, ALLERGY, V62, P1270, DOI 10.1111/j.1398-9995.2007.01543.x; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Harper EG, 2008, J INVEST DERMATOL, V128, P1173, DOI 10.1038/sj.jid.5701169; Hassan AS, 2007, J AM ACAD DERMATOL, V56, P217, DOI 10.1016/j.jaad.2006.08.025; Hata TR, 2008, J ALLERGY CLIN IMMUN, V122, P829, DOI 10.1016/j.jaci.2008.08.020; Heller M, 2007, BRIT J DERMATOL, V157, P127, DOI 10.1111/j.1365-2133.2007.07947.x; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Howell MD, 2006, J ALLERGY CLIN IMMUN, V117, P836, DOI 10.1016/j.jaci.2005.12.1345; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Irvine AD, 2007, J INVEST DERMATOL, V127, P504, DOI 10.1038/sj.jid.5700695; Jacobi A, 2005, J AM ACAD DERMATOL, V52, P522, DOI 10.1016/j.jaad.2004.11.022; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kalliomaki M, 2007, J ALLERGY CLIN IMMUN, V119, P1019, DOI 10.1016/j.jaci.2006.12.608; Kang JS, 2007, INT IMMUNOPHARMACOL, V7, P1589, DOI 10.1016/j.intimp.2007.08.009; Karsak M, 2007, SCIENCE, V316, P1494, DOI 10.1126/science.1142265; Katayama I, 1996, BRIT J DERMATOL, V135, P237, DOI 10.1111/j.1365-2133.1996.tb01153.x; Klubal R, 1997, J INVEST DERMATOL, V108, P336, DOI 10.1111/1523-1747.ep12286482; KOGA C, 2008, J INVEST DE IN PRESS; Kopp MV, 2008, PEDIATRICS, V121, pE850, DOI 10.1542/peds.2007-1492; Krathen RA, 2005, J AM ACAD DERMATOL, V53, P338, DOI 10.1016/j.jaad.2005.02.014; Lane JE, 2006, J AM ACAD DERMATOL, V54, P68, DOI 10.1016/j.jaad.2005.09.030; Lee J, 2008, J ALLERGY CLIN IMMUN, V121, P116, DOI 10.1016/j.jaci.2007.10.043; Liu AH, 2006, J ALLERGY CLIN IMMUN, V117, P1063, DOI 10.1016/j.jaci.2006.03.027; Liu PT, 2007, J IMMUNOL, V179, P2060, DOI 10.4049/jimmunol.179.4.2060; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Maurer D, 1996, J IMMUNOL, V157, P607; Mazereeuw-Hautier J, 2006, ARCH DERMATOL, V142, P396, DOI 10.1001/archderm.142.3.396; Meggitt SJ, 2006, LANCET, V367, P839, DOI 10.1016/S0140-6736(06)68340-2; Mittermann I, 2004, CURR OPIN ALLERGY CL, V4, P367, DOI 10.1097/00130832-200410000-00007; Moul DK, 2008, J AM ACAD DERMATOL, V58, P984, DOI 10.1016/j.jaad.2008.02.007; Murray ML, 2007, CLIN EXP DERMATOL, V32, P23, DOI 10.1111/j.1365-2230.2006.02290.x; Nagelkerken L, 2008, J INVEST DERMATOL, V128, P1165, DOI 10.1038/sj.jid.5701182; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Ny A, 2004, ACTA DERM-VENEREOL, V84, P18, DOI 10.1080/0001555031004924; Oldhoff JM, 2006, INT ARCH ALLERGY IMM, V141, P290, DOI 10.1159/000095299; Oldhoff JM, 2005, ALLERGY, V60, P693, DOI 10.1111/j.1398-9995.2005.00791.x; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Ong YE, 2005, J ALLERGY CLIN IMMUN, V116, P558, DOI 10.1016/j.jaci.2005.05.035; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Pajno GB, 2007, J ALLERGY CLIN IMMUN, V120, P164, DOI 10.1016/j.jaci.2007.04.008; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Paus R, 2006, J CLIN INVEST, V116, P1174, DOI 10.1172/JCI28553; Peng WM, 2007, J INVEST DERMATOL, V127, P1261, DOI 10.1038/sj.jid.5700657; Phipps S, 2004, J INVEST DERMATOL, V122, P1406, DOI 10.1111/j.0022-202X.2004.22619.x; Proksch E, 2003, CLIN DERMATOL, V21, P134, DOI 10.1016/S0738-081X(02)00370-X; Reich K, 2001, J IMMUNOL, V167, P6321, DOI 10.4049/jimmunol.167.11.6321; Rieg S, 2005, J IMMUNOL, V174, P8003, DOI 10.4049/jimmunol.174.12.8003; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; Schauber J, 2008, J ALLERGY CLIN IMMUN, V122, P261, DOI 10.1016/j.jaci.2008.03.027; Sediva A, 2008, J ALLERGY CLIN IMMUN, V121, P1515, DOI 10.1016/j.jaci.2008.03.007; Sevilla LM, 2007, J CELL BIOL, V179, P1599, DOI 10.1083/jcb.200706187; Simon D, 2008, J ALLERGY CLIN IMMUN, V122, P423, DOI 10.1016/j.jaci.2008.06.010; Simon D, 2008, J ALLERGY CLIN IMMUN, V121, P122, DOI 10.1016/j.jaci.2007.11.016; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Stary G, 2005, INT ARCH ALLERGY IMM, V138, P278, DOI 10.1159/000088865; Stary G, 2007, J EXP MED, V204, P1441, DOI 10.1084/jem.20070021; Takiguchi R, 2007, J AM ACAD DERMATOL, V56, P222, DOI 10.1016/j.jaad.2006.08.031; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Uchida Y, 2008, J DERMATOL SCI, V51, P37, DOI 10.1016/j.jdermsci.2008.02.007; Valenta R, 1996, J INVEST DERMATOL, V107, P203, DOI 10.1111/1523-1747.ep12329617; Verhagen J, 2006, J ALLERGY CLIN IMMUN, V117, P176, DOI 10.1016/j.jaci.2005.10.040; Vigo PG, 2006, J AM ACAD DERMATOL, V55, P168, DOI 10.1016/j.jaad.2005.12.045; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Weatherhead SC, 2007, BRIT J DERMATOL, V156, P346, DOI 10.1111/j.1365-2133.2006.07686.x; Weinberg JM, 2006, ARCH DERMATOL, V142, P555, DOI 10.1001/archderm.142.5.555; Werfel T, 2006, ALLERGY, V61, P202, DOI 10.1111/j.1398-9995.2006.00974.x; Zhang Y, 2006, ARCH DERMATOL RES, V297, P425, DOI 10.1007/s00403-006-0641-9	101	59	65	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1074	1081		10.1016/j.jaci.2008.09.042	http://dx.doi.org/10.1016/j.jaci.2008.09.042			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	18992925				2022-12-18	WOS:000261711800005
J	Polte, T; Hennig, C; Hansen, G				Polte, Tobias; Hennig, Christian; Hansen, Gesine			Allergy prevention starts before conception: Maternofetal transfer of tolerance protects against the development of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; tolerance; pregnancy; primary prevention	DAY-CARE ATTENDANCE; REGULATORY T-CELLS; MATERNAL TRANSMISSION; ATOPIC SENSITIZATION; AIRWAY INFLAMMATION; BREAST-MILK; RISK; EXPOSURE; IGE; SUPPRESSION	Background: Allergy prevention must start early because environmental exposures during pregnancy and young life determine disease risk. Objective: In this study we analyzed whether prevention can start even earlier before conception by transfer of immunologic tolerance from the mother to the offspring preventing the offspring from having asthma. Methods: BALB/c mice were orally tolerized with ovalbumin before conception by means of oral application of antigen. The offspring of tolerized and naive mothers were immunized with ovalbumin at 6 weeks and 4 months of age and analyzed in our murine asthma model. Results: Although the offspring of naive mothers had an asthma-like phenotype, the offspring of tolerized mice were completely protected, even when immunized as late as 8 months after birth. Critically involved in the tolerance transfer was allergen-specific IgG, levels of which were increased in the sera of the mother, fetus, and pup and breast milk. FcRn(-/-) mice, which cannot transport IgG through the placenta, transferred tolerance to the offspring only when the missing diaplacental IgG transfer was compensated by IgG transfer through breast milk from tolerant mothers but not when weaned by naive wet nurses. Inhibition of IFN-gamma, produced by memory T cells in the offspring, abrogated the protective effect of maternal tolerance, demonstrating a crucial role for IFN-gamma in the maintenance of allergen-specific tolerance. Conclusion: Our data show that maternal immunologic memory has a significant and persistent effect on the immune response of the offspring. (J Allergy Clin Immunol 2008;122:1022-30.)	[Polte, Tobias; Hennig, Christian; Hansen, Gesine] Hannover Med Sch, Dept Pediat, Div Pediat Pulmonol & Neonatol, D-30625 Hannover, Germany; [Polte, Tobias] Univ Halle Wittenberg, Dept Pediat, Halle, Germany; [Polte, Tobias] Univ Leipzig, UFZ, Helmholtz Ctr Environm Res, Leipzig, Germany; [Polte, Tobias] Univ Leipzig, Fac Med, Leipzig, Germany	Hannover Medical School; Martin Luther University Halle Wittenberg; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Leipzig University; Leipzig University	Hansen, G (corresponding author), Hannover Med Sch, Dept Pediat, Div Pulmonol & Neonatol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	hansen.gesine@mh-hannover.de			Deutsche Forschungsgemeinschaft [SFB 587, B14]; Bundesministerium fur Bildung und Forschung [FKZ 14/28]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF))	Supported by the Deutsche Forschungsgemeinschaft (SFB 587, B14) and the Bundesministerium fur Bildung und Forschung (FKZ 14/28).	Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394; Bacchetta R, 2007, J ALLERGY CLIN IMMUN, V120, P227, DOI 10.1016/j.jaci.2007.06.023; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Bergmann RL, 2002, CLIN EXP ALLERGY, V32, P205, DOI 10.1046/j.1365-2222.2002.01274.x; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; Cohn L, 1999, J EXP MED, V190, P1309, DOI 10.1084/jem.190.9.1309; De Rose V, 2004, J LEUKOCYTE BIOL, V76, P423, DOI 10.1189/jlb.0503247; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Gerhold K, 2006, J ALLERGY CLIN IMMUN, V118, P666, DOI 10.1016/j.jaci.2006.05.022; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Huang TJ, 2001, J IMMUNOL, V166, P207, DOI 10.4049/jimmunol.166.1.207; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; JARRETT E, 1979, NATURE, V280, P145, DOI 10.1038/280145a0; Kihlstrom A, 2003, ALLERGY, V58, P871, DOI 10.1034/j.1398-9995.2003.00232.x; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Lack G, 1996, J IMMUNOL, V157, P1432; Leme AS, 2006, J IMMUNOL, V176, P762, DOI 10.4049/jimmunol.176.2.762; Li XM, 1996, J IMMUNOL, V157, P3216; Lima C, 2005, J IMMUNOL, V175, P3554, DOI 10.4049/jimmunol.175.6.3554; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; Matson AP, 2007, J IMMUNOL, V179, P1282, DOI 10.4049/jimmunol.179.2.1282; Mcgee HS, 2006, IMMUNOL RES, V35, P219, DOI 10.1385/IR:35:3:219; Medesan C, 1996, EUR J IMMUNOL, V26, P2533, DOI 10.1002/eji.1830261038; Oddy WH, 2002, J ALLERGY CLIN IMMUN, V110, P65, DOI 10.1067/mai.2002.125296; Pincus-Knackstedt MK, 2006, J IMMUNOL, V177, P8484, DOI 10.4049/jimmunol.177.12.8484; Polte T, 2006, J CLIN INVEST, V116, P1025, DOI 10.1172/JCI23792; Roopenian DC, 2003, J IMMUNOL, V170, P3528, DOI 10.4049/jimmunol.170.7.3528; RUIZ RGG, 1992, CLIN EXP ALLERGY, V22, P762, DOI 10.1111/j.1365-2222.1992.tb02816.x; Schonberger HJ, 2005, PEDIATR ALLERGY IMMU, V16, P27, DOI 10.1111/j.1399-3038.2005.00243.x; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Seeger M, 1998, EUR J IMMUNOL, V28, P2124, DOI 10.1002/(SICI)1521-4141(199807)28:07<2124::AID-IMMU2124>3.0.CO;2-A; Stern PJ, 2007, J IMP COMMONW HIST, V35, P1, DOI 10.1080/03086530601143362; Umetsu Dale T, 2006, Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M, P211; Umetsu DT, 2006, IMMUNOL REV, V212, P238, DOI 10.1111/j.0105-2896.2006.00413.x; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; Verhasselt V, 2008, NAT MED, V14, P170, DOI 10.1038/nm1718; Wu L, 2004, CELL MOL IMMUNOL, V1, P112; Zinkernagel RM, 2001, NEW ENGL J MED, V345, P1331, DOI 10.1056/NEJMra012493	39	59	62	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					1022	1030		10.1016/j.jaci.2008.09.014	http://dx.doi.org/10.1016/j.jaci.2008.09.014			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	19000583				2022-12-18	WOS:000260940100025
J	Sharma, S; Litonjua, AA; Tantisira, KG; Fuhlbrigge, AL; Szefler, SJ; Strunk, RC; Zeiger, RS; Murphy, AJ; Weiss, ST				Sharma, Sunita; Litonjua, Augusto A.; Tantisira, Kelan G.; Fuhlbrigge, Anne L.; Szefler, Stanley J.; Strunk, Robert C.; Zeiger, Robert S.; Murphy, Amy J.; Weiss, Scott T.		Childhood Asthma Management	Clinical predictors and outcomes of consistent bronchodilator response in the childhood asthma management program	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; consistent bronchodilator response; outcomes	LUNG-FUNCTION; MILD; PHARMACOGENETICS; REVERSIBILITY; FLUTICASONE; MONTELUKAST; OBSTRUCTION; CHILDREN; TRIAL	Background: Among asthmatic subjects, bronchodilator response (BDR) to inhaled beta(2)-adrenergic agonists is variable, and the significance of a consistent response over time is unknown. Objective: We assessed baseline clinical variables and determined the clinical outcomes associated with a consistently positive BDR over 4 years in children with mild-to-moderate persistent asthma. Methods: In the 1041 participants in the Childhood Asthma Management Program, subjects with a change in FEV(1) of 12% or greater (and 200 mL) after inhaled beta(2)-agonist administration at each of their yearly follow-up visits (consistent BDR) were compared with those who did not have a consistent BDR. Results: We identified 52 children with consistent BDRs over the 4-year trial. Multivariable logistic regression modeling demonstrated that lower baseline prebronchodilator FEV(1) values (odds ratio, 0.71; P<.0001), higher log10 IgE levels (odds ratio, 1.97; P = .002), and lack of treatment with inhaled corticosteroids (odds ratio, 0.31; P = .009) were associated with a consistent BDR. Individuals who had a consistent BDR had more hospital visits (P = .007), required more prednisone bursts (P = .0007), had increased nocturnal awakenings caused by asthma (P < .0001), and missed more days of school (P = .03) than nonresponders during the 4-year follow-up. Conclusions: We have identified predictors of consistent BDR and determined that this phenotype is associated with poor clinical outcomes. (J Allergy Clin Immunol 2008;122:921-8.)	[Sharma, Sunita; Litonjua, Augusto A.; Tantisira, Kelan G.; Fuhlbrigge, Anne L.; Murphy, Amy J.; Weiss, Scott T.] Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; [Sharma, Sunita; Litonjua, Augusto A.; Tantisira, Kelan G.; Fuhlbrigge, Anne L.; Murphy, Amy J.; Weiss, Scott T.] Harvard Univ, Sch Med, Boston, MA USA; [Sharma, Sunita; Litonjua, Augusto A.; Tantisira, Kelan G.; Fuhlbrigge, Anne L.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Szefler, Stanley J.] Natl Jewish Med & Res Ctr, Dept Pediat, Div Pediat Clin Pharmacol, Denver, CO USA; [Szefler, Stanley J.] Natl Jewish Med & Res Ctr, Dept Pediat, Div Allergy, Denver, CO USA; [Szefler, Stanley J.] Natl Jewish Med & Res Ctr, Dept Pediat, Div Immunol, Denver, CO USA; [Strunk, Robert C.] Washington Univ, Sch Med, Dept Pediat, Div Allergy & Pulm Med, St Louis, MO 63110 USA; [Strunk, Robert C.] St Louis Childrens Hosp, St Louis, MO 63178 USA; [Zeiger, Robert S.] Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA USA; [Sharma, Sunita; Litonjua, Augusto A.; Tantisira, Kelan G.; Fuhlbrigge, Anne L.; Murphy, Amy J.; Weiss, Scott T.] Brigham & Womens Hosp, Ctr Genom Med, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; National Jewish Health; National Jewish Health; National Jewish Health; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Kaiser Permanente; Harvard University; Brigham & Women's Hospital	Sharma, S (corresponding author), Brigham & Womens Hosp, Channing Lab, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.	ssharma4@partners.org		Zeiger, Robert/0000-0001-5788-5063; Litonjua, Augusto/0000-0003-0422-5875	National Heart, Lung, and Blood Institute [NO1-HR-16044, NO1-HR-16045, NO1-HR-16046, NO1-HR-16047, NO1-HR-16048, NO1-HR-16049, NO1-HR-16050, NO1-HR-16051, NO1-HR-16052]; General Clinical Research Center [M01RR00051, M01RR0099718-24, M01RR02719-14]; National Center for Research Resources [RR00036]; National Heart, Lung, and Blood Institute, National Institutes of Health [U01 HL075419, U01 HL65899, P01 HL083069, T32 HL07427]; Novartis; Sepracor; Boehringer Ingelheim; GlaxoSmithKline; Merck; DIVISION OF LUNG DISEASES [N01HR016052, N01HR016051, N01HR016047, N01HR016049, N01HR016048, N01HR016046, N01HR016045, N01HR016044, N01HR016050] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036, M01RR002719, M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL075419, T32HL007427, P01HL083069, U01HL065899] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Heart, Lung, and Blood Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Novartis(Novartis); Sepracor; Boehringer Ingelheim(Boehringer Ingelheim); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The Childhood Asthma Management Program is supported by contracts NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052 with the National Heart, Lung, and Blood Institute and General Clinical Research Center grants M01RR00051, M01RR0099718-24, M01RR02719-14, and RR00036 from the National Center for Research Resources. Additional support for this study was provided by grants U01 HL075419, U01 HL65899, P01 HL083069,and T32 HL07427 from the National Heart, Lung, and Blood Institute, National Institutes of Health.; Disclosure of potential conflict of interest: A. L. Fuhlbrigge has served on the speakers' bureau and respiratory specialist advisory panel for GlaxoSmithKline laid Merck, has received funding from Novartis and Sepracor, and has received research grants from Boehringer Ingelheim, GlaxoSmithKline, and Merck. S. J. Szefler has served as a consultant for AstraZeneca. GlaxoSmithKline, Aventis, Genentech, and Merck and has received research grants from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI): the Childhood Asthma Management Program; NHLBI Childhood Asthma Research and Education; the NIH/NHLBI Asthma Clinical Research Network: the NIH/National Institute of Allergy and Infections Diseases Inner-City Asthma Consortium: and Ross Pharmaceuticals. R. S. Zeiger has served as a consultant for AstraZeneca, Acrocrine, Merck, Schering-Plough, Genentech, Dynavac, and GlaxoSmithKline and has received research grant front Sanofi-Aventis. GlaxoSmithKline, Genentech and the NHLBI. S. T. Weiss has received research support from the NIH and Genentech. The rest of the authors have declared that they have no conflict of interest.	Abramson Michael J, 2003, Am J Respir Med, V2, P287; Beydon N, 2007, RESP MED, V101, P2482, DOI 10.1016/j.rmed.2007.07.005; Bousquet J, 2007, ALLERGY, V62, P102, DOI 10.1111/j.1398-9995.2006.01305.x; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; DALES RE, 1988, AM REV RESPIR DIS, V138, P317, DOI 10.1164/ajrccm/138.2.317; Deykin A, 2007, AM J RESP CRIT CARE, V175, P228, DOI 10.1164/rccm.200601-112OC; Drazen JM, 2000, BRIT MED BULL, V56, P1054, DOI 10.1258/0007142001903535; ELIASSON O, 1985, AM REV RESPIR DIS, V132, P858; Kitch BT, 2004, CHEST, V126, P1875, DOI 10.1378/chest.126.6.1875; Litonjua AA, 2004, CHEST, V126, P66, DOI 10.1378/chest.126.1.66; Martin RJ, 2007, J ALLERGY CLIN IMMUN, V119, P73, DOI 10.1016/j.jaci.2006.10.035; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; O'Byrne PM, 2006, LANCET, V368, P794, DOI 10.1016/S0140-6736(06)69289-1; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; POSTMA DS, 1986, AM REV RESPIR DIS, V134, P276; Raby BA, 2001, CURR OPIN MOL THER, V3, P554; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Tantisira KG, 2006, J ALLERGY CLIN IMMUN, V117, P1264, DOI 10.1016/j.jaci.2006.01.050; Tantisira KG, 2005, CURR OPIN MOL THER, V7, P209; Weiss ST, 2006, PHARMACOGENOMICS J, V6, P311, DOI 10.1038/sj.tpj.6500387; Xu XP, 2002, AM J RESP CRIT CARE, V166, P774; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012	24	59	61	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					921	928		10.1016/j.jaci.2008.09.004	http://dx.doi.org/10.1016/j.jaci.2008.09.004			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	18848350	Green Accepted			2022-12-18	WOS:000260940100010
J	Cecilia, M; Shreffler, WG				Cecilia, M.; Shreffler, Wayne G.			T(H)2 adjuvants: Implications for food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						adjuvant; T(H)2; food allergy; allergen; cholera toxin; helminth; glycan; DC-SIGN; protease; protease activated receptor; superallergen; OX40L; TSLP; T-cell immunoglobulin mucin protein; Notch; Jagged; Delta	THYMIC STROMAL LYMPHOPOIETIN; INTESTINAL EPITHELIAL-CELLS; DENDRITIC CELLS; T-CELL; ORAL TOLERANCE; OX40 LIGAND; IN-VIVO; MURINE MODEL; HORSERADISH-PEROXIDASE; CHOLERA-TOXIN	A persistent question for immunologists studying allergic disease has been to define the characteristics of a molecule that make it allergenic. There has been substantial progress elucidating mechanisms of innate priming of T(H)2 immunity in the past several years. These accumulating data demonstrate that T(H)2 immunity is actively induced by an array of molecules, many of which were first discovered in the context of antihelminthic immune responses. Similar intrinsic or associated activities are now known to account for the T(H)2 immunogenicity of some allergens, and may prove to play a role for many more. In this review, we discuss what has been discovered regarding molecules that induce innate immune activation and the pathways that promote T(H)2-polarized immune responses generally, and specifically what role these mechanisms may play in food allergy from models of food allergy and the study of T(H)2 gastrointestinal adjuvants.	Mt Sinai Sch Med, Inst Immunol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Shreffler, WG (corresponding author), Dept Pediat, Div Pediat Allergy & Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	wayne.shreffler@mssm.edu		berin, cecilia/0000-0002-9051-9249; Shreffler, Wayne/0000-0001-6465-137X				Adel-Patient K, 2005, CLIN EXP ALLERGY, V35, P539, DOI 10.1111/j.1365-2222.2005.02225.x; Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Amsen D, 2007, IMMUNITY, V27, P89, DOI 10.1016/j.immuni.2007.05.021; Angeli V, 2001, J EXP MED, V193, P1135, DOI 10.1084/jem.193.10.1135; Anjuere F, 2004, J IMMUNOL, V173, P5103, DOI 10.4049/jimmunol.173.8.5103; Anosova NG, 2008, MUCOSAL IMMUNOL, V1, P59, DOI 10.1038/mi.2007.7; Arestides RSS, 2002, EUR J IMMUNOL, V32, P2874, DOI 10.1002/1521-4141(2002010)32:10<2874::AID-IMMU2874>3.0.CO;2-4; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aumuller E, 2004, PARASITE IMMUNOL, V26, P387, DOI 10.1111/j.0141-9838.2004.00724.x; Balic A, 2004, EUR J IMMUNOL, V34, P3047, DOI 10.1002/eji.200425167; Bashir MEH, 2004, J IMMUNOL, V172, P6978, DOI 10.4049/jimmunol.172.11.6978; Bashir MEH, 2002, J IMMUNOL, V169, P3284, DOI 10.4049/jimmunol.169.6.3284; Berin MC, 2006, ALLERGY, V61, P64, DOI 10.1111/j.1398-9995.2006.01012.x; Berin MC, 1997, GASTROENTEROLOGY, V113, P856, DOI 10.1016/S0016-5085(97)70180-X; Bilsborough J, 2003, IMMUNOLOGY, V108, P481, DOI 10.1046/j.1365-2567.2003.01606.x; Blazquez AB, 2008, J IMMUNOL, V180, P4441, DOI 10.4049/jimmunol.180.7.4441; Breiteneder H, 2005, J ALLERGY CLIN IMMUN, V115, P14, DOI 10.1016/j.jaci.2004.10.022; Brunner R, 2007, CLIN EXP ALLERGY, V37, P1566, DOI 10.1111/j.1365-2222.2007.02813.x; Caparros E, 2006, BLOOD, V107, P3950, DOI 10.1182/blood-2005-03-1252; Chehade M, 2005, J ALLERGY CLIN IMMUN, V115, P3, DOI 10.1016/j.jaci.2004.11.008; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; CORNELL R, 1971, LAB INVEST, V25, P42; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Dillon S, 2006, J CLIN INVEST, V116, P916, DOI 10.1172/JCI27203; Ebeling C, 2007, J IMMUNOL, V179, P2910, DOI 10.4049/jimmunol.179.5.2910; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Ekkens MJ, 2003, J IMMUNOL, V170, P384, DOI 10.4049/jimmunol.170.1.384; Falcone FH, 1996, EUR J IMMUNOL, V26, P1147, DOI 10.1002/eji.1830260528; Falcone FH, 2005, INFLAMM RES, V54, pS13, DOI 10.1007/s00011-004-0405-y; Falcone FH, 2004, CLIN REV ALLERG IMMU, V26, P61, DOI 10.1385/CRIAI:26:1:61; Faveeuw C, 2003, EUR J IMMUNOL, V33, P1271, DOI 10.1002/eji.200323717; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Foss N, 2006, INT ARCH ALLERGY IMM, V141, P141, DOI 10.1159/000094716; Frey A, 1996, J EXP MED, V184, P1045, DOI 10.1084/jem.184.3.1045; Frossard CP, 2001, PEDIATR RES, V49, P417, DOI 10.1203/00006450-200103000-00018; Gough L, 2003, CLIN EXP ALLERGY, V33, P1159, DOI 10.1046/j.1365-2222.2003.01716.x; Gramaglia I, 2000, J IMMUNOL, V165, P3043, DOI 10.4049/jimmunol.165.6.3043; Haas H, 1999, EUR J IMMUNOL, V29, P918, DOI 10.1002/(SICI)1521-4141(199903)29:03&lt;918::AID-IMMU918&gt;3.0.CO;2-T; Harrington LE, 2006, CURR OPIN IMMUNOL, V18, P349, DOI 10.1016/j.coi.2006.03.017; Hofer MF, 1999, J INVEST DERMATOL, V112, P171, DOI 10.1046/j.1523-1747.1999.00492.x; Homer RJ, 2006, AM J PHYSIOL-LUNG C, V291, pL502, DOI 10.1152/ajplung.00364.2005; Hoshino A, 2003, EUR J IMMUNOL, V33, P861, DOI 10.1002/eji.200323455; Hoyne GF, 2000, INT IMMUNOL, V12, P177, DOI 10.1093/intimm/12.2.177; Huang FP, 2000, J EXP MED, V191, P435, DOI 10.1084/jem.191.3.435; HUSBY S, 1994, J IMMUNOL, V152, P4663; Ishii N, 2003, EUR J IMMUNOL, V33, P2372, DOI 10.1002/eji.200324031; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Ito T, 2006, P NATL ACAD SCI USA, V103, P13138, DOI 10.1073/pnas.0603107103; Iwasaki A, 2001, J IMMUNOL, V166, P4884, DOI 10.4049/jimmunol.166.8.4884; Iwasaki A, 1999, J EXP MED, V190, P229, DOI 10.1084/jem.190.2.229; Jacob C, 2005, J BIOL CHEM, V280, P31936, DOI 10.1074/jbc.M506338200; Jankovic D, 2000, J IMMUNOL, V164, P3047, DOI 10.4049/jimmunol.164.6.3047; Jankovic D, 2006, CHEM IMMUNOL ALLERGY, V90, P65, DOI 10.1159/000088881; Jenkins SJ, 2007, J IMMUNOL, V179, P3515, DOI 10.4049/jimmunol.179.6.3515; Karg K, 2007, FREE RADICAL RES, V41, P25, DOI 10.1080/10715760600939734; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Kelsall BL, 1996, J EXP MED, V183, P237, DOI 10.1084/jem.183.1.237; Kolarich D, 2000, ANAL BIOCHEM, V285, P64, DOI 10.1006/abio.2000.4737; Kong WY, 1997, P NATL ACAD SCI USA, V94, P8884, DOI 10.1073/pnas.94.16.8884; Kraft S, 2007, NAT REV IMMUNOL, V7, P365, DOI 10.1038/nri2072; Kraus TA, 2004, GASTROENTEROLOGY, V126, P1771, DOI 10.1053/j.gastro.2004.03.076; Kuchroo VK, 2003, NAT REV IMMUNOL, V3, P454, DOI 10.1038/nri1111; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Laurence A, 2007, NAT IMMUNOL, V8, P903, DOI 10.1038/ni0907-903; Lavelle EC, 2001, IMMUNOLOGY, V102, P77, DOI 10.1046/j.1365-2567.2001.01157.x; Lee SY, 2005, J KOREAN MED SCI, V20, P566, DOI 10.3346/jkms.2005.20.4.566; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Linton PJ, 2003, J EXP MED, V197, P875, DOI 10.1084/jem.20021290; LIU LM, 1995, IMMUNOLOGY, V84, P241; LIU LM, 1993, J EXP MED, V177, P1299, DOI 10.1084/jem.177.5.1299; LIU LX, 1992, AM J TROP MED HYG, V46, P520, DOI 10.4269/ajtmh.1992.46.520; Liu T, 2007, MOL IMMUNOL, V44, P3580, DOI 10.1016/j.molimm.2007.03.004; Luccioli S, 2002, J ALLERGY CLIN IMMUN, V110, P117, DOI 10.1067/mai.2002.125828; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Maekawa Y, 2003, IMMUNITY, V19, P549, DOI 10.1016/S1074-7613(03)00270-X; Maillard I, 2003, IMMUNITY, V19, P781, DOI 10.1016/S1074-7613(03)00325-X; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; Mariani V, 2007, J IMMUNOL, V178, P7623, DOI 10.4049/jimmunol.178.12.7623; Marone Gianni, 2007, Chem Immunol Allergy, V93, P195, DOI 10.1159/000100896; Mattner F, 1996, EUR J IMMUNOL, V26, P1553, DOI 10.1002/eji.1830260722; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Meyers JH, 2005, NAT IMMUNOL, V6, P455, DOI 10.1038/ni1185; Milling SWF, 2007, EUR J IMMUNOL, V37, P87, DOI 10.1002/eji.200636199; Minter LM, 2005, NAT IMMUNOL, V6, P680, DOI 10.1038/ni1209x; Mishra A, 2007, AM J PHYSIOL-LUNG C, V293, pL305, DOI 10.1152/ajplung.00147.2007; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Murata K, 2000, J EXP MED, V191, P365, DOI 10.1084/jem.191.2.365; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Nakae S, 2007, BLOOD, V110, P2565, DOI 10.1182/blood-2006-11-058800; Neutra MR, 2001, NAT IMMUNOL, V2, P1004, DOI 10.1038/ni1101-1004; Noben-Trauth N, 2000, J IMMUNOL, V165, P3620, DOI 10.4049/jimmunol.165.7.3620; NobenTrauth N, 1997, P NATL ACAD SCI USA, V94, P10838, DOI 10.1073/pnas.94.20.10838; NOSSAL GJV, 1999, FUNDAMENTAL IMMUNOLO, P1387; Oh K, 2007, BLOOD, V109, P2921, DOI 10.1182/blood-2006-07-037739; Osborne BA, 2007, NAT REV IMMUNOL, V7, P64, DOI 10.1038/nri1998; Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843; Phillips C, 2003, J LEUKOCYTE BIOL, V73, P165, DOI 10.1189/jlb.0702356; Pramod SN, 2007, CLIN EXP IMMUNOL, V148, P391, DOI 10.1111/j.1365-2249.2007.03368.x; Rao KVN, 2002, J BIOL CHEM, V277, P31207, DOI 10.1074/jbc.M204114200; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Rimoldi M, 2005, NAT IMMUNOL, V6, P507, DOI 10.1038/ni1192; Rogers PR, 2001, IMMUNITY, V15, P445, DOI 10.1016/S1074-7613(01)00191-1; Sabatos CA, 2003, NAT IMMUNOL, V4, P1102, DOI 10.1038/ni988; Salazar-Gonzalez RM, 2006, IMMUNITY, V24, P623, DOI 10.1016/j.immuni.2006.02.015; Salek-Ardakani S, 2003, J EXP MED, V198, P315, DOI 10.1084/jem.20021937; Santos J, 1999, AM J PHYSIOL-GASTR L, V277, pG391, DOI 10.1152/ajpgi.1999.277.2.G391; Saunders PR, 2002, DIGEST DIS SCI, V47, P208, DOI 10.1023/A:1013204612762; Schramm G, 2003, J BIOL CHEM, V278, P18384, DOI 10.1074/jbc.M300497200; Schramm G, 2007, J IMMUNOL, V178, P6023, DOI 10.4049/jimmunol.178.10.6023; Seshasayee D, 2007, J CLIN INVEST, V117, P3868, DOI 10.1172/JCI33559; Shreedhar VK, 2003, INFECT IMMUN, V71, P504, DOI 10.1128/IAI.71.1.504-509.2003; Shreffler WG, 2006, J IMMUNOL, V177, P3677, DOI 10.4049/jimmunol.177.6.3677; SNIDER DP, 1994, J IMMUNOL, V153, P647; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Song JX, 2004, NAT IMMUNOL, V5, P150, DOI 10.1038/ni1030; Soroosh P, 2006, J IMMUNOL, V176, P5975, DOI 10.4049/jimmunol.176.10.5975; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Sporri R, 2005, NAT IMMUNOL, V6, P163, DOI 10.1038/ni1162; Strickland I, 1999, J INVEST DERMATOL, V112, P249, DOI 10.1046/j.1523-1747.1999.00502.x; Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x; Sun JF, 2007, J IMMUNOL, V179, P6696, DOI 10.4049/jimmunol.179.10.6696; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; Tu LL, 2005, J EXP MED, V202, P1037, DOI 10.1084/jem.20050923; Umetsu SE, 2005, NAT IMMUNOL, V6, P447, DOI 10.1038/ni1186; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI [10.1016/S0091-6749(03)01719-6, 10.1016/mai.2003.1681]; van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200; Van der Kleij D, 2002, J INFECT DIS, V185, P531, DOI 10.1086/338574; van Die I, 2003, GLYCOBIOLOGY, V13, P471, DOI 10.1093/glycob/cwg052; van Wijk F, 2005, J IMMUNOL, V174, P174, DOI 10.4049/jimmunol.174.1.174; Vergnolle N, 2004, J CLIN INVEST, V114, P1444, DOI 10.1172/JCI200421689; Viney JL, 1998, J IMMUNOL, V160, P5815; Voehringer D, 2006, J EXP MED, V203, P1435, DOI 10.1084/jem.20052448; WALKER WA, 1972, J CELL BIOL, V54, P195, DOI 10.1083/jcb.54.2.195; WARSHAW AL, 1971, LAB INVEST, V25, P675; Wiener Z, 2007, J INVEST DERMATOL, V127, P906, DOI 10.1038/sj.jid.5700616; Williamson E, 1999, J IMMUNOL, V163, P3668; Worbs T, 2006, J EXP MED, V203, P519, DOI 10.1084/jem.20052016; Yamaguchi N, 2006, GUT, V55, P954, DOI 10.1136/gut.2005.084954; Yang PC, 2006, AM J PATHOL, V168, P104, DOI 10.2353/ajpath.2006.050575; Yang PC, 2007, GASTROENTEROLOGY, V133, P1522, DOI 10.1053/j.gastro.2007.08.006; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zaph C, 2007, NATURE, V446, P552, DOI 10.1038/nature05590; Zeng YC, 1997, J BIOL CHEM, V272, P31340, DOI 10.1074/jbc.272.50.31340; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336	151	59	62	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1311	1320		10.1016/j.jaci.2008.04.023	http://dx.doi.org/10.1016/j.jaci.2008.04.023			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18539190				2022-12-18	WOS:000256771700002
J	Staumont-Salle, D; Abboud, G; Brenuchon, C; Kanda, A; Roumier, T; Lavogiez, C; Fleury, S; Remy, P; Papin, JP; Bertrand-Michel, J; Terce, F; Staels, B; Delaporte, E; Capron, M; Dombrowicz, D				Staumont-Salle, Delphine; Abboud, Georges; Brenuchon, Celine; Kanda, Akira; Roumier, Thomas; Lavogiez, Celine; Fleury, Sebastien; Remy, Patrick; Papin, Jean-Paul; Bertrand-Michel, Justine; Terce, Francois; Staels, Bart; Delaporte, Emmanuel; Capron, Monique; Dombrowicz, David			Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peroxisome proliferator-activated receptor alpha; atopic dermatitis; allergy; inflammation; human; mouse	NF-KAPPA-B; THYMIC STROMAL LYMPHOPOIETIN; PPAR-ALPHA; NUCLEAR RECEPTORS; GAMMA; ROLES; DIFFERENTIATION; EXPRESSION; FEATURES; TARGETS	Background: The peroxisome proliferator-activated receptors (PPARs) alpha, beta/delta, and gamma are ligand-activated transcription factors belonging to the nuclear receptor superfamily. In addition to their regulatory role on lipid and glucose metabolism, they exert anti-inflammatory properties. In skin both PPAR-alpha and PPAR-beta/delta regulate keratinocyte proliferation/differentiation and contribute to wound healing. The 3 PPAR isoforms are expressed by several cell types recruited into the dermis during inflammation. Objective: We have investigated the role of PPAR-et in the regulation of atopic dermatitis (AD), a common skin inflammatory disease. Methods: We chose a mouse model of inflammatory dermatosis with immunologic features of AD and used epicutaneous sensitization with ovalbumin in the absence of adjuvant, which mimics the human pathology. Results: On antigen sensitization, PPAR-alpha-deficient mice display increased epidermal thickening, dermal recruitment of inflammatory cells, lung inflammation, airway hyperresponsiveness, and IgE and IgG2a production compared with their wild-type counterparts. Increased inflammation was correlated to an enhancement of T(H)2 and, to a greater extent, TO responses and to increased skin expression of nuclear factor kappa B. Interestingly, PPAR-alpha expression was decreased in eczematous skin from patients with AD compared with skin from nonatopic donors, suggesting that defective PPAR-alpha expression might contribute to the pathology. Topical application of WY14643, a specific PPAR-alpha agonist, significantly decreased antigen-induced skin inflammation in the AD model. Conclusion: PPAR-alpha acts as a negative regulator of skin inflammation in AD.	[Staumont-Salle, Delphine; Abboud, Georges; Brenuchon, Celine; Kanda, Akira; Roumier, Thomas; Lavogiez, Celine; Fleury, Sebastien; Remy, Patrick; Papin, Jean-Paul; Capron, Monique; Dombrowicz, David] Inst Pasteur, INSERM, U547, F-59019 Lille, France; [Staumont-Salle, Delphine; Lavogiez, Celine; Delaporte, Emmanuel] Claude Huriez Hosp, Dept Dermatol, Lille, France; [Staumont-Salle, Delphine; Abboud, Georges; Brenuchon, Celine; Kanda, Akira; Roumier, Thomas; Lavogiez, Celine; Fleury, Sebastien; Remy, Patrick; Papin, Jean-Paul; Staels, Bart; Capron, Monique; Dombrowicz, David] Univ Lille 2, Lille, France; [Bertrand-Michel, Justine; Terce, Francois] IFR30, F-59019 Lille, France; [Bertrand-Michel, Justine; Terce, Francois] Univ Toulouse 3, F-31062 Toulouse, France; [Terce, Francois] INSERM, U363, Toulouse, France; [Staels, Bart] INSERM, U545, Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; Universite de Lille; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Dombrowicz, D (corresponding author), Inst Pasteur, INSERM, U547, 1 Rue Prof Calmette BP245, F-59019 Lille, France.	david.dombrowicz@pasteur-lille.fr	Capron, monique/Z-2207-2019; Tercé, François/M-5863-2018; Dombrowicz, David/F-7044-2013; Staels, Bart/N-9497-2016	Capron, monique/0000-0001-5625-5158; Tercé, François/0000-0003-4488-2167; Dombrowicz, David/0000-0002-0485-8923; Staels, Bart/0000-0002-3784-1503; Fleury, Sebastien/0000-0002-0679-3086				Angeli W, 2003, J IMMUNOL, V170, P5295, DOI 10.4049/jimmunol.170.10.5295; Bailey ST, 2005, NAT IMMUNOL, V6, P966, DOI 10.1038/ni1005-966; Chinetti G, 2003, CURR OPIN LIPIDOL, V14, P459, DOI 10.1097/00041433-200310000-00006; Cunard R, 2002, J IMMUNOL, V168, P2795, DOI 10.4049/jimmunol.168.6.2795; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Dunn SE, 2007, J EXP MED, V204, P321, DOI 10.1084/jem.20061839; Glass CK, 2006, NAT REV IMMUNOL, V6, P44, DOI 10.1038/nri1748; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hontecillas R, 2007, J IMMUNOL, V178, P2940, DOI 10.4049/jimmunol.178.5.2940; Komuves LG, 2000, J INVEST DERMATOL, V115, P353, DOI 10.1046/j.1523-1747.2000.00073.x; Lefebvre P, 2006, J CLIN INVEST, V116, P571, DOI 10.1172/JCI27989; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Li M, 2005, P NATL ACAD SCI USA, V102, P14795, DOI 10.1073/pnas.0507385102; Maeyama K, 2005, J PHARMACOL SCI, V97, P190, DOI 10.1254/jphs.FMJ04008X6; Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148; Michalik L, 2007, BBA-MOL CELL BIOL L, V1771, P991, DOI 10.1016/j.bbalip.2007.02.004; Michalik L, 2006, PHARMACOL REV, V58, P726, DOI 10.1124/pr.58.4.5; Moraes LA, 2006, PHARMACOL THERAPEUT, V110, P371, DOI 10.1016/j.pharmthera.2005.08.007; Nguyen H, 2006, CELL, V127, P171, DOI 10.1016/j.cell.2006.07.036; Plager DA, 2007, EXP DERMATOL, V16, P28, DOI 10.1111/j.1600-0625.2006.00504.x; Ricote M, 2007, BBA-MOL CELL BIOL L, V1771, P926, DOI 10.1016/j.bbalip.2007.02.013; Schlezinger JJ, 2002, J IMMUNOL, V169, P6831, DOI 10.4049/jimmunol.169.12.6831; Spencer NFL, 1997, INT IMMUNOL, V9, P1581, DOI 10.1093/intimm/9.10.1581; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Tan NS, 2001, GENE DEV, V15, P3263, DOI 10.1101/gad.207501; Trifilieff A, 2003, BRIT J PHARMACOL, V139, P163, DOI 10.1038/sj.bjp.0705232; Tripp RA, 2003, J VIROL, V77, P6580, DOI 10.1128/JVI.77.11.6580-6584.2003; Vanden Berghe W, 2003, ADV EXP MED BIOL, V544, P181; Watanabe N, 2004, NAT IMMUNOL, V5, P426, DOI 10.1038/ni1048; Woerly G, 2003, J EXP MED, V198, P411, DOI 10.1084/jem.20021384; Yang Q, 2006, J INVEST DERMATOL, V126, P374, DOI 10.1038/sj.jid.5700056	33	59	61	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					962	968		10.1016/j.jaci.2007.12.1165	http://dx.doi.org/10.1016/j.jaci.2007.12.1165			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18249437				2022-12-18	WOS:000254884000022
J	Panettieri, RA; Covar, R; Grant, E; Hillyer, EV; Bacharier, L				Panettieri, Reynold A., Jr.; Covar, Ronina; Grant, Evalyn; Hillyer, Elizabeth V.; Bacharier, Leonard			Natural history of asthma: Persistence versus progression - does the beginning predict the end?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; epidemiology; progression; persistence; remodeling; wheezing; childhood asthma; adult asthma; atopy; inhaled corticosteroids	AIR-FLOW OBSTRUCTION; EXHALED NITRIC-OXIDE; MUSCLE-CELL PROLIFERATION; CHILDHOOD ASTHMA; LUNG-FUNCTION; PRIMARY PREVENTION; FOLLOW-UP; ALLERGEN AVOIDANCE; DIFFICULT ASTHMA; SMOOTH-MUSCLE	Environmental exposures during the early years and airway obstruction that develops during this time, in conjunction with genetic susceptibility, are important factors in the development of persistent asthma in childhood. Established risk factors for childhood asthma include frequent wheezing during the first 3 years, a parental history of asthma, a history of eczema, allergic rhinitis, wheezing apart from colds, and peripheral blood eosinophilia, as well as allergic sensitization to aeroallergens and certain foods. Risk factors for the development of asthma in adulthood remain ill defined. Moreover, reasons for variability in the clinical course of asthma-persistence in some individuals and progression in others-remain an enigma. The distinction between disease persistence and disease progression suggests that these are different entities or phenotypes. There is currently no consensus on whether disease progression requires either airway inflammation or airway remodeling or the combination of the two. For patients with irreversible airway obstruction, inflammation might, in part, be necessary but perhaps not entirely sufficient to induce the irreversible component, some of which could be attributed to alterations in the structure of the bronchial wall. Intervening with intermittent or daily inhaled corticosteroids in high-risk infants and children does not prevent disease progression or impaired lung growth. These findings, however, might not apply to adults, and further study in adults is needed to determine the effect of inhaled corticosteroid therapy on disease progression.	[Panettieri, Reynold A., Jr.] Univ Penn, Sch Med, Dept Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA; [Covar, Ronina] Natl Jewish Med & Res Ctr, Ira J & Jacqueline Neimark Lab Clin Pharmacol, Dept Pediat, Denver, CO USA; [Covar, Ronina] Natl Jewish Med & Res Ctr, Div Pediat Clin Pharmacol, Dept Pediat, Denver, CO USA; [Covar, Ronina] Natl Jewish Med & Res Ctr, Div Allergy Clin Immunol, Dept Pediat, Denver, CO USA; [Grant, Evalyn] Merck & Co Inc, W Point, NJ USA; [Bacharier, Leonard] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63130 USA; [Bacharier, Leonard] St Louis Childrens Hosp, St Louis, MO USA	University of Pennsylvania; National Jewish Health; National Jewish Health; National Jewish Health; Merck & Company; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Panettieri, RA (corresponding author), Univ Penn, Sch Med, Dept Med, Pulm Allergy & Crit Care Div, 125 S 31st St,TRL Suite 1200,Room 1211, Philadelphia, PA 19104 USA.	rap@mail.med.upenn.edu	panettieri, reynold/AAG-9485-2019	Hillyer, Elizabeth/0000-0003-3022-5692; Bacharier, Leonard/0000-0003-0432-2704				Arshad SH, 2007, J ALLERGY CLIN IMMUN, V119, P307, DOI 10.1016/j.jaci.2006.12.621; Barbato A, 2003, AM J RESP CRIT CARE, V168, P798, DOI 10.1164/rccm.200305-650OC; Becker A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/j.jaci.2004.01.754; Bergeron C, 2006, CHEST, V129, P1068, DOI 10.1378/chest.129.4.1068; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; BOULET LP, 1995, AM J RESP CRIT CARE, V152, P865, DOI 10.1164/ajrccm.152.3.7663797; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; .British Thoracic Society, SCOTT INT GUID NETW; Brutsche MH, 2006, THORAX, V61, P671, DOI 10.1136/thx.2005.052241; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Busse W, 2005, CHEST, V127, P1312, DOI 10.1378/chest.127.4.1312; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Chan-Yeung M, 2006, CURR OPIN ALLERGY CL, V6, P146, DOI 10.1097/01.all.0000225150.91661.34; Cokugras H, 2001, THORAX, V56, P25, DOI 10.1136/thorax.56.1.25; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; CRONER S, 1992, ALLERGY, V47, P150, DOI 10.1111/j.1398-9995.1992.tb00956.x; de Blic J, 2004, J ALLERGY CLIN IMMUN, V113, P94, DOI 10.1016/j.jaci.2003.10.045; Doherty T, 2007, CURR OPIN IMMUNOL, V19, P676, DOI 10.1016/j.coi.2007.07.017; Espinosa K, 2003, J ALLERGY CLIN IMMUN, V111, P1032, DOI 10.1067/mai.2003.1451; Global Initiative for asthma, GINA REP GLOB STRAT; Guerra S, 2002, J ALLERGY CLIN IMMUN, V109, P419, DOI 10.1067/mai.2002.121701; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Hedlund U, 2006, EUR RESPIR J, V28, P303, DOI 10.1183/09031936.06.00108105; Horak E, 2003, BRIT MED J, V326, P422, DOI 10.1136/bmj.326.7386.422; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; JEFFERY PK, 2004, P AM THORAC SOC, V1, P76; Jenkins HA, 2003, CHEST, V124, P1318, DOI 10.1378/chest.124.4.1318; Jenkins HA, 2003, CHEST, V124, P32, DOI 10.1378/chest.124.1.32; Just J, 2002, J ALLERGY CLIN IMMUN, V110, P42, DOI 10.1067/mai.2002.123304; Krawiec ME, 2001, AM J RESP CRIT CARE, V163, P1338, DOI 10.1164/ajrccm.163.6.2005116; Kuiper S, 2007, J ALLERGY CLIN IMMUN, V120, P388, DOI 10.1016/j.jaci.2007.03.038; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lazaar AL, 2006, CLIN CHEST MED, V27, P53, DOI 10.1016/j.ccm.2005.10.003; Lazaar AL, 2003, AM J MED, V115, P652, DOI 10.1016/j.amjmed.2003.07.010; Le Bourgeois M, 2002, CHEST, V122, P791, DOI 10.1378/chest.122.3.791; Lemanske RF, 2006, J ALLERGY CLIN IMMUN, V117, pS456, DOI 10.1016/j.jaci.2005.07.006; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; Lundback B, 2001, RESP MED, V95, P685, DOI 10.1053/rmed.2001.1126; Marguet C, 1999, AM J RESP CRIT CARE, V159, P1533, DOI 10.1164/ajrccm.159.5.9805028; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; Nicholson PJ, 2005, OCCUP ENVIRON MED, V62, P290, DOI 10.1136/oem.2004.016287; Nickel R, 2002, PEDIAT ALLERG IMM-UK, V13, P7, DOI 10.1034/j.1399-3038.13.s.15.4.x; O'Byrne PM, 2006, CHEST, V129, P1478, DOI 10.1378/chest.129.6.1478; Ogawa Y, 2006, J ALLERGY CLIN IMMUN, V118, P789, DOI 10.1016/j.jaci.2006.08.009; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Panettieri RA, 1998, AM J RESP CELL MOL, V19, P453, DOI 10.1165/ajrcmb.19.3.2999; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Payne DNR, 2004, THORAX, V59, P862, DOI 10.1136/thx.2003.017244; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Pijnenburg MW, 2005, AM J RESP CRIT CARE, V172, P831, DOI 10.1164/rccm.200503-458OC; Porsbjerg C, 2006, CHEST, V129, P309, DOI 10.1378/chest.129.2.309; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-1404OC; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Schonberger HJAM, 2005, EUR RESPIR J, V25, P660, DOI 10.1183/09031936.05.00067704; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Singh AM, 2007, AM J RESP CRIT CARE, V175, P108, DOI 10.1164/rccm.200603-435PP; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Stevenson EC, 1997, CLIN EXP ALLERGY, V27, P1027, DOI 10.1111/j.1365-2222.1997.tb01254.x; Strunk RC, 2006, J ALLERGY CLIN IMMUN, V118, P1040, DOI 10.1016/j.jaci.2006.07.053; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Taylor DR, 2006, THORAX, V61, P817, DOI 10.1136/thx.2005.056093; Taylor DR, 2006, J ALLERGY CLIN IMMUN, V117, P259, DOI 10.1016/j.jaci.2005.11.010; Ulrik CS, 1999, EUR RESPIR J, V13, P904, DOI 10.1034/j.1399-3003.1999.13d35.x; van Schayck OCP, 2007, J ALLERGY CLIN IMMUN, V119, P1323, DOI 10.1016/j.jaci.2007.02.024; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	80	59	63	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					607	613		10.1016/j.jaci.2008.01.006	http://dx.doi.org/10.1016/j.jaci.2008.01.006			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18328890				2022-12-18	WOS:000253918900010
J	LaRosa, DF; Orange, JS				LaRosa, David F.; Orange, Jordan S.			Lymphocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						lymphocyte; adaptive immune system; T cell; B cell; natural killer cell	REGULATORY T-CELLS; MEMORY B-CELL; EPITHELIAL-CELLS; NKT CELLS; SELF; SELECTION; EFFECTOR; ANTIGENS; IMMUNITY; LINEAGE	Lymphocytes are white blood cells uniform in appearance but varied in function and include T, B, and natural killer cells. These cells are responsible for antibody production, direct cell-mediated killing of virus-infected and tumor cells, and regulation of the immune response. Advances in immunology have led to the characterization of newly appreciated effector populations such as IL-17-producing T cells, T cells with regulatory function, and natural killer T cells, thus revising established paradigms. This chapter provides an overview of the major lymphocyte populations with emphasis on their development, distinguishing characteristics, and functions.	[Orange, Jordan S.] Childrens Hosp Philadelphia, Div Immunol, Philadelphia, PA 19104 USA; [LaRosa, David F.; Orange, Jordan S.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Orange, JS (corresponding author), Childrens Hosp Philadelphia, Div Immunol, 3615 Civic Ctr Blvd,ARC-1016H, Philadelphia, PA 19104 USA.	orange@mail.med.upenn.edu	Orange, Jordan S/D-5239-2009	orange, jordan/0000-0001-7117-7725				Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Aschenbrenner K, 2007, NAT IMMUNOL, V8, P351, DOI 10.1038/ni1444; Bergtold A, 2005, IMMUNITY, V23, P503, DOI 10.1016/j.immuni.2005.09.013; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Blom B, 2006, ANNU REV IMMUNOL, V24, P287, DOI 10.1146/annurev.immunol.24.021605.090612; Chang JT, 2007, SCIENCE, V315, P1687, DOI 10.1126/science.1139393; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; Freud AG, 2006, IMMUNOL REV, V214, P56, DOI 10.1111/j.1600-065X.2006.00451.x; Intlekofer AM, 2005, NAT IMMUNOL, V6, P1236, DOI 10.1038/ni1268; Kalia V, 2006, CURR OPIN IMMUNOL, V18, P255, DOI 10.1016/j.coi.2006.03.020; La Motte-Mohs RN, 2005, BLOOD, V105, P1431, DOI 10.1182/blood-2004-04-1293; Landers CD, 2005, IMMUNOL RES, V31, P25, DOI 10.1385/IR:31:1:25; Lauritsen JPH, 2006, IMMUNOL REV, V209, P176, DOI 10.1111/j.0105-2896.2006.00349.x; Mattner J, 2005, NATURE, V434, P525, DOI 10.1038/nature03408; McHeyzer-Williams LJ, 2005, ANNU REV IMMUNOL, V23, P487, DOI 10.1146/annurev.immunol.23.021704.115732; Miller JP, 2006, J IMMUNOL, V176, P6405, DOI 10.4049/jimmunol.176.11.6405; Moffett A, 2006, NAT REV IMMUNOL, V6, P584, DOI 10.1038/nri1897; Nel AE, 2002, J ALLERGY CLIN IMMUN, V109, P758, DOI 10.1067/mai.2002.124259; Nichols KE, 2005, NAT MED, V11, P340, DOI 10.1038/nm1189; Notarangelo LD, 2006, J ALLERGY CLIN IMMUN, V117, P855, DOI 10.1016/j.jaci.2006.01.043; Orange JS, 2006, CLIN IMMUNOL, V118, P1, DOI 10.1016/j.clim.2005.10.011; Pillai S, 2005, ANNU REV IMMUNOL, V23, P161, DOI 10.1146/annurev.immunol.23.021704.115728; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Umetsu DT, 2006, NAT REV IMMUNOL, V6, P953, DOI 10.1038/nri1968; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Zhou DP, 2004, SCIENCE, V306, P1786, DOI 10.1126/science.1103440	27	59	63	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2		2			S364	S369		10.1016/j.jaci.2007.06.016	http://dx.doi.org/10.1016/j.jaci.2007.06.016			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266IB	18241683				2022-12-18	WOS:000253426600002
J	Su, RC; Becker, AB; Kozyrskyj, AL; HayGlass, KT				Su, Ruey-Chyi; Becker, Allan B.; Kozyrskyj, Anita L.; HayGlass, Kent T.			Epigenetic regulation of established human type 1 versus type 2 cytokine responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; PBMCv; T(H)1/T(H)2; cytokine	HISTONE DEACETYLASE INHIBITORS; CELL-DIFFERENTIATION; IFN-GAMMA; GENE; ACETYLATION; CHROMATIN; TH1; EXPRESSION; MODULATION; PLASTICITY	Background: Multiple biologic factors influence maintenance of immunologic responsiveness. Here, we studied whether epigenetics has a regulatory function in maintaining preestablished T(H)1-like and T(H)2-like immunity in human beings. Objective: We focused on delineating the role of endogenous histone deacetylase (HDAC) activity in regulating cytokine recall responses. Methods: Using RT-PCR and ELISA, the effect of increasing cellular acetylation on T(H)1/T(H)2 cytokine expression was systematically examined in 58 children by inhibiting HDAC activity with trichostatin A. Results: Phytohemagglutinin activation selectively stimulates antigen-experienced CD45RO(+) T cells, eliciting recall cytokine responses. Trichostatin A reduced HDAC activity by approximately 1/3. The resulting cellular hyperacetylation led to increased T(H)2-associated (IL-13, 139%; IL-5, 168%; P <.0001) and reduced T(H)1-associated recall responses (IFN-gamma, 76%; CXCL10, 47%; P <.0001). IL-2 and IL-10 production were reduced 25% to 55% (P <.0001). These alterations in T(H)2-associated and T(H)1-associated recall responses were associated with increased expression of Gata-3 and sphingosine kinase 1, a T(H)1-negative regulator, independent of T-bet expression. Overall, inhibition of endogenous HDAC activity shifted T(H)1:T(H)2 ratios by 3-fold to 8-fold (P <=.0001), skewing recall responses toward a more T(H)2-like phenotype, independent of the stimulus used. Conclusion: Endogenous HDAC activity plays a crucial role in maintaining the balance of pre-established T(H)1-like and T(H)2-like responses, inhibiting excessive T(H)2 immunity.	[Su, Ruey-Chyi; Becker, Allan B.; HayGlass, Kent T.] Univ Manitoba, Dept Immunol, Winnipeg, MB R3E 0W3, Canada; [Becker, Allan B.] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3E 0W3, Canada; [Kozyrskyj, Anita L.; HayGlass, Kent T.] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3E 0W3, Canada	University of Manitoba; University of Manitoba; University of Manitoba	HayGlass, KT (corresponding author), Univ Manitoba, Dept Immunol, 730 William Ave, Winnipeg, MB R3E 0W3, Canada.	hayglass@cc.umanitoba.ca		HayGlass, Kent/0000-0002-4621-7737				Adcock IM, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-21; Ailenberg M, 2002, BIOCHEM BIOPH RES CO, V298, P110, DOI 10.1016/S0006-291X(02)02420-8; Ansel KM, 2006, ANNU REV IMMUNOL, V24, P607, DOI 10.1146/annurev.immunol.23.021704.115821; Aung HT, 2006, FASEB J, V20, P1315, DOI 10.1096/fj.05-5360com; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Barnes PJ, 2006, CHEST, V129, P151, DOI 10.1378/chest.129.1.151; Brogdon JL, 2007, BLOOD, V109, P1123, DOI 10.1182/blood-2006-04-019711; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chang SJ, 2005, P NATL ACAD SCI USA, V102, P17095, DOI 10.1073/pnas.0502129102; Chi T, 2004, NAT REV IMMUNOL, V4, P965, DOI 10.1038/nri1501; Cui KR, 2004, MOL CELL BIOL, V24, P4476, DOI 10.1128/MCB.24.10.4476-4486.2004; Dauphinee SM, 2006, LAB INVEST, V86, P9, DOI 10.1038/labinvest.3700366; Gangur V, 1998, FASEB J, V12, P705, DOI 10.1096/fasebj.12.9.705; GOWANS J D, 1961, GP, V24, P106; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Han S, 2007, IMMUNOL LETT, V108, P143, DOI 10.1016/j.imlet.2006.12.001; Hew M, 2006, AM J RESP CRIT CARE, V174, P134, DOI 10.1164/rccm.200512-1930OC; Ito K, 2001, FASEB J, V15, pA473; Koch A, 2004, AM J RESP CELL MOL, V30, P342, DOI 10.1165/rcmb.2003-0122OC; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; KRUISBEEK AM, 1999, CURRENT PROTOCOLS IM, P1; Lang SE, 2003, ONCOGENE, V22, P2836, DOI 10.1038/sj.onc.1206376; Lee GR, 2006, IMMUNITY, V24, P369, DOI 10.1016/j.immuni.2006.03.007; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Long MX, 2006, J IMMUNOL, V176, P1036, DOI 10.4049/jimmunol.176.2.1036; Messi M, 2003, NAT IMMUNOL, V4, P78, DOI 10.1038/ni872; Miller SI, 2005, NAT REV MICROBIOL, V3, P36, DOI 10.1038/nrmicro1068; Mishra N, 2003, J CLIN INVEST, V111, P539, DOI 10.1172/JC1200316153; Mishra N, 2001, P NATL ACAD SCI USA, V98, P2628, DOI 10.1073/pnas.051507098; NOWELL PC, 1960, CANCER RES, V20, P462; Papeleu P, 2005, CRIT REV TOXICOL, V35, P363, DOI 10.1080/10408440590935639; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Skapenko A, 2004, J EXP MED, V199, P423, DOI 10.1084/jem.20031323; Smale ST, 2002, ANNU REV IMMUNOL, V20, P427, DOI 10.1146/annurev.immunol.20.100301.064739; Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356; STEFURA WP, 2008, IN PRESS METHODS IMM; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Su RC, 2004, NAT GENET, V36, P502, DOI 10.1038/ng1351; Sundrud MS, 2003, J IMMUNOL, V171, P3542, DOI 10.4049/jimmunol.171.7.3542; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Usui T, 2003, IMMUNITY, V18, P415, DOI 10.1016/S1074-7613(03)00057-8; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wang Y, 2004, COLD SPRING HARB SYM, V69, P161, DOI 10.1101/sqb.2004.69.161; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007; Yang JF, 2005, J IMMUNOL, V175, P6580, DOI 10.4049/jimmunol.175.10.6580; Zhang Y, 2004, FASEB J, V18, pA232; Zhou WS, 2004, P NATL ACAD SCI USA, V101, P2440, DOI 10.1073/pnas.0306002101	48	59	65	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					57	63		10.1016/j.jaci.2007.09.004	http://dx.doi.org/10.1016/j.jaci.2007.09.004			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17980413				2022-12-18	WOS:000252372000009
J	Jeon, SG; Oh, SY; Park, HK; Kim, YS; Shim, EJ; Lee, HS; Oh, MH; Bang, B; Chun, EY; Kim, SH; Gho, YS; Zhu, Z; Kim, YY; Kim, YK				Jeon, Seong Gyu; Oh, Sun-Young; Park, Hye-Kyung; Kim, You-Sun; Shim, Eun-Jin; Lee, Hyun-Seung; Oh, Min-Hee; Bang, Boram; Chun, Eun-Young; Kim, Sang-Heon; Gho, Yong Song; Zhu, Zhou; Kim, You-Young; Kim, Yoon-Keun			T(H)2 and T(H)1 lung inflammation induced by airway allergen sensitization with low and high doses of double-stranded RNA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						double-stranded RNA; virus; allergic inflammation; T(H)1; T(H)2	RIG-I; INNATE; ASTHMA; INTERFERON; EXPOSURE; TYPE-1; RECOGNITION; ACTIVATION; ENDOTOXIN; RESPONSES	Background: Although respiratory viral infections in early childhood can enhance the development of airway allergen sensitization, the exact mechanisms of the effects of viral infections on the adaptive immune response to inhaled allergens are controversial. Ob jective: We sought to evaluate the effects of double-stranded RNA (dsRNA) on airway sensitization to inhaled allergens. Methods: Novel mouse models were created through simultaneous airway sensitization to an allergen and low or high doses of dsRNA. The mouse models were applied to Toll-like receptor 3-, IL-13-, IL-4-, signal transducer and activator of transcription (STAT) 6-, IFN-gamma- and T-box expressed in T cells (T-bet)-deficient mice to evaluate underlying pathophysiologic mechanisms in the development of allergic lung inflammation. Results: We found that airway allergen sensitization with dsRNA induced lung inflammation that was not present in Toll-like receptor 3-deficient mice. Moreover, lung inflammation enhanced by low-dose dsRNA was impaired in IL-13-deficient mice, whereas lung inflammation by high-dose dsRNA was impaired in IFN-,gamma-deficient mice. The models also demonstrated that low-dose dsRNA enhanced IL-4 expression during allergen sensitization and that inflammation enhanced by low-dose dsRNA was not present in IL-4- or STAT6-deficient mice. In contrast, the present study showed that high-dose dsRNA enhanced IFN-,gamma expression during allergen sensitization and that the development of lung inflammation enhanced by high-dose dsRNA was impaired in T-bet-deficient mice. Conclusion: These findings suggest that airway allergen exposure during respiratory viral infections might induce asthma induced by both T(H)1 and T(H)2 immune responses to inhaled allergens. Clinical implications: Targeting both T(H)1 and T(H)2 lung inflammation might be important in the treatment of virus-associated asthma.	Pohang Univ Sci & Technol, Postech Biotech Ctr, Dept Life Sci, Pohang 790784, Gyeongbukdo, South Korea; Johns Hopkins Univ, Ctr Asthma & Allergy, Div Clin Immunol & Allergy, Baltimore, MD USA; Seoul Natl Univ, Coll Med, Inst Allergy & Clin Immunol, Dept Internal Med, Seoul, South Korea	Pohang University of Science & Technology (POSTECH); Johns Hopkins University; Seoul National University (SNU)	Kim, YK (corresponding author), Pohang Univ Sci & Technol, Postech Biotech Ctr, Dept Life Sci, San 31 Hyojadong, Pohang 790784, Gyeongbukdo, South Korea.	juinea@postech.ac.kr		Oh, Min-Hee/0000-0003-1581-4288				Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Dahl ME, 2004, NAT IMMUNOL, V5, P337, DOI 10.1038/ni1041; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Guidotti LG, 2001, ANNU REV IMMUNOL, V19, P65, DOI 10.1146/annurev.immunol.19.1.65; Guillot L, 2005, J BIOL CHEM, V280, P5571, DOI 10.1074/jbc.M410592200; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jeon SG, 2007, J ALLERGY CLIN IMMUN, V119, P831, DOI 10.1016/j.jaci.2006.12.653; Kang DC, 2002, P NATL ACAD SCI USA, V99, P637, DOI 10.1073/pnas.022637199; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kim YK, 2007, J IMMUNOL, V178, P5375, DOI 10.4049/jimmunol.178.8.5375; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Kulka M, 2004, J ALLERGY CLIN IMMUN, V114, P174, DOI 10.1016/j.jaci.2004.03.049; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Levy DE, 2002, J EXP MED, V195, pF15, DOI 10.1084/jem.20020075; Martinez FD, 2002, PEDIATRICS, V109, P362; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; Sherrill DL, 1999, J ALLERGY CLIN IMMUN, V104, P28, DOI 10.1016/S0091-6749(99)70110-7; Simpson JL, 2007, THORAX, V62, P211, DOI 10.1136/thx.2006.061358; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stevenson EC, 1997, CLIN EXP ALLERGY, V27, P1027, DOI 10.1111/j.1365-2222.1997.tb01254.x; Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Wang ZD, 2000, J EXP MED, V192, P1587, DOI 10.1084/jem.192.11.1587; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	29	59	60	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					803	812		10.1016/j.jaci.2007.05.030	http://dx.doi.org/10.1016/j.jaci.2007.05.030			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17610940				2022-12-18	WOS:000250157700013
J	Blanch, A; Roche, O; Urrutia, I; Gamboa, P; Fontan, G; Lopez-Trascasa, M				Blanch, Alvaro; Roche, Olga; Urrutia, Ignacio; Gamboa, Pedro; Fontan, Gumersindo; Lopez-Trascasa, Margarita			First case of homozygous C1 inhibitor deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hereditary angioedema; C1 inhibitor; classical complement activation pathway; serine protease inhibitor; homozygous C1NH mutation	HEREDITARY ANGIONEUROTIC EDEMA; C1 ESTERASE INHIBITOR; ANGIOEDEMA; COMPLEMENT; DISEASES	Background: C1 Inhibitor (C1-Inh) deficiency causes angioedema and can be hereditary (HAE), caused by mutations in the C1-Inh gene (C1NH), or acquired (AAE). Patients with HAE show a complement profile different from that of patients with AAE with normal levels of C1 (C1q, C1r, and C1s). Objective: We sought to characterize the complement profile of a patient with HAE and a mutation in homozygosis in the C1NH gene (c.1576T > G, Ile462Ser) and study his family. Methods: Biochemical diagnosis of HAE was confirmed by analyzing the C1NH gene. Further studies on the levels and activation states of the C1q, C1r, C1s, and C1-Inh components of the classical pathway of complement activation were also performed. Results: Another 7 members of the family were given diagnoses of HAE: 1 was homozygous and 6 were heterozygous for the C1NH mutation c.1576T > G. The homozygous patients showed undetectable C1q levels, reduced C1s levels, the circulating active form of C1r and a C1-Inh mostly in its cleaved inactive form in plasma. Conclusion: This is the first report of patients homozygous for a mutation affecting the coding region of C1NH. These patients showed a unique activation and consumption profile of the classical complement activation pathway different from that commonly observed in patients with HAE but similar to that of patients with AAE. Clinical implications: The most common HAE treatment is attenuated androgens, which increase the C1NH gene transcription levels. Because the homozygous patients lack a wild-type allele, long-term prophylactic treatment with attenuated androgens might not be advisable.	Hosp Univ La Paz, Unidad Immunol, Madrid 28046, Spain; Hosp Basurto, Serv Alergol, Bilbao, Spain	Hospital Universitario La Paz; Basurto Hospital	Lopez-Trascasa, M (corresponding author), Hosp Univ La Paz, Unidad Immunol, Paseo Castellana 261, Madrid 28046, Spain.	mlopeztrascasa.hulp@salud.madrid.org	Roche, UCLM/F-5697-2019; Roche, Olga/K-9342-2014; López-Trascasa, Margarita/L-2699-2014	Roche, UCLM/0000-0003-1884-8256; López-Trascasa, Margarita/0000-0001-8594-282X				AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; Blanch Alvaro, 2002, Hum Mutat, V20, P405, DOI 10.1002/humu.9073; Bork K, 2000, MAYO CLIN PROC, V75, P349, DOI 10.4065/75.4.349; Bork K, 2003, ARCH INTERN MED, V163, P1229, DOI 10.1001/archinte.163.10.1229; Bowen T, 2004, J ALLERGY CLIN IMMUN, V114, P629, DOI 10.1016/j.jaci.2004.06.043; Caliezi C, 2000, PHARMACOL REV, V52, P91; Cicardi M, 2003, MEDICINE, V82, P274, DOI 10.1097/00005792-200307000-00006; DESMET BJGL, 1993, BLOOD, V81, P56, DOI 10.1182/blood.V81.1.56.bloodjournal81156; Gaboriaud C, 2004, TRENDS IMMUNOL, V25, P368, DOI 10.1016/j.it.2004.04.008; LACROIX MB, 1989, BIOCHEM J, V257, P885, DOI 10.1042/bj2570885; Roche O, 2005, ANN ALLERG ASTHMA IM, V94, P498, DOI 10.1016/S1081-1206(10)61121-0; Roche O, 2005, HUM MUTAT, V26, P135, DOI 10.1002/humu.20197; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Tosi M, 1998, IMMUNOBIOLOGY, V199, P358, DOI 10.1016/S0171-2985(98)80040-5; Verpy E, 1996, AM J HUM GENET, V59, P308; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; Zahedi R, 1997, J IMMUNOL, V159, P983	20	59	61	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1330	1335		10.1016/j.jaci.2006.07.035	http://dx.doi.org/10.1016/j.jaci.2006.07.035			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17137866				2022-12-18	WOS:000242880300020
J	Greiner, AN; Meltzer, EO				Greiner, Alexander N.; Meltzer, Eli O.			Pharmacologic rationale for treating allergic and nonallergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergic rhinitis; nonallergic rhinitis; nonallergic rhinitis with eosinophilia syndrome; perennial nonallergic rhinitis; pharmacotherapy; H1-antihistamines; intranasal corticosteroids; antileukotrienes; capsaicin; cromolyn sodium	AZELASTINE NASAL SPRAY; PLACEBO-CONTROLLED TRIAL; INTRANASAL FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR ANTAGONISTS; FEXOFENADINE HYDROCHLORIDE 120; DOUBLE-BLIND; IDIOPATHIC RHINITIS; PERENNIAL RHINITIS; CROMOLYN SODIUM; VASOMOTOR RHINITIS	Allergic rhinitis (AR) and perennial nonallergic rhinitis (PNAR) represent conditions affecting millions of individuals across the world. Although the diagnosis of AR might be presumptively based on the types of symptoms and the history of allergen triggers, confirmation requires documentation of specific IgE reactivity. In contrast, PNAR is a condition with similar symptomatology but in which the patient has no identifiable specific allergic sensitivities. This review presents the diverse options of currently available pharmacologic agents for the treatment of AR and PNAR, including intranasal corticosteroids, Hl-antihistamines, decongestants, cromolyn sodium, antileukotrienes, anticholinergics, capsaicin, anti-IgE, and intranasal saline. Furthermore, appropriate stepped-up, stepped-down pharmacotherapeutic algorithms are described for the various forms of rhinitis.	Allergy & Asthma Med Grp, San Diego, CA 92123 USA; Res Ctr, San Diego, CA 92123 USA		Greiner, AN (corresponding author), Allergy & Asthma Med Grp, 9610 Granite Ridge Dr,Suite B, San Diego, CA 92123 USA.	greineran@yahoo.com						Abdelaziz MM, 1998, J ALLERGY CLIN IMMUN, V101, P410, DOI 10.1016/S0091-6749(98)70256-8; Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Albanesi C, 1998, CLIN EXP ALLERGY, V28, P101; Allen DB, 2002, ALLERGY ASTHMA PROC, V23, P407; *AM AC ALL ASTHM I, 2000, ALL REP; Arikan OK, 2006, ACTA OTO-LARYNGOL, V126, P37, DOI 10.1080/00016480510012219; AYARS GH, 1989, AM REV RESPIR DIS, V140, P125; Banov CH, 2001, ANN ALLERG ASTHMA IM, V86, P28, DOI 10.1016/S1081-1206(10)62352-6; Barnes ML, 2006, CLIN EXP ALLERGY, V36, P676, DOI 10.1111/j.1365-2222.2006.02478.x; BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; Blom HM, 1997, CLIN EXP ALLERGY, V27, P796, DOI 10.1046/j.1365-2222.1997.670842.x; BORUM P, 1979, J ALLERGY CLIN IMMUN, V63, P253, DOI 10.1016/0091-6749(79)90109-X; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; BRONSKY EA, 1995, J ALLERGY CLIN IMMUN, V95, P1117, DOI 10.1016/S0091-6749(95)70215-6; Cameron L, 2003, J IMMUNOL, V171, P3816, DOI 10.4049/jimmunol.171.7.3816; Carney AS, 2002, CLIN EXP ALLERGY, V32, P1436, DOI 10.1046/j.1365-2745.2002.01465.x; Casale TB, 2001, AM J RESP CRIT CARE, V164, pS18, DOI 10.1164/ajrccm.164.supplement_1.2103023; Cervin A, 1999, AM J RESP CRIT CARE, V160, P1724, DOI 10.1164/ajrccm.160.5.9902102; Charpin D, 1995, EUR ARCH OTO-RHINO-L, V252, P455, DOI 10.1007/BF02114749; Chen ST, 2006, PEDIAT ALLERG IMM-UK, V17, P49, DOI 10.1111/j.1399-3038.2005.00351.x; Chervinsky P, 2004, ANN ALLERG ASTHMA IM, V92, P367, DOI 10.1016/S1081-1206(10)61576-1; Chervinsky P, 2003, ANN ALLERG ASTHMA IM, V91, P160, DOI 10.1016/S1081-1206(10)62171-0; Ciprandi G, 2004, ALLERGY, V59, P16, DOI 10.1111/j.0108-1675.2004.00390.x; Cockburn IM, 1999, J OCCUP ENVIRON MED, V41, P948, DOI 10.1097/00043764-199911000-00005; COHAN RH, 1976, J ALLERGY CLIN IMMUN, V58, P121, DOI 10.1016/0091-6749(76)90147-0; Coker HA, 2003, J IMMUNOL, V171, P5602, DOI 10.4049/jimmunol.171.10.5602; Corren J, 1999, J ALLERGY CLIN IMMUN, V104, pS144, DOI 10.1016/S0091-6749(99)70310-6; Corren J, 2005, CLIN THER, V27, P543, DOI 10.1016/j.clinthera.2005.04.012; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; Day JH, 2005, ALLERGY ASTHMA PROC, V26, P275; Day JH, 2004, ALLERGY ASTHMA PROC, V25, P59; Day JH, 1998, J ALLERGY CLIN IMMUN, V101, P638, DOI 10.1016/S0091-6749(98)70172-1; Di Lorenzo G, 2004, CLIN EXP ALLERGY, V34, P259, DOI 10.1111/j.1365-2222.2004.01877.x; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Druce HM, 1998, J CLIN PHARMACOL, V38, P382, DOI 10.1002/j.1552-4604.1998.tb04439.x; Fujita M, 1999, EUR J PHARMACOL, V369, P349, DOI 10.1016/S0014-2999(99)00037-0; Garavello W, 2005, INT ARCH ALLERGY IMM, V137, P310, DOI 10.1159/000086462; Garay R, 2004, ALLERGY, V59, P4, DOI 10.1111/j.0108-1675.2004.00388.x; Geha RS, 2001, J ALLERGY CLIN IMMUN, V107, P752, DOI 10.1067/mai.2001.114239; Gilmore TM, 1996, AM J IND MED, V30, P234; GOETZ DW, 1989, J ALLERGY CLIN IMMUN, V84, P316, DOI 10.1016/0091-6749(89)90414-4; GROSSMAN J, 1995, J ALLERGY CLIN IMMUN, V95, P1123, DOI 10.1016/S0091-6749(95)70216-4; Hamasaki Y, 1996, ANN ALLERG ASTHMA IM, V76, P469, DOI 10.1016/S1081-1206(10)63465-5; Hampel F, 2003, ANN ALLERG ASTHMA IM, V91, P354, DOI 10.1016/S1081-1206(10)61682-1; Hansen B, 2002, RHINOLOGY, V40, P10; Hindmarch I, 1999, CLIN EXP ALLERGY, V29, P133, DOI 10.1046/j.1365-2222.1999.0290s3133.x; Holm AF, 1998, CLIN OTOLARYNGOL, V23, P69; Horak F, 2006, CURR MED RES OPIN, V22, P151, DOI 10.1185/030079906X80305; Howarth PH, 1999, J ALLERGY CLIN IMMUN, V104, P927, DOI 10.1016/S0091-6749(99)70070-9; Hwang KK, 2001, J ALLERGY CLIN IMMUN, V107, pS153; KAISER HB, 1995, J ALLERGY CLIN IMMUN, V95, P1128, DOI 10.1016/S0091-6749(95)70217-2; Kim KT, 2005, ANN ALLERG ASTHMA IM, V94, P73, DOI 10.1016/S1081-1206(10)61289-6; KIRKEGAARD J, 1987, J ALLERGY CLIN IMMUN, V79, P585, DOI 10.1016/S0091-6749(87)80153-7; Kurowski M, 2004, ALLERGY, V59, P280, DOI 10.1046/j.1398-9995.2003.00416.x; LaForce CF, 2004, ANN ALLERG ASTHMA IM, V93, P154, DOI 10.1016/S1081-1206(10)61468-8; LINDBERG S, 1993, ALLERGY, V48, P602, DOI 10.1111/j.1398-9995.1993.tb00756.x; LOFKVIST T, 1977, ACTA ALLERGOL, V32, P35; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Lundblad L, 2001, ACTA OTO-LARYNGOL, V121, P505, DOI 10.1080/000164801300366679; MALM L, 1983, ACTA OTO-LARYNGOL, V96, P149, DOI 10.3109/00016488309132885; Malm L, 1993, ALLERGIC NONALLERGIC, P95; MELTZER EO, 1994, ANN ALLERGY, V72, P354; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V105, P917, DOI 10.1067/mai.2000.106040; Meltzer EO, 2005, ANN ALLERG ASTHMA IM, V95, P600, DOI 10.1016/S1081-1206(10)61025-3; Meltzer EO, 1997, ALLERGY, V52, P33, DOI 10.1111/j.1398-9995.1997.tb04820.x; Meltzer EO, 2002, CLIN THER, V24, P942, DOI 10.1016/S0149-2918(02)80009-1; Meltzer EO, 1997, ANN ALLERG ASTHMA IM, V78, P485, DOI 10.1016/S1081-1206(10)63236-X; Milgrom H, 1999, ANN ALLERG ASTHMA IM, V83, P105, DOI 10.1016/S1081-1206(10)62620-8; Minshall E, 1998, OTOLARYNG HEAD NECK, V118, P648, DOI 10.1016/S0194-5998(98)70235-9; Moinuddin R, 2004, ANN ALLERG ASTHMA IM, V92, P73, DOI 10.1016/S1081-1206(10)61713-9; Mucha SM, 2006, ARCH OTOLARYNGOL, V132, P164, DOI 10.1001/archotol.132.2.164; Murphy K. R., 2004, Journal of Allergy and Clinical Immunology, V113, pS175, DOI 10.1016/j.jaci.2004.01.065; Nathan RA, 2005, CHEST, V128, P1910, DOI 10.1378/chest.128.4.1910; Nathan RA, 1997, J ALLERGY CLIN IMMUN, V99, pS808, DOI 10.1016/S0091-6749(97)80040-1; NELSON BL, 1982, J ALLERGY CLIN IMMUN, V70, P125, DOI 10.1016/0091-6749(82)90240-8; Numata T, 1999, INT ARCH ALLERGY IMM, V119, P304, DOI 10.1159/000024208; Nunes C, 2000, J INVEST ALLERG CLIN, V10, P20; ORIE NGM, 1970, DISODIUM CROMOGLYCAT, P33; Passalacqua G, 1993, Allergol Immunopathol (Madr), V21, P79; Patel P, 2005, ANN ALLERG ASTHMA IM, V95, P551, DOI 10.1016/S1081-1206(10)61018-6; Philip G, 2002, CLIN EXP ALLERGY, V32, P1020, DOI 10.1046/j.1365-2222.2002.01422.x; Powe DG, 2004, ALLERGY, V59, P204, DOI 10.1046/j.1398-9995.2003.00315.x; Powe DG, 2001, CLIN EXP ALLERGY, V31, P864, DOI 10.1046/j.1365-2222.2001.01106.x; Pullerits T, 2002, J ALLERGY CLIN IMMUN, V109, P949, DOI 10.1067/mai.2002.124467; Purello-D'Ambrosio F, 1999, CLIN EXP ALLERGY, V29, P1143; RATNER PH, 1994, J ALLERGY CLIN IMMUN, V94, P818, DOI 10.1016/0091-6749(94)90148-1; Ratner PH, 2003, ANN ALLERG ASTHMA IM, V90, P536, DOI 10.1016/S1081-1206(10)61847-9; Ratner PH, 1998, J FAM PRACTICE, V47, P118; Richardson GS, 2002, J CLIN PSYCHOPHARM, V22, P511, DOI 10.1097/00004714-200210000-00012; Rinne J, 2002, J ALLERGY CLIN IMMUN, V109, P426, DOI 10.1067/mai.2002.121703; Scadding GK, 2001, CURR OPIN ALLERGY CL, V1, P15, DOI 10.1097/00130832-200102000-00004; Schenkel EJ, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.2.e22; Settipane RA, 2001, ANN ALLERG ASTHMA IM, V86, P494, DOI 10.1016/S1081-1206(10)62896-7; Shamsi Z, 2000, HUM PSYCHOPHARM CLIN, V15, pS3, DOI 10.1002/1099-1077(200010)15:1+<::AID-HUP247>3.0.CO;2-S; Shinoda M, 1997, AM J RHINOL, V11, P237, DOI 10.2500/105065897781751901; Simons FER, 2004, NEW ENGL J MED, V351, P2203, DOI 10.1056/NEJMra033121; SIMONS FER, 2003, MIDDLETONS ALLERGY P, P834; SIMONS FER, 2002, HISTAMINE H1 ANTIHIS, P141; Skoner DP, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.2.e23; Smurthwaite Lyn, 2002, Curr Allergy Asthma Rep, V2, P231, DOI 10.1007/s11882-002-0024-z; Soper JW, 2000, AVIAT SPACE ENVIR MD, V71, P1206; Storms W W, 1994, Ear Nose Throat J, V73, P382; STORMS WW, 1989, J ALLERGY CLIN IMMUN, V83, P1083, DOI 10.1016/0091-6749(89)90450-8; Suissa S, 2004, AM J RESP CRIT CARE, V169, P83, DOI 10.1164/rccm.200305-640OC; Sussman GL, 1999, J ALLERGY CLIN IMMUN, V104, P100, DOI 10.1016/S0091-6749(99)70120-X; Talbot AR, 1997, LARYNGOSCOPE, V107, P500, DOI 10.1097/00005537-199704000-00013; TOGIAS A, 1990, Journal of Allergy and Clinical Immunology, V85, P182; TOGIAS A, 1991, Journal of Allergy and Clinical Immunology, V87, P148, DOI 10.1016/0091-6749(91)91320-S; Tomooka LT, 2000, LARYNGOSCOPE, V110, P1189, DOI 10.1097/00005537-200007000-00023; van Adelsberg J, 2003, ALLERGY, V58, P1268, DOI 10.1046/j.1398-9995.2003.00261.x; Van Cauwenberge P, 2000, CLIN EXP ALLERGY, V30, P891; van Rijswijk JB, 2005, ALLERGY, V60, P1471, DOI 10.1111/j.1398-9995.2005.00975.x; Van Rijswijk JB, 2003, ALLERGY, V58, P754, DOI 10.1034/j.1398-9995.2003.00203.x; van Rijswijk JB, 2003, RHINOLOGY, V41, P25; Vignola AM, 2004, ALLERGY, V59, P709, DOI 10.1111/j.1398-9995.2004.00550.x; WANG D, 1995, EUR ARCH OTO-RHINO-L, V252, pS40, DOI 10.1007/BF02484433; Webb DR, 2002, ANN ALLERG ASTHMA IM, V88, P385, DOI 10.1016/S1081-1206(10)62369-1; Weiler JM, 2000, ANN INTERN MED, V132, P354, DOI 10.7326/0003-4819-132-5-200003070-00004; Weiner JM, 1998, BMJ-BRIT MED J, V317, P1624, DOI 10.1136/bmj.317.7173.1624; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; Wilson AM, 2004, AM J MED, V116, P338, DOI 10.1016/j.amjmed.2003.10.030; Wilson AM, 2002, CLIN EXP ALLERGY, V32, P126, DOI 10.1046/j.0022-0477.2001.01252.x; Wilson AM, 1998, J ALLERGY CLIN IMMUN, V102, P598, DOI 10.1016/S0091-6749(98)70275-1; Wilson AM, 2002, CLIN EXP ALLERGY, V32, P1504, DOI 10.1046/j.1365-2745.2002.01509.x; Wilson AM, 2001, CLIN EXP ALLERGY, V31, P61, DOI 10.1046/j.1365-2222.2001.00964.x; Wilson AM, 1998, J ALLERGY CLIN IMMUN, V101, P470, DOI 10.1016/S0091-6749(98)70354-9; WOLF G, 1995, LARYNGO RHINO OTOL, V74, P289, DOI 10.1055/s-2007-997742; WOOD CC, 1995, J ALLERGY CLIN IMMUN, V95, P1111, DOI 10.1016/S0091-6749(95)70214-8; WRIGHT AL, 1994, PEDIATRICS, V94, P895; Yoneda K, 1997, JPN J PHARMACOL, V73, P145, DOI 10.1254/jjp.73.145	130	59	71	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					985	996		10.1016/j.jaci.2006.06.029	http://dx.doi.org/10.1016/j.jaci.2006.06.029			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088121				2022-12-18	WOS:000244282300001
J	Hindley, J; Wunschmann, S; Satinover, SM; Woodfolk, JA; Chew, FT; Chapman, MD; Pomes, A				Hindley, James; Wunschmann, Sabina; Satinover, Shama M.; Woodfolk, Judith A.; Chew, Fook Tim; Chapman, Martin D.; Pomes, Anna			Bla g 6: A troponin C allergen from Blattella germanica with IgE binding calcium dependence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	62nd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 03-07, 2006	Miami Beach, FL	Amer Acad Allergy, Asthma & Immunol		asthma; allergy; allergens; cockroach; calcium binding proteins; multiplex array technology	COCKROACH ALLERGEN; CRYSTAL-STRUCTURE; MOLECULAR-CLONING; MAJOR ALLERGEN; SWISS-MODEL; IDENTIFICATION; TROPOMYOSIN; REACTIVITY; ANTIBODIES; DROSOPHILA	Background: The known cockroach allergens do not appear to account for the full repertoire of IgE responses. Objective: To identify and investigate the importance of other Blattella germanica allergens contributing to cockroach allergy. Methods: A B germanica cDNA library was screened with pooled sera from patients with cockroach allergy. Three isoallergens of troponin C (Bla g 6) were cloned and expressed in Pichia pastoris. Homology modeling was performed by using Swiss-Model. IgE responses to purified allergens were simultaneously measured in 104 sera by using a fluorescent multiplex array system. The effect of calcium on IgE binding was investigated by ELISA. Results: Three isoallergens, Bla g 6.0101, Bla g 6.0201, and Bla g 6.0301, were identified which share homology with insect troponin Cs and vertebrate calmodulins (61% to 78% and 42% to 44% amino acid identity, respectively) and have 2 EF-hand calcium binding domains. Molecular models of Bla g 6 showed 2 structurally homologous lobes connected by a linker that confers flexibility to the allergen. The prevalence of IgE binding to recombinant Bla g 6 was 14%. Calcium depletion by 10 mmol/L ethyleneglycol-bis-(beta-aminoethylether)-N,N,N',N'-tetraacetic acid did not significantly affect IgE binding in most cases. Interestingly, addition of 10 mmol/L CaCl2 after calcium depletion increased IgE binding by approximately 2-fold, a finding not previously reported for calcium binding allergens. Conclusion: Bla g 6 is a troponin allergen with a calcium dependent IgE reactivity that may be involved in muscle contraction. Clinical implications: Bla g 6 homologous allergens may occur among other insects and cause cosensitization or allergenic cross-reactivity.	INDOOR Biotechnol Inc, Charlottesville, VA 22903 USA; Cardiff Univ, Sch Biosci, Cardiff, Wales; Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA USA; Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore	INDOOR Biotechnologies; Cardiff University; University of Virginia; National University of Singapore	Pomes, A (corresponding author), INDOOR Biotechnol Inc, 1216 Harris St, Charlottesville, VA 22903 USA.	apomes@inbio.com	Chew, Fook Tim/E-7259-2010; Pomés, Anna/H-7010-2019	Chew, Fook Tim/0000-0003-1337-5146; Pomés, Anna/0000-0002-8729-1829; Hindley, James/0000-0002-3262-2897; Chapman, Martin/0000-0002-0845-3632				Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; Arruda LK, 2001, J ALLERGY CLIN IMMUN, V107, P419, DOI 10.1067/mai.2001.112854; ARRUDA LK, 1995, INT ARCH ALLERGY IMM, V107, P295, DOI 10.1159/000237006; Asturias JA, 1999, J IMMUNOL, V162, P4342; CHAPMAN MD, 1999, Patent No. 5869288; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; Fan Y, 2005, INSECT MOL BIOL, V14, P45, DOI 10.1111/j.1365-2583.2004.00530.x; Flower DR, 1996, BIOCHEM J, V318, P1; FYRBERG C, 1994, BIOCHEM GENET, V32, P119, DOI 10.1007/BF00554420; Gore JC, 2004, J MED ENTOMOL, V41, P953, DOI 10.1603/0022-2585-41.5.953; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gupta Ramneek, 2002, Pac Symp Biocomput, P310; Gustchina A, 2005, J MOL BIOL, V348, P433, DOI 10.1016/j.jmb.2005.02.062; Helm R, 1996, J ALLERGY CLIN IMMUN, V98, P172, DOI 10.1016/S0091-6749(96)70240-3; Herranz R, 2005, J MOL EVOL, V60, P31, DOI 10.1007/s00239-004-0031-x; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Jeong KY, 2003, ALLERGY, V58, P1059, DOI 10.1034/j.1398-9995.2003.00167.x; Ledesma A, 2002, CLIN EXP ALLERGY, V32, P1476, DOI 10.1046/j.1365-2745.2002.01493.x; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; Pomes A, 1998, J BIOL CHEM, V273, P30801, DOI 10.1074/jbc.273.46.30801; Pomes A, 2002, EUR J BIOCHEM, V269, P3086, DOI 10.1046/j.1432-1033.2002.02990.x; Pomes A, 2002, AM J RESP CRIT CARE, V165, P391, DOI 10.1164/ajrccm.165.3.2104027; POMES A, 2001, ALLERGY CLIN IMMUNOL, V13, P162; Pomes A, 2001, CURR OPIN ALLERGY CL, V1, P549, DOI 10.1097/00130832-200112000-00010; Qiu F, 2003, BIOCHEM J, V371, P811, DOI 10.1042/BJ20021814; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; Satinover SM, 2005, J ALLERGY CLIN IMMUN, V115, P803, DOI 10.1016/j.jaci.2005.01.018; SATINOVER SM, 2005, J ALLERGY CLIN IMMUN, V115, pS164; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Smith W, 2004, CLIN EXP ALLERGY, V34, P1732, DOI 10.1111/j.1365-2222.2004.02090.x; Soman J, 1999, PROTEINS, V37, P510, DOI 10.1002/(SICI)1097-0134(19991201)37:4<510::AID-PROT2>3.0.CO;2-T; Takeda S, 2003, NATURE, V424, P35, DOI 10.1038/nature01780; TOH GT, 2003, ALLERGY S73, V57, P98; Valenta R, 1998, INT ARCH ALLERGY IMM, V117, P160, DOI 10.1159/000024005; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; Wunschmann S, 2005, J ALLERGY CLIN IMMUN, V116, P140, DOI 10.1016/j.jaci.2005.04.024	41	59	68	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1389	1395		10.1016/j.jaci.2006.02.017	http://dx.doi.org/10.1016/j.jaci.2006.02.017			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	053UX	16751002				2022-12-18	WOS:000238332300028
J	Zuyderduyn, S; Ninaber, DK; Hiemstra, PS; Rabe, KF				Zuyderduyn, Suzanne; Ninaber, Dennis K.; Hiemstra, Pieter S.; Rabe, Klaus F.			The antimicrobial peptide LL-37 enhances IL-8 release by human airway smooth muscle cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human airway smooth muscle cells; asthma; chronic obstructive pulmonary disease; inflammation; antimicrobial peptides; chemokines; IL-8; extracellular signal-regulated kinase	HUMAN CATHELICIDIN LL-37; RECEPTOR-LIKE 1; MAST-CELL; INTERLEUKIN-8 SYNTHESIS; CHEMOKINE RELEASE; GENE-EXPRESSION; INDUCTION; ACTIVATION; DEFENSINS; NEUTROPHILS	Background: Human airway smooth muscle (HASM) cells release various chemokines that are involved in recruitment of inflammatory cells, which can be found within or in the vicinity of the airway smooth muscle layer in patients with inflammatory lung diseases. Inflammatory cells contain antimicrobial peptides including the cathelicidin LL-37 and neutrophil defensins (HNP1-3). Objective: The aim of the study was to determine the effects of antimicrobial peptides on IL-8 (CXC chemokine ligand 8) release by HASM cells, and to study the underlying mechanisms. Methods: Human airway smooth muscle cells were stimulated with LL-37 and HNP1-3, and IL-8 protein and mRNA levels were determined by sandwich ELISA and PCR. Phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 was detected by using Western blot. Results: LL-37 enhanced IL-8 release by HASM cells, which was dependent on ERK1/2 activation. Receptors known to be involved in LL-37-induced signaling, including the epidermal growth factor receptor and formyl peptide receptors, were not involved in LL-37 signaling in HASM cells. The purinergic receptor antagonist suramin did block LL-37-induced ERK1/2 phosphorylation and IL-8 release, and expression of mRNA for the purinergic receptor P2X(7) was detected in HASM cells. HNP1-3 did increase ERK1/2 phosphorylation, but did not enhance IL-8 release by HASM cells. Conclusion: These data show that HASM cells respond to the antimicrobial peptide LL-37 by releasing IL-8, suggesting that LL-37 is a regulator of the inflammatory process in various inflammatory lung diseases by enhancing IL-8 production. Clinical implications: LL-37 released by inflammatory cells may amplify inflammation through induction of IL-8 release by airway smooth muscle.	Leiden Univ, Med Ctr, Dept Pulmonol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Zuyderduyn, S (corresponding author), Leiden Univ, Med Ctr, Dept Pulmonol, C3-P,POB 9600, NL-2300 RC Leiden, Netherlands.	S.Zuyderduyn@lumc.nl	Hiemstra, Pieter S/K-8587-2018; Rabe, Klaus F./AAW-6296-2021	Hiemstra, Pieter S/0000-0002-0238-5982; Rabe, Klaus F./0000-0002-7020-1401				Aarbiou J, 2004, AM J RESP CELL MOL, V30, P193, DOI 10.1165/rcmb.2002-0267OC; Aarbiou J, 2002, J LEUKOCYTE BIOL, V72, P167; Baraldo S, 2004, THORAX, V59, P308, DOI 10.1136/thx.2003.012146; Bowdish DME, 2004, J IMMUNOL, V172, P3758, DOI 10.4049/jimmunol.172.6.3758; Braff MH, 2005, J IMMUNOL, V174, P4271, DOI 10.4049/jimmunol.174.7.4271; Brightling CE, 2005, AM J RESP CRIT CARE, V171, P1103, DOI 10.1164/rccm.200409-1220OC; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; Di Nardo A, 2003, J IMMUNOL, V170, P2274, DOI 10.4049/jimmunol.170.5.2274; Elssner A, 2004, J IMMUNOL, V172, P4987, DOI 10.4049/jimmunol.172.8.4987; Gendron FP, 2003, AM J PHYSIOL-CELL PH, V284, pC571, DOI 10.1152/ajpcell.00286.2002; Govindaraju V, 2005, J PHARMACOL EXP THER, V315, P941, DOI 10.1124/jpet.105.089698; Hirst SJ, 2003, RESP PHYSIOL NEUROBI, V137, P309, DOI 10.1016/S1569-9048(03)00155-1; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; Jijon HB, 2002, AM J PHYSIOL-CELL PH, V283, pC31, DOI 10.1152/ajpcell.00113.2001; Khine AA, 2006, BLOOD, V107, P2936, DOI 10.1182/blood-2005-06-2314; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Lambrecht G, 2002, CURR PHARM DESIGN, V8, P2371, DOI 10.2174/1381612023392973; Lazaar Aili L., 2001, Current Opinion in Pharmacology, V1, P259, DOI 10.1016/S1471-4892(01)00046-7; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; Moore PE, 2002, AM J PHYSIOL-LUNG C, V282, pL847, DOI 10.1152/ajplung.00245.2001; Nagaoka I, 2006, J IMMUNOL, V176, P3044, DOI 10.4049/jimmunol.176.5.3044; Nassar T, 2002, BLOOD, V100, P4026, DOI 10.1182/blood-2002-04-1080; Oltmanns U, 2005, AM J RESP CELL MOL, V32, P334, DOI 10.1165/rcmb.2004-0321OC; Oltmanns U, 2003, BRIT J PHARMACOL, V139, P1228, DOI 10.1038/sj.bjp.0705345; Oono T, 2002, ARCH DERMATOL RES, V294, P185, DOI 10.1007/s00403-002-0310-6; Ovrevik J, 2004, TOXICOL SCI, V81, P480, DOI 10.1093/toxsci/kfh214; Page S, 2001, AM J PHYSIOL-LUNG C, V281, pL1313, DOI 10.1152/ajplung.2001.281.6.L1313; Panenka W, 2001, J NEUROSCI, V21, P7135, DOI 10.1523/JNEUROSCI.21-18-07135.2001; Robinson DS, 2004, J ALLERGY CLIN IMMUN, V114, P58, DOI 10.1016/j.jaci.2004.03.034; Salinthone S, 2004, AM J PHYSIOL-GASTR L, V287, pG627, DOI 10.1152/ajpgi.00462.2003; Shaykhiev R, 2005, AM J PHYSIOL-LUNG C, V289, pL842, DOI 10.1152/ajplung.00286.2004; Sorensen O, 1997, BLOOD, V90, P2796; Sorensen OE, 2001, BLOOD, V97, P3951, DOI 10.1182/blood.V97.12.3951; STEIN CA, 1989, J CLIN ONCOL, V7, P499, DOI 10.1200/JCO.1989.7.4.499; Tjabringa GS, 2006, INT ARCH ALLERGY IMM, V140, P103, DOI 10.1159/000092305; Tjabringa GS, 2005, PULM PHARMACOL THER, V18, P321, DOI 10.1016/j.pupt.2005.01.001; Tjabringa GS, 2003, J IMMUNOL, V171, P6690, DOI 10.4049/jimmunol.171.12.6690; Tokumaru S, 2005, J IMMUNOL, V175, P4662, DOI 10.4049/jimmunol.175.7.4662; Ullmann H, 2005, J MED CHEM, V48, P7040, DOI 10.1021/jm050301p; van Wetering S, 2005, J LEUKOCYTE BIOL, V77, P444, DOI 10.1189/jlb.0604367; Vanaudenaerde BM, 2003, J HEART LUNG TRANSPL, V22, P1280, DOI 10.1016/S1053-2498(02)01234-2; vanWetering S, 1997, AM J PHYSIOL-LUNG C, V272, pL888, DOI 10.1152/ajplung.1997.272.5.L888; Wuyts WA, 2003, RESP MED, V97, P811, DOI 10.1016/S0954-6111(03)00036-2; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; ZANETTIM, 2004, J LEUKOCYTE BIOL, V75, P39; Zuyderduyn S, 2004, J ALLERGY CLIN IMMUN, V114, P791, DOI 10.1016/j.jaci.2004.06.037	48	59	65	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1328	1335		10.1016/j.jaci.2006.03.022	http://dx.doi.org/10.1016/j.jaci.2006.03.022			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16750994				2022-12-18	WOS:000238332300019
J	Rawas-Qalaji, MM; Simons, FER; Simons, KJ				Rawas-Qalaji, MM; Simons, FER; Simons, KJ			Sublingual epinephrine tablets versus intramuscular injection of epinephrine: Dose equivalence for potential treatment of anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						epinephrine; adrenaline; sublingual tablet; sublingual absorption; EpiPen; anaphylaxis; systemic allergic reaction	FIRST-AID TREATMENT; EPIPEN JR; CHILDREN; PHARMACOKINETICS; ABSORPTION; RISK; AUTOINJECTORS; FOOD	Background: Epinephrine autoinjectors are underused in the emergency treatment of anaphylaxis in the community, perhaps in part because of fear of needles. Objectives: To determine the sublingual epinephrine dose from a novel fast-disintegrating tablet required to achieve epinephrine plasma concentrations (EPPCs) similar to those obtained after epinephrine 0.3 mg intramuscular injection. Methods: In a prospective 5-way crossover study, sublingual tablets containing epinephrine 0, 10, 20, and 40 mg, and epinephrine 0.3 mg intramuscular in the thigh (EpiPen) were compared in a validated rabbit model. Blood samples were collected before dosing and 5, 10, 15, 20, 30, 40, 60, 90, 120, 150, and 180 minutes afterward. EPPCs were measured by using high-performance liquid chromatography-electrochemical detection. Pharmacokinetic parameters were calculated by using WinNonlin. Results: The area under the curve (AUC), maximum concentration (C-max), and time at which C-max was achieved (T-max) did not differ significantly (P > .05) after epinephrine 40 mg (AUC = 1861 +/- 537 ng/mL/min, C-max = 31.0 +/- 13.1 ng/mL, and T-max = 9 +/- 2 minutes) and epinephrine 0.3 mg intramuscular (AUC = 2431 +/- 386 ng/mL/min, C-max = 50.3 +/- 17.1 ng/mL, and T-max = 21 +/- 5 minutes). The AUC after tablets containing epinephrine 0 mg (AUC = 472 +/- 126 ng/mL/min), epinephrine 10 mg (AUC 335 152 ng/mL/min), and epinephrine 20 mg (AUC = 801 160 ng/mL/min) did not differ significantly from each other, but were significantly lower (P < .05) than the AUC after epinephrine 0.3 mg intramuscularly. Conclusion: Sublingual administration of epinephrine 40 mg from this tablet formulation resulted in EPPCs similar to those obtained after epinephrine 0.3 mg intramuscular injection in the thigh. Clinical implications: For treatment of anaphylaxis in the community, self-injectable epinephrine is underused. This novel, fast-disintegrating epinephrine tablet formulation for sublingual administration is a feasible alternative that warrants further development.	Univ Manitoba, Fac Pharm, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Sect Allergy & Clin Immunol, Dept Pediat & Child Hlth, Fac Med, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba	Simons, KJ (corresponding author), Univ Manitoba, Fac Pharm, Room 202,50 Sifton Rd, Winnipeg, MB R3T 2N2, Canada.	simons@ms.umanitoba.ca						Birudaraj R, 2005, J PHARM SCI-US, V94, P70, DOI 10.1002/jps.20208; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; CUNNINGHAM FE, 1994, J CLIN ANESTH, V6, P430, DOI 10.1016/S0952-8180(05)80018-2; Estelle F, 2001, J ALLERGY CLIN IMMUN, V108, P871, DOI 10.1067/mai.2001.119409; GANHAO MF, 1991, J CHROMATOGR-BIOMED, V564, P55, DOI 10.1016/0378-4347(91)80069-O; Gold MS, 2000, J ALLERGY CLIN IMMUN, V106, P171, DOI 10.1067/mai.2000.106041; Gu XC, 1999, BIOPHARM DRUG DISPOS, V20, P401, DOI 10.1002/1099-081X(199911)20:8<401::AID-BDD204>3.0.CO;2-L; Gu XC, 2002, BIOPHARM DRUG DISPOS, V23, P213, DOI 10.1002/bdd.312; HJEMDAHL P, 1987, METHOD ENZYMOL, V142, P521; HJEMDAHL P, 1984, ACTA PHYSIOL SCAND, P43; Korenblat P, 1999, ALLERGY ASTHMA PROC, V20, P383, DOI 10.2500/108854199778251834; KROBOTH PD, 1995, J CLIN PSYCHOPHARM, V15, P259, DOI 10.1097/00004714-199508000-00004; LIEBERMAN P, 2003, MIDDLETONS ALLERGY P, P1497; McLean-Tooke APC, 2003, BMJ-BRIT MED J, V327, P1332, DOI 10.1136/bmj.327.7427.1332; MOTWANI JG, 1991, CLIN PHARMACOKINET, V21, P83, DOI 10.2165/00003088-199121020-00001; MYCEK MJ, 2000, LIPPINCOTTS ILLUSTRA, P60; Olfert ED, 1993, GUIDE CARE USE EXPT; Price TM, 1997, OBSTET GYNECOL, V89, P340; RAWASQALAJI MM, 2004, AM ASS PHARM SCI J, V6; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; SHERWOOD L, 2004, HUMAN PHYSL CELLS SY, P526; Sicherer SH, 2000, PEDIATRICS, V105, P359, DOI 10.1542/peds.105.2.359; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P837, DOI 10.1016/j.jaci.2004.01.079; Simons FER, 2001, J ALLERGY CLIN IMMUN, V108, P1040, DOI 10.1067/mai.2001.119916; Simons FER, 2005, ANN ALLERG ASTHMA IM, V94, P534, DOI 10.1016/S1081-1206(10)61129-5; Simons FER, 2000, PEDIATRICS, V106, P1040, DOI 10.1542/peds.106.5.1040; Simons FER, 2002, J ALLERGY CLIN IMMUN, V109, P171, DOI 10.1067/mai.2002.120758; Simons FER, 1998, J ALLERGY CLIN IMMUN, V101, P33, DOI 10.1016/S0091-6749(98)70190-3; Simons FER, 2000, J ALLERGY CLIN IMMUN, V105, P1025, DOI 10.1067/mai.2000.106042; *US PHARM CONV INC, 1990, OFF MON EP INJ	30	59	71	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					398	403		10.1016/j.jaci.2005.12.1310	http://dx.doi.org/10.1016/j.jaci.2005.12.1310			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461140				2022-12-18	WOS:000235687300021
J	Davey, G; Berhane, Y; Duncan, P; Aref-Adib, G; Britton, J; Venn, A				Davey, G; Berhane, Y; Duncan, P; Aref-Adib, G; Britton, J; Venn, A			Use of acetaminophen and the risk of self-reported allergic symptoms and skin sensitization in Butajira, Ethiopia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						acetaminophen; allergic sensitisation; aspirin; asthma; developing country; eczema; Ethiopia; paracetamol; rhinitis	PARACETAMOL USE; ASTHMA; GLUTATHIONE; DISEASE	Background: Studies in developed countries suggest that acetaminophen use is associated with increased risk of asthma, but it is unclear whether this association is causal. Objective: To determine the relation among acetaminophen use, asthma, and allergy, and to explore potential biases in acetaminophen use, in a developing country population. Methods: We surveyed 7649 adults and children from Butajira, Ethiopia, collecting data on self-reported symptoms of allergic disease, skin sensitization to Dermatophagoides pteronyssinus and cockroach, acetaminophen use, and potential confounders. We then collected detailed data on indications for acetaminophen use and reasons for aspirin avoidance in a nested follow-up study. Results: Allergic symptoms increased significantly with frequency of acetaminophen use, with odds ratios in those using > 3 tablets in the past month relative to none 1.89 (95% CI, 1.51-2.36) for wheeze, 2.14 (1.72-2.67) for nocturnal shortness of breath, 2.52 (1.99-3.20) for rhinitis, and 1.90 (1.39-2.61) for eczema. Cockroach sensitization was also more common in the highest acetantinophen category (odds ratio, 1.40; 95% Cl, 1.10-1.79), but D pteronyssinus sensitization was not. Less than 1% of participants with asthma or wheeze in our nested study reported avoidance of aspirin because of asthma symptoms. None volunteered using acetaminophen to treat allergic symptoms. Conclusion: There is a dose-related association between acetaminophen use and self-reported allergic symptoms in this population that is not a result of aspirin avoidance, reverse causation, or other bias. Acetaminophen may therefore be involved in the etiology of asthma and allergic disease.	Univ Addis Ababa, Dept Community Hlth, Addis Ababa, Ethiopia; Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG7 2RD, England	Addis Ababa University; University of Nottingham	Davey, G (corresponding author), POB 26905-1000, Addis Ababa, Ethiopia.	nerurkar@ethionet.et		Davey, Gail/0000-0003-2796-7468				Barr RG, 2004, AM J RESP CRIT CARE, V169, P836, DOI 10.1164/rccm.200304-596OC; Berhane Y, 1999, ETHIOP J HEALTH DEV, P13; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; BURNEY PGJ, 1989, INT J EPIDEMIOL, V18, P165, DOI 10.1093/ije/18.1.165; Cohet C, 2004, J EPIDEMIOL COMMUN H, V58, P852, DOI 10.1136/jech.2003.019182; Davey G, 2005, CLIN EXP ALLERGY, V35, P301, DOI 10.1111/j.1365-2222.2005.02181.x; Droge W, 2000, P NUTR SOC, V59, P595, DOI 10.1017/S0029665100000847; Eneli I, 2005, CHEST, V127, P604, DOI 10.1378/chest.127.2.604; Kelly FK, 1999, LANCET, V354, P482, DOI 10.1016/S0140-6736(99)01812-7; McKeever TM, 2005, AM J RESP CRIT CARE, V171, P966, DOI 10.1164/rccm.200409-1269OC; Melaku K, 2003, ETHIOPIAN MED J, V41, P371; Newson RB, 2000, EUR RESPIR J, V16, P817, DOI 10.1183/09031936.00.16581700; Nuttall SL, 2003, J CLIN PHARM THER, V28, P289, DOI 10.1046/j.1365-2710.2003.00493.x; Peterson JD, 1998, P NATL ACAD SCI USA, V95, P3071, DOI 10.1073/pnas.95.6.3071; Shaheen SO, 2005, CLIN EXP ALLERGY, V35, P18, DOI 10.1111/j.1365-2222.2005.02151.x; Shaheen SO, 2000, THORAX, V55, P266, DOI 10.1136/thorax.55.4.266; Shaheen SO, 2002, THORAX, V57, P958, DOI 10.1136/thorax.57.11.958; Varner A, 2000, THORAX, V55, P882; Wong ICK, 2000, THORAX, V55, P882, DOI 10.1136/thorax.55.10.882	19	59	62	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					863	868		10.1016/j.jaci.2005.05.045	http://dx.doi.org/10.1016/j.jaci.2005.05.045			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210062				2022-12-18	WOS:000235686600022
J	Chen, WG; Ericksen, MB; Levin, LS; Hershey, GKK				Chen, WG; Ericksen, MB; Levin, LS; Hershey, GKK			Functional effect of the R110Q IL13 genetic variant alone and in combination with IL4RA genetic variants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						genetics; cytokine receptors; cytokines; signal transduction; atopy	IL-4 RECEPTOR-ALPHA; ASTHMA-SUSCEPTIBILITY LOCI; ETHNICALLY DIVERSE POPULATIONS; GENOME-WIDE SEARCH; SERUM IGE LEVELS; ALLERGIC-ASTHMA; INTERLEUKIN-4 RECEPTOR; BAROMETRIC PLETHYSMOGRAPHY; AIRWAYS HYPERREACTIVITY; SIGNAL-TRANSDUCTION	Background: IL-13 is a key mediator of allergic asthma. IL-13 mediates its effects via its receptor, a heterodimer composed of IL-4Ralpha and IL-13Ralpha1. Polymorphic variants of both IL-13 and IL-4Ra have been shown to be associated with atopy. Objective: We examined the functional consequences of the Q110 IL-13 variant in vitro and in vivo to determine whether it displays enhanced functional activity compared with R110 IL-13, both in the context of I50Q551 IL-4Ra and of the atopy-associated variant V50R551 IL-4Ralpha. Methods: We used a mouse cell line stably expressing human IL-4Ralpha and IL-13Ralpha1 that readily responds to human IL-4 and IL-13. For in vivo analyses, we used BALB/c mice. Results: The Q110 IL-13 variant displayed significantly increased activity compared with R110 IL-13. Furthermore, mice treated with Q110 IL-13 variant displayed increased airways hyperresponsiveness relative to R110 IL-13. We then examined the functional consequences of Q110 IL-13 variant in combination with an atopy-associated variant of its receptor, IL-4Ralpha (V50R551). Q110 IL-13 variant had increased activity on these cells as well, and, strikingly, the effect was greater than that observed in cells expressing I50Q551 IL-4Ralpha. Conclusion: Either Q110 IL-13 variant or V50R551 IL-4Ralpha variant has enhanced function alone, but the 2 together have a synergistic effect on IL-13-dependent gene induction. Our data demonstrate the importance of relatively small individual differences in gene products from common single nucleotide polymorphisms that may result in larger combined differences. Furthermore, a relatively modest change in function from a single nucleotide polymorphism can result in an important biological difference in vivo.	Childrens Hosp, Med Ctr, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Med Ctr, Ctr Biostat Serv, Cincinnati, OH 45267 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Hershey, GKK (corresponding author), Childrens Hosp, Med Ctr, Dept Pediat, Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Gurjit.Hershey@chmcc.org		Khurana Hershey, Gurjit/0000-0001-6663-977X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046652] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI46652-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andrews RP, 2001, J IMMUNOL, V166, P1716, DOI 10.4049/jimmunol.166.3.1716; Arima K, 2002, J ALLERGY CLIN IMMUN, V109, P980, DOI 10.1067/mai.2002.124656; Deichmann K, 1997, BIOCHEM BIOPH RES CO, V231, P696, DOI 10.1006/bbrc.1997.6115; Deichmann KA, 1998, CLIN EXP ALLERGY, V28, P151; deVries JE, 1996, CHEM IMMUNOL, V63, P204; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Finotto S, 2001, J EXP MED, V193, P1247, DOI 10.1084/jem.193.11.1247; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; HUANG SK, 1995, J IMMUNOL, V155, P2688; Izuhara K, 2000, J ALLERGY CLIN IMMUN, V106, pS65, DOI 10.1067/mai.2000.106776; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kraan TCTMV, 1999, GENES IMMUN, V1, P61, DOI 10.1038/sj.gene.6363630; Kruse S, 1999, IMMUNOLOGY, V96, P365; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lundblad LKA, 2002, J APPL PHYSIOL, V93, P1198, DOI 10.1152/japplphysiol.00080.2002; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Mitsuyasu H, 1999, J IMMUNOL, V162, P1227; Nakamura Y, 1996, AM J RESP CELL MOL, V15, P680, DOI 10.1165/ajrcmb.15.5.8918375; Noguchi E, 1999, CLIN EXP ALLERGY, V29, P228; Noguchi E, 1999, AM J RESP CRIT CARE, V160, P342, DOI 10.1164/ajrccm.160.1.9807130; Noguchi E, 1997, AM J RESP CRIT CARE, V156, P1390, DOI 10.1164/ajrccm.156.5.9702084; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; Petak F, 2001, J APPL PHYSIOL, V90, P2221, DOI 10.1152/jappl.2001.90.6.2221; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; Risma KA, 2002, J IMMUNOL, V169, P1604, DOI 10.4049/jimmunol.169.3.1604; Rosa-Rosa L, 1999, J ALLERGY CLIN IMMUN, V104, P1008, DOI 10.1016/S0091-6749(99)70082-5; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; Sandford AJ, 2000, J ALLERGY CLIN IMMUN, V106, P135, DOI 10.1067/mai.2000.107926; Shirakawa T, 2000, IMMUNOL TODAY, V21, P60, DOI 10.1016/S0167-5699(99)01492-9; Takeda K, 1996, J IMMUNOL, V157, P3220; TANG MLK, 1995, CLIN EXP ALLERGY, V25, P515, DOI 10.1111/j.1365-2222.1995.tb01088.x; Webb DC, 2000, J IMMUNOL, V165, P108, DOI 10.4049/jimmunol.165.1.108; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190; Yang M, 2001, AM J RESP CELL MOL, V25, P522, DOI 10.1165/ajrcmb.25.4.4620; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	56	59	67	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					553	560		10.1016/j.jaci.2004.04.044	http://dx.doi.org/10.1016/j.jaci.2004.04.044			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356556				2022-12-18	WOS:000223799600013
J	Farkas, L; Kvale, EO; Johansen, FE; Jahnsen, FL; Lund-Johansen, F				Farkas, L; Kvale, EO; Johansen, FE; Jahnsen, FL; Lund-Johansen, F			Plasmacytoid dendritic cells activate allergen-specific T(H)2 memory cells: Modulation by CpG oligodeoxynucleotides	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; Th cytokines; allergy; antigen presentation; CpG oligodeoxynucleotide	T-CELLS; IMMUNOSTIMULATORY DNA; AIRWAY INFLAMMATION; ADAPTIVE IMMUNITY; INTERFERON-ALPHA; CYTOKINE; ANTIGEN; DIFFERENTIATION; NAIVE; BLOOD	Background: Plasmacytoid dendritic cells (PDCs) accumulate in the nasal mucosa of allergic rhinitis patients, but their function in upper airway allergy has not been determined. CpG oligodeoxynucleotides, potent adjuvants in immunotherapeutic strategies in animal models, are especially effective at activating PDCs. These cells are therefore potential targets for immunomodulation in humans. Objective: In this study, PDCs were compared with CD11c(+) dendritic cells (DCs), a very potent antigen-presenting cell type, for their capacity to induce allergen-dependent activation of T(H)2 memory cells. Then, we investigated whether CpG-activated PDCs were able to modulate the allergen-specific T(H)2 memory response. Methods: DCs were isolated from patients with upper airway allergy and cocultured with autologous CD4(+) T cells with or without grass pollen extract and CpG. In some experiments cells were restimulated with allergen-pulsed monocyte-derived DCs. T-cell activation was measured by their proliferative response and cytokine production. Results: PDCs stimulated allergen-dependent T-cell proliferation and T(H)2 cytokine production as efficiently as CD11c(+) DCs. CpG-activated PDCs inhibited allergen-dependent proliferation of T(H)2 memory cells and markedly increased IFN-gamma production in PDC/T-cell cocultures; the former effect depended on the CpG-induced IFN-alpha/beta production by the PDCs. Conclusion: Our results demonstrated that PDCs efficiently drive allergen-dependent T(H)2 memory responses, suggesting that they play an active role in the allergic reaction. However, in the presence of CpG, PDCs were responsible for increased production of the T(H)1-related cytokines IFN-alpha and IFN-gamma, indicating that mucosal PDCs may be targets for CpG-based immunotherapeutic strategies against airway allergy.	Univ Hosp, Rikshosp, Inst Pathol, LIIPAT,Sect Immune Regulat & Allergy, N-0027 Oslo, Norway; Univ Hosp, Rikshosp, Inst Pathol, LIIPAT,Sect Secretory Immun, N-0027 Oslo, Norway; Ullevaal Univ Hosp, Dept Hematol, Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Oslo	Farkas, L (corresponding author), Univ Hosp, Rikshosp, Inst Pathol, LIIPAT,Sect Immune Regulat & Allergy, N-0027 Oslo, Norway.	lorant.farkas@labmed.uio.no		Lund-Johansen, Fridtjof/0000-0002-2445-1258				Aldebert D, 1996, BLOOD, V87, P2354, DOI 10.1182/blood.V87.6.2354.bloodjournal8762354; Benson M, 2001, CLIN EXP ALLERGY, V31, P361, DOI 10.1046/j.1365-2222.2001.01045.x; Broide DH, 2001, J CLIN IMMUNOL, V21, P175, DOI 10.1023/A:1011078930363; BUTTERFIELD JH, 1994, ANN INTERN MED, V121, P648, DOI 10.7326/0003-4819-121-9-199411010-00003; de Baey A, 2000, J EXP MED, V191, P743, DOI 10.1084/jem.191.4.743; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; Fonteneau JF, 2003, BLOOD, V101, P3520, DOI 10.1182/blood-2002-10-3063; Geginat J, 2001, J EXP MED, V194, P1711, DOI 10.1084/jem.194.12.1711; Horner AA, 2002, J ALLERGY CLIN IMMUN, V110, P706, DOI 10.1067/mai.2002.129122; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Ikeda RK, 2003, AM J RESP CELL MOL, V28, P655, DOI 10.1165/rcmb.4853; Ito T, 1999, J IMMUNOL, V163, P1409; Jahnsen FL, 2000, J IMMUNOL, V165, P4062, DOI 10.4049/jimmunol.165.7.4062; Julia V, 2002, IMMUNITY, V16, P271, DOI 10.1016/S1074-7613(02)00276-5; Kadowaki N, 2000, J EXP MED, V192, P219, DOI 10.1084/jem.192.2.219; KleinJan A, 2000, EUR RESPIR J, V15, P491, DOI 10.1034/j.1399-3003.2000.15.11.x; Krieg AM, 2003, NAT MED, V9, P831, DOI 10.1038/nm0703-831; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Krug A, 2003, J EXP MED, V197, P899, DOI 10.1084/jem.20021091; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lore K, 2003, J IMMUNOL, V171, P4320, DOI 10.4049/jimmunol.171.8.4320; MacDonald KPA, 2002, BLOOD, V100, P4512, DOI 10.1182/blood-2001-11-0097; MARSHALL JD, 1993, CELL IMMUNOL, V152, P18, DOI 10.1006/cimm.1993.1264; Olweus J, 1997, P NATL ACAD SCI USA, V94, P12551, DOI 10.1073/pnas.94.23.12551; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Parish C. R., 2001, CURRENT PROTOCOLS IM; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Tighe H, 2000, EUR J IMMUNOL, V30, P1939, DOI 10.1002/1521-4141(200007)30:7<1939::AID-IMMU1939>3.0.CO;2-#; Tough DF, 1999, IMMUNOL REV, V170, P39, DOI 10.1111/j.1600-065X.1999.tb01327.x	32	59	63	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					436	443		10.1016/j.jaci.2004.04.035	http://dx.doi.org/10.1016/j.jaci.2004.04.035			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316529				2022-12-18	WOS:000223405600036
J	Kawaguchi, M; Kokubu, F; Odaka, M; Watanabe, S; Suzuki, S; Leki, K; Matsukura, S; Kurokawa, M; Adachi, M; Huang, SK				Kawaguchi, M; Kokubu, F; Odaka, M; Watanabe, S; Suzuki, S; Leki, K; Matsukura, S; Kurokawa, M; Adachi, M; Huang, SK			Induction of granulocyte-macrophage colony-stimulating factor by a new cytokine, ML-1 (IL-17F), via Raf I-MEK-ERK pathway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchial epithelial cells; ERK1/2; GM-CSF; MAP; kinase; Raf1	BRONCHIAL EPITHELIAL-CELLS; NF-KAPPA-B; GM-CSF; SIGNAL-TRANSDUCTION; TNF-ALPHA; ACTIVATION; KINASE; EXPRESSION; ASTHMA; EOSINOPHILS	Background: ML-1 (IL-17F) is a recently discovered cytokine, and its function remains elusive. GM-CSF is a crucial cytokine for the maturation of various cell types and regulates allergic airway inflammation. Objective: The functional effect of ML-1 in the expression of GM-CSF was investigated. Methods: The levels of gene and protein expression in normal human bronchial epithelial cells (NHBEs) in the presence or absence of various kinase inhibitors or, in some cases, of a Raf1 dominant-negative mutant were determined by RT-PCR and ELISA, respectively. Western blotting was performed to investigate kinase activation. Results: The results showed first that ML-1 induces, in a time-dependent and dose-dependent manner, the gene and protein expression for GM-CSF NHBEs, which are associated with activation of Raf1 and MAP kinase kinase (MEK) kinases. Selective MEK inhibitors, PD98059 and U0126, and Raf1 kinase inhibitor I significantly inhibited ML-1-induced GM-CSF production. Furthermore, overexpression of Raf1 dominant-negative mutants inhibited IL-17F-induced GMCSF expression. The combination of PD98059 and Ranf1 kinase inhibitor I completely blocked GM-CSF production, whereas 2 protein kinase C inhibitors, Ro-31-7549 and GF109203X, and a phosphatidylinositol 3-kinase inhibitor, LY294002, showed no inhibitory effect. Conclusion: These findings suggest that ML-1 induces GM-CSF expression through the activation of the Raf1-MEK-extracellular signal-regulated kinase 1/2 pathway.	Johns Hopkins Univ, Ctr Asthma & Allergy, Baltimore, MD 21224 USA; Showa Univ, Sch Med, Dept Internal Med 1, Tokyo 142, Japan	Johns Hopkins University; Showa University	Huang, SK (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	skhuang@jhmi.edu	Huang, Shau-Ku/F-5509-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040274] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-40274] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARM JP, 1992, ADV IMMUNOL, V51, P323, DOI 10.1016/S0065-2776(08)60491-5; Awane M, 1999, J IMMUNOL, V162, P5337; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Boland S, 2000, AM J PHYSIOL-LUNG C, V278, pL25, DOI 10.1152/ajplung.2000.278.1.L25; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; CHURCHILL L, 1992, IMMUNOLOGY, V75, P189; COX G, 1991, AM J RESP CELL MOL, V4, P525, DOI 10.1165/ajrcmb/4.6.525; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; Hashimoto S, 2000, CLIN EXP ALLERGY, V30, P48; Hymowitz SG, 2001, EMBO J, V20, P5332, DOI 10.1093/emboj/20.19.5332; JAGELS MA, 1991, AM J RESP CELL MOL B, V21, P418; Kawaguchi M, 2002, J BIOL CHEM, V277, P15229, DOI 10.1074/jbc.C100641200; Kawaguchi M, 2001, J ALLERGY CLIN IMMUN, V108, P804, DOI 10.1067/mai.2001.119027; Kawaguchi M, 2001, J IMMUNOL, V167, P4430, DOI 10.4049/jimmunol.167.8.4430; Khwaja A, 1994, Curr Opin Hematol, V1, P216; Kim J, 2000, J IMMUNOL, V165, P3384, DOI 10.4049/jimmunol.165.6.3384; Laan M, 2001, BRIT J PHARMACOL, V133, P200, DOI 10.1038/sj.bjp.0704063; Lei XF, 1998, CLIN EXP IMMUNOL, V113, P157; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MASUDA T, 1992, RESPIRATION, V59, P238; Nakamura Y, 1996, AM J RESP CELL MOL, V15, P680, DOI 10.1165/ajrcmb.15.5.8918375; Oh JW, 1999, ANN ALLERG ASTHMA IM, V82, P491; Park CS, 1998, EUR RESPIR J, V12, P872, DOI 10.1183/09031936.98.12040872; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; Puddicombe SM, 2000, CLIN EXP ALLERGY, V30, P7; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; SOLOPERTO M, 1991, AM J PHYSIOL, V260, pL530, DOI 10.1152/ajplung.1991.260.6.L530; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Soukup JM, 2003, CLIN IMMUNOL, V107, P178, DOI 10.1016/S1521-6616(03)00038-X; Starnes T, 2001, J IMMUNOL, V167, P4137, DOI 10.4049/jimmunol.167.8.4137; Vignola AM, 1999, J ALLERGY CLIN IMMUN, V103, P563, DOI 10.1016/S0091-6749(99)70225-3; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Yamashita N, 2002, CELL IMMUNOL, V219, P92, DOI 10.1016/S0008-8749(02)00565-8; Yao ZB, 1997, CYTOKINE, V9, P794, DOI 10.1006/cyto.1997.0240; YOUNG DA, 1990, J IMMUNOL, V145, P607; Yousefi S, 1997, INT ARCH ALLERGY IMM, V112, P9, DOI 10.1159/000237424	38	59	68	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					444	450		10.1016/j.jaci.2004.03.047	http://dx.doi.org/10.1016/j.jaci.2004.03.047			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316530				2022-12-18	WOS:000223405600037
J	Mekori, YA				Mekori, YA			The mastocyte: The "other" inflammatory cell in immunopathogenesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							TUMOR-NECROSIS-FACTOR; HUMAN MAST-CELLS; ACTIVATED T-CELLS; NEUTROPHIL RECRUITMENT; GENE-EXPRESSION; TNF-ALPHA; HYPERSENSITIVITY; RELEASE; DISEASE; RI		Meir Hosp, Dept Med, Kefar Sava, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Mekori, YA (corresponding author), Meir Hosp, Dept Med B, IL-44281 Kefar Sava, Israel.	ymekori@clalit.org.il						Akin C, 2004, J ALLERGY CLIN IMMUN, V114, P13, DOI 10.1016/j.jaci.2004.04.046; Baram D, 2001, J IMMUNOL, V167, P4008, DOI 10.4049/jimmunol.167.7.4008; Baumann U, 2001, J IMMUNOL, V167, P1022, DOI 10.4049/jimmunol.167.2.1022; Benoist C, 2002, NATURE, V420, P875, DOI 10.1038/nature01324; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; Boyce JA, 2003, J ALLERGY CLIN IMMUN, V111, P24, DOI 10.1067/mai.2003.60; Bryce PJ, 2004, IMMUNITY, V20, P381, DOI 10.1016/S1074-7613(04)00080-9; Chen RY, 2001, J CLIN INVEST, V108, P1151, DOI 10.1172/jci11494; Crummy F, 2004, J ALLERGY CLIN IMMUN, V114, P34, DOI 10.1016/j.jaci.2004.03.006; Escribano L, 2004, J ALLERGY CLIN IMMUN, V114, P28, DOI 10.1016/j.jaci.2004.02.042; GORDON JR, 1994, J EXP MED, V180, P2027, DOI 10.1084/jem.180.6.2027; Henz BM, 2001, EXP DERMATOL, V10, P1, DOI 10.1034/j.1600-0625.2001.100101.x; Inamura N, 1998, J IMMUNOL, V160, P4026; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; Krishnaswamy G, 2001, FRONT BIOSCI-LANDMRK, V6, pD1109, DOI 10.2741/krishnas; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; Lora JM, 2003, J ALLERGY CLIN IMMUN, V112, P1119, DOI 10.1016/j.jaci.2003.08.042; Malamud V, 2003, J NEUROIMMUNOL, V138, P115, DOI 10.1016/S0165-5728(03)00090-0; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Marshall JS, 2004, J ALLERGY CLIN IMMUN, V114, P21, DOI 10.1016/j.jaci.2004.04.045; McLachlan JB, 2003, NAT IMMUNOL, V4, P1199, DOI 10.1038/ni1005; Mekori YA, 1999, J ALLERGY CLIN IMMUN, V104, P517, DOI 10.1016/S0091-6749(99)70316-7; MEKORI YA, 1993, J IMMUNOL, V151, P3775; MEKORI YA, 1985, J IMMUNOL, V135, P879; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Okayama Y, 2000, J IMMUNOL, V164, P4332, DOI 10.4049/jimmunol.164.8.4332; Ott VL, 2003, NAT IMMUNOL, V4, P974, DOI 10.1038/ni971; Robinson DS, 2004, J ALLERGY CLIN IMMUN, V114, P58, DOI 10.1016/j.jaci.2004.03.034; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; Skokos D, 2003, J IMMUNOL, V170, P3037, DOI 10.4049/jimmunol.170.6.3037; Sylvestre DL, 1996, IMMUNITY, V5, P387, DOI 10.1016/S1074-7613(00)80264-2; Tanzola MB, 2003, J IMMUNOL, V171, P4385, DOI 10.4049/jimmunol.171.8.4385; Tkaczyk C, 2000, J ALLERGY CLIN IMMUN, V105, P134, DOI 10.1016/S0091-6749(00)90188-X; TORII I, 1993, IMMUNOLOGY, V78, P482; Valent P, 2004, J ALLERGY CLIN IMMUN, V114, P3, DOI 10.1016/j.jaci.2004.02.045; van Houwelingen AH, 2002, J IMMUNOL, V168, P5297, DOI 10.4049/jimmunol.168.10.5297; Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; ZHANG Y, 1992, SCIENCE, V258, P1957, DOI 10.1126/science.1470922	39	59	60	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					52	57		10.1016/j.jaci.2004.04.015	http://dx.doi.org/10.1016/j.jaci.2004.04.015			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15241344				2022-12-18	WOS:000222534300008
J	Jeal, H; Draper, A; Jones, M; Harris, J; Welsh, K; Taylor, AN; Cullinan, P				Jeal, H; Draper, A; Jones, M; Harris, J; Welsh, K; Taylor, AN; Cullinan, P			HLA associations with occupational sensitization to rat lipocalin allergens: A model for other animal allergies?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						lipocalin; Rat n 1; occupational allergy; HLA animal; allergy	MHC CLASS-II; DNA; PROTEIN; PCR	Background: Laboratory animal allergy is a common occupational health problem affecting between 11% and 44% of exposed researchers. Allergy to rats and mice is most common, probably because these are the animals most frequently used. Objective: We hypothesized that HLA class II molecules, involved in the presentation of allergen to the T cell and likely candidates for controlling the immune response, might be associated with sensitization to rat urinary proteins among laboratory animal handlers. Methods: We undertook a cross-sectional study of 741 employees at 6 pharmaceutical sites across the United Kingdom who had contact at work with laboratory rats. In all, 109 cases with specific sensitization to rat proteins and 397 referents were HLA-typed for DRB1 and DQB1 loci. Amino acid analyses of significantly associated HLA molecules were carried out. Results: HLA-DR7 was associated with sensitization (odds ratio [OR], 1.82; CI, 1.12-2.97), respiratory symptoms at work (OR, 2.96; CI, 1.64-5.37) and, most strongly, sensitization with symptoms (OR, 3.81; CI, 1.90-7.65). HLA-DR3 was protective against sensitization (OR, 0.55; CI, 0.31-0.97). Amino acid analyses of these 2 molecules indicated a biologically plausible explanation for the associations. Conclusion: HLA phenotype is an important determinant of individual susceptibility to sensitization and asthma among laboratory animal workers. Similar mechanisms might apply in other animal allergies.	Imperial Coll NHLI, Dept Environm & Occupat Med, Fac Med, London SW3 6LR, England; Imperial Coll NHLI, Dept Interstitial Lung Dis, London SW3 6LR, England	Imperial College London; Imperial College London	Jones, M (corresponding author), Imperial Coll NHLI, Dept Environm & Occupat Med, Fac Med, 1B Manresa Rd, London SW3 6LR, England.			Draper, Adrian/0000-0002-6197-5181				[Anonymous], 1989, ALLERGY S10, V10, P1; BUNCE M, 1994, TISSUE ANTIGENS, V43, P7, DOI 10.1111/j.1399-0039.1994.tb02290.x; Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; DRAPER A, 2002, IN PRESS OCCUP ENV M; Flower DR, 1996, BIOCHEM J, V318, P1; GORDON S, 1994, CLIN EXP ALLERGY, V24, P1070, DOI 10.1111/j.1365-2222.1994.tb02745.x; Jeal H, 2002, J ALLERGY CLIN IMMUN, V109, pS178, DOI 10.1016/S0091-6749(02)81664-5; JONES MG, 2000, AM J RESP CRIT CARE, V161, pA594; LONGBOTTOM JL, 1983, P 11 INT C ALL CLIN, P525; LOW B, 1988, TISSUE ANTIGENS, V31, P224, DOI 10.1111/j.1399-0039.1988.tb02085.x; Mapp CE, 1997, AM J RESP CRIT CARE, V156, pS139, DOI 10.1164/ajrccm.156.4.12-t-12; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Sjostedt L, 1996, AM J IND MED, V30, P415; SJOSTEDT L, 1995, INDOOR ENVIRON, V4, P67; Taylor AJN, 1999, AM J RESP CRIT CARE, V160, P435; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; YOUNG RP, 1995, AM J RESP CRIT CARE, V151, P219, DOI 10.1164/ajrccm.151.1.7812558	20	59	62	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					795	799		10.1067/mai.2003.176	http://dx.doi.org/10.1067/mai.2003.176			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704360				2022-12-18	WOS:000182258500020
J	Chinen, J; Rosenblatt, HM; Smith, EO; Shearer, WT; Noroski, LM				Chinen, J; Rosenblatt, HM; Smith, EO; Shearer, WT; Noroski, LM			Long-term assessment of T-cell populations in DiGeorge syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunodeficiency; DiGeorge syndrome; 22q11 deletion; velocardiofacial syndrome; T-cell counts	VELOCARDIOFACIAL-SYNDROME; GRAVES-DISEASE; DELETION; IMMUNODEFICIENCY; SPECTRUM; LIFE	Patients with DiGeorge syndrome present with a broad range of T-cell deficiency. Partial DiGeorge syndrome (pDGS) is a preferred designation for patients with detectable T-cell function. Among immunology experts, there is no uniform opinion on the necessity of T-cell precautions for pDGS patients. Few studies have addressed the natural course of their immune function over time. Objective: The objective of this study was to describe the natural history of immune parameters in pDGS. Methods: We reviewed the medical records of 45 pDGS patients. Peripheral blood T-cell subsets counts and percentages were recorded at 1, 6, 12, 18, 24, 30, 48, 60, 72, 96, and 120 months of age, and the rates of change of T-cell measurements over the follow-up period (slopes) were calculated for each individual. Humoral immunity was evaluated by quantification of immunoglobulins and by testing antibody titers to recall antigens. Results: T-cell subsets counts from pDGS patients were generally lower than those of age-matched normal populations but were not severely depressed (ie, CD4(+) T-cell percentage less than 15%). The median of the slopes for CD3(+), CD4+, and CD8(+) T-cell percentages were -0.7%, -0.8%, and -0.1%/month, respectively, in the first year of age and 0.1%/month for each subpopulation from 12 to 120 months of age. Lymphoproliferative responses to phytohemagglutinin were adequate at all ages. Immunoglobulin deficiencies or inadequate production of specific antibodies were not detected. Conclusions: In our pDGS patient cohort, a significant deterioration of T-cell number or function did not occur over time. Clinical implications of this finding include the possibility of discontinuing T-cell deficiency precautions and frequency of reevaluations of pDGS patients with stable and adequate immune function.	Baylor Coll Med, Allergy & Immunol Sect, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Childrens Nutr Res Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Chinen, J (corresponding author), Texas Childrens Hosp, Allergy & Immunol Serv, 6621 Fannin St MC 1-3291, Houston, TX 77030 USA.			Shearer, William/0000-0002-2483-2130	NCRR NIH HHS [RR-00188] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		[Anonymous], 1994, MMWR Recomm Rep, V43, P1; BARRETT DJ, 1981, J CLIN LAB IMMUNOL, V6, P1; BASTIAN J, 1989, J PEDIATR-US, V115, P391, DOI 10.1016/S0022-3476(89)80837-6; Berend SA, 2000, AM J MED GENET, V91, P313, DOI 10.1002/(SICI)1096-8628(20000410)91:4<313::AID-AJMG13>3.3.CO;2-L; Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799; CONLEY ME, 1979, J PEDIATR-US, V94, P883, DOI 10.1016/S0022-3476(79)80207-3; DENNY T, 1992, JAMA-J AM MED ASSOC, V267, P1484, DOI 10.1001/jama.267.11.1484; DRISCOLL DA, 1992, AM J HUM GENET, V50, P924; ETZIONI A, 1989, EUR J PEDIATR, V150, P144; Greig F, 1996, J PEDIATR-US, V128, P563, DOI 10.1016/S0022-3476(96)70372-4; Jawad AF, 2001, J PEDIATR-US, V139, P715, DOI 10.1067/mpd.2001.118534; JUNKER AK, 1995, J PEDIATR-US, V127, P231, DOI 10.1016/S0022-3476(95)70300-4; Kawamura T, 2000, ENDOCR J, V47, P91, DOI 10.1507/endocrj.47.91; KOMFELD SJ, 2000, J ALLERGY CLIN IMMUN, V105, P983; Lindsay EA, 2001, NATURE, V410, P97, DOI 10.1038/35065105; LISCHNER HW, 1975, ORIGINAL ARTICLE SER, V11, P16; Markert ML, 1998, J PEDIATR-US, V132, P15, DOI 10.1016/S0022-3476(98)70478-0; Markert ML, 1999, NEW ENGL J MED, V341, P1180, DOI 10.1056/NEJM199910143411603; MAYUMI M, 1989, EUR J PEDIATR, V148, P512; MULLER W, 1989, EUR J PEDIATR, V149, P96, DOI 10.1007/BF01995856; Pierdominici M, 2000, CLIN EXP IMMUNOL, V121, P127, DOI 10.1046/j.1365-2249.2000.01247.x; PONG AJH, 1985, J PEDIATR-US, V106, P619, DOI 10.1016/S0022-3476(85)80087-1; SCHUBERT MS, 1992, ANN ALLERGY, V69, P231; SMITH CA, 1998, CLIN IMMUNOL IMMUNOP, V86, P141; Sullivan KE, 1999, CLIN DIAGN LAB IMMUN, V6, P906, DOI 10.1128/CDLI.6.6.906-911.1999; *US CENS BUR, 2001, HISP POP CENS 2000 B, P7	26	59	63	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					573	579		10.1067/mai.2003.165	http://dx.doi.org/10.1067/mai.2003.165			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642839				2022-12-18	WOS:000181639500020
J	Wamboldt, MZ; Laudenslager, M; Wamboldt, FS; Kelsay, K; Hewitt, J				Wamboldt, MZ; Laudenslager, M; Wamboldt, FS; Kelsay, K; Hewitt, J			Adolescents with atopic disorders have an attenuated cortisol response to laboratory stress	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cortisol; reactivity; HPA axis; atopy; adolescents	ENDOGENOUS CORTISOL; ASTHMA; CHILDREN; DERMATITIS; DISEASE; ATTACKS	Background: Patients with allergic disorders have been noted to have variations in cortisol patterns under natural conditions as well as a differential cortisol response to stress. Objective: The main goal of this study was to examine hypothalamic-pituitary-adrenal (HPA) axis differences in atopic adolescents. Methods: Subjects were a community sample of 202 adolescents (52% male; mean age, 16.2 years). Atopic status was determined by skin testing and clinical history. Saliva samples for cortisol assay were obtained 4 times during a "typical day" and at 4 time points during laboratory procedures. Results: One third of the sample (33%) had a clinical atopic disorder, primarily allergic rhinitis; 39% had positive skin test results without clinical symptoms; and 27% had no signs or symptoms of allergic disorders. There were no significant effects of atopic status on home cortisol patterns. Presence of clinical atopy was significantly (P < .05) associated with lower cortisol levels in response to laboratory stressors. Conclusions: Adolescents with a history of atopic illnesses had an attenuated cortisol response to the stress of laboratory procedures compared with adolescents with positive skin test results alone or nonatopic adolescents. An attenuated cortisol response to a stressor may help us understand the link between stress and exacerbation of atopic illness. (J Allergy Clin Immunol 2003;111:509-14.).	Natl Jewish Med & Res Ctr, Denver, CO USA; Univ Colorado, Ctr Hlth Sci, Dept Psychiat, Denver, CO USA; Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Boulder	Wamboldt, MZ (corresponding author), Natl Jewish Med & Res Ctr, Denver, CO USA.		Laudenslager, Mark L/D-1057-2018	Laudenslager, Mark L/0000-0002-9815-3026	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037373] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00051] Funding Source: Medline; NHLBI NIH HHS [R01HL45157] Funding Source: Medline; NIMH NIH HHS [MH37373, K8MH01486] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Buske-Kirschbaum A, 1998, ANN NY ACAD SCI, V840, P747, DOI 10.1111/j.1749-6632.1998.tb09613.x; Buske-Kirschbaum A, 2001, PSYCHOTHER PSYCHOSOM, V70, P6, DOI 10.1159/000056219; Cookson WOC, 2002, CHEST, V121, p7S, DOI 10.1378/chest.121.3_suppl.7S-a; Cydulka RK, 1998, ANN EMERG MED, V31, P558, DOI 10.1016/S0196-0644(98)70201-X; Fujitaka M, 2000, CLIN CHIM ACTA, V299, P101, DOI 10.1016/S0009-8981(00)00278-3; HERRSCHER RF, 1992, J CLIN INVEST, V90, P596, DOI 10.1172/JCI115898; KALLENBACH JM, 1990, EUR RESPIR J, V3, P171; Kauffmann F, 1999, AM J RESP CRIT CARE, V160, P1428, DOI 10.1164/ajrccm.160.4.16040_1; KING RM, 1991, J PSYCHOSOM RES, V35, P697, DOI 10.1016/0022-3999(91)90120-D; Landstra AM, 2002, AM J RESP CRIT CARE, V165, P708, DOI 10.1164/ajrccm.165.5.2102115; Lundback B, 1998, CLIN EXP ALLERGY, V28, P3; McEwen BS, 1998, ANN NY ACAD SCI, V840, P33, DOI 10.1111/j.1749-6632.1998.tb09546.x; Nomura S, 1997, EUR J PEDIATR, V156, P323, DOI 10.1007/s004310050610; Peebles RS, 2000, CLIN EXP ALLERGY, V30, P1257; Rietveld S, 2000, CLIN EXP ALLERGY, V30, P1058; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; Schleimer Robert P., 2000, Journal of Allergy and Clinical Immunology, V106, pS270; Tonelli L, 2001, IMMUNOL REV, V184, P203, DOI 10.1034/j.1600-065x.2001.1840118.x; Tromp S W, 1968, Rev Allergy, V22, P1027; Wamboldt MZ, 2001, J AM ACAD CHILD PSY, V40, P945, DOI 10.1097/00004583-200108000-00017; Wright RJ, 1998, THORAX, V53, P1066, DOI 10.1136/thx.53.12.1066; Young SE, 2000, AM J MED GENET, V96, P684, DOI 10.1002/1096-8628(20001009)96:5<684::AID-AJMG16>3.0.CO;2-G; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4	23	59	61	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					509	514		10.1067/mai.2003.140	http://dx.doi.org/10.1067/mai.2003.140			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642830				2022-12-18	WOS:000181639500011
J	Antony, AB; Tepper, RS; Mohammed, KA				Antony, AB; Tepper, RS; Mohammed, KA			Cockroach extract antigen increases bronchial airway epithelial permeability	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchial airway epithelial cells; cockroach extract antigen; vascular endothelial growth factor; bronchial epithelial permeability	ENDOTHELIAL GROWTH-FACTOR; MICROVASCULAR PERMEABILITY; ALLERGEN EXPOSURE; FACTOR VEGF; ASTHMA; EXPRESSION; CHILDREN; INFLAMMATION; INDUCTION; DISEASE	Background: The bronchial epithelial cells of airways are subject to recurrent environmental injury throughout the life of an individual. Recently, a high incidence of asthma has been reported in inner-city children. The increased incidence of asthma in inner-city children is thought to be caused, in part, by frequent exposure to allergens of the common household pest the cockroach. Objective: We sought to investigate whether cockroach extract antigen (CrAg) induces vascular permeability factor, also known as vascular endothelial growth factor (VEGF), and whether it increases permeability in bronchial airway epithelial cells (BAECs). Methods: We estimated CrAg-induced VEGF release in BAECs by using an ELISA and VEGF mRNA expression by using an RT-PCR reaction. The influence of CrAg on BAEC barrier function was estimated by measuring electrical resistance with an electric cell substrate impedance-sensing system. Results: Our results demonstrate that CrAg induces VEGF release in BAECs in a time-dependent manner. The VEGF induction was also confirmed by means of VEGF mRNA expression in CrAg-stimulated BAECs. CrAg decreased electrical resistance across BAEC monolayers. The maximum decrease in electrical resistance was noticed 6 hours after activation and reached a plateau thereafter. Neutralizing antibodies to VEGF significantly inhibited the decrease in BAEC electrical resistance caused by CrAg. Conclusions: These data suggest that CrAg induces VEGF release in BAECs and alters bronchial airway permeability.	Vet Affairs Med Ctr, Dept Med, Div Pulm Allergy Crit Care & Occupat Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46204 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Indiana University System; Indiana University-Purdue University Indianapolis	Mohammed, KA (corresponding author), Vet Affairs Med Ctr, Dept Med, Div Pulm Allergy Crit Care & Occupat Med, 1481 W 10th St,11P, Indianapolis, IN 46202 USA.							Alp H, 1999, J ALLERGY CLIN IMMUN, V103, pS106; BROWN LF, 1997, EXS, V79, P233; Chapoval AI, 2001, NAT IMMUNOL, V2, P269, DOI 10.1038/85339; CHUNG KF, 1990, EUR RESPIR J, V3, P329; Cohen AW, 1999, AM J PHYSIOL-HEART C, V277, pH2038, DOI 10.1152/ajpheart.1999.277.5.H2038; Fernandez-Caldas E, 2001, ANN ALLERG ASTHMA IM, V87, P196, DOI 10.1016/S1081-1206(10)62225-9; Ferrara N, 1997, EXS, V79, P209; FICK RB, 1987, J APPL PHYSIOL, V63, P1147, DOI 10.1152/jappl.1987.63.3.1147; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; HOGG JC, 1982, CHEST, V82, pS8, DOI 10.1378/chest.82.1_Supplement.8S; ITO A, 1995, PATHOL INT, V45, P715, DOI 10.1111/j.1440-1827.1995.tb03387.x; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; Laitinen A, 1990, Eur Respir J Suppl, V12, p658s; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; Lee CG, 2000, AM J RESP CELL MOL, V23, P662, DOI 10.1165/ajrcmb.23.5.4188; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li XR, 2001, INT J BIOCHEM CELL B, V33, P421, DOI 10.1016/S1357-2725(01)00027-9; Lichtenbeld HC, 1999, MICROVASC RES, V57, P357, DOI 10.1006/mvre.1998.2140; MENDOZA J, 1970, ANN ALLERGY, V28, P159; Mohammed KA, 2001, AM J PHYSIOL-LUNG C, V281, pL119, DOI 10.1152/ajplung.2001.281.1.L119; Mohammed KA, 2000, J INFECT DIS, V181, P1693, DOI 10.1086/315422; Nagura S, 2001, HUM PATHOL, V32, P10, DOI 10.1053/hupa.2001.21139; Nicosia RF, 1998, AM J PATHOL, V153, P11, DOI 10.1016/S0002-9440(10)65539-3; Nishi JI, 2000, LEUKEMIA LYMPHOMA, V38, P387, DOI 10.3109/10428190009087030; Pomes A, 2002, AM J RESP CRIT CARE, V165, P391, DOI 10.1164/ajrccm.165.3.2104027; REGNARD J, 1992, RESP MED, V86, P179, DOI 10.1016/S0954-6111(06)80051-X; ROBERTS WG, 1995, J CELL SCI, V108, P2369; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218	30	59	61	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2002	110	4					589	595		10.1067/mai.2002.127798	http://dx.doi.org/10.1067/mai.2002.127798			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	602JJ	12373266				2022-12-18	WOS:000178501900008
J	Sussman, GL; Beezhold, DH; Kurup, VP				Sussman, GL; Beezhold, DH; Kurup, VP			Allergens and natural rubber proteins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on Natural Rubber Latex Sensitivity	FEB 09-10, 2001	SAN FRANCISCO, CA	Malaysian Rubber Res Inst		natural rubber latex; latex allergenic proteins; health care workers; children with spina bifida; skin prick test	HEV B 1; ELONGATION-FACTOR; SPINA-BIFIDA; LATEX ALLERGY; MOLECULAR-CLONING; MAJOR ALLERGEN; CELL EPITOPES; BRASILIENSIS; IGE; IDENTIFICATION	Background: Allergy to natural rubber latex (NRL) results from exposure to proteins derived from Hevea brasiliensis. Type I latex hypersensitivity is observed in certain occupational and other high-risk groups with frequent exposure to NRL products. This includes health care workers (HCWs), workers in the latex industry, children with spina bifida, and atopic individuals. Objectives: Early reliable diagnosis and avoidance are required for better patient care. Standardized reagents are not presently available for in vitro and in vivo testing and treatment of patients with latex allergy. However, a number of allergens have been isolated and characterized from Hevea latex and NRL products. Currently, a total of 11 major and minor allergens are designated by the International Allergen Nomenclature Committee. This article reviews the structural and functional characteristics of these latex allergenic proteins. Results: NRL-allergenic proteins include those involved in the biosynthesis of polyisoprene and coagulation of latex rubber elongation factor, small rubber particle protein, prohevein, and patatin. Pathogenesis-related proteins include beta-1,3-glucanases, chitinases, and hevamine; and the structural proteins include microhelix protein complex, proline-rich protein, profilins, enolases, and manganese superoxide dismutase. Recombinant allergens demonstrated skin test reactivity in patients with latex allergy. The minimal level of skin test reactivity was about 70 pg/mL for NRL and 1 ng/mL for recombinant allergens. The use of selected recombinant latex allergens (Hev b 5, Hev b 6, and Hev b 7) in skin prick tests identified 93% of allergic individuals, mainly health care workers. Conclusions: Recombinant latex allergens are clinically reactive and can be produced in a standardized manner, which could potentially provide safe and sensitive reagents for the diagnosis and treatment of type I latex allergy.	Univ Toronto, Toronto, ON, Canada; Guthrie Res Inst, Dept Immunobiol, Sayre, PA USA; Med Coll Wisconsin, Dept Pediat, Div Allergy Immunol, Milwaukee, WI 53226 USA	University of Toronto; Medical College of Wisconsin	Sussman, GL (corresponding author), 202 St Clair Ave W, Toronto, ON M4V 1R2, Canada.			Beezhold, Donald/0000-0001-5543-5747				ACHATZ G, 1995, MOL IMMUNOL, V32, P213, DOI 10.1016/0161-5890(94)00108-D; Akasawa A, 1996, J BIOL CHEM, V271, P25389, DOI 10.1074/jbc.271.41.25389; Akasawa A., 1996, Journal of Allergy and Clinical Immunology, V97, P321, DOI 10.1016/S0091-6749(96)80771-8; ALENIUS H, 1995, CLIN EXP ALLERGY, V25, P659, DOI 10.1111/j.1365-2222.1995.tb01114.x; ALENIUS H, 1994, J LAB CLIN MED, V123, P712; ATTANYAKA DPSTG, 1991, PLANT MOL BIOL, V16, P1079, DOI 10.1007/BF00016080; Banerjee B, 1997, J IMMUNOL, V159, P5724; Blanco C, 1999, J ALLERGY CLIN IMMUN, V103, P507, DOI 10.1016/S0091-6749(99)70478-1; Bohle B, 2000, J IMMUNOL, V164, P4393, DOI 10.4049/jimmunol.164.8.4393; Bokma E, 1997, FEBS LETT, V411, P161, DOI 10.1016/S0014-5793(97)00682-0; BREITENEDER H, 1998, ALLERGY CLIN IMMUNOL, V10, P101; Breton F., 1995, Journal of Natural Rubber Research, V10, P37; BROEKAERT W, 1990, P NATL ACAD SCI USA, V87, P7633, DOI 10.1073/pnas.87.19.7633; Chen ZP, 1997, J ALLERGY CLIN IMMUN, V100, P684, DOI 10.1016/S0091-6749(97)70174-X; CHYE ML, 1995, PLANT MOL BIOL, V29, P397, DOI 10.1007/BF00043663; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; de Silva HD, 2000, J ALLERGY CLIN IMMUN, V105, P1017, DOI 10.1067/mai.2000.105806; DENNIS MS, 1989, J BIOL CHEM, V264, P18618; DENNIS MS, 1989, J BIOL CHEM, V264, P18608; DURING K, 1993, PLANT MOL BIOL, V23, P209, DOI 10.1007/BF00021432; Fuchs T, 1997, J ALLERGY CLIN IMMUN, V100, P356, DOI 10.1016/S0091-6749(97)70249-5; GIDROL X, 1994, J BIOL CHEM, V269, P9278; GRAHAM LS, 1994, CAN J BOT, V72, P1057, DOI 10.1139/b94-132; Hemmann S, 1998, EUR J IMMUNOL, V28, P1155, DOI 10.1002/(SICI)1521-4141(199804)28:04&lt;1155::AID-IMMU1155&gt;3.0.CO;2-6; Johnson BD, 1999, INT ARCH ALLERGY IMM, V120, P270, DOI 10.1159/000024279; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; Kelly KJ, 1990, MMWR-MORBID MORTAL W, V40, P437; Kostyal DA, 1998, CLIN EXP IMMUNOL, V112, P355; Kurup VP, 1996, INT ARCH ALLERGY IMM, V109, P58, DOI 10.1159/000237232; Kurup VP, 2000, CLIN EXP ALLERGY, V30, P359; LU LJ, 1995, J IMMUNOL, V155, P2721; MARTIN MN, 1991, PLANT PHYSIOL, V95, P469, DOI 10.1104/pp.95.2.469; MIAO ZH, 1993, PLANT MOL BIOL, V23, P267, DOI 10.1007/BF00029003; Nieto A, 1998, J ALLERGY CLIN IMMUN, V101, pS207; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; Oh SK, 1999, J BIOL CHEM, V274, P17132, DOI 10.1074/jbc.274.24.17132; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; Posch A, 1999, CLIN EXP ALLERGY, V29, P667, DOI 10.1046/j.1365-2222.1999.00502.x; Posch A, 1997, J ALLERGY CLIN IMMUN, V99, P385, DOI 10.1016/S0091-6749(97)70057-5; Raulf-Heimsoth M, 1998, CLIN EXP ALLERGY, V28, P339; RaulfHeimsoth M, 1996, J ALLERGY CLIN IMMUN, V98, P640, DOI 10.1016/S0091-6749(96)70098-2; Sanchez-Monge R, 1999, CLIN EXP ALLERGY, V29, P673, DOI 10.1046/j.1365-2222.1999.00526.x; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; Slater JE, 1996, J BIOL CHEM, V271, P25394, DOI 10.1074/jbc.271.41.25394; Sowka S, 1998, J BIOL CHEM, V273, P28091, DOI 10.1074/jbc.273.43.28091; Sowka S, 1998, EUR J BIOCHEM, V255, P213, DOI 10.1046/j.1432-1327.1998.2550213.x; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; STRICKLAND JA, 1995, PLANT PHYSIOL, V109, P667, DOI 10.1104/pp.109.2.667; SUBRAMANIAM A, 1995, IMMUNOL ALLERGY CLIN, V15, P1; Sunderasan E., 1996, J RUBBER RES, V10, P82; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; VALLIER P, 1995, CLIN EXP ALLERGY, V25, P332, DOI 10.1111/j.1365-2222.1995.tb01051.x; VANSCHELTINGA ACT, 1994, STRUCTURE, V2, P1181, DOI 10.1016/S0969-2126(94)00120-0; Wagner B, 1999, J ALLERGY CLIN IMMUN, V104, P1084, DOI 10.1016/S0091-6749(99)70093-X; WRIGHT CS, 1986, J BIOL CHEM, V261, P7191; YAGAMI T, 1995, J ALLERGY CLIN IMMUN, V96, P677, DOI 10.1016/S0091-6749(95)70267-9; Yagami T, 1998, J ALLERGY CLIN IMMUN, V101, P379, DOI 10.1016/S0091-6749(98)70251-9; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0; Yip L, 2000, INT ARCH ALLERGY IMM, V121, P292, DOI 10.1159/000024342; Yusof F., 1998, Journal of Rubber Research, V1, P95	63	59	66	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2		S			S33	S39		10.1067/mai.2002.124969	http://dx.doi.org/10.1067/mai.2002.124969			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	586ET	12170241				2022-12-18	WOS:000177572200006
J	He, F; Morita, H; Hashimoto, H; Hosoda, M; Kurisaki, JI; Ouwehand, AC; Isolauri, E; Benno, Y; Salminen, S				He, F; Morita, H; Hashimoto, H; Hosoda, M; Kurisaki, JI; Ouwehand, AC; Isolauri, E; Benno, Y; Salminen, S			Intestinal Bifidobacterium species induce varying cytokine production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INFANTS; MICROFLORA; HEALTHY		Takanashi Milk Prod Co Ltd, Tech Res Lab, Yokohama, Kanagawa, Japan; Natl Inst Agrobiol Sci, Tsukuba, Ibaraki, Japan; Univ Turku, Dept Biochem, FIN-20014 Turku, Finland; Univ Turku, Dept Food Chem, FIN-20014 Turku, Finland; Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland; RIKEN, JCM, Wako, Saitama 35101, Japan	National Institute of Agrobiological Sciences - Japan; Finland National Institute for Health & Welfare; University of Turku; University of Turku; University of Turku; RIKEN	He, F (corresponding author), Takanashi Milk Prod Co Ltd, Tech Res Lab, Yokohama, Kanagawa, Japan.			Ouwehand, Arthur/0000-0001-8348-0633				Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; He F, 2001, FEMS IMMUNOL MED MIC, V30, P43, DOI 10.1016/S0928-8244(00)00232-7; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kirjavainen PV, 2001, FEMS IMMUNOL MED MIC, V32, P1, DOI 10.1111/j.1574-695X.2001.tb00526.x; Ouwehand AC, 2001, J ALLERGY CLIN IMMUN, V108, P144, DOI 10.1067/mai.2001.115754; Park SY, 1999, INT J FOOD MICROBIOL, V46, P231, DOI 10.1016/S0168-1605(98)00197-4	7	59	64	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					1035	1036		10.1067/mai.2002.124894	http://dx.doi.org/10.1067/mai.2002.124894			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063538				2022-12-18	WOS:000176442700024
J	Adkinson, NF; Essayan, D; Gruchalla, R; Haggerty, H; Kawabata, T; Sandler, JD; Updyke, L; Shear, NH; Wierda, D				Adkinson, NF; Essayan, D; Gruchalla, R; Haggerty, H; Kawabata, T; Sandler, JD; Updyke, L; Shear, NH; Wierda, D		The Hlth & Environm Sci Inst Task	Task Force Report: Future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adverse drug reactions; drug allergy; drug development; drug hypersensitivity; immunotoxicology	LYMPH-NODE ASSAY; T-CELLS; CONTACT ALLERGY; ANIMAL-MODELS; HLA-DR; SENSITIZATION; AUTOIMMUNE; ANTIGENS; CD4(+); SKIN	Immune-mediated drug hypersensitivity reactions (IDHR) have a significant impact on clinical practice, drug development, and public health. However, research to understand IDHR mechanisms and to develop diagnostic and predictive tests has been limited. To stimulate more research, a task force with representatives from the key stakeholders (research clinicians, regulatory scientists, and immunotoxicologists from the pharmaceutical industry) was assembled to identify critical data gaps and opportunities and to make recommendations on how to overcome some of the barriers to IDHR research and address research needs. It is hoped that this report will act as a springboard for future discussions and progress toward increased funding and development of organizational structures for IDHR research.	ILSI Hlth & Environm Sci Inst, Washington, DC 20036 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; US FDA, Rockville, MD 20857 USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Bristol Myers Squibb Co, Syracuse, NY USA; Pfizer Global Res & Dev, Groton, CT USA; Univ Toronto, Toronto, ON, Canada; Eli Lilly & Co, Greenfield, IN USA	Johns Hopkins University; US Food & Drug Administration (FDA); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Bristol-Myers Squibb; Pfizer; University of Toronto; Eli Lilly	Sandler, JD (corresponding author), ILSI Hlth & Environm Sci Inst, 1126 16th St NW, Washington, DC 20036 USA.	dsandler@ilsi.org						ADKINSON NF, 1984, J ALLERGY CLIN IMMUN, V74, P567, DOI 10.1016/0091-6749(84)90108-8; Ahmad N, 1996, SKIN PHARMACOL, V9, P231; Albers R, 1997, TOXICOL APPL PHARM, V143, P102, DOI 10.1006/taap.1996.8078; ALBERS R, 1996, TOXICOLOGIST, V30, P62; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; BARKE KE, 1993, LIFE SCI, V53, P1391, DOI 10.1016/0024-3205(93)90581-M; Basketter DA, 1995, FOOD CHEM TOXICOL, V33, P1051, DOI 10.1016/0278-6915(95)00073-9; BATCHELOR JR, 1980, LANCET, V1, P1107; BATES DW, 1997, JAMA-J AM MED ASSOC, V29, P307; BAYARD PJ, 1992, J ACQ IMMUN DEF SYND, V5, P1237; BEISER SM, 1967, METHODS IMMUNOLOGY I, V1, P120; Bigazzi PE, 1997, TOXICOLOGY, V119, P1, DOI 10.1016/S0300-483X(96)03591-3; BLOKSMA N, 1995, CRIT REV TOXICOL, V25, P369, DOI 10.3109/10408449509049338; BORDA IT, 1968, J AMER MED ASSOC, V205, P645, DOI 10.1001/jama.205.9.645; *BOST COLL DRUG SU, 1973, JAMA-J AM MED ASSOC, V224, P613; Brewer T, 1999, JAMA-J AM MED ASSOC, V281, P824, DOI 10.1001/jama.281.9.824; BROCKLEHURST WE, 1978, HDB EXPT IMMUNOLOGY, P211; CARR A, 1991, J CLIN IMMUNOL, V11, P55, DOI 10.1007/BF00917741; CAULSON EJ, 1976, METHODS IMMUNOLOGY I, P1; CAVANI A, 1995, J IMMUNOL, V154, P1232; Choquet-Kastylevsky G, 1998, TOXICOLOGY, V129, P27, DOI 10.1016/S0300-483X(98)00060-2; CHRIST DD, 1988, DRUG METAB DISPOS, V16, P135; CLARK DWJ, 1985, DRUGS, V29, P342, DOI 10.2165/00003495-198529040-00003; CLARKE JB, 1995, INT ARCH ALLERGY IMM, V108, P24, DOI 10.1159/000237113; CLASSEN DC, 1997, JAMA-J AM MED ASSOC, V29, P301; Croft M, 1997, CRIT REV IMMUNOL, V17, P89, DOI 10.1615/CritRevImmunol.v17.i1.40; Cumberbatch M, 1997, IMMUNOLOGY, V92, P388, DOI 10.1046/j.1365-2567.1997.00360.x; Dearman RJ, 1999, J APPL TOXICOL, V19, P299, DOI 10.1002/(SICI)1099-1263(199909/10)19:5<299::AID-JAT591>3.0.CO;2-C; DESWARTE RD, 1984, J ALLERGY CLIN IMMUN, V74, P209, DOI 10.1016/0091-6749(84)90246-X; GERBERICK GF, 1993, AM J CONTACT DERMATI, V4, P205; GILLILAND BC, 1991, IMMUNOL ALLERGY CLIN, V11, P525; GLEICHMANN H, 1981, CLIN IMMUNOL IMMUNOP, V18, P203, DOI 10.1016/0090-1229(81)90026-X; Griem P, 1998, EUR J IMMUNOL, V28, P1941, DOI 10.1002/(SICI)1521-4141(199806)28:06<1941::AID-IMMU1941>3.0.CO;2-H; Griem P, 1998, IMMUNOL TODAY, V19, P133, DOI 10.1016/S0167-5699(97)01219-X; Hostynek JJ, 1996, CURR PROBL DERMATOL, V25, P18; IDSOE O, 1968, B WORLD HEALTH ORGAN, V38, P159; KAROL MH, 1994, EUR RESPIR J, V7, P555, DOI 10.1183/09031936.94.07030555; KATSUTANI N, 1992, INT J IMMUNOPHARMACO, V14, P681, DOI 10.1016/0192-0561(92)90131-4; KERNS DL, 1973, AM J DIS CHILD, V125, P187, DOI 10.1001/archpedi.1973.04160020023004; Kiefer H, 1979, IMMUNOLOGICAL METHOD, V1, P137; Kim YO, 2000, DRUG INF J, V34, P25, DOI 10.1177/009286150003400103; Kimber I, 1997, HUM ECOL RISK ASSESS, V3, P385, DOI 10.1080/10807039709383695; KINNAIRD A, 1989, INT ARCH ALLER A IMM, V89, P202, DOI 10.1159/000234947; Kosuda LL, 1996, EXPT IMMUNOTOXICOLOG, P419; Kubicka-Muranyi M., 1994, Immunobiology, V191, P225; Kurtz KM, 2000, J ALLERGY CLIN IMMUN, V105, P184, DOI 10.1016/S0091-6749(00)90196-9; Larrey D, 1997, J HEPATOL, V26, P12, DOI 10.1016/S0168-8278(97)80492-8; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Leeder JS, 1998, PHARMACOGENETICS, V8, P211, DOI 10.1097/00008571-199806000-00004; LEHMAN B, 1997, PAREXELS PHARM R D S, P50; LEWELLYN GC, 2000, TOXICOLOGIST, V54, P197; MAGNUSSON B, 1969, J INVEST DERMATOL, V52, P268, DOI 10.1038/jid.1969.42; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462; MOSELEY E K, 1991, Journal of Allergy and Clinical Immunology, V87, P226, DOI 10.1016/0091-6749(91)91631-3; MOTLEY RJ, 1989, CONTACT DERMATITIS, V21, P285, DOI 10.1111/j.1600-0536.1989.tb03221.x; Naor D, 1977, Prog Allergy, V22, P107, DOI 10.1159/000314206; Olson H, 2000, REGUL TOXICOL PHARM, V32, P56, DOI 10.1006/rtph.2000.1399; OVARY Z, 1975, INT ARCH ALLER A IMM, V48, P16, DOI 10.1159/000231289; Padovan E, 1997, EUR J IMMUNOL, V27, P1303, DOI 10.1002/eji.1830270602; Park BE, 1998, CHEM RES TOXICOL, V11, P969, DOI 10.1021/tx980058f; PAYNE MP, 1994, J CHEM INF COMP SCI, V34, P154, DOI 10.1021/ci00017a019; Raucy JL, 1999, J BIOCHEM MOL TOXIC, V13, P223, DOI 10.1002/(SICI)1099-0461(1999)13:3/4<223::AID-JBT14>3.0.CO;2-Z; Rawlins MD, 1991, TXB ADVERSE DRUG REA, P18; ROBINSON MK, 1990, TOXICOLOGY, V61, P91, DOI 10.1016/0300-483X(90)90012-6; Romano A, 1999, J ALLERGY CLIN IMMUN, V103, P1186, DOI 10.1016/S0091-6749(99)70197-1; ROMANO A, 1995, ALLERGY, V50, P113; Romano A, 1998, ANN ALLERG ASTHMA IM, V80, P433, DOI 10.1016/S1081-1206(10)62997-3; Rose N, 1998, AUTOIMMUNE DIS; ROUJEAU JC, 1987, ARCH DERMATOL, V123, P1171, DOI 10.1001/archderm.123.9.1171; SARLO K, 1992, FUND APPL TOXICOL, V18, P107, DOI 10.1016/0272-0590(92)90202-S; Schnyder B, 2000, CLIN EXP ALLERGY, V30, P590; Schnyder B, 2000, J IMMUNOL, V164, P6647, DOI 10.4049/jimmunol.164.12.6647; SULLIVAN TJ, 1989, J ALLERGY CLIN IMMUN, V83, P270; Tran C, 1998, J CLIN PHARMACOL, V38, P1003, DOI 10.1177/009127009803801103; TSUTSUI H, 1992, J IMMUNOL, V149, P706; Wang B, 1999, J IMMUNOL, V162, P277; Ware JA, 1998, CHEM RES TOXICOL, V11, P164, DOI 10.1021/tx970182j; WEAVER JL, 2000, TOXICOLOGIST, V49, P120; WEAVER JL, 1999, TOXICOL SCI, V48, P316; Weltzien HU, 1996, TOXICOLOGY, V107, P141, DOI 10.1016/0300-483X(95)03253-C; WOOLEY PH, 1980, NEW ENGL J MED, V303, P300, DOI 10.1056/NEJM198008073030602; Zanni MP, 1997, J IMMUNOL, V158, P1139	83	59	63	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					S461	S478		10.1067/mai.2002.122214	http://dx.doi.org/10.1067/mai.2002.122214			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11897992				2022-12-18	WOS:000174586400033
J	Schlievert, PM				Schlievert, PM			Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	IVIG Advisory Meeting	OCT 26-29, 2000	SANTA BARBARA, CA	Bayer Biol		superantigens; staphylococci; streptococci; enterotoxins; toxic shock syndrome; scarlet fever toxins; Kawasaki syndrome; atopic dermatitis; psoriasis	PYROGENIC EXOTOXIN; TOXOIDS	Pyrogenic toxin superantigens comprise a large family of exotoxins made by Staphylococcus aureus and group A streptococci. These toxins include toxic shock syndrome toxin-1, the staphylococcal enterotoxins, and the streptococcal pyrogenic exotoxins (synonyms: scarlet fever toxins and erythrogenic toxins), all of which have the ability to cause toxic shock syndromes and related illnesses. These toxins have a similar three-dimensional structure that allows them to interact with relatively invariant regions of major histocompatibility complex class II molecules on the surface of antigen-presenting cells and with certain variable regions of the T-cell receptor-beta chain. The consequence of these interactions (and other immunobiological properties of the toxins) is the exaggerated release of bioactive cytokines. The latter molecules are responsible for the clinical signs of illness associated with these toxins.	Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Schlievert, PM (corresponding author), Univ Minnesota, Sch Med, Dept Microbiol, 410 Delaware St SE, Minneapolis, MN 55455 USA.			Schlievert, Patrick/0000-0001-8314-9369				[Anonymous], 1999, JAMA, V282, P1123; BOHACH GA, 1990, CRIT REV MICROBIOL, V17, P251, DOI 10.3109/10408419009105728; Dinges MM, 2000, CLIN MICROBIOL REV, V13, P16, DOI 10.1128/CMR.13.1.16-34.2000; Earhart CA, 1998, BIOCHEMISTRY-US, V37, P7194, DOI 10.1021/bi9721896; Kaul R, 1999, CLIN INFECT DIS, V28, P800, DOI 10.1086/515199; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; Leung DYM, 1998, ARTHRITIS RHEUM-US, V41, P1538, DOI 10.1002/1529-0131(199809)41:9<1538::AID-ART3>3.0.CO;2-M; Li HM, 1999, ANNU REV IMMUNOL, V17, P435, DOI 10.1146/annurev.immunol.17.1.435; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; McCormick JK, 2000, J IMMUNOL, V165, P2306, DOI 10.4049/jimmunol.165.4.2306; PRASAD GS, 1993, BIOCHEMISTRY-US, V32, P13762, DOI 10.1021/bi00213a001; Roggiani M, 2000, INFECT IMMUN, V68, P5011, DOI 10.1128/IAI.68.9.5011-5017.2000	12	59	65	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4		S			S107	S110		10.1067/mai.2001.117820	http://dx.doi.org/10.1067/mai.2001.117820			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	487KL	11586276	Bronze			2022-12-18	WOS:000171874200006
J	Schmidt, BMW; Kusma, M; Feuring, M; Timmer, WE; Neuhauser, M; Bethke, T; Stuck, BA; Hormann, K; Wehling, M				Schmidt, BMW; Kusma, M; Feuring, M; Timmer, WE; Neuhauser, M; Bethke, T; Stuck, BA; Hormann, K; Wehling, M			The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; PDE4 inhibitors; asthma; rhinomanometry	INTRANASAL FLUTICASONE PROPIONATE; NASAL AIR-FLOW; DIFFERENTIAL REGULATION; PDE INHIBITORS; ASTHMA; NEUTROPHILS; SUPPRESSION; ANTAGONISTS; EXPRESSION; ISOZYMES	Background: The beneficial effects of phosphodiesterase 4 (PDE4) inhibitors in allergic asthma have been shown in previous preclinical and clinical studies. Because allergic rhinitis and asthma share several epidemiologic and pathophysiologic factors, PDE4 inhibitors might also be effective in allergic rhinitis. Objective: The main objective of this study was to investigate the efficacy of oral roflumilast (500 mug/day) in allergic rhinitis. Methods: In a randomized, placebo-controlled, double-blinded, crossover study, 25 subjects (16 male, 9 female; median age, 28 years) with histories of allergic rhinitis but asymptomatic at screening received roflumilast (500 pg once daily) and placebo for 9 days each with a washout period of at least 14 days in between treatment periods. In each of the treatment periods, controlled intranasal allergen provocation with pollen extracts was performed daily beginning the third day of treatment, each time approximately 2 hours after study drug administration. Five and 30 minutes after each allergen provocation, rhinal airflow was measured by means of anterior rhinomanometry and the subjective symptoms obstruction, itching, and rhinorrhea were assessed by means of a standardized visual analog scale. Results: Rhinal airflow improved almost consistently during the 9 days of roflumilast treatment, and it was significantly higher at study day 9 on roflumilast in comparison with placebo, a result also found for itching and rhinorrhea. With respect to the subjective obstruction score, a significant difference in comparison with placebo could be demonstrated within 4 days. Conclusion: This study shows that a PDE4 inhibitor, roflumilast effectively controls symptoms of allergic rhinitis. Thus PDE4 inhibitors might be a future treatment option not only in allergic asthma but also in allergic rhinitis or the combination of the 2 diseases.	Univ Heidelberg, Mannheim Univ Hosp, Fac Clin Med, Inst Clin Pharmacol, D-68167 Mannheim, Germany; Byk Gulden Lomberg GmbH, Constance, Germany; Univ Heidelberg, Mannheim Univ Hosp, Dept Otorhinolaryngol, D-68167 Mannheim, Germany	Ruprecht Karls University Heidelberg; Altana; Ruprecht Karls University Heidelberg	Wehling, M (corresponding author), Univ Heidelberg, Mannheim Univ Hosp, Fac Clin Med, Inst Clin Pharmacol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.							[Anonymous], 1997, ICH HARMONISED TRIPA; Au BT, 1998, BRIT J PHARMACOL, V123, P1260, DOI 10.1038/sj.bjp.0701723; BAUER P, 1991, STAT MED, V10, P871, DOI 10.1002/sim.4780100609; Bielekova B, 2000, J IMMUNOL, V164, P1117, DOI 10.4049/jimmunol.164.2.1117; Blease K, 1998, BRIT J PHARMACOL, V124, P229, DOI 10.1038/sj.bjp.0701833; BOEQUET J, 1998, ALLERGY S, V53, pS1; Bundschuh DS, 2001, J PHARMACOL EXP THER, V297, P280; Corren J, 1997, J ALLERGY CLIN IMMUN, V99, pS781, DOI 10.1016/S0091-6749(97)70127-1; Crocker IC, 1998, J ALLERGY CLIN IMMUN, V102, P797, DOI 10.1016/S0091-6749(98)70020-X; Danielsson J, 1997, ALLERGY, V52, P331, DOI 10.1111/j.1398-9995.1997.tb00999.x; Day JH, 1996, J ALLERGY CLIN IMMUN, V97, P1050, DOI 10.1016/S0091-6749(96)70257-9; Dousa MK, 1997, CLIN NEPHROL, V47, P187; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; Giembycz MA, 2000, DRUGS, V59, P193, DOI 10.2165/00003495-200059020-00004; GIEMBYCZ MA, 1997, ALLERGY ALLERGIC DIS, P531; Hatzelmann A, 2001, J PHARMACOL EXP THER, V297, P267; Jones TR, 1998, CAN J PHYSIOL PHARM, V76, P210, DOI 10.1139/cjpp-76-2-210; Kozma CM, 1996, PHARMACOECONOMICS, V10, P4, DOI 10.2165/00019053-199610010-00002; Kyrein HJ, 1996, ARZNEIMITTEL-FORSCH, V46, P794; Onrust SV, 1998, DRUGS, V56, P725, DOI 10.2165/00003495-199856040-00018; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; Schmidt BMW, 1999, J CLIN PHARMACOL, V39, P1062, DOI 10.1177/00912709922011836; Schudt C, 1999, PULM PHARMACOL THER, V12, P123, DOI 10.1006/pupt.1999.0182; SENN S, 1993, CROSS TRIALS CLIN RE; SIBBALD B, 1991, THORAX, V46, P895, DOI 10.1136/thx.46.12.895; Simola M, 1997, CLIN OTOLARYNGOL, V22, P260, DOI 10.1046/j.1365-2273.1997.00033.x; SMALL P, 1991, ANN ALLERGY, V67, P520; Souness JE, 1999, BIOCHEM PHARMACOL, V58, P991, DOI 10.1016/S0006-2952(99)00176-8; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; VERGHESE MW, 1995, J PHARMACOL EXP THER, V272, P1313; Wang P, 1999, MOL PHARMACOL, V56, P170, DOI 10.1124/mol.56.1.170; Weiner JM, 1998, BMJ-BRIT MED J, V317, P1624, DOI 10.1136/bmj.317.7173.1624; Wiseman LR, 1997, DRUGS, V53, P885, DOI 10.2165/00003495-199753050-00014; Yaniv E, 1997, AM J OTOLARYNG, V18, P29, DOI 10.1016/S0196-0709(97)90045-4	35	59	75	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					530	536						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590377				2022-12-18	WOS:000171760300010
J	KleinJan, A; McEuen, AR; Dijkstra, MD; Buckley, MG; Walls, AF; Fokkens, WJ				KleinJan, A; McEuen, AR; Dijkstra, MD; Buckley, MG; Walls, AF; Fokkens, WJ			Basophil and eosinophil accumulation and mast cell degranulation in the nasal mucosa of patients with hay fever after local allergen provocation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen provocation; allergic rhinitis; basophils; chymase; eosinophils; hay fever; grass pollen; mast cells; nasal mucosa; tryptase	METACHROMATIC CELLS; INDUCED RHINITIS; IN-VIVO; TRYPTASE; CHYMASE; CHALLENGE; IDENTIFICATION; NEUTROPHILS; ANTIBODIES; HISTAMINE	Background: Basophils and mast cells have certain similarities and are believed to be important in upper and lower respiratory allergy. Objective: We sought to apply immunohistology to investigate the distribution and numbers of mast cells and basophils in the nasal mucosa after allergen provocation, Methods: Allergen challenge with grass pollen was performed in 9 patients with seasonal allergic rhinitis out of the hay fever season. Nasal biopsy specimens were taken before and approximately 1 hour, 24 hours, and 1 week after intranasal allergen provocation, We determined relative numbers and their phenotypic characteristics by using mAbs specific for tryptase, chymase, IgE, eosinophils (BMK-13), and a new mAb against basophils (BB1) by using immunohistochemistry in frozen sections. Results: In the nasal mucosa at baseline, practically no basophils were found in the epithelium, A significant increase in numbers was found in the epithelium and lamina propria of the nasal mucosa in the early phase as early as 1 hour after allergen provocation. At 24 hours and 1 week after allergen provocation, a significant increase in basophil numbers was Found in the lamina propria only. The proportion of mast cells staining for chymase in the lamina propria decreased from a median of 38% (range, 0%-82%) to 14% (range, 0%-78%) within 1 hour of allergen provocation. The proportion of mast cells staining for chymase increased from 1% (range, 0%-86%) at baseline to 21% (range, 3%-85%) within 1 hour of allergen provocation. One week after provocation, mast cells returned to baseline numbers. A definite tissue eosinophilia was observed after allergen provocation. Conclusion: Basophil numbers are increased in the epithelium and lamina propria of the nasal mucosa of subjects with rhinitis after allergen challenge, with influx already apparent at 1 hour. Moreover, changes in mast cell percentages and numbers were observed within 1 hour of allergen provocation.	Erasmus MC, Dept Otorhinolaryngol, Rotterdam, Netherlands; Southampton Gen Hosp, Immunopharmacol Grp, Southampton SO9 4XY, Hants, England	Erasmus University Rotterdam; Erasmus MC; University of Southampton	KleinJan, A (corresponding author), Erasmus Univ, Dept Otorhinolaryngol, Room Ee1655,Dr Molewaterplein 50, NL-3015 GD Rotterdam, Netherlands.		Fokkens, Wytske WJ/ABF-2185-2020					ARZUBIAGA C, 1991, J ALLERGY CLIN IMMUN, V87, P88, DOI 10.1016/0091-6749(91)90216-B; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BENYON RC, 1989, BRIT J PHARMACOL, V97, P898, DOI 10.1111/j.1476-5381.1989.tb12030.x; BORRES MP, 1990, ALLERGY, V45, P98, DOI 10.1111/j.1398-9995.1990.tb00465.x; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051, DOI 10.1164/ajrccm.161.6.9906121; ENERBACK L, 1986, INT ARCH ALLER A IMM, V80, P44, DOI 10.1159/000234024; FOKKENS W J, 1988, Rhinology (Utrecht), V26, P293; FOKKENS WJ, 1992, CLIN EXP ALLERGY, V22, P701, DOI 10.1111/j.1365-2222.1992.tb00194.x; FOKKENS WJ, 2000, IN PRESS AM J RHINOL; Godthelp T, 1996, J ALLERGY CLIN IMMUN, V97, P800, DOI 10.1016/S0091-6749(96)80158-8; GOLDSTEIN SM, 1992, J IMMUNOL, V148, P2475; He SH, 1997, J IMMUNOL, V159, P6216; He SH, 1998, BRIT J PHARMACOL, V125, P1491, DOI 10.1038/sj.bjp.0702223; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; JULIUSSON S, 1994, APMIS, V102, P153, DOI 10.1111/j.1699-0463.1994.tb04860.x; Kanbe N, 1998, ALLERGY, V53, P981, DOI 10.1111/j.1398-9995.1998.tb03800.x; KleinJan A, 1996, ALLERGY, V51, P614, DOI 10.1111/j.1398-9995.1996.tb02295.x; KleinJan A, 1999, J ALLERGY CLIN IMMUN, V103, P441, DOI 10.1016/S0091-6749(99)70469-0; Li LX, 1998, J IMMUNOL, V161, P5079; LOZEWICZ S, 1990, J ALLERGY CLIN IMMUN, V85, P125, DOI 10.1016/0091-6749(90)90233-T; McEuen AR, 1999, LAB INVEST, V79, P27; MOSIMANN BL, 1993, J ALLERGY CLIN IMMUN, V92, P95, DOI 10.1016/0091-6749(93)90043-F; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; PIPKORN U, 1989, AM REV RESPIR DIS, V140, P729, DOI 10.1164/ajrccm/140.3.729; SCHLEIMER RP, 1985, J ALLERGY CLIN IMMUN, V76, P369, DOI 10.1016/0091-6749(85)90656-6; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; VIEGAS M, 1987, INT ARCH ALLER A IMM, V82, P275, DOI 10.1159/000234205; WALLS AF, 1990, CLIN EXP ALLERGY, V20, P581, DOI 10.1111/j.1365-2222.1990.tb03153.x	29	59	62	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2000	106	4					677	686		10.1067/mai.2000.109621	http://dx.doi.org/10.1067/mai.2000.109621			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	365ZP	11031338	Bronze			2022-12-18	WOS:000089980600011
J	Skoner, DP; Szefler, SJ; Welch, M; Walton-Bowen, K; Cruz-Rivera, M; Smith, JA				Skoner, DP; Szefler, SJ; Welch, M; Walton-Bowen, K; Cruz-Rivera, M; Smith, JA			Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						budesonide; budesonide inhalation suspension; asthma; inhaled corticosteroid; pediatric; growth	INHALED CORTICOSTEROIDS; FLUTICASONE PROPIONATE; MILD ASTHMA; BECLOMETHASONE DIPROPIONATE; LINEAR GROWTH; DOUBLE-BLIND; EFFICACY; SALBUTAMOL; SALMETEROL; FENOTEROL	Background: Results of recent growth studies suggest that inhaled glucocorticosteroids may affect growth in children. Objective: Three 52-week, open-label extension studies (studies A, B, and C) were conducted to compare the effects of budesonide inhalation suspension (BIS) with conventional asthma therapy (CAT) on long-term safety, including intermediate-term growth, in 3 different pediatric asthma populations. Methods: Pediatric asthma patients (ages 6 months to 8 years) from 3 multicenter, randomized, 12-week, double-blind, placebo-controlled studies were eligible to enroll in the 52-week, open-label extension studies. The extension studies were multicenter, randomized, open-label, active-controlled, parallel-group studies performed at 26 centers in the United States. Subjects in each extension study were randomized in a 2:1 ratio to receive either BIS or CAT. BIS was initially administered at a dose of 9.5 mg once (studies A and C) or twice daily (study B), with attempts made at each clinical visit to gradually reduce the dose to the minimum effective dose that maintains asthma control, as judged by the investigator. CAT consisted of any available therapy for asthma, including inhaled glucocorticosteroids in studies B and C only. Height SD scores, growth velocity, and skeletal age (only in studies B and C) were examined. Results: In total, 670 subjects were randomized; 223 subjects received CAT and 447 received BIS. Mean ages at entry were 63.0 months and 60.9 months in CAT and BIS groups, respectively. Median total daily doses of BIS ranged from 0.5 to 1.0 mg and the mean duration of treatment exposure was 304 +/- 119 days and 342 +/- 83 days in CAT and BIS groups, respectively. Changes in height SD scores differed significantly between the BIS and CAT groups in study A (-0.19, P =.003), and there was a small, statistically significant decrease in growth velocity (-0.8 cm/y, P =.002) in the BIS-treated group compared with the CAT group. No significant differences were observed between BIS and CAT groups in the changes in height SD scores or in growth velocities in studies B (+0.10 and +0.7 cm/y, respectively) and C (+0.12 and +0.8 cm/y, respectively). No differences in skeletal age were observed between BIS and CAT groups in studies B and C. Conclusion: There was a small, statistically significant decrease in growth velocity in the BIS-treated group compared with the CAT group in the study (study A) where inhaled glucocorticosteroid use was prohibited before entry and in the CAT group during the study. In the studies (B and C) where inhaled glucocorticosteroids were allowed in the CAT group, no differences were observed in height SD scores or growth velocity. The clinical relevance of these effects, including impact on final adult height, remain to be determined in prospectively planned studies that assess growth in children.	Childrens Hosp Pittsburgh, Dept Allergy, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Dept Immunol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15261 USA; Univ Colorado, Hlth Sci Ctr, Dept Clin Pharmacol, Natl Jewish Med & Res Ctr, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA; AstraZeneca LP, Wayne, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; AstraZeneca	Skoner, DP (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat, Div Allergy Immunol & Infect Dis, 3705 5th Ave & DeSoto, Pittsburgh, PA 15213 USA.							AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Agertoft L, 1998, AM J RESP CRIT CARE, V157, P178, DOI 10.1164/ajrccm.157.1.9707072; Agertoft Lone, 1996, European Respiratory Journal Supplement, V9, p294S; Allen DB, 1998, J PEDIATR-US, V132, P472, DOI 10.1016/S0022-3476(98)70023-X; ALLEN DB, 1998, J RESP DIS, V19, P1023; Baker JW, 1999, PEDIATRICS, V103, P414, DOI 10.1542/peds.103.2.414; BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715, DOI 10.1164/ajrccm.151.6.7767512; Doull IJM, 1998, ARCH DIS CHILD, V78, P172, DOI 10.1136/adc.78.2.172; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAUSPIE R, 1977, J ALLERGY CLIN IMMUN, V59, P200, DOI 10.1016/0091-6749(77)90150-6; Jonasson G, 1998, EUR RESPIR J, V12, P1099, DOI 10.1183/09031936.98.12051099; Kemp JP, 1999, ANN ALLERG ASTHMA IM, V83, P231, DOI 10.1016/S1081-1206(10)62646-4; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LIPWORTH BJ, 1995, THORAX, V50, P54, DOI 10.1136/thx.50.1.54; LOHMAN TG, 1991, ANTHROPOMORPHIC STAN; McCowan C, 1998, BMJ-BRIT MED J, V316, P668, DOI 10.1136/bmj.316.7132.668; *MED EC, 1998, PHYS DESK REF, P1126; MERKUS PJFM, 1993, PEDIATRICS, V91, P1121; *NAT CTR HLTH STAT, 1997, VIT HLTH STAT, V165, P1; *NAT HEART LUNG BL, 1997, NIH PUBL; NEWNHAM DM, 1993, THORAX, V48, P656, DOI 10.1136/thx.48.6.656; NINAN TK, 1992, ARCH DIS CHILD, V67, P703, DOI 10.1136/adc.67.6.703; PEDERSEN S, 1995, J ALLERGY CLIN IMMUN, V95, P29, DOI 10.1016/S0091-6749(95)70149-4; Pedersen S, 1997, ALLERGY, V52, P1, DOI 10.1111/j.1398-9995.1997.tb05047.x; Price JF, 1997, PEDIATR PULM, V24, P178; Reid A, 1996, ACTA PAEDIATR, V85, P421, DOI 10.1111/j.1651-2227.1996.tb14053.x; Roche AF., 1988, ASSESSING SKELETAL M; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Shapiro G, 1998, J ALLERGY CLIN IMMUN, V102, P789, DOI 10.1016/S0091-6749(98)70019-3; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; Skoner DP, 1999, J ALLERGY CLIN IMMUN, V103, pS61; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; Todd G, 1996, LANCET, V348, P27, DOI 10.1016/S0140-6736(96)03339-9; *US DEP HHS, 1981, GUID PED WEIGH MEAS; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; Verberne AAPH, 1998, AM J RESP CRIT CARE, V158, P213, DOI 10.1164/ajrccm.158.1.9706048; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067; VOLOVITZ B, 1993, NEW ENGL J MED, V329, P1703, DOI 10.1056/NEJM199312023292305; Welch MJ, 1998, PEDIATR ANN, V27, P752, DOI 10.3928/0090-4481-19981101-11; WOLTHERS OD, 1992, PEDIATRICS, V89, P839; WOLTHERS OD, 1991, BMJ-BRIT MED J, V303, P163, DOI 10.1136/bmj.303.6795.163; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4	43	59	64	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				259	268		10.1016/S0091-6749(00)90074-5	http://dx.doi.org/10.1016/S0091-6749(00)90074-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669845				2022-12-18	WOS:000085402200009
J	Van Uden, J; Raz, E				Van Uden, J; Raz, E			Immunostimulatory DNA and applications to allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunostimulatory DNA sequences; CpG motifs; DNA immunotherapy; DNA immunotherapeutics; allergic disease	MYCOBACTERIUM-BOVIS BCG; DEOXYRIBONUCLEIC-ACID FRACTION; NATURAL-KILLER ACTIVITY; INTRADERMAL GENE IMMUNIZATION; CDNA-ENCODING PROTEINS; IGE ANTIBODY-FORMATION; BACTERIAL-DNA; CPG MOTIFS; PLASMID DNA; SYNTHETIC OLIGONUCLEOTIDES	The vertebrate immune system reacts to certain sequences of DNA with a strong T(H)1-inducing innate response, These sequences, termed immunostimulatory DNA sequences, are net fully defined but generally consist of a central nonmethylated CG dinucleotide, flanked by less highly conserved sequences (hence the alternate name CpG motifs). These sequences seem to be rare in vertebrates but relatively common in many loner organisms, including bacteria and viruses, It is likely that these sequences represent a danger signal to the immune system; a powerful T(H)1 response is induced against colocalized foreign antigen. This can be used to modify an allergic response away from a pathogenic T(H)2-dominated immune profile toward a nonpathogenic and even protective T(H)1 profile.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Van Uden, J (corresponding author), Univ Calif San Diego, Dept Med, 128 Stein Clin Res Bldg,9500 Gilman Dr, La Jolla, CA 92093 USA.				NIAID NIH HHS [AI 40682] Funding Source: Medline; NIGMS NIH HHS [GM 07198] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI040682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007198] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagarazzi ML, 1998, VACCINE, V16, P1836, DOI 10.1016/S0264-410X(98)00178-9; Ballas ZK, 1996, J IMMUNOL, V157, P1840; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bestor TH, 1998, CIBA F SYMP, V214, P187; Bestor TH, 1998, NOVART FDN SYMP, V214, P95; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1485, DOI 10.1093/nar/8.7.1485; BIRD AP, 1993, COLD SPRING HARB SYM, V58, P281, DOI 10.1101/SQB.1993.058.01.033; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; Broide D, 1999, INT ARCH ALLERGY IMM, V118, P453, DOI 10.1159/000024162; Broide D, 1998, J IMMUNOL, V161, P7054; Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623; COSSUM PA, 1994, J PHARMACOL EXP THER, V269, P89; Cowdery J, 1996, J IMMUNOL, V156, P4570; CROOKE RM, 1995, J PHARMACOL EXP THER, V275, P462; Crooke ST., 1995, THERAPEUTIC APPL OLI; Davis HL, 1997, GENE THER, V4, P181, DOI 10.1038/sj.gt.3300380; Dinarello CA, 1996, CURR TOP MICROBIOL, V216, P133; Feltquate DM, 1997, J IMMUNOL, V158, P2278; FIELD AK, 1967, P NATL ACAD SCI USA, V58, P1004, DOI 10.1073/pnas.58.3.1004; Freund J, 1937, P SOC EXP BIOL MED, V37, P509; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; GILKESON GS, 1995, J CLIN INVEST, V95, P1398, DOI 10.1172/JCI117793; Gilkeson GS, 1996, J EXP MED, V183, P1389, DOI 10.1084/jem.183.4.1389; GILKESON GS, 1989, J IMMUNOL, V142, P1482; GILKESON GS, 1993, CLIN IMMUNOL IMMUNOP, V68, P283, DOI 10.1006/clin.1993.1129; Goodman JS, 1998, INT ARCH ALLERGY IMM, V116, P177, DOI 10.1159/000023943; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Halpern MD, 1996, CELL IMMUNOL, V167, P72, DOI 10.1006/cimm.1996.0009; Han SS, 1999, INT IMMUNOL, V11, P871, DOI 10.1093/intimm/11.6.871; Hsu CH, 1996, INT IMMUNOL, V8, P1405, DOI 10.1093/intimm/8.9.1405; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Inchauspe G, 1997, DNA CELL BIOL, V16, P185, DOI 10.1089/dna.1997.16.185; KATAOKA T, 1992, JPN J CANCER RES, V83, P244, DOI 10.1111/j.1349-7006.1992.tb00094.x; Kline JN, 1998, J IMMUNOL, V160, P2555; Klinman DM, 1999, VACCINE, V17, P19, DOI 10.1016/S0264-410X(98)00151-0; Klinman DM, 1997, J IMMUNOL, V158, P3635; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 1998, P NATL ACAD SCI USA, V95, P12631, DOI 10.1073/pnas.95.21.12631; KURAMOTO E, 1989, MICROBIOL IMMUNOL, V33, P929, DOI 10.1111/j.1348-0421.1989.tb00980.x; KURAMOTO E, 1992, JPN J CANCER RES, V83, P1128, DOI 10.1111/j.1349-7006.1992.tb02734.x; LAMPSON GP, 1967, P NATL ACAD SCI USA, V58, P782, DOI 10.1073/pnas.58.2.782; Lapatschek MS, 1998, ANTISENSE NUCLEIC A, V8, P357, DOI 10.1089/oli.1.1998.8.357; Lee DJ, 1997, INT ARCH ALLERGY IMM, V113, P227, DOI 10.1159/000237554; Liang H, 1996, J CLIN INVEST, V98, P1119, DOI 10.1172/JCI118894; Lipford GB, 1997, EUR J IMMUNOL, V27, P3420, DOI 10.1002/eji.1830271242; Macfarlane DE, 1997, IMMUNOLOGY, V91, P586, DOI 10.1046/j.1365-2567.1997.00301.x; Martin-Orozco E, 1999, INT IMMUNOL, V11, P1111, DOI 10.1093/intimm/11.7.1111; MASHIBA H, 1988, JPN J MED SCI BIOL, V41, P197, DOI 10.7883/yoken1952.41.197; MESSINA JP, 1991, J IMMUNOL, V147, P1759; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Ockenhouse CF, 1998, J INFECT DIS, V177, P1664, DOI 10.1086/515331; Pertmer TM, 1996, J VIROL, V70, P6119, DOI 10.1128/JVI.70.9.6119-6125.1996; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; Romagnani S, 1995, CURR OPIN IMMUNOL, V7, P745, DOI 10.1016/0952-7915(95)80042-5; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; Schwartz DA, 1999, J IMMUNOL, V163, P224; Schwartz DA, 1997, J CLIN INVEST, V100, P68, DOI 10.1172/JCI119523; Segal BM, 1997, J IMMUNOL, V158, P5087; SHIMADA S, 1986, JPN J CANCER RES, V77, P808; SHIMADA S, 1985, J NATL CANCER I, V74, P681; Shiver JW, 1996, J PHARM SCI-US, V85, P1317, DOI 10.1021/js9600991; Sonehara K, 1996, J INTERF CYTOK RES, V16, P799, DOI 10.1089/jir.1996.16.799; Sparwasser T, 1998, EUR J IMMUNOL, V28, P2045, DOI 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8; Sparwasser T, 1997, NATURE, V386, P336, DOI 10.1038/386336a0; Sparwasser T, 1999, J IMMUNOL, V162, P2368; Stacey KJ, 1996, J IMMUNOL, V157, P2116; Sun SQ, 1998, J EXP MED, V188, P2335, DOI 10.1084/jem.188.12.2335; Sur S, 1999, J IMMUNOL, V162, P6284; Tighe H, 1998, IMMUNOL TODAY, V19, P89, DOI 10.1016/S0167-5699(97)01201-2; TOKUNAGA T, 1984, J NATL CANCER I, V72, P955; TOKUNAGA T, 1992, MICROBIOL IMMUNOL, V36, P55, DOI 10.1111/j.1348-0421.1992.tb01642.x; UGEN KE, 1998, VACCINE, V16, P1518; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; Weber RW, 1997, JAMA-J AM MED ASSOC, V278, P1881, DOI 10.1001/jama.278.22.1881; YAMAMOTO S, 1988, JPN J CANCER RES, V79, P866, DOI 10.1111/j.1349-7006.1988.tb00049.x; YAMAMOTO S, 1992, J IMMUNOL, V148, P4072; YAMAMOTO T, 1994, ANTISENSE RES DEV, V4, P119, DOI 10.1089/ard.1994.4.119; YAMAMOTO T, 1994, JPN J CANCER RES, V85, P775, DOI 10.1111/j.1349-7006.1994.tb02947.x; YAMAMOTO T, 1994, MICROBIOL IMMUNOL, V38, P831, DOI 10.1111/j.1348-0421.1994.tb01867.x; Yi AK, 1996, J IMMUNOL, V157, P5394; Yi AK, 1996, J IMMUNOL, V157, P4918; Yi AK, 1998, J IMMUNOL, V160, P1240; Yi AK, 1998, J IMMUNOL, V160, P5898; Yi AK, 1998, J IMMUNOL, V161, P4493; Yi AK, 1998, J IMMUNOL, V160, P4755; Yi AK, 1996, J IMMUNOL, V156, P558; ZILBERSTEIN A, 1978, P NATL ACAD SCI USA, V75, P4734, DOI 10.1073/pnas.75.10.4734	92	59	72	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					902	910		10.1016/S0091-6749(99)70066-7	http://dx.doi.org/10.1016/S0091-6749(99)70066-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550730	Bronze			2022-12-18	WOS:000083778400008
J	Barnes, KC; Freidhoff, LR; Nickel, R; Chiu, YF; Juo, SH; Hizawa, N; Naidu, RP; Ehrlich, E; Duffy, DL; Schou, C; Levett, PN; Marsh, DG; Beaty, TH				Barnes, KC; Freidhoff, LR; Nickel, R; Chiu, YF; Juo, SH; Hizawa, N; Naidu, RP; Ehrlich, E; Duffy, DL; Schou, C; Levett, PN; Marsh, DG; Beaty, TH			Dense mapping of chromosome 12q13.12-q23.3 and linkage to asthma and atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergic rhinitis; linkage analysis; chromosome 12q; IFN-gamma	DIABETES-MELLITUS IDDM; INTERFERON-GAMMA GENE; ALLERGIC RHINITIS; ANTIGEN CHALLENGE; IL-4; MARKERS; POLYMORPHISM; INFLAMMATION; MACROPHAGES; GENERATION	Background: Asthma is a complex disease characterized by a high prevalence of allergic diathesis and the almost ubiquitous presence of upper airway disease (eg, rhinitis). Previously, we observed linkage of asthma among Afro-Caribbean families to markers in chromosome 12q, which contains a number of genes encoding for products closely related to allergic airway inflammation and disease. Objective: To identify susceptibility loci in chromosome 12q contributing to the genetics of upper and lower airway diseases and to expand the region to include genes encoding IFN-gamma (IFNG) and one of the signal transducers and activators of transcription (STAT6), we conducted further linkage studies among 33 multiplex families. Methods: We characterized 528 subjects from Barbados for asthma; 82% were characterized for allergic rhinitis. Two-point and multipoint linkage analysis of 22 microsatellite markers (spanning similar to 79 centimorgan) was performed. Results-Affected sib-pair analysis revealed significant evidence for linkage to asthma over approximately 30 cM (P < .05 to .002), with the best evidence for linkage at a CA repeat polymorphism in the first intron of IFNG in 12q21.1 (P = .002). Evidence of linkage to allergic rhinitis was observed in the same region (D12S313, P = 0.006, and IFNGCA, P = .01, respectively). Multipoint linkage analysis also provided evidence for linkage to asthma, with the best nonparametric link-age analysis score at D12S326 (nonparametric linkage score = 3.8, P = .0008). Modest evidence for linkage to allergic rhinitis was observed next to D12S326 at D12S1052 (P = .036). Conclusions: Our findings suggest that (1) one or more loci in the chromosome 12q13.12-q23.3 region are contributing to the expression of the clinical phenotype asthma and the strongest evidence for linkage is in a region near the gene encoding IFNG and (2) a susceptibility locus for both asthma and allergic rhinitis maps to this region.	Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA; Hokkaido Univ, Dept Med 1, Sapporo, Hokkaido 060, Japan; Univ W Indies, Sch Clin Med & Res, Fac Med, Bridgetown, Barbados; ALK Labs, Horsholm, Denmark	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Rockefeller University; Hokkaido University; University West Indies Mona Jamaica; University of the West Indies Open Campus	Barnes, KC (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.		Duffy, David L/B-7392-2013; Chiu, Yen-Feng/E-3847-2010; Juo, Suh-Hang/C-9545-2009; Juo, Suh-Hang/A-1765-2010	Duffy, David L/0000-0001-7227-632X; 	NCRR NIH HHS [1P41 RR03655] Funding Source: Medline; PHS HHS [A120059] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003655] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Asderakis A., 1997, Immunology, V92, P62; AWATA T, 1994, DIABETOLOGIA, V37, P1159, DOI 10.1007/BF00418381; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; BLUMENTHAL MN, 1995, CLIN EXP ALLERGY, V25, P29, DOI 10.1111/j.1365-2222.1995.tb00416.x; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRAMAN SS, 1987, CHEST, V91, P671, DOI 10.1378/chest.91.5.671; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; DUFFY DL, 1995, SIBPAIR 0988 PROGRAM; Gray P W, 1983, Basic Life Sci, V25, P35; GREEN P, 1990, CRIMAP; Grossman J, 1997, CHEST, V111, pS11, DOI 10.1378/chest.111.2_Supplement.11S; Hayden C, 1997, CLIN EXP ALLERGY, V27, P1412, DOI 10.1111/j.1365-2222.1997.tb02985.x; HENDERSON WR, 1994, ANN ALLERGY, V72, P272; Holgate ST, 1997, NAT GENET, V15, P227, DOI 10.1038/ng0397-227; HOLGATE ST, 1989, J ALLERGY CLIN IMMUN, V83, P537, DOI 10.1016/0091-6749(89)90035-3; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HOWARTH PH, 1994, AM J RESP CRIT CARE, V150, P518; HUMBERT M, 1996, AM J RESP CRIT CARE, V154, P1479; HUMPERT M, 1997, AM J RESP CELL MOL B, V16, P1; Kapsali T., 1997, Journal of Allergy and Clinical Immunology, V99, pS138; Kjellman N I, 1993, Pediatr Allergy Immunol, V4, P38; KLEINETEBBE J, 1992, CLIN EXP ALLERGY, V22, P475, DOI 10.1111/j.1365-2222.1992.tb00150.x; KOHI F, 1990, ANN ALLERGY, V65, P228; KRAUTER K, 1995, NATURE, V377, P321; Krug N, 1996, AM J RESP CELL MOL, V14, P319, DOI 10.1165/ajrcmb.14.4.8600935; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; NACLERIO RM, 1991, AM REV RESPIR DIS, V143, pS91, DOI 10.1164/ajrccm/143.5_Pt_2.S91; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; Nickel R, 1997, GENOMICS, V46, P159, DOI 10.1006/geno.1997.5013; Onoue Y, 1993, Arerugi, V42, P846; OTT J, 1989, P NATL ACAD SCI USA, V86, P4175, DOI 10.1073/pnas.86.11.4175; Pociot F, 1997, J INTERF CYTOK RES, V17, P87, DOI 10.1089/jir.1997.17.87; RASP G, 1992, LARYNGO RHINO OTOL, V71, P298, DOI 10.1055/s-2007-997299; Redington A. E., 1993, Thorax, V48, P1081; RIMPELA AH, 1995, SCAND J SOC MED, V23, P60, DOI 10.1177/140349489502300111; *SAGE, 1992, STAT AN GEN EP; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; SMITH JM, 1983, ALLERGY PRINCIPLES P, P771; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Svaren J, 1997, GENOMICS, V41, P33, DOI 10.1006/geno.1997.4609; *SYSTAT INC, 1992, SYSTAT WIND; Takeda K, 1996, J IMMUNOL, V157, P3220; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WANG D, 1995, EUR ARCH OTO-RHINO-L, V252, pS40, DOI 10.1007/BF02484433; WILKINSON J, 1997, AM J RESP CRIT CARE, V155, pA257	53	59	62	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				485	491		10.1016/S0091-6749(99)70398-2	http://dx.doi.org/10.1016/S0091-6749(99)70398-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452776				2022-12-18	WOS:000082364800047
J	Seppala, U; Alenius, H; Turjanmaa, K; Reunala, T; Palosuo, T; Kalkkinen, N				Seppala, U; Alenius, H; Turjanmaa, K; Reunala, T; Palosuo, T; Kalkkinen, N			Identification of patatin as a novel allergen for children with positive skin prick test responses to raw potato	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; children; food; IgE; patatin; potato	BIRCH POLLEN; CROSS-REACTIVITY; VEGETABLES; FRUITS; GLYCOPROTEIN; PROFILIN; EXTRACTS; SEQUENCE; ASTHMA; TUBER	Background: Peeling of ram potatoes may cause allergic symptoms, such as sneezing, wheezing, and contact urticaria, for adults. For children, potatoes as food may cause various allergic reactions. However, the identity and molecular structure of the putative allergens in potato have remained unknown, Objective: The aim of our study was to identify possible major allergens in potato by using sera of atopic children suspected of having food allergy and having positive skin prick test responses to raw potato, Methods: Potato proteins were purified by standard methods of protein chemistry and characterized with amino-terminal sequencing and mass spectrometry, The IgE-binding ability of the purified proteins was verified by immunoblotting and ELISA with IgE antibodies from the sera of atopic children having positive skin prick test responses to raw potato. Results: Immunoblotting showed strong IgE binding to a 43-kd protein, identified as patatin, the main storage protein of potato tubers. In ELISA, 20 of 27 (74%) children with positive skin prick test responses to potato and none of the control subjects showed specific binding of IgE antibodies to purified patatin, A positive wheal-and-pare reaction was seen in 8 of 14 children prick tested with purified patatin, Conclusion: These results show that patatin in potatoes is a significant, previously unrecognized, IgE-binding protein for children with a positive skin prick test response to raw potato. Further studies are needed to confirm the clinical importance of potatoes, and especially patatin, as a food allergen.	Natl Publ Hlth Inst, FIN-00300 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, Helsinki, Finland; Tampere Univ, Dept Dermatol, FIN-33101 Tampere, Finland; Inst Occupat Hlth, Helsinki, Finland; Univ Helsinki, Hosp Skin & Allerg Dis, Helsinki, Finland	Finland National Institute for Health & Welfare; University of Helsinki; Tampere University; Finnish Institute of Occupational Health; University of Helsinki	Palosuo, T (corresponding author), Natl Publ Hlth Inst, Mannerheimintie 166, FIN-00300 Helsinki, Finland.		Kalkkinen, Nisse EJ/B-3923-2010	Alenius, Harri/0000-0003-0106-8923				ANDERSON JA, 1996, CRIT REV FOOD SCI NU, V36, P19; BONIERBALE MW, 1990, MOL CELLULAR BIOL PO, V3, P13; CASTELLS MC, 1986, J ALLERGY CLIN IMMUN, V78, P1110, DOI 10.1016/0091-6749(86)90258-7; Delgado J, 1996, CONTACT DERMATITIS, V35, P179, DOI 10.1111/j.1600-0536.1996.tb02342.x; DREBORG S, 1983, ALLERGY, V38, P162; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; ERIKSSON NE, 1978, ALLERGY, V33, P189, DOI 10.1111/j.1398-9995.1978.tb01533.x; GEGENHEIMER P, 1990, METHOD ENZYMOL, V182, P174; HALMEPURO L, 1984, INT ARCH ALLER A IMM, V74, P235, DOI 10.1159/000233550; HANNUKSELA M, 1977, CONTACT DERMATITIS, V3, P79, DOI 10.1111/j.1600-0536.1977.tb03603.x; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; KOSIER T, 1981, Plant Physiology (Rockville), V67, P92; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHTI A, 1980, ALLERGY, V35, P297, DOI 10.1111/j.1398-9995.1980.tb01770.x; LEHRER SB, 1997, ALLERGY ALLERGIC DIS, P961; Martinez A, 1997, ALLERGY, V52, P155, DOI 10.1111/j.1398-9995.1997.tb00969.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NATER JP, 1967, J ALLERGY, V40, P202, DOI 10.1016/0021-8707(67)90082-2; ORTOLANI C, 1993, ANN ALLERGY, V71, P470; PARK WD, 1983, PLANT PHYSIOL, V71, P156, DOI 10.1104/pp.71.1.156; Partington JC, 1996, PHYTOCHEMISTRY, V42, P1499, DOI 10.1016/0031-9422(96)00185-9; PEARSON RSB, 1966, ACTA ALLERGOL, V21, P507, DOI 10.1111/j.1398-9995.1966.tb03170.x; QUIRCE S, 1989, ALLERGY, V44, P532, DOI 10.1111/j.1398-9995.1989.tb04197.x; RACUSEN D, 1980, J FOOD BIOCHEM, V4, P43, DOI 10.1111/j.1745-4514.1980.tb00876.x; SAMPSON HA, 1985, J PEDIAT, V107, P193; Senda K, 1996, PLANT CELL PHYSIOL, V37, P347, DOI 10.1093/oxfordjournals.pcp.a028952; TUFT L, 1942, J ALLERGY, V13, P547; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; WAHL R, 1990, INT ARCH ALLER A IMM, V92, P168, DOI 10.1159/000235209	29	59	62	4	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	1				165	171		10.1016/S0091-6749(99)70541-5	http://dx.doi.org/10.1016/S0091-6749(99)70541-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	158JM	9893201				2022-12-18	WOS:000078112300025
J	Gantner, F; Tenor, H; Gekeler, V; Schudt, C; Wendel, A; Hatzelmann, A				Gantner, F; Tenor, H; Gekeler, V; Schudt, C; Wendel, A; Hatzelmann, A			Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: A comparative study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						phosphodiesterases; phosphodiesterase 4 subtypes; atopic dermatitis; rolipram; zardaverine; RS-25344; T cell proliferation; cyclic 3'5' adenosine monophosphate; armor necrosis factor-alpha	CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AMP-SPECIFIC PHOSPHODIESTERASE; CAMP-SPECIFIC PHOSPHODIESTERASE; CYTOKINE PRODUCTION; PROSTAGLANDIN E(2); TISSUE MACROPHAGES; MONONUCLEAR-CELLS; T-LYMPHOCYTES; DERMATITIS; INHIBITORS	Background: Several previous reports have suggested an increased activity of cAMP phosphodiesterases (PDEs) and a higher sensitivity of these enzymes toward PDE inhibitors in leukocytes of patients suffering from atopic dermatitis. Objective: The purpose of the present study was to comprehensively analyze and compare the PDE expression and activity profile of highly purified populations of leukocytes from normal and atopic blood donors. In addition, the influence of PDE inhibitors on function of leukocytes from normal and atopic individuals was investigated. Methods: Density gradient centrifugation, elutriation, and magnetic cell sorting techniques were used to purify eosinophils, monocytes, and B and T lymphocytes from peripheral human blood. Complementary DNA-polymerase chain reaction was used to analyze PDE4 subtype messenger RNA (mRNA) expression levels in addition to PDE isoenzyme activities. PDE4 inhibitor sensitivity was determined in monocyte homogenates from both groups. Functionally, suppression of lipopolysaccharide-induced synthesis of tumor necrosis factor-alpha in monocytes as well as phytohemagglutinin-induced T cell proliferation in peripheral blood mononuclear cell fractions by PDE4 and PDE3/4 inhibitors was compared. Results: Identical PDE activities and mRNA expression profiles were found in all cells from normal and atopic donors except that there was an increase in the mRNA levels of PDE4A and PDE4B2 in atopic T cells, which was, however, not reflected in overall PDE4 activity. In addition, no differences in sensitivity of the functional responses to PDE inhibitors were noted. The mixed PDE3/4 inhibitor zardaverine was a more potent inhibitor of T cell proliferation than rolipram, a selective PDE4 inhibitor. Conclusion: No evidence for alterations of PDE activities in atopy is provided by our findings.	BYK GULDEN LOMBERG GMBH, DEPT BIOCHEM, D-78467 CONSTANCE, GERMANY; UNIV KONSTANZ, FAC BIOL, DEPT BIOCHEM PHARMACOL, D-7750 CONSTANCE, GERMANY	Altana; University of Konstanz								ALVAREZ R, 1995, MOL PHARMACOL, V48, P616; Alvarez R., 1994, CAN J PHYSL PHARM S1, V72, P510; Banner KH, 1995, BRIT J PHARMACOL, V116, P3169, DOI 10.1111/j.1476-5381.1995.tb15120.x; BAUER AC, 1980, N-S ARCH PHARMACOL, V311, P193, DOI 10.1007/BF00510259; BECK J, 1995, BRIT J HAEMATOL, V89, P356, DOI 10.1111/j.1365-2141.1995.tb03312.x; Chan S, 1996, J ALLERGY CLIN IMMUN, V97, P85, DOI 10.1016/S0091-6749(96)70286-5; CHAN SC, 1993, J IMMUNOL, V151, P3345; CHAN SC, 1993, J ALLERGY CLIN IMMUN, V91, P1179, DOI 10.1016/0091-6749(93)90321-6; CHAN SC, 1993, J LAB CLIN MED, V121, P44; CHAN SC, 1993, J INVEST DERMATOL, V100, P681, DOI 10.1111/1523-1747.ep12472344; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; Crocker IC, 1996, IMMUNOPHARMACOLOGY, V31, P223, DOI 10.1016/0162-3109(95)00053-4; DENT G, 1996, PHOSPHODIESTERASE IN, P115; ELLIOTT ST, 1979, ARCH DERMATOL, V115, P1424, DOI 10.1001/archderm.115.12.1424; ENGELS P, 1994, FEBS LETT, V350, P291, DOI 10.1016/0014-5793(94)00788-8; ENGELS P, 1995, FEBS LETT, V358, P305, DOI 10.1016/0014-5793(94)01460-I; ESSAYAN DM, 1994, J IMMUNOL, V153, P3408; Gantner F, 1997, BRIT J PHARMACOL, V121, P221, DOI 10.1038/sj.bjp.0701124; GANTNER F, 1995, INFLAMM RES, V44, P264; Giembycz MA, 1996, BRIT J PHARMACOL, V118, P1945, DOI 10.1111/j.1476-5381.1996.tb15629.x; GOLDBERG BJ, 1994, J ALLERGY CLIN IMMUN, V93, P166; GREWE SR, 1982, J ALLERGY CLIN IMMUN, V70, P452, DOI 10.1016/0091-6749(82)90008-2; Hanifin JM, 1996, J INVEST DERMATOL, V107, P51, DOI 10.1111/1523-1747.ep12297888; HANIFIN JM, 1995, J INVEST DERMATOL, V105, pS84, DOI 10.1111/1523-1747.ep12316116; HATZELMANN A, 1995, BRIT J PHARMACOL, V114, P821, DOI 10.1111/j.1476-5381.1995.tb13278.x; HOLDEN CA, 1986, J INVEST DERMATOL, V87, P372, DOI 10.1111/1523-1747.ep12524844; JAKOB T, 1990, CLIN EXP IMMUNOL, V79, P380; JUNG HC, 1995, J CLIN INVEST, V95, P55, DOI 10.1172/JCI117676; Manning CD, 1996, J PHARMACOL EXP THER, V276, P810; OBERNOLTE R, 1993, GENE, V129, P239, DOI 10.1016/0378-1119(93)90274-7; Palfreyman Malcolm N., 1995, Drugs of the Future, V20, P793; RIVIER A, 1995, CLIN EXP IMMUNOL, V100, P314; ROBICSEK SA, 1991, BIOCHEM PHARMACOL, V42, P869, DOI 10.1016/0006-2952(91)90047-9; SETTE C, 1994, J BIOL CHEM, V269, P9245; SETTE C, 1994, J BIOL CHEM, V269, P18271; TENOR H, 1995, CLIN EXP ALLERGY, V25, P616, DOI 10.1111/j.1365-2222.1995.tb01109.x; Tenor H, 1996, BRIT J PHARMACOL, V118, P1727, DOI 10.1111/j.1476-5381.1996.tb15598.x; TENOR H, 1995, CLIN EXP ALLERGY, V25, P625, DOI 10.1111/j.1365-2222.1995.tb01110.x; Thompson W J, 1979, Adv Cyclic Nucleotide Res, V10, P69; Torphy Theodore J., 1994, P397; TORPHY TJ, 1992, J PHARMACOL EXP THER, V263, P1195; TORPHY TJ, 1995, J BIOL CHEM, V270, P23598, DOI 10.1074/jbc.270.40.23598; VERGHESE MW, 1995, MOL PHARMACOL, V47, P1164; WILISCH A, 1993, CANCER LETT, V69, P139, DOI 10.1016/0304-3835(93)90166-7; ZIEGLERHEITBROCK HWL, 1993, EUR J IMMUNOL, V23, P2053, DOI 10.1002/eji.1830230902	45	59	60	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1997	100	4					527	535		10.1016/S0091-6749(97)70146-5	http://dx.doi.org/10.1016/S0091-6749(97)70146-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YA529	9338548				2022-12-18	WOS:A1997YA52900017
J	WOODFOLK, JA; HAYDEN, ML; COUTURE, N; PLATTSMILLS, TAE				WOODFOLK, JA; HAYDEN, ML; COUTURE, N; PLATTSMILLS, TAE			CHEMICAL TREATMENT OF CARPETS TO REDUCE ALLERGEN - COMPARISON OF THE EFFECTS OF TANNIC-ACID AND OTHER TREATMENTS ON PROTEINS DERIVED FROM DUST MITES AND CATS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TANNIC ACID; BENZYL BENZOATE; INDOOR ALLERGENS; ALBUMIN; ELISA	FEL-D-I; HOUSE DUST; BRONCHIAL HYPERREACTIVITY; IGE ANTIBODIES; ASTHMA; EXPOSURE; AVOIDANCE; ACARICIDE; CHILDREN; RISK	Background: Several chemical treatments have been recommended for reducing mite and other allergen levels in carpets, including the protein-denaturing agent tannic acid (TA). Objective: We evaluated the efficacy of TA and other treatments on mite and car allergens in carpets within houses. The effects of TA were assessed on Der p 1 and Der f 1, on group II mite allergens, and an the major car allergen Fel d 1. Method: Carpet treatments tested were benzyl benzoate moist powder, a 3% TA spray, and two carpet cleaners (Host and Capture). Carpets were treated twice and dust samples collected on a biweekly basis for 8 weeks: these samples were extracted in saline solution alone. Additional studies evaluated the effects of TA on 17 carpets. Carpets were treated twice (on days 0 and 28) and samples collected on days 0, 1, 7, 14, 28, and 42. Eighteen carpets were untreated controls. Dust samples were extracted separately in both saline solution and in the presence of 5% bovine serum albumin. Results: Benzyl benzoate and the two carpet cleaners reduced group I dust mite allergen concentrations in carpet dust. In addition, benzyl benzoate and TA reduced airborne group I mite allergens by more than 64%. Further studies showed that in keeping with in vitro studies, TA inhibited the assay and bovine serum albumin abrogated this effect. Significant reductions after treatment occurred only for Der f 1 and group 2 dust mite allergens (p = 0.005 and p = 0.035, respectively), However, for all mite allergens the percentage changes after treatment were significant when. compared with untreated carpets (p < 0.005 for Der f I and group 2 mite, p < 0.02 for Dec p 1) but not for cat allergen (p > 0.3). The results suggested that repeated application of TA was necessary to maintain reduced allergen concentrations. Conclusion: Carpet treatments can reduce mite-derived allergen levels in airborne and carpet dust. However; the effects do not appear to be maintained for long periods, are not dramatic, and are different for different allergens.			WOODFOLK, JA (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, DEPT MED, DIV ALLERGY & CLIN IMMUNOL, BOX 225, CHARLOTTESVILLE, VA 22908 USA.			Platts-Mills, Thomas/0000-0002-1263-329X	NIAID NIH HHS [U01 AI-34607, AI-20565] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, R37AI020565, U01AI034607] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASQUITH TN, 1987, J AGR FOOD CHEM, V35, P331, DOI 10.1021/jf00075a012; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BISCHOFF E, 1987, ALLERGOLOGIE, V10, P473; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; COLLOFF MJ, 1986, CLIN ALLERGY, V16, P41, DOI 10.1111/j.1365-2222.1986.tb01952.x; DESAINTGEORGESGRIDELET D, 1988, REV FR ALLERGOL, V28, P131, DOI 10.1016/S0335-7457(88)80063-7; DESCHAMPS AM, 1980, J FERMENT TECHNOL, V58, P93; DORWARD AJ, 1988, THORAX, V43, P98, DOI 10.1136/thx.43.2.98; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; EZAKIFURUICHI E, 1987, AGR BIOL CHEM TOKYO, V51, P115, DOI 10.1080/00021369.1987.10867976; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GREEN WF, 1984, LANCET, V2, P160; GREEN WF, 1989, CLIN EXP ALLERGY, V19, P203, DOI 10.1111/j.1365-2222.1989.tb02365.x; Hagerman A.E., 1980, THESIS PURDUE U W LA; HAGERMAN AE, 1981, J BIOL CHEM, V256, P4494; HAGERMAN AE, 1978, J AGR FOOD CHEM, V26, P809, DOI 10.1021/jf60218a027; HART BJ, 1992, CLIN EXP ALLERGY, V22, P923, DOI 10.1111/j.1365-2222.1992.tb02065.x; HAYDEN ML, 1992, J ALLERGY CLIN IMMUN, V89, P536, DOI 10.1016/0091-6749(92)90320-2; HELLERHAUPT A, 1974, J MED ENTOMOL, V11, P551; KANG BC, 1991, J ALLERGY CLIN IMMUN, V87, P1073, DOI 10.1016/0091-6749(91)92152-Q; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MAY KR, 1945, J SCI INSTRUM, V22, P187, DOI 10.1088/0950-7671/22/10/303; MCMANUS JP, 1985, J CHEM SOC PERK T 2, P1429, DOI 10.1039/p29850001429; MILLER A, 1992, J ALLERGY CLIN IMMUN, V89, P257; MILLER JD, 1989, J ALLERGY CLIN IMMUN, V83, P262; MITCHELL EB, 1985, CLIN ALLERGY, V15, P235, DOI 10.1111/j.1365-2222.1985.tb02280.x; MURRAY AB, 1983, PEDIATRICS, V71, P418; NATERMAN HYMAN, 1941, JOUR ALLERGY, V12, P378, DOI 10.1016/S0021-8707(41)90265-4; OVSYANNIKOVA IG, 1994, J ALLERGY CLIN IMMUN, V94, P537, DOI 10.1016/0091-6749(94)90211-9; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; PENAUD A, 1975, Clinical Allergy, V5, P109, DOI 10.1111/j.1365-2222.1975.tb01842.x; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; STRUMEYE.DH, 1970, BIOCHEM J, V118, P899, DOI 10.1042/bj1180899; THOMPSON PJ, 1993, J ALLERGY CLIN IMMUN, V91, P251; TOVEY ER, 1992, CLIN EXP ALLERGY, V22, P67, DOI 10.1111/j.1365-2222.1992.tb00116.x; VERVLOET D, 1982, J ALLERGY CLIN IMMUN, V69, P290, DOI 10.1016/S0091-6749(82)80006-7; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; WALSHAW MJ, 1986, Q J MED, V58, P199; WOODFOLK JA, 1994, J ALLERGY CLIN IMMUN, V94, P19, DOI 10.1016/0091-6749(94)90066-3	46	59	61	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1995	96	3					325	333		10.1016/S0091-6749(95)70051-X	http://dx.doi.org/10.1016/S0091-6749(95)70051-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RU660	7560634				2022-12-18	WOS:A1995RU66000004
J	KUNG, TT; STELTS, D; ZURCHER, JA; WATNICK, AS; JONES, H; MAUSER, PJ; FERNANDEZ, X; UMLAND, S; KREUTNER, W; CHAPMAN, RW; EGAN, RW				KUNG, TT; STELTS, D; ZURCHER, JA; WATNICK, AS; JONES, H; MAUSER, PJ; FERNANDEZ, X; UMLAND, S; KREUTNER, W; CHAPMAN, RW; EGAN, RW			MECHANISMS OF ALLERGIC PULMONARY EOSINOPHILIA IN THE MOUSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INTERFERON-GAMMA; ACCUMULATION; ASTHMA		SCHERING PLOUGH CORP,RES INST,DEPT ALLERGY & IMMUNOL,KENILWORTH,NJ 07033	Merck & Company; Schering Plough Corporation								ALEXANDER P, 1969, SCAND J HAEMATOL, V6, P319; ARM JP, 1992, ADV IMMUNOL, V51, P323, DOI 10.1016/S0065-2776(08)60491-5; Bass DA, 1980, EOSINOPHIL HLTH DISE, P275; COFFMAN RL, 1986, J IMMUNOL, V136, P949; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; GULBENKIAN AR, 1992, AM REV RESPIR DIS, V146, P263, DOI 10.1164/ajrccm/146.1.263; GULBENKIAN AR, 1990, AM REV RESPIR DIS, V142, P680, DOI 10.1164/ajrccm/142.3.680; JONES DG, 1993, J COMP PATHOL, V108, P317, DOI 10.1016/S0021-9975(08)80204-6; KITAMURA Y, 1978, BLOOD, V52, P447; MAUSER PJ, 1993, AM REV RESPIR DIS, V148, P1623, DOI 10.1164/ajrccm/148.6_Pt_1.1623; MCKENZIE ANJ, 1992, CHEM IMMUNOL, V51, P135; MOSMANN TR, 1987, J IMMUNOL, V138, P1813; OJIMAUCHIYAMA A, 1991, LIPIDS, V26, P1200, DOI 10.1007/BF02536531; OWEN WF, 1987, J IMMUNOL, V138, P532	15	59	63	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1217	1224		10.1016/0091-6749(94)90335-2	http://dx.doi.org/10.1016/0091-6749(94)90335-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798563				2022-12-18	WOS:A1994QA02000015
J	LEE, BJ; NACLERIO, RM; BOCHNER, BS; TAYLOR, RM; LIM, MC; BAROODY, FM				LEE, BJ; NACLERIO, RM; BOCHNER, BS; TAYLOR, RM; LIM, MC; BAROODY, FM			NASAL CHALLENGE WITH ALLERGEN UP-REGULATES THE LOCAL EXPRESSION OF VASCULAR ENDOTHELIAL ADHESION MOLECULES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ADHESION MOLECULES; INTERCELLULAR ADHESION MOLECULE-1; E-SELECTIN; VASCULAR CELL ADHESION MOLECULE-1; ALLERGIC RHINITIS; NASAL BIOPSY; EOSINOPHIL	MUCOSAL CELLULAR-CHANGES; LEUKOCYTE ADHESION; ACTIVATED EOSINOPHILS; ANTIGEN CHALLENGE; MAST-CELLS; T-CELLS; NEUTROPHILS; ADHERENCE; INTERLEUKIN-1; RHINITIS	To understand the events involved in selective eosinophil migration into allergic inflammatory sites, we studied the expression of vascular endothelial adhesion molecules in the nasal mucosa. Ten subjects with asymptomatic seasonal allergic rhinitis and 13 nonallergic subjects underwent localized allergen challenge of one inferior turbinate. Twenty-four hours later; biopsy specimens were obtained from the inferior turbinates, bilaterally in the seasonally allergic subjects and unilaterally in the nonallergic control subjects. The specimens were divided, sectioned, and either stained for identification of eosinophils or analyzed immunohistochemically for intercellularlar adhesion molecule-1, E-selectin, vascular cell adhesion molecule-1 (VCAM-1) and von Willebrand's factor. Intercellular adhesion molecule-1 expression was observed in all mucosal specimens, with no significant difference among groups. E-selectin showed minimal baseline expression, and low levels were significantly induced on the challenged mucosa of the allergic compared with nonallergic subjects (p < 0.05). VCAM-2 was expressed basally and was significantly upregulated by allergen challenge compared with the nonchallenged side and nonallergic control subjects (p < 0.05). Submucosal eosinophils increased significantly in allergic subjects 24 hours after antigen challenge, compared with nonallergic control subjects and weakly correlated with VCAM-1 expression (r(s) = 0.33, p = 0.06). Our results suggest that endothelial activation accompanies allergic inflammation. Furthermore because the counter ligand for VCAM-1, very late activation antigen-4, is present on eosinophils, VCAM-1 upregulation may contribute to the selective recruitment of these cells to the nasal mucosa.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NHLBI NIH HHS [HL 49545] Funding Source: Medline; NIAID NIH HHS [AI 27429, AI 31335] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049545] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI027429, R01AI031335] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTMAN L C, 1991, Journal of Allergy and Clinical Immunology, V87, P304, DOI 10.1016/0091-6749(91)91941-L; BACHERT C, 1991, AM J RHINOL, V5, P227; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BIRDSALL HH, 1992, J IMMUNOL, V148, P2717; BOCHNER BS, 1987, J IMMUNOL, V139, P2297; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BOCHNER BS, 1994, IN PRESS EOSINOPHILS; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; DURHAM SR, 1992, J IMMUNOL, V148, P2390; FREW AJ, 1988, J IMMUNOL, V141, P4158; GAGA M, 1991, J IMMUNOL, V147, P816; GEORAS SN, 1992, AM J RESP CELL MOL, V7, P261, DOI 10.1165/ajrcmb/7.3.261; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GRABER N, 1990, J IMMUNOL, V145, P819; KOCH AE, 1991, LAB INVEST, V64, P313; KYANAUNG U, 1991, J IMMUNOL, V146, P521; LEUNG DYM, 1991, J CLIN INVEST, V87, P1805, DOI 10.1172/JCI115201; LIM M, 1993, J ALLERGY CLIN IMMUN, V91, P181; LIMMOMBAY M, 1992, J ALLERGY CLIN IMMUN, V89, P205; LOBB RR, 1992, ADHESION ITS ROLE IN, P1; MASON DY, 1978, J CLIN PATHOL, V31, P454, DOI 10.1136/jcp.31.5.454; MONTEFORT S, 1992, AM J RESP CELL MOL, V7, P393, DOI 10.1165/ajrcmb/7.4.393; MONTEFORT S, 1993, J ALLERGY CLIN IMMUN, V91, P346; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POBER JS, 1986, J IMMUNOL, V136, P1680; RICE GE, 1991, AM J PATHOL, V138, P385; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; RUCO LP, 1992, AM J PATHOL, V140, P1337; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SCHLEIMER RP, 1986, J IMMUNOL, V136, P649; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; THORNHILL MH, 1990, J IMMUNOL, V144, P3060; VADAS MA, 1992, ADHESION ITS ROLE IN, P65; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; WALSH GM, 1991, J IMMUNOL, V146, P3419; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430	41	59	60	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	1				1006	1016		10.1016/0091-6749(94)90119-8	http://dx.doi.org/10.1016/0091-6749(94)90119-8			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PY230	7528231				2022-12-18	WOS:A1994PY23000009
J	CARBALLIDO, JM; CARBALLIDOPERRIG, N; OBERLISCHRAMMLI, A; HEUSSER, CH; BLASER, K				CARBALLIDO, JM; CARBALLIDOPERRIG, N; OBERLISCHRAMMLI, A; HEUSSER, CH; BLASER, K			REGULATION OF IGE AND IGG(4) RESPONSES BY ALLERGEN-SPECIFIC T-CELL CLONES TO BEE VENOM PHOSPHOLIPASE A(2) IN-VITRO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T-H CELLS; INTERLEUKIN-4; TGG(4); IGE; BEE STING ALLERGY	HUMAN B-CELLS; INTERFERON-GAMMA; SECRETION INVITRO; HUMAN-LYMPHOCYTES; IGG4 ANTIBODIES; IMMUNE-RESPONSE; HONEYBEE VENOM; INTERLEUKIN-4; IMMUNOTHERAPY; IL-4	An in vitro antibody response to bee venom phospholipase A(2) (PLA) from peripheral blood mononuclear cells of bee sting-sensitized individuals was achieved after stimulation with PLA and pokeweed mitogen. This stimulation resulted in a secretion of T-H1-associated cytokines and induced PLA-specific and nonspecific IgG(4) antibody production but not IgE production. The addition of interleukin-4 (IL-4) to this system decreased the secretion of IgG antibodies, whereas secretion of polyspecific IgE was induced. The mitogen was nor required if peripheral blood mononuclear cells were enriched with autologous, PLA-specific, resting T-cell clones in the presence of the antigen. In these experiments the cytokine profile of the particular clone determined the antibody class generated. Low ratios of IL-4 to interferon-gamma, induced by the antigen alone or obtained by neutralizing anti-IL-4 antibodies, enhanced IgG(4) antibody formation, whereas IgE levels increased at high ratios of IL-4 to interferon-gamma. These results suggest a complementary regulation of the main isotypes, IgE and IgG(4) implicated in allergic and protective hyperimmune responses.	CIBI LTD,BASEL,SWITZERLAND		CARBALLIDO, JM (corresponding author), SWISS INST ALLERGY & ASTHMA RES,OBERE STR 22,CH-7270 DAVOS,SWITZERLAND.							AALBERSE RC, 1983, J IMMUNOL, V130, P722; ANDERSSON U, 1990, EUR J IMMUNOL, V20, P1591, DOI 10.1002/eji.1830200727; CARBALLIDO JM, 1993, J IMMUNOL, V150, P3582; CARBALLIDO JM, 1992, EUR J IMMUNOL, V22, P1357, DOI 10.1002/eji.1830220605; CARBALLIDO JM, 1992, INT ARCH ALLERGY IMM, V99, P366, DOI 10.1159/000236286; CHRETIEN I, 1990, EUR J IMMUNOL, V20, P243, DOI 10.1002/eji.1830200203; DELPRETE G, 1988, J IMMUNOL, V140, P4193; FERRANTE A, 1986, INT ARCH ALLER A IMM, V81, P284, DOI 10.1159/000234148; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; GASCAN H, 1991, J IMMUNOL, V147, P8; GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; GRAFT DF, 1987, CLIN REV ALLERG, V5, P149; HELD W, 1989, SCAND J IMMUNOL, V29, P203, DOI 10.1111/j.1365-3083.1989.tb01117.x; JONES B, 1987, IMMUNOL REV, V99, P5, DOI 10.1111/j.1600-065X.1987.tb01169.x; KEMENY DM, 1987, INT ARCH ALLER A IMM, V83, P113, DOI 10.1159/000234343; KIMATA H, 1991, CLIN EXP IMMUNOL, V84, P395; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LUCAS AH, 1990, SPRINGER SEMIN IMMUN, V12, P385; LUNDGREN M, 1989, EUR J IMMUNOL, V19, P1311, DOI 10.1002/eji.1830190724; MAGGI E, 1992, J IMMUNOL, V148, P2142; NINOMIYA C, 1992, CLIN EXP IMMUNOL, V89, P261; NOELLE RJ, 1989, J IMMUNOL, V143, P1807; NOELLE RJ, 1991, FASEB J, V5, P2770, DOI 10.1096/fasebj.5.13.1833257; NUSSLEIN HG, 1991, INT ARCH ALLER A IMM, V95, P257, DOI 10.1159/000235438; NUSSLEIN HG, 1990, J CLIN LAB ANAL, V4, P414, DOI 10.1002/jcla.1860040605; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PFEIFFER C, 1991, IMMUNOL REV, V123, P65, DOI 10.1111/j.1600-065X.1991.tb00606.x; RANDOLPH CC, 1986, J ALLERGY CLIN IMMUN, V77, P823, DOI 10.1016/0091-6749(86)90379-9; RIEBEN R, 1989, J IMMUNOL METHODS, V119, P1, DOI 10.1016/0022-1759(89)90374-8; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SNAPPER CM, 1988, IMMUNOL REV, V102, P51, DOI 10.1111/j.1600-065X.1988.tb00741.x; SOBOTKA AK, 1976, J ALLERGY CLIN IMMUN, V57, P29, DOI 10.1016/0091-6749(76)90076-2; SOLOWAY P, 1991, J EXP MED, V174, P847, DOI 10.1084/jem.174.4.847; SONDERGAARD I, 1992, ALLERGY, V47, P467, DOI 10.1111/j.1398-9995.1992.tb00666.x; SPIEGELBERG HL, 1991, INT ARCH ALLER A IMM, V94, P181, DOI 10.1159/000235357; SPIEGELBERG HL, 1991, CLIN EXP IMMUNOL, V84, P400; THYPHRONITIS G, 1989, P NATL ACAD SCI USA, V86, P5580, DOI 10.1073/pnas.86.14.5580; WEN L, 1987, EUR J IMMUNOL, V17, P887, DOI 10.1002/eji.1830170624	42	59	59	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1994	93	4					758	767		10.1016/0091-6749(94)90256-9	http://dx.doi.org/10.1016/0091-6749(94)90256-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NH497	8163785				2022-12-18	WOS:A1994NH49700009
J	REISMAN, RE; LIVINGSTON, A				REISMAN, RE; LIVINGSTON, A			VENOM IMMUNOTHERAPY - 10 YEARS OF EXPERIENCE WITH ADMINISTRATION OF SINGLE VENOMS AND 50 MU-G MAINTENANCE DOSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						VENOM ANAPHYLAXIS; SINGLE VENOMS; 50 MU-G DOSE	ALLERGY; ALLERGENICITY; ANTIGENICITY	For the past 10 years, we have administered venom immunotherapy with single venoms, whenever it is possible, and maintenance doses of 50-mu-g. The choice of venoms was based on clinical history, skin test reactions, and a knowledge of venom cross-reactivity. There have been 258 re-stings in 108 patients with only three systemic reactions (2.7% per patient; 1.2% per sting). Two of these re-stings reactions were very mild, hives and facial edema, in patients who had had initial severe anaphylaxis. Five other patients had transient ill-defined symptoms, not considered allergic after re-stings. The patients covered a wide age range. Twenty-seven patients, nine under age 16 years, had initial dermal reactions only, and 44 patients had severe anaphylaxis. Most patients had multiple positive skin tests. Seventy-five patients received single venoms (yellow jacket, 58; honeybee, 15; hornet, 2), and 30 patients received two venoms. Re-stings occurred from 1 month to 8 years, (mean, 2 years) after starting treatment. Results indicate that this approach with 50-mu-g top doses and single venom immunotherapy may be sufficient in most patients with an associated decrease in the cost as well as possible increased morbidity associated with the use of multiple venom antigens.	SUNY BUFFALO,SCH MED,DEPT MED,DIV ALLERGY,BUFFALO,NY 14214; SUNY BUFFALO,SCH MED,DEPT PEDIAT,DIV ALLERGY,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								BOUSQUET J, 1987, ALLERGY, V42, P401, DOI 10.1111/j.1398-9995.1987.tb00355.x; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V68, P254, DOI 10.1016/0091-6749(81)90148-2; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V67, P290, DOI 10.1016/0091-6749(81)90024-5; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V70, P281, DOI 10.1016/0091-6749(82)90064-1; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V69, P268, DOI 10.1016/S0091-6749(82)80003-1; REISMAN RE, 1979, CLIN ALLERGY, V9, P167, DOI 10.1111/j.1365-2222.1979.tb01538.x; REISMAN RE, 1983, J ALLERGY CLIN IMMUN, V73, P246; SCHUBERTH KC, 1983, J PEDIATR-US, V102, P361, DOI 10.1016/S0022-3476(83)80649-0; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X	12	59	60	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1992	89	6					1189	1195		10.1016/0091-6749(92)90304-K	http://dx.doi.org/10.1016/0091-6749(92)90304-K			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HZ748	1607552	Bronze			2022-12-18	WOS:A1992HZ74800015
J	HUSS, K; SQUIRE, EN; CARPENTER, GB; SMITH, LJ; HUSS, RW; SALATA, K; SALERNO, M; AGOSTINELLI, D; HERSHEY, J				HUSS, K; SQUIRE, EN; CARPENTER, GB; SMITH, LJ; HUSS, RW; SALATA, K; SALERNO, M; AGOSTINELLI, D; HERSHEY, J			EFFECTIVE EDUCATION OF ADULTS WITH ASTHMA WHO ARE ALLERGIC TO DUST MITES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EDUCATION; COMPUTER; ASTHMA; MITE ALLERGY; ENVIRONMENT; ALLERGEN; HOME VISITS; SYMPTOMATOLOGY; AVOIDANCE; ADHERENCE	HOUSE DUST; AVOIDANCE; TRIAL; DERMATOPHAGOIDES; MORTALITY; CHILDHOOD; PATIENT	The effects of supplementary computer instruction in house dust mite-avoidance measures on adherence to implementing measures, on home dust mite-allergen levels, and on symptomatology were investigated in 52 adult patients with mite-associated asthma. Twenty-six patients received conventional instruction (counseling and written instruction) and the other 26 patients received conventional plus 22 minutes of interactive computer-assisted instruction. Instructions were aimed at mite-avoidance measures. Pre- and postinstruction dust samples were collected, and adherence was monitored. All patients kept symptom diaries twice a day. Patients' progress was followed for 12 weeks, and all patients completed the study. Adherence, number of observed and self-reported mite-avoidance measures implemented after visit, was higher for the computer group (p = 0.023). The computer-instructed group achieved significantly lower levels of mite allergen in bedroom carpets (p = 0.004) with mean levels of mite allergen declining from 6.5 +/- 7.6 to 2.2 +/- 4.3-mu-g/gm of dust (two-site monoclonal antibody assays), whereas levels for the conventional-instructed group did not change. Moreover, by study weeks 9 and 10, the computer-instructed group was significantly less symptomatic (p = 0.033). Mean symptom scores for this group decreased from 12.4 to 7.7, compared with 16.4 to 14.3. Conventional instruction supplemented with computer instruction is suggested in mite education.	CATHOLIC UNIV AMER,SCH NURSING,WASHINGTON,DC 20064	Catholic University of America	HUSS, K (corresponding author), WALTER REED ARMY MED CTR,ALLERGY IMMUNOL SERV,WASHINGTON,DC 20307, USA.							ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; CLUSS PA, 1985, MEASUREMENT STRATEGI, P401; COCKCROFT DW, 1983, LANCET, V2, P253; HUSS K, 1987, AVOIDANCE MEASURES H; KERREBIJN KF, 1970, BRONCHITIS, V3, P38; KINSMAN RA, 1973, PSYCHOSOM MED, V35, P250, DOI 10.1097/00006842-197305000-00008; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; LYONS C, 1982, HEART LUNG, V11, P340; MURRAY AB, 1983, PEDIATRICS, V71, P418; NICKLAS RA, 1989, ANN ALLERGY, V63, P578; PLATTSMILLS TAE, 1987, HOSP PRACT, V22, P91; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; PLATTSMILLS TAE, 1990, ALLERGY PROC, V11, P269, DOI 10.2500/108854190778879729; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; REED C, 1983, ALLERGY PRINCIPLES P, P811; RUBIN DH, 1986, PEDIATRICS, V77, P1; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P716, DOI 10.1136/adc.49.9.716; SLY RM, 1989, J ALLERGY CLIN IMMUN, V84, P421, DOI 10.1016/0091-6749(89)90351-5; SPECTOR SL, 1985, ANN ALLERGY, V55, P552; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; WALSHAW MJ, 1986, Q J MED, V58, P199; 1990, MMWR, V39, P493	25	59	60	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1992	89	4					836	843		10.1016/0091-6749(92)90439-9	http://dx.doi.org/10.1016/0091-6749(92)90439-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN860	1560167	Bronze			2022-12-18	WOS:A1992HN86000009
J	MATTHIESEN, F; SCHUMACHER, MJ; LOWENSTEIN, H				MATTHIESEN, F; SCHUMACHER, MJ; LOWENSTEIN, H			CHARACTERIZATION OF THE MAJOR ALLERGEN OF CYNODON-DACTYLON (BERMUDA GRASS) POLLEN, CYN D-I	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						GRASS; POLLEN; ALLERGEN; CHARACTERIZATION; PURIFICATION; CYNODON-DACTYLON; CYN D-I; MONOCLONAL ANTIBODIES	LOLIUM-PERENNE POLLEN; MONOCLONAL-ANTIBODIES; CROSS-ALLERGENICITY; P-I; IDENTIFICATION; IMMUNOASSAY; PROTEINS; EXTRACTS; BINDING	An allergen from Cynodon dactylon (Bermuda grass) pollen, Cyn d I, has been purified by a combination of concanavalin A-Sepharose affinity chromatography, and carboxymethyl-Sepharose chromatography. The allergen constitutes the major allergenic component of the pollen extract as observed by immunoelectrophoretic techniques, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, an IgE-inhibition experiment, and skin testing. In sodium dodecyl sulfate-polyacrylamide gel electrophoresis, Cyn d I is presented as a dominant 32 kd band and a minor 29 kd band, both binding IgE. Both bands are identified by monospecific rabbit antibodies (Abs) raised against Cyn d I. These Abs only weakly precipitate allergens from other grass species, indicating that Cyn d I possesses some unique immunochemical properties. Two of four purified murine monoclonal Abs raised against Cyn d I also bind to both bands of Cyn d I, indicating that the bands represent isoallergens with slightly different immunochemical properties. All four monoclonal Abs cross-react with pollen components from other grass species, especially Poa pratensis and Dactylis glomerata. The NH2-terminal sequence corresponding to approximately 10% of the complete sequence was determined, and it revealed high homology to the corresponding sequence of the major allergen of Lolium perenne, Lol p I. From the amino acid composition determination and immunoelectrophoretic comparison, the amount of Cyn d I in the source whole-pollen extract was estimated to be 15% wt/wt.	UNIV ARIZONA,DEPT PEDIAT,TUCSON,AZ 85721	University of Arizona	MATTHIESEN, F (corresponding author), ALK RES,BOGE ALLE 10 12,DK-2970 HORSHOLM,DENMARK.							BAER H, 1986, J ALLERGY CLIN IMMUN, V78, P624, DOI 10.1016/0091-6749(86)90080-1; BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; COTTAM GP, 1986, BIOCHEM J, V234, P305, DOI 10.1042/bj2340305; FORD SA, 1987, J ALLERGY CLIN IMMUN, V79, P711, DOI 10.1016/0091-6749(87)90201-6; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; KAHN CR, 1986, MOL IMMUNOL, V23, P1281, DOI 10.1016/0161-5890(86)90013-1; KARLSTAM B, 1982, J IMMUNOL METHODS, V54, P119, DOI 10.1016/0022-1759(82)90120-X; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P129, DOI 10.1016/0091-6749(76)90148-2; Lewis W. H., 1983, AIRBORNE ALLERGENIC, P105; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; MARSH DG, 1987, J ALLERGY CLIN IMMUN, V80, P639, DOI 10.1016/0091-6749(87)90282-X; MARSH DG, 1970, J ALLERGY, V46, P107, DOI 10.1016/0021-8707(70)90078-X; MARTIN BG, 1985, ANN ALLERGY, V54, P99; MATTHIESEN F, 1988, J ALLERGY CLIN IMMUN, V81, P266; MATTHIESEN F, 1989, J ALLERGY CLIN IMMUN, V83, P1124, DOI 10.1016/0091-6749(89)90456-9; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P309, DOI 10.1111/j.1365-2222.1991.tb01662.x; MATTHIESEN F, 1990, Clinical and Experimental Allergy, V20, P47; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P297, DOI 10.1111/j.1365-2222.1991.tb01661.x; ORREN A, 1977, S AFR MED J, V51, P586; OUTHERLONY O, 1978, HDB EXPT IMMUNOLOGY, V19, P1; PARK KB, 1988, ANAL BIOCHEM, V180, P55; PEREZ M, 1990, J BIOL CHEM, V265, P16210; SCHUMACHER MJ, 1988, J ALLERGY CLIN IMMUN, V82, P608, DOI 10.1016/0091-6749(88)90972-4; SCHUMACHER MJ, 1985, ANN ALLERGY, V55, P584; SHEN HD, 1988, CLIN ALLERGY, V18, P401, DOI 10.1111/j.1365-2222.1988.tb02888.x; SINGH MB, 1985, INT ARCH ALLER A IMM, V78, P300, DOI 10.1159/000233901; STANDRING R, 1987, INT ARCH ALLER A IMM, V83, P96, DOI 10.1159/000234338; WATSON L, 1974, NATURE, V249, P574, DOI 10.1038/249574a0; WATSON L, 1983, P SYDNEY ALLERGEN GR, V3, P37; WEEKS I, 1983, CLIN CHEM, V29, P1474	32	59	65	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1991	88	5					763	774		10.1016/0091-6749(91)90184-P	http://dx.doi.org/10.1016/0091-6749(91)90184-P			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GQ452	1955635	Bronze			2022-12-18	WOS:A1991GQ45200012
J	ZORATTI, EM; SEDGWICK, JB; VRTIS, RR; BUSSE, WW				ZORATTI, EM; SEDGWICK, JB; VRTIS, RR; BUSSE, WW			THE EFFECT OF PLATELET-ACTIVATING-FACTOR ON THE GENERATION OF SUPEROXIDE ANION IN HUMAN EOSINOPHILS AND NEUTROPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PAF; EOSINOPHILS; SUPEROXIDE GENERATION; NEUTROPHILS; INTRACELLULAR CALCIUM	FACTOR PAF-ACETHER; HYPODENSE EOSINOPHILS; ENDOTHELIAL-CELLS; DE-GRANULATION; RELEASE; STIMULATION; DENSITY; PHAGOCYTOSIS; ANTAGONIST; BASOPHILS	The precise role of platelet-activating factor (PAF) in asthma has yet to be established. Nonetheless, the potential relationship between PAF and asthma appears to include the eosinophil (EOS) as an important link. Thus, to evaluate the effect of PAF on leukocyte-dependent inflammation, purified populations of human blood EOSs and neutrophils were isolated from the same subject. The two granulocyte populations were then incubated with PAF, and superoxide anion (O2-) generation was measured by reduction of cytochrome c in a microassay system. Both granulocyte cell types generated O2- when they were incubated with PAF. However, the generation of O2- was 3.4 times greater with EOSs (9.8 +/- 1.5 nmole of cytochrome c reduced per 5 x 10(5) cells) than neutrophils (2.9 +/- 0.4 nmole of cytochrome c reduced per 5 x 10(5) cells; p < 0.0001). When the effect of PAF on [Ca++]i of neutrophils occurred with lower concentrations of PAF. Furthermore, when similar experiments were conducted in the presence of an extracellular calcium chelator, ethylene glycol-bis-(beta-aminoethylether)-N,N,N', N'-tetraacetic acid, there was partial suppression in both the cellular fluorescence and O2-generation to PAF; this suggests that full expression of EOS generation of O2- by PAF requires both intracellular mobilization and a transmembrane influx of Ca++. Our data indicate that PAF can stimulate leukocyte O2- generation, but this response is greater in the EOS than the neutrophil. Therefore, our findings support the observation that the EOS is more responsive to PAF activation than other granulocytes and that this difference may contribute to participation of PAF in asthma.	UNIV WISCONSIN,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023181, R01AI015685, R01AI026609] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-15685, AI-23181, AI-26609] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APELDORF WJ, 1985, BIOCHEM BIOPH RES CO, V132, P674; ARCHER CB, 1984, BRIT J DERMATOL, V110, P45, DOI 10.1111/j.1365-2133.1984.tb07310.x; ARNOUX B, 1980, EUR J CLIN INVEST, V10, P437, DOI 10.1111/j.1365-2362.1980.tb02082.x; ARNOUX B, 1985, AM REV RESPIR DIS, V131, P2; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CAMUSSI G, 1983, AM J PATHOL, V112, P78; CAMUSSI G, 1983, J IMMUNOL, V131, P2397; CASALSSTENZEL J, 1987, J PHARMACOL EXP THER, V241, P974; CASALSSTENZEL J, 1987, IMMUNOPHARMACOLOGY, V3, P7; CHUNG KF, 1987, AM REV RESPIR DIS, V135, P159; CUSS FM, 1986, LANCET, V2, P189; DILLON PK, 1988, INFLAMMATION, V12, P563, DOI 10.1007/BF00914318; FRICK WE, 1989, AM REV RESPIR DIS, V139, P1401, DOI 10.1164/ajrccm/139.6.1401; FRICK WE, 1988, J ALLERGY CLIN IMMUN, V82, P119, DOI 10.1016/0091-6749(88)90061-9; GATEU O, 1984, AM REV RESPIR DIS, V133, P129; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HENSON PM, 1976, J EXP MED, V143, P937, DOI 10.1084/jem.143.4.937; HWANG SB, 1988, J BIOL CHEM, V263, P3225; JOUVINMARCHE E, 1984, FED PROC, V43, P1924; KAJITA T, 1985, INT ARCH ALLER A IMM, V78, P406, DOI 10.1159/000233922; KIMANI G, 1988, J IMMUNOL, V140, P3161; KOENDERMAN L, 1989, J IMMUNOL, V142, P623; KROEGEL C, 1989, BIOCHEM BIOPH RES CO, V162, P511, DOI 10.1016/0006-291X(89)92027-5; KROEGEL C, 1989, J IMMUNOL, V142, P3518; KROEGEL C, 1988, IMMUNOLOGY, V64, P559; LAVIS JC, 1983, EXP MOL PATHOL, V38, P100; LEE TC, 1984, J BIOL CHEM, V259, P5526; MACDONALD AJ, 1986, J ALLERGY CLIN IMMUN, V77, P227; OJIMAUCHIYAMA A, 1988, LIPIDS, V23, P815, DOI 10.1007/BF02536227; PRIN L, 1983, INT ARCH ALLER A IMM, V72, P336, DOI 10.1159/000234893; RUBIN AE, 1987, AM REV RESPIR DIS, V163, P1145; SANCHEZCRESPO M, 1980, IMMUNOLOGY, V40, P645; SEDGWICK J B, 1991, Journal of Allergy and Clinical Immunology, V87, P240, DOI 10.1016/0091-6749(91)91687-O; SEDGWICK JB, 1988, J ALLERGY CLIN IMMUN, V81, P876, DOI 10.1016/0091-6749(88)90945-1; SEDGWICK JB, 1990, AM REV RESPIR DIS, V142, P120, DOI 10.1164/ajrccm/142.1.120; SHAW JO, 1981, J IMMUNOL, V127, P1250; TAKIZAWA H, 1988, INT ARCH ALLER A IMM, V86, P375, DOI 10.1159/000234622; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V58, P593, DOI 10.1016/0006-3002(62)90073-2; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WINQVIST I, 1982, IMMUNOLOGY, V47, P531; YAMADA K, 1988, J CHROMATOGR-BIOMED, V433, P243, DOI 10.1016/S0378-4347(00)80603-9	42	59	59	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1991	88	5					749	758		10.1016/0091-6749(91)90182-N	http://dx.doi.org/10.1016/0091-6749(91)90182-N			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GQ452	1659593				2022-12-18	WOS:A1991GQ45200010
J	KITA, H; ABUGHAZALEH, R; SANDERSON, CJ; GLEICH, GJ				KITA, H; ABUGHAZALEH, R; SANDERSON, CJ; GLEICH, GJ			EFFECT OF STEROIDS ON IMMUNOGLOBULIN-INDUCED EOSINOPHIL DEGRANULATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article								Because glucocorticoids are a mainstay in the treatment of asthma and other allergic diseases, we tested the effect of various steroid hormones on secretory IgA- and IgG-induced eosinophil degranulation in vitro. Human normodense eosinophils were purified by discontinuous Percoll density gradient, and hypodense eosinophils were obtained by culture of normodense cells with recombinant human interleukin (rIL)-5. Eosinophils were incubated with various steroids, including dexamethasone, hydrocortisone, methylprednisolone, estradiol, or dihydrotestosterone at concentrations from 10(-9) to 10(-4) Mol/L. Sepharose 4B beads coupled to ovalbumin, secretory IgA, or IgG were added as targets of degranulation and incubated at 37-degrees-C for 4 hours. In some experiments, rIL-5 was added to eosinophils before addition of beads to activate the cells. The release of eosinophil-derived neurotoxin was measured by radioimmunoassay as an index of degranulation. Dexamethasone (10(-9) to 10(-4) mol/L), hydrocortisone (10(-9) to 10(-4) mol/L), estradiol (10(-9) to 10(-7) mol/L), and dihydrotestosterone (10(-9) to 10(-4) mol/L) had no effect on normodense eosinophil degranulation. Methylprednisolone, 10(-5) mol/L, inhibited degranulation of normodense eosinophils up to 20%, whereas 10(-4) mol/L inhibited degranulation of hypodense eosinophils, up to 30%. Overall, no difference in inhibition by steroids was observed between normodense and hypodense eosinophils. rIL-5 enhanced immunoglobulin-induced eosinophil degranulation, but this effect of rIL-5 was not blocked by any of the steroids tested. These results suggest that eosinophil degranulation and rIL-5-mediated eosinophil activation are not direct targets of glucocorticoids and that the beneficial effects of glucocorticoids on allergic inflammation in vivo are not likely due to direct effects on eosinophil degranulation.	MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, ALLERG DIS RES LAB, ROCHESTER, MN 55905 USA; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	Mayo Clinic; Mayo Clinic; MRC National Institute for Medical Research					NIAID NIH HHS [AI 15231, AI 09728] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015231, R01AI009728, R37AI009728, R01AI015231] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; ALTMAN LC, 1981, J CLIN INVEST, V67, P28, DOI 10.1172/JCI110024; BUTTERFIELD JH, 1986, J ALLERGY CLIN IMMUN, V78, P450, DOI 10.1016/0091-6749(86)90032-1; CAMPBELL HD, 1987, P NATL ACAD SCI USA, V84, P6629, DOI 10.1073/pnas.84.19.6629; CHURCH MK, 1978, BRIT J PHARMACOL, V62, P481, DOI 10.1111/j.1476-5381.1978.tb07751.x; CLARK RAF, 1979, BLOOD, V53, P633; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; DOR PJ, 1984, AM REV RESPIR DIS, V130, P1072; DWYER J, 1967, AUSTRALAS ANN MED, V16, P297; FAUCI AS, 1976, ANN INTERN MED, V84, P304, DOI 10.7326/0003-4819-84-3-304; FEIGELSON M, 1966, J BIOL CHEM, V241, P5819; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; FUJISAWA T, 1990, J IMMUNOL, V144, P642; FUKUDA T, 1985, AM REV RESPIR DIS, V132, P981; GAUDERER CA, 1978, P SOC EXP BIOL MED, V157, P129, DOI 10.3181/00379727-157-40006; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GLEICH GJ, 1984, NEW ENGL J MED, V310, P1621, DOI 10.1056/NEJM198406213102501; HALLAM C, 1982, CLIN EXP IMMUNOL, V48, P641; HAMANAKA Y, 1970, ACTA ENDOCRINOL-COP, V64, P439, DOI 10.1530/acta.0.0640439; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; JONES DG, 1974, J PHARM PHARMACOL, V26, P917, DOI 10.1111/j.2042-7158.1974.tb09208.x; LEIFERMAN KM, 1986, J AM ACAD DERMATOL, V15, P513, DOI 10.1016/S0190-9622(86)70203-X; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; PETERSON AP, 1981, J ALLERGY CLIN IMMUN, V68, P212, DOI 10.1016/0091-6749(81)90186-X; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; ROTMAN B, 1966, P NATL ACAD SCI USA, V55, P134, DOI 10.1073/pnas.55.1.134; SANDERSON CJ, 1985, J EXP MED, V162, P60, DOI 10.1084/jem.162.1.60; SCHLEIMER R, 1989, ANTIINFLAMMATORY STE, pP564; STEVENSO.RD, 1973, CLIN EXP IMMUNOL, V14, P417; TSURUFUJI S, 1979, NATURE, V280, P408, DOI 10.1038/280408a0; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; WINQVIST I, 1984, IMMUNOLOGY, V51, P1; YAMAGUCHI Y, 1988, J EXP MED, V167, P43, DOI 10.1084/jem.167.1.43; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737	35	59	60	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1991	87	1	1				70	77		10.1016/0091-6749(91)90214-9	http://dx.doi.org/10.1016/0091-6749(91)90214-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX985	1991924				2022-12-18	WOS:A1991EX98500009
J	GOODMAN, DL; MCDONNELL, JT; NELSON, HS; VAUGHAN, TR; WEBER, RW				GOODMAN, DL; MCDONNELL, JT; NELSON, HS; VAUGHAN, TR; WEBER, RW			CHRONIC URTICARIA EXACERBATED BY THE ANTIOXIDANT FOOD PRESERVATIVES, BUTYLATED HYDROXYANISOLE (BHA) AND BUTYLATED HYDROXYTOLUENE (BHT)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											GOODMAN, DL (corresponding author), FITZSIMONS ARMY MED CTR,ALLERGY CLIN IMMUNOL SERV,AURORA,CO 80045, USA.							BABICH H, 1982, ENVIRON RES, V29, P1, DOI 10.1016/0013-9351(82)90002-0; CLONINGER P, 1974, ANN ALLERGY, V32, P131; FISHERMAN EW, 1976, ANN ALLERGY, V36, P400; FISHERMAN EW, 1973, ANN ALLERGY, V31, P126; GIBSON A, 1980, CLIN ALLERGY, V10, P699, DOI 10.1111/j.1365-2222.1980.tb02154.x; GREEN GR, 1965, ANN ALLERGY, V23, P30; JUHLIN L, 1981, BRIT J DERMATOL, V104, P369, DOI 10.1111/j.1365-2133.1981.tb15306.x; JUHLIN L, 1985, URTICARIAS, P105; KAPLAN AP, 1988, ALLERGY PRINCIPLES P, P1377; MONERETVAUTRIN DA, 1986, ALLERGY, V41, P546, DOI 10.1111/j.1398-9995.1986.tb00342.x; MONROE EW, 1985, URTICARIAS, P189; MOOREROBINSON M, 1967, BRIT MED J, V4, P264; OSMUNDSEN PE, 1980, CONTACT DERMATITIS, V6, P452, DOI 10.1111/j.1600-0536.1980.tb05564.x; ROEDPETERSEN J, 1976, BRIT J DERMATOL, V94, P233, DOI 10.1111/j.1365-2133.1976.tb04379.x; STEVENSON DD, 1980, J ALLERGY CLIN IMMUN, V66, P82, DOI 10.1016/0091-6749(80)90143-8; STEVENSON DD, 1986, J ALLERGY CLIN IMMUN, V78, P182, DOI 10.1016/0091-6749(86)90011-4; THUNE P, 1975, DERMATOLOGICA, V151, P360, DOI 10.1159/000251361; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V64, P32, DOI 10.1016/0091-6749(79)90080-0	18	59	61	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	1				570	575		10.1016/S0091-6749(05)80214-3	http://dx.doi.org/10.1016/S0091-6749(05)80214-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EG454	2229816				2022-12-18	WOS:A1990EG45400018
J	FADEL, R; DAVID, B; HERPINRICHARD, N; BORGNON, A; RASSEMONT, R; RIHOUX, JP				FADEL, R; DAVID, B; HERPINRICHARD, N; BORGNON, A; RASSEMONT, R; RIHOUX, JP			INVIVO EFFECTS OF CETIRIZINE ON CUTANEOUS REACTIVITY AND EOSINOPHIL MIGRATION INDUCED BY PLATELET-ACTIVATING FACTOR (PAF-ACETHER) IN MAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									INST PASTEUR, SERV ALLERGOL, F-75724 PARIS 15, FRANCE; UNION CHEM BELGE SA, PHARMACEUT SECTOR, Braine lAlleud, BELGIUM	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	FADEL, R (corresponding author), INST PASTEUR, UNITE IMMUNOALLERGIE, 28 RUE DR ROUX, F-75724 PARIS 15, FRANCE.							ARCHER CB, 1985, BRIT J PHARMACOL, V85, P109, DOI 10.1111/j.1476-5381.1985.tb08836.x; ARCHER CB, 1985, BRIT J DERMATOL, V112, P285, DOI 10.1111/j.1365-2133.1985.tb04855.x; BARNES PJ, 1988, J ALLERGY CLIN IMMUN, V81, P919, DOI 10.1016/0091-6749(88)90952-9; BASRAN G S, 1983, European Journal of Pharmacology, V86, P143; BRIK A, 1987, J ALLERGY CLIN IMMUN, V80, P51, DOI 10.1016/S0091-6749(87)80190-2; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; CHUNG KF, 1988, J ALLERGY CLIN IMMUN, V81, P1192, DOI 10.1016/0091-6749(88)90890-1; COYLE AJ, 1988, EUR J PHARMACOL, V148, P51, DOI 10.1016/0014-2999(88)90453-0; FADEL R, 1988, J ALLERGY CLIN IMMUN, V81, P178, DOI 10.1016/0091-6749(88)90277-1; FADEL R, 1987, CLIN ALLERGY, V17, P373, DOI 10.1111/j.1365-2222.1987.tb02027.x; FELARCA AB, 1971, J ALLERGY CLIN IMMUN, V48, P125, DOI 10.1016/0091-6749(71)90007-8; FOWLER JW, 1966, J ALLERGY, V37, P19, DOI 10.1016/0021-8707(66)90106-7; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GENDREAUREID L, 1986, J ALLERGY CLIN IMMUN, V77, P335, DOI 10.1016/S0091-6749(86)80114-2; GHOSH SK, 1989, JUL BRIT THOR SOC M; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GUINOT P, 1986, PROSTAGLANDINS, V32, P160, DOI 10.1016/0090-6980(86)90161-9; HENOCQ E, 1988, J ALLERGY CLIN IMMUN, V81, P691, DOI 10.1016/0091-6749(88)91040-8; JUHLIN L, 1987, J ALLERGY CLIN IMMUN, V80, P599, DOI 10.1016/0091-6749(87)90014-5; KURIHARA K, 1989, J ALLERGY CLIN IMMUN, V83, P83, DOI 10.1016/0091-6749(89)90480-6; LATRIGUEMARTEI C, 1982, AGENTS ACTIONS, V12, P703; LEE TC, 1984, J BIOL CHEM, V259, P5526; LEPREVOST C, 1988, INT ARCH ALLER A IMM, V87, P9, DOI 10.1159/000234641; MICHEL L, 1987, J INVEST DERMATOL, V88, P675, DOI 10.1111/1523-1747.ep12470331; MICHEL L, 1988, J ALLERGY CLIN IMMUN, V82, P101, DOI 10.1016/0091-6749(88)90058-9; ROBERTS NM, 1988, J ALLERGY CLIN IMMUN, V82, P236, DOI 10.1016/0091-6749(88)91005-6; SHALIT M, 1989, J ALLERGY CLIN IMMUN, V83, P691, DOI 10.1016/0091-6749(89)90084-5; SIGAL CE, 1987, J CLIN IMMUNOL, V7, P179, DOI 10.1007/BF00916012; TAMURA N, 1987, BIOCHEM BIOPH RES CO, V142, P638, DOI 10.1016/0006-291X(87)91462-8; VENGE P, 1987, INT ARCH ALLER A IMM, V82, P333, DOI 10.1159/000234219; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765	31	59	60	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1990	86	3	1				314	320		10.1016/S0091-6749(05)80093-4	http://dx.doi.org/10.1016/S0091-6749(05)80093-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA859	1976664				2022-12-18	WOS:A1990EA85900004
J	NICKLAS, RA				NICKLAS, RA			PARADOXICAL BRONCHOSPASM ASSOCIATED WITH THE USE OF INHALED BETA AGONISTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									US FDA,OFF DRUG EVALUAT & RES,ROCKVILLE,MD 20857	US Food & Drug Administration (FDA)								ALLEGRA L, 1980, EUR J RESPIR DIS, V61, P41; AVIADO DM, 1972, C TOXIC HAZARDS HALO, P63; BATEMAN JRM, 1979, THORAX, V34, P40, DOI 10.1136/thx.34.1.40; BEASLEY CRW, 1987, BRIT MED J, V294, P1197, DOI 10.1136/bmj.294.6581.1197-a; CACOUB P, 1986, PRESSE MED, V150, P803; CLARK RJ, 1986, LANCET, V1, P74; COCHRANE GM, 1975, THORAX, V30, P300, DOI 10.1136/thx.30.3.300; CONNELLY CK, 1982, BRIT MED J, V294, P1197; FANTA CH, 1986, AM J MED, V80, P5, DOI 10.1016/0002-9343(86)90041-0; FRASER P M, 1971, British Journal of Diseases of the Chest, V65, P71, DOI 10.1016/0007-0971(71)90008-8; GONG H, 1981, CHEST, V80, P167, DOI 10.1378/chest.80.2.167; GRAFFLONNEVIG V, 1979, J ALLERGY CLIN IMMUN, V64, P534, DOI 10.1016/0091-6749(79)90064-2; HETZEL MR, 1977, BMJ-BRIT MED J, V1, P808, DOI 10.1136/bmj.1.6064.808; HUTT N, 1986, REV FR ALLERGOL, V26, P147, DOI 10.1016/S0335-7457(86)80008-9; INMAN WHW, 1969, LANCET, V2, P279; KOEPKE JW, 1984, JAMA-J AM MED ASSOC, V251, P2982, DOI 10.1001/jama.251.22.2982; KOEPKE JW, 1983, J ALLERGY CLIN IMMUN, V72, P504, DOI 10.1016/0091-6749(83)90588-2; LEYNADIER F, 1985, ALLERGY, V40, P540, DOI 10.1111/j.1398-9995.1985.tb00264.x; MACDONALD JB, 1976, BRIT MED J, V1, P1493, DOI 10.1136/bmj.1.6024.1493; MACQUIN I, 1984, J PHYSL PARIS, V79, P80; MALISH DM, 1985, IMMUNOL ALLERGY PRAC, V7, P31; MANN JS, 1984, BRIT MED J, V289, P469, DOI 10.1136/bmj.289.6443.469; MCGIVERN DV, 1984, BRIT MED J, V288, P447, DOI 10.1136/bmj.288.6415.447; MOLER FW, 1988, J ALLERGY CLIN IMMUN, V81, P1101, DOI 10.1016/0091-6749(88)90876-7; NEWHOUSE MT, 1986, NEW ENGL J MED, V315, P870, DOI 10.1056/NEJM198610023151406; OCALLAGHAN C, 1986, LANCET, V2, P1424, DOI 10.1016/S0140-6736(86)92735-2; ORMEROD LP, 1980, BRIT MED J, V280, P687, DOI 10.1136/bmj.280.6215.687; PATEL KR, 1983, BRIT MED J, V286, P1318, DOI 10.1136/bmj.286.6374.1318; PRENDIVILLE A, 1987, ARCH DIS CHILD, V62, P997, DOI 10.1136/adc.62.10.997; PRENDIVILLE A, 1987, THORAX, V42, P86, DOI 10.1136/thx.42.2.86; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; REISMAN RE, 1970, J ALLERGY, V46, P152; SCHOEFFEL RE, 1981, BRIT MED J, V283, P1285, DOI 10.1136/bmj.283.6302.1285; SEARS MR, 1986, EUR J RESPIR DIS, V69, P175; SHEPPARD D, 1983, AM REV RESPIR DIS, V127, P691; SHIM C, 1987, CHEST, V91, P207, DOI 10.1378/chest.91.2.207; SHIM CS, 1987, ANN INTERN MED, V106, P700, DOI 10.7326/0003-4819-106-5-700; SIEGEL D, 1985, AM REV RESPIR DIS, V132, P283; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; STABLEFORTH D, 1983, THORAX, V38, P801, DOI 10.1136/thx.38.11.801; STEINBRUGGER B, 1987, AUST PAEDIATR J, V23, P379; STERLING GM, 1969, THORAX, V24, P228, DOI 10.1136/thx.24.2.228; STOLLEY PD, 1972, AM REV RESPIR DIS, V105, P883; SUNAGA Y, 1986, KOKYU TO JUNKAN, V5, P467; TRAUTLEIN J, 1976, CHEST, V70, P711, DOI 10.1378/chest.70.6.711; VALIC F, 1977, BRIT J IND MED, V34, P130; VANDEWALKER ML, 1986, CHEST, V90, P198, DOI 10.1378/chest.90.2.198; YARBROUGH J, 1985, ANN ALLERGY, V55, P55; 1988, CURRENT PROBL, P22	49	59	59	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1990	85	5					959	964		10.1016/0091-6749(90)90084-H	http://dx.doi.org/10.1016/0091-6749(90)90084-H			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DD959	1970585				2022-12-18	WOS:A1990DD95900022
J	KOSHTE, VL; KAGEN, SL; AALBERSE, RC				KOSHTE, VL; KAGEN, SL; AALBERSE, RC			CROSS-REACTIVITY OF IGE ANTIBODIES TO CADDIS FLY WITH ARTHROPODA AND MOLLUSCA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,PUBLICAT SECRETARIAT,POB 9406,1006 AK AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,CLIN & EXPTL IMMUNOL LAB,AMSTERDAM,NETHERLANDS; COLL WISCONSIN,DEPT MED,APPLETON,WI	University of Amsterdam; Medical College of Wisconsin								AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; AALBERSE RC, 1983, RECENT DEV RAST OTHE, P17; BAUR X, 1982, J ALLERGY CLIN IMMUN, V69, P66, DOI 10.1016/0091-6749(82)90090-2; BAUR X, 1983, CLIN EXP IMMUNOL, V54, P599; BROCK T, 1961, ANN ALLERGY, V19, P288; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; ELRAB MOG, 1980, J ALLERGY CLIN IMMUN, V66, P190; FEINBERG S, 1949, ALLERGY PRACTICE, P458; GOODMAN M, 1983, H-S Z PHYSIOL CHEM, V364, P205, DOI 10.1515/bchm2.1983.364.1.205; ITO K, 1986, ANN ALLERGY, V57, P199; KAGEN S L, 1984, Journal of Allergy and Clinical Immunology, V73, P187; KAGEN SL, 1986, J ALLERGY CLIN IMMUN, V77, P140; KAGEN SL, 1986, J ALLERGY CLIN IMMUN, V77, P192; KAY AB, 1978, CLIN EXP IMMUNOL, V34, P106; KINO T, 1987, J ALLERGY CLIN IMMUN, V79, P857, DOI 10.1016/0091-6749(87)90233-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OKA S, 1987, J ALLERGY CLIN IMMUN, V80, P57, DOI 10.1016/S0091-6749(87)80191-4; OSGOOD H, 1957, J ALLERGY, V28, P113, DOI 10.1016/0021-8707(57)90017-5; Parlato S.J., 1929, J ALLERGY, V1, P35; PERLMAN F, 1958, J ALLERGY, V29, P302, DOI 10.1016/0021-8707(58)90037-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	21	59	58	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1989	84	2					174	183		10.1016/0091-6749(89)90322-9	http://dx.doi.org/10.1016/0091-6749(89)90322-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL836	2547857				2022-12-18	WOS:A1989AL83600007
J	OHMAN, JL				OHMAN, JL			ALLERGEN IMMUNOTHERAPY IN ASTHMA - EVIDENCE FOR EFFICACY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TUFTS UNIV,NEW ENGLAND MED CTR,DIV ALLERGY,BOSTON,MA 02111	Tufts Medical Center; Tufts University								AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; COCKCROFT DW, 1988, J ALLERGY CLIN IMMUN, V81, P111, DOI 10.1016/0091-6749(88)90229-1; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; FRANKLAND AW, 1954, LANCET, V1, P1055; FRANKLIN W, 1967, JAMA-J AM MED ASSOC, V201, P95; FRICK OL, 1986, J ALLERGY CLIN IMMUN, V78, P1013, DOI 10.1016/0091-6749(86)90295-2; HILL DJ, 1982, BRIT MED J, V284, P306, DOI 10.1136/bmj.284.6312.306; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; KARLSSON R, 1986, ALLERGY, V41, P141, DOI 10.1111/j.1398-9995.1986.tb00290.x; KHOT A, 1988, CLIN ALLERGY, V18, P351, DOI 10.1111/j.1365-2222.1988.tb02882.x; KURATA JH, 1976, ANN ALLERGY, P398; LARSEN JN, 1988, J ALLERGY CLIN IMMUN, V82, P318, DOI 10.1016/0091-6749(88)90002-4; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; MAUNSELL K, 1971, LANCET, V1, P967; MCALLEN MK, 1969, ACTA ALLERGOL, V24, P421, DOI 10.1111/j.1398-9995.1969.tb03756.x; NEWTON DAG, 1978, BRIT J DIS CHEST, V72, P21, DOI 10.1016/0007-0971(78)90004-9; Noon L, 1911, LANCET, V1, P1572; NORMAN P S, 1973, P211; NORMAN PS, 1988, J ALLERGY CLIN IMMUN, V81, P992, DOI 10.1016/0091-6749(88)90167-4; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OHMAN JL, 1978, J AM VET MED ASSOC, V172, P1403; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; PAULI G, 1984, J ALLERGY CLIN IMMUN, V74, P524, DOI 10.1016/0091-6749(84)90389-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; PRICE JF, 1984, CLIN ALLERGY, V14, P209, DOI 10.1111/j.1365-2222.1984.tb02200.x; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; SMITH AP, 1971, BRIT MED J, V4, P204, DOI 10.1136/bmj.4.5781.204; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TOCHINDA M, 1973, J ALLERGY CLIN IMMUN, V51, P131; VALOVIRTA E, 1984, ANN ALLERGY, V53, P85; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3; YUNGINGER JW, 1984, J ALLERGY CLIN IMMUN, V73, P316, DOI 10.1016/0091-6749(84)90402-0; 1979, BR J DIS CHEST, V73, P260; 1986, J ALLERGY CLIN IMMUN, V77, P271	40	59	59	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1989	84	2					133	140		10.1016/0091-6749(89)90313-8	http://dx.doi.org/10.1016/0091-6749(89)90313-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL836	2668379				2022-12-18	WOS:A1989AL83600001
J	LILJA, G; SUNDIN, B; GRAFFLONNEVIG, V; HEDLIN, G; HEILBORN, H; NORRLIND, K; PEGELOW, KO; LOWENSTEIN, H				LILJA, G; SUNDIN, B; GRAFFLONNEVIG, V; HEDLIN, G; HEILBORN, H; NORRLIND, K; PEGELOW, KO; LOWENSTEIN, H			IMMUNOTHERAPY WITH CAT-DANDER AND DOG-DANDER EXTRACTS .4. EFFECTS OF 2 YEARS OF TREATMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV HOSP SACHS,STOCKHOLM,SWEDEN; UNIV HOSP HUDDINGE,STOCKHOLM,SWEDEN; UNIV HOSP DANDERYD,STOCKHOLM,SWEDEN; UNIV COPENHAGEN,PROT LAB,DK-1168 COPENHAGEN K,DENMARK	Danderyds Hospital; University of Copenhagen								AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; BLANDS J, 1977, ACTA ALLERGOL, V32, P147, DOI 10.1111/j.1398-9995.1977.tb01346.x; COCKCROFT DW, 1983, LANCET, V2, P253; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; HEDLIN G, 1986, J ALLERGY CLIN IMMUN, V77, P488, DOI 10.1016/0091-6749(86)90184-3; LOWENSTEIN H, 1986, J ALLERGY CLIN IMMUN, V77, P497, DOI 10.1016/0091-6749(86)90185-5; MURRAY A, 1985, ANN ALLERGY, V54, P542; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OSTERBALLE O, 1982, ALLERGY, V37, P553, DOI 10.1111/j.1398-9995.1982.tb02340.x; OSTERBALLE O, 1981, ALLERGY, V36, P183, DOI 10.1111/j.1398-9995.1981.tb01834.x; PEGELOW KO, 1984, ALLERGY, V39, P275, DOI 10.1111/j.1398-9995.1984.tb00864.x; PLATTSMILLS TAE, 1982, LANCET, V2, P675; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; VALOVIRTA E, 1986, ANN ALLERGY, V57, P173	15	59	60	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					37	44		10.1016/0091-6749(89)90475-2	http://dx.doi.org/10.1016/0091-6749(89)90475-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419	2913138				2022-12-18	WOS:A1989T041900006
J	EARL, HS; SULLIVAN, TJ				EARL, HS; SULLIVAN, TJ			ACUTE DESENSITIZATION OF A PATIENT WITH CYSTIC-FIBROSIS ALLERGIC TO BOTH BETA-LACTAM AND AMINOGLYCOSIDE ANTIBIOTICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV ALLERGY & IMMUNOL,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas								ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P794; AHLSTEDT S, 1980, CRC CR REV TOXICOL, V7, P219, DOI 10.3109/10408448009032925; ARNDT KA, 1976, JAMA-J AM MED ASSOC, V235, P918, DOI 10.1001/jama.235.9.918; BROWN LA, 1982, J ALLERGY CLIN IMMUN, V69, P51, DOI 10.1016/0091-6749(82)90087-2; CALDWELL JR, 1974, JAMA-J AM MED ASSOC, V230, P77, DOI 10.1001/jama.230.1.77; CARRINGTON DM, 1986, J ALLERGY CLIN IMMUN, V77, P224; CROFTON J, 1953, BRIT MED J, V2, P1014, DOI 10.1136/bmj.2.4844.1014; de Weck A L, 1972, Int Arch Allergy Appl Immunol, V42, P798; FERNANDEZ MN, 1982, TRANSFUSION, V22, P344, DOI 10.1046/j.1537-2995.1982.22482251230.x; FISHER AA, 1983, CUTIS, V32, P510; FISHER AA, 1982, ANN ALLERGY, V49, P97; GREENBERGER PA, 1984, J ALLERGY CLIN IMMUN, V74, P600, DOI 10.1016/0091-6749(84)90113-1; HODSON ME, 1984, POSTGRAD MED J, V60, P225, DOI 10.1136/pgmj.60.701.225; JOHNSON AR, 1975, IMMUNOLOGY, V28, P1067; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; KRAFT D, 1981, CLIN ALLERGY, V11, P579, DOI 10.1111/j.1365-2222.1981.tb02178.x; MACGLASHAN DW, 1981, J IMMUNOL, V127, P2410; MARQUARDT DL, 1978, J IMMUNOL, V120, P871; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; MENDOZA GR, 1982, INT ARCH ALLER A IMM, V69, P282, DOI 10.1159/000233185; MOSS RB, 1984, J PEDIATR-US, V104, P460, DOI 10.1016/S0022-3476(84)81117-8; NORN S, 1974, CLIN EXP IMMUNOL, V18, P431; PARKER CW, 1967, METHODS IMMUNOLOGY I, V1, P133; PARKER CW, 1980, CLIN IMMUNOLOGY, P1219; PHILBIN DM, 1982, KLIN WOCHENSCHR, V60, P1056, DOI 10.1007/BF01716971; RAY MC, 1983, J IMMUNOL, V131, P1096; SAXON A, 1985, AM J MED, V78, P19, DOI 10.1016/0002-9343(85)90198-6; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P500, DOI 10.1016/0091-6749(82)90174-9; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; SULLIVAN TJ, 1985, NEW ENGL REG ALLERGY, V6, P160; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P275, DOI 10.1016/S0091-6749(82)80004-3; SULLIVAN TJ, 1984, J ALLERGY CLIN IMMUN, V74, P594, DOI 10.1016/0091-6749(84)90112-X; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P260, DOI 10.1016/S0091-6749(82)80002-X; SULLIVAN TJ, 1984, ALLERGY THEORY PRACT, P409; VERVLOET D, 1983, J ALLERGY CLIN IMMUN, V71, P552, DOI 10.1016/0091-6749(83)90436-0; VERVLOET D, 1985, J ALLERGY CLIN IMMUN, V76, P222, DOI 10.1016/0091-6749(85)90705-5; WENDEL GD, 1985, NEW ENGL J MED, V312, P1229, DOI 10.1056/NEJM198505093121905; WILSON HTH, 1958, BRIT MED J, V1, P1378, DOI 10.1136/bmj.1.5084.1378	38	59	60	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1987	79	3					477	483		10.1016/0091-6749(87)90365-4	http://dx.doi.org/10.1016/0091-6749(87)90365-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G4795	3819228	Bronze			2022-12-18	WOS:A1987G479500010
J	KALINER, M				KALINER, M			MECHANISMS OF GLUCOCORTICOSTEROID ACTION IN BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KALINER, M (corresponding author), NIAID, CLIN INVEST LAB, ALLERGY SECT, BLDG 10, ROOM 11 C-205, BETHESDA, MD 20205 USA.							ARKINS JA, 1968, J ALLERGY, V41, P209, DOI 10.1016/0021-8707(68)90043-9; BLACKWELL GJ, 1980, NATURE, V287, P147, DOI 10.1038/287147a0; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BRUCE C, 1976, THORAX, V31, P724, DOI 10.1136/thx.31.6.724; BURGE PS, 1982, EUR J RESPIR DIS, V63, P163; BURKA JF, 1979, BRIT J PHARMACOL, V65, P35, DOI 10.1111/j.1476-5381.1979.tb17331.x; BUSH RK, 1978, ARCH INTERN MED, V138, P1244, DOI 10.1001/archinte.138.8.1244; BUTLER WT, 1975, TRANSPLANT P, V7, P49; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CLAMAN HN, 1972, NEW ENGL J MED, V287, P388, DOI 10.1056/NEJM197208242870806; CLARKE PS, 1982, J ASTHMA, V19, P91, DOI 10.3109/02770908209104741; DAERON M, 1982, J IMMUNOL, V129, P1212; DAVIES AO, 1983, J CLIN INVEST, V71, P565, DOI 10.1172/JCI110801; DAVIES AO, 1980, J CLIN ENDOCR METAB, V51, P599, DOI 10.1210/jcem-51-3-599; EASTON JG, 1981, J ALLERGY CLIN IMMUN, V67, P388, DOI 10.1016/0091-6749(81)90084-1; FLOWER R, 1981, TRENDS PHARMACOL SCI, V2, P186, DOI 10.1016/0165-6147(81)90307-2; FLOWER RJ, 1974, PHARMACOL RES COMMUN, V26, P33; FRASER CM, 1980, BIOCHEM BIOPH RES CO, V94, P390, DOI 10.1016/S0006-291X(80)80233-6; HAMMOND CV, 1982, INT ARCH ALLER A IMM, V67, P284, DOI 10.1159/000233032; HIRATA F, 1980, P NATL ACAD SCI-BIOL, V77, P2533, DOI 10.1073/pnas.77.5.2533; IIZUKA H, 1983, J INVEST DERMATOL, V80, P524, DOI 10.1111/1523-1747.ep12535121; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; KALINER M, 1984, FED PROC, V43, P2846; KALINER M, 1984, J ALLERGY CLIN IMMUN, V73, P318, DOI 10.1016/0091-6749(84)90403-2; KOVACS EM, 1965, BRIT J PHARM CHEMOTH, V24, P574, DOI 10.1111/j.1476-5381.1965.tb01748.x; KUMAR L, 1971, PEDIATRICS, V47, P848; LAVKER RM, 1984, CLIN RES, V32, pA597; LIU AYC, 1984, TRENDS PHARMACOL SCI, V5, P106; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; MAROM Z, 1984, AM REV RESPIR DIS, V129, P62; MARQUARDT DL, 1983, J IMMUNOL, V131, P934; MARTIN GL, 1980, J ALLERGY CLIN IMMUN, V66, P204, DOI 10.1016/0091-6749(80)90040-8; MYGIND N, 1977, CLIN ALLERGY, V7, P69, DOI 10.1111/j.1365-2222.1977.tb01426.x; NAKAZAWA T, 1976, J ALLERGY CLIN IMMUN, V58, P1, DOI 10.1016/0091-6749(76)90101-9; PARKER CW, 1973, J CLIN INVEST, V52, P1342, DOI 10.1172/JCI107306; PEPYS J, 1974, CLIN ALLERGY, V4, P13, DOI 10.1111/j.1365-2222.1974.tb01358.x; POOTHULLIL J, 1976, J ALLERGY CLIN IMMUN, V57, P164, DOI 10.1016/0091-6749(76)90035-X; REBUCK JW, 1953, ANN NY ACAD SCI, V56, P715, DOI 10.1111/j.1749-6632.1953.tb27394.x; RICKETTI AJ, 1984, J ALLERGY CLIN IMMUN, V74, P68, DOI 10.1016/0091-6749(84)90089-7; Rose B, 1941, AM J PHYSIOL, V131, P0589; SCHLEIMER RP, 1981, NATURE, V292, P454, DOI 10.1038/292454a0; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; SCHLEIMER RP, 1982, J IMMUNOL, V129, P1632; SHEA C, 1978, ANN CLIN LAB SCI, V8, P30; SLOTT RI, 1975, J ALLERGY CLIN IMMUN, V55, P232, DOI 10.1016/0091-6749(75)90142-6; SLOTT RI, 1974, J ALLERGY CLIN IMMUN, V54, P229, DOI 10.1016/0091-6749(74)90065-7; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; WARD PA, 1966, J EXP MED, V124, P209, DOI 10.1084/jem.124.2.209; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2	49	59	60	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					321	329		10.1016/0091-6749(85)90648-7	http://dx.doi.org/10.1016/0091-6749(85)90648-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	2410476				2022-12-18	WOS:A1985APE8900012
J	ACKERMAN, MN; FRIEDMAN, RA; DOYLE, WJ; BLUESTONE, CD; FIREMAN, P				ACKERMAN, MN; FRIEDMAN, RA; DOYLE, WJ; BLUESTONE, CD; FIREMAN, P			ANTIGEN-INDUCED EUSTACHIAN-TUBE OBSTRUCTION - AN INTRANASAL PROVOCATIVE CHALLENGE TEST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PITTSBURGH,SCH MED,DEPT ALLERGY & IMMUNOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT OTOLARYNGOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT PEDIAT,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NINDS NIH HHS [1 PO1-NS-16337] Funding Source: Medline; PHS HHS [1 ROL-AL 19262] Funding Source: Medline; DRS NIH HHS [BRS-G SO7 BR20] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016337] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); DRS NIH HHS; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLUESTONE CD, 1975, ANN OTO RHINOL LARYN, V84, P333, DOI 10.1177/000348947508400308; BLUESTONE CD, 1981, ANN OTO RHINOL LARYN, V90, P552, DOI 10.1177/000348948109000608; BLUESTONE CD, 1978, PEDIATRICS, V61, P753; BLUESTONE CD, 1982, NEW ENGL J MED, V306, P1399, DOI 10.1056/NEJM198206103062305; BLUESTONE CD, 1977, LARYNGOSCOPE, V87, P493; BLUESTONE CD, 1975, HDB CLIN IMPEDANCE A, P127; DERLACKI EL, 1965, ANN ALLERGY, V23, P288; DRAPER WL, 1967, LARYNGOSCOPE, V77, P636, DOI 10.1288/00005537-196704000-00016; FERNANDEZ AA, 1965, SOUTH MED J, V58, P581, DOI 10.1097/00007611-196505000-00007; FISCHER TJ, 1978, PEDIATRICS, V62, P443; FRIEDMAN RA, 1983, J ALLERGY CLIN IMMUN, V71, P442, DOI 10.1016/0091-6749(83)90459-1; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; LIM DJ, 1976, ANN OTO RHINOL LARYN, V85, P117, DOI 10.1177/00034894760850S222; MOGI G, 1976, ANN OTO RHINOL LARYN, V85, P97, DOI 10.1177/00034894760850S219; PAPARELLA M M, 1970, Annals of Otology Rhinology and Laryngology, V79, P766; PHILLIPS MJ, 1974, LANCET, V2, P1176; RANKIN JD, 1970, ARCHIV OTOLARYNGOL, V92, P14; REISMAN RE, 1975, PEDIATR CLIN N AM, V22, P251; SENTURIA B H, 1960, Laryngoscope, V70, P287	19	59	59	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					604	609		10.1016/0091-6749(84)90519-0	http://dx.doi.org/10.1016/0091-6749(84)90519-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS045	6715726				2022-12-18	WOS:A1984SS04500012
J	KALINER, M; MAROM, Z; PATOW, C; SHELHAMER, J				KALINER, M; MAROM, Z; PATOW, C; SHELHAMER, J			HUMAN RESPIRATORY MUCUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WALTER REED ARMY MED CTR,DEPT HEAD & NECK SURG,WASHINGTON,DC 20012; NIH,BETHESDA,MD 20205	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; National Institutes of Health (NIH) - USA	KALINER, M (corresponding author), NIAID,ALLERG DIS SECT,BLDG 10,ROOM 11C205,BETHESDA,MD 20205, USA.							BERNSTEIN IL, 1964, DIS CHEST, V46, P469, DOI 10.1378/chest.46.4.469; BOAT TF, 1976, ARCH BIOCHEM BIOPHYS, V177, P95, DOI 10.1016/0003-9861(76)90419-7; BOAT TF, 1975, CHEST, V67, P325; BORIN MI, 1972, J LAB CLIN MED, V80, P275; BROGAN TD, 1960, BRIT J EXP PATHOL, V41, P288; CHAKRIN LW, 1973, AM REV RESPIR DIS, V108, P69; FALLIERS CJ, 1966, J ALLERGY, V38, P183, DOI 10.1016/0021-8707(66)90041-4; FREEMAN G, 1964, ARCH ENVIRON HEALTH, V8, P125, DOI 10.1080/00039896.1964.10663640; GALLAGHER JT, 1975, PROC R SOC SER B-BIO, V192, P49, DOI 10.1098/rspb.1975.0151; Gallagher JT, 1977, MUCUS HLTH DISEASE, P91; HAVEZ R, 1976, BRONCHIAL ASTHMA, P409; HIRSCH SR, 1967, J ALLERGY, V39, P265, DOI 10.1016/0021-8707(67)90090-1; HIRSCH SR, 1975, NEW DIRECTIONS ASTHM, P351; INNES IR, 1970, PHARMACOL BASIS, P524; JONES R, 1978, BRIT MED BULL, V34, P9, DOI 10.1093/oxfordjournals.bmb.a071466; KEAL EE, 1971, POSTGRAD MED J, V47, P171, DOI 10.1136/pgmj.47.545.171; KEAL EE, 1975, NEW DIRECTIONS ASTHM, P223; KILBURN KH, 1968, AM REV RESPIR DIS, V98, P449; LAMB D, 1968, J PATHOL BACTERIOL, V96, P97, DOI 10.1002/path.1700960111; LIEDTKE CM, 1982, CHEST S, V81, P20; LOPEZVIDRIERO M, 1975, THORAX, V30, P624, DOI 10.1136/thx.30.6.624; LOPEZVIDRIERO MT, 1975, THORAX, V30, P543, DOI 10.1136/thx.30.5.543; MANN S P, 1971, Histochemical Journal, V3, P319, DOI 10.1007/BF01005014; MAROM Z, 1983, J CLIN INVEST, V72, P122, DOI 10.1172/JCI110949; MAROM Z, 1981, J CLIN INVEST, V67, P1695, DOI 10.1172/JCI110207; MAROM Z, 1982, AM REV RESP DIS, V126, P499; MAROM Z, AM REV RESPIR DIS; MAROM Z, 1983, CLIN RES, V31, P513; MAROM Z, PROSTAGLANDINS; MASSARO GD, 1982, J CLIN INVEST, V70, P608, DOI 10.1172/JCI110653; MASSARO GD, 1981, J CLIN INVEST, V67, P345, DOI 10.1172/JCI110041; MASSON PL, 1965, BIOCHIM BIOPHYS ACTA, V111, P466, DOI 10.1016/0304-4165(65)90056-5; MEYRICK B, 1970, J ANAT, V107, P281; MEYRICK B, 1969, THORAX, V24, P729, DOI 10.1136/thx.24.6.729; NADEL JA, 1977, AM REV RESPIR DIS, V115, P117; OLIVER RE, 1975, AM REV RESPIR DIS, V112, P811; PATOW CA, 1983, J ALLERGY CLIN IMMUN, V71, P89, DOI 10.1016/0091-6749(83)90127-6; PATOW CA, UNPUB HUMAN NASAL MU; PATOW CA, OTOLARYNGOL HEAD NEC; PHELPS CF, 1978, BRIT MED BULL, V34, P43, DOI 10.1093/oxfordjournals.bmb.a071456; PHIPPS RJ, 1980, AM REV RESPIR DIS, V121, P359; PHIPPS RJ, 1982, CLIN SCI, V63, P23, DOI 10.1042/cs0630023; POTTER JL, 1963, ANN NY ACAD SCI, V106, P692; QUINTON PM, 1979, NATURE, V279, P551, DOI 10.1038/279551a0; SACKNER MA, 1977, RESPIRATION, V34, P181, DOI 10.1159/000193824; SHELHAMER J, EAR NOSE THROAT J; SHELHAMER JH, 1980, J CLIN INVEST, V66, P1400, DOI 10.1172/JCI109993; SHELHAMER JH, 1982, CHEST, V81, P365; STURGESS J, 1973, BRIT J EXP PATHOL, V54, P388; STURGESS J, 1972, CLIN SCI, V43, P533, DOI 10.1042/cs0430533; 1976, PEDIATRICS, V57, P272	51	59	62	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	3					318	323		10.1016/0091-6749(84)90403-2	http://dx.doi.org/10.1016/0091-6749(84)90403-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SK155	6366031				2022-12-18	WOS:A1984SK15500004
J	LEBOWITZ, MD; BARBEE, R; BURROWS, B				LEBOWITZ, MD; BARBEE, R; BURROWS, B			FAMILY CONCORDANCE OF IGE, ATOPY, AND DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LEBOWITZ, MD (corresponding author), UNIV ARIZONA,COLL MED,DIV RESP SCI,WESTEND RES LABS,TUCSON,AZ 85724, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-14136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON HR, 1981, INT J EPIDEMIOL, V10, P45, DOI 10.1093/ije/10.1.45; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288, DOI 10.1016/0091-6749(74)90015-3; BLUMENTHAL M, 1979, J ALLERGY CLIN IMMUN, V63, P169; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; DONNER A, 1980, BIOMETRICS, V36, P19, DOI 10.2307/2530491; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; ELSTON RC, 1971, HUM HERED, V21, P523, DOI 10.1159/000152448; FREIDHOFF LR, 1981, AM J MED GENET, V9, P323, DOI 10.1002/ajmg.1320090409; GERRARD JW, 1978, AM J HUM GENET, V30, P46; GERRARD JW, 1980, ANN ALLERGY, V44, P261; GERRARD JW, 1977, ANN ALLERGY, V38, P396; LALOUEL JM, HUM HERED; LEBOWITZ MD, 1975, AM J EPIDEMIOL, V102, P153, DOI 10.1093/oxfordjournals.aje.a112142; LEBOWITZ MD, 1975, AM J EPIDEMIOL, V102, P137, DOI 10.1093/oxfordjournals.aje.a112141; LEIGH D, 1967, BRONCHIAL ASTHMA; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MEYERS DA, 1981, J ALLERGY CLIN IMMUN, V67, P167, DOI 10.1016/0091-6749(81)90056-7; MEYERS DA, 1981, J ALLERGY CLIN IMM S, V67, P55; MORTON NE, 1974, AM J HUM GENET, V26, P489; OTT J, 1979, AM J HUM GENET, V31, P161; RAO DC, 1980, AM J HUM GENET, V32, P620; RAO DC, 1981, SEP IMM WORKSH OM; SCHWARZ M, 1952, ACTA ALLERGOL S, V5; SIBBALD B, 1980, THORAX, V35, P671, DOI 10.1136/thx.35.9.671; SIBBALD B, 1979, THORAX, V34, P332, DOI 10.1136/thx.34.3.332; SIBBALD B, 1980, ARCH DIS CHILD, V55, P354, DOI 10.1136/adc.55.5.354; SIBBALD B, 1981, THESIS U LONDON; SMITH JM, 1965, AM REV RESPIR DIS, V92, P31; SOOTHILL JF, 1976, CLIN ALLERGY, V6, P305, DOI 10.1111/j.1365-2222.1976.tb01911.x; TURTON CWG, 1979, THORAX, V34, P670, DOI 10.1136/thx.34.5.670; WARREN CPW, 1982, J ALLERGY CLIN IMMUN, V69, P370, DOI 10.1016/0091-6749(82)90148-8	34	59	60	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	2					259	264		10.1016/S0091-6749(84)80017-2	http://dx.doi.org/10.1016/S0091-6749(84)80017-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SF020	6699309				2022-12-18	WOS:A1984SF02000007
J	PAULI, G; BESSOT, JC; BIGOT, H; DELAUME, G; HORDLE, DA; HIRTH, C; THIERRY, R				PAULI, G; BESSOT, JC; BIGOT, H; DELAUME, G; HORDLE, DA; HIRTH, C; THIERRY, R			CLINICAL AND IMMUNOLOGICAL EVALUATION OF TYROSINE-ADSORBED DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT - A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV STRASBOURG 1, FAC MED, PNEUMOPHTISIOL CLIN, F-67070 STRASBOURG, FRANCE; CNRS, CTR CALCUL, UNITE STAT, STRASBOURG, FRANCE; BIOSCI RES CTR, EPSOM, SURREY, ENGLAND	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; GlaxoSmithKline								Aalberse R C, 1975, Dev Biol Stand, V29, P197; ARAUJOFONTAINE A, 1974, REV FR ALLERGOL, V2, P81; ARLIAN L G, 1977, Journal of Medical Entomology, V14, P484, DOI 10.1093/jmedent/14.4.484; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; ASSEM ESK, 1975, CLIN ALLERGY, V3, P161; BESSOT JC, 1975, REV FR ALLERGOL, V15, P73, DOI 10.1016/S0335-7457(75)80016-5; CARLSEN SD, 1979, ALLERGY, V34, P155, DOI 10.1111/j.1398-9995.1979.tb01563.x; CHAI H, 1968, J ALLERGY, V41, P23, DOI 10.1016/0021-8707(68)90005-1; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHAPMAN MD, 1978, CLIN EXP IMMUNOL, V34, P126; CHAPMAN MD, 1980, INT ARCH ALLER A IMM, V61, P431, DOI 10.1159/000232471; CHIARAMONTE LT, 1982, J ALLERGY CLIN IMMUN, V69, P509, DOI 10.1016/0091-6749(82)90175-0; D'SOUZA M F, 1973, Clinical Allergy, V3, P177, DOI 10.1111/j.1365-2222.1973.tb01320.x; GADDIE J, 1976, BRIT MED J, V2, P561, DOI 10.1136/bmj.2.6035.561; LEMAO J, 1980, J ALLERGY CLIN IMMUN, V65, P381, DOI 10.1016/0091-6749(80)90217-1; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MANSFIELD LE, 1982, ANN ALLERGY, V48, P205; MARYGABRIEL SX, 1977, CLIN ALLERGY, V7, P325; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MILLER ACML, 1976, ACTA ALLERGOL, V31, P35, DOI 10.1111/j.1398-9995.1976.tb01477.x; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; MORAN DM, 1978, J IMMUNOL METHODS, V24, P183, DOI 10.1016/0022-1759(78)90099-6; NEWTON DAG, 1978, BRIT J DIS CHEST, V72, P21, DOI 10.1016/0007-0971(78)90004-9; PAULI G, 1979, ALLERGY, V34, P311; PAULI G, 1979, J ALLERGY CLIN IMMUN, V63, P245, DOI 10.1016/0091-6749(79)90108-8; PAULI G, 1981, COMPTES RENDUS REUNI, P106; Siegel S., 1956, NONPARAMETRIC STAT B; SMITH AP, 1971, BRIT MED J, V4, P204, DOI 10.1136/bmj.4.5781.204; Spieksma F. Th. M., 1967, Acarologia, V9, P226; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; VIRCHOW C, 1976, CLIN ALLERGY, V6, P147, DOI 10.1111/j.1365-2222.1976.tb01892.x; Voorhorst R., 1964, Allergie Asthma, V10, P329; WAGNER M, 1972, THESIS U STRASBOURG; WARNER JO, 1978, LANCET, V2, P912; 1979, BR J DIS CHEST, V73, P260	35	59	59	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					524	535		10.1016/0091-6749(84)90389-0	http://dx.doi.org/10.1016/0091-6749(84)90389-0			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN620	6208231				2022-12-18	WOS:A1984TN62000011
J	STEVENS, WJ; BRIDTS, CH				STEVENS, WJ; BRIDTS, CH			IGG-CONTAINING AND IGE-CONTAINING CIRCULATING IMMUNE-COMPLEXES IN PATIENTS WITH ASTHMA AND RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											STEVENS, WJ (corresponding author), UNIV INSTELLING ANTWERP,IMMUNOL SECT,B-2610 WILRIJK,BELGIUM.		BRIDTS, Chris HM/M-7933-2016	BRIDTS, Chris HM/0000-0002-3324-7320				ARROYAVE CM, 1977, CLIN ALLERGY, V7, P173, DOI 10.1111/j.1365-2222.1977.tb01439.x; BERRENS L, 1974, ANN NY ACAD SCI, V221, P153, DOI 10.1111/j.1749-6632.1974.tb28213.x; BROSTOFF J, 1977, LANCET, V2, P741; BROSTOFF J, 1979, LANCET, V1, P1268; BUTTERWORTH AE, 1975, NATURE, V256, P727, DOI 10.1038/256727a0; CANO PO, 1977, CLIN ALLERGY, V7, P167, DOI 10.1111/j.1365-2222.1977.tb01438.x; CREIGHTON WD, 1973, J IMMUNOL, V111, P1219; DELESPESSE G, 1979, CLIN ALLERGY, V9, P503, DOI 10.1111/j.1365-2222.1979.tb02515.x; DESSAINT JP, 1980, CELL IMMUNOL, V51, P280, DOI 10.1016/0008-8749(80)90260-9; GILMORE NJ, 1978, J ALLERGY CLIN IMMUN, V61, P168, DOI 10.1016/0091-6749(78)90371-8; HAFNER GE, 1981, RESPIRATION, V41, P248; HUNNINGHAKE GW, 1981, J CLIN INVEST, V68, P259, DOI 10.1172/JCI110242; ISHIZAKA T, 1972, J IMMUNOL, V108, P848; KEMLER BJ, 1979, CLIN ALLERGY, V9, P473, DOI 10.1111/j.1365-2222.1979.tb02511.x; KOHLER PF, 1979, J ALLERGY CLIN IMMUN, V63, P297, DOI 10.1016/0091-6749(79)90122-2; LEVINSON AI, 1978, J ALLERGY CLIN IMMUN, V62, P109, DOI 10.1016/0091-6749(78)90087-8; MELEWICZ FM, 1979, FED PROC, V38, P925; MERETEY K, 1979, J IMMUNOL METHODS, V26, P223, DOI 10.1016/0022-1759(79)90247-3; NORMAN PS, 1971, J ALLERGY, V47, P273, DOI 10.1016/S0091-6749(71)80005-2; PHANUPHAK P, 1980, AM J MED, V68, P479, DOI 10.1016/0002-9343(80)90285-5; Santoro F., 1977, Revista do Instituto de Medicina Tropical de Sao Paulo, V19, P156; STEIN MR, 1978, J ALLERGY CLIN IMMUN, V62, P211, DOI 10.1016/0091-6749(78)90209-9; STENDARDI L, 1980, CLIN ALLERGY, V10, P405, DOI 10.1111/j.1365-2222.1980.tb02123.x; STEVENS E, 1979, MAST CELL ITS ROLE H, P296; STEVENS WJ, 1980, EUR J RESPIR DIS, V61, P203; STEVENS WJ, 1981, IMMUNOL LETT, V3, P1, DOI 10.1016/0165-2478(81)90086-9; STEVENS WJ, 1980, ALLERGOL IMMUNOPATHO, V8, P427; STEVENS WJ, 1980, PROG RESPIR RES, V14, P51; WILLIAMS RC, 1972, J CLIN INVEST, V51, P955, DOI 10.1172/JCI106890; YANG WH, 1979, J ALLERGY CLIN IMMUN, V63, P300, DOI 10.1016/0091-6749(79)90123-4; 1977, WHO TECHNICAL REPORT, V606	31	59	59	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	2					276	282		10.1016/S0091-6749(84)80020-2	http://dx.doi.org/10.1016/S0091-6749(84)80020-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SF020	6699311	Bronze			2022-12-18	WOS:A1984SF02000010
J	STEVENSON, DD; SIMON, RA				STEVENSON, DD; SIMON, RA			SULFITES AND ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											STEVENSON, DD (corresponding author), SCRIPPS CLIN & RES FDN,DIV ALLERGY & IMMUNOL,LA JOLLA,CA 92037, USA.							BAKER GJ, 1981, MED J AUSTRALIA, V2, P614, DOI 10.5694/j.1326-5377.1981.tb113018.x; BAKER GJ, 1982, THOR SOC AUST, V12, P213; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; GOLDFARB F, 1984, J ALLERGY CLIN IMMUN, V73, P135; JACOBSEN D W, 1984, Journal of Allergy and Clinical Immunology, V73, P135; KOEPKE JW, 1984, JAMA-J AM MED ASSOC, V251, P2982, DOI 10.1001/jama.251.22.2982; KOEPKE JW, 1983, J ALLERGY CLIN IMMUN, V72, P514; LANG NA, 1961, HDB CHEM, P996; NADEL J A, 1973, P29; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; SIMON R A, 1982, Journal of Allergy and Clinical Immunology, V69, P118; STEVENSON DD, 1981, J ALLERGY CLIN IMMUN, V68, P26, DOI 10.1016/0091-6749(81)90119-6; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P429; TWAROG FJ, 1982, JAMA-J AM MED ASSOC, V248, P2030, DOI 10.1001/jama.248.16.2030; YOST DM, 1944, SULFUR GROUP OXYACID, P325	15	59	59	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					469	472		10.1016/0091-6749(84)90380-4	http://dx.doi.org/10.1016/0091-6749(84)90380-4			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN620	6491092				2022-12-18	WOS:A1984TN62000002
J	DESHAZO, RD				DESHAZO, RD			CURRENT CONCEPTS ABOUT THE PATHOGENESIS OF SILICOSIS AND ASBESTOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											DESHAZO, RD (corresponding author), TULANE UNIV,SCH MED,CLIN IMMUNOL SECT,NEW ORLEANS,LA 70112, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL015092] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-15092] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allison A C, 1979, Front Biol, V48, P149; ALLISON AC, 1977, LUNG BIOPSY HLTH DIS, V15; ARAI DT, 1978, ASBESTOS RELATED DIS, P1; ATTYGALLE D, 1954, BRIT J IND MED, V11, P245; Baetjer Anna M., 1944, JOUR INDUST HYG AND TOXICOL, V26, P101; BATEMAN E, 1980, IN VITRO EFFECTS MIN, P289; BATEMAN ED, 1981, OCCUPATIONAL LUNG DI, P237; BECKLAKE MR, 1976, AM REV RESPIR DIS, V114, P187; BIGNON J, 1978, AM REV RESPIR DIS, V117, P56; Bitterman P, 1981, Chest, V80, P38; BOZELKA BE, UNPUB ASBESTOS INDUC; BURRELL R, 1981, HLTH EFFECTS SYNTHET, P82; CRYSTAL RG, 1981, CHEST, V80, P335; DAUBER J H, 1976, American Review of Respiratory Disease, V113, P94; DAUBER JH, 1981, HLTH EFFECTS SYNTHET, P94; DAVIES R, 1981, HLTH EFFECTS SYNTHET, P67; Davis G S, 1981, Chest, V80, P8; DAVIS HV, 1971, AM IND HYG ASSOC J, V32, P599, DOI 10.1080/0002889718506512; DESHAZO RD, UNPUB IMMUNOLOGIC AB; DESHAZO RD, 1982, CLIN RES, V30, P512; DOLL JN, INT ARCH ALLERGY APP; DOLL NJ, 1980, J ALLERGY CLIN IMMUN, V65, P170; DOLL NJ, 1982, FED P, V41, P3354; FISHER GL, 1980, J RETICULOENDOTH SOC, V27, P513; GABOR S, 1980, IN VITRO EFFECTS MIN, P131; Gadek J, 1981, Chest, V80, P63; GAUMER HR, 1979, AM REV RESPIR DIS, V119, P216; GAUMER HR, 1980, FED PROC, V39, P1132; GERBER MA, 1970, AM J CLIN PATHOL, V53, P204; HARINGTON JS, 1971, ENVIRON RES, V4, P95, DOI 10.1016/0013-9351(71)90038-7; HEPPLESTON AG, 1981, HLTH EFFECTS SYNTHET, P62; KAGAMIMORI S, 1980, BRIT J EXP PATHOL, V61, P55; KAGAN E, 1977, CLIN EXP IMMUNOL, V28, P261; KAGAN E, 1977, CLIN EXP IMMUNOL, V28, P268; KAGAN E, 1979, AM J MED, V67, P325, DOI 10.1016/0002-9343(79)90408-X; Kagan E, 1981, Chest, V80, P11; KAGAN E, 1980, ADV EXP MED BIOL, V121, P539; KRAVIS TC, 1976, J CLIN INVEST, V58, P1223, DOI 10.1172/JCI108576; LEVY MH, 1975, J IMMUNOL, V115, P41; LIEBEN J, 1966, ARCH ENVIRON HEALTH, V13, P619, DOI 10.1080/00039896.1966.10664628; LUGANO EM, 1981, J RETICULOENDOTH SOC, V30, P381; MANCINO D, 1977, INT ARCH ALLER A IMM, V53, P97, DOI 10.1159/000231738; MANCINO D, 1978, INT ARCH ALLER A IMM, V57, P155, DOI 10.1159/000232096; MILLER K, 1977, J RETICULOENDOTH SOC, V21, P307; MILLER K, 1980, ENVIRON RES, V22, P31, DOI 10.1016/0013-9351(80)90116-4; MILLER K, 1978, CRC CR REV TOXICOL, V5, P319, DOI 10.3109/10408447809081010; MILLER SD, 1974, J IMMUNOL, V113, P1533; MORGAN JE, UNPUB IN VITRO EFFEC; MORGAN JE, 1981, CLIN RES, V29, P867; PIERCE JA, 1981, J LAB CLIN MED, V97, P463; POSTLETHWAITE AE, 1976, J EXP MED, V144, P1188, DOI 10.1084/jem.144.5.1188; RICHARDS RJ, 1973, LIFE SCI 2-BIOCH GEN, V12, P441, DOI 10.1016/0024-3205(73)90332-9; ROLAPLESZCZYNSKI M, 1981, J IMMUNOL, V127, P2535; Schoenberger C, 1981, Chest, V80, P70; SCHOENBERGER C, 1980, American Review of Respiratory Disease, V121, P257; SCHUYLER M, 1977, AM REV RESPIR DIS, V116, P147; Simon R, 1981, Chest, V80, P45; STANKUS RP, 1980, BASIC CLIN ASPECTS G, P305; STANKUS RP, 1981, CURRENT PULMONOLOGY, V13, P61; TSUKAMOTO Y, 1981, J IMMUNOL, V127, P673; TURNERWARWICK M, 1970, BMJ-BRIT MED J, V3, P492, DOI 10.1136/bmj.3.5721.492; WAGNER MMF, 1979, CLIN EXP IMMUNOL, V38, P323; WAHL SM, 1978, J IMMUNOL, V121, P942; WERB Z, 1980, J EXP MED, V152, P1340, DOI 10.1084/jem.152.5.1340; WILSON MR, 1977, J ALLERGY CLIN IMMUN, V60, P218, DOI 10.1016/0091-6749(77)90133-6; ZISKIND M, 1976, AM REV RESPIR DIS, V113, P643	66	59	59	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	1					41	49		10.1016/0091-6749(82)90200-7	http://dx.doi.org/10.1016/0091-6749(82)90200-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NY715	6282950				2022-12-18	WOS:A1982NY71500011
J	EKWO, E; WEINBERGER, M				EKWO, E; WEINBERGER, M			EVALUATION OF A PROGRAM FOR PHARMACOLOGIC MANAGEMENT OF CHILDREN WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,HOSP & CLIN,DEPT PEDIAT,IOWA CITY,IA 52242; UNIV IOWA,HOSP & CLIN,DN PEDIAT ALLERGY & PULM,IOWA CITY,IA 52242	University of Iowa; University of Iowa								FESSEL WJ, 1972, NEW ENGL J MED, V286, P134, DOI 10.1056/NEJM197201202860305; FLEISS JL, 1973, STATISTICAL METHODS, P99; HAMBLETON G, 1977, LANCET, V1, P381; HENDELES L, 1977, MAR AM C ALL IMM NEW; LICHTENSTEIN LM, 1975, NEW DIRECTIONS ASTHM, P457; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; OSBORNE CE, 1975, PEDIATRICS, V56, P625; RUBINFELD AR, 1976, LANCET, V1, P882; WEINBERGER M, 1976, AM J HOSP PHARM, V33, P1071, DOI 10.1093/ajhp/33.10.1071; WYATT R, 1978, J PEDIATR-US, V92, P125, DOI 10.1016/S0022-3476(78)80093-6; 1962, AM REV RESPIR DIS, V85, P762	11	59	59	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	4					240	247		10.1016/0091-6749(78)90198-7	http://dx.doi.org/10.1016/0091-6749(78)90198-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EV080	632473				2022-12-18	WOS:A1978EV08000023
J	BUCKLEY, RH; SEYMOUR, F; SANAL, SO; OWNBY, DR; BECKER, WG				BUCKLEY, RH; SEYMOUR, F; SANAL, SO; OWNBY, DR; BECKER, WG			LYMPHOCYTE-RESPONSES TO PURIFIED RAGWEED ALLERGENS INVITRO .1. PROLIFERATIVE RESPONSES IN NORMAL, NEWBORN, AGAMMAGLOBULINEMIC, AND ATOPIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									DUKE UNIV,SCH MED,DEPT PEDIAT,DURHAM,NC 27710; DUKE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710	Duke University; Duke University			Buckley, Rebecca/AAB-1578-2019					BASHAM TY, 1975, J IMMUNOL, V114, P715; BLACK PL, 1976, IMMUNOGENETICS, V3, P349, DOI 10.1007/BF01576967; BUCKLEY RH, 1975, J CLIN INVEST, V55, P157, DOI 10.1172/JCI107906; CHESS L, 1974, J IMMUNOL, V113, P1122; DOUGLAS SD, 1972, TRANSPLANT REV, V11, P39; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; GATIEN JG, 1975, CLIN IMMUNOL IMMUNOP, V4, P32, DOI 10.1016/0090-1229(75)90036-7; GEHA RS, 1975, J CLIN INVEST, V56, P386, DOI 10.1172/JCI108103; GIRARD JP, 1967, J ALLERGY, V39, P65, DOI 10.1016/0021-8707(67)90113-X; HARTZMAN RJ, 1971, TRANSPLANTATION, V11, P268, DOI 10.1097/00007890-197103000-00005; ISHIZAKA K, 1974, J IMMUNOL, V113, P70; ISHIZAKA K, 1975, J IMMUNOL, V114, P110; KANELLAKES TM, 1975, J ALLERGY CLIN IMMUN, V56, P407, DOI 10.1016/0091-6749(75)90134-7; KING TP, 1967, ANN ALLERGY, V25, P541; LEIKEN S, 1970, 5TH P LEUK CULT C NE; Ling N.R., 1975, LYMPHOCYTE STIMULATI; LIS H, 1973, ANNU REV BIOCHEM, V42, P541, DOI 10.1146/annurev.bi.42.070173.002545; MAINI RN, 1971, CLIN EXP IMMUNOL, V9, P449; NG AK, 1976, J BACTERIOL, V126, P511, DOI 10.1128/JB.126.1.511-515.1976; OKUMURA K, 1971, J IMMUNOL, V107, P1682; PEAVY DL, 1970, J IMMUNOL, V105, P1453; RAFF RA, 1968, J BACTERIOL, V95, P2035, DOI 10.1128/JB.95.6.2035-2043.1968; RICH RR, 1974, J IMMUNOL, V112, P1360; RICHTER M, 1968, J ALLERGY, V41, P140, DOI 10.1016/0021-8707(68)90054-3; ROCKLIN RE, 1974, J CLIN INVEST, V53, P735, DOI 10.1172/JCI107612; SCHIFF RI, 1974, J IMMUNOL, V112, P376; SCHMIDTKE JR, 1975, J IMMUNOL, V114, P742; TADA T, 1971, J IMMUNOL, V107, P1137; TAKATSU K, 1975, J IMMUNOL, V115, P1469; WAXDAL MJ, 1975, IMMUNE RECOGNITION; WEISBERG SC, 1972, J ALLERGY CLIN IMMUN, V49, P125; ZEITZ SJ, 1966, J ALLERGY, V38, P321, DOI 10.1016/0021-8707(66)90030-X	32	59	59	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	1					70	78		10.1016/0091-6749(77)90180-4	http://dx.doi.org/10.1016/0091-6749(77)90180-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CS828	833376				2022-12-18	WOS:A1977CS82800012
J	LEUNG, P; KALISKER, A; BELL, TD				LEUNG, P; KALISKER, A; BELL, TD			VARIATION IN THEOPHYLLINE CLEARANCE RATE WITH TIME IN CHRONIC CHILDHOOD ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL ASTHMA CTR,DENVER,CO 80204									CORNISH HH, 1957, J BIOL CHEM, V228, P315; ELLIS EF, 1976, PEDIATRICS, V58, P542; GREENBLATT DJ, 1975, NEW ENGL J MED, V293, P702, DOI 10.1056/NEJM197510022931406; GREENBLATT DJ, 1975, NEW ENGL J MED, V293, P964, DOI 10.1056/NEJM197511062931905; JACOBS MH, 1976, JAMA-J AM MED ASSOC, V235, P1983, DOI 10.1001/jama.235.18.1983; JENNE JW, 1972, CLIN PHARMACOL THER, V13, P349; LEVY G, 1976, J CLIN PHARMACOL, V16, P329, DOI 10.1002/j.1552-4604.1976.tb01528.x; LEVY G, 1975, J PEDIATR-US, V86, P789, DOI 10.1016/S0022-3476(75)80374-X; LOHMANN SM, 1976, J PHARMACOL EXP THER, V196, P213; LOUGHNAN PM, 1976, J PEDIATR-US, V88, P874, DOI 10.1016/S0022-3476(76)81136-5; MASELLI R, 1970, J PEDIATR, V76, P777, DOI 10.1016/S0022-3476(70)80305-5; MITENKO P, 1974, CLIN PHARMACOL THER, V16, P721; MITENKO PA, 1973, CLIN PHARMACOL THER, V14, P509; MITOMA C, 1969, ARCH BIOCHEM BIOPHYS, V134, P434, DOI 10.1016/0003-9861(69)90303-8; NICHOLSON DP, 1973, AM REV RESPIR DIS, V108, P241; SCHACK JA, 1949, J PHARMACOL EXP THER, V97, P283; STREM E, 1975, OCT PED AC M WASH DC; WEINBERGER M, 1975, J ALLERGY CLIN IMMUN, V55, P94; WEINBERGER M, 1976, J ALLERGY CLIN IMMUN, V57, P262; WEINBERGER MW, 1976, JAMA-J AM MED ASSOC, V235, P2110, DOI 10.1001/jama.235.19.2110	20	59	59	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	6					440	444		10.1016/0091-6749(77)90007-0	http://dx.doi.org/10.1016/0091-6749(77)90007-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DJ990	864102				2022-12-18	WOS:A1977DJ99000006
J	Skevaki, C; Karsonova, A; Karaulov, A; Xie, M; Renz, H				Skevaki, Chrysanthi; Karsonova, Antonina; Karaulov, Alexander; Xie, Min; Renz, Harald			Asthma-associated risk for COVID-19 development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						SARS-CoV-2; COVID-19; asthma; endotypes; type 2 asthma; non-type 2 asthma	INCREASED PREVALENCE; ANTIVIRAL IMMUNITY; EXACERBATIONS; CORONAVIRUS; RESPONSES; SEVERITY; CELLS; INFECTIONS; INTERFERON; OUTBREAK	The newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a pandemic (coronavirus disease 2019 [COVID-19]). It is now well established that certain comorbidities define high-risk patients. They include hypertension, diabetes, and coronary artery disease. In contrast, the context with bronchial asthma is controversial and shows marked regional differences. Because asthma is the most prevalent chronic inflammatory lung disease worldwide and SARS-CoV-2 primarily affects the upper and lower airways leading to marked inflammation, the question arises about the possible clinical and pathophysiological association between asthma and SARS-CoV-2/COVID-19. Here, we analyze the global epidemiology of asthma among patients with COVID-19 and propose the concept that patients suffering from different asthma endotypes (type 2 asthma vs non-type 2 asthma) present with a different risk profile in terms of SARS-CoV-2 infection, development of COVID-19, and progression to severe COVID-19 outcomes. This concept may have important implications for future COVID-19 diagnostics and immune-based therapy developments.	[Skevaki, Chrysanthi; Renz, Harald] Philipps Univ Marburg, Univ Giessen & Marburg Lung Ctr UGMLC, Inst Lab Med, German Ctr Lung Res DZL, Marburg, Germany; [Skevaki, Chrysanthi; Renz, Harald] German Ctr Lung Res DZL, Marburg, Germany; [Karsonova, Antonina; Karaulov, Alexander; Renz, Harald] Sechenov Univ, Dept Clin Immunol & Allergol, Lab Immunopathol, Moscow, Russia; [Xie, Min] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Resp & Crit Care Med, Tongji Med Coll, Wuhan, Peoples R China	Philipps University Marburg; Sechenov First Moscow State Medical University; Huazhong University of Science & Technology	Renz, H (corresponding author), Philipps Univ Marburg, Inst Lab Med, Baldinger Str, D-35043 Marburg, Germany.	harald.renz@uk-gm.de	Karsonova, Antonina V./U-8600-2017; Karaulov, Alexander V/C-2482-2016	Karsonova, Antonina V./0000-0002-8697-9816; Karaulov, Alexander V/0000-0002-1930-5424; xie, min/0000-0003-4052-1647	Universities Giessen Marburg Lung Center (UGMLC); German Center for Lung Disease (DZL German Lung Center) [82DZL00502]; German Center for Lung Research; University Hospital Giessen and Marburg; Deutsche Forschungsgemeinschaft (DFG) [1021, 317/1-1, 309, 428518790]; Foundation for Pathobiochemistry and Molecular Diagnostics	Universities Giessen Marburg Lung Center (UGMLC); German Center for Lung Disease (DZL German Lung Center); German Center for Lung Research; University Hospital Giessen and Marburg; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Foundation for Pathobiochemistry and Molecular Diagnostics	H.R. is funded by the Universities Giessen Marburg Lung Center (UGMLC) and the German Center for Lung Disease (DZL German Lung Center, no. 82DZL00502) for UGMLC. C.S. is funded by UGMLC and the German Center for Lung Research, University Hospital Giessen and Marburg research funding according to article 2, section 3 cooperation agreement, the Deutsche Forschungsgemeinschaft (DFG)-funded Sonderforschungsbereich (SFB), Collaborative Research Center (CRC) (grant no. 1021 [C04]), the DFG-funded KFO (Klinische Forschungsgruppe), Germany (grant no. 309 [P10]), and SK 317/1-1 (project number 428518790) as well as by the Foundation for Pathobiochemistry and Molecular Diagnostics.	Aggarwal Amit, 2020, J Assoc Physicians India, V68, P19; Agrawal S, 2014, J ASTHMA, V51, P814, DOI 10.3109/02770903.2014.913619; Avdeev S, 2020, ALLERGY, V75, P2703, DOI 10.1111/all.14420; Balz K, 2020, RES SQ; Bao W, 2010, AM J PHYSIOL-CELL PH, V299, pC1212, DOI 10.1152/ajpcell.00228.2010; Bian H, 2020, MEPLAZUMAB TREATS CO, DOI [10.1101/2020. 03.21.20040691, DOI 10.1101/2020.03.21.20040691, 10.1101/2020.03.21.20040691]; Borobia AM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061733; Bradding P, 2020, J ALLERGY CLIN IMMUN, V146, P208, DOI 10.1016/j.jaci.2020.05.013; Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9; Butler MW, 2020, J ALLERGY CLIN IMMUN, V146, P334, DOI 10.1016/j.jaci.2020.04.061; Cakebread JA, 2011, J ALLERGY CLIN IMMUN, V127, P1148, DOI 10.1016/j.jaci.2011.01.023; Caminati M, 2020, J ALLERGY CLIN IMMUN, V146, P541, DOI 10.1016/j.jaci.2020.05.049; Carli G, 2021, ALLERGY, V76, P866, DOI 10.1111/all.14426; Centers for Disease Control and Prevention, ASTHM PREV; Chuchalin AG, 2014, INT J CHRONIC OBSTR, V9, P963, DOI 10.2147/COPD.S67283; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Docherty A. B., 2020, JS NGUYEN VAN TAM, DOI [10.1101/2020.04.23.20076042v1, DOI 10.1101/2020.04.23.20076042, 10.1136/bmj.m1985]; Domachowske JB, 1998, J INFECT DIS, V177, P1458, DOI 10.1086/515322; Dunn RM, 2018, ALLERGY, V73, P284, DOI 10.1111/all.13258; Del-Rio-Navarro BE, 2020, WORLD ALLERGY ORGAN, V13, DOI 10.1016/j.waojou.2019.100092; Fitzpatrick S, 2012, CLIN EXP ALLERGY, V42, P747, DOI 10.1111/j.1365-2222.2011.03863.x; Gemes K, 2020, EUR J EPIDEMIOL, V35, P401, DOI 10.1007/s10654-020-00646-z; Gibson PG, 2002, EUR RESPIR J, V20, p44S, DOI 10.1183/09031936.02.00004402; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Gonzales-van Horn SR, 2015, J LEUKOCYTE BIOL, V98, P185, DOI 10.1189/jlb.3RU0315-099R; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huang KW, 2019, LANCET, V394, P407, DOI 10.1016/S0140-6736(19)31147-X; Ibrahim LF, 2020, EMERG MED AUSTRALAS, V32, P801, DOI 10.1111/1742-6723.13550; Jackson DJ, 2020, J ALLERGY CLIN IMMUN, V146, P203, DOI 10.1016/j.jaci.2020.04.009; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Marcello RK, 2020, PLOS ONE, V15, DOI [10.1371/journal.pone.0243027, 10.1101/2020.05.29.20086645]; Khawaja AP, 2020, ASS COVID 19 HOSP 40, DOI [10.1101/2020.05.06.20092957, DOI 10.1101/2020.05.06.20092957]; Kuo Chih-Hsi Scott, 2017, Eur Respir J, V49, DOI 10.1183/13993003.02135-2016; Lebre MC, 2008, J ALLERGY CLIN IMMUN, V122, P969, DOI 10.1016/j.jaci.2008.08.028; Leung JM, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00688-2020; Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI 10.1016/j.jaci.2020.04.006; Libraty DH, 2007, VIROLOGY, V368, P317, DOI 10.1016/j.virol.2007.07.015; Lieberman-Cribbin W, 2020, CHEST, V158, P2290, DOI 10.1016/j.chest.2020.05.575; Lin JT, 2018, RESP MED, V137, P48, DOI 10.1016/j.rmed.2018.02.010; Liu F, 2020, INT J INFECT DIS, V95, P183, DOI 10.1016/j.ijid.2020.03.013; MAGGI E, 1992, J IMMUNOL, V148, P2142; Marshall JS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174241; Morais-Almeida M, 2020, INT ARCH ALLERGY IMM, V181, P680, DOI 10.1159/000509057; Mukai K, 2018, IMMUNOL REV, V282, P121, DOI 10.1111/imr.12634; Musharrafieh Umayya, 2020, Asthma Res Pract, V6, P3, DOI 10.1186/s40733-020-00056-8; Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Oliveira TB, 2020, ALLERGOL IMMUNOPATH, V48, P537, DOI 10.1016/j.aller.2020.03.010; Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683; Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647; Peltola V, 2009, J MED VIROL, V81, P1831, DOI 10.1002/jmv.21590; Peters MC, 2020, AM J RESP CRIT CARE, V202, P83, DOI 10.1164/rccm.202003-0821OC; Peters MC, 2016, LANCET RESP MED, V4, P574, DOI 10.1016/S2213-2600(16)30048-0; Petrie S, 2020, EPIDEMIOL REP, P15; Phipps S, 2007, BLOOD, V110, P1578, DOI 10.1182/blood-2007-01-071340; Prieto-Alhambra D, 2020, HOSP 30 DAY FATALITY, DOI [10.1101/2020.05.04.20090050v1, DOI 10.1101/2020.05.04.20090050V1]; Qin C, 2020, CLIN INFECT DIS, V395, P497; Regina J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240781; Rezende LFM, 2020, REV SAUDE PUBL, V54, DOI 10.11606/s1518-8787.2020054002596; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Ruiz S, 2008, J BIOL CHEM, V283, P5554, DOI 10.1074/jbc.M708566200; Sajuthi SP, 2020, TYPE 2 INTERFERON IN; Selin LK, 1998, J EXP MED, V188, P1705, DOI 10.1084/jem.188.9.1705; Shabrawishi M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237130; Shi WD, 2020, ALLERGY, V75, P2405, DOI 10.1111/all.14434; Skevaki C, 2018, J ALLERGY CLIN IMMUN, V142, P804, DOI 10.1016/j.jaci.2017.07.056; Solis P., 2020, COVID 19 FATALITY CO, DOI [10.1101/2020.04.21.20074591, DOI 10.1101/2020.04.21.20074591]; [王科雯 Wang Kewen], 2020, [测绘通报, Bulletin of Surveying and Mapping], P1; Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045; Wang XD, 2016, ALLERGY, V71, P1170, DOI 10.1111/all.12874; Wang XL, 2020, CELL MOL IMMUNOL, V17, P894, DOI 10.1038/s41423-020-0498-4; Welsh RM, 2010, IMMUNOL REV, V235, P244, DOI 10.1111/j.0105-2896.2010.00897.x; Welsh RM, 2002, NAT REV IMMUNOL, V2, P417, DOI 10.1038/nri820; White SR, 2019, J ALLERGY CLIN IMMUN, V144, P304, DOI 10.1016/j.jaci.2019.04.007; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yamaya M, 2020, RESPIR INVESTIG, V58, P155, DOI 10.1016/j.resinv.2019.12.005; Yang JM, 2020, J ALLERGY CLIN IMMUN, V146, P790, DOI 10.1016/j.jaci.2020.08.008; Yang LT, 2006, CLIN IMMUNOL, V120, P171, DOI 10.1016/j.clim.2006.05.002; Yao H, 2014, INT J BIOL SCI, V10, P43, DOI 10.7150/ijbs.6818; Zhang JJ, 2020, ALLERGY, V75, P1809, DOI 10.1111/all.14316; Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238; Zheng M, 2020, SINGLE CELL RNA EXPR; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zhu J, 2019, J ALLERGY CLIN IMMUN, V143, P114, DOI 10.1016/j.jaci.2018.04.003; Zhu ZZ, 2020, J ALLERGY CLIN IMMUN, V146, P327, DOI 10.1016/j.jaci.2020.06.001; Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035	91	58	61	3	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2020	146	6					1295	1301		10.1016/j.jaci.2020.09.017	http://dx.doi.org/10.1016/j.jaci.2020.09.017			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC3XH	33002516	Green Published, Bronze			2022-12-18	WOS:000596937900010
J	Bachert, C; Zhang, N; Cavaliere, C; Wen, WP; Gevaert, E; Krysko, O				Bachert, Claus; Zhang, Nan; Cavaliere, Carlo; Wen Weiping; Gevaert, Elien; Krysko, Olga			Biologics for chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Chronic rhinosinusitis; nasal polyps; endotypes; type 2 inflammation; biologics	INNATE LYMPHOID-CELLS; STAPHYLOCOCCUS-AUREUS ENTEROTOXINS; ANTI-IGE; DOUBLE-BLIND; MAST-CELLS; EXPRESSION; RECEPTOR; INTERLEUKIN-5; INFLAMMATION; TISSUE	With the increasing recognition of the role of type 2 immune responses in chronic rhinosinusitis, its severity, recurrence, and comorbidities, several biologics targeting IL-4, IL-5, and IL-13 as well as IgE have been administered in small proof-of-concept studies. Recently, the first phase 3 trials have been reported with dupilumab, an IL-4 receptor antagonist, demonstrating a significant and clinically relevant reduction of the disease burden from polyp size and sinus involvement to symptoms and smell; these changes consecutively led to an important increase in quality of life. Finally, the biologic versus placebo treatment reduced the need for systemic glucocorticosteroids and sinus surgery significantly and clinically meaningfully. Dupilumab today is registered for the treatment of chronic rhinosinusitis with nasal polyps in Europe and the United States. Within a year, 2 further phase 3 trials with omalizumab and mepolizumab will be reported. With this development, without any doubt, a new era for the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps has begun. Questions on the indication of the biologics, the selection of patients, and finally criteria for monitoring the efficacy in individual patients need to be urgently answered, and care pathways need to be established integrating the current standard of care including surgery.	[Bachert, Claus; Zhang, Nan; Wen Weiping] Sun Yat Sen Univ, Affiliated Hosp 1, Int Airway Res Ctr, 58 Zhong Shan Er Lu, Guangzhou 510080, Peoples R China; [Bachert, Claus; Zhang, Nan; Gevaert, Elien; Krysko, Olga] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium; [Bachert, Claus; Zhang, Nan; Gevaert, Elien; Krysko, Olga] Univ Ghent, Dept Otorhinolaryngol, Ghent, Belgium; [Bachert, Claus] Univ Stockholm, Karolinska Inst, Div ENT Dis, CLINTEC, Stockholm, Sweden; [Cavaliere, Carlo] Sapienza Univ Rome, Dept Oral & Maxillofacial Sci, Rome, Italy	Sun Yat Sen University; Ghent University; Ghent University; Karolinska Institutet; Stockholm University; Sapienza University Rome	Bachert, C (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Int Airway Res Ctr, 58 Zhong Shan Er Lu, Guangzhou 510080, Peoples R China.	claus.bachert@ugent.be	Krysko, Olga/C-2481-2009; Bachert, Claus/J-8825-2012; 温, 家琦/GYV-3177-2022; Cavaliere, Carlo/B-3031-2018	Krysko, Olga/0000-0001-5019-0752; Cavaliere, Carlo/0000-0002-0378-8935				Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; Akinlade B, 2019, BRIT J DERMATOL, V181, P459, DOI 10.1111/bjd.17869; Allen JS, 1997, AM J OTOLARYNG, V18, P239, DOI 10.1016/S0196-0709(97)90003-X; Andrews AL, 2006, J ALLERGY CLIN IMMUN, V118, P858, DOI 10.1016/j.jaci.2006.06.041; Baba S, 2014, CLIN EXP ALLERGY, V44, P701, DOI 10.1111/cea.12287; Bachert C, 1997, J ALLERGY CLIN IMMUN, V99, P837, DOI 10.1016/S0091-6749(97)80019-X; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Bachert C, 2020, J ALLERGY CLIN MUNOL; Bachert C, 2019, PILUMAB REDUCES OPAC, DOI 10.4193/Rhin18.282.; Bachert C, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01592-2019; Bachert C, 2019, LANCET, V394, P1638, DOI 10.1016/S0140-6736(19)31881-1; Bachert C, 2020, ALLERGY, V75, P148, DOI 10.1111/all.13984; Bachert C, 2020, ALLERGY, V75, P240, DOI 10.1111/all.13823; Bachert C, 2019, J ALLER CL IMM-PRACT, V7, P2447, DOI 10.1016/j.jaip.2019.03.023; Bachert C, 2018, J ALLERGY CLIN IMMUN, V141, P1543, DOI 10.1016/j.jaci.2018.03.004; Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330; Bachert C, 2017, J ALLERGY CLIN IMMUN, V140, P1024, DOI 10.1016/j.jaci.2017.05.044; Bachert C, 2015, J ALLERGY CLIN IMMUN, V136, P1431, DOI 10.1016/j.jaci.2015.10.010; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Bleecker E. R., 2018, EUR RESPIR J, P52; Bleecker ER, 2016, LANCET, V388, P2115, DOI 10.1016/S0140-6736(16)31324-1; BOCHNER BS, 1995, J IMMUNOL, V154, P799; Bourdin A, 2021, J ASTHMA, V58, P514, DOI 10.1080/02770903.2019.1705333; Cao PP, 2014, CLIN EXP ALLERGY, V44, P690, DOI 10.1111/cea.12304; Chan Marcia A, 2013, Clin Transl Allergy, V3, P29, DOI 10.1186/2045-7022-3-29; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; Darisipudi MN, 2018, MICROORGANISMS, V6, DOI 10.3390/microorganisms6030087; Vennera MD, 2011, THORAX, V66, P824, DOI 10.1136/thx.2010.152835; Derycke L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097581; DONOVAN R, 1970, INT ARCH ALLER A IMM, V37, P154, DOI 10.1159/000230229; FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Gevaert E, 2020, J ALLERGY CLIN IMMUN, V145, P427, DOI 10.1016/j.jaci.2019.08.027; Gevaert E, 2017, J ALLERGY CLIN IMMUN, V139, P1849, DOI 10.1016/j.jaci.2017.01.019; Gevaert P, 2005, ALLERGY, V60, P71, DOI 10.1111/j.1398-9995.2004.00621.x; Gevaert P, 2013, ALLERGY, V68, P55, DOI 10.1111/all.12054; Gevaert P, 2003, ALLERGY, V58, P371, DOI 10.1034/j.1398-9995.2003.00110.x; Gevaert P, 2009, ALLERGY, V64, P725, DOI 10.1111/j.1398-9995.2008.01885.x; Gevaert P, 2020, J ALLERGY CLIN IMMUN; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056; Hayashi H, 2016, J ALLERGY CLIN IMMUN, V137, P1585, DOI 10.1016/j.jaci.2015.09.034; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Holgate ST, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-17; Hosemann W., 2013, GMS CURR TOP OTORHIN, V12, P6; Hox V, 2020, CLIN TRANSL ALLERGY, V10, DOI 10.1186/s13601-019-0303-6; Hulse KE, 2013, J ALLERGY CLIN IMMUN, V131, P1075, DOI 10.1016/j.jaci.2013.01.043; Humbert M, 2019, J ALLER CL IMM-PRACT, V7, P1418, DOI 10.1016/j.jaip.2019.02.030; Jonstam K, 2019, ALLERGY, V74, P743, DOI 10.1111/all.13685; KALINER M, 1973, NEW ENGL J MED, V289, P277, DOI 10.1056/NEJM197308092890601; Kato A, 2013, J ALLERGY CLIN IMMUN, V131, P933, DOI 10.1016/j.jaci.2013.02.023; Kohanski MA, 2018, J ALLERGY CLIN IMMUN, V142, P460, DOI 10.1016/j.jaci.2018.03.019; Kohanski MA, 2018, J ALLERGY CLIN IMMUN, V141, P1561, DOI 10.1016/j.jaci.2018.03.003; Krysko O, 2011, ALLERGY, V66, P396, DOI 10.1111/j.1398-9995.2010.02498.x; Kuperman DA, 2008, CURR MOL MED, V8, P384, DOI 10.2174/156652408785161032; Laidlaw TM, 2019, LARYNGOSCOPE, V129, pE61, DOI 10.1002/lary.27564; Lan F, 2018, AM J RESP CRIT CARE, V198, P452, DOI 10.1164/rccm.201710-2112OC; LaPorte SL, 2008, CELL, V132, P259, DOI 10.1016/j.cell.2007.12.030; Liang HE, 2012, NAT IMMUNOL, V13, P58, DOI 10.1038/ni.2182; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Manson ML, 2019, IL 13 IL 4 NOT IL 5, DOI 10.1016/j.jaci.2019.10.037; Mechtcheriakova D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025611; Mitchell PD, 2017, HANDB EXP PHARMACOL, V237, P131, DOI 10.1007/164_2016_65; Mygind N, 2000, THORAX, V55, pS79, DOI 10.1136/thorax.55.suppl_2.S79; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005; Nagarkar DR, 2012, J ALLERGY CLIN IMMUN, V130, P225, DOI 10.1016/j.jaci.2012.04.019; Nair P, 2020, J ALLER CL IMM-PRACT, V8, P555, DOI 10.1016/j.jaip.2019.09.036; Numata T, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-019-0952-1; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Paris G, 2014, INT FORUM ALLERGY RH, V4, P15, DOI 10.1002/alr.21237; Persson EK, 2019, SCIENCE, V364, P751, DOI 10.1126/science.aaw4295; Pinto JM, 2010, RHINOLOGY, V48, P318, DOI [10.4193/Rhin09.144, 10.4193/Rhino09.144]; Pope SM, 2001, J ALLERGY CLIN IMMUN, V108, P594, DOI 10.1067/mai.2001.118600; Poposki JA, 2017, IMMUN INFLAMM DIS, V5, P233, DOI 10.1002/iid3.161; Pothoven KL, 2017, TISSUE BARRIERS, V5, DOI 10.1080/21688370.2017.1341367; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Reh DD, 2010, AM J RHINOL ALLERGY, V24, P105, DOI 10.2500/ajra.2010.24.3446; Romagnani S, 2000, ANN ALLERG ASTHMA IM, V85, P9, DOI 10.1016/S1081-1206(10)62426-X; Scheerens H, 2019, J ALLERGY CLIN IMMUN, V143, P805, DOI 10.1016/j.jaci.2018.10.011; Schreiber J, 2019, J ALLERGY CLIN IMMUN, V143, P2279, DOI 10.1016/j.jaci.2019.01.018; Seibold MA, 2018, ANN AM THORAC SOC, V15, pS98, DOI 10.1513/AnnalsATS.201711-868MG; Shamji MH, 2019, J ALLERGY CLIN IMMUN, V143, P1067, DOI 10.1016/j.jaci.2018.09.039; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; Shi LL, 2014, AM J RESP CRIT CARE, V190, P628, DOI 10.1164/rccm.201402-0234OC; Silva-Filho J L, 2014, Biophys Rev, V6, P111, DOI 10.1007/s12551-013-0133-z; Simon HU, 1997, J IMMUNOL, V158, P3902; Sintobin I, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.00198-2019; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; TAILLENS J P, 1952, Rev Laryngol Otol Rhinol (Bord), V73, P20; Tiotiu A, 2020, J INVEST ALLERG CLIN, V30, P49, DOI 10.18176/jiaci.0391; Tojima I, 2016, CLIN IMMUNOL, V170, P1, DOI 10.1016/j.clim.2016.07.010; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Van Crombruggen K, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00742-2018; Van Crombruggen K, 2011, J ALLERGY CLIN IMMUN, V128, P728, DOI 10.1016/j.jaci.2011.07.049; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Wang M, 2019, J ALLERGY CLIN IMMUN, V144, P1254, DOI 10.1016/j.jaci.2019.06.023; Weinstein SF, 2019, J ALLER CL IMM-PRACT, V7, P589, DOI 10.1016/j.jaip.2018.08.021; Wu D, 2019, J ALLERGY CLIN IMMUN, V144, P345, DOI 10.1016/j.jaci.2019.03.029; Wu LC, 2014, NAT REV IMMUNOL, V14, P247, DOI 10.1038/nri3632; Wynn TA, 2015, NAT REV IMMUNOL, V15, P271, DOI 10.1038/nri3831; Yasruel Z, 1997, AM J RESP CRIT CARE, V155, P1413, DOI 10.1164/ajrccm.155.4.9105087; Zhang N, 2011, ALLERGY, V66, P141, DOI 10.1111/j.1398-9995.2010.02448.x; Zhang N, 2006, AM J RHINOL, V20, P445, DOI 10.2500/ajr.2006.20.2887; Zhang Y, 2019, ALLERGY, V74, P131, DOI 10.1111/all.13489	107	58	64	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2020	145	3					725	739		10.1016/j.jaci.2020.01.020	http://dx.doi.org/10.1016/j.jaci.2020.01.020			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KT1GD	32145872	Bronze			2022-12-18	WOS:000518756700001
J	Dyjack, N; Goleva, E; Rios, C; Kim, BE; Bin, LH; Taylor, P; Bronchick, C; Hall, CF; Richers, BN; Seibold, MA; Leung, DYM				Dyjack, Nathan; Goleva, Elena; Rios, Cydney; Kim, Byung Eui; Bin, Lianghua; Taylor, Patricia; Bronchick, Caroline; Hall, Clifton F.; Richers, Brittany N.; Seibold, Max A.; Leung, Donald Y. M.			Minimally invasive skin tape strip RNA sequencing identifies novel characteristics of the type 2-high atopic dermatitis disease endotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Skin; atopic dermatitis; RNA sequencing; type 2 immune response; inflammation	GENOME-WIDE ASSOCIATION; DENDRITIC CELLS; FILAGGRIN; DUPILUMAB; BARRIER; IMMUNE; SUBPHENOTYPES; LEUKOTRIENES; EXPRESSION; SIGNATURE	Background: Expression profiling of skin biopsy specimens has established molecular features of the skin in patients with atopic dermatitis (AD). The invasiveness of biopsies has prevented their use in defining individual-level AD pathobiological mechanisms (endotypes) in large research studies. Objective: We sought to determine whether minimally invasive skin tape strip transcriptome analysis identifies gene expression dysregulation in AD and molecular disease endotypes. Methods: We sampled nonlesional and lesional skin tape strips and biopsy specimens from white adult patients with AD (18 male and 12 female patients; age [mean SE], 36.3 +/- 2.2 years) and healthy control subjects (9 male and 16 female subjects; age [mean +/- SE], 34.8 +/- 2.2 years). AmpliSeq whole-transcriptome sequencing was performed on extracted RNA. Differential expression, clustering/pathway analyses, immunostaining of skin biopsy specimens, and clinical trait correlations were performed. Results: Skin tape expression profiles were distinct from skin biopsy profiles and better sampled epidermal differentiation complex genes. Skin tape expression of 29 immune and epidermis-related genes (false discovery rate < 5%) separated patients with AD from healthy subjects. Agnostic gene set analyses and clustering revealed 50% of patients with AD exhibited a type 2 inflammatory signature (type 2-high endotype) characterized by differential expression of 656 genes, including overexpression of IL13, IL4R, CCL22, CCR4 (log(2) fold change = 5.5, 2.0, 4.0, and 4.1, respectively) and at a pathway level by T(H)2/dendritic cell activation. Both expression and immunostaining of skin biopsy specimens indicated this type 2-high group was enriched for inflammatory, type 2-skewed dendritic cells expressing FceRI. The type 2-high endotype group exhibited more severe disease by using both the Eczema Area and Severity Index score and body surface area covered by lesions. Conclusion: Minimally invasive expression profiling of nonlesional skin reveals stratification in AD molecular pathology by type 2 inflammation that correlates with disease severity.	[Dyjack, Nathan; Rios, Cydney; Seibold, Max A.] Natl Jewish Hlth, Ctr Genes Environm & Hlth, Denver, CO USA; [Goleva, Elena; Kim, Byung Eui; Bin, Lianghua; Taylor, Patricia; Bronchick, Caroline; Hall, Clifton F.; Richers, Brittany N.; Seibold, Max A.; Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA; [Seibold, Max A.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Aurora, CO USA; [Leung, Donald Y. M.] Univ Colorado Denver, Dept Pediat, Dept Med, Aurora, CO USA	National Jewish Health; National Jewish Health; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Seibold, MA; Leung, DYM (corresponding author), Natl Jewish Hlth, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.; Seibold, MA (corresponding author), Natl Jewish Hlth, Dept Pediat, Ctr Genes Environm & Hlth, 1400 Jackson St, Denver, CO 80206 USA.	seiboldm@njhealth.org; Leungd@NJHealth.org		Kim, Byung Eui/0000-0003-4923-1814; Bin, Lianghua/0000-0002-3786-0106; Dyjack, Nathan/0000-0001-6944-6252	National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal Diseases (NIAMS) [R01 AR41256]; NIH/National Institute of Allergy and Infectious Diseases (NIAID) [U19 AI117673]; NIH/National Center for Research Resources (NCRR) [UL1 RR025780]; Edelstein Family Chair of Pediatric Allergy-Immunology at National Jewish Health; NIH [P01 HL132821-01A1, R01 HL135156-01, R01 MD010443-02, R01 HL128439-03]; Department of Defense [W81WH-16-2-0018]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL135156, P01HL132821, R01HL128439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI117673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [R01MD010443] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal Diseases (NIAMS); NIH/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Edelstein Family Chair of Pediatric Allergy-Immunology at National Jewish Health; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	Supported in part by National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal Diseases (NIAMS) grant R01 AR41256, NIH/National Institute of Allergy and Infectious Diseases (NIAID) grant U19 AI117673, NIH/National Center for Research Resources (NCRR) grant UL1 RR025780 and the Edelstein Family Chair of Pediatric Allergy-Immunology at National Jewish Health. To M.A.S.: NIH grant nos. P01 HL132821-01A1, R01 HL135156-01, R01 MD010443-02, and R01 HL128439-03; and Department of Defense grant no. W81WH-16-2-0018.	Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Bieber T, 2017, J ALLERGY CLIN IMMUN, V139, pS58, DOI 10.1016/j.jaci.2017.01.008; Bieber T, 2011, CLIN REV ALLERG IMMU, V41, P254, DOI 10.1007/s12016-010-8224-0; Brunner PM, 2017, ALLERGY, V72, P2017, DOI 10.1111/all.13223; Brunner PM, 2017, J ALLERGY CLIN IMMUN, V139, pS65, DOI 10.1016/j.jaci.2017.01.011; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Cole C, 2014, J ALLERGY CLIN IMMUN, V134, P82, DOI 10.1016/j.jaci.2014.04.021; Denzin LK, 1997, SCIENCE, V278, P106, DOI 10.1126/science.278.5335.106; Elmose C, 2015, J ALLERGY CAIRO, V2015; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Ewald DA, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0133-x; Gao PS, 2010, J ALLERGY CLIN IMMUN, V125, P1403, DOI 10.1016/j.jaci.2010.03.016; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Grill JI, 2017, MOL CELL ENDOCRINOL, V439, P286, DOI 10.1016/j.mce.2016.09.014; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Hanifin IM, 2007, DERMATITIS, V18, P82, DOI 10.2310/6620.2007.06034; Harper JI, 2010, BRIT J DERMATOL, V162, P397, DOI 10.1111/j.1365-2133.2009.09467.x; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Huber W, 2015, NAT METHODS, V12, P115, DOI [10.1038/NMETH.3252, 10.1038/nmeth.3252]; Hutter C, 2012, BLOOD, V120, P5199, DOI 10.1182/blood-2012-02-410241; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Kraft S, 2007, NAT REV IMMUNOL, V7, P365, DOI 10.1038/nri2072; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Li S, 2017, BRIT J DERMATOL, V177, pE125, DOI 10.1111/bjd.15409; Li WL, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2270-1; Liu M, 2015, ALLERGOL INT, V64, P17, DOI 10.1016/j.alit.2014.09.001; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luo WJ, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-161; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; Poole A, 2014, J ALLERGY CLIN IMMUN, V133, P670, DOI 10.1016/j.jaci.2013.11.025; Reynolds SD, 2016, AM J RESP CELL MOL, V55, P323, DOI 10.1165/rcmb.2015-0274MA; Sasagawa S, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00142; Sean D, 2007, BIOINFORMATICS, V23, P1846, DOI 10.1093/bioinformatics/btm254; Silverberg JI, 2014, DERMATITIS, V25, P107, DOI 10.1097/DER.0000000000000034; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Simpson EL, 2014, J ALLERGY CLIN IMMUN, V134, P818, DOI 10.1016/j.jaci.2014.08.005; Singh RK, 2010, PHARMACOLOGY, V85, P336, DOI 10.1159/000312669; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Szeles L, 2010, MOL ENDOCRINOL, V24, P2218, DOI 10.1210/me.2010-0215; Thompson MD, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00299; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yoshida K, 2014, J ALLERGY CLIN IMMUN, V134, P856, DOI 10.1016/j.jaci.2014.08.001	52	58	62	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1298	1309		10.1016/j.jaci.2017.10.046	http://dx.doi.org/10.1016/j.jaci.2017.10.046			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	29309794	Bronze, Green Accepted			2022-12-18	WOS:000429197800016
J	Muehling, LM; Lawrence, MG; Woodfolk, JA				Muehling, Lyndsey M.; Lawrence, Monica G.; Woodfolk, Judith A.			Pathogenic CD4(+) T cells in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergens; IgE; T(H)1; T(H)2; T(H)17; T(H)22; follicular helper T cell; GATA-3; T-bet; thymic stromal lymphopoietin; IL-25; IL-33; epithelial barrier; T-cell epitopes; T-cell plasticity	INNATE LYMPHOID-CELLS; THYMIC STROMAL LYMPHOPOIETIN; SUBLINGUAL ALLERGEN IMMUNOTHERAPY; TRANSCRIPTION FACTOR GATA-3; DUST-MITE ALLERGEN; DENDRITIC CELLS; T(H)2 CELLS; TH2 DIFFERENTIATION; B-CELLS; ENVIRONMENTAL EXPOSURE	Asthma encompasses a variety of clinical phenotypes that involve distinct T cell-driven inflammatory processes. Improved understanding of human T-cell biology and the influence of innate cytokines on T-cell responses at the epithelial barrier has led to new asthma paradigms. This review captures recent knowledge on pathogenic CD4(+) T cells in asthmatic patients by drawing on observations in mouse models and human disease. In patients with allergic asthma, T(H)2 cells promote IgE-mediated sensitization, airway hyperreactivity, and eosinophilia. Here we discuss recent discoveries in the myriad molecular pathways that govern the induction of T(H)2 differentiation and the critical role of GATA-3 in this process. We elaborate on how cross-talk between epithelial cells, dendritic cells, and innate lymphoid cells translates to T-cell outcomes, with an emphasis on the actions of thymic stromal lymphopoietin, IL-25, and IL-33 at the epithelial barrier. New concepts on how T-cell skewing and epitope specificity are shaped by multiple environmental cues integrated by dendritic cell "hubs'' are discussed. We also describe advances in understanding the origins of atypical T(H)2 cells in asthmatic patients, the role of T(H)1 cells and other non-T(H)2 types in asthmatic patients, and the features of T-cell pathogenicity at the single-cell level. Progress in technologies that enable highly multiplexed profiling of markers within a single cell promise to overcome barriers to T-cell discovery in human asthmatic patients that could transform our understanding of disease. These developments, along with novel T cell-based therapies, position us to expand the assortment of molecular targets that could facilitate personalized treatments.	[Muehling, Lyndsey M.; Lawrence, Monica G.; Woodfolk, Judith A.] Univ Virginia, Sch Med, Dept Med, Div Allergy, Charlottesville, VA 22908 USA	University of Virginia	Woodfolk, JA (corresponding author), Univ Virginia, Sch Med, Div Allergy, POB 801355, Charlottesville, VA 22908 USA.	jaw4m@virginia.edu		Muehling, Lyndsey/0000-0003-3203-3264	National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01 AR059058]; NIH/National Institute of Allergy and Infectious Diseases [U01 AI100799]; NIH [T32 AI007496]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI100799, T32AI007496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR059058] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIH/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by the National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases grant R01 AR059058 and NIH/National Institute of Allergy and Infectious Diseases grant U01 AI100799 (to J.A.W.) and NIH grant T32 AI007496 (to L.M.M.).	Akbari M, 2014, J IMMUNOL, V192, P2271, DOI 10.4049/jimmunol.1301914; Aktar MK, 2015, ALLERGY, V70, P846, DOI 10.1111/all.12633; Allam JP, 2011, ALLERGY, V66, P532, DOI 10.1111/j.1398-9995.2010.02510.x; Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Anderson WC, 2015, J ALLERGY CLIN IMMUN, V136, P848, DOI 10.1016/j.jaci.2015.07.007; Archila LD, 2016, CLIN EXP ALLERGY, V46, P871, DOI 10.1111/cea.12746; Balaji H, 2011, J ALLERGY CLIN IMMUN, V128, P92, DOI 10.1016/j.jaci.2011.02.043; Ballesteros-Tato A, 2016, IMMUNITY, V44, P259, DOI 10.1016/j.immuni.2015.11.017; Bell BD, 2013, NAT IMMUNOL, V14, P364, DOI 10.1038/ni.2541; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Bourgeois EA, 2015, J EXP MED, V212, P149, DOI 10.1084/jem.20141505; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Bredo G, 2015, IMMUN INFLAMM DIS, V3, P455, DOI 10.1002/iid3.87; Bruchard M, 2015, NAT IMMUNOL, V16, P859, DOI 10.1038/ni.3202; Campbell JD, 2009, J EXP MED, V206, P1535, DOI 10.1084/jem.20082901; Castanhinha S, 2015, J ALLERGY CLIN IMMUN, V136, P312, DOI 10.1016/j.jaci.2015.01.016; Chan PY, 2016, SCIENCE, V352, P99, DOI 10.1126/science.aaf1358; Chattopadhyay PK, 2014, NAT IMMUNOL, V15, P128, DOI 10.1038/ni.2796; Chen ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051268; Cheng D, 2014, AM J RESP CRIT CARE, V190, P639, DOI 10.1164/rccm.201403-0505OC; Cho S, 2016, J EXP MED, V213, P235, DOI 10.1084/jem.20150990; Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Coquet JM, 2015, IMMUNITY, V43, P318, DOI 10.1016/j.immuni.2015.07.015; Couroux P, 2015, CLIN EXP ALLERGY, V45, P974, DOI 10.1111/cea.12488; Crapster-Pregont M, 2012, J ALLERGY CLIN IMMUN, V129, P1621, DOI 10.1016/j.jaci.2012.01.052; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P104, DOI 10.1016/j.jaci.2015.01.020; De Grove KC, 2017, J ALLERGY CLIN IMMUN, V139, P246, DOI 10.1016/j.jaci.2016.03.044; de Wit J, 2015, J ALLERGY CLIN IMMUN, V135, P1053, DOI 10.1016/j.jaci.2014.08.012; DeLong JH, 2011, J ALLERGY CLIN IMMUN, V127, P1211, DOI 10.1016/j.jaci.2011.02.028; Delong T, 2016, SCIENCE, V351, P711, DOI 10.1126/science.aad2791; Archila LD, 2015, J ALLERGY CLIN IMMUN, V136, P983, DOI 10.1016/j.jaci.2015.01.029; Dimeloe S, 2010, J STEROID BIOCHEM, V120, P86, DOI 10.1016/j.jsbmb.2010.02.029; Dominguez-Villar M, 2011, NAT MED, V17, P673, DOI 10.1038/nm.2389; Drake LY, 2014, ALLERGY, V69, P1300, DOI 10.1111/all.12446; Dullaers M, 2017, J ALLERGY CLIN IMMUN, V140, P76, DOI 10.1016/j.jaci.2016.09.020; DuPage M, 2016, NAT REV IMMUNOL, V16, P149, DOI 10.1038/nri.2015.18; Ebensen T, 2007, VACCINE, V25, P1464, DOI 10.1016/j.vaccine.2006.10.033; Ebert LA, 2005, MOL IMMUNOL, V42, P799, DOI 10.1016/j.molimm.2004.06.040; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Endo Y, 2015, IMMUNITY, V42, P294, DOI 10.1016/j.immuni.2015.01.016; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Froidure A, 2014, ALLERGY, V69, P1068, DOI 10.1111/all.12435; Gabriele L, 2013, J ALLERGY CLIN IMMUN, V132, P686, DOI 10.1016/j.jaci.2013.02.037; Gauvreau GM, 2014, CLIN EXP ALLERGY, V44, P29, DOI 10.1111/cea.12235; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Gold MJ, 2014, J ALLERGY CLIN IMMUN, V133, P1142, DOI 10.1016/j.jaci.2014.02.033; Gomez-Rodriguez J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10857; Green BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100645; Gueguen C, 2016, J ALLERGY CLIN IMMUN, V137, P545, DOI 10.1016/j.jaci.2015.09.015; Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015; Hanel KH, 2016, J IMMUNOL, V196, P3233, DOI 10.4049/jimmunol.1402943; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Headley MB, 2009, J IMMUNOL, V182, P1641, DOI 10.4049/jimmunol.182.3.1641; Henault J, 2016, NAT IMMUNOL, V17, P196, DOI 10.1038/ni.3326; Hinks Timothy, 2015, Lancet, V385 Suppl 1, pS42, DOI 10.1016/S0140-6736(15)60357-9; Hinz D, 2015, CLIN EXP ALLERGY, V45, P1601, DOI 10.1111/cea.12507; Hirahara K, 2016, INT IMMUNOL, V28, P163, DOI 10.1093/intimm/dxw006; Ho IC, 2009, NAT REV IMMUNOL, V9, P125, DOI 10.1038/nri2476; Homburg U, 2015, J ALLERGY CLIN IMMUN, V136, P797, DOI 10.1016/j.jaci.2015.02.018; Hondowicz BD, 2016, IMMUNITY, V44, P155, DOI 10.1016/j.immuni.2015.11.004; Huang T, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86689; Hui CCK, 2014, CLIN EXP ALLERGY, V44, P953, DOI 10.1111/cea.12330; Hulse KE, 2010, J ALLERGY CLIN IMMUN, V125, P247, DOI 10.1016/j.jaci.2009.10.027; Ichimiya S, 2017, J HUM GENET, V62, P81, DOI 10.1038/jhg.2016.88; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; Islam SA, 2012, NAT MED, V18, P705, DOI 10.1038/nm.2760; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jackson DJ, 2016, J ALLERGY CLIN IMMUN, V137, P659, DOI 10.1016/j.jaci.2016.01.002; Jackson DJ, 2015, J ALLERGY CLIN IMMUN, V136, P497, DOI 10.1016/j.jaci.2015.01.028; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; Janss T, 2016, EUR J IMMUNOL, V46, P2614, DOI 10.1002/eji.201646513; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kanno Y, 2012, ANNU REV IMMUNOL, V30, P707, DOI 10.1146/annurev-immunol-020711-075058; Karosiene E, 2013, IMMUNOGENETICS, V65, P711, DOI 10.1007/s00251-013-0720-y; Kast JI, 2012, J ALLERGY CLIN IMMUN, V130, P544, DOI 10.1016/j.jaci.2012.04.044; Kim A, 2015, CURR OPIN IMMUNOL, V34, P9, DOI 10.1016/j.coi.2014.12.005; Kirstein F, 2016, J ALLERGY CLIN IMMUN, V137, P1852, DOI 10.1016/j.jaci.2015.10.036; Koenen HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood-2008-01-133967; Krug N, 2015, NEW ENGL J MED, V372, P1987, DOI 10.1056/NEJMoa1411776; Kuwahara M, 2012, NAT IMMUNOL, V13, P778, DOI 10.1038/ni.2362; Lai TW, 2016, SCI REP-UK, V6, DOI 10.1038/srep22835; Lam EPS, 2016, J ALLERGY CLIN IMMUN, V137, P1514, DOI 10.1016/j.jaci.2015.10.019; Larche Mark, 2014, Ann Am Thorac Soc, V11 Suppl 5, pS292, DOI 10.1513/AnnalsATS.201402-090AW; Ledford D, 2017, J ALLERGY CLIN IMMUN, V140, P162, DOI 10.1016/j.jaci.2016.08.054; Lee HY, 2014, EXP LUNG RES, V40, P66, DOI 10.3109/01902148.2013.870261; Lee JB, 2016, J ALLERGY CLIN IMMUN, V137, P1216, DOI 10.1016/j.jaci.2015.09.019; Leelatian N, 2015, METHODS MOL BIOL, V1346, P99, DOI 10.1007/978-1-4939-2987-0_8; Ling MF, 2016, ANN AM THORAC SOC, V13, pS25, DOI 10.1513/AnnalsATS.201507-431MG; Liu WM, 2017, J ALLERGY CLIN IMMUN, V139, P1548, DOI 10.1016/j.jaci.2016.08.032; Llop-Guevara A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088714; Loftus PA, 2015, INT FORUM ALLERGY RH, V5, pS7, DOI 10.1002/alr.21547; Macaubas C, 2006, J IMMUNOL, V176, P5069, DOI 10.4049/jimmunol.176.8.5069; MacDonald KG, 2015, J ALLERGY CLIN IMMUN, V135, P946, DOI 10.1016/j.jaci.2014.12.1932; Machado Y, 2016, J ALLERGY CLIN IMMUN, V137, P1525, DOI 10.1016/j.jaci.2015.09.026; Makrinioti H, 2014, LANCET RESP MED, V2, P226, DOI 10.1016/S2213-2600(13)70261-3; Mascarell L, 2015, ALLERGY, V70, P408, DOI 10.1111/all.12576; McClymont SA, 2011, J IMMUNOL, V186, P3918, DOI 10.4049/jimmunol.1003099; Mehta AK, 2016, J ALLERGY CLIN IMMUN, V137, P278, DOI 10.1016/j.jaci.2015.05.007; Melum GR, 2014, J ALLERGY CLIN IMMUN, V134, P613, DOI 10.1016/j.jaci.2014.05.010; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Meylan F, 2017, SEMIN IMMUNOPATHOL, V39, P21, DOI 10.1007/s00281-016-0612-y; Mingueneau M, 2016, J ALLERGY CLIN IMMUN, V137, P1809, DOI 10.1016/j.jaci.2016.01.024; Mirchandani AS, 2014, J IMMUNOL, V192, P2442, DOI 10.4049/jimmunol.1300974; Mitson-Salazar A, 2016, J ALLERGY CLIN IMMUN, V137, P907, DOI 10.1016/j.jaci.2015.08.007; Morita H, 2016, J ALLERGY CLIN IMMUN, V138, P1253, DOI 10.1016/j.jaci.2016.09.011; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Muehling LM, 2016, J IMMUNOL, V197, P3214, DOI 10.4049/jimmunol.1600663; Murakami-Satsutani N, 2014, ALLERGOL INT, V63, P443, DOI 10.2332/allergolint.13-OA-0672; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Nouri-Shirazi M, 2015, SCAND J IMMUNOL, V81, P110, DOI 10.1111/sji.12254; Novak EJ, 2001, J IMMUNOL, V166, P6665, DOI 10.4049/jimmunol.166.11.6665; O'Garra A, 2016, J IMMUNOL, V196, P4423, DOI 10.4049/jimmunol.1600646; O'Gorman WE, 2015, J ALLERGY CLIN IMMUN, V136, P1326, DOI 10.1016/j.jaci.2015.04.008; O'Hehir RE, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-015-0587-0; Overacre AE, 2016, CURR OPIN IMMUNOL, V39, P39, DOI 10.1016/j.coi.2015.12.009; Patel D, 2013, J ALLERGY CLIN IMMUN, V131, P103, DOI 10.1016/j.jaci.2012.07.028; PETITFRERE C, 1993, IMMUNOLOGY, V79, P146; Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006; Pothoven KL, 2015, J ALLERGY CLIN IMMUN, V136, P737, DOI 10.1016/j.jaci.2015.01.043; Prickett SR, 2013, CLIN EXP ALLERGY, V43, P684, DOI 10.1111/cea.12113; Prickett SR, 2011, J ALLERGY CLIN IMMUN, V127, P608, DOI 10.1016/j.jaci.2010.09.027; Prussin C, 2009, J ALLERGY CLIN IMMUN, V124, P1326, DOI 10.1016/j.jaci.2009.09.048; Pua HH, 2016, IMMUNITY, V44, P821, DOI 10.1016/j.immuni.2016.01.003; Qiu P, 2011, NAT BIOTECHNOL, V29, P886, DOI 10.1038/nbt.1991; Ramesh M, 2016, J ALLERGY CLIN IMMUN, V137, P1764, DOI 10.1016/j.jaci.2015.12.1327; Raundhal M, 2015, J CLIN INVEST, V125, P3037, DOI 10.1172/JCI80911; Reefer AJ, 2010, J ALLERGY CLIN IMMUN, V126, P1049, DOI 10.1016/j.jaci.2010.07.023; Renand A, 2015, J ALLERGY CLIN IMMUN, V136, P1627, DOI 10.1016/j.jaci.2015.07.031; Rigas D, 2017, J ALLERGY CLIN IMMUN, V139, P1468, DOI 10.1016/j.jaci.2016.08.034; Ritz SA, 2002, AM J RESP CELL MOL, V27, P428, DOI 10.1165/rcmb.4824; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P639, DOI 10.1016/j.jaci.2016.06.003; Robinette ML, 2016, J ALLERGY CLIN IMMUN, V138, P1243, DOI 10.1016/j.jaci.2016.09.006; Romeo MJ, 2014, J ALLERGY CLIN IMMUN, V133, P952, DOI 10.1016/j.jaci.2013.08.006; Rotiroti G, 2012, J ALLERGY CLIN IMMUN, V130, P918, DOI 10.1016/j.jaci.2012.06.052; Roux M, 2016, J ALLERGY CLIN IMMUN, V138, P451, DOI 10.1016/j.jaci.2016.03.039; Ryan JF, 2016, P NATL ACAD SCI USA, V113, pE1286, DOI 10.1073/pnas.1520180113; Ryjenkov DA, 2005, J BACTERIOL, V187, P1792, DOI 10.1128/JB.187.5.1792-1798.2005; Sahoo A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5732; Salazar F, 2016, J ALLERGY CLIN IMMUN, V137, P1841, DOI 10.1016/j.jaci.2015.10.033; Salazar F, 2013, J ALLERGY CLIN IMMUN, V132, P27, DOI 10.1016/j.jaci.2013.02.001; Sallusto F, 2016, ANNU REV IMMUNOL, V34, P317, DOI 10.1146/annurev-immunol-032414-112056; Saravia J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005217; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Schutze N, 2016, J IMMUNOL; Sehra S, 2015, J ALLERGY CLIN IMMUN, V136, P433, DOI 10.1016/j.jaci.2015.01.021; Seneviratne SL, 2002, J CLIN INVEST, V110, P1283, DOI 10.1172/JCI200215753; Seumois G, 2014, NAT IMMUNOL, V15, P777, DOI 10.1038/ni.2937; Shih HY, 2016, CELL, V165, P1120, DOI 10.1016/j.cell.2016.04.029; Shikotra A, 2012, J ALLERGY CLIN IMMUN, V129, P104, DOI 10.1016/j.jaci.2011.08.031; Slovick A, 2017, J ALLERGY CLIN IMMUN, V139, P1830, DOI 10.1016/j.jaci.2016.09.024; Soto-Quiros M, 2012, J ALLERGY CLIN IMMUN, V129, P1499, DOI 10.1016/j.jaci.2012.03.040; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Steelant B, 2016, J ALLERGY CLIN IMMUN, V137, P1043, DOI 10.1016/j.jaci.2015.10.050; Stott B, 2013, J ALLERGY CLIN IMMUN, V132, P446, DOI 10.1016/j.jaci.2013.03.050; Subramaniam S, 2016, EUR J IMMUNOL, V46, P242, DOI 10.1002/eji.201545869; Tanaka S, 2011, NAT IMMUNOL, V12, P77, DOI 10.1038/ni.1966; Tatsuno K, 2015, J INVEST DERMATOL, V135, P3017, DOI 10.1038/jid.2015.318; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026; Teraki Y, 2013, J ALLERGY CLIN IMMUN, V132, P971, DOI 10.1016/j.jaci.2013.07.029; Tjota MY, 2014, CURR OPIN IMMUNOL, V31, P44, DOI 10.1016/j.coi.2014.09.006; Tjota MY, 2014, J ALLERGY CLIN IMMUN, V134, P706, DOI 10.1016/j.jaci.2014.06.013; Townley RG, 2012, ANN ALLERG ASTHMA IM, V109, P365, DOI 10.1016/j.anai.2012.04.004; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Tworek D, 2016, AM J RESP CRIT CARE, V193, P957, DOI 10.1164/rccm.201509-1751OC; van de Veen W, 2016, J ALLERGY CLIN IMMUN, V138, P654, DOI 10.1016/j.jaci.2016.07.006; Van Dyken SJ, 2016, NAT IMMUNOL, V17, P1381, DOI 10.1038/ni.3582; van Helden MJ, 2013, CURR OPIN IMMUNOL, V25, P745, DOI 10.1016/j.coi.2013.10.002; Vaughan Kerrie, 2010, J Allergy (Cairo), V2010, P628026, DOI 10.1155/2010/628026; Verhoef PA, 2016, J ALLERGY CLIN IMMUN, V137, P591, DOI 10.1016/j.jaci.2015.07.050; Virchow JC, 2016, JAMA-J AM MED ASSOC, V315, P1715, DOI 10.1001/jama.2016.3964; Vita R, 2015, NUCLEIC ACIDS RES, V43, pD405, DOI 10.1093/nar/gku938; Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613; Wambre E, 2011, CLIN EXP ALLERGY, V41, P192, DOI 10.1111/j.1365-2222.2010.03641.x; Wambre E, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Wambre E, 2012, J ALLERGY CLIN IMMUN, V129, P544, DOI 10.1016/j.jaci.2011.08.034; Wang C, 2015, CURR OPIN IMMUNOL, V37, P6, DOI 10.1016/j.coi.2015.08.001; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Wang YQ, 2013, NAT IMMUNOL, V14, P714, DOI 10.1038/ni.2623; Wawrzyniak P, 2017, J ALLERGY CLIN IMMUN, V139, P93, DOI 10.1016/j.jaci.2016.03.050; Westernberg L, 2016, J ALLERGY CLIN IMMUN, V138, P571, DOI 10.1016/j.jaci.2015.11.034; Williams JW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3990; Wisniewski JA, 2015, CLIN EXP ALLERGY, V45, P1201, DOI 10.1111/cea.12537; Woodfolk JA, 2007, J ALLERGY CLIN IMMUN, V119, P280, DOI 10.1016/j.jaci.2006.11.008; Worm M, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Worm M, 2011, J ALLERGY CLIN IMMUN, V127, P89, DOI 10.1016/j.jaci.2010.11.029; Yang HY, 2016, IMMUNITY, V45, P83, DOI 10.1016/j.immuni.2016.06.022; Yu Q, 2009, NAT IMMUNOL, V10, P992, DOI 10.1038/ni.1762; Zaleska A, 2014, ALLERGY, V69, P1162, DOI 10.1111/all.12461; Zeng WP, 2017, J ALLERGY CLIN IMMUN, V139, P508, DOI 10.1016/j.jaci.2016.04.033; Zhang QL, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-35; Zhang YX, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad4322; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhou HH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040610	197	58	66	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1523	1540		10.1016/j.jaci.2017.02.025	http://dx.doi.org/10.1016/j.jaci.2017.02.025			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28442213	Bronze, Green Accepted			2022-12-18	WOS:000417206000006
J	Metz, M; Schutz, A; Weller, K; Gorczyza, M; Zimmer, S; Staubach, P; Merk, HF; Maurer, M				Metz, Martin; Schuetz, Andrea; Weller, Karsten; Gorczyza, Marina; Zimmer, Sebastian; Staubach, Petra; Merk, Hans F.; Maurer, Marcus			Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DIAGNOSIS		[Metz, Martin; Schuetz, Andrea; Weller, Karsten; Gorczyza, Marina; Maurer, Marcus] Charite, Dept Dermatol & Allergy, Berlin, Germany; [Zimmer, Sebastian; Staubach, Petra] Univ Med Ctr Mainz, Dept Dermatol, Mainz, Germany; [Merk, Hans F.] Rhein Westfal TH Aachen, Dept Dermatol & Allergy, Aachen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Johannes Gutenberg University of Mainz; RWTH Aachen University	Maurer, M (corresponding author), Charite, Dept Dermatol & Allergy, Berlin, Germany.	marcus.maurer@charite.de	Metz, Martin/B-8799-2009; Maurer, Marcus/ABG-2174-2020	Metz, Martin/0000-0002-4070-9976; Maurer, Marcus/0000-0002-4121-481X; Weller, Karsten/0000-0003-4437-0313	Novartis; Else Kroner-Fresenius-Stiftung	Novartis(Novartis); Else Kroner-Fresenius-Stiftung	We thank Hesna Gozlukaya and Nikki Rooks for excellent technical assistance and the team of the Charite urticaria clinic, a GA<SUP>2</SUP>LEN Urticaria Center of Reference and Excellence (UCARE, www.ga2len.net/ucare), for support and helpful discussions. The trial was an investigator-initiated trial funded, in part, by Novartis and by intramural grants. M. Metz is supported by the Else Kroner-Fresenius-Stiftung.	Abajian M, 2012, CURR ALLERGY ASTHM R, V12, P281, DOI 10.1007/s11882-012-0269-0; Boyce JA, 2006, J ALLERGY CLIN IMMUN, V117, P1415, DOI 10.1016/j.jaci.2006.04.003; Casale TB, 2015, J ALLER CL IMM-PRACT, V3, P743, DOI 10.1016/j.jaip.2015.04.015; Grabbe J, 2001, J INVEST DERM SYMP P, V6, P135, DOI 10.1046/j.0022-202x.2001.00025.x; KAPLAN AP, 1981, NEW ENGL J MED, V305, P1074, DOI 10.1056/NEJM198110293051808; Magerl M, 2016, ALLERGY, V71, P780, DOI 10.1111/all.12884; Magerl M, 2015, J EUR ACAD DERMATOL, V29, P2043, DOI 10.1111/jdv.12739; Metz M, 2014, J DERMATOL SCI, V73, P57, DOI 10.1016/j.jdermsci.2013.08.011; NEWCOMB RW, 1973, AM J MED, V54, P174, DOI 10.1016/0002-9343(73)90221-0; Siebenhaar F, 2007, CLIN EXP DERMATOL, V32, P241, DOI 10.1111/j.1365-2230.2007.02376.x; Singleton R, 2016, CUTIS, V97, P59	11	58	61	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					864	+		10.1016/j.jaci.2017.01.043	http://dx.doi.org/10.1016/j.jaci.2017.01.043			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28389393	Bronze			2022-12-18	WOS:000409241500028
J	Loxham, M; Davies, DE				Loxham, Matthew; Davies, Donna E.			Phenotypic and genetic aspects of epithelial barrier function in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; tight junction; innate immunity; cytokine; homeostasis	THYMIC STROMAL LYMPHOPOIETIN; AIR-POLLUTION EXPOSURE; EMERGENCY-DEPARTMENT VISITS; GROWTH-FACTOR RECEPTOR; TIGHT JUNCTION; ALLERGIC SENSITIZATION; GENOMEWIDE ASSOCIATION; MESENCHYMAL TRANSITION; CELL-DIFFERENTIATION; RHINOVIRUS INFECTION	The bronchial epithelium is continuously exposed to a multitude of noxious challenges in inhaled air. Cellular contact with most damaging agents is reduced by the action of the mucociliary apparatus and by formation of a physical barrier that controls passage of ions and macromolecules. In conjunction with these defensive barrier functions, immunomodulatory cross-talk between the bronchial epithelium and tissue-resident immune cells controls the tissue microenvironment and barrier homeostasis. This is achieved by expression of an array of sensors that detect a wide variety of viral, bacterial, and nonmicrobial (toxins and irritants) agents, resulting in production of many different soluble and cell-surface molecules that signal to cells of the immune system. The ability of the bronchial epithelium to control the balance of inhibitory and activating signals is essential for orchestrating appropriate inflammatory and immune responses and for temporally modulating these responses to limit tissue injury and control the resolution of inflammation during tissue repair. In asthmatic patients abnormalities in many aspects of epithelial barrier function have been identified. We postulate that such abnormalities play a causal role in immune dysregulation in the airways by translating gene-environment interactions that underpin disease pathogenesis and exacerbation.	[Loxham, Matthew; Davies, Donna E.] Univ Southampton, Southampton NIHR Resp Biomed Res Unit, Fac Med, Clin & Expt Sci,Sir Henry Wellcome Labs,Univ Hosp, Southampton, Hants, England	University of Southampton	Davies, DE (corresponding author), Univ Southampton, Clin & Expt Sci, Southampton Gen Hosp, Fac Med, Tremona Rd, Southampton SO16 6YD, Hants, England.	donnad@soton.ac.uk		Davies, Donna/0000-0002-5117-2991; Loxham, Matthew/0000-0001-6459-538X	Medical Research Council (MRC [UK]); National Centre for Reduction Refinement and Replacement of Animals in Research (NC3Rs [UK]); Asthma UK; Asthma Allergy and Inflammation Research Charity (AAIR); National Institute for Health Research (NIHR [UK]); Biotechnology and Biological Sciences Research Council (BBSRC); BBSRC [BB/P011365/1] Funding Source: UKRI; MRC [G0900453] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/P011365/1] Funding Source: researchfish; Medical Research Council [G0900453] Funding Source: researchfish; National Centre for the Replacement [G1001598/1] Funding Source: researchfish	Medical Research Council (MRC [UK])(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Centre for Reduction Refinement and Replacement of Animals in Research (NC3Rs [UK]); Asthma UK; Asthma Allergy and Inflammation Research Charity (AAIR); National Institute for Health Research (NIHR [UK])(National Institute for Health Research (NIHR)); Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Centre for the Replacement	Supported by the Medical Research Council (MRC [UK]), the National Centre for Reduction Refinement and Replacement of Animals in Research (NC3Rs [UK]), Asthma UK, the Asthma Allergy and Inflammation Research Charity (AAIR), the National Institute for Health Research (NIHR [UK]), and the Biotechnology and Biological Sciences Research Council (BBSRC).	Ahmad A, 2012, ANN THORAC MED, V7, P226, DOI 10.4103/1817-1737.102182; Al-Daghri NM, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-1; Amaral AFS, 2014, THORAX, V69, P558, DOI 10.1136/thoraxjnl-2013-204574; Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Asgrimsson V, 2006, ANTIMICROB AGENTS CH, V50, P1805, DOI 10.1128/AAC.50.5.1805-1812.2006; Balaci L, 2007, AM J HUM GENET, V80, P1103, DOI 10.1086/518259; Balda MS, 2009, BBA-BIOMEMBRANES, V1788, P761, DOI 10.1016/j.bbamem.2008.11.024; Beale J, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009124; Bedke N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044580; Beisswenger C, 2006, J IMMUNOL, V177, P1833, DOI 10.4049/jimmunol.177.3.1833; Bigler J, 2016, AM J RESP CRIT CARE; Bjerkan L, 2016, MULTIPLE FUNCTIONS N, P9; Blank F, 2011, IMMUNOBIOLOGY, V216, P86, DOI 10.1016/j.imbio.2010.02.006; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Bochkov YA, 2015, P NATL ACAD SCI USA, V112, P5485, DOI 10.1073/pnas.1421178112; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Borchers MT, 2006, AM J PHYSIOL-LUNG C, V291, pL222, DOI 10.1152/ajplung.00327.2005; Bowatte G, 2017, J ALLERGY CLIN IMMUN, V139, P122, DOI 10.1016/j.jaci.2016.05.008; Bowatte G, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0664-z; Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039; Bryceson YT, 2006, IMMUNOL REV, V214, P73, DOI 10.1111/j.1600-065X.2006.00457.x; Bucchieri F, 2002, AM J RESP CELL MOL, V27, P179, DOI 10.1165/ajrcmb.27.2.4699; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Cayrol C, 2009, P NATL ACAD SCI USA, V106, P9021, DOI 10.1073/pnas.0812690106; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; Chang TS, 2014, J ALLERGY CLIN IMMUN, V133, P363, DOI 10.1016/j.jaci.2013.09.002; Cheng D, 2014, AM J RESP CRIT CARE, V190, P639, DOI 10.1164/rccm.201403-0505OC; Clark NA, 2010, ENVIRON HEALTH PERSP, V118, P284, DOI 10.1289/ehp.0900916; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; Daniels MJD, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010102; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI [10.1139/Y08-004, 10.1139/y08-004]; Denlinger LC, 2017, AM J RESP CRIT CARE, V195, P302, DOI 10.1164/rccm.201602-0419OC; Denney L, 2015, IMMUNITY, V43, P945, DOI 10.1016/j.immuni.2015.10.012; Djukanovic R, 2014, AM J RESP CRIT CARE, V190, P145, DOI 10.1164/rccm.201312-2235OC; Dong HM, 2016, SCI REP-UK, V6, DOI 10.1038/srep39559; Duan YY, 2016, EXP CELL RES, V349, P109, DOI 10.1016/j.yexcr.2016.10.004; Durack J, 2016, J ALLERGY CLIN IMMUN; Erzurum SC, 2016, ANN AM THORAC SOC, V13, pS35, DOI 10.1513/AnnalsATS.201506-385MG; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Fahy JV, 2002, CHEST, V122, p320S, DOI 10.1378/chest.122.6_suppl.320S; Fajt ML, 2015, J ALLERGY CLIN IMMUN, V135, P299, DOI 10.1016/j.jaci.2014.12.1871; Farhadi N, 2014, J ALLERGY CLIN IMMUN, V133, P827, DOI 10.1016/j.jaci.2013.09.048; Fedorov IA, 2005, THORAX, V60, P389, DOI 10.1136/thx.2004.030262; Findlay EG, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/140937; Gangl K, 2009, ALLERGY, V64, P398, DOI 10.1111/j.1398-9995.2008.01861.x; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Garrod D, 2008, BBA-BIOMEMBRANES, V1778, P572, DOI 10.1016/j.bbamem.2007.07.014; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Gavala ML, 2011, IMMUNOL REV, V242, P69, DOI 10.1111/j.1600-065X.2011.01031.x; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Gern JE, 2002, AM J MED, V112, p19S; Gerovac BJ, 2016, AM J RESP CELL MOL, V54, P554, DOI 10.1165/rcmb.2015-0227OC; Gerovac BJ, 2014, AM J RESP CELL MOL, V51, P516, DOI 10.1165/rcmb.2013-0237OC; Ghio AJ, 2001, AM J RESP CRIT CARE, V164, P704, DOI 10.1164/ajrccm.164.4.2011089; Gielen V, 2015, J ALLERGY CLIN IMMUN, V136, P177, DOI 10.1016/j.jaci.2014.11.039; Gonzalez-Mariscal L, 2008, BBA-BIOMEMBRANES, V1778, P729, DOI 10.1016/j.bbamem.2007.08.018; Gordon ED, 2016, P NATL ACAD SCI USA, V113, P8765, DOI 10.1073/pnas.1601914113; Gosney JR, 1997, MICROSC RES TECHNIQ, V37, P107, DOI 10.1002/(SICI)1097-0029(19970401)37:1<107::AID-JEMT11>3.0.CO;2-V; Grainge C, 2014, AM J RESP CRIT CARE, V190, P477, DOI 10.1164/rccm.201401-0107LE; Grainge CL, 2011, NEW ENGL J MED, V364, P2006, DOI 10.1056/NEJMoa1014350; Gregory LG, 2013, THORAX, V68, P82, DOI 10.1136/thoraxjnl-2012-202003; Hackett TL, 2013, AM J RESP CELL MOL, V49, P662, DOI 10.1165/rcmb.2013-0124OC; Hackett TL, 2009, AM J RESP CRIT CARE, V180, P122, DOI 10.1164/rccm.200811-1730OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hallstrand TS, 2014, CLIN IMMUNOL, V151, P1, DOI 10.1016/j.clim.2013.12.003; Hamilton LM, 2003, CLIN EXP ALLERGY, V33, P233, DOI 10.1046/j.1365-2222.2003.01593.x; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Harada M, 2007, AM J RESP CELL MOL, V36, P491, DOI 10.1165/rcmb.2006-0090OC; Hatsushika K, 2007, CLIN EXP ALLERGY, V37, P1165, DOI 10.1111/j.1365-2222.2007.02768.x; Heijink I, 2014, THORAX, V69, P5, DOI 10.1136/thoraxjnl-2013-203520; Hristova M, 2016, J ALLERGY CLIN IMMUN, V137, P1545, DOI 10.1016/j.jaci.2015.10.003; Hsu KJ, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-4; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V136, P874, DOI 10.1016/j.jaci.2015.05.044; Hui CCK, 2014, CLIN EXP ALLERGY, V44, P953, DOI 10.1111/cea.12330; Ivanov AI, 2013, INT REV CEL MOL BIO, V303, P27, DOI 10.1016/B978-0-12-407697-6.00002-7; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Janssen WJ, 2016, EUR RESPIR J, V48, P1201, DOI 10.1183/13993003.00120-2015; Johnson JR, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-118; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kaarteenaho-Wiik R, 2009, J HISTOCHEM CYTOCHEM, V57, P187, DOI 10.1369/jhc.2008.951566; Kast JI, 2012, J ALLERGY CLIN IMMUN, V130, P544, DOI 10.1016/j.jaci.2012.04.044; Kelly FJ, 2011, CLIN EXP ALLERGY, V41, P1059, DOI 10.1111/j.1365-2222.2011.03776.x; Kicic A, 2016, CLIN EXP ALLERGY, V46, P1441, DOI 10.1111/cea.12767; Kim Tae Hoon, 2014, Immune Netw, V14, P128, DOI 10.4110/in.2014.14.3.128; Kiwamoto T, 2015, J ALLERGY CLIN IMMUN, V135, P1329, DOI 10.1016/j.jaci.2014.10.027; Kojima T, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/947072; Kondo M, 2002, AM J RESP CELL MOL, V27, P536, DOI 10.1165/rcmb.4682; Koppelman GH, 2009, AM J RESP CRIT CARE, V180, P929, DOI 10.1164/rccm.200810-1621OC; Kozu Y, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0078-z; Krause G, 2008, BBA-BIOMEMBRANES, V1778, P631, DOI 10.1016/j.bbamem.2007.10.018; Krug SM, 2014, SEMIN CELL DEV BIOL, V36, P166, DOI 10.1016/j.semcdb.2014.09.002; Lachowicz-Scroggins ME, 2016, AM J RESP CRIT CARE, V194, P1296; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; Larsson N, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006979; Lefaudeux D, 2016, J ALLERGY CLIN IMMUN; Lefrancais E, 2012, P NATL ACAD SCI USA, V109, P1673, DOI 10.1073/pnas.1115884109; Li X, 2015, ALLERGY, V70, P1309, DOI 10.1111/all.12683; Li XN, 2011, J ALLERGY CLIN IMMUN, V127, P1457, DOI 10.1016/j.jaci.2011.01.056; London NR, 2016, J ALLERGY CLIN IMMUN, V138, P1736, DOI 10.1016/j.jaci.2016.06.027; Lopez-Souza N, 2009, J ALLERGY CLIN IMMUN, V123, P1384, DOI 10.1016/j.jaci.2009.03.010; Loser S, 2016, J ALLERGY CLIN IMMUN; Loza MJ, 2016, ANN AM THORAC SOC, V13, pS102, DOI 10.1513/AnnalsATS.201508-519MG; Malig BJ, 2013, AM J EPIDEMIOL, V178, P58, DOI 10.1093/aje/kws451; Martin N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043545; Mayer AK, 2008, EUR J IMMUNOL, V38, P1689, DOI 10.1002/eji.200737936; McConnell R, 2010, ENVIRON HEALTH PERSP, V118, P1021, DOI 10.1289/ehp.0901232; Meng JF, 2010, ALLERGY ASTHMA IMMUN, V2, P215, DOI 10.4168/aair.2010.2.4.215; Miller M, 2014, J IMMUNOL, V192, P3475, DOI 10.4049/jimmunol.1303047; Minelli C, 2010, INT J EPIDEMIOL, V39, P539, DOI 10.1093/ije/dyp337; Modena BD, 2016, AM J RESP CRIT CARE; Modena BD, 2014, AM J RESP CRIT CARE, V190, P1363, DOI 10.1164/rccm.201406-1099OC; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moheimani F, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0434-4; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Mortensen LJ, 2014, EUR RESPIR J, V43, P792, DOI 10.1183/09031936.00021613; Muraro A, 2016, J ALLERGY CLIN IMMUN, V137, P1347, DOI 10.1016/j.jaci.2016.03.010; Myers JMB, 2014, J ALLERGY CLIN IMMUN, V134, P891, DOI 10.1016/j.jaci.2014.03.037; Nadel JA, 2013, PULM PHARMACOL THER, V26, P510, DOI 10.1016/j.pupt.2013.02.003; Nagarkar DR, 2015, J ALLERGY CLIN IMMUN, V136, P202, DOI 10.1016/j.jaci.2015.01.036; Nagarkar DR, 2012, J ALLERGY CLIN IMMUN, V130, P225, DOI 10.1016/j.jaci.2012.04.019; NAYLOR BERNARD, 1962, THORAX, V17, P69, DOI 10.1136/thx.17.1.69; Nelson WJ, 2008, BIOCHEM SOC T, V36, P149, DOI 10.1042/BST0360149; Nieuwenhuis MAE, 2017, ALLERGY, V72, P792, DOI 10.1111/all.13062; Nievers MG, 1999, MATRIX BIOL, V18, P5, DOI 10.1016/S0945-053X(98)00003-1; Niimi T, 2001, MOL CELL BIOL, V21, P7380, DOI 10.1128/MCB.21.21.7380-7390.2001; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; Obeidy P, 2009, INT J BIOCHEM CELL B, V41, P2364, DOI 10.1016/j.biocel.2009.07.005; Ober C, 2016, ANN AM THORAC SOC, V13, pS85, DOI 10.1513/AnnalsATS.201507-459MG; Olivera DS, 2007, INHAL TOXICOL, V19, P13, DOI 10.1080/08958370600985768; Ordonez C, 2000, AM J RESP CRIT CARE, V162, P2324, DOI 10.1164/ajrccm.162.6.2001041; Park JA, 2015, PHYSIOLOGY, V30, P293, DOI 10.1152/physiol.00004.2015; Park JA, 2009, AM J RESP CELL MOL, V41, P459, DOI 10.1165/rcmb.2008-0195OC; Pauls K, 2001, J INVEST DERMATOL, V117, P569, DOI 10.1046/j.0022-202x.2001.01481.x; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Piper E, 2013, EUR RESPIR J, V41, P330, DOI 10.1183/09031936.00223411; Porter JC, 2009, FASEB J, V23, P492, DOI 10.1096/fj.08-115899; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Progatzky F, 2016, AM J PHYSIOL-LUNG C, V310, pL551, DOI 10.1152/ajplung.00323.2015; Puddicombe SM, 2003, AM J RESP CELL MOL, V28, P61, DOI 10.1165/rcmb.4715; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Qiu RF, 2013, FEBS J, V280, P2014, DOI 10.1111/febs.12225; Reid L, 2005, AM J RESP CRIT CARE, V172, P136, DOI 10.1164/rccm.200502-203WS; Reynolds SD, 2000, AM J PATHOL, V156, P269, DOI 10.1016/S0002-9440(10)64727-X; Rezaee F, 2014, AM J RESP CELL MOL, V50, P857, DOI 10.1165/rcmb.2013-0541RT; Rock JR, 2010, DIS MODEL MECH, V3, P545, DOI 10.1242/dmm.006031; Roeder T, 2012, ADV EXP MED BIOL, V710, P37, DOI 10.1007/978-1-4419-5638-5_5; Rouse BT, 2010, NAT REV IMMUNOL, V10, P514, DOI 10.1038/nri2802; Roy MG, 2014, NATURE, V505, P412, DOI 10.1038/nature12807; Saatian B, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.24333; Saenz SA, 2010, TRENDS IMMUNOL, V31, P407, DOI 10.1016/j.it.2010.09.001; Sajjan U, 2008, AM J RESP CRIT CARE, V178, P1271, DOI 10.1164/rccm.200801-136OC; Schedel M, 2015, J ALLERGY CLIN IMMUN, V136, P893, DOI 10.1016/j.jaci.2015.03.014; Schlingmann B, 2015, SEMIN CELL DEV BIOL, V42, P47, DOI 10.1016/j.semcdb.2015.04.009; Schroer KT, 2011, J ALLERGY CLIN IMMUN, V128, P539, DOI 10.1016/j.jaci.2011.04.018; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; Semlali A, 2010, J ALLERGY CLIN IMMUN, V125, P844, DOI 10.1016/j.jaci.2010.01.044; Shahana S, 2005, RESP MED, V99, P429, DOI 10.1016/j.rmed.2004.08.013; Shikotra A, 2012, J ALLERGY CLIN IMMUN, V129, P104, DOI 10.1016/j.jaci.2011.08.031; Singhania A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168680; Smith DE, 2011, J LEUKOCYTE BIOL, V89, P383, DOI 10.1189/jlb.0810470; Snelgrove RJ, 2008, NAT IMMUNOL, V9, P1074, DOI 10.1038/ni.1637; Stevens PT, 2008, CLIN EXP ALLERGY, V38, P1901, DOI 10.1111/j.1365-2222.2008.03093.x; Sugita K., 2017, J ALLERGY CLIN IMMUN; Swamy M, 2010, NAT IMMUNOL, V11, P656, DOI 10.1038/ni.1905; Sweerus K, 2017, J ALLERGY CLIN IMMUN, V139, P72, DOI 10.1016/j.jaci.2016.02.035; Swindle EJ, 2009, J ALLERGY CLIN IMMUN, V124, P23, DOI 10.1016/j.jaci.2009.05.037; Tai HY, 2006, ALLERGY, V61, P382, DOI 10.1111/j.1398-9995.2005.00958.x; Takeyama K, 2001, AM J RESP CRIT CARE, V163, P511, DOI 10.1164/ajrccm.163.2.2001038; Tellez GF, 2015, AM J PHYSIOL-LUNG C, V309, pL725, DOI 10.1152/ajplung.00346.2014; Tellez GF, 2014, EUR RESPIR J, V43, P671, DOI 10.1183/09031936.00179713; Thomas B, 2010, J ALLERGY CLIN IMMUN, V126, P722, DOI 10.1016/j.jaci.2010.05.046; Thornton DJ, 2008, ANNU REV PHYSIOL, V70, P459, DOI 10.1146/annurev.physiol.70.113006.100702; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Tschumperlin DJ, 2003, AM J RESP CELL MOL, V28, P142, DOI 10.1165/rcmb.2002-0121OC; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 2008, ONCOGENE, V27, P6930, DOI 10.1038/onc.2008.344; Tworek D, 2016, AM J RESP CRIT CARE, V193, P957, DOI 10.1164/rccm.201509-1751OC; Ueda T, 2008, J ALLERGY CLIN IMMUN, V121, P659, DOI 10.1016/j.jaci.2007.10.005; Ueki IF, 2013, J EXP MED, V210, P1929, DOI 10.1084/jem.20121401; Uller L, 2010, THORAX, V65, P626, DOI 10.1136/thx.2009.125930; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vawda S, 2014, AM J EPIDEMIOL, V179, P432, DOI 10.1093/aje/kwt269; Veres TZ, 2011, AM J PATHOL, V179, P603, DOI 10.1016/j.ajpath.2011.04.039; Vermeer PD, 2003, AM J RESP CELL MOL, V28, P286, DOI 10.1165/rcmb.4887; Villa M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12652; Vivier E, 2004, SCIENCE, V306, P1517, DOI 10.1126/science.1103478; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wang WL, 2013, INT ARCH ALLERGY IMM, V160, P18, DOI 10.1159/000341665; Wang Y, 2017, TOXICOL SCI; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wawrzyniak P, 2017, J ALLERGY CLIN IMMUN, V139, P93, DOI 10.1016/j.jaci.2016.03.050; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Worgall TS, 2017, CURR OPIN CLIN NUTR, V20, P99, DOI 10.1097/MCO.0000000000000349; Wu Q, 2013, VIROLOGY, V446, P199, DOI 10.1016/j.virol.2013.08.005; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Yao YS, 2016, HUM IMMUNOL, V77, P1291, DOI 10.1016/j.humimm.2016.09.011; Young MT, 2014, AM J RESP CRIT CARE, V190, P914, DOI 10.1164/rccm.201403-0525OC; Zhang YM, 2012, CURR OPIN PULM MED, V18, P6, DOI 10.1097/MCP.0b013e32834dc532	202	58	59	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1736	1751		10.1016/j.jaci.2017.04.005	http://dx.doi.org/10.1016/j.jaci.2017.04.005			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	28583446	Green Published, hybrid, Green Accepted			2022-12-18	WOS:000402724600002
J	Nademi, Z; Slatter, MA; Dvorak, CC; Neven, B; Fischer, A; Suarez, F; Booth, C; Rao, K; Laberko, A; Rodina, J; Bertrand, Y; Koltan, S; Debski, R; Flood, T; Abinun, M; Gennery, AR; Hambleton, S; Ehl, S; Cant, AJ				Nademi, Zohreh; Slatter, Mary; Dvorak, Christopher; Neven, Benedicte; Fischer, Alain; Suarez, Felipe; Booth, Claire; Rao, Kanchan; Laberko, Alexandra; Rodina, Julia; Bertrand, Yves; Koltan, Sylwia; Debski, Robert; Flood, Terence; Abinun, Mario; Gennery, Andrew R.; Hambleton, Sophie; Ehl, Stephan; Cant, Andrew			Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PHOSPHOINOSITIDE 3-KINASE; HUMAN IMMUNODEFICIENCY; MUTATIONS; FRAMEWORK; CTLA-4; GENE		[Nademi, Zohreh; Slatter, Mary; Flood, Terence; Abinun, Mario; Gennery, Andrew R.; Hambleton, Sophie; Cant, Andrew] NHS Fdn Trust, Great North Childrens Hosp, Newcastle Tyne Hosp, Newcastle Upon Tyne, Tyne & Wear, England; [Nademi, Zohreh; Slatter, Mary; Abinun, Mario; Gennery, Andrew R.; Hambleton, Sophie; Cant, Andrew] Univ Newcastle Tyne, Inst Cellular Med, Primary Immunodeficiency Grp, Newcastle Upon Tyne, Tyne & Wear, England; [Dvorak, Christopher] Univ Calif San Francisco, Benioff Childrens Hosp, San Francisco, CA 94143 USA; [Neven, Benedicte; Fischer, Alain] Necker Enfants Malades Univ Hosp, Pediat Hematol Immunol & Rheumatol Unit, Paris, France; [Suarez, Felipe] Necker Enfants Malades Univ Hosp, Dept Hematol, Paris, France; [Booth, Claire] NHS Fdn Trust, Dept Pediat Immunol, Great Ormond St Hosp Children, London, England; [Rao, Kanchan] NHS Fdn, Dept Bone Marrow Transplant, Great Ormond St Hosp Children, London, England; [Laberko, Alexandra; Rodina, Julia] Ctr Pediat Hematol Oncol Immunol, Moscow, Russia; [Bertrand, Yves] Hosp Civils Lyon, Inst Hematol & Oncol Pediat, Lyon, France; [Bertrand, Yves] Univ Claude Bernard Lyon, Lyon, France; [Koltan, Sylwia; Debski, Robert] Nicolaus Copernicus Univ, Dept Pediat Hematol & Oncol, Coll Med Bydgoszcz, Torun, Poland; [Ehl, Stephan] Univ Freiburg, Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany	Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; University of California System; University of California San Francisco; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Oxford University Hospitals NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Nicolaus Copernicus University; University of Freiburg	Nademi, Z (corresponding author), NHS Fdn Trust, Great North Childrens Hosp, Newcastle Tyne Hosp, Newcastle Upon Tyne, Tyne & Wear, England.; Nademi, Z (corresponding author), Univ Newcastle Tyne, Inst Cellular Med, Primary Immunodeficiency Grp, Newcastle Upon Tyne, Tyne & Wear, England.	zohreh.nademi@nuth.nhs.uk	Koltan, Sylwia/B-4557-2018; Ehl, Stephan/AAM-6006-2020; Dvorak, Christopher C/AAX-1630-2020; Booth, Claire/I-3667-2016	Koltan, Sylwia/0000-0001-7663-6580; Dvorak, Christopher C/0000-0002-6146-3952; Hambleton, Sophie/0000-0001-7954-3267; Ehl, Stephan/0000-0002-9265-2721; Booth, Claire/0000-0002-2626-5037	BMBF; UCB; Novimmue; Novartis; Biotest; Baxalta; The Sir Jules Thorn Charitable Trust [12JTA] Funding Source: researchfish	BMBF(Federal Ministry of Education & Research (BMBF)); UCB(UCB Pharma SA); Novimmue; Novartis(Novartis); Biotest; Baxalta; The Sir Jules Thorn Charitable Trust	C. C. Dvorak has received board membership from Jazz Pharmaceuticals and Chimerix, Inc. S. Ehl's institution has received a grant from BMBF. He has received consultancy fees from UCB, Novimmue, and Novartis; grants from UCB; and payment for lectures from Biotest and Baxalta. The rest of the authors declare that they have no relevant conflicts of interest.	Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; Deau MC, 2014, J CLIN INVEST, V124, P3923, DOI 10.1172/JCI75746; Dvorak C, 2008, BONE MARROW TRANSPL, V41, P119, DOI 10.1038/sj.bmt.1705890; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kang S, 2006, P NATL ACAD SCI USA, V103, P1289, DOI 10.1073/pnas.0510772103; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Lougaris V, 2015, CLIN IMMUNOL, V159, P33, DOI 10.1016/j.clim.2015.04.014; Lucas CL, 2014, J EXP MED, V211, P2537, DOI 10.1084/jem.20141759; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Metzler WJ, 1997, NAT STRUCT BIOL, V4, P527, DOI 10.1038/nsb0797-527; Petrovski S, 2016, J CLIN IMMUNOL, V36, P462, DOI 10.1007/s10875-016-0281-6; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Qureshi OS, 2011, SCIENCE, V332, P600, DOI 10.1126/science.1202947; Vermijlen D, 2014, CELL MOL IMMUNOL, V11, P320, DOI 10.1038/cmi.2014.11; Walsh CM, 2014, J CLIN INVEST, V124, P3688, DOI 10.1172/JCI77198	19	58	62	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					1046	1049		10.1016/j.jaci.2016.09.040	http://dx.doi.org/10.1016/j.jaci.2016.09.040			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27847301	Bronze			2022-12-18	WOS:000397295800042
J	Liu, AH; Babineau, DC; Krouse, RZ; Zoratti, EM; Pongracic, JA; O'Connor, GT; Wood, RA; Hershey, GKK; Kercsmar, CM; Gruchalla, RS; Kattan, M; Teach, SJ; Makhija, M; Pillai, D; Lamm, CI; Gern, JE; Sigelman, SM; Gergen, PJ; Togias, A; Visness, CM; Busse, WW				Liu, Andrew H.; Babineau, Denise C.; Krouse, Rebecca Z.; Zoratti, Edward M.; Pongracic, Jacqueline A.; O'Connor, George T.; Wood, Robert A.; Hershey, Gurjit K. Khurana; Kercsmar, Carolyn M.; Gruchalla, Rebecca S.; Kattan, Meyer; Teach, Stephen J.; Makhija, Melanie; Pillai, Dinesh; Lamm, Carin I.; Gern, James E.; Sigelman, Steven M.; Gergen, Peter J.; Togias, Alkis; Visness, Cynthia M.; Busse, William W.			Pathways through which asthma risk factors contribute to asthma severity in inner-city children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; children; inner-city; allergy; sensitization; inflammation; lung function; pulmonary physiology; rhinitis; environmental tobacco smoke exposure	ALLERGIC RHINITIS; ADOLESCENTS; MORBIDITY; EXACERBATIONS; VALIDATION; EXPOSURE; VALIDITY; VIOLENCE; STRESS; IMPACT	Background: Pathway analyses can be used to determine how host and environmental factors contribute to asthma severity. Objective: To investigate pathways explaining asthma severity in inner-city children. Methods: On the basis of medical evidence in the published literature, we developed a conceptual model to describe how 8 risk-factor domains (allergen sensitization, allergic inflammation, pulmonary physiology, stress, obesity, vitamin D, environmental tobacco smoke [ETS] exposure, and rhinitis severity) are linked to asthma severity. To estimate the relative magnitude and significance of hypothesized relationships among these domains and asthma severity, we applied a causal network analysis to test our model in an Inner-City Asthma Consortium study. Participants comprised 6- to 17-year-old children (n = 561) with asthma and rhinitis from 9 US inner cities who were evaluated every 2 months for 1 year. Asthma severity was measured by a longitudinal composite assessment of day and night symptoms, exacerbations, and controller usage. Results: Our conceptual model explained 53.4% of the variance in asthma severity. An allergy pathway (linking allergen sensitization, allergic inflammation, pulmonary physiology, and rhinitis severity domains to asthma severity) and the ETS exposure pathway (linking ETS exposure and pulmonary physiology domains to asthma severity) exerted significant effects on asthma severity. Among the domains, pulmonary physiology and rhinitis severity had the largest significant standardized total effects on asthma severity (-0.51 and 0.48, respectively), followed by ETS exposure (0.30) and allergic inflammation (0.22). Although vitamin D had modest but significant indirect effects on asthma severity, its total effect was insignificant (0.01). Conclusions: The standardized effect sizes generated by a causal network analysis quantify the relative contributions of different domains and can be used to prioritize interventions to address asthma severity.	[Liu, Andrew H.] Natl Jewish Hlth, Denver, CO USA; [Liu, Andrew H.] Childrens Hosp Colorado, 13123 East 16th Ave,Box B395, Aurora, CO 80045 USA; [Liu, Andrew H.] Univ Colorado, Sch Med, Aurora, CO USA; [Babineau, Denise C.; Krouse, Rebecca Z.; Visness, Cynthia M.] Rho Fed Syst Div, Chapel Hill, NC USA; [Zoratti, Edward M.] Henry Ford Hlth Syst, Detroit, MI USA; [Pongracic, Jacqueline A.; Makhija, Melanie] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [O'Connor, George T.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Hershey, Gurjit K. Khurana; Kercsmar, Carolyn M.] Cincinnati Childrens Hosp, Cincinnati, OH USA; [Gruchalla, Rebecca S.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Kattan, Meyer; Lamm, Carin I.] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Teach, Stephen J.; Pillai, Dinesh] Childrens Natl Hlth Syst, Washington, DC USA; [Teach, Stephen J.; Pillai, Dinesh] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA; [Gern, James E.; Busse, William W.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Sigelman, Steven M.; Gergen, Peter J.; Togias, Alkis] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA	National Jewish Health; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Henry Ford Health System; Henry Ford Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago; Boston University; Johns Hopkins University; Cincinnati Children's Hospital Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; Columbia University; Children's National Health System; George Washington University; University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Liu, AH (corresponding author), Childrens Hosp Colorado, 13123 East 16th Ave,Box B395, Aurora, CO 80045 USA.	Andrew.liu@childrenscolorado.org			National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services [HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01]; National Center for Research Resources (NCRR); National Center for Advancing Translational Sciences (NCATS), NIH [NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075, NCATS/NIH UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, UL1TR001105]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000154, UL1TR000077, UL1TR000040, UL1TR001082, UL1TR000075, UL1TR000150, UL1TR001105, UL1TR000451] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI114271, UM2AI117870] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services; National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences (NCATS), NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (under contract nos. HHSN272200900052C and HHSN272201000052I, and 1UM1AI114271-01). Additional support was provided by the National Center for Research Resources (NCRR), and the National Center for Advancing Translational Sciences (NCATS), NIH (under grant nos. NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075 and NCATS/NIH UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, and UL1TR001105). GlaxoSmithKline (GSK) provided Ventolin, Flovent, Advair, and Flonase under a clinical trial agreement with NIH NIAID; GSK did not have a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit the manuscript for publication.	[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Gergen PJ, 2001, RESP PHYSIOL, V128, P39, DOI 10.1016/S0034-5687(01)00263-8; Kattan M, 2010, J ALLERGY CLIN IMMUN, V125, P584, DOI 10.1016/j.jaci.2010.01.053; Kuczmarski R.J., 2000, CDC GROWTH CHARTS US; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P267, DOI 10.1016/j.jaci.2010.05.031; MacCallum RC, 1996, PSYCHOL METHODS, V1, P130, DOI 10.1037/1082-989X.1.2.130; MacKinnon D. P., 2008, INTRO STAT MEDIATION; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Muthen L., 2017, STAT ANAL LATENT VAR, V8th; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Pongracic JA, 2016, J ALLERGY CLIN IMMUN, V138, P1030, DOI 10.1016/j.jaci.2016.06.059; Rand CS, 2012, J ALLERGY CLIN IMMUN, V129, pS136, DOI 10.1016/j.jaci.2011.12.987; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sandberg S, 2004, THORAX, V59, P1046, DOI 10.1136/thx.2004.024604; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schatz M, 2007, AM J MANAG CARE, V13, P661; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V135, P1465, DOI 10.1016/j.jaci.2014.12.1942; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Visness CM, 2010, J ASTHMA, V47, P822, DOI 10.3109/02770903.2010.489388; Wildfire JJ, 2012, J ALLERGY CLIN IMMUN, V129, P694, DOI 10.1016/j.jaci.2011.12.962; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Wright RJ, 2001, ENVIRON HEALTH PERSP, V109, P1085, DOI 10.2307/3454965; Yeh E, 2011, NICOTINE TOB RES, V13, P1045, DOI 10.1093/ntr/ntr127; Zoratti EM, 2016, J ALLERGY CLIN IMMUN, V138, P1016, DOI 10.1016/j.jaci.2016.06.061	33	58	58	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1042	1050		10.1016/j.jaci.2016.06.060	http://dx.doi.org/10.1016/j.jaci.2016.06.060			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27720018	Green Accepted, Bronze			2022-12-18	WOS:000385499400009
J	Bryce, PJ; Falahati, R; Kenney, LL; Leung, J; Bebbington, C; Tomasevic, N; Krier, RA; Hsu, CL; Shultz, LD; Greiner, DL; Brehm, MA				Bryce, Paul J.; Falahati, Rustom; Kenney, Laurie L.; Leung, John; Bebbington, Christopher; Tomasevic, Nenad; Krier, Rebecca A.; Hsu, Chia-Lin; Shultz, Leonard D.; Greiner, Dale L.; Brehm, Michael A.			Humanized mouse model of mast cell-mediated passive cutaneous anaphylaxis and passive systemic anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cell; humanized mice; NSG; NSG-SGM3; passive cutaneous anaphylaxis; PCA; passive systemic anaphylaxis; PSA	HEMATOPOIETIC STEM-CELLS; PERIPHERAL-BLOOD; ALLERGY MODEL; MURINE MODEL; MICE; RESPONSES; MATURE; INFLAMMATION; ACTIVATION; INFECTION	Background: Mast cells are a critical component of allergic responses in humans, and animal models that allow the in vivo investigation of their contribution to allergy and evaluation of new human-specific therapeutics are urgently needed. Objective: To develop a new humanized mouse model that supports human mast cell engraftment and human IgE-dependent allergic responses. Methods: This model is based on the NOD-scid IL2rg(null) SCF/GM-CSF/IL3 (NSG-SGM3) strain of mice engrafted with human thymus, liver, and hematopoietic stem cells (termed Bone marrow, Liver, Thymus [BLT]). Results: Large numbers of human mast cells develop in NSG-SGM3 BLT mice and populate the immune system, peritoneal cavity, and peripheral tissues. The human mast cells in NSG-SGM3 BLT mice are phenotypically similar to primary human mast cells and express CD117, tryptase, and Fc epsilon RI. These mast cells undergo degranulation in an IgE-dependent and -independent manner, and can be readily cultured in vitro for additional studies. Intradermal priming of engrafted NSG-SGM3 mice with a chimeric IgE containing human constant regions resulted in the development of a robust passive cutaneous anaphylaxis response. Moreover, we describe the first report of a human mast cell antigen-dependent passive systemic anaphylaxis response in primed mice. Conclusions: NSG-SGM3 BLT mice provide a readily available source of human mast cells for investigation of mast cell biology and a preclinical model of passive cutaneous anaphylaxis and passive systemic anaphylaxis that can be used to investigate the pathogenesis of human allergic responses and to test new therapeutics before their advancement to the clinic.	[Bryce, Paul J.; Krier, Rebecca A.; Hsu, Chia-Lin] Northwestern Univ, Dept Med, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60611 USA; [Falahati, Rustom; Leung, John; Bebbington, Christopher; Tomasevic, Nenad] Allakos Inc, San Carlos, IL USA; [Kenney, Laurie L.; Greiner, Dale L.; Brehm, Michael A.] Univ Massachusetts, Sch Med, Dept Mol Med, Diabet Ctr Excellence, 368 Plantat St,AS7-2053, Worcester, MA 01605 USA; [Shultz, Leonard D.] Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA	Northwestern University; Feinberg School of Medicine; University of Massachusetts System; University of Massachusetts Worcester; Jackson Laboratory	Brehm, MA (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Med, Diabet Ctr Excellence, 368 Plantat St,AS7-2053, Worcester, MA 01605 USA.	michael.brehm@umassmed.edu	Falahati, Rustom/Q-4098-2016	Krier-Burris, Rebecca/0000-0001-9722-215X; Brehm, Michael/0000-0001-6813-3262	National Institutes of Health [2R01AI076456-06A1, R01AI05839-06A1, 1R24 OD018259-01]; NATIONAL CANCER INSTITUTE [P30CA034196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI105839, R01AI076456, P01AI046629] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [R24OD018259] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in whole or in part by the National Institutes of Health (grant nos. 2R01AI076456-06A1 and R01AI05839-06A1 to P.J.B. and 1R24 OD018259-01 to M.A.B., L.D.S., and D.L.G.). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.	Andersen HB, 2008, J IMMUNOL METHODS, V336, P166, DOI 10.1016/j.jim.2008.04.016; Baena-Cagnani C E, 2001, Curr Allergy Asthma Rep, V1, P297, DOI 10.1007/s11882-001-0037-z; BENSLEY SH, 1952, STAIN TECHNOL, V27, P269, DOI 10.3109/10520295209105090; Billerbeck E, 2011, BLOOD, V117, P3076, DOI 10.1182/blood-2010-08-301507; BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; Covassin L, 2013, CLIN EXP IMMUNOL, V174, P372, DOI 10.1111/cei.12180; GALLI SJ, 1984, PROG ALLERGY, V34, P1; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Ganeshan K, 2009, J ALLERGY CLIN IMMUN, V123, P231, DOI 10.1016/j.jaci.2008.10.011; Gilfillan AM, 2009, IMMUNOL REV, V228, P149, DOI 10.1111/j.1600-065X.2008.00742.x; Guhl S, 2011, BIOSCI BIOTECH BIOCH, V75, P382, DOI 10.1271/bbb.100745; Guhl S, 2010, EXP DERMATOL, V19, P845, DOI 10.1111/j.1600-0625.2010.01103.x; Guhl S, 2010, J GEN VIROL, V91, P1256, DOI 10.1099/vir.0.019505-0; Holm M, 2008, J IMMUNOL METHODS, V336, P213, DOI 10.1016/j.jim.2008.04.019; Hsu CL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011944; Hudson SA, 2011, J CLIN IMMUNOL, V31, P1045, DOI 10.1007/s10875-011-9589-4; Ito R, 2013, J IMMUNOL, V191, P2890, DOI 10.4049/jimmunol.1203543; Kambe N, 2004, BLOOD, V103, P860, DOI 10.1182/blood-2003-04-1160; Kambe N, 2001, BLOOD, V97, P2045, DOI 10.1182/blood.V97.7.2045; Karra L, 2009, CURR OPIN IMMUNOL, V21, P708, DOI 10.1016/j.coi.2009.09.010; Kim SH, 2007, FOOD CHEM TOXICOL, V45, P2138, DOI 10.1016/j.fct.2007.05.011; Kovarova M, 2012, CURR PROTOC IMMUNOL; Kulka M., 2010, CURR PROTOC IMMUNOL; Lee YN, 2011, BLOOD, V117, P3629, DOI 10.1182/blood-2010-07-293548; Li XM, 2001, J ALLERGY CLIN IMMUN, V108, P639, DOI 10.1067/mai.2001.118787; McNamara LA, 2011, CURR OPIN HIV AIDS, V6, P43, DOI 10.1097/COH.0b013e32834086b3; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Miller PH, 2013, BLOOD, V121, pE1, DOI 10.1182/blood-2012-09-456566; Mueller UR, 2007, CURR OPIN ALLERGY CL, V7, P337, DOI 10.1097/ACI.0b013e328259c328; Nelson AM, 2009, INT J BIOL SCI, V5, P603; Osterfeld H, 2010, J ALLERGY CLIN IMMUN, V125, P469, DOI 10.1016/j.jaci.2009.09.054; PARWARESCH MR, 1985, PATHOL RES PRACT, V179, P439, DOI 10.1016/S0344-0338(85)80184-9; Reber LL, 2014, PHARMACOL THERAPEUT, V142, P416, DOI 10.1016/j.pharmthera.2014.01.004; Robinson AM, 2003, NEUROREPORT, V14, P1891, DOI 10.1097/00001756-200310270-00002; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311; Takagi S, 2012, BLOOD, V119, P2768, DOI 10.1182/blood-2011-05-353201; Tanaka S, 2012, J IMMUNOL, V188, P6145, DOI 10.4049/jimmunol.1103660; TANAKA T, 1983, J BIOL CHEM, V258, P3552; Taub DD, 2004, CELL IMMUNOL, V230, P65, DOI 10.1016/j.cellimm.2004.09.005; Triggiani M, 2014, CURR OPIN ALLERGY CL, V14, P309, DOI 10.1097/ACI.0000000000000071; Wang XS, 2006, INT IMMUNOPHARMACOL, V6, P839, DOI 10.1016/j.intimp.2005.12.004; Wechsler JB, 2013, ALLERGY, V68, P1338, DOI 10.1111/all.12227; Wechsler JB, 2014, J ALLERGY CLIN IMMUN, V133, P1735, DOI 10.1016/j.jaci.2013.12.024; Weigmann B, 2012, J ALLERGY CLIN IMMUN, V129, P1126, DOI 10.1016/j.jaci.2011.11.036; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; Wunderlich M, 2010, LEUKEMIA, V24, P1785, DOI 10.1038/leu.2010.158	47	58	59	8	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					769	779		10.1016/j.jaci.2016.01.049	http://dx.doi.org/10.1016/j.jaci.2016.01.049			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27139822	Green Accepted, Bronze			2022-12-18	WOS:000385496000013
J	Lemanske, RF; Kakumanu, S; Shanovich, K; Antos, N; Cloutier, MM; Mazyck, D; Phipatanakul, W; Schantz, S; Szefler, S; Vandlik, R; Williams, P				Lemanske, Robert F., Jr.; Kakumanu, Sujani; Shanovich, Kathleen; Antos, Nicholas; Cloutier, Michelle M.; Mazyck, Donna; Phipatanakul, Wanda; Schantz, Shirley; Szefler, Stanley; Vandlik, Renee; Williams, Paul			Creation and implementation of SAMPRO (TM): A school-based asthma management program	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; school; school nurse; children; asthma action plan; education; environment; triggers	ACTION PLANS; HEALTH CENTERS; CARE; CHILDREN; IMPACT; BURDEN; ACCESS	Clinicians who care for children with asthma have an obligation to coordinate asthma care with the schools. Aside from routine clinical care of asthmatic children, providers must educate the family and child about the need for an asthma treatment plan in school and support the school nurse meeting the needs of the student requiring school-based asthma care. The following article was developed by multiple stakeholders to address this need. It describes the 4 components of the School-based Asthma Management Program (SAMPRO (TM)). SAMPRO (TM) details elements necessary for the education of children, families, clinicians, and school-based personnel based on a "circle of support'' that would enhance multidirectional communication and promote better care for children with asthma within the school setting.	[Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat & Med, Madison, WI 53706 USA; [Shanovich, Kathleen] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53706 USA; [Antos, Nicholas] Med Coll Wisconsin, Childrens Hosp Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; [Cloutier, Michelle M.] Univ Connecticut, Hlth Ctr Farmington, Dept Pediat, Hartford, CT 06112 USA; [Cloutier, Michelle M.] CT Childrens Med Ctr, Asthma Ctr, Hartford, CT USA; [Kakumanu, Sujani] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Kakumanu, Sujani] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA; [Mazyck, Donna; Schantz, Shirley] Natl Assoc Sch Nurses, Silver Spring, MD USA; [Phipatanakul, Wanda] Harvard Med Sch, Boston Childrens Hosp, Div Allergy & Immunol, Boston, MA USA; [Szefler, Stanley] Univ Colorado, Sch Med, Childrens Hosp Colorado, Breathing Inst, Aurora, CO USA; [Szefler, Stanley] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Vandlik, Renee] Amer Acad Allergy Asthma & Immunol, Milwaukee, WI USA; [Williams, Paul] Univ Washington, Sch Med, Allergist NW Asthma & Allergy Ctr, Dept Pediat, Seattle, WA 98195 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Children's Hospital of Wisconsin; Medical College of Wisconsin; University of Connecticut; Connecticut Children's Medical Center; University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Washington; University of Washington Seattle	Lemanske, RF (corresponding author), 750 Highland Ave 4235 HSLC, Madison, WI 53705 USA.	rfl@medicine.wisc.edu		Szefler, Stanley/0000-0002-6911-3199; Antos, Nicholas/0000-0002-7380-120X	American Academy of Allergy, Asthma Immunology; National Association of School Nurses; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI110397, K24AI106822] Funding Source: NIH RePORTER	American Academy of Allergy, Asthma Immunology; National Association of School Nurses; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by funds provided by the American Academy of Allergy, Asthma & Immunology and the National Association of School Nurses.	Abramson MJ, 2001, AM J RESP CRIT CARE, V163, P12, DOI 10.1164/ajrccm.163.1.9910042; Akinbami, 2006, STATE CHILDHOOD ASTH, V381; Allison MA, 2007, PEDIATRICS, V120, pe887, DOI 10.1542/peds.2006-2314; [Anonymous], 2015, INSIDE STORY GUIDE I; Bergman DA, 2008, INT J TELEMED APPL, V2008, DOI 10.1155/2008/159276; Borowsky B, 2013, PEDIAT ALLER IMM PUL, V26, P76, DOI 10.1089/ped.2013.0231; Briggs AH, 2006, ALLERGY, V61, P531, DOI 10.1111/j.1398-9995.2006.01038.x; Bruzzese JM, 2009, J ALLERGY CLIN IMMUN, V124, P195, DOI 10.1016/j.jaci.2009.05.040; Campbell JD, 2015, AM J PUBLIC HEALTH, V105, P2366, DOI 10.2105/AJPH.2015.302685; Centers for Disease Control and Prevention, 2012, RES SCH HLTH POL PRA; Chute Christopher G, 2014, EGEMS (Wash DC), V2, P1101, DOI 10.13063/2327-9214.1101; Cicutto L, 2014, J ALLERGY CLIN IMMUN, V134, P1223, DOI 10.1016/j.jaci.2014.10.004; Cowie RL, 1997, CHEST, V112, P1534, DOI 10.1378/chest.112.6.1534; Frey S, 2016, ACAD PEDIAT; Glasgow RE, 1999, AM J PUBLIC HEALTH, V89, P1322, DOI 10.2105/AJPH.89.9.1322; Hanson TK, 2013, J SCHOOL HEALTH, V83, P915, DOI 10.1111/josh.12110; Hollenbach JP, 2014, J ALLERGY CLIN IMMUN, V134, P1245, DOI 10.1016/j.jaci.2014.10.014; Huffaker M, 2014, J ALLERGY CLIN IMMUN, V134, P1232, DOI 10.1016/j.jaci.2014.09.010; Hunt P, 2015, J SCHOOL HEALTH, V85, P802, DOI 10.1111/josh.12305; Johnson Kathleen H, 2012, NASN Sch Nurse, V27, P26; Kuhn L, 2015, J AM BOARD FAM MED, V28, P382, DOI 10.3122/jabfm.2015.03.140248; Liao O, 2006, J SCHOOL HEALTH, V76, P313, DOI 10.1111/j.1746-1561.2006.00119.x; Moonie S, 2008, J SCHOOL HEALTH, V78, P140, DOI 10.1111/j.1746-1561.2007.00276.x; Moricca ML, 2013, J SCH NURS, V29, P104, DOI 10.1177/1059840512452668; Morphew T, 2013, POPUL HEALTH MANAG, V16, P261, DOI 10.1089/pop.2012.0060; Murray RD, 2008, PEDIATRICS, V121, P1052, DOI 10.1542/peds.2008-0382; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Richmond CM, 2011, J URBAN HEALTH, V88, pS68, DOI 10.1007/s11524-010-9478-9; Rodriguez E, 2013, J SCHOOL HEALTH, V83, P842, DOI 10.1111/josh.12102; Tabak RG, 2012, AM J PREV MED, V43, P337, DOI 10.1016/j.amepre.2012.05.024; Tortolero SR, 2002, J SCHOOL HEALTH, V72, P33, DOI 10.1111/j.1746-1561.2002.tb06509.x; Voigt Chris, 2011, J AHIMA, V82, P38; Webber MP, 2003, ARCH PEDIAT ADOL MED, V157, P125, DOI 10.1001/archpedi.157.2.125; Yin HS, 2013, PEDIATRICS, V131, pE116, DOI 10.1542/peds.2012-0612; Yoos HL, 2007, NURS RES, V56, P167, DOI 10.1097/01.NNR.0000270023.44618.a7	35	58	58	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					711	723		10.1016/j.jaci.2016.06.015	http://dx.doi.org/10.1016/j.jaci.2016.06.015			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	DY9ZM	27596707	hybrid, Green Published, Green Accepted			2022-12-18	WOS:000385496000006
J	Oettgen, HC				Oettgen, Hans C.			Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; mast cells; anaphylaxis	FC-EPSILON-RI; CLASS-SWITCH RECOMBINATION; HISTAMINE-RELEASING FACTOR; LOW-AFFINITY RECEPTOR; MAST-CELL SURVIVAL; PLASMACYTOID DENDRITIC CELLS; BASOPHILIC LEUKEMIA-CELLS; X-LINKED IMMUNODEFICIENCY; IN-VIVO; ANTI-IGE	Fifty years ago, after a long search, IgE emerged as the circulating factor responsible for triggering allergic reactions. Its extremely low concentration in plasma created significant hurdles for scientists working to reveal its identity. We now know that IgE levels are invariably increased in patients affected by atopic conditions and that IgE provides the critical link between the antigen recognition role of the adaptive immune system and the effector functions of mast cells and basophils at mucosal and cutaneous sites of environmental exposure. This review discusses the established mechanisms of action of IgE in pathologic immediate hypersensitivity, as well as its multifaceted roles in protective immunity, control of mast cell homeostasis, and its more recently revealed immunomodulatory functions. (J Allergy Clin Immunol 2016; 137:1631-45.)	[Oettgen, Hans C.] Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Oettgen, Hans C.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Oettgen, HC (corresponding author), Boston Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.	hans.oettgen@childrens.harvard.edu		Oettgen, Hans/0000-0003-1199-1391	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI119918, T32AI007512] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI119918, T32 AI007512] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akahoshi M, 2011, J CLIN INVEST, V121, P4180, DOI 10.1172/JCI46139; Akdis M, 2012, NAT IMMUNOL, V13, P312, DOI 10.1038/ni.2266; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ALSHISHTAWY MM, 1991, INT ARCH ALLER A IMM, V96, P348, DOI 10.1159/000235520; Arnold JN, 2007, ANNU REV IMMUNOL, V25, P21, DOI 10.1146/annurev.immunol.25.022106.141702; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; Bax HJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep09538; Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; BROWN SJ, 1982, J IMMUNOL, V129, P790; Bryce PJ, 2004, IMMUNITY, V20, P381, DOI 10.1016/S1074-7613(04)00080-9; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Burton OT, 2014, IMMUNITY, V41, P141, DOI 10.1016/j.immuni.2014.05.017; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Cameron L, 2003, J IMMUNOL, V171, P3816, DOI 10.4049/jimmunol.171.7.3816; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; Castells M, 1998, NEW ENGL J MED, V338, P202; Castigh E, 2007, IMMUNOL RES, V38, P102, DOI 10.1007/s12026-007-8000-2; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; Cernadas M, 1999, AM J RESP CELL MOL, V20, P1; Chaudhuri J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng LE, 2015, J EXP MED, V212, P513, DOI 10.1084/jem.20141671; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Dardalhon V, 2008, NAT IMMUNOL, V9, P1347, DOI 10.1038/ni.1677; Dehlink E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019098; DELESPESSE G, 1988, IMMUNOL INVEST, V17, P363, DOI 10.3109/08820138809049845; DELPRETE G, 1988, J IMMUNOL, V140, P4193; Denzel A, 2008, NAT IMMUNOL, V9, P733, DOI 10.1038/ni.1621; DIERKS SE, 1993, J IMMUNOL, V150, P2372; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; Dold S, 1998, J ALLERGY CLIN IMMUN, V102, P414, DOI 10.1016/S0091-6749(98)70129-0; Durrani SR, 2012, J ALLERGY CLIN IMMUN, V130, P489, DOI 10.1016/j.jaci.2012.05.023; Eggel A, 2014, J ALLERGY CLIN IMMUN, V133, P1709, DOI 10.1016/j.jaci.2014.02.005; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Finkelman Fred, 2003, Curr Protoc Immunol, VChapter 6, DOI 10.1002/0471142735.im0628s54; Frossi B, 2011, EUR J IMMUNOL, V41, P1872, DOI 10.1002/eji.201041300; FUJIWARA H, 1994, P NATL ACAD SCI USA, V91, P6835, DOI 10.1073/pnas.91.15.6835; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; FURUICHI K, 1985, P NATL ACAD SCI USA, V82, P1522, DOI 10.1073/pnas.82.5.1522; Galli SJ, 2016, AM J PATHOL, V186, P212, DOI 10.1016/j.ajpath.2015.07.025; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; Gilfillan AM, 2009, IMMUNOL REV, V228, P149, DOI 10.1111/j.1600-065X.2008.00742.x; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Greer AM, 2014, J CLIN INVEST, V124, P1187, DOI 10.1172/JCI68964; Gurish MF, 2004, J IMMUNOL, V172, P1139, DOI 10.4049/jimmunol.172.2.1139; Gustavsson S, 2000, J IMMUNOL, V164, P3990, DOI 10.4049/jimmunol.164.8.3990; GUSTAVSSON S, 1994, J IMMUNOL, V152, P4793; Hackney JA, 2009, ADV IMMUNOL, V101, P163, DOI 10.1016/S0065-2776(08)01005-5; Haczku A, 2000, AM J RESP CRIT CARE, V161, P952, DOI 10.1164/ajrccm.161.3.9905046; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Harris JM, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0347-2; He JS, 2013, J EXP MED, V210, P2755, DOI 10.1084/jem.20131539; HELM B, 1989, P NATL ACAD SCI USA, V86, P9465, DOI 10.1073/pnas.86.23.9465; HEYMAN B, 1993, EUR J IMMUNOL, V23, P1739, DOI 10.1002/eji.1830230754; HIGGINBOTHAM RD, 1965, J IMMUNOL, V95, P867; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V119, P654, DOI 10.1016/j.jaci.2006.12.609; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; JOSEPH M, 1983, NATURE, V303, P810, DOI 10.1038/303810a0; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Kambayashi T, 2009, J IMMUNOL, V182, P4686, DOI 10.4049/jimmunol.0803180; Kashiwakura JI, 2012, J CLIN INVEST, V122, P218, DOI 10.1172/JCI59072; Kato A, 2006, J IMMUNOL, V177, P7164, DOI 10.4049/jimmunol.177.10.7164; Kato A, 2009, J ALLERGY CLIN IMMUN, V123, P369, DOI 10.1016/j.jaci.2008.11.022; Kawakami T, 2005, J IMMUNOL, V175, P4167, DOI 10.4049/jimmunol.175.7.4167; Kawakami T, 2014, ALLERGY ASTHMA IMMUN, V6, P6, DOI 10.4168/aair.2014.6.1.6; KEHRY MR, 1989, CELL IMMUNOL, V118, P504, DOI 10.1016/0008-8749(89)90397-3; Khan SH, 2010, J ALLERGY CLIN IMMUN, V125, P265, DOI 10.1016/j.jaci.2009.09.038; Kim B, 2012, NATURE, V491, P613, DOI 10.1038/nature11546; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; King CL, 1997, J IMMUNOL, V158, P294; Kisselgof AB, 1998, INT IMMUNOL, V10, P1377, DOI 10.1093/intimm/10.9.1377; Kitaura J, 2003, P NATL ACAD SCI USA, V100, P12911, DOI 10.1073/pnas.1735525100; Kitawaki T, 2006, INT IMMUNOL, V18, P1789, DOI 10.1093/intimm/dxl113; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KULCZYCKI A, 1974, J EXP MED, V139, P600, DOI 10.1084/jem.139.3.600; Laffleur B, 2015, CELL REP; Lambrecht BN, 2014, J ALLERGY CLIN IMMUN, V134, P499, DOI 10.1016/j.jaci.2014.06.036; Lantz CS, 1997, J IMMUNOL, V158, P2517; Le T, 2009, J ALLERGY CLIN IMMUN, V123, P217, DOI 10.1016/j.jaci.2008.09.013; LEE WT, 1986, J IMMUNOL, V136, P4573; Legendre C, 1997, NEW ENGL J MED, V337, P822, DOI 10.1056/NEJM199709183371204; Lilla JN, 2011, BLOOD, V118, P6930, DOI 10.1182/blood-2011-03-343962; Logsdon SL, 2015, CURR TOP MICROBIOL, V388, P39, DOI 10.1007/978-3-319-13725-4_3; Longerich S, 2006, CURR OPIN IMMUNOL, V18, P164, DOI 10.1016/j.coi.2006.01.008; Looney TJ, 2016, J ALLERGY CLIN IMMUN, V137, P579, DOI 10.1016/j.jaci.2015.07.014; MACDONALD SM, 1995, SCIENCE, V269, P688, DOI 10.1126/science.7542803; MacGlashan D, 2004, J ALLERGY CLIN IMMUN, V114, P1317, DOI 10.1016/j.jaci.2004.08.037; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; Manis JP, 2002, IMMUNITY, V16, P607, DOI 10.1016/S1074-7613(02)00306-0; Marichal T, 2013, IMMUNITY, V39, P963, DOI 10.1016/j.immuni.2013.10.005; Martin RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110609; Mathias CB, 2009, J IMMUNOL, V182, P2416, DOI 10.4049/jimmunol.0801569; MATSUDA H, 1990, J IMMUNOL, V144, P259; MAURER D, 1995, J IMMUNOL, V154, P6285; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; Mazzoni A, 2006, J IMMUNOL, V177, P3577, DOI 10.4049/jimmunol.177.6.3577; McCoy KD, 2006, IMMUNITY, V24, P329, DOI 10.1016/j.immuni.2006.01.013; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; Metz M, 2006, SCIENCE, V313, P526, DOI 10.1126/science.1128877; Min B, 2004, J EXP MED, V200, P507, DOI 10.1084/jem.20040590; Mukai K, 2005, IMMUNITY, V23, P191, DOI 10.1016/j.immuni.2005.06.011; Nakae S, 2007, J ALLERGY CLIN IMMUN, V120, P48, DOI 10.1016/j.jaci.2007.02.046; Nakamura GR, 2002, P NATL ACAD SCI USA, V99, P1303, DOI 10.1073/pnas.022635599; Noti M, 2014, J ALLERGY CLIN IMMUN, V133, P1390, DOI 10.1016/j.jaci.2014.01.021; Novak N, 2010, CLIN EXP IMMUNOL, V161, P28, DOI 10.1111/j.1365-2249.2010.04162.x; Oettgen HC, 2015, ADV IMMUNOL, V127, P203, DOI 10.1016/bs.ai.2015.03.001; Palm NW, 2013, IMMUNITY, V39, P976, DOI 10.1016/j.immuni.2013.10.006; Pandey V, 2004, J IMMUNOL, V172, P4048, DOI 10.4049/jimmunol.172.7.4048; Pavri R, 2010, CELL, V143, P122, DOI 10.1016/j.cell.2010.09.017; Payet ME, 1999, J IMMUNOL, V163, P217; Payet-Jamroz M, 2001, J IMMUNOL, V166, P4863, DOI 10.4049/jimmunol.166.8.4863; Piconese S, 2009, BLOOD, V114, P2639, DOI 10.1182/blood-2009-05-220004; PIRRON U, 1990, EUR J IMMUNOL, V20, P1547, DOI 10.1002/eji.1830200721; Platzer B, 2015, MUCOSAL IMMUNOL, V8, P516, DOI 10.1038/mi.2014.85; Poddighe D, 2014, J BIOL REG HOMEOS AG, V28, P91; Poncet P, 1999, J LEUKOCYTE BIOL, V66, P105, DOI 10.1002/jlb.66.1.105; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Reber LL, 2012, TRENDS IMMUNOL, V33, P613, DOI 10.1016/j.it.2012.09.008; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Rivas MN, 2015, IMMUNITY, V42, P512, DOI 10.1016/j.immuni.2015.02.004; Rodewald HR, 2012, IMMUNITY, V37, P13, DOI 10.1016/j.immuni.2012.07.007; Rosenwasser LJ, 2011, CURR ALLERGY ASTHM R, V11, P178, DOI 10.1007/s11882-011-0179-6; Rosenwasser LJ, 2003, J ALLERGY CLIN IMMUN, V112, P563, DOI 10.1067/mai.2003.1709; Rowe RK, 2015, IMMUNOL ALLERGY CLIN, V35, P115, DOI 10.1016/j.iac.2014.09.012; Saini SS, 2000, J ALLERGY CLIN IMMUN, V106, P514, DOI 10.1067/mai.2000.108431; Sallmann E, 2011, J IMMUNOL, V187, P164, DOI 10.4049/jimmunol.1003392; Sandomenico A, 2009, MOL IMMUNOL, V46, P3300, DOI 10.1016/j.molimm.2009.07.025; SAXON A, 1991, J IMMUNOL, V147, P4000; Schroeder JT, 2008, J ALLERGY CLIN IMMUN, V121, P486, DOI 10.1016/j.jaci.2007.09.049; SEDER RA, 1991, P NATL ACAD SCI USA, V88, P2835, DOI 10.1073/pnas.88.7.2835; Seidl KJ, 1998, INT IMMUNOL, V10, P1683, DOI 10.1093/intimm/10.11.1683; Sereda MJ, 2008, TRENDS PARASITOL, V24, P272, DOI 10.1016/j.pt.2008.03.006; Shade KTC, 2015, J EXP MED, V212, P457, DOI 10.1084/jem.20142182; SHAMPAIN MP, 1982, AM REV RESPIR DIS, V126, P493; Shen CH, 2001, J IMMUNOL, V166, P411, DOI 10.4049/jimmunol.166.1.411; SHERR E, 1989, J IMMUNOL, V142, P481; Simpson A, 2005, J ALLERGY CLIN IMMUN, V116, P744, DOI 10.1016/j.jaci.2005.06.032; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Soulas-Sprauel P, 2007, ONCOGENE, V26, P7780, DOI 10.1038/sj.onc.1210875; Stavnezer J, 2014, J IMMUNOL, V193, P5370, DOI 10.4049/jimmunol.1401849; STEEVES EBT, 1990, INT J PARASITOL, V20, P655, DOI 10.1016/0020-7519(90)90124-6; Stoltz DJ, 2013, CLIN EXP ALLERGY, V43, P233, DOI 10.1111/cea.12050; Sykes A, 2012, J ALLERGY CLIN IMMUN, V129, P1506, DOI 10.1016/j.jaci.2012.03.044; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Talay O, 2012, NAT IMMUNOL, V13, P396, DOI 10.1038/ni.2256; Tanaka S, 2002, J EXP MED, V196, P229, DOI 10.1084/jem.20012037; Tong P, 2015, CURR TOP MICROBIOL, V388, P21, DOI 10.1007/978-3-319-13725-4_2; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; Voehringer D, 2004, IMMUNITY, V20, P267, DOI 10.1016/S1074-7613(04)00026-3; von Bubnoff D, 2003, CLIN EXP DERMATOL, V28, P184, DOI 10.1046/j.1365-2230.2003.01209.x; von Bubnoff D, 2002, J IMMUNOL, V169, P6170, DOI 10.4049/jimmunol.169.11.6170; von Bubnoff D, 2002, J IMMUNOL, V169, P1810, DOI 10.4049/jimmunol.169.4.1810; Wada T, 2010, J CLIN INVEST, V120, P2867, DOI 10.1172/JCI42680; Wan T, 2002, NAT IMMUNOL, V3, P681, DOI 10.1038/ni811; Wiegand TW, 1996, J IMMUNOL, V157, P221; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Wu LC, 2014, NAT REV IMMUNOL, V14, P247, DOI 10.1038/nri3632; Wuerffe R, 2007, IMMUNITY, V27, P711, DOI 10.1016/j.immuni.2007.09.007; Xiong HZ, 2012, J EXP MED, V209, P353, DOI 10.1084/jem.20111941; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; Yamaguchi M, 1999, J IMMUNOL, V162, P5455; Yang PC, 2000, J CLIN INVEST, V106, P879, DOI 10.1172/JCI9258; Yang ZY, 2012, IMMUNITY, V36, P857, DOI 10.1016/j.immuni.2012.02.009; YU P, 1994, NATURE, V369, P753, DOI 10.1038/369753a0; Zaidi AK, 2010, J ALLERGY CLIN IMMUN, V125, P902, DOI 10.1016/j.jaci.2009.12.996; ZHANG J, 1993, EMBO J, V12, P3529, DOI 10.1002/j.1460-2075.1993.tb06027.x; Zhong WW, 2014, IMMUNOLOGY, V142, P202, DOI 10.1111/imm.12240; Zhou JS, 2013, MOL BIOSYST, V9, P2853, DOI 10.1039/c3mb70286c	188	58	64	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1631	1645		10.1016/j.jaci.2016.04.009	http://dx.doi.org/10.1016/j.jaci.2016.04.009			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	27263999	Bronze, Green Accepted			2022-12-18	WOS:000377527200001
J	Triebner, K; Johannessen, A; Puggini, L; Benediktsdottir, B; Bertelsen, RJ; Bifulco, E; Dharmage, SC; Dratva, J; Franklin, KA; Gislason, T; Holm, M; Jarvis, D; Leynaert, B; Lindberg, E; Malinovschi, A; Macsali, F; Norback, D; Omenaas, ER; Rodriguez, FJ; Saure, E; Schlunssen, V; Sigsgaard, T; Skorge, TD; Wieslander, G; Zemp, E; Svanes, C; Hustad, S; Real, FG				Triebner, Kai; Johannessen, Ane; Puggini, Luca; Benediktsdottir, Bryndis; Bertelsen, Randi J.; Bifulco, Ersilia; Dharmage, Shyamali C.; Dratva, Julia; Franklin, Karl A.; Gislason, Thorarinn; Holm, Mathias; Jarvis, Deborah; Leynaert, Benedicte; Lindberg, Eva; Malinovschi, Andrei; Macsali, Ferenc; Norback, Dan; Omenaas, Ernst R.; Rodriguez, Francisco J.; Saure, Eirunn; Schlunssen, Vivi; Sigsgaard, Torben; Skorge, Trude D.; Wieslander, Gunilla; Zemp, Elisabeth; Svanes, Cecilie; Hustad, Steinar; Real, Francisco Gomez			Menopause as a predictor of new-onset asthma: A longitudinal Northern European population study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Amenorrhea; asthma; estrogens; longitudinal; menopausal asthma; menopause; respiratory symptoms; reproductive aging; Respiratory Health in Northern Europe; sex hormones	FEMALE SEX-HORMONES; RESPIRATORY HEALTH; LUNG-FUNCTION; WOMEN; SYMPTOMS; ESTROGEN; QUESTIONNAIRE; HYSTERECTOMY; INFLAMMATION; ASSOCIATION	Background: There is limited and conflicting evidence on the effect of menopause on asthma. Objectives: We sought to study whether the incidence of asthma and respiratory symptoms differ by menopausal status in a longitudinal population-based study with an average follow-up of 12 years. Methods: The Respiratory Health in Northern Europe study provided questionnaire data pertaining to respiratory and reproductive health at baseline (1999-2001) and follow-up (2010-2012). The study cohort included women aged 45 to 65 years at follow-up, without asthma at baseline, and not using exogenous hormones (n = 2322). Menopausal status was defined as nonmenopausal, transitional, early postmenopausal, and late postmenopausal. Associations with asthma (defined by the use of asthma medication, having asthma attacks, or both) and respiratory symptoms scores were analyzed by using logistic (asthma) and negative binomial (respiratory symptoms) regressions, adjusting for age, body mass index, physical activity, smoking, education, and study center. Results: The odds of new-onset asthma were increased in women who were transitional (odds ratio, 2.40; 95% CI, 1.09-5.30), early postmenopausal (odds ratio, 2.11; 95% CI, 1.06-4.20), and late postmenopausal (odds ratio, 3.44; 95% CI, 1.31-9.05) at follow-up compared with nonmenopausal women. The risk of respiratory symptoms increased in early postmenopausal (coefficient, 0.40; 95% CI, 0.06-0.75) and late postmenopausal (coefficient, 0.69; 95% CI, 0.15-1.23) women. These findings were consistent irrespective of smoking status and across study centers. Conclusions: New-onset asthma and respiratory symptoms increased in women becoming postmenopausal in a longitudinal population-based study. Clinicians should be aware that respiratory health might deteriorate in women during reproductive aging.	[Triebner, Kai; Johannessen, Ane; Bifulco, Ersilia; Omenaas, Ernst R.; Hustad, Steinar; Real, Francisco Gomez] Univ Bergen, Dept Clin Sci, N-5021 Bergen, Norway; [Bertelsen, Randi J.; Saure, Eirunn; Skorge, Trude D.; Svanes, Cecilie] Univ Bergen, Dept Occupat Med, N-5021 Bergen, Norway; [Bifulco, Ersilia; Hustad, Steinar] Univ Bergen, Core Facil Metab, N-5021 Bergen, Norway; [Puggini, Luca] Natl Univ Ireland, Dept Elect Engn, Maynooth, Kildare, Ireland; [Benediktsdottir, Bryndis; Gislason, Thorarinn] Univ Iceland, Fac Med, Reykjavik, Iceland; [Dharmage, Shyamali C.] Univ Melbourne, Melbourne Sch Populat Hlth, Allergy & Lung Hlth Unit, Melbourne, Vic 3010, Australia; [Dratva, Julia; Zemp, Elisabeth] Swiss Trop & Publ Hlth Inst, Dept Publ Hlth & Epidemiol, Basel, Switzerland; [Dratva, Julia; Zemp, Elisabeth] Univ Basel, CH-4003 Basel, Switzerland; [Franklin, Karl A.] Umea Univ, Dept Surg & Perioperat Sci, S-90187 Umea, Sweden; [Gislason, Thorarinn] Natl Univ Hosp Iceland, Landspitali, Dept Resp Med & Sleep, Reykjavik, Iceland; [Holm, Mathias] Gothenburg Univ, Dept Occupat & Environm Med, S-41124 Gothenburg, Sweden; [Jarvis, Deborah] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Resp Epidemiol Occupat Med & Publ Hlth, London SW7 2AZ, England; [Leynaert, Benedicte] Inserm UMR1152 Team Epidemiol, Paris, France; [Lindberg, Eva] Uppsala Univ, Dept Med Sci Lung Med & Allergol, S-75105 Uppsala, Sweden; [Malinovschi, Andrei] Uppsala Univ, Clin Physiol, Dept Med Sci, S-75105 Uppsala, Sweden; [Macsali, Ferenc; Real, Francisco Gomez] Haukeland Hosp, Dept Gynecol & Obstet, N-5021 Bergen, Norway; [Norback, Dan; Wieslander, Gunilla] Uppsala Univ, Dept Med Sci Occupat & Environm Med, S-75105 Uppsala, Sweden; [Rodriguez, Francisco J.] Univ Malaga, Dept Appl Math, E-29071 Malaga, Spain; [Schlunssen, Vivi; Sigsgaard, Torben] Aarhus Univ, Dept Publ Hlth, DK-8000 Aarhus C, Denmark	University of Bergen; University of Bergen; University of Bergen; Maynooth University; University of Iceland; University of Melbourne; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Umea University; Landspitali National University Hospital; University of Gothenburg; Imperial College London; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Uppsala University; Uppsala University; University of Bergen; Haukeland University Hospital; Uppsala University; Universidad de Malaga; Aarhus University	Triebner, K (corresponding author), Univ Bergen, Dept Clin Sci, Jonas Lies Veg 87, N-5021 Bergen, Norway.	kai.triebner@uib.no	Triebner, Kai/ABD-5137-2021; Leynaert, Benedicte/N-5251-2018; Triebner, Kai/AAP-4219-2021; Bertelsen, Randi J/N-6917-2017; Sigsgaard, Torben/AAC-1292-2020; Svanes, Cecilie/N-7556-2017	Bertelsen, Randi J/0000-0001-5319-525X; Sigsgaard, Torben/0000-0002-2043-7571; Svanes, Cecilie/0000-0001-8512-5192; Franklin, Karl/0000-0002-5306-1697; Jarvis, Deborah/0000-0002-1753-3896; Gomez Real, Francisco/0000-0001-5407-3270; Leynaert, Benedicte/0000-0001-5045-2492; Norback, Dan/0000-0002-5174-6668; Johannessen, Ane/0000-0003-3269-8354; Schlunssen, Vivi/0000-0003-4915-1734	Norwegian Research Council [228174, 214123]; Bergen Medical Research Foundation; Western Norwegian Regional Health Authorities [911 892, 911 631]; Norwegian Labour Inspection; Norwegian Asthma and Allergy Association; Faculty of Health of Aarhus University [240008]; Wood Dust Foundation [444508795]; Danish Lung Association; Swedish Heart-Lung Foundation; Vardal Foundation for Health Care Science and Allergy Research; Swedish council for working life and social research; Bror Hjerpstedt Foundation; Swedish Asthma and Allergy Association; Icelandic Research Council; Estonian Science Foundation [4350]	Norwegian Research Council(Research Council of NorwayEuropean Commission); Bergen Medical Research Foundation; Western Norwegian Regional Health Authorities; Norwegian Labour Inspection; Norwegian Asthma and Allergy Association; Faculty of Health of Aarhus University; Wood Dust Foundation; Danish Lung Association; Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Vardal Foundation for Health Care Science and Allergy Research; Swedish council for working life and social research(Swedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte)); Bror Hjerpstedt Foundation; Swedish Asthma and Allergy Association; Icelandic Research Council; Estonian Science Foundation	K.T. has received a PhD scholarship from the Norwegian Research Council (project no. 228174). This project also funded the estrogen measurements. Respiratory Health in Northern Europe (RHINE) was supported financially by the Norwegian Research Council (grant no. 214123), the Bergen Medical Research Foundation, the Western Norwegian Regional Health Authorities (grant nos. 911 892 and 911 631), the Norwegian Labour Inspection, the Norwegian Asthma and Allergy Association, the Faculty of Health of Aarhus University (project no. 240008), the Wood Dust Foundation (project no. 444508795), the Danish Lung Association, the Swedish Heart-Lung Foundation, the Vardal Foundation for Health Care Science and Allergy Research, the Swedish council for working life and social research, the Bror Hjerpstedt Foundation, the Swedish Asthma and Allergy Association, the Icelandic Research Council, and the Estonian Science Foundation (grant no. 4350).	ABRAMSON MJ, 1991, J ASTHMA, V28, P129, DOI 10.3109/02770909109082737; [Anonymous], 2015, GLOB STRAT ASTHM MAN; Atwood CS, 2008, AGEING RES REV, V7, P114, DOI 10.1016/j.arr.2007.12.002; Bai J, 1998, CHEST, V114, P1343, DOI 10.1378/chest.114.5.1343; Balzano G, 2007, Monaldi Arch Chest Dis, V67, P135; Balzano G, 2001, ALLERGY, V56, P13, DOI 10.1034/j.1398-9995.2001.00128.x; Barr RG, 2004, ARCH INTERN MED, V164, P379, DOI 10.1001/archinte.164.4.379; Becklake MR, 1999, THORAX, V54, P1119, DOI 10.1136/thx.54.12.1119; Bengtsson AK, 2004, BLOOD, V104, P1404, DOI 10.1182/blood-2003-10-3380; Bjermer L, 2007, J ALLERGY CLIN IMMUN, V120, P1269, DOI 10.1016/j.jaci.2007.09.017; Blacquiere MJ, 2010, INT ARCH ALLERGY IMM, V153, P173, DOI 10.1159/000312635; Bradding Peter, 2008, Allergy Asthma Clin Immunol, V4, P84, DOI 10.1186/1710-1492-4-2-84; BRAMBILLA DJ, 1994, AM J EPIDEMIOL, V140, P1091, DOI 10.1093/oxfordjournals.aje.a117209; Carr MC, 2003, J CLIN ENDOCR METAB, V88, P2404, DOI 10.1210/jc.2003-030242; Cooper GS, 1999, OBSTET GYNECOL, V94, P969, DOI 10.1016/S0029-7844(99)00429-9; Douin-Echinard V, 2011, J LEUKOCYTE BIOL, V90, P145, DOI 10.1189/jlb.0210073; Dratva J, 2009, MENOPAUSE, V16, P385, DOI 10.1097/gme.0b013e31818aefef; Farquhar CM, 2005, BJOG-INT J OBSTET GY, V112, P956, DOI 10.1111/j.1471-0528.2005.00696.x; Fauser BCJM, 2004, HUM REPROD, V19, P41, DOI 10.1093/humrep/deh098; Garamszegi C, 1998, J PSYCHOSOM OBST GYN, V19, P165, DOI 10.3109/01674829809025694; Harlow SD, 2000, MATURITAS, V36, P93, DOI 10.1016/S0378-5122(00)00145-6; Jarvis D, 2008, ALLERGY, V63, P95, DOI 10.1111/j.1398-9995.2007.01530.x; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; Johannessen A, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-63; de Oliveira APL, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-115; LINDHEIM SR, 1994, J SOC GYNECOL INVEST, V1, P150, DOI 10.1177/107155769400100210; Macsali F, 2012, EXPERT REV RESP MED, V6, P187, DOI [10.1586/ers.12.15, 10.1586/ERS.12.15]; Macsali F, 2009, J ALLERGY CLIN IMMUN, V123, P391, DOI 10.1016/j.jaci.2008.10.041; Melgert BN, 2007, CURR ALLERGY ASTHM R, V7, P143, DOI 10.1007/s11882-007-0012-4; Pekkanen J, 2005, EUR RESPIR J, V26, P28, DOI 10.1183/09031936.05.00120104; Real FG, 2008, CLIN RESPIR J, V2, P111, DOI 10.1111/j.1752-699X.2008.00093.x; Real FG, 2008, J ALLERGY CLIN IMMUN, V121, P72, DOI 10.1016/j.jaci.2007.08.057; Real FG, 2007, J ALLERGY CLIN IMMUN, V120, P557, DOI 10.1016/j.jaci.2007.04.041; Songur N, 2010, J WOMENS HEALTH, V19, P1145, DOI 10.1089/jwh.2009.1715; Speroff L., 1999, CLIN GYNECOLOGICAL E, V6th Edition; Subbarao P, 2009, CAN MED ASSOC J, V181, pE181, DOI 10.1503/cmaj.080612; Sunyer J, 2007, ALLERGY, V62, P142, DOI 10.1111/j.1398-9995.2006.01184.x; Taylor SM, 2004, MENOPAUSE, V11, P40, DOI 10.1097/01.GME.0000074820.41532.50; The North American Menopause Society, 2004, MEN PRACT CLIN GUID; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183, DOI 10.1164/ajrccm.152.4.7551368; Vegeto E, 2002, MOL PSYCHIATR, V7, P236, DOI 10.1038/sj.mp.4001007; WHO, 2014, WORLD HLTH STAT; Wilkosz P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108343; World Health Organization (WHO ), 1996, WHO SCI GROUP RES ME; Zemp E, 2012, MATURITAS, V73, P212, DOI 10.1016/j.maturitas.2012.08.010; Zierau O, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00169	47	58	58	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					50	+		10.1016/j.jaci.2015.08.019	http://dx.doi.org/10.1016/j.jaci.2015.08.019			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26435006	hybrid, Green Published, Green Accepted			2022-12-18	WOS:000367724300043
J	Tesi, B; Sieni, E; Neves, C; Romano, F; Cetica, V; Cordeiro, AI; Chiang, S; Schlums, H; Galli, L; Avenali, S; Tondo, A; Canessa, C; Henter, JI; Nordenskjold, M; Hsu, AP; Holland, SM; Neves, JE; Azzari, C; Bryceson, YT				Tesi, Bianca; Sieni, Elena; Neves, Conceiceto; Romano, Francesca; Cetica, Valentina; Cordeiro, Ana Isabel; Chiang, Samuel; Schlums, Heinrich; Galli, Luisa; Avenali, Stefano; Tondo, Annalisa; Canessa, Clementina; Henter, Jan-Inge; Nordenskjold, Magnus; Hsu, Amy P.; Holland, Steven M.; Neves, Joeto E.; Azzari, Chiara; Bryceson, Yenan T.			Hemophagocytic lymphohistiocytosis in 2 patients with underlying IFN-gamma receptor deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INTERFERON-GAMMA; INFLAMMATION; PERFORIN; IMMUNITY; ANEMIA; MICE		[Tesi, Bianca; Henter, Jan-Inge] Karolinska Univ Hosp Solna, Karolinska Inst, Dept Womens & Childrens Hlth, Childhood Canc Res Unit, Stockholm, Sweden; [Tesi, Bianca; Nordenskjold, Magnus] Karolinska Univ Hosp, Karolinska Inst, Dept Mol Med & Surg, Clin Genet Unit, Stockholm, Sweden; [Tesi, Bianca; Nordenskjold, Magnus] Karolinska Univ Hosp, Karolinska Inst, Ctr Mol Med, Stockholm, Sweden; [Sieni, Elena; Tondo, Annalisa] Anna Meyer Childrens Univ Hosp, Dept Pediat Hematol Oncol, Florence, Italy; [Neves, Conceiceto; Cordeiro, Ana Isabel; Neves, Joeto E.] Pediat Univ Hosp, Hosp Dona Estefania, Primary Immunodeficiencies Unit, Lisbon, Portugal; [Neves, Conceiceto; Cordeiro, Ana Isabel; Neves, Joeto E.] NOVA Med Sch, Chron Dis Res Ctr, CEDOC, Lisbon, Portugal; [Romano, Francesca; Canessa, Clementina; Azzari, Chiara] Univ Florence, Dept Pediat Immunol, Florence, Italy; [Romano, Francesca; Canessa, Clementina; Azzari, Chiara] Anna Meyer Childrens Univ Hosp, Jeffrey Modell Ctr Primary Immunodeficiencies, Florence, Italy; [Chiang, Samuel; Schlums, Heinrich] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Med, Ctr Infect Med, Stockholm, Sweden; [Galli, Luisa] Anna Meyer Childrens Univ Hosp, Dept Pediat Infect Dis, Florence, Italy; [Avenali, Stefano] Anna Meyer Childrens Univ Hosp, Dept Pediat Intens Care, Florence, Italy; [Hsu, Amy P.; Holland, Steven M.] NIAID, NIH, Bethesda, MD 20892 USA; [Bryceson, Yenan T.] Univ Bergen, Dept Clin Sci, Broegelmann Res Lab, N-5020 Bergen, Norway	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Florence; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; Karolinska Institutet; Karolinska University Hospital; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Bergen	Tesi, B (corresponding author), Karolinska Univ Hosp Solna, Karolinska Inst, Dept Womens & Childrens Hlth, Childhood Canc Res Unit, Stockholm, Sweden.	Yenan.Bryceson@ki.se	Bryceson, Yenan T/D-2121-2018; chiang, samuel/M-9267-2016; Sieni, Elena/J-8729-2018; Chiang, Samuel CC/O-5960-2019; Cetica, Valentina/J-2885-2018; Azzari, Chiara/AAB-8584-2019; Tesi, Bianca/AAH-6304-2021	Bryceson, Yenan T/0000-0002-7783-9934; Sieni, Elena/0000-0002-6192-9812; Chiang, Samuel CC/0000-0001-6597-6117; Cetica, Valentina/0000-0001-8549-4158; Azzari, Chiara/0000-0001-7236-1655; Tesi, Bianca/0000-0002-8253-2507; Farela Neves, Joao/0000-0003-4740-6094; Schlums, Heinrich/0000-0002-2895-7766; Henter, Jan-Inge/0000-0002-0629-2126; Nordenskjold, Magnus/0000-0002-4974-425X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000647] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bafica A, 2005, J EXP MED, V202, P1715, DOI 10.1084/jem.20051782; Begin P, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-7; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Canna SW, 2013, ARTHRITIS RHEUM-US, V65, P1764, DOI 10.1002/art.37958; Faitelson Y, 2014, CLIN IMMUNOL, V155, P118, DOI 10.1016/j.clim.2014.09.008; Filipe-Santos O, 2006, SEMIN IMMUNOL, V18, P347, DOI 10.1016/j.smim.2006.07.010; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Jordan MB, 2004, BLOOD, V104, P735, DOI 10.1182/blood-2003-10-3413; Jouanguy E, 2000, J CLIN INVEST, V105, P1429, DOI 10.1172/JCI9166; Milner JD, 2010, BLOOD, V116, P2476, DOI 10.1182/blood-2009-11-255174; Robins H, 2012, J IMMUNOL METHODS, V375, P14, DOI 10.1016/j.jim.2011.09.001; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Schmid JP, 2009, EMBO MOL MED, V1, P112, DOI 10.1002/emmm.200900009; van Dommelen SLH, 2006, IMMUNITY, V25, P835, DOI 10.1016/j.immuni.2006.09.010; Zoller EE, 2011, J EXP MED, V208, P1203, DOI 10.1084/jem.20102538	15	58	61	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1638	1641		10.1016/j.jaci.2014.11.030	http://dx.doi.org/10.1016/j.jaci.2014.11.030			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25592983	Green Submitted			2022-12-18	WOS:000355933400028
J	Hernandez, ML; Mills, K; Almond, M; Todoric, K; Aleman, MM; Zhang, HT; Zhou, HB; Peden, DB				Hernandez, Michelle L.; Mills, Katherine; Almond, Martha; Todoric, Krista; Aleman, Maria M.; Zhang, Hongtao; Zhou, Haibo; Peden, David B.			IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Endotoxin; neutrophil; asthma; induced sputum; LPS; IL-1 beta; IL-1 receptor antagonist; anakinra; innate immunity	ATOPIC ASTHMATIC SUBJECTS; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; INHALED ENDOTOXIN; EOSINOPHILIC INFLAMMATION; EPITHELIAL-CELLS; INNATE IMMUNITY; IN-VIVO; EXPRESSION; CHALLENGE	Background: Asthma with neutrophil predominance is challenging to treat with corticosteroids. Novel treatment options for asthma include those that target innate immune activity. Recent literature has indicated a significant role for IL-1 beta in both acute and chronic neutrophilic asthma. Objective: This study used inhaled endotoxin (LPS) challenge as a model of innate immune activation to (1) assess the safety of the IL-1 receptor antagonist anakinra in conjunction with inhaled LPS and (2) to test the hypothesis that IL-1 blockade will suppress the acute neutrophil response to challenge with inhaled LPS. Methods: In a phase I clinical study 17 healthy volunteers completed a double-blind, placebo-controlled crossover study in which they received 2 daily subcutaneous doses of 1 mg/kg anakinra (maximum dose, 100 mg) or saline (placebo). One hour after the second treatment dose, subjects underwent an inhaled LPS challenge. Induced sputum was assessed for neutrophils 4 hours after inhaled LPS. The effect of anakinra compared with placebo on airway neutrophil counts and airway proinflammatory cytokine levels after LPS challenge was compared by using a linear mixed-model approach. Results: Anakinra pretreatment significantly diminished airway neutrophilia compared with placebo. LPS-induced IL-1 beta, IL-6, and IL-8 levels were significantly reduced during the anakinra treatment period compared with those seen after placebo. Subjects tolerated the anakinra treatment well without an increased frequency of infections attributable to anakinra treatment. Conclusions: Anakinra effectively reduced airway neutrophilic inflammation and resulted in no serious adverse events in a model of inhaled LPS challenge. Anakinra is a potential therapeutic candidate for treatment of asthma with neutrophil predominance in diseased populations.	[Hernandez, Michelle L.; Mills, Katherine; Almond, Martha; Todoric, Krista; Aleman, Maria M.; Peden, David B.] Univ N Carolina, Gillings Sch Global Publ Hlth, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27515 USA; [Zhang, Hongtao; Zhou, Haibo] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Hernandez, ML (corresponding author), 104 Mason Farm Rd,CB 7310, Chapel Hill, NC 27599 USA.	michelle_hernandez@med.unc.edu	ZHOU, Haibo/M-7373-2017	Aleman, Maria M./0000-0002-1714-0363; Peden, David/0000-0003-4526-4627	National Institute of Environmental Health Sciences [K23 ES021745]; National Institute of Allergy and Infectious Diseases [U19AI077437]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126, K23ES021745] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	M.L.H. is supported by National Institute of Environmental Health Sciences grant K23 ES021745. K.M., M.A., H.Z., H.Z., and D.B.P. are supported by National Institute of Allergy and Infectious Diseases grant U19AI077437.	Alexis NE, 2006, J ALLERGY CLIN IMMUN, V117, P1396, DOI 10.1016/j.jaci.2006.02.030; Alexis NE, 2005, J ALLERGY CLIN IMMUN, V115, P345, DOI 10.1016/j.jaci.2004.11.040; Alexis NE, 2003, J ALLERGY CLIN IMMUN, V112, P353, DOI 10.1067/mai.2003.1651; Alexis NE, 2001, J ALLERGY CLIN IMMUN, V108, P577; Alexis NE, 2008, ANN ALLERG ASTHMA IM, V100, P206, DOI 10.1016/S1081-1206(10)60444-9; Alexis NE, 2009, J ALLERGY CLIN IMMUN, V124, P1222, DOI 10.1016/j.jaci.2009.07.036; Baines KJ, 2014, J ALLERGY CLIN IMMUN, V133, P997, DOI 10.1016/j.jaci.2013.12.1091; Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Biovitrum, PHYS PACK INS KIN AN; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Broide DH, 2000, BLOOD, V95, P263; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Dougherty RH, 2009, CLIN EXP ALLERGY, V39, P193, DOI 10.1111/j.1365-2222.2008.03157.x; Esnault S, 2012, CLIN EXP ALLERGY, V42, P1756, DOI 10.1111/j.1365-2222.2012.04060.x; Fujisawa T, 2011, AM J RESP CELL MOL, V45, P246, DOI 10.1165/rcmb.2009-0313OC; Fujisawa T, 2009, J IMMUNOL, V183, P6236, DOI 10.4049/jimmunol.0900614; Gern JE, 2002, NAT REV IMMUNOL, V2, P132, DOI 10.1038/nri725; Gohlke H, 2004, AM J RESP CRIT CARE, V169, P1217, DOI 10.1164/rccm.200302-281OC; Hernandez ML, 2013, FREE RADICAL BIO MED, V60, P56, DOI 10.1016/j.freeradbiomed.2013.02.001; Hernandez ML, 2012, J ALLERGY CLIN IMMUN, V130, P869, DOI 10.1016/j.jaci.2012.05.026; Hernandez ML, 2010, J ALLERGY CLIN IMMUN, V126, P537, DOI 10.1016/j.jaci.2010.06.043; Hernandez ML, 2010, INHAL TOXICOL, V22, P648, DOI 10.3109/08958371003610966; Jones B., 2003, DESIGN ANAL CROSS OV, V2nd edn; Kimura G, 2013, CHEST, V144, P99, DOI 10.1378/chest.12-2610; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297, DOI 10.1164/ajrccm.160.1.9808144; Konno S, 1996, INT ARCH ALLERGY IMM, V109, P73, DOI 10.1159/000237234; Lay JC, 2007, J ALLERGY CLIN IMMUN, V120, P719, DOI 10.1016/j.jaci.2007.05.005; Leaker BR, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-137; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; Papi A, 2013, J ALLERGY CLIN IMMUN, V132, P1075, DOI 10.1016/j.jaci.2013.05.028; Peden DB, 2005, J ALLERGY CLIN IMMUN, V115, P213, DOI 10.1016/j.jaci.2004.12.003; PUJOL JL, 1990, INT ARCH ALLER A IMM, V91, P207, DOI 10.1159/000235117; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Sousa AR, 1996, AM J RESP CRIT CARE, V154, P1061, DOI 10.1164/ajrccm.154.4.8887608; Stoppelenburg AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078461; ULICH TR, 1991, AM J PATHOL, V138, P521; ULICH TR, 1990, AM J PATHOL, V137, P1173; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wenzel SE, 2009, AM J RESP CRIT CARE, V179, P549, DOI 10.1164/rccm.200809-1512OC; Wood LG, 2011, CLIN EXP ALLERGY, V41, P640, DOI 10.1111/j.1365-2222.2010.03669.x; Yang CM, 2010, J CELL PHYSIOL, V224, P516, DOI 10.1002/jcp.22153	41	58	62	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					379	385		10.1016/j.jaci.2014.07.039	http://dx.doi.org/10.1016/j.jaci.2014.07.039			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25195169	Green Accepted, Bronze, Green Published			2022-12-18	WOS:000349372300009
J	Park, HW; Dahlin, A; Tse, S; Duan, QL; Schuemann, B; Martinez, FD; Peters, SP; Szefler, SJ; Lima, JJ; Kubo, M; Tamari, M; Tantisira, KG				Park, Heung-Woo; Dahlin, Amber; Tse, Szeman; Duan, Qing Ling; Schuemann, Brooke; Martinez, Fernando D.; Peters, Stephen P.; Szefler, Stanley J.; Lima, John J.; Kubo, Michiaki; Tamari, Mayumi; Tantisira, Kelan G.			Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; child; glucocorticoid; pharmacogenomics; polymorphism	RANDOMIZED CONTROLLED TRIAL; GENOME-WIDE ASSOCIATION; CHILDHOOD ASTHMA; PERSISTENT ASTHMA; SEVERE EXACERBATIONS; MEDICATION USE; POOR RESPONSE; LUNG-FUNCTION; CHILDREN; PERCEPTION	Background: To date, genome-wide association studies (GWASs) of inhaled corticosteroid (ICS) response in asthmatic patients have focused primarily on lung function and exacerbations. Objective: We hypothesized that GWAS analysis could identify novel genetic markers predicting a symptomatic response to ICSs. Methods: We analyzed differences in asthma symptoms in response to ICSs in 124 white children from the Childhood Asthma Management Program (CAMP) trial using scores from diary cards. Of the 440,862 single nucleotide polymorphisms (SNPs) analyzed, the top 100 ranked SNPs were pursued for replication initially in subjects from the pediatric Childhood Asthma Research and Education trials (77 white children) and then in subjects from the adult Asthma Clinical Research Network (110 white adults) and Leukotriene Modifier or Corticosteroid or Corticosteroid-Salmeterol trials (110 white adults). Results: The lowest P value for GWAS analysis in the CAMP trial was 8.94 x 10(-8) (rs2388639). Of the 60 SNPs available in the Childhood Asthma Research and Education Network trials, rs1558726 (combined P = 1.02 x 10(-5)), rs2388639 (combined P = 8.56 x 10(-9)), and rs10044254 (combined P = 9.16 x 10(-8)) independently replicated. However, these 3 SNPs were not additionally replicated in the adult asthmatic patients of the remaining trials. rs10044254 lies in the intronic region of F-box and leucine-rich repeat protein 7 (FBXL7) and is associated with decreased expression in immortalized B cells derived from CAMP participants. Conclusions: We have identified a novel SNP, rs10044254, associated with both decreased expression of FBXL7 and improved symptomatic response to ICSs in 2 independent pediatric cohorts. Our results suggest that there might be a specific genetic mechanism regulating symptomatic response to ICSs in children that does not carry over to adults.	[Park, Heung-Woo; Dahlin, Amber; Tse, Szeman; Duan, Qing Ling; Schuemann, Brooke; Tantisira, Kelan G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med,Dept Med, Boston, MA 02115 USA; [Park, Heung-Woo] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea; [Martinez, Fernando D.] Univ Arizona, Coll Med, Arizona Resp Ctr, Tucson, AZ USA; [Peters, Stephen P.] Wake Forest Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC USA; [Peters, Stephen P.] Wake Forest Sch Med, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC USA; [Szefler, Stanley J.] Natl Jewish Hlth, Dept Pediat & Pharmacol, Denver, CO USA; [Szefler, Stanley J.] Univ Colorado, Denver Sch Med, Denver, CO 80202 USA; [Lima, John J.] Nemours Childrens Clin, Ctr Pharmacogen & Translat Res, Jacksonville, FL USA; [Kubo, Michiaki; Tamari, Mayumi] RIKEN, Ctr Integrat Med Sci, Yokohama, Kanagawa, Japan; [Tantisira, Kelan G.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Seoul National University (SNU); University of Arizona; Wake Forest University; Wake Forest University; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; RIKEN; Harvard University; Brigham & Women's Hospital	Tantisira, KG (corresponding author), Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.	kelan.tantisira@channing.harvard.edu	Tamari, Mayumi/N-5378-2015; Kubo, Michiaki/N-7947-2015; Park, Heung-Woo/AAW-7690-2020	Park, Heung-Woo/0000-0002-6970-3228; Szefler, Stanley/0000-0002-6911-3199	National Institutes of Health [R01 NR013391, R01 HL092197, U01 HL065899]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL065899, R37HL066289, R01HL092197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR013391] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [221S0001] Funding Source: KAKEN	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by National Institutes of Health grants R01 NR013391, R01 HL092197, and U01 HL065899.	[Anonymous], 2007, 3 NAEPP; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Bahadori Katayoun, 2009, BMC Pulm Med, V9, P24, DOI 10.1186/1471-2466-9-24; Banzett RB, 2000, AM J RESP CRIT CARE, V162, P1178, DOI 10.1164/ajrccm.162.3.9909112; Boushey HA, 1998, J ALLERGY CLIN IMMUN, V102, pS5, DOI 10.1016/S0091-6749(98)70001-6; British Thoracic Society, 2005, BRIT GUID MAN ASTHM; BURDON JGW, 1982, AM REV RESPIR DIS, V126, P825; Cassavaugh JM, 2011, J CELL BIOCHEM, V112, P3882, DOI 10.1002/jcb.23321; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Foster MW, 2013, NITRIC OXIDE-BIOL CH, V34, P37, DOI 10.1016/j.niox.2013.02.079; FRITZ GK, 1990, J DEV BEHAV PEDIATR, V11, P69; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Halterman JS, 2003, AMBUL PEDIATR, V3, P102, DOI 10.1367/1539-4409(2003)003<0102:APPIPA>2.0.CO;2; Hawkins GA, 2009, J ALLERGY CLIN IMMUN, V123, P1376, DOI 10.1016/j.jaci.2009.01.049; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Jadhav Trafina, 2009, J Proteomics Bioinform, V2, P316; Kolodziejski PJ, 2002, P NATL ACAD SCI USA, V99, P12315, DOI 10.1073/pnas.192345199; Kopel SJ, 2010, BIOL PSYCHOL, V84, P135, DOI 10.1016/j.biopsycho.2009.11.007; Koster ES, 2011, ALLERGY, V66, P1546, DOI 10.1111/j.1398-9995.2011.02701.x; Krishnan JA, 2012, J ALLERGY CLIN IMMUN, V129, pS124, DOI 10.1016/j.jaci.2011.12.981; Lang JE, 2013, PHARMACOGEN PERS MED, V6, P73, DOI 10.2147/PGPM.S30626; Lansing RW, 2009, RESP PHYSIOL NEUROBI, V167, P53, DOI 10.1016/j.resp.2008.07.012; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Littner MR, 2005, CHEST, V128, P1128, DOI 10.1378/chest.128.3.1128; Lozano P, 2003, ARCH PEDIAT ADOL MED, V157, P81, DOI 10.1001/archpedi.157.1.81; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Marchini J, 2010, NAT REV GENET, V11, P499, DOI 10.1038/nrg2796; Martin RJ, 2007, J ALLERGY CLIN IMMUN, V119, P73, DOI 10.1016/j.jaci.2006.10.035; McGeachie MJ, 2013, PHARMACOGENOMICS J, V13, P306, DOI 10.1038/tpj.2012.15; Mougey EB, 2013, PHARMACOGENOMICS J, V13, P242, DOI 10.1038/tpj.2012.5; Mougey EB, 2009, PHARMACOGENET GENOM, V19, P129, DOI 10.1097/FPC.0b013e32831bd98c; Nandi D, 2006, J BIOSCIENCES, V31, P137, DOI 10.1007/BF02705243; Peters SP, 2007, NEW ENGL J MED, V356, P2027; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Rogers AJ, 2009, PHARMACOGENOMICS, V10, P1231, DOI [10.2217/pgs.09.86, 10.2217/PGS.09.86]; Schwartz AL, 2009, ANNU REV PHARMACOL, V49, P73, DOI 10.1146/annurev.pharmtox.051208.165340; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Stouffer SA, 1949, STUDIES SOCIAL PSYCO, V1; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Szefler SJ, 2010, J ALLERGY CLIN IMMUN, V125, P285, DOI 10.1016/j.jaci.2009.10.026; Tantisira KG, 2007, J ALLERGY CLIN IMMUN, V120, P1285, DOI 10.1016/j.jaci.2007.09.005; Tantisira KG, 2012, AM J RESP CRIT CARE, V185, P1286, DOI 10.1164/rccm.201111-2061OC; Tantisira KG, 2011, NEW ENGL J MED, V365, P1173, DOI 10.1056/NEJMoa0911353; The Global Initiative for Asthma (GINA), 2010, GUID ASTHM MAN PREV; van Dalen C, 2008, ARCH PEDIAT ADOL MED, V162, P1169, DOI 10.1001/archpedi.162.12.1169; Wu AC, 2011, CHEST, V140, P100, DOI 10.1378/chest.10-2794; Yoos HL, 1999, NURS RES, V48, P2, DOI 10.1097/00006199-199901000-00002; Zhao J, 2012, NAT IMMUNOL, V13, P651, DOI 10.1038/ni.2341	53	58	61	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					664	+		10.1016/j.jaci.2013.12.1042	http://dx.doi.org/10.1016/j.jaci.2013.12.1042			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24486069	Green Accepted			2022-12-18	WOS:000332397600006
J	van Anrooij, B; van der Veer, E; de Monchy, JGR; van der Heide, S; Kluin-Nelemans, JC; Vader, PCV; van Doormaal, JJ; Elberink, JNGO				van Anrooij, Bjorn; van der Veer, Eveline; de Monchy, Jan G. R.; van der Heide, Sicco; Kluin-Nelemans, Johanna C.; Vader, Pieter C. van Voorst; van Doormaal, Jasper J.; Elberink, Joanne N. G. Oude			Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hymenoptera venom-induced anaphylaxis; mastocytosis; tryptase; histamine metabolites; mast cell	LINE SERUM TRYPTASE; HISTAMINE; ALLERGY; IMMUNOTHERAPY; METABOLITES; DISORDERS; MUTATION; NETWORK; URINE	Background: Increased basal serum tryptase (bsT) levels are a well-described risk factor for Hymenoptera venom-induced anaphylaxis (HVAn) in patients allergic to Hymenoptera venom. Increased bsT levels might also indicate the presence of mastocytosis. In this study we evaluated whether the risk of HVAn increases with increasing mast cell load in patients with mastocytosis. Methods: Consecutive patients with different subtypes of mastocytosis (n = 329) admitted to the University Medical Center Groningen were retrospectively assessed. As markers for mast cell load, levels of both bsT and the urinary histamine metabolites methylhistamine and methylimidazole acetic acid (MIMA) were used. Results: In the entire patient group, irrespective of disease subtype and Hymenoptera venom exposure, HVAn prevalence gradually increased with increasing marker levels to a maximum of 36% to 47% at a bsT level of 28.0 mu g/L, a methylhistamine level of 231.0 mu mol/mol creatinine, and a MIMA level of 2.7 mmol/mol creatinine but decreased thereafter with a further increase in these levels. In patients with indolent systemic mastocytosis with a history of Hymenoptera venom exposure after age 15 years or greater (n = 152), MIMA and age at the most recent Hymenoptera sting were independent predictors for HVAn (odds ratios of 0.723 [P = .001] and 1.062 [P < .001], respectively). Conclusions: In patients with mastocytosis, HVAn prevalence does not increase constantly with increasing levels of mast cell load parameters: after a gradual increase to a maximum of near 50%, it decreases with a further increase in these levels. In the indolent systemic mastocytosis population, all mast cell load markers were independent negative predictors of HVAn. These findings suggest a complex pathophysiologic association between mast cell load and HVAn risk in patients with mastocytosis.	[van Anrooij, Bjorn; de Monchy, Jan G. R.; van Doormaal, Jasper J.; Elberink, Joanne N. G. Oude] Univ Groningen, Univ Med Ctr Groningen, Dept Allergol, Groningen, Netherlands; [van der Veer, Eveline; van der Heide, Sicco] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Dept Lab Med, NL-9700 AB Groningen, Netherlands; [Kluin-Nelemans, Johanna C.] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Dept Hematol, NL-9700 AB Groningen, Netherlands; [Vader, Pieter C. van Voorst] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Dept Dermatol, NL-9700 AB Groningen, Netherlands; [de Monchy, Jan G. R.; Elberink, Joanne N. G. Oude] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, NL-9700 AB Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Groningen	Elberink, JNGO (corresponding author), Univ Med Ctr Groningen, Dept Allergol, Huispostcode AA23,POB 30-001, NL-9700 RB Groningen, Netherlands.	j.n.g.oude.elberink@umcg.nl	Kluin-Nelemans, Johanna C/F-8658-2018	Kluin-Nelemans, Johanna C/0000-0003-2617-9427; van der Veer, Eveline/0000-0002-4825-9981	ALK-Abello; MSD	ALK-Abello; MSD	P. C. van Voorst Vader has consultant arrangements with the Department of Dermatology and is employed by the University Medical Center Groningen, The Netherlands. J. N. G. Oude Elberink has received payment for lectures, including service on speakers' bureaus from ALK-Abello and MSD. The rest of the authors declare that they have no relevant conflicts of interest.	Antonicelli L, 2002, CURR OPIN ALLERGY CL, V2, P341, DOI 10.1097/00130832-200208000-00008; Bilo MB, 2009, CLIN EXP ALLERGY, V39, P1467, DOI 10.1111/j.1365-2222.2009.03324.x; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; Cabrera R, 2010, SCAND J IMMUNOL, V72, P293, DOI 10.1111/j.1365-3083.2010.02427.x; Cichocka-Jarosz E, 2011, J INVEST ALLERG CLIN, V21, P260; Dugas-Breit S, 2010, CLIN EXP ALLERGY, V40, P643, DOI 10.1111/j.1365-2222.2009.03436.x; Frossi B, 2010, TRENDS IMMUNOL, V31, P97, DOI 10.1016/j.it.2009.12.007; Fuchiwaki T, 2011, EUR J IMMUNOL, V41, P2947, DOI 10.1002/eji.201141423; Galli SJ, 2008, NAT REV IMMUNOL, V8, P478, DOI 10.1038/nri2327; Garcia-Montero AC, 2006, BLOOD, V108, P2366, DOI 10.1182/blood-2006-04-015545; Granerus G, 1998, BRIT J DERMATOL, V139, P858; Guenova E, 2010, ALLERGY, V65, P919, DOI 10.1111/j.1398-9995.2009.02302.x; Horny HP, 2008, WHO CLASSIFICATION T, P54; Kennedy MK, 2006, IMMUNOLOGY, V118, P143, DOI 10.1111/j.1365-2567.2006.02354.x; KEYZER JJ, 1981, CLIN CHIM ACTA, V113, P165, DOI 10.1016/0009-8981(81)90150-9; KEYZER JJ, 1982, CLIN CHIM ACTA, V121, P379, DOI 10.1016/0009-8981(82)90247-9; Kristensen T, 2012, EUR J HAEMATOL, V89, P42, DOI 10.1111/j.1600-0609.2012.01789.x; Lim KH, 2009, BLOOD, V113, P5727, DOI 10.1182/blood-2009-02-205237; Ludolph-Hauser D, 2001, LANCET, V357, P361, DOI 10.1016/S0140-6736(00)03647-3; Metcalfe DD, 2009, J ALLERGY CLIN IMMUN, V123, P687, DOI 10.1016/j.jaci.2009.02.003; Muller UR, 2009, CLIN EXP ALLERGY, V39, P620, DOI 10.1111/j.1365-2222.2009.03251.x; Niedoszytko M, 2011, ALLERGY, V66, P648, DOI 10.1111/j.1398-9995.2010.02521.x; Niedoszytko M, 2009, ALLERGY, V64, P1237, DOI 10.1111/j.1398-9995.2009.02118.x; OOSTING E, 1988, AGENTS ACTIONS, V23, P307, DOI 10.1007/BF02142572; Rueff F, 2010, J ALLERGY CLIN IMMUN, V126, P105, DOI 10.1016/j.jaci.2010.04.025; Rueff F, 2009, J ALLERGY CLIN IMMUN, V124, P1047, DOI 10.1016/j.jaci.2009.08.027; Sampson HA, 2006, ANN EMERG MED, V47, P373, DOI 10.1016/j.annemergmed.2006.01.018; Saraiva M, 2002, J EXP MED, V196, P829, DOI 10.1084/jem.20020319; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Stoevesandt J, 2012, J ALLERGY CLIN IMMUN, V130, P698, DOI 10.1016/j.jaci.2012.03.024; Teodosio C, 2012, LEUKEMIA, V26, P951, DOI 10.1038/leu.2011.293; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; Vegh AB, 2011, ANN ALLERG ASTHMA IM, V106, P342, DOI 10.1016/j.anai.2010.12.015; Wimazal F, 2012, INT ARCH ALLERGY IMM, V157, P399, DOI 10.1159/000329218	34	58	58	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					125	130		10.1016/j.jaci.2012.12.1578	http://dx.doi.org/10.1016/j.jaci.2012.12.1578			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23498593	Bronze			2022-12-18	WOS:000321052300017
J	Chan, YR; Chen, K; Duncan, SR; Lathrop, KL; Latoche, JD; Logar, AJ; Pociask, DA; Wahlberg, BJ; Ray, P; Ray, A; Pilewski, JM; Kolls, JK				Chan, Yvonne R.; Chen, Kong; Duncan, Steven R.; Lathrop, Kira L.; Latoche, Joseph D.; Logar, Alison J.; Pociask, Derek A.; Wahlberg, Brendon J.; Ray, Prabir; Ray, Anuradha; Pilewski, Joseph M.; Kolls, Jay K.			Patients with cystic fibrosis have inducible IL-17(+)IL-22(+) memory cells in lung draining lymph nodes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TH17; TH22; IL-17; IL-22; cystic fibrosis; Pseudomonas species; Aspergillus species; chronic infectious disease; memory T-cell response; lung transplant	OBSTRUCTIVE PULMONARY-DISEASE; COLONY-STIMULATING FACTOR; MUCOSAL HOST-DEFENSE; REGULATORY T-CELLS; IL-17 RECEPTOR; TH17 CELLS; TGF-BETA; MATRIX METALLOPROTEINASES; NEUTROPHIL RECRUITMENT; KLEBSIELLA-PNEUMONIAE	Background: IL-17 is an important cytokine signature of the T-H differentiation pathway T(H)17. This T-cell subset is crucial in mediating autoimmune disease or antimicrobial immunity in animal models, but its presence and role in human disease remain to be completely characterized. Objective: We set out to determine the frequency of TH17 cells in patients with cystic fibrosis (CF), a disease in which there is recurrent infection with known pathogens. Methods: Explanted lungs from patients undergoing transplantation or organ donors (CF samples = 18; non-CF, nonbronchiectatic samples = 10) were collected. Hilar nodes and parenchymal lung tissue were processed and examined for TH17 signature by using immunofluorescence and quantitative real-time PCR. T cells were isolated and stimulated with antigens from Pseudomonas aeruginosa and Aspergillus species. Cytokine profiles and staining with flow cytometry were used to assess the reactivity of these cells to antigen stimulation. Results: We found a strong IL-17 phenotype in patients with CF compared with that seen in control subjects without CF. Within this tissue, we found pathogenic antigen-responsive CD4 1 IL-17 1 cells. There were double-positive IL-17 1 IL-22 1 cells [TH17(22)], and the IL-22 1 population had a higher proportion of memory characteristics. Antigen-specific TH17 responses were stronger in the draining lymph nodes compared with those seen in matched parenchymal lungs. Conclusion: Inducible proliferation of TH17(22) with memory cell characteristics is seen in the lungs of patients with CF. The function of these individual subpopulations will require further study regarding their development. T cells are likely not the exclusive producers of IL-17 and IL-22, and this will require further characterization. (J Allergy Clin Immunol 2013; 131:1117-29.)	[Chan, Yvonne R.; Duncan, Steven R.; Latoche, Joseph D.; Wahlberg, Brendon J.; Ray, Prabir; Ray, Anuradha; Pilewski, Joseph M.] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA; [Lathrop, Kira L.] Univ Pittsburgh, Inst Eye & Ear, Pittsburgh, PA 15213 USA; [Chen, Kong; Logar, Alison J.; Pociask, Derek A.; Kolls, Jay K.] Childrens Hosp Pittsburgh, Pediat Res Inst, Richard King Mellon Fdn, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Chan, YR (corresponding author), Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, 3459 5th Ave,NW 628 MUH, Pittsburgh, PA 15213 USA.	chany3@upmc.edu	Kolls, Jay/AAH-1829-2019; Pilewski, Joseph/AAF-5149-2021	Kolls, Jay/0000-0001-5151-6304; Latoche, Joseph/0000-0002-4800-5623	National Heart, Lung, and Blood Institute; National Institutes of Health [K08 HL089189, P50 HL084932]; Howard Hughes Medical Institute; CF Foundation; Novartis; confocal imaging resources of the Core Grant for Vision Research at the University of Pittsburgh [NIH P30-EY08098]; Cystic Fibrosis Foundation; NIH; NATIONAL EYE INSTITUTE [P30EY008098] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL079142, K08HL089189, R01HL062052] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); CF Foundation; Novartis(Novartis); confocal imaging resources of the Core Grant for Vision Research at the University of Pittsburgh; Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by research grants from the National Heart, Lung, and Blood Institute, National Institutes of Health (K08 HL089189 to Y.R.C. and P50 HL084932 to J.K.K. and J.M.P.), the Howard Hughes Medical Institute (Early Career Physician Scientist Award to Y.R.C.), the CF Foundation (to J.M.P.), and Novartis (to J.K.K. and J.M.P.). Also supported by the confocal imaging resources of the Core Grant for Vision Research at the University of Pittsburgh (NIH P30-EY08098).; Disclosure of potential conflict of interest: Y.R. Chan has received research support from the Howard Hughes Medical Institute and the National Institutes of Health (NIH) and has received payment from Novartis for contract performance of experiments. S. R. Duncan and K. Lathrop have received research support from the NIH. J.M. Pilewski has received research support from the Cystic Fibrosis Foundation and the NIH. J.K. Kolls has received research support from the NIH, is chair of the board for MiniVax, is coinventor on a patent submitted by Louisiana State University Health Sciences Center, and has received travel compensation from MiniVax. The rest of the authors declare that they have no relevant conflicts of interest.	Arce F, 2009, MOL THER, V17, P1643, DOI 10.1038/mt.2009.149; Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710; Barczyk A, 2003, RESP MED, V97, P726, DOI 10.1053/rmed.2003.1507; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Braun RK, 2009, TRANSPLANTATION, V88, P1341, DOI 10.1097/TP.0b013e3181bcde7b; Carvalho A, 2010, BONE MARROW TRANSPL, V45, P1645, DOI 10.1038/bmt.2010.28; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chan YR, 2009, J IMMUNOL, V182, P4947, DOI 10.4049/jimmunol.0803282; Coakley RD, 2003, P NATL ACAD SCI USA, V100, P16083, DOI 10.1073/pnas.2634339100; Conti HR, 2009, J EXP MED, V206, P299, DOI 10.1084/jem.20081463; Deteix C, 2010, J IMMUNOL, V184, P5344, DOI 10.4049/jimmunol.0902999; Di Stefano A, 2009, CLIN EXP IMMUNOL, V157, P316, DOI 10.1111/j.1365-2249.2009.03965.x; Dorschner RA, 2006, FASEB J, V20, P35, DOI 10.1096/fj.05-4406com; Dubin PJ, 2007, AM J PHYSIOL-LUNG C, V292, pL519, DOI 10.1152/ajplung.00312.2006; Elkington PTG, 2006, THORAX, V61, P259, DOI 10.1136/thx.2005.051979; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Garvy BA, 1997, INFECT IMMUN, V65, P5052, DOI 10.1128/IAI.65.12.5052-5056.1997; Gibbons FK, 2005, J CLIN IMMUNOL, V25, P437, DOI 10.1007/s10875-005-5625-6; Happel KI, 2005, J EXP MED, V202, P761, DOI 10.1084/jem.20050193; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009; Kao CY, 2004, J IMMUNOL, V173, P3482, DOI 10.4049/jimmunol.173.5.3482; Karlsen JR, 2010, J BIOL CHEM, V285, P14088, DOI 10.1074/jbc.M109.017129; Kolls JK, 2008, NAT REV IMMUNOL, V8, P829, DOI 10.1038/nri2433; Kreindler JL, 2010, J CLIN INVEST, V120, P3242, DOI 10.1172/JCI42388; Kreindler JL, 2009, AM J PHYSIOL-LUNG C, V296, pL257, DOI 10.1152/ajplung.00344.2007; Kruisbeek A, 2001, CURRENT PROTOCOLS IM, P31; Laan M, 2003, EUR RESPIR J, V21, P387, DOI 10.1183/09031936.03.00303503; Laan M, 1999, J IMMUNOL, V162, P2347; Lebre MC, 2005, IMMUNOL CELL BIOL, V83, P525, DOI 10.1111/j.1440-1711.2005.01365.x; Lefrancois L., 2001, CURR PROTOC IMMUNOL, VChapter 3, P19, DOI [10.1002/0471142735.im0319s17, DOI 10.1002/0471142735.IM0319S17]; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; McAllister F, 2005, J IMMUNOL, V175, P404, DOI 10.4049/jimmunol.175.1.404; Meshi B, 2002, AM J RESP CELL MOL, V26, P52, DOI 10.1165/ajrcmb.26.1.4253; Morris A, 2004, AM J RESP CRIT CARE, V170, P408, DOI 10.1164/rccm.200401-094OC; Morris A, 2008, COPD, V5, P43, DOI 10.1080/15412550701817656; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Naess LM, 1998, INFECT IMMUN, V66, P959; Newcomb DC, 2011, J ALLERGY CLIN IMMUN, V127, P1006, DOI 10.1016/j.jaci.2010.11.043; Newcomb DC, 2009, J IMMUNOL, V182, P5317, DOI 10.4049/jimmunol.0803868; Newcomb DC, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Onishi RM, 2010, IMMUNOLOGY, V129, P311, DOI 10.1111/j.1365-2567.2009.03240.x; Papi A, 2006, AM J RESP CRIT CARE, V173, P1114, DOI 10.1164/rccm.200506-859OC; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418; Patel IS, 2002, THORAX, V57, P759, DOI 10.1136/thorax.57.9.759; Peric M, 2008, J IMMUNOL, V181, P8504, DOI 10.4049/jimmunol.181.12.8504; Puel A, 2010, J EXP MED, V207, P291, DOI 10.1084/jem.20091983; Raffatellu M, 2008, NAT MED, V14, P421, DOI 10.1038/nm1743; Romani L, 2008, NATURE, V451, P211, DOI 10.1038/nature06471; ROUVIER E, 1993, J IMMUNOL, V150, P5445; Rowe HM, 2006, MOL THER, V13, P310, DOI 10.1016/j.ymthe.2005.08.025; Sethi S, 2000, CHEST, V117, p286S, DOI 10.1378/chest.117.5_suppl_1.286S; Shan M, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranlsmed.3000154; Shen F, 2005, J LEUKOCYTE BIOL, V77, P388, DOI 10.1189/jlb.0904490; Stoltz DA, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000928; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Vokaer B, 2010, J IMMUNOL, V185, P3417, DOI 10.4049/jimmunol.0903961; Walsh KP, 2009, J IMMUNOL, V183, P1577, DOI 10.4049/jimmunol.0803803; Wang SH, 2011, CLIN TRANSPLANT, V25, pE177, DOI 10.1111/j.1399-0012.2010.01362.x; Whittington HA, 2004, AM J RESP CELL MOL, V31, P220, DOI 10.1165/rcmb.2003-0285OC; Wilkinson TMA, 2003, AM J RESP CRIT CARE, V167, P1090, DOI 10.1164/rccm.200210-1179OC; Xie AN, 2011, TRANSPLANTATION, V91, P27, DOI 10.1097/TP.0b013e3181fdd948; Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Ye P, 2001, AM J RESP CELL MOL, V25, P335, DOI 10.1165/ajrcmb.25.3.4424; YOO ZB, 1995, J IMMUNOL, V155, P5483; Yu JJ, 2007, BLOOD, V109, P3794, DOI 10.1182/blood-2005-09-010116; Zelante T, 2007, EUR J IMMUNOL, V37, P2695, DOI 10.1002/eji.200737409	73	58	59	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1117	+		10.1016/j.jaci.2012.05.036	http://dx.doi.org/10.1016/j.jaci.2012.05.036			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	22795370	Green Accepted			2022-12-18	WOS:000317187200022
J	Mehrotra, P; Hollenbeck, A; Riley, JP; Li, F; Patel, RJ; Akhtar, N; Goenka, S				Mehrotra, Purvi; Hollenbeck, Andrew; Riley, Jonathan P.; Li, Fang; Patel, Ravi J.; Akhtar, Nahid; Goenka, Shreevrat			Poly (ADP-ribose) polymerase 14 and its enzyme activity regulates T(H)2 differentiation and allergic airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-4; signal transducer and activator of transcription 6; poly (ADP-ribose) polymerase 14; T(H)2 cells; Gata3; lung inflammation; airway hyperresponsiveness; poly (ADP-ribose) polymerase inhibitor; allergic airway disease	TRANSCRIPTION FACTOR 6; SIGNAL TRANSDUCER; GENE-EXPRESSION; TH2 CYTOKINES; STAT6; ASTHMA; POLY(ADP-RIBOSE); CELLS; IL-4; INFLAMMATION	Background: IL-4 and signal transducer and activator of transcription 6 (STAT6) play an important role in the progression of allergic airway disease (AAD) or asthma. IL-4 and STAT6 mediate T(H)2 responses in T cells and immunoglobulin class-switching to IgE in B cells. Both T(H)2 responses and IgE promote the asthmatic condition. We have previously demonstrated that poly (ADP-ribose) polymerase (PARP) 14, a member of the PARP family of proteins, regulates the transcription function of STAT6. However, the role of PARP-14 in AAD is not known. Objective: Here we investigate the role of PARP-14 and the enzyme activity associated with it in a model of AAD dependent on airway hyperresponsiveness and lung inflammation. We also elucidate the mechanism by which PARP-14 regulates AAD. Methods: The role of PARP-14 and its enzyme activity in AAD and T(H)2 differentiation were examined by using a murine model of AAD and in vitro T-H cell differentiation. Results: PARP-14-deficient animals show reduced lung pathology and IgE levels when compared with control animals. Treating mice with a pharmacologic inhibitor for PARP activity reduced the severity of airway hyperresponsiveness and lung inflammation. Mechanistically, our data indicate that PARP-14 and its enzyme activity aid in the differentiation of T cells toward a T(H)2 phenotype by regulating the binding of STAT6 to the Gata3 promoter. Conclusion: PARP-14 and the catalytic activity associated with it promote T(H)2 differentiation and AAD in a murine model, and targeting PARP-14 might be a potential new therapy for allergic asthma. (J Allergy Clin Immunol 2013;131:521-31.)	Indiana Univ Sch Med, HB Wells Ctr Pediat Res, Indianapolis, IN USA; Indiana Univ Sch Med, Dept Pediat Microbiol & Immunol, Indianapolis, IN USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington					National Institutes of Health [HL093105]; Showalter Foundation; National Institutes of Health/National Heart, Lung, and Blood Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL093105] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Showalter Foundation; National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grant HL093105 and a Showalter Foundation grant.; S. Goenka has received research support, travel support, and payment for writing/reviewing from the National Institutes of Health/National Heart, Lung, and Blood Institute, and has received provision of writing assistance from the Indiana University School of Medicine. The rest of the authors declare that they have no relevant conflicts of interest.	Ahyi ANN, 2009, J IMMUNOL, V183, P1598, DOI 10.4049/jimmunol.0803302; Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; Betz BC, 2010, J EXP MED, V207, P933, DOI 10.1084/jem.20091548; Broide DH, 2011, J ALLERGY CLIN IMMUN, V127, P689, DOI 10.1016/j.jaci.2011.01.027; Datta R, 2011, ALLERGY, V66, P853, DOI 10.1111/j.1398-9995.2011.02549.x; Fanta CH, 2009, NEW ENGL J MED, V360, P1002, DOI 10.1056/NEJMra0804579; Goenka S, 2006, P NATL ACAD SCI USA, V103, P4210, DOI 10.1073/pnas.0506981103; Goenka S, 2007, J BIOL CHEM, V282, P18732, DOI 10.1074/jbc.M611283200; Goenka S, 2011, IMMUNOL RES, V50, P87, DOI 10.1007/s12026-011-8205-2; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Kuperman DA, 2008, CURR MOL MED, V8, P384, DOI 10.2174/156652408785161032; Mehrotra P, 2011, J BIOL CHEM, V286, P1767, DOI 10.1074/jbc.M110.157768; Mustapha O, 2006, J IMMUNOL, V177, P6489, DOI 10.4049/jimmunol.177.9.6489; Onodera A, 2010, J EXP MED, V207, P2493, DOI 10.1084/jem.20100760; Paul WE, 2010, IMMUNOL CELL BIOL, V88, P236, DOI 10.1038/icb.2010.2; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Sehra S, 2008, J IMMUNOL, V180, P3551, DOI 10.4049/jimmunol.180.5.3551; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Stritesky GL, 2011, IMMUNITY, V34, P39, DOI 10.1016/j.immuni.2010.12.013; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; van Rijt LS, 2004, J IMMUNOL METHODS, V288, P111, DOI 10.1016/j.jim.2004.03.004; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Wei L, 2010, IMMUNITY, V32, P840, DOI 10.1016/j.immuni.2010.06.003; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhu JF, 2002, IMMUNITY, V16, P733, DOI 10.1016/S1074-7613(02)00317-5	27	58	60	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					521	+		10.1016/j.jaci.2012.06.015	http://dx.doi.org/10.1016/j.jaci.2012.06.015			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	22841009	Green Accepted			2022-12-18	WOS:000314661500032
J	Chawes, BLK; Poorisrisak, P; Johnston, SL; Bisgaard, H				Chawes, Bo L. K.; Poorisrisak, Porntiva; Johnston, Sebastian L.; Bisgaard, Hans			Neonatal bronchial hyperresponsiveness precedes acute severe viral bronchiolitis in infants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bronchial responsiveness; infants; lung function measurements; viral bronchiolitis	RESPIRATORY-SYNCYTIAL-VIRUS; PROSPECTIVE BIRTH COHORT; HIGH-RISK CHILDREN; LUNG-FUNCTION; EARLY-LIFE; RHINOVIRUS ILLNESSES; PREDISPOSING FACTOR; ATOPIC-DERMATITIS; CHILDHOOD ASTHMA; YOUNG INFANTS	Background: Respiratory syncytial virus and other respiratory tract viruses lead to common colds in most infants, whereas a minority develop acute severe bronchiolitis often requiring hospitalization. We hypothesized that such an excessive response to respiratory tract viral infection is caused by host factors reflected in pre-existing increased bronchial responsiveness. Objective: We sought to compare bronchial responsiveness and lung function in 1-month-old neonates who later develop acute severe bronchiolitis with those who do not. Methods: We measured infant lung function (n = 402) and bronchial responsiveness to methacholine (n = 363) using the raised-volume rapid thoracoabdominal compression technique before any respiratory symptoms in 1-month-old neonates from the Copenhagen Prospective Study of Asthma in Childhood birth cohort born to mothers with asthma. The children were prospectively monitored for respiratory symptoms and given a diagnosis of acute severe bronchiolitis according to a fixed algorithm. Results: Thirty-four (8.5%) infants had acute severe bronchiolitis before 2 years of age, 21 (62%) were hospitalized, and 23 (67%) of the cases were associated with respiratory syncytial virus. Children who later had acute severe bronchiolitis irrespective of viral species had a 2.5-fold increased responsiveness to methacholine (provocative dose of methacholine producing a 15% decrease in transcutaneous oxygen pressure [PD15]) at age 1 month compared with control subjects (median PD15 in cases vs control subjects, 0.13 vs 0.33 mu mol; P = .01), whereas differences in baseline airflow were not significant for forced expiratory volume at 0.5 seconds (mean z score for cases vs control subjects, -0.18 vs -0.01; P = .36) and forced expiratory flow at 50% of forced vital capacity (mean z score for cases vs control subjects, -0.37 vs -0.09; P = .13). Conclusion: Bronchial hyperresponsiveness in at-risk neonates precedes acute severe bronchiolitis in response to infections with respiratory tract virus. (J Allergy Clin Immunol 2012;130:354-61.)	[Chawes, Bo L. K.; Poorisrisak, Porntiva; Bisgaard, Hans] Univ Copenhagen, DK-2820 Gentofte, Denmark; [Chawes, Bo L. K.; Poorisrisak, Porntiva; Bisgaard, Hans] Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, DK-2820 Gentofte, Denmark; [Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, MRC, London SW7 2AZ, England; [Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, Asthma UK Ctr Allerg Mech Asthma, London SW7 2AZ, England; [Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, Ctr Resp Infect, London SW7 2AZ, England	University of Copenhagen; University of Copenhagen; Imperial College London; Imperial College London; University of London; King's College London; Imperial College London	Bisgaard, H (corresponding author), Univ Copenhagen, Ledreborg Alle 34, DK-2820 Gentofte, Denmark.	bisgaard@copsac.com	Bisgaard, Hans/N-4761-2016; Johnston, Sebastian Lennox/I-2423-2012; Kronow, Joern/B-1054-2011	Bisgaard, Hans/0000-0003-4131-7592; Johnston, Sebastian Lennox/0000-0003-3009-9200; Chawes, Bo/0000-0001-6846-6243	Chair from Asthma UK [CH11SJ]; MRC Centre [G1000758]; ERC [233015, 260895]; Lundbeck Foundation; Pharmacy Foundation; Augustinus Foundation; Danish Medical Research Council; Danish Pediatric Asthma Centre; Merck; Lundbeck Foundation [R16-2007-1694] Funding Source: researchfish; Medical Research Council [G1000758] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish	Chair from Asthma UK; MRC Centre(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); ERC(European Research Council (ERC)European Commission); Lundbeck Foundation(Lundbeckfonden); Pharmacy Foundation; Augustinus Foundation; Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish Pediatric Asthma Centre; Merck(Merck & Company); Lundbeck Foundation(Lundbeckfonden); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	The Copenhagen Studies on Asthma in Childhood (COPSAC) is funded by private and public research funds listed on www.copsac.com. The Lundbeck Foundation, the Danish Strategic Research Council, the Pharmacy Foundation of 1991, the Augustinus Foundation, the Danish Medical Research Council, and the Danish Pediatric Asthma Centre provided the core support for the COPSAC research center. S.L.J. is supported by a Chair from Asthma UK (CH11SJ), MRC Centre Grant G1000758, ERC FP7 Advanced grant 233015, and Predicta FP7 Collaborative Project grant 260895.; S. L. Johnston has consultant arrangements with AstraZeneca, Centocor, Sanofi-Pasteur, Synairgen, GlaxoSmithKline, and Chiesi and has a share option with Synairgen. H. Bisgaard has consulted for Merck and Chiesi; has received lecture fees from Merck; receives research support from the Lundbeck Foundation, the Pharmacy Foundation of 1991, the Augustinus Foundation, the Danish Medical Research Council, and the Danish Pediatric Asthma Centre; and has provided legal consultation or expert witness testimony for the European Medicines Agency (EMEA) on guidelines on pediatric studies for documenting asthma drugs. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2005, AM J RESP CRIT CARE, V172, P1463; [Anonymous], 2006, PEDIATRICS, V118, P1774; Ballardini N, 2006, ALLERGY, V61, P337, DOI 10.1111/j.1398-9995.2005.00936.x; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2012, AM J RESP CRIT CARE; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V127, P1155, DOI 10.1016/j.jaci.2011.02.007; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Bisgaard H, 2009, J ALLERGY CLIN IMMUN, V123, P651, DOI 10.1016/j.jaci.2008.11.036; Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; Bush A, 2007, BMJ-BRIT MED J, V335, P1037, DOI 10.1136/bmj.39374.600081.AD; Fjaerli Hans-Olav, 2004, BMC Pediatr, V4, P25, DOI 10.1186/1471-2431-4-25; Goetghebuer T, 2004, PEDIATR PULM, V38, P321, DOI 10.1002/ppul.20069; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; Halkjaer LB, 2006, ARCH DERMATOL, V142, P561, DOI 10.1001/archderm.142.5.561; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Kuehni CE, 2009, AM J RESP CRIT CARE, V179, P1079, DOI 10.1164/rccm.200904-0567ED; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Loland L, 2006, CHEST, V129, P669, DOI 10.1378/chest.129.3.669; Loland L, 2008, CHEST, V133, P115, DOI 10.1378/chest.07-1328; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; Muller-Pebody B, 2002, EPIDEMIOL INFECT, V129, P99, DOI 10.1017/S095026880200729X; Murray CS, 2002, THORAX, V57, P388, DOI 10.1136/thorax.57.5.388; Nielsen HE, 2003, ACTA PAEDIATR, V92, P1314, DOI 10.1080/08035250310006304; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Simoes EAF, 2010, J ALLERGY CLIN IMMUN, V126, P256, DOI 10.1016/j.jaci.2010.05.026; Singh AM, 2007, AM J RESP CRIT CARE, V175, P108, DOI 10.1164/rccm.200603-435PP; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Smyth RL, 2006, LANCET, V368, P312, DOI 10.1016/S0140-6736(06)69077-6; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stensballe LG, 2006, PEDIATRICS, V118, pE1360, DOI 10.1542/peds.2006-0907; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811, DOI 10.1164/ajrccm/147.4.811; Wickman M, 2003, PEDIATR ALLERGY IMMU, V14, P441, DOI 10.1046/j.0905-6157.2003.00079.x; Young S, 2000, EUR RESPIR J, V15, P151, DOI 10.1034/j.1399-3003.2000.15a28.x; YOUNG S, 1995, ARCH DIS CHILD, V72, P16, DOI 10.1136/adc.72.1.16	38	58	59	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					354	+		10.1016/j.jaci.2012.04.045	http://dx.doi.org/10.1016/j.jaci.2012.04.045			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22713595	Green Published, Bronze			2022-12-18	WOS:000307002200013
J	Bougault, V; Loubaki, L; Joubert, P; Turmel, J; Couture, C; Laviolette, M; Chakir, J; Boulet, LP				Bougault, Valerie; Loubaki, Lionel; Joubert, Philippe; Turmel, Julie; Couture, Christian; Laviolette, Michel; Chakir, Jamila; Boulet, Louis-Philippe			Airway remodeling and inflammation in competitive swimmers training in indoor chlorinated swimming pools	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; airway inflammation; airway remodeling; bronchial biopsies; swimmers	RESPIRATORY SYMPTOMS; BRONCHIAL RESPONSIVENESS; ASTHMA; EXERCISE; HYPERRESPONSIVENESS; EPITHELIUM; PREVALENCE; EXPOSURES; BIOPSIES; ATHLETE	Background: Airway disorders are common in regular chlorinated swimming pool attendees, particularly competitive athletes, but the impact of intense swimming training on airway function and structure remains unclear. Objective: This study aimed to evaluate airway inflammation and remodeling in elite swimmers. Methods: Twenty-three elite swimmers were tested during off-training season. All had exhaled nitric oxide measurement, methacholine test, eucapnic voluntary hyperpnea challenge, allergy skin prick tests, and bronchoscopy with bronchial biopsies. Clinical data and tissues from 10 age-matched mild-asthmatic and 10 healthy nonallergic subjects were used for comparison. Results: Swimmers had increased airway mucosa eosinophil and mast cell counts than did controls (P < .05). They had more goblet cell hyperplasia and higher mucin expression than did healthy or asthmatic subjects (P < .05). A greater submucosal type I and III collagen expression and tenascin deposition was also observed in swimmers than in controls (P < .05). Neither exhaled nitric oxide nor airway responsiveness to methacholine or eucapnic voluntary hyperpnea challenge correlated with these inflammatory and remodeling changes. Conclusion: Intense, long-term swimming training in indoor chlorinated swimming pools is associated with airway changes similar to those seen in mild asthma, but with higher mucin expression. These changes were independent from airway hyperresponsiveness. The long-term physiological and clinical consequences of these changes remain to be clarified. (J Allergy Clin Immunol 2012;129:351-8.)	[Bougault, Valerie; Loubaki, Lionel; Joubert, Philippe; Turmel, Julie; Couture, Christian; Laviolette, Michel; Chakir, Jamila; Boulet, Louis-Philippe] Inst Univ Cardiol & Pneumol Quebec, Ctr Rech, Quebec City, PQ, Canada; [Bougault, Valerie] Univ Lille Nord France, EA 4488, UDSL2, Lille, France	Laval University; Universite de Lille - ISITE; Universite de Lille	Bougault, V (corresponding author), Univ Lille 2, Fac Sci Sport & Educ Phys, 9 Rue Univ, F-59790 Ronchin, France.	valerie.bougault@univ-lille2.fr	; Bougault, Valerie/G-9904-2018	Joubert, Philippe/0000-0001-7784-6387; Bougault, Valerie/0000-0002-2258-6562	Groupe de recherche en sante respiratoire from Universite Laval (GESER), Quebec, Quebec, Canada; 3M; AstraZeneca; GlaxoSmithKline; MerckFrosst; Novartis; Schering; Altair; Asmacure; Boehringer-Ingelheim; Genentech; Pharmaxis; Wyeth; CIHR	Groupe de recherche en sante respiratoire from Universite Laval (GESER), Quebec, Quebec, Canada; 3M(3M); AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); MerckFrosst; Novartis(Novartis); Schering; Altair; Asmacure; Boehringer-Ingelheim(Boehringer Ingelheim); Genentech(Roche HoldingGenentech); Pharmaxis; Wyeth(Wyeth); CIHR(Canadian Institutes of Health Research (CIHR))	Valerie Bougault was supported in part by a grant from the Groupe de recherche en sante respiratoire from Universite Laval (GESER), Quebec, Quebec, Canada.; L.-P. Boulet is on advisory boards for AstraZeneca, GlaxoSmithKline, MerckFrosst, and Novartis; receives lecture fees from 3M, AstraZeneca, GlaxoSmithKline, MerckFrosst, and Novartis; receives research support from AstraZeneca, GlaxoSmithKline, MerckFrosst, Schering, Altair, Asmacure, Boehringer-Ingelheim, Genentech, Pharmaxis, Wyeth; is an advisor for the Conseil du Medicament du Quebe and AETMIS and a member of the Quebec Workmen Compensation Board Respiratory Committee; is chair of the Canadian Thoracic Society Respiratory Guidelines Committee and chair of the GINA Guidelines Dissemination and Implementation Committee; is holder of the Laval University Chair on Knowledge Transfer, Prevention, and Education in Respiratory and Cardiovascular Health; and is a member of the Knowledge Translation (KT Canada) supported by the CIHR. The rest of the authors declare that they have no relevant conflicts of interest.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Amin K, 2000, AM J RESP CRIT CARE, V162, P2295, DOI 10.1164/ajrccm.162.6.9912001; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P419, DOI 10.1067/mai.2000.108914; Anderson SD, 2003, CLIN REV ALLERG IMMU, V24, P27, DOI 10.1385/CRIAI:24:1:27; Bernard A, 2007, CURR MED CHEM, V14, P1771; Bernard A, 2007, PEDIATRICS, V119, P1095, DOI 10.1542/peds.2006-3333; Bonetto G, 2006, AM J RESP CRIT CARE, V174, P545, DOI 10.1164/rccm.200509-1392OC; Bougault V, 2009, EUR RESPIR J, V33, P740, DOI 10.1183/09031936.00117708; Bougault V, 2011, J ALLERGY CLIN IMMUN, V127, P892, DOI 10.1016/j.jaci.2010.11.003; Bougault V, 2010, CHEST, V138, p31S, DOI 10.1378/chest.09-1689; Bougault V, 2009, SPORTS MED, V39, P295, DOI 10.2165/00007256-200939040-00003; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Carbonnelle S, 2002, BIOMARKERS, V7, P464, DOI 10.1080/13547500210166612; Chakir J, 2010, EUR RESPIR J, V35, P48, DOI 10.1183/09031936.00130008; Chakir J, 2002, CLIN EXP ALLERGY, V32, P578, DOI 10.1046/j.0954-7894.2002.01323.x; Chimenti L, 2007, AM J RESP CRIT CARE, V175, P442, DOI 10.1164/rccm.200608-1086OC; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; DISTEFANO A, 1993, AM REV RESPIR DIS, V147, P1005, DOI 10.1164/ajrccm/147.4.1005; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; Fahy JV, 2001, AM J RESP CRIT CARE, V164, pS46, DOI 10.1164/ajrccm.164.supplement_2.2106066; Fitch KD, 2008, J ALLERGY CLIN IMMUN, V122, P254, DOI 10.1016/j.jaci.2008.07.003; Hallstrand TS, 2007, J ALLERGY CLIN IMMUN, V119, P1092, DOI 10.1016/j.jaci.2007.01.005; Helenius IJ, 1998, ALLERGY, V53, P346, DOI 10.1111/j.1398-9995.1998.tb03904.x; Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646, DOI 10.1016/S0091-6749(98)70173-3; Karjalainen EM, 2000, AM J RESP CRIT CARE, V161, P2086, DOI 10.1164/ajrccm.161.6.9907025; Karjalainen EM, 2003, RESP MED, V97, P1045, DOI 10.1016/S0954-6111(03)00136-7; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; Labonte I, 2008, CAN RESPIR J, V15, P431, DOI 10.1155/2008/202615; Langdeau JB, 2000, AM J RESP CRIT CARE, V161, P1479, DOI 10.1164/ajrccm.161.5.9909008; Lemiere C, 2000, J ALLERGY CLIN IMMUN, V106, P1163; Lemiere C, 1997, EUR RESPIR J, V10, P241, DOI 10.1183/09031936.97.10010241; Levesque B, 2006, INT ARCH OCC ENV HEA, V80, P32, DOI 10.1007/s00420-006-0100-0; PEATFIELD AC, 1986, J PHYSIOL-LONDON, V380, P429, DOI 10.1113/jphysiol.1986.sp016295; Potts, 1994, THESIS U BRIT COLUMB; Tchorzewska-Cieslak B., 2010, ENV HLTH CRIT, P521; Tschumperlin DJ, 2006, ANNU REV PHYSIOL, V68, P563, DOI 10.1146/annurev.physiol.68.072304.113102; Turcotte H, 2003, RESP MED, V97, P955, DOI 10.1016/S0954-6111(03)00123-9; ZWICK H, 1990, LUNG, V168, P111, DOI 10.1007/BF02719681	38	58	60	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					351	U122		10.1016/j.jaci.2011.11.010	http://dx.doi.org/10.1016/j.jaci.2011.11.010			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22196771	Bronze			2022-12-18	WOS:000299951700008
J	Lai, YY; Chen, B; Shi, JB; Palmer, JN; Kennedy, DW; Cohen, NA				Lai, Yinyan; Chen, Bei; Shi, Jianbo; Palmer, James N.; Kennedy, David W.; Cohen, Noam A.			Inflammation-mediated upregulation of centrosomal protein 110, a negative modulator of ciliogenesis, in patients with chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; ciliated epithelial cell; ciliogenesis; cytokine; inflammation; centrosomal protein 110	CHRONIC SINUSITIS; PSEUDOMONAS-AERUGINOSA; EXPRESSION; CILIA; CENTRIOLE; INTERLEUKIN-5; ELECTRON; CP110; EOSINOPHILS; DUPLICATION	Background: Sinonasal mucosa in patients with chronic rhinosinusitis (CRS) is often devoid of motile cilia. This defect is presumed to result from prolonged inflammation, infection, or both. However, the mechanism underlying this observation is unknown. Recently, centrosomal protein 110 (Cp110) was shown to prevent the terminal step in ciliary maturation (ie, elongation), suggesting that Cp110 might be involved in pathological states in which ciliation is abnormal. Objectives: First, we sought to investigate the expression of Cp110 in sinonasal mucosa from patients with CRS and control subjects. Second, we sought to determine the extent that inflammatory cytokines modulate Cp110 expression and ciliary maturation in vitro. Methods: Sinonasal mucosal specimens from patients with and without CRS were analyzed for Cp110 mRNA and protein expression. Furthermore, human and murine nasal respiratory epithelial cultures were used to investigate Cp110 expression under normal growth conditions and in the presence of exogenous proinflammatory cytokines. Results: Increased Cp110 mRNA and protein expression was found in sinonasal mucosal specimens from patients with CRS compared with that seen in control specimens. During ciliogenesis in vitro, the expression of Cp110 gradually decreased in cultures derived from patients without CRS but remained increased in cultures derived from patients with CRS. Furthermore, cultures grown in the presence of proinflammatory cytokines demonstrated increased levels of Cp110 expression with concomitant inhibition of ciliogenesis. Conclusion: Increased Cp110 expression in mucosa from patients with CRS might contribute to the poor ciliation observed in patients with CRS. Exogenous cytokine exposure maintains increased levels of Cp110 expression. Regulation of Cp110 expression by inflammation warrants additional investigation because it might offer a novel target in the management of respiratory tract diseases. (J Allergy Clin Immunol 2011;128:1207-15.)	[Lai, Yinyan; Chen, Bei; Palmer, James N.; Kennedy, David W.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA; [Lai, Yinyan; Shi, Jianbo] Sun Yat Sen Univ, Otorhinolaryngol Hosp, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China; [Palmer, James N.; Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Div Otolaryngol, Philadelphia, PA USA	University of Pennsylvania; Sun Yat Sen University; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Cohen, NA (corresponding author), Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg,5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA.	cohenn@uphs.upenn.edu		Cohen, Noam/0000-0002-9462-3932	China Scholarship Council; Flight Attendant Medical Research Institute [082478]	China Scholarship Council(China Scholarship Council); Flight Attendant Medical Research Institute	Supported by the China Scholarship Council and the Flight Attendant Medical Research Institute Clinical Innovator Award (082478; to N.A.C.).	Antunes MB, 2007, BIOTECHNIQUES, V43, P195, DOI 10.2144/000112531; Bendouah Z, 2006, OTOLARYNG HEAD NECK, V134, P991, DOI 10.1016/j.otohns.2006.03.001; Bhargave G, 2008, AM J RHINOL, V22, P7, DOI 10.2500/ajr.2008.22.3125; Biedlingmaier JF, 1998, OTOLARYNG HEAD NECK, V118, P165, DOI 10.1016/S0194-5998(98)80005-3; Carvalho-Santos Z, 2010, J CELL SCI, V123, P1414, DOI 10.1242/jcs.064931; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; Cohen NA, 2006, ANN OTO RHINOL LARYN, V115, P20; Danielsen A, 2006, EUR ARCH OTO-RHINO-L, V263, P282, DOI 10.1007/S00405-005-1031-1; FINOTTO S, 1994, J IMMUNOL, V153, P2278; Ghaffar O, 1998, OTOLARYNG HEAD NECK, V118, P504, DOI 10.1016/S0194-5998(98)70209-8; Gomperts BN, 2007, AM J RESP CELL MOL, V37, P339, DOI 10.1165/rcmb.2006-0400OC; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; Gudis DA, 2010, OTOLARYNG CLIN N AM, V43, P461, DOI 10.1016/j.otc.2010.02.007; Hagiwara H, 2004, INT REV CYTOL, V234, P101, DOI 10.1016/S0074-7696(04)34003-9; Hamilos DL, 1998, CLIN EXP ALLERGY, V28, P1145; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; Kleylein-Sohn J, 2007, DEV CELL, V13, P190, DOI 10.1016/j.devcel.2007.07.002; Kuehnemund M, 2004, LARYNGOSCOPE, V114, P561, DOI 10.1097/00005537-200403000-00032; Lee CH, 1998, ANN OTO RHINOL LARYN, V107, P665, DOI 10.1177/000348949810700807; Lennard CM, 2000, AM J RHINOL, V14, P367, DOI 10.2500/105065800779954329; Matsui H, 2006, P NATL ACAD SCI USA, V103, P18131, DOI 10.1073/pnas.0606428103; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Moritz KB, 1996, INT J DEV BIOL, V40, P27; Ozcan C, 2005, EUR ARCH OTO-RHINO-L, V262, P55, DOI 10.1007/s00405-003-0729-1; Peters AT, 2010, J ALLERGY CLIN IMMUN, V125, P397, DOI 10.1016/j.jaci.2009.10.072; Prince AA, 2008, AM J RHINOL, V22, P239, DOI 10.2500/ajr.2008.22.3180; Psaltis AJ, 2008, AM J RHINOL, V22, P1, DOI 10.2500/ajr.2008.22.3119; Ramanathan M, 2007, AM J RHINOL, V21, P373, DOI 10.2500/ajr.2007.21.3034; Reimer A, 1978, Acta Otolaryngol Suppl, V356, P1; Riechelmann H, 2005, CLIN EXP ALLERGY, V35, P1186, DOI 10.1111/j.1365-2222.2005.02316.x; Schmidt TI, 2009, CURR BIOL, V19, P1005, DOI 10.1016/j.cub.2009.05.016; Spektor A, 2007, CELL, V130, P678, DOI 10.1016/j.cell.2007.06.027; Strnad P, 2007, DEV CELL, V13, P203, DOI 10.1016/j.devcel.2007.07.004; Tamashiro Edwin, 2009, Braz. j. otorhinolaryngol., V75, P903; Tamashiro E, 2009, AM J RHINOL ALLERGY, V23, P597, DOI 10.2500/ajra.2009.23.3398; Tamashiro E, 2009, AM J RHINOL ALLERGY, V23, P117, DOI 10.2500/ajra.2009.23.3280; TOSKALA E, 1995, J LARYNGOL OTOL, V109, P509, DOI 10.1017/S0022215100130580; Tsang WY, 2008, DEV CELL, V15, P187, DOI 10.1016/j.devcel.2008.07.004; Tsang WY, 2009, DEV CELL, V16, P649, DOI 10.1016/j.devcel.2009.03.004; Varmark H, 2004, J CELL BIOCHEM, V91, P904, DOI 10.1002/jcb.20013; Woodworth BA, 2007, AM J RHINOL, V21, P533, DOI 10.2500/ajr.2007.21.3068; Wright ED, 1998, OTOLARYNG HEAD NECK, V118, P490, DOI 10.1016/S0194-5998(98)70207-4	42	58	61	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1207	U526		10.1016/j.jaci.2011.09.001	http://dx.doi.org/10.1016/j.jaci.2011.09.001			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21982113				2022-12-18	WOS:000298342700008
J	Yao, WG; Tepper, RS; Kaplan, MH				Yao, Weiguo; Tepper, Robert S.; Kaplan, Mark H.			Predisposition to the development of IL-9-secreting T cells in atopic infants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BETA		[Yao, Weiguo; Tepper, Robert S.; Kaplan, Mark H.] Indiana Univ Sch Med, Dept Pediat, Wells Ctr Pediat Res, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington	Yao, WG (corresponding author), Indiana Univ Sch Med, Dept Pediat, Wells Ctr Pediat Res, Indianapolis, IN 46202 USA.	mkaplan2@iupui.edu		Kaplan, Mark/0000-0002-2923-8245	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057459, U19AI070448] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL080071-05, R01 HL080071, HL080071] Funding Source: Medline; NIAID NIH HHS [U19 AI070448, AI070448, R01 AI057459, U19 AI070448-04, AI057459, R01 AI057459-06, U19 AI070448-05] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chang HC, 2010, NAT IMMUNOL, V11, P527, DOI 10.1038/ni.1867; Dardalhon V, 2008, NAT IMMUNOL, V9, P1347, DOI 10.1038/ni.1677; Devos S, 2006, CLIN EXP ALLERGY, V36, P174, DOI 10.1111/j.1365-2222.2006.02422.x; Erpenbeck VJ, 2003, CHEST, V123, p370S; Goswami R, 2011, J IMMUNOL, V186, P3283, DOI 10.4049/jimmunol.1003049; Jenmalm MC, 2001, CLIN EXP ALLERGY, V31, P1528, DOI 10.1046/j.1365-2222.2001.01190.x; Tepper RS, 2008, J ALLERGY CLIN IMMUN, V122, P760, DOI 10.1016/j.jaci.2008.07.022; Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659; YAO W, 2010, J ALLERGY CLIN IMMUN, V126	9	58	58	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1357	1360		10.1016/j.jaci.2011.06.019	http://dx.doi.org/10.1016/j.jaci.2011.06.019			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21798577	Green Accepted, Bronze			2022-12-18	WOS:000298342700032
J	Szefler, SJ				Szefler, Stanley J.			Advancing asthma care: The glass is only half full!	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; childhood asthma; asthma therapy; asthma statistics; asthma management; asthma guidelines; asthma disease management; inhaled corticosteroids; long-acting beta-adrenergic agonists; leukotriene receptor antagonists; omalizumab; asthma surveillance; asthma mortality; asthma hospitalizations; asthma exacerbations; asthma progression; personalized medicine; public health	1ST 6 YEARS; CHILDHOOD ASTHMA; INNER-CITY; LONG-TERM; NATIONAL-INSTITUTES; MANAGEMENT PROGRAM; PRESCHOOL-CHILDREN; NATURAL-HISTORY; MODERATE ASTHMA; NITRIC-OXIDE	Over the past 20 years, there has been a concerted effort in the United States to reduce morbidity related to chronic disease, including asthma. Attention was initially directed toward asthma in response to the recognition that asthma mortality was increasing and that the burden of disease was significant. These efforts to address asthma mortality led to many new initiatives to develop clinical practice guidelines, implement the asthma guidelines into clinical practice, conduct research to fill the gaps in the guidelines, and continuously revise the asthma guidelines as more information became available. An assessment of our progress shows significant accomplishments in relation to reducing asthma mortality and hospitalizations. Consequently, we are now at a crossroads in asthma care. Although we have recognized some remarkable accomplishments in reducing asthma mortality and morbidity, the availability of new tools to monitor disease activity, including biomarkers and epigenetic markers, along with information technology systems to monitor asthma control hold some promise in identifying gaps in disease management. These advances should prompt the evolution of new strategies and new treatments to further reduce disease burden. It now becomes imperative to continue a focus on ways to further reduce the burden of asthma and prevent its onset. (J Allergy Clin Immunol 2011;128:485-94.)	[Szefler, Stanley J.] Natl Jewish Hlth, Dept Pediat, Div Pediat Clin Pharmacol, Denver, CO 80206 USA; Natl Jewish Hlth, Dept Pediat, Div Allergy & Immunol, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pediat, Boulder, CO 80309 USA; Univ Colorado, Sch Med, Dept Pharmacol, Boulder, CO 80309 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Szefler, SJ (corresponding author), Natl Jewish Hlth, Dept Pediat, Div Pediat Clin Pharmacol, 1400 Jackson St,Rm J304,Molly Blank Bldg, Denver, CO 80206 USA.	szeflers@njhealth.org		Szefler, Stanley/0000-0002-6911-3199	Public Health Services [HR-16048, HL64288, HL 51834, AI-25496, HL081335, HL075416]; Colorado Cancer, Cardiovascular and Pulmonary Disease Program; National Institutes of Health (NIH) [1 UL1 RR025780]; National Center for Research Resources (NCRR); NIH/National Heart, Lung, and Blood Institute (NHLBI); NHLBI Childhood Asthma Research and Education (CARE); NIH/NHLBI Asthma Clinical Research Network (ACRN); NIH/National Institute of Allergy and Infectious Diseases Inner City Asthma Consortium; GlaxoSmithKline; NIH/NHLBI Asthma Net; National Institute of Environmental Health Sciences/US Environmental Protection Agency Childhood Environmental Health Center; DIVISION OF LUNG DISEASES [N01HR016048] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL081335, R21HL087811, U10HL064288, U10HL098075, U01HL075416, U10HL051834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES018181] Funding Source: NIH RePORTER	Public Health Services(United States Department of Health & Human ServicesUnited States Public Health Service); Colorado Cancer, Cardiovascular and Pulmonary Disease Program; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI Childhood Asthma Research and Education (CARE)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/NHLBI Asthma Clinical Research Network (ACRN)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/National Institute of Allergy and Infectious Diseases Inner City Asthma Consortium(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); GlaxoSmithKline(GlaxoSmithKline); NIH/NHLBI Asthma Net(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Environmental Health Sciences/US Environmental Protection Agency Childhood Environmental Health Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported in part by Public Health Services research grants HR-16048, HL64288, HL 51834, AI-25496, HL081335, and HL075416 and the Colorado Cancer, Cardiovascular and Pulmonary Disease Program. Supported in part by Colorado CTSA grant 1 UL1 RR025780 from the National Institutes of Health (NIH) and the National Center for Research Resources (NCRR).; Disclosure of potential conflict of interest: S. J. Szefler is a consultant for GlaxoSmithKline, Genentech, Merck, Boehringer Ingelheim, Novartis, and Schering-Plough and has received research support from the NIH/National Heart, Lung, and Blood Institute (NHLBI) Childhood Management Program (CAMP), the NHLBI Childhood Asthma Research and Education (CARE), the NIH/NHLBI Asthma Clinical Research Network (ACRN), the NIH/National Institute of Allergy and Infectious Diseases Inner City Asthma Consortium, GlaxoSmithKline, NIH/NHLBI Asthma Net, and a National Institute of Environmental Health Sciences/US Environmental Protection Agency Childhood Environmental Health Center grant.	[Anonymous], WORK RELATED LUNG DI; [Anonymous], HLTH PEOPLE 2000 MID; Apter AJ, 2011, J ALLERGY CLIN IMMUN, V127, P116, DOI 10.1016/j.jaci.2010.11.017; Austen KF, 2007, J ALLERGY CLIN IMMUN, V119, P34, DOI 10.1016/j.jaci.2006.10.008; Bacharier LB, 2009, J ALLERGY CLIN IMMUN, V123, P1077, DOI 10.1016/j.jaci.2008.12.1120; Bacharier LB, 2008, J ALLERGY CLIN IMMUN, V122, P1127, DOI 10.1016/j.jaci.2008.09.029; Barnett SBL, 2011, J ALLERGY CLIN IMMUN, V127, P145, DOI 10.1016/j.jaci.2010.10.020; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2010, J ALLERGY CLIN IMMUN, V126, P187, DOI 10.1016/j.jaci.2010.07.011; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P529, DOI 10.1016/j.jaci.2010.01.036; CDC National Asthma Control Program, AM BREATH EAS; Centers for Disease Control and Prevention, GUID STAT HLTH AG DE; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; Covar RA, 2008, J ALLERGY CLIN IMMUN, V122, P741, DOI 10.1016/j.jaci.2008.08.021; Covar RA, 2010, J ALLERGY CLIN IMMUN, V125, P359, DOI 10.1016/j.jaci.2009.10.037; Denlinger LC, 2007, J ALLERGY CLIN IMMUN, V119, P3, DOI 10.1016/j.jaci.2006.10.015; Drazen JM, 2007, J ALLERGY CLIN IMMUN, V119, P28, DOI 10.1016/j.jaci.2006.06.011; Fitzpatrick AM, 2010, J ALLERGY CLIN IMMUN, V125, P851, DOI 10.1016/j.jaci.2010.01.048; Gern JE, 2010, J ALLERGY CLIN IMMUN, V125, P545, DOI 10.1016/j.jaci.2010.01.037; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Holloway JW, 2010, J ALLERGY CLIN IMMUN, V126, P200, DOI 10.1016/j.jaci.2010.06.006; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; Kazani S, 2010, J ALLERGY CLIN IMMUN, V125, P295, DOI 10.1016/j.jaci.2009.12.014; Kelly HW, 2003, J PEDIATR-US, V142, P286, DOI 10.1067/mpd.2003.86; Koh HK, 2010, NEW ENGL J MED, V362, P1653, DOI 10.1056/NEJMp1001601; Krishnan JA, 2011, J ALLERGY CLIN IMMUN, V127, P123, DOI 10.1016/j.jaci.2010.08.032; Lemanske RF, 2010, J ALLERGY CLIN IMMUN, V126, P449, DOI 10.1016/j.jaci.2010.05.039; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; Martin RJ, 2007, J ALLERGY CLIN IMMUN, V119, P73, DOI 10.1016/j.jaci.2006.10.035; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 2007, J ALLERGY CLIN IMMUN, V119, P30, DOI 10.1016/j.jaci.2006.10.020; Martinez FD, 2011, LANCET, V377, P650, DOI 10.1016/S0140-6736(10)62145-9; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; National Asthma Educational Program, 1991, PUBL US DEP HLTH HUM; National Center for Health Statistics, HLTH PEOPL 2000 FIN; National Heart Lung and Blood Institute National Institutes of Health, 1992, PUBL US DEP HLTH HUM; National Institute for Occupational Safety and Health, 2004, WORK HLTH CHARTB; National Institute of Environmental Health Sciences, ASTHM WHAT NIEHS IS; *NIH, NIH PUBL; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Rabinovitch N, 2010, J ALLERGY CLIN IMMUN, V126, P545, DOI 10.1016/j.jaci.2010.07.008; Searing DA, 2010, J ALLERGY CLIN IMMUN, V125, P995, DOI 10.1016/j.jaci.2010.03.008; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Strunk RC, 2006, J ALLERGY CLIN IMMUN, V118, P1040, DOI 10.1016/j.jaci.2006.07.053; Strunk RC, 2007, J ALLERGY CLIN IMMUN, V119, P36, DOI 10.1016/j.jaci.2006.09.038; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Szefler SJ, 2011, J ALLERGY CLIN IMMUN, V127, P102, DOI 10.1016/j.jaci.2010.11.018; Szefler SJ, 2010, J ALLERGY CLIN IMMUN, V125, P521, DOI 10.1016/j.jaci.2010.01.025; Szefler SJ, 2010, J ALLERGY CLIN IMMUN, V125, P285, DOI 10.1016/j.jaci.2009.10.026; Togias A, 2010, J ALLERGY CLIN IMMUN, V125, P540, DOI 10.1016/j.jaci.2010.01.040; *US DEP HHS, HLTH PEOPL 2010 MIDC; US Environmental Protection Agency, ID ENV RISKS ASTHM; von Mutius E, 2007, NEW ENGL J MED, V357, P1545, DOI 10.1056/NEJMe078119; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025; Zahran Hatice S., 2011, Morbidity and Mortality Weekly Report, V60, P547; [No title captured]	63	58	59	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					485	494		10.1016/j.jaci.2011.07.010	http://dx.doi.org/10.1016/j.jaci.2011.07.010			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21798579	Green Accepted, Bronze			2022-12-18	WOS:000294283400006
J	Shreffler, WG				Shreffler, Wayne G.			Microarrayed recombinant allergens for diagnostic testing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Microarray-based immunoassay; microarray-based allergy testing; component-resolved diagnostics; molecular allergy diagnosis	COMPONENT-RESOLVED DIAGNOSTICS; BASOPHIL-HISTAMINE-RELEASE; SEQUENTIAL EPITOPES; PROTEIN MICROARRAYS; IGE; TOOL; SENSITIZATION; IMMUNOGLOBULINS; AUTOANTIBODIES; IDENTIFICATION	The development of protein microarray-based immunoassays and the availability of recombinant allergens have, to a significant extent, emerged together over the past decade. Their long-anticipated wider application to allergy diagnosis has recently begun to accelerate. This review discusses some of the strengths and weaknesses of molecularly defined allergy testing and the microarray platform. Several recent applications of microarray assays to allergy testing are also summarized. Promising findings, particularly in the context of food and latex allergy, point to the potential for greater resolution between clinical reactivity and asymptomatic sensitization with this platform. (J Allergy Clin Immunol 2011;127:843-9.)	[Shreffler, Wayne G.] Harvard Univ, Food Allergy Ctr, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA; [Shreffler, Wayne G.] Harvard Univ, Ctr Immunol & Inflammatory Dis, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Shreffler, WG (corresponding author), Harvard Univ, Food Allergy Ctr, Sch Med, Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.	wshreffler@partners.org		Shreffler, Wayne/0000-0001-6465-137X				Alizadeh A, 1999, COLD SPRING HARB SYM, V64, P71, DOI 10.1101/sqb.1999.64.71; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Ayuso R, 2010, J ALLERGY CLIN IMMUN, V125, P1286, DOI 10.1016/j.jaci.2010.03.010; Bacarese-Hamilton T, 2005, METH MOLEC MED, V114, P195; Balboni I, 2008, PROTEOMICS, V8, P3443, DOI 10.1002/pmic.200800146; Barrett NA, 2009, J IMMUNOL, V182, P1119, DOI 10.4049/jimmunol.182.2.1119; Bauermeister K, 2009, J ALLERGY CLIN IMMUN, V124, P1273, DOI 10.1016/j.jaci.2009.07.033; Beyer K, 2003, J ALLERGY CLIN IMMUN, V112, P202, DOI 10.1067/mai.2003.1621; Cerecedo I, 2008, J ALLERGY CLIN IMMUN, V122, P589, DOI 10.1016/j.jaci.2008.06.040; Christensen LH, 2008, J ALLERGY CLIN IMMUN, V122, P298, DOI 10.1016/j.jaci.2008.05.026; Constantin C, 2009, ALLERGY, V64, P1030, DOI 10.1111/j.1398-9995.2009.01955.x; Cretich M, 2009, PROTEOMICS, V9, P2098, DOI 10.1002/pmic.200800651; Cruz-Fisher MI, 2011, INFECT IMMUN, V79, P246, DOI 10.1128/IAI.00626-10; De Knop KJ, 2010, ADV CLIN CHEM, V50, P87, DOI 10.1016/S0065-2423(10)50005-2; Deinhofer K, 2004, METHODS, V32, P249, DOI 10.1016/j.ymeth.2003.08.018; Drouvalakis KA, 2008, BIOSENS BIOELECTRON, V23, P1413, DOI 10.1016/j.bios.2007.11.022; Ebo DG, 2010, CLIN EXP ALLERGY, V40, P339, DOI 10.1111/j.1365-2222.2009.03345.x; Ebo DG, 2010, CLIN EXP ALLERGY, V40, P348, DOI 10.1111/j.1365-2222.2009.03370.x; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; Forester JP, 2010, ANN ALLERG ASTHMA IM, V105, P249, DOI 10.1016/j.anai.2010.02.001; Gadermaier G, 2008, ALLERGY, V63, P1543, DOI 10.1111/j.1398-9995.2008.01780.x; Hamilton RG, 2008, J ALLERGY CLIN IMMUN, V122, P305, DOI 10.1016/j.jaci.2008.05.009; Hamilton RG, 2010, IMMUNOL RES, V47, P273, DOI 10.1007/s12026-009-8160-3; Hamilton RG, 2010, J ALLERGY CLIN IMMUN, V126, P33, DOI 10.1016/j.jaci.2010.03.014; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Hochwallner H, 2010, CLIN EXP ALLERGY, V40, P1809, DOI 10.1111/j.1365-2222.2010.03602.x; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; Hueber W, 2003, CLIN EXP RHEUMATOL, V21, pS59; Jahn-Schmid B, 2003, CLIN EXP ALLERGY, V33, P1443, DOI 10.1046/j.1365-2222.2003.01784.x; Jin C, 2010, J ALLERGY CLIN IMMUN, V125, P184, DOI 10.1016/j.jaci.2009.08.037; Kattah MG, 2008, NAT MED, V14, P1284, DOI 10.1038/nm.1755; Knol EF, 2010, CLIN EXP ALLERGY, V40, P190, DOI 10.1111/j.1365-2222.2009.03402.x; Koppelman SJ, 2004, CLIN EXP ALLERGY, V34, P583, DOI 10.1111/j.1365-2222.2004.1923.x; Lewis SA, 2005, CLIN EXP ALLERGY, V35, P767, DOI 10.1111/j.1365-2222.2005.02252.x; Lin J, 2007, CLIN EXP ALLERGY, V37, P1854, DOI 10.1111/j.1365-2222.2007.02803.x; Lin J, 2009, METHODS MOL BIOL, V524, P259, DOI 10.1007/978-1-59745-450-6_19; Lin XP, 2002, J ALLERGY CLIN IMMUN, V109, P879, DOI 10.1067/mai.2002.123238; MacBeath G, 2002, NAT GENET, V32, P526, DOI 10.1038/ng1037; Mita H, 2000, CLIN EXP ALLERGY, V30, P1582, DOI 10.1046/j.1365-2222.2000.00921.x; Mittermann I, 2010, J ALLERGY CLIN IMMUN, V125, P1300, DOI 10.1016/j.jaci.2010.03.017; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Noga O, 2008, INT ARCH ALLERGY IMM, V146, P66, DOI 10.1159/000112504; Ott H, 2010, J INVEST ALLERG CLIN, V20, P129; Ott H, 2010, EUR J DERMATOL, V20, P54, DOI 10.1684/ejd.2010.0810; Radauer C, 2008, J ALLERGY CLIN IMMUN, V121, P847, DOI 10.1016/j.jaci.2008.01.025; Renault NK, 2011, J IMMUNOL METHODS, V364, P21, DOI 10.1016/j.jim.2010.10.004; Riechelmann H, 2002, ANN ALLERG ASTHMA IM, V88, P624, DOI 10.1016/S1081-1206(10)61895-9; Rondon C, 2009, J ALLERGY CLIN IMMUN, V124, P1005, DOI 10.1016/j.jaci.2009.07.018; Roth-Walter F, 2008, ALLERGY, V63, P882, DOI 10.1111/j.1398-9995.2008.01673.x; Sastre J, 2010, CLIN EXP ALLERGY, V40, P1442, DOI 10.1111/j.1365-2222.2010.03585.x; Shreffler WG, 2006, J IMMUNOL, V177, P3677, DOI 10.4049/jimmunol.177.6.3677; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Utz PJ, 2005, IMMUNOL REV, V204, P264, DOI 10.1111/j.0105-2896.2005.00251.x; Valent P, 2004, METHODS, V32, P265, DOI 10.1016/j.ymeth.2003.08.006; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Vereda A, 2010, J ALLERGY CLIN IMMUN, V126, P596, DOI 10.1016/j.jaci.2010.06.023; Vicario M, 2010, GUT, V59, P12, DOI 10.1136/gut.2009.178020; Vigh-Conrad KA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010174; Wang J, 2010, J ALLERGY CLIN IMMUN, V125, P695, DOI 10.1016/j.jaci.2009.12.017; Wohrl S, 2006, ALLERGY, V61, P633, DOI 10.1111/j.1398-9995.2006.01078.x	63	58	62	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					843	849		10.1016/j.jaci.2011.02.011	http://dx.doi.org/10.1016/j.jaci.2011.02.011			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21458654				2022-12-18	WOS:000289055800001
J	Strait, RT; Mahler, A; Hogan, S; Khodoun, M; Shibuya, A; Finkelman, FD				Strait, Richard T.; Mahler, Ashley; Hogan, Simon; Khodoun, Marat; Shibuya, Akira; Finkelman, Fred D.			Ingested allergens must be absorbed systemically to induce systemic anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mouse; food allergy; IgE; IgA; IgG; allergic diarrhea; blocking antibodies	IMMUNOGLOBULIN-A; FOOD ALLERGY; UNITED-STATES; MAST-CELLS; IN-VIVO; INTESTINAL PERMEABILITY; SALMONELLA-TYPHIMURIUM; VIBRIO-CHOLERAE; DEFICIENT MICE; J-CHAIN	Background: IgE-mediated food allergy is a common cause of enteric disease and is responsible for approximately 100 systemic anaphylaxis deaths in the United States each year. IgG antibodies can protect against IgE-mediated systemic anaphylaxis induced by injected antigens by neutralizing antigens before they can bind to mast cell-associated IgE. Objective: We have investigated whether IgA and IgG antibodies can similarly protect against systemic, IgE-mediated anaphylaxis induced by ingested antigens and, if so, whether IgA and IgG antibodies protect by neutralizing antigens before or after their systemic absorption. Methods: Murine passive and active anaphylaxis models were used to study the abilities of serum versus gut lumenal IgA antibodies and serum IgG antibodies to inhibit systemic anaphylaxis induced by ingested allergens in normal mice, mice deficient in the ability to secrete IgA into the intestines, and mice in which intestinal IL-9 overexpression has induced intestinal mastocytosis and increased intestinal permeability. Results: IgE-mediated systemic anaphylaxis and mast cell degranulation induced by antigen ingestion are suppressed by both serum antigen-specific IgA and IgG, but not by IgA within the gut lumen. Conclusion: Systemic rather than enteric antibodies protect against systemic anaphylaxis induced by ingested antigen. This implies that ingested antigens must be absorbed systemically to induce anaphylaxis and suggests that immunization protocols that increase serum levels of antigen-specific, non-IgE antibodies should protect against severe food allergy. (J Allergy Clin Immunol 2011;127:982-9.)	[Strait, Richard T.; Mahler, Ashley] Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH USA; [Hogan, Simon] Cincinnati Childrens Hosp Med Ctr, Div Allergy Immunol, Cincinnati, OH USA; [Finkelman, Fred D.] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH USA; [Strait, Richard T.; Hogan, Simon] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Khodoun, Marat; Finkelman, Fred D.] Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH USA; [Finkelman, Fred D.] Vet Adm Med Ctr, Cincinnati, OH 45220 USA; [Shibuya, Akira] Univ Tsukuba, Dept Immunol, Inst Basic Med Sci, Tsukuba, Ibaraki, Japan	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University of Tsukuba	Finkelman, FD (corresponding author), Cincinnati Vet Affairs Med Ctr, Dept Med Rheumatol, Cincinnati, OH 45220 USA.	ffinkelman@pol.net			US Department of Veterans Affairs; National Institutes of Health [RO1 AI072040]; NIH [P30DK078392]; Cincinnati Children's Digestive Disease Core; Food Allergy Anaphylaxis Network; Grants-in-Aid for Scientific Research [21249026] Funding Source: KAKEN; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072040, R21AI079947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392] Funding Source: NIH RePORTER	US Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cincinnati Children's Digestive Disease Core; Food Allergy Anaphylaxis Network; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by a Merit Award from the US Department of Veterans Affairs (F. D. F.), RO1 AI072040 from the National Institutes of Health (F. D. F.), and P30DK078392 from the NIH and the Cincinnati Children's Digestive Disease Core (R.T.S.).; Disclosure of potential conflict of interest: S. Hogan has received research support from the National Institutes of Health and the Food Allergy Anaphylaxis Network and is on the Journal's editorial board. F. D. Finkelman has received honoraria from Amgen and Abbott, is treasurer for FASEB, and is associate editor for the Journal. The rest of the authors have declared that they have no conflict of interest.	APTER FM, 1993, INFECT IMMUN, V61, P5279, DOI 10.1128/IAI.61.12.5279-5285.1993; Bischoff SC, 2007, IMMUNOL REV, V217, P329, DOI 10.1111/j.1600-065X.2007.00523.x; Bischoff SC, 2009, SEMIN IMMUNOPATHOL, V31, P185, DOI 10.1007/s00281-009-0165-4; Borrelli O, 2009, AM J GASTROENTEROL, V104, P454, DOI 10.1038/ajg.2008.109; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Cho Y, 2006, BIOCHEM BIOPH RES CO, V345, P474, DOI 10.1016/j.bbrc.2006.04.084; Clark S, 2005, CURR OPIN ALLERGY CL, V5, P293, DOI 10.1097/01.all.0000168797.14487.73; Cortegano I, 2000, GLYCOBIOLOGY, V10, P237, DOI 10.1093/glycob/10.3.237; Cunningham-Rundles C, 2001, J CLIN IMMUNOL, V21, P303, DOI 10.1023/A:1012241117984; CZINN SJ, 1993, VACCINE, V11, P637, DOI 10.1016/0264-410X(93)90309-L; de Silva IL, 2008, ALLERGY, V63, P1071, DOI 10.1111/j.1398-9995.2008.01719.x; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Eigenmann PA, 2008, CLIN EXP IMMUNOL, V151, P546, DOI 10.1111/j.1365-2249.2007.03582.x; Fagarasan S, 2003, NAT REV IMMUNOL, V3, P63, DOI 10.1038/nri982; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; Forbes EE, 2008, J EXP MED, V205, P897, DOI 10.1084/jem.20071046; Frossard CP, 2007, J ALLERGY CLIN IMMUN, V119, P952, DOI 10.1016/j.jaci.2006.12.615; Getahun A, 2009, SCAND J IMMUNOL, V70, P277, DOI 10.1111/j.1365-3083.2009.02298.x; Groschwitz KR, 2009, P NATL ACAD SCI USA, V106, P22381, DOI 10.1073/pnas.0906372106; HENDRICKSON BA, 1995, J EXP MED, V182, P1905, DOI 10.1084/jem.182.6.1905; Heyman M, 2005, EUR J GASTROEN HEPAT, V17, P1279, DOI 10.1097/00042737-200512000-00003; Johansen FE, 1999, J EXP MED, V190, P915, DOI 10.1084/jem.190.7.915; LEE CK, 1994, INFECT IMMUN, V62, P887, DOI 10.1128/IAI.62.3.887-891.1994; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Lycke N, 1999, J IMMUNOL, V163, P913; Matasar MJ, 2003, CURR ALLERGY ASTHM R, V3, P30, DOI 10.1007/s11882-003-0007-8; MICHETTI P, 1992, INFECT IMMUN, V60, P1786, DOI 10.1128/IAI.60.5.1786-1792.1992; Moneret-Vautrin DA, 2005, ALLERGY, V60, P443, DOI 10.1111/j.1398-9995.2005.00785.x; Neugut AI, 2001, ARCH INTERN MED, V161, P15, DOI 10.1001/archinte.161.1.15; REIMANN HJ, 1985, CLIN ALLERGY, V15, P195, DOI 10.1111/j.1365-2222.1985.tb02273.x; Reljic R, 2004, IMMUNOL LETT, V93, P51, DOI 10.1016/j.imlet.2004.01.015; Reljic R, 2006, IMMUNOL LETT, V107, P80, DOI 10.1016/j.imlet.2006.04.014; Sakamoto N, 2001, EUR J IMMUNOL, V31, P1310, DOI 10.1002/1521-4141(200105)31:5<1310::AID-IMMU1310>3.0.CO;2-N; Sampson HA, 2003, PEDIATRICS, V111, P1601; Shen YW, 2009, FORENSIC SCI INT, V186, P1, DOI 10.1016/j.forsciint.2008.12.007; Shibuya A, 2000, NAT IMMUNOL, V1, P441, DOI 10.1038/80886; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Strait RT, 2003, J IMMUNOL, V170, P3835, DOI 10.4049/jimmunol.170.7.3835; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Uren TK, 2003, J IMMUNOL, V170, P2531, DOI 10.4049/jimmunol.170.5.2531; Ventura MT, 2006, DIGEST LIVER DIS, V38, P732, DOI 10.1016/j.dld.2006.06.012	43	58	60	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					982	U234		10.1016/j.jaci.2011.01.034	http://dx.doi.org/10.1016/j.jaci.2011.01.034			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21354602	Green Accepted, Bronze			2022-12-18	WOS:000289055800020
J	Nomura, I; Morita, H; Hosokawa, S; Hoshina, H; Fukuie, T; Watanabe, M; Ohtsuka, Y; Shoda, T; Terada, A; Takamasu, T; Arai, K; Ito, Y; Ohya, Y; Saito, H; Matsumoto, K				Nomura, Ichiro; Morita, Hideaki; Hosokawa, Shinichi; Hoshina, Hiroaki; Fukuie, Tatsuki; Watanabe, Misa; Ohtsuka, Yoshikazu; Shoda, Tetsuo; Terada, Akihiko; Takamasu, Tetsuya; Arai, Katsuhiro; Ito, Yushi; Ohya, Yukihiro; Saito, Hirohisa; Matsumoto, Kenji			Four distinct subtypes of non-IgE-mediated gastrointestinal food allergies in neonates and infants, distinguished by their initial symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INDUCED ENTEROCOLITIS SYNDROME; CHALLENGE		[Nomura, Ichiro; Fukuie, Tatsuki; Ohya, Yukihiro] Natl Ctr Child Hlth & Dev, Div Allergy, Tokyo, Japan; [Arai, Katsuhiro] Natl Ctr Child Hlth & Dev, Div Gastroenterol, Tokyo, Japan; [Ito, Yushi] Natl Ctr Child Hlth & Dev, Div Neonatol, Tokyo, Japan; [Nomura, Ichiro; Morita, Hideaki; Saito, Hirohisa; Matsumoto, Kenji] Natl Res Ctr Child Hlth & Dev, Dept Allergy & Immunol, Tokyo, Japan; [Morita, Hideaki] Keio Univ, Sch Med, Dept Pediat, Tokyo, Japan; [Hosokawa, Shinichi] Osaka Med Ctr, Osaka, Japan; [Hosokawa, Shinichi] Res Inst Maternal & Child Hlth, Osaka, Japan; [Hoshina, Hiroaki] Kyorin Univ, Sch Med, Dept Pediat, Tokyo, Japan; [Watanabe, Misa] Toho Univ, Omori Med Ctr, Dept Pediat 1, Tokyo, Japan; [Ohtsuka, Yoshikazu] Juntendo Univ, Sch Med, Dept Pediat, Tokyo 113, Japan; [Shoda, Tetsuo] Yokohama City Minato Red Cross Hosp, Dept Pediat, Yokohama, Kanagawa, Japan; [Terada, Akihiko] Daido Hosp, Dept Pediat Allergy, Nagoya, Aichi, Japan; [Takamasu, Tetsuya] Kanagawa Childrens Med Ctr, Dept Allergy, Yokohama, Kanagawa, Japan	National Center for Child Health & Development - Japan; National Center for Child Health & Development - Japan; National Center for Child Health & Development - Japan; National Center for Child Health & Development - Japan; Keio University; Osaka Medical Center for Cancer & Cardiovascular Diseases; Kyorin University; Toho University; Juntendo University	Nomura, I (corresponding author), Natl Ctr Child Hlth & Dev, Div Allergy, Tokyo, Japan.	nomura-i@ncchd.go.jp; matsumoto-k@ncchd.go.jp	Morita, Hideaki/ADL-2008-2022; Morita, Hideaki/S-2214-2016	Morita, Hideaki/0000-0003-0928-8322; Shoda, Tetsuo/0000-0001-8337-5438; Fukuie, Tatsuki/0000-0003-4962-2137; Saito, Hirohisa/0000-0002-6630-8337				Chung HL, 2002, J ALLERGY CLIN IMMUN, V109, P150, DOI 10.1067/mai.2002.120562; Hwang JB, 2009, ARCH DIS CHILD, V94, P425, DOI 10.1136/adc.2008.143289; Lake AM, 2000, J PEDIATR GASTR NUTR, V30, pS58, DOI 10.1097/00005176-200001001-00009; Mehr S, 2009, PEDIATRICS, V123, pe459, DOI 10.1542/peds.2008-2029; Monti G, 2011, J ALLERGY CLIN IMMUN, V127, P679, DOI 10.1016/j.jaci.2010.10.017; Nowak-Wegrzyn A, 2009, CURR OPIN ALLERGY CL, V9, P371, DOI 10.1097/ACI.0b013e32832d6315; POWELL G K, 1986, Comprehensive Therapy, V12, P28; POWELL GK, 1978, J PEDIATR-US, V93, P553, DOI 10.1016/S0022-3476(78)80887-7; Savilahti E, 2000, J PEDIATR GASTR NUTR, V30, pS61, DOI 10.1097/00005176-200001001-00010; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Yen JM, 2010, PEDIATR NEONATOL, V51, P116, DOI 10.1016/S1875-9572(10)60021-6	11	58	61	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					685	U214		10.1016/j.jaci.2011.01.019	http://dx.doi.org/10.1016/j.jaci.2011.01.019			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21377037				2022-12-18	WOS:000288018400023
J	Song, Y; Qu, CF; Srivastava, K; Yang, N; Busse, P; Zhao, W; Li, XM				Song, Ying; Qu, Chunfeng; Srivastava, Kamal; Yang, Nan; Busse, Paula; Zhao, Wei; Li, Xiu-Min			Food allergy herbal formula 2 protection against peanut anaphylactic reaction is via inhibition of mast cells and basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut anaphylaxis; Chinese herbal medicine; mast cells/basophils; Fc epsilon RI	FC-EPSILON-RI; CYTOKINE PRODUCTION; IN-VIVO; PULMONARY INFLAMMATION; MOUSE BASOPHIL; UP-REGULATION; MURINE MODEL; T-CELL; IGE; EXPRESSION	Background: Mast cells and basophils are key effector cells of IgE-mediated anaphylactic reactions. The Chinese herbal formula, food allergy herbal formula 2 (FAHF-2), protects against peanut anaphylaxis in mice. However, the mechanisms underlying this effect are not fully elucidated. Objective: To investigate whether FAHF-2 inhibits mast cell/basophil numbers and IgE-mediated activation. Methods: Mice with peanut allergy (PNA mice) were treated with FAHF-2 intragastrically for 7 weeks and challenged intragastrically with peanut 1 day and 4 weeks posttreatment. Peripheral blood basophil numbers and peritoneal mast cell numbers and Fc epsilon RI expression were determined. Direct effects of FAHF-2 on the murine mast cell line MC/9, and effects of 4 fractions and 3 compounds isolated from FAHF-2 on rat basophilic leukemia cells (RBL-2H3) and human skin mast cells degranulation and on the IgE-mediated spleen tyrosine kinase signaling pathway, were determined. Results: Although all sham-treated PNA mice developed anaphylaxis, FAHF-2-treated PNA mice were protected against anaphylaxis after peanut challenge at 1 day and 4 weeks posttherapy. Reduction of peripheral blood basophils began after 1 week of treatment and continued for at least 4 weeks posttherapy. The number and FceRI expression of peritoneal mast cells were also significantly decreased 4 weeks posttherapy. FAHF-2-treated MC/9 cells showed significantly reduced IgE-induced FceRI expression, Fc epsilon RI g mRNA subunit expression, proliferation, and histamine release on challenge. Fraction 2 from FAHF-2 inhibited RBL-2H3 cell and human mast cell degranulation. Three compounds from fraction 2-berberine, palmatine, and jatrorrhizine-inhibited RBL-2H3 cell degranulation via suppressing spleen tyrosine kinase phosphorylation. Conclusion: Food allergy herbal formula 2 reduction of basophils and mast cell numbers as well as suppression of IgE-mediated mast cell activation may contribute to FAHF-2's persistent protection against peanut anaphylaxis. (J Allergy Clin Immunol 2010;126:1208-17.)	[Song, Ying; Qu, Chunfeng; Srivastava, Kamal; Yang, Nan; Busse, Paula; Li, Xiu-Min] Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, New York, NY 10029 USA; [Zhao, Wei] Virginia Commonwealth Univ, Div Allergy & Immunol, Dept Pediat, Richmond, VA USA	Icahn School of Medicine at Mount Sinai; Virginia Commonwealth University	Li, XM (corresponding author), Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	xiu-min.li@mssm.edu	Song, Ying/C-9949-2013; li, xiu/GXV-1745-2022	Song, Ying/0000-0001-7735-4008; 	Dugan Family Foundation; Food Allergy Initiative; National Institutes of Health [1R01AT001495-01A1, 2 R01 AT001495-05A1]; AAAAI; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001495] Funding Source: NIH RePORTER	Dugan Family Foundation; Food Allergy Initiative; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AAAAI; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	Supported by the Dugan Family Foundation, the Food Allergy Initiative, and National Institutes of Health grant no. 1R01AT001495-01A1 and no. 2 R01 AT001495-05A1 to X.-M.L.; Disclosure of potential conflict of interest: P. Busse is a consultant for ViroPharma, receives research support from the AAAAI and the NIH, and has provided legal consultation services/expert witness testimony in cases related to hereditary angioedema. W. Zhao receives research support from the NIH. X.-M. Li is a consultant for the Food Allergy Initiative, has received research support from the Food Allergy Initiative and the NIH, and has shares of US patent PCT/US05/08600 on FAHF-2 and Herbal Springs LLC. The rest of the authors have declared that they have no conflict of interest.	Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Busse PJ, 2007, CLIN EXP ALLERGY, V37, P1392, DOI 10.1111/j.1365-2222.2007.02775.x; Caldas ED, 2004, FOOD CHEM TOXICOL, V42, P599, DOI 10.1016/j.fct.2003.11.004; Casale TB, 2001, J ALLERGY CLIN IMMUN, V108, pS84, DOI 10.1067/mai.2001.116433; Chen XJ, 2000, APMIS, V108, P633, DOI 10.1034/j.1600-0463.2000.d01-9.x; Dolan SP, 2003, J AGR FOOD CHEM, V51, P1307, DOI 10.1021/jf026055x; Dvorak AM, 2000, BLOOD, V96, P1616, DOI 10.1182/blood.V96.4.1616.h8001608e_1616_1617; Galli SJ, 2000, CURR OPIN HEMATOL, V7, P32, DOI 10.1097/00062752-200001000-00007; Han EH, 2009, FOOD CHEM TOXICOL, V47, P1659, DOI 10.1016/j.fct.2009.04.025; Ishikawa Y, 2008, J MED FOOD, V11, P14, DOI 10.1089/jmf.2006.163; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Kattan JD, 2008, PHYTOTHER RES, V22, P651, DOI 10.1002/ptr.2357; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kitaura J, 2004, J IMMUNOL, V173, P4317, DOI 10.4049/jimmunol.173.7.4317; Kitaura J, 2003, P NATL ACAD SCI USA, V100, P12911, DOI 10.1073/pnas.1735525100; Lantz CS, 1997, J IMMUNOL, V158, P2517; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Li XM, 2001, J ALLERGY CLIN IMMUN, V108, P639, DOI 10.1067/mai.2001.118787; Li Y, 2008, J AGR FOOD CHEM, V56, P12073, DOI 10.1021/jf802732n; Luccioli S, 2002, J ALLERGY CLIN IMMUN, V110, P117, DOI 10.1067/mai.2002.125828; Passante E, 2009, INFLAMM RES, V58, P611, DOI [10.1007/s00011-009-0028-4, 10.1007/s00011-009-0644-z]; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Qian WZ, 2010, BIOCHEM BIOPH RES CO, V395, P547, DOI 10.1016/j.bbrc.2010.04.063; Qu C, 2007, CLIN EXP ALLERGY, V37, P846, DOI 10.1111/j.1365-2222.2007.02718.x; Raman P, 2004, J AGR FOOD CHEM, V52, P7822, DOI 10.1021/jf049150+; Srivastava KD, 2009, J ALLERGY CLIN IMMUN, V123, P443, DOI 10.1016/j.jaci.2008.12.1107; Srivastava KD, 2005, J ALLERGY CLIN IMMUN, V115, P171, DOI 10.1016/j.jaci.2004.10.003; Torrero MN, 2009, CLIN EXP ALLERGY, V39, P361, DOI 10.1111/j.1365-2222.2008.03154.x; US Food and Drug Administration Center for Drug Evaluation and Research, GUID IND BOT DRUG PR; Valent P, 2010, CURR OPIN HEMATOL, V17, P60, DOI 10.1097/MOH.0b013e328331fae9; Wang JL, 2007, CLIN EXP ALLERGY, V37, P651, DOI 10.1111/j.1365-2222.2007.02682.x; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; Zaidi AK, 2010, J IMMUNOL, V184, P1463, DOI 10.4049/jimmunol.0901865; Zhao W, 2005, J IMMUNOL, V175, P2635, DOI 10.4049/jimmunol.175.4.2635	35	58	64	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1208	U216		10.1016/j.jaci.2010.09.013	http://dx.doi.org/10.1016/j.jaci.2010.09.013			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	21134573	Bronze, Green Accepted			2022-12-18	WOS:000284947800020
J	Honda, T; Nakajima, S; Egawa, G; Ogasawara, K; Malissen, B; Miyachi, Y; Kabashima, K				Honda, Tetsuya; Nakajima, Saeko; Egawa, Gyohei; Ogasawara, Kouetsu; Malissen, Bernard; Miyachi, Yoshiki; Kabashima, Kenji			Compensatory role of Langerhans cells and langerin-positive dermal dendritic cells in the sensitization phase of murine contact hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							T-CELLS; IDENTIFICATION; POPULATION; DISTINCT; DEVELOP; SKIN; MICE		[Honda, Tetsuya; Nakajima, Saeko; Egawa, Gyohei; Miyachi, Yoshiki; Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan; [Egawa, Gyohei; Kabashima, Kenji] Kyoto Univ, Ctr Innovat Immunoregulat Technol & Therapeut, Grad Sch Med, Kyoto, Japan; [Ogasawara, Kouetsu] Tohoku Univ, Dept Immunobiol, Inst Dev Aging & Canc, Sendai, Miyagi 980, Japan; [Malissen, Bernard] Univ Aix Marseille 2, Ctr Immunol Marseille Luminy, Marseille, France	Kyoto University; Kyoto University; Tohoku University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Honda, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan.	hontetsu@kuhp.kyoto-u.ac.jp; kaba@kuhp.kyoto-u.ac.jp	Nakajima, Saeko/AAB-1577-2021; Malissen, Bernard/AAK-4659-2020; Kabashima, Kenji/G-2521-2014	Egawa, Gyohei/0000-0002-6101-4719; Malissen, Bernard/0000-0003-1340-9342; Kabashima, Kenji/0000-0002-0773-0554; Nakajima, Saeko/0000-0003-0831-1447				Bennett CL, 2005, J CELL BIOL, V169, P569, DOI 10.1083/jcb.200501071; Bennett CL, 2007, J IMMUNOL, V179, P6830, DOI 10.4049/jimmunol.179.10.6830; Bogunovic M, 2006, J EXP MED, V203, P2627, DOI 10.1084/jem.20060667; Bursch LS, 2007, J EXP MED, V204, P3147, DOI 10.1084/jem.20071966; Ginhoux F, 2007, J EXP MED, V204, P3133, DOI 10.1084/jem.20071733; Kaplan DH, 2005, IMMUNITY, V23, P611, DOI 10.1016/j.immuni.2005.10.008; Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004; Merad M, 2004, NAT MED, V10, P510, DOI 10.1038/nm1038; Nagao K, 2009, P NATL ACAD SCI USA, V106, P3312, DOI 10.1073/pnas.0807126106; Poulin LF, 2007, J EXP MED, V204, P3119, DOI 10.1084/jem.20071724	10	58	59	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1154	1156		10.1016/j.jaci.2009.12.005	http://dx.doi.org/10.1016/j.jaci.2009.12.005			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20226508				2022-12-18	WOS:000277686700027
J	Weidinger, S; Baurecht, H; Wagenpfeil, S; Henderson, J; Novak, N; Sandilands, A; Chen, HJ; Rodriguez, E; O'Regan, GM; Watson, R; Liao, HH; Zhao, YW; Barker, JNWN; Allen, M; Reynolds, N; Meggitt, S; Northstone, K; Smith, GD; Strobl, C; Stahl, C; Kneib, T; Klopp, N; Bieber, T; Behrendt, H; Palmer, CNA; Wichmann, HE; Ring, J; Illig, T; McLean, WHI; Irvine, AD				Weidinger, Stephan; Baurecht, Hansjoerg; Wagenpfeil, Stefan; Henderson, John; Novak, Natalija; Sandilands, Aileen; Chen, Huijia; Rodriguez, Elke; O'Regan, Grainne M.; Watson, Rosemarie; Liao, Haihui; Zhao, Yiwei; Barker, Jonathan N. W. N.; Allen, Michael; Reynolds, Nick; Meggitt, Simon; Northstone, Kate; Smith, George D.; Strobl, Carolin; Stahl, Caroline; Kneib, Thomas; Klopp, Norman; Bieber, Thomas; Behrendt, Heidrun; Palmer, Colin N. A.; Wichmann, H. -Erich; Ring, Johannes; Illig, Thomas; McLean, W. H. Irwin; Irvine, Alan D.			Analysis of the individual and aggregate genetic contributions of previously identified serine peptidase inhibitor Kazal type 5 (SPINK5), kallikrein-related peptidase 7 (KLK7), and filaggrin (FLG) polymorphisms to eczema risk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eczema; atopy; skin barrier; stratum corneum; epistasis	OF-FUNCTION MUTATIONS; CAUSE ICHTHYOSIS VULGARIS; ATOPIC-DERMATITIS; NETHERTON-SYNDROME; FUNCTION VARIANTS; RARE MUTATIONS; SKIN BARRIER; EARLY-ONSET; ASSOCIATION; PREDISPOSE	Background: Polymorphisms in the serine protease inhibitor gene serine peptidase inhibitor Kazal type 5 (SPINK-5) and the serine protease kallikrein-related peptidase 7 gene (KLK7) appear to confer risk to eczema in some cohorts, but these findings have not been widely replicated. These genes encode proteins thought to be involved in the regulation of posttranslation processing of filaggrin (FLG), the strongest identified genetic risk factor for eczema to date. Objectives: We sought to clarify the individual risk of eczema conferred by the SPINK5 polymorphism rs2303067 (Glu420Lys) and a previously described insertion in the 3' untranslated region of KLK7 and to examine potential epistatic effects between these variants and FLG mutations. Methods: Initially, we examined the effects of these polymorphisms and FLG in 486 unrelated patients from a German family-based study, an additional 287 German patients, and 418 unrelated Irish/English patients with eczema (n for 3 genes studied = 1191 vs 4544 control subjects). We then additionally studied the SPINK5 polymorphism and FLG mutations in 1583 patients with eczema from the Avon Longitudinal Study of Parents and Children cohort (sample size for 2 genes studied = 2774 vs 10,607 control subjects). Results: No association was seen with the SPINK5 or KLK7 variants in the case-control analysis; however, a weaker effect was observed for the SPINK5 variant with maternal transmission in the family-based study. No interactions were seen between the polymorphisms in KLK7, SPINK5, and FLG. Conclusion: The SPINK5 420LysSer mutation confers a risk of eczema when maternally inherited but is not a major eczema risk factor. The KLK7 insertion appears to confer no risk of eczema. We found no interaction between the SPINK5 risk allele or the putative KLK7 risk allele and FLG mutations.	[Weidinger, Stephan; Stahl, Caroline; Ring, Johannes] Tech Univ Munich, Dept Dermatol & Allergy Biederstein, D-80802 Munich, Germany; [Weidinger, Stephan; Baurecht, Hansjoerg; Rodriguez, Elke; Behrendt, Heidrun] Tech Univ Munich, German Res Ctr Environm Hlth, Helmholtz Zentrum Munich, Div Environm Dermatol & Allergy, D-80802 Munich, Germany; [Weidinger, Stephan; Baurecht, Hansjoerg; Rodriguez, Elke; Behrendt, Heidrun] Tech Univ Munich, ZAUM Ctr Allergy & Environm, D-80802 Munich, Germany; [Baurecht, Hansjoerg; Wagenpfeil, Stefan; Stahl, Caroline] Tech Univ Munich, IMSE, D-80802 Munich, Germany; [Wagenpfeil, Stefan; Ring, Johannes] Tech Univ Munich, GSISH, D-80802 Munich, Germany; [Henderson, John; Bieber, Thomas] Univ Bristol, Dept Community Based Med, Bristol BS8 1TH, Avon, England; [Novak, Natalija] Univ Bonn, Dept Dermatol & Allergy, D-5300 Bonn, Germany; [Sandilands, Aileen; Chen, Huijia; Liao, Haihui; Zhao, Yiwei; McLean, W. H. Irwin] Univ Dundee, Epithelial Genet Grp, Human Genet Unit, Div Pathol & Neurosci, Dundee DD1 4HN, Scotland; [O'Regan, Grainne M.; Watson, Rosemarie; Irvine, Alan D.] Our Ladys Childrens Hosp, Dept Pediat Dermatol, Dublin, Ireland; [Barker, Jonathan N. W. N.; Allen, Michael] Guys Hosp, St Johns Inst Dermatol, London, England; [Reynolds, Nick; Meggitt, Simon] Univ Newcastle, Dept Dermatol, Callaghan, NSW 2308, Australia; [Northstone, Kate] Univ Bristol, Dept Med Sociol, Bristol BS8 1TH, Avon, England; [Smith, George D.] Univ Bristol, MRC, Ctr Causal Analyses Translat Epidemiol, Bristol BS8 1TH, Avon, England; [Strobl, Carolin; Kneib, Thomas] Univ Munich, Dept Stat, Munich, Germany; [Klopp, Norman; Wichmann, H. -Erich; Illig, Thomas] German Res Ctr Environm Hlth, Helmholtz Zentrum Munich, Dept Epidemiol, Munich, Germany; [Palmer, Colin N. A.] Univ Dundee, Biomed Res Ctr, Populat Phamacogenet Grp, Dundee DD1 4HN, Scotland; [Irvine, Alan D.] Univ Dublin Trinity Coll, Dept Clin Med, Dublin 2, Ireland	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Technical University of Munich; Technical University of Munich; Technical University of Munich; University of Bristol; University of Bonn; University of Dundee; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Newcastle; University of Bristol; University of Bristol; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Dundee; Trinity College Dublin	Weidinger, S (corresponding author), Tech Univ Munich, Dept Dermatol & Allergy Biederstein, D-80802 Munich, Germany.	weidinger@lrz.tum.de; irvinea@tcd.ie	Study, GoDARTS/K-9448-2016; Northstone, Kate/A-8165-2011; Palmer, Colin NA/C-7053-2008; Irvine, Alan D/A-3982-2008; Davey Smith, George/A-7407-2013; Ring, Johannes/GLN-4341-2022; Rodríguez, Elke/C-4259-2013; Baurecht, Hansjoerg/C-4035-2013; McLean, William HI/C-6352-2009; Weidinger, Stephan/C-8461-2011; Wichmann, Heinz Erich/AAA-5695-2022	Northstone, Kate/0000-0002-0602-1983; Palmer, Colin NA/0000-0002-6415-6560; Irvine, Alan D/0000-0002-9048-2044; Davey Smith, George/0000-0002-1407-8314; Ring, Johannes/0000-0001-8236-3152; Rodríguez, Elke/0000-0003-3692-3950; Baurecht, Hansjoerg/0000-0002-9265-5594; Weidinger, Stephan/0000-0003-3944-252X; Kneib, Thomas/0000-0003-3390-0972; McLean, William Henry Irwin/0000-0001-5539-5757; Strobl, Carolin/0000-0003-0952-3230; Venkatasubramanian, Siddharth/0000-0002-5860-0768; s, hema/0000-0002-3440-9475; Barker, Jonathan/0000-0002-9030-183X; Reynolds, Nick/0000-0002-6484-825X	German Ministry of Education and Research (BMBF); National Genome Research Network (NGFN) [NUW-S31T05]; University Hospital "Rechts der Isar." Technical University Munich [KKF-07/04, KKF-27/05]; The UK Medical Research Council; Wellcome Trust; University of Bristol; Department of Paediatric Dermatology. Our Lady's Childlen's Hospital, Dublin; Chief Scientists Office of the Scottish Executive Generation Scotland Initiative; British Skin Foundation/National Eczema Association; Dystrophic Epidermolysis Bullosa Research Association; Medical Research Council [G07003 14]; Medical Research Council [G9815508, G0700314, G0600705] Funding Source: researchfish; MRC [G0600705, G0700314] Funding Source: UKRI	German Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); National Genome Research Network (NGFN); University Hospital "Rechts der Isar." Technical University Munich; The UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); University of Bristol; Department of Paediatric Dermatology. Our Lady's Childlen's Hospital, Dublin; Chief Scientists Office of the Scottish Executive Generation Scotland Initiative; British Skin Foundation/National Eczema Association; Dystrophic Epidermolysis Bullosa Research Association; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the German Ministry of Education and Research (BMBF) as part of the National Genome Research Network (NGFN) with grain NUW-S31T05. S. Weidinger and S. Wagenpfeil are supported by research grants KKF-07/04 and KKF-27/05 of the University Hospital "Rechts der Isar." Technical University Munich. In addition. Dr Weidinger is supported by a grant from the "Wilhelm-Vaillant Stiftung" The UK Medical Research Council, the Wellcome Trust. and the University of Bristol provide core Support for Avon Longitudinal Study of Parents and Children. Additional funding was obtained from the Department of Paediatric Dermatology. Our Lady's Childlen's Hospital, Dublin, and by a grant from Tenovus (Tayside) to C.N.P. C.N.P. is Supported by the Chief Scientists Office of the Scottish Executive Generation Scotland Initiative. The McLean laboratory is Supported by grants from British Skin Foundation/National Eczema Association. the Pachyonychia Congenita Project. the Dystrophic Epidermolysis Bullosa Research Association. the Medical Research Council (reference no. G07003 14). and anonymous donations front atopic families in the Tayside region of Scotland.	Barker JNWN, 2007, J INVEST DERMATOL, V127, P564, DOI 10.1038/sj.jid.5700587; Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Bitoun E, 2003, HUM MOL GENET, V12, P2417, DOI 10.1093/hmg/ddg247; BREZGER A, 2007, BAYESX SOFTWARE BAYE; Brown SJ, 2008, J ALLERGY CLIN IMMUN, V121, P940, DOI 10.1016/j.jaci.2008.01.013; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Descargues P, 2005, NAT GENET, V37, P56, DOI 10.1038/ng1493; Ekelund E, 2008, ACTA DERM-VENEREOL, V88, P15, DOI 10.2340/00015555-0383; FLEISS JL, 1980, BIOMETRICS, V36, P343, DOI 10.2307/2529990; Folster-Holst R, 2005, BRIT J DERMATOL, V152, P1365, DOI 10.1111/j.1365-2133.2005.06602.x; Forster MR, 2000, J MATH PSYCHOL, V44, P205, DOI 10.1006/jmps.1999.1284; Glazier AM, 2002, SCIENCE, V298, P2345, DOI 10.1126/science.1076641; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Hubiche T, 2007, ACTA DERM-VENEREOL, V87, P499, DOI 10.2340/00015555-0329; Hudson TJ, 2006, NAT GENET, V38, P399, DOI 10.1038/ng0406-399; Jones RW, 2000, EUR J HUM GENET, V8, P653, DOI 10.1038/sj.ejhg.5200502; Kato A, 2003, BRIT J DERMATOL, V148, P665, DOI 10.1046/j.1365-2133.2003.05243.x; Komatsu N, 2002, J INVEST DERMATOL, V118, P436, DOI 10.1046/j.0022-202x.2001.01663.x; Lunetta KL, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-32; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; McLean WHI, 2007, J INVEST DERMATOL, V127, P8, DOI 10.1038/sj.jid.5700609; Moore JH, 2003, HUM HERED, V56, P73, DOI 10.1159/000073735; Moore JH, 2005, NAT GENET, V37, P13, DOI 10.1038/ng0105-13; MORAR N, 2006, J ALLERGY CLIN IMMUN, V118, P5; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; Morar N, 2007, J INVEST DERMATOL, V127, P1667, DOI 10.1038/sj.jid.5700739; Nishio Y, 2003, GENES IMMUN, V4, P515, DOI 10.1038/sj.gene.6363889; Nomura T, 2008, J INVEST DERMATOL, V128, P1436, DOI 10.1038/sj.jid.5701205; Nomura T, 2007, J ALLERGY CLIN IMMUN, V119, P434, DOI 10.1016/j.jaci.2006.12.646; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Rathmann W, 2003, DIABETOLOGIA, V46, P182, DOI 10.1007/s00125-002-1025-0; RESING KA, 1989, J BIOL CHEM, V264, P1837; RESING KA, 1995, J BIOL CHEM, V270, P28193; RESING KA, 1984, J CELL BIOL, V99, P1372, DOI 10.1083/jcb.99.4.1372; Rodriguez E, 2008, PHARMACOGENOMICS, V9, P399, DOI 10.2217/14622416.9.4.399; Rogers AJ, 2007, J ALLERGY CLIN IMMUN, V120, P1332, DOI 10.1016/j.jaci.2007.09.037; Ruether A, 2006, BRIT J DERMATOL, V155, P1093, DOI 10.1111/j.1365-2133.2006.07500.x; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sandilands A, 2006, J INVEST DERMATOL, V126, P1770, DOI 10.1038/sj.jid.5700459; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V119, P1462, DOI 10.1016/j.jaci.2007.02.013; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Stemmler S, 2007, J INVEST DERMATOL, V127, P722, DOI 10.1038/sj.jid.5700579; Strobl C, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-25; TEAM RDC, 2007, R LANGUAGE ENV STAT; van Beijsterveldt CEM, 2007, EUR RESPIR J, V29, P516, DOI 10.1183/09031936.00065706; Vasilopoulos Y, 2004, J INVEST DERMATOL, V123, P62, DOI 10.1111/j.0022-202X.2004.22708.x; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; Weedon MN, 2006, PLOS MED, V3, P1877, DOI 10.1371/journal.pmed.0030374; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Weidinger S, 2007, J INVEST DERMATOL, V127, P724, DOI 10.1038/sj.jid.5700630; Weinberg CR, 1999, AM J HUM GENET, V65, P229, DOI 10.1086/302466; WILLIAMS JC, 1994, VA J SOC POLY L, V1, P383	57	58	59	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					560	568		10.1016/j.jaci.2008.05.050	http://dx.doi.org/10.1016/j.jaci.2008.05.050			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18774391	Green Submitted			2022-12-18	WOS:000259234000018
J	Severino, MG; Cortellini, G; Bonadonna, P; Francescato, E; Panzini, I; Macchia, D; Campi, P; Spadolini, I; Canonica, WG; Passalacqua, G				Severino, Maurizio G.; Cortellini, Gabriele; Bonadonna, Patrizia; Francescato, Elisabetta; Panzini, Ilaria; Macchia, Donatella; Campi, Paolo; Spadolini, Igino; Canonica, Walter G.; Passalacqua, Giovanni			Sublingual immunotherapy for large local reactions caused by honeybee sting: A double-blind, placebo-controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hymenoptera venom allergy; sublingual immunotherapy; large local reaction; sting challenge	ALLERGIC RHINITIS; VENOM IMMUNOTHERAPY; CHILDREN; IMPACT; RHINOCONJUNCTIVITIS; EFFICACY; ASTHMA	Background: Sublingual immunotherapy (SLIT) proved effective and safe in respiratory allergy, and thus its use in hymenoptera allergy can be hypothesized. Objective: We sought to assess, in a proof-of-concept study, whether SLIT might potentially be beneficial in hymenoptera allergy. The sting challenge in large local reactions (LLRs) was used to test this hypothesis. Methods: We performed a randomized, double-blind, placebo-controlled study involving patients with LLRs who were monosensitized to honeybee. After the baseline sting challenge, they were randomized to either SLIT or placebo for 6 months. The treatment (Anallergo, Florence, Italy) involved a 6-week build-up period, followed by maintenance with 525 mu g of venom monthly. The sting challenge was repeated after 6 months. Results: Thirty patients (18 male patients; mean age, 44.5 years) were enrolled, and 26 completed the study, with 1 dropout in the active group and 3 dropouts in the placebo group. In the active group the median of the peak maximal diameter of the LLRs decreased from 20.5 to 8.5 cm (P =.014), whereas no change was seen in the placebo group (23.0 vs 20.5 cm, P = not significant). The diameter was reduced more than 50% in 57% of patients. One case of generalized urticaria occurred in a placebo-treated patient at sting challenge. No adverse event caused by SLIT was reported. Conclusion: Honeybee SLIT significantly reduced the extent of LLRs, and its safety profile was good. Although LLRs are not an indication for immunotherapy, this proof-of-concept study suggests that SLIT in hymenoptera allergy deserves further investigation. Trials involving systemic reactions and dose-ranging studies are needed.	[Canonica, Walter G.; Passalacqua, Giovanni] Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy; [Severino, Maurizio G.; Macchia, Donatella; Campi, Paolo] Nuovo Osped San Giovanni Dio, Allergy Clin, Florence, Italy; [Bonadonna, Patrizia] Verona Gen Hosp, Allergy Unit, Verona, Italy; [Francescato, Elisabetta] Entomon SAS, Florence, Italy; [Spadolini, Igino] Anallergo, Florence, Italy	University of Genoa; Presidio Ospedaliero San Giovanni di Dio	Passalacqua, G (corresponding author), Univ Genoa, Dept Internal Med, Padiglione Maragliano,Lgo R Benzi 10, I-16132 Genoa, Italy.	passalacqua@unige.it	canonica, giorgio walter/ABF-2037-2020	canonica, giorgio walter/0000-0001-8467-2557; Macchia, Donatella/0000-0001-9143-4186				Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bonifazi F, 2005, ALLERGY, V60, P1459, DOI 10.1111/j.1398-9995.2005.00960.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Dubois AEJ, 2003, CURR OPIN ALLERGY CL, V3, P283, DOI [10.1097/00130832-200308000-00008, 10.1097/01.all.0000083956.99396.fe]; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Golden DBK, 2006, J ALLERGY CLIN IMMUN, V117, P670, DOI 10.1016/j.jaci.2005.12.1313; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; GREEN AW, 1980, J ALLERGY CLIN IMMUN, V66, P186, DOI 10.1016/0091-6749(80)90037-8; Hamilton RG, 2001, ANN ALLERG ASTHMA IM, V87, P134, DOI 10.1016/S1081-1206(10)62207-7; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; Kelly D, 2007, J ALLERGY CLIN IMMUN, V119, pS79, DOI 10.1016/j.jaci.2006.11.333; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; MAURIELLO PM, 1984, J ALLERGY CLIN IMMUN, V74, P494, DOI 10.1016/0091-6749(84)90384-1; Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; Nettis E, 2007, BRIT J DERMATOL, V156, P674, DOI 10.1111/j.1365-2133.2006.07738.x; Pajno GB, 2003, CLIN EXP ALLERGY, V33, P1641, DOI 10.1111/j.1365-2222.2003.01809.x; Pajno GB, 2007, J ALLERGY CLIN IMMUN, V120, P164, DOI 10.1016/j.jaci.2007.04.008; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Passalacqua G, 2007, J ALLERGY CLIN IMMUN, V119, P881, DOI 10.1016/j.jaci.2007.01.045; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; Rolinck-Werninghaus C, 2005, INT ARCH ALLERGY IMM, V136, P134, DOI 10.1159/000083320; Savolainen J, 2007, ALLERGY, V62, P949, DOI 10.1111/j.1398-9995.2007.01426.x; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; *WHO, 1998, ALLERGY S72, V53, P3; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x	28	58	59	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					44	48		10.1016/j.jaci.2008.03.031	http://dx.doi.org/10.1016/j.jaci.2008.03.031			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18468672	Bronze			2022-12-18	WOS:000257605100007
J	Casale, TB; Stokes, JR				Casale, Thomas B.; Stokes, Jeffrey R.			Immunomodulators for allergic respiratory disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						immunomodulators; monoclonal antibodies; transcription factors; cytokine blockers	ANTI-IGE ANTIBODY; FC-EPSILON-RI; HUMANIZED MONOCLONAL-ANTIBODY; ATOPIC-DERMATITIS; AIRWAY HYPERRESPONSIVENESS; SUPLATAST TOSILATE; ANTI-INTERLEUKIN-5 ANTIBODY; MEPOLIZUMAB THERAPY; ANTI-IL-5 TREATMENT; RAGWEED ALLERGY	New knowledge about the pathogenesis of allergic and immunologic diseases has led to a variety of novel targeted therapeutic approaches. Many immunomodulators are currently under development for the therapy of asthma and allergic and immunologic diseases and are undergoing human clinical trials. The study of immunomodulators in human subjects is ultimately required to determine their therapeutic utility because several agents showing promise in in vitro and animal models have failed in human studies. Novel therapeutic approaches include Toll-like receptor 4 and 9 agonists, immunostimulatory oligodeoxynucleotides, oral and parenterally administered cytokine blockers, and specific cytokine receptor antagonists. Transcription factor modulators targeting syk kinase, peroxisome proliferator-activated receptor gamma, and nuclear factor kappa B are also being evaluated for the treatment of allergic diseases, especially asthma. The anti-IgE mAb omalizumab is already used for the treatment of allergic asthma, but its potential role for other allergic diseases has yet to be clearly defined. Overall, the development of new agents that inhibit specific immunopathogenic mechanisms holds promise for beneficial outcomes for patients with the least amount of risk. However,agents that are too specific in their targets might not exhibit therapeutic benefits because of the redundancy of the immune system and the heterogeneity of diseases such as asthma. The goal of this review is to summarize the data from human clinical trials with immunomodulators, discussing the rationale for their use, efficacy results, and putative adverse events associated with them.	[Casale, Thomas B.; Stokes, Jeffrey R.] Creighton Univ, Dept Med, Div Allergy Immunol, Omaha, NE 68178 USA	Creighton University	Casale, TB (corresponding author), Creighton Univ, Dept Internal Med, Div Allergy Immunol, 601 N 30 St,Suite 5850, Omaha, NE 68131 USA.	tbcasale@creighton.edu	Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377				Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Bernstein DI, 2007, J ALLERGY CLIN IMMUN, V119, pS78, DOI 10.1016/j.jaci.2006.11.332; Berry M, 2007, CURR OPIN PHARMACOL, V7, P279, DOI 10.1016/j.coph.2007.03.001; Bhattacharjee RN, 2006, MINI-REV MED CHEM, V6, P287, DOI 10.2174/138955706776073411; Blanchard C, 2005, CLIN EXP ALLERGY, V35, P1096, DOI 10.1111/j.1365-2222.2005.02299.x; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; Bree A, 2007, J ALLERGY CLIN IMMUN, V119, P1251, DOI 10.1016/j.jaci.2007.02.009; Brightling C, 2008, J ALLERGY CLIN IMMUN, V121, P5, DOI 10.1016/j.jaci.2007.10.028; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Buttner C, 2003, EUR RESPIR J, V21, P799, DOI 10.1183/09031936.03.00027302; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; Casale TB, 2006, ANN ALLERG ASTHMA IM, V97, P454, DOI 10.1016/S1081-1206(10)60934-9; Chervinsky P, 2003, ANN ALLERG ASTHMA IM, V91, P160, DOI 10.1016/S1081-1206(10)62171-0; Conte Michael S, 2005, Vasc Endovascular Surg, V39, P15, DOI 10.1177/153857440503900102; Corren J, 2003, J ALLERGY CLIN IMMUN, V111, P87, DOI 10.1067/mai.2003.49; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, P1373, DOI 10.1016/j.jaci.2007.09.032; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Easthope S, 2001, DRUGS, V61, P253, DOI 10.2165/00003495-200161020-00008; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Gagliardo R, 2003, AM J RESP CRIT CARE, V168, P1190, DOI 10.1164/rccm.200205-479OC; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; Gauvreau GM, 2006, AM J RESP CRIT CARE, V174, P15, DOI 10.1164/rccm.200601-057OC; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Hanf G, 2004, EUR RESPIR J, V23, P414, DOI 10.1183/09031936.04.00024504; Hashimoto Y, 2002, DIABETES CARE, V25, P401, DOI 10.2337/diacare.25.2.401; HAYASHI R, 2006, AM J MED, V119, P897; HAYASHI R, 2006, AM J MED, V19, pE1; Higgins D, 2006, J ALLERGY CLIN IMMUN, V118, P504, DOI 10.1016/j.jaci.2006.05.001; Horiguchi T, 2001, J ASTHMA, V38, P331, DOI 10.1081/JAS-100000041; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Kline Joel N, 2007, Proc Am Thorac Soc, V4, P283, DOI 10.1513/pats.200701-019AW; Klion AD, 2004, BLOOD, V103, P2939, DOI 10.1182/blood-2003-10-3620; Krathen RA, 2005, J AM ACAD DERMATOL, V53, P338, DOI 10.1016/j.jaad.2005.02.014; Krieg Arthur M, 2007, Proc Am Thorac Soc, V4, P289, DOI 10.1513/pats.200701-021AW; Krieg AM, 2007, J CLIN INVEST, V117, P1184, DOI 10.1172/JCI31414; Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Lane JE, 2006, J AM ACAD DERMATOL, V54, P68, DOI 10.1016/j.jaad.2005.09.030; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Limb SL, 2007, J ALLERGY CLIN IMMUN, V120, P1378, DOI 10.1016/j.jaci.2007.09.022; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Marshall JD, 2001, J ALLERGY CLIN IMMUN, V108, P191, DOI 10.1067/mai.2001.116984; Meltzer EO, 2005, J ALLERGY CLIN IMMUN, V115, P791, DOI 10.1016/j.jaci.2005.01.040; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; Nelson HS, 2005, J ALLERGY CLIN IMMUN, V115, P676, DOI 10.1016/j.jaci.2005.01.037; *NIH NAT HEART LUN, 2007, PUBL NIH NAT HEART L; Noga O, 2003, INT ARCH ALLERGY IMM, V131, P46, DOI 10.1159/000070434; Oldhoff JM, 2005, ALLERGY, V60, P693, DOI 10.1111/j.1398-9995.2005.00791.x; Plewako H, 2002, J ALLERGY CLIN IMMUN, V110, P68, DOI 10.1067/mai.2002.125488; Plotz S, 2003, NEW ENGL J MED, V349, P2334, DOI 10.1056/NEJMoa031261; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Richards ML, 2004, J MED CHEM, V47, P6451, DOI 10.1021/jm049288j; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P1144, DOI 10.1016/j.jaci.2004.03.003; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Spears M, 2006, CLIN EXP ALLERGY, V36, P1494, DOI 10.1111/j.1365-2222.2006.02604.x; Spector SL, 2007, ANN ALLERG ASTHMA IM, V99, P190, DOI 10.1016/S1081-1206(10)60644-8; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Tamaoki J, 2000, LANCET, V356, P273, DOI 10.1016/S0140-6736(00)02501-0; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Vignola AM, 2004, ALLERGY, V59, P709, DOI 10.1111/j.1398-9995.2004.00550.x; Vigo PG, 2006, J AM ACAD DERMATOL, V55, P168, DOI 10.1016/j.jaad.2005.12.045; Yoshida M, 2002, J ASTHMA, V39, P545, DOI 10.1081/JAS-120004925; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3	70	58	61	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					288	296		10.1016/j.jaci.2007.11.040	http://dx.doi.org/10.1016/j.jaci.2007.11.040			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18269921				2022-12-18	WOS:000253337800001
J	Chew, GL; Perzanowski, MS; Canfield, SM; Goldstein, IF; Mellins, RB; Hoepner, LA; Ashby-Thompson, M; Jacobson, JS				Chew, Ginger L.; Perzanowski, Matthew S.; Canfield, Stephen M.; Goldstein, Inge F.; Mellins, Robert B.; Hoepner, Lori A.; Ashby-Thompson, Maxine; Jacobson, Judith S.			Cockroach allergen levels and associations with cockroach-specific IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cockroach; cat; mouse; allergen; IgE; inner-city; atopy; allergy; children	INNER-CITY CHILDREN; MIDDLE-CLASS CHILDREN; NEW-YORK-CITY; MOUSE ALLERGEN; INDOOR ALLERGENS; BIRTH COHORT; RISK-FACTORS; MONOCLONAL-ANTIBODIES; CHILDHOOD ASTHMA; MEXICAN-AMERICAN	Background: Among inner-city children with asthma, cockroach allergen exposure has been associated with allergic sensitization. Objective: We hypothesized that cockroach allergen levels in homes would be associated with sensitization to cockroach allergens in children. Methods: From a low-income preschool program, 341 four-year-old children selected on the basis of the willingness of their caregivers to participate in the study were enrolled. Dust from their beds and kitchens were analyzed for cockroach (Bla g 2), mouse (mouse urinary proteins), and cat allergens (Fel d 1). Serum samples were analyzed for allergen-specific IgE antibodies by immunoassay. Results: Bla g 2 levels > 1 U/g in children's bed and kitchen dust samples were independently associated with cockroach-specific IgE (odds ratio [OR], 2.7; 95% CI, 1.1-6.4; and OR, 3.4; 95% CI, 1.2-9.4, respectively), adjusting for sex, ethnicity, asthma, pet ownership, mother's allergic sensitization, environmental tobacco smoke, and having lived in other homes. Bla g 2 was associated (OR, 3.6; 95% CI, 1.0-13.1) with cockroach-specific IgE among children with asthma. Among children without asthma, the ORs were similar (OR, 3.0; 95% CI, 0.9-10.3), but the association was not statistically significant. Conclusion: Concentrations of the major cockroach allergen, Bla g 2, in settled dust were associated with cockroach-specific IgE independent of other factors in a cohort of 4-year-old inner-city children.	[Chew, Ginger L.; Perzanowski, Matthew S.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA; [Goldstein, Inge F.; Ashby-Thompson, Maxine; Jacobson, Judith S.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA; [Hoepner, Lori A.] Columbia Univ, Mailman Sch Publ Hlth, Data Coordinating Ctr, New York, NY 10032 USA; [Canfield, Stephen M.] Columbia Univ, Coll Phys & Surg, Dept Med, Div Pulm, New York, NY 10027 USA; [Hoepner, Lori A.] Columbia Univ, Coll Phys & Surg, Pediat Pulmonary Div, New York, NY 10027 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Chew, GL (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, 60 Haven Ave,B-1, New York, NY 10032 USA.	cg288@columbia.edu	Ashby-Thompson, Maxine/AGZ-3894-2022	Ashby-Thompson, Maxine/0000-0001-9752-2208; Hoepner, Lori/0000-0002-4404-8140	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL068236] Funding Source: Medline; NIEHS NIH HHS [P30 ES009089] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Almqvist C, 2003, J ALLERGY CLIN IMMUN, V111, P800, DOI 10.1067/mai.2003.1334; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; Chew GL, 2003, ENVIRON HEALTH PERSP, V111, P1348, DOI 10.1289/ehp.6124; Cohn RD, 2004, J ALLERGY CLIN IMMUN, V113, P1167, DOI 10.1016/j.jaci.2003.12.592; Corburn J, 2006, HEALTH PLACE, V12, P167, DOI 10.1016/j.healthplace.2004.11.002; DEANDRADE AD, 1995, J ALLERGY CLIN IMMUN, V95, P1158, DOI 10.1016/S0091-6749(95)70071-4; Eldeirawi K, 2005, J ALLERGY CLIN IMMUN, V116, P42, DOI 10.1016/j.jaci.2005.03.041; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; Garg R., 2003, ASTHMA FACTS, VSecond; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Goldstein I F, 1987, Experientia Suppl, V51, P133; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Holt Patrick G, 2004, Paediatr Respir Rev, V5 Suppl A, pS27, DOI 10.1016/S1526-0542(04)90006-1; Holt PG, 2005, NAT IMMUNOL, V6, P957, DOI 10.1038/ni1005-957; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Johnson CC, 2004, J ALLERGY CLIN IMMUN, V114, P105, DOI 10.1016/j.jaci.2004.04.007; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Kramer U, 2004, BRIT J DERMATOL, V150, P111, DOI 10.1111/j.1365-2133.2004.05710.x; Lara M, 2006, PEDIATRICS, V117, P43, DOI 10.1542/peds.2004-1714; Matsui EC, 2004, J ALLERGY CLIN IMMUN, V113, P910, DOI 10.1016/j.jaci.2004.02.034; Matsui EC, 2003, J ALLERGY CLIN IMMUN, V112, P87, DOI 10.1067/mai.2003.1588; Miller RL, 2001, AM J RESP CRIT CARE, V164, P995, DOI 10.1164/ajrccm.164.6.2011107; Nickel R, 2005, CLIN EXP ALLERGY, V35, P619, DOI 10.1111/j.1365-2222.2005.02237.x; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Perzanowski MS, 2006, J ALLERGY CLIN IMMUN, V117, P1082, DOI 10.1016/j.jaci.2005.12.1348; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Rauh VA, 2002, ENVIRON HEALTH PERSP, V110, P323, DOI 10.1289/ehp.02110s2323; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Rylander R, 1998, MEDIAT INFLAMM, V7, P105, DOI 10.1080/09629359891252; Salari K, 2005, GENET EPIDEMIOL, V29, P76, DOI 10.1002/gepi.20079; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Savilahti R, 2001, ALLERGY, V56, P175, DOI 10.1034/j.1398-9995.2001.056002175.x; Scirica CV, 2007, J ALLERGY CLIN IMMUN, V119, P81, DOI 10.1016/j.jaci.2006.09.002; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; VERHOEFF AP, 1994, CLIN EXP ALLERGY, V24, P1061, DOI 10.1111/j.1365-2222.1994.tb02744.x; World Health Organization, 2003, PREV ALL ALL ASTHM	48	58	58	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					240	245		10.1016/j.jaci.2007.08.024	http://dx.doi.org/10.1016/j.jaci.2007.08.024			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17936887				2022-12-18	WOS:000252372000037
J	Kelly, A; Bowen, H; Jee, YK; Mahfiche, N; Soh, C; Lee, T; Hawrylowicz, C; Lavender, P				Kelly, Audrey; Bowen, Holly; Jee, Young-Koo; Mahfiche, Nabila; Soh, Cecilia; Lee, Tak; Hawrylowicz, Catherine; Lavender, Paul			The glucocorticoid receptor beta isoform can mediate transcriptional repression by recruiting histone deacetylases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokine gene regulation; glucocorticoid receptor; transcription	INSENSITIVE ASTHMA; POMC GENE; T-CELLS; EXPRESSION; LYMPHOCYTES; MECHANISMS; DISEASE; ELEMENT; BINDING; DNA	Background: The glucocorticoid receptor (GR) is able to participate in regulation of transcription by a variety of mechanisms, one of which involves DNA binding and recruitment of regulatory cofactors. The best-studied forms of the receptor are the 777-amino-acid alpha and the 742-amino-acid beta variants. The beta isoform, which does not bind cortisol in human subjects, has been proposed to be a dominant-negative inhibitor of the transcriptional activation-competent GR alpha isoform. Objective: GR alpha has roles in both transcriptional activation and repression. We wished to determine the influence of GR beta on genes that are normally transcriptionally repressed by glucocorticoids. We studied IL5 and IL13, which both contribute to the asthmatic phenotype. Methods: We used transient transfection systems and coimmunoprecipitation experiments to determine whether GR beta has repressive activity on the promoters of the human IL5 and IL13 genes. Results: GRP is able to act as a transcriptional repressor of cytokine genes and mediates its function through the recruitment of histone deacetylase complexes. Conclusion: GR alpha and GR beta act in a similar manner on IL5 and IL13 promoters, serving to repress transcription. In this circumstance GR beta does not act as a dominant-negative inhibitor of GR alpha.	[Kelly, Audrey; Bowen, Holly; Mahfiche, Nabila; Soh, Cecilia; Lee, Tak; Hawrylowicz, Catherine; Lavender, Paul] Guys Hosp, Asthma UK Ctr Allerg Mech Asthma, MRC, Univ London Kings Coll, London SE1 9RT, England; [Jee, Young-Koo] Dankook Univ, Coll Med, Div Allergy & Pulmonary Med, Cheonan, South Korea	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Dankook University	Lavender, P (corresponding author), Guys Hosp, Asthma UK Ctr Allerg Mech Asthma, MRC, Univ London Kings Coll, 5th Floor Thomas Guy House, London SE1 9RT, England.	paul.lavender@kcl.ac.uk	Lee, Tak/AAA-9526-2020; Hawrylowicz, Catherine/Q-8483-2017	Lee, Tak/0000-0002-7554-4059; Lavender, Paul/0000-0001-8710-0263; Jee, Young-Koo/0000-0001-5800-8038; Hawrylowicz, Catherine/0000-0002-2337-7463	Medical Research Council [G0400503B] Funding Source: researchfish; Asthma UK [06/032] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK		BAMBERGER CM, 1995, J CLIN INVEST, V95, P2435, DOI 10.1172/JCI117943; Bilodeau S, 2006, GENE DEV, V20, P2871, DOI 10.1101/gad.1444606; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Codlin S, 2003, J ALLERGY CLIN IMMUN, V111, P826, DOI 10.1067/mai.2003.1377; Cousins DJ, 2002, J IMMUNOL, V169, P2498, DOI 10.4049/jimmunol.169.5.2498; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; Goleva E, 2006, AM J RESP CRIT CARE, V173, P607, DOI 10.1164/rccm.200507-1046OC; Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600, DOI 10.1164/ajrccm.159.5.9804131; Hawrylowicz C, 2002, J ALLERGY CLIN IMMUN, V109, P369, DOI 10.1067/mai.2002.121455; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; Honda M, 2000, GASTROENTEROLOGY, V118, P859, DOI 10.1016/S0016-5085(00)70172-7; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Jee YK, 2005, J BIOL CHEM, V280, P23243, DOI 10.1074/jbc.M503659200; Lavender P, 1997, ONCOGENE, V14, P2721, DOI 10.1038/sj.onc.1201243; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; Lewis-Tuffin LJ, 2007, MOL CELL BIOL, V27, P2266, DOI 10.1128/MCB.01439-06; Li LB, 2006, J LEUKOCYTE BIOL, V79, P818, DOI 10.1189/jlb.0805466; Lu NZ, 2005, MOL CELL, V18, P331, DOI 10.1016/j.molcel.2005.03.025; Oakley RH, 1996, J BIOL CHEM, V271, P9550, DOI 10.1074/jbc.271.16.9550; Oakley RH, 1999, J BIOL CHEM, V274, P27857, DOI 10.1074/jbc.274.39.27857; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; Smith PJ, 2001, J IMMUNOL, V167, P2502, DOI 10.4049/jimmunol.167.5.2502; Sousa AR, 2000, J ALLERGY CLIN IMMUN, V105, P943, DOI 10.1067/mai.2000.106486; Stevens A, 2003, MOL ENDOCRINOL, V17, P845, DOI 10.1210/me.2002-0320; Strickland I, 2001, J EXP MED, V193, P585, DOI 10.1084/jem.193.5.585; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; Yudt MR, 2003, MOL CELL BIOL, V23, P4319, DOI 10.1128/MCB.23.12.4319-4330.2003	31	58	66	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					203	208		10.1016/j.jaci.2007.09.010	http://dx.doi.org/10.1016/j.jaci.2007.09.010			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18028994				2022-12-18	WOS:000252372000031
J	Bjermer, L				Bjermer, Leif			Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anti-inflammatory effects; anti-IgE; asthma; atopic dermatitis; beta(2)-agonist; eosinophilic inflammation; inflammatory mediators; inhaled corticosteroids; leukotriene receptor antagonist; paradigm shift; small airways; systemic inflammation; rhinitis	SEASONAL ALLERGIC RHINITIS; EOSINOPHILIC AIRWAY INFLAMMATION; LEUKOTRIENE MODIFIER THERAPY; RESPIRATORY HEALTH SURVEY; QUALITY-OF-LIFE; ATOPIC-DERMATITIS; BRONCHIAL HYPERRESPONSIVENESS; INHALED CORTICOSTEROIDS; ANTAGONIST MONTELUKAST; MYOCARDIAL-INFARCTION	Inflammation is a key pathology in asthma. In the central airways local inflammation leads to irreversible remodeling and airway dysfunction. Complex inflammatory changes also occur in the nose, sinuses, and small airways. In particular, rhinitis and asthma are linked by a common pathogenic process with common inflammatory cells, mediators, and cytokines. Cross-communication between the airways and bone marrow through inflammatory mediators in the circulation leads to systemic propagation of airway inflammation. Treatment of asthma has traditionally focused on relieving bronchospasm with beta(2)-agonists, which do not affect inflammation. Treatment of eosinophilic inflammation in the central airways with inhaled corticosteroids reduces local inflammation and improves pulmonary function but does not improve the systemic manifestations of asthma. If asthma is a systemic disease, the underlying systemic pathology should be targeted by identifying common disease mediators, mechanisms, or both that are triggered only during active disease. Of currently available therapies, leukotriene receptor antagonists block the action of cysteinyl leukotrienes and thus improve both asthma and rhinitis and other conditions systemically linked with asthma. Other potential treatments include receptor-blocking molecules and synthesis inhibitors related to eicosanoid inflammation. Treatment of asthma as a systemic disease requires clinical trials that evaluate the effects of new treatments on both lung function and the wider systemic pathology.	[Bjermer, Leif] Univ Lund Hosp, Dept Resp Med & Allergol, S-22185 Lund, Sweden	Lund University; Skane University Hospital	Bjermer, L (corresponding author), Univ Lund Hosp, Dept Resp Med & Allergol, S-22185 Lund, Sweden.	leif.bjermer@med.lu.se	Bjermer, Leif H/I-4899-2014	Bjermer, Leif H/0000-0002-3441-8099				*AM LUNG ASS, 2006, TRENDS ASTHM MORB MO; Baiardini I, 2006, ALLERGY, V61, P1259, DOI 10.1111/j.1398-9995.2006.01221.x; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; Beeh KM, 2003, CLIN EXP ALLERGY, V33, P475, DOI 10.1046/j.1365-2222.2003.01632.x; Bernstein CN, 2005, GASTROENTEROLOGY, V129, P827, DOI 10.1053/j.gastro.2005.06.021; Bjermer L, 2003, BMJ-BRIT MED J, V327, P891, DOI 10.1136/bmj.327.7420.891; Bjermer L, 2001, RESP MED, V95, P703, DOI 10.1053/rmed.2001.1148; Bjermer Leif, 2004, Treat Respir Med, V3, P235, DOI 10.2165/00151829-200403040-00004; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Bousquet J, 2005, CLIN EXP ALLERGY, V35, P728, DOI 10.1111/j.1365-2222.2005.02274.x; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Braunstahl GJ, 2005, J ALLERGY CLIN IMMUN, V115, P142, DOI 10.1016/j.jaci.2004.10.041; Braunstahl GJ, 2003, CLIN EXP ALLERGY, V33, P579, DOI 10.1046/j.1365-2222.2003.01652.x; Brinkman L, 1997, CLIN EXP ALLERGY, V27, P1043, DOI 10.1111/j.1365-2222.1997.tb01256.x; Brinkman L, 1997, EUR RESPIR J, V10, P1033, DOI 10.1183/09031936.97.10051033; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Carucci JA, 1998, ARCH DERMATOL, V134, P785, DOI 10.1001/archderm.134.7.785; Chetta A, 2005, CLIN EXP ALLERGY, V35, P1437, DOI 10.1111/j.1365-2222.2005.02360.x; Crystal-Peters J, 2002, J ALLERGY CLIN IMMUN, V109, P57, DOI 10.1067/mai.2002.120554; Denburg Judah A., 2000, Journal of Allergy and Clinical Immunology, V106, pS242; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; Dodig Slavica, 2005, Acta Pharmaceutica (Zagreb), V55, P123; Ekici A, 2005, CHEST, V128, P3358, DOI 10.1378/chest.128.5.3358; Erbagci Z, 2002, J ALLERGY CLIN IMMUN, V110, P484, DOI 10.1067/mai.2002.126676; Global Initiative for Asthma, 2006, GLOB STRAT ASTHM MAN; Goldbart AD, 2005, AM J RESP CRIT CARE, V172, P364, DOI 10.1164/rccm.200408-1064OC; Hallstrand TS, 2004, BLOOD, V104, P3086, DOI 10.1182/blood-2004-05-1775; Hazarika S, 2004, AM J PHYSIOL-HEART C, V286, pH1720, DOI 10.1152/ajpheart.01064.2003; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051; Heyman M, 2005, EUR J GASTROEN HEPAT, V17, P1279, DOI 10.1097/00042737-200512000-00003; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Kheirandish L, 2006, PEDIATRICS, V117, pE61, DOI 10.1542/peds.2005-0795; Kips JC, 1999, CLIN EXP ALLERGY, V29, P1457; Kowal K, 2006, CLIN EXP ALLERGY, V36, P426, DOI 10.1111/j.1365-2222.2006.02446.x; Kyllonen H, 2006, CLIN EXP ALLERGY, V36, P192, DOI 10.1111/j.1365-2222.2006.02419.x; Lampinen M, 2004, ALLERGY, V59, P793, DOI 10.1111/j.1398-9995.2004.00469.x; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee YM, 2004, CHEST, V126, P1840, DOI 10.1378/chest.126.6.1840; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; Linden M, 1999, ALLERGY, V54, P212, DOI 10.1034/j.1398-9995.1999.00756.x; Meltzer Eli O, 2004, J Manag Care Pharm, V10, P310; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V105, P917, DOI 10.1067/mai.2000.106040; Merkus PJFM, 2004, EUR RESPIR J, V23, P861, DOI 10.1183/09031936.04.00031504; Mitchell RB, 2006, INT J PEDIATR OTORHI, V70, P395, DOI 10.1016/j.ijporl.2005.10.020; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; NACLERIO RM, 1993, J ALLERGY CLIN IMMUN, V92, P717, DOI 10.1016/0091-6749(93)90015-8; ONUFRAK S, 2006, ATHEROSCLEROSIS; Philip G, 2004, CURR MED RES OPIN, V20, P1549, DOI 10.1185/030079904X3348; Polosa R, 2000, EUR RESPIR J, V16, P793; Roberts G, 2003, J ALLERGY CLIN IMMUN, V112, P168, DOI 10.1067/mai.2003.1569; Rolin S, 2006, EUR J PHARMACOL, V533, P89, DOI 10.1016/j.ejphar.2005.12.058; Salpeter SR, 2004, CHEST, V125, P2309, DOI 10.1378/chest.125.6.2309; Sharma J. N., 2006, Inflammopharmacology, V14, P10, DOI 10.1007/s10787-006-1496-6; Shiraishi Y, 2005, J PHARMACOL EXP THER, V312, P954, DOI 10.1124/jpet.104.078212; Shirasaki H, 2002, CLIN EXP ALLERGY, V32, P1007, DOI 10.1046/j.1365-2222.2002.01425.x; Strunk RC, 2006, NEW ENGL J MED, V354, P2689, DOI 10.1056/NEJMct055184; Suissa S, 2003, AM J MED, V115, P377, DOI 10.1016/S0002-9343(03)00393-0; Sutherland ER, 2005, J ALLERGY CLIN IMMUN, V116, P1179, DOI 10.1016/j.jaci.2005.09.028; Togias Alkis, 2004, Journal of Allergy and Clinical Immunology, V113, pS8, DOI 10.1016/j.jaci.2003.09.051; Tutluoglu B, 2005, CLIN APPL THROMB-HEM, V11, P77, DOI 10.1177/107602960501100109; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; Varas-Lorenzo C, 2007, ATHEROSCLEROSIS, V192, P376, DOI 10.1016/j.atherosclerosis.2006.05.019; WALLAERT B, 1995, J EXP MED, V182, P1897, DOI 10.1084/jem.182.6.1897; Wang JL, 2005, J ALLERGY CLIN IMMUN, V115, P1076, DOI 10.1016/j.jaci.2005.02.014; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; Wohlsen A, 2003, EUR RESPIR J, V21, P1024, DOI 10.1183/09031936.03.00027502; Wood LJ, 1999, AM J RESP CRIT CARE, V159, P1457, DOI 10.1164/ajrccm.159.5.9808123; Yanase DJ, 2001, J AM ACAD DERMATOL, V44, P89, DOI 10.1067/mjd.2001.111352	70	58	62	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1269	1275		10.1016/j.jaci.2007.09.017	http://dx.doi.org/10.1016/j.jaci.2007.09.017			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	18073122				2022-12-18	WOS:000251653800004
J	Polte, T; Behrendt, AK; Hansen, G				Polte, Tobias; Behrendt, Ann-Kathrin; Hansen, Gesine			Direct evidence for a critical role of CD30 in the development of allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; costimulation; T(H)2 cells; CD30; immunotherapy	INDUCED AIRWAY HYPERREACTIVITY; T-CELLS; PERIPHERAL-BLOOD; HODGKINS-DISEASE; ATOPIC DISEASE; SOLUBLE CD30; LIGAND CD153; MURINE MODEL; EXPRESSION; INFLAMMATION	Background: CD30 is a costimulatory molecule belonging to the TNF receptor superfamily that is expressed on activated T and B cells. Several studies have demonstrated a positive correlation between expression of CD30 or increased levels of soluble CD30 and the development and severity of allergic diseases. However, thus far, the evidence for a role of CD30 in allergic diseases, such as asthma, is only indirect. Objective: The aim of the study was to directly investigate the role of CD30 in a murine asthma model. Methods: CD30-deficient (B6.129P2-Tnfrsf8(tm1Mak)/J) and wild-type (WT) mice were immunized to ovalbumin (OVA) to induce an asthma-like phenotype and compared in our murine asthma model. Moreover, CD30/CD30 ligand signaling was blocked in OVA-immunized WT animals by using mAbs against CD30 receptor and its ligand, CD153. Results: The absence of CD30 in OVA-immunized CD30-deficient mice resulted in significantly reduced airway inflammation, serum IgE levels, and T(H)2 cytokine levels. The same effect was observed when CD30/CD153 signaling was blocked in OVA-immunized WT animals with mAbs against CD30 or CD30 ligand. Conclusion: Our results directly demonstrate that CD30/CD153 interaction plays an important role in the induction of TH2 cell-mediated allergic asthma. Clinical implications: These findings provide evidence for a role of the costimulatory molecule CD30 in allergic asthma.	Hannover Med Sch, Dept Pediat, Div Pediat Pulm & Neonatol, D-30625 Hannover, Germany; Univ Halle Wittenberg, Dept Pediat, Halle, Germany	Hannover Medical School; Martin Luther University Halle Wittenberg	Hansen, G (corresponding author), Hannover Med Sch, Dept Pediat, Div Pediat Pulm & Neonatol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Hansen.Gesine@mh-hannover.de						Bengtsson A, 2001, ALLERGY, V56, P593, DOI 10.1034/j.1398-9995.2001.00137.x; Blazar BR, 2004, J IMMUNOL, V173, P2933, DOI 10.4049/jimmunol.173.5.2933; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Bowen MA, 1996, J IMMUNOL, V156, P442; Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148; DELPRETE G, 1995, J EXP MED, V182, P1655, DOI 10.1084/jem.182.6.1655; Dummer W, 1997, BRIT J DERMATOL, V137, P185, DOI 10.1046/j.1365-2133.1997.18031887.x; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; Gonzalo JA, 2001, NAT IMMUNOL, V2, P597, DOI 10.1038/89739; Gourgiotis D, 2004, J ASTHMA, V41, P285, DOI 10.1081/JAS-120026085; Gruss HJ, 1997, IMMUNOL TODAY, V18, P156, DOI 10.1016/S0167-5699(97)84661-0; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hansen G, 2000, J IMMUNOL, V164, P223, DOI 10.4049/jimmunol.164.1.223; Harlin H, 2002, J IMMUNOL, V169, P2451, DOI 10.4049/jimmunol.169.5.2451; Holmlund U, 2003, CLIN EXP ALLERGY, V33, P1531, DOI 10.1046/j.1365-2222.2003.01792.x; Horie R, 1998, SEMIN IMMUNOL, V10, P457, DOI 10.1006/smim.1998.0156; Jember AGH, 2001, J EXP MED, V193, P387, DOI 10.1084/jem.193.3.387; Keane-Myers AM, 1998, J IMMUNOL, V160, P1036; Kim MY, 2003, IMMUNITY, V18, P643, DOI 10.1016/S1074-7613(03)00110-9; Lack G, 1996, J IMMUNOL, V157, P1432; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Padrid PA, 1998, AM J RESP CELL MOL, V18, P453, DOI 10.1165/ajrcmb.18.4.3055; Podack ER, 2002, ANN NY ACAD SCI, V975, P101, DOI 10.1111/j.1749-6632.2002.tb05945.x; Polte T, 2006, J CLIN INVEST, V116, P1025, DOI 10.1172/JCI23792; Scherf W, 2005, EUR J IMMUNOL, V35, P198, DOI 10.1002/eji.200425209; Shimozato O, 1999, BIOCHEM BIOPH RES CO, V256, P519, DOI 10.1006/bbrc.1999.0336; Tarkowski M, 2003, CURR OPIN HEMATOL, V10, P267, DOI 10.1097/00062752-200307000-00003; Watts TH, 1999, CURR OPIN IMMUNOL, V11, P286, DOI 10.1016/S0952-7915(99)80046-6	28	58	59	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					942	948		10.1016/j.jaci.2006.07.014	http://dx.doi.org/10.1016/j.jaci.2006.07.014			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030250				2022-12-18	WOS:000241434200025
J	Palacin, A; Cumplido, J; Figueroa, J; Ahrazem, O; Sanchez-Monge, R; Carrillo, T; Salcedo, G; Blanco, C				Palacin, Aranzazu; Cumplido, Jose; Figueroa, Javier; Ahrazem, Oussama; Sanchez-Monge, Rosa; Carrillo, Teresa; Salcedo, Gabriel; Blanco, Carlos			Cabbage lipid transfer protein Bra o 3 is a major allergen responsible for cross-reactivity between plant foods and pollens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen. anaphylaxis; Brassica oleracea; cabbage; cross-reactivity; food allergy; lipid transfer protein; mugwort pollen; mustard; peach	MUSTARD ALLERGY; ARTEMISIA POLLEN; IGE; HYPERSENSITIVITY; IDENTIFICATION; ANAPHYLAXIS; CHALLENGES; CHILDREN; BINDING; FRUITS	Background: Food IgE-mediated allergy to members of the Brassicaceae family has been increasingly reported. Objective: To characterize cabbage-Brassica oleracea var capitata-allergy and its major allergens. Methods: A prospective study was performed, recruiting 17 patients allergic to cabbage, and control subjects. Skin prick tests and double-blind placebo-controlled food challenges were performed. A major allergen was isolated from cabbage by RP-HPLC and characterized by N-terminal amino acid sequencing and matrix-assisted laser desorption/ionization mass spectrometry analysis. Specific IgE determinations, IgE immunoblots, and CAP-inhibition assays were also performed. Results: Skin prick test and specific IgE were positive to cabbage in all patients. Five of them referred anaphylactic reactions when eating cabbage, and in another 5 patients, cabbage allergy was further confirmed by double-blind placebo-controlled food challenge. Most of them showed associated sensitizations to mugwort pollen, mustard, and peach. A 9-kd cabbage IgE-binding protein, Bra o 3, was identified as a lipid transfer protein (LTP) with 50% of identity to peach UP Pru p 3. Skin prick test with Bra o 3 showed positive results in 12 of 14 cases (86%). On CAP inhibition assays, Bra o 3 managed to inhibit significantly the IgE binding to cabbage, mugwort pollen, and peach. Both Bra o 3 and Pru p 3 were recognized by IgE from the patients' sera. Conclusion: Bra o 3, a cabbage LTP, is a major allergen in this food, cross-reacting with mugwort pollen and with other plant foods, such as peach. Clinical implications: Cabbage IgE-mediated allergy is a potentially severe condition that can present with other plant food and pollen allergies.	Hosp Univ Gran Canaria Dr Negrin, Serv Alergia, Las Palmas Gran Canaria, Spain; Univ Politecn Madrid, Dept Biotechnol, Escuela Tecn Super Ingn Agron, Madrid, Spain	Universidad Politecnica de Madrid	Blanco, C (corresponding author), Hosp Gran Canaria Dr Negrin, Serv Alergia, C Bco Ballena S-N, Las Palmas Gran Canaria, Spain.	cblague@gobiernodecanarias.org	Ahrazem, oussama/AAV-1392-2021; Blanco, Carlos/B-3895-2012	Ahrazem, oussama/0000-0001-9183-9319; Blanco, Carlos/0000-0002-2893-6594				Asero R, 2002, ALLERGY, V57, P900, DOI 10.1034/j.1398-9995.2002.t01-1-23541.x; Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; BLAISS MS, 1987, ANN ALLERGY, V58, P248; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caballero T, 2002, ANN ALLERG ASTHMA IM, V89, P166, DOI 10.1016/S1081-1206(10)61933-3; CALNAN CD, 1981, CONTACT DERMATITIS, V7, P279; DELAPENA MAG, 1991, INT ARCH ALLER A IMM, V96, P263, DOI 10.1159/000235505; Diaz-Perales A, 2003, J ALLERGY CLIN IMMUN, V111, P628, DOI 10.1067/mai.2003.75; Diaz-Perales A, 2000, CLIN EXP ALLERGY, V30, P1403, DOI 10.1046/j.1365-2222.2000.00909.x; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Figueroa J, 2005, ALLERGY, V60, P48, DOI 10.1111/j.1398-9995.2005.00644.x; Garcia-Selles FJ, 2002, INT ARCH ALLERGY IMM, V128, P115, DOI 10.1159/000059401; JORRO G, 1995, J INVEST ALLERG CLIN, V5, P54; KANNY G, 1995, ANN ALLERG ASTHMA IM, V75, P340; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lombardero M, 2004, CLIN EXP ALLERGY, V34, P1415, DOI 10.1111/j.1365-2222.2004.02053.x; Marvin LF, 2003, CLIN CHIM ACTA, V337, P11, DOI 10.1016/j.cccn.2003.08.008; MENENDEZARIAS L, 1988, EUR J BIOCHEM, V177, P159, DOI 10.1111/j.1432-1033.1988.tb14357.x; Palomares O, 2005, ANN ALLERG ASTHMA IM, V94, P586, DOI 10.1016/S1081-1206(10)61138-6; Rance F, 2000, ALLERGY, V55, P496, DOI 10.1034/j.1398-9995.2000.00383.x; Rance F, 2003, ALLERGY, V58, P287, DOI 10.1034/j.1398-9995.2003.00109.x; Rance F, 1999, PEDIAT ALLERG IMM-UK, V10, P33, DOI 10.1034/j.1399-3038.1999.101008.x; Salcedo G, 2004, CLIN EXP ALLERGY, V34, P1336, DOI 10.1111/j.1365-2222.2004.02018.x; SANCHEZMADRID F, 1984, J IMMUNOL METHODS, V73, P367, DOI 10.1016/0022-1759(84)90412-5; STAGER J, 1991, ALLERGY, V46, P475, DOI 10.1111/j.1398-9995.1991.tb04228.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vieths S, 2002, ANN NY ACAD SCI, V964, P47	27	58	59	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1423	1429		10.1016/j.jaci.2006.01.026	http://dx.doi.org/10.1016/j.jaci.2006.01.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751008				2022-12-18	WOS:000238332300034
J	Mothes, N; Niggemann, B; Jenneck, C; Hagemann, T; Weidinger, S; Bieber, T; Valenta, R; Novak, N				Mothes, N; Niggemann, B; Jenneck, C; Hagemann, T; Weidinger, S; Bieber, T; Valenta, R; Novak, N			The cradle of IgE autoreactivity in atopic eczema lies in early infancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DERMATITIS		Med Univ Vienna, Dept Pathophysiol, Ctr Physiol & Pathophysiol, Vienna, Austria; Univ Hosp Charite, Dept Pediat Pneumol & Immunol, Berlin, Germany; Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany; Univ Bonn, Dept Dermatol, D-53105 Bonn, Germany	Medical University of Vienna; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Technical University of Munich; University of Bonn	Mothes, N (corresponding author), Med Univ Vienna, Dept Pathophysiol, Ctr Physiol & Pathophysiol, Vienna, Austria.		Weidinger, Stephan/C-8461-2011	Weidinger, Stephan/0000-0003-3944-252X; Valenta, Rudolf/0000-0001-5944-3365				Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Mittermann I, 2004, CURR OPIN ALLERGY CL, V4, P367, DOI 10.1097/00130832-200410000-00007; Natter S, 1998, FASEB J, V12, P1559, DOI 10.1096/fasebj.12.14.1559; Schmid-Grendelmeier P, 2005, J ALLERGY CLIN IMMUN, V115, P1068, DOI 10.1016/j.jaci.2005.01.065; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1996, J INVEST DERMATOL, V107, P203, DOI 10.1111/1523-1747.ep12329617	6	58	59	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					706	709		10.1016/j.jaci.2005.06.025	http://dx.doi.org/10.1016/j.jaci.2005.06.025			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159648				2022-12-18	WOS:000235686500038
J	Carr, WW; Martin, B; Howard, RS; Cox, L; Borish, L				Carr, WW; Martin, B; Howard, RS; Cox, L; Borish, L		Immunotherapy Comm	Comparison of test devices for skin prick testing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						skin testing; device; performance; variability; pain	PERFORMANCE	Background: Allergy skin testing guides developing avoidance plans and writing an immunotherapy prescription. The goal for the allergist is to apply allergen skin testing to the appropriate patient population by using a device that minimizes both false-negative and false-positive findings while minimizing patient discomfort. New skin testing devices continue to be developed with a trend toward production of multiheaded devices. Data on the performance of these devices in a head-to-head prospective fashion are limited. Objective: Our goal was to study 8 commonly used devices to compare their performance in a head-to-head fashion. Methods: In a prospective, double-blind fashion, the performance of 8 skin test devices was evaluated. Devices were tested with histamine and saline on both the arms and back of each subject. Devices were rotated over 4 testing sessions, at least a week apart, so each device was tested in each anatomic testing location. Performance elements examined included wheal, flare, pain, sensitivity, specificity, and intradevice variability. Results: We found significant differences in all areas of device performance among all devices examined. Multiheaded devices also demonstrated significant intradevice variability and were more painful than single devices. Furthermore, multiheaded devices bad larger reactions on the back, whereas single devices had larger reactions on the arms. Conclusion: Statistically significant differences exist among all devices tested. Providers should consider this data when choosing a device that suits their practice setting and ensure that technicians are sufficiently trained on the correct use of that device.	Walter Reed Army Med Ctr, Dept Allergy & Immunol, Silver Spring, MD USA; Walter Reed Army Med Ctr, Dept Clin Invest, Silver Spring, MD USA; Univ Virginia, Asthma & Allerg Dis Ctr, Hlth Syst, Charlottesville, VA 22903 USA	United States Department of Defense; United States Army; United States Department of Defense; United States Army; University of Virginia	Carr, WW (corresponding author), Walter Reed Army Inst Res, Div Expt Therapeut, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	wmcarr@comcast.net	Cox, Linda/AAP-1697-2021	Cox, Linda/0000-0002-5258-6870				ADINOFF AD, 1989, J ALLERGY CLIN IMMUN, V84, P168, DOI 10.1016/0091-6749(89)90321-7; Li JT, 2003, ANN ALLERG ASTHMA IM, V90, P1, DOI 10.1016/S1081-1206(10)63600-9; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V101, P153, DOI 10.1016/S0091-6749(98)70409-9; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P750, DOI 10.1016/0091-6749(93)90019-C; Nelson HS, 2004, J ALLERGY CLIN IMMUN, V113, P1218, DOI 10.1016/j.jaci.2004.01.566; SPECTOR SL, 1995, J ALLERGY CLIN IMMUN, V96, P707; The European Academy of Allergology and Clinical Immunology, 1993, ALLERGY          S14, V48, P7; WONGBAKER, 2001, WONGS ESSENTIALS PED, P1301	8	58	66	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					341	346		10.1016/j.jaci.2005.03.035	http://dx.doi.org/10.1016/j.jaci.2005.03.035			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16108145				2022-12-18	WOS:000235686400016
J	Nilsson, C; Linde, A; Montgomery, SM; Gustafsson, L; Nasman, P; Blomberg, MT; Lilja, G				Nilsson, C; Linde, A; Montgomery, SM; Gustafsson, L; Nasman, P; Blomberg, MT; Lilja, G			Does early EBV infection protect against IgE sensitization?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						childhood; CMV; EBV; IgE; infections; sensitization; serology; viral infections	BARR-VIRUS-INFECTION; CYTOMEGALOVIRUS-INFECTION; EARLY-CHILDHOOD; ATOPIC DISEASE; CORD BLOOD; ANTIBODIES; CHILDREN; CELLS; LIFE; SCHOOLCHILDREN	Background: There is indirect evidence that an increased infectious burden is associated with a decreased prevalence of IgE-mediated allergy during childhood. Objective: To determine whether there is a relation between the serostatus of 13 different viruses and parentally reported infections and IgE sensitization in 2-year-old children. To investigate whether there is an interaction between cytomegalovirus (CMV) and Epstein-Barr virus (EBV) in relation to IgE sensitization. Methods: A total of 246 infants were followed prospectively to 2 years of age with clinical examinations, skin prick test, and specific IgE analyses and through analysis of seropositivity against adenovirus, influenza, parainfluenza, respiratory syncytial virus, CMV, EBV, herpes simplex virus, human herpesvirus 6, and varicella-zoster virus. Results: There was some evidence that IgE sensitization (24%) tended to be more common among children who were seropositive against few compared with children who were seropositive against many viruses, but this was not statistically significant, and there was no consistent trend across the groups. IgE sensitization was statistically significantly less prevalent at 2 years of age among infants who were seropositive against EBV but not other viruses (adjusted odds ratio, 0.34; 95% CI, 0.14-0.86). The interaction of seropositivity against both CMV and EBV antibodies indicated a further reduction in the risk for IgE sensitization (adjusted odds ratio for interaction, 0.10; 95% CI, 0.01-0.92), indicating effect modification associated with seropositivity against CMV. Conclusion: Our results indicate that acquisition of EBV infection during the first 2 years of life is associated with a reduced risk of IgE sensitization, and this effect is enhanced by CMV coinfection.	Sachs Childrens Hosp, Dept Pediat, Stockholm, Sweden; Swedish Inst Infect Dis Control, Ctr Microbiol & Tumor Biol, Karolinska Inst, Stockholm, Sweden; Karolinska Hosp, Karolinska Inst, Dept Med, Clin Epidemiol Unit, S-10401 Stockholm, Sweden; Orebro Univ Hosp, Clin Res Ctr, Stockholm, Sweden; Royal Inst Technol, Stockholm, Sweden; Stockholm Univ, Dept Immunol, S-10691 Stockholm, Sweden	Karolinska Institutet; Swedish Institute for Infectious Disease Control; Karolinska Institutet; Karolinska University Hospital; Orebro University; Royal Institute of Technology; Stockholm University	Nilsson, C (corresponding author), Stockholm S Hosp, Sachs Childrens Hosp, Dept Pediat, S-11883 Stockholm, Sweden.	caroline.nilsson@sodersjukhuset.se	Näsman, Per/N-4999-2018; Montgomery, Scott/AAN-2546-2020	Näsman, Per/0000-0001-7606-8771; Montgomery, Scott/0000-0001-6328-5494				ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; Ahlfors K, 1999, SCAND J INFECT DIS, V31, P443, DOI 10.1080/00365549950163969; Benn CS, 2004, BRIT MED J, V328, P1223, DOI 10.1136/bmj.38069.512245.FE; Blanco-Quiros A, 1999, PEDIATR PULM, V28, P175, DOI 10.1002/(SICI)1099-0496(199909)28:3<175::AID-PPUL3>3.0.CO;2-U; Calvani M, 1997, PEDIATR ALLERGY IMMU, V8, P91, DOI 10.1111/j.1399-3038.1997.tb00150.x; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; Cohen JI, 2000, NEW ENGL J MED, V343, P481, DOI 10.1056/NEJM200008173430707; GRILLNER L, 1988, J INFECT DIS, V157, P1080, DOI 10.1093/infdis/157.5.1080; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; JOHNSTON SL, 1995, AM J RESP CRIT CARE, V152, pS46, DOI 10.1164/ajrccm/152.4_Pt_2.S46; Lau Susanne, 2002, Paediatr Respir Rev, V3, P265, DOI 10.1016/S1526-0542(02)00189-6; LINDE A, 1987, J MED VIROL, V21, P109, DOI 10.1002/jmv.1890210203; LINDE A, 1990, J CLIN MICROBIOL, V28, P211, DOI 10.1128/JCM.28.2.211-215.1990; Ljungman P, 1998, TRANSPLANTATION, V66, P1330, DOI 10.1097/00007890-199811270-00012; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; Nilsson C, 2004, CLIN EXP ALLERGY, V34, P373, DOI 10.1111/j.1365-2222.2004.01896.x; Raftery MJ, 2004, J IMMUNOL, V173, P3383, DOI 10.4049/jimmunol.173.5.3383; Rentenaar RJ, 2000, J CLIN INVEST, V105, P541, DOI 10.1172/JCI8229; Salek-Ardakani S, 2002, VIROLOGY, V304, P342, DOI 10.1006/viro.2002.1716; Schauer U, 2002, EUR RESPIR J, V20, P1277, DOI 10.1183/09031936.02.00019902; Sidorchuk A, 2004, J ALLERGY CLIN IMMUN, V114, P1434, DOI 10.1016/j.jaci.2004.08.009; Sidorchuk A, 2003, PEDIATR INFECT DIS J, V22, P642, DOI 10.1097/00006454-200307000-00014; Smits HH, 2005, CURR ALLERGY ASTHM R, V5, P42, DOI 10.1007/s11882-005-0053-5; Stepanova L, 2002, J CLIN VIROL, V24, P193, DOI 10.1016/S1386-6532(01)00246-3; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; STRANNEGARD IL, 1981, INT ARCH ALLER A IMM, V64, P314, DOI 10.1159/000232709; SUNDQVIST VA, 1984, J CLIN MICROBIOL, V20, P94, DOI 10.1128/JCM.20.1.94-98.1984; SUNDQVIST VA, 1981, J VIROL METHODS, V2, P301, DOI 10.1016/0166-0934(81)90029-X; Wu CA, 2001, J IMMUNOL, V167, P2798, DOI 10.4049/jimmunol.167.5.2798; Yobo EODA, 1997, THORAX, V52, P161, DOI 10.1136/thx.52.2.161	31	58	60	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					438	444		10.1016/j.jaci.2005.04.027	http://dx.doi.org/10.1016/j.jaci.2005.04.027			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083803	Green Published, Bronze			2022-12-18	WOS:000235686400031
J	Koreck, AI; Csoma, Z; Bodai, L; Ignacz, F; Kenderessy, AS; Kadocsa, E; Szabo, G; Bor, Z; Erdei, A; Szony, B; Homey, B; Dobozy, A; Kemeny, L				Koreck, AI; Csoma, Z; Bodai, L; Ignacz, F; Kenderessy, AS; Kadocsa, E; Szabo, G; Bor, Z; Erdei, A; Szony, B; Homey, B; Dobozy, A; Kemeny, L			Rhinophototherapy: A new therapeutic tool for the management of allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; phototherapy; eosinophils; T cells; IL-5; apoptosis	GRASS-POLLEN IMMUNOTHERAPY; ULTRAVIOLET-B LASER; HISTAMINE-RELEASE; HUMAN BASOPHILS; IN-VITRO; IMMUNE-RESPONSES; MESSENGER-RNA; NASAL-MUCOSA; MAST-CELLS; T-CELLS	Background: Phototherapy has a profound immunosuppressive effect and is able to inhibit hypersensibility reactions in the skin. Objective: We evaluated whether phototherapy using a combination of UV-B (5%), UV-A (25%), and visible light (70%), referred to as mUV/VIS, is effective in treating allergic rhinitis. Methods: We conducted a randomized, double-blind study, in 49 patients with hay fever. The study was performed during the ragweed season. Each intranasal cavity was illuminated 3 times a week for 3 weeks with mUV/VIS or with low-intensity visible light. Symptom scores, inflammatory cells, and their mediators were assessed in nasal lavages. In vitro effects of mUV/VIS irradiation on T-cell and eosinophil apoptosis and its inhibitory effect on mediator release from basophils were examined. Results: Rhinophototherapy was tolerated well and resulted in a significant improvement of clinical symptoms for sneezing (P < .016), rhinorrhea (P < .007), nasal itching (P < .014), and total nasal score (P < .004). None of the scores improved significantly in the control group. Scores for nasal obstruction slightly improved after mUV/VIS treatment and significantly increased in the control group (P < .017). In the nasal lavage, phototherapy significantly reduced the number of eosinophils and the level of eosinophil cationic protein and IL-5. In vitro irradiation of T cells and eosinophils with mUV/VIS light dose-dependently induced apoptosis. Furthermore, mUV/VIS irradiation inhibited the mediator release from RBL-2H3 basophils. Conclusion: These results suggest that phototherapy is an effective modality to treat allergic rhinitis and offer new options for the treatment of immune-mediated mucosal diseases.	Univ Szeged, Dept Dermatol & Allergol, H-6720 Szeged, Hungary; Univ Szeged, Dept Opt & Quantum Elect, H-6720 Szeged, Hungary; Univ Szeged, Dept Otorhinolaryngol Head & Neck Surg, H-6720 Szeged, Hungary; Eotvos Lorand Univ, Dept Immunol, Budapest, Hungary; Univ Dusseldorf, Dept Dermatol, Res Lab Dermato Immunol & Oncol, D-4000 Dusseldorf, Germany; Hungarian Acad Sci, Dermatol Res Grp, Szeged, Hungary	Szeged University; Szeged University; Szeged University; Eotvos Lorand University; Heinrich Heine University Dusseldorf; Hungarian Academy of Sciences	Koreck, AI (corresponding author), Univ Szeged, Dept Dermatol & Allergol, Koranyi Fasor 6, H-6720 Szeged, Hungary.	akoreck@yahoo.com	Kemeny, Lajos/ABF-1339-2021; Bodai, Laszlo/A-9764-2012; Erdei, Anna/AAN-5988-2020	Kemeny, Lajos/0000-0002-2119-9501; Bodai, Laszlo/0000-0001-8411-626X; Erdei, Anna/0000-0002-3622-6680				Benson M, 2000, J ALLERGY CLIN IMMUN, V106, P307, DOI 10.1067/mai.2000.108111; BERTHON B, 1994, BIOCHEM PHARMACOL, V47, P789, DOI 10.1016/0006-2952(94)90478-2; Bonis B, 1997, LANCET, V350, P1522, DOI 10.1016/S0140-6736(05)63945-1; BRADDING P, 1995, AM J RESP CRIT CARE, V151, P1900, DOI 10.1164/ajrccm.151.6.7767538; Csoma Z, 2004, J PHOTOCH PHOTOBIO B, V75, P137, DOI 10.1016/j.jphotobiol.2004.05.001; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Fiset PO, 2003, J ALLERGY CLIN IMMUN, V111, P580, DOI 10.1067/mai.2003.179; Garssen J, 1999, IMMUNOLOGY, V97, P506; Hoffmann A, 1999, ALLERGY, V54, P446, DOI 10.1034/j.1398-9995.1999.00917.x; Holgate ST, 2000, CLIN EXP ALLERGY, V30, P1; HOWARTH PH, 1995, INT ARCH ALLERGY IMM, V107, P390, DOI 10.1159/000237048; Howarth PH, 2000, ALLERGY, V55, P7, DOI 10.1034/j.1398-9995.2000.00802.x; JENKLER J, 1989, J AM ACAD DERMATOL, V22, P49; KALIMO K, 1983, ARCH DERMATOL RES, V275, P374, DOI 10.1007/BF00417336; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kita H, 2000, J ALLERGY CLIN IMMUN, V106, P521, DOI 10.1067/mai.2000.108430; Koreck A, 2004, J PHOTOCH PHOTOBIO B, V77, P93, DOI 10.1016/j.jphotobiol.2004.08.008; Kronauer C, 2003, PHOTOCHEM PHOTOBIOL, V77, P531, DOI 10.1562/0031-8655(2003)077<0531:IOUUAU>2.0.CO;2; Law AW, 2003, J ALLERGY CLIN IMMUN, V111, P296, DOI 10.1067/mai.2003.68; Monfrecola G, 2003, J EUR ACAD DERMATOL, V17, P646, DOI 10.1046/j.1468-3083.2003.00679.x; Nghiem DX, 2002, J INVEST DERMATOL, V119, P600, DOI 10.1046/j.1523-1747.2002.01845.x; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; Novak Z, 2002, J PHOTOCH PHOTOBIO B, V67, P32, DOI 10.1016/S1011-1344(02)00280-4; Oettgen HC, 1999, J CLIN INVEST, V104, P829, DOI 10.1172/JCI8205; Ozawa M, 1999, J EXP MED, V189, P711, DOI 10.1084/jem.189.4.711; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; Salib RJ, 2003, DRUG SAFETY, V26, P863, DOI 10.2165/00002018-200326120-00003; Scheinfeld NS, 2003, CLIN DERMATOL, V21, P241, DOI 10.1016/S0738-081X(02)00364-4; Simons F. Estelle R., 2003, Journal of Allergy and Clinical Immunology, V112, pS42, DOI 10.1016/S0091-6749(03)01876-1; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; VERMEER BJ, 1994, J PHOTOCH PHOTOBIO B, V24, P149, DOI 10.1016/1011-1344(94)07033-4; Walsh GM, 1997, CLIN EXP ALLERGY, V27, P482, DOI 10.1111/j.1365-2222.1997.tb00735.x; Walsh GM, 1999, CRIT REV CL LAB SCI, V36, P453, DOI 10.1080/10408369991239277; Wedi B, 1998, J ALLERGY CLIN IMMUN, V102, P1013, DOI 10.1016/S0091-6749(98)70340-9; WHITE MV, 1991, J IMMUNOL, V147, P667; Wilson DR, 2001, J ALLERGY CLIN IMMUN, V107, P971, DOI 10.1067/mai.2001.115483; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356	37	58	61	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					541	547		10.1016/j.jaci.2004.11.005	http://dx.doi.org/10.1016/j.jaci.2004.11.005			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753902				2022-12-18	WOS:000227687000017
J	Lametschwandtner, G; Biedermann, T; Schwarzler, C; Gunther, C; Kund, J; Fassl, S; Hinteregger, S; Carballido-Perrig, N; Szabo, SJ; Glimcher, LH; Carballido, JM				Lametschwandtner, G; Biedermann, T; Schwarzler, C; Gunther, C; Kund, J; Fassl, S; Hinteregger, S; Carballido-Perrig, N; Szabo, SJ; Glimcher, LH; Carballido, JM			Sustained T-bet expression confers polarized human T(H)2 cells with T(H)1-like cytokine production and migratory capacities	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)1/T(H)2 cells; T-bet; cytokines; chemokines; allergy; atopic dermatitis	GENE-EXPRESSION; HELPER-CELLS; T-HELPER-2; MEMORY; TH1; ASSOCIATION; LYMPHOCYTES; RESPONSES; REVERSAL; DEFINES	Background: The transcription factor T-bet mediates IFN-gamma production by T(H)1 cells and suppresses T(H)2 cytokine production when ectopically expressed in polarized murine T(H)2 cells. Thus T-bet-mediated inhibition of T(H)2 cytokine production might be beneficial for the treatment of allergic diseases like asthma or atopic dermatitis. Objective: We sought to investigate the effects of ectopic T-bet expression in highly polarized human T(H)2 cells obtained from skin biopsy specimens of patients with atopic dermatitis. Methods: The cytokine production of T(H)2 cells retrovirally transfected with a vector expressing human T-bet was determined by means of intracellular FACS staining and ELISA. The effects of T-bet transfection were analyzed at the mRNA level by means of real-time PCR and DNA microarrays and confirmed by using functional chemokine response assays. Results: Transfection of T-bet into T(H)2 cells induced high levels of IFN-gamma and suppressed IL-5, but IL-2 and IL-4 production remained unchanged. T-bet transfection also induced IL-12Rbeta2 and CXCR3 expression on human T(H)2 cells, whereas the IL-18 receptor was only induced as a consequence of T-bet-mediated increased responsiveness to IL-12. Furthermore, sustained T-bet expression in human T(H)2 cells induced IL-2 production and decreased the secretion of IL-4. In addition, the chemokine receptor repertoire of these cells was changed toward a T(H)1-Iike profile. Conclusion: The combined switch in cytokine pattern and migratory potential of highly polarized human T(H)2 cells mediated by T-bet might provide an additional advantage for the treatment of allergic diseases.	Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Novartis Res Inst, A-1235 Vienna, Austria	Harvard University; Harvard T.H. Chan School of Public Health; Novartis	Carballido, JM (corresponding author), Novartis Res Inst, Brunnerstr 59, A-1235 Vienna, Austria.		Günther, Claudia/AGG-8982-2022	Biedermann, Tilo/0000-0002-5352-5105				Afkarian M, 2002, NAT IMMUNOL, V3, P549, DOI 10.1038/ni794; Andrew DP, 2001, J IMMUNOL, V166, P103, DOI 10.4049/jimmunol.166.1.103; Annunziato F, 2001, J ALLERGY CLIN IMMUN, V108, P815; AUTRAN B, 1995, J IMMUNOL, V154, P1408; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Carballido JM, 1997, J IMMUNOL, V159, P4316; Chan SC, 1996, J INVEST DERMATOL, V106, P1131, DOI 10.1111/1523-1747.ep12340181; Colantonio L, 1999, BLOOD, V94, P2981, DOI 10.1182/blood.V94.9.2981.421k27_2981_2989; ELSON LH, 1995, J IMMUNOL, V154, P4294; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Hamalainen H, 2001, GENOME BIOL, V2; Iwasaki M, 2002, J INVEST DERMATOL, V119, P609, DOI 10.1046/j.1523-1747.2002.01862.x; Khanolkar A, 2001, VIROLOGY, V287, P79, DOI 10.1006/viro.2001.1020; Kim CH, 2001, J CLIN INVEST, V107, P595, DOI 10.1172/JCI11902; Kim CH, 2001, J CLIN INVEST, V108, P1331, DOI 10.1172/JCI200113543; Messi M, 2003, NAT IMMUNOL, V4, P78, DOI 10.1038/ni872; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Nagai S, 2001, INT IMMUNOL, V13, P367, DOI 10.1093/intimm/13.3.367; Pernis A, 1995, SCIENCE, V269, P245; Rogge L, 2000, NAT GENET, V25, P96, DOI 10.1038/75671; Saraiva M, 2002, J EXP MED, V196, P829, DOI 10.1084/jem.20020319; Song ZM, 1996, J IMMUNOL, V156, P424; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942; Willheim M, 1997, J ALLERGY CLIN IMMUN, V100, P348, DOI 10.1016/S0091-6749(97)70248-3; Zhang Y, 2002, P NATL ACAD SCI USA, V99, P878, DOI 10.1073/pnas.022326699	27	58	75	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					987	994		10.1016/j.jaci.2004.02.004	http://dx.doi.org/10.1016/j.jaci.2004.02.004			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131585				2022-12-18	WOS:000221269000025
J	Vichyanond, P; Tantimongkolsuk, C; Dumrongkigchaiporn, P; Jirapongsananuruk, O; Visitsunthorn, N; Kosrirukvongs, P				Vichyanond, P; Tantimongkolsuk, C; Dumrongkigchaiporn, P; Jirapongsananuruk, O; Visitsunthorn, N; Kosrirukvongs, P			Vernal keratoconjunctivitis: Result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ATOPIC-DERMATITIS; INSIGHTS		Mahidol Univ, Fac Med, Siriraj Hosp, Dept Pediat, Bangkok 10700, Thailand; Mahidol Univ, Fac Med, Siriraj Hosp, Dept Ophthalmol, Bangkok 10700, Thailand	Mahidol University; Mahidol University	Vichyanond, P (corresponding author), Mahidol Univ, Fac Med, Siriraj Hosp, Dept Pediat, Bangkok 10700, Thailand.			Jirapongsananuruk, Orathai/0000-0002-1603-1106; Visitsunthorn, Nualanong/0000-0002-4342-5100				Bielory L, 2000, J ALLERGY CLIN IMMUN, V106, P1019, DOI 10.1067/mai.2000.111238; Boguniewicz M, 1998, J ALLERGY CLIN IMMUN, V102, P637, DOI 10.1016/S0091-6749(98)70281-7; Bonini S, 2000, OPHTHALMOLOGY, V107, P1157, DOI 10.1016/S0161-6420(00)00092-0; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Leonardi A, 2002, PROG RETIN EYE RES, V21, P319, DOI 10.1016/S1350-9462(02)00006-X; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; MAGGI E, 1991, J IMMUNOL, V146, P1169; Meltzer EO, 1988, AM J RHINOL, V2, P47, DOI DOI 10.2500/105065888781693212; Pucci N, 2002, ANN ALLERG ASTHMA IM, V89, P298, DOI 10.1016/S1081-1206(10)61958-8; Tabbara KF, 1999, CAN J OPHTHALMOL, V34, P88	10	58	59	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					355	358		10.1016/j.jaci.2003.10.065	http://dx.doi.org/10.1016/j.jaci.2003.10.065			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767456				2022-12-18	WOS:000188885700029
J	Yao, TC; Kuo, ML; See, LC; Chen, LC; Yan, DC; Ou, LS; Shaw, CK; Huang, JL				Yao, TC; Kuo, ML; See, LC; Chen, LC; Yan, DC; Ou, LS; Shaw, CK; Huang, JL			The RANTES promoter polymorphism: A genetic risk factor for near-fatal asthma in Chinese children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; near fatal asthma; polymorphism; RANTES; chemokine; Chinese; children	CHEMOKINE RANTES; EOSINOPHIL RECRUITMENT; DISEASE PROGRESSION; REGULATORY REGION; HIV-INFECTION; LAVAGE FLUID; SUSCEPTIBILITY; SEVERITY; MCP-1; INFLAMMATION	Background: RANTES promoter polymorphisms were found associated with asthma/atopy in some studies but not others, possibly reflecting the genetic heterogeneity among different ethnicities and different asthma severity. Objective: The purpose of this investigation was to test the genetic association between the RANTES -28C/G and -403G/A polymorphisms and asthma/atopy in a cohort of Chinese children, with particular emphasis on those patients who had experienced life-threatening asthma attacks. Methods: Forty-eight children with near-fatal asthma, 134 children with mild-to-moderate asthma, 69 children with allergic disorders but no asthma, and 107 nonasthmatic nonatopic control children were genotyped through use of a PCR-based assay. Results: No significant difference was demonstrated for frequency of the RANTES -28C/G polymorphism when the mild-to-moderate asthma, atopic/nonasthmatic, and normal control groups were compared. The RANTES -28G allele was present in a significantly higher proportion of the children with nearfatal asthma compared with the nonasthmatic nonatopic controls (odds ratio, 2.93 [1.41-6.06]; P =.006) and the children with mild-to-moderate asthma (odds ratio, 3.52 [1.73-7.161; P = .001). The frequency of -28G allele carriage correlated with asthma severity. The RANTES -28G allele was also associated with an increased blood eosinophil count and a higher degree of bronchial hyperresponsiveness. The RANTES -403G/A polymorphism did not influence asthma/atopy susceptibility, blood eosinophil count, or bronchial hyperresponsiveness. Interestingly, a higher frequency of -403A allele carriage was observed in the moderate asthma subgroup compared with the mild asthma analog. Conclusions: We conclude that the RANTES -28C/G polymorphism exacerbates asthma severity, representing a genetic risk factor for life-threatening asthma attacks in Chinese children. In addition, the linkage disequilibrium between these 2 polymorphisms is a potential confounder that must be considered in the design and interpretation of RANTES gene association studies. (J Allergy Clin Immunol 2003;111:1285-92.).	Chang Gung Childrens Hosp, Div Allergy Asthma & Rhumatol, Dept Pediat, Taoyuan, Taiwan; Chang Gung Childrens Hosp, Hlth Res Div, Taoyuan, Taiwan; Chang Gung Univ, Coll Med, Biostat Consulting Ctr, Dept Publ Hlth, Taoyuan, Taiwan; Tzu Chi Univ, Dept Publ Hlth, Hualien, Peoples R China	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University	Huang, JL (corresponding author), Chang Gung Childrens Hosp, Div Allergy Asthma & Rhumatol, Dept Pediat, 5 Fu Hsin St, Taoyuan, Taiwan.		Kuo, Min-Liang/C-4872-2009	Huang, Jing-Long/0000-0002-3530-7753; See, Lai-Chu/0000-0002-1379-8969				Al Sharif F, 1999, EUR J IMMUNOGENET, V26, P373; ALAM R, 1993, J IMMUNOL, V150, P3442; Alam R, 1996, AM J RESP CRIT CARE, V153, P1398, DOI 10.1164/ajrccm.153.4.8616572; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292; Chihara J, 1997, J ALLERGY CLIN IMMUN, V100, pS52, DOI 10.1016/S0091-6749(97)70005-8; Cockcroft DW, 1996, J ALLERGY CLIN IMMUN, V98, P1016, DOI 10.1016/S0091-6749(96)80185-0; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812, DOI 10.1164/ajrccm.162.5.2002113; DONLON TA, 1990, GENOMICS, V6, P548, DOI 10.1016/0888-7543(90)90485-D; Fryer AA, 2000, GENES IMMUN, V1, P509, DOI 10.1038/sj.gene.6363717; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; Hajeer AH, 1999, EUR J IMMUNOGENET, V26, P375, DOI 10.1046/j.1365-2370.1999.00163.x; HSIEH KH, 1988, J ASTHMA, V25, P73, DOI 10.3109/02770908809071357; HUNAG JL, 1991, ARCH ENVIRON HEALTH, V46, P296; Kao CC, 2001, ASIAN PAC J ALLERGY, V19, P63; Kimata H, 1996, J EXP MED, V183, P2397, DOI 10.1084/jem.183.5.2397; Koppelman GH, 2002, J ALLERGY CLIN IMMUN, V109, P498, DOI 10.1067/mai.2002.122235; Kozma GT, 2002, ALLERGY, V57, P160, DOI 10.1034/j.1398-9995.2002.1s3361.x; KUNA P, 1992, J IMMUNOL, V149, P636; Lamblin C, 1998, AM J RESP CRIT CARE, V157, P394, DOI 10.1164/ajrccm.157.2.97-02099; Liu HL, 1999, P NATL ACAD SCI USA, V96, P4581, DOI 10.1073/pnas.96.8.4581; Lukacs NW, 1997, J IMMUNOL, V158, P4398; Marsh DG, 1997, NAT GENET, V15, P389; McDermott DH, 2000, AIDS, V14, P2671, DOI 10.1097/00002030-200012010-00006; Moriuchi H, 1997, J IMMUNOL, V158, P3483; NELSON PJ, 1993, J IMMUNOL, V151, P2601; *NHLBI WHO, 2002, NAT I HLTH NAT HEART; Nickel RG, 2000, J IMMUNOL, V164, P1612, DOI 10.4049/jimmunol.164.3.1612; RICHARDS GN, 1993, THORAX, V48, P1105, DOI 10.1136/thx.48.11.1105; Sandford AJ, 2000, J ALLERGY CLIN IMMUN, V106, P135, DOI 10.1067/mai.2000.107926; Szalai C, 2001, J ALLERGY CLIN IMMUN, V108, P375, DOI 10.1067/mai.2001.117930; Szalai C, 2001, ATHEROSCLEROSIS, V158, P233, DOI 10.1016/S0021-9150(01)00423-3; Takada T, 2001, TISSUE ANTIGENS, V58, P293, DOI 10.1034/j.1399-0039.2001.580502.x; Teran LM, 1996, J IMMUNOL, V157, P1806; TERWILLINGER JD, 1994, HDB HUMAN GENETIC LI; Tillie-Leblond I, 2000, AM J RESP CRIT CARE, V162, P586, DOI 10.1164/ajrccm.162.2.9907014; Weir TD, 1998, AM J RESP CRIT CARE, V158, P787, DOI 10.1164/ajrccm.158.3.9801035; Weiss ST, 2001, ANN ALLERG ASTHMA IM, V87, P5, DOI 10.1016/S1081-1206(10)62188-6; WICSCH DG, 1998, ALLERGY PRINCIPLES P, P799; Ying S, 1999, J IMMUNOL, V163, P6321	41	58	68	0	10	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1285	1292		10.1067/mai.2003.1506	http://dx.doi.org/10.1067/mai.2003.1506			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789231				2022-12-18	WOS:000183424700019
J	Stumvoll, S; Westritschnig, K; Lidholm, J; Spitzauer, S; Colombo, P; Duro, G; Kraft, D; Geraci, D; Valenta, R				Stumvoll, S; Westritschnig, K; Lidholm, J; Spitzauer, S; Colombo, P; Duro, G; Kraft, D; Geraci, D; Valenta, R			Identification of cross-reactive and genuine Parietaria judaica pollen allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Parietaria; recombinant allergens; rPar j 2; cross-reactivity; diagnosis	MAJOR ALLERGEN; RAGWEED POLLEN; CDNA CLONING; IMMUNOTHERAPY; IGE; EXPRESSION; PROTEIN; BINDING; PROFILIN; EXTRACT	Background: The weed Parietaria judaica is one of the most important pollen allergen sources in the Mediterranean area. Objective: We sought to identify P judaica pollen allergen, which might be used to serologically distinguish genuine Parietaria sensitization and cross-reactivity to allergens from other weed species (eg, mugwort and ragweed). Methods: The allergen profile of P judaica IgE-reactive sera from weed pollen-sensitized allergic individuals from the Mediterranean region (n = 36) with high Parietaria pollen exposure and from weed pollen-allergic patients with little or no Parietaria exposure (Austria, n = 42; Scandinavia, n = 8; United States, n = 19) was established by CAP FEIA, measurements and by IgE immunoblot inhibition experiments with recombinant allergens. Results: The majority (83%) of the Mediterranean weed pollen-allergic patients mounted high IgE antibody levels (mean specific IgE, 20.89 kUA/L) against recombinant (r) Par j 2, whereas only 7% of the non-Mediterranean weed-allergic patients showed low IgE reactivity to rPar j 2 (mean specific IgE, 1.03 WAIL). The cytoskeletal protein profilin and a 2-EF-hand calcium-binding allergen were identified as cross-reactive Parietaria allergens, which were recognized preferentially by Parietaria-positive, non-Mediterranean weed pollen-allergic patients. Conclusion: rPar j 2 might be used as a diagnostic marker allergen to identify weed pollen-allergic patients who are genuinely sensitized against Parietaria pollen and thus would be particularly suited for specific immunotherapy with Parietaria pollen extract.	Univ Vienna, AKH, Dept Pathophysiol, Vienna, Austria; Pharmacia Diagnost AB, S-75182 Uppsala, Sweden; Univ Vienna, AKH, Dept Med & Clin Chem, Vienna, Austria; Ist Biomed & Immunol Mol Alberto Monroy, Palermo, Italy	University of Vienna; Pfizer; Pharmacia Corporation; University of Vienna; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR)	Valenta, R (corresponding author), Gen Hosp Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Colombo, Paolo/ABD-2985-2020; Colombo, Paolo/O-7284-2019	Colombo, Paolo/0000-0002-0908-1359; Valenta, Rudolf/0000-0001-5944-3365; Duro, Giovanni/0000-0002-9724-2561; Lidholm, Jonas/0000-0002-7779-3411				Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1111/j.1365-2222.1997.tb00672.x; Bousquet J, 1999, ALLERGY, V54, P37, DOI 10.1111/j.1398-9995.1999.tb04438.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P1039, DOI 10.1016/0091-6749(90)90048-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Charpin J., 1974, ATLAS EUROPEAN ALLER; Colombo P, 1998, ALLERGY, V53, P917, DOI 10.1111/j.1398-9995.1998.tb03791.x; COSTA MA, 1994, FEBS LETT, V341, P182, DOI 10.1016/0014-5793(94)80453-2; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; DAMATO G, 1989, J ALLERGY CLIN IMMUN, V83, P116, DOI 10.1016/0091-6749(89)90485-5; Duro G, 1996, FEBS LETT, V399, P295, DOI 10.1016/S0014-5793(96)01328-2; FALAGIANI P, 1990, POLLINOSIS; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FRENZ DA, 1995, ANN ALLERG ASTHMA IM, V75, P417; Heiss S, 1996, J ALLERGY CLIN IMMUN, V98, P938, DOI 10.1016/S0091-6749(96)80010-8; Hiller KM, 1998, SCAND J IMMUNOL, V48, P26; Hirschwehr R, 1998, J ALLERGY CLIN IMMUN, V101, P196, DOI 10.1016/S0091-6749(98)70384-7; HOLGATE ST, 1988, CLIN ALLERGY, V18, P549, DOI 10.1111/j.1365-2222.1988.tb02906.x; Kazemi-Shirazi L, 2002, INT ARCH ALLERGY IMM, V127, P259, DOI 10.1159/000057742; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Niederberger V, 1999, FASEB J, V13, P843, DOI 10.1096/fasebj.13.8.843; ORTOLANI C, 1994, ALLERGY, V49, P13, DOI 10.1111/j.1398-9995.1994.tb00767.x; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; Plaschke P, 1996, ALLERGY, V51, P461, DOI 10.1111/j.1398-9995.1996.tb00163.x; SERAFINI V, 1975, ACTA ALLERGOL, V11, P3; SUSANI M, 1995, BIOCHEM BIOPH RES CO, V215, P250, DOI 10.1006/bbrc.1995.2460; Tinghino R, 2002, J ALLERGY CLIN IMMUN, V109, P314, DOI 10.1067/mai.2002.121528; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1998, INT ARCH ALLERGY IMM, V117, P160, DOI 10.1159/000024005; van Ree R, 1999, Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M, P87; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567	33	58	62	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					974	979		10.1067/mai.2003.1376	http://dx.doi.org/10.1067/mai.2003.1376			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743560				2022-12-18	WOS:000182904500010
J	Blair, C; Nelson, M; Thompson, K; Boonlayangoor, S; Haney, L; Gabr, U; Baroody, FM; Naclerio, RM				Blair, C; Nelson, M; Thompson, K; Boonlayangoor, S; Haney, L; Gabr, U; Baroody, FM; Naclerio, RM			Allergic inflammation enhances bacterial sinusitis in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; sinusitis; murine; ovalbumin; Streptococcus pneumoniae	RHINITIS; CHILDREN; SINUSES; ANTIGEN; ADULTS	Background: Although it is not proven, one factor considered important in the development of sinusitis is allergic rhinitis. Objective: The purpose of this study was to determine whether ongoing allergic rhinitis enhances the infection and inflammation associated with Streptococcus pneumoniae acute sinus infection. Methods: BALB/c mice were sensitized to ovalbumin by intraperitoneal injection. After infection of the sinuses by S pneumoniae, either with or without concomitant administration of ovalbumin to induce allergic inflammation, mice were killed at various times and their heads were prepared for histologic evaluation of the sinuses. Results: Mice became allergic to ovalbumin and developed eosinophilia in the sinus and lung cavities in response to ovalbumin administration to each of the respective cavities. In comparison with controls, the mice with ongoing nasal allergic inflammation that were inoculated with S pneumoniae had significantly more bacteria recovered at sacrifice and had significantly more inflammation, as indicated by neutrophil, eosinophil, and mononuclear influx into the sinus mucosa. The percentage of the sinus area occupied by neutrophil clusters was also increased after infection in the allergic mice in comparison with the control mice. Conclusion: Our data demonstrate that mice can be sensitized to ovalbumin and develop a localized allergic reaction in the skin, nose, or lung. An ongoing local allergic response augments bacterial infection in these animals. We also demonstrate that allergic sensitization alone, allergen exposure alone, or an allergic response at a distal site, the lung, does not augment the sinus infection.	Univ Chicago, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA; Univ Chicago, Clin Microbiol Labs, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Naclerio, RM (corresponding author), Univ Chicago, Sect Otolaryngol Head & Neck Surg, 5841 S Maryland Ave,MC1035, Chicago, IL 60637 USA.				NIAID NIH HHS [AI45583] Funding Source: Medline; NIDCD NIH HHS [DC02714] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002714] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BENNINGER MS, 1992, AM J RHINOL, V6, P37, DOI 10.2500/105065892781874829; BERLINGER NT, 1985, LARYNGOSCOPE, V95, P29; BINDER E, 1984, Rhinology (Utrecht), V22, P255; BORNER K, 1998, ARCH OTOLARYNOL HEAD, V124, P1227; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051, DOI 10.1164/ajrccm.161.6.9906121; CONNER BL, 1989, ANN ALLERGY, V62, P457; ENBERG RN, 1989, ANN ALLERGY, V63, P513; FRIEDMAN WH, 1975, LARYNGOSCOPE, V85, P1999, DOI 10.1288/00005537-197512000-00005; Gabr U, 2000, J ALLERGY CLIN IMMUN, V105, pS212, DOI 10.1016/S0091-6749(00)91057-1; GROVE R, 1990, J ALLERGY CLIN IMMUN, V11, P271; ITOH K, 1992, ACTA OTO-LARYNGOL, V112, P882, DOI 10.3109/00016489209137487; Iwens P., 1994, Rhinology (Utrecht), V32, P65; KARLSSON G, 1994, ACTA OTO-LARYNGOL, P26; KENNEDY DW, 1985, ARCH OTOLARYNGOL, V111, P576; Leipzig JR, 1996, J ALLERGY CLIN IMMUN, V98, P1130, DOI 10.1016/S0091-6749(96)80206-5; MOXON ER, 1981, REV INFECT DIS, V3, P354; Musher DM, 2000, PRINCIPLES PRACTICE, P2128; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; SALOGA J, 1993, J CLIN INVEST, V91, P133, DOI 10.1172/JCI116162; SAVOLAINEN S, 1989, ALLERGY, V44, P116, DOI 10.1111/j.1398-9995.1989.tb02234.x; SHAPIRO GG, 1985, PEDIATR INFECT DIS J, V4, pS55, DOI 10.1097/00006454-198511001-00003; SHAPIRO GG, 1991, PEDIATRICS, V87, P311; Slavin RG, 2000, ANN ALLERG ASTHMA IM, V85, P275, DOI 10.1016/S1081-1206(10)62529-X; SPECTOR SL, 1992, J ALLERGY CLIN IMMUN, V90, P518, DOI 10.1016/0091-6749(92)90178-5; TOSKALA E, 1995, J LARYNGOL OTOL, V109, P509, DOI 10.1017/S0022215100130580; UMETSU DT, 1985, NEW ENGL J MED, V313, P1247, DOI 10.1056/NEJM198511143132002; VAN DISHOECK H A, 1957, Pract Otorhinolaryngol (Basel), V19, P502; Wald ER, 1998, AM J MED SCI, V316, P13, DOI 10.1097/00000441-199807000-00003	28	58	62	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					424	429		10.1067/mai.2001.117793	http://dx.doi.org/10.1067/mai.2001.117793			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544463				2022-12-18	WOS:000171215400015
J	Liu, MC; Proud, D; Lichtenstein, LM; Hubbard, WC; Bochner, BS; Stealey, BA; Breslin, L; Xiao, HQ; Freidhoff, LR; Schroeder, JT; Schleimer, RP				Liu, MC; Proud, D; Lichtenstein, LM; Hubbard, WC; Bochner, BS; Stealey, BA; Breslin, L; Xiao, HQ; Freidhoff, LR; Schroeder, JT; Schleimer, RP			Effects of prednisone on the cellular responses and release of cytokines and mediators after segmental allergen challenge of asthmatic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						glucocorticoids; inflammation; asthma; cytokines	INHALED BECLOMETHASONE DIPROPIONATE; AIRWAY INFLAMMATION; MAST-CELLS; ANTIGEN CHALLENGE; ATOPIC ASTHMA; MESSENGER-RNA; MILD ASTHMA; INHIBITION; EXPRESSION; THERAPY	Background: Systemic glucocorticoids are a major therapy for the management of allergic inflammation and asthma; however, information about their effects in vivo are limited . Objective: This study was performed to examine the effects of prednisone on inflammatory mediators, cytokines, and cellular responses in the model of segmental allergen challenge (SAC) of allergic asthmatic subjects. Methods: The effects of a 3-day pretreatment with oral prednisone (30 mg twice daily) on the physiologic and inflammatory responses to SAC were studied in 10 allergic asthmatic subjects in a double-blind, placebo-con trolled, crossover protocol. Results: Prednisone improved baseline FEV1 by 10% and modestly inhibited the SAC-induced fall in FEV1 at 30 minutes and at 6 to 8 hours. Five minutes after challenge, levels of histamine, PGD(2),9 alpha ,11 beta -PGF(2), and thromboxane B-2 increased in bronchoalveolar lavage fluid (median increase, 5- to 14-fold); prednisone did not inhibit these responses. Prednisone inhibited (median decrease, 66 % -97 %) the total influx of inflammatory cells, specifically eosinophils, basophils, and some subsets of T lymphocytes (CD4, CD45RA, and CD45RO cells) assessed 19 hours after SAC, but it did not inhibit the influx of neutrophils. Increases in soluble E-selectin, kinins, and albumin were also inhibited by the glucocorticoid (median decrease, 36 %-74 %). Prednisone treatment inhibited the appearance of mRNA, protein, or both for T(H)2 cytokines (IL-4 and IL-5), as well as for IL-2 and transforming growth factor alpha, but did not inhibit increases of immunoreactive GM-CSF in bronchoalveolar lavage fluid. Conclusion: These studies indicate that prednisone suppresses multiple components of allergic airway inflammation, including cell recruitment, adhesion molecule expression or release, airway permeability, and production of cytokines potentially involved in airway immunity or remodeling.	Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Liu, MC (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049545] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI031867, R01AI044885] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 49545] Funding Source: Medline; NIAID NIH HHS [U19 AI31867, AI44885, R01 AI31891] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERGSTRAND H, 1990, THORAX, V45, P362, DOI 10.1136/thx.45.5.362; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BOCHNER BS, 1987, J IMMUNOL, V139, P2303; BORISH L, 1992, J IMMUNOL, V149, P3078; BURGE PS, 1982, CLIN ALLERGY, V12, P523, DOI 10.1111/j.1365-2222.1982.tb02551.x; COHAN VL, 1989, AM REV RESPIR DIS, V140, P951, DOI 10.1164/ajrccm/140.4.951; DAHL R, 1982, EUR J RESPIR DIS S, V122, P167; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; DUDDRIDGE M, 1993, EUR RESPIR J, V6, P489; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953, DOI 10.1164/ajrccm.149.4.8143061; ENERBACK L, 1986, INT ARCH ALLER A IMM, V80, P44, DOI 10.1159/000234024; FAUCI AS, 1975, BLOOD, V46, P235; GAURUS SN, 1992, AM J RESP CELL MOL B, V7, P261; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; HONG SL, 1976, P NATL ACAD SCI USA, V73, P1730, DOI 10.1073/pnas.73.5.1730; HUANG SK, 1994, J IMMUNOL METHODS, V168, P167, DOI 10.1016/0022-1759(94)90052-3; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; LAITINEN LA, 1991, AM REV RESPIR DIS, V143, P423, DOI 10.1164/ajrccm/143.2.423; LAITINEN LA, 1997, INHALED GLUCOCORTICO, P121; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; LIU MC, 1990, AM REV RESPIR DIS, V142, P126, DOI 10.1164/ajrccm/142.1.126; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; Naseer T, 1997, AM J RESP CRIT CARE, V155, P845, DOI 10.1164/ajrccm.155.3.9117015; OSWALD IP, 1994, J IMMUNOL, V153, P1707; PETERS SP, 1989, J ALLERGY CLIN IMMUN, V83, pA310; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; SCHLEIMER RP, 1997, TOPICAL GLUCOCORTICO; SCHLEIMER RP, 1997, TOPICAL GLUCOCORTICO, P203; SCHLEIMER RP, 1992, MAST CELL HLTH DIS, P483; Schwiebert LM, 1996, AM J RESP CRIT CARE, V154, pS16, DOI 10.1164/ajrccm/154.2_Pt_2.S16; SIM TC, 1995, AM J RESP CRIT CARE, V152, P927, DOI 10.1164/ajrccm.152.3.7545059; SVENSJO E, 1985, CURRENT CLIN PRACTIC, V25, P136; VANDEGRAAF EA, 1991, AM REV RESPIR DIS, V143, P362, DOI 10.1164/ajrccm/143.2.362; WANG JH, 1994, J ALLERGY CLIN IMMUN, V94, P1025, DOI 10.1016/0091-6749(94)90121-X; Wang JH, 1996, AM J RESP CELL MOL, V14, P27, DOI 10.1165/ajrcmb.14.1.8534483; WOOLCOCK AJ, 1988, CLIN ALLERGY, V18, P165, DOI 10.1111/j.1365-2222.1988.tb02856.x	40	58	61	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1					29	38						10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	458AN	11447379				2022-12-18	WOS:000170171200004
J	Kettner, A; Hughes, GJ; Frutiger, S; Astori, M; Roggero, M; Spertini, F; Corradin, G				Kettner, A; Hughes, GJ; Frutiger, S; Astori, M; Roggero, M; Spertini, F; Corradin, G			Api m 6: A new bee venom allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Api m 6; IgE; bee venom; Hymenoptera; allergens; T cells; immunotherapy; matrix-assisted laser desorption-ionization time of flight mass spectrometry; carboxypeptidase	BIRCH POLLEN ALLERGEN; MASS-SPECTROMETRY; MAJOR ALLERGEN; CDNA CLONING; T-CELLS; IMMUNOTHERAPY; REACTIVITY; ISOFORMS; PEPTIDES; BET-V-1	Background: Characterization of the primary structure of allergens is a prerequisite for the design of new diagnostic and therapeutic tools for allergic diseases. Objective: The purpose of this study was the identification and characterization of a low-molecular-weight, IgE-binding, bee venom (BV) allergen. Methods: BV proteins were separated by using size exclusion chromatography and HPLC, IgE antibody binding to purified proteins was analyzed by means of immunoblotting, and T-cell response was analyzed by means of proliferation assay. Amino acid sequence was determined with 2 approaches, namely Edman degradation and carboxy terminal analysis with mass spectrometry, Results: Api m 6, which migrated as an 8-kd band in SDS-PAGE, was frequently (42%) recognized by IgE from BV-hypersensitive patients, In addition, PBMCs from BV-hypersensitive patients, as well as from a normal control subject, proliferated in response to this allergen. Api m 6 exists as 4 isoforms of 7190, 7400, 7598, and 7808 d, respectively. Amino acid sequences obtained from HPLC-purified preparations revealed that the isoforms were constituted of a common central core of 67 residues, only differing in the amino- and carboxy-terminal ends, Api m 6 showed no significant sequence homology with known proteins. Conclusions: We have Identified and sequenced a new BV allergen that elicits a strong IgE and T-cell response in a large number of BV-hypersensitive patients. Api m 6 should be considered in the diagnostic and therapeutic approach of BV immunotherapy on the basis of peptides or recombinant proteins.	Univ Lausanne, Inst Biochem, Lausanne, Switzerland; CHU Vaudois, Div Immunol & Allergy, Lausanne, Switzerland; Ctr Med Univ Geneva, Dept Biochem Med, Geneva, Switzerland	University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva	Corradin, G (corresponding author), Inst Biochim, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.							Banks B.E.C., 1986, P329; BELLO J, 1982, BIOCHEMISTRY-US, V21, P461, DOI 10.1021/bi00532a007; BOND JF, 1991, J IMMUNOL, V146, P3380; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; DAVIS C G, 1990, New Biologist, V2, P410; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; GMACHL M, 1993, P NATL ACAD SCI USA, V90, P3569, DOI 10.1073/pnas.90.8.3569; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HOFFMAN DR, 1976, J ALLERGY CLIN IMMUN, V58, P551, DOI 10.1016/0091-6749(76)90201-3; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P364, DOI 10.1016/0091-6749(77)90019-7; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P147, DOI 10.1016/0091-6749(77)90217-2; Jeep S, 1996, ALLERGY, V51, P540, DOI 10.1111/j.1398-9995.1996.tb00110.x; Kammerer R, 1997, CLIN EXP ALLERGY, V27, P1016, DOI 10.1111/j.1365-2222.1997.tb01253.x; Kettner A, 1999, CLIN EXP ALLERGY, V29, P394, DOI 10.1046/j.1365-2222.1999.00492.x; KING TP, 1995, ALLERGY, V50, P765, DOI 10.1111/j.1398-9995.1995.tb01222.x; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; KREIL G, 1977, FED PROC, V36, P2081; KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGHT WC, 1976, J ALLERGY CLIN IMMUN, V58, P322, DOI 10.1016/0091-6749(76)90138-X; LOWY PH, 1971, ARCH BIOCHEM BIOPHYS, V145, P338, DOI 10.1016/0003-9861(71)90044-0; Mueller H L, 1966, J Asthma Res, V3, P331; MULLER U, 1993, ALLERGY, V48, P37; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; PATTERSON DH, 1995, ANAL CHEM, V67, P3971, DOI 10.1021/ac00117a024; PAULL BR, 1977, J ALLERGY CLIN IMMUN, V59, P334, DOI 10.1016/0091-6749(77)90056-2; PEREZ M, 1990, J BIOL CHEM, V265, P16210; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; SCHUMACHER MJ, 1992, J ALLERGY CLIN IMMUN, V90, P59, DOI 10.1016/S0091-6749(06)80011-4; SHKENDER.S, 1973, FEBS LETT, V33, P343, DOI 10.1016/0014-5793(73)80226-1; Shkenderov S., 1976, P263; SHKENDEROV S, 1982, TOXICON, V20, P317, DOI 10.1016/0041-0101(82)90234-3; Sparholt SH, 1997, CLIN EXP ALLERGY, V27, P932; SPERTINI F, 1991, J IMMUNOL, V146, P47; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; VLASAK R, 1984, EUR J BIOCHEM, V145, P279, DOI 10.1111/j.1432-1033.1984.tb08549.x; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330	38	58	66	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					914	920		10.1067/mai.2001.113867	http://dx.doi.org/10.1067/mai.2001.113867			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344362	Bronze			2022-12-18	WOS:000168812300023
J	Liggett, SB				Liggett, SB			The pharmacogenetics of beta(2)-adrenergic receptors: Relevance to asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adenylyl cyclase; beta-agonist; tachyphylaxis; pharmacogenetics	GENETIC POLYMORPHISMS; ASSOCIATION; CELLS	The beta(2)-adrenergic receptor (beta(2)AR) is the molecular target for beta-agonists used in the treatment of asthma, In the human population, 4 polymorphisms of the beta(2)AR coding block have been found, 3 of which result in receptors that have different properties compared with wild-type. To date, clinical studies suggest that these beta(2)AR polymorphisms may alter asthmatic phenotype and the response to beta-agonist therapy, making these variants the first of undoubtedly several genetic loci that will ultimately be found that will provide for individualized therapy in asthma.	Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Liggett, SB (corresponding author), 231 Bethesda Ave,ML 0564,Room 7511, Cincinnati, OH 45267 USA.		liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045967, R37HL045967, P01HL041496] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41496, HL53436, HL45967] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		COQUERET O, 1995, CLIN EXP ALLERGY, V25, P304, DOI 10.1111/j.1365-2222.1995.tb01047.x; D'Amato M, 1998, AM J RESP CRIT CARE, V158, P1968, DOI 10.1164/ajrccm.158.6.9804126; Dewar JC, 1997, J ALLERGY CLIN IMMUN, V100, P261, DOI 10.1016/S0091-6749(97)70234-3; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GREEN SA, 1993, J BIOL CHEM, V268, P23116; Green SA, 1995, PULM PHARMACOL, V8, P1, DOI 10.1006/pulp.1995.1001; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; Hancox RJ, 1998, EUR RESPIR J, V11, P589; LIGGETT SB, 1996, GENETICS ASTHMA, P455; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; SZEFLER SJ, 1991, CLIN PHARMACOL THER, V49, P59, DOI 10.1038/clpt.1991.11; Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; Turki J, 1996, P NATL ACAD SCI USA, V93, P10483, DOI 10.1073/pnas.93.19.10483	16	58	64	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	2	S			S487	S492		10.1016/S0091-6749(00)90048-4	http://dx.doi.org/10.1016/S0091-6749(00)90048-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286JG	10669529				2022-12-18	WOS:000085439600006
J	Hoffmann-Sommergruber, K; Demoly, P; Crameri, R; Breiteneder, H; Ebner, C; Machado, MLD; Blaser, K; Ismail, C; Scheiner, O; Bousquet, J; Menz, G				Hoffmann-Sommergruber, K; Demoly, P; Crameri, R; Breiteneder, H; Ebner, C; Machado, MLD; Blaser, K; Ismail, C; Scheiner, O; Bousquet, J; Menz, G			IgE reactivity to Api g 1, a major celery allergen, in a Central European population is based on primary sensitization by Bet v 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Api g 1; Bet v 1; celery allergy; birch pollen allergy; mugwort pollen allergy; skin prick tests; cross-reactivity	BIRCH POLLEN ALLERGEN; TREE POLLEN; CROSS-REACTIVITY; CLONING; IDENTIFICATION; PROFILIN; MUGWORT; BET-V-1; PURIFICATION; EXPRESSION	Background: Up to 70% of patients with tree pollen allergy display allergic symptoms when eating certain fruits and vegetables. Homologous proteins with allergenic features are present in a wide range of plant species and can cause allergic reactions. Objective: The aim of this study was to evaluate recombinant Api g 1, a major celery allergen, for In vivo and in vitro diagnosis of celery allergy in populations from Davos, Switzerland, and Montpellier, France. Methods: A group of patients with celery and birch pollen allergy from Davos was tested, and the results from those tests were compared with results from a group of patients allergic to celery from Montpellier. Skin prick tests were performed with a commercial celery extract, crude celery, and purified recombinant Api g 1. Quantitative and qualitative serology was done with natural and recombinant allergens by means of RASTs and immunoblotting. Results: Recombinant Api g 1 allowed accurate in vivo diagnosis of celery allergy in all patients from the Swiss group. RAST results with celery extract were negative in 8 of 24 patients; results of immunoblotting with celery extract were negative in 4 of 24 patients, and results of immunoblotting with recombinant (r)Api g 1 were negative in 8 of 24 patients. In the French group 11 of 12 patients had a positive skin reaction with crude celery extract, but only 2 patients reacted with rApi g 1. RAST results for celery were positive in 8 of 12 patients. In immunoblotting experiments 8 patient sera displayed IgE directed against various celery allergens, whereas no patients sera had rApi g I-specific IgE. Conclusion: Our results document that rADi g 1 allows accurate in vivo diagnosis only in areas where birch trees are common. In areas where no birch trees grow, primary sensitization takes place through different pollen allergens (eg, mugwort pollen). Moreover, it became evident that birch pollen and celery allergy are highly related in Central Europe, whereas in Southern Europe the mugwort-celery type is predominant.	Univ Vienna, Inst Gen & Expt Pathol, A-1090 Vienna, Austria; Hop Arnaud de Villeneuve, Serv Malad Resp, Montpellier, France; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Univ Agr Vienna, Inst Appl Microbiol, Vienna, Austria; Hochgebirgsklin Davos Wolfgang, Davos, Switzerland	University of Vienna; Universite de Montpellier; CHU de Montpellier; Swiss Institute of Allergy & Asthma Research; University of Natural Resources & Life Sciences, Vienna	Hoffmann-Sommergruber, K (corresponding author), Univ Vienna, Inst Gen & Expt Pathol, AKH EBO 3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Margit, Laimer/P-7096-2019; Demoly, Pascal/Y-9938-2019; Bousquet, Jean/O-4221-2019	Margit, Laimer/0000-0002-6796-8126; Demoly, Pascal/0000-0001-7827-7964; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X				Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; DELAHOZ F, 1990, MOL IMMUNOL, V27, P651, DOI 10.1016/0161-5890(90)90008-N; Demoly P., 1998, ALLERGY PRINCIPLES P, V5th ed., P430; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Elfman L, 1997, INT ARCH ALLERGY IMM, V113, P249, DOI 10.1159/000237561; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GodnicCvar J, 1997, J ALLERGY CLIN IMMUN, V99, P354, DOI 10.1016/S0091-6749(97)70053-8; Grote M, 1998, J ALLERGY CLIN IMMUN, V101, P250, DOI 10.1016/S0091-6749(98)70390-2; Hirschwehr R, 1998, J ALLERGY CLIN IMMUN, V101, P196, DOI 10.1016/S0091-6749(98)70384-7; Hoffmann-Sommergruber K, 1999, CLIN EXP ALLERGY, V29, P840, DOI 10.1046/j.1365-2222.1999.00529.x; JANKIEWICZ A, 1998, ALLERGO J, V2, P87; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; Leitner A, 1998, ALLERGY, V53, P36, DOI 10.1111/j.1398-9995.1998.tb03771.x; Menz G, 1996, CLIN EXP ALLERGY, V26, P50, DOI 10.1111/j.1365-2222.1996.tb00056.x; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; Scheurer S, 1997, MOL IMMUNOL, V34, P619, DOI 10.1016/S0161-5890(97)00072-2; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; Wen J, 1997, MOL PHYLOGENET EVOL, V8, P317, DOI 10.1006/mpev.1997.0447; WUTHRICH B, 1993, ALLERGOLOGIE, V16, P280	28	58	60	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				478	484		10.1016/S0091-6749(99)70397-0	http://dx.doi.org/10.1016/S0091-6749(99)70397-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452775				2022-12-18	WOS:000082364800046
J	McFadden, ER; Casale, TB; Edwards, TB; Kemp, JP; Metzger, J; Nelson, HS; Storms, WW; Neidl, MJ				McFadden, ER; Casale, TB; Edwards, TB; Kemp, JP; Metzger, J; Nelson, HS; Storms, WW; Neidl, MJ			Administration of budesonide once daily by means of Turbuhaler to subjects with stable asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; budesonide; inhalation; glucocorticosteroids; Turbuhaler; once daily; quality of life	METERED-DOSE INHALER; QUALITY-OF-LIFE; DOSING FREQUENCY; CORTICOSTEROIDS; EFFICACY; TWICE; MODERATE; SAFETY	Background: Optimal management of chronic, mild-to-moderate asthma with inhaled steroids may include use of the lowest possible doses, as recommended in guidelines, and a reduction in the frequency of daily administration for greater convenience. Lower doses and once daily treatment with inhaled steroids must be rigorously evaluated in controlled clinical trials. Objectives: The objective of this study was to assess the efficacy and safety of once daily treatment with budesonide in subjects with stable asthma, Methods: Once daily budesonide was assessed in 309 adult subjects, including those who were and were not using an inhaled steroid at baseline, The subjects were stratified by inhaled steroid use and randomly assigned to one of 3 treatments: 200 mu g budesonide, 400 mu g budesonide, or placebo administered by means of Turbuhaler once daily in the morning for 6 weeks. Beyond this point, treatment was continued unchanged for another 12 weeks (maintenance) in those receiving 200 mu g budesonide once daily and placebo. In those who received 400 mu g budesonide once daily, the dose was reduced to 200 mu g once daily at week 6 and held constant for the remaining 12 weeks (400/200 mu g group). Primary efficacy endpoints were mean change from baseline in FEV1 and morning peak expiratory flow. Results: Once daily budesonide was well tolerated and resulted in significant improvements in all efficacy endpoints, even though baselines were well stabilized. Baseline lung function was elevated with little room for improvement; however, mean increases in FEV1 during the maintenance period were 0.10 L and 0.11 L in the 200 mu g and 400/200 mu g groups, respectively, versus a decrease of -0.09 L in the placebo arm (P <.001). Results for peak expiratory flow were similar. Significant improvements in secondary endpoints, including symptoms, beta-agonist use, and quality of life, also developed with budesonide 200 and 400 mu g once daily. Conclusion: Inhaled budesonide, in doses as low as 200 mu g, may be an appropriate introductory or maintenance dose in subjects with stable, mild-to-moderate asthma.	Univ Hosp Cleveland, Cleveland, OH 44106 USA; Nebraska Med Res Inst, Papillion, NE USA; Albany Med Ctr, Ctr Asthma & Allergy, Albany, NY USA; Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA; E Carolina Univ, Sch Med, Greenville, NC USA; Natl Jewish Med & Res Ctr, Denver, CO USA; Asthma & Allergy Associates PC, Colorado Springs, CO USA; Astra Pharmaceut LP, Westborough, MA USA	University Hospitals of Cleveland; Albany Medical College; University of North Carolina; East Carolina University; National Jewish Health	McFadden, ER (corresponding author), Univ Hosp Cleveland, 11100 Euclid Ave, Cleveland, OH 44106 USA.		Casale, Thomas B/K-4334-2013	Casale, Thomas B/0000-0002-3149-7377				BARNES PJ, 1993, AM REV RESPIR DIS, V148, pS1, DOI 10.1164/ajrccm/148.4_Pt_2.S1; Bender B, 1997, ANN ALLERG ASTHMA IM, V79, P177, DOI 10.1016/S1081-1206(10)63001-3; Busse WW, 1998, J ALLERGY CLIN IMMUN, V101, P457, DOI 10.1016/S0091-6749(98)70353-7; Campbell LM, 1991, BR J CLIN RES, V2, P111; CAMPBELL LM, 1995, EUR J CLIN RES, V7, P1; CHRISHOLM SL, 1998, RESP MED, V92, P421; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; EDSBACKER S, 1993, BUDESONIDE TURBUHALE, P10; ENGEL T, 1989, ALLERGY, V44, P220, DOI 10.1111/j.1398-9995.1989.tb02266.x; GAGNON M, 1994, CHEST, V105, P1732, DOI 10.1378/chest.105.6.1732; JONES AH, 1994, RESP MED, V88, P293, DOI 10.1016/0954-6111(94)90059-0; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; MALO JL, 1989, AM REV RESPIR DIS, V140, P624, DOI 10.1164/ajrccm/140.3.624; *NAT ASTHM ED PROG, 1997, 974051 NIH PUBL; PINCUS DJ, 1995, J ALLERGY CLIN IMMUN, V95, P1172, DOI 10.1016/S0091-6749(95)70073-0; THORSSON L, 1994, EUR RESPIR J, V7, P1839, DOI 10.1183/09031936.94.07101839; TOOGOOD JH, 1982, J ALLERGY CLIN IMMUN, V70, P288, DOI 10.1016/0091-6749(82)90065-3; Toogood JH, 1998, J ALLERGY CLIN IMMUN, V102, P705, DOI 10.1016/S0091-6749(98)70007-7; *US DEP HLTH HUM S, 1996, MORB MORT 1996 CHART; Venables T., 1996, BRIT J CLIN PHARMACO, V7, P15; ZuWallack RL, 1997, J ALLERGY CLIN IMMUN, V99, P278, DOI 10.1016/S0091-6749(97)70043-5	22	58	59	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					46	52		10.1016/S0091-6749(99)70112-0	http://dx.doi.org/10.1016/S0091-6749(99)70112-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400838				2022-12-18	WOS:000081738900007
J	Meltzer, EO; Berger, WE; Berkowitz, RB; Bronsky, EA; Dvorin, DJ; Finn, AF; Galant, SP; Grossman, J; Hampel, FC; Ratner, PH; Ruff, ME; Schenkel, EJ; Segal, AT; Segall, N; Stewart, GE; Tripathy, I; Skoner, DP; Anolik, R; Dockhorn, RJ; van Bavel, J; Mesarina-Wicki, B; Nolop, KB				Meltzer, EO; Berger, WE; Berkowitz, RB; Bronsky, EA; Dvorin, DJ; Finn, AF; Galant, SP; Grossman, J; Hampel, FC; Ratner, PH; Ruff, ME; Schenkel, EJ; Segal, AT; Segall, N; Stewart, GE; Tripathy, I; Skoner, DP; Anolik, R; Dockhorn, RJ; van Bavel, J; Mesarina-Wicki, B; Nolop, KB			A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						seasonal allergic rhinitis; pediatrics; mometasone furoate	BECLOMETHASONE DIPROPIONATE AEROSOL; TOLERABILITY; EFFICACY; SAFETY	Background: The efficacy and safety of mometasone furoate aqueous nasal spray (MFNS; Nasonex) 200 mu g once daily for the treatment and prophylaxis of seasonal allergic rhinitis (SAR) and treatment of perennial rhinitis have been demonstrated in adults. However, the dose response of MFNS in pediatric patients has not yet been characterized. Objective: This study was conducted to determine the dose-response relationship of 3 different doses of MFNS in a pediatric population. Methods: This was a multicenter, double-blind, active- and placebo-controlled study of 679 children 6 to 11 years of age with histories of SAR and documented positive skin test responses. Patients were randomized to one of the following treatment groups for 4 weeks: MFNS 25 mu g once daily, MFNS 100 mu g once daily, MFNS 200 mu g once daily, beclomethasone dipropionate 84 mu g twice daily (168 mu g/day), or placebo. Physician evaluations were performed at days 4, 8, 15, and 29, and patient evaluations were analyzed for days 1 to 15 and 16 to 29. Results: The mean reduction from baseline in physician-evaluated total nasal symptom scores at day 8 (the primary efficacy variable) was significantly greater in the MFNS and beclomethasone dipropionate groups than in the placebo group (P less than or equal to.02). No significant differences were observed among the 3 MFNS groups. However, as treatment continued, symptoms in patients treated with MFNS 100 or 200 mu g once daily continued to improve, whereas those treated with MFNS 25 mu g once daily demonstrated little further improvement. By day 29, MFNS 100 and 200 mu g once daily both were significantly more effective than MFNS 25 mu g once daily in relieving symptoms of SAR, but MFNS 200 mu g provided no additional benefit over MFNS 100 mu g. All doses of MFNS were well tolerated, and cosyntropin stimulation tests performed before and after treatment found no evidence of hypothalamic-pituitary-adrenal axis suppression. Conclusion: These results indicate that the most appropriate therapeutic dosage of MFNS in the treatment of SAR in children 6 to 11 years of age is 100 mu g once daily. In addition, MFNS at doses up to 200 mu g once daily for 4 weeks was well tolerated and had no detectable effects on hypothalamic-pituitary-adrenal axis function.	Allergy & Asthma Med Grp & Res Ctr, APC, San Diego, CA 92123 USA; Allergy & Asthma Immunol Res Fdn, Atlanta, GA 30301 USA; Intermountain Clin Res, Salt Lake City, UT 84101 USA; Asthma & Allergy Ctr Charleston, Charleston, SC 29401 USA; VIVRA Res Partners, Tucson, AZ 85701 USA; Sylvania Res, San Antonio, TX 78201 USA; Dallas Asthma & Allergy Ctr, Dallas, TX 75201 USA; Asthma & Allergy Care Florida, Ocala, FL 34470 USA; Clin Res Ozarks Inc, Rolla, MO 65401 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; Asthma & Allergy Specialists PC, Philadelphia, PA 19104 USA; Int Med Tech Consultants Inc, Lenexa, KS 66210 USA; Schering Plough Res Inst, Kenilworth, NJ 07033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Merck & Company; Schering-Plough Research Institute	Meltzer, EO (corresponding author), Allergy & Asthma Med Grp & Res Ctr, APC, 9610 Granite Ridge Dr,Suite B, San Diego, CA 92123 USA.							BONER A, 1995, ALLERGY, V50, P498, DOI 10.1111/j.1398-9995.1995.tb01185.x; Brannan MD, 1997, CLIN THER, V19, P1330, DOI 10.1016/S0149-2918(97)80008-2; Brannan MD, 1996, J ALLERGY CLIN IMMUN, V97, P62; Bronsky EA, 1997, ANN ALLERG ASTHMA IM, V79, P51, DOI 10.1016/S1081-1206(10)63084-0; Davies RJ, 1997, CLIN THER, V19, P27; Drouin M, 1996, ANN ALLERG ASTHMA IM, V77, P153, DOI 10.1016/S1081-1206(10)63502-8; Fireman P, 1997, J ALLERGY CLIN IMMUN, V99, pS787, DOI 10.1016/S0091-6749(97)70130-1; GALANT SP, 1994, J PEDIATR-US, V125, P628; Graft D, 1996, J ALLERGY CLIN IMMUN, V98, P724, DOI 10.1016/S0091-6749(96)70119-7; Hebert JR, 1996, ALLERGY, V51, P569; Onrust SV, 1998, DRUGS, V56, P725, DOI 10.2165/00003495-199856040-00018; PRAHL P, 1975, ARCH DIS CHILD, V50, P875, DOI 10.1136/adc.50.11.875; Rachelefsky GS, 1998, J ALLERGY CLIN IMMUN, V101, pS236; RICKETTI AJ, 1985, ALLERGIC DIS DIAGNOS, P208; SHORE SC, 1977, ARCH DIS CHILD, V52, P486, DOI 10.1136/adc.52.6.486; SLY RM, 1980, ALLERGIC DIS INFANCY, P746; Spector SL, 1997, J ALLERGY CLIN IMMUN, V99, pS773, DOI 10.1016/S0091-6749(97)70126-X; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; WRIGHT AL, 1994, PEDIATRICS, V94, P895	19	58	60	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					107	114		10.1016/S0091-6749(99)70121-1	http://dx.doi.org/10.1016/S0091-6749(99)70121-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400847				2022-12-18	WOS:000081738900016
J	Kusunoki, T; Asai, K; Harazaki, M; Korematsu, S; Hosoi, S				Kusunoki, T; Asai, K; Harazaki, M; Korematsu, S; Hosoi, S			Month of birth and prevalence of atopic dermatitis in schoolchildren: Dry skin in early infancy as a possible etiologic factor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; allergy; dry skin; epidemiology month of birth; water holding capacity	CYTOKINE PRODUCTION; BARRIER DISRUPTION; ALLERGIC RHINITIS; STRATUM-CORNEUM; MICE; SENSITIZATION; SEASON; ASTHMA; KERATINOCYTES; PATHOGENESIS	Background: Month of birth has been shown to affect later development of allergic diseases. Objective: We sought to evaluate the relationship between month of birth and the prevalence of atopic dermatitis (AD) in a large-scale general population of schoolchildren and to elucidate the possible mechanism for this relationship. Methods: Questionnaire data on the prevalence of allergic diseases were obtained for 33,725 schoolchildren aged 7 to 15 years. In a separate study the water-holding capacity of "uninvolved" skin,was compared for children with and without AD. Results: We found striking differences in the prevalence of AD according to the month of birth (chi(2) = 34.9, P < .0001). Overall, those born in autumn showed the highest (7.5%), and those born in spring showed the lowest (5.5%), prevalence of AD. There was little or no such tendency for the prevalence of bronchial asthma (chi(2) = 17.2, P = .103) and allergic rhinitis (chi(2) = 24, P = .01). We found no statistical variation across birth month in the ratio of AD with no other allergic disease/total AD, indicating that this deviation was observed whatever the allergic predisposition of the subjects. In a separate study a significantly lower water-holding capacity of uninvolved skin was observed in children with AD even from early infancy. Conclusion: These findings lead us to speculate that the climate in early infancy affects the skin condition and that those born in autumn have dry skin in early infancy, which may ultimately result in a higher prevalence of AD among young schoolchildren. This might be at least one of the "nonallergic" etiologic factors of this complex disease.	Kyoto Univ, Dept Pediat, Kyoto 606, Japan	Kyoto University	Kusunoki, T (corresponding author), Kyoto Univ Hosp, Dept Pediat, Sakyo Ku, 54 Shogoin, Kyoto 6068507, Japan.		Kusunoki, Takashi/AAE-5512-2019					AALBERSE RC, 1992, CLIN EXP ALLERGY, V22, P1003, DOI 10.1111/j.1365-2222.1992.tb03028.x; ABERG N, 1989, CLIN EXP ALLERGY, V19, P643, DOI 10.1111/j.1365-2222.1989.tb02761.x; Aoki Toshiyuki, 1998, Allergology International, V47, P137, DOI 10.2332/allergolint.47.137; ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x; BECK HI, 1987, ACTA DERM-VENEREOL, V67, P448; BJORKSTEN F, 1980, CLIN ALLERGY, V10, P581; COOPER KD, 1994, J INVEST DERMATOL, V102, P128, DOI 10.1111/1523-1747.ep12371746; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; IMOKAWA G, 1991, J INVEST DERMATOL, V96, P523, DOI 10.1111/1523-1747.ep12470233; Keil U, 1996, TOXICOL LETT, V86, P99, DOI 10.1016/0378-4274(96)03680-6; KITAGAKI H, 1995, J INVEST DERMATOL, V105, P749, DOI 10.1111/1523-1747.ep12325538; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; Nagai H, 1997, J ALLERGY CLIN IMMUN, V100, pS39; NICKOLOFF BJ, 1994, J AM ACAD DERMATOL, V30, P535, DOI 10.1016/S0190-9622(94)70059-1; Nilsson L, 1997, ARCH DIS CHILD, V76, P341, DOI 10.1136/adc.76.4.341; Nishijima T, 1997, J INVEST DERMATOL, V109, P175, DOI 10.1111/1523-1747.ep12319282; Nishioka K, 1998, J ALLERGY CLIN IMMUN, V101, P28, DOI 10.1016/S0091-6749(98)70189-7; Pastore S, 1997, J CLIN INVEST, V99, P3009, DOI 10.1172/JCI119496; Pastore S, 1998, J ALLERGY CLIN IMMUN, V101, P538, DOI 10.1016/S0091-6749(98)70361-6; QUOIX E, 1988, ALLERGY, V43, P127, DOI 10.1111/j.1398-9995.1988.tb00406.x; Sarpong SB, 1998, J ALLERGY CLIN IMMUN, V101, P566, DOI 10.1016/S0091-6749(98)70369-0; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; TAGAMI H, 1982, J INVEST DERMATOL, V78, P425, DOI 10.1111/1523-1747.ep12507756; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; TUPKER RA, 1995, BRIT J DERMATOL, V133, P365, DOI 10.1111/j.1365-2133.1995.tb02662.x; WJST M, 1992, CLIN EXP ALLERGY, V22, P1026, DOI 10.1111/j.1365-2222.1992.tb03032.x; Wood LC, 1997, EXP DERMATOL, V6, P98, DOI 10.1111/j.1600-0625.1997.tb00154.x; WOOD LC, 1992, J CLIN INVEST, V90, P482, DOI 10.1172/JCI115884	28	58	59	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1148	1152		10.1016/S0091-6749(99)70191-0	http://dx.doi.org/10.1016/S0091-6749(99)70191-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359898				2022-12-18	WOS:000080929500025
J	Li, JTC; Ford, LB; Chervinsky, P; Weisberg, SC; Kellerman, DJ; Faulkner, KG; Herje, NE; Hamedani, A; Harding, SM; Shah, T				Li, JTC; Ford, LB; Chervinsky, P; Weisberg, SC; Kellerman, DJ; Faulkner, KG; Herje, NE; Hamedani, A; Harding, SM; Shah, T			Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Thoracic-Society	MAY 16-22, 1997	SAN FRANCISCO, CA	Amer Thorac Soc		asthma; bone mineral density; fluticasone propionate; hypothalamic-pituitary-adrenal axis; inhaled corticosteroids; longterm safety; posterior subcapsular cataract	INHALED BECLOMETHASONE DIPROPIONATE; LONG-TERM TREATMENT; INDUCED OSTEOPOROSIS; CORTICOSTEROIDS; THERAPY; OBSTRUCTION; SALBUTAMOL; INHALATION; CATARACTS; AEROSOL	Background: Although inhaled corticosteroids are widely used for the treatment of inflammation in asthma, prospective, long-term, placebo-controlled trials characterizing their systemic safety with chronic use are lacking. Objective: This study was designed to prospectively evaluate the long-term safety of inhaled fluticasone propionate therapy. Methods: Fluticasone propionate powder, 500 mu g, or placebo was administered twice daily by means of the Diskhaler for 104 weeks to 64 adults with mild persistent asthma in a randomized, double-blind, parallel-groop study. Primary safety variables were measured at baseline and every 6 months thereafter Although evaluation of efficacy was not an objective of this study, pulmonary function testing was performed at monthly intervals. Results: Two years of treatment with fluticasone propionate had no significant effects on the skeletal system. No clinically significant changes were observed in ophthalmic parameters (glaucoma and posterior subcapsular cataracts). Mean change from baseline in lumbar spine (L-1 to L-4) bone density at week 104 was not significantly different between fluticasone propionate (-0.006 +/- 0.008 g/cm(2)) and placebo (-0.007 +/- 0.010 g/cm(2)). Markers of bone formation (serum osteocalcin) and resorption (urinary N-telopeptide) did not differ significantly between treatment groups. The effects of fluticasone propionate treatment on the hypothalamic-pituitary-adrenal axis were minimal, with no alterations in morning plasma cortisol concentrations and minor but statistically significant decreases in poststimulation mean peak plasma cortisol concentrations (P = .021) and 8-hour plasma cortisol area under the curve values (P = .020) at week 104. Drug-related adverse events were primarily topical effects of inhaled corticosteroids. Pulmonary function improved significantly during 2 years of fluticasone propionate treatment. Conclusion: Fluticasone propionate powder, 500 mu g twice daily for up to 2 years, was efficacious and well tolerated, with no clinically relevant effects on the hypothalamic-pituitary-adrenal axis, bone density, or ophthalmic parameters in adults with mild asthma.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Asthma & Allergy Clin Ctr PC, Papillon, NE 68108 USA; New England Res Ctr Inc, N Dartmouth, MA 02747 USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA; Oregon Osteoporosis Ctr, Portland, OR 97201 USA	Mayo Clinic; GlaxoSmithKline; Oregon Osteoporosis Center	Li, JTC (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.							Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603; ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; ALI NJ, 1991, THORAX, V46, P160, DOI 10.1136/thx.46.3.160; ALLEN MB, 1989, BRIT MED J, V299, P432, DOI 10.1136/bmj.299.6696.432; ALS OS, 1985, ARTHRITIS RHEUM, V28, P369, DOI 10.1002/art.1780280403; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; AYRES JG, 1995, EUR RESPIR J, V8, P579; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Esmailpour N, 1997, EUR RESPIR J, V10, P1496, DOI 10.1183/09031936.97.10071496; FALCOZ C, 1997, BR J CLIN PHARM, V43, P541; FAULKNER KG, 1995, OSTEOPOROSIS INT, V5, P218, DOI 10.1007/BF01774010; HARDING SM, 1990, RESP MED, V84, P25, DOI 10.1016/S0954-6111(08)80004-2; HERRALA J, 1994, BONE, V15, P621, DOI 10.1016/8756-3282(94)90309-3; HOGGER P, 1994, STEROIDS, V59, P597, DOI 10.1016/0039-128X(94)90054-X; KERSTJENS HAM, 1994, THORAX, V49, P652, DOI 10.1136/thx.49.7.652; LAITINEN A, 1994, AM J RESP CRIT CARE, V150, pS14, DOI 10.1164/ajrccm/150.5_Pt_2.S14; Lipworth BJ, 1997, THORAX, V52, P1036, DOI 10.1136/thx.52.12.1036; LOCASCIO V, 1990, BONE MINER, V8, P39, DOI 10.1016/0169-6009(91)90139-Q; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; Mack M, 1997, CLIN CHEM, V43, P540; MELCHOR R, 1993, THORAX, V48, P506, DOI 10.1136/thx.48.5.506; *NIH, 1997, NIH PUBL; NOONAN MJ, 1997, AM J RESP CRIT CARE, V155, P115; OPATOWSKY I, 1995, OPHTHALMOLOGY, V102, P177; PACKE GE, 1992, THORAX, V47, P414, DOI 10.1136/thx.47.6.414; Pearce G, 1998, BRIT J RHEUMATOL, V37, P292; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; PHILLIPPS GH, 1990, RESP MED, V84, P19, DOI 10.1016/S0954-6111(08)80003-0; POUW EM, 1991, BRIT MED J, V302, P627, DOI 10.1136/bmj.302.6777.627; Robinson DS, 1996, J ASTHMA, V33, P5, DOI 10.3109/02770909609077758; RUEGSEGGER P, 1983, EUR J CLIN PHARMACOL, V25, P615, DOI 10.1007/BF00542348; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; TOOGOOD JH, 1993, J ALLERGY CLIN IMMUN, V91, P571, DOI 10.1016/0091-6749(93)90263-F	35	58	61	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1062	1068		10.1016/S0091-6749(99)70180-6	http://dx.doi.org/10.1016/S0091-6749(99)70180-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	207GT	10359887				2022-12-18	WOS:000080929500014
J	de Vries, JE; Carballido, JM; Aversa, G				de Vries, JE; Carballido, JM; Aversa, G			Receptors and cytokines involved in allergic T-H2 cell responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on New Trends in Immunopharmacology 1997	JUL   12, 1997	TOKYO, JAPAN	Novartis Pharma K K Tokyo		IL-4; IL-13; IFN-gamma; IL-4R; IL-13R; T-H2 cells; CD150; SLAM; IgE	HUMAN B-CELLS; LYMPHOCYTIC ACTIVATION MOLECULE; CD4(+) T-CELLS; INTERLEUKIN-13 RECEPTOR; IGE PRODUCTION; BINDING SUBUNIT; ALPHA CHAIN; IL-4; COMPONENT; CLONING	Cytokines produced by allergen-specific T-H2 cells play a central role in the induction and maintenance of allergic responses. Therefore antagonizing T-H2 differentiation and T-H2 effector functions will provide an effective way to intervene in allergic diseases. This article discusses that antagonizing the effects of IL-4 and IL-13 by IL-4R alpha antagonists inhibits human T-H2 development and IgE synthesis. In addition, it is shown that the activation of allergen-specific T-H2 cells with an agonistic anti-CDw150 mAb redirects the cytokine production profile of these T-H2 cells to a T-H0 phenotype.	Novartis Res Inst, A-1235 Vienna, Austria	Novartis	de Vries, JE (corresponding author), Novartis Res Inst, A-1235 Vienna, Austria.							Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; Aversa G, 1997, J IMMUNOL, V158, P4036; BRINKMANN V, 1995, J IMMUNOL, V154, P3078; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; CARBALLIDO JM, 1995, J IMMUNOL, V155, P4162; Carballido JM, 1997, J IMMUNOL, V159, P4316; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; de Vries J E, 1993, Semin Immunol, V5, P431, DOI 10.1006/smim.1993.1049; Erb KJ, 1996, IMMUNOL CELL BIOL, V74, P206, DOI 10.1038/icb.1996.29; Gauchat JF, 1997, EUR J IMMUNOL, V27, P971, DOI 10.1002/eji.1830270425; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; Jung T, 1996, EUR J IMMUNOL, V26, P571, DOI 10.1002/eji.1830260311; Keegan AD, 1996, IMMUNOLOGIST, V4, P194; KIMATA H, 1994, J EXP MED, V180, P727, DOI 10.1084/jem.180.2.727; MATTHEWS DJ, 1995, BLOOD, V85, P38, DOI 10.1182/blood.V85.1.38.bloodjournal85138; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; Obiri NI, 1997, J IMMUNOL, V158, P756; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Punnonen J, 1997, J EXP MED, V185, P993, DOI 10.1084/jem.185.6.993; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Sornasse T, 1996, J EXP MED, V184, P473, DOI 10.1084/jem.184.2.473; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; YSSEL H, 1992, J IMMUNOL, V148, P738; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	31	58	63	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	2	S			S492	S496		10.1016/S0091-6749(99)70166-1	http://dx.doi.org/10.1016/S0091-6749(99)70166-1			5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199TV	10329853				2022-12-18	WOS:000080500200012
J	Salmun, LM; Barlan, I; Wolf, HM; Eibl, M; Twarog, FJ; Geha, RS; Schneider, LC				Salmun, LM; Barlan, I; Wolf, HM; Eibl, M; Twarog, FJ; Geha, RS; Schneider, LC			Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: A double-blind, placebo-controlled, randomized trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; intravenous immunoglobulin; steroids	LYMPHOCYTE-T ACTIVATION; BRONCHOALVEOLAR LAVAGE; THROMBOCYTOPENIC PURPURA; BRONCHIAL BIOPSIES; KAWASAKI-DISEASE; CHILDHOOD ASTHMA; CELL ACTIVATION; GAMMA-GLOBULIN; ATOPIC ASTHMA; PATHOGENESIS	Background: There is a significant group of patients with severe asthma who require chronic use of systemic steroids for control of their disease. These patients are at risk for severe side effects from oral steroids. Intravenous immunoglobulin. (IVIG) has immunomodulatory properties, and a few open-label trials have suggested its possible benefit in individuals with severe asthma. Objective: This study was designed to;assess the potential benefit of MG asa steroid-sparing agent in patients with severe asthma. Methods: Thirty-eight immunocompetent steroid-requiring patients with severe asthma were randomly enrolled in a double-blind, placebo-controlled trial of MG, Results: Of the 38 patients enrolled, 28 patients completed the study. A significant reduction in oral steroid requirement was observed in both the IVIG-treated (n = 16) and the placebo-treated (n = 12)patients. Further exploration of the results showed that MG, but not placebo, had a significant steroid-sparing effect in patients requiring high doses of oral steroids (ie, >2000 mg in the year before the study). Within this subgroup, IVIG treatment (n = 9) resulted in a significant decrease in oral Steroid requirement, with a median of 16.4 mg/day during the pretreatment period to 3 mg/day during the treatment phase (P = .0078). No significant decrease in oral steroid requirement was observed in placebo-treated patients (n = 8) within this subgroup. Objective and subjective parameters of the patients' asthma were unchanged in spite of the: steroid tapering achieved is the group treated with MG. Conclusion: IVIG may be a useful steroid-sparing agent in patients with severe asthma requiring high doses of oral steroids.	Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Marmara Univ Hosp, Dept Pediat, Istanbul, Turkey; Univ Vienna, Sch Med, Dept Immunol, Vienna, Austria	Harvard University; Harvard Medical School; Marmara University; University of Vienna	Schneider, LC (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.				NCRR NIH HHS [M01 RR02172] Funding Source: Medline; NIAID NIH HHS [T32 AI07306] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007306] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BALLOW M, 1994, PEDIATR INFECT DIS J, V13, P806, DOI 10.1097/00006454-199409000-00012; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BERNATOWSKAMATUSZKIEWICZ E, 1991, CLIN EXP IMMUNOL, V85, P193; BUSSEL J, 1983, J PEDIATR, V103, P654; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; CORRIGAN CJ, 1988, LANCET, V1, P1129; CROSS D, 1991, J ALLERGY CLIN IMMUN, V87, P120, DOI 10.1016/0091-6749(91)90223-B; DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704; DEBRE M, 1993, LANCET, V342, P945, DOI 10.1016/0140-6736(93)92000-J; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; FANTA CH, 1983, AM J MED, V74, P845, DOI 10.1016/0002-9343(83)91076-8; FRIDAY GA, 1988, PEDIATR CLIN N AM, V35, P1149; IMBACH P, 1981, LANCET, V1, P1228; JAKOBSSON T, 1994, ALLERGY, V49, P413, DOI 10.1111/j.1398-9995.1994.tb00833.x; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KALINER MA, 1993, JAMA-J AM MED ASSOC, V269, P1994, DOI 10.1001/jama.269.15.1994; LEUNG DYM, 1989, LANCET, V2, P1298; LEUNG DYM, 1992, CLIN REV ALLERG, V10, P93; MARINI M, 1992, CHEST, V102, P661, DOI 10.1378/chest.102.3.661; MAZER BD, 1991, J ALLERGY CLIN IMMUN, V87, P976, DOI 10.1016/0091-6749(91)90420-S; MAZER BD, 1989, CLIN IMMUNOL IMMUNOP, V53, pS156, DOI 10.1016/0090-1229(89)90081-0; *MED SECT AM LUNG, 1987, AM REV RESPIR DIS, V136, P225; MORI PG, 1983, ARCH DIS CHILD, V58, P851, DOI 10.1136/adc.58.11.851; NEWBURGER JW, 1991, NEW ENGL J MED, V324, P1633, DOI 10.1056/NEJM199106063242305; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Stiehm E R, 1992, Curr Probl Pediatr, V22, P335, DOI 10.1016/0045-9380(92)90022-Q; TAYLOR WR, 1992, PEDIATRICS, V90, P657; VIGNOLA AM, 1993, AM REV RESPIR DIS, V148, P689, DOI 10.1164/ajrccm/148.3.689; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851	33	58	59	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				810	815		10.1016/S0091-6749(99)70424-0	http://dx.doi.org/10.1016/S0091-6749(99)70424-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329814				2022-12-18	WOS:000080470200015
J	Hodson, T; Custovic, A; Simpson, A; Chapman, M; Woodcock, A; Green, R				Hodson, T; Custovic, A; Simpson, A; Chapman, M; Woodcock, A; Green, R			Washing the dog reduces dog allergen levels, but the dog needs to be washed twice a week	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dog allergen; airborne; dog washing; asthma	FEL-D-I; COCKROACH ALLERGENS; DOMESTIC ALLERGENS; PARTICLE-SIZE; PUBLIC PLACES; DUST MITE; F-I; CAT; FEL-D-1; CAN-F-1	Background: Many asthmatic patients allergic to dogs refuse to part with their dog, and it is essential to develop techniques for lowering exposure with a dog in the home. Objective: This study investigated the effect of dog washing on the subsequent recovery of Can f 1 from dog hair clippings and on the airborne allergen over a 7 day period. Methods: Dogs, which had not been washed for at least the previous 3 weeks, were washed with a hand-held shower and proprietary shampoo. Hair clippings and dander samples from 25 dogs were collected before and immediately after washing, After these initial studies, 16 dogs had a small tuft of hair clipped from the collar or spinal area before washing and then daily for the next 7 days. Air sampling was performed in 5 homes, and the air samples were collected (airflow rate, 9; L/min) over an 8-hour period per day on 10 consecutive day's (3 days of baseline sampling before washing and then 7 consecutive days after washing), Can f 1 level was measured by using 2-site ELISA. Results: Washing significantly reduced recoverable Can f 1 from clippings (84% reduction: from 73 mu g/g to 12 mu g/g [geometric mean]; P < .0001) and from dander samples (86% reduction: from 347 mu g/g to 50 mu g/g [geometric mean]; P < .0001). There was a significant reduction in Can f 1 levels in dog hair over the observed 8-day period (F = 18.4, P < .0001). By using a multiple comparison test, this observed significance was found to be due to the difference between the baseline levels and those on days 1 and 2 after washing, with no difference in the baseline Can f 1 compared with days 3 to 7. Airborne Can f 1 levels showed a downward trend, which reached statistical significance when the data were grouped into 3 sampling periods as follows: baseline (ie, mean of 3 days before sampling) was compared with days 1 to 4 after washing (41% reduction, 95% CI 13%-60%) and days 5 to 7 after washing (61% reduction, 95% CI 2%-84%; P = .014). Conclusions: Washing the dog reduces recoverable allergen from dog hair and dander. The dog needs to be washed at least twice a week to maintain the reduction in recoverable Can f 1 from its hair. Washing the dog achieves a modest reduction in the level of airborne Can f 1 in homes with a dog.	Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Woodcock, A (corresponding author), Wythenshawe Hosp, NW Lung Ctr, Southmoor Rd, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Chapman, Martin/0000-0002-0845-3632; Simpson, Angela/0000-0003-2733-6666; Woodcock, Ashley/0000-0002-5428-8578				Avner DB, 1997, J ALLERGY CLIN IMMUN, V100, P307, DOI 10.1016/S0091-6749(97)70242-2; BLANDS J, 1977, ACTA ALLERGOL, V32, P147, DOI 10.1111/j.1398-9995.1977.tb01346.x; Custovic A, 1998, CLIN EXP ALLERGY, V28, P53, DOI 10.1046/j.1365-2222.1998.00183.x; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1111/j.1365-2222.1996.tb00521.x; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94, DOI 10.1164/ajrccm.155.1.9001295; Custovic A, 1998, THORAX, V53, P63, DOI 10.1136/thx.53.1.63; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; DEGROOT H, 1991, J ALLERGY CLIN IMMUN, V87, P1056, DOI 10.1016/0091-6749(91)92150-Y; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; KLUCKA CV, 1995, J ALLERGY CLIN IMMUN, V95, P1164, DOI 10.1016/S0091-6749(95)70072-2; LINDGREN S, 1988, J ALLERGY CLIN IMMUN, V82, P196, DOI 10.1016/0091-6749(88)90999-2; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; Perzanowski MS, 1997, J ALLERGY CLIN IMMUN, V100, P428, DOI 10.1016/S0091-6749(97)70261-6; SCHOU C, 1993, CLIN EXP ALLERGY, V23, P7, DOI 10.1111/j.1365-2222.1993.tb02477.x; SCHOU C, 1991, CLIN EXP ALLERGY, V21, P321, DOI 10.1111/j.1365-2222.1991.tb01663.x; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; Wood RA, 1997, J ALLERGY CLIN IMMUN, V100, P290, DOI 10.1016/S0091-6749(97)70239-2	19	58	60	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					581	585		10.1016/S0091-6749(99)70227-7	http://dx.doi.org/10.1016/S0091-6749(99)70227-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200004				2022-12-18	WOS:000079723900007
J	de Vries, IJM; Langeveld-Wildschut, EG; van Reijsen, FC; Dubois, GR; van den Hoek, JA; Bihari, IC; van Wichen, D; de Weger, RA; Knol, EF; Thepen, T; Bruijnzeel-Koomen, CAFM				de Vries, IJM; Langeveld-Wildschut, EG; van Reijsen, FC; Dubois, GR; van den Hoek, JA; Bihari, IC; van Wichen, D; de Weger, RA; Knol, EF; Thepen, T; Bruijnzeel-Koomen, CAFM			Adhesion molecule expression on skin endothelia in atopic dermatitis: Effects of TNF-alpha and IL-4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adhesion molecules; atopic dermatitis; allergic inflammation; atopy patch test; microvascular endothelium; IL-4 receptor; TNF-alpha; endothelium; skin microvasculature	TUMOR-NECROSIS-FACTOR; MAST-CELLS; PATCH TEST; T-CELLS; VASCULAR ENDOTHELIUM; HUMAN EOSINOPHILS; IN-SITU; SELECTIN; INTERLEUKIN-1; INFLAMMATION	Background: Atopic dermatitis (AD) is characterized by skin infiltrates of leukocytes, such as lymphocytes and eosinophils. Objective: To describe the mechanisms determining this inflammatory process, we have analyzed expression of adhesion molecules and their regulation on skin endothelial cells (ECs). Methods: Expression of adhesion molecules on ECs was analyzed by immunohistochemistry by using Ulex europaeus agglutin 1 as a pan-endothelial marker. Results: Vascular cell adhesion molecule-1 (VCAM-1), E-selectin, and P-selectin were not found in skin of nonatopic individuals, whereas expression of these sur face molecules was observed in nonlesional skin of patients with AD and was even more pronounced in lesional skin or after epicutaneous application of aeroallergen, Induction of adhesion molecule expression was examined on both macrovascular ECs from human umbilical cord vein (HUVECs) and human microvascular ECs (HMEC-1) from skin, TNF-alpha very potently upregulated adhesion molecule expression in vitro on both EC cell types. To verify the in vivo relevance of TNF-alpha, we performed TNF-alpha staining in the skin. TNF-alpha was observed in the dermis of nonatopic skin, both in chymase-containing mast cells and CD68+ macrophages. The increase in the number of TNF alpha-containing cells was concomitant with the increase in adhesion molecule expression in the skin of patients with AD. IL-4 is supposed to be important in atopic diseases because of its IgE- and VCAM-1-inducing properties. However, IL-4 addition failed to induce VCAM-1 expression on HMEC-1, although in the same set of experiments, a clear induction of VCAM-1 expression by IL-4 on HUVECs was demonstrated, Flow cytometry revealed the absence of IL-4 receptor alpha-chains on HMEC-1 and their presence on HUVECs, Immunohistochemistry examination on skin sections showed no binding of the IL-4R alpha-chain antibodies to ECs. Conclusion: We conclude that adhesion molecule expression is increased in the skin of patients with AD. Most probably, this increased expression is not a (direct) effect of IL-4 on skin endothelium, but other cytokines, such as TNF-alpha, might be responsible for this increased adhesion molecule expression. Continuous adhesion molecule expression may facilitate T-cell extravasation in a nonantigen-specific manner, thus explaining the presence of increased T-cell numbers in nonlesional skin of patients with AD.	Univ Utrecht Hosp, Dept Dermatol Allergol G02 124, NL-3508 GA Utrecht, Netherlands; Univ Utrecht Hosp, Dept Pathol, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Knol, EF (corresponding author), Univ Utrecht Hosp, Dept Dermatol Allergol G02 124, POB 85500, NL-3508 GA Utrecht, Netherlands.		de Vries, Jolanda I.J.M./F-5563-2010	de Vries, Jolanda I.J.M./0000-0002-8653-4040; Knol, Edward/0000-0001-7368-9820				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P92; BOS JD, 1989, ARCH DERMATOL RES, V281, P24, DOI 10.1007/BF00424268; BRUIJNZEELKOOME.C, 1988, BRIT J DERMATOL, V118, P229; CHU W, 1994, J IMMUNOL, V153, P4179; DUBOIS GR, 1994, J INVEST DERMATOL, V102, P843, DOI 10.1111/1523-1747.ep12382362; GORDON JR, 1994, J EXP MED, V180, P2027, DOI 10.1084/jem.180.6.2027; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; GROVES RW, 1991, BRIT J DERMATOL, V124, P117, DOI 10.1111/j.1365-2133.1991.tb00419.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HOLTHOFER H, 1982, LAB INVEST, V47, P60; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LangeveldWildschut EG, 1996, J ALLERGY CLIN IMMUN, V98, P1019, DOI 10.1016/S0091-6749(96)80186-2; LANGEVELDWILDSCHUT EG, 1995, J ALLERGY CLIN IMMUN, V96, P66, DOI 10.1016/S0091-6749(95)70034-X; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LUSCINSKAS FW, 1995, J EXP MED, V181, P1179, DOI 10.1084/jem.181.3.1179; MOSER R, 1989, J CLIN INVEST, V83, P444, DOI 10.1172/JCI113903; MOSER R, 1992, BLOOD, V79, P2937; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; POBER JS, 1986, J IMMUNOL, V137, P1893; REITAMO S, 1986, BRIT J DERMATOL, V114, P303, DOI 10.1111/j.1365-2133.1986.tb02821.x; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SCHWARTZ LB, 1994, CURR OPIN IMMUNOL, V6, P91, DOI 10.1016/0952-7915(94)90039-6; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SWERLICK RA, 1992, J IMMUNOL, V149, P698; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; vanReijsen FC, 1997, J INVEST DERMATOL, V108, P530, DOI 10.1111/1523-1747.ep12291799; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220	32	58	59	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					461	468		10.1016/S0091-6749(98)70136-8	http://dx.doi.org/10.1016/S0091-6749(98)70136-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768589				2022-12-18	WOS:000076212800022
J	Kepley, CL; Wilson, BS; Oliver, JM				Kepley, CL; Wilson, BS; Oliver, JM			Identification of the Fc epsilon RI-activated tyrosine kinases Lyn, Syk, and Zap-70 in human basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE receptor; IgE; basophils; allergy; signal transduction; tyrosine kinases	AFFINITY IGE RECEPTOR; CELL ANTIGEN RECEPTOR; EPIDERMAL LANGERHANS CELLS; MEDIATED HISTAMINE-RELEASE; TUMOR MAST-CELLS; TCR-ZETA-CHAIN; SIGNAL-TRANSDUCTION; LEUKEMIA-CELLS; CROSS-LINKING; RBL-2H3 CELLS	Background: In human blood basophils, cross-linking the high-affinity IgE receptor Fc epsilon RI with multivalent antigen activates a signaling pathway leading to Ca2+ mobilization, actin polymerization, shape changes, secretion, and cytokine production. Methods and Results: The role of tyrosine kinases in human Fc epsilon RI signaling was explored by using human basophils isolated by Percoll gradient centrifugation followed by negative and/or positive selection with antibody-coated magnetic beads. Fc epsilon RI cross-linking of more than 95% pure basophil preparations activates the protein-tyrosine kinases Lyn and Syk, previously linked to Fc epsilon RI-coupled rodent mast cell activation, as well as Zap-70, previously implicated in T-cell receptor signaling, and causes the tyrosine phosphorylation of multiple proteins. The presence of Lyn, Syk, and Zap-70 in basophils was confirmed by Western blotting in lysates of highly purified basophils and independently by confocal fluorescence microscopy in cells labeled simultaneously with kinase-specific antibodies and with the basophil-specific antibody 2D7. Comparable amounts of Lyn and Syk were found in basophils and B cells, whereas T cells appear to have greater amounts of Zap-70 than basophils, The tyrosine kinase inhibitor piceatannol spares IgE-mediated Lyn activation but inhibits IgE-induced Syk and Zap-70 activation as well as overall protein tyrosine phosphorylation and secretion. Overall protein-tyrosine phosphorylation increases steadily over a range of anti-IgE concentrations that are low to optimal for secretion. However, tyrosine phosphorylation continues to increase at high anti-IgE concentrations that elicit very little secretion (the characteristic high-dose inhibition of secretion). Conclusions: Our data demonstrate the association of anti-IgG-stimulated, protein-tyrosine phosphorylation by a cascade of tyrosine kinases, including Zap-70 as well as Lyn and Syk, with the initiation of Fc epsilon RI-mediated signaling in human basophils.	Univ New Mexico, Sch Med, Dept Pathol, Asthma Res Ctr, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Ctr Canc Res & Treatment, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico	Kepley, CL (corresponding author), Univ New Mexico, Sch Med, Dept Pathol, Asthma Res Ctr, Canc Res Facil,Room 203, Albuquerque, NM 87131 USA.				NHLBI NIH HHS [HL56384-01] Funding Source: Medline; NIGMS NIH HHS [R01GM49814-04] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049814] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL A, 1993, J BIOL CHEM, V268, P15900; BARKER SA, 1995, MOL BIOL CELL, V6, P1145, DOI 10.1091/mbc.6.9.1145; BECKER EL, 1972, J EXP MED, V135, P376, DOI 10.1084/jem.135.2.376; Benhamou M, 1996, J LEUKOCYTE BIOL, V59, P461, DOI 10.1002/jlb.59.3.461; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BISCHOFF SC, 1990, P NATL ACAD SCI USA, V87, P6813, DOI 10.1073/pnas.87.17.6813; BISCHOFF SC, 1990, J EXP MED, V172, P1577, DOI 10.1084/jem.172.6.1577; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; BJERKE T, 1993, J IMMUNOL METHODS, V157, P49, DOI 10.1016/0022-1759(93)90069-J; Black KM, 1996, INT ARCH ALLERGY IMM, V111, P142, DOI 10.1159/000237359; BOCHNER BS, 1994, ANNU REV IMMUNOL, V12, P295; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BU JY, 1995, P NATL ACAD SCI USA, V92, P5106, DOI 10.1073/pnas.92.11.5106; CHABAY R, 1980, J BIOL CHEM, V255, P4628; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1994, J IMMUNOL, V152, P4758; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; DAHINDEN CA, 1993, ADV EXP MED BIOL, V351, P99; DEMBO M, 1980, CELL, V22, P59, DOI 10.1016/0092-8674(80)90154-3; DVORAK AM, 1980, LAB INVEST, V43, P126; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; EISEMAN E, 1992, NATURE, V355, P78; FOX CC, 1985, INT ARCH ALLER A IMM, V77, P130, DOI 10.1159/000233767; GALLI SJ, 1984, PROG ALLERGY, V34, P1; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; HAMAWY MM, 1995, CELL SIGNAL, V7, P535, DOI 10.1016/0898-6568(95)00024-J; HOWARD FD, 1990, P NATL ACAD SCI USA, V87, P7015, DOI 10.1073/pnas.87.18.7015; Huby RDJ, 1997, J CELL BIOL, V137, P1639, DOI 10.1083/jcb.137.7.1639; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; ISHIZAKA T, 1973, J IMMUNOL, V111, P500; KAGEYSOBOTKA A, 1982, FED PROC, V41, P12; KAMPS MP, 1991, METHOD ENZYMOL, V201, P101; Kaplan A P, 1991, Clin Exp Allergy, V21 Suppl 1, P8, DOI 10.1111/j.1365-2222.1991.tb01699.x; KEPLEY C, 1994, J IMMUNOL METHODS, V175, P1, DOI 10.1016/0022-1759(94)90326-3; KEPLEY CL, 1995, J IMMUNOL, V154, P6548; KNOL EF, 1990, AGENTS ACTIONS, V30, P49, DOI 10.1007/BF01968995; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; KUNA P, 1993, J IMMUNOL, V150, P1932; LAW CL, 1994, J BIOL CHEM, V269, P12310; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LICHTENSTEIN LM, 1970, IMMUNOLOGY, V19, P831; MACGLASHAN D, 1983, J IMMUNOL, V130, P2330; MACGLASHAN D, 1991, J IMMUNOL, V147, P2259; MACGLASHAN DW, 1994, J LEUKOCYTE BIOL, V55, P13, DOI 10.1002/jlb.55.1.13; MACGLASHAN DW, 1995, CHEM IMMUNOL, V61, P88; MACGLASHAN DW, 1986, J IMMUNOL, V136, P2231; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; MAEYAMA K, 1988, J IMMUNOL, V140, P3919; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARONE G, 1981, INT ARCH ALLER A IMM, V65, P339, DOI 10.1159/000232773; MASSEY WA, 1989, J IMMUNOL, V143, P1875; Maurer D, 1996, J IMMUNOL, V157, P607; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; MCCLOSKEY MA, 1993, J IMMUNOL, V151, P3237; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; NGUYEN KL, 1990, J ALLERGY CLIN IMMUN, V85, P1020, DOI 10.1016/0091-6749(90)90046-7; OFFERMANNS S, 1994, J IMMUNOL, V152, P250; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; OLIVER JM, 1997, IGE RECEPTOR FCE R1, P139; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Paolini R, 1996, J BIOL CHEM, V271, P15987, DOI 10.1074/jbc.271.27.15987; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PARK JG, 1995, P NATL ACAD SCI USA, V92, P7381, DOI 10.1073/pnas.92.16.7381; PRICE DJ, 1995, BBA-MOL CELL RES, V1265, P133, DOI 10.1016/0167-4889(94)00213-X; REDDIGARI SR, 1992, J ALLERGY CLIN IMMUN, V89, P666, DOI 10.1016/0091-6749(92)90372-9; RISKE F, 1991, J BIOL CHEM, V266, P11245; SANTINI F, 1993, J BIOL CHEM, V268, P22716; SCHROEDER JT, 1994, J ALLERGY CLIN IMMUN, V94, P1189, DOI 10.1016/0091-6749(94)90331-X; Shores E, 1997, J IMMUNOL, V159, P222; SOBOTKA AK, 1979, J IMMUNOL, V122, P511; STANLEY E, 1991, MOL CELL BIOL, V11, P3399, DOI 10.1128/MCB.11.7.3399; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TSAI M, 1993, EUR J IMMUNOL, V23, P3286, DOI 10.1002/eji.1830231234; TURNER H, 1995, J BIOL CHEM, V270, P9500, DOI 10.1074/jbc.270.16.9500; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WARNER JA, 1989, J LEUKOCYTE BIOL, V45, P558, DOI 10.1002/jlb.45.6.558; WARNER JA, 1989, J IMMUNOL, V142, P1669; WARNER JA, 1990, J IMMUNOL, V145, P1897; WEETALL M, 1993, J IMMUNOL, V150, P4072; WILSON BS, 1995, J BIOL CHEM, V270, P4013, DOI 10.1074/jbc.270.8.4013; WOFSY C, 1995, J BIOL CHEM, V270, P20264, DOI 10.1074/jbc.270.35.20264; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YANO H, 1993, J BIOL CHEM, V268, P25846; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	88	58	58	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					304	315		10.1016/S0091-6749(98)70100-9	http://dx.doi.org/10.1016/S0091-6749(98)70100-9			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723676				2022-12-18	WOS:000075537100025
J	van Reijsen, FC; Felius, A; Wauters, EAK; Bruijnzeel-Koomen, CAFM; Koppelman, SJ				van Reijsen, FC; Felius, A; Wauters, EAK; Bruijnzeel-Koomen, CAFM; Koppelman, SJ			T-cell reactivity for a peanut-derived epitope in the skin of a young infant with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Univ Utrecht Hosp, Dept Dermatol Allergol, NL-3508 GA Utrecht, Netherlands; Univ Hosp Children & Youth Het Wilhelmina Kinderz, Dept Gen Pediat & Infect Dis, Utrecht, Netherlands; TNO, Nutr & Food Res Inst, Div Biochem & Gene Technol, Zeist, Netherlands	Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Netherlands Organization Applied Science Research	van Reijsen, FC (corresponding author), Univ Utrecht Hosp, Dept Dermatol Allergol, Hp Nr G02-124,POB 85500, NL-3508 GA Utrecht, Netherlands.							ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; Eigenmann PA, 1996, J ALLERGY CLIN IMMUN, V98, P969, DOI 10.1016/S0091-6749(96)80014-5; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I	4	58	59	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	1				207	209		10.1016/S0091-6749(98)70410-5	http://dx.doi.org/10.1016/S0091-6749(98)70410-5			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YZ342	9500753				2022-12-18	WOS:000072244800009
J	Lopata, AL; Zinn, C; Potter, PC				Lopata, AL; Zinn, C; Potter, PC			Characteristics of hypersensitivity reactions and identification of a unique 49 kd IgE-binding protein (Hal-m-1) in abalone (Haliotis midae)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; IgE; mollusks; abalone; shellfish hypersensitivity; lymphocytes	SHRIMP ALLERGENS; TROPOMYOSIN; REACTIVITY; CRUSTACEA; SHELLFISH; LIMPET; FISH	Background: There is a paucity of published data on the clinical presentation and the nature of the allergens involved in hypersensitivity to mollusks. This study reports the clinical and immunologic findings in 38 patients with reported immediate and delayed adverse reactions to abalone (Haliotis midae, Class Gastropoda). Methods: Patients were recruited as part of a South African seafood allergy survey, Allergic symptoms were assessed by a self-administered questionnaire, A total of 38 patients with abalone sensitivity were recruited, Specific IgE responses to abalone and other mollusks were studied by using RAST and inhibition ELISAs, Skin prick tests and lymphocyte proliferation assays mere also performed on several of the subjects, Allergenic components of Haliotis midae were identified with Western blotting. Results: Twenty five of the 38 patients in the study were first seen with immediate symptoms, and 13 had delayed reactions. Seventeen of the sera tested were RAST positive. Skin prick tests responses with abalone extract mere positive in all subjects with positive RAST responses (n = 8) and in 6 of 13 subjects with negative RAST responses. Five of the subjects with positive RAST responses had positive results on Western blotting and demonstrated binding to two major allergens with molecular weights of 38 and 49 kd. The 49 kd IgE-binding protein has been designated as Hal-m-1. Conclusions: Abalone allergens are heat-stable proteins,vith molecular weights of 38 and 49 kd, later designated as Hal-m-1 according to International Union of Immunological Societies allergen nomenclature regulation. Our studies indicate a clear clinical and immunologic heterogeneity in patients reactive to abalone.	UNIV CAPE TOWN,ZA-7925 CAPE TOWN,SOUTH AFRICA; GROOTE SCHUUR HOSP,ZA-7925 CAPE TOWN,SOUTH AFRICA	University of Cape Town; University of Cape Town			Lopata, Andreas L/C-3831-2012; Lopata, Andreas L/O-2143-2017; Lopata, Andreas/C-8160-2009	Lopata, Andreas L/0000-0002-2940-9235; Lopata, Andreas L/0000-0002-2940-9235; 				AMOROSO S, 1988, INT ARCH ALLER A IMM, V85, P69, DOI 10.1159/000234476; CARRILLO T, 1992, ANN ALLERGY, V68, P483; CARRILLO T, 1991, ALLERGY, V46, P515, DOI 10.1111/j.1398-9995.1991.tb00614.x; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49, DOI 10.1159/000236802; DAUL CB, 1987, J ALLERGY CLIN IMMUN, V80, P716, DOI 10.1016/0091-6749(87)90293-4; DAUL CB, 1993, CLIN REV ALLERG, V11, P201; DELACUESTA CG, 1989, ALLERGOL IMMUNOPATH, V17, P337; EASTAUGH J, 1989, ARCH INTERN MED, V149, P1735, DOI 10.1001/archinte.149.8.1735; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRER SB, 1987, J ALLERGY CLIN IMMUN, V80, P133, DOI 10.1016/0091-6749(87)90121-7; LEHRER SB, 1990, J ALLERGY CLIN IMMUN, V85, P1005, DOI 10.1016/0091-6749(90)90044-5; MORGAN JE, 1989, J ALLERGY CLIN IMMUN, V83, P1112, DOI 10.1016/0091-6749(89)90454-5; MORGAN JE, 1989, CLIN EXP ALLERGY, V19, P431, DOI 10.1111/j.1365-2222.1989.tb02410.x; MORIKAWA A, 1990, ANN ALLERGY, V65, P415; ONEIL C, 1993, CLIN REV ALLERG, V11, P183; SAMPSON HA, 1991, FOOD ALLERGY ADVERSE, P99; SHANTI KN, 1993, J IMMUNOL, V151, P5354; SHIBASAKI M, 1989, ANN ALLERGY, V63, P421; WARING NP, 1984, J ALLERGY CLIN IMMUN, V76, P440; Zinn C, 1997, S AFR MED J, V87, P146	20	58	61	0	10	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					642	648		10.1016/S0091-6749(97)70168-4	http://dx.doi.org/10.1016/S0091-6749(97)70168-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389294	Bronze			2022-12-18	WOS:A1997YG20200011
J	Jeoung, BJ; Reese, G; Hauck, P; Oliver, JB; Daul, CB; Lehrer, SB				Jeoung, BJ; Reese, G; Hauck, P; Oliver, JB; Daul, CB; Lehrer, SB			Quantification of the major brown shrimp allergen Pen a 1 (tropomyosin) by a monoclonal antibody-based sandwich ELISA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; shrimp; crustacea; Pen a 1 monoclonal antibodies; sandwich ELISA; cross-reactivity; quantification	PENAEUS-AZTECUS; IGE; IDENTIFICATION; DERMATOPHAGOIDES; IMMUNOASSAYS; REACTIVITY; CRUSTACEA; COCKROACH; BINDING; MITE	Background: Among 13 allergens found in extracts of cooked brown shrimp (Penaeus aztecus) the 36 kd muscle protein tropomyosin has been identified as the only major shrimp allergen (Pen a 1), Cross-reacting molecules with similar molecular weights were detected in other crustacea species such as crab, lobster, and crawfish. Because Pen a 1 and Pen a 1-like allergens are important in crustacea allergy, the aim of this study was to develop a monoclonal antibody (mAb)-based sandwich ELISA to quantify Pen a 1 and to evaluate Pen a 1 levels in four commercial shrimp, crab, and lobster extracts. Methods: Two Pen a 1-specific mAbs with different epitope specificities mere selected. ELISA plates coated with captured mAb 3.2 were incubated with samples containing Pen a 1. Bound Pen a 1 was detected by a combination of biotinylated mAb 4.9.5 and alkaline phosphatase-labeled streptavidin. Results: The optimized sandwich ELISA could detect Pen a 1 concentrations ranging from 4 to 125 ng/ml, Four commercial shrimp extracts demonstrated a 40-fold difference in Pen a 1 levels (24 to 920 mu g/ml), Crab and lobster extracts contained detectable levels of Pen a 1-like proteins, No reactivity to cockroach, house dust mite, oyster, codfish, or peanut extracts was detected, which indicates that the developed assay is crustacea-specific. Conclusion: A sensitive sandwich assay was developed to quantify Pen a 1. This assay will be helpful to standardize shrimp extracts in regard to the content of the major allergen, Pen a 1, and to study cross-reactivities among and evaluate occupational exposure to different crustacea species.	TULANE UNIV,MED CTR,DEPT MED,ALLERGY & CLIN IMMUNOL SECT,NEW ORLEANS,LA 70112; CENT LABS,PORT WASHINGTON,NY	Tulane University								AKERSTROM B, 1985, J IMMUNOL, V135, P2589; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; CHAPMAN MD, 1988, ALLERGY, V43, P7, DOI 10.1111/j.1398-9995.1988.tb05042.x; CRESPO JF, 1995, ALLERGY, V50, P918, DOI 10.1111/j.1398-9995.1995.tb02499.x; DAUL C B, 1991, Journal of Allergy and Clinical Immunology, V87, P192, DOI 10.1016/0091-6749(91)91497-H; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49, DOI 10.1159/000236802; DAUL CB, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P291; DAVID TJ, 1993, FOOD FOOD ADDITIVE I, P157; DESJARDINS A, 1995, J ALLERGY CLIN IMMUN, V96, P608, DOI 10.1016/S0091-6749(95)70259-8; DIAMANDIS EP, 1991, CLIN CHEM, V37, P625; HOFFMAN DR, 1987, ANN ALLERGY, V47, P17; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LEHRER SB, 1987, J ALLERGY CLIN IMMUN, V80, P133, DOI 10.1016/0091-6749(87)90121-7; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V92, P837; LIN RY, 1993, J ALLERGY CLIN IMMUN, V92, P837, DOI 10.1016/0091-6749(93)90061-J; LOMBARDERO M, 1988, J IMMUNOL METHODS, V108, P71, DOI 10.1016/0022-1759(88)90404-8; NAGPAL S, 1989, J ALLERGY CLIN IMMUN, V83, P26, DOI 10.1016/0091-6749(89)90474-0; ONEIL CE, 1985, J ALLERGY CLIN IMMUN, V55, P374; OVSYANNIKOVA IG, 1994, J ALLERGY CLIN IMMUN, V94, P537, DOI 10.1016/0091-6749(94)90211-9; PLATTSMILLS TAE, 1991, J ALLERGY CLIN IMMUN, V87, P621, DOI 10.1016/0091-6749(91)90379-3; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; REESE G, 1995, INT ARCH ALLERGY IMM, V107, P245, DOI 10.1159/000236992; SAMPSON HA, 1991, FOOD ALLERGY ADVERSE, P99; WARING NP, 1985, J ALLERGY CLIN IMMUN, V76, P440, DOI 10.1016/0091-6749(85)90724-9; WITTEMAN AM, 1994, INT ARCH ALLERGY IMM, V105, P56, DOI 10.1159/000236803; Wu CH, 1996, ANN ALLERG ASTHMA IM, V76, P195, DOI 10.1016/S1081-1206(10)63422-9	26	58	71	0	16	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					229	234		10.1016/S0091-6749(97)70229-X	http://dx.doi.org/10.1016/S0091-6749(97)70229-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275145				2022-12-18	WOS:A1997XR35100014
J	Binkley, KE; Kutcher, S				Binkley, KE; Kutcher, S			Panic response to sodium lactate infusion in patients with multiple chemical sensitivity syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						environmental hypersensitivity; multiple chemical sensitivity; panic disorder; sodium lactate infusion	DISORDER; PROVOCATION; HYPOTHESIS; ALLERGY; ATTACKS	Background: Many patients who are first seen with what has been called multiple chemical sensitivity syndrome (RIGS) experience symptoms suggestive of panic disorder including chest tightness, shortness of breath, palpitations, paresthesias, lightheadedness, and mental confusion, Although such patients are often convinced that these symptoms reflect toxic effects of environmental ''chemicals;'' direct evidence of this is lacking. To the contrary, a previous study has shown that some of these individuals exhibit hyperventilation responses on exposure to nonnoxious stimuli, and it has been suggested that the resulting bypocarbia accounts for their symptoms, We postulated that some patients with self-identified MCS had an underlying condition similar to panic disorder and would therefore demonstrate similar responses to provocative challenges, such as sodium lactate infusion. Methods: Patients referred to an allergy and clinical immunology service for evaluation of ''chemical sensitivity'' mere investigated to rule out underlying medical conditions, including asthma, as a cause of their symptoms and we were enrolled for study after giving informed consent. After a standardized psychiatric assessment was performed, patients underwent single-blind intravenous infusions of normal saline solution (placebo) and sodium lactate (which reproduces symptoms in individuals with underlying panic disorder), All patients mere referred for independent psychiatric assessment. Results: The standardized psychiatric assessment identified four of five patients as meeting DSM III-R diagnostic criteria for panic disorder along with other depressive and/or anxiety-related disorders, All five patients with self-identified chemical sensitivity exhibited a positive symptomatic response to sodium lactate compared with placebo infusion, Independent psychiatric assessment confirmed the diagnosis of panic disorder on the basis of DSM III-R criteria in each of the five patients, Conclusions: These results suggest that MCS may have a neurobiologic basis similar, if not identical, to that of panic disorder, We speculate that treatments with demonstrated efficacy in panic disorder may also be of benefit in MCS, and conversely, treatments that reinforce anticipatory anxiety and avoidance behavior in patients with MCS may be detrimental.	UNIV TORONTO,DEPT MED,ST MICHAELS HOSP,DIV CLIN IMMUNOL & ALLERGY,TORONTO,ON M5S 1A1,CANADA; DALHOUSIE UNIV,QUEEN ELIZABETH II HLTH SCI CTR,DEPT PSYCHIAT,HALIFAX,NS,CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Dalhousie University; Queen Elizabeth II Health Sciences Centre			Telch, Michael J/E-7027-2010	Kutcher, Stan/0000-0002-9646-3063				*AM AC ALL IMM, 1986, J ALLERGY CLIN IMMUN, V78, P269; *AM PSY ASS, 1987, DIAGN STAT MAN MENT, P139; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Black DW, 1996, PSYCHOSOMATICS, V37, P390, DOI 10.1016/S0033-3182(96)71554-2; *CA MED ASS SCI BO, 1986, W J MED, V144, P239; COWLEY DS, 1990, ARCH GEN PSYCHIAT, V47, P277; CULLEN MR, 1987, OCCUP MED, V2, P655; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; DILLON D, 1986, PSYCHIAT RES, V20, P997; GOETZ RR, 1993, ARCH GEN PSYCHIAT, V50, P280; GORMAN JM, 1989, AM J PSYCHIAT, V146, P148; GUGLIELMI RS, 1994, J BEHAV THER EXP PSY, V25, P197; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; HOWARD LM, 1993, BRIT MED J, V307, P747, DOI 10.1136/bmj.307.6907.747; Johnson MR, 1995, PSYCHIAT CLIN N AM, V18, P681, DOI 10.1016/S0193-953X(18)30019-4; KAHN E, 1989, ANN INTERN MED, V111, P104, DOI 10.7326/0003-4819-111-2-104; KAPLAN HI, 1994, KAPLAN SADOCKS SYNOP, P582; KLEIN DF, 1993, ARCH GEN PSYCHIAT, V50, P306; Leznoff A, 1997, J ALLERGY CLIN IMMUN, V99, P438, DOI 10.1016/S0091-6749(97)70067-8; LIEBOWITZ MR, 1984, ARCH GEN PSYCHIAT, V41, P764; Price Lawrence H., 1995, P1311; Spitzer RL, 1986, STRUCTURED CLIN INTE; STAUDENMAYER H, 1993, REGUL TOXICOL PHARM, V18, P44, DOI 10.1006/rtph.1993.1043; STEWART DE, 1987, CAN FAM PHYSICIAN, V33, P405	24	58	59	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					570	574		10.1016/S0091-6749(97)70086-1	http://dx.doi.org/10.1016/S0091-6749(97)70086-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	WU274	9111504				2022-12-18	WOS:A1997WU27400022
J	Kendall, JC; Li, XH; Galli, SJ; Gordon, JR				Kendall, JC; Li, XH; Galli, SJ; Gordon, JR			Promotion of mouse fibroblast proliferation by IgE-dependent activation of mouse mast cells: Role for mast cell tumor necrosis factor-alpha And transforming growth factor-beta 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Association-of-Immunologists	MAY 21-26, 1993	DENVER, CO	Amer Assoc Immunologists		mast cell; fibroblast; fibrosis; TNF-alpha; TGF-beta 1; cytokines; proliferation; inflammation	FACTOR-BETA; TNF-ALPHA; EXPRESS; CYTOKINES; EOSINOPHILS; TGF-BETA-1; MEDIATORS; TISSUE	Pathologic fibroblast proliferation or tissue fibrosis develops in certain chronic allergic diseases and in a wide array of other inflammatory disorders in which mast cell activation is also a prominent feature. In this study we investigated a number of potential mechanisms by which IgE-dependent activation of mouse mast cells might influence the proliferation of mouse fibroblasts in vitro. We found that supernatants from in vitro-derived mast cells that had been activated by IgE and specific antigen (but not those from quiescent mast cells) promoted the proliferation of mouse embryonic skin or 3T3 fibroblasts, and we showed that this effect was detectable in the absence of fetal calf serum. We analyzed the kinetics with which the fibroblast-proliferative activity was secreted from bone marrow-derived cultured mast cells and found that it was released both rapidly (i.e., in 30 minutes or less) and for a more prolonged period (i.e., for more than 2 hours) after IgE-dependent mast cell activation. We then measured the levels at which the mast cells produce a number of cytokines that are known to affect fibroblasts (IL-1, IL-6, transforming growth factor-beta 1 [TGF-beta 1], and tumor necrosis factor-alpha [TNF-alpha]) and assessed their relative effects, as recombinant cytokines, on fibroblast proliferation. Our mast cells secreted high levels of TGF-beta 1 and TNF-alpha, intermediate amounts of IL-6, and low levels of IL-1. We titrated the fibroproliferative effects of each of these cytokines and determined that at a dose of 50 pg/ml their rank order of activity was TGF-beta 1 > TNF-alpha > IL-1 > IL-6, with all but IL-6 having significant effects. The ability of supernatants from activated bone marrow-derived cultured mast cells to promote fibroblast proliferation was partially diminished by absorption with neutralizing antibodies against either TNF-alpha or TGF-beta 1, and absorption of the supernatants with a combination of antibodies against TNF-alpha and TGF-beta 1 reduced their ability to induce fibroblast proliferation by approximately 50% (p less than or equal to 0.001, n = 5). These findings show that IgE-dependent activation of mouse mast cells can result in the release of mediators that promote fibroblast proliferation in the absence of any other cell type and suggest that mast cell-derived TNF-alpha and TGF-beta 1 contribute substantially to this effect. They also suggest that these cytokines exert their effects through synergistic interactions with other mast cell mediators.	UNIV SASKATCHEWAN,WESTERN COLL VET MED,DEPT VET MICROBIOL,SASKATOON,SK S7N 0W0,CANADA; HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT PATHOL,BOSTON,MA	University of Saskatchewan; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Gordon, John/D-7621-2013	Gordon, John/0000-0003-3830-8070	NIAID NIH HHS [AI 22674, AI 23990] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023990, R37AI023990, R01AI022674] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIENENSTOCK J, 1986, MAST CELL DIFFERENTI, P391; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CLAMAN HN, 1993, MAST CELL HLTH DIS, P653; COSTA JJ, 1993, J CLIN INVEST, V91, P2673, DOI 10.1172/JCI116506; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; DAYTON ET, 1989, J IMMUNOL, V142, P4307; FRANZEN L, 1980, CELL TISSUE KINET, V13, P635, DOI 10.1111/j.1365-2184.1980.tb00502.x; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GORDON J, 1996, IGE RECEPTOR FEEPSIL, P209; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GORDON JR, 1994, J EXP MED, V180, P2027, DOI 10.1084/jem.180.6.2027; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; KOVACS EJ, 1991, IMMUNOL TODAY, V12, P17, DOI 10.1016/0167-5699(91)90107-5; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; LEMANSKE RF, 1988, ALLERGY PRINCIPLES P, P224; LIU FT, 1980, J IMMUNOL, V124, P2728; MONROE JG, 1988, CLIN IMMUNOL IMMUNOP, V49, P292, DOI 10.1016/0090-1229(88)90119-5; OHNO I, 1992, J CLIN INVEST, V89, P1662, DOI 10.1172/JCI115764; PENNINGTON DW, 1992, J CLIN INVEST, V90, P35, DOI 10.1172/JCI115853; RUOSS SJ, 1991, J CLIN INVEST, V88, P493, DOI 10.1172/JCI115330; SEMPOWSKI GD, 1994, J IMMUNOL, V152, P3606; TSAI M, 1990, FASEB J, V4, pA1944; WAHL SM, 1994, CURRENT PROTOCOLS IM; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WONG DTW, 1991, BLOOD, V78, P2702; YAMASHITA Y, 1992, THORAX, V47, P634, DOI 10.1136/thx.47.8.634; YOUNG JDE, 1987, P NATL ACAD SCI USA, V84, P9175, DOI 10.1073/pnas.84.24.9175	31	58	58	1	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	1				113	123						11	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WD061	9003219				2022-12-18	WOS:A1997WD06100016
J	Smith, PM; Suphioglu, C; Griffith, IJ; Theriault, K; Knox, RB; Singh, MB				Smith, PM; Suphioglu, C; Griffith, IJ; Theriault, K; Knox, RB; Singh, MB			Cloning and expression in yeast Pichia pastoris of a biologically active form of Cyn d 1, the major allergen of Bermuda grass pollen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cyn d 1; Bermuda grass; pollen allergens; cDNA cloning; expression 1; yeast; IgE binding	CYNODON-DACTYLON POLLEN; ALCOHOL OXIDASE GENES; AMB-A-II; LOL-P-I; RYE-GRASS; METHYLOTROPHIC YEAST; IMMUNOCHEMICAL CHARACTERIZATION; MONOCLONAL-ANTIBODIES; CROSS-ALLERGENICITY; SIGNAL SEQUENCES	Background: Pollen of grasses, such as Bermuda grass (Cynodon dactylon), repre Objective: In this report we attempted to clone and express a biologically active from of recombinant Cyn d 1, the major allergen of Bermuda grass pollen, in the yeast Pichia pastoris. Methods: Clones encoding Cyn d 1 were isolated by screening a Bermuda grass pollen complementary DNA library with specific monoclonal antibodies and by polymerase chain reaction amplification. Recombinant Cyn d 1 was expressed in Escherichia coli and yeast. The expressed proteins were analyzed by Western blotting to assess binding to Cyn d 1-specific monoclonal antibodies and IgE from sera of patients allergic to Bermuda grass pollen. Results: Two isoforms of Cyn d 1 were cloned. Recombinant Cyn d 1 expressed in bacteria bound two monoclonal antibodies raised against Cyn d 1 but was not recognized by IgE from sera of patients allergic to Bermuda grass pollen. Cyn d 1 expressed in yeast bound both the monoclonal antibodies and human IgE. Conclusion: an IgE-reactive Cyn d 1 was expressed in yeast but not in bacteria, suggesting that posttranslational modifications (e.g., glycosylation), which occur in eukaryotic cells such as yeast, are necessary for the production of a biologically active allergen.	UNIV MELBOURNE, SCH BOT, PARKVILLE, VIC 3052, AUSTRALIA; IMMULOG PHARMACEUT CORP, WALTHAM, MA USA	University of Melbourne			Smith, Penelope MC/C-6156-2012; Smith, Penelope/AAR-5369-2020; Smith, Penelope Mary Collina/AHB-8349-2022	Smith, Penelope MC/0000-0001-9841-1112; Smith, Penelope Mary Collina/0000-0001-9841-1112; Singh, Mohan/0000-0001-9427-8975				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; AVJIOGLU A, 1992, MOL ANAL POLLEN ALLE; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; BOND JF, 1993, J ALLERGY CLIN IMMUN, V91, P339; BROADWATER AH, 1993, GENE, V131, P227, DOI 10.1016/0378-1119(93)90297-G; BUSH RK, 1989, J ALLERGY CLIN IMMUN, V84, P814, DOI 10.1016/0091-6749(89)90344-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COTTAM GP, 1986, BIOCHEM J, V234, P305, DOI 10.1042/bj2340305; CREGG JM, 1989, MOL CELL BIOL, V9, P1316, DOI 10.1128/MCB.9.3.1316; CREGG JM, 1987, BIO-TECHNOL, V5, P479, DOI 10.1038/nbt0587-479; EKRAMODDOULLAH AKM, 1990, INT ARCH ALLER A IMM, V93, P371, DOI 10.1159/000235268; ESCH RE, 1989, J IMMUNOL, V142, P179; ESCH RE, 1989, MOL IMMUNOL, V26, P557, DOI 10.1016/0161-5890(89)90007-2; FORD SA, 1987, J ALLERGY CLIN IMMUN, V79, P711, DOI 10.1016/0091-6749(87)90201-6; FROHMAN MA, 1990, P NATL ACAD SCI USA, V785, P8998; GRIFFITH IJ, 1991, INT ARCH ALLER A IMM, V96, P296, DOI 10.1159/000235512; GRIFFITH IJ, 1991, FEBS LETT, V279, P210, DOI 10.1016/0014-5793(91)80151-R; GRINNA LS, 1989, YEAST, V5, P107, DOI 10.1002/yea.320050206; HAN SH, 1993, J ALLERGY CLIN IMMUN, V91, P1035, DOI 10.1016/0091-6749(93)90217-4; Hopkins SA, 1992, PHARM ENG, V12, P48; KOUTZ P, 1989, YEAST, V5, P167, DOI 10.1002/yea.320050306; KUO MC, 1993, MOL IMMUNOL, V30, P1077, DOI 10.1016/0161-5890(93)90154-4; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MARSH DG, 1970, J ALLERGY, V46, P107, DOI 10.1016/0021-8707(70)90078-X; MARTIN BG, 1985, ANN ALLERGY, V54, P99; MATTHIESEN F, 1991, J ALLERGY CLIN IMMUN, V88, P763, DOI 10.1016/0091-6749(91)90184-P; MATTHIESEN F, 1992, 15 EUR C ALL CLIN IM; MEESE E, 1990, NUCLEIC ACIDS RES, V18, P1923, DOI 10.1093/nar/18.7.1923; ONG EK, 1990, INT ARCH ALLER A IMM, V93, P338, DOI 10.1159/000235263; PEREZ M, 1990, J BIOL CHEM, V265, P16210; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; ROUX KH, 1990, BIOTECHNIQUES, V8, P48; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUMACHER MJ, 1985, ANN ALLERGY, V55, P584; SHEN HD, 1988, CLIN ALLERGY, V18, P401, DOI 10.1111/j.1365-2222.1988.tb02888.x; SINGH MB, 1985, INT ARCH ALLER A IMM, V78, P300, DOI 10.1159/000233901; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; SMITH PM, 1994, MOL BIOL IMMUNOLOGY, P157; SREEKRISHNA K, 1988, J BASIC MICROB, V28, P265, DOI 10.1002/jobm.3620280410; SUPHIOGLU C, 1993, ALLERGY, V48, P273, DOI 10.1111/j.1398-9995.1993.tb00728.x; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; TSCHOPP JF, 1987, BIO-TECHNOL, V5, P1305, DOI 10.1038/nbt1287-1305; VANREE R, 1992, CLIN EXP ALLERGY, V22, P611; VANREE R, 1993, J ALLERGY CLIN IMMUN, V91, P187; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	46	58	64	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					331	343		10.1016/S0091-6749(96)70158-6	http://dx.doi.org/10.1016/S0091-6749(96)70158-6			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757211	Bronze			2022-12-18	WOS:A1996VC99500013
J	SIMONS, FER; SUSSMAN, GL; SIMONS, KJ				SIMONS, FER; SUSSMAN, GL; SIMONS, KJ			EFFECT OF THE H-2-ANTAGONIST CIMETIDINE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF THE H-2-ANTAGONISTS HYDROXYZINE AND CETIRIZINE IN PATIENTS WITH CHRONIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CHRONIC-IDIOPATHIC URTICARIA; INDUCED CUTANEOUS WHEAL; HUMAN-SKIN; H-2-RECEPTOR ANTAGONISTS; FLARE REACTIONS; COMBINED H-1; RANITIDINE; HISTAMINE; COMBINATION; METABOLISM	Background: Concomitant administration of an H-1-receptor antagonist with an H-2-receptor antagonist may enhance the wheal and flare suppression produced by the H-1-antagonist. This synergism may be due, at least in part to a pharmacokinetic effect. Methods: In a randomized, double-blind, parallel-group study in 16 patients with chronic urticaria, we investigated the pharmacokinetics and suppressive effect on the histamine-induced wheal and flare of a single dose of hydroxyzine 25 mg or cetirizine 10 mg, given before and after treatment with cimetidine 600 mg every 12 hours for 10 days. Results: When hydroxyzine was administered with cimetidine, the partial hydroxyzine area under the curve increased significantly (p < 0.05) to 303 +/- 92 ng/ml/hr from 227 +/- 77 ng/ml/hr after administration of hydroxyzine alone, and the concentration of cetirizine arising from hydroxyzine was lower. When hydroxyzine was given with cimetidine, wheal and flare suppression increased compared with when hydroxyzine was given alone, but the differences were not statistically significant ( p > 0.05). When cetirizine was administered with cimetidine, the pharmacokinetics of cetirizine did not change significantly, and no enhancement of wheal and flare suppression was observed. Conclusions: In this study co-administration of hydroxyzine with cimetidine resulted in significantly increased serum hydroxyzine concentrations and increased wheal and flare suppression, thus confirming the rationale for a trial of concomitant administration of these medications in some patients with chronic urticaria unresponsive to treatment with an H-1-antagonist alone. We found no therapeutic rationale for co-administration of cetirizine with cimetidine in urticaria treatment. These medications may be co-administered safely without fear of medication interaction.	UNIV MANITOBA,FAC MED,WINNIPEG,MB R3T 2N2,CANADA; UNIV TORONTO,FAC MED,TORONTO,ON,CANADA; UNIV MANITOBA,FAC PHARM,WINNIPEG,MB R3T 2N2,CANADA; UNIV MANITOBA,FAC SCI,WINNIPEG,MB R3T 2N2,CANADA	University of Manitoba; University of Toronto; University of Manitoba; University of Manitoba								[Anonymous], 1980, PRINCIPLES PROCEDURE; AYMARD JP, 1988, MED TOXICOL ADV DRUG, V3, P430, DOI 10.1007/BF03259895; BLEEHEN SS, 1987, BRIT J DERMATOL, V117, P81, DOI 10.1111/j.1365-2133.1987.tb04095.x; Cantu TG, 1991, ANN INTERN MED, V114, P1027, DOI 10.7326/0003-4819-114-12-1027; CHEN XY, 1994, PHARMACEUT RES, V11, P295, DOI 10.1023/A:1018971828065; COMMENS CA, 1978, BRIT J DERMATOL, V99, P675, DOI 10.1111/j.1365-2133.1978.tb07062.x; COOK LJ, 1983, ACTA DERM-VENEREOL, V63, P265; FELDMAN M, 1990, NEW ENGL J MED, V323, P1672; GENGO FM, 1987, CLIN PHARMACOL THER, V42, P265, DOI 10.1038/clpt.1987.145; GIBALDI M, 1982, PHARMACOKINETICS, P1; HARVEY RP, 1980, J ALLERGY CLIN IMMUN, V65, P136, DOI 10.1016/0091-6749(80)90198-0; HOLLISTER LE, 1975, PSYCHOPHARMACOL COMM, V1, P61; HONIG PK, 1993, EUR J CLIN PHARMACOL, V45, P41, DOI 10.1007/BF00315348; JOHNSON CE, 1984, CLIN PHARMACY, V3, P60; KAPLAN AP, 1993, ALLERGY PRINCIPLES P, P1553; KAUR S, 1981, BRIT J DERMATOL, V104, P185, DOI 10.1111/j.1365-2133.1981.tb00043.x; KLOTZ U, 1987, PHARMACOL THERAPEUT, V33, P157, DOI 10.1016/0163-7258(87)90045-3; LEFEBVRE RA, 1988, INT J CLIN PHARM RES, V8, P463; LEVANDER S, 1991, EUR J CLIN PHARMACOL, V41, P435, DOI 10.1007/BF00626365; MANSFIELD LE, 1983, ANN ALLERGY, V50, P264; MARKS R, 1977, BRIT J CLIN PHARMACO, V4, P367, DOI 10.1111/j.1365-2125.1977.tb00725.x; MATTHEWS CNA, 1979, BRIT J DERMATOL, V101, P57, DOI 10.1111/j.1365-2133.1979.tb15293.x; MILLER J, 1989, J ALLERGY CLIN IMMUN, V84, P895, DOI 10.1016/0091-6749(89)90386-2; MONROE EW, 1981, ARCH DERMATOL, V117, P404, DOI 10.1001/archderm.117.7.404; NATHAN RA, 1981, J ALLERGY CLIN IMMUN, V67, P171, DOI 10.1016/0091-6749(81)90057-9; PAUL E, 1986, EUR J CLIN PHARMACOL, V31, P277, DOI 10.1007/BF00981123; PAUL E, 1988, EUR J CLIN PHARMACOL, V34, P591, DOI 10.1007/BF00615222; PHANUPHAK P, 1978, CLIN ALLERGY, V8, P429, DOI 10.1111/j.1365-2222.1978.tb01493.x; PULVER K, 1986, ANN ALLERGY, V56, P520; SAHA N, 1993, INT J CLIN PHARM TH, V31, P322; SALE ME, 1994, CLIN PHARMACOL THER, V54, P295; SALO OP, 1986, ACTA DERM-VENEREOL, V66, P349; SEIDEL WF, 1990, J ALLERGY CLIN IMMUN, V86, P1029, DOI 10.1016/S0091-6749(05)80249-0; SHUMAKER RC, 1986, DRUG METAB REV, V17, P331, DOI 10.3109/03602538608998295; SIMONS FER, 1984, J ALLERGY CLIN IMMUN, V73, P69, DOI 10.1016/0091-6749(84)90486-X; SMITH JA, 1979, ANN ALLERGY, V42, P353; SMITH SR, 1988, CLIN PHARMACOKINET, V15, P44, DOI 10.2165/00003088-198815010-00004; SOMOGYI A, 1987, CLIN PHARMACOKINET, V12, P321, DOI 10.2165/00003088-198712050-00002; THOMAS RHM, 1985, BRIT J CLIN PHARMACO, V20, P377, DOI 10.1111/j.1365-2125.1985.tb05080.x; THOMAS RHM, 1985, J ALLERGY CLIN IMMUN, V76, P864, DOI 10.1016/0091-6749(85)90761-4; VANROOIJ J, 1993, BRIT J CLIN PHARMACO, V35, P661; WALSH JK, 1992, ANN ALLERGY, V69, P195; WATSON WTA, 1989, J ALLERGY CLIN IMMUN, V84, P457, DOI 10.1016/0091-6749(89)90358-8; WOOD SG, 1987, ANN ALLERGY, V59, P31	44	58	61	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					685	693		10.1016/S0091-6749(95)70173-7	http://dx.doi.org/10.1016/S0091-6749(95)70173-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QM017	7897151				2022-12-18	WOS:A1995QM01700008
J	RATNER, PH; FINDLAY, SR; HAMPEL, F; VANBAVEL, J; WIDLITZ, MD; FREITAG, JJ				RATNER, PH; FINDLAY, SR; HAMPEL, F; VANBAVEL, J; WIDLITZ, MD; FREITAG, JJ			A DOUBLE-BLIND, CONTROLLED TRIAL TO ASSESS THE SAFETY AND EFFICACY OF AZELASTINE NASAL SPRAY IN SEASONAL ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						AZELASTINE NASAL SPRAY; SYMPTOMATIC SEASONAL ALLERGIC RHINITIS; MAJOR SYMPTOM COMPLEX; TOTAL SYMPTOM COMPLEX		Background: Azelastine solution is a topically (nasal) administered antiallergy drug with a preclinical profile suggestive of efficacy in patients with allergic rhinitis. Objectives: The study was designed to compare the effectiveness and safety of two dosages of azelastine nasal spray (2 sprays per nostril once daily and twice daily) with that of placebo in the treatment of patients with symptomatic seasonal allergic rhinitis. Methods: Two hundred fifty-one patients (12 years of age or older) were randomized to treatment in this 2-week, double-blind, parallel-group study. Primary efficacy variables were Major Symptom Complex (nose blows, sneezes, runny nose, itchy nose, watery eyes) and Total Symptoms Complex (Major Symptom Complex plus itchy eyes/ears/throat/palate, cough, postnasal drip). Results: Patients treated with azelastine had mean percent improvements in Total and Major Symptom Complex scores that were consistently superior to placebo at each evaluation point. Overall, improvements were statistically significant (p less than or equal to 0.05) in the Total Symptoms Complex for both azelastine groups and in the Major Symptom Complex for the twice daily group with a trend toward statistical significance for the once daily group. Azelastine was superior to placebo in improving all individual rhinitis symptoms. Adverse experiences in the azelastine groups were minor and infrequent. Conclusion: The results support the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis.	FINDLAY RES ASSOCIATES INC,AUSTIN,TX; AUSTIN DIAGNOST CLIN,ALLERGY ASSOCIATES,AUSTIN,TX; WALLACE LABS,PRINCETON,NJ		RATNER, PH (corresponding author), SYLVANA RES,7711 LOUIS PASTEUR,SUITE 406,SAN ANTONIO,TX 78229, USA.							ACHTERRATHTUCKERMANN U, 1988, EXPERIENTIA, V44, P993, DOI 10.1007/BF01939898; CHAND N, 1988, EUR J PHARMACOL, V150, P95, DOI 10.1016/0014-2999(88)90754-6; CHAND N, 1986, AGENTS ACTIONS, V19, P164, DOI 10.1007/BF01966201; CHAND N, 1987, American Review of Respiratory Disease, V135, pA318; CHAND N, 1985, INT J IMMUNOPHARMACO, V7, P833, DOI 10.1016/0192-0561(85)90045-1; CHAND N, 1984, PHARMACOLOGIST, V26, P152; CHAND N, 1987, PHARMACOLOGIST, V29, P173; MELTZER E, 1990, Clinical and Experimental Allergy, V20, P100; MYGIND N, 1980, TOPICAL STEROID TREA; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; PERHACH JL, 1989, ALLERGY ASTHMA NEW T, P230; SHIN MH, 1992, CLIN EXP ALLERGY, V22, P289, DOI 10.1111/j.1365-2222.1992.tb03085.x; WEILER J M, 1991, Journal of Allergy and Clinical Immunology, V87, P219, DOI 10.1016/0091-6749(91)91602-P; YAMANAKA T, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1203; 1994, PHYSICIANS DESK REFE, P475	15	58	61	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1994	94	5					818	825		10.1016/0091-6749(94)90148-1	http://dx.doi.org/10.1016/0091-6749(94)90148-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PR240	7963150				2022-12-18	WOS:A1994PR24000005
J	CALDERON, MA; LOZEWICZ, S; PRIOR, A; JORDAN, S; TRIGG, CJ; DAVIES, RJ				CALDERON, MA; LOZEWICZ, S; PRIOR, A; JORDAN, S; TRIGG, CJ; DAVIES, RJ			LYMPHOCYTE INFILTRATION AND THICKNESS OF THE NASAL MUCOUS-MEMBRANE IN PERENNIAL AND SEASONAL ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RHINITIS; PERENNIAL; SEASONAL; LYMPHOCYTES; NASAL MUCOSA	BASOPHIL MAST-CELL; MAJOR BASIC-PROTEIN; INTERLEUKIN-5 IL-5; EOSINOPHIL GROWTH; ASTHMA; DIFFERENTIATION; IMMUNOHISTOLOGY; PROVOCATION; NEUTROPHILS; EPITHELIUM	We have used immunocytochemical techniques to study infiltration by lymphocytes in biopsy specimens of the nasal mucosal membrane in 24 atopic patients and 10 normal volunteers. Twelve patients had perennial rhinitis and 12 had seasonal allergic rhinitis (SR) to grass pollen. Biopsy specimens were taken both in and out of the pollen season in patients with SR. Biopsy specimens were strained with the indirect immunoperoxidase technique and monoclonal antibodies to CD3, CD4, CD8, CD22, and CD25. T helper cells (CD4+) and CD25 + cells were significantly more numerous in patients exposed to allergen (those with perennial rhinitis and SR in season) compared with normal volunteers, whereas values for SR out of season were intermediate. The thickness of the nasal epithelium was significantly (p < 0.05) greater in biopsy specimens from patients with perennial rhinitis (mean, 51.43 mum) than in those from patients with SR in season (median, 32.44 mum). These results suggest that in allergic rhinitis, natural exposure to allergen is accompanied by increased infiltration of the nasal mucous membrane by T-helper and CD25 + cells.	ST BARTHOLOMEWS HOSP,DEPT EAR NOSE & THROAT,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT IMMUNOCYTOCHEM,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London	DAVIES, RJ (corresponding author), ST BARTHOLOMEWS HOSP,DEPT RESP MED & ALLERGY,LONDON EC1A 7BE,ENGLAND.							AYARS GH, 1989, AM REV RESPIR DIS, V140, P125; BASCOM R, 1989, J ALLERGY CLIN IMMUN, V84, P338, DOI 10.1016/0091-6749(89)90418-1; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; DENBURG JA, 1989, CLIN EXP ALLERGY, V19, P249, DOI 10.1111/j.1365-2222.1989.tb02379.x; DENBURG JA, 1987, INT ARCH ALLER A IMM, V82, P321, DOI 10.1159/000234217; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; FOKKENS WJ, 1990, INT ARCH ALLER A IMM, V93, P66, DOI 10.1159/000235281; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GOMEZ E, 1986, J ALLERGY CLIN IMMUN, V78, P637, DOI 10.1016/0091-6749(86)90082-5; INAGAKI M, 1985, Rhinology (Utrecht), V23, P213; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P7145; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LEUNG DYM, 1988, J ALLERGY CLIN IMMUN, V81, P303, DOI 10.1016/0091-6749(88)90776-2; LOZEWICZ S, 1990, J ALLERGY CLIN IMMUN, V85, P125, DOI 10.1016/0091-6749(90)90233-T; LOZEWICZ S, 1989, J ALLERGY CLIN IMMUN, V83, P307; NAGAYA H, 1985, J ALLERGY CLIN IMMUN, V75, P388, DOI 10.1016/0091-6749(85)90077-6; OHNISHI M, 1988, J ALLERGY CLIN IMMUN, V81, P1149, DOI 10.1016/0091-6749(88)90883-4; OKUDA M, 1988, RHINOLOGY S1, V26, P136; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; PHILLIPS L, 1987, J ALLERGY CLIN IMMUN, V79, P933, DOI 10.1016/0091-6749(87)90243-0; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; SUSTIEL A, 1989, CLIN EXP ALLERGY, V19, P11, DOI 10.1111/j.1365-2222.1989.tb02337.x; TAKATSU K, 1988, IMMUNOL REV, V102, P107, DOI 10.1111/j.1600-065X.1988.tb00743.x; TAMIR R, 1987, J ALLERGY CLIN IMMUN, V75, P591; TESTA B, 1992, LARYNGOSCOPE, V102, P327; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; Yen C H, 1991, Arerugi, V40, P65; Yoshimi R, 1991, Nihon Jibiinkoka Gakkai Kaiho, V94, P641	32	58	58	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1994	93	3					635	643		10.1016/S0091-6749(94)70075-3	http://dx.doi.org/10.1016/S0091-6749(94)70075-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ND140	8151063				2022-12-18	WOS:A1994ND14000010
J	NACLERIO, RM; ADKINSON, NF; CRETICOS, PS; BAROODY, FM; HAMILTON, RG; NORMAN, PS				NACLERIO, RM; ADKINSON, NF; CRETICOS, PS; BAROODY, FM; HAMILTON, RG; NORMAN, PS			INTRANASAL STEROIDS INHIBIT SEASONAL INCREASES IN RAGWEED-SPECIFIC IMMUNOGLOBULIN-E ANTIBODIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RAGWEED; INTRANASAL STEROIDS; SERUM RAGWEED IGE; BECLOMETHANSONE; TRIAMCINOLONE; ALLERGIC RHINITIS	BECLOMETHASONE DIPROPIONATE; TOPICAL GLUCOCORTICOSTEROIDS; RHINITIS; IMMUNOTHERAPY; PRETREATMENT; ASTEMIZOLE	We performed two seasonal studies to evaluate the effect of continuous treatment with intranasal steroids, beginning approximately 1 week before the apperance of ragweed pollen, on the level of ragweed-specific IgE antibodies in serum. In both studies the control groups showed the anticipated rise in ragweed-specific IgE antibodies after the ragweed season. In the first study, employing aqueous beclomethasone dipropionate (168 mug twice daily), no rise occurred in serum ragweed IgE after seasonal exposure and the level actually decreased in eight of 12 treated subjects. In the second study, with triamcinolone acetonide (220 mug twice daily), the expected rise in ragweed IgE antibody was also reduced, although less dramatically, probably as a result of the lower potency of the dose delivered. Our studies not only support the benefits of intranasal steroids in the treatment of seasonal allergic rhinitis but also suggest that specific IgE production may be down-regulated by their continuous use, which may alter the subsequent clinical course of the disease.	JOHNS HOPKINS UNIV, SCH MED, DEPT OTOLARYNGOL HEAD & NECK SURG, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CLIN IMMUNOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University					NIAID NIH HHS [AI 31867, AI 31335] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031335, U01AI031867, U19AI031867] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P794; ANDERSSON M, 1988, J ALLERGY CLIN IMMUN, V82, P1019, DOI 10.1016/0091-6749(88)90139-X; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; ENERBACK L, 1986, INT ARCH ALLER A IMM, V19, P17; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; HARDING SM, 1976, CLIN ALLERGY, V6, P369, DOI 10.1111/j.1365-2222.1976.tb01918.x; HASTIE R, 1979, LAB INVEST, V40, P554; Haynes Jr RC, 1985, PHARMACOL BASIS THER, P1459; HILLAS J, 1980, CLIN ALLERGY, V10, P253, DOI 10.1111/j.1365-2222.1980.tb02104.x; JUNIPER EF, 1989, J ALLERGY CLIN IMMUN, V83, P627, DOI 10.1016/0091-6749(89)90075-4; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LINDER A, 1987, ALLERGY, V42, P583, DOI 10.1111/j.1398-9995.1987.tb00388.x; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; OTSUKA H, 1986, CLIN ALLERGY, V16, P589, DOI 10.1111/j.1365-2222.1986.tb01998.x; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; SCHLEIMER RP, 1988, ALLERGY PRINCIPLES P, P739; SIEGEL SC, 1988, J ALLERGY CLIN IMMUN, V81, P984, DOI 10.1016/0091-6749(88)90166-2; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; WIHL JA, 1985, J ALLERGY CLIN IMMUN, V75, P720, DOI 10.1016/0091-6749(85)90100-9	20	58	58	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1993	92	5					717	721		10.1016/0091-6749(93)90015-8	http://dx.doi.org/10.1016/0091-6749(93)90015-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG982	8227863				2022-12-18	WOS:A1993MG98200013
J	WOODFOLK, JA; LUCZYNSKA, CM; DEBLAY, F; CHAPMAN, MD; PLATTSMILLS, TAE				WOODFOLK, JA; LUCZYNSKA, CM; DEBLAY, F; CHAPMAN, MD; PLATTSMILLS, TAE			THE EFFECT OF VACUUM CLEANERS ON THE CONCENTRATION AND PARTICLE-SIZE DISTRIBUTION OF AIRBORNE CAT ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						VACUUM CLEANERS; AIRBORNE CAT ALLERGEN; DOUBLE-THICKNESS DUST BAG; ELECTROSTATIC FILTER	FEL-D-I; MONOCLONAL-ANTIBODIES; CASCADE IMPACTOR; DUST MITE; ASTHMA; SKIN; DERMATOPHAGOIDES; PURIFICATION; DOMESTICUS; EXPOSURE	Background: Vacuum cleaners are essential for the removal of dust from the surface of carpets; however, they may also contribute to airborne dust both by leakage through the cleaner and disturbance of floor dust. Methods: The present studies used established techniques for measuring airborne Fel d I to study the effects of vacuum cleaners on airborne cat allergen under laboratory conditions and in houses with cats. Nine different models were loaded with dust containing 50 mg Fel d I and run for 15 minutes in a laboratory room (volume approximately 18 m3). Leakage was expressed as the airborne concentration of allergen in nanograms per cubic meter. Results: Cleaners incorporating a double-thickness dust bag either did not leak, that is, less than 0.4 ng Fel d I/m3 or had minor leakage approximately 5 ng/m3. Vacuum cleaners with single-thickness paper bags leaked more, that is, 15 to > 90 ng/m3 with the exception of the cleaner with an efficient outer bag. Detailed studies on a vacuum cleaner that leaked showed that placing dust in the bag, replacing the dust bag with a double-thickness bag, and placing an electrostatic filter over the exhaust reduced levels from greater than 90 ng/m3 to less than 2 ng/m3. Two water-filter vacuum cleaners each emitted cat allergen (up to > 100 ng/m3) with a mean of approximately 90% on particles less than 2.5 mum diameter. This emission could be almost completely controlled by taping electrostatic filter paper over the air outlet. Conclusions: In houses with cats, different models of vacuum cleaners could either reduce or increase total airborne allergen, and could also selectively increase certain particle sizes. These results suggest that cat allergen is a good model for studying the effectiveness of vacuum cleaners recommended to allergic patients.	UNIV VIRGINIA, HLTH SCI CTR,DEPT MED,DIV ALLERGY & CLIN IMMUNOL, BOX 225, CHARLOTTESVILLE, VA 22908 USA	University of Virginia				Chapman, Martin/0000-0002-0845-3632	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020565, R01AI020565, R01AI030840] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20565, AI-30840] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON MC, 1981, J IMMUNOL, V127, P972; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHARPIN C, 1991, J ALLERGY CLIN IMMUN, V88, P77, DOI 10.1016/0091-6749(91)90303-6; DABROWSKI AJ, 1990, J ALLERGY CLIN IMMUN, V86, P462, DOI 10.1016/S0091-6749(05)80200-3; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; DEGROOT H, 1988, J ALLERGY CLIN IMMUN, V82, P778, DOI 10.1016/0091-6749(88)90079-6; FINDLAY SR, 1983, AM REV RESPIR DIS, V128, P1008; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LOWENSTEIN H, 1985, ALLERGY, V40, P430, DOI 10.1111/j.1398-9995.1985.tb02682.x; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MAY KR, 1945, J SCI INSTRUM, V22, P187, DOI 10.1088/0950-7671/22/10/303; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OHMAN JL, 1978, J AM VET MED ASSOC, V172, P1403; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; SWANSON MC, 1989, J ALLERGY CLIN IMMUN, V83, P776, DOI 10.1016/0091-6749(89)90014-6; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TWIGGS JT, 1991, ANN ALLERGY, V66, P431; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; WENTZ PE, 1990, J ALLERGY CLIN IMMUN, V85, P94, DOI 10.1016/0091-6749(90)90228-V; WOOD RA, 1992, J ALLERGY CLIN IMMUN, V89, P126, DOI 10.1016/S0091-6749(05)80049-1; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P730, DOI 10.1016/0091-6749(89)90006-7	27	58	58	1	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1993	91	4					829	837		10.1016/0091-6749(93)90339-H	http://dx.doi.org/10.1016/0091-6749(93)90339-H			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KY251	8473670				2022-12-18	WOS:A1993KY25100002
J	DOYLE, WJ; SKONER, DP; FIREMAN, P; SEROKY, JT; GREEN, I; RUBEN, F; KARDATZKE, DR; GWALTNEY, JM				DOYLE, WJ; SKONER, DP; FIREMAN, P; SEROKY, JT; GREEN, I; RUBEN, F; KARDATZKE, DR; GWALTNEY, JM			RHINOVIRUS-39 INFECTION IN ALLERGIC AND NONALLERGIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RHINOVIRUS; ALLERGY; EUSTACHIAN TUBE; URI; NASAL WORK	NASAL RESPONSIVENESS; RHINITIS PATIENTS; EUSTACHIAN-TUBE; MIDDLE-EAR; COLDS; HYPERSENSITIVITY; METHACHOLINE; HISTAMINE; CHALLENGE; ATROPINE	To determine if individuals with allergic rhinitis are hyperresponsive to upper respiratory tract viral infections, 20 allergic and 18 nonallergic, susceptible, adult volunteers were challenged and infected with rhinovirus type 39 before the pollen seasons. Before challenge and on each of 6 days of cloister, all volunteers were interviewed for symptoms and completed a test battery consisting of evaluations of secretion production by weighed tissues, nasal patency by active posterior rhinomanometry, nasal clearance by the dyed saccharin technique, pulmonary function by spirometry, eustachian tube function by sonotubometry, and middle ear status by tympanometry. The symptomatology and pathophysiology resulting from the rhinovirus infection were consistent with those reported in previous studies with this challenge system. Between-group comparisons revealed no differences in symptom presentation, nasal secretion production, or overall pathophysiologic response. However, for decreased mucociliary clearance rate, increased nasal congestion, eustachian tube dysfunction, and symptoms of sneezing, the allergic group demonstrated an earlier onset compared with that of the nonallergic group. The biologic significance of the differences in onset of dysfunction is tempered by the observation that the temporal pattern of responses in the allergic group was similar with that of nonallergic subjects in previous studies. The results of the present study do not support the hypothesis of a physiologic hyperresponsiveness to rhinovirus type 39 infection in allergic subjects during nonallergy seasons.	CHILDRENS HOSP PITTSBURGH,DEPT OTOLARYNGOL,PITTSBURGH,PA; CHILDRENS HOSP PITTSBURGH,DEPT PEDIAT,DIV ALLERGY IMMUNOL & RHEUMATOL,PITTSBURGH,PA; UNIV PITTSBURGH,SCH MED,SCH MED,DEPT MED,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH PUBL HLTH,DEPT BIOSTAT,PITTSBURGH,PA 15260; UNIV VIRGINIA,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22903	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Virginia					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019262] Funding Source: NIH RePORTER; NCRR NIH HHS [MO/RR 000 84] Funding Source: Medline; NIAID NIH HHS [AI 19262, R01 AI019262] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASAKURA K, 1984, ARCH OTO-RHINO-LARYN, V239, P273, DOI 10.1007/BF00464255; BERNSTEIN JM, 1983, AM J OTOL, V5, P66; CALLOW KA, 1988, CLIN ALLERGY, V18, P119, DOI 10.1111/j.1365-2222.1988.tb02851.x; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; Doyle W. J., 1988, AM J RHINOL, V2, P149, DOI DOI 10.2500/105065888781692961; DOYLE WJ, 1990, J ALLERGY CLIN IMMUN, V86, P924, DOI 10.1016/S0091-6749(05)80156-3; DOYLE WJ, 1988, PEDIATR INFECT DIS J, V7, P229, DOI 10.1097/00006454-198803000-00033; GAFFEY MJ, 1987, AM REV RESPIR DIS, V135, P241; GAFFEY MJ, 1988, ANTIMICROB AGENTS CH, V32, P1644, DOI 10.1128/AAC.32.11.1644; GWALTNEY JM, 1966, AM REV RESPIR DIS, V93, P362; HAENEY M, 1985, J ROY COLL PHYS LOND, V19, P147; HAYDEN FG, 1982, ANTIMICROB AGENTS CH, V21, P892, DOI 10.1128/AAC.21.6.892; HSIA J, 1990, J INFECT DIS, V162, P591, DOI 10.1093/infdis/162.3.591; JACKSON RT, 1981, ARCH OTOLARYNGOL, V107, P288; KALINER M, 1976, J ALLERGY CLIN IMMUN, V58, P308, DOI 10.1016/0091-6749(76)90136-6; KATZ DH, 1984, ALLERGY, V39, P81, DOI 10.1111/j.1398-9995.1984.tb01940.x; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LEUNG D Y M, 1984, Clinical Immunology Reviews, V3, P1; MCBRIDE TP, 1989, ARCH OTOLARYNGOL, V115, P1054; NACLERIO RM, 1988, J INFECT DIS, V157, P133, DOI 10.1093/infdis/157.1.133; OKUDA M, 1983, ANN ALLERGY, V51, P51; PELIKAN Z, 1990, J ALLERGY CLIN IMMUN, V86, P484, DOI 10.1016/S0091-6749(05)80203-9; SKONER DP, 1989, AM J RHINOL, V3, P53; SMITH LJ, 1980, J ALLERGY CLIN IMMUN, V66, P374, DOI 10.1016/0091-6749(80)90116-5; SPERBER S, UNPUB J INFECT DIS; TURNER RB, 1982, J INFECT DIS, V145, P849, DOI 10.1093/infdis/145.6.849; VANWIJK RG, 1987, CLIN ALLERGY, V17, P563; VANWIJK RG, 1987, RHINOLOGY, V225, P41	28	58	58	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1992	89	5					968	978		10.1016/0091-6749(92)90219-R	http://dx.doi.org/10.1016/0091-6749(92)90219-R			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HU542	1316390	Bronze, Green Published			2022-12-18	WOS:A1992HU54200007
J	JALONEN, T				JALONEN, T			IDENTICAL INTESTINAL PERMEABILITY CHANGES IN CHILDREN WITH DIFFERENT CLINICAL MANIFESTATIONS OF COWS MILK ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGY; INFANT; INTESTINAL ABSORPTION; MILK; PERMEABILITY	FOOD ALLERGY; IMMUNE-RESPONSE; ABSORPTION; ANTIGEN; INTOLERANCE; INFANTS; JEJUNUM; ECZEMA	To determine the relationship between clinical symptoms of cow's milk allergy (CMA) and intestinal permeability, 51 children (mean age, 13 months) were studied during a diagnostic milk provocation test. Intestinal permeability was assessed by orally administered lactulose (4 gm) and mannitol (0.8 gm) immediately before (day 0) the milk challenge and 3 days later (day 3). Twenty-four patients evinced cutaneous symptoms and 27, gastrointestinal symptoms. The mean (95% confidence interval) urinary lactulose/mannitol recovery ratios before the milk challenge were, in both groups of patients, comparable to the level of that of control patients, 0.02 (0.01 and 0.03). A rise in lactulose/mannitol excretion ratios followed cow's milk administration by day 3 in patients with skin symptoms, 0.06 (0.03 and 0.13), as well as in patients with gastrointestinal symptoms, 0.08 (0.04, 0.17). These levels were significantly different from the control level, p = 0.003, and the prechallenge level, p = 0.01. This difference was caused by a concomitant increase in urinary recovery of lactulose and a decrease of mannitol. These results indicate that the intestinal barrier is equally altered in patients with different clinical manifestations of CMA and further suggest that enhancement of mucous membrane permeability is not a primary defect in the pathogenesis of CMA but rather a secondary phenomen, possibly caused by a hypersensitivity reaction in the intestinal mucosa.			JALONEN, T (corresponding author), UNIV TAMPERE,DEPT CLIN SCI,POB 607,SF-33101 TAMPERE,FINLAND.							BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; CURTIS GH, 1990, GASTROENTEROLOGY, V98, P1558, DOI 10.1016/0016-5085(90)91090-S; DUMONT GCL, 1984, CLIN ALLERGY, V14, P55; DUPONT C, 1989, J PEDIATR GASTR NUTR, V8, P459, DOI 10.1097/00005176-198905000-00007; FIRER MA, 1987, INT ARCH ALLER A IMM, V84, P173, DOI 10.1159/000234419; HEYMAN M, 1984, J PEDIATR GASTR NUTR, V3, P357, DOI 10.1097/00005176-198406000-00009; HEYMAN M, 1990, INT ARCH ALLER A IMM, V92, P242, DOI 10.1159/000235184; HEYMAN M, 1988, PEDIATR RES, V24, P197, DOI 10.1203/00006450-198808000-00012; HILL DJ, 1988, CLIN ALLERGY, V18, P469, DOI 10.1111/j.1365-2222.1988.tb02897.x; ISOLAURI E, 1989, J PEDIATR GASTR NUTR, V8, P466, DOI 10.1097/00005176-198905000-00008; ISOLAURI E, 1990, PEDIATR RES, V28, P582, DOI 10.1203/00006450-199012000-00006; ISOLAURI E, 1991, PEDIATRICS, V88, P90; JACKSON PG, 1981, LANCET, V1, P1285; JALONEN T, IN PRESS PEDIATR RES; LAKER MF, 1980, CLIN CHEM, V26, P441; LIFSCHITZ CH, 1990, J PEDIATR GASTR NUTR, V10, P283, DOI 10.1097/00005176-199004000-00002; MCCALLA R, 1980, ALLERGY, V35, P563, DOI 10.1111/j.1398-9995.1980.tb01806.x; PATRICK MK, 1988, PEDIATR CLIN N AM, V35, P17; POWELL GK, 1989, DIGEST DIS SCI, V34, P781, DOI 10.1007/BF01540354; SCHRANDER JJP, 1990, J PEDIATR GASTR NUTR, V10, P189, DOI 10.1097/00005176-199002000-00008; STROBEL S, 1984, GUT, V25, P1241, DOI 10.1136/gut.25.11.1241; SWEELEY CC, 1963, J AM CHEM SOC, V85, P2497, DOI 10.1021/ja00899a032; WALKER WA, 1986, J ALLERGY CLIN IMMUN, V78, P1003, DOI 10.1016/0091-6749(86)90293-9; WALKER WA, 1987, ANN ALLERGY, V59, P7; WERSHIL WK, 1988, IMMUNOL ALLERGY CLIN, V8, P485; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed	26	58	62	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1991	88	5					737	742		10.1016/0091-6749(91)90180-V	http://dx.doi.org/10.1016/0091-6749(91)90180-V			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GQ452	1955632				2022-12-18	WOS:A1991GQ45200008
J	EGGLESTON, PA; NEWILL, CA; ANSARI, AA; PUSTELNIK, A; LOU, SR; EVANS, R; MARSH, DG; LONGBOTTOM, JL; CORN, M				EGGLESTON, PA; NEWILL, CA; ANSARI, AA; PUSTELNIK, A; LOU, SR; EVANS, R; MARSH, DG; LONGBOTTOM, JL; CORN, M			TASK-RELATED VARIATION IN AIRBORNE CONCENTRATIONS OF LABORATORY-ANIMAL ALLERGENS - STUDIES WITH RAT-N-I	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV HOSP,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT ENVIRONM HLTH SCI & IMMUNOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INFECT DIS,BALTIMORE,MD 21218; CARDIOTHORAC INST,DEPT PAEDIAT,LONDON SW3 6HP,ENGLAND	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University	EGGLESTON, PA (corresponding author), JOHNS HOPKINS UNIV HOSP,DEPT PEDIAT,CMSC 1103,601 N WOLFE ST,BALTIMORE,MD 21205, USA.				NHLBI NIH HHS [HL 30532] Funding Source: Medline; NIAID NIH HHS [AI 21073, N01-AI-52591] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021073, N01AI052591] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COCKCROFT A, 1981, LANCET, V1, P827; CORN M, 1983, J ALLERGY CLIN IMMUN, V72, P231, DOI 10.1016/0091-6749(83)90026-X; CORN M, 1988, ANN OCCUP HYG     S1, V32, P435; DAVIES GE, 1981, INT ARCH ALLER A IMM, V66, P158; EVANS R, 1987, J ALLERGY CLIN IMMUN, V79, P183; FINDLAY SR, 1983, AM REV RESPIR DIS, V128, P1008; IRWIN JF, 1971, BIOCHIM BIOPHYS ACTA, V252, P328, DOI 10.1016/0304-4165(71)90014-6; LAPERCHE Y, 1983, CELL, V32, P453, DOI 10.1016/0092-8674(83)90465-8; LONGBOTTOM JL, 1984, J IMMUNOL METHODS, V68, P297, DOI 10.1016/0022-1759(84)90160-1; LUTSKY II, 1975, ANN ALLERGY, V35, P201; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P505, DOI 10.1016/0091-6749(87)90369-1; SLOVAK AJM, 1981, BRIT J IND MED, V38, P38; SWANSON MC, 1984, AM REV RESPIR DIS, V129, P844, DOI 10.1164/arrd.1984.129.5.844; TAYLOR AN, 1977, LANCET, V2, P847; TWIGGS JT, 1982, J ALLERGY CLIN IMMUN, V69, P522, DOI 10.1016/0091-6749(82)90177-4; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8	17	58	59	1	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1989	84	3					347	352		10.1016/0091-6749(89)90419-3	http://dx.doi.org/10.1016/0091-6749(89)90419-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AR199	2778241				2022-12-18	WOS:A1989AR19900012
J	REID, LM				REID, LM			THE PRESENCE OR ABSENCE OF BRONCHIAL MUCUS IN FATAL ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	REID, LM (corresponding author), CHILDRENS HOSP MED CTR,DEPT PATHOL,300 LONGWOOD AVE,BOSTON,MA 02115, USA.							BHASKAR KR, 1981, J BIOL CHEM, V256, P7583; BHASKAR KR, 1986, EXP LUNG RES, V10, P401, DOI 10.3109/01902148609058290; Cardell BS, 1959, THORAX, V14, P341; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; KEAL EE, 1975, NEW DIRECTIONS ASTHM, P233; LOPEZVIDRIERO MT, 1985, BRONCHIAL ASTHMA MEC, P218; LOPEZVIDRIERO MT, 1983, ASTHMA, P79; REID LM, 1978, STATUS ASTHMATICUS, P59	8	58	58	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			415	416		10.1016/0091-6749(87)90064-9	http://dx.doi.org/10.1016/0091-6749(87)90064-9			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037	3624695	Bronze			2022-12-18	WOS:A1987K103700015
J	KONIG, P; HORDVIK, NL; KREUTZ, C				KONIG, P; HORDVIK, NL; KREUTZ, C			THE PREVENTIVE EFFECT AND DURATION OF ACTION OF NEDOCROMIL SODIUM AND CROMOLYN SODIUM ON EXERCISE-INDUCED ASTHMA (EIA) IN ADULTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KONIG, P (corresponding author), UNIV MISSOURI, DEPT CHILD HLTH, HOSP DR, COLUMBIA, MO 65212 USA.							ALTOUNYAN REC, 1985, PROG RESPIR RES, V19, P397; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P459; [Anonymous], 1979, AM REV RESPIR DIS, V119, P831; CRIMI N, EUR J RESPIR DIS; CROMWELL O, 1986, J ALLERGY CLIN IMMUN, V77, P184; DELBONO L, 1986, EUR J RESPIR DIS, V69, P268; EADY RP, 1985, BRIT J PHARMACOL, V85, P323, DOI 10.1111/j.1476-5381.1985.tb08864.x; EDWARDS AM, 1985, J ALLERGY CLIN IMMUN, V75, P199, DOI 10.1016/0091-6749(85)90514-7; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V64, P642, DOI 10.1016/0091-6749(79)90028-9; FYANS P, 1984, RESPIRATION S1, V46, P931; HILLER EJ, 1975, BRIT J DIS CHEST, V69, P103; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; KONIG P, 1974, THESIS U LONDON LOND; LAL S, 1984, THORAX, V39, P809, DOI 10.1136/thx.39.11.809; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; NEWMAN SP, 1981, EUR J RESPIR DIS, V62, P3; ROBERTS JA, 1985, CLIN ALLERGY, V15, P377, DOI 10.1111/j.1365-2222.1985.tb03006.x; SHAW RJ, 1985, BRIT J DIS CHEST, V79, P385, DOI 10.1016/0007-0971(85)90073-7; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; TAUSSIG LM, 1980, J PEDIATR-US, V97, P668, DOI 10.1016/S0022-3476(80)80039-4; TOOGOOD JH, 1981, J ALLERGY CLIN IMMUN, V67, P317, DOI 10.1016/0091-6749(81)90028-2; YOUNGCHAIYUD P, 1986, CLIN ALLERGY, V16, P129, DOI 10.1111/j.1365-2222.1986.tb00756.x	22	58	58	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					64	68		10.1016/S0091-6749(87)80018-0	http://dx.doi.org/10.1016/S0091-6749(87)80018-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810	3027153	Bronze			2022-12-18	WOS:A1987F881000014
J	KOPONEN, M; PICHLER, WJ; DEWECK, AL				KOPONEN, M; PICHLER, WJ; DEWECK, AL			T-CELL REACTIVITY TO PENICILLIN - PHENOTYPIC ANALYSIS OF INVITRO ACTIVATED CELL SUBSETS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									INSELSPITAL,INST CLIN IMMUNOL,CH-3010 BERN,SWITZERLAND	University of Bern; University Hospital of Bern				Pichler, Werner J./0000-0002-8117-359X				BATCHELO.FR, 1965, NATURE, V206, P362, DOI 10.1038/206362a0; BIDDISON WE, 1981, J IMMUNOL, V127, P2231; BIDDISON WE, 1980, J IMMUNOL, V124, P548; CLAAS FHJ, 1985, PROG ALLERGY, V36, P135; CLAAS FHJ, 1982, HUM IMMUNOL, V5, P83, DOI 10.1016/0198-8859(82)90033-7; DAMLE NK, 1984, J IMMUNOL, V132, P644; DARZYNKIEWICZ Z, 1976, P NATL ACAD SCI USA, V73, P2881, DOI 10.1073/pnas.73.8.2881; de Weck A L, 1974, Monogr Allergy, V8, P120; DEWAELE M, 1981, NEW ENGL J MED, V304, P460; GATENBY PA, 1982, J IMMUNOL, V129, P1997; KANSAS GS, 1985, J IMMUNOL, V134, P2995; MCMICHAEL AJ, 1980, J EXP MED, V152, P195; MEUER SC, 1982, P NATL ACAD SCI-BIOL, V79, P4395, DOI 10.1073/pnas.79.14.4395; REINHERZ EL, 1980, J IMMUNOL, V125, P1269; RIKINSON AB, 1980, NATURE, V283, P235; SHAPIRO HM, 1981, CYTOMETRY, V2, P143, DOI 10.1002/cyto.990020302; SHAW S, 1980, J EXP MED, V151, P235, DOI 10.1084/jem.151.1.235; THORLEYLAWSON DA, 1977, J EXP MED, V146, P495, DOI 10.1084/jem.146.2.495; TOSATO G, 1979, NEW ENGL J MED, V301, P1133, DOI 10.1056/NEJM197911223012101; VANARSDEL PP, 1983, ALLERGY PRINCIPLES P, P1133; VICKERS MR, 1974, IMMUNOLOGY, V26, P425; WALKER C, CLIN IMUNOL; WALKER C, IMMUNOBIOLOGY; WALLACE LE, 1982, NATURE, V297, P413, DOI 10.1038/297413a0	24	58	58	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	1				645	652		10.1016/0091-6749(86)90083-7	http://dx.doi.org/10.1016/0091-6749(86)90083-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5682	3021832				2022-12-18	WOS:A1986E568200014
J	JICK, H				JICK, H			ADVERSE DRUG-REACTIONS - THE MAGNITUDE OF THE PROBLEM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											JICK, H (corresponding author), BOSTON UNIV,MED CTR,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,WALTHAM,MA 02154, USA.			Jick, Hershel/0000-0003-4270-5992				[Anonymous], 1973, Lancet, V1, P1399; [Anonymous], 1974, BR MED J, V1, P440; BORDA IT, 1968, J AMER MED ASSOC, V205, P645, DOI 10.1001/jama.205.9.645; JICK H, 1979, NEW ENGL J MED, V300, P218, DOI 10.1056/NEJM197902013000502; JICK H, 1978, AM J EPIDEMIOL, V107, P1; JICK H, 1979, JAMA-J AM MED ASSOC, V242, P2310, DOI 10.1001/jama.242.21.2310; JICK H, 1974, NEW ENGL J MED, V291, P824, DOI 10.1056/NEJM197410172911605; JICK H, 1970, J AMER MED ASSOC, V213, P1455, DOI 10.1001/jama.213.9.1455; JICK H, 1978, JAMA-J AM MED ASSOC, V239, P1403, DOI 10.1001/jama.239.14.1403; LAWSON DH, 1976, AM J PUBLIC HEALTH, V66, P644, DOI 10.2105/AJPH.66.7.644; LEVY M, 1974, NEW ENGL J MED, V290, P1158, DOI 10.1056/NEJM197405232902102; MILLER RR, 1973, AM J HOSP PHARM, V30, P584, DOI 10.1093/ajhp/30.7.584; MILLER RR, 1979, CHEST, V75, P356, DOI 10.1378/chest.75.3.356	13	58	60	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					555	557		10.1016/0091-6749(84)90106-4	http://dx.doi.org/10.1016/0091-6749(84)90106-4			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ163	6491102				2022-12-18	WOS:A1984TQ16300003
J	RAMIREZ, DA				RAMIREZ, DA			THE NATURAL-HISTORY OF MOUNTAIN CEDAR POLLINOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											RAMIREZ, DA (corresponding author), BROOKE ARMY MED CTR, ALLERGY IMMUNOL SERV, FT SAM HOUSTON, TX 78234 USA.							Black J, 1929, J ALLERGY, V1, P71; BROWN WG, 1979, J ALLERGY CLIN IMMUN, V63, P328, DOI 10.1016/0091-6749(79)90127-1; FEIN BT, 1962, J ALLERGY, V33, P141; FRENCH SW, 1930, J ALLERGY, V1, P286; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GREEN GR, 1971, J ALLERGY CLIN IMMUN, V48, P331, DOI 10.1016/0091-6749(71)90079-0; GREENERT S, 1971, LANCET, V2, P1121; HOWIE M, 1972, CLIN ALLERGY, V2, P285; JOHNSON P, 1966, EUR POLYM J, V1, P63; Kahn I, 1931, SOUTH MED J, V24, P729; Kahn IS, 1924, J AMER MED ASSOC, V82, P871, DOI 10.1001/jama.1924.02650370039013; KING TP, 1979, J ALLERGY CLIN IMMUN, V64, P159, DOI 10.1016/0091-6749(79)90090-3; KONTOUKARAKITSOS K, 1975, J ALLERGY CLIN IMMUN, V55, P241, DOI 10.1016/0091-6749(75)90143-8; LOEFFLER JA, 1973, ANN ALLERGY, V31, P331; MARSH DG, 1972, IMMUNOLOGY, V22, P1013; PENCE HL, 1976, J ALLERGY CLIN IMMUN, V58, P39, DOI 10.1016/0091-6749(76)90105-6; SALVAGGIO J, 1969, J ALLERGY, V44, P344, DOI 10.1016/0021-8707(69)90026-4; SALVAGGIO J, 1966, J ALLERGY, V38, P31, DOI 10.1016/0021-8707(66)90070-0; SALVAGGIO JE, 1964, J ALLERGY, V35, P62, DOI 10.1016/0021-8707(64)90050-4; SAMTER M, 1955, REGIONAL ALLERGY US; SETTIPANE GA, 1972, J ALLERGY CLIN IMMUN, V50, P146, DOI 10.1016/0091-6749(72)90045-0; SHAFIEE A, 1981, J ALLERGY CLIN IMMUN, V67, P472, DOI 10.1016/0091-6749(81)90101-9; SHIDA T, 1970, JPN J ALLERGY, V19, P739; SMITH JM, 1974, MED CLIN N AM, V58, P3; SMITH JM, 1965, AM REV RESPIR DIS, V92, P16; SMITH JM, 1978, ALLERGY PRINCIPLES P; STENIUS B, 1971, Clinical Allergy, V1, P37, DOI 10.1111/j.1365-2222.1971.tb02446.x; SUVURUNGSI R, 1982, 38TH ANN M AM AC ALL; YOO TJ, 1975, ANN ALLERGY, V34, P87	29	58	59	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	1					88	93		10.1016/0091-6749(84)90489-5	http://dx.doi.org/10.1016/0091-6749(84)90489-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SB990	6537956	Bronze			2022-12-18	WOS:A1984SB99000013
J	AGARWAL, MK; SWANSON, MC; REED, CE; YUNGINGER, JW				AGARWAL, MK; SWANSON, MC; REED, CE; YUNGINGER, JW			IMMUNOCHEMICAL QUANTITATION OF AIRBORNE SHORT RAGWEED, ALTERNARIA, ANTIGEN-E, AND ALT-I ALLERGENS - A 2-YEAR PROSPECTIVE-STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55905; MAYO MED SCH,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO MED SCH,DEPT INTERNAL MED ALLERGY,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; Mayo Clinic					NIAID NIH HHS [AI-16791] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016791] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARWAL MK, 1981, J ALLERGY CLIN IMMUN, V68, P194, DOI 10.1016/0091-6749(81)90183-4; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; DIXON WJ, 1969, INTRO STATISTICAL AN, P222; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; MILES RM, 1983, J ALLERGY CLIN IMMUN, V71, P36, DOI 10.1016/0091-6749(83)90544-4; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P789; OGDEN EC, 1967, J ALLERGY, V40, P1, DOI 10.1016/0021-8707(67)90053-6; SHAFIEE A, 1973, J PHARM SCI, V62, P1654, DOI 10.1002/jps.2600621015; Yunginger J. W., 1980, MANUAL CLIN IMMUNOLO, P778; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5	10	58	58	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	1					40	45		10.1016/0091-6749(83)90050-7	http://dx.doi.org/10.1016/0091-6749(83)90050-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QZ198	6682872				2022-12-18	WOS:A1983QZ19800005
J	ELLIS, EF				ELLIS, EF			ASTHMA IN CHILDHOOD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ELLIS, EF (corresponding author), CHILDRENS HOSP, BUFFALO, NY 14222 USA.							ALTOUNYAN REC, 1980, CLIN ALLERGY, V10, P481, DOI 10.1111/j.1365-2222.1980.tb02162.x; ANDERSON SD, 1975, AUST NZ J MED, V5, P544, DOI 10.1111/j.1445-5994.1975.tb03860.x; ANTIC R, 1976, AM REV RESPIR DIS, V114, P851; ARMAND J, 1973, LYON MED, V229, P485; AZIZIRAD H, 1975, CLIN PEDIATR, V14, P572, DOI 10.1177/000992287501400610; BARZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288; BECROFT DMO, 1971, J CLIN PATHOL, V24, P72, DOI 10.1136/jcp.24.1.72; BENZVI Z, 1983, AM REV RESPIR DIS, V127, P101, DOI 10.1164/arrd.1983.127.1.101; BENZVI Z, 1982, PEDIATRICS, V70, P348; BERDON WE, 1972, SEMIN ROENTGENOL, V7, P39, DOI 10.1016/0037-198X(72)90029-6; BERNSTEIN IL, 1981, J ALLERGY CLIN IMMUN, V68, P247; BERQUIST WE, 1981, PEDIATRICS, V68, P29; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BLAND M, 1978, ARCH DIS CHILD, V53, P100, DOI 10.1136/adc.53.2.100; BLOCK J, 1964, PSYCHOSOM MED, V26, P307, DOI 10.1097/00006842-196407000-00003; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BURROWS B, 1977, AM REV RESPIR DIS, V115, P751; CAMERON P, 1969, J ALLERGY, V43, P336, DOI 10.1016/0021-8707(69)90078-1; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COLLEY JRT, 1974, BRIT MED J, V2, P201, DOI 10.1136/bmj.2.5912.201; COOKSON JB, 1980, THORAX, V35, P833, DOI 10.1136/thx.35.11.833; COOPER DM, 1977, CHEST, V71, P361, DOI 10.1378/chest.71.3.361; CORR D, 1982, J AEROSOL SCI, V13, P1, DOI 10.1016/0021-8502(82)90002-7; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; CREER TL, 1974, J BEHAV THER EXP PSY, V5, P259, DOI 10.1016/0005-7916(74)90074-3; CREER TL, 1978, ALLERGY PRINCIPLES P, P796; CROMPTON GK, 1982, EUR J RESPIR DIS, V63, P489; DAWSON B, 1969, LANCET, V1, P827; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; DERRICK EH, 1972, AUST NZ J MED, V2, P235, DOI 10.1111/j.1445-5994.1972.tb03068.x; DRAZEN JM, 1980, P NATL ACAD SCI-BIOL, V77, P4354, DOI 10.1073/pnas.77.7.4354; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; EGGLESTON PA, 1983, CLIN REV ALLERG, V1, P19; EISEN AH, 1963, PEDIATRICS, V31, P859; ELLIS EF, 1981, CONTROVERSIES CHILD, P341; ELLIS EF, 1978, ALLERGY PRINCIPLES P, P443; ELLIS EF, 1983, CURRENT THERAPY ALLE; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; ENGEL J, 1962, LUNG STRUCTURE, P28; EVANS HE, 1973, AM REV RESPIR DIS, V108, P672; FALLIERS CJ, 1971, J ALLERGY, V47, P207, DOI 10.1016/S0091-6749(71)80466-9; FERGUSSON DM, 1980, ARCH DIS CHILD, V55, P358, DOI 10.1136/adc.55.5.358; FIELD WINIFRED E. H., 1968, BRIT J PIS CHEST, V62, P11, DOI 10.1016/S0007-0971(68)80025-7; FREEMAN GL, 1964, AM J DIS CHILD, V107, P549, DOI 10.1001/archpedi.1964.02080060551001; FRICK OL, 1979, J ALLERGY CLIN IMMUN, V63, P228, DOI 10.1016/0091-6749(79)90106-4; GALANT SP, 1978, NEW ENGL J MED, V299, P933, DOI 10.1056/NEJM197810262991707; GIRDANY BR, 1979, GASTROESOPHAGEAL REF, P57; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; GODFREY S, 1978, J ALLERGY CLIN IMMUN, V62, P335, DOI 10.1016/0091-6749(78)90133-1; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; GRAHAM PJ, 1967, BRIT J PREV SOC MED, V21, P78; GREEN ER, 1981, J PEDIATR-US, V98, P832, DOI 10.1016/S0022-3476(81)80862-1; GREENBURG L, 1964, ARCH ENVIRON HEALTH, V8, P642, DOI 10.1080/00039896.1964.10663734; GURWITZ D, 1981, J PEDIATR-US, V98, P551, DOI 10.1016/S0022-3476(81)80758-5; GURWITZ D, 1980, AM REV RESPIR DIS, V122, P95; HALPERN SR, 1973, J ALLERGY CLIN IMMUN, V51, P139, DOI 10.1016/0091-6749(73)90019-5; HENDELES L, 1978, AM J DIS CHILD, V132, P876; HENDELES L, 1983, PHARMACOTHERAPY, V3, P2; HENDERSON WR, 1979, NEW ENGL J MED, V300, P642, DOI 10.1056/NEJM197903223001203; HERBST JJ, 1981, PEDIATRICS, V68, P132; HERXHEIMER H, 1974, NEW ENGL J MED, V291, P1419; HILL DJ, 1972, AM REV RESPIR DIS, V106, P873, DOI 10.1164/arrd.1972.106.6.873; HOGG JC, 1970, NEW ENGL J MED, V282, P1283, DOI 10.1056/NEJM197006042822302; HOGG JC, 1977, DISORDERS RESPIRATOR, P183; HORN MEC, 1979, THORAX, V34, P23, DOI 10.1136/thx.34.1.23; HOZOURI K, 1982, Journal of Allergy and Clinical Immunology, V69, P121; JOLLEY SG, 1980, J PEDIATR-US, V96, P194, DOI 10.1016/S0022-3476(80)80801-8; KATTAN M, 1977, PEDIATRICS, V59, P683; KELLY E, 1969, J PSYCHOSOM RES, V13, P377, DOI 10.1016/0022-3999(69)90007-5; KINSMAN RA, 1977, PSYCHOSOM MED, V39, P102, DOI 10.1097/00006842-197703000-00005; KONIG P, 1973, ARCH DIS CHILD, V48, P942, DOI 10.1136/adc.48.12.942; KONIG P, 1973, ARCH DIS CHILD, V48, P513, DOI 10.1136/adc.48.7.513; KRAEPELIEN S, 1954, Acta Paediatr Suppl, V43, P149, DOI 10.1111/j.1651-2227.1954.tb15464.x; LANG WR, 1969, BRIT MED J, V1, P73, DOI 10.1136/bmj.1.5636.73; LEIGH D, 1967, BRONCHIAL ASTHMA GEN; LEVY G, 1982, NEW ENGL J MED, V307, P676, DOI 10.1056/NEJM198209093071109; LICHENSTEIN LM, 1978, AM REV RESPIR DIS, V117, P91; LOPEZ M, 1978, ALLERGY PRINCIPLES P, P965; LOUGHLIN GM, 1979, J PEDIATR-US, V94, P365, DOI 10.1016/S0022-3476(79)80572-7; MANSELL A, 1972, J APPL PHYSIOL, V33, P711, DOI 10.1152/jappl.1972.33.6.711; MANTLE J, 1974, CLIN ALLERGY, V4, P161, DOI 10.1111/j.1365-2222.1974.tb01373.x; MARTIN AJ, 1982, AUST PAEDIATR J, V18, P84; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; MASON WD, 1980, J ALLERGY CLIN IMMUN, V66, P119, DOI 10.1016/0091-6749(80)90058-5; MATHE AA, 1975, AM REV RESPIR DIS, V111, P313; MATSUBA K, 1972, AM REV RESPIR DIS, V105, P908; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MCINTOSH K, 1976, J ALLERGY CLIN IMMUN, V57, P595, DOI 10.1016/0091-6749(76)90011-7; MCLEAN JA, 1973, J AM ACAD CHILD PSY, V12, P142, DOI 10.1097/00004583-197301000-00011; MERRETT TG, 1976, CLIN ALLERGY, V6, P131, DOI 10.1111/j.1365-2222.1976.tb01890.x; MIKLICH DR, 1977, J ALLERGY CLIN IMMUN, V60, P285, DOI 10.1016/0091-6749(77)90107-5; MILLS JE, 1969, J PHYSIOL-LONDON, V203, P337, DOI 10.1113/jphysiol.1969.sp008867; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; MORRIS HG, 1974, J ALLERGY CLIN IMMUN, V54, P350, DOI 10.1016/0091-6749(74)90025-6; MULLER N, 1979, J APPL PHYSIOL, V46, P688, DOI 10.1152/jappl.1979.46.4.688; MULLER NL, 1979, PEDIATR CLIN N AM, V26, P503; MYGIND N, 1977, BRIT J CLIN PHARMACO, V4, pS287, DOI 10.1111/j.1365-2125.1977.tb04523.x; NADEL JA, 1965, J APPL PHYSIOL, V20, P164, DOI 10.1152/jappl.1965.20.1.164; NADEL JA, 1973, ASTHMA PHYSL IMMUNOP; NEUHAUS EC, 1958, PSYCHOSOM MED, V20, P181, DOI 10.1097/00006842-195805000-00003; NEWTH CJL, 1982, AUST NZ J MED, V12, P232, DOI 10.1111/j.1445-5994.1982.tb02467.x; NORMAN PS, 1973, ASTHMA PHYSL IMMUNOP; NORRISH M, 1977, ARCH DIS CHILD, V52, P912, DOI 10.1136/adc.52.12.912; ORDMAN DAVID, 1955, S AFRICAN MED JOUR, V29, P173; OREHEK J, 1975, BMJ-BRIT MED J, V1, P123, DOI 10.1136/bmj.1.5950.123; PORTER R, 1971, CIBA F STUDY GROUP, V38; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; PURCELL K, 1961, PSYCHOSOM MED, V23, P305, DOI 10.1097/00006842-196107000-00007; REED CE, 1983, ALLERGY PRINCIPLES P; REID L, 1977, PEDIATR RES, V11, P210; REYNOLDS EOR, 1972, PULMONARY DISORDERS; RICHARDS W, 1981, CLIN PEDIATR, V20, P453, DOI 10.1177/000992288102000705; RICHARDSON PS, 1969, BMJ-BRIT MED J, V3, P143, DOI 10.1136/bmj.3.5663.143; ROONEY JC, 1971, J PEDIATR-US, V79, P744, DOI 10.1016/S0022-3476(71)80385-2; SANDERS S, 1968, J ALLERGY, V41, P319, DOI 10.1016/0021-8707(68)90074-9; SCADDING JG, 1977, ASTHMA, P1; Schiffer C. G, 1963, CHILDRENS BUREAU PUB, V405; SCHWARTZ AL, 1980, AM J DIS CHILD, V134, P474, DOI 10.1001/archpedi.1980.02130170024009; SCHWARTZ M, 1952, ACTA ALLERG KBH S2, V5, P3; SETTIPANE GA, 1974, J ALLERGY CLIN IMMUN, V53, P200, DOI 10.1016/0091-6749(74)90081-5; SHAPIRO GG, 1983, CLIN REV ALLERG, V1, P39; SIBBALD B, 1980, THORAX, V35, P671, DOI 10.1136/thx.35.9.671; SIBBALD B, 1979, THORAX, V34, P332, DOI 10.1136/thx.34.3.332; SIBBALD B, 1980, ARCH DIS CHILD, V55, P354, DOI 10.1136/adc.55.5.354; SIEGEL SC, 1978, ALLERGY PRINCIPLES P, P722; SIMONS FER, 1982, AM J DIS CHILD, V136, P790, DOI 10.1001/archpedi.1982.03970450032008; SIMONS FER, 1981, AM J DIS CHILD, V135, P214, DOI 10.1001/archpedi.1981.02130270006004; SIMS DG, 1978, BRIT MED J, V1, P11, DOI 10.1136/bmj.1.6104.11; SINTEK C, 1979, J PEDIATR-US, V94, P314, DOI 10.1016/S0022-3476(79)80856-2; Smith J M, 1975, Allergol Immunopathol (Madr), V3, P127; SMITH JM, 1961, BRIT MED J, V1, P711, DOI 10.1136/bmj.1.5227.711; SMITH JM, 1965, AM REV RESPIR DIS, V92, P16; SMITH JM, 1978, ALLERGY PRINCIPLES P, P644; SMITH JM, 1971, CLIN ALLERGY, V1, P51; STEWART CJ, 1981, LANCET, V2, P747; STOKES GM, 1981, J PEDIATR-US, V98, P871, DOI 10.1016/S0022-3476(81)80577-X; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TABACHNIK E, 1982, J PEDIATR-US, V100, P489, DOI 10.1016/S0022-3476(82)80467-8; TABACHNIK E, 1981, J ALLERGY CLIN IMMUN, V67, P339, DOI 10.1016/0091-6749(81)90077-4; TAL A, 1976, PSYCHOSOM MED, V38, P190, DOI 10.1097/00006842-197605000-00005; THIRINGER G, 1977, BRIT J CLIN PHARMACO, V4, pS293, DOI 10.1111/j.1365-2125.1977.tb04524.x; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; Tromp S W, 1968, Rev Allergy, V22, P1027; TURNER JM, 1968, J APPL PHYSIOL, V25, P664, DOI 10.1152/jappl.1968.25.6.664; TURNERWARWICK M, 1982, CURRENT PERSPECTIVES, P53; WEINBERGER M, 1981, J PEDIATR-US, V99, P145, DOI 10.1016/S0022-3476(81)80982-1; WEINBERGER M, 1983, NEW ENGL J MED, V308, P760, DOI 10.1056/NEJM198303313081306; WEINBERGER M, 1982, EUR J RESPIR DIS, V63, P243; WEINBERGER M, 1981, PEDIATR CLIN N AM, V28, P47; WEISS ST, 1980, AM REV RESPIR DIS, V122, P697, DOI 10.1164/arrd.1980.122.5.697; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; WINTER HS, 1981, PEDIATRICS, V68, P134; WITTIG HJ, 1969, PEDIATR CLIN N AM, V16, P55; WITTIG HJ, 1959, J ALLERGY, V30, P19, DOI 10.1016/0021-8707(59)90054-1; WYATT R, 1978, NEW ENGL J MED, V299, P1387, DOI 10.1056/NEJM197812212992504; YORKSTON NJ, 1974, J PSYCHOSOM RES, V18, P371, DOI 10.1016/0022-3999(74)90058-0; ZACH MS, 1980, AM REV RESPIR DIS, V121, P979; ZAPLETAL A, 1971, Bulletin de Physio-Pathologie Respiratoire, V7, P139; ZIFFERBLATT SM, 1975, PREV MED, V4, P173, DOI 10.1016/0091-7435(75)90082-1; 1982, THORAX, V37, P241; PB81182115, P162; 1980, AM REV RESPIR DIS, V121, P203; 1980, AM REV RESPIR DIS, V121, P619	166	58	62	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	5					526	539		10.1016/0091-6749(83)90479-7	http://dx.doi.org/10.1016/0091-6749(83)90479-7			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RS163	6417212				2022-12-18	WOS:A1983RS16300005
J	GREENBERGER, PA; PATTERSON, R; GHORY, A; ARKINS, JA; WALSH, T; GRAVES, T; SAKER, J				GREENBERGER, PA; PATTERSON, R; GHORY, A; ARKINS, JA; WALSH, T; GRAVES, T; SAKER, J			LATE SEQUELAE OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN,MILWAUKEE,WI 53233; USN,REG MED CTR,DIV PULM,SAN DIEGO,CA 92134; SPARROW HOSP,LANSING,MI	Medical College of Wisconsin; United States Department of Defense; United States Navy	GREENBERGER, PA (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611, USA.		Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NHLBI NIH HHS [HL 15389] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P243, DOI 10.1016/0091-6749(78)90214-2; KATZENSTEIN AL, 1975, AM REV RESPIR DIS, V111, P497; MCCARTHY D S, 1970, Clinical Radiology, V21, P366, DOI 10.1016/S0009-9260(70)80070-8; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; OWEN GC, 1974, CLIN ALLERGY, V4, P141, DOI 10.1111/j.1365-2222.1974.tb01371.x; PATTERSON R, 1974, INT ARCH ALLER A IMM, V46, P150, DOI 10.1159/000231119; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; ROSENBERG M, 1977, CHEST, V72, P597, DOI 10.1378/chest.72.5.597; ROSENBERG M, 1978, AM J MED, V64, P599, DOI 10.1016/0002-9343(78)90579-X; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; TURNERWARWICK M, 1975, CHEST, V68, P346, DOI 10.1378/chest.68.3.346; WANG JLF, 1978, AM REV RESPIR DIS, V117, P917	13	58	58	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	4					327	335		10.1016/0091-6749(80)90029-9	http://dx.doi.org/10.1016/0091-6749(80)90029-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KM254	7419834				2022-12-18	WOS:A1980KM25400011
J	PATEL, KR; KERR, JW; MACDONALD, EB; MACKENZIE, AM				PATEL, KR; KERR, JW; MACDONALD, EB; MACKENZIE, AM			EFFECT OF THYMOXAMINE AND CROMOLYN SODIUM ON POSTEXERCISE BRONCHOCONSTRICTION IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WESTERN INFIRM,DEPT RESP MED,GLASGOW,SCOTLAND; KNIGHTSWOOD HOSP,GLASGOW G3 2XG,SCOTLAND									ALSTON WC, 1974, BRIT MED J, V1, P90, DOI 10.1136/bmj.1.5898.90; ANDERSON SD, 1971, THORAX, V26, P396, DOI 10.1136/thx.26.4.396; ASTIN TW, 1972, CLIN SCI, V42, P725, DOI 10.1042/cs0420725; BATES D V, 1962, Med Serv J Can, V18, P211; BATES DV, 1971, RESPIRATORY FUNCTION, P93; BIRMINGHAM AT, 1965, J PHARM PHARMACOL, V17, P449, DOI 10.1111/j.2042-7158.1965.tb07701.x; BROWNLEE G, 1966, ANGIOLOGY, V17, P186, DOI 10.1177/000331976601700306; CASTRODELAMATA R, 1962, J PHARMACOL EXP THER, V135, P197; COTES JE, 1965, LUNG FUNCTION ASSESS, P318; CROMPTON GK, 1968, THORAX, V23, P165, DOI 10.1136/thx.23.2.165; EVERITT BJ, 1969, J PHARM PHARMACOL, V21, P97, DOI 10.1111/j.2042-7158.1969.tb08204.x; FALLIERS CJ, 1971, J ALLERGY, V47, P207, DOI 10.1016/S0091-6749(71)80466-9; FISHER HK, 1970, AM REV RESPIR DIS, V101, P885; GRANERUS G, 1971, SCAND J RESPIR DIS, V52, P131; INOUE S, 1967, J ALLERGY, V40, P337, DOI 10.1016/0021-8707(67)90023-8; IRVING MH, 1974, NATURE, V248, P531, DOI 10.1038/248531a0; JONES RS, 1963, ARCH DIS CHILD, V38, P539, DOI 10.1136/adc.38.202.539; JONES RS, 1972, THORAX, V27, P572, DOI 10.1136/thx.27.5.572; KOZLOWSKI S, 1973, CLIN SCI MOL MED, V45, P723; LEFCOE NM, 1971, AM REV RESPIR DIS, V104, P562; MATHEWS K P, 1970, Algerie Medicale, V72, P241; MCNEILL RS, 1966, Q J MED, V35, P55; MICHELSON AL, 1958, J LAB CLIN MED, V51, P57; MIDDLETON E, 1968, J ALLERG, V42, P228; MUITTARI A, 1969, BRIT MED J, V4, P170, DOI 10.1136/bmj.4.5676.170-a; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PATEL KR, 1975, BRIT MED J, V2, P360, DOI 10.1136/bmj.2.5967.360; PATEL KR, 1973, CLIN ALLERGY, V3, P439, DOI 10.1111/j.1365-2222.1973.tb01351.x; PIPER P, 1971, ANN NY ACAD SCI, V180, P363, DOI 10.1111/j.1749-6632.1971.tb53205.x; PRIME FJ, 1972, B PHYSIO-PATHOL RESP, V8, P99; QUANJER P H, 1971, Scandinavian Journal of Respiratory Diseases Supplementum, V77, P32; REBUCK AS, 1968, LANCET, V2, P429; SIMONSSON BG, 1972, SCAND J RESPIR DIS, V53, P227; SIMONSSON BG, 1972, THORAX, V27, P169, DOI 10.1136/thx.27.2.169; SLY RM, 1967, J ALLERGY, V40, P93, DOI 10.1016/0021-8707(67)90102-5; SMITH AP, 1975, ASTHMA PHYSIOLOGY IM; TAYLOR WA, 1974, INT ARCH ALLER A IMM, V46, P104, DOI 10.1159/000231116; VENDSALU A, 1960, ACTA PHYSIOL SCAND S, V173, P8	38	58	58	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	4					285	292		10.1016/0091-6749(76)90084-1	http://dx.doi.org/10.1016/0091-6749(76)90084-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BM689	131139				2022-12-18	WOS:A1976BM68900001
J	ROBERTS, RC; WENZEL, FJ; EMANUEL, DA				ROBERTS, RC; WENZEL, FJ; EMANUEL, DA			PRECIPITATING ANTIBODIES IN A MIDWEST DAIRY FARMING POPULATION TOWARD ANTIGENS ASSOCIATED WITH FARMERS LUNG-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MARSHFIELD CLIN,MARSHFIELD,WI; MARSHFIELD MED FDN,MARSHFIELD,WI 54449	Marshfield Clinic								CHMELIK F, 1975, AM REV RESPIR DIS, V111, P201; EDWARDS JH, 1972, J LAB CLIN MED, V79, P683; EMANUEL DA, 1975, CHEST, V67, P293, DOI 10.1378/chest.67.3.293; FINK JN, 1973, CHEST, V64, P416, DOI 10.1378/chest.64.4.416; FLAHERTY DK, 1974, J LAB CLIN MED, V84, P298; GUMP D, 1974, PULMONARY SCOR EXCER; KAWAI T, 1973, CHEST, V64, P420, DOI 10.1378/chest.64.4.420; KURUP VP, 1975, INT J SYST BACTERIOL, V25, P150, DOI 10.1099/00207713-25-2-150; PEPYS J, 1965, THORAX, V20, P21, DOI 10.1136/thx.20.1.21; PEPYS J., 1962, THORAX, V17, P366, DOI 10.1136/thx.17.4.366; STAHMANN MA, 1962, CONSULTANT C CONTRIB; WENZEL FJ, 1974, AM REV RESPIR DIS, V109, P464; 1973, WISCONSIN STATISTICA	13	58	58	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	6					518	524		10.1016/0091-6749(76)90002-6	http://dx.doi.org/10.1016/0091-6749(76)90002-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	BV054	932340				2022-12-18	WOS:A1976BV05400002
J	ROSENTHAL, RR; NORMAN, PS; SUMMER, WR				ROSENTHAL, RR; NORMAN, PS; SUMMER, WR			BRONCHOPROVOCATION - EFFECT ON PRIMING AND DESENSITIZATION PHENOMENON IN LUNG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DEPT MED,CLIN IMMUNOL DIV,5601LOCH RAVEN BLVD,BALTIMORE,MD 21239	Johns Hopkins University								CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; HERXHEIMER H, 1951, INT ARCH ALLER A IMM, V2, P40, DOI 10.1159/000227899; HOLMES TH, 1951, PSYCHOSOM MED, V63, P71; ITKIN IH, 1963, J ALLERGY, V34, P97, DOI 10.1016/0021-8707(63)90062-5	5	58	58	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	5					338	346		10.1016/0091-6749(75)90127-X	http://dx.doi.org/10.1016/0091-6749(75)90127-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW330	1181351				2022-12-18	WOS:A1975AW33000003
J	Leopold, DA; Elkayam, D; Messina, JC; Kosik-Gonzalez, C; Djupesland, PG; Mahmoud, RA				Leopold, Donald A.; Elkayam, David; Messina, John C.; Kosik-Gonzalez, Colette; Djupesland, Per G.; Mahmoud, Ramy A.			NAVIGATE II: Randomized, double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sinusitis; nasal polyps; intranasal drug; corticosteroids; fluticasone; inflammation	ENDOSCOPIC SINUS SURGERY; CHRONIC RHINOSINUSITIS; MOMETASONE FUROATE; ORAL STEROIDS; EFFICACY; SPRAY; PROPIONATE; PLACEBO; TOLERABILITY; MANAGEMENT	Background: Chronic rhinosinusitis is common and sometimes complicated by nasal polyps (NPs). Corticosteroid nasal sprays are often unsatisfactory because they are ineffective at delivering medication to high/deep sites of inflammation. Objective: We sought to assess whether an exhalation delivery system with fluticasone (EDS-FLU) capable of high/deep drug deposition improves outcomes. Methods: Patients (n = 323) 18 years and older with moderate-to-severe congestion and NPs were randomized to twice-daily EDS-FLU (93, 186, or 372 mg) or exhalation delivery system (EDS)-placebo for 24 weeks (16 double-blind plus 8 open-label when all received 372 mg). Coprimary end points were change in nasal congestion/obstruction at 4 weeks and summed bilateral polyp grade at 16 weeks. Secondary end points included symptoms, polyp elimination, and functioning. Results: EDS-FLU was superior on both coprimary end points (P <.001 vs EDS-placebo, all doses). Mean polyp grade improved continuously through week 24 (P <.009, all comparisons), with polyps eliminated on at least 1 side in approximately 25% of patients at week 24 versus 8.7% with EDS-placebo (P <.014, all comparisons). Sino-Nasal Outcomes Test scores also improved significantly versus those in patients receiving EDS-placebo (221.1 to 221.4 vs 211.7 at week 16, P <. 05 all doses). At the end of the double-blind period, EDS-FLU (all doses) significantly improved all 4 defining disease symptoms. In most patients (68%), those receiving EDS-FLU reported "much" or "very much" improvement. The number of patients eligible for surgery decreased by 62%-67%. The safety profile was similar to that reported in prior trials evaluating conventional corticosteroid nasal sprays in comparable populations. Conclusion: EDS-FLU produces clinically and statistically significant improvement in all 4 diagnostically defining disease symptoms, polyp grade, and quality of life in patients with chronic rhinosinusitis with NPs.	[Leopold, Donald A.] Univ Vermont, Dept Surg, Coll Med, 111 Colchester Ave,Main Campus,West Pavil,Level 4, Burlington, VT 05401 USA; [Elkayam, David] Bellingham Asthma Allergy & Immunol Clin, Bellingham, WA USA; [Messina, John C.; Kosik-Gonzalez, Colette; Mahmoud, Ramy A.] OptiNose US, Yardley, PA USA; [Djupesland, Per G.] OptiNose AS, Oslo, Norway	University of Vermont	Leopold, DA (corresponding author), Univ Vermont, Dept Surg, Coll Med, 111 Colchester Ave,Main Campus,West Pavil,Level 4, Burlington, VT 05401 USA.	donald.a.leopold@med.uvm.edu			OptiNose US	OptiNose US	We thank the patients who participated in this study and the principal study investigators (see Appendix E1). Editorial assistance with drafting the report following the authors' guidance, incorporating comments according to authors' feedback, and providing support with submission was provided by Benjamin J. Epstein, PharmD, of ECIR Medical Communications, funded by OptiNose US.	[Anonymous], 2017, BMJ, V357, DOI [DOI 10.1136/BMJ.J1415, 10.1136/bmj.j2212, DOI 10.1136/BMJ.J2212]; [Anonymous], 2017, XHANCE PACK INS; Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330; Baguley C, 2014, INT FORUM ALLERGY RH, V4, P525, DOI 10.1002/alr.21315; Becker SS, 2009, OTOLARYNG CLIN N AM, V42, P377, DOI 10.1016/j.otc.2009.01.002; Benninger MS, 1997, ARCH OTOLARYNGOL, V123, P1175; Bhattacharyya N, 2011, OTOLARYNG HEAD NECK, V144, P440, DOI 10.1177/0194599810391852; Casale TB, 2018, J ALLER CL IMM-PRACT, V6, P183, DOI 10.1016/j.jaip.2017.05.028; Chong LY, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011996.pub2; DeConde AS, 2017, LARYNGOSCOPE, V127, P550, DOI 10.1002/lary.26391; Djupesland P, 2016, 62 ANN M AM RHIN SOC; Djupesland PG, 2012, J AEROSOL MED PULM D, V25, P280, DOI 10.1089/jamp.2011.0924; Durham PL, 2009, J ALLERGY CLIN IMMUN, V123, pS136, DOI 10.1016/j.jaci.2008.12.503; Emanuel IA, 2014, AM J RHINOL ALLERGY, V28, P117, DOI 10.2500/ajra.2014.28.4026; Ferguson L, 2009, J PAIN S, V10, pS73, DOI DOI 10.1016/J.JPAIN.2009.01.258; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056; Gillett S, 2009, CLIN OTOLARYNGOL, V34, P467, DOI 10.1111/j.1749-4486.2009.01975.x; GLIKLICH RE, 1995, OTOLARYNG HEAD NECK, V113, P104, DOI 10.1016/S0194-5998(95)70152-4; Hamilos DL, 2011, J ALLERGY CLIN IMMUN, V128, P693, DOI 10.1016/j.jaci.2011.08.004; Hansen FS, 2010, RHINOLOGY, V48, P292, DOI 10.4193/Rhino09.178; Hastan D, 2011, ALLERGY, V66, P1216, DOI 10.1111/j.1398-9995.2011.02646.x; Hays RD, 2005, SLEEP MED, V6, P41, DOI 10.1016/j.sleep.2004.07.006; Hirsch AG, 2017, ALLERGY, V72, P274, DOI 10.1111/all.13042; Hopkins C, 2009, CLIN OTOLARYNGOL, V34, P447, DOI 10.1111/j.1749-4486.2009.01995.x; Hopkins C, 2009, LARYNGOSCOPE, V119, P2459, DOI 10.1002/lary.20653; Hull BP, 2017, OTOLARYNG CLIN N AM, V50, P61, DOI 10.1016/j.otc.2016.08.006; Hurst H, 2004, J MANIP PHYSIOL THER, V27, P26, DOI 10.1016/j.jmpt.2003.11.003; Keith P, 2000, CLIN EXP ALLERGY, V30, P1460, DOI 10.1046/j.1365-2222.2000.00932.x; Kennedy P, 2016, ALLERGY RHINOL, V7, pE50, DOI 10.2500/ar.2016.7.0142; Lam K, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0540-2; Larsen PL, 2004, LARYNGOSCOPE, V114, P710, DOI 10.1097/00005537-200404000-00022; Leach CL, 2015, J AEROSOL MED PULM D, V28, P334, DOI 10.1089/jamp.2014.1180; LILDHOLDT T, 1995, CLIN OTOLARYNGOL, V20, P26, DOI 10.1111/j.1365-2273.1995.tb00007.x; Messina J, 2017, J ALLERGY CLIN IMMUN, V139, pAB253, DOI 10.1016/j.jaci.2016.12.815; Orlandi RR, 2016, INT FORUM ALLERGY RH, V6, pS22, DOI 10.1002/alr.21695; Palmer JN, 2018, INT FORUM ALLERGY RH; Penttila M, 2000, CLIN EXP ALLERGY, V30, P94; Rudmik L, 2016, INT FORUM ALLERGY RH, V6, P557, DOI 10.1002/alr.21769; Small CB, 2005, J ALLERGY CLIN IMMUN, V116, P1275, DOI 10.1016/j.jaci.2005.07.027; Soler ZM, 2011, LARYNGOSCOPE, V121, P2672, DOI 10.1002/lary.21847; Stevens WW, 2014, J ALLERGY CLIN IMMUN, V133, P1503, DOI 10.1016/j.jaci.2014.03.022; Stjarne P, 2006, ARCH OTOLARYNGOL, V132, P179, DOI 10.1001/archotol.132.2.179; Stjarne P, 2006, ACTA OTO-LARYNGOL, V126, P606, DOI 10.1080/00016480500452566; Vaidyanathan S, 2011, ANN INTERN MED, V154, P293, DOI 10.7326/0003-4819-154-5-201103010-00003; Van Zele T, 2010, J ALLERGY CLIN IMMUN, V125, P1069, DOI 10.1016/j.jaci.2010.02.020; Vlckova I, 2009, RHINOLOGY, V47, P419, DOI 10.4193/Rhin09.024; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weber Rainer, 1999, Rhinology (Utrecht), V37, P69	50	57	57	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					126	+		10.1016/j.jaci.2018.06.010	http://dx.doi.org/10.1016/j.jaci.2018.06.010			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	29928924	hybrid			2022-12-18	WOS:000454918300019
J	Fazlollahi, M; Lee, TD; Andrade, J; Oguntuyo, K; Chun, Y; Grishina, G; Grishin, A; Bunyavanich, S				Fazlollahi, Mina; Lee, Tricia D.; Andrade, Jade; Oguntuyo, Kasopefoluwa; Chun, Yoojin; Grishina, Galina; Grishin, Alexander; Bunyavanich, Supinda			The nasal microbiome in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Nasal; microbiome; 16S rRNA sequencing; asthma; upper respiratory tract; upper airway	PATHOGENIC BACTERIA; AIRWAY MICROBIOME; CHILDHOOD ASTHMA; DISEASE; EXACERBATIONS; COMMUNITIES; INFECTIONS; SEVERITY; RHINITIS; ABSCESS	Background: Nasal microbiota may influence asthma pathobiology. Objective: We sought to characterize the nasal microbiome of subjects with exacerbated asthma, nonexacerbated asthma, and healthy controls to identify nasal microbiota associated with asthma activity. Methods: We performed 16S ribosomal RNA sequencing on nasal swabs obtained from 72 primarily adult subjects with exacerbated asthma (n = 20), nonexacerbated asthma (n = 31), and healthy controls (n = 21). Analyses were performed using Quantitative Insights into Microbial (QIIME); linear discriminant analysis effect size (LEfSe); Phylogenetic Investigation of Communities by Reconstruction of Unobserved States; and Statistical Analysis of Metagenomic Profiles (PICRUSt); and Statistical Analysis of Metagenomic Profiles (STAMP). Species found to be associated with asthma activity were validated using quantitative PCR. Metabolic pathways associated with differentially abundant nasal taxa were inferred through metagenomic functional prediction. Results: Nasal bacterial composition significantly differed among subjects with exacerbated asthma, nonexacerbated asthma, and healthy controls (permutational multivariate ANOVA, P = 2.2 X 10(-2)). Relative to controls, the nasal microbiota of subjects with asthma were enriched with taxa from Bacteroidetes (Wilcoxon-Mann-Whitney, r = 0.33, P = 5.1 X 10(-3)) and Proteobacteria (r = 0.29, P = 1.4 X 10(-2)). Four species were differentially abundant based on asthma status after correction for multiple comparisons: Prevotella buccalis, P-adj = 1.0 X 10(-2); Dialister invisus, P-adj = 9.1 X 10(-3); Gardnerella vaginalis, P-adj = 2.8 X 10(-3); Alkanindiges hongkongensis, P-adj = 2.6 X 10(-3). These phyla and species were also differentially abundant based on asthma activity (exacerbated asthma vs nonexacerbated asthma vs controls). Quantitative PCR confirmed species overrepresentation in asthma relative to controls for Prevotella buccalis (fold change = 130, P = 2.1 X 10(-4)) and Gardnerella vaginalis (fold change = 160, P = 6.8 X 10(-4)). Metagenomic inference revealed differential glycerolipid metabolism (Kruskal-Wallis, P = 1.9 X 10(-4)) based on asthma activity. Conclusions: Nasal microbiome composition differs in subjects with exacerbated asthma, nonexacerbated asthma, and healthy controls. The identified nasal taxa could be further investigated for potential mechanistic roles in asthma and as possible biomarkers of asthma activity.	[Fazlollahi, Mina; Andrade, Jade; Oguntuyo, Kasopefoluwa; Chun, Yoojin; Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Lee, Tricia D.; Andrade, Jade; Grishina, Galina; Grishin, Alexander; Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Div Allergy & Immunol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Bunyavanich, S (corresponding author), Icahn Sch Med Mt Sinai, 1425 Madison Ave,1498, New York, NY 10029 USA.	supinda@post.harvard.edu		Lee, Tricia/0000-0003-4380-1572; Oguntuyo, Kasopefoluwa/0000-0001-7824-2892	National Institutes of Health [K08AI093538, R01AI118833]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI118833, K08AI093538] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the National Institutes of Health (K08AI093538, R01AI118833). Computational infrastructure provided by the Department of Scientific Computing at the Icahn School of Medicine at Mount Sinai.	Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Bahrani-Mougeot FK, 2007, J CLIN MICROBIOL, V45, P1588, DOI 10.1128/JCM.01963-06; Bassis CM, 2015, MBIO, V6, DOI 10.1128/mBio.00037-15; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bittar F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002908; Blaxter M, 2005, PHILOS T R SOC B, V360, P1935, DOI 10.1098/rstb.2005.1725; Bunyavanich S, 2016, J ALLERGY CLIN IMMUN, V138, P1122, DOI 10.1016/j.jaci.2016.03.041; Calvert L D, 2005, J Infect, V51, pE27, DOI 10.1016/j.jinf.2004.08.002; Castro-Nallar E, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0121-1; Chung KF, 2017, J ALLERGY CLIN IMMUN, V139, P1071, DOI 10.1016/j.jaci.2017.02.004; Comhair SAA, 2015, J IMMUNOL, V195, P643, DOI 10.4049/jimmunol.1500736; Compalati E, 2010, EXPERT REV CLIN IMMU, V6, P413, DOI [10.1586/ECI.10.15, 10.1586/eci.10.15]; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; Denner DR, 2016, J ALLERGY CLIN IMMUN, V137, P1398, DOI 10.1016/j.jaci.2015.10.017; Depner M, 2017, J ALLERGY CLIN IMMUN, V139, P826, DOI 10.1016/j.jaci.2016.05.050; Domann E, 2003, J CLIN MICROBIOL, V41, P5500, DOI 10.1128/JCM.41.12.5500-5510.2003; Downes J, 2003, INT J SYST EVOL MICR, V53, P1937, DOI 10.1099/ijs.0.02640-0; Durack J, 2017, J ALLERGY CLIN IMMUN, V140, P63, DOI 10.1016/j.jaci.2016.08.055; Faith DP, 2006, MOL PHYLOGENET EVOL, V38, P553, DOI 10.1016/j.ympev.2005.08.018; Faner R, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02086-2016; Fanning LB, 2013, ANN ALLERG ASTHMA IM, V111, P155, DOI 10.1016/j.anai.2013.06.031; Garg R., 2003, ASTHMA FACTS, VSecond; Gilstrap DL, 2013, J ALLERGY CLIN IMMUN, V131, P1449, DOI 10.1016/j.jaci.2013.03.004; Goleva E, 2013, AM J RESP CRIT CARE, V188, P1193, DOI 10.1164/rccm.201304-0775OC; Green BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100645; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Huang YJ, 2017, J ALLERGY CLIN IMMUN, V139, P1099, DOI 10.1016/j.jaci.2017.02.007; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V136, P874, DOI 10.1016/j.jaci.2015.05.044; Huang YJ, 2013, AM J RESP CRIT CARE, V187, P1382, DOI 10.1164/rccm.201303-0488WS; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Illumina, 2017, PREPARING 16S RIBOSO; Kanmani P, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01613; Kim CK, 2018, ALLERGY ASTHMA IMMUN, V10, P12, DOI [10.4168/aair.2018.10.1.12, 10.4168/aair.2018.10.6.686]; Kinjo Y, 2005, NATURE, V434, P520, DOI 10.1038/nature03407; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Larsen JM, 2017, IMMUNOLOGY, V151, P363, DOI 10.1111/imm.12760; LEGRAND JC, 1989, J CLIN MICROBIOL, V27, P1132, DOI 10.1128/JCM.27.5.1132-1134.1989; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; Lynch Susan V, 2014, Ann Am Thorac Soc, V11 Suppl 1, pS57, DOI 10.1513/AnnalsATS.201306-158MG; Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013; Nadkarni MA, 2002, MICROBIOL-SGM, V148, P257, DOI 10.1099/00221287-148-1-257; New York State Department of Health, 2022, CHOK PREV CHILDR; Parks DH, 2014, BIOINFORMATICS, V30, P3123, DOI 10.1093/bioinformatics/btu494; Perez-Losada M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170543; Sandrock CE, 2015, CLIN REV ALLERG IMMU, V48, P104, DOI 10.1007/s12016-014-8435-x; Savage JH, 2018, ALLERGY, V73, P145, DOI 10.1111/all.13232; Schauberger E, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0628-3; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Tomosada Y, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-40; Vissers M, 2014, MUCOSAL IMMUNOL, V7, P227, DOI 10.1038/mi.2013.93; Wagener AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080257; Woo PCY, 2005, SYST APPL MICROBIOL, V28, P316, DOI 10.1016/j.syapm.2005.01.003; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Zelaya H, 2015, INFLAMM RES, V64, P589, DOI 10.1007/s00011-015-0837-6; Zhang QL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152724	58	57	62	2	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					834	+		10.1016/j.jaci.2018.02.020	http://dx.doi.org/10.1016/j.jaci.2018.02.020			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29518419	Green Accepted, Bronze			2022-12-18	WOS:000443726500016
J	Sverrild, A; Kiilerich, P; Brejnrod, A; Pedersen, R; Porsbjerg, C; Bergqvist, A; Erjefalt, JS; Kristiansen, K; Backer, V				Sverrild, Asger; Kiilerich, Pia; Brejnrod, Asker; Pedersen, Rebecca; Porsbjerg, Celeste; Bergqvist, Anders; Erjefalt, Jonas S.; Kristiansen, Karsten; Backer, Vibeke			Eosinophilic airway inflammation in asthmatic patients is associated with an altered airway microbiome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway inflammation; asthma; bacteria; microbiome; noneosinophilic asthma; bronchoalveolar lavage	MAST-CELLS; ACTIVATION; DISEASE	Background: Asthmatic patients have higher microbiome diversity and an altered composition, with more Proteobacteria and less Bacteroidetes compared with healthy control subjects. Studies comparing airway inflammation and the airway microbiome are sparse, especially in subjects not receiving anti-inflammatory treatment. Objective: We sought to describe the relationship between the airway microbiome and patterns of airway inflammation in steroid-free patients with asthma and healthy control subjects. Methods: Bronchoalveolar lavage fluid was collected from 23 steroid-free nonsmoking patients with asthma and 10 healthy control subjects. Bacterial DNA was extracted from and subjected to Illumina MiSeq sequencing of the 16S rDNA V4 region. Eosinophils and neutrophils in the submucosa were quantified by means of immunohistochemical identification and computerized image analysis. Induced sputum was obtained, and airway hyperresponsiveness to mannitol and fraction of exhaled nitric oxide values were measured. Relationships between airway microbial diversity and composition and inflammatory profiles were analyzed. Results: In asthmatic patients airway microbial composition was associated with airway eosinophilia and AHR to mannitol but not airway neutrophilia. The overall composition of the airway microbiome of asthmatic patients with the lowest levels of eosinophils but not asthmatic patients with the highest levels of eosinophils deviated significantly from that of healthy subjects. Asthmatic patients with the lowest levels of eosinophils had an altered bacterial abundance profile, with more Neisseria, Bacteroides, and Rothia species and less Sphingomonas, Halomonas, and Aeribacillus species compared with asthmatic patients with more eosinophils and healthy control subjects. Conclusion: The level of eosinophilic airway inflammation correlates with variations in the microbiome across asthmatic patients, whereas neutrophilic airway inflammation does not. This warrants further investigation on molecular pathways involved in both patients with eosinophilic and those with noneosinophilic asthma.	[Sverrild, Asger; Porsbjerg, Celeste; Backer, Vibeke] Univ Hosp Bispebjerg, Copenhagen, Denmark; [Kiilerich, Pia; Brejnrod, Asker; Kristiansen, Karsten] Univ Copenhagen, Dept Biol, Copenhagen, Denmark; [Pedersen, Rebecca] Statens Serum Inst, Copenhagen, Denmark; [Bergqvist, Anders; Erjefalt, Jonas S.] Lund Univ, Resp Med & Allergol & Expt Med Sci, Lund, Sweden	University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Statens Serum Institut; Lund University	Sverrild, A (corresponding author), Bispebjerg Hosp, Dept Resp Med L, Entrance 66,Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark.	asgersverrild@gmail.com	Kristiansen, Karsten/J-5148-2014; Sverrild, Asger/GPC-7753-2022; Backer, Vibeke/AAQ-9379-2021; Sverrild, Asger/AAT-3258-2021; Backer, Vibeke/I-9573-2014	Kristiansen, Karsten/0000-0002-6024-0917; Backer, Vibeke/0000-0002-7806-7219; Sverrild, Asger/0000-0003-0625-6405; Porsbjerg, Celeste/0000-0003-4825-9436; Erjefalt, Jonas/0000-0002-6716-3010; Brejnrod, Asker/0000-0002-1327-2051	Capital Region of Copenhagen; University of Copenhagen	Capital Region of Copenhagen; University of Copenhagen	Supported by the Capital Region of Copenhagen and a full-grant scholarship provided by the University of Copenhagen.	Anderson SD, 1997, AM J RESP CRIT CARE, V156, P758, DOI 10.1164/ajrccm.156.3.9701113; Andersson CK, 2011, ALLERGY, V66, P1590, DOI 10.1111/j.1398-9995.2011.02723.x; Andersson CK, 2011, J ALLERGY CLIN IMMUN, V127, P905, DOI 10.1016/j.jaci.2011.01.022; [Anonymous], 2006, AM J RESP CRIT CARE, V173, P811, DOI 10.1164/rrcm.2061014; Brix S, 2015, J ALLERGY CLIN IMMUN, V135, P277, DOI 10.1016/j.jaci.2014.09.036; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; CLARKE KR, 1993, AUST J ECOL, V18, P117, DOI 10.1111/j.1442-9993.1993.tb00438.x; Cole JR, 2009, NUCLEIC ACIDS RES, V37, pD141, DOI 10.1093/nar/gkn879; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Green BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100645; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Hofstra JJ, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1081-y; Holm JB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125495; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V136, P874, DOI 10.1016/j.jaci.2015.05.044; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Kanemitsu Y, 2014, AM J RESP CRIT CARE, V190, P472, DOI 10.1164/rccm.201403-0562LE; Kim HY, 2012, J ALLERGY CLIN IMMUN, V129, P216, DOI 10.1016/j.jaci.2011.10.036; Larsen JM, 2015, IMMUNOLOGY, V144, P333, DOI 10.1111/imm.12376; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Meyer EH, 2006, P NATL ACAD SCI USA, V103, P2782, DOI 10.1073/pnas.0510282103; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Paulson JN, 2013, NAT METHODS, V10, P1200, DOI [10.1038/NMETH.2658, 10.1038/nmeth.2658]; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Qiu YS, 2007, THORAX, V62, P475, DOI 10.1136/thx.2006.066670; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Segal LN, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-19; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Singleton TE, 2005, J IMMUNOL, V174, P3545, DOI 10.4049/jimmunol.174.6.3545; Sverrild A, 2016, CLIN EXP ALLERGY, V46, P288, DOI 10.1111/cea.12609; Sze MA, 2015, AM J RESP CRIT CARE, V192, P438, DOI 10.1164/rccm.201502-0223OC; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Zemanick ET, 2015, ANN AM THORAC SOC, V12, P221, DOI 10.1513/AnnalsATS.201407-310OC	39	57	61	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					407	+		10.1016/j.jaci.2016.10.046	http://dx.doi.org/10.1016/j.jaci.2016.10.046			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28042058	Bronze			2022-12-18	WOS:000406855500013
J	Hose, AJ; Depner, M; Illi, S; Lau, S; Keil, T; Wahn, U; Fuchs, O; Pfefferle, PI; Schmausser-Hechfellner, E; Genuneit, J; Lauener, R; Karvonen, AM; Roduit, C; Dalphin, JC; Riedler, J; Pekkanen, J; von Mutius, E; Ege, MJ; Bauer, CP; Forster, J; Zepp, F; Wahn, V; Schuster, A; Bergmann, RL; Bergmann, KE; Reich, A; Grabenhenrich, L; Schaub, B; Loss, GJ; Renz, H; Kabesch, M; Roponen, M; Hyvarinen, A; Tiittanen, P; Remes, S; Braun-Fahrlander, C; Frei, R; Kaulek, V; Dalphin, ML; Doekes, G; Blumer, N; Frey, U				Hose, Alexander J.; Depner, Martin; Illi, Sabina; Lau, Susanne; Keil, Thomas; Wahn, Ulrich; Fuchs, Oliver; Pfefferle, Petra Ina; Schmausser-Hechfellner, Elisabeth; Genuneit, Jon; Lauener, Roger; Karvonen, Anne M.; Roduit, Caroline; Dalphin, Jean-Charles; Riedler, Josef; Pekkanen, Juha; von Mutius, Erika; Ege, Markus J.; Bauer, Carl Peter; Forster, Johannes; Zepp, Fred; Wahn, Volker; Schuster, Antje; Bergmann, Renate L.; Bergmann, Karl E.; Reich, Andreas; Grabenhenrich, Linus; Schaub, Bianca; Loss, Georg J.; Renz, Harald; Kabesch, Michael; Roponen, Marjut; Hyvarinen, Anne; Tiittanen, Pekka; Remes, Sami; Braun-Fahrlander, Charlotte; Frei, Remo; Kaulek, Vincent; Dalphin, Marie-Laure; Doekes, Gert; Blumer, Nicole; Frey, Urs		MAS Study Grp; PASTURE Study Grp	Latent class analysis reveals clinically relevant atopy phenotypes in 2 birth cohorts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; IgE; sensitization; asthma; lung function; cytokines; severe atopy; atopic diseases; latent class analysis; unsupervised clustering; path analysis; epidemiology	RESPIRATORY SYMPTOMS; INHALANT ALLERGENS; SKIN-TEST; SENSITIZATION; ASTHMA; CHILDHOOD; RISK; IGE; CHILDREN; LIFE	Background: Phenotypes of childhood-onset asthma are characterized by distinct trajectories and functional features. For atopy, definition of phenotypes during childhood is less clear. Objective: We sought to define phenotypes of atopic sensitization over the first 6 years of life using a latent class analysis (LCA) integrating 3 dimensions of atopy: allergen specificity, time course, and levels of specific IgE (sIgE). Methods: Phenotypes were defined by means of LCA in 680 children of the Multizentrische Allergiestudie (MAS) and 766 children of the Protection against allergy: Study in Rural Environments (PASTURE) birth cohorts and compared with classical nondisjunctive definitions of seasonal, perennial, and food sensitization with respect to atopic diseases and lung function. Cytokine levels were measured in the PASTURE cohort. Results: The LCA classified predominantly by type and multiplicity of sensitization (food vs inhalant), allergen combinations, and sIgE levels. Latent classes were related to atopic disease manifestations with higher sensitivity and specificity than the classical definitions. LCA detected consistently in both cohorts a distinct group of children with severe atopy characterized by high seasonal sIgE levels and a strong propensity for asthma; hay fever; eczema; and impaired lung function, also in children without an established asthma diagnosis. Severe atopy was associated with an increased IL-5/IFN-gamma ratio. A path analysis among sensitized children revealed that among all features of severe atopy, only excessive sIgE production early in life affected asthma risk. Conclusions: LCA revealed a set of benign, symptomatic, and severe atopy phenotypes. The severe phenotype emerged as a latent condition with signs of a dysbalanced immune response. It determined high asthma risk through excessive sIgE production and directly affected impaired lung function.	[Hose, Alexander J.; Depner, Martin; Illi, Sabina; Fuchs, Oliver; Schmausser-Hechfellner, Elisabeth; von Mutius, Erika; Ege, Markus J.; Loss, Georg J.] Ludwig Maximilians Univ Munchen, Dr von Hauner Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany; [Lau, Susanne; Wahn, Ulrich] Charite Univ Med Berlin, Dept Pediat Pneumol & Immunol, Berlin, Germany; [Keil, Thomas] Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Bergmann, Renate L.; Bergmann, Karl E.] Charite Univ Med Berlin, Dept Obstet, Berlin, Germany; [Reich, Andreas; Grabenhenrich, Linus] Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Keil, Thomas] Univ Wurzburg, Inst Clin Epidemiol & Biometry, Wurzburg, Germany; [Fuchs, Oliver; von Mutius, Erika; Ege, Markus J.] CPC M, Munich, Germany; [Fuchs, Oliver; von Mutius, Erika; Ege, Markus J.] German Ctr Lung Res DZL, Munich, Germany; [Fuchs, Oliver] Univ Bern, Inselspital, Dept Pediat, Div Resp Med, Bern, Switzerland; [Fuchs, Oliver] Univ Basel, Univ Childrens Hosp UKBB, Basel, Switzerland; [Pfefferle, Petra Ina] Philipps Univ Marburg, CBBM, Fachbereich Med, Zentrum Tumor & Immunbiol ZTI Marburg, Marburg, Germany; [Pfefferle, Petra Ina] German Ctr Lung Res, Marburg, Germany; [Genuneit, Jon] Ulm Univ, Inst Epidemiol & Med Biometry, Ulm, Germany; [Lauener, Roger; Roduit, Caroline] CK CARE, Davos, Switzerland; [Lauener, Roger] Childrens Hosp Eastern Switzerland, St Gallen, Switzerland; [Karvonen, Anne M.; Pekkanen, Juha] Natl Inst Hlth & Welf, Dept Hlth Protect, Kuopio, Finland; [Roduit, Caroline] Univ Zurich, Childrens Hosp, Zurich, Switzerland; [Dalphin, Jean-Charles] Univ Besancon, Dept Resp Dis, Univ Hosp, UMR Chronoenvironm CNRS6249, Besancon, France; [Riedler, Josef] Childrens Hosp Schwarzach, Schwarzach, Austria; [Riedler, Josef] Paracelsus Med Private Univ Salzburg, Teaching Hosp, Salzburg, Austria; [Pekkanen, Juha] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; [Bauer, Carl Peter] Tech Univ Munich, Dept Pediat, Munich, Germany; [Forster, Johannes] St Josefs Hosp, Dept Paediat, Freiburg, Germany; [Zepp, Fred] Univ Med Ctr Mainz, Ctr Paediat & Adolescent Med, Mainz, Germany; [Wahn, Volker] Charite, Univ Childrens Hosp, Berlin, Germany; [Schuster, Antje] Univ Med Ctr Dusseldorf, Dept Paediat, Dusseldorf, Germany; [Loss, Georg J.] Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA; [Renz, Harald] Philipps Univ Marburg, Dept Clin Chem & Mol Diagnost, Marburg, Germany; [Kabesch, Michael] KUNO Childrens Univ Hosp Regensburg, Dept Pediat Pneumol & Allergy, Campus St Hedwig, Regensburg, Germany; [Kabesch, Michael] Hannover Med Sch, Clin Pediat Pneumol & Neonatol, Hannover, Germany; [Roponen, Marjut] Univ Eastern Finland, Inhalat Toxicol Lab, Dept Environm Sci, Kuopio, Finland; [Remes, Sami] Kuopio Univ Hosp, Dept Pediat, Kuopio, Finland; [Braun-Fahrlander, Charlotte] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Braun-Fahrlander, Charlotte] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Dalphin, Marie-Laure] Univ Besancon, Dept Pediat, Univ Hosp, Besancon, France; [Doekes, Gert] Univ Utrecht, Div Environm Epidemiol, IRAS, Utrecht, Netherlands; [Blumer, Nicole] Philipps Univ Marburg, Dept Clin Chem & Mol Diagnost, Marburg, Germany	University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; University of Bern; University Hospital of Bern; University of Basel; Philipps University Marburg; Ulm University; Finland National Institute for Health & Welfare; University Children's Hospital Zurich; University of Zurich; Universite de Franche-Comte; CHU Besancon; Paracelsus Private Medical University; University of Helsinki; Technical University of Munich; Johannes Gutenberg University of Mainz; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; University of California System; University of California San Diego; Philipps University Marburg; Hannover Medical School; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; University of Basel; Swiss Tropical & Public Health Institute; Swiss Institute of Allergy & Asthma Research; University of Zurich; Universite de Franche-Comte; CHU Besancon; Utrecht University; Philipps University Marburg	Hose, AJ (corresponding author), Ludwig Maximilians Univ Munchen, Dr von Hauner Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany.	Alexander.Hose@med.uni-muenchen.de	Genuneit, Jon/I-9323-2012; Roduit, Caroline/S-4928-2017; Roponen, Marjut/C-2086-2017; riedler, josef/AAQ-4666-2020; Frei, Remo/AAI-9180-2020; Kabesch, Michael/GZM-1583-2022; Kabesch, Michael/AAB-5701-2020; Schaub, Bianca/B-9935-2019; Ege, Markus/C-1962-2012; Loss, Georg/AAE-7296-2019; Reich, Andreas/B-1204-2016	Genuneit, Jon/0000-0001-5764-1528; Roponen, Marjut/0000-0002-4442-9090; Schaub, Bianca/0000-0003-1652-8873; Ege, Markus/0000-0001-6643-3923; Loss, Georg/0000-0003-1090-812X; Reich, Andreas/0000-0002-3729-0772; Lau, Susanne/0000-0002-5189-4265; Roduit, Caroline/0000-0002-5988-0570; Grabenhenrich, Linus/0000-0002-9300-6625; Frey, Urs/0000-0003-3773-2822; Hyvarinen, Anne/0000-0002-2823-0866; von Mutius, Erika/0000-0002-8893-4515	German Federal Ministry of Education and Research (BMBF) [07015633, 07 ALE 27, 01EE9405/5, 01EE9406]; German Research Foundation (DFG) [KE 1462/2-1]; European Commission [QLK4-CT-2001-00250, FOOD-CT-2006-31708, KBBE-2007-2-2-06]; European Research Council [250268]; German Federal Ministry of Education and Research (BMBF)	German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); German Research Foundation (DFG)(German Research Foundation (DFG)); European Commission(European CommissionEuropean Commission Joint Research Centre); European Research Council(European Research Council (ERC)European Commission); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	The Multizentrische Allergiestudie (MAS) study was funded by grants from the German Federal Ministry of Education and Research (BMBF; reference nos. 07015633, 07 ALE 27, 01EE9405/5, and 01EE9406) and the German Research Foundation (DFG; reference no. KE 1462/2-1). The funders had no role in the design, management, data collection, analysis, or interpretation of the data or in the writing of the manuscript or the decision to submit for publication. For PASTURE, work was supported by the European Commission (research grants QLK4-CT-2001-00250, FOOD-CT-2006-31708, and KBBE-2007-2-2-06), the European Research Council (Grant 250268), and the German Federal Ministry of Education and Research (BMBF; project German Center for Lung Research [DZL]). The funding sources did not influence the study design; the collection, analysis, and interpretation of data; the writing of the manuscript; and the decision to submit the paper for publication. The corresponding author had full access to all of the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis.	Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Burbach GJ, 2009, ALLERGY, V64, P1507, DOI 10.1111/j.1398-9995.2009.02089.x; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Ciprandi G, 2011, EUR J INTERN MED, V22, pE75, DOI 10.1016/j.ejim.2011.05.009; de Jong AB, 2011, PEDIAT ALLERG IMM-UK, V22, P166, DOI 10.1111/j.1399-3038.2010.00993.x; Depner M, 2014, AM J RESP CRIT CARE, V189, P129, DOI 10.1164/rccm.201307-1198OC; Depner M, 2013, J ALLERGY CLIN IMMUN, V131, P781, DOI 10.1016/j.jaci.2012.11.048; Garden FL, 2013, CLIN EXP ALLERGY, V43, P633, DOI 10.1111/cea.12095; Gelardi M, 2015, INFLAMM RES, V64, P373, DOI 10.1007/s00011-015-0826-9; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Havstad S, 2014, J ALLERGY CLIN IMMUN, V134, P722, DOI 10.1016/j.jaci.2014.01.022; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Just J, 2014, PEDIAT ALLERG IMM-UK, V25, P668, DOI 10.1111/pai.12287; Kulig M, 1998, CLIN EXP ALLERGY, V28, P1397, DOI 10.1046/j.1365-2222.1998.00439.x; Lanza ST, 2007, STRUCT EQU MODELING, V14, P671, DOI 10.1080/10705510701575602; Lazic N, 2013, ALLERGY, V68, P764, DOI 10.1111/all.12134; Matricardi PM, 2009, CLIN EXP ALLERGY, V39, P1551, DOI 10.1111/j.1365-2222.2009.03348.x; Matricardi PM, 2009, ALLERGY, V64, P1093, DOI 10.1111/j.1398-9995.2009.02055.x; Migueres M, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-16; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176, DOI 10.1164/ajrccm.165.2.2104032; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Sherrill D, 1999, CLIN EXP ALLERGY, V29, P905; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Stanojevic S, 2008, AM J RESP CRIT CARE, V177, P253, DOI 10.1164/rccm.200708-1248OC; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008; Toppila-Salmi S, 2015, ALLERGY, V70, P1112, DOI 10.1111/all.12670; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x	32	57	58	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1935	+		10.1016/j.jaci.2016.08.046	http://dx.doi.org/10.1016/j.jaci.2016.08.046			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	27771325	Bronze, Green Accepted, Green Published			2022-12-18	WOS:000402724600024
J	Tham, R; Vicendese, D; Dharmage, SC; Hyndman, RJ; Newbigin, E; Lewis, E; O'Sullivan, M; Lowe, AJ; Taylor, P; Bardin, P; Tang, MLK; Abramson, MJ; Erbas, B				Tham, Rachel; Vicendese, Don; Dharmage, Shyamali C.; Hyndman, Rob J.; Newbigin, Ed; Lewis, Emma; O'Sullivan, Molly; Lowe, Adrian J.; Taylor, Philip; Bardin, Philip; Tang, Mimi L. K.; Abramson, Michael J.; Erbas, Bircan			Associations between outdoor fungal spores and childhood and adolescent asthma hospitalizations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Outdoor fungi; asthma; hospitalization; child; adolescent; case-crossover design	AIR-POLLUTION; EMERGENCY VISITS; CASE-CROSSOVER; CHILDREN; EXACERBATIONS; ADMISSIONS; ALLERGENS; EXPOSURE; RHINOVIRUS; INFECTION	Background: Childhood asthma is a significant public health problem and severe exacerbations can result in diminished quality of life and hospitalization. Objective: We sought to examine the contribution of outdoor fungi to childhood and adolescent asthma hospitalizations. Methods: The Melbourne Air Pollen Children and Adolescent study is a case-crossover study of 644 children and adolescents (aged 2-17 years) hospitalized for asthma. The Melbourne Air Pollen Children and Adolescent study collected individual data on human rhinovirus infection and sensitization to Alternaria and Cladosporium and daily counts of ambient concentrations of fungal spores, pollen, and air pollutants. Conditional logistic regression models were used to assess associations with increases in spore counts while controlling for potential confounding and testing interactions. Results: Exposure to Alternaria (adjusted odds ratio [aOR], 1.07; 95% CI, 1.03-1.11), Leptosphaeria (aOR, 1.05; 95% CI, 1.02-1.07), Coprinus (aOR, 1.04; 95% CI, 1.01-1.07), Drechslera (aOR, 1.03; 95% CI, 1.00-1.05), and total spores (aOR, 1.05; 95% CI, 1.01-1.09) was significantly associated with child asthma hospitalizations independent of human rhinovirus infection. There were significant lagged effects up to 3 days with Alternaria, Leptosphaeria, Cladosporium, Sporormiella, Coprinus, and Drechslera. Some of these associations were significantly greater in participants with Cladosporium sensitization. Conclusions: Exposures to several outdoor fungal spore taxa, including some not reported in previous research, are associated with the risk of child and adolescent asthma hospitalization, particularly in individuals sensitized to Cladosporium. We need further studies to examine cross-reactivity causing asthma exacerbations. Identifying sensitization to multiple fungal allergens in children with asthma could support the design and implementation of more effective strategies to prevent asthma exacerbations.	[Tham, Rachel; Dharmage, Shyamali C.; Lowe, Adrian J.; Tang, Mimi L. K.] Univ Melbourne, Allergy & Lung Hlth Unit, Ctr Epidemiol & Biostat, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia; [Vicendese, Don; Erbas, Bircan] La Trobe Univ, Sch Publ Hlth, Coll Sci Hlth & Engn, Bundoora, Vic, Australia; [Hyndman, Rob J.] Monash Univ, Dept Econometr & Business Stat, Clayton, Vic, Australia; [Newbigin, Ed; Lewis, Emma] Univ Melbourne, Sch Biosci, Melbourne, Vic, Australia; [O'Sullivan, Molly; Lowe, Adrian J.; Tang, Mimi L. K.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Allergy & Immune Disorders, Melbourne, Vic, Australia; [Taylor, Philip] Deakin Univ, Sch Life & Environm Sci, Geelong, Vic, Australia; [Bardin, Philip] Monash Med Ctr, Monash Lung & Sleep, Melbourne, Vic, Australia; [Bardin, Philip] Univ Melbourne, Melbourne, Vic, Australia; [Bardin, Philip] Hudson Inst, Melbourne, Vic, Australia; [Tang, Mimi L. K.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Abramson, Michael J.] Monash Univ, Dept Epidemiol & Prevent Med, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia	University of Melbourne; La Trobe University; Monash University; University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Deakin University; Monash University; University of Melbourne; Hudson Institute of Medical Research; University of Melbourne; Monash University	Erbas, B (corresponding author), La Trobe Univ, Sch Publ Hlth, Rm 129,Hlth Sci 1, Bundoora, Vic 3086, Australia.	b.erbas@latrobe.edu.au	Tham, Rachel/AAB-9329-2019; Tham, Rachel/AFM-0823-2022; Abramson, Michael/AAQ-2671-2020; Tang, Mimi/ABD-8350-2020; Tham, Rachel/AAH-3336-2022; Hyndman, Rob/A-2268-2008	Tham, Rachel/0000-0001-9362-5189; Abramson, Michael/0000-0002-9954-0538; Tang, Mimi/0000-0002-3839-5293; Vicendese, Don/0000-0002-0176-0314; Newbigin, Ed/0000-0002-9644-302X; Hyndman, Rob/0000-0002-2140-5352	National Health and Medical Research Council (NHMRC) [541934]; NHMRC PhD Postgraduate Scholarship and a Centre for Air quality & health Research and evaluation (NHMRC Centre of Research Excellence); NHMRC	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC PhD Postgraduate Scholarship and a Centre for Air quality & health Research and evaluation (NHMRC Centre of Research Excellence)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	The Melbourne Air Pollen Children and Adolescent Health study was funded by the National Health and Medical Research Council (NHMRC) Project ID: 541934, but the NHMRC had no part in the study design, collection, analysis, or interpretation of the data, the writing of this manuscript, or the decision to submit it for publication. R.T. is funded by an NHMRC PhD Postgraduate Scholarship and a Centre for Air quality & health Research and evaluation (NHMRC Centre of Research Excellence) top-up scholarship. S.C.D. and A.J.L. are funded by the NHMRC.	Agarwal R, 2011, CURR ALLERGY ASTHM R, V11, P403, DOI 10.1007/s11882-011-0217-4; Anderson HR, 2013, AIR QUAL ATMOS HLTH, V6, P47, DOI 10.1007/s11869-011-0144-5; Asher I, 2014, INT J TUBERC LUNG D, V18, P1269, DOI 10.5588/ijtld.14.0170; Atkinson RW, 2006, OCCUP ENVIRON MED, V63, P580, DOI 10.1136/oem.2005.024448; Australian Institute of Health and Welfare, 2013, ASTHM HOSP AUSTR 201; Australian Institute of Health and Welfare (AIHW), AUSTR I HLTH WELF AI, V4; Bizzintino J, 2011, EUR RESPIR J, V37, P1037, DOI 10.1183/09031936.00092410; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; Burge HA, 2002, J ALLERGY CLIN IMMUN, V110, P544, DOI 10.1067/mai.2002.128674; Chakraborty P, 2014, AEROBIOLOGIA, V30, P137, DOI 10.1007/s10453-013-9312-4; Crameri R, 2014, ALLERGY, V69, P176, DOI 10.1111/all.12325; Crameri R, 2009, MYCOSES, V52, P99, DOI 10.1111/j.1439-0507.2008.01644.x; Dales RE, 2000, AM J RESP CRIT CARE, V162, P2087, DOI 10.1164/ajrccm.162.6.2001020; Dales RE, 2004, J ALLERGY CLIN IMMUN, V113, P303, DOI 10.1016/j.jaci.2003.11.016; Dales RE, 2003, CHEST, V123, P745, DOI 10.1378/chest.123.3.745; Dennekamp M, 2010, EPIDEMIOLOGY, V21, P494, DOI 10.1097/EDE.0b013e3181e093db; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; Erbas B, 2007, CLIN EXP ALLERGY, V37, P1641, DOI 10.1111/j.1365-2222.2007.02818.x; Erbas B, 2012, J BIOMET BIOSTAT, pS7; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Garrett MH., 1997, AEROBIOLOGIA BOLOGNA, V13, P121, DOI [10.1007/BF02694428, DOI 10.1007/BF02694428]; HASNAIN SM, 1993, GRANA, V32, P315, DOI 10.1080/00173139309429996; Hasnain SM, 2007, AEROALLERGEN MONITOR; Irga PJ, 2016, AEROBIOLOGIA, V32, P171, DOI 10.1007/s10453-015-9388-0; Jaakkola JJK, 2003, EUR RESPIR J, V21, p81S, DOI 10.1183/09031936.03.00402703; James TY, 2006, NATURE, V443, P818, DOI 10.1038/nature05110; Janes H, 2005, EPIDEMIOLOGY, V16, P717, DOI 10.1097/01.ede.0000181315.18836.9d; Kirkwood B.R., 2010, ESSENTIAL MED STAT; Knutsen AP, 2012, J ALLERGY CLIN IMMUN, V129, P280, DOI 10.1016/j.jaci.2011.12.970; Levetin E, 2015, J ALLERGY CLIN IMMUN, V4; Li SS, 2014, ANN ALLERG ASTHMA IM, V112, P348, DOI 10.1016/j.anai.2014.01.007; Lierl MB, 2003, ANN ALLERG ASTHMA IM, V90, P28, DOI 10.1016/S1081-1206(10)63610-1; Lyons TW, 2011, ANN ALLERG ASTHMA IM, V106, P301, DOI 10.1016/j.anai.2010.12.009; Mitakakis TZ, 2001, AEROBIOLOGIA, V17, P171, DOI [10.1023/A:1011028412526, DOI 10.1023/A:1011028412526]; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Newson R, 2000, OCCUP ENVIRON MED, V57, P786, DOI 10.1136/oem.57.11.786; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; Pongracic JA, 2010, J ALLERGY CLIN IMMUN, V125, P593, DOI 10.1016/j.jaci.2009.10.036; Quan S, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0363-6; Raphoz M, 2010, ARCH ENVIRON OCCUP H, V65, P201, DOI 10.1080/19338241003730937; Rawlinson WD, 2003, J INFECT DIS, V187, P1314, DOI 10.1086/368411; Tham R, 2014, PEDIAT ALLERG IMM-UK, V25, P439, DOI 10.1111/pai.12257; Tischer C, 2011, EUR RESPIR J, V38, P812, DOI 10.1183/09031936.00184010; Wang HC, 2007, J ASTHMA, V44, P839, DOI 10.1080/02770900701751666	44	57	57	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1140	+		10.1016/j.jaci.2016.06.046	http://dx.doi.org/10.1016/j.jaci.2016.06.046			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27523960				2022-12-18	WOS:000398771800009
J	Beutier, H; Gillis, CM; Iannascoli, B; Godon, O; England, P; Sibilano, R; Reber, LL; Galli, SJ; Cragg, MS; Van Rooijen, N; Mancardi, DA; Bruhns, P; Jonsson, F				Beutier, Heloise; Gillis, Caitlin M.; Iannascoli, Bruno; Godon, Ophelie; England, Patrick; Sibilano, Riccardo; Reber, Laurent L.; Galli, Stephen J.; Cragg, Mark S.; Van Rooijen, Nico; Mancardi, David A.; Bruhns, Pierre; Jonsson, Friederike			IgG subclasses determine pathways of anaphylaxis in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; IgG; mouse model; basophil; neutrophil; monocyte; macrophage; IgG Fc receptor; platelet-activating factor; histamine	FC-GAMMA-RIV; PLATELET-ACTIVATING-FACTOR; SYSTEMIC-ANAPHYLAXIS; MAST-CELLS; IN-VIVO; MEDIATED ANAPHYLAXIS; DENDRITIC CELLS; MOUSE; RECEPTORS; MACROPHAGES	Background: Animal models have demonstrated that allergen-specific IgGconfers sensitivity to systemic anaphylaxis that relies on IgG Fc receptors (Fc gamma Rs). Mouse IgG(2a) and IgG(2b) bind activating Fc gamma RI, Fc gamma RIII, and FcgRIVand inhibitory Fc gamma RIIB; mouse IgG(1) binds only Fc gamma RIII and Fc gamma RIIB. Although these interactions are of strikingly different affinities, these 3 IgG subclasses have been shown to enable induction of systemic anaphylaxis. Objective: We sought to determine which pathways control the induction of IgG(1)-, IgG(2a)-, and IgG(2b-)dependent passive systemic anaphylaxis. Methods: Mice were sensitized with IgG(1)(-), IgG(2a)(-), or IgG(2b-) anti-trinitrophenyl mAbs and challenged with trinitrophenyl-BSA intravenously to induce systemic anaphylaxis that was monitored by using rectal temperature. Anaphylaxis was evaluated in mice deficient for FcgRs injected with mediator antagonists or in which basophils, monocytes/macrophages, or neutrophils had been depleted. Fc gamma R expression was evaluated on these cells before and after anaphylaxis. Results: Activating Fc gamma RIII is the receptor primarily responsible for all 3 models of anaphylaxis, and subsequent downregulation of this receptor was observed. These models differentially relied on histamine release and the contribution of mast cells, basophils, macrophages, and neutrophils. Strikingly, basophil contribution and histamine predominance in mice with IgG(1)- and IgG(2b)- induced anaphylaxis correlated with the ability of inhibitory Fc gamma RIIB to negatively regulate these models of anaphylaxis. Conclusion: We propose that the differential expression of inhibitory FcgRIIB on myeloid cells and its differential binding of IgG subclasses controls the contributions of mast cells, basophils, neutrophils, and macrophages to IgG subclass-dependent anaphylaxis. Collectively, our results unravel novel complexities in the involvement and regulation of cell populations in IgG-dependent reactions in vivo.	[Beutier, Heloise; Gillis, Caitlin M.; Iannascoli, Bruno; Godon, Ophelie; Reber, Laurent L.; Mancardi, David A.; Bruhns, Pierre; Jonsson, Friederike] Inst Pasteur, Unit Antibodies Therapy & Pathol, Dept Immunol, 25 Rue Docteur Roux, F-75015 Paris, France; [Beutier, Heloise; Gillis, Caitlin M.; Iannascoli, Bruno; Godon, Ophelie; Reber, Laurent L.; Mancardi, David A.; Bruhns, Pierre; Jonsson, Friederike] INSERM, U1222, Paris, France; [Beutier, Heloise; Gillis, Caitlin M.] Univ Paris 06, Paris, France; [England, Patrick] CNRS UMR3528, Ctr Innovat & Rech Technol CiTech, Plate Forme Biophys Mol, Inst Pasteur, Paris, France; [Sibilano, Riccardo; Galli, Stephen J.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Sibilano, Riccardo; Galli, Stephen J.] Stanford Univ, Sch Med, Sean N Parker Ctr Allergy & Asthma Res, Stanford, CA 94305 USA; [Cragg, Mark S.] Univ Southampton, Antibody & Vaccine Grp, Canc Sci Unit, Fac Med,Southampton Gen Hosp, Southampton SO9 5NH, Hants, England; [Van Rooijen, Nico] Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol, Amsterdam, Netherlands	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Stanford University; Stanford University; University of Southampton; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Bruhns, P; Jonsson, F (corresponding author), Inst Pasteur, Unit Antibodies Therapy & Pathol, Dept Immunol, 25 Rue Docteur Roux, F-75015 Paris, France.	bruhns@pasteur.fr; joensson@pasteur.fr	Bruhns, Pierre/F-5567-2013; Van Rooijen, Nico/Z-1578-2019; Jönsson, Friederike/H-7525-2014; Reber, Laurent L/K-4148-2014; Cragg, Mark S/E-5965-2010; Gillis, Caitlin/AAJ-8475-2020	Bruhns, Pierre/0000-0002-4709-8936; Jönsson, Friederike/0000-0002-1667-8065; Reber, Laurent L/0000-0003-3384-6769; Cragg, Mark S/0000-0003-2077-089X; Gillis, Caitlin/0000-0001-9892-206X; ENGLAND, Patrick/0000-0001-6410-5918	Institut Pasteur; Institut National de la Sante et de la Recherche Medicale (INSERM); European Research Council (ERC)-Seventh Frame-work Program [ERC-2013-CoG 616050]; Societe Francaise d'Allergologie (SFA; Soutien de la Recherche en Allergologie); Balsan company; University Pierre et Marie Curie; Institut Carnot Pasteur Maladies Infectieuses; NIH/NIAMS [R01 AR067145]; Department of Pathology at Stanford University; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR067145] Funding Source: NIH RePORTER	Institut Pasteur(European Commission); Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); European Research Council (ERC)-Seventh Frame-work Program(European Research Council (ERC)); Societe Francaise d'Allergologie (SFA; Soutien de la Recherche en Allergologie); Balsan company; University Pierre et Marie Curie; Institut Carnot Pasteur Maladies Infectieuses; NIH/NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Department of Pathology at Stanford University; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by Institut Pasteur, Institut National de la Sante et de la Recherche Medicale (INSERM), the European Research Council (ERC)-Seventh Frame-work Program (ERC-2013-CoG 616050), Societe Francaise d'Allergologie (SFA; Soutien de la Recherche en Allergologie), and the Balsan company. H.B. is supported by a fellowship from the University Pierre et Marie Curie. C.M.G. is a scholar of the Pasteur Paris University International Doctoral Program and supported by a stipend from the Institut Carnot Pasteur Maladies Infectieuses. F.J. is an employee of the Centre National de La Recherche Scientifique (CNRS). R.S. and S.J.G. are supported by NIH/NIAMS grant R01 AR067145 and the Department of Pathology at Stanford University.	Biburger M, 2012, IMMUNOL LETT, V143, P53, DOI 10.1016/j.imlet.2012.01.002; Biburger M, 2011, IMMUNITY, V35, P932, DOI 10.1016/j.immuni.2011.11.009; Brown SGA, 2013, J ALLERGY CLIN IMMUN, V132, P1141, DOI 10.1016/j.jaci.2013.06.015; Bruhns P, 2005, CURR OPIN IMMUNOL, V17, P662, DOI 10.1016/j.coi.2005.09.012; Bruhns P, 2012, BLOOD, V119, P5640, DOI 10.1182/blood-2012-01-380121; CAMUSSI G, 1981, IMMUNOLOGY, V42, P191; CAPRON M, 1989, CLIN EXP ALLERGY, V19, P3; Cassard L, 2012, J IMMUNOL, V189, P2995, DOI 10.4049/jimmunol.1200968; Finkelman FD, 2005, J ALLERGY CLIN IMMUN, V115, P449, DOI 10.1016/j.jaci.2004.12.1125; Gavin AL, 1998, J IMMUNOL, V160, P20; Guilliams M, 2014, NAT REV IMMUNOL, V14, P94, DOI 10.1038/nri3582; IFF ET, 1966, INT ARCH ALLER A IMM, V30, P313, DOI 10.1159/000229815; Jiao DL, 2014, CELL IMMUNOL, V289, P97, DOI 10.1016/j.cellimm.2014.03.018; Jonsson F, 2013, J LEUKOCYTE BIOL, V94, P643, DOI 10.1189/jlb.1212623; Jonsson F, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00016; Jonsson F, 2012, BLOOD, V119, P2533, DOI 10.1182/blood-2011-07-367334; Jonsson F, 2011, J CLIN INVEST, V121, P1484, DOI 10.1172/JCI45232; Khodoun MV, 2013, J ALLERGY CLIN IMMUN, V132, P1375, DOI 10.1016/j.jaci.2013.09.008; Khodoun MV, 2011, P NATL ACAD SCI USA, V108, P12413, DOI 10.1073/pnas.1105695108; Lilla JN, 2011, BLOOD, V118, P6930, DOI 10.1182/blood-2011-03-343962; Makabe-Kobayashi Y, 2002, J ALLERGY CLIN IMMUN, V110, P298, DOI 10.1067/mai.2002.125977; Mancardi DA, 2008, J CLIN INVEST, V118, P3738, DOI 10.1172/JCI36452; Mancardi DA, 2013, BLOOD, V121, P1563, DOI 10.1182/blood-2012-07-442541; Mancardi DA, 2011, J IMMUNOL, V186, P1899, DOI 10.4049/jimmunol.1003642; Million M, 1997, EUR J PHARMACOL, V334, P67, DOI 10.1016/S0014-2999(97)01142-4; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948; Nimmerjahn F, 2005, IMMUNITY, V23, P41, DOI 10.1016/j.immuni.2005.05.010; Nimmerjahn F, 2010, P NATL ACAD SCI USA, V107, P19396, DOI 10.1073/pnas.1014515107; Ohnmacht C, 2010, IMMUNITY, V33, P364, DOI 10.1016/j.immuni.2010.08.011; Reber LL, 2013, J ALLERGY CLIN IMMUN, V132, P881, DOI 10.1016/j.jaci.2013.06.008; Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155; Saylor CA, 2010, J IMMUNOL, V184, P336, DOI 10.4049/jimmunol.0902752; Smith KGC, 2010, NAT REV IMMUNOL, V10, P328, DOI 10.1038/nri2762; Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Syed SN, 2009, EUR J IMMUNOL, V39, P3343, DOI 10.1002/eji.200939884; Tan PS, 2003, J IMMUNOL, V170, P2549, DOI 10.4049/jimmunol.170.5.2549; Tipton TRW, 2015, BLOOD, V126, P2643, DOI 10.1182/blood-2015-09-671339; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; UNKELESS JC, 1975, J EXP MED, V142, P1520, DOI 10.1084/jem.142.6.1520; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; Veri MC, 2007, IMMUNOLOGY, V121, P392, DOI 10.1111/j.1365-2567.2007.02588.x; Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0; Williams EL, 2012, EUR J IMMUNOL, V42, P2109, DOI 10.1002/eji.201142302; Yucel R, 2004, J BIOL CHEM, V279, P40906, DOI 10.1074/jbc.M400808200	48	57	58	2	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					269	+		10.1016/j.jaci.2016.03.028	http://dx.doi.org/10.1016/j.jaci.2016.03.028			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27246523	Green Accepted, Bronze, Green Submitted			2022-12-18	WOS:000393996800028
J	Zhang, ZH; Myers, JMB; Brandt, EB; Ryan, PH; Lindsey, M; Mintz-Cole, RA; Reponen, T; Vesper, SJ; Forde, F; Ruff, B; Bass, SA; LeMasters, GK; Bernstein, DI; Lockey, J; Budelsky, AL; Hershey, GKK				Zhang, Zhonghua; Myers, Jocelyn M. Biagini; Brandt, Eric B.; Ryan, Patrick H.; Lindsey, Mark; Mintz-Cole, Rachael A.; Reponen, Tiina; Vesper, Stephen J.; Forde, Frank; Ruff, Brandy; Bass, Stacey A.; LeMasters, Grace K.; Bernstein, David I.; Lockey, James; Budelsky, Alison L.; Hershey, Gurjit K. Khurana			beta-Glucan exacerbates allergic asthma independent of fungal sensitization and promotes steroid-resistant T(H)2/T(H)17 responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood asthma; beta-glucan; fungi; house dust mite; IL-17A; fungal exposure; allergy	RELATIVE MOLDINESS INDEX; CHILDHOOD ASTHMA; CLADOSPORIUM-CLADOSPORIOIDES; AIRWAY HYPERRESPONSIVENESS; EXPOSURE; DECTIN-1; IL-17; CELLS; RECOGNITION; PREDICTOR	Background: Allergic sensitization to fungi has been associated with asthma severity. As a result, it has been largely assumed that the contribution of fungi to allergic disease is mediated through their potent antigenicity. Objective: We sought to determine the mechanism by which fungi affect asthma development and severity. Methods: We integrated epidemiologic and experimental asthma models to explore the effect of fungal exposure on asthma development and severity. Results: We report that fungal exposure enhances allergen-driven T(H)2 responses, promoting severe allergic asthma. This effect is independent of fungal sensitization and can be reconstituted with beta-glucan and abrogated by neutralization of IL-17A. Furthermore, this severe asthma is resistant to steroids and characterized by mixed T(H)2 and T(H)17 responses, including IL-13(+)IL-17(+)CD4(+) double- producing effector T cells. Steroid resistance is dependent on fungus-induced TH17 responses because steroid sensitivity was restored in IL-17rc 2/2 mice. Similarly, in children with asthma, fungal exposure was associated with increased serum IL-17A levels and asthma severity. Conclusion: Our data demonstrate that fungi are potent immunomodulators and have powerful effects on asthma independent of their potential to act as antigens. Furthermore, our results provide a strong rationale for combination treatment strategies targeting IL-17A for this subgroup of fungus-exposed patients with difficult-to-treat asthma.	[Zhang, Zhonghua; Myers, Jocelyn M. Biagini; Brandt, Eric B.; Lindsey, Mark; Mintz-Cole, Rachael A.; Forde, Frank; Ruff, Brandy; Bass, Stacey A.; LeMasters, Grace K.; Hershey, Gurjit K. Khurana] Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH 45229 USA; [Ryan, Patrick H.] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Zhang, Zhonghua; Myers, Jocelyn M. Biagini; Brandt, Eric B.; Ryan, Patrick H.; Lindsey, Mark; Mintz-Cole, Rachael A.; Forde, Frank; Ruff, Brandy; Bass, Stacey A.; LeMasters, Grace K.; Hershey, Gurjit K. Khurana] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Reponen, Tiina; LeMasters, Grace K.; Lockey, James] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; [Bernstein, David I.] Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH USA; [Vesper, Stephen J.] US EPA, Cincinnati, OH 45268 USA; [Budelsky, Alison L.] Amgen Inc, Dept Inflammat Res, Seattle, WA USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; United States Environmental Protection Agency; Amgen	Hershey, GKK (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Asthma Res & Allergy Immunol, 3333 Burnet Ave,MLC 7037, Cincinnati, OH 45229 USA.	Gurjit.Hershey@cchmc.org	zhang, zh/GWV-4677-2022; Ryan, Patrick/HDO-1133-2022	Brandt, Eric/0000-0003-0617-4100; Biagini, Jocelyn/0000-0002-4378-6133	National Institutes of Health grant [2U19AI70235, R01ES011170, R01ES019890]; National Institute of Environmental Health Sciences grant [T32 ES010957]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T35HL113229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES019890, R01ES011170, T32ES010957, P30ES006096] Funding Source: NIH RePORTER	National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Environmental Health Sciences grant; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institutes of Health grants 2U19AI70235 (to G.K.K.H. and J.M.B.M.), R01ES011170 (to G.K.L.), R01ES019890 (to P.H.R.), and National Institute of Environmental Health Sciences grant T32 ES010957 (to Z.Z.).	Agache I, 2010, RESP MED, V104, P1131, DOI 10.1016/j.rmed.2010.02.018; Agrawal T, 2013, CLIN EXP ALLERGY, V43, P672, DOI 10.1111/cea.12102; Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Alyasin S, 2013, IRAN J IMMUNOL, V10, P177, DOI IJIv10i3A6; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Bell MC, 2013, J ALLER CL IMM-PRACT, V1, P110, DOI 10.1016/j.jaip.2013.01.005; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; Bloom Barbara, 2009, Vital Health Stat 10, P1; Brandt EB, 2015, J ALLERGY CLIN IMMUN, V136, P295, DOI 10.1016/j.jaci.2014.11.043; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Chesne J, 2014, AM J RESP CRIT CARE, V190, P1094, DOI 10.1164/rccm.201405-0859PP; Chien JW, 2013, CLIN EXP ALLERGY, V43, P1018, DOI 10.1111/cea.12119; Cho SH, 2006, ANN ALLERG ASTHMA IM, V97, P539, DOI 10.1016/S1081-1206(10)60947-7; Cosmi L, 2011, ALLERGY, V66, P989, DOI 10.1111/j.1398-9995.2011.02576.x; Dennehy KM, 2009, EUR J IMMUNOL, V39, P1379, DOI 10.1002/eji.200838543; Douwes J, 2005, INDOOR AIR, V15, P160, DOI 10.1111/j.1600-0668.2005.00333.x; Eduard W, 2009, CRIT REV TOXICOL, V39, P799, DOI 10.3109/10408440903307333; Fuller GLJ, 2007, J BIOL CHEM, V282, P12397, DOI 10.1074/jbc.M609558200; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Ho AW, 2010, SEMIN IMMUNOPATHOL, V32, P33, DOI 10.1007/s00281-009-0185-0; Hu Y, 2010, J IMMUNOL, V184, P4307, DOI 10.4049/jimmunol.0903614; Iossifova YY, 2009, ANN ALLERG ASTHMA IM, V102, P131, DOI 10.1016/S1081-1206(10)60243-8; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; Iwakura Y, 2011, IMMUNITY, V34, P149, DOI 10.1016/j.immuni.2011.02.012; Kataoka K, 2002, J BIOL CHEM, V277, P36825, DOI 10.1074/jbc.M206756200; Kovacic MB, 2012, PEDIAT ALLER IMM PUL, V25, P104, DOI 10.1089/ped.2011.0116; LeMasters GK, 2006, J PEDIATR-US, V149, P505, DOI 10.1016/j.jpeds.2006.06.035; McIntosh M, 2005, APPL MICROBIOL BIOT, V68, P163, DOI 10.1007/s00253-005-1959-5; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Meklin T, 2004, J ENVIRON MONITOR, V6, P615, DOI 10.1039/b400250d; Mintz-Cole RA, 2013, J ALLERGY CLIN IMMUN, V132, P159, DOI 10.1016/j.jaci.2013.01.003; Mintz-Cole RA, 2012, J IMMUNOL, V189, P3609, DOI 10.4049/jimmunol.1200589; Myers JMB, 2012, J PEDIATR-US, V160, P1050, DOI 10.1016/j.jpeds.2012.02.040; Nanzer AM, 2013, J ALLERGY CLIN IMMUN, V132, P297, DOI 10.1016/j.jaci.2013.03.037; National Asthma Education and Prevention Program (NAEPP) NHLBI, 2007, NATL HEART LUNG BLOO, P213; O'Driscoll B Ronan, 2005, BMC Pulm Med, V5, P4, DOI 10.1186/1471-2466-5-4; O'Sullivan MM, 2012, J ASTHMA, V49, P911, DOI 10.3109/02770903.2012.724131; Osorio F, 2008, EUR J IMMUNOL, V38, P3274, DOI 10.1002/eji.200838950; Pleis John R, 2009, Vital Health Stat 10, P1; Reponen T, 2012, J ALLERGY CLIN IMMUN, V130, P639, DOI 10.1016/j.jaci.2012.05.030; Reponen T, 2011, ANN ALLERG ASTHMA IM, V107, P120, DOI 10.1016/j.anai.2011.04.018; Ryan PH, 2007, ENVIRON HEALTH PERSP, V115, P278, DOI 10.1289/ehp.9480; Ryan PH, 2009, AM J RESP CRIT CARE, V180, P1068, DOI 10.1164/rccm.200808-1307OC; Sharpe RA, 2015, J ALLERGY CLIN IMMUN, V135, P110, DOI 10.1016/j.jaci.2014.07.002; Tassi I, 2009, EUR J IMMUNOL, V39, P1369, DOI 10.1002/eji.200839313; Taylor PR, 2007, NAT IMMUNOL, V8, P31, DOI 10.1038/ni1408; Vesper S, 2009, J URBAN HEALTH, V86, P850, DOI 10.1007/s11524-009-9384-1; Vesper SJ, 2007, J EXPO SCI ENV EPID, V17, P88, DOI 10.1038/sj.jes.7500528; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; WHO, 2009, WHO GUID IND AIR QUA; Zhan XB, 2012, APPL MICROBIOL BIOT, V93, P525, DOI 10.1007/s00253-011-3740-2	53	57	59	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					54	+		10.1016/j.jaci.2016.02.031	http://dx.doi.org/10.1016/j.jaci.2016.02.031			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27221135	Green Accepted, Bronze			2022-12-18	WOS:000393996800007
J	De Schryver, S; Halbrich, M; Clarke, A; La Vieille, S; Eisman, H; Alizadehfar, R; Joseph, L; Morris, J; Ben-Shoshan, M				De Schryver, Sarah; Halbrich, Michelle; Clarke, Ann; La Vieille, Sebastien; Eisman, Harley; Alizadehfar, Reza; Joseph, Lawrence; Morris, Judy; Ben-Shoshan, Moshe			Tryptase levels in children presenting with anaphylaxis: Temporal trends and associated factors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; children; diagnosis; milk allergy; tryptase	SERUM TRYPTASE; CLINICAL CHARACTERISTICS; PLASMA HISTAMINE; DIAGNOSTIC-VALUE; MANAGEMENT; ALLERGY; FOOD; SEVERITY; INFANTS; FUTURE	Background: The diagnosis of anaphylaxis currently relies on suggestive clinical history after exposure to a potential triggering factor because no reliable diagnostic marker is available to confirm the diagnosis. Objectives: We aimed to evaluate tryptase levels in children with anaphylaxis and to examine predictors of elevated tryptase level (defined as >= 11.4 mu g/L during reaction and for those with a baseline level, defined as a reaction level of at least 2 ng/mL + 1.2 x [postreaction tryptase level]). Methods: Children presenting with anaphylaxis to the Montreal Children's Hospital were recruited over a 4-year period. Symptoms, triggers, and management of anaphylaxis were documented. Levels during the reaction and approximately 9 months after the reaction were compared on the basis of paired means using the t distribution. Multivariate linear and logistic regressions were used to evaluate the association between tryptase levels and risk factors. Results: Over a 4-year period, 203 children had serum tryptase levels measured. Among these, 39 children (19.2%; 95% CI, 14.1%-25.4%) had elevated levels. Only severe reactions were associated with reaction levels of 11.4 mu g/L or more (odds ratio, 6.5; 95% CI, 2.2-19.0). Milk-induced anaphylaxis and severe reactions were more likely associated with increased tryptase levels (beta-adjusted, 4.0; 95% CI, 0.95-7.0, and 7.5; 95% CI, 4.8-10.3, respectively). Reaction levels exceeding the threshold level of 2 ng/mL + 1.2 x (postreaction tryptase level) detected most of the anaphylactic reactions, particularly if baseline levels were taken within 2 months of the reaction. Conclusions: Tryptase levels are particularly useful for the diagnosis of severe and/or milk-induced anaphylaxis. Assessing the difference between reaction and postreaction tryptase levels may improve diagnostic sensitivity.	[De Schryver, Sarah; Alizadehfar, Reza; Ben-Shoshan, Moshe] Montreal Childrens Hosp, Dept Pediat, Div Allergy & Clin Immunol, 1001 Blvd Decarie, Montreal, PQ H4A 3J1, Canada; [Halbrich, Michelle] Univ Manitoba, Dept Paediat, Div Paediat Allergy & Clin Immunol, Winnipeg, MB, Canada; [Clarke, Ann] Univ Calgary, Dept Med, Div Rheumatol, Calgary, AB, Canada; [La Vieille, Sebastien] Hlth Canada, Food Directorate, Ottawa, ON K1A 0L2, Canada; [Eisman, Harley] Montreal Childrens Hosp, Dept Pediat, Dept Emergency Med, 1001 Blvd Decarie, Montreal, PQ H4A 3J1, Canada; [Joseph, Lawrence] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; [Morris, Judy] Hop Sacre Coeur, Dept Emergency Med, Montreal, PQ H4J 1C5, Canada	McGill University; University of Manitoba; University of Calgary; Health Canada; McGill University; McGill University; Universite de Montreal	Ben-Shoshan, M (corresponding author), Montreal Childrens Hosp, 1001 Blvd Decarie, Montreal, PQ H4A 3J1, Canada.	moshebenshoshan@gmail.com	La Vieille, Sébastien/AAC-5087-2019	Ben-Shoshan, Moshe/0000-0001-9083-1518; La Vieille, Sebastien/0000-0001-5368-1266	Allergy, Genes, and Environment (AllerGen) Network of Centres of Excellence [12canFAST3]; Health Canada; Sanofi	Allergy, Genes, and Environment (AllerGen) Network of Centres of Excellence; Health Canada; Sanofi(Sanofi-Aventis)	This study was supported by the Allergy, Genes, and Environment (AllerGen) Network of Centres of Excellence (grant no. 12canFAST3), Health Canada, and by Sanofi.	Ben-Shoshan M, 2011, ALLERGY, V66, P1, DOI 10.1111/j.1398-9995.2010.02422.x; Ben-Shoshan M, 2013, J ALLERGY CLIN IMMUN, V132, P739, DOI 10.1016/j.jaci.2013.06.016; Berroa F, 2014, CLIN EXP ALLERGY, V44, P270, DOI 10.1111/cea.12237; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Brown SGA, 2013, J ALLERGY CLIN IMMUN, V132, P1141, DOI 10.1016/j.jaci.2013.06.015; Enrique E, 1999, ALLERGY, V54, P602, DOI 10.1034/j.1398-9995.1999.00882.x; Fellinger C, 2014, ALLERGOL IMMUNOPATH, V42, P544, DOI 10.1016/j.aller.2014.05.002; Hogan AD, 1997, METHODS, V13, P43, DOI 10.1006/meth.1997.0494; Kronborg H, 2015, SCAND J PUBLIC HEALT, V43, P138, DOI 10.1177/1403494814567171; Laroche D, 2014, ANESTHESIOLOGY, V121, P272, DOI 10.1097/ALN.0000000000000276; Lieberman P, 2013, J ALLER CL IMM-PRACT, V1, P539, DOI 10.1016/j.jaip.2013.03.008; OHTSUKA T, 1993, ANN ALLERGY, V71, P139; Sala-Cunill A, 2013, INT ARCH ALLERGY IMM, V160, P192, DOI 10.1159/000339749; Sampson HA, 2006, ANN EMERG MED, V47, P373, DOI 10.1016/j.annemergmed.2006.01.018; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Simons FER, 2015, J ALLERGY CLIN IMMUN, V135, P1125, DOI 10.1016/j.jaci.2014.09.014; Simons FER, 2013, INT ARCH ALLERGY IMM, V162, P193, DOI 10.1159/000354543; Sprung J, 2015, ANESTHESIOLOGY, V122, P713, DOI 10.1097/ALN.0000000000000584; Stone SF, 2009, J ALLERGY CLIN IMMUN, V124, P786, DOI 10.1016/j.jaci.2009.07.055; Vadas P, 2013, J ALLERGY CLIN IMMUN, V131, P144, DOI 10.1016/j.jaci.2012.08.016; Wongkaewpothong P, 2014, ALLERGY ASTHMA IMMUN, V6, P304, DOI 10.4168/aair.2014.6.4.304; Wood RA, 2014, J ALLERGY CLIN IMMUN, V133, P461, DOI 10.1016/j.jaci.2013.08.016	23	57	57	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1138	1142		10.1016/j.jaci.2015.09.001	http://dx.doi.org/10.1016/j.jaci.2015.09.001			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26478007	Bronze			2022-12-18	WOS:000373351200020
J	Geerdink, RJ; Pillay, J; Meyaard, L; Bont, L				Geerdink, Ruben J.; Pillay, Janesh; Meyaard, Linde; Bont, Louis			Neutrophils in respiratory syncytial virus infection: A target for asthma prevention	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Neutrophil; respiratory syncytial virus; asthma; respiratory syncytial virus bronchiolitis; lower respiratory tract infection; neutrophil extracellular traps; immunopathology; asthma prevention; immune regulation; treatment	LUNG INJURY; RSV BRONCHIOLITIS; CHILDHOOD ASTHMA; INFLUENZA-VIRUS; EARLY-LIFE; MAST-CELL; BACTERIAL-COLONIZATION; PATHOGENIC BACTERIA; AIRWAY INFLAMMATION; PULMONARY-DISEASE	Lower respiratory tract infections by respiratory syncytial virus (RSV) are the foremost cause of infant hospitalization and are implicated in lasting pulmonary impairment and the development of asthma. Neutrophils infiltrate the airways of pediatric patients with RSV-induced bronchiolitis in vast numbers: approximately 80% of infiltrated cells are neutrophils. However, why neutrophils are recruited to the site of viral respiratory tract infection is not clear. In this review we discuss the beneficial and pathologic contributions of neutrophils to the immune response against RSV infection. Neutrophils can limit viral replication and spread, as well as stimulate an effective antiviral adaptive immune response. However, low specificity of neutrophil antimicrobial armaments allows for collateral tissue damage. Neutrophil-induced injury to the airways during the delicate period of infant lung development has lasting adverse consequences for pulmonary architecture and might promote the onset of asthma in susceptible subjects. We suggest that pharmacologic modulation of neutrophils should be explored as a viable future therapy for severe RSV-induced bronchiolitis and thereby prevent the inception of subsequent asthma. The antiviral functions of neutrophils suggest that targeting of neutrophils in patients with RSV-induced bronchiolitis is best performed under the umbrella of antiviral treatment.	[Geerdink, Ruben J.; Meyaard, Linde; Bont, Louis] Univ Med Ctr Utrecht, Dept Immunol, Lab Translat Immunol, NL-3508 AB Utrecht, Netherlands; [Pillay, Janesh] Univ Med Ctr Utrecht, Dept Resp Med, Lab Translat Immunol, NL-3508 AB Utrecht, Netherlands; [Pillay, Janesh] Univ Med Ctr Utrecht, Dept Anaesthesiol, NL-3508 AB Utrecht, Netherlands; [Bont, Louis] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Paediat, NL-3508 AB Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis	Bont, L (corresponding author), Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Rm KE 04-133-1,POB 85090, NL-3508 AB Utrecht, Netherlands.	l.bont@umcutrecht.nl		Pillay, Janesh/0000-0001-8037-6638; Meyaard, Linde/0000-0003-0707-4793; Geerdink, Ruben/0000-0003-2976-4015				Amulic B, 2012, ANNU REV IMMUNOL, V30, P459, DOI 10.1146/annurev-immunol-020711-074942; Bacharier LB, 2012, J ALLERGY CLIN IMMUN, V130, P91, DOI 10.1016/j.jaci.2012.02.010; Backman K, 2014, ACTA PAEDIATR, V103, P850, DOI 10.1111/apa.12662; Bardoel BW, 2014, CELL HOST MICROBE, V15, P526, DOI 10.1016/j.chom.2014.04.011; Barletta KE, 2012, ARTERIOSCL THROM VAS, V32, P856, DOI 10.1161/ATVBAHA.111.226845; Bataki EL, 2005, CLIN EXP IMMUNOL, V140, P470, DOI 10.1111/j.1365-2249.2005.02780.x; Beauvillain C, 2007, BLOOD, V110, P2965, DOI 10.1182/blood-2006-12-063826; Beeh KM, 2006, CLIN EXP ALLERGY, V36, P142, DOI 10.1111/j.1365-2222.2006.02418.x; Beigelman A, 2015, J ALLERGY CLIN IMMUN, V135, P1171, DOI 10.1016/j.jaci.2014.10.001; Beigelman A, 2014, CURR OPIN ALLERGY CL, V14, P137, DOI 10.1097/ACI.0000000000000036; Beigelman A, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-90; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Blanken MO, 2013, NEW ENGL J MED, V369, P782, DOI 10.1056/NEJMc1307429; Boelen A, 2002, J MED VIROL, V66, P552, DOI 10.1002/jmv.2180; Bonnelykke K, 2015, J ALLERGY CLIN IMMUN, V136, P81, DOI 10.1016/j.jaci.2015.02.024; Bottazzi B, 2010, ANNU REV IMMUNOL, V28, P157, DOI 10.1146/annurev-immunol-030409-101305; Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039; Bradley LM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002641; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021; Cavarra E, 1996, LAB INVEST, V75, P273; Charmoy M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000755; Costantini C, 2011, BLOOD, V117, P1677, DOI 10.1182/blood-2010-06-287243; Currie SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073659; Demirkhanyan LH, 2012, J BIOL CHEM, V287, P28821, DOI 10.1074/jbc.M112.375949; DeVincenzo JP, 2014, NEW ENGL J MED, V371, P711, DOI 10.1056/NEJMoa1401184; Dienz O, 2012, MUCOSAL IMMUNOL, V5, P258, DOI 10.1038/mi.2012.2; Drescher B, 2013, VIRUS RES, V171, P1, DOI 10.1016/j.virusres.2012.11.002; Duffy D, 2012, IMMUNITY, V37, P917, DOI 10.1016/j.immuni.2012.07.015; EVERARD ML, 1994, ARCH DIS CHILD, V71, P428, DOI 10.1136/adc.71.5.428; EVERARD ML, 1992, EUR J PEDIATR, V151, P638, DOI 10.1007/BF01957564; Feldman AS, 2015, AM J RESP CRIT CARE, V191, P34, DOI 10.1164/rccm.201405-0901PP; Filardy AA, 2010, J IMMUNOL, V185, P2044, DOI 10.4049/jimmunol.1000017; Folsgaard NV, 2013, AM J RESP CRIT CARE, V187, P589, DOI 10.1164/rccm.201207-1297OC; Friedlander AL, 2010, CHEST, V138, P1202, DOI 10.1378/chest.10-0196; Funchal GA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124082; Gabriel C, 2013, DNA CELL BIOL, V32, P665, DOI 10.1089/dna.2013.2211; Gern JE, 2005, J ALLERGY CLIN IMMUN, V115, P668, DOI 10.1016/j.jaci.2005.01.057; Goetghebuer T, 2004, CLIN EXP ALLERGY, V34, P801, DOI 10.1111/j.1365-2222.2004.1947.x; Guyot N, 2014, AM J PATHOL, V184, P2197, DOI 10.1016/j.ajpath.2014.04.015; Han B, 2012, LAB INVEST, V92, P1285, DOI 10.1038/labinvest.2012.92; Hashimoto Y, 2007, J IMMUNOL, V178, P2448, DOI 10.4049/jimmunol.178.4.2448; Hay Douglas W. P., 2001, Current Opinion in Pharmacology, V1, P242, DOI 10.1016/S1471-4892(01)00043-1; Hemmers S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022043; Henderson J, 2005, PEDIAT ALLERG IMM-UK, V16, P386, DOI 10.1111/j.1399-3038.2005.00298.x; Henriksen PA, 2014, CURR OPIN HEMATOL, V21, P23, DOI 10.1097/MOH.0000000000000001; Hervas D, 2012, EUR J CLIN MICROBIOL, V31, P1975, DOI 10.1007/s10096-011-1529-y; Hosakote YM, 2011, AM J RESP CRIT CARE, V183, P1550, DOI 10.1164/rccm.201010-1755OC; Hosakote YM, 2009, AM J RESP CELL MOL, V41, P348, DOI 10.1165/rcmb.2008-0330OC; Hufford MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046581; Hufford MM, 2011, J EXP MED, V208, P167, DOI 10.1084/jem.20101850; Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023; Jaeger BN, 2012, J EXP MED, V209, P565, DOI 10.1084/jem.20111908; James KM, 2013, J ALLERGY CLIN IMMUN, V132, P227, DOI 10.1016/j.jaci.2013.01.009; Janssen R, 2007, J INFECT DIS, V196, P826, DOI 10.1086/520886; Jaovisidha P, 1999, J IMMUNOL, V163, P2816; Jenne CN, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004546; Jenne CN, 2013, CELL HOST MICROBE, V13, P169, DOI 10.1016/j.chom.2013.01.005; Kearley J, 2011, AM J RESP CRIT CARE, V183, P865, DOI 10.1164/rccm.200909-1462OC; Kim JS, 2013, NAT IMMUNOL, V14, P611, DOI 10.1038/ni.2607; KLEBANOFF SJ, 1992, J CLIN INVEST, V89, P2014, DOI 10.1172/JCI115810; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Le Cras TD, 2004, AM J PHYSIOL-LUNG C, V287, pL718, DOI 10.1152/ajplung.00084.2004; Louis R, 2006, CLIN EXP ALLERGY, V36, P563, DOI 10.1111/j.1365-2222.2006.02493.x; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Lukens MV, 2010, J VIROL, V84, P2374, DOI 10.1128/JVI.01807-09; Mansbach JM, 2012, J ALLERGY CLIN IMMUN, V130, P1007, DOI 10.1016/j.jaci.2012.07.044; Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024; Marguet C, 2008, PEDIAT ALLERG IMM-UK, V19, P157, DOI 10.1111/j.1399-3038.2007.00600.x; McNamara PS, 2004, LANCET, V363, P1031, DOI 10.1016/S0140-6736(04)15838-8; McNamara PS, 2003, ARCH DIS CHILD, V88, P922, DOI 10.1136/adc.88.10.922; Mejias A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001549; Mejias A, 2008, BIOL-TARGETS THER, V2, P433; Miller BE, 2014, EUR J DRUG METAB PH, V39, P173, DOI 10.1007/s13318-014-0179-8; Mocsai A, 2013, J EXP MED, V210, P1283, DOI 10.1084/jem.20122220; Mukherjee S, 2011, AM J PATHOL, V179, P248, DOI 10.1016/j.ajpath.2011.03.003; Nagata DED, 2014, AM J PATHOL, V184, P1807, DOI 10.1016/j.ajpath.2014.02.004; Narasaraju T, 2011, AM J PATHOL, V179, P199, DOI 10.1016/j.ajpath.2011.03.013; Newcomb DC, 2013, AM J RESP CELL MOL, V48, P711, DOI 10.1165/rcmb.2013-0017OC; Newcomb DC, 2013, THORAX, V68, P717, DOI 10.1136/thoraxjnl-2012-202404; Nguyen-Van-Tam JS, 2015, CLIN MICROBIOL INFEC, V21, P222, DOI 10.1016/j.cmi.2014.11.020; Nicholas C, 2011, J ALLERGY CLIN IMMUN, V127, pAB136, DOI 10.1016/j.jaci.2010.12.541; Odobasic D, 2013, BLOOD, V121, P4195, DOI 10.1182/blood-2012-09-456483; Pillay J, 2012, J CLIN INVEST, V122, P327, DOI 10.1172/JCI57990; Puga I, 2012, NAT IMMUNOL, V13, P170, DOI 10.1038/ni.2194; Reading PC, 2008, J IMMUNOL, V180, P3391, DOI 10.4049/jimmunol.180.5.3391; Regnier SA, 2013, PEDIATR INFECT DIS J, V32, P820, DOI 10.1097/INF.0b013e31829061e8; Saffarzadeh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032366; Saitoh T, 2012, CELL HOST MICROBE, V12, P109, DOI 10.1016/j.chom.2012.05.015; Scapini P, 2014, BLOOD, V124, P710, DOI 10.1182/blood-2014-03-453217; Schnoeller C, 2014, AM J RESP CRIT CARE, V189, P194, DOI [10.1164/rccm.201307-1227OC, 10.1164/rccm.201307-227OC]; Sehra S, 2015, J ALLERGY CLIN IMMUN, V136, P433, DOI 10.1016/j.jaci.2015.01.021; Sheeran P, 1999, PEDIATR INFECT DIS J, V18, P115, DOI 10.1097/00006454-199902000-00007; Shirey KA, 2010, MUCOSAL IMMUNOL, V3, P291, DOI 10.1038/mi.2010.6; SIGURS N, 1995, PEDIATRICS, V95, P500; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Simpson JL, 2008, AM J RESP CRIT CARE, V177, P148, DOI 10.1164/rccm.200707-1134OC; Smyth RL, 2002, PEDIATR PULM, V33, P339, DOI 10.1002/ppul.10080; Smyth RL, 2006, LANCET, V368, P312, DOI 10.1016/S0140-6736(06)69077-6; Sporri R, 2008, J IMMUNOL, V181, P7121, DOI 10.4049/jimmunol.181.10.7121; Steevels TAM, 2013, EUR J IMMUNOL, V43, P1297, DOI 10.1002/eji.201242916; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stensballe LG, 2009, J ALLERGY CLIN IMMUN, V123, P131, DOI 10.1016/j.jaci.2008.10.042; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Stokes KL, 2013, J VIROL, V87, P10070, DOI 10.1128/JVI.01347-13; Stoppelenburg AJ, 2014, AM J PATHOL, V184, P1274, DOI 10.1016/j.ajpath.2014.01.033; Stoppelenburg AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078461; Tanaka S, 2009, J IMMUNOL, V183, P7523, DOI 10.4049/jimmunol.0803828; Tate MD, 2012, IMMUNOL CELL BIOL, V90, P197, DOI 10.1038/icb.2011.26; Tate MD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017618; Tate MD, 2009, J IMMUNOL, V183, P7441, DOI 10.4049/jimmunol.0902497; Tecle T, 2007, J IMMUNOL, V178, P8046, DOI 10.4049/jimmunol.178.12.8046; Thomas AO, 2014, PEDIAT ALLERG IMM-UK, V25, P122, DOI 10.1111/pai.12147; Van Avondt K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078459; van Gisbergen KPJM, 2005, FEBS LETT, V579, P6159, DOI 10.1016/j.febslet.2005.09.089; van Gisbergen KPJM, 2005, J EXP MED, V201, P1281, DOI 10.1084/jem.20041276; VANSTRIJP JAG, 1989, ARCH VIROL, V104, P287, DOI 10.1007/BF01315550; Voraphani N, 2014, AM J RESP CRIT CARE, V190, P392, DOI 10.1164/rccm.201311-2095OC; Watanabe Y, 2005, BIOCHEM BIOPH RES CO, V337, P881, DOI 10.1016/j.bbrc.2005.09.133; Welliver TP, 2007, J INFECT DIS, V195, P1126, DOI 10.1086/512615; Wilson SS, 2013, J MOL BIOL, V425, P4965, DOI 10.1016/j.jmb.2013.09.038; Wu PS, 2011, EXPERT REV ANTI-INFE, V9, P731, DOI [10.1586/eri.11.92, 10.1586/ERI.11.92]; Yang CW, 2013, J EXP MED, V210, P375, DOI 10.1084/jem.20122183; Yasui K, 2005, PEDIATR INT, V47, P190, DOI 10.1111/j.1442-200x.2005.02039.x; Zomer-Kooijker K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087162	128	57	59	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					838	847		10.1016/j.jaci.2015.06.034	http://dx.doi.org/10.1016/j.jaci.2015.06.034			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	26277597	Green Published, Bronze			2022-12-18	WOS:000362976300002
J	Kowalski, ML; Woessner, K; Sanak, M				Kowalski, Marek L.; Woessner, Katharine; Sanak, Marek			Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug-related urticaria and angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin; angioedema; nonsteroidal anti-inflammatory drugs; urticaria	PHENOTYPE-BASED CLASSIFICATION; CHRONIC IDIOPATHIC URTICARIA; HYPERSENSITIVITY REACTIONS; NSAIDS HYPERSENSITIVITY; ASPIRIN DESENSITIZATION; A-444C POLYMORPHISM; ALLERGIC REACTIONS; CLINICAL-PATTERNS; PROVOCATION TESTS; SKIN-TEST	Nonsteroidal anti-inflammatory drug (NSAID)-induced urticarial and angioedema reactions are among the most commonly encountered drug hypersensitivity reactions in clinical practice. Three major clinical phenotypes of NSAID-induced acute skin reactions manifesting with angioedema, urticaria, or both have been distinguished: NSAID-exacerbated cutaneous disease, nonsteroidal anti-inflammatory drug-induced urticaria/angioedema (NIUA), and single NSAID-induced urticaria and angioedema. In some patients clinical history alone might be sufficient to establish the diagnosis of a specific type of NSAID hypersensitivity, whereas in other cases oral provocation challenges are necessary to confirm the diagnosis. Moreover, classification of the type of cutaneous reaction is critical for proper management. For example, in patients with single NSAID-induced reactions, chemically nonrelated COX-1 inhibitors can be safely used. However, there is cross-reactivity between the NSAIDs in patients with NSAID-exacerbated cutaneous disease and NIUA, and thus only use of selective COX-2 inhibitors can replace the culprit drug if the chronic treatment is necessary, although aspirin desensitization will allow for chronic treatment with NSAIDs in some patients with NIUA. In this review we present a practical clinical approach to the patient with NSAID-induced urticaria and angioedema.	[Kowalski, Marek L.] Med Univ Lodz, Dept Immunol Rheumatol & Allergy, PL-92213 Lodz, Poland; [Woessner, Katharine] Scripps Clin Med Grp, Allergy & Immunol, La Jolla, CA USA; [Sanak, Marek] Jagiellonian Univ, Coll Med, Dept Med, Krakow, Poland	Medical University Lodz; Jagiellonian University; Collegium Medicum Jagiellonian University	Kowalski, ML (corresponding author), Med Univ Lodz, Dept Clin Immunol & Allergy Rheumatol & Allergy, 251 Pomorska Str, PL-92213 Lodz, Poland.	Marek.Kowalski@csk.umed.lodz.pl	Sanak, Marek/AAV-1628-2021	Sanak, Marek/0000-0001-7635-8103	Merck; TEVA; Shire; Meda; AstraZeneca	Merck(Merck & Company); TEVA(Teva Pharmaceutical Industries); Shire; Meda; AstraZeneca(AstraZeneca)	K. Woessner has consultant arrangements with and has received payments for lectures from Merck, TEVA, Shire, Meda, and AstraZeneca. The rest of the authors declare that they have no relevant conflicts of interest.	Asero R, 2007, CLIN EXP DERMATOL, V32, P661, DOI 10.1111/j.1365-2230.2007.02464.x; Asero R, 2000, ANN ALLERG ASTHMA IM, V85, P156, DOI 10.1016/S1081-1206(10)62457-X; Asero R, 2003, J ALLERGY CLIN IMMUN, V111, P1095, DOI 10.1067/mai.2003.1444; Asero R, 2007, INT ARCH ALLERGY IMM, V144, P226, DOI 10.1159/000103996; Asero R, 2013, INT ARCH ALLERGY IMM, V160, P126, DOI 10.1159/000342424; Aun MV, 2014, J ALLER CL IMM-PRACT, V2, P414, DOI [10.1016/j.jaip.2014.03.014, 10.1016/j.jaip.2014.08.015]; Ayuso P, 2013, CLIN EXP ALLERGY, V43, P1097, DOI 10.1111/cea.12140; Bae JS, 2007, J ALLERGY CLIN IMMUN, V119, P449, DOI 10.1016/j.jaci.2006.10.006; Bernstein JA, 2014, J ALLERGY CLIN IMMUN, V133, P1270, DOI 10.1016/j.jaci.2014.02.036; Blanca-Lopez N, 2013, CLIN EXP ALLERGY, V43, P85, DOI 10.1111/cea.12013; Blanca-Lopez N, 2014, CURR OPIN ALLERGY CL, V14, P271, DOI 10.1097/ACI.0000000000000077; Borges MS, 2001, ANN ALLERG ASTHMA IM, V87, P201, DOI 10.1016/S1081-1206(10)62226-0; Brockow K, 2013, ALLERGY, V68, P702, DOI 10.1111/all.12142; Caimmi S, 2012, INT ARCH ALLERGY IMM, V159, P306, DOI 10.1159/000337660; Chaudhry T, 2012, INTERN MED J, V42, P665, DOI 10.1111/j.1445-5994.2011.02601.x; CZERNIAWSKAMYSIK G, 1981, ALLERGY, V36, P381, DOI 10.1111/j.1398-9995.1981.tb01842.x; Dona I, 2014, ALLERGY, V69, P438, DOI 10.1111/all.12335; Dona I, 2012, J INVEST ALLERG CLIN, V22, P363; Dona I, 2011, CLIN EXP ALLERGY, V41, P86, DOI 10.1111/j.1365-2222.2010.03651.x; Erbagci Z, 2004, J DERMATOL, V31, P376, DOI 10.1111/j.1346-8138.2004.tb00688.x; Canto MG, 2009, CURR OPIN ALLERGY CL, V9, P293, DOI 10.1097/ACI.0b013e32832db943; Gomez E, 2009, CLIN EXP ALLERGY, V39, P1217, DOI 10.1111/j.1365-2222.2009.03237.x; Hammond TG, 2014, J PHARMACOL EXP THER, V350, P387, DOI 10.1124/jpet.114.215079; Hedman J, 1999, INT J EPIDEMIOL, V28, P717, DOI 10.1093/ije/28.4.717; Hsieh CW, 2014, INT J MOL SCI, V15, P12591, DOI 10.3390/ijms150712591; KATZ Y, 1993, ALLERGY, V48, P366, DOI 10.1111/j.1398-9995.1993.tb02407.x; Kidon MI, 2005, PEDIATRICS, V116, pE675, DOI 10.1542/peds.2005-0969; Kowalski ML, 2014, ALLERGY, V69, P815; Kowalski ML, 2013, ALLERGY, V68, P1219, DOI 10.1111/all.12260; Kowalski ML, 2011, ALLERGY, V66, P818, DOI 10.1111/j.1398-9995.2011.02557.x; Kowalski Marek L, 2006, Treat Respir Med, V5, P399, DOI 10.2165/00151829-200605060-00005; Kowalski ML, 2015, ALLERGY ASTHMA IMMUN, V7, P312, DOI 10.4168/aair.2015.7.4.312; Kowalski ML, 2013, IMMUNOL ALLERGY CLIN, V33, P135, DOI 10.1016/j.iac.2012.10.008; Kowalski ML, 1999, ALLERGY ASTHMA PROC, V20, P347, DOI 10.2500/108854199778251799; Kowalski ML, 1998, CLIN EXP ALLERGY, V28, P1153; Laidlaw TM, 2012, BLOOD, V119, P3790, DOI 10.1182/blood-2011-10-384826; Leeyaphan C, 2010, J EUR ACAD DERMATOL, V24, P685, DOI 10.1111/j.1468-3083.2009.03489.x; Mastalerz L, 2005, CURR ALLERGY ASTHM R, V5, P277, DOI 10.1007/s11882-005-0067-z; Mastalerz L, 2004, J ALLERGY CLIN IMMUN, V113, P771, DOI 10.1016/j.jaci.2003.12.323; Matsuo H, 2013, ALLERGOL INT, V62, P503, DOI 10.2332/allergolint.13-OA-0536; McMullan KL, 2013, CLIN CARDIOL, V36, P25, DOI 10.1002/clc.22054; Nizankowska-Mogilnicka E, 2007, ALLERGY, V62, P1111, DOI 10.1111/j.1398-9995.2007.01409.x; Osaki F, 2014, ANAL BIOCHEM, V449, P59, DOI 10.1016/j.ab.2013.12.016; Palikhe S, 2014, ANN ALLERG ASTHMA IM, V113, P276, DOI 10.1016/j.anai.2014.06.011; Park H-S, 2013, MIDDLETONS ALLERGY P, P1296; Patrignani P., 2014, BIOCHIM BIOPHYS ACTA, V1851, P422; Perkins JR, 2015, TRENDS PHARMACOL SCI, V36, P172, DOI 10.1016/j.tips.2014.12.003; Posthumus J, 2012, J ALLERGY CLIN IMMUN, V130, P814, DOI 10.1016/j.jaci.2012.04.037; Quiralte J, 2007, J INVEST ALLERG CLIN, V17, P182; Quiralte J, 2014, ALLERGY, V69, P814, DOI 10.1111/all.12377; Quiralte J, 1996, J ALLERGY CLIN IMMUN, V98, P678, DOI 10.1016/S0091-6749(96)70102-1; Quiralte J, 1997, ANN ALLERG ASTHMA IM, V78, P293, DOI 10.1016/S1081-1206(10)63184-5; Rajan JP, 2014, J ALLER CL IMM-PRACT, V2, P168, DOI 10.1016/j.jaip.2013.10.002; Sanchez-Borges M, 2015, J EUR ACAD DERMATOL, V29, P698, DOI 10.1111/jdv.12658; Sanchez-Borges M, 2010, J INVEST ALLERG CLIN, V20, P139; Sanchez-Borges M, 2009, J INVEST ALLERG CLIN, V19, P375; Sanchez-Borges Mario, 2002, Am J Clin Dermatol, V3, P599; SanchezBorges M, 1997, CUTIS, V59, P311; Schubert B, 2005, EUR J DERMATOL, V15, P164; Slowik SM, 2009, ANN ALLERG ASTHMA IM, V102, P171, DOI 10.1016/S1081-1206(10)60252-9; Stevenson DD, 2001, ANN ALLERG ASTHMA IM, V87, P177, DOI 10.1016/S1081-1206(10)62221-1; Stevenson DD, 2014, ALLERGY ASTHMA PROC, V35, P92, DOI 10.2500/aap.2014.35.1015; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Torres MJ, 2009, J INVEST ALLERG CLIN, V19, P80; Torres MJ, 2014, IMMUNOL ALLERGY CLIN, V34, P507, DOI 10.1016/j.iac.2014.04.001; Torres R, 2015, MOL IMMUNOL, V63, P61, DOI 10.1016/j.molimm.2014.03.007; Torres-Galvan MJ, 2001, ANN ALLERG ASTHMA IM, V87, P506, DOI 10.1016/S1081-1206(10)62265-X; Vidal C, 2013, J ALLERGY CLIN IMMUN, V132, P989, DOI 10.1016/j.jaci.2013.04.045; Viola M, 2011, CLIN EXP ALLERGY, V41, P96, DOI 10.1111/j.1365-2222.2010.03648.x; White AA, 2013, ALLERGY ASTHMA PROC, V34, P138, DOI 10.2500/aap.2013.34.3644; Woessner KM, 2013, IMMUNOL ALLERGY CLIN, V33, P237, DOI 10.1016/j.iac.2012.12.002; Zembowicz A, 2004, J CUTAN PATHOL, V31, P323, DOI 10.1111/j.0303-6987.2004.0195.x; Zembowicz A, 2003, ARCH DERMATOL, V139, P1577, DOI 10.1001/archderm.139.12.1577	74	57	58	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					245	251		10.1016/j.jaci.2015.06.021	http://dx.doi.org/10.1016/j.jaci.2015.06.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	26254051	Green Published			2022-12-18	WOS:000359004900003
J	Mathieu, AL; Verronese, E; Rice, GI; Fouyssac, F; Bertrand, Y; Picard, C; Chansel, M; Walter, JE; Notarangelo, LD; Butte, MJ; Nadeau, KC; Csomos, K; Chen, DJ; Chen, K; Delgado, A; Riga, C; Bardin, C; Schuetz, C; Moshous, D; Reumaux, H; Plenat, F; Phan, A; Zabot, MT; Balme, B; Viel, S; Bienvenu, J; Cochat, P; van der Burg, M; Caux, C; Kemp, EH; Rouvet, I; Malcus, C; Meritet, JF; Lim, A; Crow, YJ; Fabien, N; Menetrier-Caux, C; De Villartay, JP; Walzer, T; Belot, A				Mathieu, Anne-Laure; Verronese, Estelle; Rice, Gillian I.; Fouyssac, Fanny; Bertrand, Yves; Picard, Capucine; Chansel, Marie; Walter, Jolan E.; Notarangelo, Luigi D.; Butte, Manish J.; Nadeau, Kari Christine; Csomos, Krisztian; Chen, David J.; Chen, Karin; Delgado, Ana; Riga, Chantal; Bardin, Christine; Schuetz, Catharina; Moshous, Despina; Reumaux, Heloise; Plenat, Francois; Phan, Alice; Zabot, Marie-Therese; Balme, Brigitte; Viel, Sebastien; Bienvenu, Jacques; Cochat, Pierre; van der Burg, Mirjam; Caux, Christophe; Kemp, E. Helen; Rouvet, Isabelle; Malcus, Christophe; Meritet, Jean-Francois; Lim, Annick; Crow, Yanick J.; Fabien, Nicole; Menetrier-Caux, Christine; De Villartay, Jean-Pierre; Walzer, Thierry; Belot, Alexandre			PRKDC mutations associated with immunodeficiency, granuloma, and autoimmune regulator-dependent autoimmunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autoimmune regulator; tolerance; DNA-dependent protein kinase catalytic subunit; PRKDC; autoimmunity; VDJ recombination; severe combined immunodeficiency; recombination-activating gene	HYPEREOSINOPHILIA OMENNS SYNDROME; CALCIUM-SENSING RECEPTOR; T-CELLS; DISEASE; AUTOANTIBODIES; DEFICIENCY; TOLERANCE; RESPONSES; DEFECTS; THYMUS	Background: PRKDC encodes for DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a kinase that forms part of a complex (DNA-dependent protein kinase [DNA-PK]) crucial for DNA double-strand break repair and V(D)J recombination. In mice DNA-PK also interacts with the transcription factor autoimmune regulator (AIRE) to promote central T-cell tolerance. Objective: We sought to understand the causes of an inflammatory disease with granuloma and autoimmunity associated with decreasing T- and B-cell counts over time that had been diagnosed in 2 unrelated patients. Methods: Genetic, molecular, and functional analyses were performed to characterize an inflammatory disease evocative of a combined immunodeficiency. Results: We identified PRKDC mutations in both patients. These patients exhibited a defect in DNA double-strand break repair and V(D)J recombination. Whole-blood mRNA analysis revealed a strong interferon signature. On activation, memory T cells displayed a skewed cytokine response typical of T(H)2 and T(H)1 but not T(H)17. Moreover, mutated DNA-PKcs did not promote AIRE-dependent transcription of peripheral tissue antigens in vitro. The latter defect correlated in vivo with production of anti-calcium-sensing receptor autoantibodies, which are typically found in AIRE-deficient patients. In addition, 9 months after bone marrow transplantation, patient 1 had Hashimoto thyroiditis, suggesting that organ-specific autoimmunity might be linked to nonhematopoietic cells, such as AIRE-expressing thymic epithelial cells. Conclusion: Deficiency of DNA-PKcs, a key AIRE partner, can present as an inflammatory disease with organ-specific autoimmunity, suggesting a role for DNA-PKcs in regulating autoimmune responses and maintaining AIRE-dependent tolerance in human subjects.	[Mathieu, Anne-Laure; Viel, Sebastien; Bienvenu, Jacques; Walzer, Thierry; Belot, Alexandre] Univ Lyon, Int Ctr Infectiol Res, CIRI, Lyon, France; [Mathieu, Anne-Laure; Viel, Sebastien; Bienvenu, Jacques; Walzer, Thierry; Belot, Alexandre] INSERM, U1111, F-69008 Lyon, France; [Mathieu, Anne-Laure; Viel, Sebastien; Bienvenu, Jacques; Walzer, Thierry; Belot, Alexandre] Ecole Normale Super Lyon, F-69364 Lyon, France; [Mathieu, Anne-Laure; Rice, Gillian I.; Viel, Sebastien; Bienvenu, Jacques; Walzer, Thierry; Belot, Alexandre] CNRS, UMR5308, Lyon, France; [Verronese, Estelle; Delgado, Ana; Riga, Chantal; Bardin, Christine; Caux, Christophe; Menetrier-Caux, Christine] Univ Lyon, Plateforme Innovat Immunomonitoring & Immunothera, Ctr Rech Cancerol Lyon, INSERM,U1052,Ctr Leon Berard, Lyon, France; [Crow, Yanick J.] Manchester Acad Hlth Ctr, Fac Med & Human Sci, Inst Human Dev, Manchester Ctr Genom Med, Manchester, Lancs, England; [Fouyssac, Fanny] CHU NANCY, Children Hosp, Dept Oncol, Vandoeuvre Les Nancy, France; [Bertrand, Yves] Univ Lyon 1, Hosp Civils Lyon, Inst Hematol & Oncol Pediat, F-69365 Lyon, France; [Picard, Capucine] Paris Descartes Univ, Necker Hosp,AP HP, Necker Branch,INSERM,U1163,Sorbonne Paris Cite,Im, Study Ctr Primary Immunodeficiencies,Lab Human Ge, Paris, France; [Moshous, Despina; De Villartay, Jean-Pierre] Univ Paris 05, Lab Dynam Genome & Syst Immunitaire, Sorbonne Paris Cite, INSERM,UMR 1163,Imagine Inst, Paris, France; [Walter, Jolan E.; Csomos, Krisztian] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pediat Allergy & Immunol, Boston, MA USA; [Walter, Jolan E.; Csomos, Krisztian] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis, Boston, MA USA; [Chansel, Marie; Notarangelo, Luigi D.] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Chansel, Marie; Notarangelo, Luigi D.] Harvard Univ, Sch Med, Boston, MA USA; [Butte, Manish J.; Nadeau, Kari Christine] Stanford Univ, Dept Pediat, Div Immunol Allergy & Rheumatol, Stanford, CA 94305 USA; [Chen, David J.] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Div Mol Radiat Biol, Dallas, TX 75390 USA; [Chen, Karin] Univ Utah, Sch Med, Dept Pediat, Div Allergy Immunol & Rheumatol, Salt Lake City, UT USA; [Schuetz, Catharina] Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Ulm, Germany; [Reumaux, Heloise] Jeanne de Flandre Hosp, Pediat Rheumatol & Emergency Unit, Lille, France; [Plenat, Francois] CHU Nancy, Hematooncol Pediat, Dept Pathol, Vandoeuvre Les Nancy, France; [Balme, Brigitte] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Dept Pathol, Lyon, France; [Zabot, Marie-Therese; Rouvet, Isabelle] Hosp Civils Lyon, Biotechnol Dept, Lyon, France; [Viel, Sebastien; Bienvenu, Jacques; Fabien, Nicole] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Dept Immunobiol, Lyon, France; [Phan, Alice; Cochat, Pierre; Belot, Alexandre] Hosp Civils Lyon, Pediat Rheumatol Nephrol & Dermatol Dept, Lyon, France; [Phan, Alice; Cochat, Pierre; Belot, Alexandre] Hosp Civils Lyon, EPICIME, Lyon, France; [Phan, Alice; Cochat, Pierre; Belot, Alexandre] Univ Lyon 1, F-69365 Lyon, France; [van der Burg, Mirjam] Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Kemp, E. Helen] Univ Sheffield, Dept Human Metab, Sheffield S10 2TN, S Yorkshire, England; [Malcus, Christophe] Hosp Civils Lyon, Hop Edouard Herriot, Cell Immunol Dept, Lyon, France; [Meritet, Jean-Francois] Hop Cochin, AP HP, Virol Unit, F-75674 Paris, France; [Lim, Annick] Inst Pasteur, Dept Immunol, Immunoscope Grp, F-75724 Paris, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; University of Manchester; CHU de Nancy; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Stanford University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Utah System of Higher Education; University of Utah; Ulm University; Universite de Lille - ISITE; CHU Lille; CHU de Nancy; CHU Lyon; CHU Lyon; CHU Lyon; CHU Lyon; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Erasmus University Rotterdam; Erasmus MC; University of Sheffield; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Belot, A (corresponding author), Hosp Civils Lyon, Hop Femme Mere Enfant, Serv Nephrol, Rhumatol,Dermatol Pediat, 57 Bd Pinel, F-69677 Bron, France.	alexandre.belot@chu.lyon.fr	Crow, Yanick J/N-6120-2014; Viel, Sebastien/A-7258-2016; Butte, Manish/AAM-8604-2020; Belot, Alexandre/C-7378-2013; Moshous, Despina/B-7507-2017; Notarangelo, Luigi D/F-9718-2016; Walzer, Thierry/L-9418-2014; Caux, Christophe/G-2851-2013; Rice, Gillian I/G-3128-2015; Butte, Manish/T-8860-2019; PHAN, Alice/E-2371-2017; de Villartay, jean pierre/H-9353-2017; Ménétrier-Caux, christine/Y-2703-2019; Kemp, Elizabeth Helen/D-1665-2011	Crow, Yanick J/0000-0001-7211-7564; Viel, Sebastien/0000-0002-5085-443X; Butte, Manish/0000-0002-4490-5595; Belot, Alexandre/0000-0003-4902-5332; Moshous, Despina/0000-0001-6719-3693; Notarangelo, Luigi D/0000-0002-8335-0262; Walzer, Thierry/0000-0002-0857-8179; Caux, Christophe/0000-0003-2438-833X; Rice, Gillian I/0000-0002-4223-0571; Butte, Manish/0000-0002-4490-5595; PHAN, Alice/0000-0003-4246-5853; de Villartay, jean pierre/0000-0001-5987-0463; Ménétrier-Caux, christine/0000-0003-4863-374X; Kemp, Elizabeth Helen/0000-0002-0313-8916; Da Cruz, Marie/0000-0002-1220-4858; Mathieu, Anne-Laure/0000-0002-2893-7001	Hospices Civils de Lyon; Societe Francaise de Rhumatologie; INSERM; ANR [ANR-14-CE14-0026-03]; National Institutes of Health [CA162804, CPRIT RP110465]; LYRIC grant [INCa_4664]; European Research Council [ERC-Stg 281025]; Institut National de la Sante et de la Recherche Medicale (INSERM); Centre National de la Recherche Scientifique (CNRS); Universite Claude Bernard Lyon 1; ENS de Lyon; NATIONAL CANCER INSTITUTE [R01CA162804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI103035] Funding Source: NIH RePORTER	Hospices Civils de Lyon; Societe Francaise de Rhumatologie; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); ANR(French National Research Agency (ANR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); LYRIC grant; European Research Council(European Research Council (ERC)European Commission); Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Universite Claude Bernard Lyon 1; ENS de Lyon; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by Hospices Civils de Lyon, Societe Francaise de Rhumatologie, INSERM and ANR (ANR-14-CE14-0026-03) (to A.B.), as well as National Institutes of Health grant CA162804 (to D.J.C.), CPRIT RP110465 (to D.J.C.), and LYRIC grant INCa_4664 (to C.C.). T.W.'s laboratory is supported by European Research Council (ERC-Stg 281025), Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite Claude Bernard Lyon 1, ENS de Lyon. Y.J.C. acknowledges the European Research Council (GA 309449).	Abramson J, 2010, CELL, V140, P123, DOI 10.1016/j.cell.2009.12.030; Anderson MS, 2011, CURR OPIN IMMUNOL, V23, P198, DOI 10.1016/j.coi.2010.11.007; Andres E, 2001, AM J MED, V111, P489, DOI 10.1016/S0002-9343(01)00884-1; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; Cavadini P, 2005, J CLIN INVEST, V115, P728, DOI 10.1172/JCI200523087; de Villartay JP, 2009, ADV EXP MED BIOL, V650, P46; DESAINTBASILE G, 1991, J CLIN INVEST, V87, P1352, DOI 10.1172/JCI115139; Ege M, 2005, BLOOD, V105, P4179, DOI 10.1182/blood-2004-12-4861; Familletti P C, 1981, Methods Enzymol, V78, P387; Felgentreff K, 2011, CLIN IMMUNOL, V141, P73, DOI 10.1016/j.clim.2011.05.007; Fischer A, 2007, IMMUNITY, V27, P835, DOI 10.1016/j.immuni.2007.11.012; Gavalas NG, 2007, J CLIN ENDOCR METAB, V92, P2107, DOI 10.1210/jc.2006-2466; Grunebaum E, 2008, J ALLERGY CLIN IMMUN, V122, P1219, DOI 10.1016/j.jaci.2008.08.031; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Guyomard S, 2003, BRIT J HAEMATOL, V123, P90, DOI 10.1046/j.1365-2141.2003.04587.x; Holtta V, 2008, INFLAMM BOWEL DIS, V14, P1175, DOI 10.1002/ibd.20475; Irla M, 2008, IMMUNITY, V29, P451, DOI 10.1016/j.immuni.2008.08.007; Lim A, 2002, J IMMUNOL METHODS, V261, P177, DOI 10.1016/S0022-1759(02)00004-2; Manuel M, 2012, ONCOIMMUNOLOGY, V1, DOI 10.4161/onci.19545; Mathis D, 2009, ANNU REV IMMUNOL, V27, P287, DOI 10.1146/annurev.immunol.25.022106.141532; Mayer A, 2004, J CLIN ENDOCR METAB, V89, P4484, DOI 10.1210/jc.2004-0021; Miossec P, 2011, ARTHRITIS RHEUM-US, V63, P2168, DOI 10.1002/art.30331; PANNETIER C, 1993, NUCLEIC ACIDS RES, V21, P577, DOI 10.1093/nar/21.3.577; Park J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074893; Poliani PL, 2009, CURR OPIN ALLERGY CL, V9, P489, DOI 10.1097/ACI.0b013e3283327e5c; Poliani PL, 2009, BLOOD, V114, P105, DOI 10.1182/blood-2009-03-211029; Rice GI, 2014, NAT GENET, V46, P503, DOI 10.1038/ng.2933; Romberg N, 2013, J CLIN INVEST, V123, P4283, DOI 10.1172/JCI69854; RUBINSTEIN S, 1981, J VIROL, V37, P755, DOI 10.1128/JVI.37.2.755-758.1981; Scapini P, 2010, J EXP MED, V207, P1757, DOI 10.1084/jem.20100086; SCHANDENE L, 1993, EUR J IMMUNOL, V23, P56, DOI 10.1002/eji.1830230110; Schuetz C, 2008, NEW ENGL J MED, V358, P2030, DOI 10.1056/NEJMoa073966; Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P1092, DOI 10.1016/j.jaci.2013.09.044; SURH CD, 1992, J EXP MED, V176, P611, DOI 10.1084/jem.176.2.611; Sutherland APR, 2005, J IMMUNOL, V174, P5537, DOI 10.4049/jimmunol.174.9.5537; ten Berge B, 2012, RHEUMATOLOGY, V51, P37, DOI 10.1093/rheumatology/ker316; Torrado E, 2010, CYTOKINE GROWTH F R, V21, P455, DOI 10.1016/j.cytogfr.2010.10.004; van der Burg M, 2009, J CLIN INVEST, V119, P91, DOI 10.1172/JCI37141; Villa A, 2008, J ALLERGY CLIN IMMUN, V122, P1082, DOI 10.1016/j.jaci.2008.09.037; Walter JE, 2010, J EXP MED, V207, P1541, DOI 10.1084/jem.20091927; Woodbine L, 2013, J CLIN INVEST, V123, P2969, DOI 10.1172/JCI67349; Zhang SS, 2004, NUCLEIC ACIDS RES, V32, P1, DOI 10.1093/nar/gkg933	42	57	58	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1578	U294		10.1016/j.jaci.2015.01.040	http://dx.doi.org/10.1016/j.jaci.2015.01.040			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25842288	Green Accepted			2022-12-18	WOS:000355933400021
J	Tang, TS; Bieber, T; Williams, HC				Tang, Ting Seng; Bieber, Thomas; Williams, Hywel C.			Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eczema; atopic dermatitis; atopic eczema; induction of remission; subclinical inflammation; long-term management	PIMECROLIMUS CREAM 1-PERCENT; FLUTICASONE PROPIONATE; MAINTENANCE TREATMENT; ENHANCED EXPRESSION; TACROLIMUS OINTMENT; LESIONAL SKIN; DOUBLE-BLIND; TOPICAL CORTICOSTEROIDS; ANTIMICROBIAL PEPTIDE; PROACTIVE TREATMENT	Background: Atopic dermatitis (AD) treatment is often initiated by symptoms or visible erythema. The role of induction of remission or treatment of inflammation that is not visible is unclear. Objective: We investigated whether (1) the notion of subclinical inflammation is scientifically sound, (2) treatment corrects subclinical inflammation, and (3) different strategies for initial clearance of AD affect long-term disease control. Methods: We conducted a systematic review based on searching MEDLINE, Embase, the Cochrane register of randomized controlled trials, and the Global Resource of Eczema Trials from inception to the end of October 2012. Results: Twenty of 26 included studies presented evidence of subclinical inflammation, with a continuum of changes in skin barrier dysfunction, the proinflammatory cytokine milieu, and lymphocytic infiltration from normal-appearing skin to posttreatment lesional skin to active skin lesions in patients with AD. Such subclinical inflammation is improved, with proactive treatment aimed at maintaining remission. Failure to achieve control of AD symptoms with initial therapy was associated with a higher risk of relapse in 14 randomized controlled trials (fluticasone: risk ratio, 1.31; 95% CI, 1.02-1.68; tacrolimus: risk ratio, 1.36; 95% CI, 1.12-1.66). Three trials on systemic therapy/phototherapy suggested that induction of remission resulted in long-term remission without maintenance therapy in approximately 15% of patients. Conclusion: Induction of remission followed by maintenance therapy might prove to be an integral part of a disease-modifying strategy for treating atopic diseases.	[Tang, Ting Seng; Bieber, Thomas; Williams, Hywel C.] Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham NG7 2NR, England; [Bieber, Thomas] Univ Bonn, Dept Dermatol & Allergy, Bonn, Germany	University of Nottingham; University of Bonn	Tang, TS (corresponding author), Univ Nottingham, Ctr Evidence Based Dermatol, Rm A103,Kings Meadow Campus, Nottingham NG7 2NR, England.	kyle.tang@gmail.com		williams, hywel/0000-0002-5646-3093	Collaborative Research Center [SFB704]; Astellas; National Institute of Health Research; National Institute for Health Research [NF-SI-0611-10246] Funding Source: researchfish	Collaborative Research Center; Astellas(Astellas Pharmaceuticals); National Institute of Health Research(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	Disclosure of potential conflict of interest: T. Bieber has received research support from the Collaborative Research Center (SFB704) and has received lecture fees from Astellas. H. C. Williams has received research funds for supporting an academic clinical fellow (T.S.T.) from the National Institute of Health Research. T. S. Tang declares no relevant conflicts of interest.	Angelova-Fischer I, 2011, EXP DERMATOL, V20, P351, DOI 10.1111/j.1600-0625.2011.01259.x; [Anonymous], CHMPEWP184632006; Asano S, 2008, BRIT J DERMATOL, V159, P97, DOI 10.1111/j.1365-2133.2008.08613.x; Ashcroft DM, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005500.pub2; Ballardini N, 2009, BRIT J DERMATOL, V161, P40, DOI 10.1111/j.1365-2133.2009.09095.x; Bangert C, 2011, DERMATOLOGY, V222, P36, DOI 10.1159/000321711; Berth-Jones J, 2003, BRIT MED J, V326, P1367, DOI 10.1136/bmj.326.7403.1367; Bieber T, 2012, ALLERGY, V67, P969, DOI 10.1111/j.1398-9995.2012.02845.x; Breneman D, 2008, J AM ACAD DERMATOL, V58, P990, DOI 10.1016/j.jaad.2008.02.008; Broccardo CJ, 2011, J ALLERGY CLIN IMMUN, V127, P186, DOI 10.1016/j.jaci.2010.10.033; Caproni M, 2007, BRIT J DERMATOL, V156, P312, DOI 10.1111/j.1365-2133.2006.07609.x; Danczak-Pazdrowska A, 2012, SKIN RES TECHNOL, V18, P162, DOI 10.1111/j.1600-0846.2011.00548.x; Eyerich K, 2013, ALLERGY, V68, P974, DOI 10.1111/all.12184; Flohr C, 2010, BRIT J DERMATOL, V163, P1333, DOI 10.1111/j.1365-2133.2010.10068.x; Gittler JK, 2013, J ALLERGY CLIN IMMUN, V131, P300, DOI 10.1016/j.jaci.2012.06.048; Glazenburg EJ, 2009, PEDIAT ALLERG IMM-UK, V20, P59, DOI 10.1111/j.1399-3038.2008.00735.x; Goto T, 2001, J DERMATOL SCI, V27, P156, DOI 10.1016/S0923-1811(01)00130-X; GRANLUND H, 1995, BRIT J DERMATOL, V132, P106, DOI 10.1111/j.1365-2133.1995.tb08633.x; Gupta J, 2008, J ALLERGY CLIN IMMUN, V121, P725, DOI 10.1016/j.jaci.2007.12.1161; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Hanifin J, 2002, BRIT J DERMATOL, V147, P528, DOI 10.1046/j.1365-2133.2002.05006.x; Harper JI, 2000, BRIT J DERMATOL, V142, P52, DOI 10.1046/j.1365-2133.2000.03241.x; Kedzierska A, 2008, BRIT J DERMATOL, V159, P1290, DOI 10.1111/j.1365-2133.2008.08817.x; Kim KH, 2006, J KOREAN MED SCI, V21, P315, DOI 10.3346/jkms.2006.21.2.315; Kirkup M E, 2003, J Dermatolog Treat, V14, P141, DOI 10.1080/09546630310013388; Mathay C, 2011, J INVEST DERMATOL, V131, P46, DOI 10.1038/jid.2010.272; Meurer M, 2004, DERMATOLOGY, V208, P365, DOI 10.1159/000078462; Meurer M, 2010, J DERMATOL TREAT, V21, P157, DOI 10.3109/09546630903410158; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; Nankervis H, GLOBAL RESOURCE ECZE; Owczarek W, 2010, CYTOKINE, V50, P181, DOI 10.1016/j.cyto.2010.02.016; Ozawa M, 2009, J AM ACAD DERMATOL, V60, P609, DOI 10.1016/j.jaad.2008.11.900; Paller AS, 2008, PEDIATRICS, V122, pE1210, DOI 10.1542/peds.2008-1343; Papoiu ADP, 2011, NEUROPEPTIDES, V45, P417, DOI 10.1016/j.npep.2011.07.008; Peserico A, 2008, BRIT J DERMATOL, V158, P801, DOI 10.1111/j.1365-2133.2008.08436.x; Pfab F, 2010, ALLERGY, V65, P84, DOI 10.1111/j.1398-9995.2009.02163.x; Rodriguez E, 2009, J ALLERGY CLIN IM S2, V123; Ruer-Mulard M, 2009, PEDIATR DERMATOL, V26, P551, DOI 10.1111/j.1525-1470.2009.00981.x; Sator PG, 2003, J AM ACAD DERMATOL, V48, P352, DOI 10.1067/mjd.2003.105; Schmitt J, 2011, BRIT J DERMATOL, V164, P415, DOI 10.1111/j.1365-2133.2010.10030.x; Schmitt J, 2012, ALLERGY, V67, P1111, DOI 10.1111/j.1398-9995.2012.02874.x; Seidenari S, 1995, ACTA DERM-VENEREOL, V75, P429; Simon D, 2006, EXP DERMATOL, V15, P441, DOI 10.1111/j.0906-6705.2006.00428.x; Simon D, 2004, J ALLERGY CLIN IMMUN, V114, P887, DOI 10.1016/j.jaci.2004.05.066; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Thaci D, 2008, BRIT J DERMATOL, V159, P1348, DOI 10.1111/j.1365-2133.2008.08813.x; Thomas KS, 2002, BRIT MED J, V324, P768, DOI 10.1136/bmj.324.7340.768; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Tzaneva S, 2010, BRIT J DERMATOL, V162, P655, DOI 10.1111/j.1365-2133.2009.09514.x; Van der Meer JB, 1999, BRIT J DERMATOL, V140, P1114; Van Smeden J, 2013, EUR J DERMATOL; VanderPloeg I, 1997, CLIN EXP IMMUNOL, V109, P526, DOI 10.1046/j.1365-2249.1997.4671365.x; Voegeli R, 2009, BRIT J DERMATOL, V161, P70, DOI 10.1111/j.1365-2133.2009.09142.x; Williams HC, 2011, BRIT J DERMATOL, V164, P231, DOI 10.1111/j.1365-2133.2011.10205.x; Wollenberg A, 2008, ALLERGY, V63, P742, DOI 10.1111/j.1398-9995.2008.01683.x; Wollenberg A, 1999, CYTOMETRY, V37, P147, DOI 10.1002/(SICI)1097-0320(19991001)37:2<147::AID-CYTO8>3.0.CO;2-Y; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Yamamoto M, 2011, J DERMATOL SCI, V61, P110, DOI 10.1016/j.jdermsci.2010.11.018; Yawalkar N, 2001, BRIT J DERMATOL, V144, P1133, DOI 10.1046/j.1365-2133.2001.04222.x; Yawalkar N, 1999, J INVEST DERMATOL, V113, P43, DOI 10.1046/j.1523-1747.1999.00619.x	61	57	65	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1615	+		10.1016/j.jaci.2013.12.1079	http://dx.doi.org/10.1016/j.jaci.2013.12.1079			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24655575	Bronze			2022-12-18	WOS:000336672500014
J	Chiu, YHM; Coull, BA; Sternthal, MJ; Kloog, I; Schwartz, J; Cohen, S; Wright, RJ				Chiu, Yueh-Hsiu Mathilda; Coull, Brent A.; Sternthal, Michelle J.; Kloog, Itai; Schwartz, Joel; Cohen, Sheldon; Wright, Rosalind J.			Effects of prenatal community violence and ambient air pollution on childhood wheeze in an urban population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Community violence; prenatal stress; traffic air pollution; particulate matter; repeated wheeze; prenatal exposure	ENVIRONMENTAL TOBACCO-SMOKE; GREATER BOSTON AREA; RESPIRATORY HEALTH; BIRTH COHORT; SOCIAL DETERMINANTS; MATERNAL SMOKING; INCIDENT ASTHMA; ALLERGEN LEVELS; EXPOSURE; STRESS	Background: Prenatal exposures to stress and physical toxins influence children's respiratory health, although few studies consider these factors together. Objectives: We sought to concurrently examine the effects of prenatal community-level psychosocial (exposure to community violence [ECV]) and physical (air pollution) stressors on repeated wheeze in 708 urban children followed to age 2 years. Methods: Multi-item ECV reported by mothers in pregnancy was summarized into a continuous score by using Rasch modeling. Prenatal black carbon exposure was estimated by using land-use regression (LUR) modeling; particulate matter with a diameter of less than 2.5 mu m (PM2.5) was estimated by using LUR modeling incorporating satellite data. Mothers reported child's wheeze every 3 months. The effects of ECV and air pollutants on repeated wheeze (>= 2 episodes) were examined by using logistic regression. Interactions between ECV and pollutants were examined. Results: Mothers were primarily black (29%) and Hispanic (55%), with lower education (62% with <= 12 years); 87 (12%) children wheezed repeatedly. In models examining concurrent exposures, ECV (odds ratio [OR], 1.95; 95% CI, 1.13-3.36; highest vs lowest tertile) and black carbon (OR, 1.84; 95% CI, 1.08-3.12; median or greater vs less than median) were independently associated with wheeze adjusting for sex, birth season, maternal atopy, education, race, and cockroach antigen. Associations were similar for PM2.5 (adjusted OR, 2.02; 95% CI, 1.20-3.40). An interaction between ECV with air pollution levels was suggested. Conclusions: These findings suggest that both prenatal community violence and air pollution can contribute to respiratory health in these urban children. Moreover, place-based psychosocial stressors might affect host resistance such that physical pollutants can have adverse effects, even at relatively lower levels.	[Chiu, Yueh-Hsiu Mathilda; Wright, Rosalind J.] Kravis Childrens Hosp, New York, NY USA; [Chiu, Yueh-Hsiu Mathilda; Wright, Rosalind J.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY USA; [Wright, Rosalind J.] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY USA; [Coull, Brent A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Coull, Brent A.; Sternthal, Michelle J.; Kloog, Itai; Schwartz, Joel] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [Schwartz, Joel] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Cohen, Sheldon] Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA; [Kloog, Itai] Ben Gurion Univ Negev, Dept Geog & Environm Dev, IL-84105 Beer Sheva, Israel	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Carnegie Mellon University; Ben Gurion University	Wright, RJ (corresponding author), One Gustave L Levy Pl,Box 1198, New York, NY 10029 USA.	rosalind.wright@mssm.edu		Chiu, Yueh-Hsiu Mathilda/0000-0003-1656-660X; Cohen, Sheldon/0000-0003-2248-4600	 [R01 ES010932];  [U01 HL072494];  [R01 HL080674];  [ES000002]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080674, U01HL072494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES023515, P30ES000002, R01ES010932] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [R01MD006086] Funding Source: NIH RePORTER	; ; ; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	The Asthma Coalition on Community, Environment, and Social Stress (ACCESS) project has been funded by grants R01 ES010932, U01 HL072494, and R01 HL080674 (R.J.W.), and biostatistical support (B.A.C.) was funded by ES000002.	Agresti A, 2013, CATEGORICAL DATA ANA; Beers MF, 2011, J CLIN INVEST, V121, P2065, DOI 10.1172/JCI45961; Berz JB, 2007, J PEDIATR PSYCHOL, V32, P154, DOI 10.1093/jpepsy/jsj123; Brennan RT, 2007, J COMMUNITY PSYCHOL, V35, P603, DOI 10.1002/jcop.20167; Carey SA, 2011, AM J PHYSIOL-LUNG C, V300, pL242, DOI 10.1152/ajplung.00177.2010; Carlsten C, 2011, OCCUP ENVIRON MED, V68, P291, DOI 10.1136/oem.2010.055152; Chen E, 2008, ENVIRON HEALTH PERSP, V116, P970, DOI 10.1289/ehp.11076; Clark C, 2008, J URBAN HEALTH, V85, P22, DOI 10.1007/s11524-007-9229-8; Clark NA, 2010, ENVIRON HEALTH PERSP, V118, P284, DOI 10.1289/ehp.0900916; Clougherty JE, 2007, ENVIRON HEALTH PERSP, V115, P1140, DOI 10.1289/ehp.9863; Cruz AA, 2010, EUR RESPIR J, V35, P239, DOI 10.1183/09031936.00070309; Do DP, 2011, HEALTH PLACE, V17, P625, DOI 10.1016/j.healthplace.2010.12.019; Frodl T, 2013, NEUROBIOL DIS, V52, P24, DOI 10.1016/j.nbd.2012.03.012; Ganz ML, 2000, AM J PUBLIC HEALTH, V90, P367, DOI 10.2105/AJPH.90.3.367; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429, DOI 10.1164/ajrccm.163.2.2006009; Girodet PO, 2011, PHARMACOL THERAPEUT, V130, P325, DOI 10.1016/j.pharmthera.2011.02.001; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Gryparis A, 2007, J R STAT SOC C-APPL, V56, P183, DOI 10.1111/j.1467-9876.2007.00573.x; Gump BB, 2008, ENVIRON HEALTH PERSP, V116, P249, DOI 10.1289/ehp.10391; Gupta RS, 2010, ANN ALLERG ASTHMA IM, V104, P299, DOI 10.1016/j.anai.2009.11.047; Hermann C, 2005, AM J EPIDEMIOL, V162, P345, DOI 10.1093/aje/kwi212; Jedrychowski W, 2009, ENVIRON INT, V35, P877, DOI 10.1016/j.envint.2009.03.004; Jedrychowski WA, 2013, INT J HYG ENVIR HEAL, V216, P395, DOI 10.1016/j.ijheh.2012.12.014; Jeong Yoolwon, 2010, J Prev Med Public Health, V43, P369, DOI 10.3961/jpmph.2010.43.5.369; Kiecolt-Glaser JK, 2002, J CONSULT CLIN PSYCH, V70, P537, DOI 10.1037//0022-006X.70.3.537; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-281OC; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; Klinnert MD, 2003, PEDIATRICS, V112, P49, DOI 10.1542/peds.112.1.49; Kloog I, 2011, ATMOS ENVIRON, V45, P6267, DOI 10.1016/j.atmosenv.2011.08.066; Knol MJ, 2007, INT J EPIDEMIOL, V36, P1111, DOI 10.1093/ije/dym157; Li CM, 2012, TOXICOL LETT, V209, P277, DOI 10.1016/j.toxlet.2012.01.004; McConnell R, 2003, AM J RESP CRIT CARE, V168, P790, DOI 10.1164/rccm.200304-466OC; McConnell R, 2010, ENVIRON HEALTH PERSP, V118, P1021, DOI 10.1289/ehp.0901232; Miller RL, 2004, CHEST, V126, P1071, DOI 10.1378/chest.126.4.1071; Morello-Frosch R, 2006, ENVIRON RES, V102, P181, DOI 10.1016/j.envres.2006.05.007; Morello-Frosch R, 2006, ENVIRON HEALTH PERSP, V114, P1150, DOI 10.1289/ehp.8930; Oken Emily, 2003, BMC Pediatr, V3, P6, DOI 10.1186/1471-2431-3-6; Park SJ, 2012, INT J MOL SCI, V13, P7915, DOI 10.3390/ijms13077915; Pickett KE, 2005, PAEDIATR PERINAT EP, V19, P368, DOI 10.1111/j.1365-3016.2005.00660.x; Pinkerton KE, 2006, CLIN EXP PHARMACOL P, V33, P269, DOI 10.1111/j.1440-1681.2006.04357.x; Prakash Ys, 2010, Expert Rev Respir Med, V4, P395, DOI 10.1586/ers.10.29; Rauh VA, 2002, ENVIRON HEALTH PERSP, V110, P323, DOI 10.1289/ehp.02110s2323; Rosati MV, 2011, INT J ENVIRON HEAL R, V21, P62, DOI 10.1080/09603123.2010.506675; Ryan PH, 2009, AM J RESP CRIT CARE, V180, P1068, DOI 10.1164/rccm.200808-1307OC; Salam MT, 2008, CURR OPIN PULM MED, V14, P3, DOI 10.1097/MCP.0b013e3282f1987a; Selner-O'Hagan MB, 1998, J CHILD PSYCHOL PSYC, V39, P215, DOI 10.1017/S002196309700187X; Shankardass K, 2009, P NATL ACAD SCI USA, V106, P12406, DOI 10.1073/pnas.0812910106; Stephanie V, 2011, INHAL TOXICOL, V23, P627, DOI 10.3109/08958378.2011.599445; Sternthal MJ, 2010, EUR RESPIR J, V36, P1400, DOI 10.1183/09031936.00003010; Stieb DM, 2012, ENVIRON RES, V117, P100, DOI 10.1016/j.envres.2012.05.007; Suglia SF, 2008, PSYCHOSOM MED, V70, P160, DOI 10.1097/PSY.0b013e318160687c; Suglia SF, 2008, J TRAUMA STRESS, V21, P479, DOI 10.1002/jts.20362; Suglia SF, 2010, INT J BEHAV MED, V17, P43, DOI 10.1007/s12529-009-9044-6; Swahn MH, 2006, AM J PUBLIC HEALTH, V96, P802, DOI 10.2105/AJPH.2005.066514; Thomson EM, 2007, ENVIRON RES, V105, P224, DOI 10.1016/j.envres.2007.06.005; Tomei F, 2003, IND HEALTH, V41, P320, DOI 10.2486/indhealth.41.320; Vrekoussis T, 2010, ANN NY ACAD SCI, V1205, P69, DOI 10.1111/j.1749-6632.2010.05686.x; Williams DR, 2009, PEDIATRICS, V123, pS174, DOI 10.1542/peds.2008-2233H; Wood S.N., 2017, GEN ADDITIVE MODELS, V2nd; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Wright RJ, 2007, PAEDIATR PERINAT EP, V21, P8, DOI 10.1111/j.1365-3016.2007.00879.x; Wright RJ, 2006, CLIN CHEST MED, V27, P413, DOI 10.1016/j.ccm.2006.04.003; Wright RJ, 2013, CURR OPIN PEDIATR, V25, P232, DOI 10.1097/MOP.0b013e32835e78cc; Wright RJ, 2011, AM J RESP CRIT CARE, V184, P752, DOI 10.1164/rccm.201106-1139ED; Wright RJ, 2010, BIOL PSYCHOL, V84, P46, DOI 10.1016/j.biopsycho.2010.01.007; Wright RJ, 2008, CIENC SAUDE COLETIVA, V13, P1729, DOI 10.1590/S1413-81232008000600008	67	57	58	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					713	+		10.1016/j.jaci.2013.09.023	http://dx.doi.org/10.1016/j.jaci.2013.09.023			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	AC3EK	24200349	Green Accepted			2022-12-18	WOS:000332397600012
J	Sharfe, N; Nahum, A; Newell, A; Dadi, H; Ngan, B; Pereira, SL; Herbrick, JA; Roifman, CM				Sharfe, Nigel; Nahum, Amit; Newell, Andrea; Dadi, Harjit; Ngan, Bo; Pereira, Sergio L.; Herbrick, Jo-Anne; Roifman, Chaim M.			Fatal combined immunodeficiency associated with heterozygous mutation in STAT1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Combined immunodeficiency; STAT1; mutation	CHRONIC MUCOCUTANEOUS CANDIDIASIS; T-CELLS; IMMUNE-SYSTEM; INBORN-ERRORS; B-CELLS; DEFICIENCY; EXPRESSION; DISEASE; HUMANS; SUBSETS	Background: Mutations in the gene for the signal transducer and activator of transcription 1, STAT1, have been shown to be associated with death at an early age due to overwhelming viral infection (complete STAT1 deficiency) or, more commonly, selective deficiencies to mycobacterial or fungal infection (typically heterozygous STAT1 mutations). Objectives: To define the molecular basis of progressive combined immunodeficiency in a group of patients with fatal infections. Methods: We studied a group of unrelated patients who displayed an unusual progressive form of combined immunodeficiency. Whole exome sequencing assisted in confirming a common genetic defect in this group, which consisted of a heterozygous mutation of the STAT1 gene. STAT1 protein level as well as function was assessed, and a detailed evaluation of the immune system, including analysis of thymus tissue, was performed. Results: Patients were found to carry de novo heterozygous mutations in STAT1 encoding T385A, I294T, or C284R amino acid substitutions. STAT1 expression appeared significantly decreased as a result of these changes but not completely absent, with diminished signaling responses. This group display progressive loss in lymphocyte number and function accompanied by increasing autoimmune features as well as severe, fatal infections. Conclusions: These findings show that some heterozygous aberrations of STAT1 can be associated with progressive combined immunodeficiency, quite distinct from the limited susceptibilities to infection previously reported for heterozygous STAT1 mutations. These mutations were not inherited, rather, arose de novo in each case. Accompanied by significant patient mortality, this finding suggests that this class of STAT1 mutation is ultimately fatal due to overwhelming infection.	[Sharfe, Nigel; Newell, Andrea; Dadi, Harjit; Roifman, Chaim M.] Hosp Sick Children, Div Immunol & Allergy, Canadian Ctr Primary Immunodeficiency, Jeffrey Modell Res Lab Diag Primary Immunodeficie, Toronto, ON M5G 1X8, Canada; [Sharfe, Nigel; Newell, Andrea; Dadi, Harjit; Roifman, Chaim M.] Univ Toronto, Toronto, ON, Canada; [Nahum, Amit; Roifman, Chaim M.] Hebrew Univ Jerusalem, Canada Israel Immunodeficiency Res Alliance, IL-76100 Rehovot, Israel; [Nahum, Amit] Hebrew Univ Jerusalem, Kaplan Med Ctr, IL-76100 Rehovot, Israel; [Ngan, Bo] Hosp Sick Children, Div Pathol, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada; [Pereira, Sergio L.; Herbrick, Jo-Anne] Hosp Sick Children, Ctr Appl Genom, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Kaplan Medical Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Roifman, CM (corresponding author), Div Allergy Immunol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	chaim.roifman@sickkids.ca	Pereira, Sergio L/B-1984-2010	Pereira, Sergio L/0000-0002-2796-5625	Immunodeficiency Canada Distinguished professor in Immunology; Canadian Center for Primary Immunodeficiency; Program for Immunogenomics; Jeffrey Modell Foundation; Genome Canada through the Ontario Genomics Institute; Canada Foundation for Innovation; Ontario Ministry of Research and Innovation	Immunodeficiency Canada Distinguished professor in Immunology; Canadian Center for Primary Immunodeficiency; Program for Immunogenomics; Jeffrey Modell Foundation; Genome Canada through the Ontario Genomics Institute(Genome Canada); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Ontario Ministry of Research and Innovation(Ministry of Research and Innovation, Ontario)	This work was supported by Immunodeficiency Canada Distinguished professor in Immunology, the Canadian Center for Primary Immunodeficiency, the Program for Immunogenomics, and the Jeffrey Modell Foundation; and the Centre for Applied Genomics at the Hospital for Sick Children was supported by Genome Canada through the Ontario Genomics Institute, Canada Foundation for Innovation, and the Ontario Ministry of Research and Innovation.	Aggarwal S, 1998, J IMMUNOL, V160, P1627; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Boisson-Dupuis S, 2012, CURR OPIN IMMUNOL, V24, P364, DOI 10.1016/j.coi.2012.04.011; Carney EF, 2012, J IMMUNOL, V189, P261, DOI 10.4049/jimmunol.1101909; Casanova JL, 2012, IMMUNITY, V36, P515, DOI 10.1016/j.immuni.2012.03.016; Chapgier A, 2006, PLOS GENET, V2, P1193, DOI 10.1371/journal.pgen.0020131; Chapgier A, 2006, J IMMUNOL, V176, P5078, DOI 10.4049/jimmunol.176.8.5078; Chapgier A, 2009, J CLIN INVEST, V119, P1502, DOI 10.1172/JCI37083; CHEUNG RK, 1993, VIROLOGY, V193, P700, DOI 10.1006/viro.1993.1178; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; Fukagawa Y, 2008, ELECTROPHORESIS, V29, P3192, DOI 10.1002/elps.200800086; Gupta S, 2008, EXP GERONTOL, V43, P266, DOI 10.1016/j.exger.2007.12.006; Kong XF, 2010, BLOOD, V116, P5895, DOI 10.1182/blood-2010-04-280586; Lee CK, 2000, J IMMUNOL, V165, P3571, DOI 10.4049/jimmunol.165.7.3571; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; McLaren JE, 2009, J GEN VIROL, V90, P2239, DOI 10.1099/vir.0.011627-0; Najjar I, 2010, BIOCHIMIE, V92, P425, DOI 10.1016/j.biochi.2010.02.009; Nishibori T, 2004, J EXP MED, V199, P25, DOI 10.1084/jem.20020509; O'Shea JJ, 2013, NEW ENGL J MED, V368, P161, DOI 10.1056/NEJMra1202117; Potestio M, 1999, EXP GERONTOL, V34, P659, DOI 10.1016/S0531-5565(99)00041-8; Richardson C, 2003, J VIROL, V77, P4439, DOI 10.1128/JVI.77.7.4439-4443.2003; Roifman CM, 2012, J ALLERGY CLIN IMMUN, V130, P177, DOI 10.1016/j.jaci.2012.04.029; Sansoni P, 2008, EXP GERONTOL, V43, P61, DOI 10.1016/j.exger.2007.06.008; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Takezaki S, 2012, J IMMUNOL, V189, P1521, DOI 10.4049/jimmunol.1200926; Tsumura M, 2012, HUM MUTAT, V33, P1377, DOI 10.1002/humu.22113; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102; Wood VHJ, 2007, ONCOGENE, V26, P4135, DOI 10.1038/sj.onc.1210496; Young P, 2008, J GEN VIROL, V89, P866, DOI 10.1099/vir.0.83414-0; Zakharova N, 2003, J BIOL CHEM, V278, P43067, DOI 10.1074/jbc.M308166200	31	57	58	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					807	817		10.1016/j.jaci.2013.09.032	http://dx.doi.org/10.1016/j.jaci.2013.09.032			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24239102	Bronze			2022-12-18	WOS:000332397600025
J	van Doormaal, JJ; Arends, S; Brunekreeft, KL; van der Wal, VB; Sietsma, J; Vader, PCV; Elberink, JNGO; Kluin-Nelemans, JC; van der Veer, E; de Monchy, JGR				van Doormaal, Jasper J.; Arends, Suzanne; Brunekreeft, Kim L.; van der Wal, V. Bauco; Sietsma, Johanna; Vader, Pieter C. van Voorst; Elberink, Joanne N. G. Oude; Kluin-Nelemans, Johanna C.; van der Veer, Eveline; de Monchy, Jan G. R.			Prevalence of indolent systemic mastocytosis in a Dutch region	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[van Doormaal, Jasper J.; Brunekreeft, Kim L.; Elberink, Joanne N. G. Oude; de Monchy, Jan G. R.] Univ Groningen, Univ Med Ctr Groningen, Dept Allergol, NL-9700 AB Groningen, Netherlands; [Arends, Suzanne] Univ Groningen, Univ Med Ctr Groningen, Dept Rheumatol & Clin Immunol, NL-9700 AB Groningen, Netherlands; [Vader, Pieter C. van Voorst] Univ Groningen, Univ Med Ctr Groningen, Dept Dermatol, NL-9700 AB Groningen, Netherlands; [Kluin-Nelemans, Johanna C.] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, NL-9700 AB Groningen, Netherlands; [van der Veer, Eveline] Univ Groningen, Univ Med Ctr Groningen, Dept Lab Med, NL-9700 AB Groningen, Netherlands; [Elberink, Joanne N. G. Oude] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD, NL-9700 AB Groningen, Netherlands; [van der Wal, V. Bauco] Martini Hosp, Dept Dermatol, Groningen, Netherlands; [Sietsma, Johanna] Martini Hosp, Dept Pathol, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Groningen; Martini Hospital; University of Groningen; Martini Hospital; University of Groningen	van Doormaal, JJ (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Allergol, NL-9700 AB Groningen, Netherlands.	j.j.van.doormaal@home.nl	Arends, Suzanne/M-5436-2015; Kluin-Nelemans, Johanna C/F-8658-2018	Arends, Suzanne/0000-0002-4422-7640; Kluin-Nelemans, Johanna C/0000-0003-2617-9427; van der Veer, Eveline/0000-0002-4825-9981				Horny HP, 2008, TUMOURS HAEMATOPOIET, V2, P54; Lim KH, 2009, BLOOD, V113, P5727, DOI 10.1182/blood-2009-02-205237; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; van Doormaal JJ, 2012, ALLERGY, V67, P683, DOI 10.1111/j.1398-9995.2012.02809.x	4	57	57	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1429	+		10.1016/j.jaci.2012.10.015	http://dx.doi.org/10.1016/j.jaci.2012.10.015			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23219169				2022-12-18	WOS:000318912200026
J	Anto, JM; Pinart, M; Akdis, M; Auffray, C; Bachert, C; Basagana, X; Carlsen, KH; Guerra, S; von Hertzen, L; Illi, S; Kauffmann, F; Keil, T; Kiley, JP; Koppelman, GH; Lupinek, C; Martinez, FD; Nawijn, MC; Postma, DS; Siroux, V; Smit, HA; Sterk, PJ; Sunyer, J; Valenta, R; Valverde, S; Akdis, CA; Annesi-Maesano, I; Ballester, F; Benet, M; Cambon-Thomsen, A; Chatzi, L; Coquet, J; Demoly, P; Gan, WN; Garcia-Aymerich, J; Gimeno-Santos, E; Guihenneuc-Jouyaux, C; Haahtela, T; Heinrich, J; Herr, M; Hohmann, C; Jacquemin, B; Just, J; Kerkhof, M; Kogevinas, M; Kowalski, ML; Lambrecht, BN; Lau, S; Carlsen, KCL; Maier, D; Momas, I; Noel, P; Oddie, S; Palkonen, S; Pin, I; Porta, D; Punturieri, A; Ranciere, F; Smith, RA; Stanic, B; Stein, RT; van de Veen, W; van Oosterhout, AJM; Varraso, R; Wickman, M; Wijmenga, C; Wright, J; Yaman, G; Zuberbier, T; Bousquet, J				Anto, Josep M.; Pinart, Mariona; Akdis, Muebeccel; Auffray, Charles; Bachert, Claus; Basagana, Xavier; Carlsen, Kai-Hakon; Guerra, Stefano; von Hertzen, Leena; Illi, Sabina; Kauffmann, Francine; Keil, Thomas; Kiley, James P.; Koppelman, Gerard H.; Lupinek, Christian; Martinez, Fernando D.; Nawijn, Martijn C.; Postma, Dirkje S.; Siroux, Valerie; Smit, Henriette A.; Sterk, Peter J.; Sunyer, Jordi; Valenta, Rudolf; Valverde, Sergio; Akdis, Cezmi A.; Annesi-Maesano, Isabella; Ballester, Ferran; Benet, Marta; Cambon-Thomsen, Anne; Chatzi, Leda; Coquet, Jonathan; Demoly, Pascal; Gan, Weiniu; Garcia-Aymerich, Judith; Gimeno-Santos, Elena; Guihenneuc-Jouyaux, Chantal; Haahtela, Tari; Heinrich, Joachim; Herr, Marie; Hohmann, Cynthia; Jacquemin, Benedicte; Just, Jocelyne; Kerkhof, Marjan; Kogevinas, Manolis; Kowalski, Marek L.; Lambrecht, Bart N.; Lau, Susanne; Carlsen, Karin C. Lodrup; Maier, Dieter; Momas, Isabelle; Noel, Patricia; Oddie, Sam; Palkonen, Susanna; Pin, Isabelle; Porta, Daniela; Punturieri, Antonello; Ranciere, Fanny; Smith, Robert A.; Stanic, Barbara; Stein, Renato T.; van de Veen, Willem; van Oosterhout, Antoon J. M.; Varraso, Raphaelle; Wickman, Magnus; Wijmenga, Cisca; Wright, John; Yaman, Gorkem; Zuberbier, Torsten; Bousquet, Jean		WHO Collaborating Ctr Asthma	Understanding the complexity of IgE-related phenotypes from childhood to young adulthood: A Mechanisms of the Development of Allergy (MeDALL) Seminar	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; Mechanisms of the Development of Allergy; Seventh Framework Program; phenotypes; IgE; asthma	WORLD-HEALTH-ORGANIZATION; T-REGULATORY-CELLS; 1ST 6 YEARS; SEVERE ASTHMA; CLUSTER-ANALYSIS; LUNG-FUNCTION; BRONCHIAL HYPERRESPONSIVENESS; DIAGNOSTIC GATEKEEPERS; KNOWLEDGE MANAGEMENT; SYSTEMS BIOLOGY	Mechanisms of the Development of Allergy (MeDALL), a Seventh Framework Program European Union project, aims to generate novel knowledge on the mechanisms of initiation of allergy. Precise phenotypes of IgE-mediated allergic diseases will be defined in MeDALL. As part of MeDALL, a scientific seminar was held on January 24, 2011, to review current knowledge on the IgE-related phenotypes and to explore how a multidisciplinary effort could result in a new integrative translational approach. This article provides a summary of the meeting. It develops challenges in IgE-related phenotypes and new clinical and epidemiologic approaches to the investigation of allergic phenotypes, including cluster analysis, scale-free models, candidate biomarkers, and IgE microarrays; the particular case of severe asthma was reviewed. Then novel approaches to the IgE-associated phenotypes are reviewed from the individual mechanisms to the systems, including epigenetics, human in vitro immunology, systems biology, and animal models. The last chapter deals with the understanding of the population-based IgE-associated phenotypes in children and adolescents, including age effect in terms of maturation, observed effects of early-life exposures and shift of focus from early life to pregnancy, gene-environment interactions, cohort effects, and time trends in patients with allergic diseases. This review helps to define phenotypes of allergic diseases in MeDALL. (J Allergy Clin Immunol 2012;129:943-54.)	[Anto, Josep M.; Pinart, Mariona; Basagana, Xavier; Guerra, Stefano; Sunyer, Jordi; Benet, Marta; Garcia-Aymerich, Judith; Gimeno-Santos, Elena; Kogevinas, Manolis; Stein, Renato T.] CREAL Ctr Res Environm Epidemiol, Barcelona 08003, Spain; [Anto, Josep M.; Pinart, Mariona; Basagana, Xavier; Guerra, Stefano; Sunyer, Jordi; Benet, Marta; Garcia-Aymerich, Judith; Gimeno-Santos, Elena; Kogevinas, Manolis] Hosp Mar Res Inst IMIM, Barcelona, Spain; [Anto, Josep M.; Pinart, Mariona; Basagana, Xavier; Guerra, Stefano; Sunyer, Jordi; Ballester, Ferran; Benet, Marta; Garcia-Aymerich, Judith; Gimeno-Santos, Elena; Kogevinas, Manolis] CIBERESP, Barcelona, Spain; [Anto, Josep M.; Sunyer, Jordi; Garcia-Aymerich, Judith] Univ Pompeu Fabra, Dept Expt & Hlth Sci, Barcelona, Spain; [Akdis, Muebeccel; Akdis, Cezmi A.; Stanic, Barbara; van de Veen, Willem; Yaman, Gorkem] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Auffray, Charles] CNRS Inst Biol Sci, Villejuif, France; [Bachert, Claus] Univ Hosp Ghent, URL Upper Airways Res Lab, Ghent, Belgium; [Carlsen, Kai-Hakon; Carlsen, Karin C. Lodrup] Oslo Univ Hosp, Dept Paediat, Oslo, Norway; [Carlsen, Kai-Hakon; Carlsen, Karin C. Lodrup] Univ Oslo, N-0316 Oslo, Norway; [Guerra, Stefano; Martinez, Fernando D.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [von Hertzen, Leena; Haahtela, Tari] Helsinki Univ Hosp, Dept Allergy, Skin & Allergy Hosp, Helsinki, Finland; [Illi, Sabina] Univ Munich, Dept Pulm & Allergy, Univ Childrens Hosp Munich, Munich, Germany; [Kauffmann, Francine; Jacquemin, Benedicte; Varraso, Raphaelle; Bousquet, Jean] INSERM, CESP Ctr Res Epidemiol & Populat Hlth, U1018, Resp & Environm Epidemiol Team, Villejuif, France; [Kauffmann, Francine; Jacquemin, Benedicte; Varraso, Raphaelle] Univ Paris 11, UMRS 1018, F-94807 Villejuif, France; [Keil, Thomas; Hohmann, Cynthia] Charite, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany; [Kiley, James P.; Gan, Weiniu; Noel, Patricia; Punturieri, Antonello; Smith, Robert A.] NHLBI, Div Lung Dis, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; [Koppelman, Gerard H.] Univ Groningen, Dept Pediat Pulmonol & Pediat Allergol, Beatrix Childrens Hosp, GRIAC Res Inst,Univ Med Ctr Groningen, Groningen, Netherlands; [Lupinek, Christian; Valenta, Rudolf] Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria; [Nawijn, Martijn C.; van Oosterhout, Antoon J. M.] Univ Groningen, Univ Med Ctr Groningen, Lab Allergol & Pulm Dis, Dept Pathol & Med Biol,GRIAC Res Inst, Groningen, Netherlands; [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Resp Med, Beatrix Childrens Hosp,GRIAC Res Inst, Groningen, Netherlands; [Siroux, Valerie] Univ Grenoble 1, INSERM, Team Environm Epidemiol Appl Reprod & Resp Hlth, U823, Grenoble, France; [Smit, Henriette A.] Univ Utrecht, Julius Ctr Hlth Sci & Primary Care, Univ Med Ctr Utrecht, NL-3508 TC Utrecht, Netherlands; [Sterk, Peter J.] Leiden Univ, Med Ctr, Dept Pulmonol, Leiden, Netherlands; [Sterk, Peter J.] Univ Amsterdam, Acad Med Ctr, Dept Pulmonol, NL-1105 AZ Amsterdam, Netherlands; [Valverde, Sergio] Univ Pompeu Fabra, ICREA Complex Syst Lab, Barcelona, Spain; [Annesi-Maesano, Isabella] EPAR U707 INSERM, Paris, France; [Annesi-Maesano, Isabella] EPAR UMR S UPMC, Paris, France; [Ballester, Ferran] Ctr Publ Hlth Res CSISP, Div Environm & Hlth, Valencia, Spain; [Ballester, Ferran] Univ Valencia, Sch Nursing, E-46003 Valencia, Spain; [Cambon-Thomsen, Anne] UMR Inserm U1027, Toulouse, France; [Cambon-Thomsen, Anne] Univ Toulouse 3, F-31062 Toulouse, France; [Chatzi, Leda] Univ Crete, Dept Social Med, Iraklion, Greece; [Coquet, Jonathan] Univ Ghent, Dept Resp Dis, Lab Immunoregulat & Mucosal Immunol, Ghent, Belgium; [Demoly, Pascal; Lambrecht, Bart N.] World Hlth Org Collaborating Ctr Asthma & Rhiniti, Montpellier, France; [Demoly, Pascal; Bousquet, Jean] Hop Arnaud de Villeneuve, Univ Hosp Montpellier, Montpellier, France; [Guihenneuc-Jouyaux, Chantal; Herr, Marie; Just, Jocelyne; Momas, Isabelle; Ranciere, Fanny] Paris Descartes Univ, Dept Publ Hlth & Biostat, Paris, France; [Heinrich, Joachim] Helmholtz Zentrum, Inst Epidemiol 1, Munich, Germany; [Just, Jocelyne] Univ Paris 06, Grp Hosp Trousseau La Roche Guyon, APHP, Ctr Asthme & Allergies, Paris, France; [Kerkhof, Marjan] Univ Groningen, Dept Epidemiol, GRIAC Res Inst, Univ Med Ctr Groningen, Groningen, Netherlands; [Kogevinas, Manolis] Natl Sch Publ Hlth, Athens, Greece; [Kowalski, Marek L.] Med Univ Lodz, Dept Immunol Rheumatol & Allergy, Lodz, Poland; [Lau, Susanne] Charite Campus Virchow, Dept Pneumol & Immunol, Berlin, Germany; [Maier, Dieter] Biomax Informat AG, Munich, Germany; [Momas, Isabelle; Ranciere, Fanny] Paris Municipal Dept Social Act Childhood & Hlth, Paris, France; [Oddie, Sam; Wright, John] Bradford Teaching Hosp Fdn Trust, Bradford Inst Hlth Res, Bradford, W Yorkshire, England; [Oddie, Sam; Wright, John] Bradford Royal Infirm, Bradford, W Yorkshire, England; [Palkonen, Susanna] EFA European Federat Allergy & Airways Dis Patien, Brussels, Belgium; [Pin, Isabelle] CHU Grenoble, F-38043 Grenoble, France; [Pin, Isabelle] Univ Grenoble 1, INSERM, U823, Inst Albert Bonniot, Grenoble, France; [Porta, Daniela] Reg Hlth Serv Lazio Reg, Dept Epidemiol, Rome, Italy; [Stein, Renato T.] Pontificia Univ Catolica RGS, Sch Med, Porto Alegre, RS, Brazil; [Wickman, Magnus] Karolinska Inst, Sachs Childrens Hosp, Stockholm, Sweden; [Wickman, Magnus] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Wijmenga, Cisca] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands; [Zuberbier, Torsten] Charite, Allergy Ctr Charite, Dept Dermatol, D-13353 Berlin, Germany	Pompeu Fabra University; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Pompeu Fabra University; Swiss Institute of Allergy & Asthma Research; University of Zurich; Centre National de la Recherche Scientifique (CNRS); Ghent University; Ghent University Hospital; University of Oslo; University of Oslo; University of Arizona; University of Helsinki; Helsinki University Central Hospital; University of Munich; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Groningen; Medical University of Vienna; University of Groningen; University of Groningen; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Utrecht University; Utrecht University Medical Center; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam; ICREA; Pompeu Fabra University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Valencia; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Crete; Ghent University; World Health Organization; Universite de Montpellier; CHU de Montpellier; UDICE-French Research Universities; Universite Paris Cite; Helmholtz Association; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Groningen; National & Kapodistrian University of Athens; Medical University Lodz; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Biomax Informatics; Bradford Royal Infirmary; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Pontificia Universidade Catolica Do Rio Grande Do Sul; Karolinska Institutet; Karolinska Institutet; University of Groningen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Anto, JM (corresponding author), CREAL Ctr Res Environm Epidemiol, Barcelona Biomedical Res Pk,Dr Aiguader 88, Barcelona 08003, Spain.	jmanto@creal.cat	Basagaña, Xavier/C-3901-2017; Wijmenga, Cisca/AAE-7719-2019; Lupinek, Christian/I-3311-2019; Anto, J M/H-2676-2014; siroux, valerie/N-1865-2013; Bachert, Claus/J-8825-2012; PIN, Isabelle/N-3020-2013; Koppelman, Gerard/AAG-9187-2020; Kogevinas, Manolis/C-3918-2017; Coquet, Jonathan M/A-5551-2015; Pinart, Mariona/L-1931-2015; Akdis, Cezmi/AAV-4844-2020; Jacquemin, Benedicte/D-8948-2018; Wright, John/H-1624-2012; Annesi-Maesano, Isabella/D-9173-2016; Sunyer, Jordi/G-6909-2014; Bousquet, Jean/O-4221-2019; Stein, Renato T/G-2975-2012; Lambrecht, Bart N/K-2484-2014; Demoly, Pascal/Y-9938-2019; guihenneuc, chantal/AAZ-9296-2020; Pinart Gilberga, Mariona/GLS-8842-2022; Heinrich, Joachim/N-1720-2013; Wijmenga, Cisca/D-2173-2009; Stein, Renato Tetelbom/K-2568-2014; Valverde, Sergi/J-3275-2012; Sterk, P.J./AAK-8175-2020; Smith, Robert/AAB-6682-2020; Porta, Daniela/J-9042-2016; J, Garcia-Aymerich/G-6867-2014; Varraso, Raphaelle/R-8740-2016; Ranciere, Fanny/F-1502-2018	Basagaña, Xavier/0000-0002-8457-1489; Wijmenga, Cisca/0000-0002-5635-1614; Lupinek, Christian/0000-0002-8612-8245; Anto, J M/0000-0002-4736-8529; siroux, valerie/0000-0001-7329-7237; Kogevinas, Manolis/0000-0002-9605-0461; Coquet, Jonathan M/0000-0002-5967-4857; Pinart, Mariona/0000-0002-8223-1325; Akdis, Cezmi/0000-0001-8020-019X; Jacquemin, Benedicte/0000-0003-1273-9892; Wright, John/0000-0001-9572-7293; Annesi-Maesano, Isabella/0000-0002-6340-9300; Sunyer, Jordi/0000-0002-2602-4110; Lambrecht, Bart N/0000-0003-4376-6834; Demoly, Pascal/0000-0001-7827-7964; guihenneuc, chantal/0000-0001-7237-7120; Pinart Gilberga, Mariona/0000-0002-8223-1325; Heinrich, Joachim/0000-0002-9620-1629; Valverde, Sergi/0000-0002-2150-9610; Porta, Daniela/0000-0002-3431-2729; J, Garcia-Aymerich/0000-0002-7097-4586; Varraso, Raphaelle/0000-0002-3338-7825; Herr, Marie/0000-0002-1836-705X; Nawijn, Martijn/0000-0003-3372-6521; Valenta, Rudolf/0000-0001-5944-3365; Koppelman, Gerard/0000-0001-8567-3252; momas, isabelle/0000-0003-4344-3787; STEIN, RENATO/0000-0003-0269-0757; Benet Mora, Marta/0000-0001-9600-3510; Ranciere, Fanny/0000-0003-3485-2247; van de Veen, Willem/0000-0001-9951-6688	Swiss National Foundation; European Union; Helse Sor-Ost; Juselius Foundation; Helsinki University; French Agency of Research; Netherlands Asthma Foundation; GlaxoSmithKline; Abbott; National Institutes of Health; Nycomed, Topinstitute Pharma; AstraZeneca; Innovative Medicines Initiative by IMI-EU (U-BIOPRED); Novartis; Stallergenes; Swiss National Science Foundation; Global Allergy and Asthma European Network; Christine Kuhne Center for Allergy Research; European Commission; Norwegian Research Council; University of Oslo; Eastern Norway Regional Health Authority; Norwegian Institute of Public Health; Norwegian Foundation for Health and Rehabilitation; Norwegian Association for Asthma and Allergy; Kloster Foundation; Voksentoppen BKL; Ulleval University Hospital; Phadia; Novartis, GlaxoSmithKline; Boehringer Ingelheim; Pfizer; Chiesi; ALK-Abello; Nycomed; Air Liquid Healthcare; Christne Kuhne Center for Allergy Research; ICREA Funding Source: Custom	Swiss National Foundation(Swiss National Science Foundation (SNSF)); European Union(European Commission); Helse Sor-Ost; Juselius Foundation; Helsinki University; French Agency of Research(French National Research Agency (ANR)); Netherlands Asthma Foundation; GlaxoSmithKline(GlaxoSmithKline); Abbott(Abbott Laboratories); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nycomed, Topinstitute Pharma; AstraZeneca(AstraZeneca); Innovative Medicines Initiative by IMI-EU (U-BIOPRED); Novartis(Novartis); Stallergenes; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Global Allergy and Asthma European Network; Christine Kuhne Center for Allergy Research; European Commission(European CommissionEuropean Commission Joint Research Centre); Norwegian Research Council(Research Council of NorwayEuropean Commission); University of Oslo; Eastern Norway Regional Health Authority; Norwegian Institute of Public Health; Norwegian Foundation for Health and Rehabilitation; Norwegian Association for Asthma and Allergy; Kloster Foundation; Voksentoppen BKL; Ulleval University Hospital; Phadia(Phadia); Novartis, GlaxoSmithKline; Boehringer Ingelheim(Boehringer Ingelheim); Pfizer(Pfizer); Chiesi(Chiesi Pharmaceuticals Inc); ALK-Abello; Nycomed; Air Liquid Healthcare; Christne Kuhne Center for Allergy Research; ICREA(ICREA)	M. Akdis has received research support from the Swiss National Foundation and the European Union. C. Auffray has received research support from the European Union. K.-H. Carlsen has received research support from Helse Sor-Ost. L. von Hertzen has received research support from the Juselius Foundation and Helsinki University. F. Kauffmann has received research support from the French Agency of Research and the European Union. T. Keil has received research support from the European Union. G. H. Koppelman has received research support from the European Union, the Netherlands Asthma Foundation, and GlaxoSmithKline. F. D. Martinez is a consultant for MedImmune, has received lecture fees from Abbott, and has received research support from the National Institutes of Health. D. S. Postma has received research support from Nycomed, Topinstitute Pharma, and AstraZeneca. P. J. Sterk has received research support from Innovative Medicines Initiative by IMI-EU (U-BIOPRED). C. A. Akdis has received research support from Novartis, Stallergenes, the Swiss National Science Foundation, the Global Allergy and Asthma European Network, and the Christine Kuhne Center for Allergy Research; has provided legal consultation/expert witness testimony on the topics of Actellion T<INF>H</INF>2-specific receptors, Aventis T-cell, B-cell regulation, and Allergopharma allergen-specific immunotherapy; is an American Academy of Allergy, Asthma & Immunology (AAAAI) fellow and interest group member; is Vice President of the European Academy of Allergy and Clinical Immunology (EAACI); and is a GA<SUP>2</SUP>LEN ex-committee member WP leader. A. Cambon-Thomsen has received research support from the European Commission FP7. K. C. Lodrup Carlsen has received research support from the Norwegian Research Council, the University of Oslo, the Eastern Norway Regional Health Authority, the Norwegian Institute of Public Health, the Norwegian Foundation for Health and Rehabilitation, the Norwegian Association for Asthma and Allergy, the Kloster Foundation, Voksentoppen BKL, AstraZeneca, Ulleval University Hospital, and Phadia; was an EACCI member at large; is chair of the Asthma and Allergy group in the pediatric section of the European Respiratory Society; and is on the GA<SUP>2</SUP>LEN executive board. D. Maier has received research support from the European Commission. S. Palkonen is employed by the European Federation of Allergy and Airways Diseases Patients' Associations, which has received grants from Novartis, GlaxoSmithKline, Boehringer Ingelheim, Pfizer, Chiesi, ALK-Abello, Stallergenes, Nycomed, AstraZeneca, and Air Liquid Healthcare. B. Stanic has received research support from the Christne Kuhne Center for Allergy Research and Education and the European Commission's Seventh Framework Programme. W. van de Veen has received research support from the Swiss National Science Foundation and the European Commission's Seventh Framework Programme. T.; Zuberbier has provided consultation for Ansell, Bayer Schering, DST, Fujisawa, HAL, Henkel, Kryolan, Leti, MSD, Novartis, Procter & Gamble, Sanofi-Aventis, Schering-Plough, Stallergenes, and UCB; is on the Scientific Advisory Board, German Society for Allergy and Clinical Immunology; is on the Expert Commission "Novel Food'' of the German Federal Ministry of Consumer Protection; is Head of the European Centre for Allergy Research Foundation (ECARF); is a committee member of the World Health Organization Initiative Allergic Rhinitis and its Impact on Asthma (ARIA); is a member of the World Allergy Organization Communications Council; and is Secretary General of the Global Allergy and Asthma European Network (GA<SUP>2</SUP>LEN). J. Bousquet has received honoraria from Stallergenes, Actelion, Almirall, AstraZeneca, Chiesi, GlaxoSmithKline, Merck, MSD, Novartis, OM Pharma, Sanofi-Aventis, Schering-Plough, Teva, and Uriach. The rest of the authors declare that they have no relevant conflicts of interest.	Aguilera I, 2009, ENVIRON HEALTH PERSP, V117, P1322, DOI 10.1289/ehp.0800256; Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P1022, DOI 10.1016/j.jaci.2009.03.034; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050; Akdis M, 2009, NAT REV DRUG DISCOV, V8, P645, DOI 10.1038/nrd2653; Akinbami Lara J, 2011, Natl Health Stat Report, P1; Anto JM, 2010, ALLERGY, V65, P1021, DOI 10.1111/j.1398-9995.2009.02301.x; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Auffray C, 2010, GENOME MED, V2, DOI 10.1186/gm178; Auffray C, 2010, CHEST, V137, P1410, DOI 10.1378/chest.09-1850; Auffray C, 2009, GENOME MED, V1, DOI 10.1186/gm2; Aysola RS, 2008, CHEST, V134, P1183, DOI 10.1378/chest.07-2779; Bachert C, 2003, J ALLERGY CLIN IMMUN, V111, P1131, DOI 10.1016/S0091-6749(03)70044-X; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, pe1, DOI DOI 10.1016/J.JACI.2010.07.007; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Balzar S, 2011, AM J RESP CRIT CARE, V183, P299, DOI 10.1164/rccm.201002-0295OC; Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918; BARKER DJP, 1989, LANCET, V2, P577; Behrmann J, 2010, J SCH NURS, V26, P183, DOI 10.1177/1059840510364844; Benton AS, 2010, J ASTHMA, V47, P728, DOI 10.3109/02770903.2010.491142; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2006, ALLERGY, V61, P671, DOI 10.1111/j.1398-9995.2006.01048.x; Bousquet J, 2004, ALLERGY, V59, P138, DOI 10.1046/j.1398-9995.2003.00359.x; Bousquet J, 2011, ALLERGY, V66, P596, DOI 10.1111/j.1398-9995.2010.02534.x; Bousquet J, 2007, GLOBAL SURVEILLANCE; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Bousquet PJ, 2008, ALLERGY, V63, P1301, DOI 10.1111/j.1398-9995.2008.01824.x; Bousquet PJ, 2010, ANN EPIDEMIOL, V20, P797, DOI 10.1016/j.annepidem.2010.05.012; Brasier AR, 2008, J ALLERGY CLIN IMMUN, V121, P30, DOI 10.1016/j.jaci.2007.10.015; Brasier AR, 2010, CTS-CLIN TRANSL SCI, V3, P147, DOI 10.1111/j.1752-8062.2010.00204.x; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Bunyavanich S, 2011, PEDIAT ALLERG IMM-UK, V22, P378, DOI 10.1111/j.1399-3038.2010.01124.x; Busacker A, 2009, CHEST, V135, P48, DOI 10.1378/chest.08-0049; Cambon-Thomsen A, 2004, NAT REV GENET, V5, P866, DOI 10.1038/nrg1473; Carlsen KCL, 2010, ALLERGY, V65, P1134, DOI 10.1111/j.1398-9995.2010.02344.x; Carroll JL, 2003, J APPL PHYSIOL, V94, P375, DOI 10.1152/japplphysiol.00809.2002; Chatzi L, 2008, THORAX, V63, P507, DOI 10.1136/thx.2007.081745; Clarisse B, 2009, PEDIAT ALLERG IMM-UK, V20, P126, DOI 10.1111/j.1399-3038.2008.00743.x; Cohen L, 2007, AM J RESP CRIT CARE, V176, P138, DOI 10.1164/rccm.200607-1062OC; Devereux G, 2006, NAT REV IMMUNOL, V6, P869, DOI 10.1038/nri1958; Dweik RA, 2010, AM J RESP CRIT CARE, V181, P1033, DOI 10.1164/rccm.200905-0695OC; Everitt B, 2004, STAT METHODS MED RES, V13, P343, DOI 10.1191/0962280204sm371ed; Everitt B., 1993, CLUSTER ANAL, V3rd; Fens N, 2009, AM J RESP CRIT CARE, V180, P1076, DOI 10.1164/rccm.200906-0939OC; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P282, DOI 10.1016/j.jaci.2010.10.036; Fitzpatrick AM, 2011, PEDIATR RES, V69, P154, DOI 10.1203/PDR.0b013e3182026370; Fitzpatrick AM, 2010, J ALLERGY CLIN IMMUN, V125, P851, DOI 10.1016/j.jaci.2010.01.048; Fitzpatrick AM, 2009, J ALLERGY CLIN IMMUN, V124, P990, DOI 10.1016/j.jaci.2009.08.039; Fitzpatrick AM, 2009, J ALLERGY CLIN IMMUN, V123, P146, DOI 10.1016/j.jaci.2008.10.047; Frey U, 2005, NATURE, V438, P667, DOI 10.1038/nature04176; Gamble C, 2010, J ALLERGY CLIN IMMUN, V126, P1149, DOI 10.1016/j.jaci.2010.08.049; Garcia-Aymerich J, 2011, THORAX, V66, P430, DOI 10.1136/thx.2010.154484; Gelfond JAL, 2011, STAT MED, V30, P2785, DOI 10.1002/sim.4282; Gomes-Alves P, 2010, CLIN BIOCHEM, V43, P168, DOI 10.1016/j.clinbiochem.2009.10.006; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Harwanegg C, 2003, CLIN EXP ALLERGY, V33, P7, DOI 10.1046/j.1365-2222.2003.01550.x; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Hens K, 2011, J MED ETHICS, V37, P179, DOI 10.1136/jme.2010.037473; Hernick AD, 2011, ENVIRON HEALTH PERSP, V119, P1, DOI 10.1289/ehp.1001988; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Hollams EM, 2010, EUR RESPIR J, V36, P509, DOI 10.1183/09031936.00184109; Holt PG, 2010, CLIN EXP IMMUNOL, V160, P22, DOI 10.1111/j.1365-2249.2010.04129.x; Inouye M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001113; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kazemi-Shirazi L, 2002, INT ARCH ALLERGY IMM, V127, P259, DOI 10.1159/000057742; Klunker S, 2009, J EXP MED, V206, P2701, DOI 10.1084/jem.20090596; Kong A, 2009, NATURE, V462, P868, DOI 10.1038/nature08625; Koppelman GH, 2011, CURR OPIN ALLERGY CL, V11, P414, DOI 10.1097/ACI.0b013e32834a9573; Kowalski ML, 2011, ALLERGY, V66, P32, DOI 10.1111/j.1398-9995.2010.02379.x; Lara A, 2008, AM J RESP CRIT CARE, V178, P673, DOI 10.1164/rccm.200710-1542OC; Lau S, 2003, EUR RESPIR J, V21, P834, DOI 10.1183/09031936.03.00037203; Levy BD, 2005, AM J RESP CRIT CARE, V172, P824, DOI 10.1164/rccm.200410-1413OC; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; Liu L, 2011, CHEST, V139, P328, DOI 10.1378/chest.10-0163; Maier D, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-38; Manolio TA, 2010, NEW ENGL J MED, V363, P166, DOI 10.1056/NEJMra0905980; Marcovitch H, 2009, J EPIDEMIOL COMMUN H, V63, P608, DOI 10.1136/jech.2008.086132; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martino DJ, 2010, ALLERGY, V65, P7, DOI 10.1111/j.1398-9995.2009.02186.x; Meiler F, 2008, ALLERGY, V63, P1455, DOI 10.1111/j.1398-9995.2008.01774.x; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Milligan G., 1998, ENCY STAT SCI; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Musk AW, 2011, EUR RESPIR J, V38, P1053, DOI 10.1183/09031936.00102110; Muskulus M, 2010, J APPL PHYSIOL, V109, P1582, DOI 10.1152/japplphysiol.01414.2009; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Outram SM, 2011, CAN J PUBLIC HEALTH, V102, P4, DOI 10.1007/BF03404869; Pakarinen J, 2008, ENVIRON MICROBIOL, V10, P3317, DOI 10.1111/j.1462-2920.2008.01723.x; Patil SP, 2011, ANN ALLERG ASTHMA IM, V106, P205, DOI 10.1016/j.anai.2010.11.019; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Pekkarinen PT, 2007, ALLERGY, V62, P281, DOI 10.1111/j.1398-9995.2006.01249.x; Poste G, 2011, NATURE, V469, P156, DOI 10.1038/469156a; Pukelsheim K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014299; Rochat MK, 2010, J ALLERGY CLIN IMMUN, V126, P1170, DOI 10.1016/j.jaci.2010.09.008; Sachs-Olsen C, 2010, J ALLERGY CLIN IMMUN, V126, P859, DOI 10.1016/j.jaci.2010.07.015; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Scholtens S, 2010, INT J OBESITY, V34, P606, DOI 10.1038/ijo.2009.194; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Semic-Jusufagic A, 2007, J ALLERGY CLIN IMMUN, V119, P930, DOI 10.1016/j.jaci.2006.12.639; Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4; Shaaban R, 2007, AM J RESP CRIT CARE, V176, P659, DOI 10.1164/rccm.200703-427OC; Shaheen SO, 2009, THORAX, V64, P411, DOI 10.1136/thx.2008.104703; Shankardass K, 2009, P NATL ACAD SCI USA, V106, P12406, DOI 10.1073/pnas.0812910106; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Siroux V, 2011, EUR RESPIR J, V38, P310, DOI 10.1183/09031936.00120810; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Sorkness RL, 2011, J ALLERGY CLIN IMMUN, V127, P1073, DOI 10.1016/j.jaci.2010.12.1079; Spergel JM, 2010, IMMUNOL ALLERGY CLIN, V30, P269, DOI 10.1016/j.iac.2010.06.003; Spycher BD, 2008, EUR RESPIR J, V31, P974, DOI 10.1183/09031936.00153507; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Szalma S, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-68; Taylor DR, 2008, POSTGRAD MED J, V84, P628, DOI 10.1136/pgmj.2008.069864; Thomsen SF, 2009, AM J RESP CRIT CARE, V179, P1091, DOI 10.1164/rccm.200809-1471OC; Valenta R, 2010, ANNU REV IMMUNOL, V28, P211, DOI 10.1146/annurev-immunol-030409-101218; von Hertzen L, 2007, ALLERGY, V62, P288, DOI 10.1111/j.1398-9995.2006.01281.x; Weatherall M, 2009, EUR RESPIR J, V34, P812, DOI 10.1183/09031936.00174408; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Willers SM, 2011, EUR RESPIR J, V37, P1060, DOI 10.1183/09031936.00106109; Wolf SM, 2008, J LAW MED ETHICS, V36, P361, DOI 10.1111/j.1748-720X.2008.00281.x; Zhang G, 2009, ALLERGY, V64, P1333, DOI 10.1111/j.1398-9995.2009.02006.x; Zink A, 2008, ANN RHEUM DIS, V67, P1041, DOI 10.1136/ard.2007.080598; Ziyab AH, 2010, CLIN EXP ALLERGY, V40, P1776, DOI 10.1111/j.1365-2222.2010.03633.x	134	57	62	0	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					943	U421		10.1016/j.jaci.2012.01.047	http://dx.doi.org/10.1016/j.jaci.2012.01.047			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22386796				2022-12-18	WOS:000302144600008
J	Capili, CR; Hettinger, A; Rigelman-Hedberg, N; Fink, L; Boyce, T; Lahr, B; Juhn, YJ				Capili, Conrad R.; Hettinger, Allison; Rigelman-Hedberg, Natalie; Fink, Lisa; Boyce, Thomas; Lahr, Brian; Juhn, Young J.			Increased risk of pertussis in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; epidemiology; outbreak; Bordetella pertussis; risk; susceptibility; immunity; adolescents; children; population	OBSTRUCTIVE PULMONARY-DISEASE; LONG-TERM USE; CHILDHOOD ASTHMA; IMMUNE-RESPONSE; INHALED CORTICOSTEROIDS; FILAGGRIN MUTATIONS; CELLULAR IMMUNITY; UNITED-STATES; EPIDEMIOLOGY; VACCINE	Background: The recent pertussis outbreak in California highlights the effect of pertussis on public health. In 2004, a pertussis outbreak occurred in Olmsted County, Minnesota, despite a high vaccine uptake. This outbreak provided a natural experiment to assess the relationship between asthma and pertussis. Objective: We sought to determine whether asthmatic subjects have a higher risk of pertussis than nonasthmatic subjects. Methods: We conducted a population-based case-control study. There were 223 pertussis cases identified by means of PCR in 2004 and 2005. We identified age-and sex-matched control subjects from 5537 patients with negative test results for pertussis. We conducted a comprehensive medical record review and applied predetermined criteria to ascertain asthma status. Conditional logistic regression was fit to assess the effect of asthma status on the risk of pertussis. Results: Of the 223 subjects, 164 were eligible for the study, and 328 matched control subjects (1: 2 matching) were enrolled. Of these 164 subjects, 50% were male, and 82% were white. The median age at the index date of pertussis was 14 years. Sixty-two (38%) of the 164 cases had asthma before the index date of pertussis compared with 85 (26%) of the 328 control subjects (odds ratio, 1.73; 95% CI, 1.12-2.67; P = .013). The population attributable risk percentage of asthma for risk of pertussis was 17%. Conclusions: Given the high prevalence of asthma and the ongoing risk of pertussis throughout the United States, consideration of defining asthmatic subjects as a target group for pertussis vaccination (eg, replacing decennial tetanus-diphtheria booster with tetanus, diphtheria, and acellular pertussis vaccine for adolescents and adults) should be given. (J Allergy Clin Immunol 2012;129:957-63.)	[Juhn, Young J.] Mayo Clin, Div Community Pediat & Adolescent Med, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; [Capili, Conrad R.; Rigelman-Hedberg, Natalie] Mayo Clin, Mayo Med Sch, Rochester, MN 55905 USA; [Lahr, Brian] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Juhn, YJ (corresponding author), Mayo Clin, Div Community Pediat & Adolescent Med, Dept Pediat & Adolescent Med, 200 1st St SW, Rochester, MN 55905 USA.	juhn.young@mayo.edu			Mayo Foundation from the National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01-AR30582]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG034676] Funding Source: NIH RePORTER	Mayo Foundation from the National Institute of Arthritis and Musculoskeletal and Skin Diseases; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by the Clinician Scholarly Award from the Mayo Foundation made possible by the Rochester Epidemiology Project (R01-AR30582) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases.	Almirall J, 2008, EUR RESPIR J, V31, P1274, DOI 10.1183/09031936.00095807; American Academy of Pediatrics, 2009, RED BOOK 2009; Anandan C, 2010, ALLERGY, V65, P152, DOI 10.1111/j.1398-9995.2009.02244.x; [Anonymous], PERT REP 2010; Bauer BA, 1997, CHEST, V111, P303, DOI 10.1378/chest.111.2.303; BEARD CM, 1992, J CLIN EPIDEMIOL, V45, P1013; Bisgard KM, 2004, PEDIATR INFECT DIS J, V23, P985, DOI 10.1097/01.inf.0000145263.37198.2b; Black S, 1997, PEDIATR INFECT DIS J, V16, pS85, DOI 10.1097/00006454-199704001-00003; Brown K., 2005, Morbidity and Mortality Weekly Report, V54, P1283; *CDCP, 2005, MMWR-MORBID MORTAL W, V53, P1213; Centers for Disease Control and Prevention, 2011, PERT FAST FACTS; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P1022; Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1; Chaplin DD, 2007, J ALLERGY CLIN IMMUN, V119, pS132, DOI 10.1016/j.jaci.2006.11.647; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; De Serres G, 2000, J INFECT DIS, V182, P174, DOI 10.1086/315648; Edwards KM, 2005, PEDIATR INFECT DIS J, V24, pS104, DOI 10.1097/01.inf.0000166154.47013.47; Fahy J V, 2000, Curr Opin Pulm Med, V6, P15, DOI 10.1097/00063198-200001000-00004; Fischer JE, 1997, J VIROL, V71, P8672, DOI 10.1128/JVI.71.11.8672-8677.1997; Flory JH, 2009, EPIDEMIOL INFECT, V137, P717, DOI 10.1017/S0950268808001489; GROVE DI, 1975, J ALLERGY CLIN IMMUN, V55, P152, DOI 10.1016/0091-6749(75)90011-1; GROVE DI, 1975, BRIT J DERMATOL, V92, P611, DOI 10.1111/j.1365-2133.1975.tb03139.x; Guris D, 1999, CLIN INFECT DIS, V28, P1230, DOI 10.1086/514776; Hellenbrand W, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-22; HOGUE CJR, 1983, AM J EPIDEMIOL, V118, P396, DOI 10.1093/oxfordjournals.aje.a113646; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; HUNT LW, 1993, JAMA-J AM MED ASSOC, V269, P1947, DOI 10.1001/jama.269.15.1947; Juhn YJ, 2007, TISSUE ANTIGENS, V69, P38, DOI 10.1111/j.1399-0039.2006.00719.x; Juhn YJ, 2005, J ALLERGY CLIN IMMUN, V116, P510, DOI 10.1016/j.jaci.2005.05.043; Juhn YJ, 2005, SOC SCI MED, V60, P2453, DOI 10.1016/j.socscimed.2004.11.034; Juhn YJ, 2008, J ALLERGY CLIN IMMUN, V122, P719, DOI 10.1016/j.jaci.2008.07.029; Juhn YJ, 2006, ANN ALLERG ASTHMA IM, V97, P469, DOI 10.1016/S1081-1206(10)60937-4; Jung JA, 2010, POSTGRAD MED, V122, P116, DOI 10.3810/pgm.2010.09.2208; Kendirli SG, 2009, ALLERGOL IMMUNOPATH, V37, P21, DOI 10.1016/S0301-0546(09)70247-2; KincyCain T, 1996, INFECT IMMUN, V64, P1437, DOI 10.1128/IAI.64.4.1437-1440.1996; Klemets P, 2010, THORAX, V65, P698, DOI 10.1136/thx.2009.132670; Koepsell T. D, 2003, EPIDEMIOLOGIC METHOD; Krassilnikova SI, 2006, J ALLERGY CLIN IMMUN, V117, pS209, DOI 10.1016/j.jaci.2005.12.825; LAHOOD N, 1993, ANN ALLERGY, V70, P289; Lethbridge-Cejku M, 2005, SUMMARY HLTH STAT US; Loeffelholz MJ, 1999, J CLIN MICROBIOL, V37, P2872, DOI 10.1128/JCM.37.9.2872-2876.1999; Loeffelholz MJ, 2000, J CLIN MICROBIOL, V38, P467; Marenholz I, 2009, J ALLERGY CLIN IMMUN, V123, P911, DOI 10.1016/j.jaci.2009.01.051; Masten B, 2003, PEDIATR PULM, V36, P522, DOI 10.1002/ppul.10362; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; Murphy DM, 2010, CHEST, V137, P1417, DOI 10.1378/chest.09-1895; O'Byrne PM, 2011, AM J RESP CRIT CARE, V183, P589, DOI 10.1164/rccm.201005-0694OC; Pichichero ME, 2006, PEDIATRICS, V117, P1084, DOI 10.1542/peds.2005-1759; Pichichero ME, 2005, JAMA-J AM MED ASSOC, V293, P3003, DOI 10.1001/jama.293.24.3003; Prescott SL, 1998, LANCET, V351, P1489, DOI 10.1016/S0140-6736(05)78871-1; Santos JCH, 2011, PEDIATR INT, V53, P576, DOI 10.1111/j.1442-200X.2011.03333.x; Schneider LC, 2008, J ALLERGY CLIN IMMUN, V121, pS272, DOI 10.1016/j.jaci.2007.12.1080; Silverstein MD, 1997, J ALLERGY CLIN IMMUN, V99, P466, DOI 10.1016/S0091-6749(97)70072-1; SILVERSTEIN MD, 1994, NEW ENGL J MED, V331, P1537, DOI 10.1056/NEJM199412083312301; Singh S, 2009, ARCH INTERN MED, V169, P219, DOI 10.1001/archinternmed.2008.550; Singh S, 2010, CURR OPIN PULM MED, V16, P118, DOI 10.1097/MCP.0b013e328334c085; St Sauver JL, 2011, AM J EPIDEMIOL, V173, P1059, DOI 10.1093/aje/kwq482; STRANNEGARD IL, 1976, INT ARCH ALLER A IMM, V50, P684, DOI 10.1159/000231547; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; Tanaka M, 2003, JAMA-J AM MED ASSOC, V290, P2968, DOI 10.1001/jama.290.22.2968; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; World Health Organization, 2005, FACT SHEET ASTHM; Yawn BP, 1999, J ALLERGY CLIN IMMUN, V103, P54, DOI 10.1016/S0091-6749(99)70525-7; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	66	57	60	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					957	963		10.1016/j.jaci.2011.11.020	http://dx.doi.org/10.1016/j.jaci.2011.11.020			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22206778	Green Accepted			2022-12-18	WOS:000302144600009
J	Meyer, N; Christoph, J; Makrinioti, H; Indermitte, P; Rhyner, C; Soyka, M; Eiwegger, T; Chalubinski, M; Wanke, K; Fujita, H; Wawrzyniak, P; Burgler, S; Zhang, S; Akdis, M; Menz, G; Akdis, C				Meyer, Norbert; Christoph, Janine; Makrinioti, Heidi; Indermitte, Philippe; Rhyner, Claudio; Soyka, Michael; Eiwegger, Thomas; Chalubinski, Maciej; Wanke, Kerstin; Fujita, Hiroyuki; Wawrzyniak, Paulina; Buergler, Simone; Zhang, Sherrie; Akdis, Muebeccel; Menz, Guenter; Akdis, Cezmi			Inhibition of angiogenesis by IL-32: Possible role in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bronchial epithelial cells; asthma; IL-32; angiogenesis; vascular endothelial growth factor; endotype	ENDOTHELIAL GROWTH-FACTOR; PROINFLAMMATORY CYTOKINE; KERATINOCYTE APOPTOSIS; CELLS; INTERLEUKIN-32; INFLAMMATION; ACTIVATION; EXPRESSION; IL-1-BETA; INDUCTION	Background: IL-32 is a proinflammatory cytokine involved in various chronic inflammatory diseases. Chronic airway inflammation in asthmatic patients results in structural airway changes, including angiogenesis. Vascular endothelial growth factor (VEGF) is a key inducer of angiogenesis in the airways of asthmatic patients. Objective: The aim of the study was to investigate the expression and function of IL-32 in patients with angiogenesis and asthma. Methods: The expression and regulation of IL-32 in normal human bronchial epithelial (NHBE) cells was analyzed by using RT-PCR, ELISA, Western blotting, immunofluorescent staining, and flow cytometry. After knockdown of IL-32 in NHBE cells by small interfering RNA (siRNA) transfections, VEGF secretion was quantified by means of ELISA. New blood vessel formation was determined with human umbilical vein endothelial cells by culturing with supernatants from IL-32 siRNA-transfected NHBE cells. IL-32 was determined in serum and induced sputum samples of asthmatic patients and healthy control subjects by means of ELISA. Results: IL-32 is expressed in NHBE cells on stimulation with IFN-gamma, TNF-alpha, T(H)1 cells, and rhinovirus. Inhibition of IL-32 expression resulted in significantly increased secretion of the proangiogenic factors VEGF and platelet-derived growth factor by NHBE cells. Human umbilical vein endothelial cells cultured in supernatants from IL-32 siRNA-transfected NHBE cells showed enhanced in vitro angiogenesis. IL-32 is detectable in induced sputum from asthmatic patients. IL-32 serum levels were significantly higher in asthmatic patients compared with those seen in healthy control subjects and correlated with response to asthma treatment. Conclusion: IL-32 is induced by IFN-gamma, TNF-alpha, T(H)1 cells, and rhinovirus in bronchial epithelial cells. It inhibits angiogenesis, and its serum levels are associated with a good treatment response in asthmatic patients. (J Allergy Clin Immunol 2012;129:964-73.)	[Meyer, Norbert; Makrinioti, Heidi; Indermitte, Philippe; Rhyner, Claudio; Soyka, Michael; Eiwegger, Thomas; Chalubinski, Maciej; Wanke, Kerstin; Fujita, Hiroyuki; Wawrzyniak, Paulina; Buergler, Simone; Akdis, Muebeccel; Akdis, Cezmi] Swiss Inst Allergy & Asthma Res SIAF, CH-7270 Davos, Switzerland; [Meyer, Norbert; Christoph, Janine; Menz, Guenter] Hochgebirgsklin Davos, Davos, Switzerland; [Eiwegger, Thomas] Med Univ Vienna, Dept Pediat, Vienna, Austria; [Zhang, Sherrie] BioLegend, San Diego, CA USA	Swiss Institute of Allergy & Asthma Research; Medical University of Vienna	Meyer, N (corresponding author), Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22, CH-7270 Davos, Switzerland.	norbert.meyer@siaf.uzh.ch; akdisac@siaf.uzh.ch	Akdis, Cezmi/AAV-4844-2020; Wawrzyniak, Paulina/AAD-7265-2020; Wawrzyniak, Paulina/AAG-3548-2019; Wawrzyniak, Paulina/HCG-8924-2022	Akdis, Cezmi/0000-0001-8020-019X; Wawrzyniak, Paulina/0000-0001-9641-2103; Eiwegger, Thomas/0000-0002-2914-7829; Chalubinski, Maciej/0000-0001-8311-9530	European Allergy and Asthma Center Davos (EACD); Swiss National Science Foundation [32-132899, 32-112306]; Christine Kuhne Center for Allergy Research and Education (CK-CARE); European Network; European Academy of Allergy and Clinical Immunology fellowship; Swiss Institute of Allergy and Asthma Research; Ulrich Miller Gierok Foundation; University Hospital of Zurich; Swiss National Foundation; European Union; Novartis; Stallergenes; Swiss National Science Foundation; Global Allergy and Asthma European Network; Christine Kuhne Center for Allergy Research	European Allergy and Asthma Center Davos (EACD); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Christine Kuhne Center for Allergy Research and Education (CK-CARE); European Network; European Academy of Allergy and Clinical Immunology fellowship; Swiss Institute of Allergy and Asthma Research; Ulrich Miller Gierok Foundation; University Hospital of Zurich; Swiss National Foundation(Swiss National Science Foundation (SNSF)); European Union(European Commission); Novartis(Novartis); Stallergenes; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Global Allergy and Asthma European Network; Christine Kuhne Center for Allergy Research	The authors' laboratory is supported by the European Allergy and Asthma Center Davos (EACD), Swiss National Science Foundation grant nos. 32-132899 and 32-112306, the Christine Kuhne Center for Allergy Research and Education (CK-CARE), and the Predicta FP7 7th frame European Network. H. M. received a European Academy of Allergy and Clinical Immunology fellowship.; C. Rhyner has received research support from and is an employee of the Swiss Institute of Allergy and Asthma Research. M. Soyka has received research support from the Ulrich Miller Gierok Foundation and the University Hospital of Zurich. M. Akdis has received research support from the Swiss National Foundation and the European Union. C. Akdis has received research support from Novartis, Stallergenes, the Swiss National Science Foundation, the Global Allergy and Asthma European Network, and the Christine Kuhne Center for Allergy Research; has served as an expert witness on the topics of T<INF>H</INF>2-specific receptors (for Acellion) T-cell and B-cell regulation (for Aventis), and allergen-specific immunotherapy (for Allergopharma); is a Fellow and interest group member for the American Academy of Allergy, Asthma & Immunology; is Vice President of the European Academy of Allergy and Clinical Immunology; and is an ex-committee member and WP leader for GA<SUP>2</SUP>LEN. The rest of the authors declare that they have no relevant conflicts of interest.	Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Aurora AB, 2005, J IMMUNOL, V175, P6319, DOI 10.4049/jimmunol.175.10.6319; Bai XY, 2010, J IMMUNOL, V184, P3830, DOI 10.4049/jimmunol.0901913; Basinski TM, 2009, J ALLERGY CLIN IMMUN, V124, P74, DOI 10.1016/j.jaci.2009.04.019; Boussat S, 2000, AM J PHYSIOL-LUNG C, V279, pL371, DOI 10.1152/ajplung.2000.279.2.L371; Burgler S, 2009, J ALLERGY CLIN IMMUN, V123, P588, DOI 10.1016/j.jaci.2008.12.017; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DAHL CA, 1992, J IMMUNOL, V148, P597; Detoraki A, 2010, ALLERGY, V65, P946, DOI 10.1111/j.1398-9995.2010.02372.x; Gabhann FM, 2008, MICROCIRCULATION, V15, P715, DOI 10.1080/10739680802095964; Goda C, 2006, INT IMMUNOL, V18, P233, DOI 10.1093/intimm/dxh339; Hasegawa H, 2011, CYTOKINE, V53, P74, DOI 10.1016/j.cyto.2010.09.002; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hong J, 2010, CYTOKINE, V49, P171, DOI 10.1016/j.cyto.2009.10.003; Honorati MC, 2004, OSTEOARTHR CARTILAGE, V12, P683, DOI 10.1016/j.joca.2004.05.009; Joosten LAB, 2006, P NATL ACAD SCI USA, V103, P3298, DOI 10.1073/pnas.0511233103; Kaminska M, 2009, J ALLERGY CLIN IMMUN, V124, P45, DOI 10.1016/j.jaci.2009.03.049; Kang JW, 2009, IMMUNOLOGY, V128, pe532, DOI 10.1111/j.1365-2567.2008.03025.x; Kim KH, 2008, J IMMUNOL METHODS, V333, P38, DOI 10.1016/j.jim.2007.12.017; Kim SH, 2005, IMMUNITY, V22, P131, DOI 10.1016/j.immuni.2004.12.003; Klunker S, 2009, J EXP MED, V206, P2701, DOI 10.1084/jem.20090596; Kobayashi H, 2009, CYTOKINE, V46, P351, DOI 10.1016/j.cyto.2009.03.007; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Li W, 2009, EUR J IMMUNOL, V39, P1019, DOI 10.1002/eji.200838885; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Meyer N, 2010, J ALLERGY CLIN IMMUN, V125, P858, DOI 10.1016/j.jaci.2010.01.016; Netea MG, 2006, PLOS MED, V3, P1310, DOI 10.1371/journal.pmed.0030277; Nishimoto KP, 2008, J IMMUNOL, V181, P4010, DOI 10.4049/jimmunol.181.6.4010; Nold MF, 2008, J IMMUNOL, V181, P557, DOI 10.4049/jimmunol.181.1.557; Nold-Petry CA, 2009, P NATL ACAD SCI USA, V106, P3883, DOI 10.1073/pnas.0813334106; Numasaki M, 2004, IMMUNOL LETT, V93, P39, DOI 10.1016/j.imlet.2004.01.014; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Psarras S, 2006, J ALLERGY CLIN IMMUN, V117, P291, DOI 10.1016/j.jaci.2005.11.005; Pukelsheim K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014299; Regamey N, 2008, AM J RESP CRIT CARE, V177, P837, DOI 10.1164/rccm.200707-977OC; Saetta M, 2000, AM J RESP CRIT CARE, V161, P1016, DOI 10.1164/ajrccm.161.3.9907080; Shioya M, 2007, CLIN EXP IMMUNOL, V149, P480, DOI 10.1111/j.1365-2249.2007.03439.x; Takayama G, 2006, J ALLERGY CLIN IMMUN, V118, P98, DOI 10.1016/j.jaci.2006.02.046; Tillie-Leblond I, 2008, ALLERGY, V63, P533, DOI 10.1111/j.1398-9995.2008.01656.x; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Trautmann A, 2001, J ALLERGY CLIN IMMUN, V108, P839, DOI 10.1067/mai.2001.118796; Wen FQ, 2003, J ALLERGY CLIN IMMUN, V111, P1307, DOI 10.1067/mai.2003.1455; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Zimmermann M, 2011, J ALLERGY CLIN IMMUN, V127, P200, DOI 10.1016/j.jaci.2010.11.005	47	57	57	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					964	U447		10.1016/j.jaci.2011.12.1002	http://dx.doi.org/10.1016/j.jaci.2011.12.1002			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22336080				2022-12-18	WOS:000302144600010
J	Dunkin, D; Berin, MC; Mayer, L				Dunkin, David; Berin, M. Cecilia; Mayer, Lloyd			Allergic sensitization can be induced via multiple physiologic routes in an adjuvant-dependent manner	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adjuvant; dendritic cell; milk allergy; mucosal; tolerance	FREE MOUSE MODEL; DENDRITIC CELLS; TRANSCUTANEOUS IMMUNIZATION; LANGERHANS CELLS; ORAL TOLERANCE; FOOD ALLERGY; TREE NUT; ANTIGEN; SKIN; PREVALENCE	Background: Oral exposure to food allergens may be limited in infancy, and the initial site of antigen exposure likely plays an important role in food allergy induction. Objective: To examine the impact of different routes of exposure by using milk allergens, with and without adjuvant, on sensitization. Methods: C3H/HeJ mice were repeatedly exposed to the milk allergen alpha-lactalbumin (ALA), with or without cholera toxin (CT). Sensitization routes used were intragastric, cutaneous, intranasal, and sublingual. Anaphylaxis severity was assessed by symptoms and body temperature in response to oral challenge. Antigen-specific serum antibodies were measured by ELISA. The mechanism of adjuvant activity of cutaneous CT was also determined. Results: Sensitization to ALA as measured by allergen-specific IgE occurred by all routes of sensitization and was maximal in response to cutaneous exposure. Sensitization was dependent on CT and did not occur to antigen alone by any route. Mucosal, but not cutaneous, exposure resulted in a robust allergen-specific IgA response. Anaphylaxis occurred in all sensitized groups when orally challenged with ALA. Topical CT induced migration of langerin(neg) dermal dendritic cells to the lymph node, resulting in enhanced proliferation and T(H)2 cytokine production from responder T cells. Conclusions: Sensitization can occur via all physiologic routes when adjuvant is present. The skin is a potent and likely important physiologic route of sensitization whereby adjuvant induces an efflux of antigen-bearing dermal dendritic cells to the lymph node that generate a proallergic T(H)2 response. (J Allergy Clin Immunol 2011;128:1251-8.)	[Dunkin, David] Mt Sinai Sch Med, Div Pediat Gastroenterol, New York, NY 10029 USA; [Berin, M. Cecilia; Mayer, Lloyd] Mt Sinai Sch Med, Inst Immunol, New York, NY 10029 USA; [Berin, M. Cecilia] Mt Sinai Sch Med, Div Pediat Allergy & Immunol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Dunkin, D (corresponding author), Mt Sinai Sch Med, Div Pediat Gastroenterol, 1 Gustave L Levy Pl,Box 1656, New York, NY 10029 USA.	David.dunkin@mssm.edu		berin, cecilia/0000-0002-9051-9249; Dunkin, David/0000-0002-7921-134X	NIH [PO1 AI044236, K12 HD052890]; National Institutes of Health (NIAID); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD052890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI044236] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by NIH grants PO1 AI044236 and K12 HD052890.; M. C. Berin receives research support from the National Institutes of Health (NIAID). The rest of the authors have declared that they have no conflict of interest.	Allam JP, 2010, J ALLERGY CLIN IMMUN, V126, P638, DOI 10.1016/j.jaci.2010.04.039; Anjuere F, 2003, J IMMUNOL, V170, P1586, DOI 10.4049/jimmunol.170.3.1586; Baral VR, 2005, POSTGRAD MED J, V81, P693, DOI 10.1136/pgmj.2004.030288; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; BERIN MC, 2008, J ALLERGY CLIN IMMUN, V121, P21; Birmingham NP, 2007, INT ARCH ALLERGY IMM, V144, P203, DOI 10.1159/000103993; Blazquez AB, 2008, J IMMUNOL, V180, P4441, DOI 10.4049/jimmunol.180.7.4441; Brix S, 2004, INT ARCH ALLERGY IMM, V135, P216, DOI 10.1159/000081306; Cecilia M, 2008, J ALLERGY CLIN IMMUN, V121, P1311, DOI 10.1016/j.jaci.2008.04.023; Chehade M, 2005, J ALLERGY CLIN IMMUN, V115, P3, DOI 10.1016/j.jaci.2004.11.008; Ebner S, 2007, J ALLERGY CLIN IMMUN, V119, P982, DOI 10.1016/j.jaci.2007.01.003; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Gonipeta B, 2009, J DAIRY SCI, V92, P4738, DOI 10.3168/jds.2008-1927; Hsieh KY, 2003, CLIN EXP ALLERGY, V33, P1067, DOI 10.1046/j.1365-2222.2003.01724.x; Hsu SC, 2010, J BIOL CHEM, V285, P7903, DOI 10.1074/jbc.M109.058370; Huvenne W, 2010, CLIN EXP ALLERGY, V40, P1079, DOI 10.1111/j.1365-2222.2010.03464.x; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jin HL, 2009, J CLIN INVEST, V119, P47, DOI 10.1172/JCI32310; King IL, 2010, J EXP MED, V207, P953, DOI 10.1084/jem.20091844; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Laouini D, 2003, J ALLERGY CLIN IMMUN, V112, P981, DOI 10.1016/j.jaci.2003.07.007; Mandron M, 2006, J ALLERGY CLIN IMMUN, V117, P1141, DOI 10.1016/j.jaci.2005.12.1360; Mascarell L, 2008, J ALLERGY CLIN IMMUN, V122, P603, DOI 10.1016/j.jaci.2008.06.034; McGowen AL, 2009, VACCINE, V27, P3544, DOI 10.1016/j.vaccine.2009.03.069; Naito S, 2007, VACCINE, V25, P8762, DOI 10.1016/j.vaccine.2007.10.031; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, P976, DOI 10.1016/j.jaci.2010.08.041; Pochard P, 2010, J ALLERGY CLIN IMMUN, V126, P92, DOI 10.1016/j.jaci.2010.04.003; Rodriguez D, 2003, J IMMUNOL, V171, P1001, DOI 10.4049/jimmunol.171.2.1001; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Roth-Walter F, 2008, ALLERGY, V63, P882, DOI 10.1111/j.1398-9995.2008.01673.x; Sen D, 2010, P NATL ACAD SCI USA, V107, P8334, DOI 10.1073/pnas.0912817107; Shreffler WG, 2006, J IMMUNOL, V177, P3677, DOI 10.4049/jimmunol.177.6.3677; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Tang H, 2010, NAT IMMUNOL, V11, P608, DOI 10.1038/ni.1883; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Worbs T, 2006, J EXP MED, V203, P519, DOI 10.1084/jem.20052016	40	57	59	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1251	U593		10.1016/j.jaci.2011.06.007	http://dx.doi.org/10.1016/j.jaci.2011.06.007			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21762973	Green Accepted			2022-12-18	WOS:000298342700014
J	Apter, AJ; Wang, XM; Bogen, DK; Rand, CS; McElligott, S; Polsky, D; Gonzalez, R; Priolo, C; Adam, B; Geer, S; Ten Have, T				Apter, Andrea J.; Wang, Xingmei; Bogen, Daniel K.; Rand, Cynthia S.; McElligott, Sean; Polsky, Daniel; Gonzalez, Rodalyn; Priolo, Chantel; Adam, Bariituu; Geer, Sabrina; Ten Have, Thomas			Problem solving to improve adherence and asthma outcomes in urban adults with moderate or severe asthma: A randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; adherence; adults; inner-city asthma; problem solving; health disparities; inhaled corticosteroids	DOSE INHALER ADHERENCE; MEDICATION ADHERENCE; DEPRESSIVE SYMPTOMS; LIFE STRESS; LOW-INCOME; QUALITY; HEALTH; QUESTIONNAIRE; VALIDATION; INTERVENTION	Background: Improving inhaled corticosteroid (ICS) adherence should improve asthma outcomes. Objective: In a randomized controlled trial we tested whether an individualized problem-solving (PS) intervention improves ICS adherence and asthma outcomes. Methods: Adults with moderate or severe asthma from clinics serving urban neighborhoods were randomized to PS (ie, defining specific barriers to adherence, proposing/weighing solutions, trying the best, assessing, and revising) or standard asthma education (AE) for 3 months and then observed for 3 months. Adherence was monitored electronically. Outcomes included the following: asthma control, FEV1, asthma-related quality of life, emergency department (ED) visits, and hospitalizations. In an intention-to-treat-analysis longitudinal models using random effects and regression were used. Results: Three hundred thirty-three adults were randomized: 49 +/- 14 years of age, 72% female, 68% African American, 7% Latino, mean FEV1 of 66% +/- 19%, and 103 (31%) with hospitalizations and 172 (52%) with ED visits for asthma in the prior year. There was no difference between groups in overall change in any outcome (P > .20). Mean adherence (61% +/- 27%) decreased significantly (P = .0004) over time by 14% and 10% in the AE and PS groups, respectively. Asthma control improved overall by 15% (P = .002). In both groups FEV1 and quality of life improved by 6% (P = .01) and 18% (P < .0001), respectively. However, the improvement in FEV1 only occurred during monitoring but not subsequently after randomization. Rates of ED visits and hospitalizations did not significantly decrease over the study period. Conclusion: PS was not better than AE in improving adherence or asthma outcomes. However, monitoring ICS use with provision of medications and attention, which was imposed on both groups, was associated with improvement in FEV1 and asthma control. (J Allergy Clin Immunol 2011;128:516-23.)	[Apter, Andrea J.; Gonzalez, Rodalyn; Priolo, Chantel; Adam, Bariituu; Geer, Sabrina] Univ Penn, Allergy & Immunol Sect, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA; [Apter, Andrea J.; McElligott, Sean; Polsky, Daniel] Univ Penn, Dept Med, Philadelphia, PA 19104 USA; [Wang, Xingmei; Ten Have, Thomas] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Bogen, Daniel K.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Rand, Cynthia S.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Johns Hopkins University; Johns Hopkins Medicine	Apter, AJ (corresponding author), Hosp Univ Penn, 829 Gates Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.	apter@mail.med.upenn.edu		Ten Have, Thomas/0000-0003-0026-3073	National Institutes of Health [HL070392, HL088469, HL099612]; National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI); Astra Zeneca/Bristol-Myers Squibb; Merck Foundation/MCAN; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL088469, RC1HL099612, R01HL073932] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Astra Zeneca/Bristol-Myers Squibb(Bristol-Myers SquibbAstraZeneca); Merck Foundation/MCAN(Merck & Company); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Sdupported by National Institutes of Health grants HL070392 and HL088469. A.J.A. was supported by HL070392, HL088469, and HL099612. X. W., D. K. B., T. T. H., R. G., C. P., B. A., and S. G. were supported by HL070392 and HL099612. D. P. was supported by HL070392.; Disclosure of potential conflict of interest: A. J. Apter receives research support from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) and Astra Zeneca/Bristol-Myers Squibb. D. K. Bogen receives research support from the NIH/NHLBI. C. S. Rand is on the advisory board for the Merck Foundation/MCAN and has consultant arrangements with TEVA. D. Polsky has consultant arrangements with GlaxoSmithKline. The rest of the authors have declared that they have no conflict of interest.	[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; APTER AJ, 2003, AM REV RESP CRIT CAR, V167, pA155; Apter AJ, 2006, J ASTHMA, V43, P705, DOI 10.1080/02770900600925585; Apter AJ, 2010, J ALLERGY CLIN IMMUN, V126, P552, DOI 10.1016/j.jaci.2010.07.014; Arean P, 2008, GERONTOLOGIST, V48, P311, DOI 10.1093/geront/48.3.311; Baker DW, 1999, PATIENT EDUC COUNS, V38, P33, DOI 10.1016/S0738-3991(98)00116-5; Bender B, 2000, ANN ALLERG ASTHMA IM, V85, P416, DOI 10.1016/S1081-1206(10)62557-4; Bender BG, 2007, PEDIATRICS, V120, pE471, DOI 10.1542/peds.2006-3457; Berg J, 1998, ANN BEHAV MED, V20, P36, DOI 10.1007/BF02893807; Bogen D, 2004, J ALLERGY CLIN IMMUN, V114, P863, DOI 10.1016/j.jaci.2004.07.017; BOSLEY CM, 1995, EUR RESPIR J, V8, P899; Bromberger JT, 2004, AM J PUBLIC HEALTH, V94, P1378, DOI 10.2105/AJPH.94.8.1378; D'Zurilla T. J., 1999, PROBLEM SOLVING THER; DOLCE JJ, 1991, CHEST, V99, P837, DOI 10.1378/chest.99.4.837; Gamble J, 2009, AM J RESP CRIT CARE, V180, P817, DOI 10.1164/rccm.200902-0166OC; George M, 2003, J ALLERGY CLIN IMMUN, V111, P967, DOI 10.1067/mai.2003.1459; Glasgow RE, 1996, DIABETES CARE, V19, P835, DOI 10.2337/diacare.19.8.835; Haynes RB, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000011.pub2; Hill-Briggs F, 2003, ANN BEHAV MED, V25, P182, DOI 10.1207/S15324796ABM2503_04; Hill-Briggs F, 2001, DIABETES CARE, V24, P959, DOI 10.2337/diacare.24.5.959; Institute of Medicine, 2003, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; Juniper EF, 2000, AM J RESP CRIT CARE, V162, P1330, DOI 10.1164/ajrccm.162.4.9912138; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Juniper EF, 2001, RESP MED, V95, P319, DOI 10.1053/rmed.2001.1034; KELLY JA, 1994, AM J PUBLIC HEALTH, V84, P1918, DOI 10.2105/AJPH.84.12.1918; Leidy NK, 1998, AM J RESP CRIT CARE, V158, P1082, DOI 10.1164/ajrccm.158.4.9708130; Lieu TA, 2004, PEDIATRICS, V114, pE102, DOI 10.1542/peds.114.1.e102; MAHONYANAYA P, 2007, AM J RESP CRIT CARE, V175, pA547; MCLEAVEY BC, 1994, SUICIDE LIFE-THREAT, V24, P382; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; Mirabeau-Beale KL, 2009, GYNECOL ONCOL, V114, P353, DOI 10.1016/j.ygyno.2009.05.009; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Nezu A. M., 1987, SO PSYCHOL, V3, P29; NEZU AM, 1985, J CONSULT CLIN PSYCH, V53, P693, DOI 10.1037/0022-006X.53.5.693; NEZU AM, 1986, PSYCHOL REP, V58, P279, DOI 10.2466/pr0.1986.58.1.279; NIDES MA, 1993, CHEST, V104, P501, DOI 10.1378/chest.104.2.501; Perri MG, 2008, ARCH INTERN MED, V168, P2347, DOI 10.1001/archinte.168.21.2347; PLATT JJ, 1993, J COGN PSYCHOTHER, V7, P21; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RAND CS, 1995, AM J RESP CRIT CARE, V152, P580, DOI 10.1164/ajrccm.152.2.7633711; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; RAND CS, 1993, AM J CARDIOL, V72, pD68, DOI 10.1016/0002-9149(93)90014-4; Riekert KA, 2002, J CLIN PSYCHOL MED S, V9, P25, DOI 10.1023/A:1014131928789; Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; SPECTOR SL, 1986, J ALLERGY CLIN IMMUN, V77, P65, DOI 10.1016/0091-6749(86)90325-8; Surkan PJ, 2006, MATERN CHILD HLTH J, V10, P375, DOI 10.1007/s10995-005-0056-9; Thorpe KE, 2009, J CLIN EPIDEMIOL, V62, P464, DOI [10.1503/cmaj.090523, 10.1016/j.jclinepi.2008.12.011]; *US DEP HHS, 2007, 3 EXP PAN US DEP HLT; Williams LK, 2007, J ALLERGY CLIN IMMUN, V120, P1153, DOI 10.1016/j.jaci.2007.08.020; Williams LK, 2010, J ALLERGY CLIN IMMUN, V126, P225, DOI 10.1016/j.jaci.2010.03.034; Wilson SR, 2010, AM J RESP CRIT CARE, V181, P566, DOI 10.1164/rccm.200906-0907OC	59	57	59	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					516	U122		10.1016/j.jaci.2011.05.010	http://dx.doi.org/10.1016/j.jaci.2011.05.010			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	812HS	21704360	Green Accepted			2022-12-18	WOS:000294283400009
J	Zeiger, RS; Schatz, M; Zhang, F; Crawford, WW; Kaplan, MS; Roth, RM; Chen, WS				Zeiger, Robert S.; Schatz, Michael; Zhang, Feng; Crawford, William W.; Kaplan, Michael S.; Roth, Richard M.; Chen, Wansu			Elevated exhaled nitric oxide is a clinical indicator of future uncontrolled asthma in asthmatic patients on inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							REFERENCE VALUES; CHILDREN		[Zeiger, Robert S.; Schatz, Michael] Kaiser Permanente So Calif Reg, San Diego, CA 92111 USA; [Zhang, Feng; Chen, Wansu] Kaiser Permanente So Calif Reg, Pasadena, CA USA; [Crawford, William W.] Kaiser Permanente So Calif Reg, Harbor City, CA USA; [Kaplan, Michael S.] Kaiser Permanente So Calif Reg, Los Angeles, CA USA; [Roth, Richard M.] Kaiser Permanente So Calif Reg, Orange, CA USA	Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; Kaiser Permanente; Kaiser Permanente	Zeiger, RS (corresponding author), Kaiser Permanente So Calif Reg, San Diego, CA 92111 USA.	robert.s.zeiger@kp.org		Zeiger, Robert/0000-0001-5788-5063				Malmberg LP, 2006, PEDIATR PULM, V41, P635, DOI 10.1002/ppul.20417; Olin AC, 2007, CHEST, V131, P1852, DOI 10.1378/chest.06-2928; PETSKY HL, 2010, THORAX          1011; Pijnenburg MW, 2005, THORAX, V60, P215, DOI 10.1136/thx.2004.023374; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P995, DOI 10.1016/j.jaci.2006.01.053; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Taylor DR, 2006, J ALLERGY CLIN IMMUN, V117, P259, DOI 10.1016/j.jaci.2005.11.010; Zeiger RS, 2010, AM J MANAG CARE, V16, P897; Zeiger RS, 2011, J ASTHMA, V48, P8, DOI 10.3109/02770903.2010.539295	9	57	62	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					412	414		10.1016/j.jaci.2011.06.008	http://dx.doi.org/10.1016/j.jaci.2011.06.008			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21807253				2022-12-18	WOS:000293280800024
J	Nakamura, Y; Harama, D; Shimokawa, N; Hara, M; Suzuki, R; Tahara, Y; Ishimaru, K; Katoh, R; Okumura, K; Ogawa, H; Shibata, S; Nakao, A				Nakamura, Yuki; Harama, Daisuke; Shimokawa, Naomi; Hara, Mutsuko; Suzuki, Ryuyo; Tahara, Yu; Ishimaru, Kayoko; Katoh, Ryohei; Okumura, Ko; Ogawa, Hideoki; Shibata, Shigenobu; Nakao, Atsuhito			Circadian clock gene Period2 regulates a time-of-day-dependent variation in cutaneous anaphylactic reaction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Circadian rhythm; clock; Period2; IgE; mast cell; anaphylactic reaction; mouse	MAST-CELLS; IMMUNE-RESPONSES; IN-VITRO; EXPRESSION; RHYTHM; MOUSE; IGE	Background: IgE-mediated immediate-type skin reaction shows a diurnal rhythm, although the precise mechanisms remain uncertain. Period2 (Per2) is a key circadian gene that is essential for endogenous clockworks in mammals. Objective: This study investigated whether Per2 regulates a time-of-day-dependent variation in IgE-mediated immediate-type skin reaction. Methods: The kinetics of a passive cutaneous anaphylactic reaction were compared between wild-type mice and mice with a loss-of-function mutation of Per2 (mPer2(m/m) mice). The effects of adrenalectomy, aging, and dexamethasone on the kinetics of a passive cutaneous anaphylactic reaction were also examined. In addition, the extent of IgE-mediated degranulation in bone marrow-derived mast cells (BMMCs) was compared between wild-type and mPer2(m/m) mice. Results: A time-of-day-dependent variation in a passive cutaneous anaphylactic reaction observed in wild-type mice was absent in mPer2(m/m) mice and in adrenalectomized and aged mice associated with the loss of rhythmic secretion of corticosterone. In addition, mPer2(m/m) mice showed decreased sensitivity to the inhibitory effects of dexamethasone on the passive cutaneous anaphylactic reactions. IgE-mediated degranulation in BMMCs was comparable between wild-type and mPer2(m/m) mice, but Per2 mutation decreased sensitivity to the inhibitory effects of dexamethasone on IgE-mediated degranulation in BMMCs. Conclusion: A circadian oscillator, Per2, regulates a time-of-day-dependent variation in a passive cutaneous anaphylactic reaction in mice. Per2 may do so by controlling the rhythmic secretion of glucocorticoid from adrenal glands and/or by gating the glucocorticoid responses of mast cells to certain times of the day (possibly when Per2 levels are high in mast cells). (J Allergy Clin Immunol 2011;127:1038-45.)	[Nakao, Atsuhito] Univ Yamanashi, Dept Immunol, Fac Med, Chuo Ku, Yamanashi 4093898, Japan; [Katoh, Ryohei] Univ Yamanashi, Dept Pathol, Fac Med, Yamanashi 4093898, Japan; [Hara, Mutsuko; Suzuki, Ryuyo; Okumura, Ko; Ogawa, Hideoki; Nakao, Atsuhito] Juntendo Univ, Sch Med, Atopy Res Ctr, Tokyo 113, Japan; [Tahara, Yu; Shibata, Shigenobu] Waseda Univ, Dept Physiol & Pharmacol, Sch Adv Sci & Engn, Tokyo, Japan	University of Yamanashi; University of Yamanashi; Juntendo University; Waseda University	Nakao, A (corresponding author), Univ Yamanashi, Dept Immunol, Fac Med, Chuo Ku, 1110 Shimokato, Yamanashi 4093898, Japan.	anakao@yamanashi.ac.jp	Tahara, Yu/Q-4324-2018	Tahara, Yu/0000-0002-3015-8883	Ministry of Education, Culture, Sports, Science, and Technology, Japan	Ministry of Education, Culture, Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	Supported in part by grants from the Ministry of Education, Culture, Sports, Science, and Technology, Japan.	Ando T, 2007, J ALLERGY CLIN IMMUN, V120, P916, DOI 10.1016/j.jaci.2007.05.023; ARONOW WS, 1973, CHEST, V63, P722, DOI 10.1378/chest.63.5.722; Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; Dibner C, 2010, ANNU REV PHYSIOL, V72, P517, DOI 10.1146/annurev-physiol-021909-135821; DICKMEIS T, 2009, NEUROSCI LETT, V457, P58; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Hamilton RG, 2010, J ALLERGY CLIN IMMUN, V125, pS284, DOI 10.1016/j.jaci.2009.09.055; Hayasaka N, 2007, ENDOCRINOLOGY, V148, P3316, DOI 10.1210/en.2007-0010; Kinet JP, 2007, IMMUNOL REV, V217, P5, DOI 10.1111/j.1600-065X.2007.00528.x; Kowalska E, 2007, COLD SPRING HARB SYM, V72, P301, DOI 10.1101/sqb.2007.72.014; KRIEGER DT, 1975, J STEROID BIOCHEM, V6, P785, DOI 10.1016/0022-4731(75)90068-0; Milcu S M, 1978, Endocrinologie, V16, P29; MILLER P, 1976, CLIN EXP IMMUNOL, V25, P177; Nakamura Y, 2008, J ALLERGY CLIN IMMUN, V122, P1208, DOI 10.1016/j.jaci.2008.09.022; PALAZZOLO DL, 1987, EXP GERONTOL, V22, P379, DOI 10.1016/0531-5565(87)90019-2; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Seery JP, 1998, ANN ALLERG ASTHMA IM, V80, P329, DOI 10.1016/S1081-1206(10)62978-X; Sei H, 2008, ENDOCRINOLOGY, V149, P3576, DOI 10.1210/en.2007-1714; So AYL, 2009, P NATL ACAD SCI USA, V106, P17582, DOI 10.1073/pnas.0909733106; Son GH, 2008, P NATL ACAD SCI USA, V105, P20970, DOI 10.1073/pnas.0806962106; Tahara Y, 2010, J BIOL RHYTHM, V25, P9, DOI 10.1177/0748730409352782; Takahashi JS, 2008, NAT REV GENET, V9, P764, DOI 10.1038/nrg2430; Tokura T, 2005, BIOSCI BIOTECH BIOCH, V69, P1974, DOI 10.1271/bbb.69.1974; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Wang XJ, 2011, BRAIN BEHAV IMMUN, V25, P127, DOI 10.1016/j.bbi.2010.09.007; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; Yang ST, 2009, ENDOCRINOLOGY, V150, P2153, DOI 10.1210/en.2008-0705; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118	30	57	59	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					1038	U301		10.1016/j.jaci.2011.02.006	http://dx.doi.org/10.1016/j.jaci.2011.02.006			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21458659				2022-12-18	WOS:000289055800027
J	Rondon, C; Blanca-Lopez, N; Aranda, A; Herrera, R; Rodriguez-Bada, JL; Canto, G; Mayorga, C; Torres, MJ; Campo, P; Blanca, M				Rondon, Carmen; Blanca-Lopez, Natalia; Aranda, Ana; Herrera, Rocio; Luis Rodriguez-Bada, Jose; Canto, Gabriela; Mayorga, Cristobalina; Jose Torres, Maria; Campo, Paloma; Blanca, Miguel			Local allergic rhinitis: Allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PERSISTENT NONALLERGIC RHINITIS; IDIOPATHIC RHINITIS; ABSENCE; IGE; DISEASE; ATOPY		[Rondon, Carmen; Jose Torres, Maria; Campo, Paloma; Blanca, Miguel] Carlos Haya Hosp, Allergy Serv, Malaga, Spain; [Blanca-Lopez, Natalia; Canto, Gabriela] Infanta Leonor Hosp, Allergy Serv, Madrid, Spain; [Aranda, Ana; Herrera, Rocio; Luis Rodriguez-Bada, Jose; Mayorga, Cristobalina] Carlos Haya Hosp, Fdn IMABIS, Res Lab, Malaga, Spain	Hospital Carlos Haya; Hospital Universitario Infanta Leonor; FIMABIS; Hospital Carlos Haya	Rondon, C (corresponding author), Carlos Haya Hosp, Allergy Serv, Malaga, Spain.	carmenrs61@gmail.com	Mayorga, Lina/FBO-7730-2022; Torres, Maria/GVU-3391-2022; Mayorga, Cristobalina/D-7167-2018; Torres Jaen, Maria Jose/T-3518-2017	Mayorga, Cristobalina/0000-0001-8852-8077; Torres Jaen, Maria Jose/0000-0001-5228-471X; RONDON SEGOVIA, CARMEN/0000-0003-0976-3402				Carney AS, 2002, CLIN EXP ALLERGY, V32, P1436, DOI 10.1046/j.1365-2745.2002.01465.x; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; HUGGINS KG, 1975, LANCET, V2, P148; Powe DG, 2003, CLIN EXP ALLERGY, V33, P1374, DOI 10.1046/j.1365-2222.2003.01737.x; Rondon C, 2008, ALLERGY, V63, P1352, DOI 10.1111/j.1398-9995.2008.01695.x; Rondon C, 2007, J ALLERGY CLIN IMMUN, V119, P899, DOI 10.1016/j.jaci.2007.01.006; Rondon C, 2009, J ALLERGY CLIN IMMUN, V123, P1098, DOI 10.1016/j.jaci.2009.02.018; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Ulanova M, 2001, INFECT IMMUN, V69, P1151, DOI 10.1128/IAI.69.2.1151-1159.2001; Wedback A, 2005, RHINOLOGY, V43, P86	10	57	61	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					1069	1071		10.1016/j.jaci.2010.12.013	http://dx.doi.org/10.1016/j.jaci.2010.12.013			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21277626				2022-12-18	WOS:000289055800033
J	Sverrild, A; Porsbjerg, C; Thomsen, SF; Backer, V				Sverrild, Asger; Porsbjerg, Celeste; Thomsen, Simon Francis; Backer, Vibeke			Airway hyperresponsiveness to mannitol and methacholine and exhaled nitric oxide: A random-sample population study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; airway hyperresponsiveness; mannitol; methacholine; diagnosis; exhaled nitric oxide; inflammation; epidemiology; population	ASTHMA; SENSITIVITY; INFLAMMATION; MARKERS; LIFE	Background: Studies of selected patient groups have shown that airway hyperresponsiveness (AHR) to mannitol is more specific than methacholine for the diagnosis of asthma, as well as more closely associated with markers of airway inflammation in asthma. Objective: We sought to compare AHR to mannitol and methacholine and exhaled nitric oxide (eNO) levels in a nonselected population sample. Methods: In 238 young adults randomly drawn from the nationwide civil registration list in Copenhagen, Denmark, AHR to mannitol and methacholine, as well as levels of eNO, were determined, and the association with asthma was analyzed. Results: In diagnosing asthma the specificity of methacholine and mannitol was 80.2% (95% CI, 77.1% to 82.9%) and 98.4% (95% CI, 96.2% to 99.4%), respectively, with a positive predictive value of 48.6% versus 90.4%, whereas the sensitivity was 68.6% (95% CI, 57.1% to 78.4%) and 58.8% (95% CI, 50.7% to 62.6%), respectively. In asthmatic subjects AHR to mannitol was associated with increased eNO levels (positive AHR to mannitol: median, 47 ppb [interquartile range, 35-68 ppb]; negative AHR to mannitol: median, 19 ppb [interquartile range, 13-30 ppb]; P = .001), whereas this was not the case for AHR to methacholine (median of 37 ppb [interquartile range, 26-51 ppb] vs 24 ppb [interquartile range, 15-39 ppb], P = .13). Conclusion: In this random population sample, AHR to mannitol was less sensitive but more specific than methacholine in the diagnosis of asthma. Furthermore, AHR to mannitol was more closely associated with ongoing airway inflammation in terms of increased eNO levels. (J Allergy Clin Immunol 2010; 126:952-8.)	[Sverrild, Asger; Porsbjerg, Celeste; Thomsen, Simon Francis; Backer, Vibeke] Bispebjerg Hosp, Dept Resp Med, Resp Res Unit, Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital	Porsbjerg, C (corresponding author), Bispebjerg Hosp, Dept Resp Med, Resp Res Unit, Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark.	Porsbjerg@dadlnet.dk	Sverrild, Asger/GPC-7753-2022; Backer, Vibeke/I-9573-2014; Backer, Vibeke/AAQ-9379-2021	Backer, Vibeke/0000-0002-7806-7219; Porsbjerg, Celeste/0000-0003-4825-9436; Sverrild, Asger/0000-0003-0625-6405	Danish Agency for Science, Technology and Innovation, an institution under the Danish Ministry of Science, Technology and Innovation; Pharmaxis	Danish Agency for Science, Technology and Innovation, an institution under the Danish Ministry of Science, Technology and Innovation; Pharmaxis	The Danish Agency for Science, Technology and Innovation, an institution under the Danish Ministry of Science, Technology and Innovation, supported the study with a 1-year scholarship. Pharmaxis provided the research team with an unrestricted grant, with which one of the research assistants was employed. Moreover, mannitol test kits were provided by Pharmaxis Ltd (Frenchs Forest, NSW, Australia).	Anderson SD, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-4; Anderson SD, 1997, AM J RESP CRIT CARE, V156, P758, DOI 10.1164/ajrccm.156.3.9701113; [Anonymous], 2006, AM J RESP CRIT CARE, V173, P811, DOI 10.1164/rrcm.2061014; BACKER V, 1991, EUR RESPIR J, V4, P1093; Berry MA, 2005, CLIN EXP ALLERGY, V35, P1175, DOI 10.1111/j.1365-2222.2005.02314.x; Brannan JD, 2003, EUR RESPIR J, V22, P491, DOI 10.1183/09031936.03.00113403; Brannan JD, 2002, RESPIROLOGY, V7, P37, DOI 10.1046/j.1440-1843.2002.00357.x; Cockcroft DW, 2006, J ALLERGY CLIN IMMUN, V117, P1244, DOI 10.1016/j.jaci.2006.02.038; Cockcroft DW, 2009, CURR ALLERGY ASTHM R, V9, P247, DOI 10.1007/s11882-009-0036-z; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Drebotg S, 1989, ALLERGY S10, V44, P22; Gade E, 2009, CLIN EXP ALLERGY, V39, P966, DOI 10.1111/j.1365-2222.2009.03274.x; Henriksen AH, 2000, EUR RESPIR J, V15, P849, DOI 10.1034/j.1399-3003.2000.15e07.x; Hewitt DJ, 2008, AM J IND MED, V51, P769, DOI 10.1002/ajim.20631; James A, 1997, Respirology, V2, P97, DOI 10.1111/j.1440-1843.1997.tb00061.x; Koskela HO, 2003, CHEST, V124, P1341, DOI 10.1378/chest.124.4.1341; Leuppi JD, 2001, AM J RESP CRIT CARE, V163, P406, DOI 10.1164/ajrccm.163.2.9912091; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Moller GM, 1999, J APPL PHYSIOL, V86, P1352, DOI 10.1152/jappl.1999.86.4.1352; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Porsbjerg C, 2008, CLIN EXP ALLERGY, V38, P43, DOI 10.1111/j.1365-2222.2007.02878.x; Porsbjerg C, 2007, CLIN EXP ALLERGY, V37, P22, DOI 10.1111/j.1365-2222.2006.02614.x; Porsbjerg C, 2009, J ASTHMA, V46, P606, DOI 10.1080/02770900903015654; Shaw DE, 2007, AM J RESP CRIT CARE, V176, P231, DOI 10.1164/rccm.200610-1427OC; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Sverrild A, 2009, J ALLERGY CLIN IMMUN, V124, P928, DOI 10.1016/j.jaci.2009.06.028; van den Toorn LM, 2000, AM J RESP CRIT CARE, V162, P953, DOI 10.1164/ajrccm.162.3.9909033; VANDEN BM, 2001, AM J RESP CRIT CARE, V163, P1546; Winder JA, 2000, ANN ALLERG ASTHMA IM, V85, P467, DOI 10.1016/S1081-1206(10)62573-2; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	30	57	57	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					952	958		10.1016/j.jaci.2010.08.028	http://dx.doi.org/10.1016/j.jaci.2010.08.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	20934208				2022-12-18	WOS:000283727100009
J	Hamilton, RG; Williams, PB				Hamilton, Robert G.; Williams, P. Brock		Specific IgE Testing Task Force; Amer Coll Allergy Asthma	Human IgE antibody serology: A primer for the practicing North American allergist/immunologist	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; human; IgE; concentration; specific activity; specific IgE to total IgE ratio; clonality; affinity	ALLERGY; DIAGNOSIS; ACCURACY; CHILDREN; ASSAYS; SENSITIZATION; EFFICACY	The allergist/immunologist judiciously diagnoses allergic disease by using confirmatory IgE antibody data from in vivo and in vitro assays after the collection of a clinical history. After an overview of historical events, clinically available allergen-specific IgE assays from Phadia, Siemens, and Hycor are contrasted by their design and performance characteristics. The assays share comparable working ranges, analytical sensitivities, and excellent precision, reproducibility, and linearity to a performance standard of <15% coefficients of variation. However, multiple interlaboratory studies have confirmed that the 3 IgE antibody assays either detect different populations of IgE antibody or do not measure the same antibodies with comparable efficiencies. The clinical consequence is that IgE antibody results from the 3 assays are not interchangeable or equivalent. Data generated with one assay cannot be directly extrapolated to published predictive outcomes based on IgE antibody levels from a different assay. The transition from allergen extract based to allergenic components reagents is discussed, emphasizing the chip-based microarray's strength in identifying IgE antibody cross-reactivity. US Food and Drug Administration cleared point-of-care IgE antibody lateral flow cassettes are overviewed. Finally, IgE antibody concentration, affinity, clonality (epitope specificity), and specific activity (specific/total IgE ratio) are examined as humoral immune response parameters measured by serologic assays that affect effector cell degranulation and ultimately allergic disease expression. (J Allergy Clin Immunol 2010;126:33-8.)	[Hamilton, Robert G.] Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr,Dept Med, Johns Hopkins Dermatol Allergy & Clin Immunol Ref, Baltimore, MD 21224 USA; [Hamilton, Robert G.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21224 USA; [Williams, P. Brock] Univ Missouri, Sch Med, Kansas City, MO 64108 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; University of Missouri System; University of Missouri Kansas City	Hamilton, RG (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr,Dept Med, Johns Hopkins Dermatol Allergy & Clin Immunol Ref, Room 1A20,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	rhamilt2@jhmi.edu			Internal Johns Hopkins University; Siemens Healthcare Diagnostics	Internal Johns Hopkins University(Johns Hopkins University); Siemens Healthcare Diagnostics	Supported by Internal Johns Hopkins University funds.; Disclosure of potential conflict of interest: R. G. Hamilton has received research support from Siemens Healthcare Diagnostics. P. B. Williams has declared that he has no conflict of interest.	Alessandri C, 2009, ITAL J PEDIATR, V35, DOI 10.1186/1824-7288-35-29; Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1, DOI 10.1016/S1081-1206(10)60305-5; Christensen LH, 2008, J ALLERGY CLIN IMMUN, V122, P298, DOI 10.1016/j.jaci.2008.05.026; DELOVINFOSSE S, 1994, ALLERGY, V49, P64, DOI 10.1111/j.1398-9995.1994.tb00776.x; Di Lorenzo G, 2009, J ALLERGY CLIN IMMUN, V123, P1103, DOI 10.1016/j.jaci.2009.02.012; Diaz-Vazquez C, 2009, PEDIAT ALLERG IMM-UK, V20, P601, DOI 10.1111/j.1399-3038.2008.00827.x; Dolen WK, 2000, J ALLERGY CLIN IMMUN, V105, P1074, DOI 10.1067/mai.2000.107151; Eckman John, 2009, Allergy Asthma Clin Immunol, V5, P2, DOI 10.1186/1710-1492-5-2; Hamilton RG, 2010, J ALLERGY CLIN IMMUN, V125, pAB223, DOI 10.1016/j.jaci.2009.12.872; Hamilton RG, 2006, J ALLERGY CLIN IMMUN, V117, P759, DOI 10.1016/j.jaci.2006.01.012; Hamilton RG, 2003, J ALLERGY CLIN IMMUN, V111, P1414, DOI 10.1067/mai.2003.1520; Hamilton RG, 2001, ANN ALLERG ASTHMA IM, V86, P353, DOI 10.1016/S1081-1206(10)62477-5; HAMILTON RG, 2010, ARCH PATH L IN PRESS, P134; HAMILTON RG, 2008, MIDDLETONS ALLERGY P, P1247; HAMILTON RG, 2010, IMMUNOL RES     0112; Hamilton RG, 2008, J ALLERGY CLIN IMMUN, V122, P305, DOI 10.1016/j.jaci.2008.05.009; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; ISHIZAKA K, 1966, J ALLERGY, V37, P169, DOI 10.1016/0021-8707(66)90091-8; Johansson SGO, 2009, ALLERGY, V64, P1472, DOI 10.1111/j.1398-9995.2009.02051.x; JOHANSSON SG, 1967, IMMUNOLOGY, V13, P381; JOHANSSON SGO, 1988, CLIN REV ALLERG, V6, P93; MATSSON PNJ, 2008, ANAL PERFORMANCE CHA; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Ott H, 2010, EUR J DERMATOL, V20, P54, DOI 10.1684/ejd.2010.0810; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sicherer SH, 2008, J ALLERGY CLIN IMMUN, V122, P413, DOI 10.1016/j.jaci.2008.05.012; Simpson A, 2005, J ALLERGY CLIN IMMUN, V116, P744, DOI 10.1016/j.jaci.2005.06.032; WIDE L, 1967, LANCET, V2, P1105; Williams PB, 2001, ANN ALLERG ASTHMA IM, V86, P196, DOI 10.1016/S1081-1206(10)62691-9; Wood RA, 2007, ANN ALLERG ASTHMA IM, V99, P34, DOI 10.1016/S1081-1206(10)60618-7; Yunginger JW, 2000, J ALLERGY CLIN IMMUN, V105, P1077, DOI 10.1067/mai.2000.107041	33	57	59	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					33	38		10.1016/j.jaci.2010.03.014	http://dx.doi.org/10.1016/j.jaci.2010.03.014			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20451984	Bronze			2022-12-18	WOS:000280061800006
J	van der Kleij, H; Charles, N; Karimi, K; Mao, YK; Foster, J; Janssen, L; Yang, PC; Kunze, W; Rivera, J; Bienenstock, J				van der Kleij, Hanneke; Charles, Nicolas; Karimi, Khalil; Mao, Yu-Kang; Foster, Jane; Janssen, Luke; Yang, Ping Chang; Kunze, Wolfgang; Rivera, Juan; Bienenstock, John			Evidence for neuronal expression of functional Fc (epsilon and gamma) receptors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SENSORY NEURONS; ACTIVATION; CELLS; MICE; RIV		[van der Kleij, Hanneke; Mao, Yu-Kang; Foster, Jane; Janssen, Luke; Yang, Ping Chang; Kunze, Wolfgang; Bienenstock, John] McMaster Univ, Brain Body Inst, St Josephs Healthcare Hamilton, Hamilton, ON L8S 4L8, Canada; [van der Kleij, Hanneke; Karimi, Khalil; Mao, Yu-Kang; Foster, Jane; Janssen, Luke; Yang, Ping Chang; Kunze, Wolfgang; Bienenstock, John] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4L8, Canada; [Charles, Nicolas; Rivera, Juan] NIAMSD, Lab Immune Cell Signaling, Natl Inst Hlth, Bethesda, MD 20892 USA	McMaster University; McMaster University; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	van der Kleij, H (corresponding author), McMaster Univ, Brain Body Inst, St Josephs Healthcare Hamilton, Hamilton, ON L8S 4L8, Canada.	bienens@mcmaster.ca	Yang, Ping-Chang/K-4669-2019; CHARLES, Nicolas/P-5430-2014; CHARLES, Nicolas/S-2214-2019; Karimi, Khalil/ABA-4735-2020; Foster, Jane/AAW-7163-2021	CHARLES, Nicolas/0000-0002-5416-5834; CHARLES, Nicolas/0000-0002-5416-5834; Karimi, Khalil/0000-0002-7245-5851; 	Intramural NIH HHS [Z01 AR041101-15] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041101] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Andoh T, 2004, FASEB J, V18, P182, DOI 10.1096/fj.02-1169fje; Andoh T, 2004, NEUROREPORT, V15, P2029, DOI 10.1097/00001756-200409150-00007; Bieber T, 1996, CURR OPIN IMMUNOL, V8, P773, DOI 10.1016/S0952-7915(96)80003-3; Furuno T, 2004, NEUROSCI LETT, V372, P185, DOI 10.1016/j.neulet.2004.08.008; Hirano M, 2007, NAT IMMUNOL, V8, P762, DOI 10.1038/ni1477; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; Mao YK, 2006, J NEUROPHYSIOL, V96, P998, DOI 10.1152/jn.00204.2006; Nimmerjahn F, 2005, IMMUNITY, V23, P41, DOI 10.1016/j.immuni.2005.05.010; Rijnierse A, 2009, J NEUROIMMUNOL, V208, P80, DOI 10.1016/j.jneuroim.2009.01.008	9	57	57	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					757	760		10.1016/j.jaci.2009.10.054	http://dx.doi.org/10.1016/j.jaci.2009.10.054			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20132972	Green Accepted			2022-12-18	WOS:000275883200041
J	Kim, SR; Lee, KS; Park, SJ; Min, KH; Choe, YH; Moon, H; Yoo, WH; Chae, HJ; Han, MK; Lee, YC				Kim, So Ri; Lee, Kyung Sun; Park, Seoung Ju; Min, Kyung Hoon; Choe, Yeong Hun; Moon, Hee; Yoo, Wan Hee; Chae, Han-Jung; Han, Myung Kwan; Lee, Yong Chul			Involvement of sirtuin 1 in airway inflammation and hyperresponsiveness of allergic airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic airway disease; histone deacetylase; hypoxia-inducible factor 1 alpha; sirtuin 1; sirtinol; vascular endothelial growth factor	ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; NF-KAPPA-B; MURINE MODEL; VASCULAR-PERMEABILITY; HISTONE ACETYLATION; TRANSCRIPTIONAL REGULATION; SIGNAL-TRANSDUCTION; FACTOR 1-ALPHA; ASTHMA	Background: Bronchial asthma is a chronic inflammatory disorder of the airways characterized by increased expression of multiple inflammatory genes. Acetylation of histones by historic acetyltransferases is associated with increased gene transcription, whereas hypoacetylation induced by histone deacetylases is associated with suppression of gene expression. Sirtuin 1 (SIRT1) is a member of the silent information regulator 2 family that belongs to class III histone deacetylase. Objective: This study aimed to investigate the role of SIRT1 and the related molecular mechanisms in the pathogenesis of allergic airway disease. Methods: fly using a murine model of ovalbumin (OVAL)induced allergic airway disease and murine tracheal epithelial cells, this study investigated the involvement of SIRT1 and its signaling networks in allergic airway inflammation and hyperresponsiveness. Results: In this study with mice after inhalation of OVA, the increased levels of SIRT1, hypoxia-inducible factor 1 alpha (HIF-1 alpha), and vascular endothelial growth factor protein in the lungs after OVA inhalation were decreased substantially by the administration of a SIRT1 inhibitor, sirtinol. We also showed that the administration of sirtinol reduced significantly the increased numbers of inflammatory cells of the airways; airway hyperresponsiveness; increased levels of IL-4, IL-5, and IL-13; and increased vascular permeability in the lungs after OVA inhalation. In addition, we have found that inhibition of SIRT1 reduced OVA-induced upregulation of HIF-1 alpha in airway epithelial cells. Conclusions: These results indicate that inhibition of SIRT1 might attenuate antigen-induced airway inflammation and hyperresponsiveness through the modulation of vascular endothelial growth factor expression mediated by HIF-1 alpha in mice. (J Allergy Clin Immunol 2010;125:449-60.)	[Kim, So Ri; Lee, Kyung Sun; Park, Seoung Ju; Min, Kyung Hoon; Choe, Yeong Hun; Moon, Hee; Yoo, Wan Hee; Lee, Yong Chul] Chonbuk Natl Univ, Sch Med, Dept Internal Med, Jeonju 561180, South Korea; [Chae, Han-Jung] Chonbuk Natl Univ, Sch Med, Dept Pharmacol, Jeonju 561180, South Korea; [Kim, So Ri; Lee, Kyung Sun; Park, Seoung Ju; Min, Kyung Hoon; Choe, Yeong Hun; Moon, Hee; Yoo, Wan Hee; Chae, Han-Jung; Lee, Yong Chul] Chonbuk Natl Univ, Sch Med, Res Ctr Pulm Disorders, Jeonju 561180, South Korea; [Han, Myung Kwan] Chonbuk Natl Univ, Sch Med, Dept Microbiol, Jeonju 561180, South Korea	Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Jeonbuk National University	Lee, YC (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Internal Med, San 2-20, Jeonju 561180, South Korea.	leeyc@chonbuk.ac.kr	Min, Kyung Hoon/C-5984-2019; Park, Seoungju/D-4444-2014; Kim, So Ri/AAS-1630-2021	Min, Kyung Hoon/0000-0003-0610-2182; Kim, So Ri/0000-0002-6074-9158; Han, Myung-Kwan/0000-0003-1931-8898; Chae, Han-Jung/0000-0003-4190-9889	Ministry for Health, Welfare and Family Affairs, Republic of Korea [A084144]; Ministry of Education, Science and Technology [R0A-2005-000-10052-0[2008]]; Korean Government [KRF-2008-313-E00249]	Ministry for Health, Welfare and Family Affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Korean Government(Korean Government)	Supported by a grant from the Korea Healthcare technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (A084144); by the Korea Science and Engineering Foundation (KOSEF) through the National Research Laboratory Program funded by the Ministry of Education, Science and Technology (R0A-2005-000-10052-0[2008]); and by a Korea Research Foundation Grant funded by the Korean Government (KRF-2008-313-E00249).	ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010; Chauhan D, 2002, BLOOD, V100, P2187, DOI 10.1182/blood-2002-02-0376; Cho JY, 2004, J CLIN INVEST, V113, P551, DOI 10.1172/JCI200419133; D'Ambrosio D, 2001, AM J RESP CRIT CARE, V164, P1266, DOI 10.1164/ajrccm.164.7.2103011; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128/MCB.23.9.3173-3185.2003; Duan W, 2005, INT IMMUNOPHARMACOL, V5, P495, DOI 10.1016/j.intimp.2004.10.015; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Feldser D, 1999, CANCER RES, V59, P3915; Ferrara N, 2008, REJUV RES, V11, P139, DOI 10.1089/rej.2007.0576; Foster PS, 2002, PHARMACOL THERAPEUT, V94, P253, DOI 10.1016/S0163-7258(02)00220-6; Gradin K, 1999, J BIOL CHEM, V274, P13511, DOI 10.1074/jbc.274.19.13511; Hamelmann E, 1999, ALLERGY, V54, P297, DOI 10.1034/j.1398-9995.1999.00085.x; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Hisahara S, 2005, J PHARMACOL SCI, V98, P200, DOI 10.1254/jphs.FMJ05001X2; Holgate ST, 2000, AM J RESP CRIT CARE, V162, pS113, DOI 10.1164/ajrccm.162.supplement_2.ras-12; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KIRSCH CM, 1992, EXP LUNG RES, V18, P447, DOI 10.3109/01902149209064339; Kwak YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440; Kwon HS, 2008, TRENDS BIOCHEM SCI, V33, P517, DOI 10.1016/j.tibs.2008.08.001; Laemmle A, 2008, J HEPATOL, V48, pS133, DOI 10.1016/S0168-8278(08)60341-4; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee KS, 2008, EUR RESPIR J, V31, P523, DOI 10.1183/09031936.00125007; Lee KS, 2008, AM J RESP CRIT CARE, V178, P787, DOI 10.1164/rccm.200801-008OC; Lee KS, 2006, J ALLERGY CLIN IMMUN, V118, P120, DOI 10.1016/j.jaci.2006.03.021; Lee KS, 2006, J ALLERGY CLIN IMMUN, V118, P403, DOI 10.1016/j.jaci.2006.04.041; Lee KS, 2006, MOL PHARMACOL, V69, P1829, DOI 10.1124/mol.106.022228; Lee KS, 2007, EXP MOL MED, V39, P756, DOI 10.1038/emm.2007.82; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; Lee YC, 2001, J ALLERGY CLIN IMMUN, V107, P1106, DOI 10.1067/mai.2001.115628; Lee YM, 2003, BIOCHEM BIOPH RES CO, V300, P241, DOI 10.1016/S0006-291X(02)02787-0; Nedachi T, 2008, AM J PHYSIOL-ENDOC M, V294, pE668, DOI 10.1152/ajpendo.00640.2007; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Rane S, 2009, CIRC RES, V104, P879, DOI 10.1161/CIRCRESAHA.108.193102; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Semenza CL, 2001, PEDIATR RES, V49, P614, DOI 10.1203/00006450-200105000-00002; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Starai VJ, 2004, J MOL BIOL, V340, P1005, DOI 10.1016/j.jmb.2004.05.010; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Tamaoki J, 1999, AM J PHYSIOL-LUNG C, V276, pL351, DOI 10.1152/ajplung.1999.276.2.L351; Tanno M, 2007, J BIOL CHEM, V282, P6823, DOI 10.1074/jbc.M609554200; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P79; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Yang SR, 2007, AM J PHYSIOL-LUNG C, V292, pL567, DOI 10.1152/ajplung.00308.2006; Yang TL, 2006, TRENDS ENDOCRIN MET, V17, P186, DOI 10.1016/j.tem.2006.04.002; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhong H, 2000, CANCER RES, V60, P1541; Zilberberg L, 2003, J BIOL CHEM, V278, P35564, DOI 10.1074/jbc.M304435200	61	57	65	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					449	460		10.1016/j.jaci.2009.08.009	http://dx.doi.org/10.1016/j.jaci.2009.08.009			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	19864008				2022-12-18	WOS:000274764000025
J	Alexis, NE; Zhou, HB; Lay, JC; Harris, B; Hernandez, ML; Lu, TS; Bromberg, PA; Diaz-Sanchez, D; Devlin, RB; Kleeberger, SR; Peden, DB				Alexis, Neil E.; Zhou, Haibo; Lay, John C.; Harris, Bradford; Hernandez, Michelle L.; Lu, Tsui-Shan; Bromberg, Philip A.; Diaz-Sanchez, David; Devlin, Robert B.; Kleeberger, Steven R.; Peden, David B.			The glutathione-S-transferase Mu 1 null genotype modulates ozone-induced airway inflammation in human subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Glutathione-S-transferase Mu 1; ozone; pollution; inflammation; polymorphonuclear neutrophil; macrophage; dendritic cell	ANTIOXIDANT SUPPLEMENTATION; ASTHMATIC-CHILDREN; ALLERGIC RESPONSES; PASSIVE SMOKING; IN-VIVO; EXPOSURE; GSTM1; M1; PHAGOCYTES; POLLUTION	Background: The glutathione-S-transferase Mu 1 (GSTM1) null genotype has been reported to be a risk factor for acute respiratory disease associated with increases in ambient air ozone levels. Ozone is known to cause an immediate decrease in lung function and increased airway inflammation. However, it is not known whether GSTM1 modulates these ozone responses in vivo in human subjects. Objective: The purpose of this study was to determine whether the GSTM1 null genotype modulates ozone responses in human subjects. Methods: Thirty-five healthy volunteers were genotyped for the GSTM1 null mutation and underwent a standard ozone exposure protocol to determine whether lung function and inflammatory responses to ozone were different between the 19 GSTM1 wild type and 16 GSTM1 null volunteers. Results: GSTM1 did not modulate lung function responses to acute ozone. Granulocyte influx 4 hours after challenge was similar between GSTM1 normal and null volunteers. However, GSTM1 null volunteers had significantly increased airway neutrophils 24 hours after challenge, as well as increased expression of HLA-DR on airway macrophages and dendritic cells. Conclusion: The GSTM1 null genotype is associated with increased airways inflammation 24 hours after ozone exposure, which is consistent with the lag time observed between increased ambient air ozone exposure and exacerbations of lung disease. (J Allergy Clin Immunol 2009;124:1222-8.)	[Alexis, Neil E.; Zhou, Haibo; Lay, John C.; Harris, Bradford; Hernandez, Michelle L.; Lu, Tsui-Shan; Bromberg, Philip A.; Peden, David B.] Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Sch Med, Chapel Hill, NC 27599 USA; [Bromberg, Philip A.; Peden, David B.] Univ N Carolina, Dept Med, Sch Med, Chapel Hill, NC 27599 USA; [Alexis, Neil E.; Lay, John C.; Harris, Bradford; Hernandez, Michelle L.; Peden, David B.] Univ N Carolina, Dept Pediat, Sch Med, Chapel Hill, NC 27599 USA; [Zhou, Haibo; Lu, Tsui-Shan] Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC USA; [Diaz-Sanchez, David; Devlin, Robert B.] US EPA, Environm Publ Hlth Div, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA; [Kleeberger, Steven R.] Natl Inst Environm Hlth Sci, Lab Resp Biol, Res Triangle Pk, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; United States Environmental Protection Agency; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Peden, DB (corresponding author), Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Sch Med, 104 Mason Farm Rd,CB 7310, Chapel Hill, NC 27599 USA.	peden@med.unc.edu	ZHOU, Haibo/M-7373-2017; Kleeberger, Steven R/F-1807-2019; Lay, John/A-6380-2012	Kleeberger, Steven R/0000-0003-2948-8452; 	National Institutes of Health [R01ES012706, P30ES010126, P01AT002620]; US Environmental Protection Agency [CR-83346301]; National Institute of Environmental Health Sciences Division of Intramural Research; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [P01AT002620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES100512, P30ES010126, R01ES012706] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Environmental Protection Agency(United States Environmental Protection Agency); National Institute of Environmental Health Sciences Division of Intramural Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institutes of Health grants R01ES012706, P30ES010126, and P01AT002620. US Environmental Protection Agency Cooperative Agreement CR-83346301, and the National Institute of Environmental Health Sciences Division of Intramural Research. Although the research described in this article has been funded wholly or in part by the United States Environmental Protection Agency through Cooperative agreement CR-83346301 with the Center for Environmental Medicine and Lung Biology at the University of North Carolina at Chapel Hill, it has not been subjected to the Agency's required peer and policy review and therefore does not necessarily reflect the views of the Agency, and no official endorsement should be inferred.	Ahmad S, 2005, FREE RADICAL BIO MED, V39, P213, DOI 10.1016/j.freeradbiomed.2005.03.009; Alexis N, 2000, CLIN IMMUNOL, V97, P21, DOI 10.1006/clim.2000.4911; Alexis NE, 2006, J ALLERGY CLIN IMMUN, V117, P1396, DOI 10.1016/j.jaci.2006.02.030; Alexis NE, 2003, J ALLERGY CLIN IMMUN, V112, P353, DOI 10.1067/mai.2003.1651; Arjomandi M, 2005, AM J RESP CRIT CARE, V172, P427, DOI 10.1164/rccm.200502-272OC; BELL DA, 1993, J NATL CANCER I, V85, P1159, DOI 10.1093/jnci/85.14.1159; Bergamaschi E, 2001, AM J RESP CRIT CARE, V163, P1426, DOI 10.1164/ajrccm.163.6.2006056; Ciencewicki J, 2008, J ALLERGY CLIN IMMUN, V122, P456, DOI 10.1016/j.jaci.2008.08.004; Dahl M, 2007, J CLIN INVEST, V117, P757, DOI 10.1172/JCI29968; David GL, 2003, AM J RESP CRIT CARE, V168, P1199, DOI 10.1164/rccm.200305-684OC; Geisler SA, 2001, AM J EPIDEMIOL, V154, P95, DOI 10.1093/aje/154.2.95; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Gilliland FD, 2006, AM J RESP CRIT CARE, V174, P1335, DOI 10.1164/rccm.200509-1424OC; Kabesch M, 2004, THORAX, V59, P569, DOI 10.1136/thx.2003.016667; Kleeberger SR, 2005, ANNU REV MED, V56, P383, DOI 10.1146/annurev.med.56.062904.144908; Lay JC, 2009, THORAX, V64, P313, DOI 10.1136/thx.2008.096222; Lay JC, 2007, J ALLERGY CLIN IMMUN, V120, P719, DOI 10.1016/j.jaci.2007.05.005; LEIKAUF GD, 1993, AM J RESP CELL MOL, V9, P594, DOI 10.1165/ajrcmb/9.6.594; Li N, 2006, ANTIOXID REDOX SIGN, V8, P88, DOI 10.1089/ars.2006.8.88; Little R. J. A, 1997, STAT ANAL MISSING DA; London Stephanie J, 2007, Proc Am Thorac Soc, V4, P217, DOI 10.1513/pats.200701-031AW; Otto-Knapp R, 2003, INFLAMM RES, V52, P51, DOI 10.1007/s000110300000; Palmer CNA, 2006, PEDIATRICS, V118, P710, DOI 10.1542/peds.2005-3030; Peden DB, 2005, J ALLERGY CLIN IMMUN, V115, P213, DOI 10.1016/j.jaci.2004.12.003; Peden DB, 2008, MIDDLETONS ALLERGY P, P495; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Romieu I, 2006, EUR RESPIR J, V28, P953, DOI 10.1183/09031936.06.00114905; Romieu I, 2004, THORAX, V59, P8; Romieu I, 2002, AM J RESP CRIT CARE, V166, P703, DOI 10.1164/rccm.2112074; Schwartz J, 2004, PEDIATRICS, V113, P1037; Trasande L, 2005, J ALLERGY CLIN IMMUN, V115, P689, DOI 10.1016/j.jaci.2005.01.056	32	57	58	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1222	1228		10.1016/j.jaci.2009.07.036	http://dx.doi.org/10.1016/j.jaci.2009.07.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH		Green Published, Green Accepted			2022-12-18	WOS:000273071500013
J	Metz, M; Gimenez-Arnau, A; Borzova, E; Grattan, CEH; Magerl, M; Maurer, M				Metz, Martin; Gimenez-Arnau, Ana; Borzova, Elena; Grattan, Clive E. H.; Magerl, Markus; Maurer, Marcus			Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHRONIC IDIOPATHIC URTICARIA; AUTOLOGOUS SERUM; AUTOANTIBODIES		[Metz, Martin; Magerl, Markus; Maurer, Marcus] Charite Univ Med Berlin, Allergie Ctr Charite, Dept Dermatol & Allergy, D-13353 Berlin, Germany; [Gimenez-Arnau, Ana] Hosp del Mar, Dept Dermatol, Barcelona, Spain; [Borzova, Elena; Grattan, Clive E. H.] Norfolk & Norwich Hosp, Dept Dermatol, Norwich NR1 3SR, Norfolk, England	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital	Metz, M (corresponding author), Charite Univ Med Berlin, Allergie Ctr Charite, Dept Dermatol & Allergy, D-13353 Berlin, Germany.	marcus.maurer@charite.de	Maurer, Marcus/ABG-2174-2020; Magerl, Markus/ABI-5335-2020; Metz, Martin/B-8799-2009; Borzova, Elena/M-9207-2018; Metz, Martin/M-5237-2013	Maurer, Marcus/0000-0002-4121-481X; Magerl, Markus/0000-0001-9218-5468; Metz, Martin/0000-0002-4070-9976; Borzova, Elena/0000-0003-1587-9137; Metz, Martin/0000-0002-4070-9976				Asero R, 2006, J ALLERGY CLIN IMMUN, V117, P1113, DOI 10.1016/j.jaci.2005.12.1343; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; Greaves MW, 2007, CLIN REV ALLERG IMMU, V33, P134, DOI 10.1007/s12016-007-0038-3; Mlynek A, 2008, ALLERGY, V63, P777, DOI 10.1111/j.1398-9995.2008.01726.x; Sabroe RA, 2006, BRIT J DERMATOL, V154, P813, DOI 10.1111/j.1365-2133.2006.07183.x; Sabroe RA, 1999, BRIT J DERMATOL, V140, P446	6	57	59	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					705	706		10.1016/j.jaci.2008.11.040	http://dx.doi.org/10.1016/j.jaci.2008.11.040			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19147213				2022-12-18	WOS:000264731200036
J	Craig, TJ; King, TS; Lemanske, RF; Wechsler, ME; Icitovic, N; Zimmerman, RR; Wasserman, S				Craig, Timothy J.; King, Tonya S.; Lemanske, Robert F., Jr.; Wechsler, Michael E.; Icitovic, Nikolina; Zimmerman, Ronald R., Jr.; Wasserman, Stephen		National Heart Lung & Blood Inst A	Aeroallergen sensitization correlates with PC(20) and exhaled nitric oxide in subjects with mild-to-moderate asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; skin testing; aeroallergens; exhaled nitric oxide; IgE; methacholine challenge	RANDOMIZED CONTROLLED TRIAL; SKIN PRICK TESTS; INHALED CORTICOSTEROIDS; PERSISTENT ASTHMA; BRONCHIAL RESPONSIVENESS; CHILDHOOD ASTHMA; AIRWAY RESPONSIVENESS; EUROPEAN MULTICENTER; RESPIRATORY ALLERGY; INDOOR ALLERGENS	Background: Aeroallergen sensitization in adult asthmatic patients from a wide geographic area has not been correlated with patients' characteristics, markers of airways inflammation, and lung function. Objective: We assessed data obtained from the Asthma Clinical Research Network trials to determine the relationship of aeroallergen sensitization to age, sex, ethnicity, and markers of inflammation and airways function. Methods: Skin testing (14 epicutaneous) was performed on 1338 subjects with objectively diagnosed mild-to-moderate asthma from 11 Asthma Clinical Research Network studies. Skin testing used identical techniques and a quality assurance program to ensure uniformity across centers. Results: Ninety-five percent of the subjects had at least 1 positive skin test response. Of these, 14% had positive reactions to 1 or 2 allergens and 81% had positive reactions to 3 or more allergens, and 2% of subjects reacted only to seasonal allergens, 26% only to perennial allergens, and 67% to both. Increasing IgE and exhaled nitric oxide values, decreasing PC(20) values, and minority ethnicity significantly correlated with the number of positive skin test responses. Subjects with late-onset asthma were less likely to be sensitized; nonetheless, 89% of subjects older than 60 years had positive responses. Conclusion: Ninety-five percent of patients with mild-to-moderate asthma might have an allergic component. Age does not significantly affect aeroallergen sensitization, but the pattern of allergic sensitization varies with ethnicity and geography. Measures used to characterize asthma, such as IgE, exhaled nitric oxide, and PC(20) values, are correlated with aeroallergen sensitization.	[Craig, Timothy J.] Penn State Univ, Coll Med, Dept Med, Div Pulm Allergy & Crit Care, Hershey, PA 17033 USA; [King, Tonya S.; Icitovic, Nikolina; Zimmerman, Ronald R., Jr.] Penn State Univ, Coll Med, Dept Med, Div Publ Hlth Sci, Hershey, PA 17033 USA; [Lemanske, Robert F., Jr.] Univ Wisconsin, Dept Pediat, Div Allergy Immunol, Madison, WI USA; [Wechsler, Michael E.] Brigham & Womens Hosp, Dept Med, Div Pulm, Boston, MA 02115 USA; [Wasserman, Stephen] Univ Calif San Diego, Dept Med, Div Allergy Immunol, San Diego, CA 92103 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Brigham & Women's Hospital; University of California System; University of California San Diego	Craig, TJ (corresponding author), Penn State Univ, Coll Med, Dept Med, Div Pulm Allergy & Crit Care, H041, Hershey, PA 17033 USA.	tcraig@psu.edu	Wechsler, Michael/AAC-5506-2019; Wechsler, Michael/B-3979-2013	Wechsler, Michael/0000-0003-3505-2946	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL056443, U10HL051834, U10HL051823, U10HL074231, U10HL074206, U10HL074208, U10HL051843, U10HL074218, U10HL074073, U10HL074204, U10HL074212, U10HL074227, U10HL074225, U10HL051845, U10HL051810, U10HL051831] Funding Source: NIH RePORTER; NHLBI NIH HHS [U10-HL51831, U10-HL51834, U10-HL74225, U10-HL74227, U10-HL51843, U10-HL74204, U10-HL74073, U10-HL56443, U10-HL51845, U10-HL74231, U10-HL74206, U10-HL74208, U10-HL51810, U10-HL74212, U10-HL74218, U10-HL51823] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1111/j.1365-2222.1997.tb00672.x; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Braback L, 2001, PEDIAT ALLERG IMM-UK, V12, P4, DOI 10.1034/j.1399-3038.2001.012001004.x; Carroll WD, 2006, ARCH DIS CHILD, V91, P405, DOI 10.1136/adc.2005.088278; CLOUGH JB, 1991, AM REV RESPIR DIS, V143, P755, DOI 10.1164/ajrccm/143.4_Pt_1.755; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; CRIMI E, 1993, ALLERGY, V48, P202, DOI 10.1111/j.1398-9995.1993.tb00714.x; DAmato G, 1997, ALLERGY, V52, P711, DOI 10.1111/j.1398-9995.1997.tb01227.x; DESJARDINS A, 1993, J ALLERGY CLIN IMMUN, V91, P979, DOI 10.1016/0091-6749(93)90210-7; Deykin A, 2007, AM J RESP CRIT CARE, V175, P228, DOI 10.1164/rccm.200601-112OC; Djukanovic R, 1996, THORAX, V51, P575, DOI 10.1136/thx.51.6.575; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Eriksson NE, 1996, J INVEST ALLERG CLIN, V6, P36; FIRZPATRICK A, 2006, J ALLERGY CLIN IMMUN, V118, P1218; Fish JE, 1997, AM J RESP CRIT CARE, V156, P1165, DOI 10.1164/ajrccm.156.4.9703012; Gruber W, 1997, EUR RESPIR J, V10, P1041, DOI 10.1183/09031936.97.10051041; Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020; Haselkorn T, 2006, J ASTHMA, V43, P745, DOI 10.1080/02770900601031540; HERBERT FA, 1982, ANN ALLERGY, V49, P311; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Huss K., 2001, ANN ALLERG ASTHMA IM, V86, P492; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Jayaratnam A, 2005, CLIN EXP ALLERGY, V35, P835, DOI 10.1111/j.1365-2222.2005.02283.x; KALLIEL JN, 1989, CHEST, V96, P1336, DOI 10.1378/chest.96.6.1336; KELLY WJW, 1990, J ALLERGY CLIN IMMUN, V85, P548, DOI 10.1016/0091-6749(90)90092-I; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-1746OC; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Lombardi C, 2001, RESP MED, V95, P9, DOI 10.1053/rmed.2000.0945; Martin RJ, 2007, J ALLERGY CLIN IMMUN, V119, P73, DOI 10.1016/j.jaci.2006.10.035; Martin RJ, 2002, AM J RESP CRIT CARE, V165, P1377, DOI 10.1164/rccm.2105013; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Plaschke P, 1999, J ALLERGY CLIN IMMUN, V104, P58, DOI 10.1016/S0091-6749(99)70114-4; Platts-Mills TAE, 2007, J ALLERGY CLIN IMMUN, V119, P297, DOI 10.1016/j.jaci.2006.12.647; Rastogi D, 2006, ANN ALLERG ASTHMA IM, V97, P636, DOI 10.1016/S1081-1206(10)61093-9; Ronchetti R, 2007, INT ARCH ALLERGY IMM, V142, P79, DOI 10.1159/000096031; Rose G, 1996, J ALLERGY CLIN IMMUN, V97, P1071, DOI 10.1016/S0091-6749(96)70260-9; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P957, DOI 10.1111/j.1365-2222.1993.tb00281.x; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P949, DOI 10.1111/j.1365-2222.1993.tb00280.x; Stevenson LA, 2001, J ALLERGY CLIN IMMUN, V108, P747, DOI 10.1067/mai.2001.119410; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Tschopp JM, 1998, ALLERGY, V53, P608, DOI 10.1111/j.1398-9995.1998.tb03937.x; Tunnicliffe WS, 1999, EUR RESPIR J, V13, P654, DOI 10.1183/09031936.99.13365499; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888; Zeldin DC, 2006, ENVIRON HEALTH PERSP, V114, P620, DOI 10.1289/ehp.8379; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7	50	57	58	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					671	677		10.1016/j.jaci.2007.12.1153	http://dx.doi.org/10.1016/j.jaci.2007.12.1153			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18234311				2022-12-18	WOS:000253918900020
J	Corren, J; Shapiro, G; Reimann, J; Deniz, Y; Wong, D; Adelman, D; Togias, A				Corren, Jonathan; Shapiro, Gail; Reimann, James; Deniz, Yamo; Wong, Dennis; Adelman, Daniel; Togias, Alkis			Allergen skin tests and free IgE levels during reduction and cessation of ornalizumab therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						omalizumab; anti-IgE; IgE; allergic rhinitis; allergen skin tests	FC-EPSILON-RI; HUMANIZED MONOCLONAL-ANTIBODY; SERUM IGE; OMALIZUMAB; BASOPHIL	Background: The recombinant humanized anti-IgE antibody omalizumab rapidly reduces serum free IgE concentrations and alleviates allergic airway disease. It is not known whether stopping or reducing the dose of omalizumab maintains adequate suppression of free IgE levels and IgE-mediated mast cell activation. Objective: To determine the effects of omalizumab on serum free IgE and immediate allergen skin test reactivity during initial therapy followed by treatment reduction and cessation. Methods: Forty patients with perennial allergic rhinitis were randomized to receive 0.015 or 0.030 mg/kg/IU/mL open-label intravenous omalizumab every 2 weeks for 28 weeks, followed by 0.0015 or 0.0050 mg/kg/IU/mL every 2 weeks for 18 weeks. Serum free IgE levels were measured and titrated dust mite allergen skin tests conducted throughout. Results: At day 98, serum free IgE concentrations were decreased by 96 % to 99 %, and wheal-and-flare reactions to skin tests were markedly suppressed. After reduced omalizumab doses (day 322), serum free IgE and allergen skin test reactivity increased significantly. On complete discontinuation of therapy (day 378), serum free IgE levels and skin test reactivity returned to baseline levels. Patients with lower initial levels of IgE had significantly less suppression of skin test reactivity. Conclusion: Omalizumab reduced serum free IgE and immediate skin test reactivity to allergen during initial, high-dose administration. These effects were not fully maintained during dose reduction and returned to baseline after cessation of chronic treatment.	[Corren, Jonathan] Allergy Res Fdn, Los Angeles, CA 90025 USA; [Shapiro, Gail] ASTHMA Inc, Seattle, WA USA; [Reimann, James; Deniz, Yamo; Wong, Dennis] Genentech Inc, San Francisco, CA USA; [Adelman, Daniel] Pharmacyclics Inc, Sunnyvale, CA USA; [Togias, Alkis] Johns Hopkins Univ, Baltimore, MD 21218 USA	Roche Holding; Genentech; Pharmacyclics; Johns Hopkins University	Corren, J (corresponding author), Allergy Res Fdn, 11620 Wilshire Blvd, Suite 200, Los Angeles, CA 90025 USA.	jcorren@ucla.edu	Wong, Dennis A/AAH-2958-2020					Belliveau Paul P, 2005, MedGenMed, V7, P27; Buhl R, 2005, CURR OPIN PULM MED, V11, P27; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; *GEN INC, 2007, OM XOL; Hochhaus G, 2003, CURR MED RES OPIN, V19, P491, DOI 10.1185/030079903125002171; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Johansson SGO, 2006, ALLERGY, V61, P1216, DOI 10.1111/j.1398-9995.2006.01172.x; Kaliner MA, 2004, CURR ALLERGY ASTHM R, V4, P237, DOI 10.1007/s11882-004-0032-2; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; MacGlashan DW, 1997, INT ARCH ALLERGY IMM, V113, P45; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Ong YE, 2005, J ALLERGY CLIN IMMUN, V116, P558, DOI 10.1016/j.jaci.2005.05.035; Saini SS, 2000, J ALLERGY CLIN IMMUN, V106, P514, DOI 10.1067/mai.2000.108431; Saini SS, 1999, J IMMUNOL, V162, P5624; Simons FER, 2002, AM J MED, V113, p38S; Walker S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub3	18	57	57	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					506	511		10.1016/j.jaci.2007.11.026	http://dx.doi.org/10.1016/j.jaci.2007.11.026			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18269927	Bronze			2022-12-18	WOS:000253337800034
J	Hancox, RJ; Welch, D; Poulton, R; Taylor, DR; McLachlan, CR; Greene, JM; Sears, MR				Hancox, Robert J.; Welch, David; Poulton, Richie; Taylor, D. Robin; McLachlan, Christene R.; Greene, Justina M.; Sears, Malcolm R.			Cigarette smoking and allergic sensitization: A 32-year population-based cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; allergy; cigarette smoking; cohort study; epidemiology	RESPIRATORY HEALTH SURVEY; TOBACCO-SMOKE; COPENHAGEN ALLERGY; PARENTAL SMOKING; IGE LEVELS; CHILDREN; ATOPY; CHILDHOOD; ASTHMA; ADULTS	Background: Cigarette smoke has immunosuppressant effects, but its effect on allergic sensitization is unclear. Objective: To investigate associations between parental and personal smoking and skin prick tests (SPTs) for atopy in a population-based birth cohort of 1037 participants followed to adulthood. Methods: Parental history of atopic disease, parental smoking, and personal smoking were obtained at multiple assessments between birth and age 32 years. Atopy was assessed by SPTs for 11 common inhaled allergens at ages 13 and 32 years. Results: Children of atopic parents were less likely to have positive SPTs at age 13 years if either parent smoked (odds ratio, 0.55; P =.009). This association was not significant after adjusting for breast-feeding history, number of siblings, and childhood socioeconomic status. Subjects with atopic parents were also less likely to develop positive results to SPTs between ages 13 and 32 years if they smoked themselves (odds ratio, 0.18; P <.001). This reduction in risk remained significant after adjusting for multiple potential confounding factors. Neither parental nor personal smoking was significantly associated with allergic sensitization among subjects whose parents did not have a history of atopic disease. Few of those with positive SPT results at age 13 years had negative tests at age 32 years, and there was no evidence that this was influenced by smoking. Conclusion: Personal and parental smoking is associated with a reduced risk of allergic sensitization in people with a family history of atopy.	[Hancox, Robert J.; Welch, David; Poulton, Richie; McLachlan, Christene R.] Univ Otago, Sch Med, Dept Prevent & Social Med, Dunedin Multidisciplinary Hlth & Dev Res Unit, Dunedin, New Zealand; [Taylor, D. Robin] Univ Otago, Dunedin Sch Med, Dept Med & Surg Sci, Dunedin, New Zealand; [Greene, Justina M.; Sears, Malcolm R.] Firestone Inst Resp Hlth, Dept Med, Hamilton, New Zealand	University of Otago; University of Otago	Hancox, RJ (corresponding author), Univ Otago, Sch Med, Dept Prevent & Social Med, Dunedin Multidisciplinary Hlth & Dev Res Unit, POB 913, Dunedin, New Zealand.	bob.hancox@otago.ac.nz	Hancox, Robert/G-4746-2011					BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; Burr ML, 1997, CLIN EXP ALLERGY, V27, P1247; Douglass JA, 2006, MED J AUSTRALIA, V185, P228, DOI 10.5694/j.1326-5377.2006.tb00539.x; Halken S, 2004, PEDIAT ALLERG IMM-UK, V15, P9, DOI 10.1111/j.1399-3038.2004.0148b.x; Hancox RJ, 2004, THORAX, V59, P376, DOI 10.1136/thx.2003.010363; Jarvis D, 1999, J ALLERGY CLIN IMMUN, V104, P934, DOI 10.1016/S0091-6749(99)70071-0; Kerkhof M, 2005, PEDIAT ALLERG IMM-UK, V16, P10, DOI 10.1111/j.1399-3038.2005.00217.x; Kramer U, 2004, BRIT J DERMATOL, V150, P111, DOI 10.1111/j.1365-2133.2004.05710.x; Kulig M, 1999, ALLERGY, V54, P220, DOI 10.1034/j.1398-9995.1999.00753.x; Kummeling I, 2006, CLIN EXP ALLERGY, V36, P489, DOI 10.1111/j.1365-2222.2006.02473.x; Kuyucu S, 2004, PEDIAT ALLERG IMM-UK, V15, P62, DOI 10.1046/j.0905-6157.2003.00115.x; Larsson ML, 2005, PEDIAT ALLERG IMM-UK, V16, P449, DOI 10.1111/j.1399-3038.2005.00247.x; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755, DOI 10.1016/S0091-6749(99)70284-8; Linneberg A, 2001, CLIN EXP ALLERGY, V31, P1409, DOI 10.1046/j.1365-2222.2001.01178.x; Linneberg A, 2001, ALLERGY, V56, P328, DOI 10.1034/j.1398-9995.2000.00509.x-i1; Murray CS, 2004, PEDIATR PULM, V37, P492, DOI 10.1002/ppul.20019; Nielsen GD, 2005, TOXICOLOGY, V216, P87, DOI 10.1016/j.tox.2005.07.022; OMENAAS E, 1994, CLIN EXP ALLERGY, V24, P530, DOI 10.1111/j.1365-2222.1994.tb00950.x; Raherison C, 2007, RESP MED, V101, P107, DOI 10.1016/j.rmed.2006.04.010; Ronmark E, 1998, RESP MED, V92, P316, DOI 10.1016/S0954-6111(98)90115-9; Salvatore S, 2005, PEDIAT ALLERG IMM-UK, V16, P558, DOI 10.1111/j.1399-3038.2005.00315.x; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Silva P., 1996, CHILD ADULT DUNEDIN; Sopori M, 2002, NAT REV IMMUNOL, V2, P372, DOI 10.1038/nri803; Strachan DP, 1998, THORAX, V53, P117, DOI 10.1136/thx.53.2.117; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Thomsen SF, 2006, ALLERGY ASTHMA PROC, V27, P110; Van Bever HP, 2002, EUR J PEDIATR, V161, P542, DOI 10.1007/s00431-002-1028-3; Wood RA, 2006, ARCH PEDIAT ADOL MED, V160, P552, DOI 10.1001/archpedi.160.5.552; Wuthrich B, 1996, INT ARCH ALLERGY IMM, V111, P396, DOI 10.1159/000237398; [No title captured]	33	57	57	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					38	42		10.1016/j.jaci.2007.09.052	http://dx.doi.org/10.1016/j.jaci.2007.09.052			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18061657				2022-12-18	WOS:000252372000006
J	McDonald, DR; Mooster, JL; Reddy, M; Bawle, E; Secord, E; Geha, RS				McDonald, Douglas R.; Mooster, Jana L.; Reddy, Malathi; Bawle, Erawati; Secord, Elizabeth; Geha, Raif S.			Heterozygous N-terminal deletion of I kappa B alpha results in functional nuclear factor kappa B haploinsufficiency, ectodermal dysplasia, and immune deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ectodermal dysplasia with immune deficiency; I kappa B alpha; nuclear factor kappa B; phosphorylation; degradation; Toll-like receptors; haploinsufficiency	TOLL-LIKE RECEPTORS; INCONTINENTIA PIGMENTI; INHERITED DISORDERS; SIGNAL-TRANSDUCTION; HUMAN-DISEASE; INNATE; MUTATIONS	Background: Nuclear factor kappa B (NF-kappa B) is a master transcriptional regulator critical for ectodermal development and normal innate and adaptive immune function. Mutations in the I kappa B kinase gamma/NF-kappa B essential modifier have been described in male subjects with the syndrome of X-finked ectodermal dysplasia with immune deficiency that results from impaired activation of NF-kappa B. Objectives: We sought to determine the genetic cause of ectodermal dysplasia with immune deficiency in a female patient. Methods: Toll-like receptor-induced production of the NF-kappa B-dependent cytokines TNF-alpha and IFN-alpha. was examined by means of ELISA, the patient's I kappa B alpha gene was sequenced, and NF-kappa B activation was evaluated by means of electrophoretic mobility shift assay and NF-kappa B-luciferase assays in transfectants. Results: Toll-like receptor function was impaired in the patient. Sequencing of the patient's I kappa B alpha gene revealed a novel heterozygous mutation at amino acid 11 (W11X). The mutant I kappa B alpha W11X protein did not undergo ligand-induced phosphorylation or degradation and retained NF-kappa B in the cytoplasm. This led to roughly a 50% decrease in NF-kappa B DNA-binding activity, leading to functional haploinsufficiency of NF-kappa B activation. Unlike the only other reported I kappa B alpha mutant associated with ectodermal dysplasia associated with immune deficiency (ED-ID), S32I, I kappa B alpha W11X exerted no dominant-negative effect. Conclusions: Functional NF-kappa B haploinsufficiency was associated with ED-ID, and this strongly suggests that normal ectodermal development and immune function are stringently dependent on NF-kappa B in that they might require more than half of normal NF-KB activity. Clinical implications: Although ED-ID is well described in male subjects, female subjects can present with a similar syndrome of ectodermal dysplasia with immune deficiency resulting from mutations in autosomal genes within the NF-kappa B pathway.	Childrens Hosp, Div Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Wayne State Univ, Childrens Hosp Michigan, Dept Pediat, Div Allergy, Detroit, MI USA; Wayne State Univ, Childrens Hosp Michigan, Dept Pediat, Div Immunol, Detroit, MI USA; Wayne State Univ, Childrens Hosp Michigan, Dept Pediat, Div Rheumatol, Detroit, MI USA; Wayne State Univ, Childrens Hosp Michigan, Dept Pediat, Div Genet, Detroit, MI USA; Wayne State Univ, Childrens Hosp Michigan, Dept Pediat, Div Metab Disorders, Detroit, MI USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Children's Hospital of Michigan; Wayne State University; Children's Hospital of Michigan; Wayne State University; Children's Hospital of Michigan; Wayne State University; Children's Hospital of Michigan; Wayne State University; Children's Hospital of Michigan; Wayne State University	Geha, RS (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035714, N01AI30070, N01AI030070] Funding Source: NIH RePORTER; NIAID NIH HHS [N01AI30070, P01AI035714] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abramoff M.D., 2004, BIOPHOT INT, V11, P36; Athman R, 2004, CURR OPIN MICROBIOL, V7, P25, DOI 10.1016/j.mib.2003.12.013; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Courtois G, 2003, J CLIN INVEST, V112, P1108, DOI 10.1172/JCI200318714; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Janssen R, 2004, J EXP MED, V200, P559, DOI 10.1084/jem.20040773; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; Kozak M, 2005, GENE, V361, P13, DOI 10.1016/j.gene.2005.06.037; Ku CL, 2005, IMMUNOL REV, V203, P10, DOI 10.1111/j.0105-2896.2005.00235.x; Lemaitre B, 2004, NAT REV IMMUNOL, V4, P521, DOI 10.1038/nri1390; McDonald DR, 2006, J ALLERGY CLIN IMMUN, V118, P1357, DOI 10.1016/j.jaci.2006.08.006; McDonald DR, 2006, MICROBES INFECT, V8, P1151, DOI 10.1016/j.micinf.2005.10.030; Orange JS, 2005, IMMUNOL REV, V203, P21, DOI 10.1111/j.0105-2896.2005.00221.x; Orange JS, 2004, J ALLERGY CLIN IMMUN, V113, P725, DOI 10.1016/j.jaci.2004.01.762; Puel A, 2004, CURR OPIN IMMUNOL, V16, P34, DOI 10.1016/j.coi.2003.11.013; Schulze-Luehrmann J, 2006, IMMUNITY, V25, P701, DOI 10.1016/j.immuni.2006.10.010; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Takeuchi O, 2001, INT IMMUNOPHARMACOL, V1, P625, DOI 10.1016/S1567-5769(01)00010-8; Tsitsikov EN, 2001, IMMUNITY, V15, P647, DOI 10.1016/S1074-7613(01)00207-2; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	24	57	59	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					900	907		10.1016/j.jaci.2007.08.035	http://dx.doi.org/10.1016/j.jaci.2007.08.035			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17931563				2022-12-18	WOS:000250157700026
J	Ratner, PH; Wingertzahn, MA; van Bavel, JH; Hampel, F; Darken, PF; Shah, T				Ratner, Paul H.; Wingertzahn, Mark A.; van Bavel, Julius H.; Hampel, Frank; Darken, Patrick F.; Shah, Tushar			Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						intranasal corticosteroid; hay fever; nasal symptoms; health-related quality of life	BENZALKONIUM CHLORIDE; PHARMACOKINETICS; HEALTHY; ASTHMA	Background: Allergic rhinitis (AR), an inflammatory disease of the nasal mucosa, affects approximately 25% of adults and 40% of children in the United States. Ciclesonide nasal spray is a corticosteroid being developed as a hypotonic formulation for AR. Objective: We sought to evaluate the efficacy, safety, and tolerability of ciclesonide nasal spray in adult and adolescent patients with seasonal AR (SAR). Methods: In this double-blind study patients (age, >= 12 years) were randomized to receive 200 mu g of intranasal ciclesonide (n = 164) or placebo (n = 163) once daily for 28 days. The primary measure was morning and evening patient-assessed reflective total nasal symptom score (TNSS). Additionally, instantaneous TNSSs, physician-assessed overall nasal signs and symptoms severity, and the results of the Rhinoconjunctivitis Quality of Life Questionnaire were evaluated. Adverse events were monitored throughout the study. Results: Ciclesonide significantly improved average morning and evening reflective and instantaneous TNSSs compared with placebo over days 1 to 14 (P < .001). Improvements were also noted over days 1 to 28 (P < .001) and over days 15 to 28 (P = .011). Ciclesonide was well tolerated. Conclusion: Intranasal ciclesonide was superior to placebo in relieving nasal symptoms in adult and adolescent patients with SAR. These results confirm the dose range-finding study in patients with SAR and support the efficacy of ciclesonide in AR. Clinical implications: In a clinical setting ciclesonide was shown to be safe and effective in the treatment of SAR in adolescent and adult patients.	Univ Texas, Hlth Sci Ctr, Sylvana Res Associates, San Antonio, TX 78229 USA; Allergy & Asthma Associates, PLLC, Florham Pk, NJ USA	University of Texas System; University of Texas Health San Antonio	Ratner, PH (corresponding author), Univ Texas, Hlth Sci Ctr, Sylvana Res Associates, 7711 Louis Pasteur Dr,Suite 407, San Antonio, TX 78229 USA.	phratner@swbell.net						Bender BG, 2003, J ALLERGY CLIN IMMUN, V111, P770, DOI 10.1067/mai.2003.1408; Bernstein IL, 2000, J ALLERGY CLIN IMMUN, V105, P39, DOI 10.1016/S0091-6749(00)90175-1; Chapman KR, 2005, ALLERGY, V60, P330, DOI 10.1111/j.1398-9995.2004.00750.x; Craig TJ, 1998, J ALLERGY CLIN IMMUN, V101, P633, DOI 10.1016/S0091-6749(98)70171-X; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P463, DOI 10.1016/S1081-1206(10)63152-3; Graf P, 1999, CLIN THER, V21, P1749, DOI 10.1016/S0149-2918(99)80053-8; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Mahadevia PJ, 2004, ANN ALLERG ASTHMA IM, V93, P345, DOI 10.1016/S1081-1206(10)61393-2; Milgrom H, 1997, ANN ALLERG ASTHMA IM, V78, P439, DOI 10.1016/S1081-1206(10)63230-9; MUTCH E, 2003, EUR RESP J S45, V22, pS267; Nave R, 2006, J CLIN PHARMACOL, V46, P461, DOI 10.1177/0091270006286437; Nave R, 2004, CLIN PHARMACOKINET, V43, P479, DOI 10.2165/00003088-200443070-00004; NUUTINEN J, 1986, Rhinology (Utrecht), V24, P265; Postma DS, 2001, EUR RESPIR J, V17, P1083, DOI 10.1183/09031936.01.00099701; Ratner P, 2006, ANN ALLERG ASTHMA IM, V96, P18; Rohatagi S, 2003, J CLIN PHARMACOL, V43, P365, DOI 10.1177/0091270002250998; Rohatagi Shashank, 2005, Am J Ther, V12, P201; Salmun Luis M, 2002, BMC Fam Pract, V3, P14, DOI 10.1186/1471-2296-3-14; *SCHER CORP, 2003, NAS MOM FUR MON; Skoner DR, 2001, J ALLERGY CLIN IMMUN, V108, pS2, DOI 10.1067/mai.2001.115569; SPECTOR SL, 1982, CLIN ALLERGY, V12, P187, DOI 10.1111/j.1365-2222.1982.tb01638.x; SPECTOR SL, 1992, J ALLERGY CLIN IMMUN, V90, P1042, DOI 10.1016/0091-6749(92)90119-M; Stoeck M, 2004, J PHARMACOL EXP THER, V309, P249, DOI 10.1124/jpet.103.059592; van Adelsberg J, 2003, ALLERGY, V58, P1268, DOI 10.1046/j.1398-9995.2003.00261.x; WINGERTZAHN M, 2006, ANN ALLERG ASTHMA S, V96, P150; Wingertzahn MA, 2006, J ALLERGY CLIN IMMUN, V117, pS167; WINGERTZAHN MA, 2005, J ALLERGY CLIN IMM S, V115, pS126, DOI DOI 10.1016/J.JACI.2004.12.516	27	57	61	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1142	1148		10.1016/j.jaci.2006.07.050	http://dx.doi.org/10.1016/j.jaci.2006.07.050			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088141				2022-12-18	WOS:000244282300021
J	Schatz, M; Zeiger, RS; Vollmer, WM; Mosen, D; Cook, EF				Schatz, Michael; Zeiger, Robert S.; Vollmer, William M.; Mosen, David; Cook, E. Francis			Determinants of future long-term asthma control	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma control; asthma severity; asthma comorbidities; asthma demographics; short-acting beta-agonists; inhaled corticosteroids; long-acting beta-agonists; asthma specialist care; asthma self-management	HEALTH-CARE UTILIZATION; INHALED CORTICOSTEROIDS; SPECIALTY CARE; UNITED-STATES; HOSPITALIZATION; MANAGEMENT; PREVENTION; SEVERITY; SYMPTOMS; MEDICATION	Background: Asthma control has been hypothesized to be inversely related to asthma severity, directly related to effective management, and also related to other definable factors, but empiric data to support this construct are few. Objective: We sought to identify independent prospective determinants of future long-term asthma control among asthma severity, management, demographic, and comorbidity predictors. Methods: Surveys were completed by a random sample of 2250 health maintenance organization members aged 18 to 56 years with persistent asthma. Linked computerized pharmacy data provided baseline and follow-up year medication dispensings. The outcome was follow-up year long-term asthma control, as assessed by using a previously validated 4-level scale based on the number of short-acting (3-agonist canister dispensings. Results: Oral corticosteroids (odds ratio [OR], 1.9) or unscheduled visits (OR, 1.2) in the prior year, any prior asthma hospitalizations (OR, 1.4), smoking (OR, 2.2), chronic obstructive pulmonary disease (OR, 1.9), male sex (OR, 1.5), black race (OR, 1.3), and lower educational level (OR, 1.1) were independently associated with poorer control in ordinal logistic regression analyses. Regular inhaled corticosteroids (OR,. 0.7), long-acting beta-agonists (OR, 0.7) and asthma specialist care (OR, 0.6) were independently associated with better control. Conclusions: Markers of asthma severity and other patient characteristics are inversely related to future asthma control, but effective management strategies are associated with improved asthma control, even after accounting for these high-risk characteristics. Clinical implications: Inhaled corticosteroids, long-acting beta-agonists, and asthma specialist care are associated with improved asthma control, even after accounting for markers of asthma severity.	Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA 92111 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Kaiser Permanente; Harvard University; Harvard T.H. Chan School of Public Health	Schatz, M (corresponding author), Kaiser Permanente Med Ctr, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.	michael.x.schatz@kp.org		Zeiger, Robert/0000-0001-5788-5063				Adams NP, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003135.pub3; Adams RJ, 2002, J ALLERGY CLIN IMMUN, V110, P58, DOI 10.1067/mai.2002.125489; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Boulet Louis-Philippe, 2002, Can Respir J, V9, P417; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Castro M, 2001, J ASTHMA, V38, P625, DOI 10.1081/JAS-100107540; Cockcroft DW, 1996, J ALLERGY CLIN IMMUN, V98, P1016, DOI 10.1016/S0091-6749(96)80185-0; Cydulka RK, 2001, ANN EMERG MED, V38, P123, DOI 10.1067/mem.2001.114305; DEPALO VA, 1994, CHEST, V106, P447, DOI 10.1378/chest.106.2.447; Eisner MD, 2002, ANN ALLERG ASTHMA IM, V89, P46, DOI 10.1016/S1081-1206(10)61910-2; Fuhlbrigge AL, 2004, CURR OPIN PULM MED, V10, P1, DOI 10.1097/00063198-200401000-00002; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; Joseph CLM, 1998, J ALLERGY CLIN IMMUN, V101, P484, DOI 10.1016/S0091-6749(98)70355-0; Laforest L, 2006, EUR RESPIR J, V27, P42, DOI 10.1183/09031936.06.00035805; Legorreta AP, 1998, ARCH INTERN MED, V158, P457, DOI 10.1001/archinte.158.5.457; Li JT, 2005, J ALLERGY CLIN IMMUN, V116, pS3, DOI 10.1016/j.jaci.2005.08.017; Liard R, 2000, EUR RESPIR J, V16, P615, DOI 10.1034/j.1399-3003.2000.16d08.x; Lieu TA, 1997, PEDIATRICS, V100, P334, DOI 10.1542/peds.100.3.334; Miller JE, 2000, AM J PUBLIC HEALTH, V90, P428, DOI 10.2105/AJPH.90.3.428; *NAT COMM QUAL ASS, 2001, HEDIS 2002, V2; National Asthma Education and Prevention Program, 1991, NIH PUBL, V91- 3642; NI CM, 2005, COCHRANE DB SYST REV; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Osborne ML, 1998, AM J RESP CRIT CARE, V157, P123, DOI 10.1164/ajrccm.157.1.9612063; Ray NF, 1998, CHEST, V113, P1277, DOI 10.1378/chest.113.5.1277; Schatz M, 2003, J ALLERGY CLIN IMMUN, V111, P503, DOI 10.1067/mai.2003.178; Schatz M, 2003, ANN ALLERG ASTHMA IM, V91, P553, DOI 10.1016/S1081-1206(10)61533-5; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P995, DOI 10.1016/j.jaci.2006.01.053; Stoloff SW, 2006, J ALLERGY CLIN IMMUN, V117, P544, DOI 10.1016/j.jaci.2006.01.005; Suissa S, 2002, THORAX, V57, P880, DOI 10.1136/thorax.57.10.880; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Tonnesen P, 2005, NICOTINE TOB RES, V7, P139, DOI 10.1080/14622200412331328411; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Vollmer WM, 1997, ARCH INTERN MED, V157, P1201, DOI 10.1001/archinte.157.11.1201; Vollmer WM, 2004, ANN ALLERG ASTHMA IM, V93, P409, DOI 10.1016/S1081-1206(10)61406-8; ZEIGER RS, 1991, J ALLERGY CLIN IMMUN, V87, P1160, DOI 10.1016/0091-6749(91)92162-T; 2002, GLOBAL INITIATIVE AS	38	57	58	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1048	1053		10.1016/j.jaci.2006.07.057	http://dx.doi.org/10.1016/j.jaci.2006.07.057			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088128				2022-12-18	WOS:000244282300008
J	Elberink, JNGO; van der Heide, S; Guyatt, GH; Dubois, AEJ				Elberink, Joanne N. G. Oude; van der Heide, S.; Guyatt, Gordon H.; Dubois, Anthony E. J.			Analysis of the burden of treatment in patients receiving an EpiPen for yellow jacket anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EpiPen; quality of life; yellow jacket allergy; venom immunotherapy; insect allergy; venom allergy; burden of treatment	FOOD	Background: Venom immunotherapy (VIT) is a treatment with established efficacy for the prevention of repeated anaphylactic reactions in patients with Hymenoptera allergy, which also allows patients to discontinue carrying an EpiPen. Despite their merits, both treatments can have negative aspects potentially important to patients. Objective: We examined possible negative aspects of the EpiPen in comparison with VIT as perceived by patients. Methods: Positive and negative aspects of both treatments were measured by using a burden of treatment questionnaire together with statements about the EpiPen. Results: One hundred ninety-three patients were included, of whom 94 consented to randomization: 47 received VIT, and 47 received the EpiPen. Of the remaining 99, 75 chose VIT, and 26 chose the EpiPen. Of the patients receiving VIT, 91.5% were (extremely) positive about their treatment, and 85% would choose VIT again. Of the patients receiving the EpiPen, only 48% were positive about their treatment, and even of these patients, 68% preferred to be treated with VIT after 1 year of carrying the EpiPen. Although most patients indicated that it is reassuring to carry an EpiPen and makes them feel safe, many patients also indicated that it is inconvenient and troublesome. Especially patients who were negative about the EpiPen indicated that they would not dare use the EpiPen if necessary and were afraid at possible side effects. Conclusion: In contrast to VIT, the EpiPen is perceived as burdensome by most patients with venom allergy. For most patients, an EpiPen is an unsuitable definitive treatment. Clinical implications: As VIT enables patients with venom allergy to get rid of the EpiPen, patients should be offered VIT.	Univ Groningen, Dept Allergol, Med Ctr, NL-9700 AB Groningen, Netherlands; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4L8, Canada	University of Groningen; McMaster University	Elberink, JNGO (corresponding author), Univ Groningen Hosp, Dept Allergol, Hanzeplein 1,POB 30001, NL-9700 RB Groningen, Netherlands.	j.n.g.oude.elberink@int.azg.nl						Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Elberink JNGO, 2002, J ALLERGY CLIN IMMUN, V109, P162, DOI 10.1067/mai.2002.120552; Elberink JNGO, 2002, J ALLERGY CLIN IMMUN, V110, P174, DOI 10.1067/mai.2002.125827; Goldberg A, 2000, J ALLERGY CLIN IMMUN, V106, P1184, DOI 10.1067/mai.2000.110927; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; MULLER U, 1993, ALLERGY, V48, P37; Portnoy J M, 1999, J Allergy Clin Immunol, V103, P963, DOI 10.1016/S0091-6749(99)70450-1; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P837, DOI 10.1016/j.jaci.2004.01.079; Spielberger C.D., 1970, STAI MANUAL	11	57	57	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					699	704		10.1016/j.jaci.2006.03.049	http://dx.doi.org/10.1016/j.jaci.2006.03.049			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950290				2022-12-18	WOS:000240649000024
J	Malmstrom, K; Pitkaranta, A; Carpen, O; Pelkonen, A; Malmberg, LP; Turpeinen, M; Kajosaari, M; Sarna, S; Lindahl, H; Haahtela, T; Makela, MJ				Malmstrom, Kristiina; Pitkaranta, Anne; Carpen, Olli; Pelkonen, Anna; Malmberg, L. Pekka; Turpeinen, Markku; Kajosaari, Merja; Sarna, Seppo; Lindahl, Harry; Haahtela, Tari; Makela, Mika J.			Human rhinovirus in bronchial epithelium of infants with recurrent respiratory symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; infant; lung function; pediatric; rhinovirus	ASTHMATIC SUBJECTS; VIRAL-INFECTIONS; LOWER AIRWAYS; COMMON COLD; CHILDREN; INFLAMMATION; ILLNESSES; VIRUSES; TISSUE; TRACT	Background: Human rhinoviruses (HRVs) are a common cause of upper respiratory tract infections. There is growing evidence that HRVs are also important in lower respiratory tract infections and often induce asthma exacerbations. Objective: We evaluated the presence of HRV in the lower respiratory tract by obtaining bronchial biopsies from infants with recurrent asthmalike respiratory symptoms. Methods: A total of 201 steroid-naive infants age 3 to 26 months with recurrent respiratory symptoms for at least 4 weeks within the preceding 2 months were studied for lung function using body plethysmography. Bronchoscopy was performed in 68 children, and bronchial biopsies were available from 59 infants for HRV detection with in situ hybridization. Results: Human rhinovirus was detected in 21 of 47 (45%) specimens. Abnormal lung function (decreased airways conductance) was found in 18 of 21 (86%) HRV+ infants and in 15 of 26 (58%) HRV- infants (P = .037). Occurrence of a respiratory infection in the 6 weeks preceding bronchoscopy correlated with HRV positivity (P = .036). Conclusion: Human rhinovirus is frequently found in the lower airways in infants with recurrent respiratory symptoms, and the majority of these HRV+ infants also showed increased airway resistance. Clinical implications: Human rhinovirus is a common pathogen causing upper and lower respiratory symptoms. Follow-up of these infants will reveal whether the presence of HRV in the bronchial biopsy and abnormal lung function with recurrent respiratory symptoms predicts subsequent asthma.	Univ Helsinki, Cent Hosp, Dept Allergy, FI-00029 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Otorhinolaryngol, FI-00029 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Pathol, FI-00029 Helsinki, Finland; Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, FI-00029 Helsinki, Finland; Univ Turku, Dept Pathol, Turku, Finland; Univ Turku, Cent Hosp, Turku, Finland; Univ Helsinki, Dept Publ Hlth, FIN-00014 Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Turku; University of Turku; University of Helsinki	Malmstrom, K (corresponding author), Univ Helsinki, Cent Hosp, Dept Allergy, POB 160, FI-00029 Helsinki, Finland.	kristiina.malmstrom@pp.fimnet.fi	Pelkonen, Anna/D-3153-2018	Pelkonen, Anna/0000-0002-1482-8947; Sarna, Seppo/0000-0003-3458-1627; Makela, Mika/0000-0002-2933-3111				ARRUDA E, 1995, J INFECT DIS, V171, P1329, DOI 10.1093/infdis/171.5.1329; Blomqvist S, 2002, J MED VIROL, V66, P263, DOI 10.1002/jmv.2140; DUFF AL, 1993, PEDIATRICS, V92, P535; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1872, DOI 10.1164/ajrccm.155.6.9196088; GREEN RM, 2002, BRIT MED J, V324, P1; Gwaltney JM, 1997, VIRAL INFECT HUMANS, P815; Hayden FG, 2004, REV MED VIROL, V14, P17, DOI 10.1002/rmv.406; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Jartti T, 2004, EMERG INFECT DIS, V10, P1095, DOI 10.3201/eid1006.030629; Jartti T, 2004, J MED VIROL, V72, P695, DOI 10.1002/jmv.20027; Jeffery P, 2003, AM J RESP CRIT CARE, V168, pS1, DOI 10.1164/rccm.200202-150WS; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; KALLAJOKI M, 1990, LAB INVEST, V63, P669; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Kraemer R, 1997, RESPIRATION, V64, P342; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Makela MJ, 1998, J CLIN MICROBIOL, V36, P539; Malmberg LP, 1999, PEDIATR PULM, V28, P356, DOI 10.1002/(SICI)1099-0496(199911)28:5<356::AID-PPUL8>3.0.CO;2-2; MCFADDEN ER, 1985, J APPL PHYSIOL, V58, P564, DOI 10.1152/jappl.1985.58.2.564; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; Mosser AG, 2002, J INFECT DIS, V185, P734, DOI 10.1086/339339; Papadopoulos NG, 2002, THORAX, V57, P328, DOI 10.1136/thorax.57.4.328; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Papadopoulos NG, 2002, CLIN EXP ALLERGY, V32, P537, DOI 10.1046/j.0954-7894.2002.01313.x; Pitkaranta A, 2001, CLIN INFECT DIS, V33, P909, DOI 10.1086/322678; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Rihkanen H, 2004, INT J PEDIATR OTORHI, V68, P903, DOI 10.1016/j.ijporl.2004.02.005; Saglani S, 2003, THORAX, V58, P1053, DOI 10.1136/thorax.58.12.1053; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-1404OC; Savolainen C, 2002, J GEN VIROL, V83, P333, DOI 10.1099/0022-1317-83-2-333; Trigg CJ, 1996, CLIN EXP ALLERGY, V26, P665, DOI 10.1111/j.1365-2222.1996.tb00593.x; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901	34	57	63	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					591	596		10.1016/j.jaci.2006.04.032	http://dx.doi.org/10.1016/j.jaci.2006.04.032			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950276				2022-12-18	WOS:000240649000010
J	Aaronson, DW; Gandhi, TK				Aaronson, DW; Gandhi, TK			Incorrect allergy injections: Allergists' experiences and recommendations for prevention	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						patient safety; medical error; anaphylaxis	DOUBLE-BLIND; IMMUNOTHERAPY; FATALITIES; PHYSICIANS; EVENTS; SAFETY	There are several reports of fatalities caused by allergen immunotherapy and skin testing. Patients have been reported who have received incorrect allergy injections. These could put them at risk for anaphylactic reaction and a possible fatality. We performed a survey to determine allergists' experiences with incorrect injections and to identify opportunities for prevention. This study was endorsed by the American Academy of Allergy, Asthma and Immunology and the Joint Council of Allergy, Asthma and Immunology. We conducted an e-mail survey of 1717 allergists, asking whether they knew of an incorrect injection administered within the last 5 years in their offices. An incorrect injection is an injection given to the wrong patient or a correct patient receiving an injection of an incorrect dose. Fifty-eight percent of responders reported an event in which a patient had received an injection meant for another patient. Seventy-four percent of responders reported that patients had received an incorrect amount of vaccine. The effect on patients ranged from local reactions to one fatality. Specific reasons given for the incorrect injections were patient name similar to that of another patient with incorrect name check and nurse error resulting in an incorrect dose. We conclude that allergy injections are a potential safety concern. There are a variety of prevention strategies that could be implemented to reduce or eliminate this risk, such as improved nurse training in the administration of allergy injections and compliance with the recommendations in the "Allergen Immunotherapy: A Practice Parameter" for use of patient-specific vials, standardized dosage sheets, and implementation of triple-checking of identity to make sure the correct patient is receiving the correct injection.	Finch Univ Hlth Sci Chicago Med Sch, N Chicago, IL 60064 USA; Brigham & Womens Hosp, Dept Patient Safety, Boston, MA 02115 USA	Chicago Medical School; Harvard University; Brigham & Women's Hospital	Aaronson, DW (corresponding author), 3500 N Lake Shore Dr,9C, Chicago, IL 60657 USA.							Blendon RJ, 2002, NEW ENGL J MED, V347, P1933, DOI 10.1056/NEJMsa022151; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Casarett D, 1999, ACAD MED, V74, P19, DOI 10.1097/00001888-199901001-00011; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; GREENBERG MA, 1986, J ALLERGY CLIN IMMUN, V77, P865, DOI 10.1016/0091-6749(86)90385-4; GREENBERG MA, 1988, J ALLERGY CLIN IMMUN, V82, P287, DOI 10.1016/0091-6749(88)91013-5; Greineder DK, 1996, J ALLERGY CLIN IMMUN, V98, pS330, DOI 10.1016/S0091-6749(96)80119-9; *JCAHO, 2004, 2004 NAT PAT SAF GOA; Kohn LT., 2000, ERR IS HUMAN BUILDIN, P245; LEAPE LL, 1991, NEW ENGL J MED, V324, P372; Leung DYM, 2004, ANN ALLERG ASTHMA IM, V93, pS1, DOI 10.1016/S1081-1206(10)61385-3; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Malling HJ, 2000, DRUG SAFETY, V23, P323, DOI 10.2165/00002018-200023040-00005; ONEIL AC, 1993, ANN INTERN MED, V119, P370, DOI 10.7326/0003-4819-119-5-199309010-00004; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; Ross RN, 2000, CLIN THER, V22, P329, DOI 10.1016/S0149-2918(00)80037-5; Ross RN, 2000, CLIN THER, V22, P342, DOI 10.1016/S0149-2918(00)80038-7; Ross RN, 2000, CLIN THER, V22, P351, DOI 10.1016/S0149-2918(00)80039-9; Thomas EJ, 2000, MED CARE, V38, P261, DOI 10.1097/00005650-200003000-00003; VERVLOET D, 1980, CLIN ALLERGY, V10, P59, DOI 10.1111/j.1365-2222.1980.tb02080.x	20	57	57	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1117	1121		10.1016/j.jaci.2004.01.756	http://dx.doi.org/10.1016/j.jaci.2004.01.756			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208593	Bronze			2022-12-18	WOS:000222091000017
J	Sullivan, SD; Buxton, M; Andersson, LF; Lamm, CJ; Liljas, B; Chen, YZ; Pauwels, RA; Weiss, KB				Sullivan, SD; Buxton, M; Andersson, LF; Lamm, CJ; Liljas, B; Chen, YZ; Pauwels, RA; Weiss, KB			Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; START; cost-effectiveness; budesonide; inhaled corticosteroids; symptom-free days	INHALED CORTICOSTEROIDS; MEDICATION; CHILDREN	Background: The Inhaled Steroid as Regular Therapy in Early Asthma (START) study reported that early intervention with budesonide in mild persistent asthma reduces severe asthmatic events and improves symptom outcomes and lung function in adults and children. Objective: We sought to estimate the incremental cost-effectiveness of early intervention with budesonide, as observed within the START study. Methods: START was a randomized, 3-year controlled trial of budesonide in early onset mild asthma among 7165 subjects ages 5 to 66 years. Three age groups (5-10, 11-17, and greater than or equal to18 years) were studied separately and overall. Differences in the probability of emergency treatments, symptom-free days (SFDs), and costs of health care were determined. Incremental cost-effectiveness ratios were estimated from the health care payer and societal perspectives. Results: Compared with usual therapy, patients receiving budesonide experienced an average of 14.1 (SE, 1.3) more SFDs per year (P < .001), fewer hospital days (69%, P < .001), and fewer emergency department visits (67%, P < .05). From the health care payer perspective, the net cost of early use of budesonide was an additional US$0.42 (SE, $0.04) per day, and the resultant cost-effectiveness ratio was $11.30 (95% Cl, $8.60-$14.90) per SFD gained. From the societal perspective, the cost offsets of lower absence from school or work reduced the net cost of early budesonide to $0.14 (SE, $0.07) per day and decreased the cost-effectiveness ratio to $3.70 (95% CI, $0.10-$8.00). Early intervention was more effective and cost saving in the youngest age group. Conclusion: Long-term treatment with budesonide appears to be cost-effective in patients with mild persistent asthma of recent onset.	Univ Washington, Dept Pharm & Hlth Serv, Seattle, WA 98195 USA; Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England; AstraZeneca R&D, Lund, Sweden; Capital Inst Pediat, Beijing, Peoples R China; Ghent Univ Hosp, Dept Resp Dis, Ghent, Belgium; Hines VA Hosp, Medw Ctr Hlth Serv & Policy Res, Hines, IL USA; Northwestern Univ, Sch Med, Ctr Healthcare Studies, Chicago, IL USA	University of Washington; University of Washington Seattle; Brunel University; AstraZeneca; Capital Institute of Pediatrics (CIP); Ghent University; Ghent University Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Northwestern University	Sullivan, SD (corresponding author), Univ Washington, Pharmaceut Outcomes Res & Policy Program, Box 357630, Seattle, WA 98195 USA.							Adams RJ, 2001, ARCH PEDIAT ADOL MED, V155, P501, DOI 10.1001/archpedi.155.4.501; ADELROTH E, 1988, LANCET, V1, P476; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Anis AH, 2001, CAN MED ASSOC J, V164, P625; Donahue JG, 2000, J ALLERGY CLIN IMMUN, V106, P1108, DOI 10.1067/mai.2000.111432; *GINA, 1995, GLOB STRAT ASTHM MAN, P1; GOLD MR, 1996, COST EFFETIVENESS HL; Haahtela T, 1998, THORAX, V53, P1005, DOI 10.1136/thx.53.12.1005; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Haddix A, 1996, PREVENTION EFFECTIVE; KOTZ S, 1998, ENCY STAT SCI, V8, P646; KOTZ S, 1998, ENCY STAT SCI, V5, P134; KOTZ S, 1998, ENCY STAT SCI, V3, P86; Krahn MD, 1996, CAN MED ASSOC J, V154, P821; Little RJA, 1987, STAT ANAL MISSING DA; Manning WG, 2001, J HEALTH ECON, V20, P461, DOI 10.1016/S0167-6296(01)00086-8; O'Byrne P, 1996, CAN RESPIR J, V3, P169; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; Paltiel AD, 2001, J ALLERGY CLIN IMMUN, V108, P39, DOI 10.1067/mai.2001.116289; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Pauwels RA, 2001, CONTROL CLIN TRIALS, V22, P405, DOI 10.1016/S0197-2456(01)00144-1; Persson U, 2003, RESP MED, V97, P1, DOI 10.1053/rmed.2002.1405; RUTTENVANMOLKEN MPMH, 1995, AM J RESP CRIT CARE, V151, P975; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Sullivan S, 1996, AM J RESP CRIT CARE, V154, pS84, DOI 10.1164/ajrccm/154.3_Pt_2.S84; Sullivan SD, 2001, CONTROL CLIN TRIALS, V22, P420, DOI 10.1016/S0197-2456(01)00137-4; Warner JO, 1998, PEDIATR PULM, V25, P1; Weiner RD, 1997, CONVULSIVE THER, V13, P49; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493, DOI 10.1067/mai.2000.109426; Willke RJ, 1998, HEALTH ECON, V7, P481, DOI 10.1002/(SICI)1099-1050(199809)7:6<481::AID-HEC353>3.3.CO;2-B; 2000, DRUG TOPIC RED BOOK	32	57	58	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1229	1236		10.1016/j.jaci.2003.09.025	http://dx.doi.org/10.1016/j.jaci.2003.09.025			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	752HC	14657888				2022-12-18	WOS:000187154200031
J	Feistritzer, C; Sturn, DH; Kaneider, NC; Djanani, A; Wiedermann, CJ				Feistritzer, C; Sturn, DH; Kaneider, NC; Djanani, A; Wiedermann, CJ			Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; coagulation; allergy; asthma; protein C	ACTIVATION; PATHWAY; ASTHMA; INFLAMMATION; EXPRESSION; THROMBIN; AIRWAYS; LUNG; IDENTIFICATION; MECHANISMS	Background: Eosinophil infiltration is a characteristic feature of allergic inflammation. Allergic responses are associated with local activation of the coagulation pathway and accumulation of fibrin. Objective: We tested whether protein C and activated protein C (APC), which are endogenous anti-inflammatory coagulation inhibitors, affect eosinophil function. Methods: Eosinophils were from venous blood of healthy donors. Cell migration and apoptosis were studied by using micropore filter assays and fluorometry, respectively. Receptor expression was investigated by means of RT-PCR and SDS-PAGE of immunoprecipitated protein. Results: Protein C and APC had no significant chemotactic effects on eosinophils. Eosinophils pretreated with protein C or APC showed significantly reduced migration toward chemoattractants. No effect of either protein C preparation was seen in eosinophil apoptosis assays. The inhibiting effect on migration was reversed by an antibody against the endothelial protein C receptor (EPCR). Synthesis of EPCR by eosinophils is suggested by demonstration of receptor mRNA expression and detection of metabolically labeled receptor protein. Conclusions: Data suggest that an EPCR is expressed by eosinophils whose activation with protein C or APC arrests directed migration. Protein C-affected eosinophil chemotaxis is a novel thrombin-independent component of the protein C pathway.	Univ Innsbruck, Dept Internal Med, Div Gen Internal Med, A-6020 Innsbruck, Austria	University of Innsbruck	Wiedermann, CJ (corresponding author), Univ Innsbruck, Dept Internal Med, Div Gen Internal Med, Anichstr 35, A-6020 Innsbruck, Austria.		Wiedermann, Christian J./ABG-9521-2020					ATKINS PC, 1992, J ALLERGY CLIN IMMUN, V89, P552, DOI 10.1016/0091-6749(92)90322-S; ATKINS PC, 1993, J ALLERGY CLIN IMMUN, V91, P956, DOI 10.1016/0091-6749(93)90354-I; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Coughlin SR, 1998, ARTERIOSCL THROM VAS, V18, P514, DOI 10.1161/01.ATV.18.4.514; Coughlin SR, 2001, THROMB HAEMOSTASIS, V86, P298; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; Fujisawa T, 2002, J ALLERGY CLIN IMMUN, V110, P139, DOI 10.1067/mai.2002.126079; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; Gabazza EC, 1999, LUNG, V177, P253, DOI 10.1007/PL00007645; Galligan L, 2001, BRIT J HAEMATOL, V115, P408, DOI 10.1046/j.1365-2141.2001.03187.x; Giembycz MA, 1999, PHARMACOL REV, V51, P213; Grewe M, 1998, J IMMUNOL, V161, P415; Grey ST, 1996, J IMMUNOL, V156, P2256; Hataji O, 2002, LUNG, V180, P47, DOI 10.1007/s004080000080; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Kobayashi H, 1998, AM J RESP CRIT CARE, V157, P1850, DOI 10.1164/ajrccm.157.6.9709078; Leavell KJ, 1996, AM J RESP CELL MOL, V14, P53, DOI 10.1165/ajrcmb.14.1.8534486; Levi-Schaffer F, 1999, P NATL ACAD SCI USA, V96, P9660, DOI 10.1073/pnas.96.17.9660; Lim KG, 1996, J IMMUNOL, V156, P2566; LUNGARELLA G, 1992, ARCH BIOCHEM BIOPHYS, V292, P128, DOI 10.1016/0003-9861(92)90060-A; Miike S, 2001, J IMMUNOL, V167, P6615, DOI 10.4049/jimmunol.167.11.6615; Moritani C, 1998, CHEST, V113, P452, DOI 10.1378/chest.113.2.452; Murakami K, 1997, AM J PHYSIOL-LUNG C, V272, pL197, DOI 10.1152/ajplung.1997.272.2.L197; Ohno I, 1997, AM J RESP CELL MOL, V16, P212, DOI 10.1165/ajrcmb.16.3.9070604; Regan LM, 1997, J BIOL CHEM, V272, P26279, DOI 10.1074/jbc.272.42.26279; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Vignola AM, 1999, J ALLERGY CLIN IMMUN, V103, P563, DOI 10.1016/S0091-6749(99)70225-3; Wardlaw AJ, 1995, ADV IMMUNOL, V60, P151, DOI 10.1016/S0065-2776(08)60586-6; White B, 2000, BLOOD, V96, P3719, DOI 10.1182/blood.V96.12.3719.h8003719_3719_3724; White B, 2000, BRIT J HAEMATOL, V110, P130, DOI 10.1046/j.1365-2141.2000.02128.x; Yan SB, 2001, CRIT CARE MED, V29, pS69, DOI 10.1097/00003246-200107001-00024; Ye XF, 1999, BIOCHEM BIOPH RES CO, V259, P671, DOI 10.1006/bbrc.1999.0846	33	57	61	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					375	381		10.1067/mai.2003.1609	http://dx.doi.org/10.1067/mai.2003.1609			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897745				2022-12-18	WOS:000184650600023
J	Weber, E; Hunter, S; Stedman, K; Dreitz, S; Olivry, T; Hillier, A; McCall, C				Weber, E; Hunter, S; Stedman, K; Dreitz, S; Olivry, T; Hillier, A; McCall, C			Identification, characterization, and cloning of a complementary DNA encoding a 60-kd house dust mite allergen (Der f 18) for human beings and dogs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						house dust mite; allergen; ELISA; cDNA cloning; monoclonal antibodies; immunomapping	DERMATOPHAGOIDES-PTERONYSSINUS; ATOPIC-DERMATITIS; IGE; REACTIVITY; EXTRACTS; ANTIBODIES; FARINAE; DER-P-1; SITES	Background: House dust mites of the Dermatophagoides genus are the most important cause of perennial allergic disease in both humans and companion animals. Although the major mite allergens for humans are proteins of relatively low molecular weight, this is not the case for dogs. Western blotting shows that canine anti-mite IgE responses are directed primarily toward proteins in the molecular weight range of 50 to 120 kd. Objective: The objectives of this study were to characterize a D farinae allergen with a molecular weight of approximately 60 kd and to isolate the cDNA coding for this allergen. Methods: A protein of apparent molecular weight of 60 kd was identified by Western blotting by using canine serum IgE from house dust mite-sensitized atopic dogs. The protein was purified from homogenized D farinae mite bodies by ammonium sulfate precipitation, followed by gel filtration and cation exchange HPLC. The presence of IgE directed to the 60-kd protein in sera from humans and dogs with dust mite allergy was measured by FcepsilonRIalpha-based ELISA. A cDNA encoding a full-length 60-kd protein was isolated from a D farinae cDNA library by a combination of both PCR amplification and hybridization screening. A panel of mAbs specific for the 60-kd protein was generated and used to localize the protein in whole body sections of D farinae mites. Results: ELISA showed that the purified protein bound IgE in 54% of the sera from patients with D farinae allergy. In addition, the 60-kd protein was able to bind IgE in 57% to 77% of D farinae-sensitized dogs. A cDNA was isolated that encoded a protein of 462 amino acids, consisting of a 25 amino acid signal sequence and a 437 amino acid mature protein. The calculated molecular weight of the mature protein is 50 kd, and the amino acid sequence contains a single N-glycosylation site. A protein database search showed homology with multiple chitinases. A mAb specific for the 60-kd chitinase recognized the allergen in the mite digestive system, but fecal pellets did not stain positively for this allergen. Conclusions: A 60-kd D farinae protein (Der f 18), with homology to chitinase, is a major allergen for humans and dogs sensitive to house dust mites.	Heska Corp, Ft Collins, CO USA; N Carolina State Univ, Coll Vet Med, Dept Clin Sci, Raleigh, NC USA; Ohio State Univ, Coll Vet Med, Dept Vet Clin Sci, Columbus, OH 43210 USA	University of North Carolina; North Carolina State University; University System of Ohio; Ohio State University	McCall, C (corresponding author), 10155 Westmoor Dr, Westminster, CO 80021 USA.		Olivry, Thierry/AAV-7869-2021; Hillier, Andrew/C-9159-2012; Olivry, Thierry/E-3289-2013	Olivry, Thierry/0000-0003-1399-0034; 				Baldo B.A., 1989, Advances in the Biosciences, V74, P13; BARD J, 1992, 2 WORLD C VET DERM M; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; CODNER EC, 1995, J AM VET MED ASSOC, V206, P812; Hillier A, 2000, J AM VET MED ASSOC, V217, P536, DOI 10.2460/javma.2000.217.536; LAKE FR, 1991, J ALLERGY CLIN IMMUN, V87, P1035, DOI 10.1016/0091-6749(91)92147-S; Lian TM, 1998, VET IMMUNOL IMMUNOP, V66, P203, DOI 10.1016/S0165-2427(98)00199-8; Masuda K, 1999, VET IMMUNOL IMMUNOP, V72, P303, DOI 10.1016/S0165-2427(99)00142-7; McCall C, 2001, VET IMMUNOL IMMUNOP, V78, P231, DOI 10.1016/S0165-2427(00)00258-0; MCCALL C, 2000, VET DERMATOL, V12, P234; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Noli C, 1996, VET IMMUNOL IMMUNOP, V52, P147, DOI 10.1016/0165-2427(96)05550-X; Nuttall TJ, 2001, RES VET SCI, V71, P51, DOI 10.1053/rvsc.2001.0485; REEDY L, 1997, ALLERGIC SKIN DIS DO; ROCKEY JH, 1967, J IMMUNOL, V98, P1143; Rodriguez J.G., 1987, P345; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schumann RJ, 2001, AM J VET RES, V62, P1344, DOI 10.2460/ajvr.2001.62.1344; SCHWARTZMAN RM, 1971, CLIN EXP IMMUNOL, V9, P549; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stedman K, 2001, VET IMMUNOL IMMUNOP, V78, P349, DOI 10.1016/S0165-2427(01)00242-2; STURE GH, 1995, VET IMMUNOL IMMUNOP, V44, P293, DOI 10.1016/0165-2427(94)05306-D; Thomas WR, 1998, ALLERGY, V53, P821, DOI 10.1111/j.1398-9995.1998.tb03987.x; THOMAS WR, 1995, CLIN EXP ALLERGY, V25, P667, DOI 10.1111/j.1365-2222.1995.tb01117.x; TOVEY ER, 1987, J ALLERGY CLIN IMMUN, V79, P93, DOI 10.1016/S0091-6749(87)80022-2	26	57	62	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					79	86		10.1067/mai.2003.1602	http://dx.doi.org/10.1067/mai.2003.1602			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847483				2022-12-18	WOS:000184010600014
J	Roberts, G; Hurley, C; Lack, G				Roberts, G; Hurley, C; Lack, G			Development of a quality-of-life assessment for the allergic child or teenager with multisystem allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						quality of life; multisystem allergic disease; asthma; rhinoconjunctivitis; eczema; children; teenagers	CLINICAL-TRIALS; ASTHMA; RHINOCONJUNCTIVITIS; INSTRUMENTS; SALMETEROL; VALIDATION; RHINITIS	Background: Health-related quality of life (HRQOL) questionnaires currently being used to evaluate allergic disease are organ-speeiric. They therefore fail to take account of the systemic aspects of allergic disease. Objective: To develop and validate a pediatric HRQOL questionnaire for allergic disease (Pediatric Allergic Disease Quality of Life Questionnaire, PADQLQ) that encapsulates problems related to the eyes, ears, nose, lungs, skin, emotions, and everyday activities. Methods: In the development phase, 77 subjects (6 to 16 years of age), with seasonal or perennial allergic problems, were asked how much they were bothered by each different area of HRQOL impairment. The highest scoring areas were used to construct the PADQLQ. In the validation phase of the study, 36 subjects (8 to 16 years of age) with seasonal allergic rhinoconjunctivitis, seasonal allergic asthma, and/or cutaneous manifestations of grass pollen allergy were assessed before and during the pollen season. Results: The PADQLQ contains 26 questions. In addition to standard symptoms (eg, rhinitis), it incorporates multiorgan symptoms that are usually overlooked (eg, hearing problems). The PADQLQ demonstrated good cross-sectional and longitudinal validity, showing a high degree of correlation with symptom scores and quality of life as measured by a visual analogue scale and two-organ specific questionnaires. The PADQLQ showed good within-subject reliability and a small minimal important difference (0.33; 95% CI, 0.11 to 0.54 on a 7-point scale). Conclusions: The PADQLQ has good cross-sectional and longitudinal validity, making it a potentially useful outcome measure in the evaluation of systemic treatments such as antihistamine medications and immunotherapy in children with multisystem allergic disease. (J Allergy Clin Immunol 2003;111:491-7.).	St Marys Hosp, London W2 1NY, England; Univ London Imperial Coll Sci Technol & Med, London, England	Imperial College London; Imperial College London	Lack, G (corresponding author), St Marys Hosp, Ground Floor Salton House,Praed St, London W2 1NY, England.			Lack, Gideon/0000-0001-7350-4021; Roberts, Graham/0000-0003-2252-1248				Austin JB, 1999, ARCH DIS CHILD, V81, P225, DOI 10.1136/adc.81.3.225; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P1, DOI 10.1016/0091-6749(94)90064-7; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P1; deGraafintVeld T, 1996, J ALLERGY CLIN IMMUN, V98, P508, DOI 10.1016/S0091-6749(96)70083-0; DYKEWICZ MS, 1998, ANN ALLERG ASTHMA IM, V81, P1; Eiser C, 1997, ARCH DIS CHILD, V77, P350, DOI 10.1136/adc.77.4.350; Fletcher Astrid, 1992, British Medical Journal, V305, P1145; Guyatt GH, 1999, J CLIN EPIDEMIOL, V52, P187, DOI 10.1016/S0895-4356(98)00157-7; Guyatt GH, 1997, PEDIATRICS, V99, P165, DOI 10.1542/peds.99.2.165; Juniper EF, 1997, EUR RESPIR J, V10, P2285, DOI 10.1183/09031936.97.10102285; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V101, P163, DOI 10.1016/S0091-6749(98)70380-X; JUNIPER EF, 1995, AM J RESP CRIT CARE, V151, P66, DOI 10.1164/ajrccm.151.1.7812574; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; RUTTENVANMOLKEN MPMH, 1995, EUR RESPIR J, V8, P888; Schipper H., 1996, QUALITY LIFE PHARMAC, V2, P11; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; Wasserfallen JB, 1997, J ALLERGY CLIN IMMUN, V100, P16, DOI 10.1016/S0091-6749(97)70189-1; 1987, AM REV RESP DIS, V136, P225	21	57	59	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					491	497		10.1067/mai.2003.138	http://dx.doi.org/10.1067/mai.2003.138			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642827				2022-12-18	WOS:000181639500008
J	Horner, AA; Raz, E				Horner, AA; Raz, E			Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: Two unique but complementary strategies for the treatment of allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunostimulatory DNA; cytosine-phosphate-guanine motif; immunotherapy; immunomodulation	DEOXYRIBONUCLEIC-ACID FRACTION; MYCOBACTERIUM-BOVIS BCG; DNA-SEQUENCES; CPG MOTIFS; BACTERIAL-DNA; IN-VITRO; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; SYNTHETIC OLIGONUCLEOTIDES; IMMUNE-RESPONSES; INTERFERON-GAMMA	Despite a number of effective pharmaceutical options for the prevention and treatment of the pathophysiologic responses that occur in sensitized patients on allergen exposure, the termination of allergic hypersensitivities remains an elusive therapeutic goal. Traditional immunotherapy with allergen extracts is the only currently used intervention that has been shown to induce allergen tolerance, but it has a limited scope of efficacy. However, recent studies suggest that immunostimulatory sequence oligodeoxynucleotide (ISS-ODN)-based interventions might offer an alternative and potentially more effective means for extinguishing T(H)2-biased hypersensitivities. Three basic ISS-ODN-based immunotherapeutic strategies have been studied to date. Immunization with allergen mixed with ISS-ODN, immunization with allergen-ISS-ODN conjugates, and immunomodulation with ISS-ODN alone all have proved efficacy in the attenuation of the allergic phenotype in mice. Preliminary results with allergen-ISS-ODN conjugate vaccines in allergic patients have also been encouraging. This article will provide our perspective on the application of ISS-ODN-based vaccination and immunomodulation to the treatment of atopic diseases and the immunologic basis for their antiallergic activities.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Horner, AA (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NIAID NIH HHS [AI01490, AI40682] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001490, P01AI040682] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; Bohle B, 1999, EUR J IMMUNOL, V29, P2344, DOI 10.1002/(SICI)1521-4141(199907)29:07<2344::AID-IMMU2344>3.0.CO;2-R; Broide D, 1999, INT ARCH ALLERGY IMM, V118, P453, DOI 10.1159/000024162; Broide D, 1998, J IMMUNOL, V161, P7054; Broide DH, 2001, J CLIN IMMUNOL, V21, P175, DOI 10.1023/A:1011078930363; Creticos PS, 2000, J ALLERGY CLIN IMMUN, V105, pS70, DOI 10.1016/S0091-6749(00)90645-6; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; Creticos PS, 2001, J ALLERGY CLIN IMMUN, V107, pS216; CRETICOS PS, 1997, ALLERGY, P726; Freund J, 1937, P SOC EXP BIOL MED, V37, P509; Fujieda S, 2000, AM J RESP CRIT CARE, V162, P232, DOI 10.1164/ajrccm.162.1.9906136; Graham LM, 2002, J ALLERGY CLIN IMMUN, V109, pS560, DOI 10.1067/mai.2002.124571; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Horner AA, 1998, CELL IMMUNOL, V190, P77, DOI 10.1006/cimm.1998.1400; Horner AA, 2002, J ALLERGY CLIN IMMUN, V110, P413, DOI 10.1067/mai.2002.126660; Horner AA, 2001, J IMMUNOL, V167, P1584, DOI 10.4049/jimmunol.167.3.1584; Horner AA, 2001, IMMUNOL REV, V179, P102, DOI 10.1034/j.1600-065X.2001.790111.x; Horner AA, 2000, J ALLERGY CLIN IMMUN, V106, P349, DOI 10.1067/mai.2000.107933; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; JUTEL M, 1995, J IMMUNOL, V154, P4187; Kline JN, 1998, J IMMUNOL, V160, P2555; Klinman DM, 1997, J IMMUNOL, V158, P3635; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Kobayashi H, 1999, CELL IMMUNOL, V198, P69, DOI 10.1006/cimm.1999.1572; Kohama Y, 1999, J ALLERGY CLIN IMMUN, V104, P1231, DOI 10.1016/S0091-6749(99)70018-7; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Liang H, 1996, J CLIN INVEST, V98, P1119, DOI 10.1172/JCI118894; Lipford GB, 2000, J IMMUNOL, V165, P1228, DOI 10.4049/jimmunol.165.3.1228; Magone MT, 2000, EUR J IMMUNOL, V30, P1841, DOI 10.1002/1521-4141(200007)30:7<1841::AID-IMMU1841>3.0.CO;2-E; Martin-Orozco E, 1999, INT IMMUNOL, V11, P1111, DOI 10.1093/intimm/11.7.1111; McCluskie MJ, 1998, J IMMUNOL, V161, P4463; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Parronchi P, 1999, J IMMUNOL, V163, P5946; Pullerits T, 2002, J ALLERGY CLIN IMMUN, V109, P949, DOI 10.1067/mai.2002.124467; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Santeliz JV, 2002, J ALLERGY CLIN IMMUN, V109, P455, DOI 10.1067/mai.2002.122156; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; Schwartz DA, 1999, J IMMUNOL, V163, P224; Serebrisky D, 2000, J IMMUNOL, V165, P5906, DOI 10.4049/jimmunol.165.10.5906; Shirota H, 2001, J IMMUNOL, V167, P66, DOI 10.4049/jimmunol.167.1.66; Sur S, 1999, J IMMUNOL, V162, P6284; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Tighe H, 2000, EUR J IMMUNOL, V30, P1939, DOI 10.1002/1521-4141(200007)30:7<1939::AID-IMMU1939>3.0.CO;2-#; TOKUNAGA T, 1984, J NATL CANCER I, V72, P955; Van Uden J, 1999, J ALLERGY CLIN IMMUN, V104, P902, DOI 10.1016/S0091-6749(99)70066-7; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; YAMAMOTO S, 1988, JPN J CANCER RES, V79, P866, DOI 10.1111/j.1349-7006.1988.tb00049.x; YAMAMOTO S, 1992, J IMMUNOL, V148, P4072; YAMAMOTO T, 1994, JPN J CANCER RES, V85, P775, DOI 10.1111/j.1349-7006.1994.tb02947.x	53	57	61	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2002	110	5					706	712		10.1067/mai.2002.129122	http://dx.doi.org/10.1067/mai.2002.129122			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	612NN	12417878				2022-12-18	WOS:000179082500004
J	Birnbaum, HG; Berger, WE; Greenberg, PE; Holland, M; Auerbach, R; Atkins, KM; Wanke, LA				Birnbaum, HG; Berger, WE; Greenberg, PE; Holland, M; Auerbach, R; Atkins, KM; Wanke, LA			Direct and indirect costs of asthma to an employer	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; costs; economics; claims data; health outcomes; workplace burden; work loss; pharmacoeconomics	UNITED-STATES; CHILDREN; CLAIMS; CARE; PREVENTION; BURDEN; RISK	Background: Asthma is a chronic inflammatory condition of the airways that has a significant effect on the use of health care resources. Objective: This study is the first of its kind to estimate the overall cost of asthma to a major employer in the United States and to profile the nature of the asthma expenses. Methods: The annual per capita cost of asthma was determined for beneficiaries of a major employer by analyzing medical, pharmaceutical, and disability claims data. The incremental cost of asthma was determined by using a case-control method matching asthmatic patients to individuals with no record of asthma treatment. Results: The use of health care services, as well as the rate of disability, was substantially higher among asthmatic patients than among control subjects. Annual per capita employer expenditures for asthmatic patients were approximately 2.5 times those for control subjects ($5385 vs $2121, respectively). Among asthmatic employees with disability claims, total costs were approximately 3 times higher than those among disability claimants in the employee control sample ($14,827 vs $5280). For asthmatic employees, wage-replacement costs for workdays lost as a result of disability and sporadic absenteeism (40%) accounted for almost as much as did medical care (43%). Conclusion: Failure to account fully for the broader consequences of asthma in terms of indirect and comorbid treatment costs would result in a significant underassessment of the cost of asthma to an employer.	Anal Grp Econ, Cambridge, MA 02138 USA; So Calif Res, Mission Viejo, CA USA; CORE Inc, Irvine, CA USA; Immunex Res & Dev Corp, Seattle, WA 98101 USA		Birnbaum, HG (corresponding author), Anal Grp Econ, 5th Floor,1 Brattle Sq, Cambridge, MA 02138 USA.							Bailey R, 1998, CHEST, V113, P28, DOI 10.1378/chest.113.1.28; Barnes PJ, 1996, EUR RESPIR J, V9, P636, DOI 10.1183/09031936.96.09040636; Barnett A, 2000, AM J MANAG CARE, V6, P1243; Birnbaum HG, 1999, PHARMACOECONOMICS, V16, P1, DOI 10.2165/00019053-199916010-00001; Birnbaum HG, 2000, J OCCUP ENVIRON MED, V42, P588, DOI 10.1097/00043764-200006000-00006; Blais L, 1998, AM J RESP CRIT CARE, V158, P126, DOI 10.1164/ajrccm.158.1.9707107; Blaiss MS, 1997, JAMA-J AM MED ASSOC, V278, P1874, DOI 10.1001/jama.278.22.1874; BLANC P, 1999, ASTHMAS IMPACT SOC S; Blanc PD, 1996, CHEST, V109, P688, DOI 10.1378/chest.109.3.688; Burton WN, 1999, J OCCUP ENVIRON MED, V41, P863, DOI 10.1097/00043764-199910000-00007; Collins J G, 1997, Vital Health Stat 10, P1; Conti, 1998, DIS MANAGE, V1, P17, DOI 10.1089/dis.1998.1.17; Frank RG, 1998, AM ECON REV, V88, P106; GRADY ML, 1992, AHCPR PUBL; Iezzoni LI, 2012, RISK ADJUSTMENT MEAS, V4th; Lenney W, 1997, PEDIATR PULM, P13; LOZANO P, 1995, JAMA-J AM MED ASSOC, V274, P469, DOI 10.1001/jama.274.6.469; Lozano P, 1997, PEDIATRICS, V99, P757, DOI 10.1542/peds.99.6.757; Lozano P, 1999, J ALLERGY CLIN IMMUN, V104, P957, DOI 10.1016/S0091-6749(99)70075-8; *NAT HEART LUNG BL, 1999, DAT FACT SHEET ASTHM; *NAT RES COUNC COM, 1999, DIG DIL INT PROP INF, P2; RAY WA, 1990, AM J EPIDEMIOL, V131, P502, DOI 10.1093/oxfordjournals.aje.a115524; *RW JOHNS FDN, 1995, WORK LARG INS DAT AV; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; Stempel DA, 1996, ARCH FAM MED, V5, P36, DOI 10.1001/archfami.5.1.36; Stempel DA, 1999, PHARMACOECONOMICS, V16, pU6; Stempel DA, 2000, AM J MANAG CARE, V6, pS382; Sullivan S, 1996, AM J RESP CRIT CARE, V154, pS84, DOI 10.1164/ajrccm/154.3_Pt_2.S84; *US DEP HHS AHCPR, 1996, SEER MED LINK DAT CO, P87; WATSON W, 1999, 13 ANN NAT DIS MAN C; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; YAZDANI C, 2000, VALUE HLTH, V3, P146; Yelin E, 1999, AM J IND MED, V35, P472, DOI 10.1002/(SICI)1097-0274(199905)35:5<472::AID-AJIM4>3.3.CO;2-J; YOUNG TK, 1991, CAN MED ASSOC J, V144, P318	36	57	61	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					264	270		10.1067/mai.2002.121310	http://dx.doi.org/10.1067/mai.2002.121310			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842295				2022-12-18	WOS:000174232600010
J	Cho, SH; Hall, IP; Wheatley, A; Dewar, J; Abraha, D; Del Mundo, J; Lee, H; Oh, CK				Cho, SH; Hall, IP; Wheatley, A; Dewar, J; Abraha, D; Del Mundo, J; Lee, H; Oh, CK			Possible role of the 4G/5G polymorphism of the plasminogen activator inhibitor I gene in the development of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INDUCED PULMONARY-FIBROSIS; PROMOTER; EXPRESSION	Asthma represents a chronic inflammatory process of the airways. The plasminogen activator inhibitor I gene (PAI1) has an essential role in promoting fibrosis after inflammation. The tissue-type, plasminogen activator and urokinase-type plasminogen activator convert plasminogen to plasmin, which enhances proteolytic degradation of the extracellular matrix (ECM). Among the inhibitors of plasminogen activators, PAI-I is the most important in the process of lunar fibrosis(1) PAI-1-overexpressing mice underwent severe lung injury and deposition of ECM after bleomycin challenge, whereas PAI-1-deficient mice were protected against such fibrotic reactions.(2) these reactions.2 These findings show that PAI-1 is closely associated with fibrosis and the accumulation of ECM after lung injury or inflammation. We previously reported that the PAT1 gene is induced in lung mast cells in asthmatic subjects.(3) These findings suggest that PAI-1 could contribute to tissue remodeling and subsequent fibrosis in asthma. The PAI1 gene has variation in the promoter region on the basis. of a single guanosine insertion-deletion (5G or 4G);(4,5) and the *4G allele, is, correlated with increased plasma PAI-1 levels.(5,6) In vitro experiments have initially shown that the *5G allele contains an additional binding site for a protein likely related to the nuclear factor KB group of transcription factors, and this binding site is absent in the *4G allele.(4) After stimulation with IL-1, HepG2 cells. transfected with the *4G allele produce 6 times more PAI-1 mRNA than these with the *5G allele. These data suggest a functional role of the. 4G/5G polymorphism in the response to cytokines, with the,*4G allele being associated with enhanced gene expression. In the present study we demonstrate that the *4G allele is preferentially transmitted to asthmatic children. These data suggest a possible role of the PAI1 gene and the 4G polymorphism in the pathophysiology of asthma.	Univ Calif Los Angeles, Harbor UCLA Med Ctr, Sch Med, Dept Pediat,Div Allergy & Immunol, Torrance, CA 90509 USA; Univ Calif Los Angeles, Harbor UCLA Med Ctr, Sch Med, Dept Pediat,Div Infect Dis, Torrance, CA 90509 USA; Univ Nottingham Hosp, Div Therapeut, Nottingham NG7 2UH, England	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Nottingham	Oh, CK (corresponding author), Univ Calif Los Angeles, Harbor UCLA Med Ctr, Sch Med, Dept Pediat,Div Allergy & Immunol, Bldg N25,1000 W Carson St, Torrance, CA 90509 USA.		Cho, Seong/I-7102-2015	Henry, Amanda/0000-0001-6299-7676; Hall, Ian/0000-0001-9933-3216				Cho SH, 2000, J IMMUNOL, V165, P3154, DOI 10.4049/jimmunol.165.6.3154; DAWSON SJ, 1993, J BIOL CHEM, V268, P10739; DEWAR J, 1999, METHODS MOL MED; Duffy DL, 1997, AM J HUM GENET, V61, pA197; Eitzman DT, 1996, J CLIN INVEST, V97, P232, DOI 10.1172/JCI118396; EITZMAN DT, 1995, J CLIN INVEST, V95, P2416, DOI 10.1172/JCI117937; ERIKSSON P, 1995, P NATL ACAD SCI USA, V92, P1851, DOI 10.1073/pnas.92.6.1851; FALK G, 1995, FIBRINOLYSIS, V9, P170, DOI 10.1016/S0268-9499(95)80007-7; Halleux CM, 1999, J CLIN ENDOCR METAB, V84, P4097, DOI 10.1210/jc.84.11.4097; HART DA, 1994, CLIN INVEST MED, V17, P69; Hermans PWM, 1999, LANCET, V354, P556, DOI 10.1016/S0140-6736(99)02220-5; Lardot C, 1998, EUR RESPIR J, V11, P912, DOI 10.1183/09031936.98.11040912	12	57	59	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					212	214		10.1067/mai.2001.117260	http://dx.doi.org/10.1067/mai.2001.117260			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496236				2022-12-18	WOS:000170584600008
J	Hizawa, N; Yamaguchi, E; Jinushi, E; Konno, S; Kawakami, Y; Nishimura, M				Hizawa, N; Yamaguchi, E; Jinushi, E; Konno, S; Kawakami, Y; Nishimura, M			Increased total serum IgE levels in patients with asthma and promoter polymorphisms at CTLA4 and FCER1B	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						total serum IgE; IgE levels; asthma; atopy; CTLA4; FCER1B; promoter polymorphism	INHIBITS AIRWAY EOSINOPHILIA; T-CELL RESPONSES; GRAVES-DISEASE; CYTOKINE PRODUCTION; ALLERGIC-ASTHMA; EARLY EXPOSURE; UP-REGULATION; MURINE MODEL; COSTIMULATION; POPULATION	Background: Increasing evidence indicates that total serum IgE levels are largely determined by genetic factors, and we recently established that the -109C/T promoter polymorphism at FCER1B is a genetic factor that affects total serum IgE levels. The gene encoding cytotoxic T lymphocyte antigen 4 (CTLA4) is another candidate factor in high IgE responsiveness, because B7-CD28/CTLA4 interaction can promote the differentiation and development of the T(H)2 lymphocyte subset. Objective: We intended to determine whether CTLA4 is associated with increased levels of total serum IgE or with the development of asthma or atopy. Methods: We performed a case-control study involving 339 patients with asthma and 305 healthy control subjects, of whom 226 of the patients with asthma and 219 of the healthy control subjects had previously been genotyped for the -109C/T promoter polymorphism at FCER1B. In the current study, we genotyped 2 polymorphisms in the CTLA4 gene, one involving the promoter (-318C/T) and the other involving exon I ((+)49A/G), in addition to the FCER1B promoter polymorphism. Results: Patients with asthma who were homozygous for the -318C allele at the CTLA4 promoter region had higher levels of total serum IgE than patients with asthma carrying the -318T allele (P = .00470). The analysis of -318C/T (at CTLA4) and -109C/T (at FCER1B) promoter polymorphisms showed a significant correlation between the combined genotypes and increased levels of total IgE in patients with asthma (P = .000014). In contrast, no correlation between total serum IgE levels and -318C/T or +49A/G genotypes was detected in 305 healthy control subjects. There was no evidence indicating an association between a putative allele for asthma or atopy and alleles at any of the CTLA4 polymorphic loci. Conclusion: Our findings suggest that promoter polymorphisms of both CTLA4 and FCER1B are genetic factors that influence total serum IgE levels in patients with asthma. This supports the theory that variance in total serum IgE levels in patients with asthma is determined by mutations in multiple genes, each of which has a relatively small effect on the phenotype.	Hokkaido Univ, Sch Med, Dept Med 1, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Hokkaido University	Hizawa, N (corresponding author), Hokkaido Univ, Sch Med, Dept Med 1, Kita Ku, N-15 W-14, Sapporo, Hokkaido 0608638, Japan.		Nishimura, Masaharu/A-4062-2012; Konno, Satoshi/G-1669-2012; Yamaguchi, Etsuro/AAB-3923-2020	Nishimura, Masaharu/0000-0002-6456-4361; 				Agarwal K, 2000, J HEPATOL, V32, P538, DOI 10.1016/S0168-8278(00)80213-5; Aizawa H, 1996, CHEST, V109, P338, DOI 10.1378/chest.109.2.338; ALLISON JP, 1995, SCIENCE, V270, P932, DOI 10.1126/science.270.5238.932; Anderson DE, 2000, NAT MED, V6, P211, DOI 10.1038/72323; Becker KG, 1998, P NATL ACAD SCI USA, V95, P9979, DOI 10.1073/pnas.95.17.9979; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Braun J, 1998, TISSUE ANTIGENS, V51, P563, DOI 10.1111/j.1399-0039.1998.tb02993.x; Burastero SE, 1999, THORAX, V54, P554, DOI 10.1136/thx.54.6.554; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Corry DB, 1999, NATURE, V402, pB18; Deichmann K, 1996, BIOCHEM BIOPH RES CO, V225, P817, DOI 10.1006/bbrc.1996.1256; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Harbo HF, 1999, TISSUE ANTIGENS, V53, P106; Heinzmann A, 2000, EUR J IMMUNOGENET, V27, P57, DOI 10.1046/j.1365-2370.2000.00198.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hizawa N, 2000, AM J RESP CRIT CARE, V161, P906, DOI 10.1164/ajrccm.161.3.9903128; Hofer MF, 1998, J ALLERGY CLIN IMMUN, V101, P96, DOI 10.1016/S0091-6749(98)70199-X; Huang DR, 2000, J NEUROIMMUNOL, V105, P69, DOI 10.1016/S0165-5728(00)00191-0; Jaffar ZH, 1999, J IMMUNOL, V163, P6283; Kitani A, 2000, J IMMUNOL, V165, P691, DOI 10.4049/jimmunol.165.2.691; Kubo M, 1999, J IMMUNOL, V163, P2432; Larche M, 1998, J IMMUNOL, V161, P6375; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Marron MP, 1997, HUM MOL GENET, V6, P1275, DOI 10.1093/hmg/6.8.1275; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Padrid PA, 1998, AM J RESP CELL MOL, V18, P453, DOI 10.1165/ajrcmb.18.4.3055; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P4018, DOI 10.1093/nar/19.14.4018-a; Schweitzer AN, 1998, J IMMUNOL, V161, P2762; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; TAKISHIMA T, 1981, CHEST, V80, P600, DOI 10.1378/chest.80.5.600; Vaidya B, 1999, HUM MOL GENET, V8, P1195, DOI 10.1093/hmg/8.7.1195; VanOosterhout AJM, 1997, AM J RESP CELL MOL, V17, P386, DOI 10.1165/ajrcmb.17.3.2679; YANAGAWA T, 1995, J CLIN ENDOCR METAB, V80, P41, DOI 10.1210/jcem.80.1.7829637	37	57	64	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1					74	79		10.1067/mai.2001.116119	http://dx.doi.org/10.1067/mai.2001.116119			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	458AN	11447385				2022-12-18	WOS:000170171200010
J	Kraft, M; Lewis, C; Pham, D; Chu, HW				Kraft, M; Lewis, C; Pham, D; Chu, HW			IL-4. IL-13, and dexamethasone augment fibroblast proliferation in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; airway remodeling; fibroblast; IL-4; IL-13	GLUCOCORTICOIDS; CYTOKINE; GROWTH; INTERLEUKIN-13; INFLAMMATION; EXPRESSION; PHENOTYPE; CELLS	Background: IL-4 and IL-13 have been shown to be critical for expression of the asthma phenotype in a murine model and may modulate human fibroblast function. Objective: We hypothesized that IL-4 and IL-13 would increase airway fibroblast proliferation and reduce the ability of dexamethasone to decrease this proliferation. Methods: Six subjects with severe asthma, 5 subjects with mild asthma, and 5 healthy subjects underwent bronchoscopy with endobronchial biopsy. Biopsy specimens were placed in Dulbecco modified Eagle medium and cultured, and only fibroblasts from the first and second passages were evaluated. Cells were incubated with IL-4 (50 ng/mL), IL-13 (10 ng/mL), and the combination for 48 hours in the presence and absence of dexamethasone, 10(-7) mol/L, and 10(-8) mol/L. Fibroblasts were also incubated with IFN-gamma at 50 ng/mL to assess the response of a T(H)1 cytokine on proliferation. Results: Fibroblast proliferation, determined by H-3-thymidine incorporation, was significantly increased by IL-4 in subjects with mild asthma as compared with IL-4 in subjects with severe asthma and healthy subjects (P = .003), IL-13 (P = .011), and the combination (P = .004), Dexamethasone also increased proliferation in the group with mild asthma as compared with the group with severe asthma and the healthy group (10(-7) mol/L, P = .02; 10(-8) mol/L, P = .02). IFN-gamma did not significantly alter airway fibroblast proliferation. Conclusion: IL-4, IL-13, and dexamethasone all significantly increased fibroblast proliferation in subjects with mild asthma.	Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Div Pulm Sci & Crit Care Med, Denver, CO USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kraft, M (corresponding author), 1400 Jackson St J107, Denver, CO USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577, K08HL003343] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36577, HL03343] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BOULET LP, 1993, EUR RESP J S17, V6, pS265; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; CONOVER CA, 1995, J CELL PHYSIOL, V163, P615, DOI 10.1002/jcp.1041630323; CROWDER MJ, 1990, ANAL REPEATED MEASUR, P87; CUTRONEO KR, 1981, COLLAGEN REL RES, V1, P557; Doucet C, 1998, INT IMMUNOL, V10, P1421, DOI 10.1093/intimm/10.10.1421; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Dube J, 1998, LAB INVEST, V78, P297; DURANT S, 1986, ENDOCR REV, V7, P254, DOI 10.1210/edrv-7-3-254; ELIAS JA, 1990, CHEST, V97, P1439, DOI 10.1378/chest.97.6.1439; GAULDIE J, 1992, AM REV RESPIR DIS, V145, pS14, DOI 10.1164/ajrccm/145.2_Pt_2.S14; HEIN R, 1994, SKIN PHARMACOL, V7, P300, DOI 10.1159/000211309; Hudon C, 1997, ANN ALLERG ASTHMA IM, V78, P195; KONDO H, 1985, EXP CELL RES, V158, P342, DOI 10.1016/0014-4827(85)90459-8; KRAFT M, 1995, EUR RESPIR J, V8, P1966, DOI 10.1183/09031936.95.08111966; KRAFT M, 2001, IN PRESS AM J RESP C; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; National Back Pain Association, 1997, GUID DIAGN MAN ASTHM, P1; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; SANO E, 1988, J INTERFERON RES, V8, P343, DOI 10.1089/jir.1988.8.343; *SAS I I, 1996, SAS STAT SOFTW CHANG; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591; Skold CM, 1999, P ASSOC AM PHYSICIAN, V111, P249, DOI 10.1046/j.1525-1381.1999.99269.x; SPAHN JD, 1995, AM J RESP CRIT CARE, V151, P1709, DOI 10.1164/ajrccm.151.6.7767511; Warshamana GS, 1998, AM J PHYSIOL-LUNG C, V274, pL499, DOI 10.1152/ajplung.1998.274.4.L499	32	57	59	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					602	606		10.1067/mai.2001.113760	http://dx.doi.org/10.1067/mai.2001.113760			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295646				2022-12-18	WOS:000168190100008
J	Finotto, S; Buerke, M; Lingnau, K; Schmitt, E; Galle, PR; Neurath, MF				Finotto, S; Buerke, M; Lingnau, K; Schmitt, E; Galle, PR; Neurath, MF			Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						stem cell factor; mast cells; antisense DNA; asthma; T(H)2 cytokines	BRONCHOALVEOLAR LAVAGE FLUID; MAST-CELL; ALLERGEN CHALLENGE; MEDIATOR RELEASE; GENE INHIBITION; MOUSE MODEL; EXPRESSION; RECEPTOR; TISSUE; INVIVO	Background: The c-kit ligand, stem cell factor (SCF), is an important activating and chemotactic factor for both mast cells and eosinophils, These cells are known to play a fundamental role in the pathogenesis of asthma. Objective: Our goal was to analyze the functional role of SCF in the pathogenesis of asthma. Methods: The expression of SCF was targeted in fibroblasts, epithelial cells, and locally in a murine model of asthma in mice induced by ovalbumin sensitization with an antisense DNA strategy. Results: We could suppress SCF expression in NIH 3T3 fibroblasts and SP1 epithelial cells by a specific antisense phosphorothioate oligonucleotide overlapping the translation start site of SCF, whereas control oligonucleotides were virtually inactive. We then focused on the role of SCF in a murine model of asthma associated with late-phase allergic inflammation in ovalbumin-sensitized mice: Local intranasal administration of FITC-labeled SCF antisense oligonucleotides led to strong DNA uptake in interstitial lung cells associated with a striking reduction of intracellular SCF expression. Such intrapulmonary blockade of SCF expression after repeated allergen challenges suppressed various signs of lung inflammation including IL-4 production and infiltration of eosinophils. SCF antisense DNA treatment was at least as effective as corticosteroid treatment. Conclusion: These data indicate a critical role for SCP in a murine asthma model and suggest that local delivery of SCF antisense oligonucleotides may be a novel approach for the treatment of inflammatory lung disorders such as asthma.	Univ Mainz, Immunol Lab, Med Clin 1, D-6500 Mainz, Germany; Univ Mainz, Med Clin 2, D-6500 Mainz, Germany; Univ Mainz, Inst Immunol, D-6500 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Finotto, S (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.		Galle, Peter R/T-5292-2018; Galle, Peter/ABE-2872-2021; Finotto, Susetta/H-2753-2019	Galle, Peter R/0000-0001-8294-0992; Galle, Peter/0000-0001-8294-0992; 				ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; BROIDE DH, 1990, J IMMUNOL, V145, P1838; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; CASALE TB, 1987, J CLIN INVEST, V80, P1507, DOI 10.1172/JCI113234; COLUMBO M, 1992, J IMMUNOL, V149, P599; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; DENBURG JA, 1995, ALLERGY, V50, P25, DOI 10.1111/j.1398-9995.1995.tb04272.x; Finotto S, 1997, J CLIN INVEST, V99, P1721, DOI 10.1172/JCI119336; FINOTTO S, 1994, CLIN EXP IMMUNOL, V95, P343; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GALLI SJ, 1993, J CLIN INVEST, V91, P148, DOI 10.1172/JCI116164; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GURA T, 1995, SCIENCE, V270, P575, DOI 10.1126/science.270.5236.575; HEINRICH MC, 1993, BLOOD, V82, P771, DOI 10.1182/blood.V82.3.771.bloodjournal823771; Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483; Henderson WR, 1997, J CLIN INVEST, V100, P3083, DOI 10.1172/JCI119863; Hogaboam G, 1998, J IMMUNOL, V160, P6166; IADEMARCO MF, 1995, J CLIN INVEST, V95, P264, DOI 10.1172/JCI117650; INEMURA A, 1994, AM J PATHOL, V144, P321; Kim YK, 1997, J ALLERGY CLIN IMMUN, V100, P389, DOI 10.1016/S0091-6749(97)70254-9; Kunisada T, 1998, J EXP MED, V187, P1565, DOI 10.1084/jem.187.10.1565; Lukacs NW, 1996, J IMMUNOL, V156, P3945; Meininger C J, 1992, Semin Cancer Biol, V3, P73; MEKORI YA, 1993, J IMMUNOL, V151, P3775; Molet S, 1999, J ALLERGY CLIN IMMUN, V104, P205, DOI 10.1016/S0091-6749(99)70137-5; PIPKORN U, 1989, CLIN EXP ALLERGY, V19, P19, DOI 10.1111/j.1365-2222.1989.tb02338.x; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; ROBINSON C, 1985, CLIN SCI, V68, P103, DOI 10.1042/cs0680103; RUSSI EW, 1984, J APPL PHYSIOL, V57, P1182, DOI 10.1152/jappl.1984.57.4.1182; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHLEIMER RP, 1986, AM REV RESPIR DIS, V133, P614; SUTTER C, 1991, EXP CELL RES, V195, P183, DOI 10.1016/0014-4827(91)90515-V; TSAI M, 1991, J EXP MED, V174, P125, DOI 10.1084/jem.174.1.125; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; WENZEL SE, 1991, J ALLERGY CLIN IMMUN, V87, P540, DOI 10.1016/0091-6749(91)90013-E; WERSHIL BK, 1992, J EXP MED, V175, P245, DOI 10.1084/jem.175.1.245; YEE NS, 1994, J EXP MED, V179, P1777, DOI 10.1084/jem.179.6.1777; Yuan Q, 1997, J EXP MED, V186, P313, DOI 10.1084/jem.186.2.313; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	45	57	66	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					279	286		10.1067/mai.2001.113049	http://dx.doi.org/10.1067/mai.2001.113049			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174194				2022-12-18	WOS:000167071400014
J	Siltanen, M; Kajosaari, M; Pohjavuori, M; Savilahti, E				Siltanen, M; Kajosaari, M; Pohjavuori, M; Savilahti, E			Prematurity at birth reduces the long-term risk of atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; allergy; gestational age; prematurity; infant; newborn; school-aged; long-term	INTERFERON-GAMMA PRODUCTION; PRETERM INFANTS; CORD-BLOOD; FOLLOW-UP; BRONCHOPULMONARY DYSPLASIA; ALLERGIC DISORDERS; CHILDREN BORN; SCHOOL-AGE; 4 REGIONS; DISEASE	Background: Antigen exposure in early life has long-lasting effects on atopic sensitization. Thus the predisposition to atopy of children born preterm can be assumed to differ from that of children born at term. Objective: The aim of this study was to evaluate the association between premature birth and atopy, Methods: At an outpatient clinic, we examined 2 groups of 10-year-old children, 72 who were born preterm (birth weight < 1500 g) and 65 who were born at term (birth weight > 2500 g). The atopy data were collected with a questionnaire, by performing skin prick testing, and by measuring the serum total IgE level, 3 allergen-specific IgE levels, the eosinophil cationic protein level, and the blood eosinophil level. The data on perinatal and neonatal events affecting the preterm children were collected from the hospital records. Results: By the age of 10 years, the children born preterm had significantly less atopy than the children born at term: 15% versus 31% of children in the 2 groups were defined as having had obvious atopy (P =.03, odds ratio 0.41, 95% CI 0.18-0.93). The mean value of total IgE le, el was significantly higher in the term group, 74 kU/L versus 41 kU/L (P =,02), By skin prick testing, the children born at term had positive reactions 2 to 3 times more often; 37% versus 17% of children in the groups had at least 1 positive reaction (P =,007), Conclusion: Our data show that prematurity at birth is linked with a decreased long-term risk of atopic sensitization.	Univ Helsinki, Hosp Children & Adolescents, FIN-00029 Helsinki, Finland	University of Helsinki	Siltanen, M (corresponding author), Univ Helsinki, Hosp Children & Adolescents, POB 280, FIN-00029 Helsinki, Finland.							ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x; AXELSSON I, 1989, ACTA PAEDIATR SCAND, V78, P532, DOI 10.1111/j.1651-2227.1989.tb17932.x; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; Braback L, 1998, CLIN EXP ALLERGY, V28, P936; CHAN KN, 1993, ARCH DIS CHILD, V69, P120, DOI 10.1136/adc.69.1.120; CHAN KN, 1989, ARCH DIS CHILD, V64, P1284, DOI 10.1136/adc.64.9.1284; CLOUGH JB, 1993, CLIN EXP ALLERGY, V23, P462, DOI 10.1111/j.1365-2222.1993.tb03231.x; DAVID TJ, 1988, ARCH DIS CHILD, V63, P435, DOI 10.1136/adc.63.4.435; DEMARTINO M, 1989, BIOL NEONATE, V56, P301, DOI 10.1159/000243138; Gronlund MM, 1999, CLIN EXP IMMUNOL, V116, P521; Gronlund MM, 1999, APMIS, V107, P655, DOI 10.1111/j.1699-0463.1999.tb01455.x; Hakulinen AL, 1996, PEDIATR PULM, V21, P353, DOI 10.1002/(SICI)1099-0496(199606)21:6<353::AID-PPUL2>3.0.CO;2-M; HALKEN S, 1995, ALLERGY, V50, P97; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P85, DOI 10.1111/j.1399-3038.1995.tb00264.x; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; Kavelaars A, 1999, PEDIATR RES, V45, P306, DOI 10.1203/00006450-199903000-00003; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201, DOI 10.1046/j.1365-2222.2000.00800.x; Kondo N, 1998, CLIN EXP ALLERGY, V28, P1340; Kotiranta-Ainamo A, 1999, CLIN EXP IMMUNOL, V115, P309, DOI 10.1046/j.1365-2249.1999.00795.x; KUEHR J, 1992, J ALLERGY CLIN IMMUN, V90, P358, DOI 10.1016/S0091-6749(05)80015-6; KUITUNEN OOM, 1994, PEDIATR RES, V35, P344, DOI 10.1203/00006450-199403000-00014; LUCAS A, 1990, ARCH DIS CHILD, V65, P411, DOI 10.1136/adc.65.4.411; LUCAS A, 1990, BRIT MED J, V300, P837, DOI 10.1136/bmj.300.6728.837; MALLET E, 1992, J PEDIATR-US, V121, pS95, DOI 10.1016/S0022-3476(05)81415-5; MULLER G, 1986, J PEDIATR-US, V109, P869, DOI 10.1016/S0022-3476(86)80716-8; NORTHWAY WH, 1990, NEW ENGL J MED, V323, P1793, DOI 10.1056/NEJM199012273232603; Oldaeus G, 1997, ARCH DIS CHILD, V77, P4, DOI 10.1136/adc.77.1.4; Olesen AB, 1997, BRIT MED J, V314, P1003, DOI 10.1136/bmj.314.7086.1003; ORANJE AP, 1995, PEDIATR ALLERGY IMMU, V7, P31; Pekkanen J, 1997, EUR RESPIR J, V10, P1787, DOI 10.1183/09031936.97.10081787; Pelkonen AS, 1997, AM J RESP CRIT CARE, V156, P1178, DOI 10.1164/ajrccm.156.4.9610028; Pelkonen AS, 1999, ARCH DIS CHILD-FETAL, V81, pF188, DOI 10.1136/fn.81.3.F188; Remes ST, 1998, ALLERGY, V53, P682, DOI 10.1111/j.1398-9995.1998.tb03954.x; ROBERTON DM, 1982, ARCH DIS CHILD, V57, P369, DOI 10.1136/adc.57.5.369; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; SAVILAHTI E, 1993, ACTA PAEDIATR, V82, P340, DOI 10.1111/j.1651-2227.1993.tb12692.x; Sudo N, 1997, J IMMUNOL, V159, P1739; VONMUTIUS E, 1993, J PEDIATR-US, V123, P223, DOI 10.1016/S0022-3476(05)81692-0; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; Warner JA, 1999, ANN ALLERG ASTHMA IM, V83, P426, DOI 10.1016/S1081-1206(10)62846-3; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D	44	57	57	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					229	234		10.1067/mai.2001.112128	http://dx.doi.org/10.1067/mai.2001.112128			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174187				2022-12-18	WOS:000167071400007
J	Fireman, P				Fireman, P			Therapeutic approaches to allergic rhinitis: Treating the child	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on Advances in Allergic Diseases - An Update for the New Millennium	FEB   11, 1999	WASHINGTON, D.C.			allergens; allergic rhinitis; antihistamines; asthma; atopy; corticosteroids; otitis media with effusion; sinusitis	MILD ASTHMA; RESPONSIVENESS; EPIDEMIOLOGY; FREQUENT; DISEASE	Allergic rhinitis is currently the most common of all chronic diseases in children. However, children frequently lack the ability to verbalize their symptoms, with the result that the condition may go undiagnosed and untreated. Unfortunately, untreated allergic rhinitis not only detrimentally affects children's physical and psychosocial well-being, quality of life, and capacity to function and learn, but it is also associated with and may contribute to potentially serious sequelae, including asthma, sinusitis, and otitis media. Because children may not accurately describe their symptoms, the classic signs of allergic rhinitis in the pediatric population, including the allergic shiner, the allergic crease, and the allergic salute, are particularly important in enabling the clinician to recognize those children who may have this condition; other significant signs include mouth breathing, snoring, chronic cough, and continual throat clearing. The options for treating allergic rhinitis in the child are the same as those for the adult, and the clinician can expect the same level of efficacy, Environmental control for allergen avoidance is an important goal, but the clinician must prescribe it within the context of the family's lifestyle to obtain compliance. Complete avoidance of inhalant allergens is not always-feasible, and medications are necessary. Oral antihistamines remain the mainstay of initial treatment for allergies. Given evidence of the significant deleterious effects of the sedating antihistamines on learning, the clinician should prescribe nonsedating second-generation agents whenever possible, Decongestants may be needed. Intranasal corticosteroids are a most effective option, and these agents lack the systemic side effects associated with orally administered steroids. In persistent disease, allergen immunotherapy injections may be considered, In all cases, the clinician should consider issues that are likely to influence compliance in the pediatric population.	Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Internal Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Fireman, P (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Pediat, 3705 5th Ave, Pittsburgh, PA 15213 USA.							*AM ACAD ALL ASTHM, 1998, RAISING STANDARD CAR; American Academy of Pediatrics, 1997, 1997 RED BOOK REP CO; BELL IR, 1990, PSYCHOSOM MED, V52, P517, DOI 10.1097/00006842-199009000-00004; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H; Corren J, 1997, J ALLERGY CLIN IMMUN, V100, P781, DOI 10.1016/S0091-6749(97)70274-4; FIREMAN P, 1992, J ALLERGY CLIN IMMUN, V90, P433, DOI 10.1016/0091-6749(92)90164-W; FIREMAN P, 1991, TODAYS THERAPEUTIC T, V9, P21; FURUKAWA CT, 1992, J ALLERGY CLIN IMMUN, V89, P332; GRANT JA, 1995, J ALLERGY CLIN IMMUN, V95, P923, DOI 10.1016/S0091-6749(95)70090-0; *INT RHIN MAN WORK, 1994, ALLERGY, V49, P5; Lemanske RF, 1997, JAMA-J AM MED ASSOC, V278, P1855, DOI 10.1001/jama.278.22.1855; Meltzer EO, 1998, CLIN PEDIATR, V37, P1, DOI 10.1177/000992289803700101; MENARDO JL, 1985, J ALLERGY CLIN IMMUN, V75, P645; NEWACHECK PW, 1994, J PEDIATR-US, V124, P40, DOI 10.1016/S0022-3476(94)70252-7; NIMMAGADDA SR, 1999, ALLERGY ETIOLOGY EPI, V20, P111; Rachelefsky GS, 1999, ANN ALLERG ASTHMA IM, V82, P296, DOI 10.1016/S1081-1206(10)62612-9; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; SHAPIRO GG, 1988, J ALLERGY CLIN IMMUN, V82, P935, DOI 10.1016/0091-6749(88)90036-X; Smith L, 1998, J ALLERGY CLIN IMMUN, V101, pS370, DOI 10.1016/S0091-6749(98)70223-4; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; WRIGHT AL, 1994, PEDIATRICS, V94, P895; YOUSSEF HH, 1996, JAMA-J AM MED ASSOC, V4, P37	24	57	63	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	2	S			S616	S621						6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	328QU	10856167				2022-12-18	WOS:000087862200005
J	Derby, L; Maier, WC				Derby, L; Maier, WC			Risk of cataract among users of intranasal corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						intranasal corticosteroids; cataract; beclomethasone dipropionate		Background: Oral corticosteroid users are at increased risk of cataract, but the risk among intranasal corticosteroids users is unknown. Objective: Our purpose was to describe the risk of cataract among users of intranasal steroids. Methods: A retrospective observational cohort study of cataract incidence was conducted among users of oral and intranasal steroids identified from the United Kingdom-based General Practice Research Database with a nested case-control analysis to control for confounding factors, The study population included 286,078 subjects aged less than 70 years old drawn from 350 general practices in England and Wales. Patients were classified as users of only intranasal corticosteroids, users of only oral corticosteroids, and nonusers of either medication. Computerized medical records were used to identify cases of cataract. Two hundred twenty-five cases were randomly selected for validation against general practitioners' held referral and hospitalization letters. Results: The incidence rate of cataract (1.0/1000 person-years) among users of intranasal corticosteroids was similar to the incidence rate among nonusers. However, oral corticosteroid users were at higher risk of cataract (2.2/1000 person-years). Approximately 70% of intranasal corticosteroid exposure mas to beclomethasone dipropionate only; the event rate in this group was similar to that in the unexposed group. Cataract risk did not increase with the number of prior prescriptions for intranasal corticosteroids. Conclusion: The use of intranasal corticosteroids was not associated with an increased risk of cataracts in this study population.	Boston Univ, Sch Med, Boston Collaborat Drug Surveillance Program, Lexington, MA 02421 USA; Glaxo Wellcome Res & Dev Ltd, Worldwide Epidemiol, Greenford, Middx, England	Boston University; GlaxoSmithKline	Derby, L (corresponding author), Boston Univ, Sch Med, Boston Collaborat Drug Surveillance Program, 11 Muzzey St, Lexington, MA 02421 USA.							Brattsand R., 1992, NEW DRUGS ASTHMA, V2, P193; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; FRAUNFELDER FT, 1990, AM J OPHTHALMOL, V109, P489, DOI 10.1016/S0002-9394(14)74627-6; Garbe E, 1998, JAMA-J AM MED ASSOC, V280, P539, DOI 10.1001/jama.280.6.539; Hodge WG, 1995, EPIDEMIOL REV, V17, P336, DOI 10.1093/oxfordjournals.epirev.a036197; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; Meltzer EO, 1997, ALLERGY, V52, P33, DOI 10.1111/j.1398-9995.1997.tb04820.x; MICHELS MI, 1967, ANN ALLERGY, V25, P569; PHILLIPS GH, 1994, RESP MED, V84, P10; WALKER A M, 1988, Journal of Clinical Research and Drug Development, V2, P227	12	57	63	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					912	916		10.1067/mai.2000.106044	http://dx.doi.org/10.1067/mai.2000.106044			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808171				2022-12-18	WOS:000087185000009
J	Taylor, AV; Swanson, MC; Jones, RT; Vives, R; Rodriguez, J; Yunginger, JW; Crespo, JF				Taylor, AV; Swanson, MC; Jones, RT; Vives, R; Rodriguez, J; Yunginger, JW; Crespo, JF			Detection and quantitation of raw fish aeroallergens from an open-air fish market	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; fish; aeroallergen; air sampling; nonoccupational exposure; immunochemical detection	ALLERGY; WORKERS	Background: IgE-mediated hypersensitivity to fish is a clinically relevant problem, particularly in several European countries. Although most allergic reactions to fish are caused by ingestion, occupational exposures to seafood allergens by inhalation have been correlated with respiratory symptoms. In Madrid, patients with fish allergy have exhibited respiratory symptoms after visits to an open-air fish market. Objective: We sought to study the possibility of passively aerosolized fish allergen in an open-air fish market through air sampling and a competitive IgE immunoassay. Methods: Air samples were collected on polytetrafluoroethylene filters by using air samplers. Samples were collected on 41 different days from both an open-air ish market and an outdoor residential area. Fish allergens were specifically quantified by competitive IgE immunoassay by using pooled sera from fish-sensitive individuals. A raw fish extract (10 mg of dry weight/mL) nas used as the reference standard. Results: Allergen was quantified in all 39 fish market air samples (2-25 ng/m(3)). The residential air samples contained no detectable allergen. The analytic limit of detection was 2 ng, allowing detection of 0.4 ng/m(3) for the air volumes collected, A concentrated (30-fold) pool of fish market air samples was tested in serial dilutions and demonstrated an identical regression line to that of the raw fish standard. Conclusion: By using air sampling and an immunochemical analytic technique, fish allergen is detectable in the air of an open-air fish market. Avoidance of a food allergen, such as fish, should include preventing exposure to aerosolized particles through inhalation in relevant environments.	Mayo Grad Sch Med, Dept Pediat & Adolescent Med, Rochester, MN USA; Mayo Clin & Mayo Fdn, Allerg Dis Res Lab, Rochester, MN 55905 USA; Univ Madrid, Hosp 12 Octubre, Serv Alergia, Madrid 3, Spain	Mayo Clinic; Mayo Clinic; Hospital Universitario 12 de Octubre	Yunginger, JW (corresponding author), Mayo Clin, 200 1st St SW, Rochester, MN 55905 USA.							Aas K., 1987, FOOD ALLERGY INTOLER, P356; AGARWAL MK, 1981, J ALLERGY CLIN IMMUN, V68, P194, DOI 10.1016/0091-6749(81)90183-4; BAHNA SL, 1994, ALLERGY, V49, P120; BURKS AW, 1997, FOOD ALLERGY ADVERSE, P245; CARTIER A, 1986, J ALLERGY CLIN IMMUN, V78, P344, DOI 10.1016/S0091-6749(86)80087-2; CRESPO JF, 1995, PEDIAT ALLERG IMM-UK, V6, P39, DOI 10.1111/j.1399-3038.1995.tb00256.x; CRESPO JF, 1995, ALLERGY, V50, P257, DOI 10.1111/j.1398-9995.1995.tb01143.x; DEMARTINO M, 1993, ANN ALLERGY, V71, P159; DOUGLAS JDM, 1995, LANCET, V346, P737, DOI 10.1016/S0140-6736(95)91505-2; DROSZCZ W, 1981, INT ARCH OCC ENV HEA, V49, P13, DOI 10.1007/BF00380804; Jones R. T., 1996, Journal of Allergy and Clinical Immunology, V97, P423, DOI 10.1016/S0091-6749(96)81179-1; PASCUAL C, 1990, REV ESP ALERGOL IMMU, V5, P41; Pascual CY, 1996, MONOGR ALLERGY, V32, P174; Rodriguez J, 1997, ALLERGY, V52, P866, DOI 10.1111/j.1398-9995.1997.tb02159.x; SAARINEN UM, 1980, LANCET, V1, P166; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; YUNGINGER JW, 1997, MANUAL CLIN LAB IMMU, P868	17	57	60	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				166	169		10.1016/S0091-6749(00)90192-1	http://dx.doi.org/10.1016/S0091-6749(00)90192-1			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629467	Bronze			2022-12-18	WOS:000084992100022
J	Hakonarson, H; Carter, C; Kim, C; Grunstein, MM				Hakonarson, H; Carter, C; Kim, C; Grunstein, MM			Altered expression and action of the low-affinity IgE receptor Fc epsilon RII (CD23) in asthmatic airway smooth muscle	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fc receptor expression; immunoglobulins; IL-1 beta; human airway smooth muscle; asthma	SERUM IGE; MONONUCLEAR PHAGOCYTES; LYMPHOCYTE RECEPTOR; CYTOKINE PRODUCTION; PERIPHERAL-BLOOD; IMMUNOGLOBULIN-E; HUMAN BASOPHILS; RESPONSIVENESS; CHILDREN; CELL	Background: Changes in cell surface expression of certain immunoglobulin Fc receptors have been demonstrated in leukocytes isolated from the lungs of atopic asthmatic individuals, This, together with emerging evidence that Fc receptors can also be expressed and activated in non-bone marrow-derived cell types, including airway smooth muscle (ASM), raises the hypothesis that the atopic asthmatic ASM phenotype is associated with an altered endogenous expression and action of specific Fc receptors present in the ASM itself. Objective: The current study addressed the above hypothesis by examining (1) whether the expression of certain key Fc receptor subtypes for IgE and IgG is altered in ASM tissue isolated from human atopic asthmatic individuals and (2) whether this altered Fc receptor expression is comparably induced in naive human ASM tissue and cultured cells after their passive sensitization with human atopic asthmatic serum or IgE immune complexes. Methods: Messenger RNA and cell surface protein expression of the individual IgG receptor subtypes Fc gamma RI, Fc gamma RII, and Fc gamma RIII, as well as the IgE receptor subtypes Fc epsilon RI and Fc epsilon RII, were examined in human ASM tissue isolated from atopic asthmatic and control (nonatopic/nonasthmatic) individuals. In addition, we examined the effects of passive sensitization of ASM tissue and cultured ASM cells with control serum, atopic asthmatic serum, or exogenously administered IgE immune complexes on Fc receptor expression and action (ie, induction of proinflammatory cytokine release), Results: The observations demonstrate that (1) human ASM tissue expresses messenger RNA and surface protein for Fc epsilon RII, as well as for ail the Fcy receptor subtypes, (2) in contrast to unaltered Fc gamma subtype expression, however, relative to control human ASM, FceRII is significantly up-regulated in inherently asthmatic ASM tissue, (3) up-regulated expression of Fc epsilon RII represents, at least in part, an inducible phenomenon that is largely attributed to IgE immune complex-coupled activation of the receptor, and (4) the latter action is associated with Fc epsilon RII-induced autologous elaboration of the proinflammatory cytokine, IL-1 beta, by the atopic sensitized ASM, Conclusion: These observations provide new evidence that human ASM tissue expresses Fc epsilon RII in addition to all 3 subtypes of Fc gamma receptors and that the expression of Fc epsilon RII is selectively increased in atopic asthmatic ASM, a phenomenon associated with IgE immune complex/Fc epsilon RII-mediated elaboration of IL-1 beta by the ASM itself.	Hosp Univ Penn, Sch Med, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst,Div Pulm Med & Allerg, Philadelphia, PA 19104 USA; Hosp Univ Penn, Sch Med, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst,Div Immunol, Philadelphia, PA 19104 USA; Hosp Univ Penn, Sch Med, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst,Div Infect Dis, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Grunstein, MM (corresponding author), Hosp Univ Penn, Sch Med, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst,Div Pulm Med & Allerg, Abramson Res Bldg,Room 410,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031467, R01HL058245] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-58245, HL-31467] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAI TR, 1990, AM REV RESPIR DIS, V141, P552, DOI 10.1164/ajrccm/141.3.552; BARNES PJ, 1988, PHARMACOL REV, V40, P49; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BORISH L, 1991, J IMMUNOL, V146, P63; BURROWS B, 1995, AM J RESP CRIT CARE, V152, P1497, DOI 10.1164/ajrccm.152.5.7582283; BURROWS B, 1995, J ALLERGY CLIN IMMUN, V95, P548, DOI 10.1016/S0091-6749(95)70317-9; BURROWS B, 1989, NEW ENGL J MED, V320, P272; Capel P J, 1994, Immunomethods, V4, P25, DOI 10.1006/immu.1994.1004; CAPRON M, 1984, J IMMUNOL, V132, P462; CHIHARA J, 1991, ANN ALLERGY, V67, P429; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CONROY MC, 1977, J IMMUNOL, V118, P1317; DAERON M, 1986, J IMMUNOL, V136, P1612; GAGRO A, 1993, INT ARCH ALLERGY IMM, V101, P203, DOI 10.1159/000236520; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GOLDIE RG, 1986, BRIT J CLIN PHARMACO, V22, P669, DOI 10.1111/j.1365-2125.1986.tb02956.x; Hakonarson H, 1998, P NATL ACAD SCI USA, V95, P5257, DOI 10.1073/pnas.95.9.5257; HAKONARSON H, 1995, AM J PHYSIOL-LUNG C, V269, pL645, DOI 10.1152/ajplung.1995.269.5.L645; Hakonarson H, 1996, J CLIN INVEST, V97, P2593, DOI 10.1172/JCI118708; Hakonarson H, 1997, J CLIN INVEST, V99, P117, DOI 10.1172/JCI119122; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; Lantz CS, 1997, J IMMUNOL, V158, P2517; LEE WT, 1987, J IMMUNOL, V139, P1191; LEE WT, 1986, J IMMUNOL, V136, P4573; LITCHFIELD TM, 1992, J ASTHMA, V29, P181, DOI 10.3109/02770909209099026; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; MATSUMOTO T, 1987, ANN ALLERGY, V58, P261; MCFADDEN ER, 1994, AM J RESP CRIT CARE, V150, P523; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; RABATIC S, 1993, CLIN EXP IMMUNOL, V94, P337; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SPIEGELBERG HL, 1981, J CLIN INVEST, V68, P845, DOI 10.1172/JCI110339; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WATSON ML, 1993, AM J RESP CELL MOL, V8, P365, DOI 10.1165/ajrcmb/8.4.365; WILLIAMS J, 1992, J IMMUNOL, V149, P2823; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663	39	57	61	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				575	584		10.1016/S0091-6749(99)70326-X	http://dx.doi.org/10.1016/S0091-6749(99)70326-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482830				2022-12-18	WOS:000082870000018
J	Liggett, SB				Liggett, SB			Molecular and genetic basis of beta(2)-adrenergic receptor function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						polymorphism; allele; adenylyl cyclase; desensitization; isomers; agonist; G-protein	BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; ASTHMATIC SUBJECTS; POLYMORPHISM; ASSOCIATION; DESENSITIZATION; PROTEIN	The beta(2)-adrenergic receptor has been cloned, mutated, and recombinantly expressed such that many structural features involved in receptor function hare been defined. Agonists bind in a pocket formed by transmembrane spanning domains 3, 5, and 6, where key contact points initiate receptor activation. An interaction with the beta-hydroxyl group of beta-agonists and Asn293 of the latter transmembrane domain is the basis of the stereoselectivity of R- vs S-isomers of catecholamine-like agonists, Sites within the receptor that serve to dampen the signal with continuous agonist exposure have also been identified and include sites for phosphorylation by protein kinase A and G-protein-coupled receptor kinases and structural features that direct the receptor toward degradation (downregulation), Several regions of the beta(2)-adrenergic receptor show genetic diversity within the human population, such that expression, coupling, and agonist regulation may be different in individuals with these polymorphisms.	Univ Cincinnati, Coll Med, Dept Med Pulm, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Dept Pharmacol, Cincinnati, OH USA	University of Cincinnati; University of Cincinnati	Liggett, SB (corresponding author), 231 Bethesda Ave,Rm 7511 MSB, Cincinnati, OH 45267 USA.		liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669				Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Dewar JC, 1997, J ALLERGY CLIN IMMUN, V100, P261, DOI 10.1016/S0091-6749(97)70234-3; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GREEN SA, 1993, J BIOL CHEM, V268, P23116; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; GREEN SA, 1996, GENETICS ASTHMA, P67; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; Hopes E, 1998, BRIT MED J, V316, P664, DOI 10.1136/bmj.316.7132.664; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; LIGGETT SB, 1997, LUNG SCI FDN, P19; LIGGETT SB, 1996, ASTHMA, P299; Liggett SB, 1993, REGULATION CELLULAR, P71; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; McGraw DW, 1998, CELL SIGNAL, V10, P197, DOI 10.1016/S0898-6568(97)00112-5; McGraw DW, 1998, J CLIN INVEST, V102, P1927, DOI 10.1172/JCI4862; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P16470; STRADER CD, 1995, J BIOL CHEM, V266, P5; Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X; TOTA MR, 1990, J BIOL CHEM, V265, P16891; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; Weir TD, 1998, AM J RESP CRIT CARE, V158, P787, DOI 10.1164/ajrccm.158.3.9801035; Wieland K, 1996, P NATL ACAD SCI USA, V93, P9276, DOI 10.1073/pnas.93.17.9276	24	57	60	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	2	S			S42	S46		10.1016/S0091-6749(99)70272-1	http://dx.doi.org/10.1016/S0091-6749(99)70272-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	233GX	10452787				2022-12-18	WOS:000082419400005
J	Peacock, CD; Misso, NLA; Watkins, DN; Thompson, PJ				Peacock, CD; Misso, NLA; Watkins, DN; Thompson, PJ			PGE(2) and dibutyryl cyclic adenosine monophosphate prolong eosinophil survival in vitro	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; apoptosis; asthma; IL-5; Fas; TNF-alpha; PGE(2); annexin V	COLONY-STIMULATING FACTOR; PROGRAMMED CELL-DEATH; MAJOR BASIC-PROTEIN; NITRIC-OXIDE; PROSTANOID RECEPTORS; NEUTROPHIL APOPTOSIS; BLOOD EOSINOPHILS; DNA FRAGMENTATION; MESSENGER-RNA; SMOOTH-MUSCLE	Background: Apoptosis represents a mechanism by which the accumulation and inflammatory potential of eosinophils in asthma might be limited. Mediators derived from the airway epithelium may influence the rate of eosinophil apoptosis. Objective: We have investigated the effects on eosinophil apoptosis of 3 mediators that are likely to be produced by the airway epithelium, namely PGE(2), TNF-alpha, and nitric oxide. Methods: Peripheral blood eosinophils from healthy adult volunteers were purified by density gradient centrifugation and negative immunomagnetic selection. Eosinophils were cultured for 16 or 40 hours with PGE(2) (10 nmol/L), dibutyryl cyclic adenosine monophosphate (AMP; 100 mu mol/L), TNF-alpha (500 U/mL), the nitric oxide donors, S-nitroso-N-acetylpenicillamine (100 mu mol/L), and 2,2'-(hydroxynitrosohydrazono)bis-ethanamine (1 mmol/L), or dibutyryl cyclic guanosine monophosphate (100 mu mol/L). Control cultures consisted of untreated, IL5-treated (100 U/mL), and anti-Fas-treated (400 ng/mL) cells. Eosinophil apoptosis was assessed by flow cytometric analysis of annexin V-FITC binding to externalized phosphatidylserine, by electrophoresis of phosphorus 32 end-labeled DNA fragments, and by flow cytometric assessment of hypodiploid DNA with propidium iodide, Results: PGE(2) and cyclic AMP inhibited spontaneous eosinophil apoptosis at both 16 and 40 hours as did the PGEP(2) receptor agonist, 11-deoxy PGE(1), at 40 hours, but these effects were not inhibited by a protein kinase A antagonist. TNF-alpha delayed apoptosis in eosinophil cultures at 16 hours, whereas S-nitroso-N-acetylpenicillamine, 2,2'-(hydroxynitrosohydrazono)bis-ethanamine, and cyclic guanosine monophosphate had little effect. Anti-Fas had little effect on spontaneous eosinophil apoptosis but significantly reduced the inhibitory effects of PGE(2), cyclic AMP, and TNF-alpha. Assessments of apoptosis by DNA fragmentation gave similar but quantitatively less sensitive results. Conclusion: Inhibition of spontaneous eosinophil apoptosis by PGE(2) appears to be mediated by EP2 receptors but is not protein kinase A dependent. By enhancing eosinophil survival, PGE(2) may increase the proinflammatory potential of these cells in chronic asthma.	Univ Western Australia, Dept Med, Perth, WA 6009, Australia; Asthma & Allergy Res Inst Inc, Asthma & Allergy Res Inst, Nedlands, WA 6009, Australia	University of Western Australia	Thompson, PJ (corresponding author), Asthma & Allergy Res Inst Inc, Sir Charles Gairdiner Hosp, Ground Floor,E Block,, Nedlands, WA 6009, Australia.		Watkins, David N/I-6113-2013					ALAM R, 1993, AM REV RESPIR DIS, V148, P1066, DOI 10.1164/ajrccm/148.4_Pt_1.1066; AROCK M, 1994, BIOCHEM BIOPH RES CO, V203, P265, DOI 10.1006/bbrc.1994.2177; BAIGELMAN W, 1983, AM J MED, V75, P929, DOI 10.1016/0002-9343(83)90871-9; BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; BEAUVAIS F, 1995, FEBS LETT, V361, P229, DOI 10.1016/0014-5793(95)00188-F; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; Collins JA, 1997, J HISTOCHEM CYTOCHEM, V45, P923, DOI 10.1177/002215549704500702; COLOTTA F, 1992, BLOOD, V80, P2012; delPozo V, 1997, J IMMUNOL, V158, P859; DIAZ P, 1984, J ALLERGY CLIN IMMUN, V74, P41, DOI 10.1016/0091-6749(84)90085-X; Druilhe A, 1996, BLOOD, V87, P2822, DOI 10.1182/blood.V87.7.2822.bloodjournal8772822; Ferreira HHA, 1996, EUR J PHARMACOL, V310, P201, DOI 10.1016/0014-2999(96)00379-2; FLAVAHAN NA, 1988, AM REV RESPIR DIS, V138, P685, DOI 10.1164/ajrccm/138.3.685; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538, DOI 10.1164/ajrccm.149.2.7508323; GOETZL EJ, 1995, J IMMUNOL, V154, P1041; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hallsworth MP, 1996, BRIT J PHARMACOL, V117, P79, DOI 10.1111/j.1476-5381.1996.tb15157.x; Hannah S, 1998, FEBS LETT, V421, P141, DOI 10.1016/S0014-5793(97)01551-2; HASTIE AT, 1987, AM REV RESPIR DIS, V135, P848, DOI 10.1164/arrd.1987.135.4.848; Hebestreit H, 1998, J EXP MED, V187, P415, DOI 10.1084/jem.187.3.415; Hiraguri M, 1997, J ALLERGY CLIN IMMUN, V100, pS45; KITA H, 1991, J IMMUNOL, V146, P2712; KNIGHT DA, 1994, CLIN EXP ALLERGY, V24, P698, DOI 10.1111/j.1365-2222.1994.tb00980.x; Levi-Schaffer F, 1998, J IMMUNOL, V160, P5554; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; LUKACS NW, 1995, J IMMUNOL, V154, P5411; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; Meagher LC, 1996, J IMMUNOL, V156, P4422; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Misso NLA, 1998, J LEUKOCYTE BIOL, V63, P124, DOI 10.1002/jlb.63.1.124; Nagata Makoto, 1993, Japanese Journal of Allergology, V42, P549; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Parvathenani LK, 1998, J BIOL CHEM, V273, P6736, DOI 10.1074/jbc.273.12.6736; PAVORD ID, 1994, LANCET, V344, P436; PAZDRAK K, 1995, J EXP MED, V181, P1827, DOI 10.1084/jem.181.5.1827; Pazdrak K, 1998, J EXP MED, V188, P421, DOI 10.1084/jem.188.3.421; REED CE, 1986, J ALLERGY CLIN IMMUN, V77, P537, DOI 10.1016/0091-6749(86)90342-8; Rossi AG, 1995, BIOCHEM BIOPH RES CO, V217, P892, DOI 10.1006/bbrc.1995.2855; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; SILBERSTEIN DS, 1986, P NATL ACAD SCI USA, V83, P1055, DOI 10.1073/pnas.83.4.1055; Simon HU, 1998, CLIN EXP ALLERGY, V28, P1321; STERN M, 1992, J IMMUNOL, V148, P3543; TAI PC, 1991, CLIN EXP IMMUNOL, V85, P312; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; Teixeira MM, 1997, BRIT J PHARMACOL, V121, P77, DOI 10.1038/sj.bjp.0701107; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; Watkins DN, 1997, AM J RESP CELL MOL, V16, P629, DOI 10.1165/ajrcmb.16.6.9191464; Yasui K, 1997, J CLIN INVEST, V100, P1677, DOI 10.1172/JCI119692	52	57	58	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					153	162		10.1016/S0091-6749(99)70127-2	http://dx.doi.org/10.1016/S0091-6749(99)70127-2			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400853	Bronze			2022-12-18	WOS:000081738900022
J	FitzGerald, JM; Chapman, KR; Della Cioppa, G; Stubbing, D; Fairbarn, MS; Till, D; Brambilla, R				FitzGerald, JM; Chapman, KR; Della Cioppa, G; Stubbing, D; Fairbarn, MS; Till, D; Brambilla, R		Canadian FO-OD1 Study Grp	Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; beta-agonists; tolerance; asthma control	INHALED BETA-AGONISTS; CLEAR CLINICAL BENEFIT; BRONCHIAL RESPONSIVENESS; AIRWAY RESPONSIVENESS; RESPIRATORY MEDICINE; ADRENERGIC AGONISTS; MILD ASTHMA; SALMETEROL; TERBUTALINE; TOLERANCE	Background: Recent studies have raised concern that regular inhalation of beta(2)-agonists may cause a worsening of asthma control compared with on-demand dosing regimens. Objective: The objective of this study was to compare the effect of twice daily formoterol (Foradil), 4 times daily albuterol, and on-demand albuterol on bronchial hyperresponsiveness (BHR), lung function measurements, symptoms, and other indicators of disease control over 6 months in patients with asthma of moderate or greater severity receiving concomitant inhaled corticosteroids, We also looked for occurrence of rebound BHR on discontinuation of treatment. Methods: This was a multicenter, parallel-group, double-blind, clinical trial. Methacholine PC20 was the primary outcome variable. Other outcome variables included symptom scores, use of rescue medication, morning peak expiratory flow (PEF), serial FEV1 measurements, and asthma exacerbations, Results: Of the 271 randomized patients, 217 completed the study. Formoterol was significantly superior to on-demand albuterol with regard to methacholine PC20, FEV1, PEF, symptom scores, and use of rescue medication at each measured time point/interval, Regular albuterol was superior to on demand albuterol with regard to PC20 and FEV1, but not PEF or various clinical scores. After a small drop in the magnitude of bronchoprotection and bronchodilatation occurring shortly after randomization, there was no evidence of progressive tolerance to either regular treatment for any of the measured variables or of rebound increase in BHR 2 days after the end of treatment. The formoterol group had the lowest number of exacerbation days, as defined by high intake of rescue bronchodilator and/or symptom scores, whereas the number of exacerbations requiring increased corticosteroid coverage was similar in the 3 groups. Conclusion: In patients with asthma of moderate or greater severity receiving inhaled corticosteroids, formoterol taken twice daily resulted in superior bronchoprotection, bronchodilatation, and clinical control compared with on-demand albuterol over 6 months. Four times daily albuterol was superior to on-demand albuterol for only some of the end paints, Progressive tolerance and a rebound increase in BHR on discontinuation of beta-agonists were not found.	Vancouver Hosp & Hlth Sci Ctr, Dept Med, Div Resp, Vancouver, BC V5Z 1M9, Canada; Toronto Hosp, Asthma Ctr, Toronto, ON M5T 2S8, Canada; Novartis Horsham Res Ctr, Dept Clin Dev & Regulatory Affairs, Horsham, W Sussex, England; Chedoke McMaster Hosp, Hamilton, ON, Canada; British Columbia Lung Assoc, Dept Clin Res, Vancouver, BC, Canada; Novartis Pharma Inc, Dept Clin Dev & Regulatory Affairs, Basel, Switzerland	University of British Columbia; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Novartis; McMaster University; Novartis	FitzGerald, JM (corresponding author), Mater Misericordiae Univ Hosp, Dept Resp Med, Eccles St, Dublin 7, Ireland.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 1993, BRIT MED J, V306, P776; BEACH JR, 1993, PULM PHARMACOL, V6, P155, DOI 10.1006/pulp.1993.1020; BHAGAT R, 1995, CHEST, V108, P1235, DOI 10.1378/chest.108.5.1235; Booth H, 1996, THORAX, V51, P1100, DOI 10.1136/thx.51.11.1100; BRODDE OE, 1985, J CLIN INVEST, V76, P1096, DOI 10.1172/JCI112063; BURROWS B, 1992, NEW ENGL J MED, V326, P560, DOI 10.1056/NEJM199202203260809; CHAPMAN KR, 1994, LANCET, V343, P1379, DOI 10.1016/S0140-6736(94)92520-8; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; COCKCROFT DW, 1983, CHEST, V84, P505, DOI 10.1378/chest.84.4.505; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CRANE J, 1989, LANCET, V1, P917; CRANE J, 1995, THORAX, V50, pS5, DOI 10.1136/thx.50.Suppl_1.S5; DALONZO GE, 1994, JAMA-J AM MED ASSOC, V271, P1412, DOI 10.1001/jama.271.18.1412; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; Ernst P, 1996, CAN RESPIR J, V3, P89; GIUNTINI CG, 1995, EUR RESPIR J, V8, P673; HUI KKP, 1982, CLIN PHARMACOL THER, V32, P566, DOI 10.1038/clpt.1982.204; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; Kalra S, 1996, CHEST, V109, P953, DOI 10.1378/chest.109.4.953; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LOFDAHL CG, 1992, EUR RESPIR J, V5, P898; *NAT ASTHM ED PROG, 1997, NIH PUBL; NELSON HS, 1995, NEW ENGL J MED, V333, P499, DOI 10.1056/NEJM199508243330807; NEWNHAM DM, 1995, THORAX, V50, P497, DOI 10.1136/thx.50.5.497; OByrne PM, 1996, NEW ENGL J MED, V335, P886, DOI 10.1056/NEJM199609193351211; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; PAGE C, 1992, RESP MED, V86, P477, DOI 10.1016/S0954-6111(96)80005-9; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; SEARS MR, 1995, AM J RESP CRIT CARE, V151, P600; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SEARS MR, 1992, EUR RESPIR J, V5, P896; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; TATTERSFIELD AE, 1994, BMJ-BRIT MED J, V109, P794; TAYLOR DR, 1994, CHEST, V106, P552, DOI 10.1378/chest.106.2.552; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; TWENTYMAN OP, 1992, RESP MED, V86, P471, DOI 10.1016/S0954-6111(96)80004-7; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426; VATHENEN AS, 1988, LANCET, V1, P554; Verberne AAPH, 1996, J ALLERGY CLIN IMMUN, V97, P938, DOI 10.1016/S0091-6749(96)80068-6; WAHEDNA I, 1993, AM REV RESPIR DIS, V148, P707, DOI 10.1164/ajrccm/148.3.707; WANNER A, 1995, AM J RESP CRIT CARE, V151, P597; YATES DH, 1995, AM J RESP CRIT CARE, V152, P1170, DOI 10.1164/ajrccm.152.4.7551366	46	57	58	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				427	435		10.1016/S0091-6749(99)70467-7	http://dx.doi.org/10.1016/S0091-6749(99)70467-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069876				2022-12-18	WOS:000079175700011
J	Finnell, RH				Finnell, RH			Teratology: General considerations and principles	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							EPILEPSY	Approximately 3% to 5% of children born in the United States manifest developmental defects. Between 2% and 3% of these birth defects can be classified as teratogen-induced malformations, which result from environmental or iatrogenic exposures during pregnancy The final manifestations of drug-induced abnormal development can be death, malformation, growth retardation, or functional disorder. In considering the potential teratogenic effects of drugs, it is important to remember that susceptibility to a drug-induced malformation depends on: (1) the genotype of the conceptus, (2) the developmental stage at which exposure occurs, (3) the mechanisms of action of the drug, (4) the access of the drug to developing tissues, and (5) the dose of the drug. Nearly all teratogen-induced birth defects are preventable if the dose-response relationship for teratogen exposure and the teratogenic activity of the drug can be clearly defined.	Texas A&M Univ, Coll Vet Med, Dept Vet Anat & Publ Hlth, Birth Defects Res Lab, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Finnell, RH (corresponding author), Texas A&M Univ, Coll Vet Med, Dept Vet Anat & Publ Hlth, Birth Defects Res Lab, College Stn, TX 77843 USA.		Finnell, Richard/D-8174-2018	Finnell, Richard/0000-0002-5962-8754				BUEHLER BA, 1990, NEW ENGL J MED, V322, P1567, DOI 10.1056/NEJM199005313222204; DELGADOESCUETA AV, 1992, NEUROLOGY, V42, P149; FINNELL RH, 1991, REPROD TOXICOL, V5, P281, DOI 10.1016/0890-6238(91)90090-3; Hale F, 1933, J HERED, V24, P105, DOI 10.1093/oxfordjournals.jhered.a103720; MURPHY ML, 1956, CANCER, V9, P955, DOI 10.1002/1097-0142(195609/10)9:5<955::AID-CNCR2820090515>3.0.CO;2-S; THIERSCH JB, 1952, AM J OBSTET GYNECOL, V63, P1298; Wilson J. G., 1977, HDB TERATOLOGY, V1, P47	7	57	66	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	2	S			S337	S342		10.1016/S0091-6749(99)70259-9	http://dx.doi.org/10.1016/S0091-6749(99)70259-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	171KA	9949334				2022-12-18	WOS:000078861500003
J	Pascual, CY; Fernandez-Crespo, J; Sanchez-Pastor, S; Padial, MA; Diaz-Pena, JM; Martin-Munoz, F; Martin-Esteban, M				Pascual, CY; Fernandez-Crespo, J; Sanchez-Pastor, S; Padial, MA; Diaz-Pena, JM; Martin-Munoz, F; Martin-Esteban, M			Allergy to lentils in Mediterranean pediatric patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food hypersensitivity; legumes; lentils; chick peas; allergens	MAJOR PEANUT ALLERGEN; ARA-H-II; ATOPIC-DERMATITIS; IGE-BINDING; ANAPHYLAXIS; HYPERSENSITIVITY; IDENTIFICATION	Background: Peanuts and soybeans are the major legumes involved in human food allergy; however, scarce data exist on adverse reactions to other temperate legumes, such as lentils. Objective: The purpose of this study was to identify patients who are allergic to lentils, to assess clinical features and other associated food allergies, and to characterize allergens in lentil extract. Methods: Twenty-two children each with a history of adverse reactions to lentils were enrolled in the study. The diagnosis of lentil allergy was based on food challenges or a concerning history of anaphylaxis, with positive skin tests and/or specific serum IgE to lentils, Lentil components were characterized by SDS-PAGE immunoblotting. Results: Twenty of 22 subjects had symptomatic allergy to lentils at the diagnostic time. The most frequent symptoms a ere oropharyngeal symptoms (40%) and acute urticaria (30%); 3 patients also reported symptoms when they were exposed to steam from cooked lentils, In 18 patients, symptoms after lentil ingestion started under 3 years of age (median, 2.7 years). Nine patients had allergic reactions to other legumes: chick peas (6 patients), peas (2 patients), and green beans (1 patient). Immunoblotting patterns obtained with patients' sera showed IgE-binding bands ranging from 14 to 84 kd. Five sera recognized 9 or more IgE-binding bands, and more than 50% of patients who were tested have specific IgE antibodies to 7 components in lentil extract. Conclusion: Allergic reactions to lentils started early in life, usually below 4 Sears of age; oropharyngeal symptoms and acute urticaria were the most common symptoms through ingestion, and symptomatic reactivity to chick peas is frequently associated.	Hosp Infantil La Paz, Lab Immunoalergia, Madrid 28046, Spain; Hosp 12 Octubre, Madrid, Spain	Hospital Universitario La Paz; Hospital Universitario 12 de Octubre	Pascual, CY (corresponding author), Hosp Infantil La Paz, Lab Immunoalergia, Castellana 261, Madrid 28046, Spain.							BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BURKS AW, 1995, J ALLERGY CLIN IMMUN, V95, P607, DOI 10.1016/S0091-6749(95)70323-3; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; CRESPO JF, 1995, PEDIAT ALLERG IMM-UK, V6, P39, DOI 10.1111/j.1399-3038.1995.tb00256.x; Garcia Ortiz J C, 1995, Allergol Immunopathol (Madr), V23, P38; Kalogeromitros D, 1996, ANN ALLERG ASTHMA IM, V77, P480, DOI 10.1016/S1081-1206(10)63354-6; Lalles JP, 1996, NUTR REV, V54, P101; LARRAMENDI CH, 1992, ALLERGY, V47, P490, DOI 10.1111/j.1398-9995.1992.tb00670.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN JA, 1992, ALLERGY, V47, P185, DOI 10.1111/j.1398-9995.1992.tb00962.x; MOROZ LA, 1980, NEW ENGL J MED, V302, P1126, DOI 10.1056/NEJM198005153022005; OGAWA T, 1995, BIOSCI BIOTECH BIOCH, V59, P831, DOI 10.1271/bbb.59.831; OGAWA T, 1993, BIOSCI BIOTECH BIOCH, V57, P1020; SAMPSON HA, 1988, ANN ALLERGY, V60, P262; SAMPSON HA, 1990, J ALLERGY CLIN IMMUN, V86, P1, DOI 10.1016/S0091-6749(05)80115-0; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; TAYLOR SL, 1987, ANN ALLERGY, V59, P93; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	21	57	60	1	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	1				154	158		10.1016/S0091-6749(99)70539-7	http://dx.doi.org/10.1016/S0091-6749(99)70539-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	158JM	9893199				2022-12-18	WOS:000078112300023
J	Leznoff, A				Leznoff, A			Provocative challenges in patients with multiple chemical sensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						multiple chemical sensitivity; hyperventilation; anxiety reaction; psychosomatic	ALLERGY	Whether multiple chemical sensitivity (MCS) is an organic disease initiated by environmental exposure or a psychologic disorder is a subject of controversy. The identification of pathophysiologic or psychophysiologic mechanisms occurring in patients with MCS after provocative challenges should he illuminating. Fifteen patients with MCS were challenged with their trigger substances and observed clinically, Prechallenge and postchallenge pulmonary function tests and PCO2, PO2, and oxygen saturation were measured, All of the patients whose symptoms were reproduced by the challenge (11 of 15) showed clinical evidence of acute hyperventilation with a rapid fall in PCO2 and no change or a rise in oxygen saturation, The symptoms and signs were consistent with an anxiety reaction with hyperventilation, Pulmonary function was unchanged; and recovery was rapid, aided in two cases by rebreathing into a paper bag. The most logical conclusion is that in these patients the MCS disorder is a manifestation of an anxiety syndrome triggered by their perception of an environmental insult, with at least some of their symptoms induced by hyperventilation.	UNIV TORONTO,DEPT MED,TORONTO,ON M5S 1A1,CANADA	University of Toronto	Leznoff, A (corresponding author), ST MICHAELS HOSP,DIV OCCUPAT MED,DIV CLIN IMMUNOL,38 SHUTER ST,TORONTO,ON M5B 1A6,CANADA.							*AM COLL PHYS, 1989, ANN INTERN MED, V111, P168; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P393; BASS C, 1985, BRIT MED J, V290, P1387, DOI 10.1136/bmj.290.6479.1387; BLACK DW, 1993, PSYCHOSOMATICS, V34, P131, DOI 10.1016/S0033-3182(93)71903-9; CULLEN M, 1987, OCCUP MED, V2, P633; GIARSSEN B, 1983, BEHAV RES THER, V21, P643; GUGLIELMI RS, 1994, J BEHAV THER EXP PSY, V25, P197; HOWARD LM, 1993, BRIT MED J, V307, P747, DOI 10.1136/bmj.307.6907.747; MARGARIAN GJ, 1982, MEDICINE, V61, P219; MOOSER SB, 1987, OCCUP MED, V2, P663; PARKER SL, 1991, INT J EAT DISORDER, V10, P433, DOI 10.1002/1098-108X(199107)10:4&lt;433::AID-EAT2260100408&gt;3.0.CO;2-H; PARKER SL, 1990, J ALLERGY CLIN IMMUN, V86, P503, DOI 10.1016/S0091-6749(05)80206-4; PEARSON DJ, 1988, J ALLERGY CLIN IMMUN, V81, P351, DOI 10.1016/0091-6749(88)90900-1; Rea WJ, 1989, CLIN ECOL, V6, P113; ROSS GH, 1992, TOXICOL IND HEALTH, V8, P87; STAUDENMAYER H, 1993, REGUL TOXICOL PHARM, V18, P44, DOI 10.1006/rtph.1993.1043; STEWART DE, 1985, CAN MED ASSOC J, V133, P1001; TERR AI, 1987, OCCUP MED, V2, P683; WINN HR, 1989, TXB PHYSIOL, P955; 1986, J ALLERGY CLIN IMMUN, V78, P269	20	57	57	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					438	442		10.1016/S0091-6749(97)70067-8	http://dx.doi.org/10.1016/S0091-6749(97)70067-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111485				2022-12-18	WOS:A1997WU27400003
J	Akdis, CA; Blesken, T; Akdis, M; Alkan, SS; Wuthrich, B; Heusser, CH; Blaser, K				Akdis, CA; Blesken, T; Akdis, M; Alkan, SS; Wuthrich, B; Heusser, CH; Blaser, K			Induction and differential regulation of bee venom phospholipase A(2)-specific human IgE and IgG(4) antibodies in vitro requires allergen-specific and nonspecific activation of T and B cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen-specific IgE; isotype regulation; bee venom phospholipase A(2); IgE antibody; IgG(4) antibody	IFN-GAMMA; NONALLERGIC INDIVIDUALS; MONOCLONAL-ANTIBODIES; DEPENDENT ACTIVATION; HUMAN-LYMPHOCYTES; INTERFERON-GAMMA; IMMUNE-RESPONSES; IGG4 ANTIBODIES; PLASMA-CELLS; CD40 LIGAND	Investigations on the mechanisms of IgE regulation in vitro have been conducted thus far in systems that allow the synthesis of total rather than specific IgE. To study the regulatory prerequisites of antigen-specific IgE antibody production, we have established a culture system that allows the generation of bee venom phospholipase A(2)-specific IgE and IgG, antibodies. Allergen-specific IgE was induced by simultaneously activating T cells and B cells specifically with allergen and polyclonally with anti-CD2 and soluble CD40 ligand in the presence of IL-4. Additional stimulation of T cells through the CD2 activation pathway by two different anti-CD2 monoclonal antibodies enhanced both the allergen-specific and the total IgE and IgG(4) responses. An optimal amount of allergen (0.1 ng/ml) resulted in the induction of both allergen-specific IgE and IgG(4) antibodies. Higher antigen doses reduced allergen-specific antibodies and enhanced total isotype production. This differential regulation of allergen-specific and total isotypes reflects different allergen dose-dependent mechanisms in specific and polyclonal activation of T and B cells. Although both isotypes require IL-4 for initial induction, opposite regulatory effects by T cells were observed for IgE and IgG(4) antibody expression. In peripheral blood mononuclear cell cultures stimulated with soluble CD40 ligand, IL-4, and phospholipase A(2), stimulation of T cells with higher amounts of anti-CD2 enhanced IgG(4) in parallel to increased IL-2 and interferon-gamma secretion but inhibited IgE synthesis. These results provide evidence for differential regulation of allergen-specific and total IgE and IgG(4) by antigen concentration and demonstrate the pivotal role of T cells controlling the synthesis of the IgE and IgG(4) antibody isotypes.	CIBA GEIGY LTD, BASEL, SWITZERLAND; UNIV ZURICH HOSP, DEPT DERMATOL, ALLERGY UNIT, CH-8091 ZURICH, SWITZERLAND	Novartis; University of Zurich; University Zurich Hospital	Akdis, CA (corresponding author), SWISS INST ALLERGY & ASTHMA RES, OBERE STR 22, CH-7270 DAVOS, SWITZERLAND.							AALBERSE RC, 1983, J IMMUNOL, V130, P722; ALKAN S, 1994, J IMMUNOASSAY, V15, P217, DOI 10.1080/15321819408009574; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; AVERSA G, 1993, J EXP MED, V177, P1575, DOI 10.1084/jem.177.6.1575; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; CARBALLIDO JM, 1993, J IMMUNOL, V150, P3582; CARBALLIDO JM, 1992, EUR J IMMUNOL, V22, P1357, DOI 10.1002/eji.1830220605; CARBALLIDO JM, 1994, J ALLERGY CLIN IMMUN, V93, P758, DOI 10.1016/0091-6749(94)90256-9; CARBALLIDO JM, 1992, INT ARCH ALLERGY IMM, V99, P366, DOI 10.1159/000236286; CASTEN LA, 1985, P NATL ACAD SCI USA, V82, P5890, DOI 10.1073/pnas.82.17.5890; COSTELLO R, 1993, EUR J IMMUNOL, V23, P608, DOI 10.1002/eji.1830230304; COUTINHO A, 1975, SCAND J IMMUNOL, V4, P89, DOI 10.1111/j.1365-3083.1975.tb02603.x; COUTINHO A, 1974, J EXP MED, V139, P74, DOI 10.1084/jem.139.1.74; DELPRETE G, 1988, J IMMUNOL, V140, P4193; Faassen AE, 1995, EUR J IMMUNOL, V25, P3249, DOI 10.1002/eji.1830251208; GASCAN H, 1992, EUR J IMMUNOL, V22, P1133, DOI 10.1002/eji.1830220505; GASCAN H, 1991, J IMMUNOL, V147, P8; GILLIS S, 1978, J IMMUNOL, V120, P2027; GRAFT DF, 1987, CLIN REV ALLERG, V5, P149; HELD W, 1989, SCAND J IMMUNOL, V29, P203, DOI 10.1111/j.1365-3083.1989.tb01117.x; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; KAGEYSABOTKA A, 1976, J ALLERGY CLIN IMMUN, V57, P29; KNOX KA, 1993, EUR J IMMUNOL, V23, P2578, DOI 10.1002/eji.1830231030; KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x; LANE P, 1992, EUR J IMMUNOL, V22, P2573, DOI 10.1002/eji.1830221016; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; LUCAS AH, 1990, SPRINGER SEMIN IMMUN, V12, P385; MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203; MULLER UR, 1995, J ALLERGY CLIN IMMUN, V96, P395, DOI 10.1016/S0091-6749(95)70059-5; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; QUINT DJ, 1989, IMMUNOLOGY, V67, P68; RANDOLPH CC, 1986, J ALLERGY CLIN IMMUN, V77, P823, DOI 10.1016/0091-6749(86)90379-9; RIEBEN R, 1989, J IMMUNOL METHODS, V119, P1, DOI 10.1016/0022-1759(89)90374-8; ROMAGNANI S, 1987, J IMMUNOL, V138, P1744; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; SCHNEIDER T, 1994, J ALLERGY CLIN IMMUN, V94, P61, DOI 10.1016/0091-6749(94)90072-8; SCHWARZ M, 1995, J IMMUNOL, V154, P5813; SHINOMIYA N, 1993, J ALLERGY CLIN IMMUN, V92, P479, DOI 10.1016/0091-6749(93)90127-2; SPIEGELBERG HL, 1990, SPRINGER SEMIN IMMUN, V12, P365; SPLAWSKI JB, 1993, J IMMUNOL, V150, P1276; SUTHERLAND M, 1993, ALLERGY, V48, P504, DOI 10.1111/j.1398-9995.1993.tb01106.x; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; VANDERPOUWKRAAN T, 1992, EUR J IMMUNOL, V22, P1237, DOI 10.1002/eji.1830220519; VANLIER RAW, 1988, EUR J IMMUNOL, V18, P167; VERCELLI D, 1990, J IMMUNOL, V144, P570; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; VERNINO L, 1992, J IMMUNOL, V148, P404; WERNERFAVRE C, 1994, IMMUNOLOGY, V81, P111; WERNERFAVRE C, 1993, EUR J IMMUNOL, V23, P2038, DOI 10.1002/eji.1830230849; WYSS M, 1993, ALLERGY, V48, P81, DOI 10.1111/j.1398-9995.1993.tb00690.x; YANG SY, 1988, J EXP MED, V168, P1457, DOI 10.1084/jem.168.4.1457; ZHANG K, 1991, J IMMUNOL, V146, P1836	56	57	57	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					345	353		10.1016/S0091-6749(97)70052-6	http://dx.doi.org/10.1016/S0091-6749(97)70052-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058690				2022-12-18	WOS:A1997WM42200011
J	Sur, S; Kita, H; Gleich, GJ; Chenier, TC; Hunt, LW				Sur, S; Kita, H; Gleich, GJ; Chenier, TC; Hunt, LW			Eosinophil recruitment is associated with IL-5, but not with RANTES, twenty-four hours after allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-5; RANTES; asthma; chemokines; cytokines; late phase reaction; eosinophils; EDN	INFLAMMATORY PROTEIN 1-ALPHA; ANTIGEN CHALLENGE; CYTOKINE RANTES; FUNCTIONAL EXPRESSION; ACTIVATED EOSINOPHILS; ENDOTHELIAL-CELLS; MESSENGER-RNA; INTERLEUKIN-5; ASTHMA; MIP-1-BETA	Several lines of evidence suggest that the chemokine RANTES may play a role in eosinophilia observed during allergic inflammation. To rest this hypothesis six patients with allergic asthma were studied. After performing bronchoalveolar lavage in a lung segment (baseline), segmental bronchoprovocation was performed with saline solution in another segment and with ragweed in a third segment. Bronchoalveolar lavage was performed 24 hours Inter in the saline-challenged (sham) and ragweed-challenged lung segments. The bronchoalveolar lavage fluids from the baseline, sham, and ragweed segments were analyzed for cell counts and for the levels of IL-5, RANTES, and eosinophil-derived neurotoxin. IL-5 levels were elevated in the ragweed (984 +/- 588 pg/ml) compared with sham segments (2.8 +/- 0.2 pg/ml, p = 0.02). Likewise, RANTES levels were elevated in the ragweed (12.93 +/- 3.4 pg/ml) compared with the sham segments (3.05 +/- 1.19 pg/ml, p = 0.006). The IL-5 levels correlated with both eosinophil numbers (r = 0.90, p < 0.02) and eosinophil-derived neurotoxin levels (r = 0.89, p < 0.02). In contrast, RANTES levels did not correlate with either eosinophil numbers or eosinophil-derived neurotoxin levels. These results indicate that although both IL-5 and RANTES are elevated 24 hours after allergen challenge only IL-5 correlates with eosinophil recruitment and degranulation.	MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,ROCHESTER,MN 55905; E CAROLINA UNIV,SCH MED,DEPT BIOSTAT,GREENVILLE,NC 27858	Mayo Clinic; Mayo Clinic; University of North Carolina; East Carolina University	Sur, S (corresponding author), E CAROLINA UNIV,SCH MED,DEPT MED,SECT ALLERGY & IMMUNOL,GREENVILLE,NC 27858, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015231, U01AI034577, U19AI034577, R37AI015231] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15231, AI 07047, AI 34577] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AALBERS R, 1993, CHEST, V103, P1178, DOI 10.1378/chest.103.4.1178; ALAM R, 1993, J IMMUNOL, V150, P3442; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; DESREUMAUX P, 1993, BLOOD, V82, P1553; DEVERGNE O, 1994, J EXP MED, V179, P1689, DOI 10.1084/jem.179.5.1689; DONLON TA, 1990, GENOMICS, V6, P548, DOI 10.1016/0888-7543(90)90485-D; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GILAT D, 1994, J IMMUNOL, V153, P4899; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; HOLGATE ST, 1991, AM REV RESPIR DIS, V143, pS66, DOI 10.1164/ajrccm/143.3_Pt_2.S66; HUNT LW, 1994, AM J RESP CRIT CARE, V149, P1471, DOI 10.1164/ajrccm.149.6.8004300; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KUNA P, 1992, J IMMUNOL, V149, P636; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; MEURER R, 1993, J EXP MED, V178, P1913, DOI 10.1084/jem.178.6.1913; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OHNISHI T, 1993, J ALLERGY CLIN IMMUN, V92, P607, DOI 10.1016/0091-6749(93)90085-T; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SCHWEIZER RC, 1994, BLOOD, V83, P3697; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; SIM TC, 1994, AM J RESP CRIT CARE, V149, P339, DOI 10.1164/ajrccm.149.2.8306027; SUR S, 1995, J ALLERGY CLIN IMMUN, V96, P661, DOI 10.1016/S0091-6749(95)70265-2; SUR S, 1993, ALLERGY PRINCIPLES P, V169, P200; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; TANAKA Y, 1994, J INVEST DERMATOL, V103, P589, DOI 10.1111/1523-1747.ep12396899; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; WENZEL SE, 1991, J ALLERGY CLIN IMMUN, V87, P540, DOI 10.1016/0091-6749(91)90013-E; ZHANG L, 1994, CLIN EXP ALLERGY, V24, P899, DOI 10.1111/j.1365-2222.1994.tb02720.x	39	57	57	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1272	1278		10.1016/S0091-6749(96)70195-1	http://dx.doi.org/10.1016/S0091-6749(96)70195-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648023				2022-12-18	WOS:A1996VD60700015
J	Llopis, MJP; Harms, G; Hardonk, MJ; Timens, W				Llopis, MJP; Harms, G; Hardonk, MJ; Timens, W			Human immune response to pneumococcal polysaccharides: Complement-mediated localization preferentially on CD21-positive splenic marginal zone B cells and follicular dendritic cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD21; CR2; follicular dendritic cells; marginal zone; pneumococcal polysaccharides; spleen; TI-2 response	HUMAN LYMPHOCYTES-B; RECEPTOR TYPE-2; CAPSULAR POLYSACCHARIDE; HUMAN SPLEEN; EXPRESSION; ACTIVATION; ANTIGENS; ANTIBODY; SYSTEM; CD21	A functionally intact spleen with a marginal zone, containing B cells with high density of surface C3d-receptors (CD21), is essential for the ability to induce a primary immune response to thymus-independent type 2 (TI-2) antigens. Main representatives of natural TI-2 antigens are capsular pneumococcal polysaccharides (PPSs). In this study the localization of different types of PPS antigen is determined in human spleen tissue. Our findings indicate that a main type of TI-2 antigen, PPS, localizes preferentially in the marginal zone. PPSs show co-localization with C3, presumably C3d, at the surface of strongly CD21+ B cells equipped for rapid activation. This enables a rapid primary humoral response. The other main PPS localization at follicular dendritic cells in germinal centers, relevant for isotype switching of anti-PPS antibodies, does not seem to be dependent on the presence of specific immunoglobulin. This may explain the finding of specific IgG in an early stage after antigenic challenge. It seems likely that complement C3 fragments (likely C3d), bound to PPSs, enable PPS localization at B-cell and follicular dendritic cell surfaces by binding to CD21, the C3d receptor.	UNIV GRONINGEN, DEPT PATHOL, 9713 EZ GRONINGEN, NETHERLANDS	University of Groningen			Timens, Wim/K-5570-2013	Timens, Wim/0000-0002-4146-6363				AHEARN JM, 1989, ADV IMMUNOL, V46, P183, DOI 10.1016/S0065-2776(08)60654-9; BOYD AW, 1985, J IMMUNOL, V134, P1516; BROWN AR, 1992, CRIT REV IMMUNOL, V11, P395; CARTER RH, 1988, J IMMUNOL, V141, P457; COOPER NR, 1988, ANNU REV IMMUNOL, V6, P85; GRIFFIOEN AW, 1993, CLIN IMMUNOL IMMUNOP, V69, P1, DOI 10.1006/clin.1993.1142; GRIFFIOEN AW, 1991, INFECT IMMUN, V59, P1839, DOI 10.1128/IAI.59.5.1839-1845.1991; GRIFFIOEN AW, 1992, J INFECT DIS, V165, pS71, DOI 10.1093/infdis/165-Supplement_1-S71; HAZLEWOOD MA, 1992, CLIN EXP IMMUNOL, V87, P404; KNAPP W, 1989, LEUCOCYTE TYPING, V4; KRAAL G, 1982, NATURE, V298, P377, DOI 10.1038/298377a0; Kroese F G, 1990, Curr Top Pathol, V84 ( Pt 1), P103; LAMAN JD, 1992, IMMUNE SYSTEM ACCESS, P201; LEE CJ, 1991, CRIT REV MICROBIOL, V18, P89, DOI 10.3109/10408419109113510; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; MACLENNAN ICM, 1991, RES IMMUNOL, V142, P346, DOI 10.1016/0923-2494(91)90089-2; MARQUART HV, 1994, J IMMUNOL, V153, P307; SCHAFFNER A, 1991, J INFECT DIS, V163, P1094, DOI 10.1093/infdis/163.5.1094; TIMENS W, 1989, EUR J IMMUNOL, V19, P2163, DOI 10.1002/eji.1830191129; TIMENS W, 1992, ANN SURG, V215, P256, DOI 10.1097/00000658-199203000-00010; TIMENS W, 1991, RES IMMUNOL, V142, P316, DOI 10.1016/0923-2494(91)90081-S; TIMENS W, 1985, AM J PATHOL, V120, P443; TIMENS W, 1989, J IMMUNOL, V143, P3200; TIMENS W, 1994, LEUCOCYTE TYPING, V5, P519; TIMENS W, 1994, LEUCOCYTE TYPING, V5, P516; VANDENEERTWEGH AJM, 1992, EUR J IMMUNOL, V22, P719, DOI 10.1002/eji.1830220315	26	57	58	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1996	97	4					1015	1024		10.1016/S0091-6749(96)80078-9	http://dx.doi.org/10.1016/S0091-6749(96)80078-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UG086	8655878				2022-12-18	WOS:A1996UG08600018
J	MALO, JL; TRUDEAU, C; GHEZZO, H; LARCHEVEQUE, J; CARTIER, A				MALO, JL; TRUDEAU, C; GHEZZO, H; LARCHEVEQUE, J; CARTIER, A			DO SUBJECTS INVESTIGATED FOR OCCUPATIONAL ASTHMA THROUGH SERIAL PEAK EXPIRATORY FLOW MEASUREMENTS FALSIFY THEIR RESULTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COMPLIANCE; PATIENT COMPLIANCE; OCCUPATIONAL DISEASES; RESPIRATORY FUNCTION TESTS	RATE RECORDS; DIAGNOSIS	Background and aim: Serial assessment of peak expiratory flow (PEF) rates has been advocated as a sensitive and specific means of investigating occupational asthma. The possibility that, for several reasons, subjects do not accurately report their values has been raised. The availability of portable instruments that assess PEF and store timings and values now makes it possible to estimate compliance and accuracy of results. Methods: Twenty-one subjects consecutively investigated for occupational asthma were asked to assess their PEF every 2 hours during the day, both at work and away from work, with a VMX instrument (Clement Clarke International, Columbus, Ohio) and record the times and values on a sheet of paper. The subjects were not aware that the data were also being stored on a computer chip. The diagnosis was occupational asthma in eight subjects, personal asthma in four subjects, and neither condition in nine subjects. Results: The mean duration of recording was 36 days (range, 14 to 79 days). At least 6048 values should have been recorded, but only 4839 (80%) were either recorded or stored. Reported values corresponded precisely to stored values in 2533 of 4839 recordings (52%). The tuning of the recording was also examined in relation to the time at which the recording was solicited; values recorded within 1 hour of the solicited time were judged as acceptable. Of the total of 3342 recordings stored, 2375 (71%) satisfied this criterion. Compliance was significantly less satisfactory in those referred by the Workers' Compensation Board (n=11). Conclusion: In this survey of 21 subjects investigated for possible occupational asthma, compliance with PEF recording, as assessed by comparing recorded and stored results and the time at which the recording was solicited, was poor.	FONDS RECH SANTE QUEBEC,MONTREAL,PQ,CANADA; UNIV MONTREAL,SCH MED,MONTREAL,PQ H3C 3J7,CANADA	Universite de Montreal	MALO, JL (corresponding author), HOP SACRE COEUR,DEPT CHEST MED,5400 W GOUIN,MONTREAL,PQ H4J 1C5,CANADA.							[Anonymous], 1987, Am Rev Respir Dis, V136, P1285; Bernstein David I., 1993, P103; BERUBE D, 1991, CHEST, V99, P831, DOI 10.1378/chest.99.4.831; Bishop Y., 1975, DISCRETE MULTIVARIAT, P393; Burge P. Sherwood, 1993, P171; BURGE PS, 1979, THORAX, V34, P308, DOI 10.1136/thx.34.3.308; BURGE PS, 1979, THORAX, V34, P317, DOI 10.1136/thx.34.3.317; Cartier Andre, 1993, P215; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COTE J, 1993, THORAX, V48, P48, DOI 10.1136/thx.48.1.48; COTE J, 1990, J ALLERGY CLIN IMMUN, V85, P592, DOI 10.1016/0091-6749(90)90098-O; EPSTEIN SW, 1969, BMJ-BRIT MED J, V1, P223, DOI 10.1136/bmj.1.5638.223; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; Malo Jean-Luc, 1993, P341; MALO JL, 1993, THORAX, V48, P1211, DOI 10.1136/thx.48.12.1211; MALO JL, 1993, REV MAL RESPIR, V10, P313; MALO JL, 1993, RESP MED, V87, P569, DOI 10.1016/S0954-6111(05)80258-6; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MALO JL, 1991, REV MAL RESPIR, V8, pR121; PERRIN B, 1992, EUR RESPIR J, V5, P40; TURNERWARWICK M, 1977, BRIT J DIS CHEST, V71, P73, DOI 10.1016/0007-0971(77)90086-9; VENABLES KM, 1984, THORAX, V39, P828, DOI 10.1136/thx.39.11.828; WOOLCOCK A, 1989, MED J AUSTRALIA, V151, P650, DOI 10.5694/j.1326-5377.1989.tb139640.x	23	57	57	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1995	96	5	1				601	607		10.1016/S0091-6749(95)70258-X	http://dx.doi.org/10.1016/S0091-6749(95)70258-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TG528	7499676	Bronze			2022-12-18	WOS:A1995TG52800005
J	TSUKAGOSHI, H; SAKAMOTO, T; XU, WB; BARNES, PJ; CHUNG, KF				TSUKAGOSHI, H; SAKAMOTO, T; XU, WB; BARNES, PJ; CHUNG, KF			EFFECT OF INTERLEUKIN-1-BETA ON AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN SENSITIZED AND NONSENSITIZED BROWN-NORWAY RATS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ACTIVE SENSITIZATION; OVALBUMIN; BROWN-NORWAY RATS; INTERLEUKIN-1-BETA; AIRWAY RESPONSIVENESS; ACETYLCHOLINE; BRADYKININ; BRONCHOALVEOLAR LAVAGE FLUID	ALVEOLAR MACROPHAGES; INTERFERON-GAMMA; GUINEA-PIG; ASTHMA; IL-1; REACTIVITY; CYTOKINES; ALPHA	Airway responsiveness (AR) to inhaled acetylcholine and bradykinin and inflammatory cell recruitment in bronchoalveolar lavage fluid (BALF) were studied in inbred male Brown-Norway. rats actively sensitized to ovalbumin and later given 500 U interleukin-1 beta (IL-1 beta) intratracheally. We examined animals 14 to 21 days after initial sensitization at 18 to 24 hours after the intratracheal administration of IL-1 beta. We evaluated AR to acetylcholine as -log PC200, which is -log(10) transformation of provocative concentration of acetylcholine producing 200% increase in lung resistance, and to bradykinin as percent increase in lung resistance. BALF was examined as an index of inflammatory changes within the lung. Although there was no significant difference in baseline lung resistance, nonsensitized and sensitized animals chat were given IL-1 beta demonstrated a significant increase of AR to bradykinin at 18 to 24 hours and a significant increase of neutrophil counts in BALF, which was already observed by, 4 to 6 hours. There was a significant correlation between AR to bradykinin and neutrophil counts in BALF in all animals (r = 0.644; p < 0.0005). We conclude that intratracheal administration of IL-1 beta induces the inflammatory changes, which are characterized by an increase in neutrophil counts in BALF and increased AR to bradykinin, and that active sensitization per se does not potentiate the effect of IL-1 beta on AR to acetylcholine or bradykinin or on airway inflammation.	ROYAL BROMPTON HOSP,NATL HEART & LUNG INST,DEPT THORAC MED,LONDON SW3 6LY,ENGLAND	Imperial College London; Royal Brompton Hospital			Chung, Kian Fan/I-8456-2019; Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Barnes, Peter/0000-0002-5122-4018				ALAM R, 1989, J IMMUNOL, V142, P3431; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; BRUNELLESCHI S, 1992, BRIT J PHARMACOL, V107, P964, DOI 10.1111/j.1476-5381.1992.tb13392.x; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DERIJK R, 1992, AM J PHYSIOL, V263, pE1092; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DUSTIN ML, 1986, J IMMUNOL, V137, P245; FIGARI IS, 1987, BLOOD, V70, P979; HEIDEL JR, 1990, J IMMUNOL, V144, P1037; LOTVALL JO, 1990, EUR J PHARMACOL, V200, P211; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V87, P794, DOI 10.1016/0091-6749(91)90125-8; MURLAS CG, 1990, AM J PHYSIOL, V258, pL361, DOI 10.1152/ajplung.1990.258.6.L361; NISHIDA T, 1988, MONOKINES OTHER NONL, P73; PRETOLANI M, 1988, AM REV RESPIR DIS, V138, P1572, DOI 10.1164/ajrccm/138.6.1572; PUJOL JL, 1990, INT ARCH ALLER A IMM, V91, P207, DOI 10.1159/000235117; SAKAMOTO T, 1993, EUR J PHARMACOL, V231, P31, DOI 10.1016/0014-2999(93)90680-G; SELIG W, 1992, EUR J PHARMACOL, V213, P331, DOI 10.1016/0014-2999(92)90621-A; TOSI MF, 1992, AM J RESP CELL MOL, V7, P214, DOI 10.1165/ajrcmb/7.2.214; ULICH TR, 1991, AM J PATHOL, V138, P1485; VONNEERGAARD K, 1927, Z KLIN MED, V105, P51	22	57	57	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1994	93	2					464	469		10.1016/0091-6749(94)90355-7	http://dx.doi.org/10.1016/0091-6749(94)90355-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MY581	8120273				2022-12-18	WOS:A1994MY58100007
J	WASERMAN, S; OLIVENSTEIN, R; RENZI, P; XU, LJ; MARTIN, JG				WASERMAN, S; OLIVENSTEIN, R; RENZI, P; XU, LJ; MARTIN, JG			THE RELATIONSHIP BETWEEN LATE ASTHMATIC RESPONSES AND ANTIGEN-SPECIFIC IMMUNOGLOBULIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BN RATS; LYMPHOCYTE SUBSETS; ALLERGIC BRONCHOCONSTRICTION	BRONCHIAL REACTIVITY; IGE ANTIBODY; MAST-CELL; ALLERGEN; RATS; CHALLENGE; LUNG; BRONCHOCONSTRICTION; RESPONSIVENESS; PROVOCATION	The aim of this study was to examine the relationships between allergen-induced early and late airway responses and antigen-specific IgE, IgG, and lymphocyte subsets in blood and bronchoalveolar lavage (BAL). Brown Norway rats were sensitized at 7 weeks of age with ovalbumin (I mg s.c.) with use of Bordetella pertussis as an adjuvant. Three weeks after sensitization, animals were anesthetized and challenged with an aerosol of ovalbumin (5% wt/vol in saline) for 5 minutes. Each animal was studied for 8 hours with repeated measurements of lung resistance. Blood was obtained at 0, 1, 2, and 3 weeks before ovalbumin challenge. Ovalbumin-specific IgE and IgG were determined by ELISA. No specific antibody was detectable before sensitization. Ovalbumin-specific IgE and IgG rose between 1 to 2 weeks after sensitization and peaked at 3 weeks. The IgE level did not correlate with the magnitude of either the early or the late responses. In a similar manner no correlation existed between the magnitude of specific IgG and the late response. However, a significant inverse correlation (r = - 0.73; p < 0.01) occurred between specific IgG and the early response. No correlation occurred between the ratio of helper (W3/25+) to suppressor (OX-8+) lymphocytes in blood and BAL and airway responses to allergen. The size of the early and late responses were correlated, suggesting a common stimulus. Despite the blunting of the early response by repeated sensitization the late response was unaffected, suggesting that the factors that determine the physiologic expression of the early and late responses are different.	MCGILL UNIV, MEAKINS CHRISTIE LABS, 3626 ST URBAIN ST, MONTREAL H2X 2P2, QUEBEC, CANADA; RESP HLTH NETWORK CTR EXCELLENCE, MONTREAL, QUEBEC, CANADA	McGill University				Martin, James/0000-0001-7574-5363				AHLSTEDT S, 1983, INT ARCH ALLER A IMM, V72, P71, DOI 10.1159/000234843; BOULET LP, 1984, CLIN ALLERGY, V14, P379, DOI 10.1111/j.1365-2222.1984.tb02219.x; CHURCH MK, 1975, IMMUNOLOGY, V29, P527; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; DAHLBACK M, 1982, ALLERGY, V37, P569, DOI 10.1111/j.1398-9995.1982.tb02342.x; DIMARIA GU, 1987, J APPL PHYSIOL, V62, P1317, DOI 10.1152/jappl.1987.62.3.1317; EIDELMAN DH, 1988, AM REV RESPIR DIS, V137, P1033, DOI 10.1164/ajrccm/137.5.1033; GAUCHAT JF, 1991, EUR RESPIR J, V4, pS30; GERBLICH AA, 1984, NEW ENGL J MED, V310, P1349, DOI 10.1056/NEJM198405243102103; HARGREAVE FE, 1974, CAN MED ASSOC J, V110, P415; HIRAI K, 1988, J IMMUNOL, V141, P3958; HIRANO T, 1989, J IMMUNOL METHODS, V119, P145, DOI 10.1016/0022-1759(89)90391-8; HOLT PG, 1987, IMMUNOLOGY, V60, P97; HUTSON PA, 1988, AM REV RESPIR DIS, V137, P548, DOI 10.1164/ajrccm/137.3.548; KALINER M, 1989, J ALLERGY CLIN IMMUN, V83, P510, DOI 10.1016/0091-6749(89)90031-6; MOIRA CY, 1986, AM REV RESPIR DIS, V133, P686; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; PAUWELS R, 1979, IMMUNOLOGY, V36, P151; Pepys J, 1973, Clin Allergy, V3, P1, DOI 10.1111/j.1365-2222.1973.tb01304.x; PRICE JF, 1982, CLIN EXP IMMUNOL, V47, P587; RENZI PM, 1991, AM REV RESPIR DIS, V143, P380, DOI 10.1164/ajrccm/143.2.380; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SEDGWICK JD, 1983, IMMUNOLOGY, V50, P625; SHAMPAIN MP, 1982, AM REV RESPIR DIS, V126, P493; SORKNESS R, 1990, J APPL PHYSIOL, V69, P1012, DOI 10.1152/jappl.1990.69.3.1012; SORKNESS R, 1988, AM REV RESPIR DIS, V138, P1152, DOI 10.1164/ajrccm/138.5.1152; VANTOORENENBERGEN AW, 1983, INT ARCH ALLER A IMM, V71, P32, DOI 10.1159/000233358	29	57	57	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	1				661	669		10.1016/0091-6749(92)90140-W	http://dx.doi.org/10.1016/0091-6749(92)90140-W			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT995	1383308				2022-12-18	WOS:A1992JT99500013
J	DHILLON, M; ROBERTS, C; NUNN, T; KUO, M				DHILLON, M; ROBERTS, C; NUNN, T; KUO, M			MAPPING HUMAN T-CELL EPITOPES ON PHOSPHOLIPASE-A2 - THE MAJOR BEE-VENOM ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LYMPHOCYTE-T; CYTOKINE; T-CELL EPITOPES; ALLERGEN; PHOSPHOLIPASE-A2	HOMOCYTOTROPIC ANTIBODY FORMATION; STIMULATORY FACTOR-I; HUMAN IGE SYNTHESIS; HOUSE DUST MITE; INTERFERON-GAMMA; LYMPHOCYTES-T; B-CELLS; MONOCLONAL-ANTIBODY; BINDING PROTEIN; ACCESSORY CELLS	Phospholipase A2 (PLA2), the major bee-venom allergen, was purified by gel filtration, inactivated by denaturing, and carboxymethylating its cysteine residues. Peripheral blood mononuclear cells from an individual (HLA-DR2 [15], Dw52, DQ1 and DQ3) allergic to bee stings were used to generate cell lines specific for PLA2 and a control antigen, tetanus toxoid. These lines were 90% CD3+, 64% CD4+ and 20% CD8+ by fluorocytometry analysis. T-lymphocyte epitope mapping done with 12 overlapping synthetic peptides of PLA2 revealed two immunodominant epitopes. These epitopes correspond to amino acid sequences 50 to 69 and 83 to 97 of PLA2. Cytokine interleukin-4 and Interferon-gamma secretion was studied from PLA2- and tetanus toxoid-specific cell lines. Interleukin-4 secretion was common to both cell lines but only tetanus-toxoid cell lines secreted interferon-gamma. No interferon-gamma was found to be secreted by PLA2-specific cell line in response to stimulation by PLA2 or the two immunodominant peptides.	IMMUNOL PHARMACEUT CORP, CAMBRIDGE, MA USA; QUEENS UNIV, DEPT MED, DIV ALLERGY & IMMUNOL, KINGSTON K7L 3N6, ONTARIO, CANADA	Queens University - Canada								ARRUDA LK, 1990, J EXP MED, V172, P1529, DOI 10.1084/jem.172.5.1529; BERZOFSKY JA, 1987, IMMUNOL REV, V98, P9, DOI 10.1111/j.1600-065X.1987.tb00518.x; BOOTHBY M, 1988, SCIENCE, V242, P1559, DOI 10.1126/science.3144043; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CARINI C, 1990, J IMMUNOL METHODS, V127, P221, DOI 10.1016/0022-1759(90)90072-4; CHANG TL, 1990, J IMMUNOL, V145, P2803; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; COFFMAN RL, 1986, J IMMUNOL, V136, P949; DEMAGISTRIS MT, 1989, J EXP MED, V169, P1519, DOI 10.1084/jem.169.5.1519; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; GOODFRIEND L, 1985, MOL IMMUNOL, V22, P899, DOI 10.1016/0161-5890(85)90076-8; HAYGLASS KT, 1991, J EXP MED, V173, P279, DOI 10.1084/jem.173.2.279; ISHIZAKA K, 1989, ADV IMMUNOL, V47, P1; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JABARA HH, 1988, FASEB J, V2, pA1441; KEMENY DM, 1983, J ALLERGY CLIN IMMUN, V71, P505, DOI 10.1016/0091-6749(83)90469-4; KULCHER K, 1989, EUR J BIOCHEM, V184, P249; LEBMAN DA, 1988, J EXP MED, V168, P853, DOI 10.1084/jem.168.3.853; LORUSSO JR, 1986, J ALLERGY CLIN IMMUN, V78, P928, DOI 10.1016/0091-6749(86)90242-3; MAGILAVY DB, 1989, J EXP MED, V170, P985, DOI 10.1084/jem.170.3.985; MURAGUCHI A, 1988, J EXP MED, V167, P332, DOI 10.1084/jem.167.2.332; OHEHIR RE, 1991, J ALLERGY CLIN IMMUN, V87, P1120, DOI 10.1016/0091-6749(91)92158-W; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67, DOI 10.1146/annurev.iy.09.040191.000435; OHEHIR RE, 1988, IMMUNOLOGY, V64, P627; OKUMURA K, 1971, J IMMUNOL, V106, P1019; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; REISMAN RE, 1988, ALLERGY PRINCIPLES P, P1345; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; ROSEN A, 1983, J IMMUNOL, V130, P2899; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; TADA T, 1971, J IMMUNOL, V106, P1012; TANIGUCH.M, 1971, J IMMUNOL, V107, P579; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WEBER A, 1987, ALLERGY, V42, P464, DOI 10.1111/j.1398-9995.1987.tb00364.x; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WONG G, 1990, IMMUNOL TODAY, V9, P137	42	57	61	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1992	90	1					42	51		10.1016/S0091-6749(06)80009-6	http://dx.doi.org/10.1016/S0091-6749(06)80009-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JE255	1378459				2022-12-18	WOS:A1992JE25500005
J	LUNDGREN, JD; DAVEY, RT; LUNDGREN, B; MULLOL, J; MAROM, Z; LOGUN, C; BARANIUK, J; KALINER, MA; SHELHAMER, JH				LUNDGREN, JD; DAVEY, RT; LUNDGREN, B; MULLOL, J; MAROM, Z; LOGUN, C; BARANIUK, J; KALINER, MA; SHELHAMER, JH			EOSINOPHIL CATIONIC PROTEIN STIMULATES AND MAJOR BASIC-PROTEIN INHIBITS AIRWAY MUCUS SECRETION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ARACHIDONIC-ACID; ASTHMA; INVITRO; GRANULE; RELEASE; PURIFICATION; EPITHELIUM; NEUROTOXIN; DAMAGE; CELLS	Possible roles of eosinophil (EO) products in modulating the release of mucus from airway explants were investigated. Cell- and membrane-free lysates from purified human EOs (1 to 20 x 10(5)) caused a dose-dependent release of respiratory glycoconjugates (RGC) from cultured feline tracheal explants. Crude extracts from isolated EO granules also stimulated RGC release, suggesting that a granular protein might be responsible. Three proteins derived from EO granules, EO-derived neurotoxin, EO cationic protein (ECP), and major basic protein (MBP) were separated by sequential sizing and affinity chromatography. ECP (0.025 to 25-mu-g/ml) caused a dose-dependent increase in RGC release from both feline and human airway explants and also stimulated the release of the serous cell-marker, lactoferrin, from human bronchial explants. EO-derived neurotoxin (0.025 to 50-mu-g/ml) failed to affect RGC release, whereas MBP (50-mu-g/ml) significantly inhibited RGC release from feline explants. Thus, ECP stimulates RGC and lactoferrin release from airway explants, whereas MBP inhibits RGC release.	NIAID, CTR CLIN, DEPT CRIT CARE MED, BETHESDA, MD 20892 USA; NIAID, DIV PARASITOL, BETHESDA, MD 20892 USA; NIAID, ALLERG DIS SECT, BETHESDA, MD 20892 USA; MT SINAI MED CTR, NEW YORK, NY 10029 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Icahn School of Medicine at Mount Sinai			Lundgren, Jens/AAE-6876-2019	Baraniuk, James Nicholas/0000-0002-1866-4177; Lundgren, Jens/0000-0001-8901-7850				ACKERMAN SJ, 1983, J IMMUNOL, V131, P2977; ACKERMAN SJ, 1983, IMMUNOBIOLOGY EOSINO, P181; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BARNES PJ, 1986, LANCET, V1, P242; CARLSON MGC, 1985, J IMMUNOL, V134, P1875; COLES SJ, 1984, J APPL PHYSIOL, V57, P1323, DOI 10.1152/jappl.1984.57.5.1323; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DOR PJ, 1984, AM REV RESPIR DIS, V130, P1072; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; HENDERSON WR, 1984, IMMUNOLOGY, V51, P679; HUTSON PA, 1988, AM REV RESPIR DIS, V137, P548, DOI 10.1164/ajrccm/137.3.548; Kaliner M, 1988, IMMUNOLOGIC DISEASES, P1067; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LEE TC, 1984, J BIOL CHEM, V259, P5526; LOGUN C, 1988, AM REV RESPIR DIS, V137, pA14; LUND J, 1989, ENDOCR RES, V15, P17, DOI 10.3109/01902148909069606; LUNDGREN JD, 1990, J ALLERGY CLIN IMMUN, V85, P399, DOI 10.1016/0091-6749(90)90147-V; LUNDGREN JD, 1990, AGENTS ACTIONS, V30, P329, DOI 10.1007/BF01966296; LUNDGREN JD, 1988, AM REV RESPIR DIS, V137, P353, DOI 10.1164/ajrccm/137.2.353; LUNDGREN JD, 1990, AM J PHYSIOL, V258, pL68, DOI 10.1152/ajplung.1990.258.2.L68; MAROM Z, 1984, J EXP MED, V159, P844, DOI 10.1084/jem.159.3.844; MAROM Z, 1981, J CLIN INVEST, V67, P1695, DOI 10.1172/JCI110207; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; SHELHAMER JH, 1980, J CLIN INVEST, V66, P1400, DOI 10.1172/JCI109993; VADAS MA, 1979, J IMMUNOL, V122, P1228; VENGE P, 1980, EOSINOPHIL HLTH DISE, P131; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WASMOEN TL, 1988, J BIOL CHEM, V263, P12559; ZHEUTLIN LM, 1984, J IMMUNOL, V133, P2180	32	57	57	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1991	87	3					689	698		10.1016/0091-6749(91)90390-A	http://dx.doi.org/10.1016/0091-6749(91)90390-A			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FB801	2005321				2022-12-18	WOS:A1991FB80100014
J	VANHOUTTE, PM				VANHOUTTE, PM			EPITHELIUM-DERIVED RELAXING FACTOR(S) AND BRONCHIAL REACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											VANHOUTTE, PM (corresponding author), MAYO CLIN & MAYO FDN,DEPT PHYSIOL & BIOPHYS,ROCHESTER,MN 55905, USA.		Vanhoutte, Paul M/B-4533-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL021584] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 21584] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARHUS LL, 1984, FED PROC, V43, P955; ADVENIER C, 1988, BRIT J PHARMACOL, V93, P295, DOI 10.1111/j.1476-5381.1988.tb11434.x; ARGARWAL DK, 1987, BIOCHEM BIOPH RES CO, V148, P178; BARNES PJ, 1985, BRIT J PHARMACOL, V86, P684; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BOUSHEY HA, 1985, BRONCHIAL ASTHMA MEC; BRUNELLESCHI S, 1987, J PHARMACOL EXP THER, V243, P356; BUSK MF, 1988, CLIN RES, V36, pA590; CARSTAIRS JR, 1984, EUR J PHARMACOL, V103, P189, DOI 10.1016/0014-2999(84)90211-5; CARSTAIRS JR, 1985, AM REV RESPIR DIS, V132, P541; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FARMER SG, 1987, TRENDS PHARMACOL SCI, V8, P8, DOI 10.1016/0165-6147(87)90021-6; FARMER SG, 1987, BRIT J PHARMACOL, V92, P231, DOI 10.1111/j.1476-5381.1987.tb11316.x; FLAVAHAN NA, 1984, FED PROC, V43, P429; FLAVAHAN NA, 1985, J APPL PHYSIOL, V58, P834, DOI 10.1152/jappl.1985.58.3.834; FLAVAHAN NA, 1985, CHEST, V87, pS189, DOI 10.1378/chest.87.5_Supplement.189S; FLAVAHAN NA, 1986, JUL P INT UN PHYS SC; FURCHGOTT RF, 1984, ANNU REV PHARMACOL, V24, P175, DOI 10.1146/annurev.pa.24.040184.001135; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GAO Y, 1987, PHYSIOLOGIST, V30, P240; GLEICH GJ, 1984, ANNU REV IMMUNOL, V2, P429, DOI 10.1146/annurev.immunol.2.1.429; GOLDIE RG, 1986, BRIT J PHARMACOL, V87, P5, DOI 10.1111/j.1476-5381.1986.tb10150.x; HAY DWP, 1985, FED PROC, V44, P506; HAY DWP, 1986, EUR J PHARMACOL, V129, P11, DOI 10.1016/0014-2999(86)90330-4; HAY DWP, 1986, LIFE SCI, V38, P2461, DOI 10.1016/0024-3205(86)90617-X; HOGG JC, 1984, AM REV RESPIR DIS, V129, P207; HOLROYDE MC, 1986, BRIT J PHARMACOL, V87, P501, DOI 10.1111/j.1476-5381.1986.tb10192.x; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; ILHAN M, 1986, EUR J PHARMACOL, V131, P293, DOI 10.1016/0014-2999(86)90586-8; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LAITINEN LA, 1976, AM REV RESPIR DIS, V113, P94; NADEL JA, 1983, ADV INTERNAL MED, V28, P207; NIJKAMP FP, 1987, EUR J PHARMACOL, V131, P315; RAEBURN D, 1986, EUR J PHARMACOL, V123, P451, DOI 10.1016/0014-2999(86)90722-3; RAEBURN D, 1986, LIFE SCI, V38, P809, DOI 10.1016/0024-3205(86)90597-7; RUBANYI GM, 1985, J PHYSIOL-LONDON, V364, P45, DOI 10.1113/jphysiol.1985.sp015728; RUFF F, IN PRESS J PHARM EXP; SHIKANO K, 1987, J PHARMACOL EXP THER, V243, P55; STUARTSMITH K, 1987, J APPL PHYSIOL, V63, P2510, DOI 10.1152/jappl.1987.63.6.2510; STUARTSMITH K, 1988, J APPL PHYSIOL, V65, P721, DOI 10.1152/jappl.1988.65.2.721; STUARTSMITH K, 1987, PHARMACOLOGIST, V29, P365; TSCHIRHART E, 1987, J PHARMACOL EXP THER, V243, P310; VANHOUTTE P M, 1987, News in Physiological Sciences, V2, P18; VANHOUTTE PM, 1988, AM REV RESPIR DIS, V138, pS24, DOI 10.1164/ajrccm/138.6_Pt_2.S24; VANHOUTTE PM, 1987, BLOOD VESSELS, V24, P141; VANHOUTTE PM, 1987, CAN J PHYSIOL PHARM, V65, P448, DOI 10.1139/y87-076; VANHOUTTE PM, 1986, ANNU REV PHYSIOL, V48, P307; VANHOUTTE PM, 1987, AIRWAYS NEURAL CONTR, P203; VANHOUTTE PM, 1986, JUL P INT UN PHYS SC; XUE QF, 1983, ARCH INT PHARMACOD T, V266, P308	51	57	57	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1989	83	5					855	861		10.1016/0091-6749(89)90095-X	http://dx.doi.org/10.1016/0091-6749(89)90095-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U7161	2654253				2022-12-18	WOS:A1989U716100001
J	TOOGOOD, JH				TOOGOOD, JH			HIGH-DOSE INHALED STEROID-THERAPY FOR ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WESTERN ONTARIO,LONDON N6A 3K7,ONTARIO,CANADA	Western University (University of Western Ontario)	TOOGOOD, JH (corresponding author), VICTORIA HOSP,ALLERGY CLIN,375 S ST,LONDON N6A 4G5,ONTARIO,CANADA.							JOHANSSON SA, 1982, EUR J RESPIR DIS, V63, P74; NADEAU J, 1986, J ALLERGY CLIN IMMUN, V77, P150; TOOGOOD JH, 1983, CHEST, V84, P349; TOOGOOD JH, 1987, J ALLERGY CLIN IMMUN, V79, P144; TOOGOOD JH, 1982, J ALLERGY CLIN IMMUN, V70, P288, DOI 10.1016/0091-6749(82)90065-3; TOOGOOD JH, 1984, AM REV RESPIR DIS, V129, P723, DOI 10.1164/arrd.1984.129.5.723; TOOGOOD JH, 1988, AM REV RESPIR DIS, V138, P57, DOI 10.1164/ajrccm/138.1.57; TOOGOOD JH, 1985, ANN ALLERGY, V55, P257; TOOGOOD JH, 1985, CLIN INVEST MED, V8, pA42; TOOGOOD JH, 1983, LANCET, V2, P790; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; TOOGOOD JH, 1978, J ALLERGY CLIN IMMUN, V61, P355, DOI 10.1016/0091-6749(78)90114-8; TOOGOOD JH, 1984, EUR J RESPIR DIS, V65, P33; TOOGOOD JH, 1985, BRONCHIAL ASTHMA MEC, P698; TOOGOOD JH, 1983, ANN R COLL PHYS SURG, V16, P308	15	57	57	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1989	83	2	2				528	536		10.1016/0091-6749(89)90034-1	http://dx.doi.org/10.1016/0091-6749(89)90034-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T4491	2645350	Bronze			2022-12-18	WOS:A1989T449100005
J	FLING, JA; RUFF, ME; PARKER, WA; WHISMAN, BA; MARTIN, ME; MOSS, RB; REID, MJ				FLING, JA; RUFF, ME; PARKER, WA; WHISMAN, BA; MARTIN, ME; MOSS, RB; REID, MJ			SUPPRESSION OF THE LATE CUTANEOUS RESPONSE BY IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WILFORD HALL USAF MED CTR,SGHMMA,DIV MED,ALLERGY IMMUNOL SERV,LACKLAND AFB,TX 78236; STANFORD UNIV,SCH MED,DEPT PEDIAT,DIV ALLERGY,PALO ALTO,CA 94304	United States Department of Defense; United States Air Force; Stanford University			Moss, Richard B./S-9218-2019	Moss, Richard B./0000-0003-3611-4221				ATKINS PC, 1988, ANN ALLERGY, V60, P27; BEHRENS BL, 1984, AM REV RESPIR DIS, V130, P1134; DANIEL AR, 1983, J ALLERGY CLIN IMMUN, V71, P137; DEVEY ME, 1976, CLIN ALLERGY, V6, P227, DOI 10.1111/j.1365-2222.1976.tb01901.x; DJURUP R, 1984, ALLERGY, V39, P51, DOI 10.1111/j.1398-9995.1984.tb01933.x; DJURUP R, 1984, ALLERGY, V39, P118; FRANKLAND AW, 1954, LANCET, V1, P1055; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; LOWRY OH, 1951, J BIOL CHEM, V193, P265; METZGER WJ, 1985, CLIN REV ALLERG, V3, P145, DOI 10.1007/BF02992980; MOSS RB, 1987, J ALLERGY CLIN IMMUN, V79, P387, DOI 10.1016/0091-6749(87)90160-6; NORMAN PS, 1980, J ALLERGY CLIN IMMUN, V65, P87, DOI 10.1016/0091-6749(80)90191-8; PIENKOWSKI MM, 1985, J ALLERGY CLIN IMMUN, V76, P729, DOI 10.1016/0091-6749(85)90679-7; REID MJ, 1982, J ALLERGY CLIN IMMUN, V70, P191, DOI 10.1016/0091-6749(82)90041-0; REID MJ, 1985, J ALLERGY CLIN IMMUN, V76, P172, DOI 10.1016/0091-6749(85)90697-9; REID MJ, 1987, 43RD P ANN M AM AC A; ROCKLIN RE, 1983, J ALLERGY CLIN IMMUN, V72, P323, DOI 10.1016/0091-6749(83)90492-X; STARR MS, 1970, INT ARCH ALLER A IMM, V38, P514, DOI 10.1159/000230304; VANDERGIESSEN M, 1976, INT ARCH ALLER A IMM, V50, P625, DOI 10.1159/000231566; WARNER JO, 1978, LANCET, V2, P912; ZETTERSTROM O, 1978, CLIN ALLERGY, V8, P77, DOI 10.1111/j.1365-2222.1978.tb00452.x	23	57	58	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					101	109		10.1016/0091-6749(89)90483-1	http://dx.doi.org/10.1016/0091-6749(89)90483-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419	2913129				2022-12-18	WOS:A1989T041900014
J	FURUKAWA, CT; DUHAMEL, TR; WEIMER, L; SHAPIRO, GG; PIERSON, WE; BIERMAN, CW				FURUKAWA, CT; DUHAMEL, TR; WEIMER, L; SHAPIRO, GG; PIERSON, WE; BIERMAN, CW			COGNITIVE AND BEHAVIORAL FINDINGS IN CHILDREN TAKING THEOPHYLLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP & MED CTR,DIV ALLERGY,SEATTLE,WA; CHILDRENS HOSP & MED CTR,DEPT CHILD PSYCHIAT & BEHAV MED,SEATTLE,WA	Seattle Children's Hospital; Seattle Children's Hospital								ACHENBACH TM, 1983, CHILD BEHAVIOR CHECK; Benton A.L., 1974, REVISED VISUAL RETEN; BRUMBACK RA, 1984, LANCET, V1, P958; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; FURUKAWA CT, 1984, LANCET, V1, P621; FURUKAWA CT, 1984, PEDIATRICS, V74, P453; Golden C.J., 1978, STROOP COLOR WORD TE; GREDEN JF, 1978, AM J PSYCHIAT, V135, P963; GREDEN JF, 1974, AM J PSYCHIAT, V131, P1089; HARDYCK CD, 1976, INTRO STATISTICS BEH; LINGWOOD D, 1981, APPLE INTERACTIVE DA; MCLOUGHLIN J, 1983, ANN ALLERGY, V51, P506; MURPHY MB, 1980, BRIT MED J, V281, P1322, DOI 10.1136/bmj.281.6251.1322; RACHELEFSKY GS, 1986, PEDIATRICS, V78, P1133; SCHRAA JC, 1982, CHEST, V82, P181, DOI 10.1378/chest.82.2.181; SPRINGER C, 1985, J ALLERGY CLIN IMMUN, V76, P64, DOI 10.1016/0091-6749(85)90806-1; TABACHNICK BG, 1983, USING MULTIVARIANT S; WASSER WG, 1981, ANN INTERN MED, V95, P191, DOI 10.7326/0003-4819-95-2-191; WECHSLER D, 1974, REVISED WECHSLER INT	19	57	57	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					83	88		10.1016/0091-6749(88)90224-2	http://dx.doi.org/10.1016/0091-6749(88)90224-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	M0274	3123538				2022-12-18	WOS:A1988M027400013
J	AHRENS, RC; HARRIS, JB; MILAVETZ, G; ANNIS, L; RIES, R				AHRENS, RC; HARRIS, JB; MILAVETZ, G; ANNIS, L; RIES, R			USE OF BRONCHIAL PROVOCATION WITH HISTAMINE TO COMPARE THE PHARMACODYNAMICS OF INHALED ALBUTEROL AND METAPROTERENOL IN PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,COLL PHARM,IOWA CITY,IA 52242	University of Iowa	AHRENS, RC (corresponding author), UNIV IOWA,DEPT PEDIAT,IOWA CITY,IA 52242, USA.				NCRR NIH HHS [RR-59] Funding Source: Medline; NIAID NIH HHS [AI-16151-02] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHRENS RC, 1984, AM REV RESPIR DIS, V129, P903; ALEXANDER MR, 1977, DRUG INTEL CLIN PHAR, V11, P526, DOI 10.1177/106002807701100902; ANDERTON RC, 1979, J ALLERGY CLIN IMMUN, V63, P315, DOI 10.1016/0091-6749(79)90125-8; BERZUK GP, 1983, CLIN PHARM, V2, P129; CHOOKANG YF, 1969, BMJ-BRIT MED J, V2, P287, DOI 10.1136/bmj.2.5652.287; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DANO P, 1971, POSTGRAD MED J, V47, P86; EGGLESTON PA, 1981, CLIN PHARMACOL THER, V29, P505, DOI 10.1038/clpt.1981.70; FINNEY DJ, 1978, STATISTICAL METHOD B, P112; GODFREY S, 1976, THORAX, V31, P137, DOI 10.1136/thx.31.2.137; HANELY SP, 1986, AM REV RESPIR DIS, V133, pA177; HOLMES TH, 1969, CLIN PHARM THER, V9, P615; JENNE J, IN PRESS ASTHMA DRUG; JENNE JW, 1982, J ALLERGY CLIN IMMUN, V70, P413, DOI 10.1016/0091-6749(82)90002-1; JOAD JP, 1987, J ALLERGY CLIN IMMUN, V79, P78, DOI 10.1016/S0091-6749(87)80020-9; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KENNEDY MC, 1969, BR MED J, V1, P22; KONIG P, 1981, J ALLERGY CLIN IMMUN, V67, P110; KRAMER CY, 1956, BIOMETRICS, V12, P307, DOI 10.2307/3001469; LARSSON S, 1977, AM REV RESPIR DIS, V116, P861; MADSEN BW, 1979, BRIT J CLIN PHARMACO, V8, P75, DOI 10.1111/j.1365-2125.1979.tb05912.x; MAKINO S, 1966, J ALLERGY, V38, P127, DOI 10.1016/0021-8707(66)90036-0; OBRYNE PM, 1982, AM REV RESPIR DIS, V125, P281; RACOVEANU C, 1971, POSTGRAD MED J, V47, P83; RIDING W D, 1970, British Journal of Diseases of the Chest, V64, P37, DOI 10.1016/S0007-0971(70)80047-X; RUFFIN RE, 1981, J ALLERGY CLIN IMMUN, V67, P285, DOI 10.1016/0091-6749(81)90023-3; SALOME CM, 1983, THORAX, V38, P854, DOI 10.1136/thx.38.11.854; SNEDECOR GW, 1967, STATISTICAL METHODS, P153; SVEDMYR N, 1985, PHARMACOTHERAPY, V5, P109; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V63, P116, DOI 10.1016/0091-6749(79)90201-X; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71; 1962, AM REV RESPIR DIS, V85, P762	33	57	57	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1987	79	6					876	882		10.1016/0091-6749(87)90235-1	http://dx.doi.org/10.1016/0091-6749(87)90235-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H9044	3294976				2022-12-18	WOS:A1987H904400007
J	CHANDLER, MJ; GRAMMER, LC; PATTERSON, R				CHANDLER, MJ; GRAMMER, LC; PATTERSON, R			PROVOCATIVE CHALLENGE WITH LOCAL-ANESTHETICS IN PATIENTS WITH A PRIOR HISTORY OF REACTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University				Grammer, Leslie/0000-0001-6860-2014	NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDRETE JA, 1971, SOUTH MED J, V64, P1118, DOI 10.1097/00007611-197109000-00018; CHERNOW B, 1983, ARCH INTERN MED, V143, P2141, DOI 10.1001/archinte.143.11.2141; COOMBS RRA, 1975, CLIN ASPECTS IMMUNOL, P1; DEJONG RH, 1978, JAMA-J AM MED ASSOC, V239, P1166, DOI 10.1001/jama.239.12.1166; DESHAZO RD, 1979, J ALLERGY CLIN IMMUN, V63, P387, DOI 10.1016/0091-6749(79)90211-2; GIOVANNITTI JA, 1979, J AM DENT ASSOC, V98, P701, DOI 10.14219/jada.archive.1979.0148; GOODMAN MH, 1938, J INVEST DERM, V1, P53; GRAMMER LC, 1984, IMMUNOL ALLERGY PRAC, V6, P438; INCAUDO G, 1978, J ALLERGY CLIN IMMUN, V61, P339, DOI 10.1016/0091-6749(78)90057-X; LANE CG, 1951, JAMA-J AM MED ASSOC, V146, P717, DOI 10.1001/jama.1951.03670080025007; SCHATZ M, 1986, CLIN REV ALLERG, V4, P215; SCHATZ M, 1984, J ALLERGY CLIN IMMUN, V74, P606, DOI 10.1016/0091-6749(84)90114-3; SCHATZ M, 1985, ALLERGIC DISEASES DI, P621	13	57	57	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1987	79	6					883	886		10.1016/0091-6749(87)90236-3	http://dx.doi.org/10.1016/0091-6749(87)90236-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H9044	3584743				2022-12-18	WOS:A1987H904400008
J	KURUP, VP; RESNICK, A; SCRIBNER, GH; GUNASEKARAN, M; FINK, JN				KURUP, VP; RESNICK, A; SCRIBNER, GH; GUNASEKARAN, M; FINK, JN			ENZYME PROFILE AND IMMUNOCHEMICAL CHARACTERIZATION OF ASPERGILLUS-FUMIGATUS ANTIGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FISK UNIV,NASHVILLE,TN 37203	Fisk University	KURUP, VP (corresponding author), MED COLL WISCONSIN,CLEMONT J ZABLOCKI VET ADM MED CTR,RES SERV 151,MILWAUKEE,WI 53295, USA.				NIAID NIH HHS [AI19104] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI019104] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARDANA EJ, 1981, CRC CR REV CL LAB SC, V13, P21; BIGUET J, 1964, ANN I PASTEUR PARIS, V107, P72; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDZKO DB, 1975, MYCOPATHOLOGIA, V57, P23, DOI 10.1007/BF00431173; DEBEAUPUIS JP, 1978, APPL ENVIRON MICROB, V36, P8, DOI 10.1128/AEM.36.1.8-10.1978; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FINK JN, 1977, J ALLERGY CLIN IMMUN, V60, P238, DOI 10.1016/0091-6749(77)90137-3; FINK JN, 1976, MANUAL CLIN IMMUNOLO, P615; GUNASEKARAN M, 1981, MYCOLOGIA, V73, P697, DOI 10.2307/3759496; HOEHNE JH, 1973, CHEST, V63, P177, DOI 10.1378/chest.63.2.177; KAUFFMAN HF, 1980, INT ARCH ALLER A IMM, V62, P252, DOI 10.1159/000232521; KIM SJ, 1979, AM REV RESPIR DIS, V120, P1297; KURUP VP, 1978, AM J CLIN PATHOL, V69, P414; KURUP VP, 1978, MICROBIOS, V19, P191; LAUFER P, 1984, J ALLERGY CLIN IMMUN, V73, P44, DOI 10.1016/0091-6749(84)90482-2; LONGBOTTOM JL, 1964, J PATHOL BACTERIOL, V88, P141, DOI 10.1002/path.1700880119; MALO JL, 1981, CLIN ALLERGY, V11, P33; McCarthy D S, 1973, Clin Allergy, V3, P57, DOI 10.1111/j.1365-2222.1973.tb01310.x; MERRIL CR, 1984, CLIN CHEM, V30, P1938; ODDS FC, 1983, J BIOL STAND, V11, P157, DOI 10.1016/S0092-1157(83)80002-X; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PIECHURA JE, 1983, IMMUNOLOGY, V49, P657; SCHONHEYDER H, 1984, INT ARCH ALLER A IMM, V74, P262, DOI 10.1159/000233555; SLAVIN RG, 1969, AM J MED, V47, P306, DOI 10.1016/0002-9343(69)90156-9; WADSWORTH C, 1962, INT ARCH ALLER A IMM, V21, P131, DOI 10.1159/000229325; YOKOTA K, 1977, MICROBIOL IMMUNOL, V21, P11, DOI 10.1111/j.1348-0421.1977.tb02803.x; YOUNG RC, 1970, MEDICINE, V49, P147, DOI 10.1097/00005792-197003000-00002	27	57	57	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1986	78	6					1166	1173		10.1016/0091-6749(86)90267-8	http://dx.doi.org/10.1016/0091-6749(86)90267-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F3026	3097110				2022-12-18	WOS:A1986F302600013
J	NELSON, HS				NELSON, HS			ADRENERGIC THERAPY OF BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review											NELSON, HS (corresponding author), FITZSIMONS ARMY MED CTR, ALLERGY IMMUNOL SERV, AURORA, CO 80045 USA.							APPEL D, 1981, LUNG, V159, P243, DOI 10.1007/BF02713922; APPEL DW, 1984, J ALLERGY CLIN IMMUN, V73, P291, DOI 10.1016/S0091-6749(84)80022-6; BANNER AS, 1979, ARCH INTERN MED, V139, P434, DOI 10.1001/archinte.139.4.434; BARCLAY J, 1981, BRIT J CLIN PHARMACO, V11, P203, DOI 10.1111/j.1365-2125.1981.tb01125.x; BARCLAY J, 1982, EUR J CLIN PHARMACOL, V22, P389, DOI 10.1007/BF00542540; BARNES PJ, 1981, THORAX, V36, P378, DOI 10.1136/thx.36.5.378; BARNES PJ, 1984, EUR J RESPIR DIS, V65, P72; BARNES PJ, 1983, BRIT J CLIN PHARMACO, V15, P677, DOI 10.1111/j.1365-2125.1983.tb01549.x; BARNES PJ, 1981, J ALLERGY CLIN IMMUN, V68, P411, DOI 10.1016/0091-6749(81)90193-7; BATEMAN JRM, 1983, BRIT J CLIN PHARMACO, V15, P695, DOI 10.1111/j.1365-2125.1983.tb01552.x; BLOOMFIELD P, 1979, BRIT MED J, V1, P848, DOI 10.1136/bmj.1.6167.848; BLUMENTHAL I, 1980, J INT MED RES, V8, P400, DOI 10.1177/030006058000800606; BORUM P, 1980, J ALLERGY CLIN IMMUN, V66, P25, DOI 10.1016/0091-6749(80)90134-7; BRANDON ML, 1978, ANN ALLERGY, V40, P86; BRANSCOMB BV, 1982, J CLIN PHARMACOL, V22, P231, DOI 10.1002/j.1552-4604.1982.tb02666.x; BRANSCOMB BV, 1978, CHEST, V73, P1002, DOI 10.1378/chest.73.6_Supplement.1002; BRETZ U, 1983, EUR J PHARMACOL, V86, P321, DOI 10.1016/0014-2999(83)90180-2; BRITTAIN RT, 1976, PHARMACOL THER PT B, V2, P423, DOI 10.1016/0306-039X(76)90001-5; BRODDE OE, 1985, J CLIN INVEST, V76, P1096, DOI 10.1172/JCI112063; Bullowa J. J. M., 1903, MED NEWS, V83, P787; BUSH RK, 1978, ANN ALLERGY, V41, P13; BUTCHERS PR, 1979, BRIT J PHARMACOL, V67, P23; Chen KK, 1924, J PHARMACOL EXP THER, V24, P339; CHERVINSKY P, 1969, ANN ALLERGY, V27, P611; CHIPPS BE, 1978, J ALLERGY CLIN IMMUN, V61, P171, DOI 10.1016/0091-6749(78)90382-2; CLAY MM, 1983, LANCET, V2, P592; COADY TJ, 1976, PRACTITIONER, V217, P273; CONNOLLY CK, 1975, BRIT MED J, V3, P21, DOI 10.1136/bmj.3.5974.21; CROMPTON GK, 1982, EUR J RESPIR DIS, V63, P101; CROMPTON GK, 1984, LANCET, V1, P795; CROWE MJ, 1985, ANN ALLERGY, V55, P476; CRUZ RS, 1974, AM REV RESPIR DIS, V109, P458; DAHL R, 1985, ALLERGY, V40, P501, DOI 10.1111/j.1398-9995.1985.tb00257.x; DAVIES AO, 1984, ANNU REV PHYSIOL, V46, P119; DAVIS B, 1979, AM REV RESPIR DIS, V120, P547; DOLLERY CT, 1974, CLIN PHARMACOL THER, V15, P59; DOLOVICH M, 1981, CHEST, V80, P911; DOLOVICH MB, 1977, AM REV RESPIR DIS, V115, P397; DOROW P, 1982, EUR J CLIN PHARMACOL, V22, P511, DOI 10.1007/BF00609623; DULFANO MJ, 1976, ANN ALLERGY, V37, P357; DUSDIEKER L, 1982, J PEDIATR-US, V101, P281; EARIS JE, 1978, BRIT MED J, V1, P1554, DOI 10.1136/bmj.1.6126.1554-a; ELLIOTT HR, 1978, BRIT MED J, V2, P799, DOI 10.1136/bmj.2.6140.799-a; ELLULMICALLEF R, 1975, LANCET, V2, P1269; FANTA CH, 1982, AM J MED, V72, P416, DOI 10.1016/0002-9343(82)90498-3; FORD RM, 1980, ANN ALLERGY, V44, P112; FRIEDMAN R, 1982, AM J DIS CHILD, V136, P1091, DOI 10.1001/archpedi.1982.03970480057013; GAYRARD P, 1980, RESPIRATION, V40, P47, DOI 10.1159/000194250; GODFREY S, 1976, THORAX, V31, P137, DOI 10.1136/thx.31.2.137; GRAY BJ, 1982, BRIT J DIS CHEST, V76, P341, DOI 10.1016/0007-0971(82)90068-7; GRONNEBERG R, 1980, ALLERGY, V35, P143, DOI 10.1111/j.1398-9995.1980.tb01729.x; HAALBOOM JRE, 1985, LANCET, V1, P1125; HEIMER D, 1980, J ALLERGY CLIN IMMUN, V66, P75, DOI 10.1016/0091-6749(80)90141-4; HOLGATE ST, 1977, LANCET, V2, P375; HOLTEN K, 1974, BRIT J DIS CHEST, V68, P111, DOI 10.1016/0007-0971(74)90023-0; HOOPER PL, 1981, NEW ENGL J MED, V305, P1455, DOI 10.1056/NEJM198112103052406; HUI KKP, 1982, CLIN PHARMACOL THER, V32, P566, DOI 10.1038/clpt.1982.204; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P193, DOI 10.1016/0091-6749(78)90207-5; JACK D, 1971, POSTGRAD MED J, V47, P8; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V59, P383, DOI 10.1016/0091-6749(77)90023-9; JOAD J, 1985, J ALLERGY CLIN IMMUN, V75, P113, DOI 10.1016/0091-6749(85)90170-8; Joseph X, 1981, Fundam Appl Toxicol, V1, P443, DOI 10.1016/S0272-0590(81)80025-5; JOSEPHSON GW, 1979, JAMA-J AM MED ASSOC, V242, P639, DOI 10.1001/jama.242.7.639; JOSEPHSON GW, 1980, CHEST, V78, P429, DOI 10.1378/chest.78.3.429; KASS I, 1980, CHEST, V78, P283, DOI 10.1378/chest.78.2.283; KEIGHLEY JF, 1966, ANN INTERN MED, V65, P985, DOI 10.7326/0003-4819-65-5-985; KEMP JP, 1984, J ALLERGY CLIN IMMUN, V73, P32, DOI 10.1016/0091-6749(84)90481-0; KING M, 1984, AM REV RESPIR DIS, V129, P511; KINNEY EL, 1978, JAMA-J AM MED ASSOC, V240, P2247, DOI 10.1001/jama.1978.03290210029010; KNEUSSL MP, 1978, J APPL PHYSIOL, V45, P307, DOI 10.1152/jappl.1978.45.2.307; KONIG P, 1985, CHEST, V88, P276, DOI 10.1378/chest.88.2.276; KRAY KT, 1985, J ALLERGY CLIN IMMUN, V75, P179, DOI 10.1016/0091-6749(85)90434-8; KURLAND G, 1979, J ALLERGY CLIN IMMUN, V63, P407, DOI 10.1016/0091-6749(79)90214-8; LARSSON S, 1977, AM REV RESPIR DIS, V116, P861; LARSSON S, 1977, J ALLERGY CLIN IMMUN, V59, P93, DOI 10.1016/0091-6749(77)90209-3; LAURSEN LC, 1985, EUR J RESPIR DIS, V66, P82; LAWFORD P, 1983, BRIT J DIS CHEST, V77, P276; LAWYER C, 1977, NEW ENGL J MED, V296, P821; LEFERINK JG, 1979, INT J CLIN PHARM BI, V17, P181; LESLIE D, 1977, BRIT MED J, V2, P768, DOI 10.1136/bmj.2.6089.768-b; LEVISON H, 1985, J PEDIATR-US, V107, P662, DOI 10.1016/S0022-3476(85)80389-9; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; LONNERHOLM G, 1984, J ALLERGY CLIN IMMUN, V73, P508, DOI 10.1016/0091-6749(84)90362-2; MANSFIELD LE, 1982, INT ARCH ALLER A IMM, V68, P13, DOI 10.1159/000233060; MARTIN GL, 1980, J ALLERGY CLIN IMMUN, V66, P204, DOI 10.1016/0091-6749(80)90040-8; MATHE AA, 1971, J PHARM PHARMACOL, V23, P905, DOI 10.1111/j.2042-7158.1971.tb09891.x; MATSON JR, 1978, J PEDIATR-US, V92, P776, DOI 10.1016/S0022-3476(78)80150-4; MCEVOY JDS, 1973, AM REV RESPIR DIS, V108, P490; MCFADDEN ER, 1985, J ALLERGY CLIN IMMUN, V76, P352, DOI 10.1016/0091-6749(85)90653-0; MCFADDEN ER, 1981, J ALLERGY CLIN IMMUN, V68, P91, DOI 10.1016/0091-6749(81)90164-0; MCGRATH JC, 1982, BIOCHEM PHARMACOL, V31, P467, DOI 10.1016/0006-2952(82)90147-2; MILLER WC, 1980, ANN ALLERGY, V44, P15; MINNEMAN KP, 1984, EUR J RESPIR DIS, V65, P7; MORGAN MDL, 1982, BRIT MED J, V285, P849, DOI 10.1136/bmj.285.6345.849; MORRIS J, 1984, BRIT J DIS CHEST, V78, P383; MUNCH EP, 1983, ALLERGY, V38, P487, DOI 10.1111/j.1398-9995.1983.tb02357.x; NELSON HS, 1983, J ALLERGY CLIN IMMUN, V72, P371, DOI 10.1016/0091-6749(83)90502-X; NELSON HS, 1977, AM REV RESPIR DIS, V116, P871; NEVILLE E, 1982, BRIT MED J, V285, P796, DOI 10.1136/bmj.285.6344.796; Newman S, 1983, PRACTICAL CARDIOL, V9, P157; NEWMAN SP, 1981, AM REV RESPIR DIS, V124, P317; NEWMAN SP, 1981, THORAX, V36, P52, DOI 10.1136/thx.36.1.52; NICKLAS RA, 1984, J ALLERGY CLIN IMMUN, V73, P20, DOI 10.1016/0091-6749(84)90479-2; NOLAN G, 1982, ANN ALLERGY, V49, P93; NOU E, 1971, SCAND J RESPIR DIS, V52, P192; NYBERG L, 1984, EUR J RESPIR DIS, V65, P149; Omini C, 1985, Prog Biochem Pharmacol, V20, P63; ORGEL HA, 1985, J ALLERGY CLIN IMMUN, V75, P55, DOI 10.1016/0091-6749(85)90012-0; PANG LM, 1977, CHEST, V72, P469, DOI 10.1378/chest.72.4.469; PARRY WH, 1976, AM J DIS CHILD, V130, P39, DOI 10.1001/archpedi.1976.02120020041006; PATERSON IC, 1976, BRIT MED J, V1, P76, DOI 10.1136/bmj.1.6001.76-a; PAVIA D, 1977, THORAX, V32, P194, DOI 10.1136/thx.32.2.194; PEDERSEN S, 1986, J ALLERGY CLIN IMMUN, V77, P505, DOI 10.1016/0091-6749(86)90186-7; PEDERSEN S, 1983, NEW ENGL J MED, V308, P1328, DOI 10.1056/NEJM198306023082205; PERSSON H, 1970, ACTA MED SCAND, P11; PETERSSON BA, 1984, ALLERGY, V39, P351, DOI 10.1111/j.1398-9995.1984.tb01952.x; PIERCE RJ, 1981, CHEST, V79, P506, DOI 10.1378/chest.79.5.506; PLUMMER AL, 1978, CHEST, V73, P994, DOI 10.1378/chest.73.6.994; PRATT HF, 1982, CLIN ALLERGY, V12, P203, DOI 10.1111/j.1365-2222.1982.tb01640.x; PRIOR JG, 1981, BRIT MED J, V282, P1931; RACHELEFSKY GS, 1980, ANN ALLERGY, V45, P207; RACHELEFSKY GS, 1981, ANN ALLERGY, V47, P143; RADERMECKER M, 1981, CLIN ALLERGY, V11, P79, DOI 10.1111/j.1365-2222.1981.tb01569.x; REED CE, 1985, J ALLERGY CLIN IMMUN, V76, P335, DOI 10.1016/0091-6749(85)90650-5; REISMAN RE, 1970, J ALLERGY, V46, P162, DOI 10.1016/0021-8707(70)90095-X; REPSHER LH, 1984, CHEST, V85, P34, DOI 10.1378/chest.85.1.34; RICHARDS DM, 1985, DRUGS, V30, P6, DOI 10.2165/00003495-198530010-00002; RIVLIN J, 1984, J PEDIATR-US, V104, P470, DOI 10.1016/S0022-3476(84)81119-1; ROGGE P, 1979, LANCET, V1, P1026; SACKNER MA, 1985, CHEST, V88, pS161; SADOUL P, 1981, CHEST, V80, P885, DOI 10.1378/chest.80.6.885; SAMUELSON WM, 1984, AM REV RESPIR DIS, V130, P1023; SAUNDERS KB, 1965, BRIT MED J, V1, P1037, DOI 10.1136/bmj.1.5441.1037; SCHOLZ H, 1984, HOSP PRACT, V19, P57; SCHUMACHER MJ, 1980, J ALLERGY CLIN IMMUN, V66, P33, DOI 10.1016/0091-6749(80)90135-9; SCHWARTZ HJ, 1976, J ALLERGY CLIN IMMUN, V58, P516, DOI 10.1016/0091-6749(76)90195-0; SCOTLAND SM, 1983, LANCET, V2, P216; SHAW RJS, 1982, BRIT J DIS CHEST, V76, P171, DOI 10.1016/0007-0971(82)90031-6; SHIM C, 1980, AM J MED, V69, P891, DOI 10.1016/S0002-9343(80)80016-7; SHIM CS, 1984, J ALLERGY CLIN IMMUN, V73, P387, DOI 10.1016/0091-6749(84)90413-5; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SIEGEL D, 1985, AM REV RESPIR DIS, V132, P283; SIEGEL SC, 1985, J ALLERGY CLIN IMMUN, V75, P698, DOI 10.1016/0091-6749(85)90096-X; SIMONSSON BG, 1972, SCAND J RESPIR DIS, V53, P227; SLY RM, 1977, J ALLERGY CLIN IMMUN, V59, P128, DOI 10.1016/0091-6749(77)90214-7; SLY RM, 1985, J ALLERGY CLIN IMMUN, V75, P443; SMITH JA, 1980, CHEST, V78, P816, DOI 10.1378/chest.78.6.816; SMITH SR, 1983, J CLIN HOSP PHARM, V8, P201, DOI 10.1111/j.1365-2710.1983.tb01051.x; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P23, DOI 10.1016/0091-6749(79)90078-2; STANESCU DC, 1972, RESPIRATION, V29, P532; STILES GL, 1983, LIFE SCI, V33, P467, DOI 10.1016/0024-3205(83)90796-8; STORMS WW, 1985, ANN ALLERGY, V55, P476; STUBBLEFIELD PG, 1978, AM J OBSTET GYNECOL, V132, P341, DOI 10.1016/0002-9378(78)90907-9; SVEDMYR N, 1985, PHARMACOTHERAPY, V5, P109; SZCZEKLIK A, 1977, LANCET, V1, P658; THIRINGER G, 1977, SCAND J RESPIR DIS, P173; THOMSON NC, 1982, AM REV RESPIR DIS, V126, P521; TINGA DJ, 1979, LANCET, V1, P1026; TIPTON WR, 1986, ANN ALLERGY, V56; TOBIN MJ, 1982, AM REV RESPIR DIS, V126, P670; TRAUTLEIN J, 1977, J CLIN PHARMACOL, V17, P76, DOI 10.1002/j.1552-4604.1977.tb04588.x; VANARSDEL PP, 1978, CHEST, V73, P997; VANDEWALKER ML, 1986, CHEST, V90, P198, DOI 10.1378/chest.90.2.198; WALDEN SM, 1984, AM REV RESPIR DIS, V130, P357; WALKER SB, 1985, PHARMACOTHERAPY, V5, P127; WALLACE RL, 1978, OBSTET GYNECOL, V51, P387, DOI 10.1097/00006250-197804000-00001; WANG RYC, 1985, J CLIN PHARMACOL, V23, P355; WEBB D R, 1982, Journal of Allergy and Clinical Immunology, V69, P116; WEBER RW, 1984, PHARMACOTHERAPY, V4, P1; WEBER RW, 1982, J ALLERGY CLIN IMMUN, V70, P417, DOI 10.1016/0091-6749(82)90003-3; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V63, P116, DOI 10.1016/0091-6749(79)90201-X; WENNER A, 1981, CHEST S6, V80, P867; WESTLING H, 1979, ACTA PHARMACOL TOX, V44, P36; WHITEHURST VE, 1983, J AM COLL TOXICOL, V2, P147, DOI 10.3109/10915818309140676; WILLIAMS SJ, 1981, THORAX, V36, P629, DOI 10.1136/thx.36.8.629; WILSON AF, 1976, J ALLERGY CLIN IMMUN, V58, P204, DOI 10.1016/0091-6749(76)90156-1; WILSON JD, 1981, LANCET, V1, P1235; WOLFE JD, 1978, NEW ENGL J MED, V298, P363, DOI 10.1056/NEJM197802162980703; WOOD DW, 1972, J ALLERGY CLIN IMMUN, V50, P75, DOI 10.1016/0091-6749(72)90002-4; ZANETTI CL, 1982, J CLIN PHARMACOL, V22, P250, DOI 10.1002/j.1552-4604.1982.tb02669.x	181	57	58	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1986	77	6					771	785		10.1016/0091-6749(86)90372-6	http://dx.doi.org/10.1016/0091-6749(86)90372-6			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C8694	2872245				2022-12-18	WOS:A1986C869400001
J	REISMAN, RE; MULLER, UR; WYPYCH, JI; LAZELL, MI				REISMAN, RE; MULLER, UR; WYPYCH, JI; LAZELL, MI			STUDIES OF COEXISTING HONEYBEE AND VESPID-VENOM SENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14203; SUNY BUFFALO,DEPT MED,DIV ALLERGY,BUFFALO,NY 14260	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								ESKRIDGE EM, 1981, TOXICON, V19, P893, DOI 10.1016/0041-0101(81)90087-8; FRANKLIN RM, 1974, P SOC EXP BIOL MED, V147, P585, DOI 10.3181/00379727-147-38393; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; LIGHT WC, 1977, J ALLERGY CLIN IMMUN, V59, P247, DOI 10.1016/0091-6749(77)90158-0; LITTLER S, 1983, J ALLERGY CLIN IMMUN, V71, P120, DOI 10.1016/0091-6749(83)90250-6; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V68, P254, DOI 10.1016/0091-6749(81)90148-2; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V67, P290, DOI 10.1016/0091-6749(81)90024-5; NAIR BC, 1976, J ALLERGY CLIN IMMUN, V58, P101, DOI 10.1016/0091-6749(76)90111-1; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V70, P281, DOI 10.1016/0091-6749(82)90064-1; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V69, P268, DOI 10.1016/S0091-6749(82)80003-1; REISMAN RE, 1981, MONOGRAPH INSECT ALL, P25; WICHER K, 1980, J ALLERGY CLIN IMMUN, V66, P244, DOI 10.1016/0091-6749(80)90047-0; WYPYCH JI, 1979, J ALLERGY CLIN IMMUN, V63, P267, DOI 10.1016/0091-6749(79)90111-8	13	57	59	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	2					246	252		10.1016/S0091-6749(84)80015-9	http://dx.doi.org/10.1016/S0091-6749(84)80015-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SF020	6699307	Bronze			2022-12-18	WOS:A1984SF02000005
J	KEMENY, DM; MACKENZIEMILLS, M; HARRIES, MG; YOULTEN, LJF; LESSOF, MH				KEMENY, DM; MACKENZIEMILLS, M; HARRIES, MG; YOULTEN, LJF; LESSOF, MH			ANTIBODIES TO PURIFIED BEE VENOM PROTEINS AND PEPTIDES .2. A DETAILED STUDY OF CHANGES IN IGE AND IGG ANTIBODIES TO INDIVIDUAL BEE VENOM ANTIGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KEMENY, DM (corresponding author), GUYS HOSP,SCH MED,DEPT MED,LONDON SE1 9RT,ENGLAND.							ADKINSON NF, 1979, J IMMUNOL, V122, P965; BRAUN L. I. B., 1925, SOUTH AFRICAN MEDICAL RECORD, V23, P408; BUSSE WW, 1975, JAMA-J AM MED ASSOC, V231, P1154, DOI 10.1001/jama.231.11.1154; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; GRANT JA, 1981, J ALLERGY CLIN IMMUN, V68, P112, DOI 10.1016/0091-6749(81)90168-8; HOFFMAN DR, 1981, ANN ALLERGY, V46, P17; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; JOHANSSON SGO, 1976, SCAND J IMMUNOL, V3, P881; KEMENY DM, 1980, CLIN ALLERGY, V10, P413, DOI 10.1111/j.1365-2222.1980.tb02124.x; KEMENY DM, 1982, INT ARCH ALLER A IMM, V68, P268, DOI 10.1159/000233110; KEMENY DM, 1983, J ALLERGY CLIN IMMUN, V71, P505, DOI 10.1016/0091-6749(83)90469-4; KEMENY DM, 1981, BIOCHEM INT, V2, P145; KEMENY DM, 1982, J IMMUNOL METHODS, V49, P89, DOI 10.1016/0022-1759(82)90369-6; KEMENY DM, PURIFICATION HYALURO; KEMENY DM, UNPUB ANTIBODIES PUR, V3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lessof M H, 1977, Monogr Allergy, V12, P253; LESSOF MH, 1978, JOHNS HOPKINS MED J, V142, P1; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LIEBERMAN P, 1971, J AMER MED ASSOC, V215, P1106; LOVELESS MH, 1962, J IMMUNOL, V89, P204; MARSH DG, 1975, ANTIGENS, V3, P271; MIYACHI S, 1979, INT ARCH ALLER A IMM, V60, P148, DOI 10.1159/000232336; MORAN DM, 1978, J IMMUNOL METHODS, V24, P183, DOI 10.1016/0022-1759(78)90099-6; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; PLATTSMILLS TAE, 1978, J IMMUNOL, V120, P1201; SETTIPANE GA, 1980, CLIN ALLERGY, V10, P659, DOI 10.1111/j.1365-2222.1980.tb02149.x; SETTIPANE GA, 1979, CLIN ALLERGY, V9, P385, DOI 10.1111/j.1365-2222.1979.tb02497.x; SHIPOLIN.RA, 1971, EUR J BIOCHEM, V20, P459, DOI 10.1111/j.1432-1033.1971.tb01414.x; WIDE L, 1967, LANCET, V2, P1105; ZIMMERMANN EM, 1980, J ALLERGY CLIN IMMUN, V66, P386, DOI 10.1016/0091-6749(80)90118-9	34	57	57	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	4					376	385		10.1016/0091-6749(83)90503-1	http://dx.doi.org/10.1016/0091-6749(83)90503-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RN330	6619452				2022-12-18	WOS:A1983RN33000008
J	ADKINSON, NF				ADKINSON, NF			RADIOALLERGOSORBENT TEST - USES AND ABUSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											ADKINSON, NF (corresponding author), GOOD SAMARITAN HOSP,BALTIMORE,MD 21239, USA.							ADKINSON NF, 1976, MANUAL CLIN IMMUNOLO, P590; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; FADAL RG, 1979, CONTINUING ED FAMILY, P37; FOUCARD T, 1976, PAEDIATRICIAN, V5, P228; FOUCARD T, 1973, ACTA PAEDIATR SCAND, V62, P633, DOI 10.1111/j.1651-2227.1973.tb17078.x; FRICK OL, 1979, J ALLERGY CLIN IMMUN, V63, P228, DOI 10.1016/0091-6749(79)90106-4; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P346, DOI 10.1016/0091-6749(75)90006-8; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P334, DOI 10.1016/0091-6749(75)90005-6; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; JOHANSSON SGO, 1978, ALLERGY, V33, P292, DOI 10.1111/j.1398-9995.1978.tb01554.x; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LYNCH NR, 1975, CLIN EXP IMMUNOL, V22, P35; MICHAELS AA, 1979, J ALLERGY CLIN IMMUN, V63, P169; NALEBUFF DJ, 1978, J CONT ED ORL ALLERG, V40, P47; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0; TURKELTAUB PC, 1978, J ALLERGY CLIN IMMUN, V61, P171, DOI 10.1016/0091-6749(78)90381-0; VERVLOET D, 1974, Clinical Allergy, V4, P359, DOI 10.1111/j.1365-2222.1974.tb01397.x; WIDE L, 1967, LANCET, V2, P1105; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294; ZEISS CR, 1973, J IMMUNOL, V110, P414; 1979, J ALLERGY CLIN IMMUN, V63, pA35	25	57	57	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	1					1	4		10.1016/0091-6749(80)90169-4	http://dx.doi.org/10.1016/0091-6749(80)90169-4			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB459	6985630				2022-12-18	WOS:A1980JB45900001
J	WOJNAR, RJ; HEARN, T; STARKWEATHER, S				WOJNAR, RJ; HEARN, T; STARKWEATHER, S			AUGMENTATION OF ALLERGIC HISTAMINE-RELEASE FROM HUMAN-LEUKOCYTES BY NON-STEROIDAL ANTI-INFLAMMATORY - ANALGESIC AGENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											WOJNAR, RJ (corresponding author), SQUIBB INST MED RES,DEPT EXPTL PATHOL,POB 4000,PRINCETON,NJ 08540, USA.							ABRISHAMI MA, 1977, ANN ALLERGY, V39, P28; ADAMS SS, 1968, J PHARM PHARMACOL, V20, P305, DOI 10.1111/j.2042-7158.1968.tb09744.x; ADCOCK JJ, 1978, PROSTAGLANDINS, V16, P179, DOI 10.1016/0090-6980(78)90020-5; ALMEYOA J, 1970, British Journal of Dermatology, V83, P707, DOI 10.1111/j.1365-2133.1970.tb15774.x; BEALL GN, 1964, MEDICINE, V43, P131; BOOT JR, 1977, PROSTAGLANDINS, V13, P927, DOI 10.1016/0090-6980(77)90222-2; BOURNE HR, 1972, J IMMUNOL, V108, P695; BURKA JF, 1975, INT ARCH ALLER A IMM, V49, P774, DOI 10.1159/000231461; CALNAN CD, 1964, BMJ-BRIT MED J, V2, P649, DOI 10.1136/bmj.2.5410.649; CARDOE N, 1977, CURR MED RES OPIN, V5, P21, DOI 10.1185/03007997709108971; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; CRESSMAN WA, 1976, CLIN PHARMACOL THER, V19, P224; CUTHBERT MF, 1974, CURR MED RES OPIN, V2, P600, DOI 10.1185/03007997409115265; DOEGLAS HMG, 1975, BRIT J DERMATOL, V93, P135, DOI 10.1111/j.1365-2133.1975.tb06732.x; ENGINEER DM, 1978, BRIT J PHARMACOL, V62, P61, DOI 10.1111/j.1476-5381.1978.tb07006.x; FLOWER RJ, 1974, PHARMACOL RES COMMUN, V26, P33; GREEN GR, 1965, ANN ALLERGY, V23, P30; GRIFFITHS MC, 1976, USAN USP DICTIONARY; GRYGLEWSKI RJ, 1975, PROSTAGLANDINS, V10, P343, DOI 10.1016/S0090-6980(75)80087-6; HEARN T, 1979, FED PROC, V38, P598; HITCHCOCK M, 1978, J PHARMACOL EXP THER, V207, P630; Juby P.F, 1974, ANTIINFLAMMATORY AGE, V1, P91; JUHLIN L, 1969, ACTA DERM-VENEREOL, V49, P26; KALINER M, 1977, J ALLERGY CLIN IMMUN, V60, P204, DOI 10.1016/0091-6749(77)90125-7; KU EC, 1975, BIOCHEM PHARMACOL, V24, P641, DOI 10.1016/0006-2952(75)90186-0; LEWELLEN ORW, 1976, SCAND J RHEUMATOL, V14, P53; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1978, J INVEST DERMATOL, V71, P65, DOI 10.1111/1523-1747.ep12544308; LIEBERMAN SV, 1964, J PHARM SCI, V53, P1492, DOI 10.1002/jps.2600531212; MANDEL HG, 1954, J PHARMACOL EXP THER, V112, P495; MICHAELS.G, 1969, ACTA DERM-VENEREOL, V49, P404; MICHAELSSON G, 1973, BRIT J DERMATOL, V88, P525, DOI 10.1111/j.1365-2133.1973.tb08014.x; MILLONIG RC, 1972, 164TH AM CHEM SOC NA; MOOREROB.M, 1967, BRIT MED J, V4, P262, DOI 10.1136/bmj.4.5574.262; NEWCOMBE DS, 1976, PROSTAGLANDINS, V12, P849, DOI 10.1016/0090-6980(76)90059-9; OKAZAKI T, 1977, J ALLERGY CLIN IMMUN, V60, P360, DOI 10.1016/0091-6749(77)90067-7; PALMER DG, 1973, AUST NZ J MED, V3, P461, DOI 10.1111/j.1445-5994.1973.tb03123.x; PRESCOTT LF, 1975, MEYLERS SIDE EFFECTS, V8, P207; PRESCOTT LF, 1978, SIDE EFFECTS DRUGS, P91; RIESS W, 1978, SCAND J RHEUMATOL, P17; RUNKEL R, 1974, CLIN PHARMACOL THER, V15, P261; SCHERRER RA, 1974, ANTIINFLAMMATORY AGE, V1, P45; SETTIPANE GA, 1975, J ALLERGY CLIN IMMUN, V56, P215, DOI 10.1016/0091-6749(75)90092-5; SOBOTKA AK, 1979, J ALLERGY CLIN IMMUN, V63, P190; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; TAUBER AI, 1973, J IMMUNOL, V111, P27; TAYLOR RJ, 1976, BIOCHEM PHARMACOL, V25, P2479, DOI 10.1016/0006-2952(76)90452-4; WALKER JL, 1975, SCAND J RHEUMATOL  S; WALKER JL, 1973, ADV BIOSCI, V9, P235; WILLKENS RF, 1974, B RHEUM DIS, V24, P770; WINDER CV, 1963, ARTHRITIS RHEUM, V6, P36, DOI 10.1002/art.1780060105	51	57	57	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	1					37	45		10.1016/0091-6749(80)90136-0	http://dx.doi.org/10.1016/0091-6749(80)90136-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ541	6155392				2022-12-18	WOS:A1980JZ54100006
J	BAHNA, SL; HORWITZ, CA; FIALA, M; HEINER, DC				BAHNA, SL; HORWITZ, CA; FIALA, M; HEINER, DC			IGE RESPONSE IN HETEROPHIL-POSITIVE INFECTIOUS-MONONUCLEOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,HARBOR GEN HOSP,SCH MED,DEPT PEDIAT,TORRANCE,CA 90509; UNIV CALIF LOS ANGELES,HARBOR GEN HOSP,SCH MED,DEPT MED,TORRANCE,CA 90509; UNIV MINNESOTA,MT SINAI HOSP,SCH MED,DEPT LAB MED,MINNEAPOLIS,MN	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Minnesota System; University of Minnesota Twin Cities								AISENBERG AC, 1966, CANCER-AM CANCER SOC, V19, P385, DOI 10.1002/1097-0142(196603)19:3<385::AID-CNCR2820190312>3.0.CO;2-S; AIUTI F, 1975, INT ARCH ALLER A IMM, V48, P353, DOI 10.1159/000231320; ARMITAGE P, 1971, STATISTICAL METHODS, P359; BAHNA SL, 1978, J ALLERGY CLIN IMMUN, V61, P177, DOI 10.1016/0091-6749(78)90400-1; BAHNA SL, 1977, 3RD INT C IMM SYDN; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; CONNELLY RR, 1974, CANCER RES, V34, P1172; EVANS AS, 1968, NEW ENGL J MED, V279, P1121, DOI 10.1056/NEJM196811212792101; EVANS AS, 1974, YALE J BIOL MED, V47, P113; FRICK O L, 1977, Annals of Allergy, V38, P449; GAILPECZALSKA KJ, 1976, CLIN EXP IMMUNOL, V23, P47; GIULIANO VJ, 1974, CLIN IMMUNOL IMMUNOP, V3, P90, DOI 10.1016/0090-1229(74)90026-9; GREAVES MF, 1975, CLIN IMMUNOL IMMUNOP, V3, P514, DOI 10.1016/0090-1229(75)90076-8; HEINER DC, 1977, 3RD INT C IMM SYDN; HENLE G, 1971, INT J CANCER, V8, P272, DOI 10.1002/ijc.2910080212; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HENLE G, 1966, J BACTERIOL, V91, P1248, DOI 10.1128/JB.91.3.1248-1256.1966; HORWITZ CA, 1976, AM J MED, V61, P333, DOI 10.1016/0002-9343(76)90369-7; HORWITZ CA, 1977, GASTROENTEROLOGY, V72, P1322; HUTT LM, 1975, J IMMUNOL, V115, P243; IDA S, 1977, J EXP MED, V145, P892, DOI 10.1084/jem.145.4.892; JONDAL M, 1973, J EXP MED, V138, P1365, DOI 10.1084/jem.138.6.1365; LEE CL, 1968, J CLIN PATHOL, V21, P631, DOI 10.1136/jcp.21.5.631; LEE WY, 1978, J IMMUNOL METHODS, V20, P185, DOI 10.1016/0022-1759(78)90255-7; LIO A, 1977, J CLIN INVEST, V59, P743; MANGI RJ, 1974, NEW ENGL J MED, V291, P1149, DOI 10.1056/NEJM197411282912202; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; NORDBRING F, 1972, Scandinavian Journal of Infectious Diseases, V4, P119, DOI 10.3109/inf.1972.4.issue-2.10; PAPAMICHAIL M, 1974, CLIN EXP IMMUNOL, V18, P1; PATTENGALE PK, 1974, NEW ENGL J MED, V291, P1145, DOI 10.1056/NEJM197411282912201; PATTENGALE PK, 1973, LANCET, V2, P93; PERELMUTTER L, 1978, J ALLERGY CLIN IMMUN, V61, P177, DOI 10.1016/0091-6749(78)90402-5; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; ROGENTINE GN, 1966, J CLIN INVEST, V45, P1467, DOI 10.1172/JCI105454; ROSDAHL N, 1974, BMJ-BRIT MED J, V2, P253, DOI 10.1136/bmj.2.5913.253; ROSENBAUM JT, 1977, CANCER-AM CANCER SOC, V39, P11, DOI 10.1002/1097-0142(197701)39:1<11::AID-CNCR2820390104>3.0.CO;2-M; SUTTON RNP, 1973, CLIN EXP IMMUNOL, V13, P359; SVEDMYR E, 1975, P NATL ACAD SCI USA, V72, P1622, DOI 10.1073/pnas.72.4.1622; THOMAS MR, 1976, ANN ALLERGY, V37, P416; WALDMANN TA, 1974, J IMMUNOL, V113, P379; WOLLHEIM FA, 1968, SCAND J HAEMATOL, V5, P97	43	57	57	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	3					167	173		10.1016/0091-6749(78)90102-1	http://dx.doi.org/10.1016/0091-6749(78)90102-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FP554	681629				2022-12-18	WOS:A1978FP55400007
J	KALINER, M				KALINER, M			HUMAN LUNG-TISSUE AND ANAPHYLAXIS .1. ROLE OF CYCLIC-GMP AS A MODULATOR OF IMMUNOLOGICALLY INDUCED SECRETORY PROCESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20014	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								BACH MK, 1977, FED PROC, V36, P376; BROCKLEHURST WE, 1960, J PHYSIOL-LONDON, V151, P416, DOI 10.1113/jphysiol.1960.sp006449; CAILLA HL, 1973, ANAL BIOCHEM, V56, P395; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; KALINER M, 1973, J EXP MED, V138, P1077, DOI 10.1084/jem.138.5.1077; KALINER M, 1974, J IMMUNOL, V112, P664; KALINER M, 1972, J EXP MED, V136, P556, DOI 10.1084/jem.136.3.556; KALINER M, 1973, NEW ENGL J MED, V289, P277, DOI 10.1056/NEJM197308092890601; KALINER M, 1977, American Review of Respiratory Disease, V115, P60; KARIM SMM, 1967, BRIT J PHARM CHEMOTH, V31, P340, DOI 10.1111/j.1476-5381.1967.tb02003.x; KUO JF, 1972, J BIOL CHEM, V247, P16; LEWIS RA, 1974, J EXP MED, V140, P1133, DOI 10.1084/jem.140.5.1133; LOWRY OH, 1951, J BIOL CHEM, V193, P265; ORANGE RP, 1971, FED PROC, V30, P1725; ORANGE RP, 1971, J EXP MED          S, V134, P136; PATTERSON NAM, 1976, J IMMUNOL, V117, P1356; PIPER PJ, 1973, ANNALS NY ACAD SCI, V180, P363; STECHSCHULTE DJ, 1967, J EXP MED, V125, P127, DOI 10.1084/jem.125.1.127; STEINER AL, 1972, ADV CYCL NUCL RES<D>, V2, P51; STONER J, 1974, MOL PHARMACOL, V10, P155; STONER J, 1973, P NATL ACAD SCI USA, V70, P3830, DOI 10.1073/pnas.70.12.3830; TAUBER AI, 1973, J IMMUNOL, V111, P27; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WALKER JL, 1973, ADV BIOSCI, V9, P235	25	57	57	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	3					204	211		10.1016/0091-6749(77)90125-7	http://dx.doi.org/10.1016/0091-6749(77)90125-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DU852	70437	Bronze			2022-12-18	WOS:A1977DU85200009
J	BARDANA, EJ; FARR, RS; MINDEN, P; MCCLATCHY, JK				BARDANA, EJ; FARR, RS; MINDEN, P; MCCLATCHY, JK			PRIMARY INTERACTION OF ANTIBODY TO COMPONENTS OF ASPERGILLI .2. ANTIBODIES IN SERA FROM NORMAL PERSONS AND FROM PATIENTS WITH ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		AACH R, 1970, AM J MED, V48, P93; BARDANA E J JR, 1970, American Journal of Medicine, V49, P789, DOI 10.1016/S0002-9343(70)80060-2; BARDANA EJ, 1971, J ALLERGY, V47, P101; BARDANA EJ, 1972, J ALLERGY CLIN IMMUN, V50, P208, DOI 10.1016/0091-6749(72)90015-2; BARDANA EJ, IN PRESS; BARDANA EJ, 1970, EXCERPTA MED, V211, P14; BIGUET J, 1962, CR HEBD ACAD SCI, V254, P3768; BRADSHAW MW, 1971, LANCET, V1, P1095; BRONNEST.R, 1965, ACTA MED SCAND, V177, P385; BURKE BJ, 1970, THORAX, V25, P702, DOI 10.1136/thx.25.6.702; CAMPBELL MJ, 1964, AM REV RESPIR DIS, V89, P186; CEROTTINI JC, 1969, ANN NY ACAD SCI, V168, P76, DOI 10.1111/j.1749-6632.1969.tb43096.x; Ciszek J, 1969, Gruzlica, V37, P439; COOMBS RRA, 1964, CLINICAL ASPECTS IMM, pCH13; DOSHI R, 1971, J PATHOL, V103, P263, DOI 10.1002/path.1711030409; FARR RS, 1958, J INFECT DIS, V103, P239, DOI 10.1093/infdis/103.3.239; FARR RS, 1968, ANN NY ACAD SCI, V154, P107, DOI 10.1111/j.1749-6632.1968.tb16700.x; GERNEZRIEUX C, 1963, PRESSE MED, V71, P1541; GLYNN A A, 1970, Infection and Immunity, V2, P162; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1327, DOI 10.1084/jem.129.6.1327; GURWITH MJ, 1971, ARCH INTERN MED, V128, P541, DOI 10.1001/archinte.128.4.541; HANSEN K, 1932, DTSCH ARCH KLIN MED, V173, P469; HENDERSON AH, 1968, THORAX, V23, P501, DOI 10.1136/thx.23.5.501; HENDERSON AH, 1968, THORAX, V23, P513, DOI 10.1136/thx.23.5.513; HENDERSON AH, 1968, THORAX, V23, P519, DOI 10.1136/thx.23.5.519; HILVERING C, 1970, THORAX, V25, P19, DOI 10.1136/thx.25.1.19; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; IRANI FA, 1971, AM REV RESPIR DIS, V103, P552; JORDAN MC, 1971, ARCH INTERN MED, V128, P576, DOI 10.1001/archinte.128.4.576; KENNEDY WPU, 1970, THORAX, V25, P691, DOI 10.1136/thx.25.6.691; KHAN TH, 1968, AM J CARDIOL, V22, P277, DOI 10.1016/0002-9149(68)90235-X; LAUSTELA E, 1969, SCAND J RESPIR DIS, V50, P309; LEEUWEN WS, 1925, ALLERG KLIN IMMUNOL, V44, P1; LONGBOTTOM JL, 1964, J PATHOL BACTERIOL, V88, P141, DOI 10.1002/path.1700880119; LOURIA DB, 1967, NEW ENGL J MED, V277, P1126, DOI 10.1056/NEJM196711232772106; LOURIA DB, 1967, NEW ENGL J MED, V277, P1065, DOI 10.1056/NEJM196711162772005; McCarthy D S, 1971, Clin Allergy, V1, P415, DOI 10.1111/j.1365-2222.1971.tb00793.x; McCarthy DS, 1971, CLIN ALLERGY, V1, P261, DOI DOI 10.1111/J.1365-2222.1971.TB; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; MINDEN P, 1969, J EXP MED, V130, P931, DOI 10.1084/jem.130.5.931; MINDEN P, 1971, INFECT IMMUN, V3, P524, DOI 10.1128/IAI.3.4.524-529.1971; MINDEN P, 1969, J IMMUNOL, V102, P832; MINDEN P, 1966, J IMMUNOL, V96, P180; MINDEN P, 1967, HDB EXPERIMENTAL IMM, pCH13; MINDEN P, 1971, IMMUNOLOGICAL DISEAS, P179; MONOD O, 1957, J Fr Med Chir Thorac, V11, P257; NETER E, 1959, AM J PUBLIC HEALTH N, V49, P1050, DOI 10.2105/AJPH.49.8.1050; NISONOFF A, 1964, Methods Med Res, V10, P134; ORIE NGM, 1960, AM REV RESPIR DIS, V82, P649; PARKER JD, 1970, AM REV RESPIR DIS, V101, P551; PEPYS J, 1959, AM REV RESPIR DIS, V80, P167; PEPYS J, 1969, HYPERSENSITIVITY DIS, P20; REDDY PA, 1970, AM REV RESPIR DIS, V101, P928; RIDDLE HFV, 1967, THORAX, V22, P478; ROBBOY SJ, 1971, ARCH INTERN MED, V128, P790, DOI 10.1001/archinte.128.5.790; SAUNDERS AM, 1968, J AMER MED ASSOC, V206, P815, DOI 10.1001/jama.206.4.815; SCHWARTZ RH, 1970, AM J DIS CHILD, V120, P432, DOI 10.1001/archpedi.1970.02100100096009; SERES JL, 1972, J NEUROSURG, V36, P221, DOI 10.3171/jns.1972.36.2.0221; SLAVIN RG, 1969, AM J MED, V47, P306, DOI 10.1016/0002-9343(69)90156-9; SOBER HA, 1956, J AM CHEM SOC, V78, P756, DOI 10.1021/ja01585a017; STEVENS EAM, 1970, THORAX, V25, P11, DOI 10.1136/thx.25.1.11; SUZUKI S, 1967, JPN J MICROBIOL, V11, P269, DOI 10.1111/j.1348-0421.1967.tb00345.x; THOMPSON RA, 1970, CLIN EXP IMMUNOL, V7, P491; Tran Van Ky P, 1968, Rev Immunol Ther Antimicrob, V32, P37; Tran Van Ky P, 1966, Rev Immunol Ther Antimicrob, V30, P13; WALDMAN RH, 1970, J IMMUNOL, V105, P43; WALTER JE, 1968, DIS CHEST, V53, P729; WOLF FT, 1969, MYCOPATH MYCOL APPL, V38, P359, DOI 10.1007/BF02052882; YOUNG RC, 1971, AM REV RESPIR DIS, V104, P710; YOUNG RC, 1970, MEDICINE, V49, P147, DOI 10.1097/00005792-197003000-00002	70	57	57	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	4					222	+		10.1016/0091-6749(72)90016-4	http://dx.doi.org/10.1016/0091-6749(72)90016-4			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N6855	4262938				2022-12-18	WOS:A1972N685500004
J	WANDERER, AA; MASELLI, R; ELLIS, EF; ISHIZAKA, K				WANDERER, AA; MASELLI, R; ELLIS, EF; ISHIZAKA, K			IMMUNOLOGIC CHARACTERIZATION OF SERUM FACTORS RESPONSIBLE FOR COLD URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		AUGUSTIN R, 1967, HDB EXPERIMENTAL IMM, P1096; AVRAMEAS S, 1969, IMMUNOCHEMISTRY, V6, P53, DOI 10.1016/0019-2791(69)90178-5; Costanzi J J, 1967, Clin Exp Immunol, V2, P167; CUATRECA.P, 1968, P NATL ACAD SCI USA, V61, P636, DOI 10.1073/pnas.61.2.636; ELLIS EF, 1969, J ALLERGY, V43, P45, DOI 10.1016/0021-8707(69)90019-7; HOUSER DD, 1970, AM J MED, V49, P23, DOI 10.1016/S0002-9343(70)80110-3; ISHIZAKA K, 1960, J IMMUNOL, V85, P163; ISHIZAKA K, 1969, J IMMUNOL, V102, P69; ISHIZAKA K, 1970, J IMMUNOL, V105, P1459; ISHIZAKA T, 1970, J IMMUNOL, V104, P854; JUHLIN L, 1961, JAMA-J AM MED ASSOC, V177, P371, DOI 10.1001/jama.1961.73040320001004; KELLY FJ, 1953, AM J MED, V15, P431, DOI 10.1016/0002-9343(53)90132-6; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MELTZER M, 1966, AM J MED, V40, P828, DOI 10.1016/0002-9343(66)90199-9; MILLER F, 1965, J BIOL CHEM, V240, P4740; RAWNSLEY HM, 1968, ARCH DERMATOL, V98, P12, DOI 10.1001/archderm.98.1.12; ROSE B, 1965, IMMUNOLOGICAL DISEAS, P713; SHERMAN WB, 1950, J ALLERGY, V21, P414, DOI 10.1016/0021-8707(50)90017-7; TADA T, 1970, Journal of Immunology, V104, P377; VILLACORTE GV, 1970, J ALLERGY, V45, P122; WOLD RT, 1968, SCIENCE, V161, P806, DOI 10.1126/science.161.3843.806	21	57	57	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	1					13	+		10.1016/0091-6749(71)90050-9	http://dx.doi.org/10.1016/0091-6749(71)90050-9			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J8503	4157463				2022-12-18	WOS:A1971J850300003
J	Finney, LJ; Glanville, N; Farne, H; Aniscenko, J; Fenwick, P; Kemp, SV; Trujillo-Torralbo, MB; Loo, SL; Calderazzo, MA; Wedzicha, JA; Mallia, P; Bartlett, NW; Johnston, SL; Singanayagam, A				Finney, Lydia J.; Glanville, Nicholas; Farne, Hugo; Aniscenko, Julia; Fenwick, Peter; Kemp, Samuel, V; Trujillo-Torralbo, Maria-Belen; Loo, Su Ling; Calderazzo, Maria Adelaide; Wedzicha, Jadwiga A.; Mallia, Patrick; Bartlett, Nathan W.; Johnston, Sebastian L.; Singanayagam, Aran			Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COPD; COVID-19; inhaled corticosteroids; viral infection	PULMONARY-DISEASE; FLUTICASONE; PROPIONATE; EXPRESSION; IMMUNITY; MODEL	Background: The mechanisms underlying altered susceptibility and propensity to severe Coronavirus disease 2019 (COVID-19) disease in at-risk groups such as patients with chronic obstructive pulmonary disease (COPD) are poorly understood. Inhaled corticosteroids (ICSs) are widely used in COPD, but the extent to which these therapies protect or expose patients to risk of severe COVID-19 is unknown. Objective: The aim of this study was to evaluate the effect of ICSs following pulmonary expression of the SARS-CoV-2 viral entry receptor angiotensin-converting enzyme-2 (ACE2). Methods: We evaluated the effect of ICS administration on pulmonary ACE2 expression in vitro in human airway epithelial cell cultures and in vivo in mouse models of ICS administration. Mice deficient in the type I IFN-a/b receptor (Ifnar12/2) and administration of exogenous IFN-b were used to study the functional role of type-I interferon signaling in ACE2 expression. We compared sputum ACE2 expression in patients with COPD stratified according to use or nonuse of ICS. Results: ICS administration attenuated ACE2 expression in mice, an effect that was reversed by exogenous IFN-b administration, and Ifnar12/2 mice had reduced ACE2 expression, indicating that type I interferon contributes mechanistically to this effect. ICS administration attenuated expression of ACE2 in airway epithelial cell cultures from patients with COPD and in mice with elastase-induced COPDlike changes. Compared with ICS nonusers, patients with COPD who were taking ICSs also had reduced sputum expression of ACE2. Conclusion: ICS therapies in COPD reduce expression of the SARS-CoV-2 entry receptor ACE2. This effect may thus contribute to altered susceptibility to COVID-19 in patients with COPD.	[Finney, Lydia J.; Farne, Hugo; Aniscenko, Julia; Fenwick, Peter; Kemp, Samuel, V; Trujillo-Torralbo, Maria-Belen; Calderazzo, Maria Adelaide; Wedzicha, Jadwiga A.; Mallia, Patrick; Johnston, Sebastian L.; Singanayagam, Aran] Imperial Coll London, Natl Heart & Lung Inst, London W2 1PG, England; [Glanville, Nicholas] Prokarium, London BioSci Innovat Ctr, London, England; [Kemp, Samuel, V] Royal Brompton & Harefield NHS Trust, London, England; [Loo, Su Ling; Bartlett, Nathan W.] Hunter Med Res Inst, Fac Hlth & Med, New Lambton Hts, NSW, Australia; [Loo, Su Ling; Bartlett, Nathan W.] Hunter Med Res Inst, Prior Res Ctr Hlth Lungs, New Lambton Hts, NSW, Australia; [Loo, Su Ling; Bartlett, Nathan W.] Univ Newcastle, Callaghan, NSW, Australia	Imperial College London; University of London; University of London Royal Veterinary College; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; Hunter Medical Research Institute; University of Newcastle; Hunter Medical Research Institute; University of Newcastle; University of Newcastle	Singanayagam, A (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, London W2 1PG, England.	a.singanayagam@imperial.ac.uk	LOO, SU-LING/ABC-2176-2021	LOO, SU-LING/0000-0002-7666-049X; Singanayagam, Aran/0000-0001-9849-0033	Wellcome Trust [WT096382AIA, 215275/Z/19/Z]; British Society for Antimicrobial Chemotherapy; National Institute for Health Research (NIHR); NIHR; Imperial College; NIHR Biomedical Research Centre; MRC [MR/P028225/1, G0800570] Funding Source: UKRI	Wellcome Trust(Wellcome Trust); British Society for Antimicrobial Chemotherapy; National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); NIHR(National Institute for Health Research (NIHR)); Imperial College; NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by a Wellcome Trust Clinical Research Training Fellowship (grant WT096382AIA [to A.S.]), a Wellcome Trust Seed Award in Science (grant 215275/Z/19/Z [to A.S.]), a British Society for Antimicrobial Chemotherapy COVID-19 grant (to A.S.) a National Institute for Health Research (NIHR) Senior Investigator Award (to S.L.J.), the NIHR Clinical Lecturer funding scheme (to P.M.) and funding from the Imperial College and NIHR Biomedical Research Centre scheme.	Alqahtani JS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233147; BOOTH CM, 2003, PEDIAT ALLERG IMM-UK, V289, P2801; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020; Halpin DMG, 2020, LANCET RESP MED, V8, P436, DOI 10.1016/S2213-2600(20)30167-3; He, 2020, NEW ENGL J MED, V382, P1700; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hung YH, 2016, INT J BIOL SCI, V12, P454, DOI 10.7150/ijbs.13379; Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712; Jackson DJ, 2020, J ALLERGY CLIN IMMUN, V146, P203, DOI 10.1016/j.jaci.2020.04.009; Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005; Kamal F, 2020, CHEST, V158, P947, DOI 10.1016/j.chest.2020.05.531; Kan-o K, 2017, J INFECT DIS, V215, P1536, DOI 10.1093/infdis/jix167; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; Leung JM, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00688-2020; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Lukassen S., 2020, BIORXIV; Mallia P, 2018, J ALLERGY CLIN IMMUN, V142, P815, DOI 10.1016/j.jaci.2017.10.017; Matsuyama S, 2020, BIORXIV, DOI [10.1101/2020.03.11.987016, DOI 10.1101/2020.03.11.987016]; Muus C., 2021, INTEGRATED ANAL SING, V27, P546, DOI [10.1101/2020.04.19.049254, DOI 10.1101/2020.04.19.049254, 10.1038/s41591-020-01227-z]; Peters MC, 2020, AM J RESP CRIT CARE, V202, P83, DOI 10.1164/rccm.202003-0821OC; Public Health England, COVID 19 GUID SOC DI; Recinos A, 2007, ATHEROSCLEROSIS, V194, P125, DOI 10.1016/j.atherosclerosis.2006.10.013; Richardson Safiya, 2020, JAMA, V323, P2052, DOI 10.1001/jama.2020.6775; Ritchie AI, 2020, LANCET, V395, P1111, DOI 10.1016/S0140-6736(20)30691-7; Sajuthi Satria P, 2020, bioRxiv, DOI 10.1101/2020.04.09.034454; Singanayagam A, 2019, AM J PHYSIOL-LUNG C, V317, pL893, DOI 10.1152/ajplung.00253.2019; Singanayagam A, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav3879; Singanayagam A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04574-1; Singanayagam A, 2015, CLIN SCI, V129, P245, DOI 10.1042/CS20140654; Singanayagam A, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-27; Sodhi CP, 2018, AM J PHYSIOL-LUNG C, V314, pL17, DOI 10.1152/ajplung.00498.2016; Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6; Thomas BJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep07176; United States Centers for Disease Control and Prevention National Notifiable Diseases Surveillance System (NNDSS), 2020, COR DIS 2019 COVID 1; Van Bever HP, 2004, PEDIAT ALLERG IMM-UK, V15, P206, DOI 10.1111/j.1399-3038.2004.00137.x; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; [王科雯 Wang Kewen], 2020, [测绘通报, Bulletin of Surveying and Mapping], P1; Wedzicha JA, 2008, AM J RESP CRIT CARE, V177, P19, DOI 10.1164/rccm.200707-973OC; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Yamaya M, 2020, RESPIR INVESTIG, V58, P155, DOI 10.1016/j.resinv.2019.12.005; Yang XH, 2007, COMPARATIVE MED, V57, P450; Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035	44	56	56	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					510	+		10.1016/j.jaci.2020.09.034	http://dx.doi.org/10.1016/j.jaci.2020.09.034		FEB 2021	15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF		hybrid, Green Submitted, Green Published			2022-12-18	WOS:000616665800012
J	Crestani, E; Harb, H; Charbonnier, LM; Leirer, J; Motsinger-Reif, A; Rachid, R; Phipatanakul, W; Kaddurah-Daouk, R; Chatila, TA				Crestani, Elena; Harb, Hani; Charbonnier, Louis-Marie; Leirer, Jonathan; Motsinger-Reif, Alison; Rachid, Rima; Phipatanakul, Wanda; Kaddurah-Daouk, Rima; Chatila, Talal A.			Untargeted metabolomic profiling identifies disease-specific signatures in food allergy and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; food allergy; invariant natural killer T cells; metabolomics; metabolites; secondary bile acids; sphingolipids; tryptophan	GUT MICROBIOTA; BILE-ACID; SPHINGOLIPIDS; CHILDREN; CELLS; PREVALENCE; PROTEINS; LESSONS; OMICS	Background: Food allergy (FA) affects an increasing proportion of children for reasons that remain obscure. Novel disease biomarkers and curative treatment options are strongly needed. Objective: We sought to apply untargeted metabolomic profiling to identify pathogenic mechanisms and candidate disease biomarkers in patients with FA. Methods: Mass spectrometry-based untargeted metabolomic profiling was performed on serum samples of children with either FA alone, asthma alone, or both FA and asthma, as well as healthy pediatric control subjects. Results: In this pilot study patients with FA exhibited a disease-specific metabolomic signature compared with both control subjects and asthmatic patients. In particular, FA was uniquely associated with a marked decrease in sphingolipid levels, as well as levels of a number of other lipid metabolites, in the face of normal frequencies of circulating natural killer T cells. Specific comparison of patients with FA and asthmatic patients revealed differences in the microbiota-sensitive aromatic amino acid and secondary bile acid metabolism. Children with both FA and asthma exhibited a metabolomic profile that aligned with that of FA alone but not asthma. Among children with FA, the history of severe systemic reactions and the presence of multiple FAs were associated with changes in levels of tryptophan metabolites, eicosanoids, plasmalogens, and fatty acids. Conclusions: Children with FA have a disease-specific metabolomic profile that is informative of disease mechanisms and severity and that dominates in the presence of asthma. Lower levels of sphingolipids and ceramides and other metabolomic alterations observed in children with FA might reflect the interplay between an altered microbiota and immune cell subsets in the gut.	[Crestani, Elena; Harb, Hani; Charbonnier, Louis-Marie; Rachid, Rima; Phipatanakul, Wanda; Chatila, Talal A.] Harvard Med Sch, Div Immunol, Boston Childrens Hosp, Boston, MA 02115 USA; [Crestani, Elena; Harb, Hani; Charbonnier, Louis-Marie; Rachid, Rima; Phipatanakul, Wanda; Chatila, Talal A.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Leirer, Jonathan] North Carolina State Univ, Bioinformat Res Ctr, Dept Stat, Raleigh, NC USA; [Motsinger-Reif, Alison] NIEHS, Biostat & Computat Biol Branch, Durham, NC USA; [Kaddurah-Daouk, Rima] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC 27706 USA; [Kaddurah-Daouk, Rima] Duke Univ, Duke Inst Brain Sci, Durham, NC 27706 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; University of North Carolina; North Carolina State University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University	Chatila, TA (corresponding author), Boston Childrens Hosp, Div Immunol, Karp Family Bldg,RB10-214,1 Blackfan Circle, Boston, MA 02115 USA.; Chatila, TA (corresponding author), Harvard Med Sch, Karp Family Bldg,RB10-214,1 Blackfan Circle, Boston, MA 02115 USA.	talal.chatila@childrens.harvard.edu	Harb, Hani/J-6517-2019; Harb, Hani/HGB-7333-2022; Motsinger-Reif, Alison/I-4167-2018	Harb, Hani/0000-0001-8218-2538; Harb, Hani/0000-0001-8218-2538; Charbonnier, Louis-Marie/0000-0002-4594-7893; Motsinger-Reif, Alison/0000-0003-1346-2493	National Institutes of Health [R01 AI065617, R21 AI132843]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported in part by the National Institutes of Health (grant nos. R01 AI065617 and R21 AI132843, to T.A.C.).	Abdel-Gadir A, 2019, NAT MED, V25, P1164, DOI 10.1038/s41591-019-0461-z; Agus A, 2018, CELL HOST MICROBE, V23, P716, DOI 10.1016/j.chom.2018.05.003; An DD, 2014, CELL, V156, P123, DOI 10.1016/j.cell.2013.11.042; An DD, 2011, P NATL ACAD SCI USA, V108, P4666, DOI 10.1073/pnas.1001501107; Antunes L, 2018, ALLERGOL IMMUNOPATH, V46, P175, DOI 10.1016/j.aller.2017.05.009; Arrieta MC, 2018, J ALLERGY CLIN IMMUN, V142, P424, DOI 10.1016/j.jaci.2017.08.041; Bai AP, 2014, J IMMUNOL, V193, P3366, DOI 10.4049/jimmunol.1400346; Breslow DK, 2010, NATURE, V463, P1048, DOI 10.1038/nature08787; Camilleri M, 2015, AM J PHYSIOL-GASTR L, V309, pG209, DOI 10.1152/ajpgi.00121.2015; Cianferoni A, 2017, CLIN EXP ALLERGY, V47, P1390, DOI 10.1111/cea.12975; Comhair SAA, 2015, J IMMUNOL, V195, P643, DOI 10.4049/jimmunol.1500736; Fiorucci S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01853; Fitzpatrick AM, 2014, J ALLERGY CLIN IMMUN, V133, pe1; Fitzpatrick AM, 2014, J ALLERGY CLIN IMMUN, V133, P258, DOI 10.1016/j.jaci.2013.10.012; Foong RX, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00089; Friedlander JL, 2013, J ALLER CL IMM-PRACT, V1, P479, DOI 10.1016/j.jaip.2013.06.007; Gupta RS, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.5630; Gupta RS, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-1235; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Hannun YA, 2018, NAT REV MOL CELL BIO, V19, P175, DOI 10.1038/nrm.2017.107; Heinken A, 2015, WIRES SYST BIOL MED, V7, P195, DOI 10.1002/wsbm.1301; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V135, P25, DOI 10.1016/j.jaci.2014.11.011; Islam KBMS, 2011, GASTROENTEROLOGY, V141, P1773, DOI 10.1053/j.gastro.2011.07.046; James B, 2019, J ALLERGY CLIN IMMUN, V144, P634, DOI 10.1016/j.jaci.2019.07.023; Johnson CH, 2016, NAT REV MOL CELL BIO, V17, P451, DOI 10.1038/nrm.2016.25; Johnson VE, 2013, P NATL ACAD SCI USA, V110, P19313, DOI 10.1073/pnas.1313476110; Joyce SA, 2017, DIGEST DIS, V35, P169, DOI 10.1159/000450907; Jyonouchi S, 2011, J ALLERGY CLIN IMMUN, V128, P102, DOI 10.1016/j.jaci.2011.02.026; Kelly RS, 2017, CHEST, V151, P262, DOI 10.1016/j.chest.2016.10.008; Kong J, 2015, ALLERGY, V70, P495, DOI 10.1111/all.12579; Lambrecht BN, 2017, NAT IMMUNOL, V18, P1076, DOI 10.1038/ni.3829; Lee-Sarwar K, 2018, J ALLERGY CLIN IMMUN, V142, P335, DOI 10.1016/j.jaci.2018.04.016; Liu XJ, 2017, TRENDS BIOCHEM SCI, V42, P274, DOI 10.1016/j.tibs.2017.01.004; Liu Y, 2018, ALLERGY ASTHMA IMMUN, V10, P628, DOI 10.4168/aair.2018.10.6.628; Loureiro C. C., 2014, J ALLERGY CLIN IMMUN, V133, pe1; MahmoudianDehkordi S, 2019, ALZHEIMERS DEMENT, V15, P76, DOI 10.1016/j.jalz.2018.07.217; Matangkasombut P, 2009, J ALLERGY CLIN IMMUN, V123, P1181, DOI 10.1016/j.jaci.2009.02.013; Miller M, 2017, J ALLERGY CLIN IMMUN, V139, P1373, DOI 10.1016/j.jaci.2016.08.053; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Motta A, 2014, J PROTEOME RES, V13, P6107, DOI 10.1021/pr5010407; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Obeso D, 2018, ALLERGY, V73, P2137, DOI 10.1111/all.13563; Olivera A, 2005, J IMMUNOL, V174, P1153, DOI 10.4049/jimmunol.174.3.1153; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Park YH, 2017, J ALLERGY CLIN IMMUN, V139, P1518, DOI 10.1016/j.jaci.2016.08.018; Patti GJ, 2012, NAT REV MOL CELL BIO, V13, P263, DOI 10.1038/nrm3314; Phipatanakul W, 2011, J ASTHMA, V48, P1007, DOI 10.3109/02770903.2011.624235; Platts-Mills TAE, 2015, J ALLERGY CLIN IMMUN, V136, P3, DOI 10.1016/j.jaci.2015.03.048; Rachid R, 2016, CURR OPIN PEDIATR, V28, P748, DOI 10.1097/MOP.0000000000000427; Reinke SN, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01740-2016; Ried JS, 2013, ALLERGY, V68, P629, DOI 10.1111/all.12110; Rooks MG, 2016, NAT REV IMMUNOL, V16, P341, DOI 10.1038/nri.2016.42; Saude EJ, 2011, J ALLERGY CLIN IMMUN, V127, P757, DOI 10.1016/j.jaci.2010.12.1077; Schauberger E, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0628-3; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Siow Deanna, 2015, Adv Biol Regul, V57, P42, DOI 10.1016/j.jbior.2014.09.002; Verrill L, 2015, ALLERGY ASTHMA PROC, V36, P458, DOI 10.2500/aap.2015.36.3895	57	56	57	7	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2020	145	3					897	906		10.1016/j.jaci.2019.10.014	http://dx.doi.org/10.1016/j.jaci.2019.10.014			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KT1GD	31669435	Green Accepted			2022-12-18	WOS:000518756700027
J	Shamji, MH; Kappen, J; Abubakar-Waziri, H; Zhang, JJ; Steveling, E; Watchman, S; Kouser, L; Eifan, A; Switzer, A; Varricchi, G; Marone, G; Couto-Francisco, NC				Shamji, Mohamed H.; Kappen, Jasper; Abubakar-Waziri, Hisham; Zhang, Jinjin; Steveling, Esther; Watchman, Shelley; Kouser, Lubna; Eifan, Aarif; Switzer, Amy; Varricchi, Gilda; Marone, Gianni; Couto-Francisco, Natalia C.			Nasal allergen-neutralizing IgG4 antibodies block IgE-mediated responses: Novel biomarker of subcutaneous grass pollen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Biomarkers of allergen immunotherapy; subcutaneous immunotherapy; IgE-facilitated allergen binding; blocking antibodies; IgG(4); IgA(1); IgA(2); allergic rhinoconjunctivitis with and without asthma	REGULATORY B-CELLS; QUALITY-OF-LIFE; CLINICAL-EFFICACY; BINDING; VACCINATION; INHIBITION; ASTHMA; RHINOCONJUNCTIVITIS; VALIDATION; ACTIVATION	Background: Grass pollen subcutaneous immunotherapy (SCIT) is associated with induction of serum IgG(4)-associated inhibitory antibodies that prevent IgE-facilitated allergen binding to B cells. Objective: We sought to determine whether SCIT induces nasal allergen-specific IgG(4) antibodies with inhibitory activity that correlates closely with clinical response. Methods: In a cross-sectional controlled study, nasal fluid and sera were collected during the grass pollen season from 10 SCIT-treated patients, 13 untreated allergic patients (with seasonal allergic rhinitis [SAR]), and 12 nonatopic control subjects. Nasal and serum IgE and IgG(4) levels to Phleum pratense components were measured by using the Immuno Solid Allergen Chip microarray. Inhibitory activity was measured by IgE-facilitated allergen binding assay. IL-10 1 regulatory B cells were quantified in peripheral blood by using flow cytometry. Results: Nasal and serum Phl p 1-and Phl p 5-specific IgE levels were increased in patients with SAR compared to nonatopic control subjects (all, P < .001) and SCIT-treated patients (nasal, P < .001; serum Phl p 5, P = .073). Nasal IgG(4) levels were increased in the SCIT group compared to those in the SAR group (P < .001) during the pollen season compared to out of season. IgG-associated inhibitory activity in nasal fluid and serum was significantly increased in the SCIT group compared to that in the SAR (both, P < .01). The magnitude of the inhibitory activity was 93% (P < .001) in nasal fluid compared to 66% (P<.001) in serum and was reversed after depletion of IgG. Both nasal fluid (r = 20.69, P =.0005) and serum (r =20.552, P =.0095) blocking activity correlated with global symptom improvement. IL-10(+) regulatory B cells were increased in season compared to out of season in the SCIT group (P <.01). Conclusion: For the first time, we show that nasal IgG(4)-associated inhibitory activity correlates closely with the clinical response to allergen immunotherapy in patients with allergic rhinitis with or without asthma.	[Shamji, Mohamed H.; Kappen, Jasper; Abubakar-Waziri, Hisham; Zhang, Jinjin; Steveling, Esther; Watchman, Shelley; Kouser, Lubna; Eifan, Aarif; Switzer, Amy; Varricchi, Gilda; Marone, Gianni; Couto-Francisco, Natalia C.] Imperial Coll, Natl Heart & Lung Inst Inflammat Repair & Dev, Immunomodulat & Tolerance Grp, Allergy & Clin Immunol, London, England; [Kappen, Jasper] Franciscus Grp, Dept Pulmonol, STZ Ctr Excellence Asthma & COPD, Rotterdam, Netherlands	Imperial College London	Shamji, MH (corresponding author), Imperial Coll London, FAAAAI, Immunomodulat & Tolerance Grp, Allergy & Clin Immunol,Inflammat Repair & Dev, Sir Alexander Fleming Bldg, London SW7 2AZ, England.	m.shamji@imperial.ac.uk	Varricchi, Gilda/A-4620-2014; zhang, jin/GXV-9154-2022; Shamji, Mohamed/AAD-1788-2019; VARRICCHI, GILDA/AAB-9563-2022; Switzer, Amy/AEP-0843-2022; Shamji, Mohamed/AAU-8811-2020	VARRICCHI, GILDA/0000-0002-9285-4657; Shamji, Mohamed/0000-0003-3425-3463; Eifan, Aarif/0000-0003-4098-4211	Imperial College Research Funds, United Kingdom; Royal Brompton Hospital NHS Trust research funds, United Kingdom; MRC [G0601303] Funding Source: UKRI	Imperial College Research Funds, United Kingdom; Royal Brompton Hospital NHS Trust research funds, United Kingdom; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was funded by Imperial College Research Funds, United Kingdom, and Royal Brompton Hospital NHS Trust research funds, United Kingdom.	Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bousquet J, 1996, INT ARCH ALLERGY IMM, V110, P207, DOI 10.1159/000237289; Burks AW, 2013, J ALLERGY CLIN IMMUN, V131, P1288, DOI 10.1016/j.jaci.2013.01.049; Calderon MA, 2007, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001936.PUB2; Compalati E, 2014, CURR OPIN PULM MED, V20, P109, DOI 10.1097/MCP.0000000000000016; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Galli SJ, 2016, J ALLERGY CLIN IMMUN, V137, P1289, DOI 10.1016/j.jaci.2016.03.006; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; Gomez E, 2015, CLIN EXP ALLERGY, V45, P1542, DOI 10.1111/cea.12578; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Juniper EF, 2000, CLIN EXP ALLERGY, V30, P132; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047; Lin SY, 2013, COMP EFFECTIVENESS R; Mobs C, 2012, J ALLERGY CLIN IMMUN, V130, P1108, DOI 10.1016/j.jaci.2012.07.056; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Passalacqua G, 2014, J ASTHMA, V51, P29, DOI 10.3109/02770903.2013.853082; Pilette C, 2007, J IMMUNOL, V178, P4658, DOI 10.4049/jimmunol.178.7.4658; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; Powell RJ, 2007, ALLERGY, V62, P1335, DOI 10.1111/j.1398-9995.2007.01455.x; Pree I, 2010, CLIN EXP ALLERGY, V40, P1346, DOI 10.1111/j.1365-2222.2010.03548.x; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; Renand A, 2018, J ALLERGY CLIN IMMUN, V141, P1750, DOI 10.1016/j.jaci.2017.09.041; Shamji MH, 2017, ALLERGY, V72, P1156, DOI 10.1111/all.13138; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Shamji MH, 2017, J ALLERGY CLIN IMMUN, V140, P1485, DOI 10.1016/j.jaci.2017.10.010; Shamji MH, 2015, J ALLERGY CLIN IMMUN, V135, P913, DOI 10.1016/j.jaci.2014.09.049; van de Veen W, 2016, J ALLERGY CLIN IMMUN, V138, P654, DOI 10.1016/j.jaci.2016.07.006; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Wollmann E, 2015, J ALLERGY CLIN IMMUN, V136, P806, DOI 10.1016/j.jaci.2015.02.034; Wurtzen PA, 2008, CLIN EXP ALLERGY, V38, P1290, DOI 10.1111/j.1365-2222.2008.03020.x	36	56	58	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					1067	1076		10.1016/j.jaci.2018.09.039	http://dx.doi.org/10.1016/j.jaci.2018.09.039			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30445057	Bronze, Green Submitted			2022-12-18	WOS:000460272900027
J	Fraczek, MG; Chishimba, L; Niven, RM; Bromley, M; Simpson, A; Smyth, L; Denning, DW; Bowyer, P				Fraczek, Marcin G.; Chishimba, Livingstone; Niven, Rob M.; Bromley, Mike; Simpson, Angela; Smyth, Lucy; Denning, David W.; Bowyer, Paul			Corticosteroid treatment is associated with increased filamentous fungal burden in allergic fungal disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Lung mycobiome; Aspergillus; steroid; antifungal; allergic bronchopulmonary aspergillosis; asthma	ASPERGILLUS-FUMIGATUS; BRONCHOPULMONARY ASPERGILLOSIS; SEVERE ASTHMA; SEQUENCE ALIGNMENT; HIGH-THROUGHPUT; RESISTANCE; PCR; SENSITIZATION; SENSITIVITY; DIAGNOSIS	Background: Allergic diseases caused by fungi are common. The best understood conditions are allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. Our knowledge of the fungal microbiome (mycobiome) is limited to a few studies involving healthy individuals, asthmatics, and smokers. No study has yet examined the mycobiome in fungal lung disease. Objectives: The main aim of this study was to determine the mycobiome in lungs of individuals with well-characterized fungal disease. A secondary objective was to determine possible effects of treatment on the mycobiome. Methods: After bronchoscopy, ribosomal internal transcribed spacer region 1 DNA was amplified and sequenced and fungal load determined by real-time PCR. Clinical and treatment variables were correlated with the main species identified. Bronchopulmonary aspergillosis (n = 16), severe asthma with fungal sensitization (n = 16), severe asthma not sensitized to fungi (n = 9), mild asthma patients (n = 7), and 10 healthy control subjects were studied. Results: The mycobiome was highly varied with severe asthmatics carrying higher loads of fungus. Healthy individuals had low fungal loads, mostly poorly characterized Malasezziales. The most common fungus in asthmatics was Aspergillus fumigatus complex and this taxon accounted for the increased burden of fungus in the high-level samples. Corticosteroid treatment was significantly associated with increased fungal load (P<.01). Conclusions: The mycobiome is highly variable. Highest loads of fungus are observed in severe asthmatics and the most common fungus is Aspergillus fumigatus complex. Individuals receiving steroid therapy had significantly higher levels of Aspergillus and total fungus in their bronchoalveolar lavage.	[Fraczek, Marcin G.; Bromley, Mike; Denning, David W.; Bowyer, Paul] Univ Manchester, Sch Biol Sci, Div Infect Immun & Resp Med, Manchester Fungal Infect Grp, Manchester, Lancs, England; [Fraczek, Marcin G.; Chishimba, Livingstone; Niven, Rob M.; Simpson, Angela; Denning, David W.; Bowyer, Paul] Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Denning, David W.] Manchester Univ NHS Fdn Trust Wythenshawe, Natl Aspergillosis Ctr, Manchester, Lancs, England; [Fraczek, Marcin G.] Univ Manchester, Manchester Inst Biotechnol, Sch Biol Sci, Manchester, Lancs, England; [Smyth, Lucy] Univ Salford, Sch Environm & Life Sci, Salford, Lancs, England	University of Manchester; University of Manchester; University of Manchester; University of Salford	Bowyer, P (corresponding author), Univ Manchester, Manchester Fungal Infect Grp, Inst Inflammat & Repair, Core Technol Facil, Manchester, Lancs, England.	paul.bowyer@manchester.ac.uk	Denning, David/AAC-6931-2019; Fraczek, Marcin/AAZ-5748-2021	Denning, David/0000-0001-5626-2251; Simpson, Angela/0000-0003-2733-6666; bowyer, paul/0000-0002-1083-9286; Bromley, Michael/0000-0002-7611-0201; Fraczek, Marcin/0000-0001-5134-4709	Medical Research Council (MRC) [MR/M02010X/1]; EU Framework 7 (FP7-2007-2013) [HEALTH-F2-2010-260338]; MRC [MR/M02010X/1] Funding Source: UKRI	Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); EU Framework 7 (FP7-2007-2013); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	M.B. and P.B. receive support from Medical Research Council (MRC) grant MR/M02010X/1. M.F., M.B., and P.B. were funded by EU Framework 7 (FP7-2007-2013) under grant agreement HEALTH-F2-2010-260338 "ALLFUN."	Agarwal R, 2013, CLIN EXP ALLERGY, V43, P850, DOI 10.1111/cea.12141; Agarwal R, 2009, INT J TUBERC LUNG D, V13, P936; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bafadhel M, 2014, EUR RESPIR J, V43, P64, DOI 10.1183/09031936.00162912; Bittinger K, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0487-y; Brown GD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004404; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Castanhinha S, 2015, J ALLERGY CLIN IMMUN, V136, P312, DOI 10.1016/j.jaci.2015.01.016; Charlson ES, 2012, AM J RESP CRIT CARE, V186, P536, DOI 10.1164/rccm.201204-0693OC; Chowdhary A, 2014, CRIT REV MICROBIOL, V40, P30, DOI 10.3109/1040841X.2012.754401; Crameri R, 2014, ALLERGY, V69, P176, DOI 10.1111/all.12325; Delhaes L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036313; Denning DW, 2015, THORAX, V70, P613, DOI 10.1136/thoraxjnl-2015-207305; Denning DW, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-14; Denning DW, 2011, CLIN INFECT DIS, V52, P1123, DOI 10.1093/cid/cir179; Denning DW, 2009, AM J RESP CRIT CARE, V179, P11, DOI 10.1164/rccm.200805-737OC; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; Du Rand IA, 2011, THORAX, V66, P1, DOI 10.1136/thoraxjnl-2011-200713; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Erb-Downward JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016384; Fraczek MG, 2014, MYCOSES, V57, P69, DOI 10.1111/myc.12103; Fraczek MG, 2013, J ANTIMICROB CHEMOTH, V68, P1486, DOI 10.1093/jac/dkt075; Gouy M, 2010, MOL BIOL EVOL, V27, P221, DOI 10.1093/molbev/msp259; Gravelat FN, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003575; Green BJ, 2003, J ALLERGY CLIN IMMUN, V111, P285, DOI 10.1067/mai.2003.57; Haslam PL, 1999, EUR RESPIR J, V14, P245, DOI 10.1034/j.1399-3003.1999.14b01.x; Kim SH, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005308; Knutsen AP, 2012, J ALLERGY CLIN IMMUN, V129, P280, DOI 10.1016/j.jaci.2011.12.970; Larsson A, 2014, BIOINFORMATICS, V30, P3276, DOI 10.1093/bioinformatics/btu531; Namvar S, 2015, CLIN EXP ALLERGY, V45, P982, DOI 10.1111/cea.12426; NG TTC, 1994, MICROBIOL-UK, V140, P2475, DOI 10.1099/13500872-140-9-2475; Nilsson RH, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000059; Normansell R, 2016, COCHRANE DB SYST REV; Overton NLD, 2016, ALLERGY ASTHMA CL IM, V12, DOI 10.1186/s13223-016-0152-y; Pashley CH, 2012, MED MYCOL, V50, P433, DOI 10.3109/13693786.2011.615762; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Philippe B, 2003, INFECT IMMUN, V71, P3034, DOI 10.1128/IAI.71.6.3034-3042.2003; Samson RA, 2014, STUD MYCOL, P141, DOI 10.1016/j.simyco.2014.07.004; SCHAFFNER A, 1982, J CLIN INVEST, V69, P617, DOI 10.1172/JCI110489; Singh M, 2015, ACTA PAEDIATR, V104, pe206, DOI 10.1111/apa.12930; Surana NK, 2015, HARRISONS PRINCIPLES, P761; Tipton L, 2016, VIRULENCE, P1; Torelli R, 2011, J CLIN MICROBIOL, V49, P4273, DOI 10.1128/JCM.05026-11	44	56	57	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					407	414		10.1016/j.jaci.2017.09.039	http://dx.doi.org/10.1016/j.jaci.2017.09.039			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29122659	Green Published, Green Submitted			2022-12-18	WOS:000440664400010
J	du Toit, G; Sayre, PH; Roberts, G; Lawson, K; Sever, ML; Bahnson, HT; Fisher, HR; Feeney, M; Radulovic, S; Basting, M; Plaut, M; Lack, G				du Toit, George; Sayre, Peter H.; Roberts, Graham; Lawson, Kaitie; Sever, Michelle L.; Bahnson, Henry T.; Fisher, Helen R.; Feeney, Mary; Radulovic, Suzana; Basting, Monica; Plaut, Marshall; Lack, Gideon		Immune Tolerance Network Learning	Allergen specificity of early peanut consumption and effect on development of allergic disease in the Learning Early About Peanut Allergy study cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; peanut allergy; allergy prevention; allergen-specific asthma; eczema; atopic dermatitis; rhinoconjunctivitis; tolerance	FOOD ALLERGY; CONTROLLED-TRIAL; INFANTS; PREVENTION; HAZELNUT; CHILDREN; IMMUNOTHERAPY; SENSITIZATION; METAANALYSIS; PREVALENCE	Background: Early introduction of dietary peanut in high-risk infants with severe eczema, egg allergy, or both prevented peanut allergy at 5 years of age in the Learning Early About Peanut Allergy (LEAP) study. The protective effect persisted after 12 months of avoiding peanuts in the 12-month extension of the LEAP study (LEAP-On). It is unclear whether this benefit is allergen and allergic disease specific. Objective: We sought to assess the effect of early introduction of peanut on the development of allergic disease, food sensitization, and aeroallergen sensitization. Methods: Asthma, eczema, and rhinoconjunctivitis were diagnosed based on clinical assessment. Reported allergic reactions and consumption of tree nuts and sesame were recorded by questionnaire. Sensitization to food allergens and aeroallergens was determined by means of skin prick testing and specific IgE measurement. Results: A high and increasing burden of food allergen and aeroallergen sensitization and allergic disease was noted across study time points; 76% of LEAP participants had at least 1 allergic disease at 60 months of age. There were no differences in allergic disease between LEAP groups. There were small differences in sensitization and reported allergic reactions for select tree nuts, with levels being higher in the LEAP consumption group. Significant resolution of eczema and sensitization to egg and milk occurred in LEAP participants and was not affected by peanut consumption. Conclusion: Early consumption of peanut in infants at high risk of peanut allergy is allergen specific and does not prevent the development of other allergic disease, sensitization to other food allergens and aeroallergens, or reported allergic reactions to tree nuts and sesame. Furthermore, peanut consumption does not hasten the resolution of eczema or egg allergy.	[du Toit, George; Fisher, Helen R.; Feeney, Mary; Radulovic, Suzana; Basting, Monica; Lack, Gideon] Kings Coll London, Dept Paediat Allergy, Div Asthma Allergy & Lung Biol, London, England; [du Toit, George; Fisher, Helen R.; Feeney, Mary; Radulovic, Suzana; Basting, Monica; Lack, Gideon] Guys & St Thomas NHS Fdn Trust, London, England; [Bahnson, Henry T.] Univ Calif San Francisco, Immune Tolerance Network, San Francisco, CA 94143 USA; [Sayre, Peter H.] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA USA; [Roberts, Graham] Univ Southampton, Southampton, Hants, England; [Roberts, Graham] Southampton NIHR Biomed Res Ctr, Southampton, Hants, England; [Roberts, Graham] David Hide Ctr, Isle Of Wight, England; [Plaut, Marshall] Natl Inst Allergy & Infect Dis, Bethesda, MD USA; [Lawson, Kaitie; Sever, Michelle L.] Rho Fed Syst Div, Chapel Hill, NC USA	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; Immune Tolerance Network; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Southampton; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lack, G (corresponding author), Guys & St Thomas NHS Fdn Trust, Childrens Allergy Unit, 2nd Floor,South Wing,Westminster Bridge Rd, London SE1 7EH, England.	Gideon.Lack@kcl.ac.uk		Lister, Dr Helen/0000-0002-5958-4587; Lack, Gideon/0000-0001-7350-4021; Du Toit, George/0000-0002-0321-2928; Roberts, Graham/0000-0003-2252-1248	National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH) [NO1-AI-15416, UM1AI109565, HHSN272200800029C, UM2AI117870]; Food Allergy Research & Education (FARE), McLean, Va; Medical Research Council & Asthma UK Centre; UK Department of Health through the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre; King's College London; King's College Hospital NHS Foundation Trust; UK Food Standards Agency; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI109565, N01AI015416, UM2AI117870] Funding Source: NIH RePORTER; Medical Research Council [G1000758B, G1000758] Funding Source: researchfish; Asthma UK [MRC-Asthma UK Centre, MRC-AsthmaUKCentre] Funding Source: researchfish	National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Food Allergy Research & Education (FARE), McLean, Va; Medical Research Council & Asthma UK Centre; UK Department of Health through the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre; King's College London; King's College Hospital NHS Foundation Trust; UK Food Standards Agency; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH) under award numbers NO1-AI-15416, UM1AI109565, HHSN272200800029C, and UM2AI117870. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Additional support came from Food Allergy Research & Education (FARE), McLean, Va; the Medical Research Council & Asthma UK Centre; the UK Department of Health through the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. The clinical trials unit is supported by the National Peanut Board, Atlanta, Ga. The UK Food Standards Agency provided additional support for the costs of phlebotomy. G.L. acknowledges the Davis Foundation for academic support.	Barre A, 2008, MOL IMMUNOL, V45, P1231, DOI 10.1016/j.molimm.2007.09.014; Bellach J, 2017, J ALLERGY CLIN IMMUN, V139, P1591, DOI 10.1016/j.jaci.2016.06.045; Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P517, DOI 10.1067/mai.2002.127434; Dalal I, 2002, ALLERGY, V57, P362, DOI 10.1034/j.1398-9995.2002.1s3412.x; Di Bona D, 2017, ALLERGY, V72, P691, DOI 10.1111/all.13104; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Du Toit G, 2016, NEW ENGL J MED, V374, P1435, DOI 10.1056/NEJMoa1514209; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Kristiansen M, 2017, PEDIAT ALLERG IMM-UK, V28, P18, DOI 10.1111/pai.12661; Masthoff LJ, 2015, ALLERGY, V70, P265, DOI 10.1111/all.12554; Muraro A, 2014, ALLERGY, V69, P590, DOI 10.1111/all.12398; Natsume O, 2017, LANCET, V389, P276, DOI 10.1016/S0140-6736(16)31418-0; Nwaru BI, 2014, ALLERGY, V69, P62, DOI 10.1111/all.12305; Palmer DJ, 2017, J ALLERGY CLIN IMMUN, V139, P1600, DOI 10.1016/j.jaci.2016.06.052; Palmer DJ, 2013, J ALLERGY CLIN IMMUN, V132, P387, DOI 10.1016/j.jaci.2013.05.002; Perkin MR, 2016, NEW ENGL J MED, V374, P1733, DOI 10.1056/NEJMoa1514210; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Santos AF, 2014, J ALLERGY CLIN IMMUN, V134, P645, DOI 10.1016/j.jaci.2014.04.039; Tan JWL, 2017, J ALLERGY CLIN IMMUN, V139, P1621, DOI 10.1016/j.jaci.2016.08.035; Venter C, 2016, PEDIAT ALLERG IMM-UK, V27, P804, DOI 10.1111/pai.12616; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC	21	56	56	2	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1343	1353		10.1016/j.jaci.2017.09.034	http://dx.doi.org/10.1016/j.jaci.2017.09.034			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	29097103	hybrid, Green Published, Green Accepted			2022-12-18	WOS:000429197800020
J	Zhou, YF; Do, DC; Ishmael, FT; Squadrito, ML; Tang, HM; Tang, HL; Hsu, MH; Qiu, LP; Li, CJ; Zhang, YQ; Becker, KG; Wan, M; Huang, SK; Gao, PS				Zhou, Yufeng; Do, Danh C.; Ishmael, Faoud T.; Squadrito, Mario Leonardo; Tang, Ho Man; Tang, Ho Lam; Hsu, Man-Hsun; Qiu, Lipeng; Li, Changjun; Zhang, Yongqing; Becker, Kevin G.; Wan, Mei; Huang, Shau-Ku; Gao, Peisong			Mannose receptor modulates macrophage polarization and allergic inflammation through miR-511-3p	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mannose receptor; miR-511-3p; macrophage; asthma	AIRWAY INFLAMMATION; PROSTAGLANDIN D-2; IMMUNE-RESPONSE; CELL SUBSETS; T-CELLS; IN-VIVO; ASTHMA; EXPRESSION; COCKROACH; MICRORNA-21	BACKGROUND: Mannose receptor (MRC1/CD206) has been suggested to mediate allergic sensitization and asthma to multiple glycoallergens, including cockroach allergens. OBJECTIVE: We sought to determine the existence of a protective mechanism through which MRC1 limits allergic inflammation through its intronic miR-511-3p. METHODS: We examined MRC1-mediated cockroach allergen uptake by lung macrophages and lung inflammation using C57BL/6 wild-type (WT) and Mrc1(-/-) mice. The role of miR-511-3p in macrophage polarization and cockroach allergen-induced lung inflammation in mice transfected with adeno-associated virus (AAV)-miR-511-3p (AAV-cytomegalovirus-miR-511-3p-enhanced green fluorescent protein) was analyzed. Gene profiling of macrophages with or without miR-511-3p overexpression was also performed. RESULTS: Mrc1(-/-) lung macrophages showed a significant reduction in cockroach allergen uptake compared with WT mice, and Mrc1(-/-) mice had an exacerbated lung inflammation with increased levels of cockroach allergen-specific IgE and T(H)2/T(H)17 cytokines in a cockroach allergen-induced mouse model compared with WT mice. Macrophages from Mrc1(-/-) mice showed significantly reduced levels of miR-511-3 and an M1 phenotype, whereas overexpression of miR-511-3p rendered macrophages to exhibit a M2 phenotype. Furthermore, mice transfected with AAV-miR-511-3p showed a significant reduction in cockroach allergen-induced inflammation. Profiling of macrophages with or without miR-511-3p overexpression identified 729 differentially expressed genes, wherein expression of prostaglandin D2 synthase (Ptgds) and its product PGD2 were significantly downregulated by miR-511-3p. Ptgds showed a robust binding to miR-511-3p, which might contribute to the protective effect of miR-511-3p. Plasma levels of miR-511-3p were significantly lower in human asthmatic patients compared with nonasthmatic subjects. CONCLUSION: These studies support a critical but previously unrecognized role of MRC1 and miR-511-3p in protection against allergen-induced lung inflammation.	[Zhou, Yufeng; Do, Danh C.; Qiu, Lipeng; Huang, Shau-Ku; Gao, Peisong] Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA; [Tang, Ho Man] Johns Hopkins Univ, Sch Med, Inst Basic Biomed Sci, Baltimore, MD USA; [Li, Changjun; Wan, Mei] Johns Hopkins Univ, Sch Med, Dept Orthoped Surg, Baltimore, MD USA; [Ishmael, Faoud T.; Hsu, Man-Hsun] Penn State Univ, Dept Med, Div Pulm Allergy & Crit Care Med, Milton S Hershey Med Ctr, University Pk, PA 16802 USA; [Squadrito, Mario Leonardo] Ecole Polytech Fed Lausanne, Swiss Inst Expt Canc Res ISREC, Sch Life Sci, Lausanne, Switzerland; [Tang, Ho Lam] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA; [Zhang, Yongqing; Becker, Kevin G.] NIA, Gene Express & Genom Unit, NIH, Baltimore, MD 21224 USA; [Zhou, Yufeng] Fudan Univ, Childrens Hosp, Shanghai, Peoples R China; [Zhou, Yufeng] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China; [Zhou, Yufeng] Minist Hlth, Key Lab Neonatal Dis, Shanghai, Peoples R China; [Huang, Shau-Ku] Natl Hlth Res Inst, Natl Inst Environm Hlth Sci, Zhunan, Taiwan; [Huang, Shau-Ku] Kaohsiung Med Univ, Res Ctr Environm Med, Kaohsiung, Taiwan; [Huang, Shau-Ku] Shen Zhen Univ, Lou Hu Hosp, Shenzhen, Peoples R China	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania State University - University Park; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Fudan University; Fudan University; National Health Research Institutes - Taiwan; Kaohsiung Medical University; Shenzhen University	Gao, PS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle,Rm 3B-71, Baltimore, MD 21224 USA.; Huang, SK (corresponding author), Natl Hlth Res Inst, 35 Keyan Rd, Zhunam 35053, Miaoli County, Taiwan.	skhuang@nhri.org.tw; pgao1@jhmi.edu	C, Danh/I-1527-2019; Squadrito, Mario Leonardo/U-2090-2019; Qiu, Lipeng/E-1079-2018	C, Danh/0000-0002-1065-7140; Hsu, Man-Hsun/0000-0002-1505-1420; zhou, Yufeng/0000-0002-6050-4951; Qiu, Lipeng/0000-0003-4382-0976; Squadrito, Mario Leonardo/0000-0002-1188-0299	US National Institutes of Health (NIH) [RO1ES021739, R21 AI109062, R21 AI121768]; National Science Foundation of China (NSFC) [81628001]; Intramural Research Program of the National Institutes of Health, National Institute on Aging; China 1000 Young Talents Plan Program; Fudan Children's Hospital; Fudan University; NSFC [81671561]; MOST [2016YFC1305102]; National Health Research Institutes [EOPP10-014, EOSP07-014]; Ministry of Health [EODOH01]; Academia Sinica [AS-105-TP-B05]; Kaohsiung Medical University, Taiwan [KMU-TP-105A04, KMU-SH000184]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI109062, R21AI121768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES021739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZICAG000616] Funding Source: NIH RePORTER	US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Intramural Research Program of the National Institutes of Health, National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); China 1000 Young Talents Plan Program; Fudan Children's Hospital; Fudan University; NSFC(National Natural Science Foundation of China (NSFC)); MOST; National Health Research Institutes(National Health Research Institutes, Japan); Ministry of Health; Academia Sinica(Academia Sinica - Taiwan); Kaohsiung Medical University, Taiwan; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by grants from the US National Institutes of Health (NIH; RO1ES021739, R21 AI109062, and R21 AI121768) and the National Science Foundation of China (NSFC; 81628001; to P.G.); the Intramural Research Program of the National Institutes of Health, National Institute on Aging; the China 1000 Young Talents Plan Program (to Y.Z.); and Fudan Children's Hospital and Fudan University for Initial Funding, NSFC 81671561, and MOST 2016YFC1305102 (to Y.Z.); and by grants from the National Health Research Institutes (EOPP10-014 and EOSP07-014 to S.-K.H.) and the Ministry of Health (EODOH01; to S.-K.H.); Academia Sinica (AS-105-TP-B05 to SK Huang) and Kaohsiung Medical University "Aim for the Top Universities Grant" and "the Talent Plan" (KMU-TP-105A04 and KMU-SH000184 to SK Huang), Taiwan.	Baer C, 2016, NAT CELL BIOL, V18, P790, DOI 10.1038/ncb3371; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bazzoni F, 2009, P NATL ACAD SCI USA, V106, P5282, DOI 10.1073/pnas.0810909106; Boskovic J, 2006, J BIOL CHEM, V281, P8780, DOI 10.1074/jbc.M513277200; Chavele KM, 2010, J CLIN INVEST, V120, P1469, DOI 10.1172/JCI41560; Comer BS, 2014, AM J PHYSIOL-LUNG C, V307, pL727, DOI 10.1152/ajplung.00174.2014; Das A, 2014, J IMMUNOL, V192, P1120, DOI 10.4049/jimmunol.1300613; Emara M, 2011, J BIOL CHEM, V286, P13033, DOI 10.1074/jbc.M111.220657; Fehervari Z., 2014, NAT IMMUNOL, V16, P64; Gao P, 2010, CLIN EXP ALLERGY, V40, P1353, DOI 10.1111/j.1365-2222.2010.03561.x; Gao PS, 2014, J IMMUNOL, V192, P4560, DOI 10.4049/jimmunol.1303461; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Graff JW, 2012, J BIOL CHEM, V287, P21816, DOI 10.1074/jbc.M111.327031; Heinsbroek SEM, 2016, MUCOSAL IMMUNOL, V9, P960, DOI 10.1038/mi.2015.113; Jandl K, 2016, J ALLERGY CLIN IMMUN, V137, P833, DOI 10.1016/j.jaci.2015.11.012; Joo M, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/503128; Juncadella IJ, 2013, NATURE, V493, P547, DOI 10.1038/nature11714; Karo-Atar D, 2015, J ASTHMA, V52, P545, DOI 10.3109/02770903.2014.988222; Kuroda E, 2016, IMMUNITY, V45, P1299, DOI 10.1016/j.immuni.2016.11.010; Lee SJ, 2003, INFECT IMMUN, V71, P437, DOI 10.1128/IAI.71.1.437-445.2003; Lee YG, 2015, AM J RESP CELL MOL, V52, P772, DOI 10.1165/rcmb.2014-0255OC; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu TX, 2011, J IMMUNOL, V187, P3362, DOI 10.4049/jimmunol.1101235; Lu TX, 2009, J IMMUNOL, V182, P4994, DOI 10.4049/jimmunol.0803560; Martinez-Nunez RT, 2011, J BIOL CHEM, V286, P1786, DOI 10.1074/jbc.M110.169367; Martinez-Pomares L, 2012, J LEUKOCYTE BIOL, V92, P1177, DOI 10.1189/jlb.0512231; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; Misharin AV, 2013, AM J RESP CELL MOL, V49, P503, DOI 10.1165/rcmb.2013-0086MA; Nakamura T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8514; Panganiban RP, 2016, J ALLERGY CLIN IMMUN, V137, P1423, DOI 10.1016/j.jaci.2016.01.029; Panganiban RPL, 2012, AM J CLIN EXP IMMUNO, V1, P154; Royer PJ, 2010, J IMMUNOL, V185, P1522, DOI 10.4049/jimmunol.1000774; Saha B, 2016, J BIOL CHEM, V291, P149, DOI 10.1074/jbc.M115.694133; Simpson LJ, 2014, NAT IMMUNOL, V15, P1162, DOI 10.1038/ni.3026; Sohn MH, 2012, ALLERGY ASTHMA IMMUN, V4, P264, DOI 10.4168/aair.2012.4.5.264; Solberg OD, 2012, AM J RESP CRIT CARE, V186, P965, DOI 10.1164/rccm.201201-0027OC; Soroosh P, 2013, J EXP MED, V210, P775, DOI 10.1084/jem.20121849; Spence S, 2013, IMMUNITY, V38, P66, DOI 10.1016/j.immuni.2012.09.013; Squadrito ML, 2013, TRENDS IMMUNOL, V34, P350, DOI 10.1016/j.it.2013.02.003; Squadrito ML, 2012, CELL REPORTS, V1, P141, DOI 10.1016/j.celrep.2011.12.005; Swain SD, 2003, INFECT IMMUN, V71, P6213, DOI 10.1128/IAI.71.11.6213-6221.2003; Togias A, 2010, J ALLERGY CLIN IMMUN, V125, P540, DOI 10.1016/j.jaci.2010.01.040; Tsai YM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064105; Urade Y, 2011, SLEEP MED REV, V15, P411, DOI 10.1016/j.smrv.2011.08.003; Vogl T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5593; Wills-Karp M, 2010, MUCOSAL IMMUNOL, V3, P104, DOI 10.1038/mi.2009.138; Xu T, 2015, J IMMUNOL, V195, P5539, DOI 10.4049/jimmunol.1501198; Zandi S, 2015, CELL REP, V10, P1173, DOI 10.1016/j.celrep.2015.01.050; Zaynagetdinov R, 2013, AM J RESP CELL MOL, V49, P180, DOI 10.1165/rcmb.2012-0366MA; Zhang PS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9888; Zhu Weizhu, 2009, BMC Res Notes, V2, P89, DOI 10.1186/1756-0500-2-89; Zou J, 2011, CIRC RES, V108, P201, DOI 10.1161/CIRCRESAHA.110.225045	52	56	62	5	45	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					350	+		10.1016/j.jaci.2017.04.049	http://dx.doi.org/10.1016/j.jaci.2017.04.049			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28629744	Bronze, Green Accepted			2022-12-18	WOS:000419312200040
J	Lukkarinen, M; Koistinen, A; Turunen, R; Lehtinen, P; Vuorinen, T; Jartti, T				Lukkarinen, Minna; Koistinen, Annamari; Turunen, Riitta; Lehtinen, Pasi; Vuorinen, Tytti; Jartti, Tuomas			Rhinovirus-induced first wheezing episode predicts atopic but not nonatopic asthma at school age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; atopy; bronchiolitis; child; eczema; rhinovirus; respiratory syncytial virus; sensitization; virus; wheeze; wheezing	RESPIRATORY SYNCYTIAL VIRUS; 1-YEAR FOLLOW-UP; EARLY-LIFE; ALLERGIC SENSITIZATION; VIRAL-INFECTIONS; CHILDREN; RISK; PREDNISOLONE; BRONCHIOLITIS; PATHOGENESIS	Background: Persistent childhood asthma is mainly atopy driven. However, limited data exist on the risk factors for childhood asthma phenotypes. Objective: We sought to identify risk factors at the first severe wheezing episode for current asthma 7 years later and separately for atopic and nonatopic asthma. Methods: One hundred twenty-seven steroid-naive children with the first severe wheezing episode (90% hospitalized/10% emergency department treated) were followed for 7 years. The primary outcome was current asthma at age 8 years, which was also analyzed separately as atopic and nonatopic asthma. Risk factors, including sensitization, viral cause, and other main asthma risk factors, were analyzed. Results: At study entry, median age was 11 months (interquartile range, 6-16 months); 17% were sensitized, and 98% were virus positive. Current asthma (n = 37) at 8 years was divided into atopic (n = 19) and nonatopic (n = 18) asthma. The risk factors for current atopic asthma at study entry were sensitization (adjusted odds ratio [OR], 12; P <.001), eczema (adjusted OR, 4.8; P=.014), and wheezing with rhinovirus (adjusted OR, 5.0; P=.035). The risk factors for nonatopic asthma were the first severe respiratory syncytial virus/rhinovirus-negative wheezing episode (adjusted OR, 8.0; P=.001), first wheezing episode at age less than 12 months (adjusted OR, 7.3; P=.007), and parental smoking (adjusted OR, 3.8; P=.028). Conclusions: The data suggest diverse asthma phenotypes and mechanisms that can be predicted by using simple clinicalmarkers at the time of the first severe wheezing episode. These findings are important for designing early intervention strategies for secondary prevention of asthma.	[Lukkarinen, Minna; Koistinen, Annamari; Turunen, Riitta; Lehtinen, Pasi; Jartti, Tuomas] Univ Turku, Dept Paediat, Turku, Finland; [Lukkarinen, Minna; Koistinen, Annamari; Turunen, Riitta; Lehtinen, Pasi; Jartti, Tuomas] Turku Univ Hosp, Turku, Finland; [Turunen, Riitta; Vuorinen, Tytti] Turku Univ Hosp, Dept Clin Virol, Div Microbiol & Genet, Turku, Finland	University of Turku; University of Turku; University of Turku	Lukkarinen, M (corresponding author), Turku Univ Hosp, Dept Paediat, POB 52, Turku 20521, Finland.	mimapo@utu.fi			Academy of Finland, Helsinki [114034, 132595, 267133]; Foundation for Pediatric Research, Helsinki; Sigrid Juselius Foundation, Helsinki; Tampere Tuberculosis Foundation, Tampere; Allergy Research Foundation, Helsinki; Finnish Cultural Foundation, Helsinki	Academy of Finland, Helsinki(Academy of Finland); Foundation for Pediatric Research, Helsinki; Sigrid Juselius Foundation, Helsinki(Sigrid Juselius Foundation); Tampere Tuberculosis Foundation, Tampere; Allergy Research Foundation, Helsinki; Finnish Cultural Foundation, Helsinki(Finnish Cultural Foundation)	Supported by the Academy of Finland (grants 114034, 132595, and 267133), Helsinki (to T.J.); the Foundation for Pediatric Research, Helsinki (to M.L. and T.J.); the Sigrid Juselius Foundation, Helsinki (to T.J.); Tampere Tuberculosis Foundation, Tampere (to M.L. and T.J.); the Allergy Research Foundation, Helsinki (to M.L. and T.J.); and the Finnish Cultural Foundation, Helsinki (to M.L. and T.J.).	Allander T, 2007, CLIN INFECT DIS, V44, P904, DOI 10.1086/512196; Bergroth E, 2016, PEDIATR INFECT DIS J, V35, P363, DOI 10.1097/INF.0000000000001017; Beydon N, 2007, AM J RESP CRIT CARE, V175, P1304, DOI 10.1164/rccm.200605-642ST; Bonnelykke K, 2015, J ALLERGY CLIN IMMUN, V136, P81, DOI 10.1016/j.jaci.2015.02.024; Bousquet J, 2014, J ALLERGY CLIN IMMUN, V133, P1535, DOI 10.1016/j.jaci.2014.01.018; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Chiu CY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102809; Civelek E, 2011, PEDIATR PULM, V46, P166, DOI 10.1002/ppul.21346; Durrani SR, 2012, J ALLERGY CLIN IMMUN, V130, P489, DOI 10.1016/j.jaci.2012.05.023; Edwards MR, 2013, MUCOSAL IMMUNOL, V6, P797, DOI 10.1038/mi.2012.118; Goksor E, 2013, PEDIAT ALLERG IMM-UK, V24, P339, DOI 10.1111/pai.12078; Holt PG, 2012, NAT MED, V18, P726, DOI 10.1038/nm.2768; Holt PG, 2011, CHEST, V139, P1165, DOI 10.1378/chest.10-2397; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2016, J ALLERGY CLIN IMMUN, V137, P659, DOI 10.1016/j.jaci.2016.01.002; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Jartti T, 2004, EMERG INFECT DIS, V10, P1095, DOI 10.3201/eid1006.030629; Jartti T, 2010, PEDIAT ALLERG IMM-UK, V21, P1008, DOI 10.1111/j.1399-3038.2010.01059.x; Jartti T, 2006, PEDIATR INFECT DIS J, V25, P482, DOI 10.1097/01.inf.0000215226.69696.0c; Jartti T, 2015, J ALLERGY CLIN IMMUN, V135, P691, DOI 10.1016/j.jaci.2014.07.001; Jartti T, 2009, PEDIATR INFECT DIS J, V28, P311, DOI 10.1097/INF.0b013e31818ee0c1; Kurukulaaratchy RJ, 2004, THORAX, V59, P563, DOI 10.1136/thx.2003.010462; Kusel MMH, 2012, EUR RESPIR J, V39, P876, DOI 10.1183/09031936.00193310; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lehtinen P, 2007, J ALLERGY CLIN IMMUN, V119, P570, DOI 10.1016/j.jaci.2006.11.003; Lukkarinen M, 2016, J ALLERGY CLIN IMMUN, V138, DOI 10.1016/j.jaci.2016.01.040; Lukkarinen M, 2015, PEDIAT ALLERG IMM-UK, V26, P687, DOI 10.1111/pai.12439; Lukkarinen M, 2013, PEDIAT ALLERG IMM-UK, V24, P237, DOI 10.1111/pai.12046; Lukkarinen MM, 2015, AM J RESP CRIT CARE, V192, P1018, DOI 10.1164/rccm.201506-1226LE; Midulla F, 2012, EUR RESPIR J, V39, P396, DOI 10.1183/09031936.00188210; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Nissen SP, 2013, PEDIAT ALLERG IMM-UK, V24, P549, DOI 10.1111/pai.12108; Ronmark E, 1999, ALLERGY, V54, P926, DOI 10.1034/j.1398-9995.1999.00044.x; Soderlund-Venermo M, 2009, EMERG INFECT DIS, V15, P1423, DOI 10.3201/eid1509.090204; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Szefler SJ, 2014, J ALLERGY CLIN IMMUN, V133, P654, DOI 10.1016/j.jaci.2014.01.012; Turunen R, 2014, PEDIAT ALLERG IMM-UK, V25, P796, DOI 10.1111/pai.12318	37	56	60	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					988	995		10.1016/j.jaci.2016.12.991	http://dx.doi.org/10.1016/j.jaci.2016.12.991			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28347734	Green Published, Bronze			2022-12-18	WOS:000412172900010
J	Steer, CA; Martinez-Gonzalez, I; Ghaedi, M; Allinger, P; Matha, L; Takei, F				Steer, Catherine A.; Martinez-Gonzalez, Itziar; Ghaedi, Maryam; Allinger, Patricia; Mathae, Laura; Takei, Fumio			Group 2 innate lymphoid cell activation in the neonatal lung drives type 2 immunity and allergen sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INFLAMMATION; CHALLENGES; IL-33		[Steer, Catherine A.; Martinez-Gonzalez, Itziar; Ghaedi, Maryam; Allinger, Patricia; Mathae, Laura; Takei, Fumio] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC, Canada; [Steer, Catherine A.; Mathae, Laura] Univ British Columbia, Interdisciplinary Oncol Program, Vancouver, BC, Canada; [Martinez-Gonzalez, Itziar; Ghaedi, Maryam; Takei, Fumio] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Allinger, Patricia] Univ Appl Sci FH, Campus Wien, Vienna, Austria	British Columbia Cancer Agency; University of British Columbia; University of British Columbia	Takei, F (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC, Canada.	ftakei@bccrc.ca		Martinez Gonzalez, Itziar/0000-0002-1695-5691; Takei, Fumio/0000-0002-3620-5046; Matha, Laura/0000-0002-4399-6851	University of British Columbia (UBC) Four-Year Fellowship; Canadian Institute of Health Research (CIHR) studentship; CIHR; Michael Smith Foundation for Health Research (MSFHR); UBC Four-Year Fellowship; CIHR [MOP-126194, MOP-119324]	University of British Columbia (UBC) Four-Year Fellowship; Canadian Institute of Health Research (CIHR) studentship; CIHR(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research (MSFHR)(Michael Smith Foundation for Health Research); UBC Four-Year Fellowship; CIHR(Canadian Institutes of Health Research (CIHR))	C.A.S. is a recipient of a University of British Columbia (UBC) Four-Year Fellowship and a Canadian Institute of Health Research (CIHR) studentship. I.M-G. is a recipient of CIHR and Michael Smith Foundation for Health Research (MSFHR) fellowships. L.M. is a recipient of a UBC Four-Year Fellowship. This work was supported by grants from the CIHR (grant nos. MOP-126194 and MOP-119324).	Barlow JL, 2013, J ALLERGY CLIN IMMUN, V132, P933, DOI 10.1016/j.jaci.2013.05.012; Friel JK, 2004, PEDIATR RES, V56, P878, DOI 10.1203/01.PDR.0000146032.98120.43; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halim TYF, 2012, IMMUNITY, V37, P463, DOI 10.1016/j.immuni.2012.06.012; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Klose CSN, 2016, NAT IMMUNOL, V17, P765, DOI 10.1038/ni.3489; Mohr E, 2016, CURR OPIN IMMUNOL, V41, P1, DOI 10.1016/j.coi.2016.04.004; Pichery M, 2012, J IMMUNOL, V188, P3488, DOI 10.4049/jimmunol.1101977; PrabhuDas M, 2011, NAT IMMUNOL, V12, P189, DOI 10.1038/ni0311-189	9	56	58	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					593	+		10.1016/j.jaci.2016.12.984	http://dx.doi.org/10.1016/j.jaci.2016.12.984			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28216436	Bronze			2022-12-18	WOS:000406855500035
J	Goswami, R; Blazquez, AB; Kosoy, R; Rahman, A; Nowak-Wegrzyn, A; Berin, MC				Goswami, Ritobrata; Blazquez, Ana Belen; Kosoy, Roman; Rahman, Adeeb; Nowak-Wegrzyn, Anna; Berin, M. Cecilia			Systemic innate immune activation in food protein-induced enterocolitis syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; non-IgE; FPIES; innate; CyTOF; RNA-sequencing	CELIAC-DISEASE PATIENTS; COWS MILK INTOLERANCE; T-CELLS; MALABSORPTION-SYNDROME; CELLULAR-RESPONSES; CLINICAL-FEATURES; PEANUT ALLERGY; CHILDREN; INSIGHTS; ANTIGEN	Background: Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE-mediated food allergy of infancy whose pathophysiology is poorly understood. Objectives: We set out to identify and phenotype allergen-responsive cells in peripheral blood of a cohort of subjects undergoing supervised food challenge for FPIES. Methods: We profiled antigen-responsive cells in PBMCs by flow cytometry, and examined cells in whole blood obtained before and after challenge by CyTOF mass cytometry and RNAseq. Results: Using a CD154-based detection approach, we observed that milk, soy, or rice-responsive T cells, and TNF-alpha-producing CD154(+) T cells, were significantly lower in those with outgrown FPIES compared with those with active FPIES. However, levels were within the normal range and were inconsistent with a role in the pathophysiology of FPIES. Profiling of whole blood by CyTOF demonstrated profound activation of cells of the innate immune system after food challenge, including monocytes, neutrophils, natural killer cells, and eosinophils. Activation was not observed in children with outgrown FPIES. We confirmed this pattern of innate immune activation in a larger cohort by RNAseq. Furthermore, we observed pan-T-cell activation and redistribution from the circulation after a positive food challenge but not in those who had outgrown their FPIES. Conclusions: Our data demonstrate a compelling role of systemic innate immune activation in adverse reactions elicited by foods in FPIES. Further investigation is needed to identify the mechanism of antigen specificity of adverse reactions to foods in FPIES.	[Goswami, Ritobrata; Blazquez, Ana Belen; Nowak-Wegrzyn, Anna; Berin, M. Cecilia] Icahn Sch Med Mt Sinai, Jaffe Food Allergy Inst, New York, NY 10029 USA; [Kosoy, Roman] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Rahman, Adeeb] Icahn Sch Med Mt Sinai, Human Immune Monitoring Core, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Berin, MC (corresponding author), Icahn Sch Med Mt Sinai, Pediat Allergy & Immunol, One Gustave L Levy Pl,Box 1198, New York, NY 10029 USA.	cecilia.berin@mssm.edu	Goswami, Ritobrata/W-9057-2019	Goswami, Ritobrata/0000-0002-4388-7962; berin, cecilia/0000-0002-9051-9249; Nowak-Wegrzyn, Anna/0000-0002-0960-9854	National Institute of Allergy and Infectious Diseases [NIAID R01AI093577, NIAID U24AI118644]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI093577, U24AI118644] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	M.C.B. was supported by the National Institute of Allergy and Infectious Diseases (grant nos. NIAID R01AI093577 and NIAID U24AI118644).	Abadie V, 2011, ANNU REV IMMUNOL, V29, P493, DOI 10.1146/annurev-immunol-040210-092915; Atzeni F, 2002, CELL IMMUNOL, V220, P20, DOI 10.1016/S0008-8749(03)00002-9; Behbehani GK, 2014, CYTOM PART A, V85A, P1011, DOI 10.1002/cyto.a.22573; Berin MC, 2015, J ALLERGY CLIN IMMUN, V135, P1108, DOI 10.1016/j.jaci.2014.12.1948; Caubet JC, 2017, J ALLERGY CLIN IMMUN, V139, P572, DOI 10.1016/j.jaci.2016.02.047; Caubet JC, 2014, J ALLERGY CLIN IMMUN, V134, P382, DOI 10.1016/j.jaci.2014.04.008; DeLong JH, 2011, J ALLERGY CLIN IMMUN, V127, P1211, DOI 10.1016/j.jaci.2011.02.028; du Pre MF, 2011, AM J GASTROENTEROL, V106, P1147, DOI 10.1038/ajg.2011.24; Esplugues E, 2011, NATURE, V475, P514, DOI 10.1038/nature10228; FREIER S, 1969, J PEDIATR-US, V75, P623, DOI 10.1016/S0022-3476(69)80458-0; HEYMAN M, 1994, GASTROENTEROLOGY, V106, P1514, DOI 10.1016/0016-5085(94)90405-7; Konstantinou GN, 2014, PEDIAT ALLERG IMM-UK, V25, P651, DOI 10.1111/pai.12288; Kosoy R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163831; KUITUNEN P, 1975, ARCH DIS CHILD, V50, P351, DOI 10.1136/adc.50.5.351; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Liu SM, 2006, J ALLERGY CLIN IMMUN, V118, P496, DOI 10.1016/j.jaci.2006.04.040; Ludman S, 2014, ANN ALLERG ASTHMA IM, V113, P290, DOI 10.1016/j.anai.2014.06.020; MCDONALD PJ, 1984, PEDIATR RES, V18, P751, DOI 10.1203/00006450-198408000-00016; Morita H, 2013, J ALLERGY CLIN IMMUN, V131, pe1; Morita H, 2013, J ALLERGY CLIN IMMUN, V131, P590, DOI 10.1016/j.jaci.2012.09.005; Nowak-Wegrzyn A, 2015, J ALLERGY CLIN IMMUN, V135, P1114, DOI 10.1016/j.jaci.2015.03.025; POWELL GK, 1978, J PEDIATR-US, V93, P553, DOI 10.1016/S0022-3476(78)80887-7; Prussin C, 2009, J ALLERGY CLIN IMMUN, V124, P1326, DOI 10.1016/j.jaci.2009.09.048; Qiu P, 2011, NAT BIOTECHNOL, V29, P886, DOI 10.1038/nbt.1991; Rahman AH, 2016, CYTOM PART A, V89A, P601, DOI 10.1002/cyto.a.22826; Raki M, 2007, P NATL ACAD SCI USA, V104, P2831, DOI 10.1073/pnas.0608610104; Ruffner MA, 2013, J ALLER CL IMM-PRACT, V1, P343, DOI 10.1016/j.jaip.2013.05.011; SAVILAHTI E, 1973, GUT, V14, P491, DOI 10.1136/gut.14.6.491; Shek LPC, 2005, ALLERGY, V60, P912, DOI 10.1111/j.1398-9995.2005.00705.x; Sopo SM, 2012, CLIN EXP ALLERGY, V42, P1257, DOI 10.1111/j.1365-2222.2012.04027.x; Stone SF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101409	31	56	60	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1885	+		10.1016/j.jaci.2016.12.971	http://dx.doi.org/10.1016/j.jaci.2016.12.971			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	28192147	Green Accepted, Bronze			2022-12-18	WOS:000402724600019
J	Loser, S; Gregory, LG; Zhang, YM; Schaefer, K; Walker, SA; Buckley, J; Denney, L; Dean, CH; Cookson, WOC; Moffatt, MF; Lloyd, CM				Loser, Stephan; Gregory, Lisa G.; Zhang, Youming; Schaefer, Katrein; Walker, Simone A.; Buckley, James; Denney, Laura; Dean, Charlotte H.; Cookson, William O. C.; Moffatt, Miriam F.; Lloyd, Clare M.			Pulmonary ORMDL3 is critical for induction of Alternaria-induced allergic airways disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ORMDL3; asthma; unfolded protein response; uric acid; Alternaria	UNFOLDED-PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM; URIC-ACID; ER STRESS; TRANSCRIPTION FACTOR; ASTHMA PATHOGENESIS; BRONCHIAL-ASTHMA; GENE-EXPRESSION; UNEXPECTED ROLE; ATF6	Background: Genome-wide association studies have identified the ORM (yeast)-like protein isoform 3 (ORMDL3) gene locus on human chromosome 17q to be a highly significant risk factor for childhood-onset asthma. Objective: We sought to investigate in vivo the functional role of ORMDL3 in disease inception. Methods: An Ormdl3-deficientmousewas generated andthe role of ORMDL3 in the generation of allergic airways disease to the fungal aeroallergen Alternaria alternata was determined. An adenoassociated viral vector was also used to reconstitute ORMDL3 expression in airway epithelial cells of Ormdl3 knockout mice. Results: Ormdl3 knockout mice were found to be protected from developing allergic airways disease and showed a marked decrease in pathophysiology, including lung function and airway eosinophilia induced by Alternaria. Alternaria is a potent inducer of cellular stress and the unfolded protein response, and ORMDL3 was found to play a critical role in driving the activating transcription factor 6-mediated arm of this response through Xbp1 and downstream activation of the endoplasmic reticulum-associated degradation pathway. In addition, ORMDL3 mediated uric acid release, another marker of cellular stress. In the knockout mice, reconstitution of Ormdl3 transcript levels specifically in the bronchial epithelium resulted in reinstatement of susceptibility to fungal allergen-induced allergic airways disease. Conclusions: This study demonstrates that ORMDL3, an asthma susceptibility gene identified by genome-wide association studies, contributes to key pathways that promote changes in airway physiology during allergic immune responses.	[Loser, Stephan; Gregory, Lisa G.; Schaefer, Katrein; Walker, Simone A.; Buckley, James; Denney, Laura; Dean, Charlotte H.; Lloyd, Clare M.] Imperial Coll London, Natl Heart & Lung Inst, Inflammat Repair & Dev Sect, London, England; [Zhang, Youming; Cookson, William O. C.; Moffatt, Miriam F.] Imperial Coll London, Natl Heart & Lung Inst, Genom Med Ctr, London, England	Imperial College London; Imperial College London	Lloyd, CM (corresponding author), Imperial Coll London, Leukocyte Biol, London SW7 2AZ, England.	c.lloyd@imperial.ac.uk	Cookson, William/HHC-1790-2022	Zhang, Youming/0000-0001-5403-4044; Gregory, Lisa/0000-0003-2199-5417; Buckley, James/0000-0001-9567-1621; Lloyd, Clare/0000-0001-8977-6726	Wellcome Trust [087618/Z/08/Z, 096964/Z/11/Z, 097117/Z/11/Z]; Medical Research Council [G1000758] Funding Source: researchfish; National Institute for Health Research [NF-SI-0512-10126] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre, MRC-Asthma UK Centre] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK	This study was funded by the Wellcome Trust (grant nos. 087618/Z/08/Z, 096964/Z/11/Z, and 097117/Z/11/Z), but it had no input to study design; collection, analysis, or interpretation of data; writing of the report, or the decision to submit the report for publication.	Adachi Y, 2008, CELL STRUCT FUNCT, V33, P75, DOI 10.1247/csf.07044; Albertoni G, 2015, BRAZ J MED BIOL RES, V48, P51, DOI 10.1590/1414-431X20144032; Bell CL, 2011, J CLIN INVEST, V121, P2427, DOI 10.1172/JCI57367; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Breslow DK, 2010, NATURE, V463, P1048, DOI 10.1038/nature08787; Cantero-Recasens G, 2010, HUM MOL GENET, V19, P111, DOI 10.1093/hmg/ddp471; Castanhinha S, 2015, J ALLERGY CLIN IMMUN, V136, P312, DOI 10.1016/j.jaci.2015.01.016; Chao HH, 2008, ACTA PHARMACOL SIN, V29, P1301, DOI 10.1111/j.1745-7254.2008.00877.x; Dales RE, 2000, AM J RESP CRIT CARE, V162, P2087, DOI 10.1164/ajrccm.162.6.2001020; Downs SH, 2001, AM J RESP CRIT CARE, V164, P455, DOI 10.1164/ajrccm.164.3.2008042; Gold MJ, 2016, MUCOSAL IMMUNOL, V9, P809, DOI 10.1038/mi.2015.104; Ha SG, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3479; Hara K, 2014, J IMMUNOL, V192, P4032, DOI 10.4049/jimmunol.1400110; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hjelmqvist L, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-6-research0027; Holgate ST, 2011, IMMUNOL REV, V242, P205, DOI 10.1111/j.1600-065X.2011.01030.x; Juncadella IJ, 2013, NATURE, V493, P547, DOI 10.1038/nature11714; Kim SR, 2013, J ALLERGY CLIN IMMUN, V132, P1397, DOI 10.1016/j.jaci.2013.08.041; Kool M, 2011, IMMUNITY, V34, P527, DOI 10.1016/j.immuni.2011.03.015; Li L, 2014, ASIAN PAC J ALLERGY, V32, P93, DOI 10.12932/AP0337.32.1.2014; LODISH HF, 1992, J BIOL CHEM, V267, P12753; Mahn K, 2009, P NATL ACAD SCI USA, V106, P10775, DOI 10.1073/pnas.0902295106; Menu P, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.132; Miller M, 2014, J IMMUNOL, V192, P3475, DOI 10.4049/jimmunol.1303047; Miller M, 2012, P NATL ACAD SCI USA, V109, P16648, DOI 10.1073/pnas.1204151109; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; O'Driscoll B Ronan, 2005, BMC Pulm Med, V5, P4, DOI 10.1186/1471-2466-5-4; Oyeniran C, 2015, J ALLERGY CLIN IMMUN, V136, P1035, DOI 10.1016/j.jaci.2015.02.031; Seibler J, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng012; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shi Y, 2009, TOXICOL SCI, V109, P247, DOI 10.1093/toxsci/kfp060; Shoulders MD, 2013, CELL REP, V3, P1279, DOI 10.1016/j.celrep.2013.03.024; Snelgrove RJ, 2014, J ALLERGY CLIN IMMUN, V134, P583, DOI 10.1016/j.jaci.2014.02.002; Tavendale R, 2008, J ALLERGY CLIN IMMUN, V121, P860, DOI 10.1016/j.jaci.2008.01.015; Tham R, 2014, PEDIAT ALLERG IMM-UK, V25, P439, DOI 10.1111/pai.12257; Todd DJ, 2008, NAT REV IMMUNOL, V8, P663, DOI 10.1038/nri2359; Walker V, 2009, DIABETES OBES METAB, V11, P823, DOI 10.1111/j.1463-1326.2009.01054.x; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Worgall TS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005765; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zhao JM, 2012, INT J ONCOL, V40, P1923, DOI 10.3892/ijo.2012.1398; Zhuang LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060630	45	56	58	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1496	+		10.1016/j.jaci.2016.07.033	http://dx.doi.org/10.1016/j.jaci.2016.07.033			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27623174	Green Accepted, Green Published, hybrid			2022-12-18	WOS:000400465300010
J	Lam, EPS; Kariyawasam, HH; Rana, BMJ; Durham, SR; McKenzie, ANJ; Powell, N; Orban, N; Lennartz-Walker, M; Hopkins, C; Ying, S; Rimmer, J; Lund, VJ; Cousins, DJ; Till, SJ				Lam, Emily P. S.; Kariyawasam, Harsha H.; Rana, Batika M. J.; Durham, Stephen R.; McKenzie, Andrew N. J.; Powell, Nicholas; Orban, Nara; Lennartz-Walker, Melissa; Hopkins, Claire; Ying, Sun; Rimmer, Joanne; Lund, Valerie J.; Cousins, David J.; Till, Stephen J.			IL-25/IL-33-responsive T(H)2 cells characterize nasal polyps with a default T(H)17 signature in nasal mucosa	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis with nasal polyps; nasal mucosa; IL-25; IL-33; IL-17RB; ST2; T-cell phenotype; T(H)2 cells; T(H)17 cells; T-cell receptor V beta repertoire; microarray	INNATE LYMPHOID-CELLS; HUMAN TH2 CELLS; CHRONIC RHINOSINUSITIS; T-CELLS; TH17 CELLS; AIRWAY INFLAMMATION; CYTOKINE PRODUCTION; TYPE-2 IMMUNITY; CUTTING EDGE; HOST-DEFENSE	Background: Chronic rhinosinusitis with nasal polyposis (CRSwNP) in Western countries is characterized by eosinophilia, IgE production, and T(H)2 cytokine expression. Type 2 innate lymphoid cells from polyps produce IL-5 and IL-13 in response to IL-25 and IL-33, although the relevance of this axis to local mucosal T-cell responses is unknown. Objective: We sought to investigate the role of the IL-25/IL-33 axis in local mucosal T-cell responses in patients with CRSwNP. Methods: Polyp tissue and blood were obtained from patients undergoing nasal polypectomy. Control nasal biopsy specimens and blood were obtained from healthy volunteers. Tissue was cultured in a short-term explant model. T-cell surface phenotype/intracellular cytokines were assessed by means of flow cytometry. T-cell receptor variable beta-chain analysis was performed with the immunoSEQ assay. Microarrays were performed for gene expression analysis. Results: IL-25 receptor (IL-17RB)-expressing T(H)2 effector cells were identified in nasal polyp tissue but not the healthy nasal mucosa or periphery. IL-17RB(+) CD4(+) polyp-derived T(H)2 cells coexpressed ST2 (IL-33 receptor) and responded to IL-25 and IL-33 with enhanced IL-5 and IL-13 production. Within IL-17RB(+) CD4(+) T cells, several identical T-cell receptor variable beta-chain complementarity-determining region 3 sequences were identified in different subjects, suggesting clonal expansion driven by a common antigen. Abundant IL-17-producing T cells were observed in both healthy nasal mucosal and polyp populations,with T(H)17-related genes the most overexpressed compared with peripheral blood T cells. Conclusion: IL-25 and IL-33 can interact locally with IL-17RB(+) ST2(+) polyp T cells to augment T(H)2 responses in patients with CRSwNP. A local T(H)17 response might be important in healthy nasal mucosal immune homeostasis.	[Lam, Emily P. S.; Lennartz-Walker, Melissa; Ying, Sun; Till, Stephen J.] Kings Coll London, Guys Hosp, Div Asthma Allergy & Lung Biol, London SE1 9RT, England; [Kariyawasam, Harsha H.; Rimmer, Joanne; Lund, Valerie J.] UCL, Royal Natl Throat Nose Ear Hosp, Allergy & Med Rhinol Sect, London WC1E 6BT, England; [Rana, Batika M. J.; McKenzie, Andrew N. J.] Med Res Council Lab Mol Biol, Cambridge, England; [Durham, Stephen R.; Orban, Nara] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sect Allergy & Clin Immunol, London SW7 2AZ, England; [Powell, Nicholas] Kings Coll London, Div Transplantat Immunol & Mucosal Biol, London SE1 9RT, England; [Powell, Nicholas] Kings Coll London, Med Res Council Ctr Transplantat, London SE1 9RT, England; [Cousins, David J.] Univ Leicester, Leicester Inst Lung Hlth, NIHR Leicester Resp Biomed Res Unit, Dept Infect Immun & Inflammat, Leicester LE1 7RH, Leics, England; [Hopkins, Claire] Guys & St Thomas Hosp, Dept ENT, London, England; [Lam, Emily P. S.; Kariyawasam, Harsha H.; Rana, Batika M. J.; Durham, Stephen R.; Lennartz-Walker, Melissa; Cousins, David J.; Till, Stephen J.] MRC, London W1N 4AL, England; [Lam, Emily P. S.; Kariyawasam, Harsha H.; Rana, Batika M. J.; Durham, Stephen R.; Lennartz-Walker, Melissa; Cousins, David J.; Till, Stephen J.] Asthma UK Ctr Allerg Mech Asthma, London, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; MRC Laboratory Molecular Biology; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); Imperial College London; University of London; King's College London; University of London; King's College London; University of Leicester; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Till, SJ (corresponding author), Kings Coll London, Guys Hosp, Div Asthma Allergy & Lung Biol, London SE1 9RT, England.	stephen.till@kcl.ac.uk		Till, Stephen/0000-0003-4518-3093; Cousins, David/0000-0003-3821-9596; Powell, Nick/0000-0003-3231-6950; Orban, Nara/0000-0002-2169-9231	Clinician Scientist Fellowship from The Health Foundation; Academy of Medical Sciences; HEFCE Clinical Senior Lectureship Award; MRC-Asthma UK PhD studentships; Medical Research Council; Asthma UK; National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London; NIHR Leicester Respiratory Biomedical Research Unit; MRC [MC_U105178805] Funding Source: UKRI; Medical Research Council [MC_U105178805] Funding Source: researchfish; Wellcome Trust [101159/Z/13/Z] Funding Source: researchfish; Asthma UK [09/020] Funding Source: researchfish	Clinician Scientist Fellowship from The Health Foundation; Academy of Medical Sciences(Academy of Medical Sciences (AMS)); HEFCE Clinical Senior Lectureship Award; MRC-Asthma UK PhD studentships(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Asthma UK; National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London; NIHR Leicester Respiratory Biomedical Research Unit; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Wellcome Trust(Wellcome TrustEuropean Commission); Asthma UK	S.J.T. was supported by a Clinician Scientist Fellowship from The Health Foundation and Academy of Medical Sciences and an HEFCE Clinical Senior Lectureship Award. B.M.J.R. and E.P.S.L. were supported by MRC-Asthma UK PhD studentships. D.J.C. was supported by grants from the Medical Research Council and Asthma UK. This research was also supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London and the NIHR Leicester Respiratory Biomedical Research Unit. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.	Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Baba S, 2014, LARYNGOSCOPE, V124, pE115, DOI 10.1002/lary.24462; Bachert C, 2008, CURR OPIN ALLERGY CL, V8, P34, DOI 10.1097/ACI.0b013e3282f4178f; Bending D, 2009, J CLIN INVEST, V119, P565, DOI 10.1172/JCI37865; Boniface K, 2010, J IMMUNOL, V185, P679, DOI 10.4049/jimmunol.1000366; Chapman TJ, 2010, J IMMUNOL, V184, P3841, DOI 10.4049/jimmunol.0902281; Corrigan CJ, 2011, J ALLERGY CLIN IMMUN, V128, P116, DOI 10.1016/j.jaci.2011.03.043; Cousins DJ, 2002, J IMMUNOL, V169, P2498, DOI 10.4049/jimmunol.169.5.2498; Davison S, 2000, CLIN EXP IMMUNOL, V121, P181, DOI 10.1046/j.1365-2249.2000.01270.x; Derycke L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097581; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Iinuma T, 2015, ANN ALLERG ASTHMA IM, V114, P289, DOI 10.1016/j.anai.2015.01.013; Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009; Kamekura R, 2012, CLIN EXP ALLERGY, V42, P218, DOI 10.1111/j.1365-2222.2011.03867.x; Kawaguchi Mio, 2009, Inflammation & Allergy Drug Targets, V8, P383; Kurowska-Stolarska M, 2008, J IMMUNOL, V181, P4780, DOI 10.4049/jimmunol.181.7.4780; Lecart S, 2002, EUR J IMMUNOL, V32, P2979, DOI 10.1002/1521-4141(2002010)32:10<2979::AID-IMMU2979>3.0.CO;2-5; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Maggi L, 2010, EUR J IMMUNOL, V40, P2174, DOI 10.1002/eji.200940257; Miljkovic D, 2014, ALLERGY, V69, P1154, DOI 10.1111/all.12440; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Patou J, 2008, J ALLERGY CLIN IMMUN, V121, P110, DOI 10.1016/j.jaci.2007.08.059; Peterson S, 2012, J ALLERGY CLIN IMMUN, V129, P119, DOI 10.1016/j.jaci.2011.08.021; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Purwar R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016245; Rathinam VAK, 2010, NAT IMMUNOL, V11, P395, DOI 10.1038/ni.1864; Reh DD, 2010, AM J RHINOL ALLERGY, V24, P105, DOI 10.2500/ajra.2010.24.3446; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sandig H, 2007, P NATL ACAD SCI USA, V104, P12440, DOI 10.1073/pnas.0705457104; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; Shin HW, 2015, J ALLERGY CLIN IMMUN, V135, P1476, DOI 10.1016/j.jaci.2015.01.003; Starnes T, 2001, J IMMUNOL, V167, P4137, DOI 10.4049/jimmunol.167.8.4137; Tamachi T, 2006, J ALLERGY CLIN IMMUN, V118, P606, DOI 10.1016/j.jaci.2006.04.051; Tanaka K, 2000, J IMMUNOL, V164, P2277, DOI 10.4049/jimmunol.164.5.2277; Terrier B, 2010, BLOOD, V116, P4523, DOI 10.1182/blood-2010-02-267542; Till SJ, 2001, J IMMUNOL, V166, P2303, DOI 10.4049/jimmunol.166.4.2303; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Wan Q, 2011, J EXP MED, V208, P1875, DOI 10.1084/jem.20102516; Wang M, 2008, ACTA OTO-LARYNGOL, V128, P901, DOI 10.1080/00016480701760122; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Williamson PA, 2011, CLIN EXP ALLERGY, V41, P1379, DOI 10.1111/j.1365-2222.2011.03793.x; Xu D, 1998, J EXP MED, V187, P787, DOI 10.1084/jem.187.5.787; Yang XXO, 2008, J EXP MED, V205, P1063, DOI 10.1084/jem.20071978; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008; Zielinski CE, 2012, NATURE, V484, P514, DOI 10.1038/nature10957	51	56	59	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1514	1524		10.1016/j.jaci.2015.10.019	http://dx.doi.org/10.1016/j.jaci.2015.10.019			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26684290	Green Published, hybrid			2022-12-18	WOS:000376180200028
J	Mondoulet, L; Dioszeghy, V; Puteaux, E; Ligouis, M; Dhelft, V; Plaquet, C; Dupont, C; Benhamou, PH				Mondoulet, Lucie; Dioszeghy, Vincent; Puteaux, Emilie; Ligouis, Melanie; Dhelft, Veronique; Plaquet, Camille; Dupont, Christophe; Benhamou, Pierre-Henri			Specific epicutaneous immunotherapy prevents sensitization to new allergens in a murine model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; treatment; food allergy; epicutaneous immunotherapy; peanut; milk; prevention	REGULATORY T-CELLS; MILK-SPECIFIC IGE; SUBLINGUAL IMMUNOTHERAPY; INHALED ALLERGEN; DELIVERY-SYSTEM; NATURAL-HISTORY; INTACT SKIN; CHILDREN; ASTHMA; PEANUT	Background: Allergy to cow's milk increases the risk of sensitization to other foods in young children. Objectives: We sought to evaluate the effect of early epicutaneous immunotherapy (EPIT) on further sensitization to peanut or house dust mite (HDM) in a murine model of sensitization to cow's milk. Methods: BALB/c mice orally sensitized to milk were epicutaneously treated with a Viaskin patch (DBV Technologies) loaded with milk proteins for 8 weeks. Mice were then sensitized to peanut or HDM. After sensitization to peanut, mice were exposed to a peanut regimen known to induce eosinophilic esophageal inflammation. After sensitization to HDM, mice were challenged with aerosols to HDM, and airway hyperresponsiveness was evaluated by using plethysmography. Humoral response was also analyzed. The role of regulatory T (Treg) cells was evaluated by adoptively transferring Treg cells from milk EPIT treated mice to naive mice before sensitization to peanut. Protection against anaphylaxis was also investigated. Methylation of the promoter region of transcription factors was analyzed by using PCR assays. Results: In milk-sensitized mice specific EPIT prevented further sensitization to peanut or HDM. EPIT significantly modified the humoral response, reduced TH2 cytokine levels, decreased eosinophilic esophageal infiltration, and suppressed airway hyperresponsiveness. The protective effect was sustained over 2 months. Moreover, the adoptive transfer of milk EPIT Treg cells completely prevented sensitization to peanut and peanutinduced anaphylaxis. Milk EPIT enhanced methylation of the GATA-3 promoter region. Conclusions: Our results showed that EPIT influences the natural history of allergy and reduces the risk of further sensitization through a Treg cell dependent mechanism.	[Mondoulet, Lucie; Dioszeghy, Vincent; Puteaux, Emilie; Ligouis, Melanie; Dhelft, Veronique; Plaquet, Camille; Benhamou, Pierre-Henri] DBV Technol, F-922220 Bagneux, France; [Dupont, Christophe] Univ Paris Descartes Hop, Necker Enfants Malades, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Mondoulet, L (corresponding author), DBV Technol, Green Square Bat D,80-84 Rue Meuniers, F-922220 Bagneux, France.	lucie.mondoulet@dbv-technologies.com		Mondoulet, Lucie/0000-0003-0110-0321	DBV Technologies	DBV Technologies	Supported by DBV Technologies.	Adel-Patient K, 2005, ALLERGY, V60, P658, DOI 10.1111/j.1398-9995.2005.00767.x; Agbotounou W, 2013, J ALLERGY CLIN IMMUN, V131, pAB91, DOI 10.1016/j.jaci.2012.12.992; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Baba M, 1989, ACI NEWS, V1, P71; Baron-Bodo V, 2012, CLIN EXP ALLERGY, V42, P1510, DOI 10.1111/j.1365-2222.2012.04044.x; Boudousquie C, 2009, CLIN EXP ALLERGY, V39, P1415, DOI 10.1111/j.1365-2222.2009.03314.x; Cadot P, 2010, INT ARCH ALLERGY IMM, V152, P233, DOI 10.1159/000283031; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Dharmage SC, 2014, ALLERGY, V69, P17, DOI 10.1111/all.12268; Dioszeghy V, 2014, CLIN EXP ALLERGY, V44, P867, DOI 10.1111/cea.12312; Dioszeghy V, 2011, J IMMUNOL, V186, P5629, DOI 10.4049/jimmunol.1003134; Dupont C, 2010, J ALLERGY CLIN IMMUN, V125, P1165, DOI 10.1016/j.jaci.2010.02.029; Eisenbarth SC, 2004, J IMMUNOL, V172, P4527, DOI 10.4049/jimmunol.172.7.4527; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Holt P, 2004, CHEM IMMUNOL, V84, P102; Holt PG, 2007, CURR OPIN ALLERGY CL, V7, P547, DOI 10.1097/ACI.0b013e3282f14a17; Holt PG, 2013, J ALLERGY CLIN IMMUN, V132, P991, DOI 10.1016/j.jaci.2013.04.049; Holt PG, 2008, DRUG TODAY, V44, P75; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Lui KO, 2009, CURR STEM CELL RES T, V4, P70, DOI 10.2174/157488809787169093; Maazi H, 2012, CLIN EXP ALLERGY, V42, P1519, DOI 10.1111/j.1365-2222.2012.04064.x; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; Marogna M, 2008, ANN ALLERG ASTHMA IM, V101, P206, DOI 10.1016/S1081-1206(10)60211-6; Moldaver DM, 2014, MUCOSAL IMMUNOL, V7, P379, DOI 10.1038/mi.2013.56; Mondoulet L, 2010, CLIN EXP ALLERGY, V40, P659, DOI 10.1111/j.1365-2222.2009.03430.x; Mondoulet L, 2012, ISRN ALLERGY, V2012; Mondoulet Lucie, 2012, Clin Transl Allergy, V2, P22, DOI 10.1186/2045-7022-2-22; Mondoulet L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031967; Mondoulet L, 2011, INT ARCH ALLERGY IMM, V154, P299, DOI 10.1159/000321822; Nasta F, 2007, IMMUNOLOGY, V121, P62, DOI 10.1111/j.1365-2567.2007.02537.x; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Proust B, 2008, INT ARCH ALLERGY IMM, V146, P212, DOI 10.1159/000115889; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Saarinen KM, 2005, J ALLERGY CLIN IMMUN, V116, P869, DOI 10.1016/j.jaci.2005.06.018; Savilahti E, 2000, J PEDIATR GASTR NUTR, V30, pS61, DOI 10.1097/00005176-200001001-00010; Senti G, 2012, J ALLERGY CLIN IMMUN, V129, P128, DOI 10.1016/j.jaci.2011.08.036; Senti G, 2009, J ALLERGY CLIN IMMUN, V124, P997, DOI 10.1016/j.jaci.2009.07.019; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; SIGURS N, 1994, J ALLERGY CLIN IMMUN, V94, P757, DOI 10.1016/0091-6749(94)90184-8; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Soyer OU, 2013, ALLERGY, V68, P161, DOI 10.1111/all.12085; Szefler SJ, 2013, J ALLERGY CLIN IMMUN, V131, P36, DOI 10.1016/j.jaci.2012.11.009; Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572; Todd DG, 2007, PEDIATRICS, V120, P1304, DOI 10.1542/peds.2007-0350; Van Hove CL, 2007, AM J RESP CELL MOL, V36, P573, DOI 10.1165/rcmb.2006-0385OC; van Rijt LS, 2012, ALLERGY, V67, P1383, DOI 10.1111/all.12017; Wahn U, 2013, PEDIAT ALLERG IMM-UK, V24, P308, DOI 10.1111/pai.12092; Wood RA, 2003, PEDIATRICS, V111, P1631; Yamashita M, 2002, J BIOL CHEM, V277, P42399, DOI 10.1074/jbc.M205876200; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128	54	56	58	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1546	U256		10.1016/j.jaci.2014.11.028	http://dx.doi.org/10.1016/j.jaci.2014.11.028			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25583102				2022-12-18	WOS:000355933400018
J	Haccuria, A; Michils, A; Michiels, S; Van Muylem, A				Haccuria, Amaryllis; Michils, Alain; Michiels, Sebastien; Van Muylem, Alain			Exhaled nitric oxide: A biomarker integrating both lung function and airway inflammation changes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen challenge; bronchoprovocation; fractional exhaled nitric oxide; asthma; house dust mite	ASTHMA MANAGEMENT; GUIDE; ALVEOLAR; ADULTS; RESPONSIVENESS; CHALLENGE; STIMULI; SF6; HE	Background: The increased fraction of exhaled nitric oxide (FENO) values observed in asthmatic patients are thought to reflect increased airway inflammation. However, FENO values can be affected by airway caliber reduction, representing a bias when using FENO values to assess asthma control. Objective: We sought to determine the effect of changes in both airway caliber and inflammation on FENO values using the allergen challenge model. Methods: FEV1 and FENO values were measured during early airway responses (EARs) and late airway responses after challenge with house dust mite allergens in 15 patients with mild allergic asthma. Helium and sulfur hexafluoride (SF6) phase III expired concentration slopes (S-He and S-SF6, respectively) from single-breath washout tests were measured to identify sites of airway constriction. Results: In EARs, FEV1 and FENO value decreases reached 36.8% and 22%, respectively (P < .001). Delta S-He was greater than Delta S-SF6 (+189.4% vs +82.2%, P = .001). In late airway responses FEV1 and FENO value decreases reached 31.7% and 28.7%, respectively (P < .001), with the same Delta S-He and Delta S-SF6 pattern (+155.8% vs +76%, P = .001). Eight hours after the EAR, FEV1 was still decreased (P < .001), whereas FENO values had returned to baseline. At 24 hours, FEV1 had returned to baseline, with FENO values increased by 38.7% (P = .04). Conclusion: In patients with mild allergic asthma, airway caliber changes modulate changes in FENO values resulting from airway inflammation. Therefore FENO should no longer be considered solely an inflammation biomarker but rather a biomarker that integrates both airway inflammation and lung function changes. Furthermore, early and late phases resulting from allergen exposure were shown to involve similar lung regions.	[Haccuria, Amaryllis; Michils, Alain; Michiels, Sebastien; Van Muylem, Alain] Univ Libre Bruxelles, Erasme Univ Hosp, Chest Dept, B-1070 Brussels, Belgium; [Haccuria, Amaryllis] CHR, Chest Dept, Namur, Belgium	Universite Libre de Bruxelles	Van Muylem, A (corresponding author), Univ Libre Bruxelles, CUB Erasme, Chest Dept, 808 Route Lennik, B-1070 Brussels, Belgium.	avmuylem@ulb.ac.be			Chiesi; Novartis; AstraZeneca; Stallergenes	Chiesi(Chiesi Pharmaceuticals Inc); Novartis(Novartis); AstraZeneca(AstraZeneca); Stallergenes	A. Haccuria has received research support from and has a board membership with Chiesi. A. Michils has received research support from Chiesi, Novartis, and AstraZeneca; is on advisory boards for Chiesi, Novartis, and AstraZeneca; has received payment for lectures from AstraZeneca, Stallergenes, and Chiesi; and has received travel support from Novartis and Chiesi. A. Van Muylem has received research support and payment for lectures from Chiesi. S. Michiels declares that he has no relevant conflicts of interest.	ALVING K, 1993, EUR RESPIR J, V6, P1368; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Berry MA, 2005, CLIN EXP ALLERGY, V35, P1175, DOI 10.1111/j.1365-2222.2005.02314.x; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; de Gouw HWFM, 1998, AM J RESP CRIT CARE, V158, P315, DOI 10.1164/ajrccm.158.1.9703005; Diamant Z, 2013, J ALLERGY CLIN IMMUN, V132, P1045, DOI 10.1016/j.jaci.2013.08.023; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Estenne M, 2000, AM J RESP CRIT CARE, V162, P1047, DOI 10.1164/ajrccm.162.3.9912063; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Garnier P, 2013, EUR RESPIR J, V9; Gauvreau GM, 1999, AM J RESP CRIT CARE, V160, P640, DOI 10.1164/ajrccm.160.2.9809130; Gelb AF, 2004, AM J RESP CRIT CARE, V170, P737, DOI 10.1164/rccm.200403-408OC; Gibson PG, 2009, CLIN EXP ALLERGY, V39, P478, DOI 10.1111/j.1365-2222.2009.03226.x; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Gustafsson PM, 2003, EUR RESPIR J, V21, P1033, DOI 10.1183/09031936.03.00049302; HAEFELIBLEUER B, 1988, ANAT RECORD, V220, P401, DOI 10.1002/ar.1092200410; Ho LP, 2000, EUR RESPIR J, V15, P1009, DOI 10.1034/j.1399-3003.2000.01506.x; HOLM S, 1979, SCAND J STAT, V6, P65; Jiang J, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-3; Kerckx Y, 2008, J APPL PHYSIOL, V104, P918, DOI 10.1152/japplphysiol.01032.2007; Ljungberg HK, 2003, PEDIATR PULM, V36, P339, DOI 10.1002/ppul.10356; Michils A, 2008, EUR RESPIR J, V31, P539, DOI 10.1183/09031936.00020407; Michils A, 2011, J APPL PHYSIOL, V110, P1241, DOI 10.1152/japplphysiol.01401.2010; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Nakagawa S, 2013, METHODS ECOL EVOL, V4, P133, DOI 10.1111/j.2041-210x.2012.00261.x; O'Byrne PM, 1999, CLIN EXP ALLERGY, V29, P27, DOI 10.1046/j.1365-2222.1999.00005.x-i2; PAIVA M, 1987, PHYSIOL REV, V67, P750, DOI 10.1152/physrev.1987.67.3.750; Pietropaoli AP, 1999, J APPL PHYSIOL, V87, P1532, DOI 10.1152/jappl.1999.87.4.1532; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; R Core Team, R LANG ENV STAT COMP; Shaw DE, 2007, AM J RESP CRIT CARE, V176, P231, DOI 10.1164/rccm.200610-1427OC; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; TWENTYMAN OP, 1994, CLIN EXP ALLERGY, V24, P245, DOI 10.1111/j.1365-2222.1994.tb00226.x; Van Muylem A, 2013, RESP PHYSIOL NEUROBI, V185, P313, DOI 10.1016/j.resp.2012.09.011; Van Muylem A, 2010, J ALLERGY CLIN IMMUN, V126, P730, DOI 10.1016/j.jaci.2010.06.019; VANMUYLEM A, 1992, AM REV RESPIR DIS, V146, P1167, DOI 10.1164/ajrccm/146.5_Pt_1.1167; Verbanck S, 2008, J APPL PHYSIOL, V104, P925, DOI 10.1152/japplphysiol.01019.2007	41	56	64	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					554	559		10.1016/j.jaci.2013.12.1070	http://dx.doi.org/10.1016/j.jaci.2013.12.1070			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24522091				2022-12-18	WOS:000341372400006
J	Agbetile, J; Bourne, M; Fairs, A; Hargadon, B; Desai, D; Broad, C; Morley, J; Bradding, P; Brightling, CE; Green, RH; Haldar, P; Pashley, CH; Pavord, ID; Wardlaw, AJ				Agbetile, Joshua; Bourne, Michelle; Fairs, Abbie; Hargadon, Beverley; Desai, Dhananjay; Broad, Clare; Morley, Joseph; Bradding, Peter; Brightling, Christopher E.; Green, Ruth H.; Haldar, Pranabashis; Pashley, Catherine H.; Pavord, Ian D.; Wardlaw, Andrew J.			Effectiveness of voriconazole in the treatment of Aspergillus fumigatus-associated asthma (EVITA3 study)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Refractory; asthma; exacerbations; Aspergillus fumigatus; allergic bronchopulmonary aspergillosis; mold; eosinophils; voriconazole; quality of life; severe asthma with fungal sensitization	ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; RANDOMIZED CONTROLLED-TRIAL; FUNGAL SENSITIZATION; ITRACONAZOLE; EXACERBATIONS; DIAGNOSIS; SPUTUM	Background: IgE sensitization to Aspergillus fumigatus and a positive sputum fungal culture result are common in patients with refractory asthma. It is not clear whether these patients would benefit from antifungal treatment. Objectives: We sought to determine whether a 3-month course of voriconazole improved asthma-related outcomes in patients with asthma who are IgE sensitized to A fumigatus. Methods: Asthmatic patients who were IgE sensitized to A fumigatus with a history of at least 2 severe exacerbations in the previous 12 months were treated for 3 months with 200 mg of voriconazole twice daily, followed by observation for 9 months, in a double-blind, placebo-controlled, randomized design. Primary outcomes were improvement in quality of life at the end of the treatment period and a reduction in the number of severe exacerbations over the 12 months of the study. Results: Sixty-five patients were randomized. Fifty-nine patients started treatment (32 receiving voriconazole and 27 receiving placebo) and were included in an intention-to-treat analysis. Fifty-six patients took the full 3 months of medication. Between the voriconazole and placebo groups, there were no significant differences in the number of severe exacerbations (1.16 vs 1.41 per patient per year, respectively; mean difference, 0.25; 95% CI, 0.19-0.31), quality of life (change in Asthma Quality of Life Questionnaire score, 0.68 vs 0.88; mean difference between groups, 0.2; 95% CI, 20.05 to 20.11), or any of our secondary outcome measures. Conclusion: We were unable to show a beneficial effect of 3 months of treatment with voriconazole in patients with moderate-to-severe asthma who were IgE sensitized to A fumigatus on either the rate of severe exacerbations, quality of life, or other markers of asthma control.	Univ Leicester, Inst Lung Hlth, Dept Infect Immun & Inflammat, Leicester, Leics, England; Glenfield Gen Hosp, Univ Hosp Leicester NHS Trust, Dept Resp Med, Leicester LE3 9QP, Leics, England	University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital	Wardlaw, AJ (corresponding author), Glenfield Gen Hosp, Inst Lung Hlth, Groby Rd, Leicester LE3 9QP, Leics, England.	aw24@le.ac.uk	Pashley, Catherine/M-9002-2015	Pashley, Catherine/0000-0003-4023-3610; Pavord, Ian/0000-0002-4288-5973; Haldar, Pranabashis/0000-0002-1572-5421; Bradding, Peter/0000-0001-8403-0319; Broad, Claire/0000-0003-1557-9126; brightling, chris/0000-0002-9345-4903; Wardlaw, Andrew/0000-0001-6583-0791	Pfizer; National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit; National Institute for Health Research [NF-SI-0512-10030, NF-SI-0510-10157, NF-SI-0512-10018] Funding Source: researchfish; Asthma UK [AUK-PHD-2013-250] Funding Source: researchfish	Pfizer(Pfizer); National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit; National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK	Supported by Pfizer and the National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.	Agarwal R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061105; Agarwal R, 2009, CHEST, V135, P805, DOI 10.1378/chest.08-2586; Agbetile J, 2012, CLIN EXP ALLERGY, V42, P782, DOI 10.1111/j.1365-2222.2012.03987.x; Bellmann R, 2013, CURR PHARM DESIGN, V19, P3629, DOI 10.2174/13816128113199990332; Blomqvist EH, 2001, J ALLERGY CLIN IMMUN, V107, P224, DOI 10.1067/mai.2001.112124; Bolland MJ, 2004, ANN PHARMACOTHER, V38, P46, DOI 10.1345/aph.1D222; Chishimba L, 2012, J ASTHMA, V49, P423, DOI 10.3109/02770903.2012.662568; Cockrill BA, 1999, ANNU REV MED, V50, P303, DOI 10.1146/annurev.med.50.1.303; Denning DW, 2009, AM J RESP CRIT CARE, V179, P11, DOI 10.1164/rccm.200805-737OC; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; Fairs A, 2010, AM J RESP CRIT CARE, V182, P1362, DOI 10.1164/rccm.201001-0087OC; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Greenberger PA, 2002, J ALLERGY CLIN IMMUN, V110, P685, DOI 10.1067/mai.2002.130179; GREENBERGER PA, 1986, ANN ALLERGY, V56, P444; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hogan C, 2011, SEMIN RESP CRIT CARE, V32, P682, DOI 10.1055/s-0031-1295716; Knutsen AP, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/843763; Menzies D, 2011, ALLERGY, V66, P679, DOI 10.1111/j.1398-9995.2010.02542.x; O'Driscoll BR, 2009, CLIN EXP ALLERGY, V39, P1677, DOI 10.1111/j.1365-2222.2009.03339.x; Pavord ID, 2010, CLIN EXP ALLERGY, V40, P62, DOI 10.1111/j.1365-2222.2009.03410.x; Raaska K, 2002, CLIN PHARMACOL THER, V72, P362, DOI 10.1067/mcp.2002.127397; Stevens DA, 2000, NEW ENGL J MED, V342, P756, DOI 10.1056/NEJM200003163421102; Treasure T, 1998, BRIT MED J, V317, P362; WARK P. A., 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001108.PUB2; Wark PAB, 2003, J ALLERGY CLIN IMMUN, V111, P952, DOI 10.1067/mai.2003.1388; Weiler S, 2011, ANTIMICROB AGENTS CH, V55, P925, DOI 10.1128/AAC.00949-10	26	56	56	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					33	39		10.1016/j.jaci.2013.09.050	http://dx.doi.org/10.1016/j.jaci.2013.09.050			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24290286	Green Submitted			2022-12-18	WOS:000338930300005
J	Nakashima, C; Otsuka, A; Kitoh, A; Honda, T; Egawa, G; Nakajima, S; Nakamizo, S; Arita, M; Kubo, M; Miyachi, Y; Kabashima, K				Nakashima, Chisa; Otsuka, Atsushi; Kitoh, Akihiko; Honda, Tetsuya; Egawa, Gyohei; Nakajima, Saeko; Nakamizo, Satoshi; Arita, Makoto; Kubo, Masato; Miyachi, Yoshiki; Kabashima, Kenji			Basophils regulate the recruitment of eosinophils in a murine model of irritant contact dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophil; basophil; fibroblast; eotaxin/CCL11; RANTES/CCL5; irritant contact dermatitis; reactive oxygen species; tumor necrosis factor	CHRONIC ALLERGIC INFLAMMATION; MAST-CELLS; PUSTULAR FOLLICULITIS; TRANSGENIC MICE; TNF-ALPHA; IN-VIVO; IL-4; IGE; INTERLEUKIN-5; RESPONSES	Background: Although eosinophils have been detected in several human skin diseases in the vicinity of basophils, how eosinophils infiltrate the skin and the role of eosinophils in the development of skin inflammation have yet to be examined. Objective: Using murine irritant contact dermatitis (ICD) as a model, we sought to clarify the roles of eosinophils in ICD and the underlying mechanism of eosinophil infiltration of the skin. Methods: We induced croton oil-induced ICD in eosinophil-deficient Delta dblGATA mice with or without a reactive oxygen species (ROS) inhibitor. We performed cocultivation with fibroblasts and bone marrow-derived basophils and evaluated eosinophil migration using a chemotaxis assay. Results: ICD responses were significantly attenuated in the absence of eosinophils or by treatment with the ROS inhibitor. ROS was produced abundantly by eosinophils, and both basophils and eosinophils were detected in human and murine ICD skin lesions. In coculture experiments, basophils attracted eosinophils, especially in the presence of fibroblasts. Moreover, basophils produced IL-4 and TNF-alpha in contact with fibroblasts and promoted the expression of eotaxin/CCL11 from fibroblasts in vitro. Conclusion: Eosinophils mediated the development of murine ICD, possibly through ROS production. Recruitment of eosinophils into the skin was induced by basophils in cooperation with fibroblasts. Our findings introduce the novel concept that basophils promote the recruitment of eosinophils into the skin through fibroblasts in the development of skin inflammation.	[Nakashima, Chisa; Otsuka, Atsushi; Kitoh, Akihiko; Honda, Tetsuya; Egawa, Gyohei; Nakajima, Saeko; Nakamizo, Satoshi; Miyachi, Yoshiki; Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto 6068507, Japan; [Arita, Makoto] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Tokyo 1138654, Japan; [Kubo, Masato] RIKEN Yokohama Inst, Integrat Med Sci IMS, Lab Cytokine Regulat, Yokohama, Kanagawa, Japan; [Kubo, Masato] Tokyo Univ Sci, Res Inst Biomed Sci, Div Mol Pathol, Chiba, Japan	Kyoto University; University of Tokyo; RIKEN; Tokyo University of Science	Otsuka, A (corresponding author), Kyoto Univ, Grad Sch Med, Dept Dermatol, Sakyo Ku, 54 Shogoin Kawara, Kyoto 6068507, Japan.	otsukamn@kuhp.kyoto-u.ac.jp; kaba@kuhp.kyoto-u.ac.jp	Nakajima, Saeko/AAB-1577-2021; Nakamizo, Satoshi/ABH-2121-2021; Kubo, Masato/A-5918-2016; Kabashima, Kenji/G-2521-2014	Nakamizo, Satoshi/0000-0001-9332-0369; Arita, Makoto/0000-0001-9902-0463; Egawa, Gyohei/0000-0002-6101-4719; Nakajima, Saeko/0000-0003-0831-1447; Kabashima, Kenji/0000-0002-0773-0554; Otsuka, Atsushi/0000-0001-7365-947X	Ministry of Education, Culture, Sports, Science and Technology; Ministry of Health, Labor and Welfare of Japan	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	Supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labor and Welfare of Japan.	Aloush V, 2010, CLIN EXP RHEUMATOL, V28, P462; Bryce PJ, 2004, IMMUNITY, V20, P381, DOI 10.1016/S1074-7613(04)00080-9; Cheung PFY, 2010, INT IMMUNOL, V22, P453, DOI 10.1093/intimm/dxq027; Denzel A, 2008, NAT IMMUNOL, V9, P733, DOI 10.1038/ni.1621; Duez C, 2004, J ALLERGY CLIN IMMUN, V114, P820, DOI 10.1016/j.jaci.2004.08.011; DVORAK HF, 1972, J EXP MED, V135, P235, DOI 10.1084/jem.135.2.235; Dyer KD, 2008, J IMMUNOL, V181, P4004, DOI 10.4049/jimmunol.181.6.4004; Egawa G, 2011, J INVEST DERMATOL, V131, P2178, DOI 10.1038/jid.2011.198; Egawa G, 2011, J INVEST DERMATOL, V131, P977, DOI 10.1038/jid.2010.386; Honda T, 2013, J INVEST DERMATOL, V133, P303, DOI 10.1038/jid.2012.284; Ito Y, 2011, ALLERGY, V66, P1107, DOI 10.1111/j.1398-9995.2011.02570.x; Kita H, 2011, IMMUNOL REV, V242, P161, DOI 10.1111/j.1600-065X.2011.01026.x; Liu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059872; Mochizuki M, 1999, INT ARCH ALLERGY IMM, V120, P19, DOI 10.1159/000053587; Mori M, 2009, INT ARCH ALLERGY IMM, V149, P31, DOI 10.1159/000210651; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; Mukai K, 2005, IMMUNITY, V23, P191, DOI 10.1016/j.immuni.2005.06.011; Nagata Makoto, 2005, Current Drug Targets - Inflammation and Allergy, V4, P503, DOI 10.2174/1568010054526322; Nakahigashi K, 2012, J ALLERGY CLIN IMMUN, V129, P536, DOI 10.1016/j.jaci.2011.11.034; Nakajima S, 2010, J IMMUNOL, V184, P5595, DOI 10.4049/jimmunol.0903260; Nathan C, 2013, NAT REV IMMUNOL, V13, P349, DOI 10.1038/nri3423; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Nosbaum A, 2009, EUR J DERMATOL, V19, P325, DOI 10.1684/ejd.2009.0686; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Obata K, 2007, BLOOD, V110, P913, DOI 10.1182/blood-2007-01-068718; Ochkur SI, 2007, J IMMUNOL, V178, P7879, DOI 10.4049/jimmunol.178.12.7879; Otsuka A, 2012, J EUR ACAD DERMATOL, V26, P527, DOI 10.1111/j.1468-3083.2011.04091.x; Otsuka A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2740; Otsuka A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025538; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Rokudai A, 2006, BIOL PHARM BULL, V29, P1102, DOI 10.1248/bpb.29.1102; Rosenberg HF, 2013, NAT REV IMMUNOL, V13, P9, DOI 10.1038/nri3341; Saeki K, 2013, J INVEST DERMATOL, V133, P2161, DOI 10.1038/jid.2013.160; Sato T, 2004, BIOCHEM BIOPH RES CO, V314, P468, DOI 10.1016/j.bbrc.2003.12.124; Sawaguchi M, 2012, J IMMUNOL, V188, P1809, DOI 10.4049/jimmunol.1101746; Schroeder JT, 2011, IMMUNOL REV, V242, P144, DOI 10.1111/j.1600-065X.2011.01023.x; Schuerwegh AJM, 2010, P NATL ACAD SCI USA, V107, P2586, DOI 10.1073/pnas.0913054107; Schuessel K, 2006, FREE RADICAL BIO MED, V40, P850, DOI 10.1016/j.freeradbiomed.2005.10.041; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Tang H, 2010, NAT IMMUNOL, V11, P608, DOI 10.1038/ni.1883; TOMINAGA A, 1991, J EXP MED, V173, P429, DOI 10.1084/jem.173.2.429; Ugajin T, 2009, J LEUKOCYTE BIOL, V86, P1417, DOI 10.1189/jlb.0609400; Wang HB, 2007, J IMMUNOL, V179, P7585, DOI 10.4049/jimmunol.179.11.7585; Yagi R, 2007, MOL CELL BIOL, V27, P8087, DOI 10.1128/MCB.00631-07; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; Yu CN, 2002, J EXP MED, V195, P1387, DOI 10.1084/jem.20020656	46	56	57	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					100	+		10.1016/j.jaci.2014.02.026	http://dx.doi.org/10.1016/j.jaci.2014.02.026			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24713170	Green Submitted			2022-12-18	WOS:000338930300014
J	Siliciano, JD; Siliciano, RF				Siliciano, Janet D.; Siliciano, Robert F.			Recent developments in the search for a cure for HIV-1 infection: Targeting the latent reservoir for HIV-1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HIV; latency; eradication; reservoir; cure; stem cell transplantation; antiretroviral therapy	HUMAN-IMMUNODEFICIENCY-VIRUS; CD4(+) T-CELLS; ACTIVE ANTIRETROVIRAL THERAPY; HISTONE DEACETYLASE INHIBITORS; IN-VITRO; HIV-1-INFECTED PATIENTS; TYPE-1 RESERVOIRS; EX-VIVO; P-TEFB; ACTIVATION	HIV-1 infection can now be readily controlled with combination antiretroviral therapy. However, the virus persists indefinitely in a stable latent reservoir in resting CD4(+) T cells. This reservoir generally prevents cure of the infection with combination antiretroviral therapy alone. However, several recent cases of potential HIV-1 cure have generated renewed optimism. Here we review these cases and consider new developments in our understanding of the latent reservoir. In addition, we consider clinical aspects of curative strategies to provide a more realistic picture of what a generally applicable cure for HIV-1 infection is likely to entail.	[Siliciano, Janet D.; Siliciano, Robert F.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Siliciano, Robert F.] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Siliciano, RF (corresponding author), Johns Hopkins Univ, Sch Med, 879 MRB,733 N Broadway, Baltimore, MD 21205 USA.	rsiliciano@jhmi.edu			Martin Delaney Collaboratory of AIDS Researchers for Eradication (US National Institutes of Health) [AI076113]; Foundation for AIDS Research [108165 50 RGRL]; Johns Hopkins Center for AIDS Research (US National Institutes of Health) [AI094189]; US National Institutes of Health [AI43222]; Howard Hughes Medical Institute; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI094189, R01AI043222] Funding Source: NIH RePORTER	Martin Delaney Collaboratory of AIDS Researchers for Eradication (US National Institutes of Health); Foundation for AIDS Research; Johns Hopkins Center for AIDS Research (US National Institutes of Health); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Martin Delaney Collaboratory of AIDS Researchers for Eradication (US National Institutes of Health grant AI076113), the Foundation for AIDS Research (108165 50 RGRL), the Johns Hopkins Center for AIDS Research (US National Institutes of Health grant AI094189), US National Institutes of Health grant AI43222, and the Howard Hughes Medical Institute.	Archin NM, 2012, NATURE, V487, P482, DOI 10.1038/nature11286; Archin NM, 2009, AIDS RES HUM RETROV, V25, P207, DOI 10.1089/aid.2008.0191; Archin NM, 2014, J INFECT DIS; Baldauf HM, 2012, NAT MED, V18, P1682, DOI 10.1038/nm.2964; Bartholomeeusen K, 2013, J BIOL CHEM, V288, P14400, DOI 10.1074/jbc.M113.464834; Beans EJ, 2013, P NATL ACAD SCI USA, V110, P11698, DOI 10.1073/pnas.1302634110; Blazkova J, 2012, J INFECT DIS, V206, P765, DOI 10.1093/infdis/jis412; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; Brenchley JM, 2004, J VIROL, V78, P1160, DOI 10.1128/JVI.78.3.1160-1168.2004; Brooks DG, 2003, IMMUNITY, V19, P413, DOI 10.1016/S1074-7613(03)00236-X; Bullen CK, 2014, NAT MED, V20, P425, DOI 10.1038/nm.3489; Burke B, 2007, J VIROL, V81, P7424, DOI 10.1128/JVI.02838-06; Buzon MJ, 2014, NAT MED, V20, P139, DOI 10.1038/nm.3445; Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Denton PW, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003872; Descours B, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-87; Doitsh G, 2014, NATURE, V505, P509, DOI 10.1038/nature12940; Dornadula G, 1999, JAMA-J AM MED ASSOC, V282, P1627, DOI 10.1001/jama.282.17.1627; Eisele E, 2012, IMMUNITY, V37, P377, DOI 10.1016/j.immuni.2012.08.010; Eriksson S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003174; Farber DL, 2014, NAT REV IMMUNOL, V14, P24, DOI 10.1038/nri3567; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Han YF, 2004, J VIROL, V78, P6122, DOI 10.1128/JVI.78.12.6122-6133.2004; He GC, 2002, DNA CELL BIOL, V21, P697, DOI 10.1089/104454902760599672; Henrich TJ, 2013, J INFECT DIS, V207, P1694, DOI 10.1093/infdis/jit086; Henrich TJ, 2014, C RETR OPP INF MAR 6; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Ho YC, 2013, CELL, V155, P540, DOI 10.1016/j.cell.2013.09.020; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; Jilek BL, 2012, NAT MED, V18, P446, DOI 10.1038/nm.2649; Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188; Josefsson L, 2013, P NATL ACAD SCI USA, V110, pE4987, DOI 10.1073/pnas.1308313110; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; Korin YD, 2002, J VIROL, V76, P8118, DOI 10.1128/JVI.76.16.8118-8123.2002; Kulkosky J, 2001, BLOOD, V98, P3006, DOI 10.1182/blood.V98.10.3006; Kulkosky J, 2002, J INFECT DIS, V186, P1403, DOI 10.1086/344357; Maldarelli F, 2007, PLOS PATHOG, V3, P484, DOI 10.1371/journal.ppat.0030046; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; O'Doherty U, 2002, J VIROL, V76, P10942, DOI 10.1128/JVI.76.21.10942-10950.2002; Palmer S, 2003, J CLIN MICROBIOL, V41, P4531, DOI 10.1128/JCM.41.10.4531-4536.2003; Palmer S, 2008, P NATL ACAD SCI USA, V105, P3879, DOI 10.1073/pnas.0800050105; Panel on Antiretroviral Guidelines for Adults and Adolescents, GUIDELINES USE ANTIR; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Persaud D, 2014, C RETR OPP INF MAR 5; Persaud D, 2013, NEW ENGL J MED, V369, P1828, DOI 10.1056/NEJMoa1302976; Peterlin BM, 2006, MOL CELL, V23, P297, DOI 10.1016/j.molcel.2006.06.014; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; Pierson T, 2000, J VIROL, V74, P7824, DOI 10.1128/JVI.74.17.7824-7833.2000; Post WS, 2014, ANN INTERN MED, V160, P458, DOI 10.7326/M13-1754; Prins JM, 1999, AIDS, V13, P2405, DOI 10.1097/00002030-199912030-00012; Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706; Sahu GK, 2006, VIROLOGY, V355, P127, DOI 10.1016/j.virol.2006.07.020; Sandler NG, 2012, NAT REV MICROBIOL, V10, P655, DOI 10.1038/nrmicro2848; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Shan L, 2012, IMMUNITY, V36, P491, DOI 10.1016/j.immuni.2012.01.014; Shen L, 2008, NAT MED, V14, P762, DOI 10.1038/nm1777; Siliciano Janet D, 2005, Methods Mol Biol, V304, P3; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Spina CA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003834; Strain MC, 2013, CURR OPIN HIV AIDS, V8, P106, DOI 10.1097/COH.0b013e32835d811b; Strain MC, 2003, P NATL ACAD SCI USA, V100, P4819, DOI 10.1073/pnas.0736332100; Sulkowski MS, 2014, NEW ENGL J MED, V370, P211, DOI 10.1056/NEJMoa1306218; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Williams SA, 2004, J BIOL CHEM, V279, P42008, DOI 10.1074/jbc.M402124200; Xing SF, 2013, DRUG DISCOV TODAY, V18, P541, DOI 10.1016/j.drudis.2012.12.008; Ylisastigui L, 2004, AIDS, V18, P1101, DOI 10.1097/00002030-200405210-00003; Yu JJQ, 2008, VIROLOGY, V379, P78, DOI 10.1016/j.virol.2008.05.030; Yukl SA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003347; Zeng M, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002437	78	56	63	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					12	19		10.1016/j.jaci.2014.05.026	http://dx.doi.org/10.1016/j.jaci.2014.05.026			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	25117799				2022-12-18	WOS:000338930300002
J	Tomazic, PV; Birner-Gruenberger, R; Leitner, A; Obrist, B; Spoerk, S; Lang-Loidolt, D				Tomazic, Peter Valentin; Birner-Gruenberger, Ruth; Leitner, Anita; Obrist, Britta; Spoerk, Stefan; Lang-Loidolt, Doris			Nasal mucus proteomic changes reflect altered immune responses and epithelial permeability in patients with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Nasal mucus; proteome; proteomics; allergic rhinitis; mass spectrometry	APOLIPOPROTEIN-A-I; BET V 1; SURFACTANT PROTEIN; SEQUENCE HOMOLOGY; MUCOSAL SURFACE; HOST-DEFENSE; COMPLEMENT; PROTEASES; FILAGGRIN; PLUNC	Background: Nasal mucus is the first-line defense barrier against (aero-) allergens. However, its proteome and function have not been clearly investigated. Objective: The role of nasal mucus in the pathophysiology of allergic rhinitis was investigated by analyzing its proteome in patients with allergic rhinitis (n = 29) and healthy control subjects (n = 29). Methods: Nasal mucus was collected with a suction device, tryptically digested, and analyzed by using liquid chromatography-tandem mass spectrometry. Proteins were identified by searching the SwissProt database and annotated by collecting gene ontology data from databases and existing literature. Gene enrichment analysis was performed by using Cytoscape/BINGO software tools. Proteins were quantified with spectral counting, and selected proteins were confirmed by means of Western blotting. Results: In total, 267 proteins were identified, with 20 (7.5%) found exclusively in patients with allergic rhinitis and 25 (9.5%) found exclusively in healthy control subjects. Five proteins were found to be significantly upregulated in patients with allergic rhinitis (apolipoprotein A-2 [APOA2], 9.7-fold; alpha 2-macroglobulin [A2M], 4.5-fold; apolipoprotein A-1 [APOA1], 3.2-fold; alpha 1-antitrypsin [SERPINA1], 2.5-fold; and complement C3 [C3], 2.3-fold) and 5 were found to be downregulated (antileukoproteinase [SLPI], 0.6-fold; WAP 4-disulfide core domain protein [WFDC2], 0.5-fold; haptoglobin [HP], 0.7-fold; IgJ chain [IGJ], 0.7-fold; and Ig hc V-III region BRO, 0.8-fold) compared with levels seen in healthy control subjects. Conclusion: The allergic rhinitis mucus proteome shows an enhanced immune response in which apolipoproteins might play an important role. Furthermore, an imbalance between cysteine proteases and antiproteases could be seen, which negatively affects epithelial integrity on exposure to pollen protease activity. This reflects the important role of mucus as the first-line defense barrier against allergens.	[Tomazic, Peter Valentin; Leitner, Anita; Lang-Loidolt, Doris] Med Univ Graz, ENT Univ Hosp, A-8036 Graz, Austria; [Birner-Gruenberger, Ruth] Med Univ Graz, Inst Pathol, A-8036 Graz, Austria; [Birner-Gruenberger, Ruth; Obrist, Britta; Spoerk, Stefan] Med Univ Graz, Med Res Ctr, Mass Spectrometry Core Facil, A-8036 Graz, Austria; [Birner-Gruenberger, Ruth; Obrist, Britta] Austrian Ctr Ind Biotechnol, Graz, Austria; [Birner-Gruenberger, Ruth; Obrist, Britta] Omics Ctr Graz, Graz, Austria	Medical University of Graz; Medical University of Graz; Medical University of Graz; Austrian Centre of Industrial Biotechnology	Tomazic, PV (corresponding author), Med Univ Graz, ENT Univ Hosp Graz, Auenbruggerpl 26, A-8036 Graz, Austria.	peter.tomazic@medunigraz.at; ruth.birner-gruenberger@medunigraz.at	Birner-Gruenberger, Ruth/E-8623-2010; lang-loidolt, doris/AAS-5236-2020; Birner-Gruenberger, Ruth/X-9433-2019	Birner-Gruenberger, Ruth/0000-0003-3950-0312; Birner-Gruenberger, Ruth/0000-0003-3950-0312				AKERLOF E, 1991, BIOCHEMISTRY-US, V30, P8986; Alimam MZ, 2000, AM J RESP CELL MOL, V22, P253, DOI 10.1165/ajrcmb.22.3.3768; ANDERSSON M, 1994, ALLERGY, V49, P242, DOI 10.1111/j.1398-9995.1994.tb02656.x; Bachman MA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000622; BARANIUK JN, 1992, ALLERGY, V47, P411, DOI 10.1111/j.1398-9995.1992.tb02081.x; Barthel SR, 2006, AM J RESP CELL MOL, V35, P378, DOI 10.1165/rcmb.2006-0027OC; Bateman A, 1998, J ENDOCRINOL, V158, P145, DOI 10.1677/joe.0.1580145; Beck WHJ, 2013, BBA-BIOMEMBRANES, V1828, P1503, DOI 10.1016/j.bbamem.2013.02.009; Bingle CD, 2002, HUM MOL GENET, V11, P937, DOI 10.1093/hmg/11.8.937; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Casado B, 2005, PROTEOMICS, V5, P2949, DOI 10.1002/pmic.200401172; Chan YR, 2009, J IMMUNOL, V182, P4947, DOI 10.4049/jimmunol.0803282; Clemmensen SN, 2011, EUR J HAEMATOL, V86, P517, DOI 10.1111/j.1600-0609.2011.01601.x; Courtney HS, 2006, J BIOL CHEM, V281, P5515, DOI 10.1074/jbc.M512538200; Craig-Barnes HA, 2010, J BIOL CHEM, V285, P13461, DOI 10.1074/jbc.M110.108837; De Benedetto A, 2008, J INVEST DERMATOL, V128, P1594, DOI 10.1038/sj.jid.5701208; Dittrich AM, 2010, CLIN EXP ALLERGY, V40, P1689, DOI 10.1111/j.1365-2222.2010.03508.x; Do TQ, 2008, J IMMUNOL, V181, P4177, DOI 10.4049/jimmunol.181.6.4177; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Evans CM, 2009, PHARMACOL THERAPEUT, V121, P332, DOI 10.1016/j.pharmthera.2008.11.001; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Furlaneto CJ, 2002, LIPIDS, V37, P925, DOI 10.1007/s11745-002-0981-4; Gakhar L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009098; Ghafouri B, 2006, J PROTEOME RES, V5, P330, DOI 10.1021/pr050341h; Ghafouri B, 2003, BIOCHEM SOC T, V31, P810, DOI 10.1042/BST0310810; Greene CM, 2011, EXPERT REV RESP MED, V5, P395, DOI [10.1586/ERS.11.20, 10.1586/ers.11.20]; Gunawan Hendra, 2008, Allergol Int, V57, P83, DOI 10.2332/allergolint.O-07-507; HEINZEL R, 1986, EUR J BIOCHEM, V160, P61, DOI 10.1111/j.1432-1033.1986.tb09940.x; Ho AS, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-58; HUGLI TE, 1975, J BIOL CHEM, V250, P8293; Joenvaara S, 2009, J ALLERGY CLIN IMMUN, V124, P135, DOI 10.1016/j.jaci.2008.11.048; Jun SW, 2008, J ALLERGY CLIN IMMUN, V122, P119, DOI 10.1016/j.jaci.2008.04.028; Kamijo S, 2013, J IMMUNOL, V190, P4489, DOI 10.4049/jimmunol.1201212; KIRCHHOFF C, 1991, BIOL REPROD, V45, P350, DOI 10.1095/biolreprod45.2.350; Kleinberger G, 2013, MOL NEUROBIOL, V47, P337, DOI 10.1007/s12035-012-8380-8; Liu YF, 2013, STAT INTERFACE, V6, P1; Lundgren DH, 2010, EXPERT REV PROTEOMIC, V7, P39, DOI 10.1586/EPR.09.69; Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551; Makino Y, 2010, J ALLERGY CLIN IMMUN, V126, P1163, DOI 10.1016/j.jaci.2010.06.031; Martinez-Bartolome S., 2013, J PROTEOMICS; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; McKown RL, 2009, EXP EYE RES, V88, P848, DOI 10.1016/j.exer.2008.09.002; Mortstedt H, 2013, J PROTEOME RES, V12, P234, DOI 10.1021/pr300802g; Nagel G, 2009, PEDIAT ALLERG IMM-UK, V20, P81, DOI 10.1111/j.1399-3038.2008.00740.x; NIEMANN MA, 1992, MATRIX, V12, P233, DOI 10.1016/S0934-8832(11)80066-1; Old WM, 2005, MOL CELL PROTEOMICS, V4, P1487, DOI 10.1074/mcp.M500084-MCP200; PERSSON CGA, 1991, CLIN EXP ALLERGY, V21, P17, DOI 10.1111/j.1365-2222.1991.tb00799.x; Raftery MJ, 2003, RESPIR RES, V4, DOI 10.1186/1465-9921-4-10; RAPHAEL GD, 1989, J CLIN INVEST, V84, P1528, DOI 10.1172/JCI114329; Renkonen J, 2009, ALLERGY, V64, P868, DOI 10.1111/j.1398-9995.2008.01919.x; Runswick S, 2007, RESPIROLOGY, V12, P834, DOI 10.1111/j.1440-1843.2007.01175.x; Sakai H, 2010, PFLUG ARCH EUR J PHY, V460, P645, DOI 10.1007/s00424-010-0844-y; SALLENAVE JM, 1991, BIOL CHEM H-S, V372, P13, DOI 10.1515/bchm3.1991.372.1.13; Samudre S, 2011, INVEST OPHTH VIS SCI, V52, P6265, DOI 10.1167/iovs.10-6220; Scott A, 2011, BIOCHEM SOC T, V39, P1437, DOI 10.1042/BST0391437; Shin SW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066644; Simon D, 2011, CURR OPIN PEDIATR, V23, P647, DOI 10.1097/MOP.0b013e32834cad0a; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SVENSSON C, 1995, J ALLERGY CLIN IMMUN, V96, P239, DOI 10.1016/S0091-6749(95)70013-7; SVENSSON C, 1990, J ALLERGY CLIN IMMUN, V85, P828, DOI 10.1016/0091-6749(90)90064-B; Tewfik MA, 2007, AM J RHINOL, V21, P680, DOI 10.2500/ajr.2007.21.3103; Thornton David J, 2004, Proc Am Thorac Soc, V1, P54, DOI 10.1513/pats.2306016; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433; Vinhas R, 2011, ALLERGY, V66, P1088, DOI 10.1111/j.1398-9995.2011.02598.x; Voynow JA, 2009, CHEST, V135, P505, DOI 10.1378/chest.08-0412; Wang JH, 2006, J CELL BIOL, V174, P689, DOI 10.1083/jcb.200605140; Wiesner J, 2010, VIRULENCE, V1, P440, DOI 10.4161/viru.1.5.12983; Wilkinson TS, 2011, BIOCHEM SOC T, V39, P1409, DOI 10.1042/BST0391409; Williams OW, 2006, AM J RESP CELL MOL, V34, P527, DOI 10.1165/rcmb.2005-0436SF; YANG CY, 1994, BIOCHEMISTRY-US, V33, P12451, DOI 10.1021/bi00207a011; Yu CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055122	71	56	57	2	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					741	750		10.1016/j.jaci.2013.09.040	http://dx.doi.org/10.1016/j.jaci.2013.09.040			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24290289				2022-12-18	WOS:000332397600016
J	Zaslona, Z; Okunishi, K; Bourdonnay, E; Domingo-Gonzalez, R; Moore, BB; Lukacs, NW; Aronoff, DM; Peters-Golden, M				Zaslona, Zbigniew; Okunishi, Katsuhide; Bourdonnay, Emilie; Domingo-Gonzalez, Racquel; Moore, Bethany B.; Lukacs, Nicholas W.; Aronoff, David M.; Peters-Golden, Marc			Prostaglandin E-2 suppresses allergic sensitization and lung inflammation by targeting the E prostanoid 2 receptor on T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergic sensitization; prostaglandin E-2; CD4 T cells	ASPIRIN-INDUCED ASTHMA; PROTEIN-KINASE-A; INDUCED BRONCHOCONSTRICTION; CYCLOOXYGENASE INHIBITION; CYCLIC-AMP; AIRWAY HYPERRESPONSIVENESS; INHALED PGE(2); PULMONARY INFLAMMATION; GENE-EXPRESSION; EP2 RECEPTOR	Background: Endogenous prostanoids have been suggested to modulate sensitization during experimental allergic asthma, but the specific role of prostaglandin (PG) E-2 or of specific E prostanoid (EP) receptors is not known. Objective: Here we tested the role of EP2 signaling in allergic asthma. Methods: Wild-type (WT) and EP2(-/-) mice were subjected to ovalbumin sensitization and acute airway challenge. The PGE(2) analog misoprostol was administered during sensitization in both genotypes. In vitro culture of splenocytes and flow-sorted dendritic cells and T cells defined the mechanism by which EP2 exerted its protective effect. Adoptive transfer of WT and EP2(-/-) CD4 T cells was used to validate the importance of EP2 expression on T cells. Results: Compared with WT mice, EP2(-/-) mice had exaggerated airway inflammation in this model. Splenocytes and lung lymph node cells from sensitized EP2(-/-) mice produced more IL-13 than did WT cells, suggesting increased sensitization. In WT but not EP2(-/-) mice, subcutaneous administration of misoprostol during sensitization inhibited allergic inflammation. PGE(2) decreased cytokine production and inhibited signal transducer and activator of transcription 6 phosphorylation by CD3/CD28-stimulated CD4(+) T cells. Coculture of flow cytometry-sorted splenic CD4(+) T cells and CD11c(+) dendritic cells from WT or EP2(-/-) mice suggested that the increased IL-13 production in EP2(-/-) mice was due to the lack of EP2 specifically on T cells. Adoptive transfer of CD4(+) EP2(-/-) T cells caused greater cytokine production in the lungs of WT mice than did transfer of WT CD4(+) T cells. Conclusion: We conclude that the PGE(2)-EP2 axis is an important endogenous brake on allergic airway inflammation and primarily targets T cells and that its agonism represents a potential novel therapeutic approach to asthma.	[Zaslona, Zbigniew; Okunishi, Katsuhide; Bourdonnay, Emilie; Domingo-Gonzalez, Racquel; Moore, Bethany B.; Peters-Golden, Marc] Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA; [Aronoff, David M.] Univ Michigan, Sch Med, Div Infect Dis, Ann Arbor, MI 48109 USA; [Lukacs, Nicholas W.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Peters-Golden, M (corresponding author), 6301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	petersm@umich.edu	Bourdonnay, Emilie/P-3115-2019; Lukacs, Nicholas W/ABH-5583-2020	Bourdonnay, Emilie/0000-0002-3579-5478; Zaslona, Zbigniew/0000-0003-3361-4140; Aronoff, David/0000-0003-4587-6121; Moore, Bethany/0000-0003-3051-745X; Domingo-Gonzalez, Racquel/0000-0002-7494-0439	Deutsche Forschungsgemeinschaft (German Research Foundation); American Lung Association; American Heart Association; National Institutes of Health [R01 HL94311, R01 HL58897, AI065543, AI032302, HD057176];  [T32 AI007413]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD057176] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058897, R01HL094311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI065543, R01AI065543, R01AI032302] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft (German Research Foundation)(German Research Foundation (DFG)); American Lung Association; American Heart Association(American Heart Association); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Deutsche Forschungsgemeinschaft (German Research Foundation, to Z.Z.), American Lung Association Senior Research Fellowships (to Z.Z., K.O., and E.B.), T32 AI007413 and American Heart Association (to R.D.-G.), and National Institutes of Health grants R01 HL94311 and R01 HL58897 (to M.P.-G.), AI065543 (to B.B.M.), AI032302 (to N.W.L.), and HD057176 (to D.M.A.).	Allmers H, 2005, J ALLERGY CLIN IMMUN, V116, P859, DOI 10.1016/j.jaci.2005.07.019; Amberbir A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022551; ANASTASSIOU ED, 1992, J IMMUNOL, V148, P2845; Aronoff DM, 2005, J IMMUNOL, V174, P595, DOI 10.4049/jimmunol.174.2.595; Aronoff DM, 2004, J IMMUNOL, V173, P559, DOI 10.4049/jimmunol.173.1.559; BETZ M, 1991, J IMMUNOL, V146, P108; Boutaud O, 2002, P NATL ACAD SCI USA, V99, P7130, DOI 10.1073/pnas.102588199; Church RJ, 2012, J IMMUNOL, V188, P4093, DOI 10.4049/jimmunol.1101873; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; FIGUEIREDO F, 1990, J BIOL CHEM, V265, P12317; Gauvreau GM, 1999, AM J RESP CRIT CARE, V159, P31, DOI 10.1164/ajrccm.159.1.9804030; Gavett SH, 1999, J CLIN INVEST, V104, P721, DOI 10.1172/JCI6890; Hartert TV, 2000, AM J RESP CRIT CARE, V162, P637, DOI 10.1164/ajrccm.162.2.9904038; Hashimoto K, 2005, J IMMUNOL, V174, P525, DOI 10.4049/jimmunol.174.1.525; Herrerias A, 2009, J INFLAMM-LOND, V6, DOI 10.1186/1476-9255-6-30; Herrerias A, 2009, INT ARCH ALLERGY IMM, V149, P323, DOI 10.1159/000205578; Jaffar Z, 2007, J IMMUNOL, V179, P6193, DOI 10.4049/jimmunol.179.9.6193; Jinnai N, 2004, HUM MOL GENET, V13, P3203, DOI 10.1093/hmg/ddh332; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Katsuyama M, 1998, BIOCHEM BIOPH RES CO, V251, P727, DOI 10.1006/bbrc.1998.9540; Kawikova I, 1996, AM J RESP CRIT CARE, V153, P590, DOI 10.1164/ajrccm.153.2.8564103; Kennedy CRJ, 1999, NAT MED, V5, P217, DOI 10.1038/5583; Kunikata T, 2005, NAT IMMUNOL, V6, P524, DOI 10.1038/ni1188; Kuroda E, 2011, IMMUNITY, V34, P514, DOI 10.1016/j.immuni.2011.03.019; Li GX, 2001, MOL CELL BIOL, V21, P4626, DOI 10.1128/MCB.21.14.4626-4635.2001; Liu T, 2012, P NATL ACAD SCI USA, V109, P12692, DOI 10.1073/pnas.1207816109; Lundequist A, 2010, J IMMUNOL, V184, P433, DOI 10.4049/jimmunol.0902835; Medeiros AI, 2009, J EXP MED, V206, P61, DOI 10.1084/jem.20082058; MELILLO E, 1994, AM J RESP CRIT CARE, V149, P1138, DOI 10.1164/ajrccm.149.5.8173753; Nakata J, 2005, RESPIROLOGY, V10, P149, DOI 10.1111/j.1440-1843.2005.00687.x; Nataraj C, 2001, J CLIN INVEST, V108, P1229, DOI 10.1172/JCI13640; Nials AT, 2008, DIS MODEL MECH, V1, P213, DOI 10.1242/dmm.000323; Oguma Tsuyoshi, 2008, Allergol Int, V57, P307, DOI 10.2332/allergolint.08-RAI-0033; Okano M, 2006, IMMUNOLOGY, V118, P343, DOI 10.1111/j.1365-2567.2006.02376.x; Okano M, 2009, J ALLERGY CLIN IMMUN, V123, P868, DOI 10.1016/j.jaci.2009.01.047; Parker Charles W., 1995, Am J Ther, V2, P772, DOI 10.1097/00045391-199510000-00007; PAVORD ID, 1993, AM REV RESPIR DIS, V148, P87, DOI 10.1164/ajrccm/148.1.87; PAVORD ID, 1995, LANCET, V345, P436, DOI 10.1016/S0140-6736(95)90409-3; Peebles RS, 2000, AM J RESP CRIT CARE, V162, P676; Peebles RS, 2005, J IMMUNOL, V175, P8253, DOI 10.4049/jimmunol.175.12.8253; Peebles RS, 2002, AM J RESP CRIT CARE, V165, P1154, DOI 10.1164/rccm.2106025; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Sastre B, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/645383; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; Smith WG, 1996, AM J RESP CRIT CARE, V154, P295, DOI 10.1164/ajrccm.154.2.8756797; Sreeramkumar V, 2012, IMMUNOL CELL BIOL, V90, P579, DOI 10.1038/icb.2011.75; Stumm CL, 2011, AM J PHYSIOL-LUNG C, V301, pL636, DOI 10.1152/ajplung.00158.2011; Sturm EM, 2008, J IMMUNOL, V181, P7273, DOI 10.4049/jimmunol.181.10.7273; SZCZEKLIK A, 1995, LANCET, V345, P1056, DOI 10.1016/S0140-6736(95)90799-8; Szczeklik A, 1996, AM J RESP CRIT CARE, V153, P567, DOI 10.1164/ajrccm.153.2.8564099; Tanaka H, 2005, CHEST, V128, P3717, DOI 10.1378/chest.128.5.3717; Thomsen SF, 2009, CLIN RESPIR J, V3, P82, DOI 10.1111/j.1752-699X.2008.00113.x; Woolard MD, 2007, J IMMUNOL, V178, P2065, DOI 10.4049/jimmunol.178.4.2065; Yang L, 2003, J CLIN INVEST, V111, P727, DOI 10.1172/JCI200316492; Zaslona Z, 2012, BLOOD, V119, P2358, DOI 10.1182/blood-2011-08-374207; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhou WS, 2008, J IMMUNOL, V181, P5360, DOI 10.4049/jimmunol.181.8.5360	57	56	58	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					379	+		10.1016/j.jaci.2013.07.037	http://dx.doi.org/10.1016/j.jaci.2013.07.037			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24075232	Green Accepted			2022-12-18	WOS:000332397100010
J	Shefler, I; Pasmanik-Chor, M; Kidron, D; Mekori, YA; Hershko, AY				Shefler, Irit; Pasmanik-Chor, Metsada; Kidron, Dvora; Mekori, Yoseph A.; Hershko, Alon Y.			T cell-derived microvesicles induce mast cell production of IL-24: Relevance to inflammatory skin diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-24; mast cells; microvesicles; T cells	FC-EPSILON-RI; ACTIVATION; CONTACT; STAT3; KERATINOCYTES; EXPRESSION; PSORIASIS; PROTEIN	Background: It has recently been shown that microvesicles derived from activated T cells can stimulate human mast cells (MCs) to degranulate and release several cytokines. Objective: The aim of this study was to characterize microvesicle-induced MC expression patterns. Through identification of unique cytokine and chemokine expression, we attempted to reveal pathogenetic roles for this pathway of MC activation. Methods: T cell-derived microvesicles were labeled with PKH67 to allow visualization of their interaction with human MCs. Consequent gene expression profiling was studied by using a whole-genome microarray and analyzed for identification of cellular pathway clusters. Expression of 3 selected genes, chemokine (C-C motif) ligand 3 (CCL3), chemokine (C-C motif) ligand 7 (CCL7), and IL24, was validated by means of quantitative RT-PCR and specific ELISA. IL24, which has not been recognized heretofore in MCs, was also tested for its effect on keratinocyte signal transducer and activator of transcription 3 phosphorylation and for its presence in MCs in psoriatic skin lesions. Results: Uptake and internalization of activated T cell-derived microvesicles into human MCs occurred within 24 hours. Microvesicles induced the upregulation of several clusters of genes, notably those that are cytokine related. Among these, IL24 appeared to be a hallmark of microvesicle-induced activation. MC-derived IL-24, in turn, activates keratinocytes in vitro, as manifested by signal transducer and activator of transcription 3 (STAT3) phosphorylation, and is produced in MCs within psoriatic lesions. Conclusion: Production of IL-24 is a unique feature of microvesicle-induced MC activation because its production by these cells has not been recognized thus far. We propose that this MC-derived cytokine might contribute to the pathologic findings in T cell-mediated skin inflammation.	[Shefler, Irit; Mekori, Yoseph A.; Hershko, Alon Y.] Meir Hosp, Lab Allergy & Clin Immunol, Kefar Sava, Israel; [Kidron, Dvora] Meir Hosp, Dept Pathol, Kefar Sava, Israel; [Shefler, Irit; Kidron, Dvora; Mekori, Yoseph A.; Hershko, Alon Y.] Tel Aviv Univ, George S Wise Fac Life Sci, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Pasmanik-Chor, Metsada] Tel Aviv Univ, George S Wise Fac Life Sci, Bioinformat Unit, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University	Mekori, YA (corresponding author), Meir Med Ctr, Dept Med B, IL-44281 Kefar Sava, Israel.	ymekori@clalit.org.il	Kidron, Debora/AAD-3531-2019		Israel Science Foundation [1084/10, 1061/09]	Israel Science Foundation(Israel Science Foundation)	A.Y.H. is the recipient of the Morasha program Fellowship of the Israel Science Foundation (grant no. 1084/10). This work was supported by a grant from the Israel Science Foundation (no. 1061/09 to Y.A.M.). Y.A.M. is the incumbent of the Reiss Chair in Dermatology at Tel Aviv University.	Ackermann L, 1999, BRIT J DERMATOL, V140, P624; Al-Nedawi K, 2009, CELL CYCLE, V8, P2014, DOI 10.4161/cc.8.13.8988; Atamas SP, 2003, CYTOKINE GROWTH F R, V14, P537, DOI 10.1016/S1359-6101(03)00060-1; Baj-Krzyworzeka M, 2006, CANCER IMMUNOL IMMUN, V55, P808, DOI 10.1007/s00262-005-0075-9; Baram D, 2001, J IMMUNOL, V167, P4008, DOI 10.4049/jimmunol.167.7.4008; Baram D, 2010, J IMMUNOL, V184, P3677, DOI 10.4049/jimmunol.0901333; Camussi G, 2010, KIDNEY INT, V78, P838, DOI 10.1038/ki.2010.278; Hershko AY, 2010, IMMUNOL LETT, V128, P98, DOI 10.1016/j.imlet.2009.10.013; Hussein MR, 2007, CELL BIOL INT, V31, P748, DOI 10.1016/j.cellbi.2006.12.006; Inamura N, 1998, J IMMUNOL, V160, P4026; Irizarry RA, 2003, STAT APPL GENET MOL, V2, DOI DOI 10.2202/1544-6115.1002; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; Kawamoto T, 2012, PLOS ONE, V7, P1; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Kunz S, 2006, EXP DERMATOL, V15, P991, DOI 10.1111/j.1600-0625.2006.00516.x; Leng RX, 2011, EXPERT OPIN THER TAR, V15, P119, DOI 10.1517/14728222.2011.534461; Maruotti N, 2007, CLIN RHEUMATOL, V26, P1, DOI 10.1007/s10067-006-0305-3; Mekori YA, 2004, J ALLERGY CLIN IMMUN, V114, P52, DOI 10.1016/j.jaci.2004.04.015; Mekori YA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00006; Miyoshi K, 2011, J INVEST DERMATOL, V131, P108, DOI 10.1038/jid.2010.255; Mor A, 2010, INFLAMMATION, V33, P119, DOI 10.1007/s10753-009-9165-8; Noh KT, 2012, J BIOL CHEM, V287, P14226, DOI 10.1074/jbc.M111.308841; Rabenhorst A, 2012, BLOOD, V120, P2042, DOI 10.1182/blood-2012-03-415638; Ratajczak J, 2006, LEUKEMIA, V20, P1487, DOI 10.1038/sj.leu.2404296; Sa SM, 2007, J IMMUNOL, V178, P2229, DOI 10.4049/jimmunol.178.4.2229; Salamon P, 2005, ALLERGY, V60, P1316, DOI 10.1111/j.1398-9995.2005.00886.x; Salamon P, 2008, J ALLERGY CLIN IMMUN, V121, P448, DOI 10.1016/j.jaci.2007.08.054; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Shefler I, 2010, J IMMUNOL, V185, P4206, DOI 10.4049/jimmunol.1000409; Shefler I, 2008, J ALLERGY CLIN IMMUN, V122, P1222, DOI 10.1016/j.jaci.2008.07.024; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475	33	56	58	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					217	+		10.1016/j.jaci.2013.04.035	http://dx.doi.org/10.1016/j.jaci.2013.04.035			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	23768573				2022-12-18	WOS:000329105700029
J	Asero, R				Asero, Riccardo			D-dimer: A biomarker for antihistamine-resistant chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PLASMA-LEVELS; TISSUE FACTOR; COAGULATION; ACTIVATION; GENERATION; EXPRESSION; PATHWAY		Clin San Carlo, Milan, Italy		Asero, R (corresponding author), Clin San Carlo, Milan, Italy.	r.asero@libero.it						Asero R, 2008, ALLERGY, V63, P176, DOI 10.1111/j.1398-9995.2007.01514.x; Asero R, 2006, J ALLERGY CLIN IMMUN, V117, P1113, DOI 10.1016/j.jaci.2005.12.1343; Asero R, 2011, ALLERGY, V66, P1339, DOI 10.1111/j.1398-9995.2011.02668.x; Asero R, 2007, J ALLERGY CLIN IMMUN, V119, P705, DOI 10.1016/j.jaci.2006.08.043; Asero R, 2010, INT ARCH ALLERGY IMM, V152, P384, DOI 10.1159/000292947; Cugno M, 1997, BLOOD, V89, P3213, DOI 10.1182/blood.V89.9.3213; Cugno M, 2009, INT ARCH ALLERGY IMM, V148, P170, DOI 10.1159/000155748; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Tedeschi A, 2009, ALLERGY, V64, P1616, DOI 10.1111/j.1398-9995.2009.02069.x; Zuberbier T, 2009, ALLERGY, V64, P1417, DOI 10.1111/j.1398-9995.2009.02179.x	10	56	58	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					983	986		10.1016/j.jaci.2013.04.037	http://dx.doi.org/10.1016/j.jaci.2013.04.037			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23763979				2022-12-18	WOS:000325096500031
J	Morita, H; Nomura, I; Orihara, K; Yoshida, K; Akasawa, A; Tachimoto, H; Ohtsuka, Y; Namai, Y; Futamura, M; Shoda, T; Matsuda, A; Kamemura, N; Kido, H; Takahashi, T; Ohya, Y; Saito, H; Matsumoto, K				Morita, Hideaki; Nomura, Ichiro; Orihara, Kanami; Yoshida, Koichi; Akasawa, Akira; Tachimoto, Hiroshi; Ohtsuka, Yoshikazu; Namai, Yoshiyuki; Futamura, Masaki; Shoda, Tetsuo; Matsuda, Akio; Kamemura, Norio; Kido, Hiroshi; Takahashi, Takao; Ohya, Yukihiro; Saito, Hirohisa; Matsumoto, Kenji			Antigen-specific T-cell responses in patients with non-IgE-mediated gastrointestinal food allergy are predominantly skewed to T(H)2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EXPRESSION; MUCOSA; ALPHA		[Morita, Hideaki; Nomura, Ichiro; Orihara, Kanami; Shoda, Tetsuo; Matsuda, Akio; Saito, Hirohisa; Matsumoto, Kenji] Natl Res Inst Child Hlth & Dev, Dept Allergy & Immunol, Tokyo, Japan; [Morita, Hideaki; Takahashi, Takao] Keio Univ, Sch Med, Dept Pediat, Tokyo, Japan; [Nomura, Ichiro; Yoshida, Koichi; Akasawa, Akira; Futamura, Masaki; Shoda, Tetsuo; Ohya, Yukihiro] Natl Ctr Child Hlth & Dev, Div Allergy, Tokyo, Japan; [Yoshida, Koichi; Akasawa, Akira] Tokyo Metropolitan Childrens Med Ctr, Dept Allergy, Tokyo, Japan; [Tachimoto, Hiroshi] Jikei Univ, Sch Med, Dept Pediat, Tokyo, Japan; [Ohtsuka, Yoshikazu] Juntendo Univ, Grad Sch Med, Dept Pediat & Adolescence Med, Tokyo, Japan; [Namai, Yoshiyuki] Ohta Nishinouchi Hosp, Dept Pediat, Koriyama, Fukushima, Japan; [Kamemura, Norio; Kido, Hiroshi] Univ Tokushima, Inst Enzyme Res, Div Enzyme Chem, Tokushima 770, Japan	National Center for Child Health & Development - Japan; Keio University; National Center for Child Health & Development - Japan; Tokyo Metropolitan Children's Medical Center; Jikei University; Juntendo University; Tokushima University	Morita, H (corresponding author), Natl Res Inst Child Hlth & Dev, Dept Allergy & Immunol, Tokyo, Japan.	nomura-i@ncchd.go.jp; matsumoto-k@ncchd.go.jp	Morita, Hideaki/ADL-2008-2022; Morita, Hideaki/S-2214-2016	Morita, Hideaki/0000-0003-0928-8322; Futamura, Masaki/0000-0002-7442-9649; Orihara, Kanami/0000-0002-2652-4529; Shoda, Tetsuo/0000-0001-8337-5438; Saito, Hirohisa/0000-0002-6630-8337				Brix S, 2003, J ALLERGY CLIN IMMUN, V112, P1216, DOI 10.1016/j.jaci.2003.08.047; Chung HL, 2002, J ALLERGY CLIN IMMUN, V109, P150, DOI 10.1067/mai.2002.120562; Giavi S, 2012, INT ARCH ALLERGY IMM, V157, P1, DOI 10.1159/000327833; Kawashima R, 2011, GASTROENTEROLOGY, V141, P2119, DOI 10.1053/j.gastro.2011.08.040; POWELL G K, 1986, Comprehensive Therapy, V12, P28; Tian CX, 2006, IMMUNOLOGY, V119, P54, DOI 10.1111/j.1365-2567.2006.02405.x	6	56	59	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					590	592		10.1016/j.jaci.2012.09.005	http://dx.doi.org/10.1016/j.jaci.2012.09.005			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23083674	Bronze			2022-12-18	WOS:000314661500043
J	Sanchez-Borges, M; Chacon, RS; Capriles-Hulett, A; Caballero-Fonseca, F; Fernandez-Caldas, E				Sanchez-Borges, Mario; Suarez Chacon, Raul; Capriles-Hulett, Arnaldo; Caballero-Fonseca, Fernan; Fernandez-Caldas, Enrique			Anaphylaxis from ingestion of mites: Pancake anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; exercise-induced anaphylaxis; food allergy; IgE; mites	SYSTEMIC-ANAPHYLAXIS; DERMATOPHAGOIDES	Oral mite anaphylaxis is a new syndrome characterized by severe allergic symptoms occurring immediately after eating foods made with mite-contaminated wheat flour. This syndrome, which is more prevalent in tropical environments, is triggered more often by pancakes, and for that reason, it has been designated "the pancake syndrome.'' Because cooked foods are able to induce the symptoms, it has been suggested that thermoresistant allergens are involved in its pathogenesis. A variety of this syndrome can occur during physical exercise (dust mite ingestion-associated exercise-induced anaphylaxis). (J Allergy Clin Immunol 2013;131:31-5.)	[Sanchez-Borges, Mario; Capriles-Hulett, Arnaldo; Caballero-Fonseca, Fernan] Ctr Med Docente La Trinidad, Allergy & Clin Immunol Dept, Caracas, Venezuela; [Suarez Chacon, Raul] Policlin Metropolitana, Caracas, Venezuela; [Fernandez-Caldas, Enrique] Inmunotek, Madrid, Spain		Sanchez-Borges, M (corresponding author), 6 Transversal Urbanizac Altamira,Piso 8,Consultor, Caracas 1060, Venezuela.	sanchezbmario@gmail.com						Barrera OM, 2011, P 22 WORLD ALL C DEC; Bernd LAG, 2001, ALLERGY, V56, P83, DOI 10.1034/j.1398-9995.2001.00922.x; Blanco C, 1997, J ALLERGY CLIN IMMUN, V99, P308, DOI 10.1016/S0091-6749(97)70047-2; DeMerell D. G., 2004, Journal of Allergy and Clinical Immunology, V113, pS235, DOI 10.1016/j.jaci.2004.01.303; Edston E, 2003, INT J LEGAL MED, V117, P299, DOI 10.1007/s00414-003-0387-2; ERBEN AM, 1993, J ALLERGY CLIN IMMUN, V92, P846, DOI 10.1016/0091-6749(93)90062-K; Geller M, 2009, REV BRAS ALERG IMUNO, V32, P199; Hannaway PJ, 2008, ANN ALLERG ASTHMA IM, V100, P397, DOI 10.1016/S1081-1206(10)60607-2; HERRANZ G., 1963, REV MED UNIV NAVARRA, V7, P137; Iglesias-Souto Javier, 2009, Clin Mol Allergy, V7, P10, DOI 10.1186/1476-7961-7-10; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; Matsumoto T, 1996, INT ARCH ALLERGY IMM, V109, P197, DOI 10.1159/000237220; Miller JD, 2007, ALLERGY ASTHMA PROC, V28, P251; Ott NL, 2004, ANN ALLERG ASTHMA IM, V92, p196a; Posthumus J, 2012, ALLERGY ASTHMA PROC, V33, P110, DOI 10.2500/aap.2012.33.3476; Sanchez-Borges M, 2006, ANN ALLERG ASTHMA IM, V96, P755, DOI 10.1016/S1081-1206(10)61079-4; Sanchez-Borges M., 2004, ALLERGY CLIN IMMUNOL, V16, P28; Sanchez-Borges M, 2007, J ALLERGY CLIN IMMUN, V120, P714, DOI 10.1016/j.jaci.2007.04.017; Sanchez-Borges M, 2012, ALLERGY RHINOL, V3, pE25, DOI 10.2500/ar.2012.3.0025; Sanchez-Machin I, 2010, ALLERGY, V65, P1345, DOI 10.1111/j.1398-9995.2010.02355.x; SanchezBorges M, 1997, J ALLERGY CLIN IMMUN, V99, P738, DOI 10.1016/S0091-6749(97)80005-X; SanchezBorges M, 1997, CUTIS, V59, P311; Skodasmith S, 1996, J ALLERGY CLIN IMMUN, V97, P182; Spiegel W. A, 1994, ANN ALLERGY, V72, P56; Takahashi K, 2011, P 22 WORLD ALL C DEC; Wen DC, 2005, ANN ALLERG ASTHMA IM, V95, P612, DOI 10.1016/S1081-1206(10)61027-7; Yan TS, 2008, ASIAN PAC J ALLERGY, V26, P165	27	56	56	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					31	35		10.1016/j.jaci.2012.09.026	http://dx.doi.org/10.1016/j.jaci.2012.09.026			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23154081	Bronze			2022-12-18	WOS:000312961200004
J	Des Roches, A; Paradis, L; Gagnon, R; Lemire, C; Begin, P; Carr, S; Chan, ES; Paradis, J; Frenette, L; Ouakki, M; Benoit, M; De Serres, G				Des Roches, Anne; Paradis, Louis; Gagnon, Remi; Lemire, Chantal; Begin, Philippe; Carr, Stuart; Chan, Edmond S.; Paradis, Jean; Frenette, Lyne; Ouakki, Manale; Benoit, Melanie; De Serres, Gaston		Canadian Inst Hlth Res Influenza	Egg-allergic patients can be safely vaccinated against influenza	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PEDIATRIC-PATIENTS; H1N1 VACCINATION; YOUNG-CHILDREN; INDIVIDUALS; ANAPHYLAXIS; POPULATION; DISEASE		[Des Roches, Anne; Paradis, Louis; Begin, Philippe] Univ Montreal, Hop St Justine, Montreal, PQ H3T 1C5, Canada; [Paradis, Louis; Paradis, Jean] Univ Montreal, Ctr Hosp Univ Montreal, Montreal, PQ, Canada; [Gagnon, Remi; Frenette, Lyne; Benoit, Melanie; De Serres, Gaston] Univ Laval, CHUQ, Quebec City, PQ, Canada; [Lemire, Chantal] Univ Sherbrooke, CHUS, Sherbrooke, PQ J1K 2R1, Canada; [Carr, Stuart] Univ Alberta, Stollery Childrens Hosp, Edmonton, AB, Canada; [Chan, Edmond S.] Univ British Columbia, BC Childrens Hosp, Vancouver, BC V5Z 1M9, Canada; [Ouakki, Manale; De Serres, Gaston] Inst Natl Sante Publ Quebec, Quebec City, PQ, Canada	Universite de Montreal; Universite de Montreal; Laval University; University of Sherbrooke; Stollery Children's Hospital; University of Alberta; BC Childrens Hospital; University of British Columbia; Institut national de sante publique du Quebec (INSPQ)	Des Roches, A (corresponding author), Univ Montreal, Hop St Justine, Montreal, PQ H3T 1C5, Canada.	gaston.deserres@inspq.qc.ca	Bégin, Philippe/AAU-9126-2021; Carr, Stuart/M-7044-2019	Chan, Edmond/0000-0003-2947-1175	Canadian Institutes of Health Research Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		BIERMAN CW, 1977, J INFECT DIS, V136, pS652, DOI 10.1093/infdis/136.Supplement_3.S652; Boden SR, 2011, J ALLERGY CLIN IMMUN, V127, pAB114, DOI 10.1016/j.jaci.2010.12.457; Chung EY, 2010, PEDIATRICS, V125, pE1024, DOI 10.1542/peds.2009-2512; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Des Roches A, 2012, J ALLERGY CLIN IMMUN; Dorsey MJ, 2005, J ALLERGY CLIN IMM S, V115, pS250; Eggesbo M, 2001, ALLERGY, V56, P403, DOI 10.1034/j.1398-9995.2001.056005403.x; Esposito S, 2008, VACCINE, V26, P4664, DOI 10.1016/j.vaccine.2008.06.095; Forsdahl BA, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000186; Fung I, 2012, J ALLERGY CLIN IMMUN, V129, P1157, DOI 10.1016/j.jaci.2011.11.038; Gagnon R, 2010, J ALLERGY CLIN IMMUN, V126, P317, DOI 10.1016/j.jaci.2010.05.037; Greenhawt MJ, 2010, ANN ALLERG ASTHMA IM, V105, P387, DOI 10.1016/j.anai.2010.08.015; Grohskopf Lisa, 2011, Morbidity and Mortality Weekly Report, V60, P1128; Hotte SL, 2008, J ALLERGY CLIN IMMUN, V121, pS239, DOI 10.1016/j.jaci.2007.12.947; Howe LE, 2011, ANN ALLERG ASTHMA IM, V106, P446, DOI 10.1016/j.anai.2011.01.024; Izurieta HS, 2000, NEW ENGL J MED, V342, P232, DOI 10.1056/NEJM200001273420402; JAMES JM, 1995, NEW ENGL J MED, V332, P1262, DOI 10.1056/NEJM199505113321904; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; Khan FS, 2012, J ALLERGY CLIN IMMUN, V129, pAB70, DOI 10.1016/j.jaci.2011.12.756; Leo S, 2010, ALLERGY ASTHMA CL IM, V6, pP4; Owens G, 2011, J ALLERGY CLIN IMMUN, V127, P264, DOI 10.1016/j.jaci.2010.10.005; Park AY, 2008, J ALLERGY CLIN IMMUN, V121, pS240, DOI 10.1016/j.jaci.2007.12.949; Paschall VL, 2011, J ALLERGY CLIN IMMUN, V127, pAB182, DOI 10.1016/j.jaci.2010.12.725; Pien GC, 2010, ALLERGY ASTHMA PROC, V31, P507, DOI 10.2500/aap.2010.31.3396; Pitt T, 2011, ALLERGY ASTHMA CL IM, V7, DOI [10.1186/1710-1492-7-S1-S1, 10.1186/1710-1492-7-S1-S10]; Ruggeberg JU, 2007, VACCINE, V25, P5675, DOI 10.1016/j.vaccine.2007.02.064; Saltzman RW, 2009, J ALLERGY CLIN IMMUN, V123, pS175, DOI 10.1016/j.jaci.2008.12.659; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Schuler JE, 2011, CAN J PUBLIC HEALTH, V102, P196, DOI 10.1007/BF03404895; Siret-Alatrista A, 2011, ALLERGY, V66, P298, DOI 10.1111/j.1398-9995.2010.02461.x; Thanik ES, 2010, J ALLERGY CLIN IMMUN, V125, pAB25, DOI 10.1016/j.jaci.2009.12.130; Upton JEM, 2012, ALLERGY ASTHMA CL IM, V8, DOI 10.1186/1710-1492-8-2; Webb L, 2011, J ALLERGY CLIN IMMUN, V128, P218, DOI 10.1016/j.jaci.2011.02.013; Zeiger RS, 2002, J ALLERGY CLIN IMMUN, V110, P834, DOI 10.1067/mai.2002.129372	34	56	58	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1213	1216		10.1016/j.jaci.2012.07.046	http://dx.doi.org/10.1016/j.jaci.2012.07.046			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	23021881	hybrid			2022-12-18	WOS:000310571400030
J	Tan, HTT; Ellis, JA; Koplin, JJ; Matheson, MC; Gurrin, LC; Lowe, AJ; Martin, PE; Dang, TD; Wake, M; Tang, MLK; Ponsonby, AL; Dharmage, SC; Allen, KJ				Tan, Hern-Tze Tina; Ellis, Justine A.; Koplin, Jennifer J.; Matheson, Melanie C.; Gurrin, Lyle C.; Lowe, Adrian J.; Martin, Pamela E.; Dang, Thanh D.; Wake, Melissa; Tang, Mimi L. K.; Ponsonby, Anne-Louise; Dharmage, Shyamali C.; Allen, Katrina J.		HealthNuts Study Investigators	Filaggrin loss-of-function mutations do not predict food allergy over and above the risk of food sensitization among infants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FOLLOW-UP; CHILDREN; DISEASE		[Tan, Hern-Tze Tina; Ellis, Justine A.; Koplin, Jennifer J.; Gurrin, Lyle C.; Lowe, Adrian J.; Martin, Pamela E.; Dang, Thanh D.; Wake, Melissa; Tang, Mimi L. K.; Ponsonby, Anne-Louise; Dharmage, Shyamali C.; Allen, Katrina J.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Wake, Melissa] Royal Childrens Hosp, Ctr Community Child Hlth, Melbourne, Vic, Australia; [Matheson, Melanie C.; Gurrin, Lyle C.; Lowe, Adrian J.; Dharmage, Shyamali C.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia; [Tang, Mimi L. K.; Allen, Katrina J.] Univ Melbourne, Dept Allergy & Immunol, Melbourne, Vic, Australia; [Tan, Hern-Tze Tina; Martin, Pamela E.; Dang, Thanh D.; Wake, Melissa; Tang, Mimi L. K.; Ponsonby, Anne-Louise; Allen, Katrina J.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Ellis, Justine A.] Univ Melbourne, Dept Physiol, Melbourne, Vic, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; University of Melbourne; University of Melbourne; University of Melbourne; University of Melbourne	Tan, HTT (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.	katie.allen@rch.org.au	Dang, Thanh/AAK-1608-2021; Ponsonby, Anne-Louise/AAE-4351-2019; Wake, Melissa/J-1396-2012; Allen, Katrina/I-4361-2018; Tang, Mimi/ABD-8350-2020; Ellis, Justine A/G-5006-2011; Matheson, Melanie C/O-4721-2015	Dang, Thanh/0000-0003-2010-5582; Wake, Melissa/0000-0001-7501-9257; Allen, Katrina/0000-0002-1921-4493; Tang, Mimi/0000-0002-3839-5293; Matheson, Melanie C/0000-0002-5822-3499; Koplin, Jennifer/0000-0002-7576-5142; Lowe, Adrian/0000-0002-4691-8162; Ellis, Justine/0000-0003-4103-4445; Gurrin, Lyle/0000-0001-7052-1969; Ponsonby, Anne-Louise/0000-0002-6581-3657; Tan, Hern-Tze Tina/0000-0002-8289-7573				Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Fewtrell MS, 2008, ARCH DIS CHILD, V93, P458, DOI 10.1136/adc.2007.127316; Flohr C, 2010, BRIT J DERMATOL, V163, P1333, DOI 10.1111/j.1365-2133.2010.10068.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Koplin JJ, 2012, J ALLERGY CLIN IMMUN, V129, P1145, DOI 10.1016/j.jaci.2011.09.044; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Osborne NJ, 2010, CLIN EXP ALLERGY, V40, P1516, DOI 10.1111/j.1365-2222.2010.03562.x; Pistiner M, 2008, J ALLERGY CLIN IMMUN, V122, P274, DOI 10.1016/j.jaci.2008.05.007; Prescott SL, 2008, ALLERGY, V63, P1481, DOI 10.1111/j.1398-9995.2008.01778.x; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Taylor AL, 2007, J ALLERGY CLIN IMMUN, V119, P184, DOI 10.1016/j.jaci.2006.08.036	13	56	56	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1211	1213		10.1016/j.jaci.2012.07.022	http://dx.doi.org/10.1016/j.jaci.2012.07.022			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	22964107	Bronze			2022-12-18	WOS:000310571400029
J	Gras, D; Bourdin, A; Vachier, I; de Senneville, L; Bonnans, C; Chanez, P				Gras, Delphine; Bourdin, Arnaud; Vachier, Isabelle; de Senneville, Laure; Bonnans, Caroline; Chanez, Pascal			An ex vivo model of severe asthma using reconstituted human bronchial epithelium	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epithelium; inflammation; resolution; asthma severity	HUMAN ALVEOLAR MACROPHAGES; AIRWAY INFLAMMATION; BASEMENT-MEMBRANE; LIPID MEDIATORS; GOBLET CELL; LIPOXINS; 15-LIPOXYGENASE; EXPRESSION; INTERLEUKIN-8; ACID	Background: Structural changes to the airways are features of severe asthma. The bronchial epithelium facilitates this remodeling process. Learning about the changes that develop in the airway epithelium could improve our understanding of asthma pathogenesis and lead to new therapeutic approaches. Objective: We sought to determine the feasibility and relevance of air-liquid interface cultures of bronchial epithelium derived from endobronchial biopsy specimens of patients with different severities of asthma for studying the airway epithelium. Methods: Human bronchial epithelial cells derived from endobronchial biopsy specimens of patients with mild and severe asthma were maintained in culture for 21 days in an air-liquid interface to reproduce a fully differentiated airway epithelium. Initially, features of remodeling that included epithelial and subepithelial layers, as well as mucus production, were assessed in paraffin-embedded endobronchial biopsy specimens to evaluate morphologic characteristics of asthmatic patients' epithelia. Ex vivo differentiated epithelia were then analyzed for morphology and function based on ultrastructural analysis, IL-8 release, lipoxin A(4) generation, mucin production, and lipoxygenase gene expression. Results: Morphologic and inflammatory imbalances initially observed in endobronchial biopsy specimens obtained from patients with severe or mild asthma persisted in the air-liquid interface reconstituted epithelium throughout the differentiation process to 21 days. Epithelium from patients with severe asthma produced greater levels of mucin, released more IL-8, and produced lower levels of lipoxin A(4) than that from patients with mild asthma. Expression of 15-lipoxygenase 2 was increased in epithelium from patients with severe asthma, whereas expression levels of MUC5AC, MUC5B, 5-lipoxygenase, and 15-lipoxygeanse 1 were similar to those of patients with mild asthma. Conclusion: Ex vivo cultures of fully differentiated bronchial epithelium from endobronchial biopsy specimens maintain inherent phenotypic differences specifically related to the severity of asthma. (J Allergy Clin Immunol 2012;129:1259-66.)	[Gras, Delphine; de Senneville, Laure; Chanez, Pascal] Univ Aix Marseille, AP HM Dept Resp Dis, Marseille, France; [Bourdin, Arnaud; Vachier, Isabelle; Bonnans, Caroline] Dept Resp Dis, Montpellier, France	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite de Montpellier	Chanez, P (corresponding author), Univ Aix Marseille, AP HM Hop Nord, Clin Bronches Allergie & Sommeil, CNRS,INSERM,U600,UMR 6212, Chemin Bourrely, F-13015 Marseille, France.	pascal.chanez@univ-amu.fr	Vachier, Isabelle/AAV-5731-2020; Gras, Delphine/AAP-7248-2020; Gras, Delphine/A-7062-2017	Vachier, Isabelle/0000-0003-2730-5165; Gras, Delphine/0000-0002-6630-2955; chanez, pascal/0000-0003-4059-0917	Centocor	Centocor	Disclosure of potential conflict of interest: P. Chanez is a consultant for Amgen, AstraZeneca, Centocor, Chiesi, GlaxoSmithKline, MSD, Novartis, and Nycomed and has received research support from Centocor. The rest of the authors declare that they have no relevant conflicts of interest.	Anzueto A, 2006, AM J MED, V119, pS46, DOI 10.1016/j.amjmed.2006.08.007; Bonnans C, 2006, AM J PATHOL, V168, P1064, DOI 10.2353/ajpath.2006.051056; Bonnans C, 2002, AM J RESP CRIT CARE, V165, P1531, DOI 10.1164/rccm.200201-053OC; Bourdin A, 2007, J ALLERGY CLIN IMMUN, V119, P1367, DOI 10.1016/j.jaci.2007.01.055; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Carayol N, 2002, AM J RESP CRIT CARE, V166, P1290, DOI 10.1164/ajrccm.166.9.267b; Chanez P, 2005, EUR RESPIR J, V25, P945, DOI 10.1183/09031936.05.00038605; Chanez P, 1996, INT ARCH ALLERGY IMM, V111, P83, DOI 10.1159/000237350; Chanez P, 2007, J ALLERGY CLIN IMMUN, V119, P1337, DOI 10.1016/j.jaci.2006.11.702; Chavis C, 1996, J EXP MED, V183, P1633, DOI 10.1084/jem.183.4.1633; CHAVIS C, 1992, EICOSANOIDS, V5, P203; Cohen L, 2007, AM J RESP CRIT CARE, V176, P138, DOI 10.1164/rccm.200607-1062OC; Djukanovic R, 1997, AM J RESP CRIT CARE, V155, P826, DOI 10.1164/ajrccm.155.3.9117012; Dorscheid DR, 2001, AM J RESP CRIT CARE, V164, P1939, DOI 10.1164/ajrccm.164.10.2103013; Fahy JV, 2002, CHEST, V122, p320S, DOI 10.1378/chest.122.6_suppl.320S; Fahy JV, 2001, AM J RESP CRIT CARE, V164, pS46, DOI 10.1164/ajrccm.164.supplement_2.2106066; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Godard P, 2002, EUR RESPIR J, V19, P61, DOI 10.1183/09031936.02.00232001; Gray T, 2004, AM J PHYSIOL-LUNG C, V286, pL320, DOI 10.1152/ajplung.00440.2002; Haworth O, 2007, EUR RESPIR J, V30, P980, DOI 10.1183/09031936.00005807; Hill EM, 1998, AM J RESP CELL MOL, V18, P662, DOI 10.1165/ajrcmb.18.5.2985; KUNKEL SL, 1991, EXP LUNG RES, V17, P17, DOI 10.3109/01902149109063278; LEVY BD, 1993, J CLIN INVEST, V92, P1572, DOI 10.1172/JCI116738; Levy BD, 2005, PROSTAG LEUKOTR ESS, V73, P231, DOI 10.1016/j.plefa.2005.05.010; Levy BD, 2005, AM J RESP CRIT CARE, V172, P824, DOI 10.1164/rccm.200410-1413OC; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517, DOI 10.1164/ajrccm.163.2.2004039; Planaguma A, 2008, AM J RESP CRIT CARE, V178, P574, DOI 10.1164/rccm.200801-061OC; Serhan CN, 2005, PROSTAG LEUKOTR ESS, V73, P141, DOI 10.1016/j.plefa.2005.05.002; SERHAN CN, 1990, J CLIN INVEST, V85, P772, DOI 10.1172/JCI114503; SIGAL E, 1992, AM J PHYSIOL, V262, pL392, DOI 10.1152/ajplung.1992.262.4.L392; Thornton DJ, 2008, ANNU REV PHYSIOL, V70, P459, DOI 10.1146/annurev.physiol.70.113006.100702; Vachier I, 2005, J ALLERGY CLIN IMMUN, V115, P55, DOI 10.1016/j.jaci.2004.09.038; Vachier I, 1998, AM J RESP CRIT CARE, V158, P963, DOI 10.1164/ajrccm.158.3.9710085; Voynow JA, 2006, AM J RESP CELL MOL, V34, P661, DOI 10.1165/rcmb.2006-0035SF; Voynow JA, 2009, CHEST, V135, P505, DOI 10.1378/chest.08-0412; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wenzel SE, 2006, AM J RESP CRIT CARE, V173, P698, DOI 10.1164/rccm.2601007; Wilson JW, 1997, CLIN EXP ALLERGY, V27, P363; Zhao JM, 2009, AM J RESP CRIT CARE, V179, P782, DOI 10.1164/rccm.200811-1744OC	40	56	57	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1259	+		10.1016/j.jaci.2012.01.073	http://dx.doi.org/10.1016/j.jaci.2012.01.073			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22409990				2022-12-18	WOS:000303418000012
J	Korosec, P; Valenta, R; Mittermann, I; Celesnik, N; Silar, M; Zidarn, M; Kosnik, M				Korosec, Peter; Valenta, Rudolf; Mittermann, Irene; Celesnik, Nina; Silar, Mira; Zidarn, Mihaela; Kosnik, Mitja			High sensitivity of CAP-FEIA rVes v 5 and rVes v 1 for diagnosis of Vespula venom allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANTIGENIC CROSS-REACTIVITY; HYMENOPTERA VENOM; MAJOR ALLERGENS; IGE; BEE		[Korosec, Peter; Celesnik, Nina; Silar, Mira; Zidarn, Mihaela; Kosnik, Mitja] Univ Clin Resp & Allerg Dis, Golnik, Slovenia; [Valenta, Rudolf; Mittermann, Irene] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Div Immunopathol, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria	Medical University of Vienna	Korosec, P (corresponding author), Univ Clin Resp & Allerg Dis, Golnik, Slovenia.	peter.korosec@klinika-golnik.si	Košnik, Mitja/AAI-2295-2019	Košnik, Mitja/0000-0002-4701-7374; Mittermann, Irene/0000-0002-6240-6730; Valenta, Rudolf/0000-0001-5944-3365; Zidarn, Mihaela/0000-0003-0515-5207; Korosec, Peter/0000-0002-0835-1599	Austrian Science Fund FWF [F 4605] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Blank S, 2010, J IMMUNOL, V184, P5403, DOI 10.4049/jimmunol.0803709; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V92, P707, DOI 10.1016/0091-6749(93)90014-7; King TP, 1996, J ALLERGY CLIN IMMUN, V98, P588, DOI 10.1016/S0091-6749(96)70093-3; Kolarich D, 2007, PROTEOMICS, V7, P1615, DOI 10.1002/pmic.200600800; Korosec P, 2011, J ALLERGY CLIN IMMUN, V128, P671, DOI 10.1016/j.jaci.2011.03.012; Mittermann I, 2010, J ALLERGY CLIN IMMUN, V125, P1300, DOI 10.1016/j.jaci.2010.03.017; Muller UR, 2009, ALLERGY, V64, P543, DOI 10.1111/j.1398-9995.2008.01794.x; Sturm GJ, 2011, J ALLERGY CLIN IMMUN, V128, P247, DOI 10.1016/j.jaci.2011.02.021	8	56	56	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1406	1408		10.1016/j.jaci.2011.12.975	http://dx.doi.org/10.1016/j.jaci.2011.12.975			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22277201	Green Accepted			2022-12-18	WOS:000303418000035
J	Brown, SD; Baxter, KM; Stephenson, ST; Esper, AM; Brown, LAS; Fitzpatrick, AM				Brown, Sheena D.; Baxter, Katherine M.; Stephenson, Susan T.; Esper, Annette M.; Brown, Lou Ann S.; Fitzpatrick, Anne M.			Airway TGF-beta 1 and oxidant stress in children with severe asthma: Association with airflow limitation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway remodeling; asthma; children; lung function; oxidant stress; TGF-beta 1	GROWTH-FACTOR-BETA; RETICULAR BASEMENT-MEMBRANE; MESSENGER-RNA EXPRESSION; EPITHELIAL LINING FLUID; TGF-BETA; LUNG; INFLAMMATION; MACROPHAGES; CHILDHOOD; INDUCTION	Background: TGF-beta 1 is thought to play a role in airway remodeling in asthmatic subjects. TGF-beta 1 expression might be mediated by an excessive burden of reactive oxygen species and oxidant stress. Objective: Given the profound airway oxidant stress we have previously observed in children with severe asthma, we sought to (1) quantify TGF-beta 1 protein and mRNA gene expression in the airways of children with mild-to-moderate and severe atopic asthma and (2) determine the relationship of airway TGF-beta 1 concentrations to oxidant burden (ie, lipid peroxidation), T(H)2-mediated eosinophilic inflammation, and airflow limitation. Methods: Bronchoalveolar lavage fluid was collected from 68 atopic children with asthma (severe asthma, n = 28) and 12 atopic adult control subjects. Airway TGF-beta 1 expression and activation were assessed in relation to airway IL-13, 8-isoprostane, and malondialdehyde concentrations. The relationship of airway TGF-beta 1 expression to airflow limitation in children with asthma was also assessed. Results: Children with severe asthma had higher total airway concentrations of TGF-beta 1 that were associated with increased protein and mRNA expression of TGF-beta 1 in airway macrophages and an increase in concentrations of the lipid peroxidation biomarkers 8-isoprostanes and malondialdehyde. TGF-beta 1 activation was also greater in children with severe asthma and was associated with higher airway 8-isoprostane, malondialdehyde, and IL-13 concentrations. Total airway TGF-beta 1 concentrations were further associated with airflow limitation. Conclusions: Children with severe asthma have increased airway TGF-beta 1 expression and activation associated with an increased airway oxidant burden. Oxidant stress might mediate the effects of TGF-beta 1 and promote airway remodeling in children with severe asthma. (J Allergy Clin Immunol 2012;129:388-96.)	[Brown, Sheena D.; Baxter, Katherine M.; Stephenson, Susan T.; Brown, Lou Ann S.; Fitzpatrick, Anne M.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA; [Esper, Annette M.] Emory Univ, Dept Med, Atlanta, GA 30322 USA; [Brown, Lou Ann S.; Fitzpatrick, Anne M.] Childrens Healthcare Atlanta Ctr Dev Lung Biol, Atlanta, GA USA	Emory University; Emory University; Children's Healthcare of Atlanta (CHOA)	Fitzpatrick, AM (corresponding author), 2015 Uppergate Dr, Atlanta, GA 30322 USA.	anne.fitzpatrick@emory.edu	Brown, Sheena/AGK-6465-2022	Fitzpatrick, Anne/0000-0002-2933-5926	National Institutes of Health [RO1 NR012021]; PHS from National Institutes of Health, National Center for Research Resources [UL1RR025008]; National Institutes of Health/National Institute of Nursing Research; National Center for Research Resources; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR012021] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); PHS from National Institutes of Health, National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institutes of Health/National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	Supported by National Institutes of Health RO1 NR012021 and supported in part by PHS Grant UL1RR025008 from the Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources.; A. M. Fitzpatrick receives research support from the National Institutes of Health/National Institute of Nursing Research and National Center for Research Resources. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; Baraldo S, 2011, EUR RESPIR J, V38, P575, DOI 10.1183/09031936.00168210; Barbato A, 2003, AM J RESP CRIT CARE, V168, P798, DOI 10.1164/rccm.200305-650OC; BarcellosHoff MH, 1996, MOL ENDOCRINOL, V10, P1077, DOI 10.1210/me.10.9.1077; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Cho JY, 2004, J CLIN INVEST, V113, P551, DOI 10.1172/JCI200419133; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P1604, DOI 10.1016/j.jaci.2011.03.031; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P282, DOI 10.1016/j.jaci.2010.10.036; Fitzpatrick AM, 2011, PEDIATR RES, V69, P154, DOI 10.1203/PDR.0b013e3182026370; Fitzpatrick AM, 2010, PEDIAT ALLER IMM PUL, V23, P131, DOI 10.1089/ped.2010.0021; Fitzpatrick AM, 2010, J ALLERGY CLIN IMMUN, V125, P851, DOI 10.1016/j.jaci.2010.01.048; Fitzpatrick AM, 2009, J ALLERGY CLIN IMMUN, V124, P990, DOI 10.1016/j.jaci.2009.08.039; Fitzpatrick AM, 2009, J ALLERGY CLIN IMMUN, V123, P146, DOI 10.1016/j.jaci.2008.10.047; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Hackett TL, 2009, AM J RESP CRIT CARE, V180, P122, DOI 10.1164/rccm.200811-1730OC; Halwani R, 2011, AM J RESP CELL MOL, V44, P127, DOI 10.1165/rcmb.2010-0027TR; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Ingram JL, 2011, AM J RESP CRIT CARE, V183, P1625, DOI 10.1164/rccm.201009-1452OC; KELLEY J, 1991, CHEST, V99, pS85, DOI 10.1378/chest.99.3_Supplement.85S; Lee KY, 2006, AM J RESP CELL MOL, V35, P407, DOI 10.1165/rcmb.2006-0012OC; Lex C, 2006, AM J RESP CRIT CARE, V174, P1286, DOI 10.1164/rccm.200603-352OC; MAGNAN A, 1994, THORAX, V49, P789, DOI 10.1136/thx.49.8.789; Mahut B, 2004, J ALLERGY CLIN IMMUN, V113, P252, DOI 10.1016/j.jaci.2003.10.038; Malmstrom K, 2011, THORAX, V66, P157, DOI 10.1136/thx.2010.139246; Michaeloudes C, 2011, AM J RESP CRIT CARE, V183; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Prieto J, 2000, RESP MED, V94, P806, DOI 10.1053/rmed.2000.0826; Rasmussen F, 2002, J ALLERGY CLIN IMMUN, V110, P220, DOI 10.1067/mai.2002.125295; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; Saglani S, 2006, EUR RESPIR J, V28, P505, DOI 10.1183/09031936.06.00056405; Sorkness RL, 2011, J ALLERGY CLIN IMMUN, V127, P1073, DOI 10.1016/j.jaci.2010.12.1079; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Vignola AM, 1996, CLIN EXP IMMUNOL, V106, P114, DOI 10.1046/j.1365-2249.1996.d01-811.x; Wenzel SE, 2002, J IMMUNOL, V169, P4613, DOI 10.4049/jimmunol.169.8.4613; Xiao YQ, 2006, J IMMUNOL, V176, P1209, DOI 10.4049/jimmunol.176.2.1209	43	56	59	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					388	U180		10.1016/j.jaci.2011.11.037	http://dx.doi.org/10.1016/j.jaci.2011.11.037			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22206775	Green Accepted			2022-12-18	WOS:000299951700013
J	Linneberg, A; Jacobsen, RK; Jespersen, L; Abildstrom, SZ				Linneberg, Allan; Jacobsen, Rikke Kart; Jespersen, Lasse; Abildstrom, Steen Z.			Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen immunotherapy; allergy; autoimmune disease; ischemic heart disease; long-term effects; mortality; pharmacoepidemiology; side effects	MAST-CELLS; TRYPTASE	Background: Subcutaneous allergen-specific immunotherapy (SCIT) is a well-documented treatment of IgE-mediated allergic disease. Little is known about potential effects of SCIT on the risk of other chronic immune-related diseases. Over the years, a few casuistic reports have caused concern that SCIT might act as a trigger of autoimmune disease. Objective: We aimed to investigate the association of SCIT with the incidence of autoimmune disease and ischemic heart disease (IHD), as well as all-cause mortality. Methods: All Danish citizens without other known diseases were linked and followed through central registries on medications and hospital admissions. Persons receiving SCIT and persons receiving conventional allergy treatment (CAT; nasal steroids or oral antihistamines) were compared with regard to mortality and development of autoimmune diseases, acute myocardial infarction (AMI), and IHD. Cox regression (survival analysis) with age as the underlying time scale was used to estimate relative risks (hazard ratios [HRs] with 95% CIs) associated with SCIT compared with CAT adjusted for age, sex, vocational status, and income. Results: During the 10-year study period (1997-2006), a total of 18,841 and 428,484 persons were followed in the SCIT and CAT groups, respectively. Receiving SCIT was associated with lower mortality (HR, 0.71; 95% CI, 0.62-0.81) and lower incidence of AMI(HR, 0.70; 95% CI, 0.52-0.93), IHD (HR, 0.88; 95% CI, 0.73-1.05), and autoimmune disease (HR, 0.86; 95% CI, 0.74-0.99). Conclusion: In this registry-based observational study, receiving SCIT compared with CAT was associated with lower risk of autoimmune disease and AMI, as well as decreased all-cause mortality. (J Allergy Clin Immunol 2012; 129: 413-9.)	[Linneberg, Allan; Jacobsen, Rikke Kart] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, DK-2600 Glostrup, Denmark; [Jespersen, Lasse; Abildstrom, Steen Z.] Copenhagen Univ Hosp, Dept Cardiol, Bispebjerg, Denmark	University of Copenhagen; University of Copenhagen	Linneberg, A (corresponding author), Glostrup Univ Hosp, Res Ctr Prevent & Hlth, 57 Nordre Ringvej,Bldg 84-85, DK-2600 Glostrup, Denmark.	alllin01@regionh.dk		Linneberg, Allan/0000-0002-0994-0184; Jacobsen, Rikke Kart/0000-0003-4677-2973				Abramson MJ, 2000, COCHRANE DB SYST REV; Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Almpanis G, 2010, INT J CARDIOL, V145, P398, DOI 10.1016/j.ijcard.2010.04.028; Andersen TF, 1999, DAN MED BULL, V46, P263; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Calderon MA, 2011, J ALLERGY CLIN IMMUN, V127, P30, DOI 10.1016/j.jaci.2010.08.024; Casale TB, 2011, J ALLERGY CLIN IMMUN, V127, P8, DOI 10.1016/j.jaci.2010.10.034; Cevik C, 2010, INT J CARDIOL, V143, P223, DOI 10.1016/j.ijcard.2010.02.040; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Deliargyris EN, 2005, ATHEROSCLEROSIS, V178, P381, DOI 10.1016/j.atherosclerosis.2004.09.008; Durham SR, 2011, J ALLERGY CLIN IMMUN, V127, P3, DOI 10.1016/j.jaci.2010.11.032; Fairweather DeLisa, 2008, Cardiovascular & Hematological Disorders - Drug Targets, V8, P80, DOI 10.2174/187152908783884957; Fosbol EL, 2009, CLIN PHARMACOL THER, V85, P190, DOI 10.1038/clpt.2008.204; Francis JN, 2004, CURR OPIN ALLERGY CL, V4, P543, DOI 10.1097/00130832-200412000-00012; Frank L, 2003, SCIENCE, V301, P163, DOI 10.1126/science.301.5630.163; Gaist D, 1997, DAN MED BULL, V44, P445; Gonzalez-Quintela A, 2010, CLIN CHEM LAB MED, V48, P701, DOI 10.1515/CCLM.2010.124; Juel K, 1999, DAN MED BULL, V46, P354; Kounis GN, 2010, INT J CARDIOL, V144, pE48, DOI 10.1016/j.ijcard.2008.12.061; Kounis NG, 2011, ATHEROSCLEROSIS, V217, P67, DOI 10.1016/j.atherosclerosis.2011.02.008; Kummeling I, 2008, CLIN EXP ALLERGY, V38, P1249, DOI 10.1111/j.1365-2222.2008.03047.x; Linneberg A, 2008, INT ARCH ALLERGY IMM, V147, P93, DOI 10.1159/000135695; Liu J, 2009, NAT MED, V15, P940, DOI 10.1038/nm.1994; Maciel BM, 2009, REV ALERG MEX, V56, P135; Nakajima H, 2003, EUR NEUROL, V50, P248, DOI 10.1159/000073867; Ozben Beste, 2008, Inflammation & Allergy Drug Targets, V7, P136, DOI 10.2174/187152808785748128; Packard RRS, 2009, SEMIN IMMUNOPATHOL, V31, P5, DOI 10.1007/s00281-009-0153-8; QUIRCE S, 1992, ALLERGY, V47, P343, DOI 10.1111/j.1398-9995.1992.tb02068.x; Sherer Yaniv, 2002, Autoimmunity Reviews, V1, P21, DOI 10.1016/S1568-9972(01)00003-9; TAYLOR RJ, 1991, J ALLERGY CLIN IMMUN, V87, P889, DOI 10.1016/0091-6749(91)90139-F; Triggiani M, 2008, CLIN EXP IMMUNOL, V153, P7, DOI 10.1111/j.1365-2249.2008.03714.x; Turkcapar N, 2005, RHEUMATOL INT, V26, P182, DOI 10.1007/s00296-005-0606-x	33	56	56	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					413	419		10.1016/j.jaci.2011.09.007	http://dx.doi.org/10.1016/j.jaci.2011.09.007			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22004944				2022-12-18	WOS:000299951700018
J	Bircher, AJ; Hofmeier, KS				Bircher, Andreas J.; Hofmeier, Kathrin Scherer			Drug hypersensitivity reactions: Inconsistency in the use of the classification of immediate and nonimmediate reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INFANT NUTRITIONAL INTERVENTION; ATOPIC-DERMATITIS; REVISED NOMENCLATURE; ALLERGIC DISEASE; BREAST-MILK; FATTY-ACIDS; RISK; ASTHMA; BIRTH; CHILDREN		[Bircher, Andreas J.; Hofmeier, Kathrin Scherer] Dept Dermatol, Allergy Unit, Basel, Switzerland		Bircher, AJ (corresponding author), Dept Dermatol, Allergy Unit, Basel, Switzerland.	andreas.bircher@unibas.ch		Scherer, Kathrin/0000-0002-5235-2556				Alexander DD, 2010, J PEDIATR GASTR NUTR, V50, P422, DOI 10.1097/MPG.0b013e3181cea52b; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bircher AJ, 1996, BRIT J DERMATOL, V135, P310, DOI 10.1046/j.1365-2133.1996.d01-996.x; Bircher AJ, 2010, MED CLIN N AM, V94, P711, DOI 10.1016/j.mcna.2010.04.001; Brockow K, 2009, ALLERGY, V64, P234, DOI 10.1111/j.1398-9995.2008.01832.x; Filipiak B, 2007, J PEDIATR-US, V151, P352, DOI 10.1016/j.jpeds.2007.05.018; Foley P, 2001, ARCH DERMATOL, V137, P293; Hanifin JM., 1980, ACTA DERM-VENEREOL, V92, P44; Hill DJ, 2000, J PEDIATR-US, V137, P475, DOI 10.1067/mpd.2000.108207; Hill DJ, 2004, PEDIAT ALLERG IMM-UK, V15, P421, DOI 10.1111/j.1399-3038.2004.00178.x; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Koletzko S, 2012, J ALLERGY CLIN IMMUN, V129, P262, DOI 10.1016/j.jaci.2011.08.038; Koplin J, 2008, J ALLERGY CLIN IMMUN, V121, P1455, DOI 10.1016/j.jaci.2008.03.017; Lodge CJ, 2011, J ALLERGY CLIN IMMUN; Lowe A, 2010, INTERN MED J, V40, P13; Lowe AJ, 2008, CLIN EXP ALLERGY, V38, P1745, DOI 10.1111/j.1365-2222.2008.03073.x; Lowe AJ, 2007, CLIN EXP ALLERGY, V37, P1624, DOI 10.1111/j.1365-2222.2007.02822.x; Lowe AJ, 2007, CLIN EXP ALLERGY, V37, P536, DOI 10.1111/j.1365-2222.2007.02691.x; Lowe AJ, 2008, J ALLERGY CLIN IMMUN, V121, P1190, DOI 10.1016/j.jaci.2008.01.034; Lowe AJ, 2011, J ALLERGY CLIN IMMUN, V128, P360, DOI 10.1016/j.jaci.2010.05.006; Lowe AJ, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4616; Lowe AJ, 2006, J ALLERGY CLIN IMMUN, V117, P682, DOI 10.1016/j.jaci.2005.10.027; Romano A, 2011, J ALLERGY CLIN IMMUN, V127, pS67, DOI 10.1016/j.jaci.2010.11.047; Seach KA, 2010, INT J OBESITY, V34, P1475, DOI 10.1038/ijo.2010.101; Stoney RM, 2004, CLIN EXP ALLERGY, V34, P194, DOI 10.1111/j.1365-2222.2004.01852.x; Szajewska H, 2010, CURR MED RES OPIN, V26, P423, DOI 10.1185/03007990903510317; Thomson JA, 2010, PEDIAT ALLERG IMM-UK, V21, P1076, DOI 10.1111/j.1399-3038.2010.01018.x; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; von Berg A, 2008, J ALLERGY CLIN IMMUN, V121, P1442, DOI 10.1016/j.jaci.2008.04.021; von Berg A, 2007, J ALLERGY CLIN IMMUN, V119, P718, DOI 10.1016/j.jaci.2006.11.017	32	56	57	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					263	264		10.1016/j.jaci.2011.08.042	http://dx.doi.org/10.1016/j.jaci.2011.08.042			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	21982115				2022-12-18	WOS:000298634000040
J	Bosco, A; Ehteshami, S; Panyala, S; Martinez, FD				Bosco, Anthony; Ehteshami, Samira; Panyala, Sujatha; Martinez, Fernando D.			Interferon regulatory factor 7 is a major hub connecting interferon-mediated responses in virus-induced asthma exacerbations in vivo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; exacerbation; picornavirus; rhinovirus; gene expression; gene networks; innate immunity; interferons; systems biology	GENE-EXPRESSION PROFILES; NF-KAPPA-B; RESPIRATORY EPITHELIUM; TRANSCRIPTION FACTOR; ANTIVIRAL RESPONSE; CHILDHOOD ASTHMA; IMMUNE-RESPONSES; NETWORK; INFECTION; BIOLOGY	Background: Exacerbations are responsible for a substantial burden of morbidity and health care use in children with asthma. Most asthma exacerbations are triggered by viral infections; however, the underlying mechanisms have not been systematically investigated. Objective: The objective of this study was to elucidate the molecular networks that underpin virus-induced exacerbations in asthmatic children in vivo. Methods: We followed exacerbation-prone asthmatic children prospectively and profiled global patterns of gene expression in nasal lavage samples obtained during an acute, moderate, picornavirus-induced exacerbation and 7 to 14 days later. Coexpression network analysis and prior knowledge was used to reconstruct the underlying gene networks. Results: The data showed that an intricate modular program consisting of more than 1000 genes was upregulated during acute exacerbations in comparison with 7 to 14 days later. The modules were enriched for coherent cellular processes, including interferon-induced antiviral responses, innate pathogen sensing, response to wounding, small nucleolar RNAs, and the ubiquitin-proteosome and lysosome degradation pathways. Reconstruction of the wiring diagram of the modules revealed the presence of hyperconnected hub nodes, most notably interferon regulatory factor 7, which was identified as a major hub linking interferon-mediated antiviral responses. Conclusions: This study provides an integrated view of the inflammatory networks that are upregulated during virus-induced asthma exacerbations in vivo. A series of innate signaling hubs were identified that could be novel therapeutic targets for asthma attacks. (J Allergy Clin Immunol 2012; 129: 88-94.)	[Bosco, Anthony; Ehteshami, Samira; Panyala, Sujatha; Martinez, Fernando D.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Bosco, Anthony] Univ Western Australia, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia; [Bosco, Anthony] Univ Western Australia, Ctr Child Hlth Res, Perth, WA 6009, Australia	University of Arizona; Telethon Kids Institute; University of Western Australia; University of Western Australia	Bosco, A (corresponding author), Telethon Inst Child Hlth Res, 100 Roberts Rd, Subiaco, WA 6008, Australia.	anthonyb@ichr.uwa.edu.au	Bosco, Anthony/AAC-6900-2022	Bosco, Anthony/0000-0002-4335-615X	National Institutes of Health [HL080083]; Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080083] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grant HL080083. A. B. is the recipient of a Medical Research Fellowship from the Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia.	Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Amit I, 2009, SCIENCE, V326, P257, DOI 10.1126/science.1179050; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Benoist C, 2006, IMMUNOL REV, V210, P229, DOI 10.1111/j.0105-2896.2006.00374.x; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Bosco A, 2010, MUCOSAL IMMUNOL, V3, P399, DOI 10.1038/mi.2010.13; Bosco A, 2009, J IMMUNOL, V182, P6011, DOI 10.4049/jimmunol.0804125; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; Chaussabel D, 2008, IMMUNITY, V29, P150, DOI 10.1016/j.immuni.2008.05.012; Chen Y, 2006, AM J RESP CELL MOL, V34, P192, DOI 10.1165/rcmb.2004-0417OC; Dougherty RH, 2009, CLIN EXP ALLERGY, V39, P193, DOI 10.1111/j.1365-2222.2008.03157.x; Fenner JE, 2006, NAT IMMUNOL, V7, P33, DOI 10.1038/ni1287; Greenwell-Wild T, 2009, BLOOD, V114, P1864, DOI 10.1182/blood-2009-03-211540; Guajardo JR, 2005, J ALLERGY CLIN IMMUN, V115, P243, DOI 10.1016/j.jaci.2004.10.032; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Hiscott J, 2007, CYTOKINE GROWTH F R, V18, P483, DOI 10.1016/j.cytogfr.2007.06.002; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Honda K, 2006, IMMUNITY, V25, P349, DOI 10.1016/j.immuni.2006.08.009; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; Hu FL, 2011, EUR J IMMUNOL, V41, P1086, DOI 10.1002/eji.201040831; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Ideker T, 2011, CELL, V144, P860, DOI 10.1016/j.cell.2011.03.007; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kanneganti TD, 2010, NAT REV IMMUNOL, V10, P688, DOI 10.1038/nri2851; Katze MG, 2008, NAT REV IMMUNOL, V8, P644, DOI 10.1038/nri2377; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Martinez FD, 2009, PEDIATRICS, V123, pS146, DOI 10.1542/peds.2008-2233D; Martinon F, 2010, NAT IMMUNOL, V11, P411, DOI 10.1038/ni.1857; Matsuzaki Y, 2006, J IMMUNOL, V177, P527, DOI 10.4049/jimmunol.177.1.527; Mobini R, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-19; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Proud D, 2008, AM J RESP CRIT CARE, V178, P962, DOI 10.1164/rccm.200805-670OC; Quinton LJ, 2011, CELL TISSUE RES, V343, P153, DOI 10.1007/s00441-010-1044-y; Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Schadt Eric E, 2005, Sci STKE, V2005, ppe40, DOI 10.1126/stke.2952005pe40; Schadt EE, 2009, NATURE, V461, P218, DOI 10.1038/nature08454; Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Subrata LS, 2009, J IMMUNOL, V183, P2793, DOI 10.4049/jimmunol.0900695; Takaoka A, 2006, CELL MICROBIOL, V8, P907, DOI 10.1111/j.1462-5822.2006.00716.x; Wang Q, 2009, J IMMUNOL, V183, P6989, DOI 10.4049/jimmunol.0901386; Yanai H, 2007, P NATL ACAD SCI USA, V104, P3402, DOI 10.1073/pnas.0611559104; Zaas AK, 2009, CELL HOST MICROBE, V6, P207, DOI 10.1016/j.chom.2009.07.006	46	56	56	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					88	94		10.1016/j.jaci.2011.10.038	http://dx.doi.org/10.1016/j.jaci.2011.10.038			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	22112518	Green Accepted			2022-12-18	WOS:000298634000011
J	Hong, XM; Wang, GY; Liu, X; Kumar, R; Tsai, HJ; Arguelles, L; Hao, K; Pearson, C; Ortiz, K; Bonzagni, A; Apollon, S; Fu, LL; Caruso, D; Pongracic, JA; Schleimer, R; Holt, PG; Bauchner, H; Wang, XB				Hong, Xiumei; Wang, Guoying; Liu, Xin; Kumar, Rajesh; Tsai, Hui-Ju; Arguelles, Lester; Hao, Ke; Pearson, Colleen; Ortiz, Kathryn; Bonzagni, Anthony; Apollon, Stephanie; Fu, Lingling; Caruso, Deanna; Pongracic, Jacqueline A.; Schleimer, Robert; Holt, Patrick G.; Bauchner, Howard; Wang, Xiaobin			Gene polymorphisms, breast-feeding, and development of food sensitization in early childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Breast-feeding; food sensitization; gene-environment interaction	ATOPIC DISEASE; PEANUT ALLERGY; ASTHMA; ASSOCIATION; BIRTH; CHILDREN; RISK; PREVALENCE; DERMATITIS; AGE	Background: The effect of breast-feeding on the development of allergic disease is uncertain. There are no data that show whether this relationship varies by individual genotypes. Objective: We sought to evaluate the effect of breast-feeding and gene-breast-feeding interactions on food sensitization (FS) in a prospective US birth cohort. Methods: This study included 970 children who were prospectively followed since birth. Breast-feeding history was obtained from a standardized questionnaire interview. FS was defined as a specific IgE level of 0.35 kU(A)/L or greater to any of 8 common food allergens. Eighty-eight potentially functional single nucleotide polymorphisms (SNPs) were genotyped from 18 genes involved in innate immunity or T(H)1/T(H)2 balance. Logistic regression models were used to test the effects of breast-feeding and gene-breast-feeding interactions on FS, with adjustment for pertinent covariates. Results: Children who were ever breast-fed (n = 739), including exclusively breast-fed children, were at a 1.5 (95% CI, 1.1-2.1; P = .019) times higher risk of FS than never breast-fed children (n = 231). This association was significantly modified by rs425648 in the IL-12 receptor beta 1 gene (IL12RB1; P for interaction = .0007): breast-feeding increased the risk of FS (odds ratio, 2.0; 95% CI, 1.4-3.1; P = .0005) in children carrying the GG genotype but decreased the risk (odds ratio, 0.6; 95% CI, 0.3-1.4; P = .252) in children carrying the GT/TT genotype. Similar interactions were observed for SNPs in the Toll-like receptor 9 (TLR9; rs352140) and thymic stromal lymphopoietin (TSLP; rs3806933) genes. The interaction between the combined genotypes of the 3 SNPs and breast-feeding on FS was even stronger (P for interaction < 10(-5)). Conclusion: Our data suggest that the effect of breast-feeding on FS was modified by SNPs in the IL12RB1, TLR9, and TSLP genes both individually and jointly. Our findings underscore the importance of considering individual genetic variations in assessing this relationship. (J Allergy Clin Immunol 2011;128:374-81.)	[Hong, Xiumei; Wang, Guoying; Liu, Xin; Tsai, Hui-Ju; Arguelles, Lester; Caruso, Deanna; Wang, Xiaobin] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Mary Ann & J Milburn Smith Child Hlth Res Program, Chicago, IL 60614 USA; [Hong, Xiumei; Wang, Guoying; Liu, Xin; Tsai, Hui-Ju; Arguelles, Lester; Caruso, Deanna; Wang, Xiaobin] Childrens Mem Res Ctr, Chicago, IL USA; [Pearson, Colleen; Ortiz, Kathryn; Bonzagni, Anthony; Apollon, Stephanie; Fu, Lingling; Bauchner, Howard] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA; [Pearson, Colleen; Ortiz, Kathryn; Bonzagni, Anthony; Apollon, Stephanie; Fu, Lingling; Bauchner, Howard] Boston Med Ctr, Boston, MA USA; [Tsai, Hui-Ju] Natl Hlth Res Inst, Inst Populat Hlth Sci, Div Biostat & Bioinformat, Zhunan, Taiwan; [Kumar, Rajesh; Pongracic, Jacqueline A.] Childrens Mem Hosp, Div Allergy & Immunol, Chicago, IL 60614 USA; [Hao, Ke] Merck Res Labs, Boston, MA USA; [Schleimer, Robert] Northwestern Univ, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60614 USA; [Holt, Patrick G.] Univ Western Australia, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia; [Holt, Patrick G.] Univ Western Australia, Ctr Child Hlth Res, Perth, WA 6009, Australia	Northwestern University; Feinberg School of Medicine; Boston University; Boston Medical Center; National Health Research Institutes - Taiwan; Ann & Robert H. Lurie Children's Hospital of Chicago; Merck & Company; Northwestern University; Feinberg School of Medicine; Telethon Kids Institute; University of Western Australia; University of Western Australia	Hong, XM (corresponding author), Northwestern Univ, Dept Pediat, Feinberg Sch Med, Mary Ann & J Milburn Smith Child Hlth Res Program, 2300 Childrens Plaza,Box 157, Chicago, IL 60614 USA.	xhong@childrensmemorial.org	Holt, Patrick G/H-1548-2011; Tsai, Hui-Ju/E-3937-2010; Wang, Guoying/F-8908-2011	Holt, Patrick G/0000-0003-1193-0935; Kumar, Rajesh/0000-0002-1962-7108; Bauchner, Howard/0000-0002-8368-9805	March of Dimes PERI [20-FY02-56]; National Institute of Environmental Health Sciences [R21 ES011666]; National Institute of Child Health and Development [R01 HD041702]; Food Allergy Initiative; National Institute of Allergy and Infectious Diseases (NIAID) [R21AI079872, U01AI090727, R21AI087888]; Department of Defense [W81XWH-10-1-0123]; National Heart, Lung, and Blood Institute [K23HL093023]; National Institutes of Health, Northwestern University [KL2RR025740]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD041702] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025741, KL2RR025740] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL093023] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI090727, R21AI087888, R21AI079872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES011666] Funding Source: NIH RePORTER	March of Dimes PERI(March of Dimes); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute of Child Health and Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Food Allergy Initiative; National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Department of Defense(United States Department of Defense); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health, Northwestern University(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The parent study was supported in part by March of Dimes PERI grants (20-FY02-56), the National Institute of Environmental Health Sciences (R21 ES011666), and the National Institute of Child Health and Development (R01 HD041702). The follow-up study was supported in part by the Food Allergy Initiative and the National Institute of Allergy and Infectious Diseases (NIAID; R21AI079872; U01AI090727) and the Department of Defense (W81XWH-10-1-0123). R. K. is supported by the National Heart, Lung, and Blood Institute (K23HL093023). X. L. and L. A. are supported by a career development award from the National Institutes of Health/Clinical and Translational Science Awards Program, Northwestern University (KL2RR025740). X. L. also is supported by the NIAID (R21AI087888).	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Caspi A, 2007, P NATL ACAD SCI USA, V104, P18860, DOI 10.1073/pnas.0704292104; Giwercman C, 2010, J ALLERGY CLIN IMMUN, V125, P866, DOI 10.1016/j.jaci.2010.01.026; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P653, DOI 10.1016/j.jaci.2009.12.018; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, pe1; Hong XM, 2010, J ALLERGY CLIN IMMUN, V126, P1059, DOI 10.1016/j.jaci.2010.08.029; Katz Y, 2010, J ALLERGY CLIN IMMUN, V126, P77, DOI 10.1016/j.jaci.2010.04.020; Kjaer HF, 2009, PEDIAT ALLERG IMM-UK, V20, P726, DOI 10.1111/j.1399-3038.2009.00862.x; Kramer MS, 2007, BMJ-BRIT MED J, V335, P815, DOI 10.1136/bmj.39304.464016.AE; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; Kusunoki T, 2010, PEDIATR ALLERGY IMMU, V21, P60, DOI 10.1111/j.1399-3038.2009.00982.x; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lowe AJ, 2006, J ALLERGY CLIN IMMUN, V117, P682, DOI 10.1016/j.jaci.2005.10.027; Mandhane PJ, 2007, J ALLERGY CLIN IMMUN, V119, P1359, DOI 10.1016/j.jaci.2007.01.043; Matheson MC, 2007, J ALLERGY CLIN IMMUN, V120, P1051, DOI 10.1016/j.jaci.2007.06.030; Mihrshahi S, 2007, CLIN EXP ALLERGY, V37, P671, DOI 10.1111/j.1365-2222.2007.02696.x; Miyake Y, 2003, CLIN EXP ALLERGY, V33, P312, DOI 10.1046/j.1365-2222.2003.t01-1-01607.x; Mook-Kanamori DO, 2009, DIABETES, V58, P992, DOI 10.2337/db08-1311; Nwaru BI, 2010, PEDIATRICS, V125, P50, DOI 10.1542/peds.2009-0813; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Pesonen M, 2006, CLIN EXP ALLERGY, V36, P1011, DOI 10.1111/j.1365-2222.2006.02526.x; Price AL, 2007, AM J HUM GENET, V80, P1024, DOI 10.1086/518313; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; Schadt EE, 2008, PLOS BIOL, V6, P1020, DOI 10.1371/journal.pbio.0060107; Schnabel E, 2010, CLIN EXP ALLERGY, V40, P450, DOI 10.1111/j.1365-2222.2009.03400.x; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Soriano-Sarabia N, 2008, JAIDS-J ACQ IMM DEF, V49, P128, DOI 10.1097/QAI.0b013e318184fb41; Takahashi N, 2005, HUM MOL GENET, V14, P3149, DOI 10.1093/hmg/ddi347; Vercelli D, 2010, CURR OPIN ALLERGY CL, V10, P145, DOI 10.1097/ACI.0b013e32833653d7; Wang XB, 2002, JAMA-J AM MED ASSOC, V287, P195, DOI 10.1001/jama.287.2.195; Wu CY, 1997, J IMMUNOL, V159, P1658	35	56	57	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					374	U391		10.1016/j.jaci.2011.05.007	http://dx.doi.org/10.1016/j.jaci.2011.05.007			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21689850	Green Accepted			2022-12-18	WOS:000293280800019
J	Stern, G; de Jongste, J; van der Valk, R; Baraldi, E; Carraro, S; Thamrin, C; Frey, U				Stern, Georgette; de Jongste, Johan; van der Valk, Ralf; Baraldi, Eugenio; Carraro, Silvia; Thamrin, Cindy; Frey, Urs			Fluctuation phenotyping based on daily fraction of exhaled nitric oxide values in asthmatic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Exhaled nitric oxide; airway inflammation; asthma control; children; time-series analysis; detrended fluctuation analysis; cross-correlation analysis; fractal	EXACERBATIONS; SPIROMETRY; MANAGEMENT; PREDICTOR; SYMPTOMS; EXPOSURE; RISK	Background: Fraction of exhaled nitric oxide (FENO), a marker of airway inflammation, has been proposed to be useful for asthma management, but conclusions are inconsistent. This might be due to the failure of mean statistics to characterize individual variability in FENO values, which is possibly a better indicator of asthma control than single measurements. Objective: We characterized fractal fluctuations in daily FENO values over time and the relationship between FENO values and symptom scores. We investigated whether these are associated with asthma severity, control, and exacerbation risk. Methods: Daily FENO values and symptom scores over 192 days in 41 atopic asthmatic children from the Childhood Asthma Respiratory Inflammatory Status Monitoring study were analyzed. Two methods of time-series analysis were used: detrended fluctuation analysis to quantify fractal patterns in fluctuations in daily FENO values (a value) and cross-correlation to quantify the strength of the relationship between daily FENO values and symptom scores. The associations of a values and cross-correlation with markers of asthma severity and control were assessed by means of regression analysis. Results: Daily fluctuations in FENO values exhibited fractal-type long-range correlations. Those subjects receiving higher doses of inhaled corticosteroids at study entry had a significantly lower a value, corresponding to more random fluctuations in FENO values in those with greater inhaled corticosteroid need. The cross-correlation between FENO values and symptom scores was significantly higher in those subjects who had exacerbations. Conclusions: Fluctuation in FENO values and their cross-correlation to symptom scores contains information on asthma severity and control. Methods that quantify the complexity of asthma over time might assist in identifying asthmatic subjects with concordance between eosinophilic inflammation and symptoms and thus increased exacerbation risk. (J Allergy Clin Immunol 2011;128:293-300.)	[Frey, Urs] Univ Basel, Univ Childrens Hosp UKBB, CH-4031 Basel, Switzerland; [Stern, Georgette; Thamrin, Cindy] Univ Hosp Bern, Dept Pediat, CH-3010 Bern, Switzerland; [de Jongste, Johan; van der Valk, Ralf] Erasmus Univ, Med Ctr, Dept Pediat, Div Pediat Resp Med, Rotterdam, Netherlands; [Baraldi, Eugenio; Carraro, Silvia] Univ Padua, Dept Pediat, Padua, Italy	University of Basel; University of Bern; University Hospital of Bern; Erasmus University Rotterdam; Erasmus MC; University of Padua	Frey, U (corresponding author), Univ Basel, Univ Childrens Hosp UKBB, POB Spitalstr 33, CH-4031 Basel, Switzerland.	urs.frey@ukbb.ch	baraldi, eugenio/AAC-5233-2022	BARALDI, EUGENIO/0000-0002-1829-3652; Thamrin, Cindy/0000-0003-3284-3558	Swiss National Foundation [3200-B0-1 12099]; Swiss Federal Office of Public Health; Aerocrine AB, Solna, Sweden; Erasmus MC-Sophia Foundation for Scientific Research	Swiss National Foundation(Swiss National Science Foundation (SNSF)); Swiss Federal Office of Public Health; Aerocrine AB, Solna, Sweden; Erasmus MC-Sophia Foundation for Scientific Research	Supported by Swiss National Foundation grant 3200-B0-1 12099 and a Swiss Federal Office of Public Health (Tobacco Prevention Fund) research grant. The data collection was financially supported by Aerocrine AB, Solna, Sweden. R.v.d.V. was supported by a travel grant from the Erasmus MC-Sophia Foundation for Scientific Research.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Artlich A, 1999, EUR RESPIR J, V13, P1396, DOI 10.1183/09031936.99.13614029; Baldwin DN, 2004, J APPL PHYSIOL, V97, P1830, DOI 10.1152/japplphysiol.00298.2004; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bodini A, 2007, CHEST, V132, P1520, DOI 10.1378/chest.07-1025; Cernelc M, 2002, J APPL PHYSIOL, V92, P1817, DOI 10.1152/japplphysiol.00675.2001; Cockcroft DW, 1996, J ALLERGY CLIN IMMUN, V98, P1016, DOI 10.1016/S0091-6749(96)80185-0; de Jongste JC, 2009, AM J RESP CRIT CARE, V179, P93, DOI 10.1164/rccm.200807-1010OC; Frey U, 2005, NATURE, V438, P667, DOI 10.1038/nature04176; Frey U, 2008, LANCET, V372, P1088, DOI 10.1016/S0140-6736(08)61450-6; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; Gelb AF, 2006, CHEST, V129, P1492, DOI 10.1378/chest.129.6.1492; GINA, 2008, GLOB STRAT ASTHM MAN; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Harkins MS, 2004, J ASTHMA, V41, P471, DOI 10.1081/JAS-120033990; Ho KKL, 1997, CIRCULATION, V96, P842; Hu K, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.011114; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Kharitonov Sergei A, 2004, Proc Am Thorac Soc, V1, P191, DOI 10.1513/pats.200402-011MS; Leuppi JD, 2002, THORAX, V57, P518, DOI 10.1136/thorax.57.6.518; Lim KG, 2008, CHEST, V133, P1232, DOI 10.1378/chest.07-1712; Michils A, 2008, EUR RESPIR J, V31, P539, DOI 10.1183/09031936.00020407; PENG CK, 1995, CHAOS, V5, P82, DOI 10.1063/1.166141; PENG CK, 1993, PHYS REV LETT, V70, P1343, DOI 10.1103/PhysRevLett.70.1343; Pijnenburg MW, 2006, PEDIAT ALLERG IMM-UK, V17, P189, DOI 10.1111/j.1399-3038.2006.00394.x; Pijnenburg MW, 2005, THORAX, V60, P215, DOI 10.1136/thx.2004.023374; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Roberts G, 2004, THORAX, V59, P752, DOI 10.1136/thx.2003.008722; Santanello NC, 1999, ARCH DIS CHILD, V80, P414, DOI 10.1136/adc.80.5.414; Smith AD, 2005, CURR OPIN ALLERGY CL, V5, P49, DOI 10.1097/00130832-200502000-00010; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Spergel JM, 2005, J ASTHMA, V42, P879, DOI 10.1080/02770900500371344; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Szefler SJ, 2009, J ALLERGY CLIN IMMUN, V123, P28, DOI 10.1016/j.jaci.2008.11.002; Taylor DR, 2008, EUR RESPIR J, V32, P545, DOI 10.1183/09031936.00155307; Taylor DR, 2006, THORAX, V61, P817, DOI 10.1136/thx.2005.056093; Thamrin C, 2009, EUR RESPIR J, V33, P486, DOI 10.1183/09031936.00106208; THAMRIN C, 2011, J ALLERGY CLIN IMMUN	41	56	57	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					293	300		10.1016/j.jaci.2011.03.010	http://dx.doi.org/10.1016/j.jaci.2011.03.010			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21489612	Bronze			2022-12-18	WOS:000293280800007
J	Hernandez, ML; Lay, JC; Harris, B; Esther, CR; Brickey, WJ; Bromberg, PA; Diaz-Sanchez, D; Devlin, RB; Kleeberger, SR; Alexis, NE; Peden, DB				Hernandez, Michelle L.; Lay, John C.; Harris, Bradford; Esther, Charles R., Jr.; Brickey, W. June; Bromberg, Philip A.; Diaz-Sanchez, David; Devlin, Robert B.; Kleeberger, Steven R.; Alexis, Neil E.; Peden, David B.			Atopic asthmatic subjects but not atopic subjects without asthma have enhanced inflammatory response to ozone	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ozone; innate immunity; asthma; atopy; hyaluronic acid; environmental airways disease; IL-1 beta; IL-10	TOLL-LIKE RECEPTOR-4; MILD ALLERGIC-ASTHMA; AIRWAY INFLAMMATION; LUNG INJURY; INNATE IMMUNITY; IN-VIVO; EXPOSURE; HEALTHY; HYALURONAN; ENDOTOXIN	Background: Asthma is a known risk factor for acute ozone-associated respiratory disease. Ozone causes an immediate decrease in lung function and increased airway inflammation. The role of atopy and asthma in modulation of ozone-induced inflammation has not been determined. Objective: We sought to determine whether atopic status modulates ozone response phenotypes in human subjects. Methods: Fifty volunteers (25 healthy volunteers, 14 atopic nonasthmatic subjects, and 11 atopic asthmatic subjects not requiring maintenance therapy) underwent a 0.4-ppm ozone exposure protocol. Ozone response was determined based on changes in lung function and induced sputum composition, including airway inflammatory cell concentration, cell-surface markers, and cytokine and hyaluronic acid concentrations. Results: All cohorts experienced similar decreases in lung function after ozone. Atopic and atopic asthmatic subjects had increased sputum neutrophil numbers and IL-8 levels after ozone exposure; values did not significantly change in healthy volunteers. After ozone exposure, atopic asthmatic subjects had significantly increased sputum IL-6 and IL-1 beta levels and airway macrophage Toll-like receptor 4, Fc epsilon RI, and CD23 expression; values in healthy volunteers and atopic nonasthmatic subjects showed no significant change. Atopic asthmatic subjects had significantly decreased IL-10 levels at baseline compared with healthy volunteers; IL-10 levels did not significantly change in any group with ozone. All groups had similar levels of hyaluronic acid at baseline, with increased levels after ozone exposure in atopic and atopic asthmatic subjects. Conclusion: Atopic asthmatic subjects have increased airway inflammatory responses to ozone. Increased Toll-like receptor 4 expression suggests a potential pathway through which ozone generates the inflammatory response in allergic asthmatic subjects but not in atopic subjects without asthma. (J Allergy Clin Immunol 2010;126:537-44.)	[Hernandez, Michelle L.; Lay, John C.; Harris, Bradford; Esther, Charles R., Jr.; Alexis, Neil E.; Peden, David B.] Univ N Carolina, Dept Pediat, Sch Med, Chapel Hill, NC 27599 USA; [Hernandez, Michelle L.; Lay, John C.; Harris, Bradford; Alexis, Neil E.; Peden, David B.] Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Sch Med, Chapel Hill, NC 27599 USA; [Bromberg, Philip A.; Peden, David B.] Univ N Carolina, Dept Med, Sch Med, Chapel Hill, NC 27599 USA; [Brickey, W. June; Peden, David B.] Univ N Carolina, Dept Microbiol Immunol, Chapel Hill, NC 27599 USA; [Kleeberger, Steven R.] Natl Inst Environm Hlth Sci, Lab Resp Biol, Res Triangle Pk, NC USA; [Diaz-Sanchez, David; Devlin, Robert B.] US EPA, Environm Publ Hlth Div, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); United States Environmental Protection Agency	Hernandez, ML (corresponding author), Univ N Carolina, Dept Pediat, Sch Med, 104 Mason Farm Rd,CB 7310, Chapel Hill, NC 27599 USA.	Michelle_Hernandez@med.unc.edu	Lay, John/A-6380-2012; Kleeberger, Steven R/F-1807-2019	Kleeberger, Steven R/0000-0003-2948-8452; Peden, David/0000-0003-4526-4627	National Institute of Environmental Health Sciences [R01ES012706, P30ES010126]; National Institute for Allergy and Infectious Diseases [U19AI077437]; National Center for Complementary and Alternative Medicine [P01AT002620]; National Institutes of Health [KL2RR025746, M01RR00046, UL1RR025747]; US Environmental Protection Agency [CR 83346301]; Center for Environmental Medicine and Lung Biology at the University of North Carolina at Chapel Hill; Environmental Protection Agency; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [P01AT002620] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR025746, UL1RR025747, M01RR000046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012706, P30ES010126, ZIAES100512] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute for Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Environmental Protection Agency(United States Environmental Protection Agency); Center for Environmental Medicine and Lung Biology at the University of North Carolina at Chapel Hill; Environmental Protection Agency(United States Environmental Protection Agency); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported in part by grants R01ES012706 and P30ES010126 from the National Institute of Environmental Health Sciences, U19AI077437 from the National Institute for Allergy and Infectious Diseases, P01AT002620 from the National Center for Complementary and Alternative Medicine, and KL2RR025746, M01RR00046, and UL1RR025747 from the National Center of Research Resources of the National Institutes of Health, as well as CR 83346301 from the US Environmental Protection Agency.; Although the research described in this article has been funded wholly or in part by the United States Environmental Protection Agency through cooperative agreement CR 83346301 with the Center for Environmental Medicine and Lung Biology at the University of North Carolina at Chapel Hill, it has not been subjected to the Agency's required peer and policy review and therefore does not necessarily reflect the views of the Agency, and no official endorsement should be inferred.; Disclosure of potential conflict of interest: P. A. Bromberg has received research support from the US Environmental Protection Agency. D. B. Peden is a consultant for Funxional Therapeutics and GlaxoSmithKline and has received research support from the National Institutes of Health and the Environmental Protection Agency. The rest of the authors have declared that they have no conflict of interest.	Abdollahi-Roodsaz S, 2009, AM J PATHOL, V175, P2004, DOI 10.2353/ajpath.2009.090262; Ahmad S, 2005, FREE RADICAL BIO MED, V39, P213, DOI 10.1016/j.freeradbiomed.2005.03.009; Alexis N, 2000, INHAL TOXICOL, V12, P1205; Alexis NE, 2006, J ALLERGY CLIN IMMUN, V117, P1396, DOI 10.1016/j.jaci.2006.02.030; Alexis NE, 2003, J ALLERGY CLIN IMMUN, V112, P353, DOI 10.1067/mai.2003.1651; Alexis NE, 2008, ENVIRON HEALTH PERSP, V116, P799, DOI 10.1289/ehp.10981; Alexis NE, 2009, J ALLERGY CLIN IMMUN, V124, P1222, DOI 10.1016/j.jaci.2009.07.036; BACKUS GS, 2006, INT C AM THOR SOC SA, pA38; Ball BA, 1996, J ALLERGY CLIN IMMUN, V98, P563, DOI 10.1016/S0091-6749(96)70090-8; BECKER S, 1991, TOXICOL APPL PHARM, V110, P403, DOI 10.1016/0041-008X(91)90042-D; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Bihl F, 2003, J IMMUNOL, V170, P6141, DOI 10.4049/jimmunol.170.12.6141; Boehlecke B, 2003, J ALLERGY CLIN IMMUN, V112, P1241, DOI 10.1016/j.jaci.2003.08.052; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Bosson J, 2003, CLIN EXP ALLERGY, V33, P777, DOI 10.1046/j.1365-2222.2003.01662.x; Braunstahl GJ, 2003, CLIN EXP ALLERGY, V33, P579, DOI 10.1046/j.1365-2222.2003.01652.x; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Brown JL, 2007, CLIN EXP ALLERGY, V37, P688, DOI 10.1111/j.1365-2222.2007.02695.x; Cho HY, 2007, FREE RADICAL BIO MED, V42, P433, DOI 10.1016/j.freeradbiomed.2006.11.021; Cho HY, 2007, AM J RESP CRIT CARE, V175, P829, DOI 10.1164/rccm.200509-1527OC; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Garantziotis S, 2010, AM J RESP CRIT CARE, V181, P666, DOI 10.1164/rccm.200903-0381OC; Garantziotis S, 2009, J BIOL CHEM, V284, P11309, DOI 10.1074/jbc.M802400200; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, pe13; Hernandez ML, 2010, INHAL TOXICOL, V22, P648, DOI 10.3109/08958371003610966; Hollingsworth JW, 2007, J IMMUNOL, V179, P4367, DOI 10.4049/jimmunol.179.7.4367; Hollingsworth JW, 2004, AM J RESP CRIT CARE, V170, P126, DOI 10.1164/rccm.200311-1499OC; Janic B, 2005, AM J PHYSIOL-LUNG C, V288, pL317, DOI 10.1152/ajplung.00125.2004; Janic B, 2003, J IMMUNOL METHODS, V272, P125, DOI 10.1016/S0022-1759(02)00440-4; Jaspers I, 1997, AM J PHYSIOL-LUNG C, V272, pL504, DOI 10.1152/ajplung.1997.272.3.L504; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56, DOI 10.1164/ajrccm.153.1.8542163; Ke BB, 2007, HUM GENE THER, V18, P355, DOI 10.1089/hum.2007.181; Kehrl HR, 1999, J ALLERGY CLIN IMMUN, V104, P1198, DOI 10.1016/S0091-6749(99)70013-8; Khatri SB, 2009, J ASTHMA, V46, P777, DOI 10.3109/02770900902779284; Kleeberger SR, 2000, AM J RESP CELL MOL, V22, P620, DOI 10.1165/ajrcmb.22.5.3912; KNUDSON RJ, 1976, AM REV RESPIR DIS, V114, P871; Konno S, 1996, INT ARCH ALLERGY IMM, V109, P73, DOI 10.1159/000237234; Lay JC, 2009, THORAX, V64, P313, DOI 10.1136/thx.2008.096222; Lay JC, 2007, J ALLERGY CLIN IMMUN, V120, P719, DOI 10.1016/j.jaci.2007.05.005; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; Park JW, 2004, AM J RESP CELL MOL, V30, P830, DOI 10.1165/rcmb.2003-0373OC; Passannante AN, 1998, J APPL PHYSIOL, V85, P1863, DOI 10.1152/jappl.1998.85.5.1863; Peden DB, 1997, J ALLERGY CLIN IMMUN, V100, P802, DOI 10.1016/S0091-6749(97)70277-X; Peden DB, 2005, J ALLERGY CLIN IMMUN, V115, P213, DOI 10.1016/j.jaci.2004.12.003; Peden DB, 2008, MIDDLETONS ALLERGY P, P495; PUJOL JL, 1990, INT ARCH ALLER A IMM, V91, P207, DOI 10.1159/000235117; Schaumann F, 2008, AM J RESP CRIT CARE, V177, P1307, DOI 10.1164/rccm.200706-870OC; Takanashi S, 1999, EUR RESPIR J, V14, P309, DOI 10.1034/j.1399-3003.1999.14b12.x; Taylor KR, 2007, J BIOL CHEM, V282, P18265, DOI 10.1074/jbc.M606352200; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Vagaggini B, 1999, EUR RESPIR J, V13, P274, DOI 10.1034/j.1399-3003.1999.13b09.x; Vagaggini B, 2002, AM J RESP CRIT CARE, V166, P1073, DOI 10.1164/rccm.2201013; Yamasaki K, 2009, J BIOL CHEM, V284, P12762, DOI 10.1074/jbc.M806084200	57	56	60	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					537	U228		10.1016/j.jaci.2010.06.043	http://dx.doi.org/10.1016/j.jaci.2010.06.043			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20816188	Green Accepted, Bronze			2022-12-18	WOS:000281512500020
J	Umetsu, DT; DeKruyff, RH				Umetsu, Dale T.; DeKruyff, Rosemarie H.			Natural killer T cells are important in the pathogenesis of asthma: The many pathways to asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; airway hyperreactivity; natural killer T cells; T(H)2 cells; innate immunity	INVARIANT NKT CELLS; AIRWAY HYPERREACTIVITY; ACTIVATION; HYPERRESPONSIVENESS; IDENTIFICATION; POPULATION; EXPRESSION; PHENOTYPE; SUBSETS; ABSENCE	The pathogenesis of bronchial asthma, a complex trait associated with a number of environmental factors (eg, allergens, infection, air pollution, exercise, and obesity), involves multiple cell types and several distinct cellular and molecular pathways. These pathways include adaptive and innate immunity and involve T(H)2 cells, mast cells, basophils, eosinophils, neutrophils, airway epithelial cells, and subsets of a newly described cell type called natural killer T (NKT) cells. A role for subsets of NKT cells in asthma has been suggested by extensive studies in animal models of asthma induced with allergen, viral infection, ozone exposure, or bacterial components, suggesting that NKT cells function in concert with T(H)2 cells or independently of adaptive immunity in causing airway hyperreactivity. The clinical relevance of NKT cells in human asthma is supported by the observation that NKT cells are present in the lungs of some patients with asthma, particularly patients with severe, poorly controlled asthma, although additional research is required to more precisely define the specific role of NKT cells in human asthma. These studies of NKT cells greatly expand our understanding of possible mechanisms that drive the development of asthma, particularly in the case of asthma associated with neutrophils, viral infection, and air pollution. (J Allergy Clin Immunol 2010;125:975-9.)	[Umetsu, Dale T.; DeKruyff, Rosemarie H.] Harvard Univ, Sch Med, Div Immunol & Allergy, Childrens Hosp Boston, Cambridge, MA 02138 USA	Harvard University; Boston Children's Hospital	Umetsu, DT (corresponding author), Karp Labs, Rm 10127,1 Blackfan Circle, Boston, MA 02115 USA.	dale.umetsu@childrens.harvard.edu			National Institutes of Health (NIH); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [RC1HL099839, R01HL062348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI083523, R01AI026322] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Disclosure of potential conflict of interest: D. T. Umetsu receives research support from the National Institutes of Health (NIH) and is an Associate Editor for Mucosal Immunology. R. H. DeKruyff receives research support from the NIH.	Agea E, 2005, J EXP MED, V202, P295, DOI 10.1084/jem.20050773; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Amano M, 1998, J IMMUNOL, V161, P1710; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; BALK SP, 1994, SCIENCE, V265, P259, DOI 10.1126/science.7517575; Bendelac A, 2007, ANNU REV IMMUNOL, V25, P297, DOI 10.1146/annurev.immunol.25.022106.141711; Bratke K, 2007, NEW ENGL J MED, V357, P194; Brown DR, 1996, J EXP MED, V184, P1295, DOI 10.1084/jem.184.4.1295; Coquet JM, 2008, P NATL ACAD SCI USA, V105, P11287, DOI 10.1073/pnas.0801631105; Das J, 2006, NAT MED, V12, P1345, DOI 10.1038/nm1206-1345; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Kim HS, 1999, J BIOL CHEM, V274, P9289, DOI 10.1074/jbc.274.14.9289; Kim S, 2008, J CLIN INVEST, V118, P2301, DOI [10.1172/JC133071, 10.1172/JCI33071]; Kinjo Y, 2006, NAT IMMUNOL, V7, P978, DOI 10.1038/ni1380; Koh YI, 2008, J IMMUNOL, V181, P4560, DOI 10.4049/jimmunol.181.7.4560; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lisbonne M, 2003, J IMMUNOL, V171, P1637, DOI 10.4049/jimmunol.171.4.1637; Maeda M, 2004, J IMMUNOL, V172, P6115, DOI 10.4049/jimmunol.172.10.6115; Matangkasombut P, 2009, MUCOSAL IMMUNOL, V2, P383, DOI 10.1038/mi.2009.96; Matangkasombut P, 2008, J ALLERGY CLIN IMMUN, V121, P1287, DOI 10.1016/j.jaci.2008.02.006; Matangkasombut P, 2009, J ALLERGY CLIN IMMUN, V123, P1181, DOI 10.1016/j.jaci.2009.02.013; Meyer EH, 2006, P NATL ACAD SCI USA, V103, P2782, DOI 10.1073/pnas.0510282103; Michel ML, 2007, J EXP MED, V204, P995, DOI 10.1084/jem.20061551; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Mutalithas K, 2007, J ALLERGY CLIN IMMUN, V119, P1274, DOI 10.1016/j.jaci.2007.02.021; Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507; Reynolds C, 2009, J ALLERGY CLIN IMMUN, V124, P860, DOI 10.1016/j.jaci.2009.07.022; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Savage AK, 2008, IMMUNITY, V29, P391, DOI 10.1016/j.immuni.2008.07.011; Stock P, 2009, J IMMUNOL, V182, P5116, DOI 10.4049/jimmunol.0804213; Subrata LS, 2009, J IMMUNOL, V183, P2793, DOI 10.4049/jimmunol.0900695; Terashima A, 2008, J EXP MED, V205, P2727, DOI 10.1084/jem.20080698; Thomas SY, 2006, NEW ENGL J MED, V354, P2613; Thomas SY, 2007, J IMMUNOL, V179, P1901, DOI 10.4049/jimmunol.179.3.1901; Vijayanand P, 2007, NEW ENGL J MED, V356, P1410, DOI 10.1056/NEJMoa064691; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhang Y, 1996, J EXP MED, V184, P1507, DOI 10.1084/jem.184.4.1507	40	56	64	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					975	979		10.1016/j.jaci.2010.02.006	http://dx.doi.org/10.1016/j.jaci.2010.02.006			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20338622	Green Accepted, Bronze			2022-12-18	WOS:000277686700003
J	Cassani, B; Poliani, PL; Moratto, D; Sobacchi, C; Marrella, V; Imperatori, L; Vairo, D; Plebani, A; Giliani, S; Vezzoni, P; Facchetti, F; Porta, F; Notarangelo, LD; Villa, A; Badolato, R				Cassani, Barbara; Poliani, Pietro Luigi; Moratto, Daniele; Sobacchi, Cristina; Marrella, Veronica; Imperatori, Laura; Vairo, Donatella; Plebani, Alessandro; Giliani, Silvia; Vezzoni, Paolo; Facchetti, Fabio; Porta, Fulvio; Notarangelo, Luigi D.; Villa, Anna; Badolato, Raffaele			Defect of regulatory T cells in patients with Omenn syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunodeficiency; V(D)J recombination; Omenn syndrome; regulatory T cells; FOXP3; anergy and tolerance; thymus and the development of lymphocytes	COMBINED IMMUNODEFICIENCY; FOXP3; LYMPHOCYTES; EXPRESSION; RETICULOENDOTHELIOSIS; REPERTOIRE; DEFICIENCY; EXPANSION	Background: Omenn syndrome (OS) is an autosomal-recessive disorder characterized by severe immunodeficiency and T-cell-mediated autoimmunity. The disease is caused by hypomorphic mutations in recombination-activating genes that hamper the process of Variable (V) Diversity (D) Joining (J) recombination, leading to the generation of autoreactive T cells. We have previously shown that in OS the expression of autoimmune regulator, a key factor governing central tolerance, is markedly reduced. Objective: Here, we have addressed the role of peripheral tolerance in the disease pathogenesis. Methods: We have analyzed forkhead box protein P3 (FOXP3) expression in peripheral blood T cells of 4 patients with OS and in lymphoid organs of 8 patients with OS and have tested the suppressive activity of sorted CD4(+) CD25(high) peripheral blood T cells in 2 of these patients. Results: We have observed that CD4(+)CD25(high)T cells isolated ex vivo from patients with OS failed to suppress proliferation of autologous or allogenic CD4+ responder T cells. Moreover, despite individual variability in the fraction of circulating FOXP3(+) CD4 cells in patients with OS, the immunohistochemical analysis of FOXP3 expression in lymph nodes and thymus of patients with OS demonstrated a severe reduction of this cell subset compared with control tissues. Conclusion: Overall, these results suggest a defect of regulatory T cells in OS leading to a breakdown of peripheral tolerance, which may actively concur to the development of autoimmune manifestations in the disease. (J Allergy Clin Immunol 2010;125:209-16.)	[Cassani, Barbara] Fdn Humanitas Ric, Rozzano, MI, Italy; [Poliani, Pietro Luigi; Facchetti, Fabio] Univ Brescia, Dept Pathol, I-25121 Brescia, Italy; [Moratto, Daniele; Imperatori, Laura; Vairo, Donatella; Plebani, Alessandro; Giliani, Silvia; Porta, Fulvio; Badolato, Raffaele] Univ Brescia, Dept Pediat, Ist Med Mol Angelo Nocivelli, I-25121 Brescia, Italy; [Sobacchi, Cristina; Marrella, Veronica; Vezzoni, Paolo; Villa, Anna] CNR, Ist Tecnol Biomed Avanzate, Segrate, MI, Italy; [Sobacchi, Cristina; Marrella, Veronica; Vezzoni, Paolo] IRCCS Ist Clin Humanitas, Rozzano, MI, Italy; [Notarangelo, Luigi D.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Notarangelo, Luigi D.] Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA; [Villa, Anna] San Raffaele Telethon Inst Gene Therapy HSR TIGET, Milan, Italy	IRCCS Humanitas Research Hospital; University of Brescia; University of Brescia; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); IRCCS Humanitas Research Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget)	Villa, A (corresponding author), CNR, ITB, Via Flli Cervi 90, I-20133 Milan, Italy.	anna.villa@itb.cnr.it	Giliani, Silvia/AAX-8843-2020; Cassani, Barbara/K-3871-2016; Notarangelo, Luigi D/F-9718-2016; Vezzoni, Paolo/K-3197-2018; Vezzoni, Paolo/R-3416-2019; SOBACCHI, CRISTINA/J-9345-2018; Facchetti, Fabio/E-7190-2010; Marrella, Veronica/ABI-1285-2020; Plebani, Alessandro/C-8593-2011; Badolato, Raffaele/A-8081-2010; Poliani, Pietro Luigi/E-8145-2010	Giliani, Silvia/0000-0001-8137-4642; Cassani, Barbara/0000-0002-4115-8109; Notarangelo, Luigi D/0000-0002-8335-0262; SOBACCHI, CRISTINA/0000-0002-2684-7184; Facchetti, Fabio/0000-0003-4975-2388; Marrella, Veronica/0000-0003-4035-8106; Badolato, Raffaele/0000-0001-7375-5410; Poliani, Pietro Luigi/0000-0002-5662-8978; Vezzoni, Paolo/0000-0002-6382-3923; Villa, Anna/0000-0003-4428-9013	Italian Telethon Foundation; Fondazione Cariplo; EU [201461]; PRIN [2007ACZMMZ_005]; Telethon [GGP07241]; FIRB/MIUR [RBIN04CHXT]; Ministero della Salute RF2007 Giovani Ricercatori Grant; Manton Foundation	Italian Telethon Foundation(Fondazione Telethon); Fondazione Cariplo(Fondazione Cariplo); EU(European Commission); PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Telethon(Fondazione Telethon); FIRB/MIUR(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Ministero della Salute RF2007 Giovani Ricercatori Grant; Manton Foundation	This work was supported by grants from the Italian Telethon Foundation to A.V., from Fondazione Cariplo (Nobel project to A.V., and L.D.N./R.B.), Fondazione Cariplo to A.V. and P.L.P., EU grant FP7 HLH-cure (project n. 201461), PRIN 2007 it. 2007ACZMMZ_005, Telethon GGP07241 to R.B., grant FIRB/MIUR (n. RBIN04CHXT) to P.V., Ministero della Salute RF2007 Giovani Ricercatori Grant to C.S., and the Manton Foundation to L.D.N.	Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014; Bacchetta R, 2007, J ALLERGY CLIN IMMUN, V120, P227, DOI 10.1016/j.jaci.2007.06.023; BASILE GD, 1991, IMMUNOL TODAY, V12, P456; Brugnoni D, 1997, EUR J IMMUNOL, V27, P2765, DOI 10.1002/eji.1830271104; Cavadini P, 2005, J CLIN INVEST, V115, P728, DOI 10.1172/JCI200523087; Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116, P949, DOI 10.1016/j.jaci.2005.08.047; Facchetti F, 1998, SPRINGER SEMIN IMMUN, V19, P459, DOI 10.1007/BF00792602; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Harville TO, 1997, J CLIN IMMUNOL, V17, P322, DOI 10.1023/A:1027330800085; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; Kekalainen E, 2007, J IMMUNOL, V178, P1208, DOI 10.4049/jimmunol.178.2.1208; Kronenberg M, 2005, NATURE, V435, P598, DOI 10.1038/nature03725; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Matangkasombut P, 2008, BLOOD, V111, P271, DOI 10.1182/blood-2007-06-096487; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; O'Garra A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801; OCHS HD, 1974, J PEDIATR-US, V85, P463, DOI 10.1016/S0022-3476(74)80445-2; OMENN GS, 1965, NEW ENGL J MED, V273, P427, DOI 10.1056/NEJM196508192730806; Ozcan E, 2008, J ALLERGY CLIN IMMUN, V122, P1054, DOI 10.1016/j.jaci.2008.10.023; Passerini L, 2008, INT IMMUNOL, V20, P421, DOI 10.1093/intimm/dxn002; Poliani PL, 2009, BLOOD, V114, P105, DOI 10.1182/blood-2009-03-211029; Rieux-Laucat F, 1998, J CLIN INVEST, V102, P312, DOI 10.1172/JCI332; Roncador G, 2005, EUR J IMMUNOL, V35, P1681, DOI 10.1002/eji.200526189; Ryan KR, 2005, J ALLERGY CLIN IMMUN, V116, P1158, DOI 10.1016/j.jaci.2005.08.036; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Signorini S, 1999, BLOOD, V94, P3468, DOI 10.1182/blood.V94.10.3468.422k34_3468_3478; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; Villa A, 2008, J ALLERGY CLIN IMMUN, V122, P1082, DOI 10.1016/j.jaci.2008.09.037; Watanabe N, 2005, NATURE, V436, P1181, DOI 10.1038/nature03886	30	56	56	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					209	216		10.1016/j.jaci.2009.10.023	http://dx.doi.org/10.1016/j.jaci.2009.10.023			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	20109747				2022-12-18	WOS:000273660500026
J	Travers, JB; Kozman, A; Mousdicas, N; Saha, C; Landis, M; Al-Hassani, M; Yao, WG; Yao, YX; Hyatt, AM; Sheehan, MP; Haggstrom, AN; Kaplan, MH				Travers, Jeffrey B.; Kozman, Amal; Mousdicas, Nico; Saha, Chandan; Landis, Megan; Al-Hassani, Mohammed; Yao, Weiguo; Yao, Yongxue; Hyatt, Ann-Marie; Sheehan, Michael P.; Haggstrom, Anita N.; Kaplan, Mark H.			Infected atopic dermatitis lesions contain pharmacologic amounts of lipoteichoic acid	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Lipoteichoic acid; Staphylococcus aureus; atopic dermatitis; TNF-alpha; IL-8	ACTIVATING-FACTOR RECEPTOR; NECROSIS-FACTOR-ALPHA; TOLL-LIKE RECEPTOR-2; STAPHYLOCOCCUS-AUREUS; HUMAN KERATINOCYTES; CYTOKINE PRODUCTION; EXPRESSION; GENE; MICE; SKIN	Background: Bacterial infection with Staphylococcus aureus is a known trigger for worsening of atopic dermatitis (AD); the exact mechanisms by which bacterial infection worsens dermatitis are unknown. Objective: We sought to characterize the amounts of the biologically active bacterial lipoprotein lipoteichoic acid (LTA) in infected AD lesions. Methods: Eighty-nine children with clinically impetiginized lesions of AD were enrolled in this study. A lesion was graded clinically by using the Eczema Area and Severity Index (EASI), wash fluid obtained from the lesion for quantitative bacterial culture, and measurement of LTA and cytokines. The staphylococcal isolate was tested for antibiotic susceptibilities. The patients were treated with a regimen that included topical corticosteroids and systemic antibiotics, and the lesion was reanalyzed after 2 weeks. Results: S aureus was identified in 79 of 89 children enrolled in the study. The bacterial colony-forming unit (CFU) counts correlated with the EASI lesional score (P = .04). LTA levels as high as 9.8 mu g/mL were measured in the wash fluid samples, and the amounts correlated with the lesional EASI scores (P = .01) and S aureus CFU (P < .001). Approximately 30% of clinically impetiginized AD lesions contained greater than 1 mu g/mL LTA, amounts that exert effects on various cell types in vitro. Moreover, injection of skin tissue ex vivo with amounts of LTA found in AD lesions resulted in epidermal cytokine gene expression. Conclusion: Pharmacologic levels of LTA are found in many infected atopic dermatitis lesions. (J Allergy Clin Immunol 2010;125:146-52.)	[Travers, Jeffrey B.; Kozman, Amal; Mousdicas, Nico; Landis, Megan; Al-Hassani, Mohammed; Yao, Yongxue; Hyatt, Ann-Marie; Sheehan, Michael P.; Haggstrom, Anita N.] Indiana Univ, Sch Med, Dept Dermatol, Indianapolis, IN 46202 USA; [Travers, Jeffrey B.; Kozman, Amal; Al-Hassani, Mohammed; Yao, Weiguo; Yao, Yongxue; Haggstrom, Anita N.; Kaplan, Mark H.] Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; [Travers, Jeffrey B.; Kozman, Amal; Al-Hassani, Mohammed; Yao, Weiguo; Yao, Yongxue; Haggstrom, Anita N.; Kaplan, Mark H.] Indiana Univ, Sch Med, HB Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Travers, Jeffrey B.] Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; [Saha, Chandan] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; [Travers, Jeffrey B.] Indiana Univ, Sch Med, Richard L Roudebush VA Med Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Travers, JB (corresponding author), Indiana Univ, Sch Med, HB Wells Ctr Pediat Res, James Whitcomb Riley Hosp Children, Rm 2659,702 Barnhill Dr, Indianapolis, IN 46202 USA.	jtravers@iupui.edu		Travers, Jeffrey/0000-0001-7232-1039	Riley Memorial Association; National Institutes of Health [HL62996, U19 AI070448]; Veteran's Administration Merit Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070448] Funding Source: NIH RePORTER	Riley Memorial Association; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veteran's Administration Merit Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by the Riley Memorial Association, National Institutes of Health grants HL62996 (J.B.T.) and U19 AI070448 (M.H.K., I.B.T.), and the Veteran's Administration Merit Award (J.B.T.).	Abramovits W, 2005, J AM ACAD DERMATOL, V53, pS86, DOI 10.1016/j.jaad.2005.04.034; Ahmad-Nejad P, 2004, J ALLERGY CLIN IMMUN, V113, P565, DOI 10.1016/j.jaci.2003.12.583; Baker BS, 2006, CLIN EXP IMMUNOL, V144, P1, DOI 10.1111/j.1365-2249.2005.02980.x; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Cardona ID, 2006, AM J CLIN DERMATOL, V7, P273, DOI 10.2165/00128071-200607050-00001; Chung HJ, 2008, J CLIN MICROBIOL, V46, P991, DOI 10.1128/JCM.00698-07; Ezepchuk YV, 1996, J INVEST DERMATOL, V107, P603, DOI 10.1111/1523-1747.ep12583377; Fournier B, 2005, CLIN MICROBIOL REV, V18, P521, DOI 10.1128/CMR.18.3.521-540.2005; Goh CL, 1997, INT J DERMATOL, V36, P653, DOI 10.1046/j.1365-4362.1997.00290.x; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hattar K, 2006, CRIT CARE MED, V34, P835, DOI 10.1097/01.CCM.0000202204.01230.44; Higaki S, 1999, INT J DERMATOL, V38, P265, DOI 10.1046/j.1365-4362.1999.00686.x; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Leung DYM, 2003, CURR OPIN PEDIATR, V15, P399, DOI 10.1097/00008480-200308000-00008; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Lorenz E, 2000, INFECT IMMUN, V68, P6398, DOI 10.1128/IAI.68.11.6398-6401.2000; MANDI Y, 1991, INT ARCH ALLER A IMM, V96, P102, DOI 10.1159/000235479; Matsui K, 2003, CLIN EXP ALLERGY, V33, P842, DOI 10.1046/j.1365-2222.2003.01666.x; Matsui K, 2002, CLIN EXP ALLERGY, V32, P783, DOI 10.1046/j.1365-2222.2002.01357.x; Matsui K, 2000, J INTERF CYTOK RES, V20, P321, DOI 10.1089/107999000312469; Mempel M, 2003, J INVEST DERMATOL, V121, P1389, DOI 10.1111/j.1523-1747.2003.12630.x; Michelsen KS, 2001, J BIOL CHEM, V276, P25680, DOI 10.1074/jbc.M011615200; Mrabet-Dahbi S, 2008, J ALLERGY CLIN IMMUN, V121, P1013, DOI 10.1016/j.jaci.2007.11.029; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Sasaki T, 2003, BRIT J DERMATOL, V148, P46, DOI 10.1046/j.1365-2133.2003.05017.x; Sehra S, 2008, CRIT REV IMMUNOL, V28, P15, DOI 10.1615/CritRevImmunol.v28.i1.20; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Travers JB, 2003, J INVEST DERMATOL, V120, P789, DOI 10.1046/j.1523-1747.2003.12149.x; Travers JB, 2008, J INVEST DERMATOL, V128, P455, DOI 10.1038/sj.jid.5701083; WILLIAMS.P, 1965, J INVEST DERMATOL, V45, P498, DOI 10.1038/jid.1965.164; WILLIAMS REA, 1990, BRIT J DERMATOL, V123, P493; Zhang QW, 2005, J CLIN INVEST, V115, P2855, DOI 10.1172/JCI25429	34	56	60	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					146	152		10.1016/j.jaci.2009.09.052	http://dx.doi.org/10.1016/j.jaci.2009.09.052			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	19962742	Green Accepted			2022-12-18	WOS:000273660500017
J	Fitzpatrick, AM; Brown, LAS; Holguin, F; Teague, WG				Fitzpatrick, Anne M.; Brown, Lou Ann S.; Holguin, Fernando; Teague, W. Gerald		Natl Heart Lung Blood Inst	Levels of nitric oxide oxidation products are increased in the epithelial lining fluid of children with persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; children; nitric oxide; nitrogen oxides; nitrosation; nitrosative stress; reactive nitrogen species	NITROSATIVE STRESS; BREATH CONDENSATE; AIRWAY; PEROXYNITRITE; INFLAMMATION; EVENTS; LAVAGE; MARKER; VALUES	Background: Children with severe allergic asthma have persistent airway inflammation and oxidant stress. Objectives: We hypothesized that children with severe allergic asthma would have increased concentrations of the nitric oxide (NO) oxidation products nitrite, nitrate, and nitrotyrosine in the proximal and distal airway epithelial lining fluid (ELF). We further hypothesized that NO oxidation products would be associated with higher exhaled NO values (fraction of exhaled nitric oxide [F-ENO]), greater allergic sensitization, and lower pulmonary function. Methods: Bronchoalveolar lavage fluid was obtained from 15 children with mild-to-moderate asthma, 30 children with severe allergic asthma, 5 nonasthmatic children, and 20 nonsmoking adults. The bronchoalveolar lavage fluid was divided into proximal and distal portions and nitrite, nitrate, and nitrotyrosine values were quantified. Results: Children with mild-to-moderate and severe allergic asthma had increased concentrations of nitrite (adult control subjects, 15 +/- 3 mu mol/L; pediatric control subjects, 23 +/- 4 mu mol/L; subjects with mild-to-moderate asthma, 56 +/- 26 mu mol/L; subjects with severe asthma, 74 +/- 18 mu mol/L), nitrate (37 +/- 13 vs 145 +/- 38 vs 711 +/- 155 vs 870 +/- 168 mu mol/L, respectively) and nitrotyrosine (2 +/- 1 vs 3 +/- 1 vs 9 +/- 3 vs 10 +/- 4 mu mol/L, respectively) in the proximal ELF. Similar results were seen in the distal ELF, although the concentrations were significantly lower (P < .05 for each). Although univariate analyses revealed no associations between NO oxidation products and clinical features, multivariate analyses revealed F-ENO values to be a significant predictor of NO oxidation in asthmatic children. Conclusions: NO oxidation products are increased in the ELF of asthmatic children. The relationship between F-ENO values and airway nitrosative stress is complicated and requires further study. (J Allergy Clin Immunol 2009;124:990-6.)	[Fitzpatrick, Anne M.; Brown, Lou Ann S.; Teague, W. Gerald] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; [Holguin, Fernando] Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA	Emory University; Emory University	Fitzpatrick, AM (corresponding author), 2015 Uppergate Dr, Atlanta, GA 30322 USA.	anne.fitzpatrick@emory.edu		Fitzpatrick, Anne/0000-0002-2933-5926	National Institutes of Health/National Institute of Nursing Research [KO1 NR010548]; National Institutes of Health/National Center for Research Resources [K 12 RR017643]; National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research [RO1 HL69170]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K12RR017643] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR010548, K01NR010584] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); National Institutes of Health/National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	Supported with funds from National Institutes of Health/National Institute of Nursing Research KO1 NR010548, National Institutes of Health/National Center for Research Resources K 12 RR017643, and National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program RO1 HL69170.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Andreadis AA, 2003, FREE RADICAL BIO MED, V35, P213, DOI 10.1016/S0891-5849(03)00278-8; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Baraldi E, 2006, ALLERGY, V61, P90, DOI 10.1111/j.1398-9995.2006.00996.x; Berry M, 2005, EUR RESPIR J, V25, P986, DOI 10.1183/09031936.05.00132404; Bove PF, 2006, FREE RADICAL BIO MED, V41, P515, DOI 10.1016/j.freeradbiomed.2006.05.011; Dweik RA, 2001, P NATL ACAD SCI USA, V98, P2622, DOI 10.1073/pnas.051629498; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Fitzpatrick AM, 2009, J ALLERGY CLIN IMMUN, V123, P146, DOI 10.1016/j.jaci.2008.10.047; FOMANEK W, 2002, EUR RESPIR J, V19, P487; Gaston B, 2005, AM J RESP CRIT CARE, V171, P1065, DOI 10.1164/rccm.2502003; Gaston B, 2002, AM J RESP CRIT CARE, V165, P387, DOI 10.1164/ajrccm.165.3.2106006; Gaston B, 2006, J ALLERGY CLIN IMMUN, V118, P817, DOI 10.1016/j.jaci.2006.06.040; Ghosh S, 2006, J IMMUNOL, V176, P5587, DOI 10.4049/jimmunol.176.9.5587; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Jones SL, 2002, EUR RESPIR J, V20, P601, DOI 10.1183/09031936.02.00285302; Kanazawa H, 2003, CHEST, V124, P1755, DOI 10.1378/chest.124.5.1755; Lex C, 2006, AM J RESP CRIT CARE, V174, P1286, DOI 10.1164/rccm.200603-352OC; MacPherson JC, 2001, J IMMUNOL, V166, P5763, DOI 10.4049/jimmunol.166.9.5763; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; *NAT HEART LUNG BL, 2002, PUBL NAT HEART LUNG; Payne D, 2001, ARCH DIS CHILD, V84, P423, DOI 10.1136/adc.84.5.423; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Que LG, 2005, SCIENCE, V308, P1618, DOI 10.1126/science.1108228; Ratnawati, 2006, PEDIATR PULM, V41, P929, DOI 10.1002/ppul.20469; RENNARD SI, 1990, AM REV RESPIR DIS, V141, P208, DOI 10.1164/ajrccm/141.1.208; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; Robroeks CMHHT, 2007, CLIN EXP ALLERGY, V37, P1303, DOI 10.1111/j.1365-2222.2007.02788.x; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Shin HW, 2007, J APPL PHYSIOL, V102, P1028, DOI 10.1152/japplphysiol.01012.2006; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Travers J, 2007, AM J RESP CRIT CARE, V176, P238, DOI 10.1164/rccm.200609-1346OC; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; Wegmann M, 2005, CLIN EXP ALLERGY, V35, P1263, DOI 10.1111/j.1365-2222.2005.02306.x; Xu WL, 2006, FREE RADICAL BIO MED, V41, P19, DOI 10.1016/j.freeradbiomed.2006.01.037	38	56	57	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					990	996		10.1016/j.jaci.2009.08.039	http://dx.doi.org/10.1016/j.jaci.2009.08.039			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19895987	Bronze, Green Accepted			2022-12-18	WOS:000272108000017
J	Bisgaard, H; Loland, L; Holst, KK; Pipper, CB				Bisgaard, Hans; Loland, Lotte; Holst, Klaus K.; Pipper, Christian B.			Prenatal determinants of neonatal lung function in high-risk newborns	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Neonatal lung function; body mass index; tobacco; paracetamol	PARACETAMOL USE; MATERNAL SMOKING; AIRWAY RESPONSIVENESS; RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; PARENTAL SMOKING; FLOW LIMITATION; CHILDREN; INFANTS; METHACHOLINE	Background: Neonatal lung function is suspected to be associated with wheezy disorders, but little is known about risk factors for the early lung function. Objectives: To study prenatal determinants of neonatal lung function. Methods: This is a clinical, prospective birth cohort study of 411 newborns, the Copenhagen Prospective Study on Asthma in Childhood, in a single-center research clinic dedicated solely to this longitudinal birth cohort study. Lung function was determined at I month of age by infant spirometry (the raised volume rapid thoraco-abdominal compression technique) and bronchial responsiveness to methacholine by transcutaneous oxygen measurements. Risk factor analyses included anthropometrics; demographics; socioeconomic factors; parental atopic history; previous deliveries; exposures during the third trimester to the mother's smoking, alcohol, and medicines; third trimester pregnancy complications including mother's asthma status; and mode of delivery. Results: Lung function was determined in 404 neonates, age 6 weeks. Neonates with body mass index in the upper quartile had 14% lower baseline forced expiratory volume at 0.5 second, and neonates of mothers smoking during the third trimester had 7% lower baseline forced expiratory volume at 0.5 second. Sex or parental atopic disease did not affect the neonatal lung function and bronchial responsiveness. Maternal intake of paracetamol during the third trimester was associated with doubling of the bronchial responsiveness in the neonates, but the statistical significance may have been driven by outliers. Bronchial responsiveness exhibited a parabola development with tripling of bronchial responsiveness reaching the nadir at 3 months of age, but this needs replication in a study with repetitive measurements within individuals. Conclusion: High body mass index in newborns and mothers smoking is associated with reduced neonatal lung function. This suggests that the association between body proportion and wheezing disorders may be a result of shared genes or prenatal nutrition. (J Allergy Clin Immunol 2009;123:651-7.)	[Bisgaard, Hans; Loland, Lotte; Pipper, Christian B.] Univ Copenhagen, Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, DK-2900 Hellerup, Denmark; Univ Copenhagen, DK-1168 Copenhagen, Denmark; [Holst, Klaus K.] Univ Copenhagen, Dept Biostat, DK-2900 Hellerup, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen	Bisgaard, H (corresponding author), Univ Copenhagen, Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, Ledreborg Alle 34, DK-2900 Hellerup, Denmark.	Bisgaard@copsac.com	Kronow, Joern/B-1054-2011; Bisgaard, Hans/N-4761-2016	Bisgaard, Hans/0000-0003-4131-7592; Pipper, Christian Bressen/0000-0003-0261-616X; Holst, Klaus/0000-0002-1364-6789	Lundbeck Foundation; Pharmacy Foundation of 1991; Augustinus Foundation; Danish Medical Research Council; Danish Pediatric Asthma Center; Aerocrine; AstraZeneca,; Altana; GlaxoSmithKline; Merck; MedImmune; NeoLab; Pfizer	Lundbeck Foundation(Lundbeckfonden); Pharmacy Foundation of 1991; Augustinus Foundation; Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish Pediatric Asthma Center; Aerocrine; AstraZeneca,(AstraZeneca); Altana; GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); MedImmune(AstraZenecaMedimmune); NeoLab; Pfizer(Pfizer)	The Copenhagen Prospective Studies on Asthma in Childhood are supported by private and public research funds. Grants above 100.000 Euro were donated by the Lundbeck Foundation, the Pharmacy Foundation of 1991, the Augustinus Foundation, the Danish Medical Research Council, and the Danish Pediatric Asthma Center.; Disclosure of potential conflict of interest: H. Bisgaard has been a consultant to, has been a paid lecturer for, and holds sponsored grants from Aerocrine, AstraZeneca, Altana, GlaxoSmithKline. Merck, MedImmune, NeoLab, and Pfizer. His employer, the Danish Pediatric Asthma Center, has received unrestricted institutional grants from Aerocrine, AstraZeneca, GlaxoSmithKline, Merck, and MedImmune and has provided legal consultation for NeoLab. The rest of the authors have declared that they have no conflict of interest.	American Thoracic Society, 2005, Am J Respir Crit Care Med, V172, P1463; Barr RG, 2004, AM J RESP CRIT CARE, V169, P836, DOI 10.1164/rccm.200304-596OC; Beasley R, 2008, LANCET, V372, P1039, DOI 10.1016/S0140-6736(08)61445-2; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Castro-Rodriguez JA, 2008, J PEDIATR-US, V152, P823, DOI 10.1016/j.jpeds.2008.01.003; Dezateux C, 1999, AM J RESP CRIT CARE, V159, P403, DOI 10.1164/ajrccm.159.2.9712029; Eneli I, 2005, CHEST, V127, P604, DOI 10.1378/chest.127.2.604; Gammelgaard A, 2006, ARCH DIS CHILD, V91, P977, DOI 10.1136/adc.2006.096073; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129, DOI 10.1164/ajrccm/145.5.1129; Hayden MJ, 1997, AM J RESP CRIT CARE, V155, P1670, DOI 10.1164/ajrccm.155.5.9154874; Johnston RA, 2008, J APPL PHYSIOL, V104, P1727, DOI 10.1152/japplphysiol.00075.2008; Johnston RA, 2007, AM J RESP CRIT CARE, V176, P650, DOI 10.1164/rccm.200702-323OC; Jones M, 2000, AM J RESP CRIT CARE, V161, P353, DOI 10.1164/ajrccm.161.2.9903026; Loland L, 2006, CHEST, V129, P669, DOI 10.1378/chest.129.3.669; Loland L, 2008, CHEST, V133, P115, DOI 10.1378/chest.07-1328; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Murray CS, 2002, THORAX, V57, P388, DOI 10.1136/thorax.57.5.388; Newson RB, 2000, EUR RESPIR J, V16, P817, DOI 10.1183/09031936.00.16581700; Palmer LJ, 2001, AM J RESP CRIT CARE, V163, P37, DOI 10.1164/ajrccm.163.1.2005013; Rebordosa C, 2008, INT J EPIDEMIOL, V37, P583, DOI 10.1093/ije/dyn070; RITZ C, 2005, J STAT SOFTWARE, V12; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; SEEFELDT SS, 1995, WEED TECHNOL, V9, P218, DOI 10.1017/S0890037X00023253; Shaheen S, 2008, EUR RESPIR J, V32, P1231, DOI 10.1183/09031936.00039208; Shaheen SO, 2005, CLIN EXP ALLERGY, V35, P18, DOI 10.1111/j.1365-2222.2005.02151.x; Shaheen SO, 2000, THORAX, V55, P266, DOI 10.1136/thorax.55.4.266; Shaheen SO, 2002, THORAX, V57, P958, DOI 10.1136/thorax.57.11.958; SHERRILL D, 1990, PEDIATR PULM, V8, P145, DOI 10.1002/ppul.1950080304; TAGER IB, 1995, AM J RESP CRIT CARE, V152, P977, DOI 10.1164/ajrccm.152.3.7663813; Taveras EM, 2008, J ALLERGY CLIN IMMUN, V121, P1161, DOI 10.1016/j.jaci.2008.03.021; Taveras EM, 2006, PEDIATR PULM, V41, P643, DOI 10.1002/ppul.20427; Tepper RS, 2005, AM J RESP CRIT CARE, V171, P78, DOI 10.1164/rccm.200406-711OC; Turner SW, 2002, AM J RESP CRIT CARE, V165, P1294, DOI 10.1164/rccm.200110-018OC; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]; Wong GWK, 2007, CLIN EXP ALLERGY, V37, P174, DOI 10.1111/j.1365-2222.2007.02649.x; YOHAI VJ, 1987, ANN STAT, V15, P642, DOI 10.1214/aos/1176350366; YOUNG S, 1994, J PEDIATR-US, V124, P681, DOI 10.1016/S0022-3476(05)81355-1; Young S, 2000, EUR RESPIR J, V15, P151, DOI 10.1034/j.1399-3003.2000.15a28.x; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704	42	56	57	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					651	657		10.1016/j.jaci.2008.11.036	http://dx.doi.org/10.1016/j.jaci.2008.11.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19152964				2022-12-18	WOS:000264731200025
J	Platts-Mills, TAE				Platts-Mills, Thomas A. E.			Allergen avoidance in the treatment of asthma: Problems with the meta-analyses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dust mites; avoidance; meta-analysis; asthma guidelines	HOUSE-DUST MITE; BRONCHIAL HYPERREACTIVITY; INTERVENTION; CHILDREN; REDUCTION; EXPOSURE; COVERS	Decreasing exposure to indoor allergens has been studied extensively and is a well accepted part of the treatment for allergic disease. The 2007 revision of the evidence-based guidelines recommends allergen avoidance as part of the management of asthma. In contrast, a recent meta-analysis concluded that dust mite avoidance is "of no use" in the treatment of asthma. There are obvious sources of bias that could have influenced the evaluation of published trials either by the guideline panel or by the group conducting the meta-analysis. An important issue is whether meta-analysis is a valid method of evaluating studies such as those on dust mite avoidance that are highly variable. Reading the published series of 4 meta-analyses on this subject from the Cochrane Library suggests that decisions about which trials to include can have a major effect on the outcome. The process of meta-analysis may also have other potential conflicts. The recent meta-analysis on dust mite avoidance appears to be seriously flawed because of the decisions about inclusion and exclusion as well as the way in which studies were evaluated. The conclusion is that the criticisms of the recommendations in the 2007 guidelines were not well founded.	Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA	University of Virginia	Platts-Mills, TAE (corresponding author), Univ Virginia, Asthma & Allerg Dis Ctr, Box 801355, Charlottesville, VA 22908 USA.	tap2z@virginia.edu		Platts-Mills, Thomas/0000-0002-1263-329X				[Anonymous], 2008, Lancet, V371, P1390, DOI 10.1016/S0140-6736(08)60605-4; Carter MC, 2001, J ALLERGY CLIN IMMUN, V108, P732, DOI 10.1067/mai.2001.119155; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Gotzsche PC, 2008, ALLERGY, V63, P646, DOI 10.1111/j.1398-9995.2008.01690.x; Gotzsche PC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001187.pub3; Gotzsche PC, 1998, BRIT MED J, V317, P1105, DOI 10.1136/bmj.317.7166.1105; Gotzsche PC, 2001, COCHRANE DB SYST REV, V3; Gotzsche PC, 2007, LANCET, V370, P2100, DOI 10.1016/S0140-6736(07)61899-6; Htut T, 2001, J ALLERGY CLIN IMMUN, V107, P55, DOI 10.1067/mai.2001.111240; Jorgensen KJ, 2004, BMJ-BRIT MED J, V328, P148, DOI 10.1136/bmj.328.7432.148; MCKEEVER K, 2008, DUST MITES TRUMP AST; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; MURRAY AB, 1983, PEDIATRICS, V71, P418; National Heart Lung and Blood Institute. National Asthma Education and Prevention Program, 2007, 3 NAT HEART LUNG BLO; Platts-Mills TAE, 1999, BRIT MED J, V318, P870; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P787, DOI 10.1067/mai.2000.110548; PLATTSMILLS TAE, 1982, LANCET, V2, P675; Portnoy JM, 2001, ANN ALLERG ASTHMA IM, V87, P28, DOI 10.1016/S1081-1206(10)62191-6; Schmidt LM, 2005, J FAM PRACTICE, V54, P334; Sheffer AL, 2004, NEW ENGL J MED, V351, P1134, DOI 10.1056/NEJMe048177; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; vanderHeide S, 1997, EUR RESPIR J, V10, P1217, DOI 10.1183/09031936.97.10061217; WALSHAW MJ, 1986, Q J MED, V58, P199; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; [No title captured]	25	56	58	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					694	696		10.1016/j.jaci.2008.07.045	http://dx.doi.org/10.1016/j.jaci.2008.07.045			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	19014759				2022-12-18	WOS:000259989000009
J	Finkelman, FD; Wills-Karp, M				Finkelman, Fred D.; Wills-Karp, Marsha			Usefulness and optimization of mouse models of allergic airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							ANTI-IGE ANTIBODY; ANIMAL-MODELS; BRONCHIAL HYPERRESPONSIVENESS; MEPOLIZUMAB THERAPY; ASTHMATIC RESPONSE; MURINE MODELS; IL-4 RECEPTOR; MICE; HYPERREACTIVITY; INTERLEUKIN-12		[Finkelman, Fred D.] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH 45220 USA; [Finkelman, Fred D.] Univ Cincinnati, Coll Med, Div Immunol, Cincinnati, OH 45221 USA; [Finkelman, Fred D.; Wills-Karp, Marsha] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Finkelman, FD (corresponding author), Cincinnati Vet Affairs Med Ctr, 3200 Vine St, Cincinnati, OH 45220 USA.	ffinkelman@pol.net			NHLBI NIH HHS [R01 HL067736, P01 HL076383, R01 HL67736, P01 HL076383-05, R01 HL067736-08] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067736, P01HL076383] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Canning BJ, 2003, CURR OPIN PHARMACOL, V3, P244, DOI 10.1016/S1471-4892(03)00045-6; Coleman RA, 1999, PULM PHARMACOL THER, V12, P87, DOI 10.1006/pupt.1999.0193; Corren J, 2003, J ALLERGY CLIN IMMUN, V111, P87, DOI 10.1067/mai.2003.49; Corry DB, 2006, IMMUNOL RES, V35, P279, DOI 10.1385/IR:35:3:279; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Epstein MM, 2004, INT ARCH ALLERGY IMM, V133, P84, DOI 10.1159/000076131; Finkelman FD, 2008, J ALLERGY CLIN IMMUN, V121, P334, DOI 10.1016/j.jaci.2007.11.028; Finn A, 2003, J ALLERGY CLIN IMMUN, V111, P278, DOI 10.1067/mai.2003.54; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Gavett SH, 1997, AM J PHYSIOL-LUNG C, V272, pL253, DOI 10.1152/ajplung.1997.272.2.L253; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gelfand EW, 2002, AM J RESP CRIT CARE, V166, P5, DOI 10.1164/rccm.2204023; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Gomez FP, 2000, BIODRUGS, V14, P21, DOI 10.2165/00063030-200014010-00003; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Guenet JL, 2005, GENOME RES, V15, P1729, DOI 10.1101/gr.3728305; Henderson WR, 2000, J IMMUNOL, V164, P3360, DOI 10.4049/jimmunol.164.6.3360; HOZAWA S, 1995, AM J RESP CRIT CARE, V152, P1198, DOI 10.1164/ajrccm.152.4.7551370; Karras JG, 2007, AM J RESP CELL MOL, V36, P276, DOI 10.1165/rcmb.2005-0456OC; Kips JC, 2003, EUR RESPIR J, V22, P374, DOI 10.1183/09031936.03.00026403; Kumar RK, 2001, IMMUNOL CELL BIOL, V79, P141, DOI 10.1046/j.1440-1711.2001.00981.x; Leonard P, 2003, BIODRUGS, V17, P1, DOI 10.2165/00063030-200317010-00001; LEWKOWICH IP, 2008, IN PRESS MIDDLETONS; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Pabst R, 2002, PATHOBIOLOGY, V70, P252, DOI 10.1159/000070737; Persson CGA, 2002, AM J RESP CRIT CARE, V166, P6, DOI 10.1164/rccm.2204001; Plotz S, 2003, NEW ENGL J MED, V349, P2334, DOI 10.1056/NEJMoa031261; Riffo-Vasquez Y, 2002, PHARMACOL THERAPEUT, V94, P185, DOI 10.1016/S0163-7258(02)00217-6; Rothenberg ME, 2006, BLOOD, V108, p115A, DOI 10.1182/blood.V108.11.373.373; SATO TA, 1993, J IMMUNOL, V150, P2717; Shapiro SD, 2006, AM J RESP CRIT CARE, V174, P1171, DOI 10.1164/rccm.2609001; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Taube C, 2004, INT ARCH ALLERGY IMM, V135, P173, DOI 10.1159/000080899; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wenzel S, 2006, AM J RESP CRIT CARE, V174, P1173, DOI 10.1164/rccm.2609002; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258	37	56	58	2	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					603	606		10.1016/j.jaci.2008.01.008	http://dx.doi.org/10.1016/j.jaci.2008.01.008			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18328889	Green Accepted			2022-12-18	WOS:000253918900009
J	Kiss, A; Montes, M; Susarla, S; Jaensson, EA; Drouin, SM; Wetsel, RA; Yao, Z; Martin, R; Hamzeh, N; Adelagun, R; Amar, S; Kheradmand, F; Corry, DB				Kiss, Attila; Montes, Martin; Susarla, Sarat; Jaensson, Elin A.; Drouin, Scott M.; Wetsel, Rick A.; Yao, Zhengbin; Martin, Rachel; Hamzeh, Nabeel; Adelagun, Rebecca; Amar, Sheila; Kheradmand, Farrah; Corry, David B.			A new mechanism regulating the initiation of allergic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)1/T(H)2 cells; chemokines; allergy; inflammation; lung	TH2 EFFECTOR FUNCTIONS; DUST MITE ALLERGEN; CUTTING EDGE; MURINE MODEL; TARGETED DISRUPTION; SIGNAL TRANSDUCER; CELL TRAFFICKING; T-CELLS; RESPONSES; RECEPTORS	Background: The earliest immune events induced by allergens are poorly understood, yet are likely essential to understanding how allergic inflammation is established. Objective: We sought to describe the earliest signaling events activated by allergen and determine their significance to allergic inflammation. Methods: A fungal-associated allergenic proteinase (FAP) or ovalbumin was administered once intranasally to wild-type mice to determine their ability to induce allergy-associated genes and initiate allergic lung inflammation. Mice deficient in recombinase activating gene 1, C3a, the C3a anaphylatoxin receptor, and MyD88 were challenged similarly to understand the requirement of these molecules and T and B cells for allergic inflammation. Adoptive T-cell transfer experiments were further performed to determine whether signal transducer and activator of transcription 6 (STAT6) was required for cell recruitment and allergic inflammation. Results: FAP, but not ovalbumin, induced eosinophilic airway inflammation and lung IL-4 production in the absence of adaptive immune cells after the transcriptional induction of allergy-specific airway chemokines. Allergen-mediated chemokine secretion and innate allergic lung inflammation occurred in the absence of STAT6, recombinase activating gene 1, C3a, C3a anaphylatoxin receptor, Toll-like receptor 4, and MyD88 but required intact proteinase activity. Furthermore, FAP induced recruitment of T(H)2 cells and eosinophils to lungs independently of STAT6, which was previously thought to be required for T(H)2 cell homing. Conclusion: FAP induces allergic lung inflammation through a previously unrecognized innate immune signaling mechanism. Clinical implications: These findings reveal a new paradigm for understanding how allergic inflammation begins and suggest novel possibilities for the prevention and treatment of allergic diseases, such as asthma.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Univ Texas Hlth Sci Ctr, Inst Mol Med, Houston, TX USA; Tanox Inc, Houston, TX USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston	Corry, DB (corresponding author), Baylor Coll Med, Dept Med, Baylor Plaza 1,BCM285, Houston, TX 77030 USA.	dcorry@bcm.tmc.edu		Hamzeh, Nabeel/0000-0001-7296-8975; Jaensson Gyllenback, Elin/0000-0002-1334-8642	NHLBI NIH HHS [HL72062, HL75243, HL69585, HL64061] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069585, R01HL064061, K02HL075243, K02HL072062] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Circolo A, 1999, IMMUNOPHARMACOLOGY, V42, P135, DOI 10.1016/S0162-3109(99)00021-1; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Comoy EE, 1998, J IMMUNOL, V160, P2456; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Corry DB, 1998, MOL MED, V4, P344, DOI 10.1007/BF03401741; Cosmi L, 2001, INT ARCH ALLERGY IMM, V125, P273, DOI 10.1159/000053827; Drouin SM, 2002, J IMMUNOL, V169, P5926, DOI 10.4049/jimmunol.169.10.5926; Drouin SM, 2001, J IMMUNOL, V167, P4141, DOI 10.4049/jimmunol.167.8.4141; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kheradmand F, 2002, J IMMUNOL, V169, P5904, DOI 10.4049/jimmunol.169.10.5904; Kildsgaard J, 2000, J IMMUNOL, V165, P5406, DOI 10.4049/jimmunol.165.10.5406; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Lee SH, 2003, NAT MED, V9, P1281, DOI 10.1038/nm932; Lim KC, 1999, AM J TROP MED HYG, V60, P487, DOI 10.4269/ajtmh.1999.60.487; Mathew A, 2002, J IMMUNOL, V169, P651, DOI 10.4049/jimmunol.169.2.651; Mathew A, 2001, J EXP MED, V193, P1087, DOI 10.1084/jem.193.9.1087; Montes M, 2006, J IMMUNOL METHODS, V317, P45, DOI 10.1016/j.jim.2006.09.013; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Redecke V, 2004, J IMMUNOL, V172, P2739, DOI 10.4049/jimmunol.172.5.2739; Scanga CA, 2002, J IMMUNOL, V168, P5997, DOI 10.4049/jimmunol.168.12.5997; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Seymour BWP, 1998, J EXP MED, V187, P721, DOI 10.1084/jem.187.5.721; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; Velasco G, 2005, AM J RESP CELL MOL, V32, P218, DOI 10.1165/rcmb.2003-0435OC; Voehringer D, 2004, IMMUNITY, V20, P267, DOI 10.1016/S1074-7613(04)00026-3; Watanabe J, 2003, J BIOL CHEM, V278, P42361, DOI 10.1074/jbc.M307752200; Xu J, 2005, J IMMUNOL, V174, P5758, DOI 10.4049/jimmunol.174.9.5758; Yamamoto J, 2000, J LEUKOCYTE BIOL, V68, P568	32	56	59	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					334	342		10.1016/j.jaci.2007.04.025	http://dx.doi.org/10.1016/j.jaci.2007.04.025			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17544098	Bronze			2022-12-18	WOS:000248654900018
J	Naqvi, M; Choudhry, S; Tsai, HJ; Thyne, S; Navarro, D; Nazario, S; Rodriguez-Santana, JR; Casal, J; Torres, A; Chapela, R; Watson, HG; Meade, K; Rodriguez-Cintron, W; LeNoir, M; Avila, PC; Burchard, EG				Naqvi, Mariam; Choudhry, Shweta; Tsai, Hui-Ju; Thyne, Shannon; Navarro, Daniel; Nazario, Sylvette; Rodriguez-Santana, Jose R.; Casal, Jesus; Torres, Alfonso; Chapela, Rocio; Watson, H. Geoffrey; Meade, Kelley; Rodriguez-Cintron, William; LeNoir, Michael; Avila, Pedro C.; Burchard, Esteban Gonzalez			Association between IgE levels and asthma severity among African American, Mexican, and Puerto Rican patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; IgE; African Americans; Mexicans; Puerto Ricans; allergy	FUNCTION REFERENCE VALUES; SKIN-TEST REACTIVITY; TOTAL SERUM IGE; LUNG-FUNCTION; AIRWAY RESPONSIVENESS; ETHNIC-DIFFERENCES; CHINESE CHILDREN; HONG-KONG; ADOLESCENTS; OMALIZUMAB	Background: High levels of IgE are associated with asthma. Whether higher levels of IgE are associated with more severe asthma is still unclear. Objective: To determine whether IgE is associated with asthma severity among Latino and African American subjects with asthma. Methods: We assessed lung function and asthma severity among African American, Mexican, and Puerto Rican patients with asthma with high IgE levels (>= 100 IU/mL; n = 492) and compared these values to those of patients with asthma with low IgE levels (< 100 IU/mL; n = 247). We also examined IgE as a continuous variable among these groups. Results: Patients with asthma with high IgE had a lower mean FEV1 (87.6 +/- 17.1, percent of predicted) than patients with asthma with low IgE (91.5 +/- 17.0; P = .031). Regardless of race and ethnicity, baseline FEV1, forced expiratory How, and FEV1/ forced vital capacity were lower among subjects with high IgE than among subjects with low IgE (P = .031, P < .0001, P = .0001, respectively). In addition, 54.7% of patients with asthma with high IgE had been previously hospitalized, compared with 44.1% of patients with asthma with low IgE (odds ratio, 1.33; 95% CI, 1.04-1.71). Conclusion: Higher IgE is associated with lower baseline lung function and more severe asthma among these populations. Clinical implications: Among patients with asthma from 3 ethnically distinct groups, total IgE levels are inversely correlated with baseline lung function and asthma severity.	Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ Puerto Rico, San Juan Vet Affairs Med Ctr, Sch Med, San Juan, PR 00936 USA; Inst Nacl Enfermedades Resp, Pediat Pulm Program, Mexico City, DF, Mexico; James A Watson Wellness Ctr, Oakland, CA USA; Childrens Hosp & Res Inst, Oakland, CA USA; Bay Area Pediat, Oakland, CA USA; Northwestern Univ, Evanston, IL 60201 USA	University of California System; University of California San Francisco; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; Northwestern University	Burchard, EG (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.	esteban@sfgh.ucsf.edu	Tsai, Hui-Ju/E-3937-2010		NCRR NIH HHS [M01 RR00083-41, 3 M01 RR000083-38S30, M01 RR01271] Funding Source: Medline; NHLBI NIH HHS [K23 HL04464, HL56443, HL51831, HL51823, HL074204, U01 HL65899, R01 HL078885, HL07185] Funding Source: Medline; NIGMS NIH HHS [GM61390] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000083, M01RR001271] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL074204, U10HL056443, R01HL078885, K23HL004464, U01HL065899, U10HL051823, U10HL051831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U19GM061390, U01GM061390] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANNESI I, 1992, CHEST, V101, P642, DOI 10.1378/chest.101.3.642; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Ayres JG, 2004, ALLERGY, V59, P701, DOI 10.1111/j.1398-9995.2004.00533.x; AZIZI BHO, 1994, RESP MED, V88, P349, DOI 10.1016/0954-6111(94)90040-X; Borish L, 2005, ANN ALLERG ASTHMA IM, V95, P247, DOI 10.1016/S1081-1206(10)61221-5; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1293OC; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P350; Davis AM, 2006, PEDIATRICS, V118, pE363, DOI 10.1542/peds.2005-2687; de Marco R, 2006, J ALLERGY CLIN IMMUN, V117, P1249, DOI 10.1016/j.jaci.2006.03.019; Elster A, 2003, ARCH PEDIAT ADOL MED, V157, P867, DOI 10.1001/archpedi.157.9.867; ENRIGHT PL, 1991, AM REV RESPIR DIS, V143, P1215, DOI 10.1164/ajrccm/143.6.1215; ENRIGHT PL, 1994, AM J RESP CRIT CARE, V149, pS9, DOI 10.1164/ajrccm/149.2_Pt_2.S9; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FREIDHOFF LR, 1993, INT ARCH ALLERGY IMM, V100, P355, DOI 10.1159/000236438; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Ip MSM, 2000, AM J RESP CRIT CARE, V162, P424, DOI 10.1164/ajrccm.162.2.9905057; Ip MSM, 2000, AM J RESP CRIT CARE, V162, P430, DOI 10.1164/ajrccm.162.2.9905058; Joseph CLM, 2000, CHEST, V117, P1336, DOI 10.1378/chest.117.5.1336; Kitch BT, 2004, CHEST, V126, P1875, DOI 10.1378/chest.126.6.1875; Korotzer B, 2000, AM J RESP CRIT CARE, V161, P1101, DOI 10.1164/ajrccm.161.4.9902063; Lieu TA, 2002, PEDIATRICS, V109, P857, DOI 10.1542/peds.109.5.857; Limb SL, 2005, J ALLERGY CLIN IMMUN, V115, P61, DOI 10.1016/j.jaci.2004.09.032; LOZANO P, 1995, JAMA-J AM MED ASSOC, V274, P469, DOI 10.1001/jama.274.6.469; Ray NF, 1998, CHEST, V113, P1277, DOI 10.1378/chest.113.5.1277; Rhodes L, 2004, JAMA-J AM MED ASSOC, V291, P1435; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Shields AE, 2004, PEDIATRICS, V113, P496, DOI 10.1542/peds.113.3.496; Siroux V, 2003, CLIN EXP ALLERGY, V33, P746, DOI 10.1046/j.1365-2222.2003.01674.x; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; Sunyer J, 1996, EUR RESPIR J, V9, P1880, DOI 10.1183/09031936.96.09091880; SUNYER J, 1995, J ALLERGY CLIN IMMUN, V95, P699, DOI 10.1016/S0091-6749(95)70175-3; *US CENS BUR, 2000, FED FIN I EX COUNC G	35	56	56	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					137	143		10.1016/j.jaci.2007.02.045	http://dx.doi.org/10.1016/j.jaci.2007.02.045			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17498790				2022-12-18	WOS:000248066400020
J	Magerl, M; Philipp, S; Manasterski, M; Friedrich, M; Maurer, M				Magerl, Markus; Philipp, Sandra; Manasterski, Maria; Friedrich, Markus; Maurer, Marcus			Successful treatment of delayed pressure urticaria with anti-TNF-alpha	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ADHESION MOLECULE; EXPRESSION		Univ Med Berlin, Charite, Dept Dermatol & Allergol, Allergie Ctr, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Magerl, M (corresponding author), Univ Med Berlin, Charite, Dept Dermatol & Allergol, Allergie Ctr, Berlin, Germany.	marcus.maurer@charite.de	Magerl, Markus/ABI-5335-2020; Maurer, Marcus/ABG-2174-2020	Magerl, Markus/0000-0001-9218-5468; Maurer, Marcus/0000-0002-4121-481X				BARLOW RJ, 1994, BRIT J DERMATOL, V131, P341, DOI 10.1111/j.1365-2133.1994.tb08521.x; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; Goffe B, 2003, J AM ACAD DERMATOL, V49, pS105, DOI 10.1016/mjd.2003.554; Haas N, 1998, ARCH DERMATOL, V134, P41, DOI 10.1001/archderm.134.1.41; Hermes B, 1999, J ALLERGY CLIN IMMUN, V103, P307, DOI 10.1016/S0091-6749(99)70506-3; Kerstan A, 2005, BRIT J DERMATOL, V153, P435, DOI 10.1111/j.1365-2133.2005.06677.x; Kobza-Black A, 2001, J INVEST DERM SYMP P, V6, P148, DOI 10.1046/j.0022-202x.2001.00030.x; KYANAUNG U, 1991, J IMMUNOL, V146, P521; Nash PT, 2005, MED J AUSTRALIA, V183, P205, DOI 10.5694/j.1326-5377.2005.tb06998.x	9	56	58	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					752	754		10.1016/j.jaci.2006.12.658	http://dx.doi.org/10.1016/j.jaci.2006.12.658			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17336621				2022-12-18	WOS:000244925000035
J	Williams, LK; Joseph, CL; Peterson, EL; Moon, C; Xi, H; Krajenta, R; Johnson, R; Wells, K; Booza, JC; Tunceli, K; Lafata, JE; Johnson, CC; Ownby, DR; Enberg, R; Pladevall, M				Williams, L. Keoki; Joseph, Christine L.; Peterson, Edward L.; Moon, Christina; Xi, Hugo; Krajenta, Richard; Johnson, Reba; Wells, Karen; Booza, Jason C.; Tunceli, Kaan; Lafata, Jennifer E.; Johnson, Christine C.; Ownby, Dennis R.; Enberg, Robert; Pladevall, Manel			Race-ethnicity, crime, and other factors associated with adherence to inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adherence; inhaled corticosteroids; asthma; race-ethnicity; crime	PATIENT ADHERENCE; SOCIOECONOMIC-STATUS; AFRICAN-AMERICAN; SOCIAL SUPPORT; ASTHMA; HEALTH; ADULTS; CARE; PREDICTORS; STEROIDS	Background: Previous studies have shown differences in adherence to inhaled corticosteroids (ICSs) by race-ethnicity, yet little is known about factors that contribute to adherence within these groups. Environmental stressors, such as crime exposure, which has been associated with asthma morbidity, might also predict ICS adherence. Objective: We sought to identify factors associated with ICS adherence among patients with asthma and among African American patients and white patients separately. Methods: Study patients with asthma were aged 18 to 50 years and were enrolled in a large southeast Michigan health maintenance organization between January 1, 1999, and December 31, 2001. The primary outcome, ICS adherence, was calculated by linking prescription-fill data with dosage information. Predictor variables included age, sex, race-ethnicity, measures of socioeconomic status (SES), average ICS copay, existing comorbidities, and crime rate in area of residence. Results: Adherence information was available for 176 patients. ICS adherence was lower among African American patients (n = 75) when compared with white patients (n = 94; 40% vs 58%, respectively; P =.002). Among white patients, adherence was significantly lower for women when compared with men. Among African American patients, age and residential crime rates were positively and negatively associated with ICS adherence, respectively. Area crime remained a predictor of adherence in African American patients, even after adjusting for multiple measures of SES. Conclusions: This study suggests that an environmental stressor, area crime, provides additional predictive insight into ICS-adherent behavior beyond typical SES factors. Clinical implications: Better understanding of environmental factors that influence ICS adherence might aid in efforts to improve it.	Henry Ford Hlth Syst, Ctr Hlth Serv Res, Detroit, MI 48202 USA; Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI 48202 USA; Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, Detroit, MI 48202 USA; Wayne State Univ, Ctr Urban Studies, Detroit, MI USA; Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Wayne State University; University System of Georgia; Augusta University	Williams, LK (corresponding author), Henry Ford Hlth Syst, Ctr Hlth Serv Res, 1 Ford Pl,3A CHSR, Detroit, MI 48202 USA.	kwillia5@hfhs.org	Spycher, Ben D/B-3308-2008; Strippoli, Marie-Pierre F/K-8164-2013	Spycher, Ben D/0000-0002-1430-5695; Strippoli, Marie-Pierre F/0000-0003-3053-484X; Johnson, Christine Cole/0000-0002-6864-6604	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068971, R01HL079055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050681, R01AI061774, R56AI050681] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL068971, HL079055] Funding Source: Medline; NIAID NIH HHS [AI061774, AI050681, AI050594] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams RJ, 2003, J ALLERGY CLIN IMMUN, V112, P445, DOI 10.1067/mai.2003.1625; Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Bender B, 2003, J ALLERGY CLIN IMMUN, V112, P489, DOI 10.1067/mai.2003.1680; Bender B, 2000, ANN ALLERG ASTHMA IM, V85, P416, DOI 10.1016/S1081-1206(10)62557-4; Bosworth HB, 2006, AM J MED, V119, P791, DOI 10.1016/j.amjmed.2006.02.013; Braveman PA, 2005, JAMA-J AM MED ASSOC, V294, P2879, DOI 10.1001/jama.294.22.2879; Charles H, 2003, J NATL MED ASSOC, V95, P17; Clark N, 1999, RESP MED, V93, P856, DOI 10.1016/S0954-6111(99)90050-1; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Diaz E, 2005, COMMUNITY MENT HLT J, V41, P521, DOI 10.1007/s10597-005-6359-x; DiMatteo MR, 2002, MED CARE, V40, P794, DOI 10.1097/01.MLR.0000024612.61915.2D; DiMatteo MR, 2004, MED CARE, V42, P200, DOI 10.1097/01.mlr.0000114908.90348.f9; George M, 2003, J ALLERGY CLIN IMMUN, V111, P967, DOI 10.1067/mai.2003.1459; Haynes R B, 2002, Cochrane Database Syst Rev, pCD000011; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; Joseph CLM, 2006, J ALLERGY CLIN IMMUN, V117, P233, DOI 10.1016/j.jaci.2005.11.004; Lindberg M, 2001, INT J QUAL HEALTH C, V13, P375, DOI 10.1093/intqhc/13.5.375; McDonald HP, 2002, JAMA-J AM MED ASSOC, V288, P2868, DOI 10.1001/jama.288.22.2868; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; SAS Institute Inc, 1999, SAS STAT US GUID VER; Schectman JM, 2002, DIABETES CARE, V25, P1015, DOI 10.2337/diacare.25.6.1015; SCHLENK EA, 1984, DIABETES CARE, V7, P566, DOI 10.2337/diacare.7.6.566; Schulz A, 2000, SOC SCI MED, V51, P1639, DOI 10.1016/S0277-9536(00)00084-8; Schulz AJ, 2002, MILBANK Q, V80, P677, DOI 10.1111/1468-0009.00028; SHEA S, 1992, AM J PUBLIC HEALTH, V82, P1607, DOI 10.2105/AJPH.82.12.1607; Steiner JF, 1997, J CLIN EPIDEMIOL, V50, P105, DOI 10.1016/S0895-4356(96)00268-5; Taylor SE, 1997, ANNU REV PSYCHOL, V48, P411, DOI 10.1146/annurev.psych.48.1.411; Tillotson LM, 1996, DIABETES EDUCATOR, V22, P133, DOI 10.1177/014572179602200206; TURNER J, 1995, CHEST, V108, P394, DOI 10.1378/chest.108.2.394; van Ryn M, 2000, SOC SCI MED, V50, P813, DOI 10.1016/S0277-9536(99)00338-X; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; WILSON W, 1986, DIABETES CARE, V9, P614, DOI 10.2337/diacare.9.6.614; Wright RJ, 1998, THORAX, V53, P1066, DOI 10.1136/thx.53.12.1066; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625	35	56	57	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					168	175		10.1016/j.jaci.2006.09.029	http://dx.doi.org/10.1016/j.jaci.2006.09.029			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	127YL	17208598	Bronze			2022-12-18	WOS:000243622200024
J	Bateman, EAL; Ardern-Jones, MR; Ogg, GS				Bateman, Elizabeth Alice Louise; Ardern-Jones, Michael Roger; Ogg, Graham Stuart			Persistent central memory phenotype of circulating Fel d 1 peptide/DRB1*0101 tetramer-binding CD4(+) T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T cells; atopic dermatitis; memory T cells; Fel d 1	BLOOD MONONUCLEAR-CELLS; ATOPIC-DERMATITIS SKIN; IN-VITRO; RECEPTOR EXPRESSION; DIAGNOSTIC-CRITERIA; ALLERGIC DISORDERS; IFN-GAMMA; LYMPHOCYTES; CAT; PREVALENCE	Background: Although substantial evidence suggests that T cells are important in the pathogenesis of atopic dermatitis (AD), little is known of the differentiation status of CD4(+) T cells specific for common environmental allergens. Objective: To determine the frequency, differentiation phenotype, and function of circulating allergen-specific CD4(+) T cells in adult individuals with severe persistent AD and controls. Methods: Using tetrameric complexes of an HLA DRB1*0101 restricted epitope from Fel d 1, the major IgE-reactive component of cat dander, we studied ex vivo and cultured T-cell frequency and phenotype in individuals with AD and healthy controls. Cytokine secretion was measured by ex vivo and cultured IFN-gamma, IL-4, and IL-10 enzyme linked immuno-spot analysis. Results: Ex vivo Fel d 1-specific DRB1*0101-restricted CD4(+) T cells express high levels of CCR7, CD62L, CD27, and CD28 and proportionately low levels of tissue-specific homing receptors and T(H)1 and T(H)2 cytokine production, placing the cells largely within the central memory subgroup. Conclusion: Circulating Fel d 1-specific DRB1*0101-restricted CD4(+) T cells maintain central memory capacity, consistent with a potential to contribute to persisting clinical atopic disease. Clinical implications: Persisting central memory characteristics of allergen-specific CD4(+) T cells in individuals with AD may contribute to chronic disease.	Univ Oxford, Weatherall Inst Mol Med, MRC, Human Immunol Unit,John Radcliffe Hosp, Oxford OX3 9DS, England	University of Oxford	Ogg, GS (corresponding author), Univ Oxford, Weatherall Inst Mol Med, MRC, Human Immunol Unit,John Radcliffe Hosp, Oxford OX3 9DS, England.	graham.ogg@clinical-medicine.ox.ac.uk		Ardern-Jones, Michael/0000-0003-1466-2016; Ogg, Graham/0000-0002-3097-045X	Medical Research Council [G116/150, MC_U137881017] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G116/150, MC_U137881017] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Appay V, 2002, J IMMUNOL METHODS, V268, P9, DOI 10.1016/S0022-1759(02)00195-3; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Counsell CM, 1996, J ALLERGY CLIN IMMUN, V98, P884, DOI 10.1016/S0091-6749(96)80004-2; Ekerfelt C, 2002, J IMMUNOL METHODS, V260, P55, DOI 10.1016/S0022-1759(01)00520-8; Gabrielsson S, 2001, CLIN EXP IMMUNOL, V126, P390, DOI 10.1046/j.1365-2249.2001.01703.x; Gabrielsson S, 1997, CLIN EXP ALLERGY, V27, P808, DOI 10.1046/j.1365-2222.1997.560878.x; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Haselden BM, 2001, J ALLERGY CLIN IMMUN, V108, P349, DOI 10.1067/mai.2001.117461; Herd RM, 1996, BRIT J DERMATOL, V135, P18; Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950; Kaplan AP, 2001, INT ARCH ALLERGY IMM, V124, P423, DOI 10.1159/000053777; KAY J, 1994, J AM ACAD DERMATOL, V30, P35, DOI 10.1016/S0190-9622(94)70004-4; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Macallan DC, 2004, J EXP MED, V200, P255, DOI 10.1084/jem.20040341; Mark PG, 1996, CLIN EXP ALLERGY, V26, P1316, DOI 10.1111/j.1365-2222.1996.tb00529.x; Pala P, 2002, CLIN EXP ALLERGY, V32, P1739, DOI 10.1046/j.1365-2222.2002.01548.x; Reefer AJ, 2004, J IMMUNOL, V172, P2763, DOI 10.4049/jimmunol.172.5.2763; Rivino L, 2004, J EXP MED, V200, P725, DOI 10.1084/jem.20040774; Romagnani S, 2002, MOL IMMUNOL, V38, P881, DOI 10.1016/S0161-5890(02)00013-5; Schaerli P, 2004, J EXP MED, V199, P1265, DOI 10.1084/jem.20032177; Schon MP, 2003, J INVEST DERMATOL, V121, P951, DOI 10.1046/j.1523-1747.2003.12563.x; Seaman MS, 2004, J VIROL, V78, P206, DOI 10.1128/JVI.78.1.206-215.2004; SENEVIRATNE S, 2006, IMMUNOLOGY      1031; Seneviratne SL, 2005, CLIN EXP IMMUNOL, V141, P107, DOI 10.1111/j.1365-2249.2005.02823.x; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; VANNEERVEN RJJ, 1994, J IMMUNOL, V152, P4203; Vestergaard C, 2003, BRIT J DERMATOL, V149, P457, DOI 10.1046/j.1365-2133.2003.05505.x; Vestergaard C, 2000, J INVEST DERMATOL, V115, P640, DOI 10.1046/j.1523-1747.2000.00115.x; Wadonda-Kabondo N, 2003, BRIT J DERMATOL, V149, P1023, DOI 10.1111/j.1365-2133.2003.05605.x; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; WILLIAMS HC, 1992, CLIN EXP DERMATOL, V17, P385, DOI 10.1111/j.1365-2230.1992.tb00244.x; Williams HC, 1996, BRIT J DERMATOL, V135, P12; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Zaph C, 2004, NAT MED, V10, P1104, DOI 10.1038/nm1108	36	56	59	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1350	1356		10.1016/j.jaci.2006.07.040	http://dx.doi.org/10.1016/j.jaci.2006.07.040			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17137868				2022-12-18	WOS:000242880300023
J	Diaz-Sanchez, D; Rumold, R; Gong, H				Diaz-Sanchez, David; Rumold, Robert; Gong, Henry, Jr.			Challenge with environmental tobacco smoke exacerbates allergic airway disease in human beings	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						environmental tobacco smoke; IgE; pollution; histamine; allergic airway disease	DIESEL EXHAUST PARTICLES; PASSIVE SMOKING; IN-VIVO; CYTOKINE PRODUCTION; PULMONARY-FUNCTION; CIGARETTE-SMOKE; ATOPIC DISEASES; IGG4 PRODUCTION; EARLY-CHILDHOOD; IMMUNE-SYSTEM	Background: Despite widespread perceptions that environmental tobacco smoke (ETS) is a potent risk factor for allergic airway disease, epiderniologic studies studying this have been equivocal. There is a clear need for experimental studies to address these questions. Objective: We directly tested the hypothesis that ETS could interact with allergen in human beings to alter immune responses and promote changes associated with allergic airway disease. Methods: In a randomized, placebo-controlled crossover study, 19 nonsmoking volunteers with ragweed allergy underwent nasal lavage followed by controlled chamber exposures to 2 hours ETS or clean air followed by another nasal lavage. Subjects immediately randomly received nasal challenge with either ragweed allergen or placebo (300 mu L saline). Lavages were also performed 10 minutes, 24 hours, and 4 and 7 days after challenge and IgE, cytokines, and histamine measured. The other arms of the study were spaced at least 6 weeks apart. Results: Environmental tobacco smoke promoted the production of allergen-specific IgE, the hallmark of allergic disease in nasal lavage fluid. Four days after exposure to ETS/ ragweed, levels were on average 16.6-fold higher than after clean air/ragweed challenge. In addition, ETS (vs air) promoted the induction of a T(H)2-cytokine nasal milieu (increased IL-4, IL-5, and IL-13 and decreased IFN-gamma production), characteristic of an active allergic response. Moreover, nasal histamine levels were 3.3-fold greater after ETS/ragweed challenge than after clean air/ragweed challenge. Conclusion: These studies provide the first experimental evidence that secondhand smoke can exacerbate allergic responses in human beings. Clinical implications: The studies suggest that patients with allergies should avoid tobacco smoke.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol Allergy, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol,Hart & Louis Lab, Los Angeles, CA 90095 USA; Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Southern California	Diaz-Sanchez, D (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol Allergy, 52-175 Ctr Hlth Sci, Los Angeles, CA 90095 USA.	ddiazsa@mednet.ucla.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009581] Funding Source: NIH RePORTER; NIEHS NIH HHS [1P01 ES 09581-01] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barfknecht T R, 1982, Dev Toxicol Environ Sci, V10, P277; BASCOM R, 1991, PHARMACOGENETICS, V1, P102, DOI 10.1097/00008571-199111000-00008; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Behrendt H, 1997, INT ARCH ALLERGY IMM, V113, P69, DOI 10.1159/000237511; Bener A, 1996, HUM BIOL, V68, P405; Bjorksten B, 1996, TOXICOL LETT, V86, P93, DOI 10.1016/0378-4274(96)03679-X; Bodner C, 1998, THORAX, V53, P28, DOI 10.1136/thx.53.1.28; Bowler RP, 2002, J ALLERGY CLIN IMMUN, V110, P349, DOI 10.1067/mai.2002.126780; BURCHFIEL CM, 1986, AM REV RESPIR DIS, V133, P966; Busse WW, 2001, AM J RESP CRIT CARE, V164, pS12, DOI 10.1164/ajrccm.164.supplement_1.2103026; BUTZ AM, 1991, J ASTHMA, V28, P255, DOI 10.3109/02770909109073382; Carlsen KCL, 2001, CURR OPIN ALLERGY CL, V1, P139; Chung K Fan, 2002, Curr Opin Investig Drugs, V3, P1157; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; Diaz-Sanchez D, 2003, CURR ALLERGY ASTHM R, V3, P146, DOI 10.1007/s11882-003-0027-4; Diaz-Sanchez D, 2000, IMMUNOLOGY, V101, P11, DOI 10.1046/j.1365-2567.2000.00108.x; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Ehrlich R, 2001, J ASTHMA, V38, P239, DOI 10.1081/JAS-100000111; Eisner MD, 2002, ENVIRON HEALTH PERSP, V110, P765, DOI 10.1289/ehp.02110765; Emmons KM, 2001, PREV MED, V32, P321, DOI 10.1006/pmed.2000.0822; EVANS D, 1987, AM REV RESPIR DIS, V135, P567; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429, DOI 10.1164/ajrccm.163.2.2006009; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Hakonarson H, 2001, CURR OPIN PEDIATR, V13, P267, DOI 10.1097/00008480-200106000-00010; Hiura TS, 1999, J IMMUNOL, V163, P5582; Holgate ST, 1999, J ALLERGY CLIN IMMUN, V104, P1139, DOI 10.1016/S0091-6749(99)70005-9; Holgate ST, 2000, CLIN EXP ALLERGY, V30, P1; *I TAHR, 1990, REF CIG; Johansson SGO, 2002, ANN ALLERG ASTHMA IM, V89, P132, DOI 10.1016/S1081-1206(10)61928-X; JOHNSON JD, 1990, CRIT REV TOXICOL, V20, P369, DOI 10.3109/10408449009089870; Kagawa J, 2002, TOXICOLOGY, V181, P349, DOI 10.1016/S0300-483X(02)00461-4; Kimata H, 1996, J EXP MED, V183, P2397, DOI 10.1084/jem.183.5.2397; KIMATA H, 1995, J IMMUNOL, V154, P3557; KOREN HS, 1990, TOXICOLOGY, V60, P15, DOI 10.1016/0300-483X(90)90159-E; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Kulig M, 1999, HUM EXP TOXICOL, V18, P241, DOI 10.1191/096032799678839987; Kumagai Y, 1997, FREE RADICAL BIO MED, V22, P479, DOI 10.1016/S0891-5849(96)00341-3; Mabilia R, 2004, ANN CHIM-ROME, V94, P733, DOI 10.1002/adic.200490091; MacGlashan D, 2000, J LEUKOCYTE BIOL, V68, P479; MACY E, 1988, FASEB J, V2, P3003, DOI 10.1096/fasebj.2.14.3263291; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752; OSAKA F, 1985, Japanese Journal of Hygiene, V40, P789; OWNBY DR, 1988, J ALLERGY CLIN IMMUN, V82, P634, DOI 10.1016/0091-6749(88)90976-1; Ozasa K, 1995, Arerugi, V44, P1361; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; RONCHETTI R, 1990, J ALLERGY CLIN IMMUN, V86, P400, DOI 10.1016/S0091-6749(05)80104-6; Rumold R, 2001, J IMMUNOL, V167, P4765, DOI 10.4049/jimmunol.167.8.4765; Serafini U, 1997, ALLERGY, V52, P955, DOI 10.1111/j.1398-9995.1997.tb01257.x; Seymour BWP, 1997, J IMMUNOL, V159, P6169; Thaqi A, 2005, INDOOR AIR, V15, P302, DOI 10.1111/j.1600-0668.2005.00361.x; *US EPA, 1992, ASS OOHAE RESP HLTH; Wagner V, 1987, Czech Med, V10, P70; Warner JO, 1999, THORAX, V54, pS46, DOI 10.1136/thx.54.2008.S46; WEISS ST, 1985, AM REV RESPIR DIS, V131, P573, DOI 10.1164/arrd.1985.131.4.573	58	56	60	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					441	446		10.1016/j.jaci.2006.04.047	http://dx.doi.org/10.1016/j.jaci.2006.04.047			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890770				2022-12-18	WOS:000239877700021
J	Maier, LM; Howson, JMM; Walker, N; Spickett, GP; Jones, RW; Ring, SM; McArdle, WL; Lowe, CE; Bailey, R; Payne, F; Todd, JA; Strachan, DP				Maier, Lisa M.; Howson, Joanna M. M.; Walker, Neil; Spickett, Gavin P.; Jones, Richard W.; Ring, Susan M.; McArdle, Wendy L.; Lowe, Christopher E.; Bailey, Rebecca; Payne, Felicity; Todd, John A.; Strachan, David P.			Association of IL 13 with total IgE: Evidence against an inverse association of atopy and diabetes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-13; gene; IgE; type I diabetes; atopy	SINGLE-NUCLEOTIDE POLYMORPHISM; LYMPHOID TYROSINE PHOSPHATASE; IL12B PROMOTER POLYMORPHISM; EPSILON-RI-BETA; LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; INTERLEUKIN-13 GENE; CHILDHOOD ECZEMA; NO EVIDENCE; ASTHMA	Background: Atopic illnesses, related to high circulating IgE levels, and the autoimmune disease type 1 diabetes, have been reported to be inversely associated. One possible explanation is that susceptibility alleles for one disease provide protection for the other. Objective: Using the largest sample sizes reported so far for the identification of genetic determinants of circulating IgE levels, we investigated associations between total serum IgE (log-transformed) and single nucleotide polymorphisms in 8 genes that are candidate susceptibility loci for IgE levels/atopic illness (IL13, IL4, IL4RA, FCER1B, IL12B, TBET) and/or type 1 diabetes (CTLA4, PTPN22, IL2RA). Methods: As many as 4570 DNA samples obtained from members of the British 1958 Birth Cohort were genotyped for 51 candidate variants, and the associations of alleles and genotypes with log-transformed serum IgE levels were evaluated by regression modeling. Results: We obtained evidence of association between IL13 variants and total serum IgE levels (P =.00002, explaining 0.59% of phenotypic variance). However, there was no evidence of association of the confirmed type 1 diabetes susceptibility genes CTLA4 and PTPN22 and the candidate gene IL2RA with IgE levels. Conclusion: Allelic variation in the IL-13 gene is robustly confirmed as a contributor to the variance of IgE levels but has no detectable effect in type 1 diabetes. Clinical implications: Although the allelic variation at the confirmed IL-13 locus explains too little of the between individual variation of circulating IgE to be of use for clinical prediction on its own, the discovery of additional susceptibility loci in the future may aid in the stratification of atopic subjects and improve risk assessment.	Univ Cambridge, Med Res Inst, Juvenile Diabet Res Fdn, Wellcome Trust Diabet & Inflammat Lab, Cambridge, England; Royal Victoria Infirm, Reg Immunol Dept, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Univ Bristol, Avon Longitudinal Study Parents & Children, Bristol, Avon, England; St Georges Univ London, Div Community Hlth Sci, London, England	University of Cambridge; Newcastle University - UK; University of Bristol; St Georges University London	Maier, LM (corresponding author), Univ Cambridge, Med Res Inst, Juvenile Diabet Res Fdn, Wellcome Trust Diabet & Inflammat Lab, Hills Rd, Cambridge, England.	lisa.maier@cimr.cam.ac.uk	Payne, Felicity/GKF-2573-2022; Todd, John A/A-3542-2010	Payne, Felicity/0000-0003-4228-581X; Todd, John A/0000-0003-2740-8148; Howson, Joanna/0000-0001-7618-0050; Walker, Neil/0000-0001-9796-7688	MRC [G0000934] Funding Source: UKRI; Medical Research Council [G0000934] Funding Source: Medline; Wellcome Trust [068545/Z/02] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Ansel KM, 2003, NAT IMMUNOL, V4, P616, DOI 10.1038/ni0703-616; Arima K, 2002, J ALLERGY CLIN IMMUN, V109, P980, DOI 10.1067/mai.2002.124656; Begovich AB, 2004, AM J HUM GENET, V75, P330, DOI 10.1086/422827; BERGHOLDT L, 2004, DIABETES, V41, pE39; Bergholdt R, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.010454; Bottini N, 2004, NAT GENET, V36, P337, DOI 10.1038/ng1323; Cardwell CR, 2003, DIABETES CARE, V26, P2568, DOI 10.2337/diacare.26.9.2568; Celedon JC, 2002, CLIN EXP ALLERGY, V32, P387, DOI 10.1046/j.1365-2222.2002.01348.x; Chapman JM, 2003, HUM HERED, V56, P18, DOI 10.1159/000073729; Chen WG, 2004, J ALLERGY CLIN IMMUN, V114, P553, DOI 10.1016/j.jaci.2004.04.044; Clayton D, 2001, LANCET, V358, P1356, DOI 10.1016/S0140-6736(01)06418-2; Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Cordell HJ, 2002, AM J HUM GENET, V70, P124, DOI 10.1086/338007; Dahlman I, 2002, NAT GENET, V30, P149, DOI 10.1038/ng825; Davoodi-Semiromi A, 2002, DIABETES, V51, P2334, DOI 10.2337/diabetes.51.7.2334; Ellis CN, 1999, CLIN IMMUNOL, V92, P49, DOI 10.1006/clim.1999.4731; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Hackstein H, 2001, IMMUNOGENETICS, V53, P264, DOI 10.1007/s002510100324; He JQ, 2003, GENES IMMUN, V4, P385, DOI 10.1038/sj.gene.6363985; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; HILL MR, 1995, BRIT MED J, V311, P776, DOI 10.1136/bmj.311.7008.776; Hinks A, 2005, ARTHRITIS RHEUM-US, V52, P1694, DOI 10.1002/art.21049; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; Hoffjan S, 2004, J ALLERGY CLIN IMMUN, V113, P511, DOI 10.1016/j.jaci.2003.10.044; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; Howard TD, 2002, J ALLERGY CLIN IMMUN, V110, P743, DOI 10.1067/mai.2002.128723; Howard TD, 2001, AM J RESP CELL MOL, V25, P377, DOI 10.1165/ajrcmb.25.3.4483; Huang TJ, 2001, J IMMUNOL, V166, P207, DOI 10.4049/jimmunol.166.1.207; Hummelshoj T, 2003, EUR J IMMUNOGENET, V30, P355, DOI 10.1046/j.1365-2370.2003.00416.x; Imagawa A, 2001, DIABETES, V50, P1269, DOI 10.2337/diabetes.50.6.1269; Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0; Khoo SK, 2004, J ALLERGY CLIN IMMUN, V113, P475, DOI 10.1016/j.jaci.2003.10.043; Kraan TCTMV, 1999, GENES IMMUN, V1, P61, DOI 10.1038/sj.gene.6363630; Lametschwandtner G, 2004, J ALLERGY CLIN IMMUN, V113, P987, DOI 10.1016/j.jaci.2004.02.004; Liu X, 2003, J ALLERGY CLIN IMMUN, V112, P382, DOI 10.1067/mai.2003.1635; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Maier LM, 2005, AM J HUM GENET, V76, P517, DOI 10.1086/428387; McCormack RM, 2002, GENES IMMUN, V3, P433, DOI 10.1038/sj.gene.6363893; Morahan G, 2002, LANCET, V360, P455, DOI 10.1016/S0140-6736(02)09676-9; Morahan G, 2001, NAT GENET, V27, P218, DOI 10.1038/84872; Munthe-Kaas MC, 2004, J ALLERGY CLIN IMMUN, V114, P280, DOI 10.1016/j.jaci.2004.03.050; Nistico L, 2002, DIABETES, V51, P1649, DOI 10.2337/diabetes.51.5.1649; Nolte H, 1997, ANN ALLERG ASTHMA IM, V79, P27, DOI 10.1016/S1081-1206(10)63080-3; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; PIPELEERS D, 1992, DIABETES METAB REV, V8, P209, DOI 10.1002/dmr.5610080303; Randolph AG, 2004, AM J HUM GENET, V75, P709, DOI 10.1086/424886; Sheikh A, 2003, J ALLERGY CLIN IMMUN, V111, P131, DOI 10.1067/mai.2003.8; Shirakawa T, 1996, HUM MOL GENET, V5, P1129, DOI 10.1093/hmg/5.8.1129; Smyth D, 2004, DIABETES, V53, P3020, DOI 10.2337/diabetes.53.11.3020; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strachan DP, 1996, BRIT MED J, V312, P1195; Strachan DP, 1999, ALLERGY, V54, P7, DOI 10.1111/j.1398-9995.1999.tb04381.x; Strachan DR, 2001, J ALLERGY CLIN IMMUN, V108, P901, DOI 10.1067/mai.2001.119408; Thomas DC, 2004, JNCI-J NATL CANCER I, V96, P421, DOI 10.1093/jnci/djh094; Todd JA, 2001, IMMUNITY, V15, P387, DOI 10.1016/S1074-7613(01)00202-3; Torres B, 2004, ARTHRITIS RHEUM-US, V50, P2211, DOI 10.1002/art.20347; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; Vella A, 2005, AM J HUM GENET, V76, P773, DOI 10.1086/429843; Vladich FD, 2005, J CLIN INVEST, V115, P747, DOI 10.1172/JCI200522818; Wang M, 2003, HUM GENET, V113, P387, DOI 10.1007/s00439-003-1001-x; Wang WYS, 2005, NAT REV GENET, V6, P109, DOI 10.1038/nrg1522; WILLIAMS HC, 1994, BRIT MED J, V308, P1132, DOI 10.1136/bmj.308.6937.1132; Williams HC, 1998, BRIT J DERMATOL, V139, P834; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Windsor L, 2004, HUM IMMUNOL, V65, P1432, DOI 10.1016/j.humimm.2004.09.001; Woitsch B, 2004, INT ARCH ALLERGY IMM, V135, P319, DOI 10.1159/000082326	69	56	63	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1306	1313		10.1016/j.jaci.2005.12.1354	http://dx.doi.org/10.1016/j.jaci.2005.12.1354			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16750991	Bronze			2022-12-18	WOS:000238332300016
J	Colas, C; Monzon, S; Venturini, M; Lezaun, A				Colas, C; Monzon, S; Venturini, M; Lezaun, A			Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Salsola kali; allergic rhinitis and asthma; allergens; immunotherapy; Zaragoza	MODIFIED ALLERGEN VACCINES; DERMATOPHAGOIDES-PTERONYSSINUS; CROSS-REACTIVITY; SKIN-TEST; POLLEN; IMMUNOTHERAPY; EXTRACTS; HYPOSENSITIZATION; VALIDATION; EFFICACY	Background: The inhalation of Salsola kali pollen is a common cause of respiratory diseases in Europe and North America. Objective: To evaluate the efficacy and safety of a depigmented and glutaraldehyde-polymerized therapeutic vaccine of S kali. Methods: The trial was randomized, double-blind, and placebo-controlled using a rush protocol in the build-up phase. Sixty patients with rhinoconjunctivitis (19 also had mild asthma) were randomly allocated to receive either active treatment (polymerized extract) or placebo. The final distribution was 41 patients in the active and 19 in the placebo group. Side effects were registered. Symptom and medication scores and the number of days free of symptoms during the pollen season were assessed to evaluate the clinical efficacy. A Rhinoconjunctivitis Quality of Life Questionnaire was completed in the previous pollen season (before treatment) and during the pollen season I year later (in the trial). Dose-response skin tests were performed at baseline and at the end of the trial. Results: There was a significant difference (P <.05) in symptom and medication scores between both groups during the pollen season, with the active group the one that had fewer symptoms and lower intake of medication. The number of days without symptoms was higher in the active group (P <.05). This group also had a significant improvement in the Rhinoconjunctivitis Quality of Life Questionnaire and a reduction in skin sensitivity. No moderate or severe systemic reactions were registered. Conclusion: Immunotherapy with this modified vaccine of S kali pollen is safe and efficacious to treat patients clinically sensitive to this pollen. Clinical implications: Patients allergic to S kali (Russian thistle) can be successfully treated with immunotherapy to improve symptoms of allergic rhinitis and asthma, reduce medication use, and improve quality of life parameters.	Hosp Clin Lozano Blesa, Serv Alergia, Zaragoza, Spain	Lozano Blesa University Clinical Hospital	Colas, C (corresponding author), Univ Hosp Lozano Blesa, Allergy Serv, Av San Juan Bosco 15, Zaragoza 50009, Spain.	algc-colas@hcu-lblesa.es		Colas Sanz, Carlos/0000-0001-8959-6784				Alvarez-Cuesta E, 2005, CLIN EXP ALLERGY, V35, P572, DOI 10.1111/j.1365-2222.2005.02245.x; Ameal A, 2005, ALLERGY, V60, P1178, DOI 10.1111/j.1398-9995.2005.00862.x; BEATLEY JC, 1973, J RANGE MANAGE, V26, P225, DOI 10.2307/3896700; BERRENS L, 1994, Patent No. 9406821; Bodtger U, 2002, ALLERGY, V57, P297, DOI 10.1034/j.1398-9995.2002.1o3532.x; Branco Ferreira M, 2005, Allergol Immunopathol (Madr), V33, P80, DOI 10.1157/13072918; Carnes J, 2003, ALLERGY, V58, P1152, DOI 10.1034/j.1398-9995.2003.00269.x; Casanovas M, 2005, CLIN EXP ALLERGY, V35, P1377, DOI 10.1111/j.1365-2222.2005.02343.x; Casanovas M, 2005, INT ARCH ALLERGY IMM, V137, P211, DOI 10.1159/000086333; Casanovas M, 2005, J INVEST ALLERG CLIN, V15, P30; Council of Europe, 1997, EUR PHARM; CRIMI N, 1988, ALLERGOL IMMUNOPATH, V16, P259; CUESTA EA, 1990, SOC ESPANOLA ALERGOL; DELAHOZ B, 1995, RINOCONJUNTIVITIS AS; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Ferrer A, 2003, J INVEST ALLERG CLIN, V13, P244; Finney D. J., 1952, STAT METHODS BIOL AS; FROST L, 1985, ALLERGY, V40, P368, DOI 10.1111/j.1398-9995.1985.tb00249.x; FROSTAD AB, 1983, CLIN ALLERGY, V13, P337, DOI 10.1111/j.1365-2222.1983.tb02609.x; Garcia-Selles J, 2003, Allergol Immunopathol (Madr), V31, P63, DOI 10.1157/13045071; Garde J, 2005, Allergol Immunopathol (Madr), V33, P100, DOI 10.1157/13072921; GOMEZ J, 1989, J ASTHMA, V26, P243, DOI 10.3109/02770908909073256; Guerra F, 2003, J INVEST ALLERG CLIN, V13, P108; *IMM SUBC E, 1993, ALLERGY S, V48, P7; JUNIPER EF, 1993, ANN ALLERGY, V70, P225; Juniper EF, 1999, J ALLERGY CLIN IMMUN, V104, P364, DOI 10.1016/S0091-6749(99)70380-5; Juniper EF, 1996, J ALLERGY CLIN IMMUN, V98, P843, DOI 10.1016/S0091-6749(96)70135-5; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; KARAWYA MS, 1972, PLANTA MED, V21, P173, DOI 10.1055/s-0028-1099539; LOBERA T, 1998, REV ESP ALLERGOL IMM, V13, P102; LOMBARDERO M, 1985, ANN ALLERGY, V54, P430; Lomson RW, 1933, J ALLERGY, V4, P225; MALLING HJ, 1993, ALLERGY, V48, P9; MOSBECH H, 1989, ALLERGY, V44, P487, DOI 10.1111/j.1398-9995.1989.tb04188.x; *NORD COUNC MED, 1989, NLN PUBL, V23; RAFIZADEH B, 1986, P 13 C EAACI 1986 MA; SHAFIEE A, 1980, CLIN ALLERGY, V10, P111, DOI 10.1111/j.1365-2222.1980.tb02087.x; SHAFIEE A, 1981, J ALLERGY CLIN IMMUN, V67, P472, DOI 10.1016/0091-6749(81)90101-9; SPITZER WO, 1987, J CHRON DIS, V40, P465, DOI 10.1016/0021-9681(87)90002-6; Vallverdu A, 1997, INT ARCH ALLERGY IMM, V112, P356, DOI 10.1159/000237480; WURTZEN PA, 1995, ALLERGY, V50, P489, DOI 10.1111/j.1398-9995.1995.tb01184.x	41	56	64	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					810	816		10.1016/j.jaci.2005.11.039	http://dx.doi.org/10.1016/j.jaci.2005.11.039			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630938				2022-12-18	WOS:000236862800014
J	Lin, JH; Liebhaber, M; Roberts, RL; Dyer, Z; Stiehm, ER				Lin, JH; Liebhaber, M; Roberts, RL; Dyer, Z; Stiehm, ER			Etanercept treatment of cutaneous granulomas in common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						common variable immunodeficiency; granuloma; TNF-alpha inhibitors; etanercept	NECROSIS-FACTOR-ALPHA; DISEASE; INFLIXIMAB; TUBERCULOSIS; SARCOIDOSIS; FEATURES	Common variable immunodeficiency (CVID) is a primary immunodeficiency characterized by hypogammaglobulinemia, poor antibody responses, and recurrent bacterial infections, usually of the sinorespiratory tract. A not uncommon complication is granuloma of the lungs, spleen, liver, and/or skin. We report the case of an 18-year-old boy with CVID and chronic granulomas of the left arm (since 13 years of age) refractory to treatment with antibiotics, intravenous immunoglobulin, antifungal agents, systemic and intralesional steroids, IFN-gamma, cyclosporine, methotrexate, hydroxy-chloroquine, localized radiation therapy, and surgical excision. The lesions improved after treatment with the systemic administration of the TNF-alpha inhibitor etanercept for 1 year. Etanercept prevents soluble TNF from binding to its cell membrane receptor, leading to inhibition of its inflammatory cascade. We recommend further trials of etanercept in patients with CVID with noninfectious recalcitrant granulomas.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Rheumatol Allergy & Immunol, Los Angeles, CA 90095 USA; Sansum Santa Barbara Med Fdn Clin, Santa Barbara, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Lin, JH (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Rheumatol Allergy & Immunol, MDCC 12-430,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	jlin@mednet.ucla.edu						Aukrust P, 1996, BLOOD, V87, P674, DOI 10.1182/blood.V87.2.674.bloodjournal872674; Ballow M, 2002, J ALLERGY CLIN IMMUN, V109, P581, DOI 10.1067/mai.2002.122466; Braun J, 2005, ARTHRITIS RHEUM, V52, P2447, DOI 10.1002/art.21197; CRYSTAL RG, 1994, HARRISONS PRINCIPLES, P1683; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Fasano MB, 1996, MEDICINE, V75, P251, DOI 10.1097/00005792-199609000-00002; Hatab AZ, 2005, J ALLERGY CLIN IMMUN, V116, P1161, DOI 10.1016/j.jaci.2005.08.041; Krupnick AI, 2001, MT SINAI J MED, V68, P326; Lin MH, 2005, ARCH DERMATOL, V141, P680, DOI 10.1001/archderm.141.6.680; Lun Karyn R, 2004, Australas J Dermatol, V45, P51, DOI 10.1111/j.1440-0960.2004.00031.x; Mechanic LJ, 1997, ANN INTERN MED, V127, P613, DOI 10.7326/0003-4819-127-8_Part_1-199710150-00005; Melikoglu M, 2005, J RHEUMATOL, V32, P98; Mohan AK, 2004, CLIN INFECT DIS, V39, P295, DOI 10.1086/421494; Mohan VP, 2001, INFECT IMMUN, V69, P1847, DOI 10.1128/IAI.69.3.1847-1855.2001; Mrusek S, 2004, CLIN EXP IMMUNOL, V137, P578, DOI 10.1111/j.1365-2249.2004.02558.x; Mullighan CG, 1997, J IMMUNOL, V159, P6236; OCONNOR CM, 1992, RESP MED, V86, P277, DOI 10.1016/S0954-6111(06)80024-7; Pasternack FR, 2005, ARCH DERMATOL, V141, P13, DOI 10.1001/archderm.141.1.13; SIEGFRIED EC, 1991, J AM ACAD DERMATOL, V25, P761, DOI 10.1016/S0190-9622(08)80965-6; Smith KJ, 2001, BRIT J DERMATOL, V144, P597, DOI 10.1046/j.1365-2133.2001.04092.x; Spickett GP, 2001, CLIN EXP ALLERGY, V31, P536, DOI 10.1046/j.1365-2222.2001.01117.x; Thatayatikom A, 2005, ANN ALLERG ASTHMA IM, V95, P293, DOI 10.1016/S1081-1206(10)61228-8; TORRELO A, 1995, PEDIATR DERMATOL, V12, P170, DOI 10.1111/j.1525-1470.1995.tb00147.x; WRIGHT JJ, 1990, BLOOD, V76, P2046	24	56	55	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					878	882		10.1016/j.jaci.2006.01.034	http://dx.doi.org/10.1016/j.jaci.2006.01.034			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630948				2022-12-18	WOS:000236862800024
J	Alexis, NE; Lay, JC; Almond, M; Bromberg, PA; Patel, DD; Peden, DB				Alexis, NE; Lay, JC; Almond, M; Bromberg, PA; Patel, DD; Peden, DB			Acute LPS inhalation in healthy volunteers induces dendritic cell maturation in vivo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						inhaled LPS; phagocytosis; dendritic cell maturation	NEUTROPHIL RESPONSE; INHALED ENDOTOXIN; ATOPIC ASTHMATICS; CD11B EXPRESSION; AIRWAY; LIPOPOLYSACCHARIDE; EXPOSURE; RESPONSIVENESS; PHAGOCYTOSIS; ASSOCIATION	Background: We have been studying the innate immune response of airways cells of healthy human volunteers to inhaled LPS, a Toll-like receptor 4 (TLR4) ligand, and have shown that macrophage phagocytic capacity is blunted. Objective: Because a primary feature of dendritic cell (DC) maturation is a loss of phagocytic capacity, we sought to determine whether acute LPS inhalation in healthy volunteers promotes DC maturation in vivo. Methods: Phagocytosis (IgG-opsonized zymosan particles) and cell-surface phenotypes were analyzed by How cytometry of induced sputum cells obtained before and 6 hours after Clinical Center Reference Endotoxin (CCRE; 20,000 EU) inhalation in 9 healthy volunteers. Results: Neutrophils were elevated in the airways after CCRE inhalation (67% +/- 6% vs 37% +/- 6%; P < .05). Phagocytosis (monocytes, macrophages) was blunted (73%, 46%; P < .05) and negatively correlated with PMN influx (R = -0.73; P < .05) after CCRE inhalation. GM-CSF and IL-1beta, potent DC maturation agents, were elevated after versus before CCRE inhalation (217 pg/mL +/- 103 pg/mL vs 722 pg/mL +/- 202 pWmL; 83 pg/mL 24 pg/mL vs 148 pg/mL 37 pg/mL, respectively; P < .05). Markers of DC maturation (CD80, CD86, HLA-DR) were upregulated on monocytes and macrophages (P < .05), and discrete populations of mature DC were observed (P < .05) after CCRE inhalation. Conclusion: Inhaled LPS, directly through TLR4 stimulation of immature DC and/or indirectly through stimulation of GMCSF and IL-1beta, induces pulmonary DC maturation in vivo. Inhaled LPS may enhance allergic airways responses to air pollution through its ability to induce DC maturation.	Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC USA; Univ N Carolina, Dept Pediat, Div Infect Dis & Immunol, Chapel Hill, NC USA; Univ N Carolina, Dept Med, Div Rheumatol, Chapel Hill, NC USA; Univ N Carolina, Dept Med, Div Allergy, Chapel Hill, NC USA; Univ N Carolina, Dept Med, Div Immunol, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Alexis, NE (corresponding author), 104 Mason Farm Rd, Chapel Hill, NC 27559 USA.	Neil_Alexis@med.unc.edu	Lay, John/A-6380-2012	Peden, David/0000-0003-4526-4627	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [P01AT002620] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062624, R01HL066559] Funding Source: NIH RePORTER; NCCIH NIH HHS [P01 AT002620] Funding Source: Medline; NCRR NIH HHS [RR00046] Funding Source: Medline; NHLBI NIH HHS [R01 HL062624, R01 HL66559, R01 HL62624, R01 HL062624-07] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexis N, 2001, J ALLERGY CLIN IMMUN, V107, P31, DOI 10.1067/mai.2001.111594; Alexis NE, 2004, J ALLERGY CLIN IMMUN, V114, P1325, DOI 10.1016/j.jaci.2004.09.002; Alexis NE, 2004, CLIN IMMUNOL, V111, P126, DOI 10.1016/j.clim.2003.12.002; Alexis NE, 2003, J ALLERGY CLIN IMMUN, V112, P353, DOI 10.1067/mai.2003.1651; Alexis NE, 2001, AM J PHYSIOL-LUNG C, V280, pL369; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; Bennouna S, 2003, J IMMUNOL, V171, P6052, DOI 10.4049/jimmunol.171.11.6052; Boehlecke B, 2003, J ALLERGY CLIN IMMUN, V112, P1241, DOI 10.1016/j.jaci.2003.08.052; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Clayton AR, 2003, ARTHRITIS RHEUM, V48, P2362, DOI 10.1002/art.11130; DeSmedt T, 1997, EUR J IMMUNOL, V27, P1229, DOI 10.1002/eji.1830270526; Eldridge MW, 2000, J TOXICOL ENV HEAL A, V61, P27, DOI 10.1080/00984100050116762; Kiertscher SM, 1996, J LEUKOCYTE BIOL, V59, P208, DOI 10.1002/jlb.59.2.208; Michel O, 2003, J ALLERGY CLIN IMMUN, V112, P923, DOI 10.1016/j.jaci.2003.05.001; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157, DOI 10.1164/ajrccm.156.4.97-02002; Palucka K, 1999, NAT MED, V5, P868, DOI 10.1038/11303; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SANDSTROM T, 1994, AM J IND MED, V25, P103, DOI 10.1002/ajim.4700250127; SANDSTROM T, 1992, EUR RESPIR J, V5, P992; Takahashi M, 2003, CELL IMMUNOL, V226, P105, DOI 10.1016/j.cellimm.2003.11.008; Vanderheyde N, 1999, TRANSPLANTATION, V67, P1342, DOI 10.1097/00007890-199905270-00009; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317	25	56	58	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					345	350		10.1016/j.jaci.2004.11.040	http://dx.doi.org/10.1016/j.jaci.2004.11.040			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696093	Bronze			2022-12-18	WOS:000227043600022
J	Haileamlak, A; Dagoye, D; Williams, H; Venn, AJ; Hubbard, R; Britton, J; Lewis, SA				Haileamlak, A; Dagoye, D; Williams, H; Venn, AJ; Hubbard, R; Britton, J; Lewis, SA			Early life risk factors for atopic dermatitis in Ethiopian children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; Ethiopia; helminthic parasites; etiology	DIAGNOSTIC-CRITERIA; SCHOOL-CHILDREN; RURAL AREA; ASTHMA; PREVALENCE; INFECTION; ECZEMA; URBAN; EPIDEMIOLOGY; CHILDHOOD	Background: Atopic dermatitis (AD) has increased in prevalence in many countries in recent decades, but the risk factors for AD in developing countries are unknown. Helminthic parasites may play a role in protecting against allergic disease, but few studies have investigated the association of AD with parasitic infection. Objective: To establish the independent effects of parasitic infection and other early life factors on the risk of AD in Ethiopia. Methods: We conducted a cross-sectional survey and nested case-control study of children age 1 to 5 years in Jimma and surrounding rural areas in southwest Ethiopia. Cases were defined according to the International Study of Asthma and Allergies in Childhood criteria for AD and confirmed by clinical examination. Information on lifestyle and other potential risk factors was collected by parental questionnaire, and stool samples were analyzed for parasites. Results: Complete data were obtained on 306 AD cases defined by International Study of Asthma and Allergies in Childhood criteria (prevalence, 4.4%) and 426 controls. There was no reduction in the risk of AD in relation to intestinal parasite infection; in fact, AD was increased in subjects with Trichuris (1.61; 95 % CI, 1.14-2.26). The risk of AD was also unrelated to family size, crowding in the home, or breast-feeding, but was related to previously unrecognized factors including malaria and access to piped drinking water. Similar findings were apparent in cases and controls confirmed by clinical examination. Conclusion: Neither intestinal parasite infection nor other proposed risk factors for AD appear to be related to the presence of the condition in young children in Ethiopia, suggesting that other factors may be more important in this population.	Univ Nottingham, Nottingham NG7 2RD, England	University of Nottingham	Lewis, SA (corresponding author), City Hosp, Div Resp Med, Clin Sci Bldg, Nottingham NG5 1PB, England.	Sarah.lewis@nottingham.ac.uk		williams, hywel/0000-0002-5646-3093				ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Cooper PJ, 2004, CLIN EXP ALLERGY, V34, P845, DOI 10.1111/j.1365-2222.2004.01958.x; Cooper PJ, 2003, AM J RESP CRIT CARE, V168, P313, DOI 10.1164/rccm.200211-1320OC; Dagoye D, 2003, AM J RESP CRIT CARE, V167, P1369, DOI 10.1164/rccm.200210-1204OC; DAGOYE D, 2004, Q J MED, V94, P1; DIEPGEN TL, 2000, EPIDEMIOLOGY ATOPIC, P96; Emerson RM, 2001, BRIT J DERMATOL, V144, P514, DOI 10.1046/j.1365-2133.2001.04077.x; Firooz A, 1999, ARCH DERMATOL, V135, P514, DOI 10.1001/archderm.135.5.514; Flohr C, 2003, BRIT J DERMATOL, V148, P871, DOI 10.1046/j.1365-2133.2003.05403.x; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; Gdalevich M, 2001, J AM ACAD DERMATOL, V45, P520, DOI 10.1067/mjd.2001.114741; HAILEAMLAK A, 2004, VALIDATION ISAAC UK; Harris JM, 2001, BRIT J DERMATOL, V144, P795, DOI 10.1046/j.1365-2133.2001.04135.x; Huang SL, 2002, CLIN EXP ALLERGY, V32, P1029, DOI 10.1046/j.1365-2745.2002.01424.x; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; Kramer U, 1998, BRIT J DERMATOL, V139, P1040; Levy RM, 2003, CLIN DERMATOL, V21, P109, DOI 10.1016/S0738-081X(02)00360-7; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Nyan OA, 2001, CLIN EXP ALLERGY, V31, P1672, DOI 10.1046/j.1365-2222.2001.00987.x; PRITCHARD DI, 1990, PARASITOLOGY, V100, P317, DOI 10.1017/S0031182000061333; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Sherriff A, 2002, ARCH DIS CHILD, V87, P26, DOI 10.1136/adc.87.1.26; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; WILLIAMS HC, 1992, CLIN EXP DERMATOL, V17, P385, DOI 10.1111/j.1365-2230.1992.tb00244.x; WILLIAMS HC, 1994, BRIT MED J, V308, P1132, DOI 10.1136/bmj.308.6937.1132; Williams HC, 1996, BRIT J DERMATOL, V135, P12; Williams HC, 2000, CLIN EXP DERMATOL, V25, P522, DOI 10.1046/j.1365-2230.2000.00698.x; Williams HC, 1995, BRIT J DERMATOL, V133, P941, DOI 10.1111/j.1365-2133.1995.tb06930.x; WUTHRICH B, 1996, ALLERGY CLIN IMMUNOL, V308, P1132; Yemaneberhan H, 2004, CLIN EXP ALLERGY, V34, P779, DOI 10.1111/j.1365-2222.2004.1946.x; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	32	56	57	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					370	376		10.1016/j.jaci.2004.10.024	http://dx.doi.org/10.1016/j.jaci.2004.10.024			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696097				2022-12-18	WOS:000227043600026
J	Pons, L; Ponnappan, U; Hall, RA; Simpson, P; Cockrell, G; West, M; Sampson, HA; Helm, RM; Burks, AW				Pons, L; Ponnappan, U; Hall, RA; Simpson, P; Cockrell, G; West, M; Sampson, HA; Helm, RM; Burks, AW			Soy immunotherapy for peanut-allergic mice: Modulation of the peanut-allergic response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; peanut hypersensitivity; immunotherapy; cross-reactivity; soybean; legumes; animal model	ANAPHYLACTIC REACTIONS; MURINE MODEL; FOOD ALLERGY; IGE BINDING; HYPERSENSITIVITY; PREVALENCE; GAMMA; VENOM	Background: Allergen-specific immunotherapy (IT) is an effective therapeutic modality to prevent further anaphylactic episodes in patients with insect sting hypersensitivity and is being investigated for peanut allergy. So far, peanut-specific IT has been unsuccessful because of the side effects of therapy. Soybean seed storage proteins share significant homology with the respective peanut allergens. Objective: This study was undertaken in mice to investigate whether specific doses of soybean would desensitize peanut-allergic mice. Methods: C3H/HeJ mice were sensitized to peanut with 3 intraperitoneal (IP) injections of crude peanut extract. The mice were desensitized by IP injections with either crude peanut or soybean extract for 4 weeks, 3 times a week. Controls included placebo desensitization with PBS and naive mice. After 2 weeks of rest, mice were challenged IP with crude peanut extract. Thirty minutes later, symptom scores and body temperatures were recorded. Serum immunoglobulins, peanut-induced splenocyte proliferation, and secreted cytokines were measured before and after desensitization. Results: The clinical symptoms in the soybean- and peanut-desensitized animals were markedly reduced compared with the placebo-treated mice. Specific IgG1 levels to crude peanut were significantly lower in the soy IT group than in the peanut IT group. The cellular response to crude peanut was also downregulated in the soy IT group, as shown by decreased peanut-specific stimulation indices and a cytokine profile skewed toward a T(H)1 response. Conclusions: Soy IT can be used to desensitize/downregulate peanut-specific response in peanut-allergic mice and could provide a new therapeutic intervention for peanut allergy.	Duke Univ, Med Ctr, Dept Pediat, Div Pediat Allergy & Immunol, Durham, NC 27710 USA; Univ Arkansas Med Sci, Dept Microbiol & Immunol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Arkansas Childrens Hosp, Dept Pediat, Little Rock, AR 72205 USA; Mt Sinai Sch Med, Dept Pediat, Div Pediat Allergy & Immunol, New York, NY USA	Duke University; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; Icahn School of Medicine at Mount Sinai	Burks, AW (corresponding author), Duke Univ, Med Ctr, Dept Pediat, Div Pediat Allergy & Immunol, Box 3530, Durham, NC 27710 USA.	Burks010@mc.duke.edu			NIAID NIH HHS [AI 001666-05] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI001666] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; Burks W, 2001, ALLERGY, V56, P121, DOI 10.1034/j.1398-9995.2001.00935.x; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; *I LAB AN RES COMM, 1996, GUID CAR US LAB AN; JANSEN JJN, 1994, J ALLERGY CLIN IMMUN, V93, P446; JUTEL M, 1995, J IMMUNOL, V154, P4187; Lee SY, 2001, CLIN IMMUNOL, V101, P220, DOI 10.1006/clim.2001.5122; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Shutov AD, 1995, J MOL EVOL, V41, P1057, DOI 10.1007/BF00173187; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; SLOAN AE, 1986, J ALLERGY CLIN IMMUN, V78, P127, DOI 10.1016/0091-6749(86)90002-3; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305	22	56	59	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					915	921		10.1016/j.jaci.2004.06.049	http://dx.doi.org/10.1016/j.jaci.2004.06.049			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480335	Bronze			2022-12-18	WOS:000224439100029
J	Mak, JCW; Leung, HCM; Ho, SP; Law, BKW; Lam, WK; Tsang, KWT; Ip, MSM; Chan-Yeung, M				Mak, JCW; Leung, HCM; Ho, SP; Law, BKW; Lam, WK; Tsang, KWT; Ip, MSM; Chan-Yeung, M			Systemic oxidative and antioxidative status in Chinese patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; superoxide dismutase; catalase; glutathione peroxidase; erythrocyte; oxidized glutathione; oxidative stress	GLUTATHIONE-PEROXIDASE ACTIVITY; OXYGEN RADICALS; SUPEROXIDE-DISMUTASE; ENHANCED PRODUCTION; HYPERRESPONSIVENESS; SELENIUM; INFLAMMATION; GENERATION; CATALASE; FLUID	Background: Patients with asthma generate an increased amount of reactive oxygen species from peripheral blood cells. Reactive oxygen species produce many of the pathophysiologic changes associated with asthma and may contribute to its pathogenesis. Objective: We investigated changes in antioxidant enzyme activities and oxidized glutathione (glutathione disulfide; GSSG) levels in erythrocytes from a group of healthy control Chinese subjects (n = 135) and patients with asthma (n = 106). Methods: Baseline pulmonary function was measured for all subjects. Antioxidant status was evaluated by measuring erythrocyte superoxide dismutase, catalase, and glutathione peroxidase activities. Oxidative stress was also measured in terms of GSSG in erythrocytes with a kinetic microassay. Results: Patients with asthma had significantly increased erythrocyte superoxide dismutase and catalase activities compared with controls (61.10 +/- 1.30 U/g hemoglobin [Hb] vs 55.51 +/- 1.82 U/g Hb [P = .018] and 0.0637 +/- 0.0021 U/g Hb vs 0.0257 +/- 0.0120 U/g Hb [P < .001] for the asthma and control groups, respectively). Conversely, erythrocyte glutathione peroxidase activity decreased (44.21 +/- 1.33 mU/g Hb vs 50.07 +/- 1.39 mU/g Hb for the asthma and control groups, respectively; P = .003). Patients with asthma also had significantly higher GSSG levels in erythrocyte hemolysates compared with controls (167.40 +/- 2.93 mumol/L vs 44.98 +/- 0.44 mumol/L for the asthma and control groups, respectively; P < .001), indicating increased oxidative stress. Conclusions: Asthma is accompanied by an alteration in systemic antioxidant status due to possible oxidative stress in this disease.	Univ Hong Kong, Dept Med, Div Resp & Crit Care Med, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Mak, JCW (corresponding author), Queen Mary Hosp, Dept Med, Div Resp Med, Room 804,Adm Block,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	judithmak@hku.hk	Mak, Judith/C-4363-2009; Ip, Mary Sau Man/C-4284-2009	Ip, Mary Sau Man/0000-0002-8692-6933; Mak, Judith/0000-0002-8234-1313				ABBE MR, 1986, CLIN CHEM, V19, P175; AEBI H, 1984, METHOD ENZYMOL, V105, P121; AGAR NS, 1986, J CLIN INVEST, V77, P319, DOI 10.1172/JCI112294; Allen S, 2001, METHODS CELL SCI, V22, P305; BARNES PJ, 1990, FREE RADICAL BIO MED, V9, P235, DOI 10.1016/0891-5849(90)90034-G; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BLUM J, 1985, ARCH BIOCHEM BIOPHYS, V240, P500, DOI 10.1016/0003-9861(85)90056-6; BUNNELL E, 1993, AM REV RESPIR DIS, V148, P1174, DOI 10.1164/ajrccm/148.5.1174; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152, DOI 10.1152/jappl.1987.63.1.152; CHANYEUNG M, 1993, AM REV RESPIR DIS, V147, P1056; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; Dauletbaev N, 2001, THORAX, V56, P13, DOI 10.1136/thorax.56.1.13; FLATT A, 1990, THORAX, V45, P95, DOI 10.1136/thx.45.2.95; HASSELMARK L, 1990, ALLERGY, V45, P523, DOI 10.1111/j.1398-9995.1990.tb00528.x; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; JAESCHKE H, 1990, AM J PHYSIOL, V258, pG499, DOI 10.1152/ajpgi.1990.258.4.G499; JARJOUR NN, 1994, J LAB CLIN MED, V123, P131; JARJOUR NN, 1992, AM REV RESPIR DIS, V146, P905, DOI 10.1164/ajrccm/146.4.905; JOSEPH BZ, 1993, INFLAMMATION, V17, P361, DOI 10.1007/BF00918997; KANAZAWA H, 1991, CHEST, V100, P1319, DOI 10.1378/chest.100.5.1319; KATSUMATA U, 1990, AM REV RESPIR DIS, V141, P1158, DOI 10.1164/ajrccm/141.5_Pt_1.1158; Kelly FK, 1999, LANCET, V354, P482, DOI 10.1016/S0140-6736(99)01812-7; KUROSAWA M, 1993, INT ARCH ALLERGY IMM, V101, P61, DOI 10.1159/000236499; MALMGREN R, 1986, ALLERGY, V41, P43, DOI 10.1111/j.1398-9995.1986.tb00273.x; Mates JM, 1999, BLOOD CELL MOL DIS, V25, P103, DOI 10.1006/bcmd.1999.0234; MILLS BJ, 1994, ANAL BIOCHEM, V222, P95, DOI 10.1006/abio.1994.1459; Misso NLA, 1996, CLIN EXP ALLERGY, V26, P838, DOI 10.1046/j.1365-2222.1996.d01-376.x; Nadeem A, 2003, J ALLERGY CLIN IMMUN, V111, P72, DOI 10.1067/mai.2003.17; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; PEARSON DJ, 1991, CLIN EXP ALLERGY, V21, P203, DOI 10.1111/j.1365-2222.1991.tb00831.x; POSTON RN, 1992, AM REV RESPIR DIS, V145, P918, DOI 10.1164/ajrccm/145.4_Pt_1.918; POWELL CVE, 1994, PEDIATR PULM, V18, P34, DOI 10.1002/ppul.1950180109; SEDGWICK JB, 1990, AM REV RESPIR DIS, V142, P120, DOI 10.1164/ajrccm/142.1.120; Smith LJ, 1997, FREE RADICAL BIO MED, V22, P1301, DOI 10.1016/S0891-5849(96)00550-3; VACHIER I, 1992, AM REV RESPIR DIS, V146, P1161, DOI 10.1164/ajrccm/146.5_Pt_1.1161; VANASBECK BS, 1985, SCIENCE, V227, P756, DOI 10.1126/science.2982213; Varshavsky BY, 2003, TERAPEVT ARKH, V75, P21	37	56	56	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					260	264		10.1016/j.jaci.2004.05.013	http://dx.doi.org/10.1016/j.jaci.2004.05.013			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316500				2022-12-18	WOS:000223405600007
J	Namazy, J; Schatz, M; Long, L; Lipkowitz, M; Lillie, MA; Voss, M; Deitz, RJ; Petitti, D				Namazy, J; Schatz, M; Long, L; Lipkowitz, M; Lillie, MA; Voss, M; Deitz, RJ; Petitti, D			Use of inhaled steroids by pregnant asthmatic women does not reduce intrauterine growth	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	59th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 07-12, 2003	Denver, CO	Amer Acad Allergy Asthma & Immunol		asthma; pregnancy; inhaled steroids; birth weight; small for gestational age	OUTCOMES	Background: Inhaled steroids are recommended for the treatment of persistent asthma during pregnancy, but their potential effects on intrauterine growth have been inadequately evaluated. Objective: The purpose of this study was to evaluate the association between maternal use of specific inhaled steroids and inhaled steroid dose during pregnancy and the incidence of infants who are small for gestational age (SGA) and mean birth weight. Methods: Pregnant asthmatic women being treated with inhaled steroids were enrolled in the study before delivery by their managing allergists. Information regarding the specific inhaled steroid and daily dose used, requirement for oral steroids, occurrence of acute asthmatic episodes, maternal race, birth weight, gestational age, and congenital malformations was obtained for each patient. SGA was defined through use of a published normative sample of American births. Results. A total of 474 women were enrolled in the study; of the 451 enrolled participants whose pregnancy ended in a singleton live birth, 396 (88%) completed the study. The incidence of infants with low birth weight, preterm births, and congenital malformations in this cohort was not greater than expected in the general population. The incidence of SGA was 7.1% (95% CI, 5.0% to 10.1%). No significant relationships between specific inhaled steroid or dose of inhaled steroid used and either SGA or mean birth weight were observed. Conclusion: These data suggest that the use of inhaled steroids by pregnant asthmatic women does not reduce intrauterine growth and supports the recommendation that inhaled steroids should be used in the management of persistent asthma during pregnancy.	Kaiser Permanente Med Care Program, Dept Allergy, San Diego, CA USA; Kaiser Permanente Med Care Program, Dept Res & Evaluat, San Diego, CA USA	Kaiser Permanente; Kaiser Permanente	Schatz, M (corresponding author), Kaiser Permanente Med Ctr, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.							Alexander GR, 1996, OBSTET GYNECOL, V87, P163, DOI 10.1016/0029-7844(95)00386-X; Alexander S, 1998, OBSTET GYNECOL, V92, P435, DOI 10.1016/S0029-7844(98)00191-4; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Dombrowski M P, 1996, J Matern Fetal Med, V5, P310; DOMBROWSKI MP, 2004, IN PRESS OBSTET GYNE; ERICSON A, 1999, INFORMATION SWEDISH, V1, P8; GREENBERGER PA, 1983, ANN INTERN MED, V98, P478, DOI 10.7326/0003-4819-98-4-478; GREENBERGER PA, 1988, NEW ENGL REG ALLERGY, V9, P539, DOI 10.2500/108854188778965555; Jana N, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P227; Kallen B, 2000, EUR J EPIDEMIOL, V16, P167, DOI 10.1023/A:1007678404911; Kallen B, 1999, OBSTET GYNECOL, V93, P392, DOI 10.1016/S0029-7844(98)00454-2; KLINE J, 1977, NEW ENGL J MED, V297, P793, DOI 10.1056/NEJM197710132971501; Norjavaara E, 2003, J ALLERGY CLIN IMMUN, V111, P736, DOI 10.1067/mai.2003.1340; Pedersen S, 2001, AM J RESP CRIT CARE, V164, P521, DOI 10.1164/ajrccm.164.4.2101050; REINISCH JM, 1978, SCIENCE, V202, P436, DOI 10.1126/science.705336; Schatz M, 2000, IMMUNOL ALLERGY CLIN, V20, P715, DOI 10.1016/S0889-8561(05)70179-X; SCHATZ M, 1990, CHEST, V98, P389, DOI 10.1378/chest.98.2.389; Schatz M, 1997, J ALLERGY CLIN IMMUN, V100, P301, DOI 10.1016/S0091-6749(97)70241-0; Wendel PJ, 1996, AM J OBSTET GYNECOL, V175, P150, DOI 10.1016/S0002-9378(96)70265-X; Zeiger RS, 2000, J ALLERGY CLIN IMMUN, V106, P995, DOI 10.1067/mai.2000.110921	20	56	57	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					427	432		10.1016/j.jaci.2003.11.046	http://dx.doi.org/10.1016/j.jaci.2003.11.046			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	802DM	15007341				2022-12-18	WOS:000220144200012
J	Nagy, A; Kozma, GT; Keszei, M; Treszl, A; Falus, A; Szalai, C				Nagy, A; Kozma, GT; Keszei, M; Treszl, A; Falus, A; Szalai, C			The development of asthma in children infected with Chlamydia pneumoniae is dependent on the modifying effect of mannose-binding lectin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						childhood asthma; mannose-binding lectin; polymorphism; bacterial infection; Chlamydia pneumoniae	ASSOCIATION; DISEASE; POLYMORPHISM; GENE; SUSCEPTIBILITY; ANTIBODIES	Background: Although several studies found associations between infection with Chlamydia pneumoniae and asthma, these were mainly restricted to the exacerbation of the symptoms in adults with known asthma. Data about the role of C pneumoniae in the initiation and development of asthma in children are controversial. Objective: We investigated the role of C pneumoniae infection in 139 children with asthma, comparing them with 174 healthy control subjects. Furthermore, we studied the modifying effect of mannose-binding lectin (MBL) variant alleles on the susceptibility to asthma in children infected with C pneumoniae. Methods: C pneumoniae-specific antibodies were measured by means of ELISA, and MBL genotypes were determined by means of PCR-RFLP. Results: There were no significant differences in the percentage of children with positive results for C pneumoniae-specific antibodies between patients and control subjects. Among asthmatic children carrying variant MBL alleles, there were significantly more patients with positive results for C pneumoniae-specific IgG than among control children with variant MBL genotypes (63.7% vs 40.7% of asthmatic vs control children, respectively; odds ratio adjusted for age and sex, 2.21; 95% CI, 1.10-4.41; P = .02). Infected children with variant MBL alleles were found to have a higher risk of asthma development than infected children with normal MBL genotype. This risk was especially high in children with chronic or recurrent infection (positive results for both IgA and IgG; adjusted odds ratio, 5.38; 95% CI, 1.75-14.36; P = .01), but no increased risk was seen in children with current C pneumoniae infection (positive results for IgM). Conclusion: This study indicates the important role of variant MBL alleles in the susceptibility to asthma in children infected with C pneumoniae.	Heim Pal Pediat Hosp, H-1958 Budapest, Hungary; Budai Childrens Hosp, Budapest, Hungary; Semmelweis Univ, Dept Genet Cell & Immunobiol, H-1085 Budapest, Hungary; Semmelweis Univ, Dept Pediat 1, H-1085 Budapest, Hungary; Hungarian Acad Sci, Sect Mol Immunol, Budapest, Hungary	Semmelweis University; Semmelweis University; Hungarian Academy of Sciences	Szalai, C (corresponding author), Heim Pal Pediat Hosp, POB 66, H-1958 Budapest, Hungary.		Szalai, Csaba/A-2041-2008; Keszei, Marton/F-3295-2014	Falus, Andras/0000-0002-6843-6789; Keszei, Marton/0000-0002-1158-2179				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Cook PJ, 1998, THORAX, V53, P254, DOI 10.1136/thx.53.4.254; EMRE U, 1994, ARCH PEDIAT ADOL MED, V148, P727, DOI 10.1001/archpedi.1994.02170070065013; Falck C, 2002, CHEST, V122, P1587, DOI 10.1378/chest.122.5.1587; Garred P, 1999, ARTHRITIS RHEUM, V42, P2145, DOI 10.1002/1529-0131(199910)42:10<2145::AID-ANR15>3.0.CO;2-#; Garred P, 1999, J CLIN INVEST, V104, P431, DOI 10.1172/JCI6861; Gencay M, 2001, AM J RESP CRIT CARE, V163, P1097, DOI 10.1164/ajrccm.163.5.2003162; Graudal NA, 2000, ARTHRITIS RHEUM, V43, P515, DOI 10.1002/1529-0131(200003)43:3<515::AID-ANR6>3.0.CO;2-T; HAHN DL, 1991, JAMA-J AM MED ASSOC, V266, P225, DOI 10.1001/jama.266.2.225; Johnston SL, 2001, AM J RESP CRIT CARE, V164, P513, DOI 10.1164/ajrccm.164.4.2105129a; Koch A, 2001, JAMA-J AM MED ASSOC, V285, P1316, DOI 10.1001/jama.285.10.1316; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; Kraft M, 2000, CLIN CHEST MED, V21, P301, DOI 10.1016/S0272-5231(05)70268-9; Lazarus R, 2002, IMMUNOL REV, V190, P9, DOI 10.1034/j.1600-065X.2002.19002.x; Lemanske RF, 2003, CHEST, V123, p385S, DOI 10.1378/chest.123.3_suppl.385S-a; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; *NIH NAT HEART LUN, 1995, NHLBI WHO WORKSH REP; Reading PC, 1997, J VIROL, V71, P8204, DOI 10.1128/JVI.71.11.8204-8212.1997; Rugonfalvi-Kiss S, 2002, CIRCULATION, V106, P1071, DOI 10.1161/01.CIR.0000027137.96791.6A; SOELL M, 1995, J IMMUNOL, V154, P851; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; Swanson AF, 1998, INFECT IMMUN, V66, P1607, DOI 10.1128/IAI.66.4.1607-1612.1998; Szalai C, 2001, J ALLERGY CLIN IMMUN, V108, P375, DOI 10.1067/mai.2001.117930; Ten RM, 1999, J ALLERGY CLIN IMMUN, V104, P419, DOI 10.1016/S0091-6749(99)70387-8; Turner M W, 2000, Rev Immunogenet, V2, P305; Wark PAB, 2002, EUR RESPIR J, V20, P834, DOI 10.1183/09031936.02.00192002	27	56	63	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					729	734		10.1016/S0091-6749(03)02010-4	http://dx.doi.org/10.1016/S0091-6749(03)02010-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564351				2022-12-18	WOS:000185831200012
J	Liu, LY; Jarjour, NN; Busse, WW; Kelly, EAB				Liu, LY; Jarjour, NN; Busse, WW; Kelly, EAB			Chemokine receptor expression on human eosinophils from peripheral blood and bronchoalveolar lavage fluid after segmental antigen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chemokine receptors; eosinophils; allergy; segmental bronchoprovocation; bronchoalveolar lavage	ALLERGEN CHALLENGE; AIRWAY INFLAMMATION; EOTAXIN EXPRESSION; CCR3; ACTIVATION; RANTES; CXCR4; HYPERRESPONSIVENESS; DEGRANULATION; RECRUITMENT	Background: The recruitment of circulating eosinophils to the lung is a characteristic feature of allergic airway inflammation. Chemokine receptors likely play a role in this complex process. However, reports of chemokine receptor expression on human eosinophils are conflicting. Objective: The aim of this study was to determine whether the chemokine receptor profile of human eosinophils change when these cells are recruited to the airway after an antigen challenge and development of an allergic inflammatory response. Methods: Blood and bronchoalveolar lavage (BAL) cells were obtained from 13 allergic subjects 48 hours after segmental bronchoprovocation with antigen. The CC chemokine receptor (CCR) 1 to 7, 9, and CXC chemokine receptor (CXCR) 1 to 4 were determined by flow cytometric analysis of whole blood and unseparated BAL cells. Results: Compared with their circulating counterparts, airway eosinophils had decreased CCR3 and increased CCR4, CCR9, and CXCR3 expression on their cell surface. Furthermore, expression of CCR3, CCR4, and CXCR3 was significantly correlated with the percentage of eosinophils in BAL fluid at 48 hours. Eosinophils also expressed CXCR4, but this receptor did not change after antigen-induced recruitment to the airway. In contrast, the expression of CCR1, CCR2, CCR5, CCR6, CCR7, CXCR1, and CXCR2 remained undetectable on either blood or BAL eosinophils. Conclusions: Our data suggest that recruitment of eosinophils to the airway is associated with a modulation of their chemokine receptor profiles. These changes in chemokine receptors could be involved in determining eosinophil function and antigen-induced airway inflammation.	Univ Wisconsin, Sch Med, Pulm & Crit Care Med Sect, Dept Med, Madison, WI 53972 USA; Univ Wisconsin, Sch Med, Sect Allergy & Immunol, Madison, WI 53972 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kelly, EAB (corresponding author), Univ Wisconsin, Sch Med, Pulm & Crit Care Med Sect, Dept Med, 600 Highland Ave,CSC K4 928, Madison, WI 53972 USA.			Kelly, Elizabeth/0000-0001-7335-6698	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR003186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056396] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR 03186] Funding Source: Medline; NHLBI NIH HHS [HL 56396] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bandeira-Melo C, 2001, AM J RESP CELL MOL, V24, P653, DOI 10.1165/ajrcmb.24.6.f209; Berkman N, 2001, AM J RESP CELL MOL, V24, P682, DOI 10.1165/ajrcmb.24.6.4301; Brown JR, 1998, CLIN EXP IMMUNOL, V114, P137; CALHOUN WJ, 1993, AM REV RESPIR DIS, V147, P1465, DOI 10.1164/ajrccm/147.6_Pt_1.1465; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Dunzendorfer S, 2001, J ALLERGY CLIN IMMUN, V108, P581, DOI 10.1067/mai.2001.118518; Fujisawa T, 2000, J ALLERGY CLIN IMMUN, V106, P507; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Holgate ST, 1997, AM J RESP CRIT CARE, V156, P1377, DOI 10.1164/ajrccm.156.5.9610064; Humbles AA, 2002, P NATL ACAD SCI USA, V99, P1479, DOI 10.1073/pnas.261462598; Kelly EAB, 2000, AM J RESP CRIT CARE, V162, P883; Lilly CM, 2001, AM J RESP CRIT CARE, V163, P1669, DOI 10.1164/ajrccm.163.7.9812044; Liu LY, 2002, J IMMUNOL, V169, P6452, DOI 10.4049/jimmunol.169.11.6452; Lukacs NW, 2002, AM J PATHOL, V160, P1353, DOI 10.1016/S0002-9440(10)62562-X; Lukacs NW, 2001, J EXP MED, V194, P551, DOI 10.1084/jem.194.4.551; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; Murdoch C, 2000, BLOOD, V95, P3032; Nagase H, 1999, ALLERGY, V54, P944, DOI 10.1034/j.1398-9995.1999.00184.x; Nagase H, 2000, J IMMUNOL, V164, P5935, DOI 10.4049/jimmunol.164.11.5935; Nagase H, 2001, J ALLERGY CLIN IMMUN, V108, P563, DOI 10.1067/mai.2001.118292; Nickel R, 1999, J ALLERGY CLIN IMMUN, V104, P723, DOI 10.1016/S0091-6749(99)70281-2; Oliveira SHP, 2002, BLOOD, V100, P4291, DOI 10.1182/blood.V100.13.4291; Petering H, 1999, BLOOD, V93, P694, DOI 10.1182/blood.V93.2.694.402k31_694_702; Sabroe I, 1999, J IMMUNOL, V162, P2946; SCHWEIZER RC, 1994, BLOOD, V83, P3697; Shi HZ, 2000, J CLIN INVEST, V105, P945, DOI 10.1172/JCI8945; SRIRAMARAO P, 1994, J IMMUNOL, V153, P4238; Sur S, 1996, J ALLERGY CLIN IMMUN, V97, P1272, DOI 10.1016/S0091-6749(96)70195-1; Tan JQ, 2000, J IMMUNOL, V165, P1548, DOI 10.4049/jimmunol.165.3.1548; Zeibecoglou K, 1999, ALLERGY, V54, P730, DOI 10.1034/j.1398-9995.1999.00058.x; Zimmermann N, 1999, J BIOL CHEM, V274, P12611, DOI 10.1074/jbc.274.18.12611; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P227, DOI 10.1067/mai.2003.139	32	56	58	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					556	562		10.1067/mai.2003.1700	http://dx.doi.org/10.1067/mai.2003.1700			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679815				2022-12-18	WOS:000185231200015
J	Prosperini, G; Rajakulasingam, K; Cacciola, RR; Spicuzza, L; Rorke, S; Holgate, ST; Di Maria, GU; Polosa, R				Prosperini, G; Rajakulasingam, K; Cacciola, RR; Spicuzza, L; Rorke, S; Holgate, ST; Di Maria, GU; Polosa, R			Changes in sputum counts and airway hyperresponsiveness after budesonide: Monitoring anti-inflammatory response on the basis of surrogate markers of airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchial hyperresponsiveness; adenosine challenge; induced sputum; budesonide	EXHALED NITRIC-OXIDE; INHALED BUDESONIDE; LUNG-FUNCTION; MILD ASTHMA; BRONCHIAL HYPERRESPONSIVENESS; ADENOSINE 5'-MONOPHOSPHATE; CONTROLLED TRIAL; DOUBLE-BLIND; RESPONSIVENESS; HISTAMINE	Background: Airway hyperresponsiveness (AHR) to pharmacologic stimuli and sputum eosinophils might be useful in the individual adjustment of long-term asthma management. However, it is not clear whether inhaled glucocorticosteroids (GCSs) provide greater protection against specific surrogate markers of airways inflammation than other means. In addition, detailed longitudinal assessment of changes in airway response with inhaled GCSs has never been carried out. Objectives: We compared changes in AHR to inhaled methacholine and adenosine 5'-monophosphate (AMP) after budesonide treatment in a randomized, double-blind, placebo-controlled, crossover study of patients with mild-to-moderate asthma. Subsequently, we undertook a separate study to examine the time course of the changes in AHR in more detail and the changes in sputum cell counts in relation to budesonide treatment. Methods: In the phase 1 of the study, patients undertook bronchial provocation studies with increasing doubling concentrations of methacholine (0.06 to 16 mg/mL) and AMP (3.125 to 800 mg/mL) before and after budesonide 0.8 mg/daily for 3 weeks. The bronchial responses to the inhaled agonists were expressed as the provocative concentration causing a 20% decline in FEV1 (PC20). In phase 2 of the study, patients attended the laboratory on 12 separate occasions to investigate changes in PC20 methacholine, PC20 AMP, and sputum cell counts before, during, and after withdrawal of therapy with inhaled budesonide 0.8 mg/daily for 6 weeks. Results: Budesonide treatment for 3 weeks significantly attenuated the constrictor response by 0.8 +/- 0.3 doubling doses for methacholine and by 2.6 +/- 0.5 doubling doses for AMP. These changes were significantly different from each other (P = .003). Significant variation in PC20 methacholine (P < .05) value, PC20 AMP (P < .001) value, percentage of sputum eosinophils (P < .001), and percentage of sputum epithelial cells (P < .001) were observed throughout the longitudinal assessment of changes in airway response to budesonide. Compared with the other surrogate markers, PC20 AMP appears to be useful in promptly detecting early inflammatory changes of the asthmatic airways; a significant change of 1.6 +/- 0.3, 2.2 +/- 0.3, and 2.8 +/- 0.3 doubling doses of PC20 AMP was observed at 1, 4, and 6 weeks, respectively, in the course of budesonide treatment. Conclusions: The present findings underline the exquisite selectivity of diverse surrogate markers of airway inflammation in response to inhaled budesonide. When compared with that to the other markers, AHR to inhaled AMP is an early and sensitive indicator of the beneficial anti-inflammatory effects of topical GCSs.	Univ Catania, Dipartimento Med Interna & Specialist, I-95125 Catania, Italy; Univ Southampton, Southampton Gen Hosp, Southampton, Hants, England; Catania Univ, Ist Ematol, Osped Ferrarotto, Catania, Italy	University of Catania; University of Southampton; University of Catania	Polosa, R (corresponding author), Univ Catania, Dipartimento Med Interna & Specialist, Via Passo Gravina 187, I-95125 Catania, Italy.		Spicuzza, Lucia/AAC-5892-2022	Spicuzza, Lucia/0000-0002-8246-8357				Burke CM, 1996, THORAX, V51, P993, DOI 10.1136/thx.51.10.993; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; Gibson PG, 2001, AM J RESP CRIT CARE, V163, P32, DOI 10.1164/ajrccm.163.1.9807061; Gronke L, 2002, CLIN EXP ALLERGY, V32, P57, DOI 10.1046/j.0022-0477.2001.01297.x; in't Veen JCCM, 1999, AM J RESP CRIT CARE, V160, P93; Jatakanon A, 1999, THORAX, V54, P108, DOI 10.1136/thx.54.2.108; Kanniess F, 2001, PULM PHARMACOL THER, V14, P141, DOI 10.1006/pupt.2001.0288; Kassel O, 1998, MOL PHARMACOL, V54, P1073, DOI 10.1124/mol.54.6.1073; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Leuppi JD, 2001, EUR RESPIR J, V18, P444, DOI 10.1183/09031936.01.00058601; Lim S, 1999, AM J RESP CRIT CARE, V159, P22, DOI 10.1164/ajrccm.159.1.9706006; Meijer RJ, 1999, THORAX, V54, P894, DOI 10.1136/thx.54.10.894; *NAT HEART LUNG BL, 1995, PUBL NAT HEART LUNG; OCONNOR BJ, 1992, AM REV RESPIR DIS, V146, P560, DOI 10.1164/ajrccm/146.3.560; Piacentini GL, 1998, CLIN EXP ALLERGY, V28, P561, DOI 10.1046/j.1365-2222.1998.00260.x; Polosa R, 2000, EUR RESPIR J, V15, P30, DOI 10.1034/j.1399-3003.2000.15a07.x; POLOSA R, 1991, J ALLERGY CLIN IMMUN, V87, P939, DOI 10.1016/0091-6749(91)90415-K; Polosa R, 2002, EUR RESPIR J, V20, P488, DOI 10.1183/09031936.02.01132002; Polosa R, 2002, THORAX, V57, P649, DOI 10.1136/thorax.57.7.649; POLOSA R, IN PRESS CLIN EXP AL; RYAN G, 1985, J ALLERGY CLIN IMMUN, V75, P25, DOI 10.1016/0091-6749(85)90007-7; Sont JK, 1996, THORAX, V51, P496, DOI 10.1136/thx.51.5.496; Svenningsson P, 1997, J PHARMACOL EXP THER, V280, P1094; Taylor DA, 1999, AM J RESP CRIT CARE, V160, P237, DOI 10.1164/ajrccm.160.1.9809046; Ulrik CS, 1999, EUR RESPIR J, V13, P904, DOI 10.1034/j.1399-3003.1999.13d35.x; Van den Berge M, 2001, AM J RESP CRIT CARE, V164, P1127, DOI 10.1164/ajrccm.164.7.2102135; Van dn Berge M, 2001, AM J RESP CRIT CARE, V163, P1546, DOI 10.1164/ajrccm.163.7.2010145; van Rensen ELJ, 1999, THORAX, V54, P403, DOI 10.1136/thx.54.5.403; vanVelzen E, 1996, THORAX, V51, P582, DOI 10.1136/thx.51.6.582; VATHENEN AS, 1991, THORAX, V46, P811, DOI 10.1136/thx.46.11.811; Weersink EJM, 1997, AM J RESP CRIT CARE, V155, P1241, DOI 10.1164/ajrccm.155.4.9105061; WEN LP, 1997, AM J PHYSIOL, V273, P921	33	56	59	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2002	110	6					855	861		10.1067/mai.2002.130050	http://dx.doi.org/10.1067/mai.2002.130050			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	624TL	12464950	Bronze			2022-12-18	WOS:000179777400006
J	Valapour, M; Guo, J; Schroeder, JT; Keen, J; Cianferoni, A; Casolaro, V; Georas, SN				Valapour, M; Guo, J; Schroeder, JT; Keen, J; Cianferoni, A; Casolaro, V; Georas, SN			Histone deacetylation inhibits IL4 gene expression in T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						gene expression; T lymphocyte; IL-4; histone deacetylase; gene transcription	INTERLEUKIN-4 GENE; CHROMATIN-STRUCTURE; TRANSCRIPTIONAL REPRESSION; COORDINATE REGULATOR; CYTOKINE EXPRESSION; NUCLEAR FACTOR; TYPE-2 TH2; NF-AT; IL-4; BINDING	Background: Dysregulated expression of IL-4 has been linked with allergic diseases. IL-4 expression is controlled at the level of gene transcription by the coordinated action of multiple factors that bind regulatory promoter elements. In addition, alterations in chromatin structure are thought to play a role in regulating the expression of cytokines in the T(H)2 gene cluster, although the biochemical basis for these alterations in human T cells is not well understood. Objective: We sought to define the role of histone acetylation in the regulation of IL4 gene expression in human T cells. Methods: IL-4 protein production was measured by means of ELISA. IL-4 promoter activity was measured with luciferase-based reporter constructs transiently transfected into Jurkat T cells. The acetylation status of histones associated with the IL4 gene was analyzed with chromatin immunoprecipitation assays. Results: IL-4 production from activated peripheral blood T cells was enhanced by the histone deacetylase inhibitor trichostatin A. Overexpression of the type I histone deacetylases 1, 2, and 3 inhibited transcription driven by the IL-4 promoter in Jurkat T cells, whereas cotransfection of the histone acetyltransferase CREB-binding protein potentiated IL-4 promoter activity. Using chromatin immunoprecipitation assays, we show that nucleosomes in the proximal IL-4 promoter are acetylated on T-cell activation. Conclusion: Our results demonstrate that the acetylation state of histones associated with the IL-4 promoter is a key regulator of IL4 gene expression.	Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol & Allergy, Baltimore, MD 21224 USA; Johns Hopkins Asthma & Allergy Ctr, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Georas, SN (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol & Allergy, Rm 4B-41,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.		Casolaro, Vincenzo/E-9144-2010	Casolaro, Vincenzo/0000-0001-9810-0488				ABE E, 1992, P NATL ACAD SCI USA, V89, P2864, DOI 10.1073/pnas.89.7.2864; Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Agarwal S, 1999, J ALLERGY CLIN IMMUN, V103, P990, DOI 10.1016/S0091-6749(99)70168-5; Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; Brown MA, 1997, CRIT REV IMMUNOL, V17, P1; Burchard EG, 1999, AM J RESP CRIT CARE, V160, P919, DOI 10.1164/ajrccm.160.3.9812024; Burke TF, 2000, BIOCHEM BIOPH RES CO, V270, P1016, DOI 10.1006/bbrc.2000.2508; CAMERINIOTERO RD, 1980, P NATL ACAD SCI-BIOL, V77, P5079, DOI 10.1073/pnas.77.9.5079; CASOLARO V, 1995, P NATL ACAD SCI USA, V92, P11623, DOI 10.1073/pnas.92.25.11623; Casolaro V, 2000, J BIOL CHEM, V275, P36605, DOI 10.1074/jbc.M007086200; Chan SC, 1996, J INVEST DERMATOL, V106, P1131, DOI 10.1111/1523-1747.ep12340181; Chen RB, 2000, J IMMUNOL, V164, P825, DOI 10.4049/jimmunol.164.2.825; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; Dangond F, 1998, BIOCHEM BIOPH RES CO, V247, P833, DOI 10.1006/bbrc.1998.8891; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; Georas S, 2000, LEUKEMIA, V14, P629, DOI 10.1038/sj.leu.2401712; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Grogan JL, 2001, IMMUNITY, V14, P205, DOI 10.1016/S1074-7613(01)00103-0; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Ho IC, 1998, J EXP MED, V188, P1859, DOI 10.1084/jem.188.10.1859; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Keen JC, 2001, AM J RESP CELL MOL, V24, P58, DOI 10.1165/ajrcmb.24.1.3870; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Kimura M, 2001, IMMUNITY, V15, P275, DOI 10.1016/S1074-7613(01)00182-0; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lee GR, 2001, IMMUNITY, V14, P447, DOI 10.1016/S1074-7613(01)00125-X; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Mohrs M, 2001, NAT IMMUNOL, V2, P842, DOI 10.1038/ni0901-842; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; Ranganath S, 1998, J IMMUNOL, V161, P3822; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; RIVAS D, 1995, J AUTOIMMUN, V8, P587, DOI 10.1016/0896-8411(95)90010-1; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; Schroeder JT, 1997, J ALLERGY CLIN IMMUN, V99, P429, DOI 10.1016/S0091-6749(97)70065-4; SCHROEDER JT, 1994, J IMMUNOL, V153, P1808; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; Szabo SJ, 1997, CURR OPIN IMMUNOL, V9, P776, DOI 10.1016/S0952-7915(97)80177-X; Takemoto N, 1998, INT IMMUNOL, V10, P1981, DOI 10.1093/intimm/10.12.1981; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; Wenner CA, 1997, J IMMUNOL, V158, P765; Wilson SB, 1998, NATURE, V391, P177, DOI 10.1038/34419; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	62	56	58	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					238	245		10.1067/mai.2002.121145	http://dx.doi.org/10.1067/mai.2002.121145			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842291	Bronze			2022-12-18	WOS:000174232600005
J	Rak, S; Heinrich, C; Jacobsen, L; Scheynius, A; Venge, P				Rak, S; Heinrich, C; Jacobsen, L; Scheynius, A; Venge, P			A double-blinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						specific immunotherapy; nasal steroid; eosinophil; bronchial	INTRANASAL FLUTICASONE PROPIONATE; EOSINOPHIL CATIONIC PROTEIN; BRONCHIAL HYPERRESPONSIVENESS; POLLEN SEASON; CHEMOTACTIC ACTIVITY; NASAL SECRETIONS; RHINITIS; RESPONSIVENESS; INFLAMMATION; HISTAMINE	Background: Both specific immunotherapy (SIT) and nasal steroid (NS) have been shown to effectively reduce symptoms of allergic rhinitis. Although a number of investigators have convincingly shown anti-inflammatory effects of tooth treatments in separate studies, few comparative studies have been performed. Objective: The purpose of this study was to compare the effects of preseason SIT with a standardized allergen extract and NS in seasonal allergic disease (rhinoconjuctivitis and asthma). Methods: We examined 41 patients allergic to birch pollen, 21 with rhinoconjunctivitis and 20 with both rhinoconjunctivitis and asthma; they were treated in a randomized, double-blinded comparative study with birch SIT and NS (budesonide 400 mug daily). Bronchial hyperresponsiveness was measured before and during the season. Changes in eosinophil number, eosinophil cationic protein, and eosinophil chemotactic activity (ECA) in peripheral blood were investigated. Results: Symptoms of rhinoconjunctivitis increased significantly less in the NS-treated patients than in the SIT-treated patients during the final 2 weeks of the season (P = .03 and P = .04, respectively). Seasonal peak expiratory now values decreased significantly only in the NS-treated patients (P = .01). In the NS-treated patients, bronchial hyperresponsiveness increased significantly during the season (P = .0001); however, SIT treatment prevented seasonal PC20 increase in the asthmatic patients. Measurement of blood eosinophils. eosinophil cationic protein, and eosinophil chemotactic activity demonstrated significant seasonal increase only in the NS-treated asthmatic patients. Conclusion: Treatment with NS was more effective than short-course preseason SIT in reducing symptoms of rhinoconjunctivitis; however, the 2 therapies were equivalent in terms of the need for rescue medication. SIT prevented seasonal increase in bronchial hyperresponsiveness, eosinophil number, eosinophil cationic, protein, and eosinophil chemotactic activity only in asthmatic patients. The mechanisms underlying bronchial hyperresponiveness developing during allergen exposure in rhinitis might be different from those operating in asthma.	Sahlgrens Univ Hosp, Dept Resp Med & Allergol, S-41345 Gothenburg, Sweden; Cent Hosp Vasteras, Dept Otolaryngol, Vasteras, Sweden; ALK Abello, Horsholm, Denmark; Karolinska Hosp & Inst, Unit Clin Allergy REs, Stockholm, Sweden; Univ Hosp, Dept Clin Chem, Uppsala, Sweden	Sahlgrenska University Hospital; Vasteras Central Hospital; ALK-Abello AS; Karolinska Institutet; Karolinska University Hospital; Uppsala University; Uppsala University Hospital	Rak, S (corresponding author), Sahlgrens Univ Hosp, Dept Resp Med & Allergol, S-41345 Gothenburg, Sweden.							ARVIDSSON M, IN PRESS J ALLERGY C; AUBIER M, 1992, AM REV RESPIR DIS, V146, P122, DOI 10.1164/ajrccm/146.1.122; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P260; Denburg JA, 1996, ALLERGY, V51, P141, DOI 10.1111/j.1398-9995.1996.tb00054.x; DURHAM SR, 1995, INT ARCH ALLERGY IMM, V107, P282, DOI 10.1159/000237003; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; GOMEZ E, 1988, BRIT MED J, V296, P1572, DOI 10.1136/bmj.296.6636.1572-a; HAKANSSON L, 1989, J ALLERGY CLIN IMMUN, V83, P933, DOI 10.1016/0091-6749(89)90108-5; HAKANSSON L, 1987, J LEUKOCYTE BIOL, V42, P689, DOI 10.1002/jlb.42.6.689; HOLM AF, 1995, ALLERGY, V50, P204, DOI 10.1111/j.1398-9995.1995.tb01134.x; JUNIPER EF, 1990, J ALLERGY CLIN IMMUN, V85, P606, DOI 10.1016/0091-6749(90)90100-I; LOWHAGEN O, 1983, EUR J RESPIR DIS, V64, P466; MELTZER EO, 1994, J ALLERGY CLIN IMMUN, V94, P708, DOI 10.1016/0091-6749(94)90178-3; MYGIND N, 1983, EUR J RESPIR DIS, V64, P16; MYGIND N, 1998, RHINITIS MECH MANAGE, P221; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; Nielsen LP, 1998, ALLERGY, V53, P778; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; RAK S, 1994, CLIN EXP ALLERGY, V24, P930, DOI 10.1111/j.1365-2222.1994.tb02724.x; RAMSDALE EH, 1985, J ALLERGY CLIN IMMUN, V75, P573; STEVENS WJ, 1980, EUR J RESPIR DIS, V61, P203; Tomassini M, 1996, J ALLERGY CLIN IMMUN, V97, P1350, DOI 10.1016/S0091-6749(96)70204-X; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; WANG D, 1995, ALLERGY, V50, P147; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; Weido AJ, 1996, ANN ALLERG ASTHMA IM, V77, P407, DOI 10.1016/S1081-1206(10)63340-6; WOOD RA, 1995, AM J RESP CRIT CARE, V151, P315, DOI 10.1164/ajrccm.151.2.7842184; ZETTERST.O, 1972, ACTA ALLERGOL, V27, P15, DOI 10.1111/j.1398-9995.1972.tb01638.x	32	56	57	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					921	928		10.1067/mai.2001.119743	http://dx.doi.org/10.1067/mai.2001.119743			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742269				2022-12-18	WOS:000172938400007
J	Blumenthal, RL; Campbell, DE; Hwang, P; DeKruyff, RH; Frankel, LR; Umetsu, DT				Blumenthal, RL; Campbell, DE; Hwang, P; DeKruyff, RH; Frankel, LR; Umetsu, DT			Human alveolar macrophages induce functional inactivation in antigen-specific CD4 T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						alveolar macrophages; tolerance; T cells; immune privilege; CD86; CD28	DENDRITIC CELLS; IN-VITRO; COSTIMULATORY MOLECULES; INCREASED EXPRESSION; SIGNAL-TRANSDUCTION; B-CELLS; LYMPHOCYTES; ACTIVATION; LIGAND; CD28	Background: Alveolar macrophages (AMCs) are the most abundant phagocytic cells in the lung, but they present antigen poorly to T cells, Objectives: The objectives of our studies were to more clearly define the mechanisms by which AMCs present antigen to T cells and to determine whether AMCs actively inhibit T-cell activation, Methods: We studied purified human CD4 T cells and compared the capacity of allogeneic AMCs and peripheral blood monocytes to induce T-cell proliferation and cytokine production. Results: We previously demonstrated that human AMCs fail to upregulate expression of B7-1 and B7-2 on stimulation with IFN-gamma, We now demonstrate that AMCs actively induce T-cell unresponsiveness (functional inactivation) in an antigen-specific manner and reduce the capacity of CD4 T cells to respond on secondary stimulation. The induction of unresponsiveness was reversed by the addition of CD28 costimulation or IL-2, However, interruption of Fas/Fas ligand interactions or of B7/CTLA-4 interactions did not prevent unresponsiveness, indicating that neither CTLA-4 triggering nor Fas-induced apoptosis was involved in the induction of T-cell unresponsiveness. Conclusions: These studies indicate that AMCs actively tolerize CD4 T cells in an antigen-specific fashion. We propose that AMCs mediate a form of immune privilege in the lungs that effectively limits immune responses in the pulmonary compartment but has little effect on systemic immunity.	Stanford Univ, Dept Pediat, Div Immunol, Stanford, CA 94305 USA; Stanford Univ, Dept Pediat, Div Immunol, Stanford, CA 94305 USA; Stanford Univ, Dept Pediat, Div Allergy & Crit Care Med, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Umetsu, DT (corresponding author), Stanford Univ, Dept Pediat, Div Immunol, Room G309, Stanford, CA 94305 USA.			Campbell, Dianne/0000-0002-0907-6963	NCRR NIH HHS [MO1 RR00070] Funding Source: Medline; NIAID NIH HHS [R01 AI26322] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026322] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agea E, 1998, CLIN EXP ALLERGY, V28, P1359; Banchereau J, 1997, TRANSFUS SCI, V18, P313; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BERNSTEIN L, 1985, AM REV RESPIR DIS, V132, P180; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BILYK N, 1995, IMMUNOLOGY, V86, P231; Bingisser RM, 1998, J IMMUNOL, V160, P5729; Blotta MH, 1996, J IMMUNOL, V156, P3133; Brandtzaeg P, 1996, ACTA OTO-LARYNGOL, V116, P149, DOI 10.3109/00016489609137812; Burastero SE, 1999, J ALLERGY CLIN IMMUN, V103, P1136, DOI 10.1016/S0091-6749(99)70189-2; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Chai JG, 1999, EUR J IMMUNOL, V29, P686, DOI 10.1002/(SICI)1521-4141(199902)29:02<686::AID-IMMU686>3.0.CO;2-N; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; CHELEN CJ, 1995, J CLIN INVEST, V95, P1415, DOI 10.1172/JCI117796; Dai H, 1999, EUR RESPIR J, V13, P1451, DOI 10.1034/j.1399-3003.1999.13f35.x; DEBOER M, 1993, EUR J IMMUNOL, V23, P3120, DOI 10.1002/eji.1830231212; ETTENSOHN DB, 1986, AM REV RESPIR DIS, V133, P1091; ETTENSOHN DB, 1989, CLIN EXP IMMUNOL, V75, P432; FAIST E, 1987, J TRAUMA, V27, P837, DOI 10.1097/00005373-198708000-00001; FIREMAN E, 1993, EUR RESPIR J, V6, P956; GANT VA, 1991, CLIN EXP IMMUNOL, V86, P494; Gao JX, 1999, IMMUNOLOGY, V98, P159; GRBIC JT, 1991, ANN SURG, V214, P253, DOI 10.1097/00000658-199109000-00008; Hirano N, 1996, LEUKEMIA, V10, P1168; HOLT PG, 1985, AUST J EXP BIOL MED, V63, P33, DOI 10.1038/icb.1985.4; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kradin RL, 1999, AM J RESP CRIT CARE, V159, P1967, DOI 10.1164/ajrccm.159.6.9810117; LEDBETTER JA, 1990, BLOOD, V75, P1531; LIPSCOMB MF, 1993, ARCH PATHOL LAB MED, V117, P1225; MCCOMBS CC, 1982, CHEST, V82, P266, DOI 10.1378/chest.82.3.266; McWilliam AS, 1996, J EXP MED, V184, P2429, DOI 10.1084/jem.184.6.2429; Nicod LP, 1997, AM J RESP CELL MOL, V17, P91, DOI 10.1165/ajrcmb.17.1.2781; Ohta K, 2000, J IMMUNOL, V164, P1185, DOI 10.4049/jimmunol.164.3.1185; Ozdemirli M, 1996, EUR J IMMUNOL, V26, P415, DOI 10.1002/eji.1830260222; RICH EA, 1991, AM J RESP CELL MOL, V4, P287, DOI 10.1165/ajrcmb/4.3.287; Santin AD, 1999, IMMUNOBIOLOGY, V200, P187, DOI 10.1016/S0171-2985(99)80069-2; SCHWAB R, 1985, J IMMUNOL, V135, P1714; Strickland D, 1996, IMMUNOLOGY, V87, P250, DOI 10.1046/j.1365-2567.1996.459542.x; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; THEPEN T, 1989, J EXP MED, V170, P499, DOI 10.1084/jem.170.2.499; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; vanderMerwe PA, 1997, J EXP MED, V185, P393, DOI 10.1084/jem.185.3.393; Viney JL, 1998, J IMMUNOL, V160, P5815; Yuschenkoff VN, 1996, J IMMUNOL, V157, P1987	44	56	62	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					258	264		10.1067/mai.2001.112845	http://dx.doi.org/10.1067/mai.2001.112845			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174191				2022-12-18	WOS:000167071400011
J	Rodriguez, J; Crespo, JF; Burks, W; Rivas-Plata, C; Fernandez-Anaya, S; Vives, R; Daroca, P				Rodriguez, J; Crespo, JF; Burks, W; Rivas-Plata, C; Fernandez-Anaya, S; Vives, R; Daroca, P			Randomized, double-blind, crossover challenge study in 53 subjects reporting adverse reactions to melon (Cucumis melo)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						melon; food hypersensitivity; double-blind; placebo-controlled; food challenge; cucurbitaceae; skin prick test; clinical study; fruit	CONTROLLED FOOD CHALLENGE; ORAL ALLERGY SYNDROME; IGE ANTIBODIES; LATEX; HYPERSENSITIVITY; REACTIVITY; ANAPHYLAXIS; BANANA; SENSITIZATION; DIAGNOSIS	Background: Few studies have evaluated IgE-mediated hypersensitivity to melon with details of clinical reactions confirmed by double-blind, placebo-controlled, food challenges (DBPCFCs). Objective: We sought to investigate clinical features (type and severity of reactions, age at onset, results of skin prick and in vitro tests, and incidence of other allergic diseases and associated food allergies) of acute allergic reactions to melon confirmed by DBPCFCs. Methods: Fifty-three consecutive adult patients complaining of adverse reactions to melon were included in the study. Skin prick tests and detection of specific IgE were performed in all patients with melon, avocado, kiwi, banana, chestnut, latex, pollen, and other offending foods. Patients first underwent an open food challenge, unless they had a convincing history of severe anaphylaxis. Positive open food challenge reactions were subsequently evaluated by DBPCFCs. Results: Actual clinical reactivity was confirmed in 19 (36%) of 53 patients. The most frequent symptom was oral allergy syndrome (n =14), but two patients experienced life-threatening reactions, including respiratory symptoms and hypotension. The positive predictive value for a skin prick test was 42%, and that for specific IgE measurement was 44%. Forty-five reactions to 15 other foods were confirmed in 18 patients. The most common foods associated with melon allergy were avocado (n=7), banana (n=7), kiwi (n=6), watermelon (n= 6), and peach (n = 5). Onset of melon-induced allergic symptoms occurred from 6 to 45 years (median, 20 years), preceded by seasonal rhinitis, asthma, or both in 88% (15/17). Conclusion: About one third of reported reactions to melon are confirmed by means of DBPCFC, which has been proven to be the most reliable procedure in the diagnosis of clinical fruit allergy. Isolated melon allergy is rare, with most patients either having allergic rhinitis, asthma, or both and associated food allergies.	Univ Madrid, Hosp 12 Octubre, Serv Alergia, Madrid 28041, Spain; Univ Arkansas Med Sci, Arkansas Childrens Hosp, Little Rock, AR 72205 USA	Hospital Universitario 12 de Octubre; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences	Rodriguez, J (corresponding author), Univ Madrid, Hosp 12 Octubre, Serv Alergia, Ctra Andalucia Km 5 400, Madrid 28041, Spain.							ANDERSON LB, 1970, J ALLERGY, V45, P310, DOI 10.1016/0021-8707(70)90037-7; ANIBARRO B, 1993, ALLERGY, V48, P130, DOI 10.1111/j.1398-9995.1993.tb00698.x; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; BIRCHER AJ, 1994, CLIN EXP ALLERGY, V24, P367, DOI 10.1111/j.1365-2222.1994.tb00248.x; BLANCO C, 1994, ANN ALLERGY, V73, P309; BLANCO C, 1994, ALLERGY, V49, P454, DOI 10.1111/j.1398-9995.1994.tb00839.x; BOCK SA, 1978, CLIN ALLERGY, V8, P559, DOI 10.1111/j.1365-2222.1978.tb01509.x; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; DECORRES LF, 1993, ANN ALLERGY, V70, P35; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; EWAN PW, 1990, ALLERGY, V45, P22, DOI 10.1111/j.1398-9995.1990.tb01080.x; Mallon DFJ, 1997, ANN ALLERG ASTHMA IM, V78, P285, DOI 10.1016/S1081-1206(10)63182-1; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; Noe D, 1998, ALLERGY, V53, P75, DOI 10.1111/j.1398-9995.1998.tb04967.x; Ortiz JCG, 1996, J INVEST ALLERG CLIN, V6, P378; ORTIZ JCG, 1995, ALLERGY, V50, P269, DOI 10.1111/j.1398-9995.1995.tb01145.x; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; RODRIGUEZ M, 1993, ANN ALLERGY, V70, P31; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V82, P718, DOI 10.1016/0091-6749(88)90070-X; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603	24	56	57	2	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					968	972		10.1067/mai.2000.110467	http://dx.doi.org/10.1067/mai.2000.110467			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080722				2022-12-18	WOS:000167865200024
J	Sanchez-Monge, R; Pascual, CY; Diaz-Perales, A; Fernandez-Crespo, J; Martin-Esteban, M; Salcedo, G				Sanchez-Monge, R; Pascual, CY; Diaz-Perales, A; Fernandez-Crespo, J; Martin-Esteban, M; Salcedo, G			Isolation and characterization of relevant allergens from boiled lentils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						lentil; allergen isolation; vicilin subunit; biotinylated protein; legumes	ASPARAGINE-LINKED GLYCANS; MAJOR PEANUT ALLERGEN; IGE-BINDING EPITOPES; PISUM-SATIVUM-L; MUTATIONAL ANALYSIS; PROTEIN; VICILIN; IDENTIFICATION; ANAPHYLAXIS; SEQUENCE	Background: Lentils seem to be the most common legume implicated in pediatric allergic patients in the Mediterranean area, However, no lentil allergen has been isolated and characterized. Objective: We sought to purify and characterize relevant IgE-binding proteins From boiled lentil extracts. Methods: IgE-binding proteins from crude and boiled lentil extracts were detected with a pool of sera from patients with lentil allergy, Allergens were isolated by gel-filtration chromatography followed by cation- and anion-exchange chromatography or by reverse-phase HPLC. Their characterization included N-terminal amino acid sequencing, complex asparagine-linked glycan detection, specific IgE immunodetection with 22 individual sera from allergic patients, and immunoblot and CAP inhibition assays. Results: Heat treatment of lentils produced substantial changes in the SDS-PAGE patterns of whole extracts, mainly a strong increase of 12- to 16-kd bands and a decrease of 25- to 45-kd components, Major IgE-binding proteins from the boiled lentil extract were located in the 12- to 16-kd and 45- to 70-kd ranges. Two allergens of 16 kd, proteins L1 and L2, and another one of 12 kd, protein L3, were purified, N-terminal sequencing indicated that all 3 were related and allowed their identification as gamma -vicilin subunits, Protein L1 was recognized by 68% of the individual sera tested and inhibited 64% of the IgE binding by commercial lentil CAPs, A second type of allergen of 66 kd, named protein H, was also isolated and identified as a seed-specific biotinylated protein. Protein H reacted with 41% of the individual sera and produced 45% inhibition in CAP inhibition assays. Conclusions: Two different types of allergens have been identified in boiled lentils. Those of 12 to 16 kd, called Len c 1, correspond to gamma -vicilin subunits, and those of 65 kd, designated Len c 2, correspond to seed-specific biotinylated protein. Homology with proteins from other legume species can explain potential cross-reactions among these foods.	ETS Ingenieros Agron, Dept Biotecnol, Unidad Bioquim, Madrid 28040, Spain; Hosp Infantil Paz, Serv Alergia, Madrid, Spain; Univ Madrid, Hosp 12 Octubre, Serv Alergia, Madrid, Spain	Hospital Universitario 12 de Octubre	Salcedo, G (corresponding author), ETS Ingenieros Agron, Dept Biotecnol, Unidad Bioquim, Madrid 28040, Spain.		Díaz-Perales, Araceli/D-8433-2016	Díaz-Perales, Araceli/0000-0002-1093-3627				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKS AW, 1988, J ALLERGY CLIN IMMUN, V81, P417, DOI 10.1016/0091-6749(88)90185-6; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; Casey R., 1986, Oxford surveys of plant molecular and cell biology. Volume 3., P1; CRESPO JF, 1995, PEDIAT ALLERG IMM-UK, V6, P39, DOI 10.1111/j.1399-3038.1995.tb00256.x; Dehaye L, 1997, PLANT MOL BIOL, V35, P605, DOI 10.1023/A:1005836405211; Diaz-Perales A, 1999, J ALLERGY CLIN IMMUN, V104, P681, DOI 10.1016/S0091-6749(99)70342-8; DUVAL M, 1994, PLANT MOL BIOL, V26, P265, DOI 10.1007/BF00039537; GATEHOUSE JA, 1983, BIOCHEM J, V212, P427, DOI 10.1042/bj2120427; Helm RM, 1998, INT ARCH ALLERGY IMM, V117, P29, DOI 10.1159/000023987; Kalogeromitros D, 1996, ANN ALLERG ASTHMA IM, V77, P480, DOI 10.1016/S1081-1206(10)63354-6; Koppelman SJ, 1999, J BIOL CHEM, V274, P4770, DOI 10.1074/jbc.274.8.4770; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIERE M, 1989, PLANT PHYSIOL, V90, P1182, DOI 10.1104/pp.90.3.1182; LYCETT GW, 1983, NUCLEIC ACIDS RES, V11, P2367, DOI 10.1093/nar/11.8.2367; MARTIN JA, 1992, ALLERGY, V47, P185, DOI 10.1111/j.1398-9995.1992.tb00962.x; Niphadkar PV, 1997, ALLERGY, V52, P115, DOI 10.1111/j.1398-9995.1997.tb02559.x; OGAWA T, 1995, BIOSCI BIOTECH BIOCH, V59, P831, DOI 10.1271/bbb.59.831; Pascual CY, 1999, J ALLERGY CLIN IMMUN, V103, P154, DOI 10.1016/S0091-6749(99)70539-7; Sandin DI, 1999, ALLERGY, V54, P1209, DOI 10.1034/j.1398-9995.1999.00299.x; Shin DS, 1998, J BIOL CHEM, V273, P13753, DOI 10.1074/jbc.273.22.13753; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; TAYLOR SL, 1987, NUTR RES ED FDN, P21; Teuber SS, 1999, J ALLERGY CLIN IMMUN, V104, P1311, DOI 10.1016/S0091-6749(99)70029-1	26	56	63	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					955	961		10.1067/mai.2000.109912	http://dx.doi.org/10.1067/mai.2000.109912			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080720				2022-12-18	WOS:000167865200022
J	Gounni, AS; Nutku, E; Koussih, L; Aris, F; Louahed, J; Levitt, RC; Nicolaides, NC; Hamid, Q				Gounni, AS; Nutku, E; Koussih, L; Aris, F; Louahed, J; Levitt, RC; Nicolaides, NC; Hamid, Q			IL-9 expression by human eosinophils: Regulation by IL-1 beta and TNF-alpha	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; IL-9; regulation; IL-1 beta; TNF-alpha	ALLERGIC AIRWAY INFLAMMATION; CD4+ T-CELLS; BRONCHOALVEOLAR LAVAGE; TRANSGENIC MICE; ATOPIC ASTHMA; INTERLEUKIN-9; CYTOKINES; HYPERRESPONSIVENESS; RECRUITMENT; ACTIVATION	Background: IL-9 is a pleiotropic cytokine that exhibits biologic activity on cells of diverse hemopoietic lineage. IL-9 stimulates the proliferation of activated T cells, enhances the production of IgE from B cells, and promotes the proliferation and differentiation of mast cells and hematopoietic progenitors. Objective: In this study we evaluated the expression of IL-9 messenger (m)RNA and protein by human peripheral blood eosinophils. We also investigated the role of IL-1 beta and TNF-alpha in the release of IL-9 from human peripheral blood eosinophils. Methods: RT-PCR, in situ hybridization, and immunocytochemistry were used to investigate the presence of IL-9 mRNA and protein in human peripheral blood eosinophils From asthmatic patients and normal control subjects. Furthermore, biologic assay was used to investigate the release of IL-9 protein from IL-1 beta- or TNF-alpha-stimulated eosinophils in vitro. Results: RT-PCR analysis showed the presence of IL-9 mRNA in human peripheral blood eosinophil RNA preparations from subjects with atopic asthma, as well as in the eosinophil-differentiated HL-60 cell line. By using in situ hybridization, a significant difference (P < .01) in IL-9 mRNA expression was detected in human peripheral blood eosinophils freshly isolated from asthmatic subjects compared with those isolated from normal control subjects. Furthermore, the percentage of IL-9 immunoreactive eosinophils from asthmatic patients was increased compared with that found in normal control subjects (P < .01). We also demonstrate that cultured human peripheral blood eosinophils from asthmatic subjects synthesize and release IL-9 protein, which is upregulated on stimulation with TNF-alpha and IL-1 beta. Conclusion: Human eosinophils express biologically active IL-9, which suggests that these cells may influence the recruitment and activation of effector cells linked to the pathogenesis of allergic disease. These observations provide further evidence for the role of eosinophils in regulating airway immune responses.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Magainin Pharmaceut Inc, Plymouth Meeting, PA USA	McGill University	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.		Gounni, Abdelilah Soussi/AAH-3456-2020	Gounni, Abdelilah/0000-0003-1265-6560; Soussi Gounni, Abdelilah/0000-0002-7282-0388				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BOCHNER BS, 1994, ANNU REV IMMUNOL, V12, P295; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Demoulin J B, 1998, Int Rev Immunol, V16, P345, DOI 10.3109/08830189809043001; Dong Q, 1999, EUR J IMMUNOL, V29, P2130, DOI 10.1002/(SICI)1521-4141(199907)29:07<2130::AID-IMMU2130>3.0.CO;2-S; FISCHKOFF SA, 1988, LEUKEMIA RES, V12, P679, DOI 10.1016/0145-2126(88)90103-8; GOSSET P, 1992, AM REV RESPIR DIS, V146, P768, DOI 10.1164/ajrccm/146.3.768; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KELLEHER K, 1991, BLOOD, V77, P1436; Lacy P, 1997, MEM I OSWALDO CRUZ, V92, P125, DOI 10.1590/S0074-02761997000800017; Lamkhioued B, 1996, ANN NY ACAD SCI, V796, P203, DOI 10.1111/j.1749-6632.1996.tb32582.x; Levitt RC, 1999, J ALLERGY CLIN IMMUN, V103, pS485, DOI 10.1016/S0091-6749(99)70165-X; Louahed J, 1996, J IMMUNOL, V156, P3704; LUKACS NW, 1995, AM J RESP CELL MOL, V13, P1; Lukacs NW, 1996, J LEUKOCYTE BIOL, V59, P13, DOI 10.1002/jlb.59.1.13; McLane MP, 1998, AM J RESP CELL MOL, V19, P713, DOI 10.1165/ajrcmb.19.5.3457; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; RENAULD JC, 1990, J IMMUNOL, V144, P4235; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; SCHWEIZER RC, 1994, BLOOD, V83, P3697; Shimbara A, 2000, J ALLERGY CLIN IMMUN, V105, P108, DOI 10.1016/S0091-6749(00)90185-4; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62	26	56	57	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					460	466		10.1067/mai.2000.109172	http://dx.doi.org/10.1067/mai.2000.109172			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984364				2022-12-18	WOS:000089471900007
J	Wiesch, DG; Meyers, DA; Bleecker, ER				Wiesch, DG; Meyers, DA; Bleecker, ER			Genetics of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; allergy; bronchial hyperresponsiveness; linkage; candidate genes; smoking; diet; viral respiratory infections; gene-environment interaction	TOTAL SERUM IGE; RESPIRATORY SYNCYTIAL VIRUS; GENOME-WIDE SEARCH; BRONCHIAL HYPERRESPONSIVENESS; AIRWAY RESPONSIVENESS; UNDERLYING ASTHMA; DIETARY-SODIUM; EARLY INFANCY; LINKAGE; INFECTION	Asthma is a complex disease with a phenotype that has been clinically difficult to define. Associated phenotypes including bronchial hyperresponsiveness and atopy have provided useful objective alternatives in genetic and epidemiologic studies. Although asthma genes have not yet been identified, much progress has been made toward this goal. Genetic studies indicate that multiple genes are involved in the pathogenesis of this disease, and chromosomal regions likely to harbor asthma susceptibility genes have been replicated in several studies. Environmental factors, including smoking, diet, and viral respiratory infections, have also been implicated in the etiology of asthma. Directly linking these exposures as causes of asthma, however, has also proved difficult, Furthermore, interaction between susceptibility, genes and environmental factors is probable and is a challenge currently being pursued by investigators worldwide. Understanding the fundamental gene-environmental interactions in the development of asthma should lead to earlier identification of susceptible individuals and more effective approaches for disease prevention.	Univ Maryland, Ctr Genet Asthma & Complex Dis, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Bleecker, ER (corresponding author), Univ Maryland, Ctr Genet Asthma & Complex Dis, 108 N Greene St,Suite 119, Baltimore, MD 21201 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL049602, R01HL048341] Funding Source: NIH RePORTER; NHLBI NIH HHS [U01 HL/AI49602, R01-HL48341] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS PF, 1995, VITAL HLTH STAT, P10; ADERELE W I, 1985, African Journal of Medicine and Medical Sciences, V14, P115; AKINKUGBE FM, 1989, J TROP PEDIATRICS, V33, P337; AMELUNG PJ, 1992, CLIN EXP ALLERGY, V22, P1077, DOI 10.1111/j.1365-2222.1992.tb00133.x; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; BLEECKER ER, 1995, CLIN EXP ALLERGY, V25, P84, DOI 10.1111/j.1365-2222.1995.tb00430.x; BRITTON J, 1994, THORAX, V49, P875, DOI 10.1136/thx.49.9.875; BURNEY PGJ, 1986, LANCET, V2, P323; BURNEY PGJ, 1989, THORAX, V44, P36, DOI 10.1136/thx.44.1.36; BUSSE WW, 1992, CHEST, V101, pS385, DOI 10.1378/chest.101.6_Supplement.385S; COOKSON WOCM, 1989, LANCET, V1, P1292; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Dewar JC, 1997, J ALLERGY CLIN IMMUN, V100, P261, DOI 10.1016/S0091-6749(97)70234-3; Drazen J, 1998, AM J RESP CRIT CARE, V157, pS233, DOI 10.1164/ajrccm.157.6.mar-5; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; GERN JE, 1996, GENETICS ASTHMA, P39; HALL CB, 1984, J PEDIATR-US, V105, P358, DOI 10.1016/S0022-3476(84)80005-0; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129, DOI 10.1164/ajrccm/145.5.1129; HENRY RL, 1983, ARCH DIS CHILD, V58, P713, DOI 10.1136/adc.58.9.713; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; HIGGINS M, 1975, J CHRON DIS, V28, P239, DOI 10.1016/0021-9681(75)90053-3; Hodge L, 1996, MED J AUSTRALIA, V164, P137, DOI 10.5694/j.1326-5377.1996.tb122010.x; Holgate ST, 1997, NAT GENET, V15, P227, DOI 10.1038/ng0397-227; HOPP RJ, 1988, ANN ALLERGY, V61, P184; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; JAVAID A, 1988, BRIT MED J, V297, P454, DOI 10.1136/bmj.297.6646.454; KAUFFMANN F, 1991, CLIN EXP ALLERGY, V21, P669, DOI 10.1111/j.1365-2222.1991.tb03194.x; Khoury M, 1993, FUNDAMENTALS GENETIC; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LIN H, 1993, J IMMUNOL, V151, P4562; LONGO G, 1987, AM J DIS CHILD, V141, P331, DOI 10.1001/archpedi.1987.04460030109037; LUOMA R, 1982, SCAND J SOC MED, V10, P49, DOI 10.1177/140349488201000203; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARTIN AJ, 1981, MED J AUSTRALIA, V2, P470, DOI 10.5694/j.1326-5377.1981.tb112942.x; MARTINEZ F, 1993, AM J HUM GENET, V55, P555; MARTINEZ FD, 1995, RESP SCI, V14, P2; MCCONNOCHIE KM, 1988, AM J PUBLIC HEALTH, V78, P34, DOI 10.2105/AJPH.78.1.34; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MIEDEMA I, 1993, AM J EPIDEMIOL, V138, P37, DOI 10.1093/oxfordjournals.aje.a116775; MISKELLY FG, 1988, ARCH DIS CHILD, V63, P388, DOI 10.1136/adc.63.4.388; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; MORGAN K, 1975, OCCUPATIONAL LUNG DI; *NAT HEART LUNG BL, 1995, PUBL NAT HEART LUNG; *NAT HEART LUNG BL, 1991, PUBL NAT HEART LUNG; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; OLUSI SO, 1979, CLIN CHIM ACTA, V92, P161, DOI 10.1016/0009-8981(79)90110-4; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734, DOI 10.1164/ajrccm.157.6.9606088; PEAT JK, 1992, EUR RESPIR J, V5, P921; PISTELLI R, 1993, EUR RESPIR J, V6, P517; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; SCHWARTZ J, 1994, EUR RESPIR J, V7, P1821, DOI 10.1183/09031936.94.07101821; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SIBBALD B, 1979, THORAX, V34, P332, DOI 10.1136/thx.34.3.332; SPARROW D, 1991, AM REV RESPIR DIS, V144, P722, DOI 10.1164/ajrccm/144.3_Pt_1.722; STINE OC, 1998, AM J RESP CRIT CARE, V157, pA855; TASHKIN DP, 1992, AM REV RESPIR DIS, V145, P301, DOI 10.1164/ajrccm/145.2_Pt_1.301; TOWNLEY RG, 1986, J ALLERGY CLIN IMMUN, V77, P101, DOI 10.1016/0091-6749(86)90330-1; U.S. Department of Health and Human Services, 1990, REP SURG GEN HLTH BE; WIESCH DG, 1998, ALLERGY PRINCIPLES P, P799; WIESCH DG, 1996, GENETICS ASTHMA, P421; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; XU J, 1995, AM J HUM GENET, V57, P425; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4; [No title captured]	71	56	59	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					895	901		10.1016/S0091-6749(99)70065-5	http://dx.doi.org/10.1016/S0091-6749(99)70065-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550729				2022-12-18	WOS:000083778400007
J	Midoro-Horiuti, T; Goldblum, RM; Kurosky, A; Wood, TG; Schein, CH; Brooks, EG				Midoro-Horiuti, T; Goldblum, RM; Kurosky, A; Wood, TG; Schein, CH; Brooks, EG			Molecular cloning of the mountain cedar (Juniperus ashei) pollen major allergen, Jun a 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; Chamaecyparis obtusa; Cha o 1; Cry j 1; Cryptomeria japonica; Jun a 1; Juniperus ashei; Juniperus sabinoides; mountain cedar; pollinosis	CRYPTOMERIA-JAPONICA POLLEN; CRY-J-I; CUPRESSUS-SEMPERVIRENS; IGE ANTIBODIES; PURIFICATION; POLLINOSIS; RECEPTOR; EPITOPES; CRY-J-1; CDNA	Background: Cedar pollens cause allergic disease in diverse geographic areas. We have recently purified and characterized the major mountain cedar (Juniperus ashei) pollen allergen, Jun a 1. Objective: A full-length complementary DNA for Jun a 1 was cloned and sequenced, and the recombinant protein was expressed, Methods: Messenger RNA from mountain cedar pollen was purified and Jun a 1 sequences were established with use of reverse transcriptase-PCR and primers based on the N-terminal amino acid sequence of Jun a 1 and the homologous protein Cry j 1. Portions of the nucleotide sequence were confirmed by comparison with N-terminal amino acid sequencing of the intact tryptic fragments of the purified native protein. Recombinant Jun a 1 was cloned into pET 30, expressed in BL21, and purified by HPLC, and its allergenicity mas analyzed by Western blotting with patient sera. Results: Jun a 1 possesses a high level of amino acid sequence homology with Cha o 1 and Cry j 1, the major allergens of Japanese cypress and Japanese cedar. The amino acid sequence of a region with putative pectate lyase activity mas identical to that of Cry j 1 and Cha o 1. Jun a 1 contained 2 potential N-glycosylation sites that mere distinct from those found in Cry j 1, The IgE from patient sera bound recombinant Jun a 1 in Western blot analysis. Conclusion: The high degree of homology of Jun a 1 with Cha o 1 and Cry j 1 may explain the cross-reactivity of conifer pollens. Differences in N-glycosylation suggest little overlap of glycopeptide epitopes.	Univ Texas, Med Branch, Dept Pediat, Child Hlth Res Ctr, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Brooks, EG (corresponding author), Univ Texas, Med Branch, Dept Pediat, Child Hlth Res Ctr, 301 Univ Blvd, Galveston, TX 77555 USA.		Wood, Thomas/GWZ-2481-2022; Wood, Thomas/B-6172-2012; Schein, Catherine H/A-1426-2012; Midoro-Horiuti, Terumi M/AIE-7522-2022	Wood, Thomas/0000-0001-8962-8571; Midoro-Horiuti, Terumi/0000-0002-0527-3644; Schein, Catherine/0000-0002-8290-2109	NIEHS NIH HHS [P30 ES006676] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAKOS MA, 1994, MOL IMMUNOL, V31, P165, DOI 10.1016/0161-5890(94)90088-4; Brooks EG, 1999, BLOOD, V93, P242, DOI 10.1182/blood.V93.1.242.401k27_242_250; FELLER DC, 1991, NATURE, V349, P720, DOI 10.1038/349720a0; FORD SA, 1991, INT ARCH ALLER A IMM, V95, P178, DOI 10.1159/000235426; GOETZ DW, 1995, ANN ALLERG ASTHMA IM, V75, P256; Ikagawa S, 1996, J ALLERGY CLIN IMMUN, V97, P53, DOI 10.1016/S0091-6749(96)70283-X; Ishikawa T, 1997, INT ARCH ALLERGY IMM, V113, P255, DOI 10.1159/000237563; LAKSHMAN DK, 1992, ANAL BIOCHEM, V203, P269, DOI 10.1016/0003-2697(92)90312-U; Malone DC, 1997, J ALLERGY CLIN IMMUN, V99, P22, DOI 10.1016/S0091-6749(97)81040-8; Mari A, 1996, J ALLERGY CLIN IMMUN, V98, P21, DOI 10.1016/S0091-6749(96)70222-1; MCCORMICK S, 1991, TRENDS GENET, V7, P298, DOI 10.1016/0168-9525(91)90312-E; Midoro-Horiuti T, 1992, Acta Paediatr Jpn, V34, P501; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PANZANI R, 1986, ANN ALLERGY, V56, P460; REID MJ, 1992, J ALLERGY CLIN IMMUN, V89, P593, DOI 10.1016/0091-6749(92)90327-X; Sato K, 1997, ANN ALLERG ASTHMA IM, V79, P57, DOI 10.1016/S1081-1206(10)63085-2; SONE T, 1994, BIOCHEM BIOPH RES CO, V199, P619, DOI 10.1006/bbrc.1994.1273; Sone T, 1998, J IMMUNOL, V161, P448; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Suzuki M, 1996, MOL IMMUNOL, V33, P451, DOI 10.1016/0161-5890(95)00147-6; TAKAHASHI Y, 1993, ALLERGY, V48, P94, DOI 10.1111/j.1398-9995.1993.tb00692.x; TANIAI M, 1993, MOL IMMUNOL, V30, P183; TANIGUCHI Y, 1995, ALLERGY, V50, P90, DOI 10.1111/j.1398-9995.1995.tb02489.x	23	56	59	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				613	617		10.1016/S0091-6749(99)70332-5	http://dx.doi.org/10.1016/S0091-6749(99)70332-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482836				2022-12-18	WOS:000082870000024
J	Sussman, GL; Mason, J; Compton, D; Stewart, J; Ricard, N				Sussman, GL; Mason, J; Compton, D; Stewart, J; Ricard, N			The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						seasonal allergic rhinitis; fexofenadine hydrochloride; pseudoephedrine hydrochloride; efficacy; antihistamine; combination therapy; health economics; work productivity; activity impairment	H-1-RECEPTOR ANTAGONISTS; TERFENADINE; HYDROCHLORIDE; TRIAL	Background: Antihistamines effectively treat seasonal allergic rhinitis (SAR), although the ability of this drug class to reduce nasal congestion is limited. Nasal decongestants effectively treat nasal congestion but not the histamine-related components of SAR. Therefore antihistamine/nasal decongestant combinations are commonly used to maximize the treatment of SAR, Fexofenadine HCl is a nonsedating, long-acting H-1 receptor antagonist that provides fast and effective relief from SAR. It is well tolerated, with no sedative or cardiotoxic effects. Objective: We sought to compare the efficacy and safety of a fexofenadine HCl/pseudoephedrine HCl combination with that of each individual component in the treatment of ragweed allergy, Methods: In this Canadian multicenter, double-blind, parallel-group study, 651 patients allergic to ragweed were randomized to receive 60 mg of fexofenadine HCl twice daily, 120 mg of sustained-release pseudoephedrine HCl twice daily, or a combination of the 2 drugs (60 mg of fexofenadine HCl/120 mg of sustained-release pseudoephedrine HCl) twice daily for 2 weeks, Efficacy analyses were based on symptom severity. In addition, a health economic assessment was performed, Results: Combination therapy was significantly more effective than pseudoephedrine alone in improving primarily histamine-mediated symptoms (sneezing; rhinorrhea; itchy nose, palate, and/or throat; and itchy, watery, red ea es) and significantly more effective than fexofenadine alone in reducing nasal congestion. Combination therapy also produced greater improvements in daily activities and work productivity compared with the individual components. No serious adverse events were reported in any of the treatment groups. In addition, no clinically significant changes in 12-lead electrocardiogram parameters, vital signs, or clinical laboratory values were observed. Conclusion: Combination therapy is more effective than fexofenadine alone or pseudoephedrine alone in relieving the full spectrum of SAR symptoms tie, both the primarily histamine-related symptoms and nasal congestion).	St Michaels Hosp, Toronto, ON M4V 1R2, Canada; Hoechst Marion Roussel, Kansas City, MO USA; Hoechst Marion Roussel, Laval, PQ, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Sussman, GL (corresponding author), St Michaels Hosp, 202 St Clair Ave W, Toronto, ON M4V 1R2, Canada.							Abdelaziz MM, 1998, J ALLERGY CLIN IMMUN, V101, P410, DOI 10.1016/S0091-6749(98)70256-8; Bernstein DI, 1997, ANN ALLERG ASTHMA IM, V79, P443, DOI 10.1016/S1081-1206(10)63041-4; CLISSOLD SP, 1989, DRUGS, V37, P42, DOI 10.2165/00003495-198937010-00003; Day JH, 1997, ANN ALLERG ASTHMA IM, V79, P533, DOI 10.1016/S1081-1206(10)63062-1; DOCKHORN RJ, 1995, ANN ALLERGY, V55, P393; DRUCE HM, 1988, JAMA-J AM MED ASSOC, V259, P260, DOI 10.1001/jama.259.2.260; GARTEIZ DA, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1185; GRANT R, 1992, GERIATRICS, V47, P12; *HM ROUSS INC, 1996, ALL FEX HYDR CAPS 60; HOWARTH PH, 1984, THORAX, V39, P668, DOI 10.1136/thx.39.9.668; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; KEMP JP, 1985, ANN ALLERGY, V54, P502; Lippert Christina, 1995, Pharmaceutical Research (New York), V12, pS390; Markham A, 1998, DRUGS, V55, P269, DOI 10.2165/00003495-199855020-00012; MELZER EO, 1990, J OCCUP MED, V32, P327; PAOLIERI F, 1995, ALLERGY S26, V50, P77; Passalacqua G, 1996, ALLERGY, V51, P666; Reilly MC, 1996, CLIN DRUG INVEST, V11, P278, DOI 10.2165/00044011-199611050-00004; REYNOLDS JEF, 1996, MARTINDALES EXTRA PH, P1588; RICKETTI AJ, 1985, ALLERGIC DISEASES DI, P207; RUSSELL TL, 1996, ANN ALLERG ASTHMA IM, V76, P96; SIMONS FER, 1989, J ALLERGY CLIN IMMUN, V84, P845, DOI 10.1016/0091-6749(89)90377-1; Simons FER, 1997, ANN ALLERG ASTHMA IM, V79, P530, DOI 10.1016/S1081-1206(10)63061-X; STORMS W, 1997, J ALLERGY CLIN IMMUN, V99, P5820; STORMS WW, 1989, J ALLERGY CLIN IMMUN, V83, P1083, DOI 10.1016/0091-6749(89)90450-8; TARNASKY PR, 1990, J FAM PRACTICE, V30, P71; Tinkeliman D., 1996, Journal of Allergy and Clinical Immunology, V97, P435, DOI 10.1016/S0091-6749(96)81227-9; WOOSLEY RL, 1993, JAMA-J AM MED ASSOC, V269, P1532, DOI 10.1001/jama.269.12.1532	28	56	60	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					100	106		10.1016/S0091-6749(99)70120-X	http://dx.doi.org/10.1016/S0091-6749(99)70120-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400846				2022-12-18	WOS:000081738900015
J	Spahn, JD; Leung, DYM; Chan, MTS; Szefler, SJ; Gelfand, EW				Spahn, JD; Leung, DYM; Chan, MTS; Szefler, SJ; Gelfand, EW			Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						glucocorticoids; inflammation; intravenous immunoglobulin; glucocorticoid-insensitive asthma; steroid-resistant asthma	STEROID-RESISTANT ASTHMA; RECEPTOR-BINDING AFFINITY; T-CELL PROLIFERATION; INFLAMMATION; EXPRESSION	Background: Intravenous immunoglobulin (IVIG) has been used as an oral glucocorticoid (GC)-sparing agent in patients with steroid-dependent asthma, Despite its use, little is known regarding its mechanism of action. Objective: We sought to determine whether the GC-sparing effects of MG in severe asthma are related to improved GC receptor (GCR)-binding affinity and subsequent enhanced GC sensitivity, Methods: In an open-label study, 11 steroid-dependent asthmatic subjects (6 GC-insensitive, 5 CC-sensitive) received monthly infusions of IVIG (2 g/kg) for 6 months, Peak expiratory flow rates and oral GC dose were recorded daily, and spirometry was performed monthly. Blood was drawn for lymphocyte stimulation assays and GCR assays at baseline and after 3 and 6 months of therapy. Lymphocytes were stimulated ex vivo with PHA in the presence and absence of IVIG and increasing concentrations of dexamethasone (DEX). Results: MG resulted in significant reductions in oral GC dose (P <.02), number of GC bursts (P =.033), and hospitalizations (P =.001) after 6 months of IVIG, Those with GC-insensitive asthma responded equally well to IVIG as those with GC-sensitive asthma. Associated with the improved clinical efficacy, IVIG acted synergistically with DEX in suppressing lymphocyte activation as measured by a shift in the DEX dose-response curve by I log-fold (P =.03), IVIG therapy was also associated with significantly improved GCR-binding affinity (P =.01), Conclusions: IVIG resulted in significant reductions in oral GC requirements and hospitalizations in a group of patients with severe asthma, with MG being as effective in patients with CC-insensitive asthma as in patients with GC-sensitive asthma, IVIG therapy acted synergistically with DEX in suppressing lymphocyte activation and significantly improved GCR-binding affinity after 3 and 6 months of therapy.	Natl Jewish Med & Res Ctr, Div Clin Pharmacol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Allergy Clin Immunol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Ira J & Jacqueline Nelmark Lab Clin Pharmacol Ped, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	National Jewish Health; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Spahn, JD (corresponding author), Natl Jewish Med & Res Ctr, Div Clin Pharmacol, 1400 Jackson St K-926, Denver, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037260, R37HL037260, P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI041022] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36577, HL-37260] Funding Source: Medline; NIAID NIH HHS [AI-41022] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADCOCK IM, 1995, J IMMUNOL, V154, P3500; ALVAREZ J, 1992, J ALLERGY CLIN IMMUN, V89, P714, DOI 10.1016/0091-6749(92)90379-G; AMRAN D, 1994, CLIN IMMUNOL IMMUNOP, V73, P180, DOI 10.1006/clin.1994.1186; CARMICHAEL J, 1981, BRIT MED J, V282, P1419, DOI 10.1136/bmj.282.6274.1419; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016, DOI 10.1164/ajrccm/144.5.1016; CRABTREE GR, 1981, METHODS HEMATOLOGY, V2, P252; GELFAND EW, 1996, CLIN EXP IMMUNOL, P10461; JAKOBSSON T, 1994, ALLERGY, V49, P413, DOI 10.1111/j.1398-9995.1994.tb00833.x; KAM JC, 1993, J IMMUNOL, V151, P3460; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; Lee T, 1996, AM J RESP CRIT CARE, V154, pS1, DOI 10.1164/ajrccm/154.2_Pt_2.S1; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; LEUNG DYM, 1987, J CLIN INVEST, V79, P468, DOI 10.1172/JCI112835; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; MAZER BD, 1991, J ALLERGY CLIN IMMUN, V87, P976, DOI 10.1016/0091-6749(91)90420-S; Salmun L. M., 1997, Journal of Allergy and Clinical Immunology, V99, pS268; SCHWARTZ HJ, 1968, ANN INTERN MED, V69, P493, DOI 10.7326/0003-4819-69-3-493; SERTL K, 1990, AM REV RESPIR DIS, V141, pS1; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; SPAHN JD, 1995, AM J RESP CRIT CARE, V151, P1709, DOI 10.1164/ajrccm.151.6.7767511; Spahn JD, 1997, J ASTHMA, V34, P177, DOI 10.3109/02770909709068188; Spahn JD, 1996, J IMMUNOL, V157, P2654; SPAHN JD, 1995, SEVERE ASTHMA PATHOG, P497; SZEFLER SJ, 1991, J ALLERGY CLIN IMMUN, V88, P147, DOI 10.1016/0091-6749(91)90323-G; Vrugt B, 1997, THORAX, V52, P662, DOI 10.1136/thx.52.7.662	26	56	61	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				421	426		10.1016/S0091-6749(99)70466-5	http://dx.doi.org/10.1016/S0091-6749(99)70466-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069875	Bronze			2022-12-18	WOS:000079175700010
J	Toogood, JH				Toogood, JH			Side effects of inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; inhaled steroids; side effects; adrenocortical suppression; cataract; glaucoma; growth; osteoporosis; infection; oropharynx complications; skin atrophy	BONE-MINERAL DENSITY; POSTERIOR SUBCAPSULAR CATARACTS; DECREASES SERUM OSTEOCALCIN; ACUTE ADRENAL INSUFFICIENCY; LONG-TERM TREATMENT; ASTHMATIC-CHILDREN; BECLOMETHASONE DIPROPIONATE; ORAL PREDNISOLONE; FLUTICASONE PROPIONATE; COLLAGEN TURNOVER	Inhaled corticosteroid (ICS) therapy carries less risk of complicating drug- or disease-related morbidity and mortality than that associated with other antiasthmatic drugs such as prednisone, theophylline, or beta(2)-agonist bronchodilators. Serious side effects are uncommon, but the risk increases with the daily dose. The degree of risk is most effectively minimized by ensuring each patient uses the smallest daily dose sufficient to maintain optimum control of their disease. Any patient in whom ocular symptoms develop while receiving ICS therapy should promptly be evaluated by an eye specialist. Growth, velocity is commonly reduced during ICS therapy and should he monitored routinely. Bone metabolism may be affected by ion or medium doses of ICS, but there is no evidence such doses cause osteoporosis or fracture, High-dose therapy may. reduce hone density and increase the risk of fracture, particularly if other risk factors for osteoporosis are present. Research is needed to better define the impact of ICS therapy in children on height and peak hone density. attained at maturity, Also, there is a need for practice guidelines specifically applicable to the prevention of bone loss during ICS treatment.	Univ Western Ontario, London Hlth Sci Ctr, Allergy Clin, London, ON N6A 4G5, Canada	London Health Sciences Centre; Western University (University of Western Ontario)	Toogood, JH (corresponding author), Univ Western Ontario, London Hlth Sci Ctr, Allergy Clin, S Campus Victoria,800 Commissioners Rd E, London, ON N6A 4G5, Canada.							ABZUG MJ, 1993, J PEDIATR-US, V123, P577, DOI 10.1016/S0022-3476(05)80954-0; Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603; AGERTOFT L, 1993, ARCH DIS CHILD, V69, P130, DOI 10.1136/adc.69.1.130; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Agertoft L, 1998, AM J RESP CRIT CARE, V157, P178, DOI 10.1164/ajrccm.157.1.9707072; ALI NJ, 1991, THORAX, V46, P160, DOI 10.1136/thx.46.3.160; Allen DB, 1998, J PEDIATR-US, V132, P472, DOI 10.1016/S0022-3476(98)70023-X; ANDERSON CJ, 1980, J ALLERGY CLIN IMMUN, V65, P140, DOI 10.1016/0091-6749(80)90199-2; [Anonymous], 1996, Arthritis Rheum, V39, P1791; Autio P, 1996, AM J RESP CRIT CARE, V153, P1172, DOI 10.1164/ajrccm.153.3.8630563; BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; BARALDI E, 1994, EUR RESPIR J, V7, P710, DOI 10.1183/09031936.94.07040710; Birkebaek NH, 1995, ARCH DIS CHILD, V73, P524, DOI 10.1136/adc.73.6.524; Boot AM, 1997, PEDIATR PULM, V24, P379, DOI 10.1002/(SICI)1099-0496(199712)24:6<379::AID-PPUL1>3.0.CO;2-C; Bootsma GP, 1996, AM J RESP CRIT CARE, V153, P924, DOI 10.1164/ajrccm.153.3.8630574; BROWN PH, 1992, BRIT J CLIN PRACT, V46, P102; BROWN PH, 1991, RESP MED, V85, P501, DOI 10.1016/S0954-6111(06)80268-4; BUSUTTIL A, 1991, AM J FOREN MED PATH, V12, P36, DOI 10.1097/00000433-199103000-00006; CAPEWELL S, 1990, BRIT MED J, V300, P1548, DOI 10.1136/bmj.300.6739.1548; CARRELAL, 1996, PEDIATRICS, V97, P921; CHALKLEY SM, 1994, MED J AUSTRALIA, V160, P611, DOI 10.5694/j.1326-5377.1994.tb125866.x; Chylack LT, 1997, NEW ENGL J MED, V337, P46, DOI 10.1056/NEJM199707033370110; CROWLEY S, 1995, J PEDIATR-US, V126, P297, DOI 10.1016/S0022-3476(95)70566-X; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; CUMMING RG, IN PRESS DRUG SAFETY; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Dluhy RG, 1998, J ALLERGY CLIN IMMUN, V101, pS447, DOI 10.1016/S0091-6749(98)70157-5; Dolovich M, 1997, Curr Opin Pulm Med, V3, P177, DOI 10.1097/00063198-199705000-00001; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715, DOI 10.1164/ajrccm.151.6.7767512; Doull IJM, 1998, ARCH DIS CHILD, V78, P172, DOI 10.1136/adc.78.2.172; DREYER EB, 1993, NEW ENGL J MED, V329, P1822, DOI 10.1056/NEJM199312093292420; Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002; *FDA, 1991, FDA MED B, V3, P21; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; HALL GM, 1994, ARTHRITIS RHEUM, V37, P1499, DOI 10.1002/art.1780371014; HANANIA NA, 1995, J ALLERGY CLIN IMMUN, V96, P571, DOI 10.1016/S0091-6749(95)70254-7; HARTER J, 1993, AAAI NEWS NOTES ISSU, V2, P12; Heuck C, 1997, STEROIDS, V62, P659, DOI 10.1016/S0039-128X(97)00053-6; HODSMAN AB, 1991, J CLIN ENDOCR METAB, V72, P530, DOI 10.1210/jcem-72-3-530; HOLLMAN GA, 1988, PEDIATRICS, V81, P452; JENNINGS BH, 1991, EUR J CLIN PHARMACOL, V40, P77, DOI 10.1007/BF00315143; JENNINGS BH, 1990, ASSESSMENT SYSTEMIC; Josse R, 1996, CAN MED ASSOC J, V155, P1113; KALRA L, 1988, CHEST, V93, P739, DOI 10.1378/chest.93.4.739; KINBERG KA, 1994, J ALLERGY CLIN IMMUN, V94, P490, DOI 10.1016/0091-6749(94)90205-4; KONIG P, 1993, J PEDIATR-US, V122, P219, DOI 10.1016/S0022-3476(06)80116-2; KONIG P, 1996, EUR RESP J S23, V9, P294; Laroche M, 1997, REV RHUM, V64, P267; LITTLEWOOD JM, 1988, LANCET, V1, P115; Luengo M, 1997, EUR RESPIR J, V10, P2110, DOI 10.1183/09031936.97.10092110; LUENGO M, 1991, EUR RESPIR J, V4, P441; LUKERT BP, 1992, J BONE MINER RES, V7, P1063; MARKOV AE, 1992, J BONE MINER RES, V7, pS97; National Library of Medicine, 1997, NATL 600, P1; Nursoy MA, 1997, PEDIATR INFECT DIS J, V16, P74, DOI 10.1097/00006454-199701000-00017; PACKE GE, 1992, THORAX, V47, P414, DOI 10.1136/thx.47.6.414; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pedersen S, 1997, ALLERGY, V52, P1, DOI 10.1111/j.1398-9995.1997.tb05047.x; POUW EM, 1991, BRIT MED J, V302, P627, DOI 10.1136/bmj.302.6777.627; Price JF, 1997, PEDIATR PULM, V24, P178; PUOLIJOKI H, 1992, BONE, V13, P285, DOI 10.1016/8756-3282(92)90072-5; REID DM, 1986, BMJ-BRIT MED J, V293, P1463, DOI 10.1136/bmj.293.6560.1463; Reid IR, 1997, NEW ENGL J MED, V337, P420, DOI 10.1056/NEJM199708073370609; ROOKLIN AR, 1979, J ALLERGY CLIN IMMUN, V63, P383, DOI 10.1016/0091-6749(79)90210-0; Roy A, 1996, EUR RESPIR J, V9, P226, DOI 10.1183/09031936.96.09020226; Saha MT, 1997, ACTA PAEDIATR, V86, P138, DOI 10.1111/j.1651-2227.1997.tb08854.x; Sarnstrand B, 1985, GLUCOCORTICOSTEROIDS, P157; SHAIKH WA, 1992, ALLERGY, V47, P327, DOI 10.1111/j.1398-9995.1992.tb02063.x; SHUNSHIN GA, 1989, BRIT J OPHTHALMOL, V73, P522, DOI 10.1136/bjo.73.7.522; Silverstein MD, 1997, J ALLERGY CLIN IMMUN, V99, P466, DOI 10.1016/S0091-6749(97)70072-1; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; SIMONS FER, 1993, LANCET, V342, P776, DOI 10.1016/0140-6736(93)91541-S; Sorva R, 1996, ACTA PAEDIATR, V85, P1176; SORVA R, 1992, J ALLERGY CLIN IMMUN, V90, P808, DOI 10.1016/0091-6749(92)90106-C; STEAD R J, 1990, Thorax, V45, P792; THOMAS BC, 1994, ACTA PAEDIATR, V83, P196, DOI 10.1111/j.1651-2227.1994.tb13050.x; Todd G, 1996, LANCET, V348, P27, DOI 10.1016/S0140-6736(96)03339-9; TOOGOOD J, 1995, J ALLERGY CLIN IMMUN, V95, P310; TOOGOOD J H, 1989, Clinical and Investigative Medicine, V12, pB5; TOOGOOD JH, 1990, AM REV RESPIR DIS, V141, pS89; TOOGOOD JH, 1993, J ALLERGY CLIN IMMUN, V91, P571, DOI 10.1016/0091-6749(93)90263-F; TOOGOOD JH, 1991, J ALLERGY CLIN IMMUN, V88, P572, DOI 10.1016/0091-6749(91)90150-M; TOOGOOD JH, 1984, EUR J RESPIR DIS, V65, P35; TOOGOOD JH, 1995, J ALLERGY CLIN IMMUN, V96, P157, DOI 10.1016/S0091-6749(95)70003-X; Toogood JH, 1997, J ALLERGY CLIN IMMUN, V99, P186, DOI 10.1016/S0091-6749(97)70094-0; VanSchoor J, 1997, CLIN EXP ALLERGY, V27, P192, DOI 10.1046/j.1365-2222.1997.d01-490.x; VanSchoor J, 1996, J ALLERGY CLIN IMMUN, V97, P113, DOI 10.1016/S0091-6749(96)70289-0; WALES JKH, 1991, LANCET, V338, P1535, DOI 10.1016/0140-6736(91)92362-6; Wang WQ, 1998, J ALLERGY CLIN IMMUN, V101, P445, DOI 10.1016/S0091-6749(98)70351-3; Whitaker K, 1996, LANCET, V348, P63, DOI 10.1016/S0140-6736(05)64394-2; Wolthers OD, 1997, PEDIATR RES, V41, P44, DOI 10.1203/00006450-199701000-00007; WOLTHERS OD, 1993, PEDIATR PULM, V16, P341, DOI 10.1002/ppul.1950160604; WONG J, 1992, BRIT MED J, V304, P1415, DOI 10.1136/bmj.304.6839.1415-a; Zimmerman B, 1998, J ALLERGY CLIN IMMUN, V101, P425, DOI 10.1016/S0091-6749(98)70260-X; ZWAAN CM, 1992, LANCET, V340, P1289, DOI 10.1016/0140-6736(92)92991-N	96	56	60	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					705	713		10.1016/S0091-6749(98)70007-7	http://dx.doi.org/10.1016/S0091-6749(98)70007-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819285	Bronze			2022-12-18	WOS:000077033400001
J	Zenner, HP; Baumgarten, C; Rasp, G; Fuchs, T; Kunkel, G; Hauswald, B; Ring, J; Effendy, I; Behrendt, W; Frosch, PJ; Przybilla, B; Brunner, FX; Merk, HF; Kapp, A; Schnitker, J; Wolf, H				Zenner, HP; Baumgarten, C; Rasp, G; Fuchs, T; Kunkel, G; Hauswald, B; Ring, J; Effendy, I; Behrendt, W; Frosch, PJ; Przybilla, B; Brunner, FX; Merk, HF; Kapp, A; Schnitker, J; Wolf, H			Short-term immunotherapy: A prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						short-term immunotherapy; specific immunotherapy; allergic rhinitis; grass pollen; rye pollen; skin prick rest; specific IgE; specific IgG4	DERMATOPHAGOIDES-PTERONYSSINUS; CLINICAL-RESPONSE; IGG SUBCLASSES; HAY-FEVER; EXTRACTS; EFFICACY; ASTHMA; TESTS; BIRCH; MITE	Background: Short-term immunotherapy (STI) can be beneficial for patients who are noncompliant,vith long-term specific immunotherapy. Objective: The efficacy and tolerance of STI with seven pre-seasonal injections of molecular standardized allergens from grass and rye pollen has been investigated in a double-blind, placebo-controlled multicenter study with 87 patients at 12 German University hospitals. Methods: Symptoms of the eyes, nose, and bronchi and use of symptomatic drugs were documented daily in diaries by patients with allergic rhinitis to grass and/or rye pollen and without bronchial asthma. Patients were monitored by skin prick test titration and measurement of levels of specific IgE and IgG4. Results: The median nasal score for the 10 weeks with the strongest symptoms during the gross pollen season was significantly lower (p = 0.014) with 35.0 for STI (n = 41) versus 69.0 for placebo (n = 40); the overall symptom score was 54.0 for STI versus 97.5 for placebo (p = 0.020). Only STI-treated patients exposed to less than 40 pollen grains per cubic meter per week showed a significantly lower nasal symptom score of 39.0 versus 75.0 for placebo (p = 0.006); these patients also had fewer nasal symptoms and less use of topical nasal drugs (p < 0.001). The threshold dose in skin prick tests was significantly higher, being 9.06 histamine equivalent for skin prick test (HEP) for STI-treated patients who received the maximum dose (n = 22) versus 4.33 HEP for placebo (p = 0.005). Specific IgE levels were significantly higher, being 55.9 SU/ml for STI versus 393 SU/ml for placebo after seven injections (p = 0.006) and level of specific IgG4 was 5.36% for STI versus 1.28% for placebo (p < 0.001). No severe systemic reactions were observed. Conclusion: Sn with seven preseasonal injections with molecular standardized allergens is effective and well tolerated.	SCHERAX ARZNEIMITTEL GMBH,D-22589 HAMBURG,GERMANY; UNIV TUBINGEN,HNO KLIN,TUBINGEN,GERMANY; FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,ABT KLIN IMMUNOL & ASTHMAPOLIKLIN,D-1000 BERLIN,GERMANY; MAXIMILIANS UNIV,KLINIKUM GROSSHADERN,HNO KLIN & POLIKLIN,MUNICH,GERMANY; UNIV GOTTINGEN,HAUTKLIN,D-3400 GOTTINGEN,GERMANY; MED ACAD CARL GUSTAV CARUS,HNO KLIN,DRESDEN,GERMANY; TECH UNIV MUNICH,DERMATOL KLIN & POLIKLIN,D-8000 MUNICH,GERMANY; KLINIKUM PHILIPPS UNIV,MED ZENTRUM HAUTKRANKHEITEN,MARBURG,GERMANY; UNIV LEIPZIG,HNO KLIN,D-7010 LEIPZIG,GERMANY; UNIV WITTEN HERDECKE,WITTEN,GERMANY; STADT KLINIKEN,HAUTKLIN,DORTMUND,GERMANY; UNIV MUNICH,DERMATOL KLIN & POLIKLIN,D-80539 MUNICH,GERMANY; UNIV WURZBURG,HNO KLIN & POLIKLIN,WURZBURG,GERMANY; RHEIN WESTFAL TH AACHEN,HAUTKLIN,D-5100 AACHEN,GERMANY; HANNOVER MED SCH,DERMATOL KLIN & POLIKLIN,HANNOVER,GERMANY; INST ANGEW STAT,BIELEFELD,GERMANY	Eberhard Karls University of Tubingen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munich; University of Gottingen; Technische Universitat Dresden; Technical University of Munich; Philipps University Marburg; Leipzig University; Witten Herdecke University; University of Munich; University of Wurzburg; RWTH Aachen University; Hannover Medical School			Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152; Kapp, Alexander/0000-0002-1748-6276; Rasp, Gerd/0000-0003-4639-4044				AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; BIRKNER T, 1990, ALLERGY, V45, P418, DOI 10.1111/j.1398-9995.1990.tb01092.x; BRUNET C, 1992, J ALLERGY CLIN IMMUN, V89, P87, DOI 10.1016/S0091-6749(05)80044-2; DJURUP R, 1985, ALLERGY, V40, P469, DOI 10.1111/j.1398-9995.1985.tb00253.x; EEC note for guidance, 1990, PHARMACOL TOXICOL, V67, P361; FLING JA, 1989, J ALLERGY CLIN IMMUN, V83, P101, DOI 10.1016/0091-6749(89)90483-1; GJESING B, 1985, J ALLERGY CLIN IMMUN, V75, P258, DOI 10.1016/0091-6749(85)90055-7; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HEDLIN G, 1990, CLIN EXP ALLERGY, V20, P491, DOI 10.1111/j.1365-2222.1990.tb03141.x; LEHMACHER W, 1991, BIOMETRICS, V47, P511, DOI 10.2307/2532142; MALLING HJ, 1993, ALLERGY, V48, P3; MCHUGH SM, 1990, J ALLERGY CLIN IMMUN, V86, P521, DOI 10.1016/S0091-6749(05)80208-8; NAKAGAWA T, 1991, CLIN EXP ALLERGY, V21, P289, DOI 10.1111/j.1365-2222.1991.tb01660.x; NUCHELPETERSEN B, 1988, ALLERGY, V43, P353; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; OSTERBALLE O, 1982, ALLERGY, V37, P379, DOI 10.1111/j.1398-9995.1982.tb02316.x; PARKER WA, 1989, J ALLERGY CLIN IMMUN, V84, P667, DOI 10.1016/0091-6749(89)90294-7; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; TURKELTAUB PC, 1990, ALLERGY, V45, P528, DOI 10.1111/j.1398-9995.1990.tb00529.x; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; WAHN U, 1988, J ALLERGY CLIN IMMUN, V82, P360, DOI 10.1016/0091-6749(88)90007-3; WIHL JA, 1988, ALLERGY, V43, P363, DOI 10.1111/j.1398-9995.1988.tb00430.x	23	56	58	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1997	100	1					23	29		10.1016/S0091-6749(97)70190-8	http://dx.doi.org/10.1016/S0091-6749(97)70190-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XP428	9257783				2022-12-18	WOS:A1997XP42800005
J	Hoffmann, A; Vieths, S; Haustein, D				Hoffmann, A; Vieths, S; Haustein, D			Biologic allergen assay for in vivo test allergens with an in vitro model of the murine type I reaction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						biologic allergen assay; animal model; final allergen products; rat basophil leukemia cell; murine IgE	BIRCH POLLEN ALLERGEN; BET-V-I; APPLE ALLERGEN; ANTIBODIES; STABILITY; RELEASE; ANTIGEN; MOUSE; IGE	Background: The determination of the biologic activity of allergenic extracts in human beings is limited for ethical and practical reasons. The establishment of a simplified in vitro model, which mimics a main event of the type I reaction, should provide true benefit for manufacturers, researchers, and clinicians. Objective: This study was designed to develop and evaluate a mediator release assay based on rat basophil leukemia cells for the purpose of investigating allergenic extracts. Methods: Rat basophil leukemia cells were passively sensitized with murine IgE raised against allergens and stimulated by serial dilutions of allergenic extracts in a dose-related manner. The allergen-specific degranulation was monitored by measuring the release of beta-hexosaminidase. Results: The investigation of standardized commercial allergen products for in vivo diagnostics (birch pollen, cat dander, and bee venom) allowed a quantitative description of differences in biologic activity in accordance with the declared activity units. The Fel d 1 content was determined in 17 cat dander extracts and correlated well with the results of a two-site binding ELISA (r = 0.93, log/log). Extremely low allergen amounts in the range of 10 to 100 pg/ml could be easily detected. Moreover, the cross-reactivity pattern of patients allergic to birch pollen could be reproduced with extracts of hazel, alder, apple, and celery. Conclusion: The assay is suitable for supplementing quality control of allergenic extracts and for the determination of biologic activity of final allergen products. As a research tool, it allows the study of IgE cross-linking properties of modified and recombinant allergens at an early stage before they are tested in human beings.			Hoffmann, A (corresponding author), PAUL EHRLICH INST,DEPT ALLERGOL,PAUL EHRLICH STR 51-59,D-63225 LANGEN,GERMANY.							BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; CARREIRA J, 1994, ARB PEI GSH, V87, P155; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; DREBORG S, 1992, ALLERGY, V47, P418, DOI 10.1111/j.1398-9995.1992.tb02082.x; DREBORG S, 1986, HDB EXPT IMMUNOLOGY; *EUR EC COMM, 1992, 927190EEC OFF OFF PU; KAWABATA TT, 1993, J IMMUNOL METHODS, V162, P9, DOI 10.1016/0022-1759(93)90401-R; KOLBE L, 1995, IMMUNOLOGY, V84, P285; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; MULLER T, 1988, INST PHYS CONF SER, V93, P15; OVARY Z, 1975, INT ARCH ALLER A IMM, V48, P16, DOI 10.1159/000231289; PAULI G, 1995, ALLERGY S, V50, P133; RUDESCHKO O, 1995, ALLERGY, V50, P575, DOI 10.1111/j.1398-9995.1995.tb01202.x; SCHONING B, 1995, J SCI FOOD AGR, V67, P431, DOI 10.1002/jsfa.2740670403; SEGAL DM, 1981, J IMMUNOL, V126, P138; TURKELTAUB PC, 1994, ARB PEI GSH, V87, P79; VALENTA R, 1995, PROGR ALLERGY CLIN I, P3; VIETHS S, 1995, ALLERGY, V50, P421, DOI 10.1111/j.1398-9995.1995.tb01172.x; WAHL R, 1991, ARB P EHRLICH I BUND, V85, P197; WEBER E, 1964, BIOL STAT, P473	20	56	61	1	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					227	232		10.1016/S0091-6749(97)70101-5	http://dx.doi.org/10.1016/S0091-6749(97)70101-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042050				2022-12-18	WOS:A1997WH83100013
J	Counsell, CM; Bond, JF; Ohman, JL; Greenstein, JL; Garman, RD				Counsell, CM; Bond, JF; Ohman, JL; Greenstein, JL; Garman, RD			Definition of the human T-cell epitopes of Fel d 1, the major allergen of the domestic cat	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cat allergen; T-cell epitopes; synthetic peptides; immunotherapy; IgE antibodies; histamine release	D-I; SEQUENCE-ANALYSIS; IMMUNOTHERAPY; PEPTIDES; SPECIFICITY; EXPRESSION; RESPONSES; ASTHMA	Background: A heterodimeric acidic glycoprotein (Fel d 1) has been defined as the major allergen of the domestic cat. Because T-cell help is required for the initiation and maintenance of allergic responses, it is of importance to determine the T-cell-reactive regions of the Fel d 1 molecule. Methods: Overlapping peptides corresponding to the two chains of Fel d 1 were tested in proliferation assays on polyclonal T-cell lines and far the ability to bind Fel d 1-specific IgE in ELISA and histamine release assays. Results: Assay of T-cell lines derived from 53 subjects allergic to cats demonstrated that the majority of T-cell reactivity is found in chain 1 of Fel d 1. Two peptides (Fel-1 and Fel-2) containing major epitopes, alone or as a mixture, efficiently activated T cells and exhibited minimal detectable reactivity with IgE by ELISA or histamine release assay. Conclusions: Two Fel d 1 peptides containing major T-cell epitopes have been identified, have been shown to bind minimal Fel d 1-specific IgE, and are now being tested for the ability to decrease T-cell responses in patients with cat allergy as a new form of immunotherapy.	IMMULOG PHARMACEUT CORP, WALTHAM, MA 02154 USA; TUFTS UNIV, NEW ENGLAND MED CTR, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University								ANDERSON MC, 1981, J IMMUNOL, V127, P972; BOND JF, 1993, MOL IMMUNOL, V30, P1529, DOI 10.1016/0161-5890(93)90461-J; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; DUFFORT O, 1987, INT ARCH ALLER A IMM, V84, P339, DOI 10.1159/000234447; DUFFORT OA, 1991, MOL IMMUNOL, V28, P301, DOI 10.1016/0161-5890(91)90141-6; ENGELHARD VH, 1994, ANNU REV IMMUNOL, V12, P181, DOI 10.1146/annurev.iy.12.040194.001145; FREIDHOFF LR, 1984, J ALLERGY CLIN IMMUN, V73, P490, DOI 10.1016/0091-6749(84)90360-9; GREENSTEIN JL, 1992, J ALLERGY CLIN IMMUN, V89, P322; GRIFFITH IJ, 1992, GENE, V113, P263, DOI 10.1016/0378-1119(92)90405-E; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67, DOI 10.1146/annurev.iy.09.040191.000435; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OHMAN JL, 1974, J IMMUNOL, V113, P1668; ROGERS BL, 1994, MOL IMMUNOL, V31, P955, DOI 10.1016/0161-5890(94)90090-6; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; VAILES LD, 1994, J ALLERGY CLIN IMMUN, V93, P22, DOI 10.1016/0091-6749(94)90229-1; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; VANMILLIGEN FJ, 1994, J ALLERGY CLIN IMMUN, V93, P34, DOI 10.1016/0091-6749(94)90230-5; VANNEERVEN RJJ, 1994, J IMMUNOL, V152, P4203; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; WALLENBECK I, 1987, ANN ALLERGY, V59, P131	24	56	62	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	1				884	894		10.1016/S0091-6749(96)80004-2	http://dx.doi.org/10.1016/S0091-6749(96)80004-2			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VU764	8939151				2022-12-18	WOS:A1996VU76400004
J	OKADA, S; INOUE, H; YAMAUCHI, K; IIJIMA, H; OHKAWARA, Y; TAKISHIMA, T; SHIRATO, K				OKADA, S; INOUE, H; YAMAUCHI, K; IIJIMA, H; OHKAWARA, Y; TAKISHIMA, T; SHIRATO, K			POTENTIAL ROLE OF INTERLEUKIN-1 IN ALLERGEN-INDUCED LATE ASTHMATIC REACTIONS IN GUINEA-PIGS - SUPPRESSIVE EFFECT OF INTERLEUKIN-1 RECEPTOR ANTAGONIST ON LATE ASTHMATIC REACTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EOSINOPHILS; BRONCHIAL ASTHMA; PULMONARY RESISTANCE	NECROSIS-FACTOR-ALPHA; HUMAN EOSINOPHILS; ANTIGEN CHALLENGE; PROTEIN; HYPERRESPONSIVENESS; CYTOKINES; DENSITY	Interleukin (IL)-1 is a pluripotential proinflammatory cytokine and is thought to be involved in the pathogenesis of bronchial asthma and late asthmatic reactions (LARs). To determine whether IL-1 plays a role in LAR, guinea pigs sensitized with Ascaris antigen were used. We evaluated IL-1 production by immunostaining with anti-IL-1 beta antibody and elucidated the action of IL-1 in LAR with recombinant IL-1 receptor antagonist. Immunostaining revealed that IL-1 beta-like immunoreactivity-positive cells increased in the airway walls and in bronchoalveolar lavage fluid after the antigen challenge. IL-1 receptor antagonist protein pretreatment reduced the generation of LAR in terms of pulmonary resistance. IL-1 receptor antagonist protein pretreatment did nor change cellular components but reduced the percentage of hypodense eosinophils in bronchoalveolar lavage fluid. We also studied the direct effect of recombinant human IL-1 beta on pulmonary resistance and eosinophil activity measured as released eosinophil peroxidase activity. Recombinant human IL-1 beta did not change pulmonary resistance but primed eosinophils to release eosinophil peroxidase activity in response to platelet activating factor. Therefore these results suggest that IL-1 was produced in sensitized pulmonary tissue of guinea pigs by allergen exposure and played a role in the generation of LAR, at least partially by modulating the activation of eosinophils.	TOHOKU UNIV, SCH MED, DEPT INTERNAL MED 1, AOBA KU, SENDAI, MIYAGI 98077, JAPAN	Tohoku University			Yamauchi, Kohei/N-2749-2016	Inoue, Hiroshi/0000-0002-9969-2152				ABRAHAM WM, 1983, AM REV RESPIR DIS, V128, P839; AIZAWA T, 1990, AM REV RESPIR DIS, V142, P133, DOI 10.1164/ajrccm/142.1.133; AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; BASKAR P, 1992, P SOC EXP BIOL MED, V199, P249; BOCHNER BS, 1990, J ALLERGY CLIN IMMUN, V86, P830, DOI 10.1016/S0091-6749(05)80143-5; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; CAPRON M, 1984, J IMMUNOL, V132, P462; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; FALUS A, 1992, IMMUNOL TODAY, V13, P154; GARTNER I, 1980, IMMUNOLOGY, V40, P133; GOSSET P, 1991, J ALLERGY CLIN IMMUN, V88, P561, DOI 10.1016/0091-6749(91)90149-I; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; HERVE P, 1992, BLOOD, V79, P3362; IIJIMA H, 1987, AM REV RESPIR DIS, V136, P922, DOI 10.1164/ajrccm/136.4.922; KROEGEL C, 1989, J IMMUNOL, V142, P3518; MATTOLI S, 1990, AM J PHYSIOL, V259, pL320, DOI 10.1152/ajplung.1990.259.4.L320; MEAD J, 1953, J APPL PHYSIOL, V5, P779, DOI 10.1152/jappl.1953.5.12.779; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; SASAKI H, 1987, AM REV RESPIR DIS, V136, P1459, DOI 10.1164/ajrccm/136.6.1459; SHAW RJ, 1985, NATURE, V316, P150, DOI 10.1038/316150a0; STREJAN G, 1967, J IMMUNOL, V98, P893; ULICH TR, 1991, AM J PATHOL, V138, P521; WEGNER C D, 1992, American Review of Respiratory Disease, V145, pA461; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WINQVIST I, 1982, IMMUNOLOGY, V47, P531; WOOLEY PH, 1993, ARTHRITIS RHEUM, V36, P1305, DOI 10.1002/art.1780360915	27	56	61	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1995	95	6					1236	1245		10.1016/S0091-6749(95)70081-1	http://dx.doi.org/10.1016/S0091-6749(95)70081-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD309	7797792				2022-12-18	WOS:A1995RD30900012
J	TRACY, JM; DEMAIN, JG; QUINN, JM; HOFFMAN, DR; GOETZ, DW; FREEMAN, TM				TRACY, JM; DEMAIN, JG; QUINN, JM; HOFFMAN, DR; GOETZ, DW; FREEMAN, TM			THE NATURAL-HISTORY OF EXPOSURE TO THE IMPORTED FIRE ANT (SOLENOPSIS-INVICTA)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IMPORTED FIRE ANT; WHOLE BODY EXTRACT; HYMENOPTERA; HYPERSENSITIVITY	HYMENOPTERA VENOM; HEALTH-HAZARD; ALLERGENS; DIAGNOSIS; INVIVO	Background: Imported fire ants (IFA) are a common cause of insect venom hypersensitivity in the southeastern United Stares. The purpose of this study was to determine the sting attack rate and development of specific IgE in an unsensitized population. Methods: Study participants consisted of 137 medical students with limited exposure to IFA-endemic areas who were temporarily training in San Antonio, Tex. Subjects were surveyed for prior IFA exposure with a questionnaire, and IFA-specific IgE was evaluated with RAST and intradermal skin testing. Evaluations were performed on arrival and reported at departure from the endemic area 3 weeks later. Results: One hundred seven subjects completed the study. Field stings were reported in 55 subjects, resulting in a sting attack rate of 51%. In these 55 subjects 53 (96%) reported a pustule or a small local reaction at the sting site, one (2%) reported an isolated large local reaction, and none reported a systemic reaction. At the 3-week follow-up skin test and RAST conversions occurred in seven subjects (13%) and in one subject (1.8%), respectively. Conclusions: Even brief exposures to IFA-endemic areas result in significant sting rates and concurrent rapid development of IFA-specific IgE in 16% of stung subjects.	WILFORD HALL USAF MED CTR,DEPT ALLERGY & IMMUNOL,PSMA,LACKLAND AFB,TX 78236; E CAROLINA UNIV,SCH MED,GREENVILLE,NC	United States Department of Defense; United States Air Force; University of North Carolina; East Carolina University								ADAMS CT, 1982, J MED ENTOMOL, V19, P366, DOI 10.1093/jmedent/19.4.366; ADAMS CT, 1981, J MED ENTOMOL, V18, P378, DOI 10.1093/jmedent/18.5.378; CLEMMER DI, 1975, SOUTHERN MED J, V68, P1133, DOI 10.1097/00007611-197509000-00017; DESHAZO RD, 1984, J ALLERGY CLIN IMMUN, V74, P841, DOI 10.1016/0091-6749(84)90188-X; DESHAZO RD, 1991, NEW ENGL J MED, V323, P462; GLANCEY B M, 1973, Journal of the Georgia Entomological Society, V8, P237; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P828, DOI 10.1016/0091-6749(88)90085-1; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P818, DOI 10.1016/0091-6749(88)90084-X; HOFFMAN DR, 1991, ANN ALLERGY, V66, P29; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V91, P71, DOI 10.1016/0091-6749(93)90298-T; Lofgren C.S., 1982, P124; Lofgren C.S., 1986, FIRE ANTS LEAF CUTTI, V1st; LOFGREN CS, 1975, ANNU REV ENTOMOL, V20, P1, DOI 10.1146/annurev.en.20.010175.000245; STABLEIN JJ, 1987, CLIN REV ALLERG, V5, P161; STAFFORD CT, 1989, SOUTHERN MED J, V82, P1520, DOI 10.1097/00007611-198912000-00015; STAFFORD CT, 1989, SOUTHERN MED J, V82, P1515, DOI 10.1097/00007611-198912000-00014; STAFFORD CT, 1992, J ALLERGY CLIN IMMUN, V90, P653, DOI 10.1016/0091-6749(92)90139-S; STAFFORD CT, 1990, ANN ALLERGY, V64, P368; STROM GB, 1983, J ALLERGY CLIN IMMUN, V72, P46, DOI 10.1016/0091-6749(83)90051-9; TRIPLETT RF, 1976, SOUTHERN MED J, V69, P258, DOI 10.1097/00007611-197603000-00002; VANDERMEER RK, 1985, FLA ENTOMOL, V68, P501, DOI 10.2307/3495147	21	56	58	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1995	95	4					824	828		10.1016/S0091-6749(95)70125-7	http://dx.doi.org/10.1016/S0091-6749(95)70125-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QT468	7722162				2022-12-18	WOS:A1995QT46800007
J	KIMATA, H				KIMATA, H			HIGH-DOSE INTRAVENOUS GAMMA-GLOBULIN TREATMENT FOR HYPERIMMUNOGLOBULINEMIA-E SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HYPERIMMUNOGLOBULINEMIA E SYNDROME; IGE PRODUCTION; INTRAVENOUS GAMMA-GLOBULIN; ECZEMA; ATOPIC DERMATITIS; INTERLEUKIN-4; KAWASAKI DISEASE	SPONTANEOUS IGE; IGG4 PRODUCTION; CELLS	Background: Hyperimmunoglobulinemia syndrome (HIES) is an inflammatory skin disease, and management of it is not satisfactory. However, high-dose intravenous gamma-globulin (IVGG) is a safe and effective treatment for Kawasaki disease. Methods: I initially treated two patients with Kawasaki disease, both of whom also had HIES, with IVGG. Subsequently, I treated patients with HIES alone, atopic dermatitis, Kawasaki disease, or idiopathic thrombocytopenic purpura with IVGG and measured serum IgE levels and in vitro spontaneous IgE production by peripheral blood mononuclear cells from patients. Direct effects of IgG on in vitro IgE production were also studied. Results: IVGG treatment remarkably improved severe eczema in patients with HIES with or without Kawasaki disease and in patients with atopic dermatitis. Moreover, serum IgE levels and in vitro spontaneous IgE production were decreased in these patients but not in patients with Kawasaki disease or idiopathic thrombocytopenic purpura. The addition of high concentrations of IgG to cultures of peripheral blood mononuclear cells from patients with HIES or atopic dermatitis decreased in vitro spontaneous IgE production. Moreover, IgG also decreased Ige production by normal B cells stimulated with interleukin-4 plus anti-CD40 monoclonal antibody. Conclusion: IVGG is effective in the treatment of severe eczema in patients with HIES and atopic dermatitis. IVGG also decreased enhanced IgE production both in vivo and in vitro.	SHINKORI HOSP,DEPT PEDIAT,HIRAKATA,OSAKA,JAPAN									DAVIS SD, 1966, LANCET, V1, P1013; DRESKIN SC, 1985, J CLIN INVEST, V75, P26, DOI 10.1172/JCI111683; KIMATA H, 1993, J IMMUNOL, V151, P6723; KIMATA H, 1993, J IMMUNOL, V150, P4630; LEUNG DYM, 1987, J CLIN INVEST, V79, P468, DOI 10.1172/JCI112835; ROUSSET F, 1991, J ALLERGY CLIN IMMUN, V87, P58, DOI 10.1016/0091-6749(91)90213-8; SOUILLET G, 1989, LANCET, V2, P1384; THOMPSON RA, 1989, LANCET, V2, P630	8	56	61	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					771	774		10.1016/S0091-6749(95)70185-0	http://dx.doi.org/10.1016/S0091-6749(95)70185-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QM017	7897163				2022-12-18	WOS:A1995QM01700020
J	SALVAGGIO, JE				SALVAGGIO, JE			INHALED PARTICLES AND RESPIRATORY-DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Symposium on Building-Related and Home-Related Complaints and Illnesses: Sick Building Syndrome	DEC 03-05, 1992	LAKE BUENA VISTA, FL				AEROSOLS				SALVAGGIO, JE (corresponding author), TULANE UNIV,MED CTR,1430 TULANE AVE,NEW ORLEANS,LA 70112, USA.							BICE D, 1975, INT ARCH ALLER A IMM, V55, P267; CLARKE SW, 1988, TXB RESPIRATORY MED, P313; DAVIES RJ, 1992, ALLERGY; DESHAZO RD, 1983, J ALLERGY CLIN IMMUN, V72, P454, DOI 10.1016/0091-6749(83)90581-X; DEY RD, 1980, FED PROC, V39, P1062; FRASER DW, 1977, NEW ENGL J MED, V297, P1189, DOI 10.1056/NEJM197712012972201; GIDEON AL, 1990, MAY ALL P, V3, P109; HARRIS RS, 1968, CLIN SCI, V34, P569; HATCH TF, 1964, PULMONARY DEPOSITION; LACEY J, 1967, T BRIT MYCOLOGICAL S, V47, P547; LEITH DE, 1977, RESPIRATORY DEFENS 2, P545; MATSUMURA Y, 1970, AM REV RESPIR DIS, V102, P430; MENZIES R, 1993, NEW ENGL J MED, V328, P821, DOI 10.1056/NEJM199303253281201; MORROW PE, 1973, ARCH INTERN MED, V131, P101, DOI 10.1001/archinte.131.1.101; MUIR D. C. F., 1967, ANN OCCUP HYG, V10, P161; SALTINI C, 1989, NEW ENGL J MED, V320, P1103, DOI 10.1056/NEJM198904273201702; SALVAGGIO JE, 1992, IMMUNOL ALLERGY CLIN, V4, P711; SALVAGGIO JS, 1987, J ALLERGY CLIN IMMUN, V4, P558; SPRINCE NL, 1991, AM REV RESPIR DIS, V143, P822, DOI 10.1164/ajrccm/143.4_Pt_1.822; STANKUS RP, 1984, SEMIN REPIR MED, V3, P282; STUART BO, 1973, ARCH INTERN MED, V131, P60, DOI 10.1001/archinte.131.1.60; THOMPSON PJ, 1992, ALLERGY	22	56	56	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2	2				304	309		10.1053/ai.1994.v94.a56009	http://dx.doi.org/10.1053/ai.1994.v94.a56009			6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG770	8077583				2022-12-18	WOS:A1994PG77000005
J	VAILES, LD; LI, Y; BAO, Y; DEGROOT, H; AALBERSE, RC; CHAPMAN, MD				VAILES, LD; LI, Y; BAO, Y; DEGROOT, H; AALBERSE, RC; CHAPMAN, MD			FINE SPECIFICITY OF B-CELL EPITOPES ON FELIS-DOMESTICUS ALLERGEN-I (FEL D-I) - EFFECT OF REDUCTION AND ALKYLATION OR DEGLYCOSYLATION ON FEL D-I STRUCTURE AND ANTIBODY-BINDING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CAT ALLERGEN; EPITOPES; MONOCLONAL ANTIBODIES; GLYCOPROTEINS; ASTHMA	HOUSEHOLD-DUST SAMPLES; AMINO-ACID-SEQUENCE; MAJOR CAT ALLERGEN; MONOCLONAL-ANTIBODIES; INHALANT ALLERGENS; IGE ANTIBODIES; DERMATOPHAGOIDES; IMMUNOTHERAPY; EXTRACT; ASTHMA	The repertoire of B-cell epitopes on the major cat allergen, Fel d I, was analyzed with monoclonal antibodies (MoAbs) in topographic mapping studies and in immunoassays with antigen derived from other cat (Felidae) species. Four essentially nonoverlapping epitopes on Fel d I, designated Fd1A to D, were defined by use of is anti Fel d I MoAbs in cross-inhibition radioimmunoassay. Only MoAbs directed against epitope Fd1B bound to putative Fel d I homologues in hair and dander extracts from seven other feline species (Panthera species, [n = 5], Leptailurus serval, and Leopardus pardalus). Quantitative monosaccharide analysis showed that Fel d I was a glycoprotein, containing high levels of fucose, as well as glucosamine, galactose, and mannose. Binding of MoAbs and human IgG or IgE antibody to native reduced and alkylated or deglycosylated Fel d I was compared by means of immunoprecipitation and immunoassay and the effects of these treatments on the structure of Fel d I were analyzed by sodium dodecylsulfate-polyacrylamide gel electrophoresis. On reduction and alkylation, Fel d I dissociated into 14 kd and 3.2 kd peptides, and deglycosylation with trifluoromethane sulfonic acid produced a 12 to 14 kd peptide. These procedures resulted in a 100- to 1000-fold loss in murine or human antibody binding activity and caused significant loss of secondary structure e, as judged by circular dichroism spectroscopy. Treatment with potassium hydroxide also caused a marked loss in antigenic reactivity. In contrast, enzymatic deglycosylation generated a 9 kd peptide, which showed strong reactivity with murine and human antibodies, comparable to native Fel d I. The results show that MoAbs define a broad repertoire of B-cell epitopes on Fel d I, one of which is expressed by other cat species. These epitopes are conformational and do not appear to involve oligosaccharide residues.	UNIV VIRGINIA,DEPT MED,DIV ALLERGY & CLIN IMMUNOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT PATHOL,CHARLOTTESVILLE,VA 22903; UNIV AMSTERDAM,NETHERLANDS BLOOD TRANSFUS SERV,CENT LAB,DEPT IMMUNOCHEM,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,AMSTERDAM,NETHERLANDS	University of Virginia; University of Virginia; University of Amsterdam; University of Amsterdam				Chapman, Martin/0000-0002-0845-3632	NIAID NIH HHS [AI-24687] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024687] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P563, DOI 10.1016/0091-6749(85)90776-6; BARTHOLOME K, 1985, J ALLERGY CLIN IMMUN, V76, P503, DOI 10.1016/0091-6749(85)90734-1; BARTLES JR, 1985, J BIOL CHEM, V260, P2792; BOND JF, 1992, J ALLERGY CLIN IMMUN, V89, P320; CHAPMAN MD, 1987, J IMMUNOL, V139, P1479; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHAPMAN MD, 1984, J IMMUNOL, V133, P2488; CHARPIN C, 1991, J ALLERGY CLIN IMMUN, V88, P77, DOI 10.1016/0091-6749(91)90303-6; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; DABROWSKI AJ, 1990, J ALLERGY CLIN IMMUN, V86, P462, DOI 10.1016/S0091-6749(05)80200-3; DANDEU JP, 1990, J CHROMATOGR, V512, P177, DOI 10.1016/S0021-9673(01)89484-X; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; DEGROOT H, 1988, J ALLERGY CLIN IMMUN, V82, P778, DOI 10.1016/0091-6749(88)90079-6; DEGROOT H, 1990, J ALLERGY CLIN IMMUN, V86, P107, DOI 10.1016/S0091-6749(05)80130-7; DIDIERLAURENT A, 1984, INT ARCH ALLER A IMM, V73, P27, DOI 10.1159/000233433; DUFFORT O, 1987, INT ARCH ALLER A IMM, V84, P339, DOI 10.1159/000234447; DUFFORT OA, 1991, MOL IMMUNOL, V28, P301, DOI 10.1016/0161-5890(91)90141-6; FINDLAY SR, 1983, AM REV RESPIR DIS, V128, P1008; GARMAN R D, 1990, Journal of Allergy and Clinical Immunology, V85, P200; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GLINERT R, 1990, J ALLERGY CLIN IMMUN, V85, P327; HAKIMUDDIN TS, 1987, METHOD ENZYMOL, V138, P341; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LOMBARDERO M, 1988, J IMMUNOL METHODS, V108, P71, DOI 10.1016/0022-1759(88)90404-8; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; LOWENSTEIN H, 1985, ALLERGY, V40, P430, DOI 10.1111/j.1398-9995.1985.tb02682.x; LOWENSTEIN H, 1986, J ALLERGY CLIN IMMUN, V77, P497, DOI 10.1016/0091-6749(86)90185-5; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67, DOI 10.1146/annurev.iy.09.040191.000435; OHMAN JL, 1982, J ALLERGY CLIN IMMUN, V69, P320; OHMAN JL, 1974, J IMMUNOL, V113, P1668; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; PONSTINGL H, 1978, BIOCHEMISTRY-US, V17, P3908, DOI 10.1021/bi00612a003; POPP RA, 1978, P NATL ACAD SCI USA, V75, P5516, DOI 10.1073/pnas.75.11.5516; ROGERS BL, 1993, 1992 P INT S MOL BIO, P259; SLUNT J, 1993, J ALLERGY CLIN IMMUN, V91, P188; SWANSON MC, 1989, J ALLERGY CLIN IMMUN, V83, P776, DOI 10.1016/0091-6749(89)90014-6; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; VANMILLIGEN FJ, 1991, J ALLERGY CLIN IMMUN, V87, P327; VANTHOF W, 1993, ALLERGY, V48, P255; WENTZ PE, 1990, J ALLERGY CLIN IMMUN, V85, P94, DOI 10.1016/0091-6749(90)90228-V; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P730, DOI 10.1016/0091-6749(89)90006-7; WOODWARD MP, 1985, J IMMUNOL METHODS, V78, P143, DOI 10.1016/0022-1759(85)90337-0	46	56	60	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1994	93	1	1				22	33		10.1016/0091-6749(94)90229-1	http://dx.doi.org/10.1016/0091-6749(94)90229-1			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MT781	7508462	Bronze			2022-12-18	WOS:A1994MT78100003
J	WEMPE, JB; TAMMELING, EP; KOETER, GH; HAKANSSON, L; VENGE, P; POSTMA, DS				WEMPE, JB; TAMMELING, EP; KOETER, GH; HAKANSSON, L; VENGE, P; POSTMA, DS			BLOOD EOSINOPHIL NUMBERS AND ACTIVITY DURING 24 HOURS - EFFECTS OF TREATMENT WITH BUDESONIDE AND BAMBUTEROL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; NOCTURNAL ASTHMA; CORTICOSTEROIDS; BETA-AGONISTS; EOSINOPHIL GRANULOCYTE	NEUTROPHIL CHEMOTACTIC ACTIVITY; NOCTURNAL ASTHMA; BRONCHIAL HYPERREACTIVITY; INHALED BUDESONIDE; CATIONIC PROTEIN; ALLERGEN CHALLENGE; LUNG-FUNCTION; BRONCHOALVEOLAR LAVAGE; POLLEN SEASON; BONE TURNOVER	The effects of the inhaled corticosteroid budesonide and the oral long-acting beta-agonist bambuterol on circadian variation of blood eosinophil numbers, serum levels of eosinophil cationic protein (ECP), serum eosinophil chemotactic activity (ECA), and serum neutrophil chemotactic activity (NCA) were studied in two groups of patients with allergic asthma. Group 1 (n = 8) had a circadian variation of peak expiratory flow (PEF) 15% or greater, and group 2 (n = 9) had a circadian PEF variation less than 15%. Both groups were randomized and crossover treated for 4 weeks with (A) 0.4 mg budesonide at 8 AM and 8 PM, (B) 20 mg bambuterol at 8 PM, and (C) placebo. At the end of each period blood eosinophil numbers, ECP, ECA, and NCA were measured during 24 hours at 4-hour intervals. No significant differences in the inflammatory parameters could be observed between the groups, although eosinophil numbers tended to be higher in group 1 than in group 2. Highest eosinophil numbers were observed at night. Budesonide reduced both eosinophil numbers and ECP levels, especially at night; bambuterol had no effect on both variables. No circadian variation or treatment effects were observed for ECA and NCA. This study suggests a role for the eosinophil in the nocturnal worsening of asthma, and it demonstrates that budesonide produces, in contrast to bambuterol, a reduction of (nocturnal) eosinophil numbers and activity.	UNIV HOSP GRONINGEN, DEPT PULM, OOSTERSINGEL 59, 9713 EH GRONINGEN, NETHERLANDS; UNIV HOSP UPPSALA, DEPT CLIN CHEM, INFLAMMATION RES LAB, UPPSALA, SWEDEN	University of Groningen; Uppsala University; Uppsala University Hospital								ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; ALI NJ, 1991, THORAX, V46, P160, DOI 10.1136/thx.46.3.160; ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; BARNES P, 1980, NEW ENGL J MED, V303, P263, DOI 10.1056/NEJM198007313030506; BARNES PJ, 1988, AM J MED, V85, P64, DOI 10.1016/0002-9343(88)90245-8; BISGAARD H, 1990, J ALLERGY CLIN IMMUN, V85, P891, DOI 10.1016/0091-6749(90)90074-E; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CARLSON M, 1991, J ALLERGY CLIN IMMUN, V87, P27, DOI 10.1016/0091-6749(91)90209-7; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DAHL R, 1978, SCAND J RESPIR DIS, V59, P319; DAHL R, 1989, J ALLERGY CLIN IMMUN, V83, P811, DOI 10.1016/0091-6749(89)90019-5; DAHL R, 1978, ALLERGY, V33, P211, DOI 10.1111/j.1398-9995.1978.tb01536.x; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; FAIRFAX AJ, 1980, THORAX, V35, P526, DOI 10.1136/thx.35.7.526; GERVAIS P, 1977, J ALLERGY CLIN IMMUN, V59, P207, DOI 10.1016/0091-6749(77)90151-8; GIBSON PG, 1990, CLIN EXP ALLERGY, V20, P661, DOI 10.1111/j.1365-2222.1990.tb02705.x; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GRIFFIN E, 1991, J ALLERGY CLIN IMMUN, V87, P548, DOI 10.1016/0091-6749(91)90014-F; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; HAKANSSON L, 1989, J ALLERGY CLIN IMMUN, V83, P933, DOI 10.1016/0091-6749(89)90108-5; HOLGATE ST, 1991, AM REV RESPIR DIS, V143, pS66, DOI 10.1164/ajrccm/143.3_Pt_2.S66; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; HUTSON PA, 1988, AM REV RESPIR DIS, V138, P1157, DOI 10.1164/ajrccm/138.5.1157; JENNINGS BH, 1991, EUR J CLIN PHARMACOL, V40, P77, DOI 10.1007/BF00315143; JOHANSSON SA, 1982, EUR J CLIN PHARMACOL, V22, P523, DOI 10.1007/BF00609625; KALLENBACH JM, 1988, CHEST, V93, P751, DOI 10.1378/chest.93.4.751; KITA H, 1991, J ALLERGY CLIN IMMUN, V87, P70, DOI 10.1016/0091-6749(91)90214-9; KRAAN J, 1988, AM REV RESPIR DIS, V137, P44, DOI 10.1164/ajrccm/137.1.44; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LORENTZSON S, 1990, THORAX, V45, P733, DOI 10.1136/thx.45.10.733; MAESEN FPV, 1990, CHEST, V98, P866, DOI 10.1378/chest.98.4.866; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; MARTIN RJ, 1990, AM REV RESPIR DIS, V141, P33, DOI 10.1164/ajrccm/141.1.33; MASUYAMA K, 1985, INT ARCH ALLER A IMM, V78, P243, DOI 10.1159/000233893; METZGER WJ, 1986, J ALLERGY CLIN IMMUN, V78, P282; MORRISON JFJ, 1990, BRIT MED J, V301, P473, DOI 10.1136/bmj.301.6750.473; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; PETERSON AP, 1981, J ALLERGY CLIN IMMUN, V68, P212, DOI 10.1016/0091-6749(81)90186-X; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; RAK S, 1990, J ALLERGY CLIN IMMUN, V86, P706, DOI 10.1016/S0091-6749(05)80174-5; SCHATZ M, 1982, ARCH INTERN MED, V142, P1515, DOI 10.1001/archinte.142.8.1515; SZEFLER SJ, 1991, CLIN PHARMACOL THER, V49, P59, DOI 10.1038/clpt.1991.11; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V84, P688, DOI 10.1016/0091-6749(89)90297-2; TOOGOOD JH, 1988, AM REV RESPIR DIS, V138, P57, DOI 10.1164/ajrccm/138.1.57; TURNERWARWICK M, 1988, AM J MED, V85, P6, DOI 10.1016/0002-9343(88)90231-8; VANAALDEREN WMC, 1989, THORAX, V44, P803, DOI 10.1136/thx.44.10.803; VENGE P, 1988, INT ARCH ALLER A IMM, V87, P306, DOI 10.1159/000234690; VENGE P, 1987, J ALLERGY CLIN IMMUN, V80, P679, DOI 10.1016/0091-6749(87)90287-9; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; YAGER D, 1991, AM REV RESPIR DIS, V143, pS52, DOI 10.1164/ajrccm/143.3_Pt_2.S52; YUKAWA T, 1990, AM REV RESPIR DIS, V141, P1446, DOI 10.1164/ajrccm/141.6.1446; 1983, LANCET, V1, P220	54	56	58	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1992	90	5					757	765		10.1016/0091-6749(92)90099-N	http://dx.doi.org/10.1016/0091-6749(92)90099-N			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ319	1430701				2022-12-18	WOS:A1992JZ31900005
J	BOCK, SA				BOCK, SA			THE INCIDENCE OF SEVERE ADVERSE REACTIONS TO FOOD IN COLORADO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									UNIV COLORADO,SCH MED,DENVER,CO 80202	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	BOCK, SA (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,1400 JACKSON ST,DENVER,CO 80206, USA.							SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	2	56	57	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	1				683	685		10.1016/0091-6749(92)90143-P	http://dx.doi.org/10.1016/0091-6749(92)90143-P			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT995	1401648				2022-12-18	WOS:A1992JT99500016
J	TURNER, BW; CAIL, WS; HENDLEY, JO; HAYDEN, FG; DOYLE, WJ; SORRENTINO, JV; GWALTNEY, JM				TURNER, BW; CAIL, WS; HENDLEY, JO; HAYDEN, FG; DOYLE, WJ; SORRENTINO, JV; GWALTNEY, JM			PHYSIOLOGICAL ABNORMALITIES IN THE PARANASAL SINUSES DURING EXPERIMENTAL RHINOVIRUS COLDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ACUTE SINUSITIS; RHINOVIRUS; COMMON COLD; ACUTE RESPIRATORY DISEASE		Six (18%) of 34 healthy, asymptomatic young adults had mucosal thickening or fluid in the paranasal sinuses on screening magnetic resonance imaging (MRI) examination. When 19 of these subjects were challenged with rhinovirus, 18 became infected. Twelve of the 18 infected subjects had technically satisfactory serial MRI examinations, and four (33%) of these developed MRI abnormalities of the ethmoid or antral sinuses that were temporally associated with the acute infection. The mean total nasal secretion weights were 22 gm/5 days in the four subjects whose MRI abnormalities were associated with the acute infection compared with 5.5 gm/5 days in the eight subjects who had normal MRI examinations during the acute infection (p = 0.06). Abnormalities of the paranasal sinuses, which were associated with increased volumes of nasal secretion, were detected by MRI examination during rhinovirus infection. These abnormalities may have a role in the pathogenesis of acute sinusitis associated with colds.	UNIV VIRGINIA, SCH MED, HLTH SCI CTR, DEPT INTERNAL MED, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT RADIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT PEDIAT, CHARLOTTESVILLE, VA 22908 USA; CHILDRENS HOSP, PITTSBURGH, PA 15213 USA; VICKS RES CTR, SHELTON, CT USA	University of Virginia; University of Virginia; University of Virginia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								DINGLE JH, 1964, ILLNESS HOME STUDY 2, P347; DUVOISIN B, 1989, AM J NEURORADIOL, V10, P599; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; GAFFEY MJ, 1988, ANTIMICROB AGENTS CH, V32, P1644, DOI 10.1128/AAC.32.11.1644; GWALTNEY JM, 1980, J INFECT DIS, V142, P811, DOI 10.1093/infdis/142.6.811; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; KNIGHT V, 1964, PROG MED VIROL, V6, P1; PAREKH HH, UNPUB AM J RHINOL; TURNER RB, 1989, DIAGNOSTIC PROCEDURE, P579; ZINREICH SJ, 1988, LARYNGOSCOPE, V98, P928	10	56	59	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			474	478		10.1016/0091-6749(92)90172-X	http://dx.doi.org/10.1016/0091-6749(92)90172-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1326574				2022-12-18	WOS:A1992JP52100013
J	MORGAN, SJ; WILLIAMS, JH; WALLS, AF; CHURCH, MK; HOLGATE, ST; MCGILL, JI				MORGAN, SJ; WILLIAMS, JH; WALLS, AF; CHURCH, MK; HOLGATE, ST; MCGILL, JI			MAST-CELL NUMBERS AND STAINING CHARACTERISTICS IN THE NORMAL AND ALLERGIC HUMAN CONJUNCTIVA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							TRYPTASE	In this study we report the numbers and metachromatic dye-staining characteristics of mast cells (MCs) in the conjunctiva of normal subjects and patients with seasonal allergic conjunctivitis caused by pollenosis. In addition, we have used a monoclonal antibody to the MC-specific enzyme, tryptase, to enumerate tryptase-positive cells immunohistochemically. Tarsal conjunctival MCs were found to be present in increased numbers in the allergic compared to the nonallergic subjects. Most of the MCs exhibited staining that was formaldehyde resistant, compatible with their identification as connective tissue MCs or basophils. The high positive staining for tryptase confirmed that the metachromatic cells stained with toluidine blue were MCs and not basophils, both in normal and allergic subjects.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT PATHOL,SOUTHAMPTON S09 4XY,ENGLAND; SOUTHAMPTON GEN HOSP,IMMUNOPHARMACOL GRP,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Southampton; University of Southampton	MORGAN, SJ (corresponding author), SOUTHAMPTON EYE HOSP,WILTON AVE,SOUTHAMPTON SO9 4XW,ENGLAND.							ALLANSMITH MR, 1986, SURV OPHTHALMOL, V30, P229, DOI 10.1016/0039-6257(86)90119-0; BLAND M, 1987, INTRO MED STATISTICS; CASTELLS M, 1986, J ALLERGY CLIN IMMUN, V77, P246; Church M. RC. B. PH. R. MA. L., 1989, MAST CELL BASOPHIL D, P161; EHRLICH P, 1876, ARCH MIKROSK ANAT, V13, P263; ENERBACK L, 1986, MAST CELL DIFFERENTI, P1; GROBER BL, 1988, J IMMUNOL, V139, P2724; IHLE JN, 1983, J IMMUNOL, V131, P282; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; IRANI AA, 1988, NER ALLERGY P, V9, P451; IRANI AMA, 1987, J IMMUNOL, V138, P4381; LEE T D G, 1985, Clinical Immunology Reviews, V4, P143; MAIER M, 1984, J IMMUNOL, V130, P2571; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; SCHECHTER NM, 1986, J IMMUNOL, V137, P962; SCHWARTZ LB, 1983, J IMMUNOL, V130, P1891; SCHWARTZ LB, 1985, J IMMUNOL, V135, P2762; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SCHWARTZ LB, 1985, J ALLERGY CLIN IMMUN, V76, P182, DOI 10.1016/0091-6749(85)90699-2; STROBEL S, 1981, J CLIN PATHOL, V34, P851, DOI 10.1136/jcp.34.8.851; WALLS AF, 1989, BIOCHEM SOC T, V17, P728, DOI 10.1042/bst0170728; WALLS AF, IN PRESS J PATHOL	22	56	61	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1991	87	1	1				111	116		10.1016/0091-6749(91)90221-9	http://dx.doi.org/10.1016/0091-6749(91)90221-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX985	1704023				2022-12-18	WOS:A1991EX98500016
J	ADINOFF, AD; ROSLONIEC, DM; MCCALL, LL; NELSON, HS				ADINOFF, AD; ROSLONIEC, DM; MCCALL, LL; NELSON, HS			IMMEDIATE SKIN-TEST REACTIVITY TO FOOD-AND-DRUG-ADMINISTRATION-APPROVED STANDARDIZED EXTRACTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO, HLTH SCI CTR, NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, NATL JEWISH CTR IMMUNOL & RESP MED, SKIN TEST LAB, DENVER, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								ADINOFF AD, 1989, J ALLERGY CLIN IMMUN, V84, P168, DOI 10.1016/0091-6749(89)90321-7; ALEXANDER HL, 1927, M CLIN N AM, V11, P399; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; Blackey CH, 1873, EXPT RES CAUSES NATU; BROWN WG, 1979, J ALLERGY CLIN IMMUN, V63, P328, DOI 10.1016/0091-6749(79)90127-1; CHAFEE FH, 1974, J ALLERGY CLIN IMMUN, V53, P193, DOI 10.1016/0091-6749(74)90080-3; Colton T, 1974, STAT MED, P160; Cooke RA, 1932, AM J MED SCI, V183, P309; CURRAN WS, 1961, ANN INTERN MED, V55, P777, DOI 10.7326/0003-4819-55-5-777; Drebotg S, 1989, ALLERGY S10, V44, P22; FERGUSON AC, 1986, CAN MED ASSOC J, V134, P1365; FREIDHOFF LR, 1981, AM J MED GENET, V9, P323, DOI 10.1002/ajmg.1320090409; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11, DOI 10.1016/0091-6749(73)90003-1; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P245, DOI 10.1016/0091-6749(73)90144-9; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GLODE MP, 1986, PEDIATR INFECT DIS J, V5, P644, DOI 10.1097/00006454-198611000-00009; GODFREY RC, 1976, CLIN ALLERGY, V6, P79, DOI 10.1111/j.1365-2222.1976.tb01415.x; HAAHTELA T, 1980, ALLERGY, V35, P433, DOI 10.1111/j.1398-9995.1980.tb01790.x; HAAHTELA T, 1981, ALLERGY, V36, P251, DOI 10.1111/j.1398-9995.1981.tb01571.x; HAAHTELA T, 1980, ALLERGY, V35, P425, DOI 10.1111/j.1398-9995.1980.tb01789.x; HAGY GW, 1971, J ALLERGY CLIN IMMUN, V48, P200, DOI 10.1016/0091-6749(71)90066-2; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; HENDRICK DJ, 1975, THORAX, V30, P2, DOI 10.1136/thx.30.1.2; HERXHEIMER H, 1954, Acta Allergol, V7, P380, DOI 10.1111/j.1398-9995.1954.tb03534.x; HUGGINS KG, 1975, LANCET, V2, P148; KASLOW J, 1989, ANN ALLERGY, V62, P270; LAVINS BJ, 1989, ANN ALLERGY, V62, P79; LINDBLAD JH, 1961, J ALLERGY, V32, P392, DOI 10.1016/0021-8707(61)90016-8; LOPEZ LR, 1988, J ALLERGY CLIN IMMUN, V81, P1143, DOI 10.1016/0091-6749(88)90882-2; MIADONNA A, 1983, CLIN ALLERGY, V13, P155, DOI 10.1111/j.1365-2222.1983.tb02583.x; MOYER DB, 1985, ANN ALLERGY, V55, P680; NELSON HS, 1983, ANN ALLERGY, V51, P411; OWNBY DR, 1982, J ALLERGY CLIN IMMUN, V69, P533, DOI 10.1016/0091-6749(82)90179-8; PIPKORN U, 1988, ALLERGY, V43, P81, DOI 10.1111/j.1398-9995.1988.tb00398.x; RELYVELD EH, 1980, ALLERGY, V35, P218, DOI 10.1111/j.1398-9995.1980.tb01752.x; SMALL P, 1985, ANN ALLERGY, V55, P68; Taylor G, 1973, Clin Allergy, V3, P103, DOI 10.1111/j.1365-2222.1973.tb01314.x; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; TURKELTAUB PC, 1986, CLIN REV ALLERG, V4, P371; VANTO T, 1983, ANN ALLERGY, V50, P340; VOORHORST R, 1973, ANN ALLERGY, V31, P137; VOORHORST R, 1980, ALLERGY, V35, P247, DOI 10.1111/j.1398-9995.1980.tb01762.x	42	56	57	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1990	86	5					766	774		10.1016/S0091-6749(05)80181-2	http://dx.doi.org/10.1016/S0091-6749(05)80181-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EJ631	2229841	Bronze			2022-12-18	WOS:A1990EJ63100009
J	JUNIPER, EF; KLINE, PA; RAMSDALE, EH; HARGREAVE, FE				JUNIPER, EF; KLINE, PA; RAMSDALE, EH; HARGREAVE, FE			COMPARISON OF THE EFFICACY AND SIDE-EFFECTS OF AQUEOUS STEROID NASAL SPRAY (BUDESONIDE) AND ALLERGEN-INJECTION THERAPY (POLLINEX-R) IN THE TREATMENT OF SEASONAL ALLERGIC RHINOCONJUNCTIVITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,DEPT MED,HAMILTON L8N 3Z5,ONTARIO,CANADA; ST JOSEPHS HOSP,FIRESTONE REG CHEST & ALLERGY CLIN,HAMILTON L8N 1Y4,ONTARIO,CANADA	McMaster University; McGill University; McMaster University	JUNIPER, EF (corresponding author), MCMASTER UNIV,MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA.							BESWICK KBJ, 1985, CURR MED RES OPIN, V9, P560, DOI 10.1185/03007998509109635; CLISSOLD SP, 1984, DRUGS, V28, P485, DOI 10.2165/00003495-198428060-00001; COCKCROFT DW, 1977, J ALLERGY CLIN IMMUN, V60, P56, DOI 10.1016/0091-6749(77)90083-5; DUNN AM, 1984, POSTGRAD MED J, V60, P404, DOI 10.1136/pgmj.60.704.404; FUCHS AM, 1959, J ALLERGY, V30, P66, DOI 10.1016/0021-8707(59)90060-7; JUNIPER EF, 1985, J ALLERGY CLIN IMMUN, V75, P578, DOI 10.1016/0091-6749(85)90033-8; JUNIPER EF, 1986, J ALLERGY CLIN IMMUN, V78, P851, DOI 10.1016/0091-6749(86)90229-0; JUNIPER EF, 1989, J ALLERGY CLIN IMMUN, V83, P627, DOI 10.1016/0091-6749(89)90075-4; JUNIPER EF, 1988, J ALLERGY CLIN IMMUN, V82, P670, DOI 10.1016/0091-6749(88)90981-5; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1980, J ALLERGY CLIN IMMUN, V65, P87, DOI 10.1016/0091-6749(80)90191-8; SACKETT DL, 1979, NEW ENGL J MED, V301, P1410, DOI 10.1056/NEJM197912273012602; SIBBALD B, 1986, CLIN ALLERGY, V16, P203, DOI 10.1111/j.1365-2222.1986.tb00767.x; SIMPSON RJ, 1988, ALLERGY S7, V43, P112	14	56	57	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1990	85	3					606	611		10.1016/0091-6749(90)90100-I	http://dx.doi.org/10.1016/0091-6749(90)90100-I			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CU668	2107241				2022-12-18	WOS:A1990CU66800011
J	RANDOLPH, CC; REISMAN, RE				RANDOLPH, CC; REISMAN, RE			EVALUATION OF DECLINE IN SERUM VENOM-SPECIFIC IGE AS A CRITERION FOR STOPPING VENOM IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO, BUFFALO GEN HOSP,DEPT MED,DIV ALLERGY, ALLERGY RES LAB, BUFFALO, NY 14260 USA	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIAID NIH HHS [5RO1 AI 140501] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARDE SH, 1983, J ALLERGY CLIN IMMUN, V71, P141, DOI 10.1016/0091-6749(83)90333-0; GOLDEN D B K, 1984, Journal of Allergy and Clinical Immunology, V73, P189; GOLDEN DBK, 1985, J ALLERGY CLIN IMMUN, V75, P208, DOI 10.1016/0091-6749(85)90550-0; GRAFT DF, 1984, J ALLERGY CLIN IMMUN, V73, P61, DOI 10.1016/0091-6749(84)90485-8; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; LIGHT WC, 1976, CLIN ALLERGY, V6, P293, DOI 10.1111/j.1365-2222.1976.tb01909.x; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V68, P254, DOI 10.1016/0091-6749(81)90148-2; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; REISMAN RE, 1979, CLIN ALLERGY, V9, P303, DOI 10.1111/j.1365-2222.1979.tb01557.x; URBANEK R, 1984, Journal of Allergy and Clinical Immunology, V73, P188	10	56	56	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1986	77	6					823	827		10.1016/0091-6749(86)90379-9	http://dx.doi.org/10.1016/0091-6749(86)90379-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C8694	3711549				2022-12-18	WOS:A1986C869400006
J	BARTHOLOME, K; KISSLER, W; BAER, H; KOPIETZSCHULTE, E; WAHN, U				BARTHOLOME, K; KISSLER, W; BAER, H; KOPIETZSCHULTE, E; WAHN, U			WHERE DOES CAT ALLERGEN-1 COME FROM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									RUHR UNIV BOCHUM,INST PATHOL,D-4630 BOCHUM,FED REP GER; US FDA,OFF BIOL,BETHESDA,MD 20014	Ruhr University Bochum; US Food & Drug Administration (FDA)	BARTHOLOME, K (corresponding author), RUHR UNIV BOCHUM,CHILDRENS HOSP,ALEXANDRINENSTR 5,D-4630 BOCHUM,FED REP GER.							ANDERSON MC, 1981, J IMMUNOL, V127, P972; BRANDT R, 1973, INT ARCH ALLER A IMM, V45, P447, DOI 10.1159/000231062; BROWN PR, 1984, INT ARCH ALLER A IMM, V74, P67, DOI 10.1159/000233518; DIDIERLAURENT A, 1984, INT ARCH ALLER A IMM, V73, P27, DOI 10.1159/000233433; GUERIN B, 1981, ANN ALLERGY, V46, P127; HOFFMAN DR, 1980, ANN ALLERGY, V45, P205; HOLFORD-STREVENS V, 1973, Clinical Allergy, V3, P225, DOI 10.1111/j.1365-2222.1973.tb01325.x; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LOWENSTEIN H, 1981, ALLERGOLOGIE, V4, P265; OHMAN JL, 1974, J IMMUNOL, V113, P1668; OHMAN JL, 1983, J ALLERGY CLIN IMMUN, V72, P288, DOI 10.1016/0091-6749(83)90033-7; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; STOKES CR, 1975, CLIN ALLERGY, V6, P241; VIANDER M, 1983, INT ARCH ALLER A IMM, V71, P252, DOI 10.1159/000233399	14	56	57	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	3					503	506		10.1016/0091-6749(85)90734-1	http://dx.doi.org/10.1016/0091-6749(85)90734-1			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ARC09	4031320	Bronze			2022-12-18	WOS:A1985ARC0900014
J	GENTON, C; FREI, PC; PECOUD, A				GENTON, C; FREI, PC; PECOUD, A			VALUE OF ORAL PROVOCATION TESTS TO ASPIRIN AND FOOD-ADDITIVES IN THE ROUTINE INVESTIGATION OF ASTHMA AND CHRONIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHU VAUDOIS,DEPT MED,DIV IMMUNOL & ALLERGY,CH-1011 LAUSANNE,SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)								ALLEN DH, 1983, J ALLERGY CLIN IMMUN, V71, P98, DOI 10.1016/0091-6749(83)90163-X; BOUSHEY HA, 1982, J ALLERGY CLIN IMMUN, V69, P335, DOI 10.1016/0091-6749(82)90142-7; FREEDMAN BJ, 1977, CLIN ALLERGY, V7, P407, DOI 10.1111/j.1365-2222.1977.tb01471.x; GIBSON A, 1980, CLIN ALLERGY, V10, P699, DOI 10.1111/j.1365-2222.1980.tb02154.x; HIRSCHBERG, 1902, DEUT MED WOCHENSCHR, V1, P416; JUHLIN L, 1972, J ALLERGY CLIN IMMUN, V50, P92, DOI 10.1016/0091-6749(72)90004-8; LEFF A, 1982, CHEST, V82, pS13; MATHISON DA, 1979, J ALLERGY CLIN IMMUN, V64, P669, DOI 10.1016/0091-6749(79)90036-8; MONERETVAUTRIN DA, 1978, RISQUE SENSIBILISATI, P101; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; RACHELEFSKY GS, 1975, PEDIATRICS, V56, P443; ROS AM, 1976, BRIT J DERMATOL, V95, P19, DOI 10.1111/j.1365-2133.1976.tb15532.x; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SCHLUMBERGER HD, 1980, PSEUDO ALLERGIC REAC, V1, P125; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; SPEER F, 1981, ANN ALLERGY, V46, P123; STENIUS BSM, 1976, CLIN ALLERGY, V6, P119, DOI 10.1111/j.1365-2222.1976.tb01889.x; VEDANTHAN PK, 1977, J ALLERGY CLIN IMMUN, V60, P8, DOI 10.1016/0091-6749(77)90077-X; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V64, P32, DOI 10.1016/0091-6749(79)90080-0; 1976, EVALUATION TOXICOLOG; 1979, ORDONNANCE ADDITIFS	21	56	56	1	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	1					40	45		10.1016/0091-6749(85)90802-4	http://dx.doi.org/10.1016/0091-6749(85)90802-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AMV84	2861222				2022-12-18	WOS:A1985AMV8400005
J	LYNCH, NR; MEDOUZE, L; DIPRISCOFUENMAYOR, MC; VERDE, O; LOPEZ, RI; MALAVE, C				LYNCH, NR; MEDOUZE, L; DIPRISCOFUENMAYOR, MC; VERDE, O; LOPEZ, RI; MALAVE, C			INCIDENCE OF ATOPIC DISEASE IN A TROPICAL ENVIRONMENT - PARTIAL INDEPENDENCE FROM INTESTINAL HELMINTHIASIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CENT UNIV VENEZUELA, WHO, PAHO, PANAMER CTR RES & TRAINING LEPROSY & TROP DIS, CARACAS, VENEZUELA; CENT UNIV VENEZUELA, INST NACL DERMATOL, CARACAS, VENEZUELA; CENT UNIV VENEZUELA, FAC VET, CARACAS, VENEZUELA	University of Central Venezuela; World Health Organization; University of Central Venezuela; University of Central Venezuela			Lynch, Natalie/GSI-7336-2022					ADERELE WI, 1981, T ROY SOC TROP MED H, V75, P675, DOI 10.1016/0035-9203(81)90146-2; ANDERSON HR, 1974, CLIN ALLERGY, V4, P171, DOI 10.1111/j.1365-2222.1974.tb01374.x; BROWN HW, BASIC CLIN PARASITOL; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; DEHOLLAIN PA, 1980, VENEZUELA DESNUTRIDA; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; GODFREY RC, 1976, NATURE, V259, P484, DOI 10.1038/259484a0; GROVE DI, 1982, ALLERGY, V37, P139, DOI 10.1111/j.1398-9995.1982.tb01889.x; HURTADO JC, 1983, J CLIN LAB IMMUNOL, V11, P75; JOHANSSON SG, 1968, LANCET, V1, P1118; KAPLAN JE, 1980, AM J TROP MED HYG, V29, P1012, DOI 10.4269/ajtmh.1980.29.1012; LARRICK JW, 1983, J ALLERGY CLIN IMMUN, V71, P184, DOI 10.1016/0091-6749(83)90097-0; LYNCH NR, 1983, INT ARCH ALLER A IMM, V72, P369, DOI 10.1159/000234899; LYNCH NR, CLIN ALLERGY; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MAZINGUE C, 1980, INT ARCH ALLER A IMM, V63, P178, DOI 10.1159/000232624; MERINO F, 1975, INVEST CLIN, V16, P122; MERRETT TG, 1976, CLIN ALLERGY, V6, P131, DOI 10.1111/j.1365-2222.1976.tb01890.x; PRESTON PJ, 1970, R NAV MED SERV, V61, P229; STANWORTH DR, 1967, LANCET, V2, P330; TURNER KJ, 1978, PAPUA NEW GUINEA MED, V21, P86; TURNER KJ, 1980, AUST J EXP BIOL MED, V58, P249, DOI 10.1038/icb.1980.25; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; 1980, CLIN ALLERGY, V10, P1	24	56	56	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	2					229	233		10.1016/S0091-6749(84)80012-3	http://dx.doi.org/10.1016/S0091-6749(84)80012-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SF020	6699305	Bronze			2022-12-18	WOS:A1984SF02000002
J	PATAKAS, D; VLACHOIANNI, E; TSARA, V; LOURIDAS, G; ARGIROPOULOU, P				PATAKAS, D; VLACHOIANNI, E; TSARA, V; LOURIDAS, G; ARGIROPOULOU, P			NIFEDIPINE IN BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PATAKAS, D (corresponding author), UNIV THESSALONIKI,SCH MED,PULM CLIN,THESSALONIKI,GREECE.							CERRINA J, 1981, AM REV RESPIR DIS, V123, P156; COBURN RF, 1977, FED PROC, V36, P2692; Cotes JE, 1975, LUNG FUNCTION; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; FANTA CH, 1980, AM REV RESPIR DIS, V123, P180; FOREMAN JC, 1977, J PHYSIOL-LONDON, V271, P193, DOI 10.1113/jphysiol.1977.sp011996; GOLD WM, 1980, PHYSL PHARM AIRWAYS, P123; HETZEL MR, 1981, THORAX, V36, P481, DOI 10.1136/thx.36.7.481; HUTCHEON M, 1974, AM REV RESPIR DIS, V110, P158; MACDONALD JB, 1980, THORAX, V35, P64, DOI 10.1136/thx.35.1.64; NADEL JA, 1981, PHYSL PHARM AIRWAYS, P196; TASHKIN DP, 1980, AM J MED, V68, P14, DOI 10.1016/0002-9343(80)90156-4; TOWNLEY RG, 1982, CHEST, V82, P401, DOI 10.1378/chest.82.4.401; TRIGGLE DJ, 1980, CHEST, V78, P174, DOI 10.1378/chest.78.1_Supplement.174; VATER W, 1976, P INT ADALAT S AMSTE, P33; WEISS E B, 1981, American Review of Respiratory Disease, V123, P42	16	56	56	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	3					269	273		10.1016/0091-6749(83)90031-3	http://dx.doi.org/10.1016/0091-6749(83)90031-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RH938	6350411				2022-12-18	WOS:A1983RH93800007
J	CONOLLY, ME; TASHKIN, DP; HUI, KKP; LITTNER, MR; WOLFE, RN				CONOLLY, ME; TASHKIN, DP; HUI, KKP; LITTNER, MR; WOLFE, RN			SELECTIVE SUBSENSITIZATION OF BETA-ADRENERGIC RECEPTORS IN CENTRAL AIRWAYS OF ASTHMATICS AND NORMAL SUBJECTS DURING LONG-TERM THERAPY WITH INHALED SALBUTAMOL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,SCH MED,CTR HLTH SCI,DEPT MED,DIV PULM DIS,LOS ANGELES,CA 90024; SEPULVEDA VET ADM MED CTR,LOS ANGELES,CA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	CONOLLY, ME (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,CTR HLTH SCI,DEPT MED,DIV PHARMACOL,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI015332] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01 HL27796-01A1] Funding Source: Medline; NIAID NIH HHS [AI 15332] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1966, HEALTH PHYS, V12, P173; BRANDON ML, 1978, ANN ALLERGY, V40, P86; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHERVINSKY P, 1969, ANN ALLERGY, V27, P611; COLUCCI WS, 1981, NEW ENGL J MED, V305, P185, DOI 10.1056/NEJM198107233050402; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; CONOLLY ME, 1971, BRIT J PHARMACOL, V43, P389; CONOLLY ME, 1976, BRIT J PHARMACOL, V58, P448; DAVIS C, 1980, BRIT J CLIN PHARMACO, V10, P417, DOI 10.1111/j.1365-2125.1980.tb01782.x; DETROYER A, 1978, AM REV RESPIR DIS, V118, P987; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; FRANKLIN TJ, 1973, NATURE-NEW BIOL, V246, P146, DOI 10.1038/newbio246146a0; GALANT SP, 1978, NEW ENGL J MED, V299, P933, DOI 10.1056/NEJM197810262991707; GIBSON GJ, 1978, BRIT J DIS CHEST, V72, P199, DOI 10.1016/0007-0971(78)90042-6; HARVEY JE, 1979, THORAX, V34, P416; HOLGATE ST, 1977, LANCET, V2, P375; HOLGATE ST, 1980, CLIN SCI, V59, P155, DOI 10.1042/cs0590155; INMAN WHW, 1974, EVALUATION BRONCHODI, P191; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V59, P383, DOI 10.1016/0091-6749(77)90023-9; KANG YFJ, 1969, BR MED J, V2, P287; KEIGHLEY JF, 1966, ANN INTERN MED, V65, P985, DOI 10.7326/0003-4819-65-5-985; LARSSON S, 1977, J ALLERGY CLIN IMMUN, V59, P93, DOI 10.1016/0091-6749(77)90209-3; LITTNER MR, 1979, ANN ALLERGY, V43, P135; MUKHERJEE C, 1975, P NATL ACAD SCI USA, V72, P1945, DOI 10.1073/pnas.72.5.1945; NELSON HS, 1977, AM REV RESPIR DIS, V116, P871; PATERSON J W, 1971, British Journal of Diseases of the Chest, V65, P21, DOI 10.1016/S0007-0971(71)80015-3; PEEL ET, 1980, AM REV RESPIR DIS, V121, P973; PLUMMER AL, 1978, CHEST, V73, P949, DOI 10.1378/chest.73.6.949; Siegel S., 1956, NONPARAMETRIC STAT B; SPEIZER FE, 1968, BRIT MED J, V1, P339, DOI 10.1136/bmj.1.5588.339; TAPLIN GV, 1977, CHEST, V71, P567, DOI 10.1378/chest.71.5.567; TASHKIN DP, 1982, AM REV RESPIR DIS, V125, P185; TASHKIN DP, 1980, AM J MED, V68, P14, DOI 10.1016/0002-9343(80)90156-4; VANMETRE TE, 1969, J ALLERGY, V43, P101, DOI 10.1016/0021-8707(69)90130-0	35	56	56	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	6					423	431		10.1016/0091-6749(82)90004-5	http://dx.doi.org/10.1016/0091-6749(82)90004-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PT744	6292279	Bronze			2022-12-18	WOS:A1982PT74400004
J	ADKINSON, NF				ADKINSON, NF			THE RADIOALLERGOSORBENT TEST IN 1981 - LIMITATIONS AND REFINEMENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ADKINSON, NF (corresponding author), GOOD SAMARITAN HOSP,DIV CLIN IMMUNOL,CINCINNATI,OH 45220, USA.							ADKINSON NF, 1980, J ALLERGY CLIN IMMUN, V65, P1, DOI 10.1016/0091-6749(80)90169-4; CONROY MC, 1977, J IMMUNOL, V118, P1317; HOFFMAN DR, ANN ALLERGY; SANTRACH PJ, 1981, J ALLERGY CLIN IMMUN, V67, P97, DOI 10.1016/0091-6749(81)90003-8; SCHELLENBERG RR, 1978, J ALLERGY CLIN IMMUN, V63, P15; ZEISS CR, 1981, J ALLERGY CLIN IMMUN, V67, P105, DOI 10.1016/0091-6749(81)90004-X; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V66, P173, DOI 10.1016/0091-6749(80)90066-4; ZIMMERMANN EM, 1980, J ALLERGY CLIN IMMUN, V66, P386, DOI 10.1016/0091-6749(80)90118-9; 1980, J ALLERGY CLIN IMMUN, V65, P231	9	56	56	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	2					87	89		10.1016/0091-6749(81)90001-4	http://dx.doi.org/10.1016/0091-6749(81)90001-4			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LB947	7451784				2022-12-18	WOS:A1981LB94700001
J	KAPLAN, AP; GAROFALO, J				KAPLAN, AP; GAROFALO, J			IDENTIFICATION OF A NEW PHYSICALLY INDUCED URTICARIA - COLD-INDUCED CHOLINERGIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KAPLAN, AP (corresponding author), SUNY STONY BROOK,CTR HLTH SCI,DEPT MED,DIV ALLERGY,STONY BROOK,NY 11794, USA.				NIAID NIH HHS [AI 16337-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI016337] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; GOREVIC PD, 1980, INT J DERMATOL, V19, P417, DOI 10.1111/j.1365-4362.1980.tb05893.x; Grant RT, 1936, CLIN SCI, V2, P253; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; SIGLER RW, 1979, J ALLERGY CLIN IMMUN, V63, P35, DOI 10.1016/0091-6749(79)90159-3; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; WAREN RP, 1974, URTICARIA, P140	7	56	56	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	6					438	441						4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MU790	7310011				2022-12-18	WOS:A1981MU79000006
J	GLEICH, GJ; ADOLPHSON, CR; YUNGINGER, JW				GLEICH, GJ; ADOLPHSON, CR; YUNGINGER, JW			MINI-RAST - COMPARISON WITH OTHER VARIETIES OF THE RADIOALLERGOSORBENT TEST FOR THE MEASUREMENT OF IMMUNOGLOBULIN-E ANTIBODIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO MED SCH,MAYO CLIN & FDN,DEPT MED,ROCHESTER,MN 55901; MAYO MED SCH,MAYO CLIN & FDN,DEPT PEDIAT,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic	GLEICH, GJ (corresponding author), MAYO MED SCH,MAYO CLIN & FDN,DEPT IMMUNOL,ROCHESTER,MN 55901, USA.							ADKINSON NF, 1976, MANUAL CLIN IMMUNOLO, P590; ADOLPHSON C, 1978, J ALLERGY CLIN IMMUN, V62, P197, DOI 10.1016/0091-6749(78)90208-7; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; DIXON WJ, 1969, INTRO STATISTICAL AN, P142; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P334, DOI 10.1016/0091-6749(75)90005-6; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; GLEICH GJ, 1978, ALLERGY PRINCIPLES P, V1, P231; ISHIZAKA K, 1970, IMMUNOCHEMISTRY, V7, P687, DOI 10.1016/0019-2791(70)90175-8; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LYNCH NR, 1975, CLIN EXP IMMUNOL, V22, P35; PAULL BR, 1978, J IMMUNOL, V120, P1917; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; VERVLOET D, 1974, Clinical Allergy, V4, P359, DOI 10.1111/j.1365-2222.1974.tb01397.x; WIDE L, 1967, LANCET, V2, P1105; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V57, P293, DOI 10.1016/0091-6749(76)90085-3; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	19	56	56	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	1					20	28		10.1016/0091-6749(80)90172-4	http://dx.doi.org/10.1016/0091-6749(80)90172-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB459	7350202				2022-12-18	WOS:A1980JB45900004
J	LIGHT, WC; REISMAN, RE; SHIMIZU, M; ARBESMAN, CE				LIGHT, WC; REISMAN, RE; SHIMIZU, M; ARBESMAN, CE			UNUSUAL REACTIONS FOLLOWING INSECT STINGS - CLINICAL FEATURES AND IMMUNOLOGICAL ANALYSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14203; SUNY BUFFALO,DEPT MED,BUFFALO,NY 14214; SUNY BUFFALO,DEPT MICROBIOL,BUFFALO,NY 14214	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								ASHWORTH B, 1964, J NEUROL NEUROSUR PS, V27, P542, DOI 10.1136/jnnp.27.6.542; BURKE DM, 1954, AMA AM J DIS CHILD, V88, P772, DOI 10.1001/archpedi.1954.02050100774011; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; DAY JM, 1962, ARCH NEUROL-CHICAGO, V7, P184, DOI 10.1001/archneur.1962.04210030022003; FOGEL BJ, 1967, AM J DIS CHILD, V114, P325, DOI 10.1001/archpedi.1967.02090240139016; FUJITA Y, 1975, INT ARCH ALLER A IMM, V49, P724, DOI 10.1159/000231456; GOLDSTEIN NP, 1965, JAMA, V193, P155; MEANS ED, 1973, NEUROLOGY, V23, P881, DOI 10.1212/WNL.23.8.881; REISMAN RE, 1962, J ALLERGY, V33, P178, DOI 10.1016/0021-8707(62)90007-2; REISMAN RE, 1975, J ALLERGY CLIN IMMUN, V56, P443, DOI 10.1016/0091-6749(75)90062-7; REISMAN RE, 1961, J ALLERGY, V32, P531, DOI 10.1016/0021-8707(61)90008-9; REISMAN RE, 1976, J ALLERGY CLIN IMMUN, V57, P547, DOI 10.1016/0091-6749(76)90005-1; ROSS ALEXANDER T., 1939, JOUR ALLERGY, V10, P382, DOI 10.1016/S0021-8707(39)90154-1; RYTAND DAVID A., 1955, STANFORD MED BULL, V13, P224; SHEEHAN RK, 1965, J AMER MED ASSOC, V193, P155, DOI 10.1001/jama.1965.03090020069022; SHIMIZO M, 1976, J ALLERGY CLIN IMMUN, V57, P211; SHIMIZU M, TO BE PUBLISHED; VALENTINE F, 1971, IN VITRO METHODS CEL; VENTERS HOMER D., 1961, AMER JOUR DIS CHILDREN, V102, P688	19	56	56	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	5					391	397		10.1016/0091-6749(77)90024-0	http://dx.doi.org/10.1016/0091-6749(77)90024-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DF215	140188				2022-12-18	WOS:A1977DF21500010
J	LOPEZ, M; SALVAGGIO, J				LOPEZ, M; SALVAGGIO, J			ALLERGENICITY AND IMMUNOGENICITY OF BASIDIOMYCETES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,SCH MED,DEPT MED,NEW ORLEANS,LA 70112	Tulane University								ADAMS KF, 1968, ACTA ALLERGOL, V23, P265, DOI 10.1111/j.1398-9995.1968.tb04059.x; Arquembourg PC, 1970, PRIMER IMMUNOELECTRO; BLATT H, 1962, PROG ALLERGY, V20, P263; BRUCE RA, 1963, INT ARCH ALLER A IMM, V22, P294, DOI 10.1159/000229372; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; DAVIES RR, 1965, ACTA ALLERGOL, V20, P508; DAVIES RR, 1963, ACTA ALLERGOL, V28, P131; GREGORY PH, 1952, NATURE, V170, P414, DOI 10.1038/170414a0; GREGORY PH, 1957, J GEN MICROBIOL, V17, P135, DOI 10.1099/00221287-17-1-135; HERXHEIMER H, 1966, LANCET, V1, P572; HERXHEIMER H, 1969, LANCET, V2, P131; HYDE H. A., 1960, ACTA ALLERGOL, V15, P159; HYDE HA, 1956, BMJ-BRIT MED J, V1, P886, DOI 10.1136/bmj.1.4972.886; KAWAI T, 1973, CHEST, V64, P420, DOI 10.1378/chest.64.4.420; KRAMER C. L., 1959, TRANS KANSAS A CAD SCI, V62, P184, DOI 10.2307/3626975; MAUNSELL K, 1954, PROG ALLERGY, V4, P457, DOI 10.1159/000313677; PHANUPHAK P, 1975, CHEST, V68, P753, DOI 10.1378/chest.68.6.753; PRINCE H, 1964, ANN ALLERGY, V22, P575; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; SALVAGGIO J, 1969, J ALLERGY, V44, P344, DOI 10.1016/0021-8707(69)90026-4; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P82, DOI 10.1016/0091-6749(71)90090-X; WIDE L, 1973, CLIN ALLERGY, V3, P583, DOI 10.1111/j.1365-2222.1973.tb03063.x; WIDE L, 1967, LANCET, V2, P1105	23	56	56	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	5					480	488		10.1016/0091-6749(76)90064-6	http://dx.doi.org/10.1016/0091-6749(76)90064-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BR201	1262615	Bronze			2022-12-18	WOS:A1976BR20100012
J	OHMAN, JL; LOWELL, FC; BLOCH, KJ				OHMAN, JL; LOWELL, FC; BLOCH, KJ			ALLERGENS OF MAMMALIAN ORIGIN .2. CHARACTERIZATION OF ALLERGENS EXTRACTED FROM RAT, MOUSE, GUINEA-PIG, AND RABBIT PELTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV, MED SCH, DEPT MED, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, MED SERV, ARTHRIT UNIT, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, MED SERV, ALLERGY UNIT, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, MED SERV, CLIN IMMUNOL UNIT, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital								ARONSSON T, 1973, INT ARCH ALLER A IMM, V45, P50, DOI 10.1159/000231000; Berrens L, 1970, Rev Allergy, V24, P917; BRANDT R, 1973, INT ARCH ALLER A IMM, V45, P447, DOI 10.1159/000231062; CESKA M, 1972, INT ARCH ALLER A IMM, V43, P427, DOI 10.1159/000230859; CESKA M, 1972, INT ARCH ALLER A IMM, V43, P419, DOI 10.1159/000230858; CESKA M, 1973, INT ARCH ALLER A IMM, V45, P808, DOI 10.1159/000231081; CESKA M, 1973, INT ARCH ALLER A IMM, V45, P405, DOI 10.1159/000231058; CHAN PCY, 1967, IMMUNOLOGY, V13, P633; HOLFORD-STREVENS V, 1973, Clinical Allergy, V3, P225, DOI 10.1111/j.1365-2222.1973.tb01325.x; HOLLEY JW, 1969, ACTA ALLERGOL, V24, P284, DOI 10.1111/j.1398-9995.1969.tb03744.x; LAURELL CB, 1965, SCAND J CLIN LAB INV, V17, P271, DOI 10.3109/00365516509075347; OHMAN JL, 1973, J ALLERGY CLIN IMMUN, V52, P231, DOI 10.1016/0091-6749(73)90061-4; OVARY Z, 1963, J EXP MED, V117, P951, DOI 10.1084/jem.117.6.951; Pepys J, 1968, CLIN ASPECTS IMMUNOL, P192; PONTERIUS G, 1973, INT ARCH ALLER A IMM, V44, P679, DOI 10.1159/000230970; Simon FA, 1942, J EXP MED, V75, P315, DOI 10.1084/jem.75.3.315; SIMON FRANK A., 1941, JOUR ALLERGY, V12, P610, DOI 10.1016/S0021-8707(41)90212-5; SQUIRE JR, 1950, CLIN SCI, V9, P127; STANWORTH DR, 1957, BIOCHEM J, V65, P582, DOI 10.1042/bj0650582; VARGA JM, 1972, INT ARCH ALLER A IMM, V42, P438, DOI 10.1159/000230624; Walker IC, 1917, J MED RES, V35, P497; Wodehouse RP, 1917, J IMMUNOL, V2, P227; YMAN L, 1973, INT ARCH ALLER A IMM, V44, P358, DOI 10.1159/000230944	23	56	56	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	1					16	24		10.1016/S0091-6749(75)80004-2	http://dx.doi.org/10.1016/S0091-6749(75)80004-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V2344	162912				2022-12-18	WOS:A1975V234400003
J	HENDERSON, LL; SWEDLUND, HA; VANDELLE.RG; MARCOUX, JP; CARRYER, HM; PETERS, GA; GLEICH, GJ				HENDERSON, LL; SWEDLUND, HA; VANDELLE.RG; MARCOUX, JP; CARRYER, HM; PETERS, GA; GLEICH, GJ			EVALUATION OF LGE TESTS IN AN ALLERGY PRACTICE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ARBESMAN CE, 1971, J ALLERGY, V47, P85; BUCKLEY RH, 1971, J ALLERGY, V47, P108; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; HEINER DC, 1970, J ALLERGY, V45, P30, DOI 10.1016/0021-8707(70)90014-6; JOHANSSO.SG, 1967, LANCET, V2, P951; JOHANSSON SG, 1968, LANCET, V1, P1118; JOHANSSON SG, 1968, IMMUNOLOGY, V14, P265; VANDELLEN RG, 1971, NEW ENGL J MED, V285, P146, DOI 10.1056/NEJM197107152850304; VATANASUK M, 1971, J ALLERGY, V47, P109; WIDE L, 1967, LANCET, V2, P1105; YUNGINGER JW, 1971, J ALLERGY, V47, P87	11	56	56	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	6					361	+		10.1016/0091-6749(71)90082-0	http://dx.doi.org/10.1016/0091-6749(71)90082-0			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L0384	4157465	Bronze			2022-12-18	WOS:A1971L038400005
J	Ostling, J; van Geest, M; Schofield, JPR; Jevnikar, Z; Wilson, S; Ward, J; Lutter, R; Shaw, DE; Bakke, PS; Caruso, M; Dahlen, SE; Fowler, SJ; Horvath, I; Krug, N; Montuschi, P; Sanak, M; Sandstrom, T; Sun, K; Pandis, I; Auffray, C; Sousa, AR; Guo, YK; Adcock, IM; Howarth, P; Chung, KF; Bigler, J; Sterk, PJ; Skipp, PJ; Djukanovic, R; Vaarala, O; Ahmed, H; Auffray, C; Bakke, P; Bansal, AT; Baribaud, F; Bates, S; Bel, EH; Bigler, J; Bisgaard, H; Boedigheimer, MJ; Bonnelykke, K; Brandsma, J; Brinkman, P; Bucchioni, E; Burg, D; Bush, A; Caruso, M; Chaiboonchoe, A; Chanez, P; Chung, KF; Compton, CH; Corfield, J; D'Amico, A; Dahlen, SE; De Meulder, B; Djukanovic, R; Erpenbeck, VJ; Erzen, D; Fichtner, K; Fitch, N; Fleming, LJ; Formaggio, E; Fowler, SJ; Frey, U; Gahlemann, M; Geiser, T; Guo, Y; Hashimoto, S; Haughney, J; Hedlin, G; Hekking, PW; Higenbottam, T; Hohlfeld, JM; Holweg, C; Horvath, I; Howarth, P; James, AJ; Knowles, R; Knox, AJ; Krug, N; Lefaudeux, D; Loza, MJ; Lutter, R; Manta, A; Masefield, S; Matthews, JG; Mazein, A; Meiser, A; Middelveld, RJM; Miralpeix, M; Montuschi, P; Mores, N; Murray, CS; Musial, J; Myles, D; Pahus, L; Pandis, I; Pavlidis, S; Powell, P; Pratico, G; Valls, MP; Rao, N; Riley, J; Roberts, A; Roberts, G; Rowe, A; Sandstrom, T; Seibold, W; Selby, A; Shaw, DE; Sigmund, R; Singer, F; Skipp, PJ; Sousa, AR; Sterk, PJ; Sun, K; Thornton, B; van Aalderen, WM; van Geest, M; Vestbo, J; Vissing, NH; Wagener, AH; Wagers, SS; Weiszhart, Z; Wheelock, CE; Wilson, SJ				Oestling, Joergen; van Geest, Marleen; Schofield, James P. R.; Jevnikar, Zala; Wilson, Susan; Ward, Jonathan; Lutter, Rene; Shaw, Dominick E.; Bakke, Per S.; Caruso, Massimo; Dahlen, Sven-Erik; Fowler, Stephen J.; Horvath, Ildiko; Krug, Norbert; Montuschi, Paolo; Sanak, Marek; Sandstrom, Thomas; Sun, Kai; Pandis, Ioannis; Auffray, Charles; Sousa, Ana R.; Guo, Yike; Adcock, Ian M.; Howarth, Peter; Chung, Kian Fan; Bigler, Jeanette; Sterk, Peter J.; Skipp, Paul J.; Djukanovic, Ratko; Vaarala, Outi; Ahmed, H.; Auffray, C.; Bakke, P.; Bansal, A. T.; Baribaud, F.; Bates, S.; Bel, E. H.; Bigler, J.; Bisgaard, H.; Boedigheimer, M. J.; Bonnelykke, K.; Brandsma, J.; Brinkman, P.; Bucchioni, E.; Burg, D.; Bush, A.; Caruso, M.; Chaiboonchoe, A.; Chanez, P.; Chung, K. F.; Compton, C. H.; Corfield, J.; D'Amico, A.; Dahlen, S. E.; De Meulder, B.; Djukanovic, R.; Erpenbeck, V. J.; Erzen, D.; Fichtner, K.; Fitch, N.; Fleming, L. J.; Formaggio, E.; Fowler, S. J.; Frey, U.; Gahlemann, M.; Geiser, T.; Guo, Y.; Hashimoto, S.; Haughney, J.; Hedlin, G.; Hekking, P. W.; Higenbottam, T.; Hohlfeld, J. M.; Holweg, C.; Horvath, I.; Howarth, P.; James, A. J.; Knowles, R.; Knox, A. J.; Krug, N.; Lefaudeux, D.; Loza, M. J.; Lutter, R.; Manta, A.; Masefield, S.; Matthews, J. G.; Mazein, A.; Meiser, A.; Middelveld, R. J. M.; Miralpeix, M.; Montuschi, P.; Mores, N.; Murray, C. S.; Musial, J.; Myles, D.; Pahus, L.; Pandis, I.; Pavlidis, S.; Powell, P.; Pratico, G.; Valls, M. Puig; Rao, N.; Riley, J.; Roberts, A.; Roberts, G.; Rowe, A.; Sandstrom, T.; Seibold, W.; Selby, A.; Shaw, D. E.; Sigmund, R.; Singer, F.; Skipp, P. J.; Sousa, A. R.; Sterk, P. J.; Sun, K.; Thornton, B.; van Aalderen, W. M.; van Geest, M.; Vestbo, J.; Vissing, N. H.; Wagener, A. H.; Wagers, S. S.; Weiszhart, Z.; Wheelock, C. E.; Wilson, S. J.		U-BIOPRED Study Grp	IL-17-high asthma with features of a psoriasis immunophenotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-17; asthma; bronchial biopsies; bronchial brushings; biomarkers; psoriasis	URINARY-EXCRETION; DOUBLE-BLIND; EXPRESSION; CELLS; EXACERBATION; INFLAMMATION; POPULATION; BRODALUMAB; PHENOTYPES; ENDOTYPES	Background: The role of IL-17 immunity is well established in patients with inflammatory diseases, such as psoriasis and inflammatory bowel disease, but not in asthmatic patients, in whom further study is required. Objective: We sought to undertake a deep phenotyping study of asthmatic patients with upregulated IL-17 immunity. Methods: Whole-genome transcriptomic analysis was performed by using epithelial brushings, bronchial biopsy specimens (91 asthmatic patients and 46 healthy control subjects), and whole blood samples (n = 498) from the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) cohort. Gene signatures induced in vitro by IL-17 and IL-13 in bronchial epithelial cells were used to identify patients with IL-17-high and IL-13-high asthma phenotypes. Results: Twenty-two of 91 patients were identified with IL-17, and 9 patients were identified with IL-13 gene signatures. The patients with IL-17-high asthma were characterized by risk of frequent exacerbations, airway (sputum and mucosal) neutrophilia, decreased lung microbiota diversity, and urinary biomarker evidence of activation of the thromboxane B2 pathway. In pathway analysis the differentially expressed genes in patients with IL-17-high asthma were shared with those reported as altered in psoriasis lesions and included genes regulating epithelial barrier function and defense mechanisms, such as IL1B, IL6, IL8, and beta-defensin. Conclusion: The IL-17-high asthma phenotype, characterized by bronchial epithelial dysfunction and upregulated antimicrobial and inflammatory response, resembles the immunophenotype of psoriasis, including activation of the thromboxane B2 pathway, which should be considered a biomarker for this phenotype in further studies, including clinical trials targeting IL-17.	[Oestling, Joergen; van Geest, Marleen; Jevnikar, Zala; Vaarala, Outi] AstraZeneca, Autoimmun IMED Biotech Unit, Inflammat, Resp, Gothenburg, Sweden; [Schofield, James P. R.; Skipp, Paul J.] Univ Southampton, Ctr Prote Res, Southampton, Hants, England; [Schofield, James P. R.; Wilson, Susan; Ward, Jonathan; Howarth, Peter; Skipp, Paul J.; Djukanovic, Ratko] Univ Southampton, NIHR Southampton Biomed Res Ctr Clin & Expt Sci, Fac Res, Southampton, Hants, England; [Wilson, Susan] Univ Southampton, Fac Med, Histochem Res Unit, Southampton, Hants, England; [Lutter, Rene] Univ Amsterdam, Dept Expt Immunol, AUMC, Amsterdam, Netherlands; [Lutter, Rene; Sterk, Peter J.] Univ Amsterdam, AUMC, Dept Resp Med, Amsterdam, Netherlands; [Shaw, Dominick E.; Knox, A. J.; Shaw, D. E.] Univ Nottingham, Resp Res Unit, Nottingham, England; [Bakke, Per S.] Univ Bergen, Inst Med, Bergen, Norway; [Caruso, Massimo; Caruso, M.] Univ Catania, Dept Clin & Expt Med, Catania, Italy; [Dahlen, Sven-Erik] Karolinska Inst, Inst Environm Med, Ctr Allergy Res, Stockholm, Sweden; [Fowler, Stephen J.] Univ Manchester, Resp & Allergy Res Grp, Manchester, Lancs, England; [Horvath, Ildiko] Semmelweis Univ, Dept Pulmonol, Budapest, Hungary; [Krug, Norbert] Fraunhofer Inst Toxicol & Expt Med Hannover, Hannover, Germany; [Montuschi, Paolo] Univ Cattolica Sacro Cuore, Fac Med, Fdn Policlin Agostino Gemelli IRCCS, Rome, Italy; [Sanak, Marek] Jagiellonian Univ, Med Coll, Lab Mol Biol & Clin Genet, Krakow, Poland; [Sandstrom, Thomas] Umea Univ, Dept Publ Hlth, Dept Med, Umea, Sweden; [Sandstrom, Thomas] Umea Univ, Clin Med Resp Med Unit, Umea, Sweden; [Sun, Kai; Pandis, Ioannis; Guo, Yike] Imperial Coll, Data Sci Inst, London, England; [Auffray, Charles] Univ Lyon, European Inst Syst Biol & Med, INSERM, CNRS,ENS,UCBL, Lyon, France; [Shaw, Dominick E.; Sousa, Ana R.] GlaxoSmithKline, Resp Therapeut Unit, Stockley Pk, England; [Adcock, Ian M.; Chung, Kian Fan] Imperial Coll London, Natl Heart & Lung Inst, Airways Dis Sect, Expt Studies, London, England; [Bigler, Jeanette; Bigler, J.; Boedigheimer, M. J.] Amgen Inc, Thousand Oaks, CA USA; [Adcock, Ian M.; Bush, A.; Chung, K. F.; Fleming, L. J.; Pavlidis, S.] Imperial Coll, Natl Heart & Lung Inst, London, England; [Ahmed, H.; Auffray, C.; Chaiboonchoe, A.; De Meulder, B.; Lefaudeux, D.; Mazein, A.] UCBL, European Inst Syst Biol & Med, CNRS, ENS,INSERM, Lyon, France; [Bakke, P.] Univ Bergen, Dept Clin Sci, Bergen, Norway; [Bansal, A. T.] St Johns Innovat Ctr, Acclarogen, Cambridge, England; [Baribaud, F.; Loza, M. J.; Rao, N.] Janssen R&D, Malvern, PA USA; [Bates, S.; Compton, C. H.; Myles, D.; Riley, J.; Sousa, A. R.] GlaxoSmithKline, Resp Therapeut Unit, London, England; [Bel, E. H.; Brinkman, P.; Hashimoto, S.; Hekking, P. W.; Lutter, R.; Sterk, P. J.; van Aalderen, W. M.] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands; [Bisgaard, H.; Bonnelykke, K.; Vissing, N. H.] Copenhagen Prospect Studies Asthma Childhood, COPSAC, Herlev, Denmark; [Bisgaard, H.; Bonnelykke, K.; Vissing, N. H.] Univ Copenhagen, Gentofte Hosp, Copenhagen, Denmark; [Brandsma, J.] Univ Southampton, Southampton, Hants, England; [Bucchioni, E.] Chiesi Pharmaceut SPA, Parma, Italy; [Burg, D.; Skipp, P. J.] Univ Southampton, Inst Life Sci, Ctr Prote Res, Southampton, Hants, England; [Bush, A.; Fleming, L. J.] Royal Brompton & Harefield NHS Trust, London, England; [Chanez, P.; Pahus, L.] Aix Marseille Univ, Clin Bronches Allergies & Sommeil, AP HM, Marseille, France; [Corfield, J.] Areteva R&D, Nottingham, England; [D'Amico, A.] Univ Roma Tor Vergata, Rome, Italy; [Dahlen, S. E.; Hedlin, G.; James, A. J.; Middelveld, R. J. M.] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Djukanovic, R.; Howarth, P.; Roberts, G.; Selby, A.] NIHR Southampton Resp Biomed Res Unit & Clin & Ex, Southampton, Hants, England; [Erpenbeck, V. J.] Novartis Inst Biomed Res, Resp Profiling, Translat Med, Basel, Switzerland; [Erzen, D.; Fichtner, K.] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Fitch, N.; Wagers, S. S.] BioSci Consulting, Maasmechelen, Belgium; [Formaggio, E.; Pratico, G.] CROMSOURCE, Verona, Italy; [Fowler, S. J.; Murray, C. S.; Vestbo, J.] Univ Manchester, Inst Inflammat & Repair, Ctr Resp Med & Allergy, Manchester, Lancs, England; [Fowler, S. J.] Univ Hosp South Manchester, Acad Hlth Sci Ctr, Manchester, Lancs, England; [Frey, U.] Univ Childrens Hosp, Basel, Switzerland; [Gahlemann, M.] Boehringer Ingelheim Schweiz GmbH, Basel, Switzerland; [Geiser, T.] Univ Hosp Bern, Dept Resp Med, Bern, Switzerland; [Guo, Y.; Meiser, A.; Pandis, I.; Sun, K.] Imperial Coll, Data Sci Inst, London, England; [Haughney, J.] Int Primary Care Resp Grp, Aberdeen, Scotland; [Hedlin, G.] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Higenbottam, T.] Allergy Therapeut, Worthing, W Sussex, England; [Hohlfeld, J. M.] Fraunhofer Inst Toxicol & Expt Med, Hannover, Germany; [Holweg, C.; Matthews, J. G.] Genentech Inc, Resp & Allergy Dis, San Francisco, CA USA; [Horvath, I.] Semmelweis Univ, Budapest, Hungary; [Knowles, R.] Arachos Pharma, Stevenge, England; [Krug, N.] Fraunhofer Inst Toxicol & Expt Med, Hannover, Germany; [Manta, A.] Roche Diagnost GmbH, Mannheim, Germany; [Masefield, S.; Powell, P.] European Lung Fdn, Sheffield, S Yorkshire, England; [Miralpeix, M.] Almirall, Barcelona, Spain; [Montuschi, P.; Mores, N.] Univ Cattolica Sacro Cuore, Milan, Italy; [Musial, J.] Jagiellonian Univ, Med Coll, Dept Med, Krakow, Poland; [Valls, M. Puig] CROMSOURCE, Barcelona, Spain; [Roberts, A.] Asthma UK, London, England; [Rowe, A.] Janssen R&D UK, High Wycombe, Bucks, England; [Sandstrom, T.] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden; [Seibold, W.] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Sigmund, R.] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Singer, F.] Univ Childrens Hosp, Zurich, Switzerland; [van Geest, M.] AstraZeneca, Molndal, Sweden; [Wagener, A. H.] Acad Med Ctr Amsterdam, Amsterdam, Netherlands; [Weiszhart, Z.] Semmelweis Univ, Budapest, Hungary; [Wheelock, C. E.] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Wilson, S. J.] Univ Southampton, Fac Med, Histochem Res Unit, Southampton, Hants, England	AstraZeneca; University of Southampton; University of Southampton; University of Southampton; University of Amsterdam; University of Amsterdam; University of Nottingham; University of Bergen; University of Catania; Karolinska Institutet; University of Manchester; Semmelweis University; Fraunhofer Gesellschaft; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Jagiellonian University; Collegium Medicum Jagiellonian University; Umea University; Umea University; Imperial College London; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; GlaxoSmithKline; Imperial College London; Amgen; Imperial College London; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Bergen; St Johns Innovation Centre - UK; GlaxoSmithKline; University of Amsterdam; Academic Medical Center Amsterdam; University of Copenhagen; Herlev & Gentofte Hospital; University of Southampton; Chiesi Pharmaceuticals Inc; University of Southampton; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Rome Tor Vergata; Karolinska Institutet; Novartis; Boehringer Ingelheim; University of Manchester; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Boehringer Ingelheim; University of Bern; University Hospital of Bern; Imperial College London; Karolinska Institutet; Fraunhofer Gesellschaft; Roche Holding; Genentech; Semmelweis University; Fraunhofer Gesellschaft; Roche Holding; Almirall; Catholic University of the Sacred Heart; Jagiellonian University; Collegium Medicum Jagiellonian University; Umea University; Boehringer Ingelheim; Boehringer Ingelheim; University Children's Hospital Zurich; AstraZeneca; University of Amsterdam; Academic Medical Center Amsterdam; Semmelweis University; Karolinska Institutet; University of Southampton	Djukanovic, R (corresponding author), Southampton Univ Hosp, Sir Henry Wellcome Labs, Mailpoint 810,Level F,South Block, Southampton SO16 6YD, Hants, England.	rd1@soton.ac.uk	Thorsen, Jonathan/AAQ-9269-2021; Horváth, Ildikó/GPP-6088-2022; Singer, Florian/AAO-1460-2021; 郭, 伊可/GYD-3212-2022; Sanak, Marek/AAV-1628-2021; Sterk, P.J./AAK-8175-2020; Brinkman, Paul/AAV-5110-2021; Fleming, Louise/ABD-7452-2020; Gómez Castellà, Cristina/B-2726-2017; James, Anna/AAY-9937-2021; Caruso, Massimo/P-4161-2016; Chung, Kian Fan/B-1872-2012	Thorsen, Jonathan/0000-0003-0200-0461; Singer, Florian/0000-0003-3471-5664; Sanak, Marek/0000-0001-7635-8103; Gómez Castellà, Cristina/0000-0001-8518-0095; Caruso, Massimo/0000-0002-4412-2080; Chung, Kian Fan/0000-0001-7101-1426; Pahus, Laurie/0000-0002-5265-2874; Adcock, Ian/0000-0003-2101-8843; van Drunen, Cornelis M/0000-0001-5503-066X; Schofield, James/0000-0003-4542-6614; Yang, Xian/0000-0002-1496-8923; Brinkman, Paul/0000-0003-4546-8478; Nordlund, Bjorn/0000-0001-9888-1659; Knox, Alan/0000-0002-5906-4143; chanez, pascal/0000-0003-4059-0917; Stokholm, Jakob/0000-0003-4989-9769; Fowler, Stephen/0000-0002-4524-1663; Rossios, Christos/0000-0003-3470-3233; von Garnier, Christophe/0000-0003-3585-9176; Fleming, Louise/0000-0002-7268-7433; Kupczyk, Maciej/0000-0003-0800-7867; Hashimoto, Simone/0000-0001-8995-3817; Murray, Clare/0000-0002-8961-8055; MONTUSCHI, Paolo/0000-0001-5589-1750; Howarth, Peter/0000-0003-0619-7927; Kots, Maxim/0000-0003-3466-4641; Reinke, Stacey/0000-0002-0758-0330; Frey, Urs/0000-0003-3773-2822; Djukanovic, Ratko/0000-0001-6039-5612; Rowe, Anthony/0000-0003-1829-1179; Balgoma Hernando, David/0000-0001-6463-4502; Nicholas, Benjamin/0000-0003-1467-9643	BBSRC [BB/M012387/1] Funding Source: UKRI	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Alnahas S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01562; Besnard AG, 2012, J MOL CELL BIOL, V4, P3, DOI 10.1093/jmcb/mjr042; Bigler J, 2017, AM J RESP CRIT CARE, V195, P1311, DOI 10.1164/rccm.201604-0866OC; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Chambers ES, 2015, J ALLERGY CLIN IMMUN, V136, P628, DOI 10.1016/j.jaci.2015.01.026; Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Djukanovic R, 2002, EUR RESPIR J, V20, p1S, DOI 10.1183/09031936.02.00000102; Egeberg A, 2015, BRIT J DERMATOL, V173, P159, DOI 10.1111/bjd.13781; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Fang HY, 2015, BRIT J DERMATOL, V172, P1066, DOI 10.1111/bjd.13518; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Guerra ES, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006175; Gurczynski SJ, 2018, AM J PHYSIOL-LUNG C, V314, pL6, DOI 10.1152/ajplung.00344.2017; Hinks TSC, 2015, J ALLERGY CLIN IMMUN, V136, P323, DOI 10.1016/j.jaci.2015.01.014; Kolbinger F, 2017, J ALLERGY CLIN IMMUN, V139, P923, DOI 10.1016/j.jaci.2016.06.038; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; Kuo CHS, 2017, AM J RESP CRIT CARE, V195, P443, DOI 10.1164/rccm.201512-2452OC; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Le Rouzic O, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02434-2016; LINDEGARD B, 1986, DERMATOLOGICA, V172, P298, DOI 10.1159/000249365; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Makihara S, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.014; Martin NT, 2016, NAT IMMUNOL, V17, P122, DOI 10.1038/ni.3370; McAleer JP, 2014, IMMUNOL REV, V260, P129, DOI 10.1111/imr.12183; Nagai H, 2015, J DERMATOL, V42, P1094, DOI 10.1111/1346-8138.12955; Oosaki R, 1997, INT ARCH ALLERGY IMM, V114, P373, DOI 10.1159/000237697; Pappu R, 2012, TRENDS IMMUNOL, V33, P343, DOI 10.1016/j.it.2012.02.008; Parulekar AD, 2018, CURR OPIN PULM MED, V24, P50, DOI 10.1097/MCP.0000000000000436; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Petsky HL, 2012, THORAX, V67, P199, DOI 10.1136/thx.2010.135574; Rathore JS, 2016, VACCINE, V34, P1504, DOI 10.1016/j.vaccine.2016.02.021; Ricciardolo FLM, 2017, J ALLERGY CLIN IMMUN, V140, P395, DOI 10.1016/j.jaci.2016.10.034; Roos AB, 2015, AM J RESP CRIT CARE, V192, P428, DOI 10.1164/rccm.201409-1689OC; Russell CB, 2014, J IMMUNOL, V192, P3828, DOI 10.4049/jimmunol.1301737; Shaw DE, 2015, EUR RESPIR J, V46, P1308, DOI 10.1183/13993003.00779-2015; Siew LQC, 2017, CLIN EXP ALLERGY, V47, P740, DOI 10.1111/cea.12907; Taylor SL, 2018, J ALLERGY CLIN IMMUN, V141, P94, DOI 10.1016/j.jaci.2017.03.044; Ueharaguchi Y, 2018, J ALLERGY CLIN IMMUN, V142, P680, DOI 10.1016/j.jaci.2018.01.054; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Zhao ST, 2017, J ASTHMA, V54, P447, DOI 10.1080/02770903.2016.1223687	43	55	56	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1198	1213		10.1016/j.jaci.2019.03.027	http://dx.doi.org/10.1016/j.jaci.2019.03.027			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	30998987	Green Accepted, Green Published, Green Submitted, Bronze			2022-12-18	WOS:000495004700013
J	Hussain, M; Bonilla-Rosso, G; Chung, CKCK; Bariswyl, L; Rodriguez, MP; Kim, BS; Engel, P; Noti, M				Hussain, Maryam; Bonilla-Rosso, German; Chung, Cheong K. C. Kwong; Bariswyl, Lukas; Rodriguez, Maria Pena; Kim, Brian S.; Engel, Philipp; Noti, Mario			High dietary fat intake induces a microbiota signature that promotes food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; diet-induced obesity; high fat diet; germ-free; microbiota; dysbiosis; basophils; mast cells; IgE	GUT MICROBIOTA; INDUCED OBESITY; BARRIER FUNCTION; SENSITIZATION; ASTHMA; INFLAMMATION; MECHANISMS; NUTRITION; RESPONSES; HEALTH	Background: Diet-induced obesity and food allergies increase in tandem, but a potential cause-and-effect relationship between these diseases of affluence remains to be tested. Objective: We sought to test the role of high dietary fat intake, diet-induced obesity, and associated changes in gut microbial community structure on food allergy pathogenesis. Methods: Mice were fed a high-fat diet (HFD) for 12 weeks before food allergen sensitization on an atopic dermatitis-like skin lesion, followed by intragastric allergen challenge to induce experimental food allergy. Germ-free animals were colonized with a signature HFD or lean microbiota for 8 weeks before induction of food allergy. Food-induced allergic responses were quantified by using a clinical allergy score, serum IgE levels, serum mouse mast cell protease 1 concentrations, and type 2 cytokine responses. Accumulation of intestinal mast cells was examined by using flow cytometry and chloroacetate esterase tissue staining. Changes in the gut microbial community structure were assessed by using high-throughput 16S ribosomal DNA gene sequencing. Results: HFD-induced obesity potentiates food-induced allergic responses associated with dysregulated intestinal effector mast cell responses, increased intestinal permeability, and gut dysbiosis. An HFD-associated microbiome was transmissible to germ-free mice, with the gut microbial community structure of recipients segregating according to the microbiota input source. Independent of an obese state, an HFD-associated gut microbiome was sufficient to confer enhanced susceptibility to food allergy. Conclusion: These findings identify HFD-induced microbial alterations as risk factors for experimental food allergy and uncouple a pathogenic role of an HFD-associated microbiome from obesity. Postdieting microbiome alterations caused by overindulgence of dietary fat might increase susceptibility to food allergy.	[Hussain, Maryam; Chung, Cheong K. C. Kwong; Bariswyl, Lukas; Rodriguez, Maria Pena; Noti, Mario] Univ Bern, Dept Expt Pathol, Inst Pathol, CH-3008 Bern, Switzerland; [Hussain, Maryam] Univ Bern, Grad Sch Cellular & Biomed Sci, Bern, Switzerland; [Kim, Brian S.] Washington Univ, Sch Med, Dept Med, Div Dermatol, St Louis, MO 63110 USA; [Bonilla-Rosso, German; Engel, Philipp] Univ Lausanne, Dept Fundamental Microbiol, Lausanne, Switzerland	University of Bern; University of Bern; Washington University (WUSTL); University of Lausanne	Noti, M (corresponding author), Univ Bern, Dept Expt Pathol, Inst Pathol, CH-3008 Bern, Switzerland.	mario.noti@pathology.unibe.ch	Rosso, Germán Bonilla/F-6548-2010; SEO, GOO-YOUNG/R-2267-2018; Kim, Brian/GZK-6649-2022	Rosso, Germán Bonilla/0000-0003-0929-2890; SEO, GOO-YOUNG/0000-0001-5517-724X; Kim, Brian/0000-0002-8100-7161; Kwong Chung, Cheong KC/0000-0002-9990-9235; Noti, Mario/0000-0001-9386-1245	Human Frontier Science Program (HFSP) Young Investigator grant [RGY0077/2016]; European Research Council Starting Grant (ERC-StG) "MicroBeeOme''; Olga Mayenfisch Stiftung; Fondation Acteria; Swiss National Science Foundation [PZ00P3_154777]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR065577, R01AR070116] Funding Source: NIH RePORTER	Human Frontier Science Program (HFSP) Young Investigator grant; European Research Council Starting Grant (ERC-StG) "MicroBeeOme''; Olga Mayenfisch Stiftung; Fondation Acteria; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by the Human Frontier Science Program (HFSP) Young Investigator grant RGY0077/2016 (to P.E.), the European Research Council Starting Grant (ERC-StG) "MicroBeeOme'' (to P.E.), the Olga Mayenfisch Stiftung (to M.N.), the Fondation Acteria (to M.N.) and the Swiss National Science Foundation (PZ00P3_154777 to M.N.).	Ahmad R, 2017, SCI REP, V7, P20; Arias-Jayo N, 2018, MICROB ECOL, V13, P14; Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Backhed F, 2007, P NATL ACAD SCI USA, V104, P979, DOI 10.1073/pnas.0605374104; Baumann S, 2013, INT ARCH ALLERGY IMM, V162, P205, DOI 10.1159/000353972; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Bik HM, 2014, BIORXIV; Blander JM, 2017, NAT IMMUNOL, V18, P851, DOI 10.1038/ni.3780; Cahenzli J, 2013, CELL HOST MICROBE, V14, P559, DOI 10.1016/j.chom.2013.10.004; Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403; Clarke SF, 2012, GUT MICROBES, V3, P186, DOI 10.4161/gmic.20168; Conlon MA, 2015, NUTRIENTS, V7, P17, DOI 10.3390/nu7010017; Cox LM, 2014, CELL, V158, P705, DOI 10.1016/j.cell.2014.05.052; Cui LJ, 2013, GENOME MED, V5, DOI 10.1186/gm467; Dalby MJ, 2017, CELL REP, V21, P1521, DOI 10.1016/j.celrep.2017.10.056; Desai MS, 2016, CELL, V167, P1339, DOI 10.1016/j.cell.2016.10.043; Dheer R, 2016, INFECT IMMUN, V84, P798, DOI 10.1128/IAI.01374-15; Garozzo M T, 2015, J Biol Regul Homeost Agents, V29, P89; Gri G, 2008, IMMUNITY, V29, P771, DOI 10.1016/j.immuni.2008.08.018; Hariri N, 2010, NUTR RES REV, V23, P270, DOI 10.1017/S0954422410000168; Haspeslagh E, 2018, CURR OPIN IMMUNOL, V54, P102, DOI 10.1016/j.coi.2018.06.007; Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC; Hijazi N, 2000, THORAX, V55, P775, DOI 10.1136/thorax.55.9.775; Hill DA, 2012, NAT MED, V18, P538, DOI 10.1038/nm.2657; Hussain M, 2018, J ALLERGY CLIN IMMUN, V141, P223, DOI 10.1016/j.jaci.2017.02.035; Johnson AMF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122195; Julia V, 2015, NAT REV IMMUNOL, V15, P308, DOI 10.1038/nri3830; Lam YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034233; Lambrecht BN, 2017, NAT IMMUNOL, V18, P1076, DOI 10.1038/ni.3829; Lang JE, 2018, J ALLERGY CLIN IMMUN, V141, P1459, DOI 10.1016/j.jaci.2017.09.043; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Li SY, 2008, OBESITY, V16, P811, DOI 10.1038/oby.2007.116; Lokaj-Berisha Violeta, 2015, Open Access Maced J Med Sci, V3, P595, DOI 10.3889/oamjms.2015.101; Macpherson AJ, 2017, NAT REV IMMUNOL, V17, P508, DOI 10.1038/nri.2017.58; Makki K, 2018, CELL HOST MICROBE, V23, P705, DOI 10.1016/j.chom.2018.05.012; Martinez-Guryn K, 2018, CELL HOST MICROBE, V23, P458, DOI 10.1016/j.chom.2018.03.011; Maslowski KM, 2011, NAT IMMUNOL, V12, P5, DOI 10.1038/ni0111-5; McCoy KD, 2018, CURR OPIN IMMUNOL, V54, P20, DOI 10.1016/j.coi.2018.05.009; McKenzie C, 2017, IMMUNOL REV, V278, P277, DOI 10.1111/imr.12556; Murphy EA, 2015, CURR OPIN CLIN NUTR, V18, P515, DOI 10.1097/MCO.0000000000000209; Nagel G, 2010, THORAX, V65, P516, DOI 10.1136/thx.2009.128256; Noti M, 2014, J ALLERGY CLIN IMMUN, V133, P1390, DOI 10.1016/j.jaci.2014.01.021; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Parks DH, 2014, BIOINFORMATICS, V30, P3123, DOI 10.1093/bioinformatics/btu494; Peters U, 2018, J ALLERGY CLIN IMMUN, V141, P1169, DOI 10.1016/j.jaci.2018.02.004; Plunkett CH, 2017, J IMMUNOL, V198, P581, DOI 10.4049/jimmunol.1601266; Poglio S, 2010, STEM CELLS, V28, P2065, DOI 10.1002/stem.523; Pruesse E, 2012, BIOINFORMATICS, V28, P1823, DOI 10.1093/bioinformatics/bts252; Renz H, 2017, J ALLERGY CLIN IMMUN, V140, P24, DOI 10.1016/j.jaci.2017.05.015; Ridaura VK, 2013, SCIENCE, V341, P1079, DOI 10.1126/science.1241214; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Rognes T, 2016, PEERJ, V4, DOI 10.7717/peerj.2584; Sicherer SH, 2018, J ALLERGY CLIN IMMUN, V141, P41, DOI 10.1016/j.jaci.2017.11.003; Singh RK, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1175-y; Sonnenburg ED, 2016, NATURE, V529, P212, DOI 10.1038/nature16504; Stefka AT, 2014, P NATL ACAD SCI USA, V111, P13145, DOI 10.1073/pnas.1412008111; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Thaiss CA, 2016, NATURE, V540, P544, DOI 10.1038/nature20796; Thorburn AN, 2014, IMMUNITY, V40, P833, DOI 10.1016/j.immuni.2014.05.014; Turnbaugh PJ, 2008, CELL HOST MICROBE, V3, P213, DOI 10.1016/j.chom.2008.02.015; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Umetsu DT, 2017, THORAX, V72, P174, DOI 10.1136/thoraxjnl-2016-209130; Visness CM, 2010, J ASTHMA, V47, P822, DOI 10.3109/02770903.2010.489388; Volynets V, 2017, J NUTR, V147, P770, DOI 10.3945/jn.116.242859; Wesemann DR, 2016, IMMUNITY, V44, P728, DOI 10.1016/j.immuni.2016.02.002; Wheeler ML, 2016, CELL HOST MICROBE, V19, P865, DOI 10.1016/j.chom.2016.05.003; Wolf KJ, 2012, CURR OBES REP, V1, DOI 10.1007/s13679-011-0001-8; Wypych TP, 2017, NUTRIENTS, V9, DOI 10.3390/nu9060537	70	55	61	9	63	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					157	+		10.1016/j.jaci.2019.01.043	http://dx.doi.org/10.1016/j.jaci.2019.01.043			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30768991	Bronze			2022-12-18	WOS:000473432800019
J	de Jesus, AA; Brehm, A; VanTries, R; Pillet, P; Parentelli, AS; Sanchez, GAM; Deng, ZM; Paut, IK; Goldbach-Mansky, R; Kruger, E				de Jesus, Adriana A.; Brehm, Anja; VanTries, Rachel; Pillet, Pascal; Parentelli, Anne-Sophie; Sanchez, Gina A. Montealegre; Deng, Zuoming; Paut, Isabelle Kone; Goldbach-Mansky, Raphaela; Krueger, Elke			Novel proteasome assembly chaperone mutations in PSMG2/PAC2 cause the autoinflammatory interferonopathy CANDLE/PRAAS4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							SUBUNIT; LIPODYSTROPHY; COMPLEX		[de Jesus, Adriana A.; VanTries, Rachel; Sanchez, Gina A. Montealegre; Goldbach-Mansky, Raphaela] NIAID, Translat Autoinflammatory Dis Sect, LCIM, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Brehm, Anja; Krueger, Elke] Charite Univ Med Berlin, CCO Inst Biochem, Berlin, Germany; [Pillet, Pascal; Parentelli, Anne-Sophie] Hop Pellegrin Enfants, Urgences Pediat, Pediat Gen Ctr Competence Arthrit Juveniles Idiop, Bordeaux, France; [Deng, Zuoming] NIAMSD, Biodata Min & Discovery Sect, NIH, Bethesda, MD 20892 USA; [Paut, Isabelle Kone] CHU Bicetre, Ctr Reference Malad Autoinflammatoires, Paris, France; [Krueger, Elke] Univ Med Greifswald, Inst Med Biochem & Mol Biol, Klinikum DZ7, Greifswald, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; CHU Bordeaux; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Greifswald Medical School	Goldbach-Mansky, R (corresponding author), NIAID, Translat Autoinflammatory Dis Sect, LCIM, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	goldbacr@mail.nih.gov	Krueger, Elke/B-1462-2012	Krueger, Elke/0000-0002-2551-242X	Intramural Research Program of the National Institutes of Health; National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases; DFG [SFB740, SFBTR186, SFBTR167]; Fritz-Thyssen-Foundation [10.16.2.022MN]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZICAR041207, ZIHAR041173] Funding Source: NIH RePORTER	Intramural Research Program of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); DFG(German Research Foundation (DFG)); Fritz-Thyssen-Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by the Intramural Research Program of the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases and by grants of the DFG (grant nos. SFB740, SFBTR186, and SFBTR167 to E.K.) and the Fritz-Thyssen-Foundation (grant no. 10.16.2.022MN to E.K. and A.B.).	ABRAMSON N, 1970, J EXP MED, V132, P1207, DOI 10.1084/jem.132.6.1207; Agarwal AK, 2010, AM J HUM GENET, V87, P866, DOI 10.1016/j.ajhg.2010.10.031; Arima K, 2011, P NATL ACAD SCI USA, V108, P14914, DOI 10.1073/pnas.1106015108; Brehm A, 2015, J CLIN INVEST, V125, P4196, DOI 10.1172/JCI81260; Brehm A, 2015, SEMIN IMMUNOPATHOL, V37, P323, DOI 10.1007/s00281-015-0486-4; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; de Jesus AA, 2015, ANNU REV IMMUNOL, V33, P823, DOI 10.1146/annurev-immunol-032414-112227; Fricke B, 2007, EMBO REP, V8, P1170, DOI 10.1038/sj.embor.7401091; Gehrs BC, 2002, AM J HEMATOL, V69, P258, DOI 10.1002/ajh.10062; Go RS, 2017, BLOOD, V129, P2971, DOI 10.1182/blood-2016-11-693689; Hirano Y, 2005, NATURE, V437, P1381, DOI 10.1038/nature04106; Kiefer K, 2012, IMMUNOL CELL BIOL, V90, P498, DOI 10.1038/icb.2012.10; Kim H, 2016, J MOL MED, V94, P1111, DOI 10.1007/s00109-016-1465-5; Kitamura A, 2011, J CLIN INVEST, V121, P4150, DOI 10.1172/JCI58414; Kochi Y, 2016, INT IMMUNOL, V28, P155, DOI 10.1093/intimm/dxw002; Kury S, 2017, AM J HUM GENET, V100, P352, DOI 10.1016/j.ajhg.2017.01.003; Le Tallec B, 2007, MOL CELL, V27, P660, DOI 10.1016/j.molcel.2007.06.025; Li X, 2007, EMBO J, V26, P2339, DOI 10.1038/sj.emboj.7601681; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Liu Y, 2012, ARTHRITIS RHEUM-US, V64, P895, DOI 10.1002/art.33368; O'Sullivan LA, 2007, MOL IMMUNOL, V44, P2497, DOI 10.1016/j.molimm.2006.11.025; Poli MC, 2018, AM J HUM GENET, V102, P1126, DOI 10.1016/j.ajhg.2018.04.010; Ramos PC, 2008, STRUCTURE, V16, P1296, DOI 10.1016/j.str.2008.07.001; Sanchez GAM, 2018, J CLIN INVEST, V128, P3041, DOI 10.1172/JCI98814; Seifert U, 2010, CELL, V142, P613, DOI 10.1016/j.cell.2010.07.036; Tomko RJ, 2010, MOL CELL, V38, P393, DOI 10.1016/j.molcel.2010.02.035; Torrelo A, 2010, J AM ACAD DERMATOL, V62, P489, DOI 10.1016/j.jaad.2009.04.046; Tough DF, 2012, IMMUNOL CELL BIOL, V90, P492, DOI 10.1038/icb.2012.7; Yashiroda H, 2008, NAT STRUCT MOL BIOL, V15, P228, DOI 10.1038/nsmb.1386; Zheng QY, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00303; 2015, J PEDIAT HEMATOL ONC, V37, P296	31	55	55	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1939	+		10.1016/j.jaci.2018.12.1012	http://dx.doi.org/10.1016/j.jaci.2018.12.1012			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30664889	Green Accepted, Bronze			2022-12-18	WOS:000466784600033
J	Ravanetti, L; Dijkhuis, A; Dekker, T; Pineros, YSS; Ravi, A; Dierdorp, BS; Erjefalt, JS; Mori, M; Pavlidis, S; Adcock, IM; Rao, NL; Lutter, R				Ravanetti, Lara; Dijkhuis, Annemiek; Dekker, Tamara; Pineros, Yanaika S. Sabogal; Ravi, Abilash; Dierdorp, Barbara S.; Erjefalt, Jonas S.; Mori, Michiko; Pavlidis, Stelios; Adcock, Ian M.; Rao, Navin L.; Lutter, Rene			IL-33 drives influenza-induced asthma exacerbations by halting innate and adaptive antiviral immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; exacerbation; IL-33; influenza; immune response; airway hyperresponsiveness; airways epithelial cells; NETosis; dendritic cells	NATURAL HELPER-CELLS; LYMPHOID-CELLS; TYPE-2 INFLAMMATION; DENDRITIC CELLS; VIRUS-INFECTION; T-CELLS; INTERLEUKIN-33; DEFICIENT; PATHWAY; ACTIVATION	Background: Influenza virus triggers severe asthma exacerbations for which no adequate treatment is available. It is known that IL-33 levels correlate with exacerbation severity, but its role in the immunopathogenesis of exacerbations has remained elusive. Objective: We hypothesized that IL-33 is necessary to drive asthma exacerbations. We intervened with the IL-33 cascade and sought to dissect its role, also in synergy with thymic stromal lymphopoietin (TSLP), in airway inflammation, antiviral activity, and lung function. We aimed to unveil the major source of IL-33 in the airways and IL-33-dependent mechanisms that underlie severe asthma exacerbations. Methods: Patients with mild asthma were experimentally infected with rhinovirus. Mice were chronically exposed to house dust mite extract and then infected with influenza to resemble key features of exacerbations in human subjects. Interventions included the anti-IL-33 receptor ST2, anti-TSLP, or both. Results: We identified bronchial ciliated cells and type II alveolar cells as a major local source of IL-33 during virus-driven exacerbation in human subjects and mice, respectively. By blocking ST2, we demonstrated that IL-33 and not TSLP was necessary to drive exacerbations. IL-33 enhanced airway hyperresponsiveness and airway inflammation by suppressing innate and adaptive antiviral responses and by instructing epithelial cells and dendritic cells of house dust mite-sensitized mice to dampen IFN-beta expression and prevent the TH1-promoting dendritic cell phenotype. IL-33 also boosted luminal NETosis and halted cytolytic antiviral activities but did not affect the T(H)2 response. Conclusion: Interventions targeting the IL-33/ST2 axis could prove an effective acute short-term therapy for virus-induced asthma exacerbations.	[Ravanetti, Lara; Dijkhuis, Annemiek; Dekker, Tamara; Pineros, Yanaika S. Sabogal; Ravi, Abilash; Dierdorp, Barbara S.; Lutter, Rene] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Expt Immunol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [Ravanetti, Lara; Dijkhuis, Annemiek; Dekker, Tamara; Pineros, Yanaika S. Sabogal; Ravi, Abilash; Dierdorp, Barbara S.; Lutter, Rene] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Resp Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [Erjefalt, Jonas S.; Mori, Michiko] Lund Univ, Dept Expt Med Sci, Lund, Sweden; [Pavlidis, Stelios; Adcock, Ian M.] Imperial Coll London, Natl Heart & Lung Inst, Airway Dis Sect, Royal Brompton Campus, London, England; [Rao, Navin L.] Janssen Res & Dev, Immunol Discovery, San Diego, CA USA	University of Amsterdam; University of Amsterdam; Lund University; Imperial College London	Ravanetti, L (corresponding author), Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Expt Immunol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.; Ravanetti, L (corresponding author), Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Resp Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	l.ravanetti@amc.nl	Sabogal, Yanaika/AAZ-5125-2020; Ravanetti, Lara/AAW-9314-2021	Sabogal, Yanaika/0000-0001-7824-9058; Adcock, Ian/0000-0003-2101-8843	U-BIOPRED Consortium from the European Community; European Federation of Pharmaceutical Industries and Associations as an IMI EU; Chiesi Farmaceutici S.p.A, Italy; Stichting Astma Bestrijding, The Netherlands [2013/009]	U-BIOPRED Consortium from the European Community; European Federation of Pharmaceutical Industries and Associations as an IMI EU; Chiesi Farmaceutici S.p.A, Italy; Stichting Astma Bestrijding, The Netherlands	Supported by internal funds; in part by the U-BIOPRED Consortium, which received funding from the European Community, and from the European Federation of Pharmaceutical Industries and Associations as an IMI EU-funded project; by Chiesi Farmaceutici S.p.A, Italy; and by Stichting Astma Bestrijding (project 2013/009), The Netherlands.	Ali S, 2007, P NATL ACAD SCI USA, V104, P18660, DOI 10.1073/pnas.0705939104; Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051; Alves JC, 2010, NAT MED, V16, P708, DOI 10.1038/nm.2156; Baraldo S, 2012, J ALLERGY CLIN IMMUN, V130, P1307, DOI 10.1016/j.jaci.2012.08.005; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Ben-Sasson SZ, 2013, J EXP MED, V210, P491, DOI 10.1084/jem.20122006; Bernink JH, 2015, IMMUNITY, V43, P146, DOI 10.1016/j.immuni.2015.06.019; Bonilla WV, 2012, SCIENCE, V335, P984, DOI 10.1126/science.1215418; Chen AI, 1999, IMMUNITY, V11, P689, DOI 10.1016/S1074-7613(00)80143-0; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corren J, 2017, NEW ENGL J MED, V377, P936, DOI 10.1056/NEJMoa1704064; Cortjens B, 2016, J PATHOL, V238, P401, DOI 10.1002/path.4660; de Kleer IM, 2016, IMMUNITY, V45, P1285, DOI 10.1016/j.immuni.2016.10.031; Donovan C, 2016, TRENDS PHARMACOL SCI, V37, P252, DOI 10.1016/j.tips.2016.01.004; Dougherty RH, 2009, CLIN EXP ALLERGY, V39, P193, DOI 10.1111/j.1365-2222.2008.03157.x; Endo Y, 2015, IMMUNITY, V42, P294, DOI 10.1016/j.immuni.2015.01.016; Gadani SP, 2015, NEURON, V85, P703, DOI 10.1016/j.neuron.2015.01.013; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Iijima K, 2014, J IMMUNOL, V193, P1549, DOI 10.4049/jimmunol.1302984; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; Jacoby DB, 2002, JAMA-J AM MED ASSOC, V287, P755, DOI 10.1001/jama.287.6.755; Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC; Johnston Sebastian L, 2007, Proc Am Thorac Soc, V4, P267, DOI 10.1513/pats.200701-030AW; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kabata H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3675; Kakkar R, 2008, NAT REV DRUG DISCOV, V7, P827, DOI 10.1038/nrd2660; Karasuyama H, 2009, NAT REV IMMUNOL, V9, P9, DOI 10.1038/nri2458; Kearley J, 2015, IMMUNITY, V42, P566, DOI 10.1016/j.immuni.2015.02.011; Kitajima M, 2011, EUR J IMMUNOL, V41, P1862, DOI 10.1002/eji.201041195; Kohlmeier JE, 2010, IMMUNITY, V33, P96, DOI 10.1016/j.immuni.2010.06.016; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Lebre MC, 2005, IMMUNOL CELL BIOL, V83, P525, DOI 10.1111/j.1440-1711.2005.01365.x; Lee JU, 2017, RESP MED, V123, P71, DOI 10.1016/j.rmed.2016.11.020; Leyva-Castillo JM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3847; Liew FY, 2016, NAT REV IMMUNOL, V16, P676, DOI 10.1038/nri.2016.95; Mahut B, 2011, J ASTHMA, V48, P224, DOI 10.3109/02770903.2011.555032; Martin NT, 2016, NAT IMMUNOL, V17, P122, DOI 10.1038/ni.3370; Mesnil C, 2016, J CLIN INVEST, V126, P3279, DOI 10.1172/JCI85664; Mjosberg J, 2016, J ALLERGY CLIN IMMUN, V138, P1265, DOI 10.1016/j.jaci.2016.09.009; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; MOLOFSKY AB, 2015, IMMUNITY, V42, P1005, DOI [DOI 10.1016/j.immuni.2015.06.006, DOI 10.1016/J.IMMUNI.2015.06.006]; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107; Oliphant CJ, 2014, IMMUNITY, V41, P283, DOI 10.1016/j.immuni.2014.06.016; Pardee AD, 2010, CANCER RES, V70, P9041, DOI 10.1158/0008-5472.CAN-10-1369; Perrigoue JG, 2007, J EXP MED, V204, P481, DOI 10.1084/jem.20061791; Pineros YSS, 2019, AM J RESP CRIT CARE, V199, P508, DOI 10.1164/rccm.201803-0461OC; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; Ravanetti L, 2017, ALLERGY, V72, P737, DOI 10.1111/all.13057; Ravi A, 2019, J ALLERGY CLIN IMMUN, V143, P442, DOI 10.1016/j.jaci.2018.09.016; Redhu NS, 2013, SCI REP-UK, V3, DOI 10.1038/srep02301; Remijsen Q, 2011, CELL DEATH DIFFER, V18, P581, DOI 10.1038/cdd.2011.1; Remijsen Q, 2011, CELL RES, V21, P290, DOI 10.1038/cr.2010.150; Ritchie AI, 2016, ANN AM THORAC SOC, V13, pS55, DOI 10.1513/AnnalsATS.201507-421MG; Salek-Ardakani S, 2003, J EXP MED, V198, P315, DOI 10.1084/jem.20021937; Silver JS, 2016, NAT IMMUNOL, V17, P626, DOI 10.1038/ni.3443; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; Smith DE, 2010, CLIN EXP ALLERGY, V40, P200, DOI 10.1111/j.1365-2222.2009.03384.x; Sonnenberg Gregory F, 2013, Immunity, V39, P622, DOI 10.1016/j.immuni.2013.08.021; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Sykes A, 2014, THORAX, V69, P240, DOI 10.1136/thoraxjnl-2012-202909; Sykes A, 2012, J ALLERGY CLIN IMMUN, V129, P1506, DOI 10.1016/j.jaci.2012.03.044; Toussaint M, 2017, NAT MED, V23, P681, DOI 10.1038/nm.4332; Umetsu DT, 2006, NAT REV IMMUNOL, V6, P953, DOI 10.1038/nri1968; Vannella KM, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1938; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Werder RB, 2018, J ALLERGY CLIN IMMUN, V141, P1607, DOI 10.1016/j.jaci.2017.07.051	68	55	56	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1355	+		10.1016/j.jaci.2018.08.051	http://dx.doi.org/10.1016/j.jaci.2018.08.051			32	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30316823	Bronze			2022-12-18	WOS:000463348900013
J	Wieder, T; Eigentler, T; Brenner, E; Rocken, M				Wieder, Thomas; Eigentler, Thomas; Brenner, Ellen; Roecken, Martin			Immune checkpoint blockade therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cytokine-induced senescence; cytotoxic T lymphocytes; interferon; T helper cells; tumor dormancy; tumor eradication; autoimmunity	IPILIMUMAB PLUS DACARBAZINE; CD8 T-CELLS; PD-1 BLOCKADE; TUMOR-CELLS; DENDRITIC CELLS; CELLULAR SENESCENCE; ACQUIRED-RESISTANCE; ANTITUMOR IMMUNITY; ANTI-PD-1 ANTIBODY; COMBINED NIVOLUMAB	Immune checkpoints are accessory molecules that either promote or inhibit T-cell activation. Two inhibitory molecules, cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), got high attention, as inhibition of CTLA-4 or PD-1 signaling provides the first immune therapy that significantly improves the survival of patients with metastatic solid cancers. Inhibition of CTLA-4 or PD-1 was first studied in and approved for patients with metastatic melanoma. Blocking immune checkpoints is also efficient in non-small-cell lung cancer, renal cell cancers, hypermutated gastrointestinal cancers, and others. Immune responses, whether directed against infections or against tumors, are divided into 2 phases: an initiation phase and an activation phase, where the immune system recognizes a danger signal and becomes activated by innate signals to fight the danger. This reaction is fundamental for the control of infections and cancer, but needs to be turned off once the danger is controlled, because persistence of this activation ultimately causes severe tissue damage. Therefore, each activation of the immune system is followed by a termination phase, where endogenous immune suppressor molecules arrest immune responses to prevent harmful damage. In the case of cancer immune therapies, therapeutic approaches classically enhanced the initiation and activation of immune responses to increase the emergence and the efficacy of cytotoxic T lymphocytes (CTL) against cancers. In sharp contrast, immune checkpoint blockade focuses on the termination of immune responses by inhibiting immune suppressor molecules. It thus prevents the termination of immune responses or even awakes those CTLs that became exhausted during an immune response. Therefore, blocking negatively regulating immune checkpoints restores the capacity of exhausted CTL to kill the cancer they infiltrate. In addition, they drive surviving cancer cells into a still poorly defined state of dormancy. As the therapy also awakes self-reactive CTL, one downside of the therapy is the induction of organ-specific autoimmune diseases. The second downside is the exorbitant drug price that withdraws patients in need from a therapy that was developed by academic research, which impairs further academic treatment development and financially charges the public health system.	[Wieder, Thomas; Eigentler, Thomas; Brenner, Ellen; Roecken, Martin] Eberhard Karls Univ Tubingen, Dept Dermatol, Liebermeisterstr 25, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Rocken, M (corresponding author), Eberhard Karls Univ Tubingen, Dept Dermatol, Liebermeisterstr 25, D-72076 Tubingen, Germany.	mrocken@med.uni-tuebingen.de	; Eigentler, Thomas/K-8570-2015	Brenner, Ellen/0000-0002-2019-5074; Eigentler, Thomas/0000-0003-0019-2770; Rocken, Martin/0000-0003-3795-7001	Wilhelm Sander Stiftung [2012.056.3]; Deutsche Krebshilfe [110664]; Deutsche Forschungsgemeinschaft [Ro764/14-1, Ro764/15-1, WI 1279/4-1, SFB-TR 156]	Wilhelm Sander Stiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The work of the authors is supported by the Wilhelm Sander Stiftung (grant no. 2012.056.3), the Deutsche Krebshilfe (grant no. 110664), and the Deutsche Forschungsgemeinschaft (grant nos. DFG Ro764/14-1, Ro764/15-1, WI 1279/4-1, and SFB-TR 156).	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Balar AV, 2017, LANCET ONCOL, V18, P1483, DOI 10.1016/S1470-2045(17)30616-2; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Benci JL, 2016, CELL, V167, P1540, DOI 10.1016/j.cell.2016.11.022; Braumuller H, 2013, NATURE, V494, P361, DOI 10.1038/nature11824; Buck MD, 2016, CELL, V166, P63, DOI 10.1016/j.cell.2016.05.035; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Campisi J, 2011, SEMIN CANCER BIOL, V21, P354, DOI 10.1016/j.semcancer.2011.09.001; Chang CH, 2016, NAT IMMUNOL, V17, P364, DOI 10.1038/ni.3415; Chen J, 2012, IMMUNOBIOLOGY, V217, P385, DOI 10.1016/j.imbio.2011.10.016; Davis BP, 2017, J ALLERGY CLIN IMMUN, V139, P1445, DOI 10.1016/j.jaci.2017.02.013; Egeter O, 2000, CANCER RES, V60, P1515; Eggermont AMM, 2016, NEW ENGL J MED, V375, P1845, DOI 10.1056/NEJMoa1611299; Eggermont AMM, 2014, LANCET, V383, P816, DOI 10.1016/S0140-6736(13)60802-8; Eigentler TK, 2016, CANCER TREAT REV, V45, P7, DOI 10.1016/j.ctrv.2016.02.003; Eigentler TK, 2003, LANCET ONCOL, V4, P748, DOI 10.1016/S1470-2045(03)01280-4; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Gao JJ, 2016, CELL, V167, P397, DOI 10.1016/j.cell.2016.08.069; Ghoneim HE, 2017, CELL, V170, DOI 10.1016/j.cell.2017.06.007; Gide TN, 2018, CLIN CANCER RES, V24, P1260, DOI 10.1158/1078-0432.CCR-17-2267; Gulley JL, 2017, LANCET ONCOL, V18, P599, DOI 10.1016/S1470-2045(17)30240-1; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hassel JC, 2017, CANCER TREAT REV, V57, P36, DOI 10.1016/j.ctrv.2017.05.003; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hirahara K, 2012, IMMUNITY, V36, P1017, DOI 10.1016/j.immuni.2012.03.024; Ho PC, 2015, CELL, V162, P1217, DOI 10.1016/j.cell.2015.08.012; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hofmann L, 2016, EUR J CANCER, V60, P190, DOI 10.1016/j.ejca.2016.02.025; Hubackova S, 2016, ONCOGENE, V35, P1236, DOI 10.1038/onc.2015.162; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Kamphorst AO, 2017, SCIENCE, V355, P1423, DOI 10.1126/science.aaf0683; Kaufman HL, 2016, LANCET ONCOL, V17, P1374, DOI 10.1016/S1470-2045(16)30364-3; Kenter GG, 2009, NEW ENGL J MED, V361, P1838, DOI 10.1056/NEJMoa0810097; Kleffel S, 2015, CELL, V162, P1242, DOI 10.1016/j.cell.2015.08.052; KNUTH A, 1989, P NATL ACAD SCI USA, V86, P2804, DOI 10.1073/pnas.86.8.2804; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; Kollmann D, 2017, ANN SURG ONCOL, V24, P2698, DOI 10.1245/s10434-017-5858-7; Kourie HR, 2017, IMMUNOTHERAPY-UK, V9, P647, DOI 10.2217/imt-2017-0029; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Landsberg J, 2012, NATURE, V490, P412, DOI 10.1038/nature11538; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Maio M, 2015, J CLIN ONCOL, V33, P1191, DOI 10.1200/JCO.2014.56.6018; Menguy S, 2018, AM J SURG PATHOL, V42, P326, DOI 10.1097/PAS.0000000000000983; Mocikat R, 2003, IMMUNITY, V19, P561, DOI 10.1016/S1074-7613(03)00264-4; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; Muller-Hermelink N, 2008, CANCER CELL, V13, P507, DOI 10.1016/j.ccr.2008.04.001; Munn DH, 2016, TRENDS IMMUNOL, V37, P193, DOI 10.1016/j.it.2016.01.002; Ni GY, 2015, CELL IMMUNOL, V293, P126, DOI 10.1016/j.cellimm.2014.12.012; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Okazaki T, 2001, P NATL ACAD SCI USA, V98, P13866, DOI 10.1073/pnas.231486598; Okazaki T, 2013, NAT IMMUNOL, V14, P1212, DOI 10.1038/ni.2762; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Parry RV, 2005, MOL CELL BIOL, V25, P9543, DOI 10.1128/MCB.25.21.9543-9553.2005; Perez-Mancera PA, 2014, NAT REV CANCER, V14, P547, DOI 10.1038/nrc3773; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Rachidi S, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aai7911; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robbins PF, 2013, NAT MED, V19, P747, DOI 10.1038/nm.3161; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Rocken M, 2010, J CLIN INVEST, V120, P1800, DOI 10.1172/JCI43424; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Schadendorf D, 2017, J CLIN ONCOL, V35, P3807, DOI 10.1200/JCO.2017.73.2289; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; Schilbach K, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1014760; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Schwartzentruber DJ, 2011, NEW ENGL J MED, V364, P2119, DOI 10.1056/NEJMoa1012863; Sen DR, 2016, SCIENCE, V354, P1165, DOI 10.1126/science.aae0491; Shalapour S, 2015, NATURE, V521, P94, DOI 10.1038/nature14395; Sheppard KA, 2004, FEBS LETT, V574, P37, DOI 10.1016/j.febslet.2004.07.083; Shi LZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12335; Stronen E, 2016, SCIENCE, V352, P1337, DOI 10.1126/science.aaf2288; Sucker A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15440; Terabe M, 2004, CURR OPIN IMMUNOL, V16, P157, DOI 10.1016/j.coi.2004.01.010; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Twyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Veilleux MS, 2017, J ALLERGY CLIN IMMUN, V139, P1423, DOI 10.1016/j.jaci.2017.03.012; Voskens CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053745; Wagner H, 2006, ADV IMMUNOL, V91, P159, DOI 10.1016/S0065-2776(06)91004-9; Walter S, 2012, NAT MED, V18, P1254, DOI 10.1038/nm.2883; Weber J, 2017, NEW ENGL J MED, V377, P1824, DOI 10.1056/NEJMoa1709030; Weide B, 2016, CLIN CANCER RES, V22, P5487, DOI 10.1158/1078-0432.CCR-16-0127; Wieder T, 2017, CANCER METAST REV, V36, P357, DOI 10.1007/s10555-017-9667-z; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Wu YH, 2017, ONCOTARGET, V8, P64066, DOI 10.18632/oncotarget.19318; Yokosuka T, 2012, J EXP MED, V209, P1201, DOI 10.1084/jem.20112741; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Ziegler A, 2009, BLOOD, V113, P3494, DOI 10.1182/blood-2008-08-175109; Zimmer L, 2016, EUR J CANCER, V60, P210, DOI 10.1016/j.ejca.2016.02.024	106	55	56	5	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1403	1414		10.1016/j.jaci.2018.02.042	http://dx.doi.org/10.1016/j.jaci.2018.02.042			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	29596939	Bronze			2022-12-18	WOS:000449429800003
J	Jimenez-Saiz, R; Chu, DK; Mandur, TS; Walker, TD; Gordon, ME; Chaudhary, R; Koenig, J; Saliba, S; Galipeau, HJ; Utley, A; King, IL; Lee, K; Ettinger, R; Waserman, S; Kolbeck, R; Jordana, M				Jimenez-Saiz, Rodrigo; Chu, Derek K.; Mandur, Talveer S.; Walker, Tina D.; Gordon, Melissa E.; Chaudhary, Roopali; Koenig, Joshua; Saliba, Sarah; Galipeau, Heather J.; Utley, Adam; King, Irah L.; Lee, Kelvin; Ettinger, Rachel; Waserman, Susan; Kolbeck, Roland; Jordana, Manel			Lifelong memory responses perpetuate humoral T(H)2 immunity and anaphylaxis in food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; mast cells; memory B cells; plasma cells; T(H)2; food allergy; anaphylaxis; IgG(1); peanut allergy; germinal centers	LIVED PLASMA-CELLS; EXPRESSING B-CELLS; IN-VIVO; BONE-MARROW; ANTIBODY-RESPONSES; GERMINAL-CENTERS; PEANUT ALLERGY; MAST-CELLS; T-CELLS; IGE	Background: A number of food allergies (eg, fish, shellfish, and nuts) are lifelong, without any disease-transforming therapies, and unclear in their underlying immunology. Clinical manifestations of food allergy are largely mediated by IgE. Although persistent IgE titers have been attributed conventionally to long-lived IgE(+) plasma cells (PCs), this has not been directly and comprehensively tested. Objective: We sought to evaluate mechanisms underlying persistent IgE and allergic responses to food allergens. Methods: We used a model of peanut allergy and anaphylaxis, various knockout mice, adoptive transfer experiments, and in vitro assays to identify mechanisms underlying persistent IgE humoral immunity over almost the entire lifespan of the mouse (18-20 months). Results: Contrary to conventional paradigms, our data show that clinically relevant lifelong IgE titers are not sustained by long-lived IgE(+) PCs. Instead, lifelong reactivity is conferred by allergen-specific long-lived memory B cells that replenish the IgE(+) PC compartment. B-cell reactivation requires allergen re-exposure and IL-4 production by CD4 T cells. We define the half-lives of antigen-specific germinal centers (23.3 days), IgE(+) and IgG(1)(+) PCs (60 and 234.4 days, respectively), and clinically relevant cell-bound IgE (67.3 days). Conclusions: These findings can explain lifelong food allergies observed in human subjects as the consequence of allergen exposures that recurrently activate memory B cells and identify these as a therapeutic target with disease-transforming potential.	[Jimenez-Saiz, Rodrigo; Chu, Derek K.; Mandur, Talveer S.; Walker, Tina D.; Gordon, Melissa E.; Chaudhary, Roopali; Koenig, Joshua; Saliba, Sarah; Galipeau, Heather J.; Jordana, Manel] McMaster Univ, Dept Pathol & Mol Med, McMaster Immunol Res Ctr, MDCL 4013,1280 Main St W, Hamilton, ON L8S 4K1, Canada; [Waserman, Susan] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Utley, Adam; Lee, Kelvin] Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA; [Utley, Adam; Lee, Kelvin] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA; [King, Irah L.] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada; [Ettinger, Rachel; Kolbeck, Roland] Med Immune, Dept Resp Inflammat & Autoimmun, Gaithersburg, MD USA	McMaster University; McMaster University; Roswell Park Cancer Institute; Roswell Park Cancer Institute; McGill University	Jordana, M (corresponding author), McMaster Univ, Dept Pathol & Mol Med, McMaster Immunol Res Ctr, MDCL 4013,1280 Main St W, Hamilton, ON L8S 4K1, Canada.	jordanam@mcmaster.ca	Koenig, Joshua/AAL-9339-2021; Jimenez-Saiz, Rodrigo/O-7384-2019	Koenig, Joshua/0000-0002-8909-5039; Jimenez-Saiz, Rodrigo/0000-0002-0606-3251; Chu, Derek/0000-0001-8269-4496; Galipeau, Heather/0000-0002-6413-0803	Food Allergy Canada; MedImmune; AllerGen NCE; National Institutes of Health [1R21AI105502]; NATIONAL CANCER INSTITUTE [T32CA085183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI105502] Funding Source: NIH RePORTER	Food Allergy Canada; MedImmune(AstraZenecaMedimmune); AllerGen NCE; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from Food Allergy Canada, MedImmune, AllerGen NCE, and the National Institutes of Health (1R21AI105502). R.J.-S., D.K.C, and J.K. are holders of a Mitacs Postdoctoral Fellowship, CIHR Vanier Scholar, and a CIHR Graduate Student Scholarship, respectively. M.J. holds a senior Canada Research Chair. R.K. and R.E. are employees of MedImmune.	Achatz-Straussberger G, 2008, EUR J IMMUNOL, V38, P3167, DOI 10.1002/eji.200838456; Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092; Arias K, 2011, J ALLERGY CLIN IMMUN, V127, P1552, DOI 10.1016/j.jaci.2011.03.044; Arias K, 2009, J ALLERGY CLIN IMMUN, V124, P307, DOI 10.1016/j.jaci.2009.03.012; Berin MC, 2013, TRENDS IMMUNOL, V34, P390, DOI 10.1016/j.it.2013.04.003; Berkowska MA, 2014, J ALLERGY CLIN IMMUN, V134, P688, DOI 10.1016/j.jaci.2014.03.036; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Chu DK, 2014, MUCOSAL IMMUNOL, V7, P1395, DOI 10.1038/mi.2014.29; Chu DK, 2014, J EXP MED, V211, P1657, DOI 10.1084/jem.20131800; Corcoran LM, 2016, CURR OPIN IMMUNOL, V39, P59, DOI 10.1016/j.coi.2015.12.008; Davies JM, 2013, J ALLERGY CLIN IMMUN, V131, P972, DOI 10.1016/j.jaci.2012.12.1569; De Silva NS, 2015, NAT REV IMMUNOL, V15, P137, DOI 10.1038/nri3804; Dogan I, 2009, NAT IMMUNOL, V10, P1292, DOI 10.1038/ni.1814; Fleischer DM, 2007, CURR ALLERGY ASTHM R, V7, P175, DOI 10.1007/s11882-007-0018-y; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; HARUNA K, 1993, CELL IMMUNOL, V151, P52, DOI 10.1006/cimm.1993.1221; He JS, 2013, J EXP MED, V210, P2755, DOI 10.1084/jem.20131539; Hebeis BJ, 2004, J EXP MED, V199, P593, DOI 10.1084/jem.20030091; HOLT PG, 1984, CELL IMMUNOL, V89, P281, DOI 10.1016/0008-8749(84)90330-7; Jimenez-Saiz R, 2013, PEANUTS BIOACTIVITIE, P137; Kaji T, 2012, J EXP MED, V209, P2079, DOI 10.1084/jem.20120127; KATONA IM, 1991, J IMMUNOL, V146, P4215; Khodoun MV, 2011, P NATL ACAD SCI USA, V108, P12413, DOI 10.1073/pnas.1105695108; Kong J, 2015, ALLERGY, V70, P495, DOI 10.1111/all.12579; Kubo S, 2003, J IMMUNOL, V170, P775, DOI 10.4049/jimmunol.170.2.775; Lemke A, 2016, MUCOSAL IMMUNOL, V9, P83, DOI 10.1038/mi.2015.38; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; London CA, 2000, J IMMUNOL, V164, P265, DOI 10.4049/jimmunol.164.1.265; Luger Elke O., 2010, Allergology International, V59, P1, DOI 10.2332/allergolint.10-RAI-0175; Luger EO, 2009, J ALLERGY CLIN IMMUN, V124, P819, DOI 10.1016/j.jaci.2009.06.047; MacLeod MKL, 2011, J IMMUNOL, V186, P2889, DOI 10.4049/jimmunol.1002955; Manz RA, 1997, NATURE, V388, P133, DOI 10.1038/40540; McHeyzer-Williams LJ, 2015, NAT IMMUNOL, V16, P296, DOI 10.1038/ni.3095; Moutsoglou DM, 2016, CLIN EXP ALLERGY, V46, P640, DOI 10.1111/cea.12715; Nagaraju KKM, 2016, EUR J IMMUNOL, V46, P1727, DOI 10.1002/eji.201545918; Neubert K, 2008, NAT MED, V14, P748, DOI 10.1038/nm1763; Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; Otte M, 2016, J ALLERGY CLIN IMMUN, V137, P1884, DOI 10.1016/j.jaci.2015.12.1333; Oyoshi MK, 2014, J ALLERGY CLIN IMMUN, V133, P309, DOI 10.1016/j.jaci.2013.12.1045; Pabst O, 2012, MUCOSAL IMMUNOL, V5, P232, DOI 10.1038/mi.2012.4; Pape KA, 2011, SCIENCE, V331, P1203, DOI 10.1126/science.1201730; Paus D, 2006, J EXP MED, V203, P1081, DOI 10.1084/jem.20060087; Quah BJC, 2007, NAT PROTOC, V2, P2049, DOI 10.1038/nprot.2007.296; Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886; Ramadani F, 2017, ALLERGY, V72, P66, DOI 10.1111/all.12911; Rozanski CH, 2011, J EXP MED, V208, P1435, DOI 10.1084/jem.20110040; STORER JB, 1966, J GERONTOL, V21, P404, DOI 10.1093/geronj/21.3.404; Swirski FK, 2002, J IMMUNOL, V169, P3499, DOI 10.4049/jimmunol.169.7.3499; Tsabouri S, 2012, PEDIAT ALLERG IMM-UK, V23, P608, DOI 10.1111/j.1399-3038.2012.01275.x; Turqueti-Neves A, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002290; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; VANOMMEN R, 1994, SCAND J IMMUNOL, V40, P1; Winter O, 2012, J IMMUNOL, V189, P5105, DOI 10.4049/jimmunol.1202317; Wisniewski JA, 2015, CLIN EXP ALLERGY, V45, P1201, DOI 10.1111/cea.12537; Wu LC, 2014, NAT REV IMMUNOL, V14, P247, DOI 10.1038/nri3632; Xiong HZ, 2012, J EXP MED, V209, P353, DOI 10.1084/jem.20111941; Yang ZY, 2014, CURR OPIN IMMUNOL, V28, P64, DOI 10.1016/j.coi.2014.02.001; Yang ZY, 2012, IMMUNITY, V36, P857, DOI 10.1016/j.immuni.2012.02.009; Zellweger F, 2016, ALLERGY, V71, P1652, DOI 10.1111/all.13059	62	55	56	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1604	+		10.1016/j.jaci.2017.01.018	http://dx.doi.org/10.1016/j.jaci.2017.01.018			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28216433	hybrid, Green Accepted			2022-12-18	WOS:000417206000015
J	Choi, S; Hoffman, EA; Wenzel, SE; Castro, M; Fain, S; Jarjour, N; Schiebler, ML; Chen, K; Lin, CL				Choi, Sanghun; Hoffman, Eric A.; Wenzel, Sally E.; Castro, Mario; Fain, Sean; Jarjour, Nizar; Schiebler, Mark L.; Chen, Kun; Lin, Ching-Long		Natl Heart Lung & Blood Inst Sever	Quantitative computed tomographic imaging-based clustering differentiates asthmatic subgroups with distinctive clinical phenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Computed tomography; image processing; severe asthma; air trapping; image registration; luminal narrowing; wall thickening; airway circularity; cluster analysis; neutrophilic asthma	OBSTRUCTIVE PULMONARY-DISEASE; SECTION CT ASSESSMENT; AIR-FLOW OBSTRUCTION; RESEARCH-PROGRAM; MULTIVARIATE-ANALYSIS; NATIONAL HEART; VOLUMETRIC CT; LUNG; AIRWAYS; COPDGENE	Background: Imaging variables, including airway diameter, wall thickness, and air trapping, have been found to be important metrics when differentiating patients with severe asthma from those with nonsevere asthma and healthy subjects. Objective: The objective of this study was to identify imaging-based clusters and to explore the association of the clusters with existing clinical metrics. Methods: We performed an imaging-based cluster analysis using quantitative computed tomography-based structural and functional variables extracted from the respective inspiration and expiration scans of 248 asthmatic patients. The imaging-based metrics included a broader set of multiscale variables, such as inspiratory airway dimension, expiratory air trapping, and registration-based lung deformation (inspiration vs expiration). Asthma subgroups derived from a clustering method were associated with subject demographics, questionnaire results, medication history, and biomarker variables. Results: Cluster 1 was composed of younger patients with early-onset nonsevere asthma and reversible airflow obstruction and normal airway structure. Cluster 2 was composed of patients with a mix of patients with nonsevere and severe asthma with marginal inflammation who exhibited airway luminal narrowing without wall thickening. Clusters 3 and 4 were dominated by patients with severe asthma. Cluster 3 patients were obese female patients with reversible airflow obstruction who exhibited airway wall thickening without airway narrowing. Cluster 4 patients were late-onset older male subjects with persistent airflow obstruction who exhibited significant air trapping and reduced regional deformation. Cluster 3 and 4 patients also showed decreased lymphocyte and increased neutrophil counts, respectively. Conclusions: Four image-based clusters were identified and shown to be correlated with clinical characteristics. Such clustering serves to differentiate asthma subgroups that can be used as a basis for the development of new therapies.	[Choi, Sanghun; Lin, Ching-Long] Univ Iowa, Dept Mech & Ind Engn, Iowa City, IA USA; [Choi, Sanghun; Lin, Ching-Long] Univ Iowa, IIHR Hydrosci & Engn, Iowa City, IA USA; [Choi, Sanghun; Hoffman, Eric A.] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA; [Hoffman, Eric A.; Lin, Ching-Long] Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; [Hoffman, Eric A.] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; [Wenzel, Sally E.] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA; [Castro, Mario] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; [Castro, Mario] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Fain, Sean; Jarjour, Nizar; Schiebler, Mark L.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Chen, Kun] Univ Connecticut, Dept Stat, Storrs, CT 06269 USA; [Natl Heart Lung & Blood Inst Sever] Severe Asthma Res Program, Bethesda, MD USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Washington University (WUSTL); Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison; University of Connecticut	Lin, CL (corresponding author), 2406 Seamans Ctr Engn Arts & Sci, Iowa City, IA 52242 USA.	ching-long-lin@uiowa.edu	Schiebler, Mark/V-5201-2019; Choi, S/AGS-7430-2022; Chen, Kun/C-2975-2015; Fain, Sean/K-4260-2016	Choi, S/0000-0001-5030-0296; Chen, Kun/0000-0003-3579-5467; Wenzel, Sally/0000-0002-4242-0164; Hoffman, Eric/0000-0001-8456-9437; Fain, Sean/0000-0001-5461-0646; schiebler, mark/0000-0002-9120-5428	National Institutes of Health [U01 HL114494, HL109152, R01 HL094315, HL112986, HL69174, HL064368, HL091762, HL069116, S10 RR022421, U10 HL109257, HL109168, UL1 RR024153, UL1 TR000448, UL1 TR000427]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427, UL1TR000448, UL1TR002345] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR022421, UL1RR024153] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069116, R01HL091762, R01HL094315, U10HL109257, R01HL069174, U10HL109152, R01HL112986, R01HL064368, U01HL114494, U10HL109168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005605] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported in part by National Institutes of Health grants: U01 HL114494, HL109152; R01 HL094315, HL112986, HL69174, HL064368, HL091762, HL069116; S10 RR022421; U10 HL109257, HL109168; UL1 RR024153 (CTSI), UL1 TR000448, UL1 TR000427 (CTSA). We thank J. Choi, M. J. Escher and A. M. Thompson for assisting with data analysis and acquisition, and SARP coordinators and patients for their contribution.	Amelon R, 2011, J BIOMECH, V44, P2489, DOI 10.1016/j.jbiomech.2011.06.009; [Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; Arakawa H, 2005, RADIOLOGY, V236, P1059, DOI 10.1148/radiol.2363041611; Aysola RS, 2008, CHEST, V134, P1183, DOI 10.1378/chest.07-2779; Barr RG, 2012, EUR RESPIR J, V39, P846, DOI 10.1183/09031936.00165410; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berger P, 2005, RADIOLOGY, V235, P1055, DOI 10.1148/radiol.2353040121; Brock G, 2008, J STAT SOFTW, V25, P1, DOI 10.18637/jss.v025.i04; Busacker A, 2009, CHEST, V135, P48, DOI 10.1378/chest.08-0049; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Castro M, 2011, J ALLERGY CLIN IMMUN, V128, P467, DOI 10.1016/j.jaci.2011.04.051; Charrad M., 2014, NBCLUST NBCLUST PACK; Choi S, 2015, J APPL PHYSL BETHESD, V118, P1286, DOI DOI 10.1152/JAPPLPHYSI0L.01094.2014; Choi S, 2015, J APPL PHYSIOL, V118, P1286, DOI 10.1152/japplphysiol.01094.2014; Choi S, 2014, J APPL PHYSIOL, V117, P593, DOI 10.1152/japplphysiol.00280.2014; Choi S, 2013, J APPL PHYSIOL, V115, P730, DOI 10.1152/japplphysiol.00113.2013; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Cowan DC, 2010, THORAX, V65, P384, DOI 10.1136/thx.2009.126722; Fain SB, 2009, IMAGING DECISIONS MR, V13, P24; Farah CS, 2015, RESPIROLOGY, V20, P975, DOI 10.1111/resp.12550; Fraley C, 2002, J AM STAT ASSOC, V97, P611, DOI 10.1198/016214502760047131; FRIEDMAN HP, 1967, J AM STAT ASSOC, V62, P1159, DOI 10.2307/2283767; Galban CJ, 2012, NAT MED, V18, P1711, DOI 10.1038/nm.2971; Gelb AF, 2002, CHEST, V121, P715, DOI 10.1378/chest.121.3.715; GOWER JC, 1966, BIOMETRIKA, V53, P325, DOI 10.2307/2333639; Gupta S, 2014, J ALLERGY CLIN IMMUN, V133, P729, DOI 10.1016/j.jaci.2013.09.039; Hackx M, 2012, RADIOLOGY, V265, P34, DOI 10.1148/radiol.12111270; Hartigan J.A., 1975, CLUSTERING ALGORITHM; Hennig C, 2014, R PACKAGE VERSION, V2, P1; Iyer KS, 2014, CHRON OBSTR PULM DIS, V1, P97, DOI 10.15326/jcopdf.1.1.2014.0111; Jarjour NN, 2012, AM J RESP CRIT CARE, V185, P356, DOI 10.1164/rccm.201107-1317PP; Johnson RA, 2007, APPL MULTIVARIATE ST; Kim SS, 2013, RADIOLOGY, V266, P626, DOI 10.1148/radiol.12120385; Kim V, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0084-3; Ledesma R., 2007, PRACT ASSESS RES EVA, V12; Li X, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1601102; Lutchen KR, 2001, AM J RESP CRIT CARE, V164, P207, DOI 10.1164/ajrccm.164.2.2008119; Mair G, 2010, RESP MED, V104, P1683, DOI 10.1016/j.rmed.2010.04.021; MARRIOTT FH, 1971, BIOMETRICS, V27, P501, DOI 10.2307/2528592; Mase GT., 2009, CONTINUUM MECH ENG; MILLIGAN GW, 1985, PSYCHOMETRIKA, V50, P159, DOI 10.1007/BF02294245; Montaudon M, 2009, RADIOLOGY, V253, P844, DOI 10.1148/radiol.2533090303; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2014, J ALLERGY CLIN IMMUN, V133, P1557, DOI 10.1016/j.jaci.2013.10.011; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Newell JD, 2015, INVEST RADIOL, V50, P40, DOI 10.1097/RLI.0000000000000093; NEWMAN KB, 1994, CHEST, V106, P105, DOI 10.1378/chest.106.1.105; R Core Team, 2013, LANG ENV STAT COMP; Raiche G, 2011, R PACKAGE PARALLEL A; Regan EA, 2010, COPD, V7, P32, DOI 10.3109/15412550903499522; Rodriguez V, 2014, MED PHYS, V41, P327, DOI 10.1118/1.4898098; Samee S, 2003, J ALLERGY CLIN IMMUN, V111, P1205, DOI 10.1067/mai.2003.1544; Schroeder JD, 2013, AM J ROENTGENOL, V201, pW460, DOI 10.2214/AJR.12.10102; SCOTT AJ, 1971, BIOMETRICS, V27, P387, DOI 10.2307/2529003; Sieren JP, 2014, MED PHYS, V41, DOI 10.1118/1.4893498; Sieren JP, 2016, AM J RESP CRIT CARE, V194, P794, DOI 10.1164/rccm.201506-1208PP; Hoffman Eric A, 2006, Proc Am Thorac Soc, V3, P519, DOI 10.1513/pats.200603-086MS; Smith BM, 2014, THORAX, V69, P987, DOI 10.1136/thoraxjnl-2014-205160; Spahn JD, 2007, ALLERGIC DIS, P385; Therneau T., 2015, PACKAGE RPART; Tschirren J, 2005, IEEE T MED IMAGING, V24, P1529, DOI 10.1109/TMI.2005.857654; Weihs C, 2005, ST CLASS DAT ANAL, P335; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025; WHEATLEY JR, 1989, EUR RESPIR J, V2, P331; Yates F, 1934, J ROYAL STAT SOC S, V1, P217, DOI DOI 10.2307/2983604; Yin YB, 2009, MED PHYS, V36, P4213, DOI 10.1118/1.3193526; Zach JA, 2012, INVEST RADIOL, V47, P596, DOI 10.1097/RLI.0b013e318262292e	68	55	55	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					690	+		10.1016/j.jaci.2016.11.053	http://dx.doi.org/10.1016/j.jaci.2016.11.053			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28143694	Bronze, Green Accepted			2022-12-18	WOS:000409241500008
J	Frisoli, ML; Harris, JE				Frisoli, Michael L.; Harris, John E.			Vitiligo: Mechanistic insights lead to novel treatments	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vitiligo; treatment; T cell; IFN-gamma; CXCL9; CXCL10; CXCR3; resident memory; regulation; stress; innate immunity; inflammasome; NLRP1; NLRP3; melanocyte; regeneration; clinical trials; repigmentation; hair	CD8(+) T-CELLS; BAND ULTRAVIOLET-B; TERM-FOLLOW-UP; GENERALIZED VITILIGO; SEGMENTAL VITILIGO; HUMAN MELANOCYTES; DISEASE-ACTIVITY; DOUBLE-BLIND; MOUSE MODEL; SKIN	Vitiligo is an autoimmune disease of the skin characterized by patchy depigmentation. Current treatments are moderately effective at reversing disease by suppressing autoimmune inflammation in the skin and promoting melanocyte regeneration. Recent basic and translational research studies have significantly improved our understanding of disease pathogenesis, which is now leading to emerging treatment strategies based on targeted therapy. Here we discuss important clinical characteristics of vitiligo, current therapies and their limitations, advances in understanding disease pathogenesis, emerging targeted treatments, and strategies to optimize clinical trials to efficiently and effectively test these new treatments.	[Frisoli, Michael L.; Harris, John E.] Univ Massachusetts, Med Sch, Dept Dermatol, 364 Plantat St,LRB 225, Amherst, MA 01605 USA	University of Massachusetts System; University of Massachusetts Amherst	Frisoli, ML (corresponding author), Univ Massachusetts, Med Sch, Dept Dermatol, 364 Plantat St,LRB 225, Amherst, MA 01605 USA.	michael.frisoli@umassmed.edu		Frisoli, Michael/0000-0002-3397-9687	Pfizer; AbbVie; Stiefel/GlaxoSmithKline; Celgene	Pfizer(Pfizer); AbbVie(AbbVie); Stiefel/GlaxoSmithKline(GlaxoSmithKline); Celgene(Bristol-Myers SquibbCelgene Corporation)	J. E. Harris has consultant arrangements with Pfizer, AbbVie, Genzyme/Sanofi, Concert Pharmaceuticals, Mitsubishi Tanabe Pharmaceuticals, Novartis, Aclaris, the Expert Institute, Biologics MD, and Dermira; is employed by UMass Medical School; has provided expert testimony for the Law Offices of Peter G. Angelos, PC; has received grants from Pfizer, AbbVie, Stiefel/GlaxoSmithKline, and Celgene; has a provisional patent application filed; and has stock/stock options in Tevido. M. L. Frisoli declares that he has no relevant conflicts of interest.	Abdou AG, 2013, ANN DIAGN PATHOL, V17, P245, DOI 10.1016/j.anndiagpath.2012.11.005; AlGhamdi KM, 2012, J DRUGS DERMATOL, V11, P534; Alkhateeb A, 2003, PIGM CELL RES, V16, P208, DOI 10.1034/j.1600-0749.2003.00032.x; Ariotti S, 2014, SCIENCE, V346, P101, DOI 10.1126/science.1254803; Bakis-Petsoglou S, 2009, BRIT J DERMATOL, V161, P910, DOI 10.1111/j.1365-2133.2009.09252.x; Bertolotti A, 2014, PIGM CELL MELANOMA R, V27, P398, DOI 10.1111/pcmr.12219; Birlea SA, 2011, J INVEST DERMATOL, V131, P371, DOI 10.1038/jid.2010.337; BOISSY RE, 1991, J INVEST DERMATOL, V97, P395, DOI 10.1111/1523-1747.ep12480976; Campbell JJ, 2010, BLOOD, V116, P767, DOI 10.1182/blood-2009-11-251926; Cavalie M, 2015, J INVEST DERMATOL, V135, P970, DOI 10.1038/jid.2014.527; Cheuk S, 2017, IMMUNITY, V46, P287, DOI 10.1016/j.immuni.2017.01.009; Cohen BE, 2015, AM J CLIN DERMATOL, V16, P463, DOI 10.1007/s40257-015-0153-5; Craiglow BG, 2015, JAMA DERMATOL, V151, P1110, DOI 10.1001/jamadermatol.2015.1520; Damsky W, 2017, J AM ACAD DERMATOL, V76, P736, DOI 10.1016/j.jaad.2016.12.005; Dell'Anna ML, 2007, CLIN EXP DERMATOL, V32, P631, DOI 10.1111/j.1365-2230.2007.02514.x; Denman CJ, 2008, J INVEST DERMATOL, V128, P2041, DOI 10.1038/jid.2008.45; Dwivedi M, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12105; Elder DE, 2009, LEVERS HISTOPATHOLOG, V174-81, P694; Esmat S, 2017, DERMATOL CLIN, V35, P171, DOI 10.1016/j.det.2016.11.008; Gawkrodger DJ, 2009, BRIT J DERMATOL, V161, P721, DOI 10.1111/j.1365-2133.2009.09292.x; Goh BK, 2017, DERMATOL CLIN, V35, P135, DOI 10.1016/j.det.2016.11.004; Harris JE, 2017, DERMATOL CLIN, V35, P151, DOI 10.1016/j.det.2016.11.006; Harris JE, 2016, J AM ACAD DERMATOL, V74, P370, DOI 10.1016/j.jaad.2015.09.073; Harris JE, 2016, IMMUNOL REV, V269, P11, DOI 10.1111/imr.12369; Harris JE, 2012, J INVEST DERMATOL, V132, P1869, DOI 10.1038/jid.2011.463; Hoffmann A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031298; Homan MWL, 2009, J AM ACAD DERMATOL, V61, P411, DOI 10.1016/j.jaad.2009.03.022; Jimbow K, 2001, BRIT J DERMATOL, V144, P55, DOI 10.1046/j.1365-2133.2001.03952.x; Jin Y, 2007, NEW ENGL J MED, V356, P1216, DOI 10.1056/NEJMoa061592; Jin Y, 2012, J INVEST DERMATOL, V132, P1730, DOI 10.1038/jid.2012.37; Jin Y, 2010, NEW ENGL J MED, V362, P1686, DOI 10.1056/NEJMoa0908547; Klarquist J, 2010, PIGM CELL MELANOMA R, V23, P276, DOI 10.1111/j.1755-148X.2010.00688.x; Komen L, 2015, BRIT J DERMATOL, V172, P437, DOI 10.1111/bjd.13432; Kroll TM, 2005, J INVEST DERMATOL, V124, P798, DOI 10.1111/j.0022-202X.2005.23653.x; Leisegang M, 2016, J CLIN INVEST, V126, P854, DOI 10.1172/JCI83465; Levandowski CB, 2013, P NATL ACAD SCI USA, V110, P2952, DOI 10.1073/pnas.1222808110; Li YL, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051002; Lim HW, 2015, JAMA DERMATOL, V151, P42, DOI 10.1001/jamadermatol.2014.1875; Maeda Y, 2014, SCIENCE, V346, P1536, DOI 10.1126/science.aaa1292; Malik BT, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aam6346; Marie J, 2014, BRIT J DERMATOL, V170, P816, DOI 10.1111/bjd.12691; Mery-Bossard L, 2017, J EUR ACAD DERMATOL, V31, P181, DOI 10.1111/jdv.13759; Meyskens FL, 2001, PIGM CELL RES, V14, P148, DOI 10.1034/j.1600-0749.2001.140303.x; Middelkamp-Hup MA, 2007, J EUR ACAD DERMATOL, V21, P942, DOI 10.1111/j.1468-3083.2006.02132.x; Mohammad TF, 2017, DERMATOL CLIN, V35, P193, DOI 10.1016/j.det.2016.11.009; Moraes-Vasconcelos D, 2008, J CLIN IMMUNOL, V28, pS11, DOI 10.1007/s10875-008-9176-5; Mosenson JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005127; Mueller SN, 2016, NAT REV IMMUNOL, V16, P79, DOI 10.1038/nri.2015.3; Mulekar SV, 2004, ARCH DERMATOL, V140, P1211, DOI 10.1001/archderm.140.10.1211; Njoo MD, 1998, ARCH DERMATOL, V134, P1532, DOI 10.1001/archderm.134.12.1532; Parsad D, 2003, CLIN EXP DERMATOL, V28, P285, DOI 10.1046/j.1365-2230.2003.01207.x; Passeron T, 2017, DERMATOL CLIN, V35, P163, DOI 10.1016/j.det.2016.11.007; Patel DC, 2002, CLIN EXP DERMATOL, V27, P641, DOI 10.1046/j.1365-2230.2002.01142.x; PURI N, 1989, ARCH DERMATOL RES, V281, P178, DOI 10.1007/BF00456389; PURI N, 1987, J INVEST DERMATOL, V88, P434, DOI 10.1111/1523-1747.ep12469795; Rashighi M, 2017, DERMATOL CLIN, V35, P257, DOI 10.1016/j.det.2016.11.014; Rashighi M, 2016, JAMA DERMATOL, V152, P1187, DOI 10.1001/jamadermatol.2016.2501; Rashighi M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007811; Regazzetti C, 2015, J INVEST DERMATOL, V135, P3105, DOI 10.1038/jid.2015.335; Ren YQ, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000523; Richmond JM, 2017, J INVEST DERMATOL, V137, P982, DOI 10.1016/j.jid.2016.10.048; Richmond JM, 2017, J INVEST DERMATOL, V137, P350, DOI 10.1016/j.jid.2016.09.016; Richmond JM, 2013, CURR OPIN IMMUNOL, V25, P676, DOI 10.1016/j.coi.2013.10.010; Rothstein B, 2017, J AM ACAD DERMATOL, V76, P1054, DOI 10.1016/j.jaad.2017.02.049; Salzes C, 2016, J INVEST DERMATOL, V136, P52, DOI 10.1038/JID.2015.398; Sasaki M, 2014, PIGM CELL MELANOMA R, V27, P754, DOI 10.1111/pcmr.12269; Schallreuter KU, 2008, INT J DERMATOL, V47, P743, DOI 10.1111/j.1365-4632.2008.03660.x; Schallreuter KU, 2013, FASEB J, V27, P3113, DOI 10.1096/fj.12-226779; Schenkel JM, 2014, IMMUNITY, V41, P886, DOI 10.1016/j.immuni.2014.12.007; Schenkel JM, 2014, SCIENCE, V346, P98, DOI 10.1126/science.1254536; Silpa-Archa N, 2017, J AM ACAD DERMATOL, V77, P318, DOI 10.1016/j.jaad.2017.01.056; Singh RK, 2016, AUTOIMMUN REV, V15, P397, DOI 10.1016/j.autrev.2016.01.004; Speeckaert R, 2017, J INVEST DERMATOL, V137, P1586, DOI 10.1016/j.jid.2017.02.012; Speeckaert R, 2017, J INVEST DERMATOL, V137, P1445, DOI 10.1016/j.jid.2017.01.033; Speeckaert R, 2016, JAMA DERMATOL, V152, P1194, DOI 10.1001/jamadermatol.2016.2366; Speeckaert R, 2015, AUTOIMMUN REV, V14, P332, DOI 10.1016/j.autrev.2014.12.003; Spritz RA, 2017, DERMATOL CLIN, V35, P245, DOI 10.1016/j.det.2016.11.013; Strassner JP, 2016, CURR OPIN IMMUNOL, V43, P81, DOI 10.1016/j.coi.2016.09.008; Strassner JP, 2017, J AM DERMATOL, V76; Szczurko O, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-21; Tembhre MK, 2015, BRIT J DERMATOL, V172, P940, DOI 10.1111/bjd.13511; Toussirot E, 2016, RMD OPEN, V2, DOI 10.1136/rmdopen-2015-000239; van den Boorn JG, 2016, IMMUNITY, V44, P1406, DOI 10.1016/j.immuni.2016.05.008; van den Boorn JG, 2011, J INVEST DERMATOL, V131, P1240, DOI 10.1038/jid.2011.16; van den Boorn JG, 2009, J INVEST DERMATOL, V129, P2220, DOI 10.1038/jid.2009.32; van Geel N, 2016, J INVEST DERMATOL, V136, P978, DOI 10.1016/j.jid.2015.12.040; Wang C, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0018907, 10.1371/journal.pone.0025832]; Wang XX, 2016, BRIT J DERMATOL, V174, P1190; Webb KC, 2015, BRIT J DERMATOL, V173, P641, DOI 10.1111/bjd.14016; Wu SW, 2015, PIGM CELL MELANOMA R, V28, P744, DOI 10.1111/pcmr.12402; Zhang YJ, 2014, J INVEST DERMATOL, V134, P183, DOI 10.1038/jid.2013.268; Zhou L, 2012, PIGM CELL MELANOMA R, V25, P602, DOI 10.1111/j.1755-148X.2012.01019.x; Zhu J, 2013, NATURE, V497, P494, DOI 10.1038/nature12110	93	55	60	1	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					654	662		10.1016/j.jaci.2017.07.011	http://dx.doi.org/10.1016/j.jaci.2017.07.011			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28778794	Bronze			2022-12-18	WOS:000409241500003
J	Heratizadeh, A; Werfel, T; Wollenberg, A; Abraham, S; Plank-Habibi, S; Schnopp, C; Sticherling, M; Apfelbacher, C; Biedermann, T; Breuer, K; Fell, I; Folster-Holst, R; Heine, G; Grimm, J; Hennighausen, L; Kugler, C; Reese, I; Ring, J; Schakel, K; Schmitt, J; Seikowski, K; von Stebut, E; Wagner, N; Wassmann-Otto, A; Wienke-Graul, U; Weisshaar, E; Worm, M; Gieler, U; Kupfer, J				Heratizadeh, Annice; Werfel, Thomas; Wollenberg, Andreas; Abraham, Susanne; Plank-Habibi, Sibylle; Schnopp, Christina; Sticherling, Michael; Apfelbacher, Christian; Biedermann, Tilo; Breuer, Kristine; Fell, Isabel; Foelster-Holst, Regina; Heine, Guido; Grimm, Jennifer; Hennighausen, Lars; Kugler, Claudia; Reese, Imke; Ring, Johannes; Schakel, Knut; Schmitt, Jochen; Seikowski, Kurt; von Stebut, Esther; Wagner, Nicola; Wassmann-Otto, Anja; Wienke-Graul, Ute; Weisshaar, Elke; Worm, Margitta; Gieler, Uwe; Kupfer, Joerg			Effects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; adulthood; patient education; multi-professional; psychosocial; disease severity; quality of life; coping	QUALITY-OF-LIFE; NATIONAL-HEALTH CARE; PATIENTS PERSPECTIVE; PEDIATRIC-PATIENTS; CLINICAL SIGNS; POSITION PAPER; DISEASE BURDEN; ECZEMA; DERMATOLOGY; VALIDATION	Background: Atopic dermatitis (AD) is a chronic relapsing skin disease prevalent in 1% to 3% of adults in Western industrialized countries. Objective: We sought to investigate the effectiveness of educational training in an outpatient setting on coping with the disease, quality of life, symptoms, and severity in adults with AD. Methods: In this German prospective, randomized controlled multicenter study, adult patients with moderate-to-severe AD were educated by referring to a comprehensive 12-hour training manual consented by a multiprofessional study group from different centers (Arbeitsgemeinschaft Neurodermitisschulung fur Erwachsene [ARNE]). Patients were randomly allocated to the intervention or waiting control groups. Study visits were performed at baseline and after 1 year (1 year of follow-up). Primary outcomes were defined as a decrease in (1) "catastrophizing cognitions'' with respect to itching (Juckreiz-Kognitions-Fragebogen questionnaire), (2) "social anxiety'' (Marburger Hautfragebogen questionnaire), (3) subjective burden by symptoms of the disease (Skindex-29 questionnaire), and (4) improvement of disease signs and symptoms assessed by using the SCORAD index at 1 year of follow-up. Data were analyzed on an intention-to-treat basis. Results: At 1 year of follow-up, patients from the intervention group (n = 168) showed a significantly better improvement compared with the waiting group (n = 147) in the following defined primary study outcomes: coping behavior with respect to itching (P < .001), quality of life assessed by using the Skindex-29 questionnaire (P < .001), and the SCORAD index (P < .001). Conclusions: This is the first randomized, controlled multicenter study on patient education in adult AD. The ARNE training program shows significant beneficial effects on a variety of psychosocial parameters, as well as AD severity.	[Heratizadeh, Annice; Werfel, Thomas; Wassmann-Otto, Anja] Hannover Med Sch, Dept Dermatol & Allergy, Div Immunodermatol & Allergy Res, Hannover, Germany; [Wollenberg, Andreas] Ludwig Maximilian Univ Munich, Dept Dermatol & Allergy, Munich, Germany; [Abraham, Susanne] Tech Univ Dresden, Med Fac Carl Gustav Carus, Dept Dermatol, Dresden, Germany; [Plank-Habibi, Sibylle; Wienke-Graul, Ute] Vital Klin GmbH & Co KG, Dept Dermatol & Allergol, Alzenau, Germany; [Schnopp, Christina; Biedermann, Tilo; Kugler, Claudia; Ring, Johannes] Tech Univ Munich, Dept Dermatol & Allergol Biederstein, Munich, Germany; [Sticherling, Michael] Univ Klinikum Erlangen, Dept Dermatol, Erlangen, Germany; [Apfelbacher, Christian; Weisshaar, Elke] Univ Hosp Heidelberg, Dept Clin Social Med, Heidelberg, Germany; [Apfelbacher, Christian] Univ Regensburg, Inst Epidemiol & Prevent Med, Med Sociol, Regensburg, Germany; [Biedermann, Tilo] Eberhard Karls Univ Tubingen, Dept Dermatol, Tubingen, Germany; [Breuer, Kristine] Dermatol Hamburg, Dept Allergol & Occupat Dermatol, Hamburg, Germany; [Fell, Isabel] Rehabil & Prevent GmbH Bad Soden, Dermatol Ctr, Bad Soden, Germany; [Foelster-Holst, Regina] Univ Klinikum Schleswig Holstein, Dept Dermatol, Campus Kiel Dermatol Venerol & Allergol, Kiel, Germany; [Heine, Guido; Worm, Margitta] Charite, Dept Dermatol & Allergy, Campus Mitte, Berlin, Germany; [Grimm, Jennifer] Dermatol Zentrum Buxtehude, Buxtehude, Germany; [Hennighausen, Lars] Acad Neurodermatitis Hessen, Psychol Practice, Hessen, Germany; [Reese, Imke] Nutr Counselling Allergol, Munich, Germany; [Ring, Johannes] CK CARE, Davos, Switzerland; [Schakel, Knut] Univ Hosp Heidelberg, Dept Dermatol, Heidelberg, Germany; [Schmitt, Jochen] Tech Univ Dresden, Med Fak Carl Gustav Carus, Ctr Evidence Based Healthcare, Dresden, Germany; [Seikowski, Kurt] Univ Leipzig, Dept Psychosomat Med, Leipzig, Germany; [von Stebut, Esther] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Dermatol, Mainz, Germany; [Wagner, Nicola] Klinikum Darmstadt Bereich Eberstadt Hautklin, Darmstadt, Germany; [Gieler, Uwe] Justus Liebig Univ, Dept Dermatol & Allergol, Giessen, Germany; [Kupfer, Joerg] Justus Liebig Univ Giessen, Inst Med Psychol, Giessen, Germany	Hannover Medical School; University of Munich; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technical University of Munich; University of Erlangen Nuremberg; Ruprecht Karls University Heidelberg; University of Regensburg; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Dermatologikum Hamburg; University of Kiel; Schleswig Holstein University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruprecht Karls University Heidelberg; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Leipzig University; Johannes Gutenberg University of Mainz; Klinikum Darmstadt; Justus Liebig University Giessen; Justus Liebig University Giessen	Heratizadeh, A (corresponding author), Hannover Med Sch, Dept Dermatol & Allergy, Div Immunodermatol & Allergy Res, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Heratizadeh.Annice@mh-hannover.de	Werfel, Thomas/B-6921-2012; Ring, Johannes/GLN-4341-2022; Abraham, Susanne/AAU-4330-2020; Heine, Guido/G-1656-2018; Kupfer, JOERG/A-5109-2008; Apfelbacher, Christian/X-1051-2019	Ring, Johannes/0000-0001-8236-3152; Abraham, Susanne/0000-0001-7457-6481; Heine, Guido/0000-0003-1467-9862; Apfelbacher, Christian/0000-0003-3805-8219; Schmitt, Jochen/0000-0003-0264-0960; Biedermann, Tilo/0000-0002-5352-5105; Dolle-Bierke, Sabine/0000-0002-3339-0709; Worm, Margitta/0000-0002-3449-1245	Astellas Pharma GmbH	Astellas Pharma GmbH(Astellas Pharmaceuticals)	This investigator-initiated study was financially supported in part by Astellas Pharma GmbH. The German Society for Dermatology (Deutsche Dermatologische Gesellschaft) endorsed this study.	Arkwright PD, 2013, J ALLER CL IMM-PRACT, V1, P142, DOI 10.1016/j.jaip.2012.09.002; Aubert-Wastiaux H, 2011, BRIT J DERMATOL, V165, P808, DOI 10.1111/j.1365-2133.2011.10449.x; Augustin M, 2004, DERMATOLOGY, V209, P14, DOI 10.1159/000078581; Beikert FC, 2014, ARCH DERMATOL RES, V306, P279, DOI 10.1007/s00403-013-1402-1; Blome C, 2016, AM J CLIN DERMATOL, V17, P163, DOI 10.1007/s40257-015-0171-3; Breuer K, 2016, ALLERGOLOGIE, V39, P100, DOI 10.5414/ALX01832; Breuer K, 2014, PEDIAT ALLERG IMM-UK, V25, P489, DOI 10.1111/pai.12249; Charman CR, 2004, ARCH DERMATOL, V140, P1513, DOI 10.1001/archderm.140.12.1513; Chida Y, 2007, INT ARCH ALLERGY IMM, V144, P1, DOI 10.1159/000101940; Chren MM, 1996, J INVEST DERMATOL, V107, P707, DOI 10.1111/1523-1747.ep12365600; Coenraads PJ, 2001, HAUTARZT, V52, P428, DOI 10.1007/s001050051337; Dagregorio G, 2005, ALLERGY, V60, P540, DOI 10.1111/j.1398-9995.2005.00732.x; Dawn A, 2009, BRIT J DERMATOL, V160, P642, DOI 10.1111/j.1365-2133.2008.08941.x; EHLERS A, 1995, J CONSULT CLIN PSYCH, V63, P624, DOI 10.1037/0022-006X.63.4.624; Ehlers A., 1993, VERHALTENSTHERAPIE, V3, P112; Evers AWM, 2009, ACTA DERM-VENEREOL, V89, P57, DOI 10.2340/00015555-0556; FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; Han YY, 2016, J ALLER CL IMM-PRACT, V4, P68, DOI 10.1016/j.jaip.2015.10.004; Hermann C., 1995, HADS D HOSP ANXIETY; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Herrmann C, 1999, PSYCHOTHER PSYCH MED, V49, P48; Hughes R, 2007, PEDIATR DERMATOL, V24, P118, DOI 10.1111/j.1525-1470.2007.00355.x; Kernick D, 2000, BRIT J GEN PRACT, V50, P555; Langenbruch A, 2014, J EUR ACAD DERMATOL, V28, P719, DOI 10.1111/jdv.12154; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Niemeier V, 2002, HAUTARZT, V53, P471, DOI 10.1007/s00105-002-0380-6; Orange AP, 1997, PEDIAT ALLERG IMM-UK, V8, P28, DOI 10.1111/j.1399-3038.1997.tb00139.x; Pickett K, 2016, BRIT J DERMATOL, V174, P1228, DOI 10.1111/bjd.14435; Reekers R, 1999, J ALLERGY CLIN IMMUN, V104, P466, DOI 10.1016/S0091-6749(99)70395-7; Ring J, 2012, J EUR ACAD DERMATOL, V26, P1176, DOI 10.1111/j.1468-3083.2012.04636.x; Ring J, 2012, J EUR ACAD DERMATOL, V26, P1045, DOI 10.1111/j.1468-3083.2012.04635.x; Schmid-Ott G, 2003, HAUTARZT, V54, P852, DOI 10.1007/s00105-003-0539-9; Schmitt J, 2014, J ALLERGY CLIN IMMUN, V134, P800, DOI 10.1016/j.jaci.2014.07.043; Schmitt J, 2013, J ALLERGY CLIN IMMUN, V132, P1337, DOI 10.1016/j.jaci.2013.07.008; Slangier U, 2003, PSYCHOL ASSESSMENT, V15, P532, DOI 10.1037/1040-3590.15.4.532; Staab D, 2006, BMJ-BRIT MED J, V332, P933, DOI 10.1136/bmj.332.7547.933; Stalder JF, 2011, ALLERGY, V66, P1114, DOI 10.1111/j.1398-9995.2011.02577.x; Stalder JF, 2013, PEDIATR DERMATOL, V30, P329, DOI 10.1111/pde.12024; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Steinke S, 2014, DERMATOLOGY, V228, P350, DOI 10.1159/000358587; Torrelo A, 2013, ACTAS DERMO-SIFILOGR, V104, P409, DOI [10.1016/j.ad.2012.12.003, 10.1016/j.adengl.2013.04.004]; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Weisshaar E, 2008, ACTA DERM-VENEREOL, V88, P234, DOI 10.2340/00015555-0432; Werfel T, 2007, ALLERGY, V62, P723, DOI 10.1111/j.1398-9995.2007.01429.x; Werfel T, 2016, J DTSCH DERMATOL GES, V14, P92, DOI [10.1111/ddg.12871, 10.1111/ddg.12884]; Werfel T, 2015, J ALLERGY CLIN IMMUN, V136, P96, DOI 10.1016/j.jaci.2015.04.015; Werfel T, 2009, J INVEST DERMATOL, V129, P1878, DOI 10.1038/jid.2009.71; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; Wollenberg A, 2016, J EUR ACAD DERMATOL, V30, P729, DOI 10.1111/jdv.13599; Wollenberg A, 2012, ANN DERMATOL, V24, P253, DOI 10.5021/ad.2012.24.3.253; Zuberbier T, 2006, J ALLERGY CLIN IMMUN, V118, P226, DOI 10.1016/j.jaci.2006.02.031	51	55	57	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					845	+		10.1016/j.jaci.2017.01.029	http://dx.doi.org/10.1016/j.jaci.2017.01.029			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	FF8CA	28242304				2022-12-18	WOS:000409241500023
J	Eastman, JJ; Cavagnero, KJ; Deconde, AS; Kim, AS; Karta, MR; Broide, DH; Zuraw, BL; White, AA; Christiansen, SC; Doherty, TA				Eastman, Jacqueline J.; Cavagnero, Kellen J.; Deconde, Adam S.; Kim, Alex S.; Karta, Maya R.; Broide, David H.; Zuraw, Bruce L.; White, Andrew A.; Christiansen, Sandra C.; Doherty, Taylor A.			Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Group 2 innate lymphoid cells; aspirin-exacerbated respiratory disease	LEUKOTRIENE RECEPTOR 1; PROSTAGLANDIN D-2; CYSTEINYL LEUKOTRIENES; CHRONIC RHINOSINUSITIS; ADAPTIVE IMMUNITY; INDUCED ASTHMA; CUTTING EDGE; T(H)2 CELLS; INFLAMMATION; ACTIVATION	Background: Aspirin-exacerbated respiratory disease (AERD) is characterized by tissue eosinophilia and mast cell activation, including abundant production of prostaglandin D-2 (PGD(2)). Group 2 innate lymphoid cells (ILC2s), which promote tissue eosinophilia and mast cell responses, undergo chemotaxis and cytokine production in response to PGD(2), but it is unknown whether ILC2s are active in patients with AERD. Objective: We sought to determine whether ILC2 numbers change in peripheral blood and the nasal mucosa during COX-1 inhibitor-induced reactions in patients with AERD. Methods: Blood and nasal scrapings were collected at baseline, during reactions, and after completion of ketorolac/aspirin challenge/desensitization in 12 patients with AERD. ILC2s and eosinophils were quantitated by means of flow cytometry. Urine was also collected, and quantification of PGD(2) metabolite and leukotriene E-4 levels was done by using ELISA. Baseline and nonsteroidal anti-inflammatory drug reaction clinical data were correlated with cell changes. Results: ILC2 numbers significantly increased in nasal mucosal samples and decreased in blood at the time of COX-1 inhibitor reactions in 12 patients with AERD. These changes were not observed in 2 patients without AERD. Furthermore, eosinophil numbers decreased in blood concurrently with significant increases in urinary PGD(2) metabolite and leukotriene E-4 levels. The magnitude of increases in nasal mucosal ILC2 numbers positively correlated with maximum symptom scores during challenges. Furthermore, blood ILC2 numbers during the reaction correlated with time for the reaction to resolve, possibly reflecting reaction severity. Conclusions: ILC2s are recruited to the nasal mucosa during COX-1 inhibitor-induced reactions in patients with AERD, correlating with enhanced production of prostaglandins and leukotrienes.	[Eastman, Jacqueline J.; Cavagnero, Kellen J.; Kim, Alex S.; Karta, Maya R.; Broide, David H.; Zuraw, Bruce L.; Christiansen, Sandra C.; Doherty, Taylor A.] Univ Calif San Diego, Dept Med, Biomed Sci Bldg,Room 5090,9500 Gilman Dr, La Jolla, CA 92093 USA; [Deconde, Adam S.] Univ Calif San Diego, Dept Surg, La Jolla, CA 92093 USA; [White, Andrew A.] Scripps Clin, Div Allergy Asthma & Immunol, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute	Doherty, TA (corresponding author), Univ Calif San Diego, Dept Med, Biomed Sci Bldg,Room 5090,9500 Gilman Dr, La Jolla, CA 92093 USA.	tdoherty@ucsd.edu		Broide, David/0000-0001-8405-9090; Cavagnero, Kellen J/0000-0003-4160-6394; Doherty, Taylor/0000-0003-3256-0398; Zuraw, Bruce/0000-0003-0640-6768	National Institutes of Health [AI114585, AI70535]; NIH [AI70535, T32 AI007469, AI107779, AI38425, AI72115]; Division of Rheumatology, Allergy and Immunology at University of California, San Diego; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007469, R01AI107779, R01AI072115, R01AI038425, R01AI114585, R37AI038425, U19AI070535] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Division of Rheumatology, Allergy and Immunology at University of California, San Diego; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants AI114585 and AI70535 (to T.A.D.), NIH grant T32 AI007469 (to J.J.E.), NIH grants AI107779, AI38425, AI70535, and AI72115 (to D.H.B.), and divisional support from the Division of Rheumatology, Allergy and Immunology at University of California, San Diego.	Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051; Bal SM, 2016, NAT IMMUNOL, V17, P636, DOI 10.1038/ni.3444; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Beasley RC, 1985, J APPL PHYSIOL, V1989, P1685; Bergmann KC, 2015, J ALLER CL IMM-PRACT, V3, P459, DOI 10.1016/j.jaip.2015.01.012; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; Buchheit KM, 2016, J ALLERGY CLIN IMMUN, V137, P1566, DOI 10.1016/j.jaci.2015.10.020; Cahill KN, 2015, J ALLERGY CLIN IMMUN, V135, P245, DOI 10.1016/j.jaci.2014.07.031; Chang JE, 2014, J ALLERGY CLIN IMMUN, V133, P899, DOI 10.1016/j.jaci.2013.09.020; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Doherty TA, 2015, J ALLERGY CLIN IMMUN, V136, P792, DOI 10.1016/j.jaci.2015.05.048; Doherty TA, 2015, J LEUKOCYTE BIOL, V97, P455, DOI 10.1189/jlb.5BT0814-374R; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Feng X, 2016, J ALLERGY CLIN IMMUN, V138, P1089, DOI 10.1016/j.jaci.2016.04.042; Gauvreau GM, 2001, AM J RESP CRIT CARE, V164, P1495, DOI 10.1164/ajrccm.164.8.2102033; Higashi N, 2012, ALLERGOL INT, V61, P393, DOI 10.2332/allergolint.11-RA-0403; Hirai H, 2002, J IMMUNOL, V168, P981, DOI 10.4049/jimmunol.168.3.981; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kim HY, 2012, J ALLERGY CLIN IMMUN, V129, P216, DOI 10.1016/j.jaci.2011.10.036; Kupczyk M, 2010, RESP MED, V104, P1404, DOI 10.1016/j.rmed.2010.04.017; Lao-Araya M, 2014, J ALLERGY CLIN IMMUN, V134, P1193, DOI 10.1016/j.jaci.2014.07.029; Lee RU, 2010, ANN ALLERG ASTHMA IM, V105, P130, DOI 10.1016/j.anai.2010.05.020; Liu T, 2015, J IMMUNOL, V195, P3537, DOI 10.4049/jimmunol.1500905; Miller RC, 2004, CLIN CHEM, V50, P924, DOI 10.1373/clinchem.2004.032292; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Nagakumar P, 2016, J ALLERGY CLIN IMMUN, V137, P624, DOI 10.1016/j.jaci.2015.06.038; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005; Parmentier CN, 2012, J ALLERGY CLIN IMMUN, V129, P1136, DOI 10.1016/j.jaci.2012.01.057; Rajan JP, 2015, J ALLERGY CLIN IMMUN, V135, P676, DOI 10.1016/j.jaci.2014.08.020; SLADEK K, 1993, EUR RESPIR J, V6, P391; Soroosh P, 2009, IMMUNOLOGY, V127, P450, DOI 10.1111/j.1365-2567.2009.03114.x; Stevens WW, 2016, J ALLER CL IMM-PRACT, V4, P565, DOI 10.1016/j.jaip.2016.04.012; Stevenson DD, 2000, ANN ALLERG ASTHMA IM, V85, P477, DOI 10.1016/S1081-1206(10)62575-6; SZCZEKLIK A, 1976, J ALLERGY CLIN IMMUN, V58, P10, DOI 10.1016/0091-6749(76)90102-0; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; Walford HH, 2014, CLIN IMMUNOL, V155, P126, DOI 10.1016/j.clim.2014.09.007; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056	39	55	56	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					101	+		10.1016/j.jaci.2016.11.023	http://dx.doi.org/10.1016/j.jaci.2016.11.023			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	28279492	Green Accepted, Bronze			2022-12-18	WOS:000404542000010
J	Feng, HX; Xun, PC; Pike, K; Wills, AK; Chawes, BL; Bisgaard, H; Cai, W; Wan, YP; He, K				Feng, Haixia; Xun, Pengcheng; Pike, Katharine; Wills, Andrew K.; Chawes, Bo L.; Bisgaard, Hans; Cai, Wei; Wan, Yanping; He, Ka			In utero exposure to 25-hydroxyvitamin D and risk of childhood asthma, wheeze, and respiratory tract infections: A meta-analysis of birth cohort studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						25(OH)D; asthma; wheeze; respiratory tract infections; meta-analysis; birth cohort studies	VITAMIN-D DEFICIENCY; CORD-BLOOD; SEX-DIFFERENCES; D LEVEL; PREGNANCY; SERUM; CHILDREN; SUPPLEMENTATION; ASSOCIATION; HEALTH	Background: Studies of the associations between in utero 25-hydroxyvitamin D (25[OH]D) exposure and risk of childhood asthma, wheeze, and respiratory tract infections are inconsistent and inconclusive. Objectives: We sought to assess associations between 25(OH)D levels in cord blood or maternal venous blood and risk of offspring's asthma, wheeze, and respiratory tract infections. Methods: Data were derived from PubMed, Embase, Google Scholar, references from relevant articles, and de novo results from published studies until December 2015. A random-effects meta-analysis was conducted among 16 birth cohort studies. Results: Comparing the highest with the lowest category of 25(OH) D levels, the pooled odds ratios were 0.84 (95% CI, 0.70-1.01; P = .064) for asthma, 0.77 (95% CI, 0.58-1.03; P = .083) for wheeze, and 0.85 (95% CI, 0.66-1.09; P = .187) for respiratory tract infections. The observed inverse association for wheeze was more pronounced and became statistically significant in the studies that measured 25(OH)D levels in cord blood (0.43; 95% CI, 0.29-0.62; P < .001). Conclusions: Accumulated evidence generated from this meta-analysis suggests that increased in utero exposure to 25(OH)D is inversely associated with the risk of asthma and wheeze during childhood. These findings are in keepingwith the results of 2 recently published randomized clinical trials of vitamin D supplementation during pregnancy.	[Feng, Haixia; Wan, Yanping] Shanghai Jiao Tong Univ, Ren Ji Hosp, Dept Clin Nutr, Shanghai, Peoples R China; [Cai, Wei] Shanghai Jiao Tong Univ, Xin Hua Hosp, Dept Clin Nutr, Sch Med, Shanghai, Peoples R China; [Cai, Wei] Shanghai Jiao Tong Univ, Xin Hua Hosp, Dept Pediat Surg, Sch Med, Shanghai, Peoples R China; [Xun, Pengcheng; He, Ka] Indiana Univ, Dept Epidemiol & Biostat, Sch Publ Hlth Bloomington, 1025 E Seventh St,C042, Bloomington, IN 47405 USA; [Pike, Katharine] UCL Inst Child Hlth, Resp Crit Care & Anaesthesia, London, England; [Wills, Andrew K.] Univ Bristol, Sch Clin Sci, Bristol, Avon, England; [Chawes, Bo L.; Bisgaard, Hans] Univ Copenhagen, Herlev & Gentofte Hosp, Copenhagen Prospect Studies Asthma Childhood COPS, Copenhagen, Denmark; [Cai, Wei] Shanghai Key Lab Pediat Gastroenterol & Nutr, Shanghai, Peoples R China; [Cai, Wei] Shanghai Inst Pediat Res, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Indiana University System; Indiana University Bloomington; University of London; University College London; University of Bristol; University of Copenhagen	He, K (corresponding author), Indiana Univ, Dept Epidemiol & Biostat, Sch Publ Hlth Bloomington, 1025 E Seventh St,C042, Bloomington, IN 47405 USA.; Wan, YP (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Clin Nutr, Shanghai 200127, Peoples R China.	wanyp204@163.com; kahe@indiana.edu	pengcheng, xun/D-3411-2013; Bisgaard, Hans/N-4761-2016; Wills, Andrew/AAO-5279-2020	pengcheng, xun/0000-0002-6245-4505; Bisgaard, Hans/0000-0003-4131-7592; Chawes, Bo/0000-0001-6846-6243; Wills, Andrew/0000-0002-9751-4707	Abbott Fund Institute of Nutrition Sciences [AFINS-2013-06]; Key Laboratory of Pediatric Gastroenterology and Nutrition, Shanghai [11DZ2260-500]; National Natural Science Foundation of China [81573140]	Abbott Fund Institute of Nutrition Sciences; Key Laboratory of Pediatric Gastroenterology and Nutrition, Shanghai; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Supported by the Abbott Fund Institute of Nutrition Sciences (AFINS-2013-06); the Key Laboratory of Pediatric Gastroenterology and Nutrition, Shanghai (11DZ2260-500); and the National Natural Science Foundation of China (81573140).	Adorini L, 2003, J CELL BIOCHEM, V88, P227, DOI 10.1002/jcb.10340; Baeke F, 2010, CURR OPIN PHARMACOL, V10, P482, DOI 10.1016/j.coph.2010.04.001; Baiz N, 2014, J ALLERGY CLIN IMMUN, V133, P147, DOI 10.1016/j.jaci.2013.05.017; Becerir T, 2014, ALLERGOL IMMUNOPATH, V42, P594, DOI 10.1016/j.aller.2013.05.004; Beckhaus AA, 2015, ALLERGY, V70, P1588, DOI 10.1111/all.12729; Burke W, 2003, AM J PREV MED, V24, P160, DOI 10.1016/S0749-3797(02)00589-5; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Camargo CA, 2011, PEDIATRICS, V127, pE180, DOI 10.1542/peds.2010-0442; Carey MA, 2007, TRENDS ENDOCRIN MET, V18, P308, DOI 10.1016/j.tem.2007.08.003; Cassim R, 2015, ALLERGY, V70, P339, DOI 10.1111/all.12583; Chawes BL, 2016, JAMA-J AM MED ASSOC, V315, P353, DOI 10.1001/jama.2015.18318; Chawes BL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099856; Chiu CY, 2015, PEDIAT ALLERG IMM-UK, V26, P337, DOI 10.1111/pai.12384; de Jongh RT, 2014, EUR RESPIR J, V43, P1181, DOI 10.1183/09031936.00116913; Demirel S, 2014, INT FORUM ALLERGY RH, V4, P980, DOI 10.1002/alr.21401; Devereux G, 2007, AM J CLIN NUTR, V85, P853, DOI 10.1093/ajcn/85.3.853; Duijts L, 2012, EUR J EPIDEMIOL, V27, P5, DOI 10.1007/s10654-012-9657-y; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Gale CR, 2008, EUR J CLIN NUTR, V62, P68, DOI 10.1038/sj.ejcn.1602680; GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237; Hart PH, 2015, PEDIATRICS, V135, pE167, DOI 10.1542/peds.2014-1860; Hewison M, 2010, ENDOCRIN METAB CLIN, V39, P365, DOI 10.1016/j.ecl.2010.02.010; Jacquemyn Y, 2013, FACTS VIEWS VIS OBGY, V5, P3; Jones AP, 2015, CLIN EXP ALLERGY, V45, P220, DOI 10.1111/cea.12449; Knapp G, 2003, STAT MED, V22, P2693, DOI 10.1002/sim.1482; Litonjua AA, 2016, JAMA-J AM MED ASSOC, V315, P362, DOI 10.1001/jama.2015.18589; Luczynska A, 2014, EUR J EPIDEMIOL, V29, P585, DOI 10.1007/s10654-014-9918-z; Magnus MC, 2013, PAEDIATR PERINAT EP, V27, P532, DOI 10.1111/ppe.12080; McCallister JW, 2008, J ASTHMA, V45, P853, DOI 10.1080/02770900802444187; Mebrahtu TF, 2015, J EPIDEMIOL COMMUN H, V69, P500, DOI 10.1136/jech-2014-204783; Miyake Y, 2014, ANN ALLERG ASTHMA IM, V113, P82, DOI 10.1016/j.anai.2014.04.023; Mohamed WAW, 2013, J TROP PEDIATRICS, V59, P29, DOI 10.1093/tropej/fms042; Moher David, 2009, Ann Intern Med, V151, P264, DOI [10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007]; Morales E, 2012, EPIDEMIOLOGY, V23, P64, DOI 10.1097/EDE.0b013e31823a44d3; Orsini N, 2012, AM J EPIDEMIOL, V175, P66, DOI 10.1093/aje/kwr265; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Pike KC, 2012, THORAX, V67, P950, DOI 10.1136/thoraxjnl-2012-201888; Pletz MW, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-53; Rajabbik MH, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-31; Rothers J, 2011, J ALLERGY CLIN IMMUN, V128, P1093, DOI 10.1016/j.jaci.2011.07.015; Science M, 2013, CLIN INFECT DIS, V57, P392, DOI 10.1093/cid/cit289; Shin Youn Ho, 2013, Korean J Pediatr, V56, P439, DOI 10.3345/kjp.2013.56.10.439; Stelmach I, 2015, RESP MED, V109, P38, DOI 10.1016/j.rmed.2014.10.016; Stevens E, 2004, PEDIATR PULM, V37, P530, DOI 10.1002/ppul.20008; Tamblyn JA, 2015, J ENDOCRINOL, V224, pR107, DOI 10.1530/JOE-14-0642; Thomas P K, 2014, J Assoc Physicians India, V62, P27; Townsend EA, 2012, ENDOCR REV, V33, P1, DOI 10.1210/er.2010-0031; Wells GA, NEWCASTLE OTTAWA SCA; Wills AK, 2013, CLIN EXP ALLERGY, V43, P1180, DOI 10.1111/cea.12172; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zosky Graeme R, 2014, Ann Am Thorac Soc, V11, P571, DOI [10.1513/AnnalsATS.201312-423OC, 10.1513/AnnalsATS.201407-331LE]	51	55	56	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1508	1517		10.1016/j.jaci.2016.06.065	http://dx.doi.org/10.1016/j.jaci.2016.06.065			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27639938	Green Submitted, Bronze			2022-12-18	WOS:000400465300011
J	Granell, R; Henderson, AJ; Sterne, JA				Granell, Raquel; Henderson, A. John; Sterne, Jonathan A.			Associations of wheezing phenotypes with late asthma outcomes in the Avon Longitudinal Study of Parents and Children: A population-based birth cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALSPAC; wheezing phenotypes; childhood; adolescence; latent class	1ST 6 YEARS; EXHALED NITRIC-OXIDE; LUNG-FUNCTION; CHILDHOOD ASTHMA; PRESCHOOL-CHILDREN; AIRWAY FUNCTION; AGE; SENSITIZATION; INFLAMMATION; LIFE	Background: Variable patterns of childhood wheezing might indicate differences in the cause and prognosis of respiratory illnesses. Better understanding of these patterns could facilitate identification of modifiable factors related to development of asthma. Objectives: We characterized childhood wheezing phenotypes from infancy to adolescence and their associations with asthma outcomes. Methods: Latent class analysis was used to derive phenotypes based on patterns of wheezing recorded at up to 14 time points from birth to 16 "years among 12,303 participants from the Avon Longitudinal Study of Parents and Children. Measures of lung function (FEV1, forced vital capacity [FVC], and forced expiratory flow between 25% and75%[FEF25-75]) and fraction of exhaled nitric oxide (FENO) were made at 14 to 15 years of age. Results: Six wheezing phenotypes were identified: never/infrequent, preschool-onset remitting, midchildhood-onset remitting, school age-onset persisting, late childhood-onset persisting, and continuous wheeze. The 3 persistent phenotypes were associated with bronchodilator reversibility of 12% or greater (BDR) from baseline (odds ratio [OR] range, 2.14-3.34), a FENO value of 35 ppb or greater (OR range, 3.82-6.24), and lung function decrements (mean range of differences: -0.22 to -0.27 SD units (SDU) for FEV1/FVC ratio and -0.21 to -0.33 SDU for FEF25-75) compared with never/infrequent wheeze. Midchildhood-onset (41/2 years) remitting wheeze was associated with BDR(OR, 1.77; 95% CI, 1.11-2.82), a FENO value of 35 ppb or greater (OR, 1.72; 95% CI, 1.14-2.59), FEV1/FVC ratio decrements (OR, -0.22 SDU; 95% CI, -0.36 to -0.08 SDU), and FEF25-75 decrements (OR, -0.16 SDU; 95% CI, -0.30 to -0.01 SDU). Preschool-onset (18 months) remitting wheeze was only associated with FEV1/FVC ratio decrements (OR, -0.15 SDU; 95% CI, -0.25 to -0.05 SDU) and FEF25-75 decrements (OR, -0.14 SDU; 95% CI, -0.24 to -0.04 SDU). The persisting phenotypes showed evidence of sex stratification during adolescence. Conclusions: Early childhood-onset wheezing that persists into adolescence represents the clearest target group for interventions to maximize lung function outcomes.	[Granell, Raquel; Henderson, A. John; Sterne, Jonathan A.] Univ Bristol, Sch Social & Community Med, Bristol BS8 1TH, Avon, England	University of Bristol	Granell, R (corresponding author), Oakfield House, Bristol BS8 2BN, Avon, England.	raquel.granell@bristol.ac.uk	Sterne, Jonathan/Z-3106-2019; Granell, Raquel/AAB-5256-2022; Granell, Raquel/AAY-4846-2020	Sterne, Jonathan/0000-0001-8496-6053; Granell, Raquel/0000-0002-4890-4012; 	Wellcome Trust [092731]; UK Medical Research Council [0401540]; National Institute for Health Research Senior Investigator award [NF-SI-0611-10168]; MRC [G0902125, G0401540] Funding Source: UKRI; Medical Research Council [G0902125, MC_PC_15018, G0401540, G9815508] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10168] Funding Source: researchfish; Asthma UK [AUK-AC-2012-01] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research Senior Investigator award; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK	The UK Medical Research Council and the Wellcome Trust (grant reference 092731) and the University of Bristol provide core support for ALSPAC study. R.G. was supported by the UK Medical Research Council (grant no. 0401540). J.A.S. is funded by National Institute for Health Research Senior Investigator award NF-SI-0611-10168.	ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; Belgrave DCM, 2014, AM J RESP CRIT CARE, V189, P1101, DOI 10.1164/rccm.201309-1700OC; BIRTCHNELL J, 1988, BRIT J MED PSYCHOL, V61, P255, DOI 10.1111/j.2044-8341.1988.tb02787.x; Bisgaard H, 2012, AM J RESP CRIT CARE, V185, P1183, DOI 10.1164/rccm.201110-1922OC; Bonds RS, 2013, CURR OPIN ALLERGY CL, V13, P92, DOI 10.1097/ACI.0b013e32835a6dd6; Boyd A, 2013, INT J EPIDEMIOL, V42, P111, DOI 10.1093/ije/dys064; CHINN S, 1992, THORAX, V47, P707, DOI 10.1136/thx.47.9.707; Collins SA, 2013, PEDIATR PULM, V48, P683, DOI 10.1002/ppul.22766; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Depner M, 2014, AM J RESP CRIT CARE, V189, P129, DOI 10.1164/rccm.201307-1198OC; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Granell R, 2013, J ALLERGY CLIN IMMUN, V131, P685, DOI 10.1016/j.jaci.2012.09.021; Granell R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048359; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Kotecha SJ, 2010, AM J RESP CRIT CARE, V181, P969, DOI 10.1164/rccm.200906-0897OC; Kreiner-Moller E, 2014, J ALLERGY CLIN IMMUN, V134, P1036, DOI 10.1016/j.jaci.2014.04.003; Kusel MMH, 2012, EUR RESPIR J, V39, P876, DOI 10.1183/09031936.00193310; Lee YJ, 2013, ACTA PAEDIATR, V102, P53, DOI 10.1111/apa.12046; Lodge CJ, 2011, J ALLERGY CLIN IMMUN, V128, P782, DOI 10.1016/j.jaci.2011.06.038; Lovett CJ, 2007, CLIN EXP ALLERGY, V37, P1594, DOI 10.1111/j.1365-2222.2007.02839.x; Malmstrom K, 2015, ANN ALLERG ASTHMA IM, V114, P90, DOI 10.1016/j.anai.2014.09.019; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; Oh MA, 2013, PEDIATR PULM, V48, P563, DOI 10.1002/ppul.22705; Panico L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111922; Pellegrino R, 2005, EUR RESPIR J, V26, P1104, DOI 10.1183/09031936.05.00026705; Postma DS, 2007, GENDER MED, V4, pS133, DOI 10.1016/S1550-8579(07)80054-4; Quanjer PH, 2010, EUR RESPIR J, V36, P1391, DOI 10.1183/09031936.00164109; Rabe-Hesketh S, 2008, STAT METHODS MED RES, V17, P5, DOI 10.1177/0962280207081236; Roberts G, 2005, CLIN EXP ALLERGY, V35, P933, DOI 10.1111/j.1365-2222.2005.02280.x; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Salam MT, 2006, J ALLERGY CLIN IMMUN, V117, P1001, DOI 10.1016/j.jaci.2006.02.004; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Spycher BD, 2012, J ALLERGY CLIN IMMUN, V130, P503, DOI 10.1016/j.jaci.2012.06.002; Stern DA, 2007, LANCET, V370, P758, DOI 10.1016/S0140-6736(07)61379-8; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Tai A, 2014, J ALLERGY CLIN IMMUN, V133, P1572, DOI 10.1016/j.jaci.2013.12.1033; Tein JY, 2013, STRUCT EQU MODELING, V20, P640, DOI 10.1080/10705511.2013.824781; Townsend EA, 2012, ENDOCR REV, V33, P1, DOI 10.1210/er.2010-0031; Turner SW, 2002, AM J RESP CRIT CARE, V165, P1294, DOI 10.1164/rccm.200110-018OC	44	55	57	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1060	+		10.1016/j.jaci.2016.01.046	http://dx.doi.org/10.1016/j.jaci.2016.01.046			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27106203	Green Published, hybrid, Green Submitted			2022-12-18	WOS:000385499400011
J	Hochstadter, E; Clarke, A; De Schryver, S; LaVieille, S; Alizadehfar, R; Joseph, L; Eisman, H; Ben-Shoshan, M				Hochstadter, Elana; Clarke, Ann; De Schryver, Sarah; LaVieille, Sebastien; Alizadehfar, Reza; Joseph, Lawrence; Eisman, Harley; Ben-Shoshan, Moshe			Increasing visits for anaphylaxis and the benefits of early epinephrine administration: A 4-year study at a pediatric emergency department in Montreal, Canada	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDREN; MANAGEMENT; ALLERGY		[Hochstadter, Elana] Univ Toronto, Hosp Sick Children, Dept Pediat Emergency Med, Toronto, ON M5G 1X8, Canada; [Clarke, Ann] Univ Calgary, Dept Med, Cumming Sch Med, Div Rheumatol, Calgary, AB, Canada; [De Schryver, Sarah; Ben-Shoshan, Moshe] McGill Univ, Montreal Childrens Hosp, Div Pediat Allergy & Immunol, Dept Pediat,Hlth Ctr, Montreal, PQ H3H 1P3, Canada; [LaVieille, Sebastien] Hlth Canada, Food Directorate, Ottawa, ON K1A 0L2, Canada; [Alizadehfar, Reza; Joseph, Lawrence] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; [Eisman, Harley] McGill Univ, Montreal Childrens Hosp, Dept Emergency Med, Ctr Hlth, Montreal, PQ H3H 1P3, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Calgary; McGill University; Health Canada; McGill University; McGill University	Ben-Shoshan, M (corresponding author), McGill Univ, Montreal Childrens Hosp, Div Pediat Allergy & Immunol, Dept Pediat,Hlth Ctr, Montreal, PQ H3H 1P3, Canada.	moshebenshoshan@gmail.com	La Vieille, Sébastien/AAC-5087-2019	La Vieille, Sebastien/0000-0001-5368-1266; Ben-Shoshan, Moshe/0000-0001-9083-1518				Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Gold MS, 2000, J ALLERGY CLIN IMMUN, V106, P171, DOI 10.1067/mai.2000.106041; Huang F, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Huang F, 2012, J ALLERGY CLIN IMMUN, V129, P162, DOI 10.1016/j.jaci.2011.09.018; Jarvinen KM, 2008, J ALLERGY CLIN IMMUN, V122, P133, DOI 10.1016/j.jaci.2008.04.031; Prescott SL, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-21; Sampson HA, 2006, ANN EMERG MED, V47, P373, DOI 10.1016/j.annemergmed.2006.01.018; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, P587, DOI 10.1016/j.jaci.2011.01.038; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Summers CW, 2008, J ALLERGY CLIN IMMUN, V121, P632, DOI 10.1016/j.jaci.2007.12.003; Vetander M, 2012, CLIN EXP ALLERGY, V42, P568, DOI 10.1111/j.1365-2222.2011.03954.x; Wood RA, 2014, J ALLERGY CLIN IMMUN, V133, P461, DOI 10.1016/j.jaci.2013.08.016	12	55	56	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1888	1890		10.1016/j.jaci.2016.02.016	http://dx.doi.org/10.1016/j.jaci.2016.02.016			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	27106202	Bronze			2022-12-18	WOS:000377527200033
J	Smits, HH; Hiemstra, PS; da Costa, CP; Ege, M; Edwards, M; Garn, H; Howarth, PH; Jartti, T; de Jong, EC; Maizels, RM; Marsland, BJ; McSorley, HJ; Muller, A; Pfefferle, PI; Savelkoul, H; Schwarze, J; Unger, WWJ; von Mutius, E; Yazdanbakhsh, M; Taube, C				Smits, Hermelijn H.; Hiemstra, Pieter S.; da Costa, Clarissa Prazeres; Ege, Markus; Edwards, Michael; Garn, Holger; Howarth, Peter H.; Jartti, Tuomas; de Jong, Esther C.; Maizels, Rick M.; Marsland, Ben J.; McSorley, Henry J.; Muller, Anne; Pfefferle, Petra I.; Savelkoul, Huub; Schwarze, Juergen; Unger, Wendy W. J.; von Mutius, Erika; Yazdanbakhsh, Maria; Taube, Christian			Microbes and asthma: Opportunities for intervention	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hygiene hypothesis; asthma; sensitization; microbes; microbiome; helminths; viruses; immune regulation	ALLERGIC AIRWAY INFLAMMATION; PLACEBO-CONTROLLED TRIAL; EXPERIMENTAL HOOKWORM INFECTION; RESPIRATORY-TRACT INFECTIONS; REGULATORY T-CELLS; HYGIENE HYPOTHESIS; CHILDHOOD ASTHMA; GUT MICROBIOTA; EARLY-LIFE; RHINOVIRUS ILLNESSES	The worldwide incidence and prevalence of asthma continues to increase. Asthma is now understood as an umbrella term for different phenotypes or endotypes, which arise through different pathophysiologic pathways. Understanding the many factors contributing to development of the disease is important for the identification of novel therapeutic targets for the treatment of certain asthma phenotypes. The hygiene hypothesis has been formulated to explain the increasing prevalence of allergic disease, including asthma. This hypothesis postulates that decreased exposure at a young age to certain infectious agents as a result of improved hygiene, increased antibiotic use and vaccination, and changes in lifestyle and dietary habits is associated with changes in the immune system, which predispose subjects to allergy. Many microbes, during their coevolution with human subjects, developed mechanisms to manipulate the human immune system and to increase their chances of survival. Improving models of asthma, as well as choosing adequate end points in clinical trials, will lead to a more complete understanding of the underlying mechanisms, thus providing an opportunity to devise primary and secondary interventions at the same time as identifying new molecular targets for treatment. This article reports the discussion and conclusion of a workshop under the auspices of the Netherlands Lung Foundation to extend our understanding of how modulation of the immune system by bacterial, parasitic, and viral infections might affect the development of asthma and to map out future lines of investigation.	[Smits, Hermelijn H.; Yazdanbakhsh, Maria] Leiden Univ, Med Ctr, Dept Parasitol, NL-2333 ZA Leiden, Netherlands; [Hiemstra, Pieter S.; Taube, Christian] Leiden Univ, Med Ctr, Dept Pulmonol, NL-2333 ZA Leiden, Netherlands; [da Costa, Clarissa Prazeres] Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-80290 Munich, Germany; [Ege, Markus; von Mutius, Erika] Univ Munich, Dr von Hauner Childrens Hosp, Marchioninistr 15, D-81377 Munich, Germany; [Edwards, Michael] Univ London Imperial Coll Sci Technol & Med, Dept Resp Med, London SW7 2AZ, England; [Edwards, Michael] Univ London Imperial Coll Sci Technol & Med, Wright Fleming Inst Infect & Immun, London SW7 2AZ, England; [Garn, Holger] Univ Marburg, Inst Lab Med & Pathobiochem, D-35032 Marburg, Germany; [Howarth, Peter H.] Univ Southampton, Fac Med, Univ Hosp Southampton, Acad Unit Clin & Expt Sci, Southampton SO9 5NH, Hants, England; [Jartti, Tuomas] Turku Univ Hosp, Dept Pediat, Turku, Finland; [de Jong, Esther C.] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1012 WX Amsterdam, Netherlands; [Maizels, Rick M.; McSorley, Henry J.] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8QQ, Lanark, Scotland; [Marsland, Ben J.] Univ Lausanne, CHUV, Serv Pneumol, Fac Biol & Med, CH-1066 Epalinges, Switzerland; [Muller, Anne] Univ Zurich, Inst Mol Canc Res, CH-8006 Zurich, Switzerland; [Pfefferle, Petra I.] Univ Marburg, Comprehens Biomat Bank Marburg CBBMR, D-35032 Marburg, Germany; [Savelkoul, Huub] Wageningen Univ, Cell Biol & Immunol Grp, NL-6700 AP Wageningen, Netherlands; [Schwarze, Juergen] Univ Edinburgh, Queens Med Res Inst, MRC Ctr Inflammat Res, Edinburgh EH8 9YL, Midlothian, Scotland; [Unger, Wendy W. J.] Erasmus MC, Dept Paediat, Rotterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Technical University of Munich; University of Munich; Imperial College London; Imperial College London; Philipps University Marburg; University of Southampton; University of Turku; University of Amsterdam; Academic Medical Center Amsterdam; University of Glasgow; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Zurich; Philipps University Marburg; Wageningen University & Research; University of Edinburgh; Erasmus University Rotterdam; Erasmus MC	Smits, HH (corresponding author), Leiden Univ, Med Ctr, Dept Parasitol, NL-2333 ZA Leiden, Netherlands.	h.h.smits@lumc.nl	Smits, Hermelijn/V-4216-2018; Schwarze, Jürgen/F-7396-2011; Hiemstra, Pieter S/K-8587-2018; Yazdanbakhsh, Maria/AAI-3996-2020; Ege, Markus/C-1962-2012; /V-8478-2019; Savelkoul, Huub FJ/F-6026-2012	Smits, Hermelijn/0000-0001-9279-2890; Hiemstra, Pieter S/0000-0002-0238-5982; Yazdanbakhsh, Maria/0000-0002-7666-1441; Ege, Markus/0000-0001-6643-3923; Garn, Holger/0000-0002-5178-4023; Howarth, Peter/0000-0003-0619-7927; von Mutius, Erika/0000-0002-8893-4515; McSorley, Henry/0000-0003-1300-7407	Dutch Lung Foundation; Boehringer Ingelheim; Galapagos; German Federal Ministry of Research (BMBF); German Research Foundation (DFG); European Commission; European Research Council; Friesland Campina; GlaxoSmithKline; Chiesi; Merck; Pfizer; German Research Foundation (DFG) [SFB/TR22]; Academy of Finland; Wellcome Trust; Rainin Foundation; Asthma UK; Medical Research Council; Abbvie; Thermo Fisher; Thermo Fisher Scientific; MEDA Pharmaceuticals; Nutritia; Mead Johnson Nutrition; Abbott; IMed-Emerade; Allergy Therapeutics; Stallergenes; German Research Foundation; Friesland-Campina; Novartis; Mundipharma; DOC Congress SRL; Oekosoziales Forum Oberoesterreich; MRC [G0901697] Funding Source: UKRI; Medical Research Council [G0901697] Funding Source: researchfish; Asthma UK [SPD-2012-172] Funding Source: researchfish	Dutch Lung Foundation; Boehringer Ingelheim(Boehringer Ingelheim); Galapagos(Galapagos NV); German Federal Ministry of Research (BMBF)(Federal Ministry of Education & Research (BMBF)); German Research Foundation (DFG)(German Research Foundation (DFG)); European Commission(European CommissionEuropean Commission Joint Research Centre); European Research Council(European Research Council (ERC)European Commission); Friesland Campina; GlaxoSmithKline(GlaxoSmithKline); Chiesi(Chiesi Pharmaceuticals Inc); Merck(Merck & Company); Pfizer(Pfizer); German Research Foundation (DFG)(German Research Foundation (DFG)); Academy of Finland(Academy of Finland); Wellcome Trust(Wellcome Trust); Rainin Foundation; Asthma UK; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Abbvie(AbbVie); Thermo Fisher; Thermo Fisher Scientific; MEDA Pharmaceuticals; Nutritia; Mead Johnson Nutrition; Abbott(Abbott Laboratories); IMed-Emerade; Allergy Therapeutics; Stallergenes; German Research Foundation(German Research Foundation (DFG)); Friesland-Campina; Novartis(Novartis); Mundipharma; DOC Congress SRL; Oekosoziales Forum Oberoesterreich; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	H. H. Smits has received grants and travel support from the Dutch Lung Foundation. P. S. Hiemstra has received travel support from Lung Foundation Netherlands and grants from Boehringer Ingelheim and Galapagos. C. Prazeres da Costa has received travel support from Longfonds, Netherlands. M. Ege has received grants from the German Federal Ministry of Research (BMBF), the German Research Foundation (DFG), the European Commission, the European Research Council, and Friesland Campina and has received royalties from Protectimmun GmbH. M. Edwards is a grant reviewer for NMRC Singapore; has consultant arrangements with Chiesi; is employed by GlaxoSmithKline; has received grants from GlaxoSmithKline, Chiesi, Merck, and Pfizer; has received payment for lectures from Pfizer; and has received travel support from the European Academy of Allergy and Clinical Immunology, the European Respiratory Society, and the American Academy of Allergy, Asthma & Immunology. H. Garn has received a grant from the German Research Foundation (DFG; SFB/TR22) and has received travel support from Lung Foundation Netherlands. T. Jartti has received a grant from the Academy of Finland. E. C. de Jong is employed by AMC, University of Amsterdam. R. M. Maizels is employed by the University of Edinburgh and has received grants from Wellcome Trust and the Rainin Foundation. B. Marsland has received travel support from the Netherlands Lung Foundation. H. J. McSorley has received a grant from Asthma UK. J. Schwarze has received travel support from the Netherlands Lung Foundation; has consultant arrangements with MEDA, GlaxoSmithKline, and Bausch & Lomb; is employed by the University of Edinburgh; has received grants from the Medical Research Council and the Wellcome Trust; has received payment for lectures from Abbvie and Thermo Fisher; and has received support for allergy study days for clinicians from Thermo Fisher Scientific, MEDA Pharmaceuticals, Nutritia, Mead Johnson Nutrition, GlaxoSmithKline, Abbott, IMed-Emerade, Allergy Therapeutics, and Stallergenes. E. von Mutius has received grants from European Research Council, the German Research Foundation, and Friesland-Campina; is on the Editorial Board for the New England Journal of Medicine; has served as an Associate Editor for the Journal of Allergy and Clinical Immunology; has provided expert testimony for the European Research Council and European Commission, UK Research Excellence Framework, AUKCAR, Messerli Research Institute, and University of Tampere; and has received payment for lectures from Novartis, Mundipharma, DOC Congress SRL, Oekosoziales Forum Oberoesterreich. The rest of the authors declare that they have no relevant conflicts of interest.	Agache I, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0529-x; Amberbir A, 2011, CLIN EXP ALLERGY, V41, P1422, DOI 10.1111/j.1365-2222.2011.03831.x; Amu S, 2010, J ALLERGY CLIN IMMUN, V125, P1114, DOI 10.1016/j.jaci.2010.01.018; Arnold IC, 2011, J CLIN INVEST, V121, P3088, DOI 10.1172/JCI45041; Beeh KM, 2013, J ALLERGY CLIN IMMUN, V131, P866, DOI 10.1016/j.jaci.2012.12.1561; Blanken MO, 2013, NEW ENGL J MED, V368, P1791, DOI 10.1056/NEJMoa1211917; Boulet LP, 2015, CURR OPIN PULM MED, V21, P1, DOI 10.1097/MCP.0000000000000125; Bourke CD, 2012, CLIN EXP ALLERGY, V42, P1582, DOI 10.1111/j.1365-2222.2012.04063.x; Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Brown EM, 2013, SEMIN IMMUNOL, V25, P378, DOI 10.1016/j.smim.2013.09.003; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Cahenzli J, 2013, CELL HOST MICROBE, V14, P559, DOI 10.1016/j.chom.2013.10.004; Cantacessi C, 2014, J INFECT DIS, V210, P1431, DOI 10.1093/infdis/jiu256; Casale TB, 2015, ALLERGY, V70, P1160, DOI 10.1111/all.12663; Chen Y, 2008, J INFECT DIS, V198, P553, DOI 10.1086/590158; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Correale J, 2011, J NEUROIMMUNOL, V233, P6, DOI 10.1016/j.jneuroim.2011.01.002; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Feary JR, 2010, CLIN EXP ALLERGY, V40, P299, DOI 10.1111/j.1365-2222.2009.03433.x; Feldman AS, 2015, PEDIAT ALLER IMM PUL, V28, P117, DOI 10.1089/ped.2014.0463; Fleming JO, 2015, PARASITE IMMUNOL, V37, P277, DOI 10.1111/pim.12175; Gaboriau-Routhiau V, 2009, IMMUNITY, V31, P677, DOI 10.1016/j.immuni.2009.08.020; Gergen PJ, 2016, J ALLER CL IMM-PRACT, V4, P22, DOI 10.1016/j.jaip.2015.07.024; Goleva E, 2013, AM J RESP CRIT CARE, V188, P1193, DOI 10.1164/rccm.201304-0775OC; Gollwitzer ES, 2014, NAT MED, V20, P642, DOI 10.1038/nm.3568; Hamid F, 2015, CURR TOP MICROBIOL, V388, P91, DOI 10.1007/978-3-319-13725-4_5; Hill DA, 2013, GUT MICROBES, V4, P76, DOI 10.4161/gmic.22759; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V135, P25, DOI 10.1016/j.jaci.2014.11.011; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jartti T, 2010, PEDIAT ALLERG IMM-UK, V21, P1008, DOI 10.1111/j.1399-3038.2010.01059.x; Jartti T, 2015, J ALLERGY CLIN IMMUN, V135, P691, DOI 10.1016/j.jaci.2014.07.001; Jartti T, 2011, PEDIAT ALLERG IMM-UK, V22, P350, DOI 10.1111/j.1399-3038.2011.01170.x; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Keet CA, 2015, J ALLERGY CLIN IMMUN, V135, P655, DOI 10.1016/j.jaci.2014.11.022; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030; Koch KN, 2015, J CLIN INVEST, V125, P3297, DOI 10.1172/JCI79337; Koloski NA, 2008, WORLD J GASTROENTERO, V14, P165, DOI 10.3748/wjg.14.165; Kopp MV, 2008, PEDIATRICS, V121, pE850, DOI 10.1542/peds.2007-1492; Lau S, 2012, J ALLERGY CLIN IMMUN, V129, P1040, DOI 10.1016/j.jaci.2012.02.005; Layland LE, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002379; Lee SC, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002880; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Leonardi-Bee J, 2006, AM J RESP CRIT CARE, V174, P514, DOI 10.1164/rccm.200603-331OC; Lluis A, 2012, CURR OPIN ALLERGY CL, V12, P158, DOI 10.1097/ACI.0b013e32835109a8; Loss GJ, 2015, AM J RESP CRIT CARE; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Lukkarinen M, 2013, PEDIAT ALLERG IMM-UK, V24, P237, DOI 10.1111/pai.12046; Maizels Rick M., 2008, V94, P112, DOI 10.1159/000154944; Malfertheiner P, 2012, GUT, V61, P646, DOI 10.1136/gutjnl-2012-302084; Marsland BJ, 2013, CHEST, V144, P632, DOI 10.1378/chest.12-2854; McSorley HJ, 2014, MUCOSAL IMMUNOL, V7, P1068, DOI 10.1038/mi.2013.123; McSorley HJ, 2012, EUR J IMMUNOL, V42, P2667, DOI 10.1002/eji.201142161; McSorley HJ, 2012, CLIN MICROBIOL REV, V25, P585, DOI 10.1128/CMR.05040-11; Michel S, 2013, ALLERGY, V68, P355, DOI 10.1111/all.12097; Mpairwe H, 2014, PEDIAT ALLERG IMM-UK, V25, P481, DOI 10.1111/pai.12251; Navarro S, 2011, MUCOSAL IMMUNOL, V4, P53, DOI 10.1038/mi.2010.51; Oertli M, 2013, P NATL ACAD SCI USA, V110, P3047, DOI 10.1073/pnas.1211248110; Oertli M, 2012, J CLIN INVEST, V122, P1082, DOI 10.1172/JCI61029; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Pfefferle PI, 2013, J ALLERGY CLIN IMMUN, V131, P1453, DOI 10.1016/j.jaci.2013.03.020; Reynolds LA, 2014, GUT MICROBES, V5, P522, DOI 10.4161/gmic.32155; Ritter M, 2010, P NATL ACAD SCI USA, V107, P20459, DOI 10.1073/pnas.1010337107; Rook GAW, 2010, CLIN EXP IMMUNOL, V160, P70, DOI 10.1111/j.1365-2249.2010.04133.x; Schaad UB, 2010, WORLD J PEDIATR, V6, P5, DOI 10.1007/s12519-010-0001-x; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; SIGURS N, 1995, PEDIATRICS, V95, P500; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Skevaki CL, 2015, PEDIATR INFECT DIS J, V34, P1296, DOI 10.1097/INF.0000000000000872; Smits HH, 2014, J ALLERGY CLIN IMMUN, V134, P1280, DOI 10.1016/j.jaci.2014.08.051; Soto-Quiros M, 2012, J ALLERGY CLIN IMMUN, V129, P1499, DOI 10.1016/j.jaci.2012.03.040; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Straubinger K, 2014, J ALLERGY CLIN IMMUN, V134, P1271, DOI 10.1016/j.jaci.2014.05.034; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; van Buul AR, 2015, EXPERT OPIN BIOL TH, V15, P1713, DOI 10.1517/14712598.2015.1084283; van den Bergh MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047711; van der Vlugt LEPM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030883; van der Vlugt LEPM, 2014, J INFECT DIS, V210, P1207, DOI 10.1093/infdis/jiu257; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Wammes LJ, 2014, LANCET INFECT DIS, V14, P1150, DOI 10.1016/S1473-3099(14)70771-6; Weber J, 2015, AM J RESP CRIT CARE, V191, P522, DOI 10.1164/rccm.201410-1899OC; Wenzel SE, 2013, PULM PHARMACOL THER, V26, P710, DOI 10.1016/j.pupt.2013.07.003; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Zaiss MM, 2015, IMMUNITY, V43, P998, DOI 10.1016/j.immuni.2015.09.012	87	55	57	0	69	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					690	697		10.1016/j.jaci.2016.01.004	http://dx.doi.org/10.1016/j.jaci.2016.01.004			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26947981	Green Accepted, Bronze			2022-12-18	WOS:000371897500004
J	Yang, JQ; Kalim, KW; Li, Y; Zhang, SM; Hinge, A; Filippi, MD; Zheng, Y; Guo, FK				Yang, Jun-Qi; Kalim, Khalid W.; Li, Yuan; Zhang, Shuangmin; Hinge, Ashwini; Filippi, Marie-Dominique; Zheng, Yi; Guo, Fukun			RhoA orchestrates glycolysis for T(H)2 cell differentiation and allergic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RhoA; T-cell metabolism; glycolysis; T(H)2 differentiation; allergic airway inflammation	MOUSE EMBRYONIC FIBROBLASTS; T-CELL; IN-VIVO; FAMILY GTPASES; CDC42 GTPASES; TH2 CELLS; ACTIVATION; MIGRATION; PROTEINS; RAC	Background: Mitochondrial metabolism is known to be important for T-cell activation. However, its involvement in effector T-cell differentiation has just begun to gain attention. Importantly, how metabolic pathways are integrated with T-cell activation and effector cell differentiation and function remains largely unknown. Objective: We sought to test our hypothesis that RhoA GTPase orchestrates glycolysis for T(H)2 cell differentiation and T(H)2-mediated allergic airway inflammation. Methods: Conditional RhoA-deficient mice were generated by crossing RhoA(flox/flox) mice with CD2-Cre transgenic mice. Effects of RhoA on T(H)2 differentiation were evaluated based on in vitro T(H)2-polarized culture conditions and in vivo in ovalbumin-induced allergic airway inflammation. Cytokine levels were measured by using intracellular staining and ELISA. T-cell metabolism was measured by using the Seahorse XF24 Analyzer and flow cytometry. Results: Disruption of RhoA inhibited T-cell activation and T(H)2 differentiation in vitro and prevented the development of allergic airway inflammation in vivo, with no effect on T(H)1 cells. RhoA deficiency in activated T cells led to multiple defects in metabolic pathways, such as glycolysis and oxidative phosphorylation. Importantly, RhoA couples glycolysis to T(H)2 cell differentiation and allergic airway inflammation through regulating IL-4 receptor mRNA expression and T(H)2-specific signaling events. Finally, inhibition of Rho-associated protein kinase, an immediate downstream effector of RhoA, blocked T(H)2 differentiation and allergic airway inflammation. Conclusion: RhoA is a key component of the signaling cascades leading to T(H)2 differentiation and allergic airway inflammation at least in part through control of T-cell metabolism and the Rho-associated protein kinase pathway.	[Yang, Jun-Qi; Kalim, Khalid W.; Li, Yuan; Zhang, Shuangmin; Hinge, Ashwini; Filippi, Marie-Dominique; Zheng, Yi; Guo, Fukun] Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [Yang, Jun-Qi] Jiangsu Inst Parasit Dis, Key Lab Parasit Dis Control & Prevent, Minist Hlth, Wuxi, Peoples R China	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Guo, FK (corresponding author), Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	fukun.guo@cchmc.org	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	National Institutes of Health [GM 108661, HL090676]; Cincinnati Cancer Center Just-In-Time Core Subsidy Program; Center for Clinical and Translational Science and Training of the University of Cincinnati Academic Health Center; National Natural Science Foundation of China [81373116]; Jiangsu Provincial Key Laboratory of Parasite Molecular Biology; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001425] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM108661] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cincinnati Cancer Center Just-In-Time Core Subsidy Program; Center for Clinical and Translational Science and Training of the University of Cincinnati Academic Health Center; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Provincial Key Laboratory of Parasite Molecular Biology; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported in part by grants from the National Institutes of Health (GM 108661 to F.G. and HL090676 to M.-D.F.), the Cincinnati Cancer Center Just-In-Time Core Subsidy Program (to F.G.), the Center for Clinical and Translational Science and Training of the University of Cincinnati Academic Health Center (to F.G.), the National Natural Science Foundation of China (81373116 to J.-Q.Y.), and the Jiangsu Provincial Key Laboratory of Parasite Molecular Biology (to J.Q.Y.).	Andrabi SA, 2014, P NATL ACAD SCI USA, V111, P10209, DOI 10.1073/pnas.1405158111; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bowen H, 2008, CLIN EXP ALLERGY, V38, P1422, DOI 10.1111/j.1365-2222.2008.03067.x; Busse PJ, 2005, J ALLERGY CLIN IMMUN, V116, P1256, DOI 10.1016/j.jaci.2005.08.059; Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016; Corre I, 2001, J EXP MED, V194, P903, DOI 10.1084/jem.194.7.903; del Pozo MA, 1999, EUR J IMMUNOL, V29, P3609; Delgoffe GM, 2011, NAT IMMUNOL, V12, P295, DOI 10.1038/ni.2005; Dott W, 2014, REDOX BIOL, V2, P224, DOI 10.1016/j.redox.2013.12.028; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Foster KG, 2010, J BIOL CHEM, V285, P14071, DOI 10.1074/jbc.R109.094003; Galandrini R, 1997, IMMUNITY, V7, P163, DOI 10.1016/S1074-7613(00)80519-1; Gerriets VA, 2012, TRENDS IMMUNOL, V33, P168, DOI 10.1016/j.it.2012.01.010; Guo FK, 2004, MOL CELL BIOL, V24, P1426, DOI 10.1128/MCB.24.3.1426-1438.2004; Gurumurthy S, 2010, NATURE, V468, P659, DOI 10.1038/nature09572; Heasman SJ, 2010, J CELL BIOL, V190, P553, DOI 10.1083/jcb.201002067; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; Kaiko GE, 2008, IMMUNOLOGY, V123, P326, DOI 10.1111/j.1365-2567.2007.02719.x; Katayama KI, 2011, P NATL ACAD SCI USA, V108, P7607, DOI 10.1073/pnas.1101347108; Kidani Y, 2013, NAT IMMUNOL, V14, P489, DOI 10.1038/ni.2570; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Martin P, 2005, P NATL ACAD SCI USA, V102, P9866, DOI 10.1073/pnas.0501202102; Melendez J, 2011, J BIOL CHEM, V286, P15132, DOI 10.1074/jbc.C111.229336; Mou F, 2012, J EXP MED, V209, P741, DOI 10.1084/jem.20111692; Nakayama T, 2010, SEMIN IMMUNOL, V22, P303, DOI 10.1016/j.smim.2010.04.010; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Roberts DJ, 2015, CELL DEATH DIFFER, V22, P248, DOI 10.1038/cdd.2014.173; Rougerie P, 2013, J IMMUNOL, V190, P748, DOI 10.4049/jimmunol.1201174; Sena LA, 2013, IMMUNITY, V38, P225, DOI 10.1016/j.immuni.2012.10.020; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vielkind S, 2005, J IMMUNOL, V175, P350, DOI 10.4049/jimmunol.175.1.350; Xu HM, 2009, BLOOD, V114, P3557, DOI 10.1182/blood-2009-02-205815; Yang JQ, 2010, EMBO J, V29, P3421, DOI 10.1038/emboj.2010.214; Yang JQ, 2009, P NATL ACAD SCI USA, V106, P1099, DOI 10.1073/pnas.0805907106; Yang K, 2013, IMMUNITY, V39, P1043, DOI 10.1016/j.immuni.2013.09.015; Zeng H, 2013, NATURE, V499, P485, DOI 10.1038/nature12297; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	41	55	58	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					231	+		10.1016/j.jaci.2015.05.004	http://dx.doi.org/10.1016/j.jaci.2015.05.004			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26100081	Green Accepted			2022-12-18	WOS:000367724300015
J	Patel, DA; You, YJ; Huang, GM; Byers, DE; Kim, HJ; Agapov, E; Moore, ML; Peebles, RS; Castro, M; Sumino, K; Shifren, A; Brody, SL; Holtzman, MJ				Patel, Dhara A.; You, Yingjian; Huang, Guangming; Byers, Derek E.; Kim, Hyun Jik; Agapov, Eugene; Moore, Martin L.; Peebles, R. Strokes; Castro, Mario; Sumino, Kaharu; Shifren, Adrian; Brody, Steven L.; Holtzman, Michael J.			Interferon response and respiratory virus control are preserved in bronchial epithelial cells in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; IFN; influenza A virus; respiratory syncytial virus; primary-culture airway epithelial cells	VIRAL-INFECTIONS; III INTERFERON; INTRANASAL INTERFERON-ALPHA-2; PROPHYLACTIC EFFICACY; RHINOVIRUS INFECTIONS; RSV BRONCHIOLITIS; IMMUNE-RESPONSES; DENDRITIC CELLS; 1ST YEAR; EXACERBATIONS	Background: Some investigators find a deficiency in IFN production from airway epithelial cells infected with human rhinovirus in asthma, but whether this abnormality occurs with other respiratory viruses is uncertain. Objective: To assess the effect of influenza A virus (IAV) and respiratory syncytial virus (RSV) infection on IFN production and viral level in human bronchial epithelial cells (hBECs) from subjects with and without asthma. Methods: Primary-culture hBECs from subjects with mild to severe asthma (n = 11) and controls without asthma (hBECs; n = 7) were infected with live or ultraviolet-inactivated IAV (WS/33 strain), RSV (Long strain), or RSV (A/2001/2-20 strain) with multiplicity of infection 0.01 to 1. Levels of virus along with IFN-beta and IFN-lambda and IFN-stimulated gene expression (tracked by 29-59-oligoadenylate synthetase 1 and myxovirus (influenza virus) resistance 1 mRNA) were determined up to 72 hours postinoculation. Results: After IAV infection, viral levels were increased 2-fold in hBECs from asthmatic subjects compared with nonasthmatic control subjects (P < .05) and this increase occurred in concert with increased IFN-lambda 1 levels and no significant difference in IFNB1, 2'-5'-oligoadenylate synthetase 1, or myxovirus (influenza virus) resistance 1mRNA levels. After RSV infections, viral levels were not significantly increased in hBECs from asthmatic versus nonasthmatic subjects and the only significant difference between groups was a decrease in IFN-lambda levels (P < .05) that correlated with a decrease in viral titer. All these differences were found only at isolated time points and were not sustained throughout the 72-hour infection period. Conclusions: The results indicate that IAV and RSV control and IFN response to these viruses in airway epithelial cells is remarkably similar between subjects with and without asthma.	[Patel, Dhara A.; You, Yingjian; Huang, Guangming; Byers, Derek E.; Kim, Hyun Jik; Agapov, Eugene; Castro, Mario; Sumino, Kaharu; Shifren, Adrian; Brody, Steven L.; Holtzman, Michael J.] Washington Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA; [Moore, Martin L.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; [Moore, Martin L.] Childrens Healthcare Atlanta Hosp, Nashville, TN USA; [Peebles, R. Strokes] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA	Washington University (WUSTL); Emory University; Vanderbilt University	Holtzman, MJ (corresponding author), Washington Univ, Sch Med, 660 South Euclid Ave,Campus Box 8052, St Louis, MO 63110 USA.	holtzmanm@wustl.edu	Sumino, Kaharu/AAA-2028-2021	Byers, Derek/0000-0001-7371-9153; Sumino, Kaharu/0000-0002-6214-2966	National Institutes of Health (National Institute of Allergy and Infectious Diseases Asthma and Allergic Diseases Cooperative Research Center) [U19-AI070489, U19-AI095227, U10-HL109257]; Clinical and Translational Science Award (CTSA) [UL1 TR000448]; Roche Postdoctoral Fellowship awards; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL069765, U10HL109257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI095227, U19AI070489] Funding Source: NIH RePORTER	National Institutes of Health (National Institute of Allergy and Infectious Diseases Asthma and Allergic Diseases Cooperative Research Center); Clinical and Translational Science Award (CTSA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Roche Postdoctoral Fellowship awards; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the National Institutes of Health (National Institute of Allergy and Infectious Diseases Asthma and Allergic Diseases Cooperative Research Center grant no. U19-AI070489 to M.J.H., grant no. U19-AI095227 to R.S.P., grant no. U10-HL109257 to M.C.), Clinical and Translational Science Award (CTSA) grant no. UL1 TR000448, and Roche Postdoctoral Fellowship awards (to D.A.P. and H.J.K.).	Alevy YG, 2012, J CLIN INVEST, V122, P4555, DOI 10.1172/JCI64896; [Anonymous], 2007, J ALLERGY CLIN IMMUN, V120, pS94, DOI 10.1016/j.jaci.2007.09.029; Bacharier LB, 2012, J ALLERGY CLIN IMMUN, V130, P91, DOI 10.1016/j.jaci.2012.02.010; Baraldo S, 2012, J ALLERGY CLIN IMMUN, V130, P1307, DOI 10.1016/j.jaci.2012.08.005; Bauer RN, 2012, J ALLERGY CLIN IMMUN, V130, P958, DOI 10.1016/j.jaci.2012.07.013; Bini EJ, 1999, MAYO CLIN PROC, V74, P367, DOI 10.4065/74.4.367; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Bufe A, 2002, INT ARCH ALLERGY IMM, V127, P82, DOI 10.1159/000048173; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Byers DE, 2013, J CLIN INVEST, V123, P3967, DOI 10.1172/JCI65570; Chapgier A, 2009, J CLIN INVEST, V119, P1502, DOI 10.1172/JCI37083; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; DOUGLAS RM, 1986, NEW ENGL J MED, V314, P65, DOI 10.1056/NEJM198601093140201; Dulek DE, 2011, BBA-GEN SUBJECTS, V1810, P1080, DOI 10.1016/j.bbagen.2011.01.012; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Fleming HE, 1999, AM J RESP CRIT CARE, V160, P100, DOI 10.1164/ajrccm.160.1.9808074; Forrest IA, 2005, EUR RESPIR J, V26, P1080, DOI 10.1183/09031936.05.00141404; Gao LL, 2010, VACCINE, V28, P4445, DOI 10.1016/j.vaccine.2010.03.062; Gehlhar K, 2006, CLIN EXP ALLERGY, V36, P331, DOI 10.1111/j.1365-2222.2006.02450.x; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Guenin S, 2009, J EXP BOT, V60, P487, DOI 10.1093/jxb/ern305; Hackett TL, 2008, STEM CELLS, V26, P2576, DOI 10.1634/stemcells.2008-0171; HAYDEN FG, 1985, ANTIVIR RES, V5, P111, DOI 10.1016/0166-3542(85)90037-3; HAYDEN FG, 1986, NEW ENGL J MED, V314, P71, DOI 10.1056/NEJM198601093140202; Henderson J, 2005, PEDIAT ALLERG IMM-UK, V16, P386, DOI 10.1111/j.1399-3038.2005.00298.x; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Hinojosa ME, 2013, AM J RESP CRIT CARE, V186, pA1330; Holtzman MJ, 2012, J CLIN INVEST, V122, P2741, DOI 10.1172/JCI60325; Iikura K, 2011, INT ARCH ALLERGY IMM, V155, P27, DOI 10.1159/000327262; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P268, DOI 10.1098/rspb.1957.0049; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2010, J ALLERGY CLIN IMMUN, V125, P1178, DOI 10.1016/j.jaci.2010.04.021; Jakiela B, 2014, AM J RESP CELL MOL, V51, P229, DOI 10.1165/rcmb.2013-0395OC; James KM, 2013, J ALLERGY CLIN IMMUN, V132, P227, DOI 10.1016/j.jaci.2013.01.009; Jartti T, 2011, CURR RESPIR MED REV, V7, P160, DOI 10.2174/157339811795589423; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Khaitov MR, 2009, ALLERGY, V64, P375, DOI 10.1111/j.1398-9995.2008.01826.x; Kloepfer KM, 2012, AM J RESP CRIT CARE, V185, P1275, DOI 10.1164/rccm.201109-1635OC; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lachowicz-Scroggins ME, 2010, AM J RESP CELL MOL, V43, P652, DOI 10.1165/rcmb.2009-0244OC; Lopez-Souza N, 2009, J ALLERGY CLIN IMMUN, V123, P1384, DOI 10.1016/j.jaci.2009.03.010; McDole JR, 2012, NATURE, V483, P345, DOI 10.1038/nature10863; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Miller EK, 2012, AM J RESP CRIT CARE, V185, P508, DOI 10.1164/rccm.201108-1462OC; MONTO AS, 1986, J INFECT DIS, V154, P128, DOI 10.1093/infdis/154.1.128; Nguyen-Van-Tam JS, 2010, THORAX, V65, P645, DOI 10.1136/thx.2010.135210; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Okabayashi T, 2011, VIRUS RES, V160, P360, DOI 10.1016/j.virusres.2011.07.011; Orens JB, 2003, J HEART LUNG TRANSPL, V22, P1183, DOI 10.1016/S1053-2498(03)00096-2; Parker D, 2012, AM J RESP CELL MOL, V46, P6, DOI 10.1165/rcmb.2011-0080OC; Patel DA, 2014, J BIOMOL SCREEN, V19, P119, DOI 10.1177/1087057113496848; Patel DA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036594; Schroth MK, 1999, AM J RESP CELL MOL, V20, P1220, DOI 10.1165/ajrcmb.20.6.3261; Shan MM, 2013, SCIENCE, V342, P447, DOI 10.1126/science.1237910; Shornick LP, 2008, J IMMUNOL, V180, P3319, DOI 10.4049/jimmunol.180.5.3319; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Slater L, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001178; Stokes KL, 2011, J VIROL, V85, P5782, DOI 10.1128/JVI.01693-10; Sumino K, 2012, J ALLERGY CLIN IMMUN, V129, P1267, DOI 10.1016/j.jaci.2012.02.033; Sykes A, 2014, THORAX, V69, P240, DOI 10.1136/thoraxjnl-2012-202909; Sykes A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065921; Szabo SM, 2012, PAEDIATR RESPIR REV, V13, pS9; Vareille M, 2012, THORAX, V67, P517, DOI 10.1136/thoraxjnl-2011-200405; Walter MJ, 2002, J CLIN INVEST, V110, P165, DOI 10.1172/JCI200214345; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2009, RESPIROLOGY, V14, P180, DOI 10.1111/j.1440-1843.2009.01480.x; WISELKA MJ, 1991, THORAX, V46, P706, DOI 10.1136/thx.46.10.706; Wu PS, 2011, EXPERT REV ANTI-INFE, V9, P731, DOI [10.1586/eri.11.92, 10.1586/ERI.11.92]; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; Zhang Y, 2005, J BIOL CHEM, V280, P34306, DOI 10.1074/jbc.M503263200	73	55	56	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1402	+		10.1016/j.jaci.2014.07.013	http://dx.doi.org/10.1016/j.jaci.2014.07.013			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25216987	Green Accepted, Bronze			2022-12-18	WOS:000346075400024
J	Thawer-Esmail, F; Jakasa, I; Todd, G; Wen, YR; Brown, SJ; Kroboth, K; Campbell, LE; O'Regan, GM; McLean, WHI; Irvine, AD; Kezic, S; Sandilands, A				Thawer-Esmail, Fatemah; Jakasa, Ivone; Todd, Gail; Wen, Yaran; Brown, Sara J.; Kroboth, Karin; Campbell, Linda E.; O'Regan, Grainne M.; McLean, W. H. Irwin; Irvine, Alan D.; Kezic, Sanja; Sandilands, Aileen			South African amaXhosa patients with atopic dermatitis have decreased levels of filaggrin breakdown products but no loss-of-function mutations in filaggrin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Thawer-Esmail, Fatemah] Univ Cape Town, Div Dermatol, ZA-7925 Cape Town, South Africa; [Jakasa, Ivone] Univ Zagreb, Fac Food Technol & Biotechnol, Dept Chem & Biochem, Analyt Chem Lab, Zagreb 41000, Croatia; [Todd, Gail; Wen, Yaran; Brown, Sara J.; Kroboth, Karin; Campbell, Linda E.; McLean, W. H. Irwin; Sandilands, Aileen] Univ Dundee, Dept Dermatol & Genet Med, Dundee, Scotland; [O'Regan, Grainne M.; Irvine, Alan D.] Our Ladys Childrens Hosp Crumlin, Dept Paediat Dermatol, Dublin, Ireland; [Irvine, Alan D.] Our Ladys Childrens Hosp Crumlin, Natl Childrens Res Ctr, Dublin, Ireland; [Irvine, Alan D.] Univ Dublin Trinity Coll, Dept Clin Med, Dublin 2, Ireland; [Kezic, Sanja] Univ Amsterdam, Acad Med Ctr, Coronel Inst Occupat Hlth, NL-1105 AZ Amsterdam, Netherlands	University of Cape Town; University of Zagreb; University of Dundee; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin; Trinity College Dublin; University of Amsterdam; Academic Medical Center Amsterdam	Thawer-Esmail, F (corresponding author), Univ Cape Town, Div Dermatol, ZA-7925 Cape Town, South Africa.	irvinea@tcd.ie	Todd, Gail/AAI-8952-2020; Irvine, Alan D/A-3982-2008	Irvine, Alan D/0000-0002-9048-2044; McLean, William Henry Irwin/0000-0001-5539-5757; Brown, Sara/0000-0002-3232-5251	Medical Research Council [G0700314] Funding Source: Medline; Wellcome Trust [098439] Funding Source: Medline; MRC [G0700314] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Harding CR, 2013, INT J COSMETIC SCI, V35, P412, DOI 10.1111/ics.12049; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Kezic S, 2011, ALLERGY, V66, P934, DOI 10.1111/j.1398-9995.2010.02540.x; Kidd JM, 2012, AM J HUM GENET, V91, P660, DOI 10.1016/j.ajhg.2012.08.025; Margolis DJ, 2012, J ALLERGY CLIN IMMUN, V130, P912, DOI 10.1016/j.jaci.2012.07.008; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; Pellerin L, 2013, J ALLERGY CLIN IMMUN, V131, P1094, DOI 10.1016/j.jaci.2012.12.1566; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Winge MCG, 2011, BRIT J DERMATOL, V165, P1074, DOI 10.1111/j.1365-2133.2011.10475.x	10	55	57	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					280	+		10.1016/j.jaci.2013.09.053	http://dx.doi.org/10.1016/j.jaci.2013.09.053			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24369804	hybrid, Green Published			2022-12-18	WOS:000329105700044
J	Hilton, ECY; Baverel, PG; Woodcock, A; Van der Graaf, PH; Smith, JA				Hilton, Emma C. Y.; Baverel, Paul G.; Woodcock, Ashley; Van der Graaf, Piet H.; Smith, Jaclyn A.			Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the C5 end point	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Capsaicin; cough; challenge; human; model; nonlinear; reflex; response; sensitivity	NOXIOUS INHIBITORY CONTROLS; GUINEA-PIGS; REFLEX SENSITIVITY; TEMPORAL SUMMATION; INHALED CAPSAICIN; MEDIATING COUGH; CHALLENGE; PAIN; EXPRESSION; THRESHOLD	Background: Inhaled capsaicin elicits cough reproducibly in human subjects and is widely used in the study of cough and antitussive therapies. However, the traditional end points C2 and C5 (the concentrations of capsaicin inducing at least 2 or 5 coughs, respectively) display extensive overlap between health and disease and therefore might not best reflect clinically relevant mechanisms. Objectives: We sought to investigate capsaicin dose responses in different disease groups. Methods: Two novel capsaicin cough challenges were compared in patients with chronic cough (CC; n = 20), asthmatic patients (n = 18), and healthy volunteers (HVs; n = 20). Increasing doubling doses of capsaicin (0.48-1000 mmol/L, 4 inhalations per dose) were administered in challenge 1, whereas the order of the doses was randomized in challenge 2. A nonlinear mixed-effects model compared dose-response parameters by disease group and sex. Parameters were also correlated with objective cough frequency. Results: The model classified subjects based on maximum cough response evoked by any concentration of capsaicin (E-max) and the capsaicin dose inducing half-maximal response (ED50). HVs and asthmatic patients were not statistically different for either parameter and therefore combined for analysis (mean ED50, 38.6 mmol/L [relative SE, 28%]; mean Emax, 4.5 coughs [ relative SE, 11%]). Compared with HVs/asthmatic patients, patients with CC had lower ED50 values (14.7 mmol/L [ relative SE, 28%], P = .008) and higher Emax values (8.6 coughs [relative SE, 11%], P < .0001). Emax values highly correlated with 24-hour cough frequency (r = 0.71, P < .001) and were 37% higher in female compared with male subjects, regardless of disease group (P < .001). Conclusions: Nonlinear mixed-effects modeling demonstrates that maximal capsaicin cough responses better discriminate health from disease and predict spontaneous cough frequency and therefore provide important insights into the mechanisms underlying CC.	[Hilton, Emma C. Y.; Woodcock, Ashley; Smith, Jaclyn A.] Univ Manchester, Resp Res Grp, Manchester M13 9PL, Lancs, England; [Baverel, Paul G.; Van der Graaf, Piet H.] Pfizer, Dept Pharmacometr, Sandwich, Kent, England; [Van der Graaf, Piet H.] Leiden Univ, Leiden Acad Ctr Drug Res, NL-2300 RA Leiden, Netherlands	University of Manchester; Pfizer; Leiden University; Leiden University - Excl LUMC	Smith, JA (corresponding author), Univ S Manchester Hosp, Educ & Res Ctr, 2nd Floor,Southmoor Rd, Manchester M23 9LT, Lancs, England.	jacky.smith@manchester.ac.uk		Woodcock, Ashley/0000-0002-5428-8578; Smith, Jaclyn/0000-0001-8837-4928	MRC [G0701918]; Medical Research Council; Medical Research Council [G0701918] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10249] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by MRC Training Fellowship and MRC Clinician Scientist Award G0701918. Disclosure of potential conflict of interest: E. C. Y. Hilton has received research support from the Medical Research Council and is employed by Novo Nordisk UK. P. G. Baverel is employed by Pfizer. A. Woodcock has a patent from Vitalograph. P. H. Van Der Graaf is employed by and owns stock in Pfizer. J. A. Smith has received research support from the Medical Research Council, has received consultancy fees from GlaxoSmithKline and Merck, and the University Hospital South Manchester owns a patent that she has invented on describing methods for cough detection from sound recordings.	Atkinson AJ, 2007, CLIN PHARMACOL THER, V82, P3, DOI 10.1038/sj.clpt.6100248; Atkinson Jr AJ, 2012, PRINCIPLES CLIN PHAR; Beal S, 2006, NONMEM USERS GUIDES; Birring SS, 2006, RESP MED, V100, P1105, DOI 10.1016/j.rmed.2005.09.023; Blake K, 2008, CHEST, V134, P981, DOI 10.1378/chest.07-2991; Canning BJ, 2004, J PHYSIOL-LONDON, V557, P543, DOI 10.1113/jphysiol.2003.057885; Carr MJ, 2004, PULM PHARMACOL THER, V17, P447, DOI 10.1016/j.pupt.2004.09.020; Creticos PS, 2002, J ALLERGY CLIN IMMUN, V110, P713, DOI 10.1067/mai.2002.129036; Davenport PW, 2007, PULM PHARMACOL THER, V20, P338, DOI 10.1016/j.pupt.2006.10.012; Decalmer SC, 2007, THORAX, V62, P329, DOI 10.1136/thx.2006.067413; Dicpinigaitis P. V., 2009, V187, P297, DOI 10.1007/978-3-540-79842-2_15; Dicpinigaitis PV, 2003, PULM PHARMACOL THER, V16, P61, DOI 10.1016/S1094-5539(02)00149-9; Fujimura M, 1996, EUR RESPIR J, V9, P1624, DOI 10.1183/09031936.96.09081624; Groneberg DA, 2004, AM J RESP CRIT CARE, V170, P1276, DOI 10.1164/rccm.200402-174OC; Gupta SK, 1999, CLIN PHARMACOL THER, V65, P672, DOI 10.1016/S0009-9236(99)90089-9; Hastie TJ, 2010, GAM GEN ADDITIVE MOD; Kastelik JA, 2002, AM J RESP CRIT CARE, V166, P961, DOI 10.1164/rccm.2109061; Kelsall A, 2009, THORAX, V64, P393, DOI 10.1136/thx.2008.106237; Lariviere M, 2007, CLIN J PAIN, V23, P506, DOI 10.1097/AJP.0b013e31806a23e8; Lieu TM, 2012, AM J PHYSIOL-LUNG C, V302, pL941, DOI 10.1152/ajplung.00366.2011; Lieu T, 2011, PULM PHARMACOL THER, V24, P276, DOI 10.1016/j.pupt.2011.02.003; Mazzone SB, 2005, J PHYSIOL-LONDON, V569, P559, DOI 10.1113/jphysiol.2005.093153; Miliqvist E, 2008, PULM PHARMACOL THER, V21, P794, DOI 10.1016/j.pupt.2008.06.002; Morice AH, 2007, EUR RESPIR J, V29, P1256, DOI 10.1183/09031936.00101006; Morice AH, 2011, LUNG, V189, P73, DOI 10.1007/s00408-010-9272-1; MORICE AH, 1987, LANCET, V2, P1116; MORICE AH, 1992, EUR RESPIR J, V5, P841; Morice AH, 2001, BRIT J CLIN PHARMACO, V52, P365, DOI 10.1046/j.0306-5251.2001.01475.x; Morice AH, 2012, LUNG, V190, P3, DOI 10.1007/s00408-011-9351-y; Morice AH, 2010, LUNG, V188, pS87, DOI 10.1007/s00408-009-9185-z; Mould DR, 2012, CPT-PHARMACOMET SYST, V1, DOI 10.1038/psp.2012.4; Mould D, 2013, CPT-PHARMACOMET SYST, V2, DOI 10.1038/psp.2013.14; OCONNELL F, 1994, AM J RESP CRIT CARE, V150, P374, DOI 10.1164/ajrccm.150.2.8049818; Pinheiro JC, 1994, 931 U WISC DEP STAT; Prudon B, 2005, CHEST, V127, P550, DOI 10.1378/chest.127.2.550; Schoemaker RC, 1996, BRIT J CLIN PHARMACO, V42, P283, DOI 10.1046/j.1365-2125.1996.04231.x; Serrao M, 2004, PAIN, V112, P353, DOI 10.1016/j.pain.2004.09.018; Smith JA, 2012, CHEST, V141, P996, DOI 10.1378/chest.11-0554; Staud R, 2003, PAIN, V101, P167, DOI 10.1016/S0304-3959(02)00325-1; Team RDC, R LANG ENV STAT COMP; Tracey I, 2002, J NEUROSCI, V22, P2748, DOI 10.1523/JNEUROSCI.22-07-02748.2002; VanderGraaf PH, 1997, INT J CLIN PHARM TH, V35, P442; WADE JR, 1994, J PHARMACOKINET BIOP, V22, P165, DOI 10.1007/BF02353542; Watanabe N, 2008, INT ARCH ALLERGY IMM, V146, P28, DOI 10.1159/000126057; WOLFINGER R, 1993, BIOMETRIKA, V80, P791, DOI 10.1093/biomet/80.4.791; YOUNG EC, 2010, THORAX S4, V65, pA53, DOI DOI 10.1136/THX.2010.150946.16; Zhang GF, 2008, J PHYSIOL-LONDON, V586, P5771, DOI 10.1113/jphysiol.2008.161042	47	55	56	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					847	+		10.1016/j.jaci.2013.04.042	http://dx.doi.org/10.1016/j.jaci.2013.04.042			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23777849				2022-12-18	WOS:000325096500011
J	Jensen, MP; Meldrum, S; Taylor, AL; Dunstan, JA; Prescott, SL				Jensen, Marie P.; Meldrum, Suzanne; Taylor, Angie L.; Dunstan, Janet A.; Prescott, Susan L.			Early probiotic supplementation for allergy prevention: Long-term outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; ATOPIC DISEASE; FOLLOW-UP; ECZEMA; CHILDREN; REDUCE; RISK; LIFE		[Jensen, Marie P.; Meldrum, Suzanne; Taylor, Angie L.; Dunstan, Janet A.; Prescott, Susan L.] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia; [Jensen, Marie P.] Aarhus Univ, Fac Sci, Aarhus, Denmark	University of Western Australia; Aarhus University	Jensen, MP (corresponding author), Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia.	sprescott@meddent.uwa.edu.au	Prescott, Susan/H-5665-2014	Meldrum, Suzanne/0000-0001-6798-8875				Boyle RJ, 2011, ALLERGY, V66, P509, DOI 10.1111/j.1398-9995.2010.02507.x; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kalliomaki M, 2007, J ALLERGY CLIN IMMUN, V119, P1019, DOI 10.1016/j.jaci.2006.12.608; Kuitunen M, 2009, J ALLERGY CLIN IMMUN, V123, P335, DOI 10.1016/j.jaci.2008.11.019; Prescott SL, 2008, ALLERGY, V63, P1481, DOI 10.1111/j.1398-9995.2008.01778.x; Taylor AL, 2007, J ALLERGY CLIN IMMUN, V119, P184, DOI 10.1016/j.jaci.2006.08.036; West CE, 2009, PEDIATR ALLERGY IMMU, V20, P430, DOI 10.1111/j.1399-3038.2009.00745.x; Wickens K, 2008, J ALLERGY CLIN IMMUN, V122, P788, DOI 10.1016/j.jaci.2008.07.011	9	55	60	1	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1209	1211		10.1016/j.jaci.2012.07.018	http://dx.doi.org/10.1016/j.jaci.2012.07.018			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	22958946	Bronze			2022-12-18	WOS:000310571400028
J	Sumino, K; Sugar, EA; Irvin, CG; Kaminsky, DA; Shade, D; Wei, CY; Holbrook, JT; Wise, RA; Castro, M				Sumino, Kaharu; Sugar, Elizabeth A.; Irvin, Charles G.; Kaminsky, David A.; Shade, Dave; Wei, Christine Y.; Holbrook, Janet T.; Wise, Robert A.; Castro, Mario		Amer Lung Assoc Asthma Clinical Re	Methacholine challenge test: Diagnostic characteristics in asthmatic patients receiving controller medications	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma diagnosis; inhaled corticosteroids; race; atopy	BRONCHIAL HYPERRESPONSIVENESS; AIRWAY HYPERRESPONSIVENESS; INHALATION CHALLENGES; RESPONSIVENESS; SENSITIVITY; SPECIFICITY; CHILDREN; POPULATION; REACTIVITY; MANNITOL	Background: The methacholine challenge test (MCT) is commonly used to assess airway hyperresponsiveness, but the diagnostic characteristics have not been well studied in asthmatic patients receiving controller medications after the use of high-potency inhaled corticosteroids became common. Objectives: We investigated the ability of the MCT to differentiate participants with a physician's diagnosis of asthma from nonasthmatic participants. Methods: We conducted a cohort-control study in asthmatic participants (n = 126) who were receiving regular controller medications and nonasthmatic control participants (n = 93) to evaluate the sensitivity and specificity of the MCT. Results: The overall sensitivity was 77% and the specificity was 96% with a threshold PC20 (the provocative concentration of methacholine that results in a 20% drop in FEV1) of 8 mg/mL. The sensitivity was significantly lower in white than in African American participants (69% vs 95%, P = .015) and higher in atopic compared with nonatopic (82% vs 52%, P = .005). Increasing the PC20 threshold from 8 to 16 mg/mL did not noticeably improve the performance characteristics of the test. African American race, presence of atopy, and lower percent predicted FEV1 were associated with a positive test result. Conclusions: The utility of the MCT to rule out a diagnosis of asthma depends on racial and atopic characteristics. Clinicians should take into account the reduced sensitivity of the MCT in white and nonatopic asthmatic patients when using this test for the diagnosis of asthma. (J Allergy Clin Immunol 2012;130:69-75.)	[Sumino, Kaharu; Castro, Mario] Washington Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA; [Sugar, Elizabeth A.; Shade, Dave; Wei, Christine Y.; Holbrook, Janet T.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Irvin, Charles G.; Kaminsky, David A.] Univ Vermont, Coll Med, Dept Med, Div Pulm Dis & Crit Care Med, Burlington, VT 05405 USA; [Wise, Robert A.] Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA	Washington University (WUSTL); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Vermont; Johns Hopkins University	Sumino, K (corresponding author), Washington Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, 660 Euclid Ave,Campus Box 8052, St Louis, MO 63110 USA.	ksumino@dom.wustl.edu	Parsons, Jonathan/E-3824-2011; Sumino, Kaharu/AAA-2028-2021	Sumino, Kaharu/0000-0002-6214-2966; Wise, Robert/0000-0002-8353-2349	American Lung Association; National Institutes of Health; US Department of Veterans Affairs; Methapharm; GlaxoSmithKline; American Lung Association-Asthma Clinical Research Center; Boehringer-Ingelheim; Asthmatx; Amgen; Ception/Cephalon; Genentech; MedImmune; Merck; Novartis	American Lung Association; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Veterans Affairs(US Department of Veterans Affairs); Methapharm; GlaxoSmithKline(GlaxoSmithKline); American Lung Association-Asthma Clinical Research Center; Boehringer-Ingelheim(Boehringer Ingelheim); Asthmatx; Amgen(Amgen); Ception/Cephalon; Genentech(Roche HoldingGenentech); MedImmune(AstraZenecaMedimmune); Merck(Merck & Company); Novartis(Novartis)	Supported by the American Lung Association. Drugs were donated by Methapharm (Provocholine) and GlaxoSmithKline (Ventolin HFA and Flovent). Neither Methapharm nor GlaxoSmithKline played any role in the design, conduct, data analysis, or interpretation of the study.; K. Sumino receives research support from the National Institutes of Health, the US Department of Veterans Affairs, and the American Lung Association. E. A. Sugar receives research support from the American Lung Association, Methapharm, and GlaxoSmithKline. C. G. Irvin is on the speakers' bureau for Merck, has consultant arrangements with Methapharm, and receives research support from the National Institutes of Health and the American Lung Association-Asthma Clinical Research Center. D. A. Kaminsky is on the American Thoracic Society Proficiency Standards Committee. J. T Holbrook receives research support from the American Lung Association, Methapharm, and GlaxoSmithKline. R. A. Wise has consultant arrangements with and is an advisor for GlaxoSmithKline, Boehringer-Ingelheim, AstraZeneca, Novartis, and Pfizer and receives research support from the American Lung Association, the National Institutes of Health, GlaxoSmithKline, and Boehringer-Ingelheim. M. Castro has consultant arrangements with Asthmatx; is on the speakers' bureau for Asthmatx, Genentech, Astra-Zeneca, Merck, and GlaxoSmithKline; is on an Advisory Board for Genentech; receives royalties from Elsevier; and receives research support from Asthmatx, Amgen, Ception/Cephalon, Genentech, MedImmune, Merck, Novartis, the National Institutes of Health, and GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest.	Anderson SD, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-4; Brannan JD, 2010, CHEST, V138, p11S, DOI 10.1378/chest.10-0231; Carlsten C, 2011, PEDIATR PULM, V46, P175, DOI 10.1002/ppul.21347; Cockcroft DW, 2006, J ALLERGY CLIN IMMUN, V117, P1244, DOI 10.1016/j.jaci.2006.02.038; COCKCROFT DW, 1992, J ALLERGY CLIN IMMUN, V89, P23, DOI 10.1016/S0091-6749(05)80037-5; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; De Meer G, 2002, AM J RESP CRIT CARE, V165, P327, DOI 10.1164/ajrccm.165.3.2104066; Foresi A, 2005, CHEST, V127, P117, DOI 10.1378/chest.127.1.117; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; Goldstein MF, 2001, CHEST, V119, P1001, DOI 10.1378/chest.119.4.1001; GOLDSTEIN MF, 1994, CHEST, V105, P1082, DOI 10.1378/chest.105.4.1082; Hanania NA, 2009, NEW ENGL J MED, V360, P1487, DOI 10.1056/NEJMoa0806290; Hewitt DJ, 2008, AM J IND MED, V51, P769, DOI 10.1002/ajim.20631; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V74, P154, DOI 10.1016/0091-6749(84)90279-3; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kerkhof M, 2003, ALLERGY, V58, P905, DOI 10.1034/j.1398-9995.2003.00230.x; Liem JJ, 2008, PEDIATR PULM, V43, P481, DOI 10.1002/ppul.20801; Litonjua AA, 1999, AM J RESP CRIT CARE, V159, P1574, DOI 10.1164/ajrccm.159.5.9803063; Lucas AEM, 2008, FAM PRACT, V25, P86, DOI 10.1093/fampra/cmn006; Luks VP, 2010, EUR RESPIR J, V36, P255, DOI 10.1183/09031936.00165109; National Institutes of Health National Heart Lung and Blood Institue National Asthma Education and Prevention Program, 1997, 974051 NIH NAT HEART; National Institutes of Health National Heart Lung and Blood Institue National Asthma Education and Prevention Program, 1997, 074051 NIH NAT HEART; NIEMINEN MM, 1992, CHEST, V102, P1537, DOI 10.1378/chest.102.5.1537; Pekkanen J, 1999, EUR RESPIR J, V14, P951, DOI 10.1034/j.1399-3003.1999.14d37.x; PERPINA M, 1993, CHEST, V104, P149, DOI 10.1378/chest.104.1.149; Prieto L, 2006, ANN ALLERG ASTHMA IM, V97, P175, DOI 10.1016/S1081-1206(10)60009-9; SHERMAN CB, 1993, AM REV RESPIR DIS, V148, P98, DOI 10.1164/ajrccm/148.1.98; Siersted HC, 2000, EUR RESPIR J, V15, P181, DOI 10.1183/09031936.00.15118100; Simon MR, 2010, J ALLERGY CLIN IMMUN, V126, P527, DOI 10.1016/j.jaci.2010.05.016; Simon MR, 2010, J ALLERGY CLIN IMMUN, V126, pe1; Skloot G, 2003, CLIN REV ALLERG IMMU, V24, P55, DOI 10.1385/CRIAI:24:1:55; Sutherland ER, 2010, J ALLERGY CLIN IMMUN, V126, P747, DOI 10.1016/j.jaci.2010.07.024; Sverrild A, 2010, J ALLERGY CLIN IMMUN, V126, P952, DOI 10.1016/j.jaci.2010.08.028; Todd DC, 2004, J ALLERGY CLIN IMMUN, V114, P517, DOI 10.1016/j.jaci.2004.06.016; Wechsler ME, 2009, LANCET, V374, P1754, DOI 10.1016/S0140-6736(09)61492-6; Weiss ST, 2000, AM J RESP CRIT CARE, V162, P50, DOI 10.1164/ajrccm.162.1.9811005; Wubbel C, 2004, CHEST, V125, P453, DOI 10.1378/chest.125.2.453	37	55	56	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					69	+		10.1016/j.jaci.2012.02.025	http://dx.doi.org/10.1016/j.jaci.2012.02.025			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22465214	Bronze			2022-12-18	WOS:000306644800009
J	Lieberman, JA; Huang, FR; Sampson, HA; Nowak-Wegrzyn, A				Lieberman, Jay A.; Huang, Faith R.; Sampson, Hugh A.; Nowak-Wegrzyn, Anna			Outcomes of 100 consecutive open, baked-egg oral food challenges in the allergy office	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HEATED EGG; CHILDREN; UTILITY; WHITE		[Lieberman, Jay A.; Huang, Faith R.; Sampson, Hugh A.; Nowak-Wegrzyn, Anna] Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, Dept Pediat, Div Allergy & Immunol, New York, NY USA	Icahn School of Medicine at Mount Sinai	Lieberman, JA (corresponding author), Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, Dept Pediat, Div Allergy & Immunol, New York, NY USA.	anna.nowak-wegrzyn@exchange.mssm.edu		Nowak-Wegrzyn, Anna/0000-0002-0960-9854				Ando H, 2008, J ALLERGY CLIN IMMUN, V122, P583, DOI 10.1016/j.jaci.2008.06.016; Knight AK, 2006, J ALLERGY CLIN IMMUN, V117, P842, DOI 10.1016/j.jaci.2005.12.1304; Konstantinou GN, 2008, J ALLERGY CLIN IMMUN, V122, P414, DOI 10.1016/j.jaci.2008.05.032; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Lieberman JA, 2011, J ALLERGY CLIN IMMUN, V128, P1120, DOI 10.1016/j.jaci.2011.07.012; Nowak-Wegrzyn AH, 2011, J ALLERGY CLIN IMMUN, V127, pAB25, DOI 10.1016/j.jaci.2010.12.112; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Urisu A, 1997, J ALLERGY CLIN IMMUN, V100, P171, DOI 10.1016/S0091-6749(97)70220-3	9	55	58	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1682	1684		10.1016/j.jaci.2012.04.007	http://dx.doi.org/10.1016/j.jaci.2012.04.007			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22657409				2022-12-18	WOS:000304764600036
J	Peterson, S; Poposki, JA; Nagarkar, DR; Chustz, RT; Peters, AT; Suh, LA; Carter, R; Norton, J; Harris, KE; Grammer, LC; Tan, BK; Chandra, RK; Conley, DB; Kern, RC; Schleimer, RP; Kato, A				Peterson, Sarah; Poposki, Julie A.; Nagarkar, Deepti R.; Chustz, Regina T.; Peters, Anju T.; Suh, Lydia A.; Carter, Roderick; Norton, James; Harris, Kathleen E.; Grammer, Leslie C.; Tan, Bruce K.; Chandra, Rakesh K.; Conley, David B.; Kern, Robert C.; Schleimer, Robert P.; Kato, Atsushi			Increased expression of CC chemokine ligand 18 in patients with chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; nasal polyps; Samter's triad; CCL18; pulmonary and activation-regulated chemokine; M2 macrophages; mast cells	ALTERNATIVELY ACTIVATED MACROPHAGES; CHRONIC SINUS DISEASE; REGULATED CHEMOKINE; COLLAGEN PRODUCTION; EPITHELIAL-CELLS; LUNG FIBROBLASTS; DENDRITIC CELLS; TNF FAMILY; PATHOGENESIS; MONOCYTES	Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with TH2-dominant inflammation, including eosinophilia, which is in contrast to chronic rhinosinusitis (CRS) without nasal polyps (NPs). CC chemokine ligand 18 (CCL18)/pulmonary and activation-regulated chemokine is known to recruit naive T cells, B cells, and immature dendritic cells, as well as to activate fibroblasts. CCL18 is thought to be involved in TH2-related inflammatory diseases, including asthma and atopic dermatitis. Objective: The objective of this study was to investigate the expression of CCL18 in patients with CRS. Methods: Using NP tissue and uncinate tissue (UT) from control subjects and patients with CRS, we examined the expression of CCL18 mRNA using real-time PCR and measured CCL18 protein using ELISA, Western blotting, and immunofluorescence. Results: Compared with UT tissue from control subjects, CCL18 mRNA levels were significantly increased in NPs (P < .001) and UT (P < .05) from patients with CRSwNP but not in UT from patients with CRS without NPs. Similarly, CCL18 protein levels were increased in NPs and UT from patients with CRSwNP, and levels were even higher in patients with Samter's triad. Immunohistochemical analysis revealed CCL18 expression in inflammatory cells, and CCL18(+) cell numbers were significantly increased in NPs. Immunofluorescence data showed colocalization of CCL18 in CD68(+)/CD163(+)/macrophage mannose receptor-positive M2 macrophages and tryptase-positive mast cells in NPs. Levels of CCL18 correlated with markers of M2 macrophages but not with tryptase levels, suggesting that M2 macrophages are major CCL18-producing cells in NPs. Conclusion: Overproduction of CCL18 might contribute to the pathogenesis of CRSwNP through its known activities, which include recruitment of lymphocytes and dendritic cells, activation of fibroblasts, and initiation of local inflammation. (J Allergy Clin Immunol 2012; 129: 119-27.)	[Peterson, Sarah; Poposki, Julie A.; Nagarkar, Deepti R.; Chustz, Regina T.; Peters, Anju T.; Suh, Lydia A.; Carter, Roderick; Norton, James; Harris, Kathleen E.; Grammer, Leslie C.; Schleimer, Robert P.; Kato, Atsushi] Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Dept Med, Chicago, IL 60611 USA; [Tan, Bruce K.; Chandra, Rakesh K.; Conley, David B.; Kern, Robert C.] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Kato, A (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Dept Med, 240 E Huron, Chicago, IL 60611 USA.	a-kato@northwestern.edu		Kato, Atsushi/0000-0001-9144-3138; Chandra, Rakesh/0000-0002-3612-0026; Grammer, Leslie/0000-0001-6860-2014	National Institutes of Health [R01 HL078860, R01 AI072570, R37 HL068546]; Ernest S. Bazley Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL068546, R01HL078860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072570] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by National Institutes of Health grants R01 HL078860, R01 AI072570, and R37 HL068546 and by a grant from the Ernest S. Bazley Trust.	Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; Atamas SP, 2003, AM J RESP CELL MOL, V29, P743, DOI 10.1165/rcmb.2003-0078OC; Bachert C, 2009, ALLERGY, V64, P520, DOI 10.1111/j.1398-9995.2009.01964.x; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Chustz RT, 2011, AM J RESP CELL MOL, V45, P145, DOI 10.1165/rcmb.2010-0075OC; Claeys S, 2004, ALLERGY, V59, P606, DOI 10.1111/j.1398-9995.2004.00471.x; De Nadai P, 2006, J IMMUNOL, V176, P6286, DOI 10.4049/jimmunol.176.10.6286; Dykewicz MS, 2010, J ALLERGY CLIN IMMUN, V125, pS103, DOI 10.1016/j.jaci.2009.12.989; EBISAWA M, 1994, J IMMUNOL, V152, P4590; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Guan P, 1999, GENOMICS, V56, P296, DOI 10.1006/geno.1998.5635; Hieshima K, 1997, J IMMUNOL, V159, P1140; Horuk R, 2009, NAT REV DRUG DISCOV, V8, P23, DOI 10.1038/nrd2734; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Kato A, 2006, J IMMUNOL, V177, P7164, DOI 10.4049/jimmunol.177.10.7164; Kato A, 2009, J IMMUNOL, V182, P7233, DOI 10.4049/jimmunol.0801375; Kern RC, 2008, AM J RHINOL, V22, P549, DOI 10.2500/ajr.2008.22.3228; Kodelja V, 1998, J IMMUNOL, V160, P1411; Kreider T, 2007, CURR OPIN IMMUNOL, V19, P448, DOI 10.1016/j.coi.2007.07.002; Krysko O, 2011, ALLERGY, V66, P396, DOI 10.1111/j.1398-9995.2010.02498.x; Luzina IG, 2006, J CELL PHYSIOL, V206, P221, DOI 10.1002/jcp.20452; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; Nardelli B, 1999, J IMMUNOL, V162, P435; Nibbs RJB, 2000, J IMMUNOL, V164, P1488, DOI 10.4049/jimmunol.164.3.1488; Noel W, 2004, TRENDS PARASITOL, V20, P126, DOI 10.1016/j.pt.2004.01.004; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Patadia M, 2010, AM J RHINOL ALLERGY, V24, P11, DOI 10.2500/ajra.2010.24.3386; Pawliczak R, 2005, CURR ALLERGY ASTHM R, V5, P463, DOI 10.1007/s11882-005-0027-7; Pivarcsi A, 2004, J IMMUNOL, V173, P5810, DOI 10.4049/jimmunol.173.9.5810; Plager DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011450; Poposki JA, 2011, J ALLERGY CLIN IMMUN, V128, P73, DOI 10.1016/j.jaci.2011.03.017; Prasse A, 2006, AM J RESP CRIT CARE, V173, P781, DOI 10.1164/rccm.200509-1518OC; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Schall TJ, 2011, NAT REV IMMUNOL, V11, P355, DOI 10.1038/nri2972; Schleimer Robert P, 2009, Proc Am Thorac Soc, V6, P288, DOI 10.1513/pats.200808-088RM; Schraufstatter I, 2004, AM J PHYSIOL-LUNG C, V286, pL494, DOI 10.1152/ajplung.00323.2002; Schutyser E, 2005, J LEUKOCYTE BIOL, V78, P14, DOI 10.1189/jlb.1204712; Schutyser E, 2001, EUR J IMMUNOL, V31, P3755, DOI 10.1002/1521-4141(200112)31:12<3755::AID-IMMU3755>3.0.CO;2-O; Stevenson DD, 2009, CURR ALLERGY ASTHM R, V9, P155, DOI 10.1007/s11882-009-0023-4; Tasaki Y, 1999, GENOMICS, V55, P353, DOI 10.1006/geno.1998.5670; Tieu DD, 2010, J ALLERGY CLIN IMMUN, V125, P667, DOI 10.1016/j.jaci.2009.11.045; van Lieshout AWT, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-23; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Viola A, 2008, ANNU REV PHARMACOL, V48, P171, DOI 10.1146/annurev.pharmtox.48.121806.154841; Walters MJ, 2010, J PHARMACOL EXP THER, V335, P61, DOI 10.1124/jpet.110.169714; Wood AJ, 2010, POSTGRAD MED J, V86, P359, DOI 10.1136/pgmj.2009.094813; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008	49	55	57	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					119	U172		10.1016/j.jaci.2011.08.021	http://dx.doi.org/10.1016/j.jaci.2011.08.021			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	21943944	Green Accepted, Bronze			2022-12-18	WOS:000298634000015
J	Toda, M; Reese, G; Gadermaier, G; Schulten, V; Lauer, I; Egger, M; Briza, P; Randow, S; Wolfheimer, S; Kigongo, V; Moncin, MDS; Fotisch, K; Bohle, B; Vieths, S; Scheurer, S				Toda, Masako; Reese, Gerald; Gadermaier, Gabriele; Schulten, Veronique; Lauer, Iris; Egger, Matthias; Briza, Peter; Randow, Stefanie; Wolfheimer, Sonja; Kigongo, Valencia; San Miguel Moncin, Maria del Mar; Foetisch, Kay; Bohle, Barbara; Vieths, Stefan; Scheurer, Stephan			Protein unfolding strongly modulates the allergenicity and immunogenicity of Pru p 3, the major peach allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pru p 3; nonspecific lipid transfer protein; hypoallergen; allergen-specific immunotherapy; immunogenicity; antigenicity; folding variant	LIPID TRANSFER PROTEIN; T-CELL RESPONSE; PARIETARIA-JUDAICA; IGE-BINDING; MITE ALLERGEN; POLLEN; IMMUNOTHERAPY; IDENTIFICATION; EPITOPES; MUTANT	Background: Allergen-specific immunotherapy for food allergies, including peach allergy, has not been established. Use of allergens with reduced allergenic potential and preserved immunogenicity could improve the safety and efficacy of allergen-specific immunotherapy. Objective: We sought to create a hypoallergenic derivative of the major peach allergen Pru p 3 and to characterize its biochemical and immunologic properties. Methods: A Pru p 3 folding variant generated by means of reduction and alkylation was investigated for structural integrity and stability to gastrointestinal enzymes. IgE reactivity and allergenic potency were determined by means of immunoblotting, ELISA, and in vitro mediator release assay with sera from patients with peach allergy. T-cell immunogenicity was investigated by using human allergen-specific T cells and CBA/J mice immunized with either native Pru p 3 (nPru p 3) or reduced and alkylated (R/A) Pru p 3. Pru p 3 processing by endolysosomal fractions of dendritic cells and antigenicity was examined in mice. Results: Unfolding of Pru p 3 reduced its high resistance to gastrointestinal proteolysis and almost completely abrogated its IgE reactivity and allergenic potency. However, R/A Pru p 3 was capable of stimulating human and murine T cells. Endolysosomal degradation of R/A Pru p 3 was accelerated in comparison with nPru p 3, but similar peptides were generated. IgG and IgE antibodies raised against nPru p 3 showed almost no cross-reactivity with R/A Pru p 3. Moreover, the antigenicity of R/A Pru p 3 was strongly reduced. Conclusion: Unfolded Pru p 3 showed reduced allergenicity and antigenicity and preserved T-cell immunogenicity. The hypoallergenic variant of Pru p 3 could be a promising vaccine candidate for specific immunotherapy of peach allergy. (J Allergy Clin Immunol 2011;128:1022-30.)	[Toda, Masako; Kigongo, Valencia] Paul Ehrlich Inst, Jr Res Grp Expt Allergy Models, D-63226 Langen, Germany; [Reese, Gerald; Lauer, Iris; Randow, Stefanie; Wolfheimer, Sonja; Foetisch, Kay; Vieths, Stefan; Scheurer, Stephan] Paul Ehrlich Inst, Div Allergol, D-63226 Langen, Germany; [Gadermaier, Gabriele; Egger, Matthias; Briza, Peter] Salzburg Univ, Dept Mol Biol, Christian Doppler Lab Allergy Diag & Therapy, A-5020 Salzburg, Austria; [Schulten, Veronique] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Vienna, Austria; [Schulten, Veronique] Med Univ Vienna, Christian Doppler Lab Immunomodulat, Vienna, Austria; [San Miguel Moncin, Maria del Mar] Pius Hosp Valls, Dept Allergy, Tarragona, Spain	Paul Ehrlich Institute; Paul Ehrlich Institute; Salzburg University; Medical University of Vienna; Medical University of Vienna	Toda, M (corresponding author), Paul Ehrlich Inst, Jr Res Grp Expt Allergy Models, Paul Ehrlich Str 51-59, D-63226 Langen, Germany.	todma@pei.de; schst@pei.de	Gadermaier, Gabriele/L-5997-2015; Toda, Masako/S-9810-2019; Scheurer, Stephan/A-6509-2019; Briza, Peter/D-7309-2012	Gadermaier, Gabriele/0000-0002-4886-417X; Scheurer, Stephan/0000-0002-2859-562X; Briza, Peter/0000-0002-4941-6782; Egger, Matthias/0000-0001-7462-5132; Bohle, Barbara/0000-0002-5105-7985	Paul-Ehrlich-Institut; Austrian Science Fund [SFBF1807-B13, W1212]; Christian Doppler Research Society; European Union; German Research Foundation; German Food Industry; Monsanto Company; Pioneer Hi-Bred International; Food Allergy Research and Resource Program; European Directorate for the Quality of Medicines and Health Care; German Ministry for Education and Research	Paul-Ehrlich-Institut; Austrian Science Fund(Austrian Science Fund (FWF)); Christian Doppler Research Society; European Union(European Commission); German Research Foundation(German Research Foundation (DFG)); German Food Industry; Monsanto Company; Pioneer Hi-Bred International; Food Allergy Research and Resource Program; European Directorate for the Quality of Medicines and Health Care; German Ministry for Education and Research(Federal Ministry of Education & Research (BMBF))	Supported in part by Paul-Ehrlich-Institut and the Austrian Science Fund, projects SFBF1807-B13 and W1212.; Disclosure of potential conflict of interest: B. Bohle receives research support from the Austrian Science Fund and the Christian Doppler Research Society. S. Vieths is an associate for the Institute for Product Quality; received an honorarium as an expert reviewer from the Food Allergy Resource and Research Program; receives honorarium for an expert seminar from Fresenius Academy; receives research support from the European Union, the German Research Foundation, the Research Fund of the German Food Industry, Monsanto Company, Pioneer Hi-Bred International, the Food Allergy Research and Resource Program, the European Directorate for the Quality of Medicines and Health Care, and the German Ministry for Education and Research; is a member of the executive committee for the European Academy of Allergy and Clinical Immunology; has served as chairman and as secretary of the Allergen Standardization Subcommittee for the International Union of Immunological Societies; is a registered expert for the European Agency for the Evaluation of Medicinal Products and the European Pharmacopoeia Commission; is chairman of Technical Committee 275 Working Group 12 Food Allergens for CEN; and is a member of the Food Allergy Working Group for the German Society for Allergy and Clinical Immunology. The rest of the authors have declared that they have no conflict of interest.	Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030; Albrecht M, 2009, J ALLERGY CLIN IMMUN, V124, P328, DOI 10.1016/j.jaci.2009.05.031; Asero R, 2011, INT ARCH ALLERGY IMM, V155, P149, DOI 10.1159/000318864; Ball T, 2009, ALLERGY, V64, P569, DOI 10.1111/j.1398-9995.2008.01910.x; Bellinghausen I, 2008, CLIN EXP ALLERGY, V38, P539, DOI 10.1111/j.1365-2222.2007.02910.x; Bonura A, 2007, INT ARCH ALLERGY IMM, V142, P274, DOI 10.1159/000097358; Bonura A, 2001, INT ARCH ALLERGY IMM, V126, P32, DOI 10.1159/000049492; Chen KW, 2008, MOL IMMUNOL, V45, P2486, DOI 10.1016/j.molimm.2008.01.006; Colombo P, 1998, J IMMUNOL, V160, P2780; De Groot AS, 2008, CURR OPIN PHARMACOL, V8, P620, DOI 10.1016/j.coph.2008.08.002; Egger M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017278; Egger M, 2010, CURR ALLERGY ASTHM R, V10, P326, DOI 10.1007/s11882-010-0128-9; Fernandez-Rivas M, 2009, ALLERGY, V64, P876, DOI 10.1111/j.1398-9995.2008.01921.x; Foetisch K, 2003, J ALLERGY CLIN IMMUN, V111, P889, DOI 10.1067/mai.2003.173; Gadermaier G, 2010, MOL IMMUNOL, V47, P1292, DOI 10.1016/j.molimm.2009.11.029; Garcia-Casado G, 2003, J ALLERGY CLIN IMMUN, V112, P599, DOI 10.1037/mai.2003.1638; Hartz C, 2010, INT ARCH ALLERGY IMM, V153, P335, DOI 10.1159/000316344; Kahlert H, 2008, INT ARCH ALLERGY IMM, V145, P193, DOI 10.1159/000109288; Korematsu S, 2000, J IMMUNOL, V165, P2895, DOI 10.4049/jimmunol.165.5.2895; Larche M, 2007, ALLERGY, V62, P325, DOI 10.1111/j.1398-9995.2006.01309.x; Lauer I, 2009, CLIN EXP ALLERGY, V39, P1427, DOI 10.1111/j.1365-2222.2009.03312.x; Linhart B, 2005, CURR OPIN IMMUNOL, V17, P646, DOI 10.1016/j.coi.2005.09.010; Mutschlechner S, 2010, J ALLERGY CLIN IMMUN, V125, P711, DOI 10.1016/j.jaci.2009.10.052; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Orlandi A, 2004, CLIN EXP ALLERGY, V34, P470, DOI 10.1111/j.1365-2222.2004.01894.x; Pacios LF, 2008, MOL IMMUNOL, V45, P2269, DOI 10.1016/j.molimm.2007.11.022; Pastorello EA, 2004, MOL NUTR FOOD RES, V48, P356, DOI 10.1002/mnfr.200400047; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; Pree I, 2007, J IMMUNOL, V179, P5309, DOI 10.4049/jimmunol.179.8.5309; Rabjohn P, 2002, INT ARCH ALLERGY IMM, V128, P15, DOI 10.1159/000057999; Reese G, 2005, J IMMUNOL, V175, P8354, DOI 10.4049/jimmunol.175.12.8354; Reese G, 2007, J ALLERGY CLIN IMMUN, V119, P944, DOI 10.1016/j.jaci.2006.11.699; Salcedo G, 2007, BBA-MOL CELL BIOL L, V1771, P781, DOI 10.1016/j.bbalip.2007.01.001; Scheurer S, 2004, J ALLERGY CLIN IMMUN, V114, P900, DOI 10.1016/j.jaci.2004.06.017; Schulten V, 2009, J ALLERGY CLIN IMMUN, V124, P100, DOI 10.1016/j.jaci.2009.02.010; Shakir EM, 2010, ANN ALLERG ASTHMA IM, V105, P340, DOI 10.1016/j.anai.2010.09.012; Thalhamer T, 2010, J ALLERGY CLIN IMMUN, V125, P926, DOI 10.1016/j.jaci.2010.01.031; Tordesillas L, 2009, MOL IMMUNOL, V46, P722, DOI 10.1016/j.molimm.2008.10.018; Vassilopoulou E, 2006, J ALLERGY CLIN IMMUN, V118, P473, DOI 10.1016/j.jaci.2006.04.057; Vrtala S, 2008, ALLERGY, V63, P299, DOI 10.1111/j.1398-9995.2007.01609.x; Vrtala S, 2007, J IMMUNOL, V179, P1730, DOI 10.4049/jimmunol.179.3.1730; Wagner S, 2008, J ALLERGY CLIN IMMUN, V121, P246, DOI 10.1016/j.jaci.2007.08.006; Wallner M, 2007, J ALLERGY CLIN IMMUN, V120, P374, DOI 10.1016/j.jaci.2007.05.021; Westritschnig K, 2007, J IMMUNOL, V179, P7624, DOI 10.4049/jimmunol.179.11.7624; Yasue M, 1998, CLIN EXP IMMUNOL, V113, P1, DOI 10.1046/j.1365-2249.1998.00616.x; Zuidmeer L, 2007, CURR OPIN ALLERGY CL, V7, P269, DOI 10.1097/ACI.0b013e32814a5401	46	55	60	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1022	U470		10.1016/j.jaci.2011.04.020	http://dx.doi.org/10.1016/j.jaci.2011.04.020			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21571358				2022-12-18	WOS:000296578200015
J	Blatman, KSH; Gonsalves, N; Hirano, I; Bryce, PJ				Blatman, Karen S. Hsu; Gonsalves, Nirmala; Hirano, Ikuo; Bryce, Paul J.			Expression of mast cell-associated genes is upregulated in adult eosinophilic esophagitis and responds to steroid or dietary therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Blatman, Karen S. Hsu; Bryce, Paul J.] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Chicago, IL 60611 USA; [Gonsalves, Nirmala; Hirano, Ikuo] Northwestern Univ, Feinberg Sch Med, Div Gastroenterol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Blatman, KSH (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Chicago, IL 60611 USA.	p-bryce@northwestern.edu		Gonsalves, Nirmala/0000-0003-0722-6099	NIAID NIH HHS [R01 AI076456-03, R01 AI076456-05, R01AI076456-03, R01 AI076456] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI076456] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P140, DOI 10.1016/j.jaci.2010.04.009; Aceves SS, 2010, J ALLERGY CLIN IMMUN, V126, P1198, DOI 10.1016/j.jaci.2010.08.050; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Gonsalves N, 2006, GASTROENTEROLOGY, V130, pA579; Gonsalves N, 2006, GASTROINTEST ENDOSC, V64, P313, DOI 10.1016/j.gie.2006.04.037; Kagalwalla AF, 2006, CLIN GASTROENTEROL H, V4, P1097, DOI 10.1016/j.cgh.2006.05.026; Lucendo AJ, 2009, PEDIAT ALLERG IMM-UK, V20, P512, DOI 10.1111/j.1399-3038.2008.00798.x; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rothenberg ME, 2009, GASTROENTEROLOGY, V137, P1238, DOI 10.1053/j.gastro.2009.07.007; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Wershil BK, 2009, IMMUNOL ALLERGY CLIN, V29, P189, DOI 10.1016/j.iac.2008.09.006	11	55	55	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1307	U335		10.1016/j.jaci.2010.12.1118	http://dx.doi.org/10.1016/j.jaci.2010.12.1118			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21333344	Green Accepted			2022-12-18	WOS:000290018600032
J	Savenije, OEM; Kerkhof, M; Reijmerink, NE; Brunekreef, B; de Jongste, JC; Smit, HA; Wijga, AH; Postma, DS; Koppelman, GH				Savenije, Olga E. M.; Kerkhof, Marjan; Reijmerink, Naomi E.; Brunekreef, Bert; de Jongste, Johan C.; Smit, Henriette A.; Wijga, Alet H.; Postma, Dirkje S.; Koppelman, Gerard H.			Interleukin-1 receptor-like 1 polymorphisms are associated with serum IL1RL1-a, eosinophils, and asthma in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL1RL1; IL1RL1-a; eosinophils; asthma; atopy; children	ALLERGIC AIRWAY INFLAMMATION; GENE POLYMORPHISMS; IL-1 FAMILY; ST2 GENE; PATHWAY; CYTOKINE; PIAMA; ATOPY	Background: IL-1 receptor-like 1 (IL1RL1) is a membrane receptor involved in TH2 inflammatory responses and eosinophilia. Single nucleotide polymorphisms (SNPs) in IL1RL1 have been associated with blood eosinophil counts in a genome-wide association study and with asthma in family-based and case-control studies. Objective: We assessed in the prospective birth cohort Prevention and Incidence of Asthma and Mite Allergy (PIAMA) whether IL1RL1 SNPs associate with levels of its soluble transcript IL1RL1 (IL1RL1-a) in serum, blood eosinophil counts, and asthma prevalence from birth to age 8 years, and whether IL1RL1-a serum levels associate with blood eosinophil counts. Methods: Fifteen IL1RL1 SNPs were genotyped. Serum IL1RL1-a levels were measured in 2 independent subsets within PIAMA, at 4 and 8 years. Blood eosinophil counts were measured in 4-year-old children. Results: In 2 independent subsets of children, 13 of 15 SNPs were associated with serum IL1RL1-a levels at ages 4 and 8 years with a consistent direction of effect for each allele. Rs11685480 allele A and rs1420102 allele A were significantly associated with lower numbers of blood eosinophils. In the total cohort, rs1041973 allele A was associated with a decreased risk of developing asthma (odds ratio, 0.70; 95% CI, 0.54-0.90). Rs1420101, recently identified in a genome-wide association study in the Icelandic population, was not associated with asthma in this study. IL1RL1-a levels were not associated with eosinophil counts. Conclusion: We demonstrate that IL1RL1 polymorphisms are associated with serum IL1RL1-a, blood eosinophils, and asthma in childhood. (J Allergy Clin Immunol 2011;127:750-6.)	[Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol, NL-9700 RB Groningen, Netherlands; [Reijmerink, Naomi E.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat, NL-9700 RB Groningen, Netherlands; [Savenije, Olga E. M.; Kerkhof, Marjan] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9700 RB Groningen, Netherlands; [Reijmerink, Naomi E.; Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, NL-9700 RB Groningen, Netherlands; [Brunekreef, Bert] Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TC Utrecht, Netherlands; [Brunekreef, Bert; Smit, Henriette A.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [de Jongste, Johan C.] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Dept Pediat, Rotterdam, Netherlands; [Wijga, Alet H.] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen; Utrecht University; Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Netherlands National Institute for Public Health & the Environment	Koppelman, GH (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol, POB 30-001, NL-9700 RB Groningen, Netherlands.	g.h.koppelman@bkk.umcg.nl	Koppelman, Gerard/AAG-9187-2020	Koppelman, Gerard/0000-0001-8567-3252; brunekreef, bert/0000-0001-9908-0060	Dutch Asthma Foundation [3.4.01.26, 3.2.06.022, 3.2.09.081JU]; Zon-Mw Netherlands [912-03-031]; NWO Spinoza premium of Prof Dr D. S. Postma; Stichting Astma Bestrijding [2009/009]; ministry of the environment; Netherlands Asthma Fund; GlaxoSmithKline; AstraZeneca; Netherlands Asthma Foundation; European Union	Dutch Asthma Foundation; Zon-Mw Netherlands(Netherlands Organization for Health Research and DevelopmentNetherlands Government); NWO Spinoza premium of Prof Dr D. S. Postma; Stichting Astma Bestrijding; ministry of the environment(Ministry of the Environment, Japan); Netherlands Asthma Fund; GlaxoSmithKline(GlaxoSmithKline); AstraZeneca(AstraZeneca); Netherlands Asthma Foundation; European Union(European Commission)	The Prevention and Incidence of Asthma and Mite Allergy study was supported by the Dutch Asthma Foundation (grant nos. 3.4.01.26, 3.2.06.022, and 3.2.09.081JU), the Zon-Mw Netherlands (grant no. 912-03-031), the NWO Spinoza premium of Prof Dr D. S. Postma, the "Stichting Astma Bestrijding'' (grant no. 2009/009), and the ministry of the environment.; J. C. de Jongste receives research support from the Netherlands Asthma Fund and ZonMW. D. S. Postma receives research support from GlaxoSmithKline and AstraZeneca and has consultant arrangements with AstraZeneca, Nycomed, and Chiesi. G. H. Koppelman receives research support from the Netherlands Asthma Foundation, GlaxoSmithKline, and the European Union. The rest of the authors have declared that they have no conflict of interest.	Ali M, 2009, TISSUE ANTIGENS, V73, P206, DOI 10.1111/j.1399-0039.2008.01185.x; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Castano R, 2009, AMJ RHINOL ALLERGY, V23, P377, DOI 10.2500/ajra.2009.23.3303; Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005; Coyle AJ, 1999, J EXP MED, V190, P895, DOI 10.1084/jem.190.7.895; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hayakawa H, 2007, J BIOL CHEM, V282, P26369, DOI 10.1074/jbc.M704916200; Hill WG, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000008; Kakkar R, 2008, NAT REV DRUG DISCOV, V7, P827, DOI 10.1038/nrd2660; Kearley J, 2009, AM J RESP CRIT CARE, V179, P772, DOI 10.1164/rccm.200805-666OC; Kerkhof M, 2009, ALLERGY, V64, P1202, DOI 10.1111/j.1398-9995.2009.02016.x; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Lin DY, 2005, GENET EPIDEMIOL, V29, P299, DOI 10.1002/gepi.20098; Lingel A, 2009, STRUCTURE, V17, P1398, DOI 10.1016/j.str.2009.08.009; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Oshikawa K, 2002, CLIN EXP ALLERGY, V32, P1520, DOI 10.1046/j.1365-2745.2002.01494.x; Oshikawa K, 2001, AM J RESP CRIT CARE, V164, P277, DOI 10.1164/ajrccm.164.2.2008120; Pinard R, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-216; Reijmerink NE, 2010, ALLERGY, V65, P199, DOI 10.1111/j.1398-9995.2009.02111.x; Reijmerink NE, 2008, J ALLERGY CLIN IMMUN, V122, P651, DOI 10.1016/j.jaci.2008.06.030; Reijmerink NE, 2010, EUR J HUM GENET, V18, P17, DOI 10.1038/ejhg.2009.128; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shimizu M, 2005, HUM MOL GENET, V14, P2919, DOI 10.1093/hmg/ddi323; Wu H, 2010, J ALLERGY CLIN IMMUN, V125, P321, DOI 10.1016/j.jaci.2009.09.007; Zhu GH, 2008, EUR J HUM GENET, V16, P1083, DOI 10.1038/ejhg.2008.67	29	55	56	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					750	U394		10.1016/j.jaci.2010.12.014	http://dx.doi.org/10.1016/j.jaci.2010.12.014			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21281963				2022-12-18	WOS:000288018400030
J	Simons, FER; Ardusso, LRF; Bilo, MB; El-Gamal, YM; Ledford, DK; Ring, J; Sanchez-Borges, M; Senna, GE; Sheikh, A; Thong, BY				Simons, F. Estelle R.; Ardusso, Ledit R. F.; Bilo, M. Beatrice; El-Gamal, Yehia M.; Ledford, Dennis K.; Ring, Johannes; Sanchez-Borges, Mario; Senna, Gian Enrico; Sheikh, Aziz; Thong, Bernard Y.		World Allergy Org	World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; acute systemic allergic reaction; food allergy; stinging insect allergy; drug allergy; epinephrine (adrenaline)	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; STINGING INSECT HYPERSENSITIVITY; EMERGENCY-DEPARTMENT; RAPID DESENSITIZATION; BIPHASIC ANAPHYLAXIS; VENOM IMMUNOTHERAPY; CLINICAL PREDICTORS; POSTMORTEM FINDINGS; SYSTEMIC REACTIONS; 1ST-AID TREATMENT	The illustrated World Allergy Organization (WAO) Anaphylaxis Guidelines were created in response to absence of global guidelines for anaphylaxis. Uniquely, before they were developed, lack of worldwide availability of essentials for the diagnosis and treatment of anaphylaxis was documented. They incorporate contributions from more than 100 allergy/immunology specialists on 6 continents. Recommendations are based on the best evidence available, supported by references published to the end of 2010. The Guidelines review patient risk factors for severe or fatal anaphylaxis, co-factors that amplify anaphylaxis, and anaphylaxis in vulnerable patients, including pregnant women, infants, the elderly, and those with cardiovascular disease. They focus on the supreme importance of making a prompt clinical diagnosis and on the basic initial treatment that is urgently needed and should be possible even in a low resource environment. This involves having a written emergency protocol and rehearsing it regularly; then, as soon as anaphylaxis is diagnosed, promptly and simultaneously calling for help, injecting epinephrine (adrenaline) intramuscularly, and placing the patient on the back or in a position of comfort with the lower extremities elevated. When indicated, additional critically important steps include administering supplemental oxygen and maintaining the airway, establishing intravenous access and giving fluid resuscitation, and initiating cardiopulmonary resuscitation with continuous chest compressions. Vital signs and cardiorespiratory status should be monitored frequently and regularly (preferably, continuously). The Guidelines briefly review management of anaphylaxis refractory to basic initial treatment. They also emphasize preparation of the patient for self-treatment of anaphylaxis recurrences in the community, confirmation of anaphylaxis triggers, and prevention of recurrences through trigger avoidance and immunomodulation. Novel strategies for dissemination and implementation are summarized. A global agenda for anaphylaxis research is proposed.	[Simons, F. Estelle R.] Univ Manitoba, Dept Pediat & Child Hlth, Fac Med, Winnipeg, MB R3T 2N2, Canada; [Ardusso, Ledit R. F.] Univ Nacl Rosario, Catedra Neumonol Alergia & Inmunol, Fac Ciencias Med, RA-2000 Rosario, Santa Fe, Argentina; [Bilo, M. Beatrice] Univ Hosp Osped Riuniti, Dept Internal Med, Allergy Unit, Ancona, Italy; [El-Gamal, Yehia M.] Ain Shams Univ, Pediat Allergy & Immunol Unit, Cairo, Egypt; [Ledford, Dennis K.] Univ S Florida, Coll Med, Tampa, FL USA; [Ring, Johannes] Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany; [Sanchez-Borges, Mario] Clin El Avila, Ctr Med Docente Trinidad, Caracas, Venezuela; [Senna, Gian Enrico] Verona Gen Hosp, Allergy Unit, Verona, Italy; [Sheikh, Aziz] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Thong, Bernard Y.] Tan Tock Seng Hosp, Dept Rheumatol Allergy & Immunol, Singapore, Singapore	University of Manitoba; National University of Rosario; Egyptian Knowledge Bank (EKB); Ain Shams University; State University System of Florida; University of South Florida; Technical University of Munich; University of Edinburgh; Tan Tock Seng Hospital	Simons, FER (corresponding author), Room FE125 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	lmcniven@hsc.mb.ca	Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152				Alrasbi M, 2007, ALLERGY, V62, P838, DOI 10.1111/j.1398-9995.2007.01434.x; Alves B, 2001, ARCH DIS CHILD, V85, P349; Asero R, 2009, INT ARCH ALLERGY IMM, V150, P271, DOI 10.1159/000222679; Baek C-H, 2010, ALLERGY, V65, P792, DOI 10.1111/j.1398-9995.2009.02233.x; Basagana M, 2008, J ALLERGY CLIN IMMUN, V121, P233, DOI 10.1016/j.jaci.2007.10.008; Bautista E, 2002, INT ARCH ALLERGY IMM, V128, P151, DOI 10.1159/000059406; Ben-Shoshan M, 2008, ANN ALLERG ASTHMA IM, V100, P570, DOI 10.1016/S1081-1206(10)60056-7; Berges-Gimeno MP, 2007, CURR ALLERGY ASTHM R, V7, P35, DOI 10.1007/s11882-007-0028-9; Bernd LAG, 2006, REV BRAS ALERG IMUNO, V29, P283; Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1, DOI 10.1016/S1081-1206(10)60305-5; Bilo MB, 2009, CLIN EXP ALLERGY, V39, P1467, DOI 10.1111/j.1365-2222.2009.03324.x; Biteker M, 2010, EUR J PEDIATR, V169, P27, DOI 10.1007/s00431-009-0965-5; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2007, ALLERGY, V62, P102, DOI 10.1111/j.1398-9995.2006.01305.x; Boyano-Martinez T, 2009, J ALLERGY CLIN IMMUN, V123, P883, DOI 10.1016/j.jaci.2008.12.1125; Boyce JA, 2010, J ALLERGY CLIN IMMUN, V126, P1105, DOI 10.1016/j.jaci.2010.10.008; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; Brockow K, 2010, CHEM IMMUNOL ALLERGY, V95, P157, DOI 10.1159/000315949; Brown SGA, 2004, EMERG MED J, V21, P149, DOI 10.1136/emj.2003.009449; Brown SGA, 2003, LANCET, V361, P1001, DOI 10.1016/S0140-6736(03)12827-9; Brown SGA, 2006, MED J AUSTRALIA, V185, P283, DOI 10.5694/j.1326-5377.2006.tb00563.x; Campbell RL, 2008, ANN ALLERG ASTHMA IM, V101, P631, DOI 10.1016/S1081-1206(10)60227-X; Castells M, 2009, IMMUNOL ALLERGY CLIN, V29, P585, DOI 10.1016/j.iac.2009.04.012; Castells MC, 2008, J ALLERGY CLIN IMMUN, V122, P574, DOI 10.1016/j.jaci.2008.02.044; Caviglia AG, 2010, J ALLERGY CLIN IMMUN, V125, P1171, DOI 10.1016/j.jaci.2010.01.045; Chacko T, 2007, IMMUNOL ALLERGY CLIN, V27, P213, DOI 10.1016/j.iac.2007.03.006; Chaudhuri K, 2008, INT J OBSTET ANESTH, V17, P350, DOI 10.1016/j.ijoa.2008.05.002; Choo KJL, 2010, ALLERGY, V65, P1205, DOI 10.1111/j.1398-9995.2010.02424.x; Comite de Alergia e Inmunologia, 1998, ARCH ARGENT PEDIATR, V96, P272; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Confino-Cohen R, 2010, ANN ALLERG ASTHMA IM, V104, P73, DOI 10.1016/j.anai.2009.11.001; Cox L, 2010, J ALLERGY CLIN IMMUN, V125, P569, DOI 10.1016/j.jaci.2009.10.060; Crotty MP, 2010, J ALLERGY CLIN IMMUN, V125, P935, DOI 10.1016/j.jaci.2009.12.003; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Druey KM, 2010, ANN INTERN MED, V153, P90, DOI 10.7326/0003-4819-153-2-201007200-00005; Ebisawa Motohiro, 2009, Allergology International, V58, P475, DOI 10.2332/allergolint.09-RAI-0143; Ellender TJ, 2008, EMERG MED CLIN N AM, V26, P759, DOI 10.1016/j.emc.2008.04.001; Ellis AK, 2007, ANN ALLERG ASTHMA IM, V98, P64, DOI 10.1016/S1081-1206(10)60861-7; Endo Tomoyuki, 2006, Nihon Naika Gakkai Zasshi, V95, P2463; Estelle F, 2006, J ALLERGY CLIN IMMUN, V117, P367, DOI 10.1016/j.jaci.2005.12.002; Field JM, 2010, CIRCULATION, V122, pS640, DOI 10.1161/CIRCULATIONAHA.110.970889; Foti C, 2009, IMMUNOPHARM IMMUNOT, V31, P414, DOI 10.1080/08923970902739078; Gaeta TJ, 2007, ANN ALLERG ASTHMA IM, V98, P360, DOI 10.1016/S1081-1206(10)60883-6; Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005; Gonzalez-Perez A, 2010, J ALLERGY CLIN IMMUN, V125, P1098, DOI 10.1016/j.jaci.2010.02.009; Greenberger PA, 2007, IMMUNOL ALLERGY CLIN, V27, P273, DOI 10.1016/j.iac.2007.03.009; Greenberger PA, 2007, ANN ALLERG ASTHMA IM, V98, P252, DOI 10.1016/S1081-1206(10)60714-4; Gueugniaud PY, 2008, NEW ENGL J MED, V359, P21, DOI 10.1056/NEJMoa0706873; Herbert LJ, 2008, J CLIN PSYCHOL MED S, V15, P261, DOI 10.1007/s10880-008-9130-y; Hershko AY, 2001, SCAND J CLIN LAB INV, V61, P449, DOI 10.1080/00365510152567086; Iribarren C, 2010, ANN ALLERG ASTHMA IM, V104, P371, DOI 10.1016/j.anai.2010.03.004; Ji KM, 2008, ALLERGY, V63, P1407, DOI 10.1111/j.1398-9995.2008.01838.x; Ji KM, 2009, REGUL TOXICOL PHARM, V55, P134, DOI 10.1016/j.yrtph.2009.06.008; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Jones DH, 2008, ANN ALLERG ASTHMA IM, V100, P452, DOI 10.1016/S1081-1206(10)60470-X; Kanwar M, 2010, ANN EMERG MED, V55, P341, DOI 10.1016/j.annemergmed.2009.11.008; Kelso JM, 2009, ANN ALLERG ASTHMA IM, V103, pS1, DOI 10.1016/S1081-1206(10)60350-X; Kemp SF, 2008, ALLERGY, V63, P1061, DOI 10.1111/j.1398-9995.2008.01733.x; Khan DA, 2010, J ALLERGY CLIN IMMUN, V125, pS126, DOI 10.1016/j.jaci.2009.10.028; King RM, 2009, ALLERGY, V64, P461, DOI 10.1111/j.1398-9995.2008.01843.x; Kishimoto TK, 2008, NEW ENGL J MED, V358, P2457, DOI 10.1056/NEJMoa0803200; Komarow HD, 2009, J ALLERGY CLIN IMMUN, V124, P845, DOI 10.1016/j.jaci.2009.06.040; Krishnan JA, 2009, AM J MED, V122, P977, DOI 10.1016/j.amjmed.2009.02.013; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; Lieberman P, 2003, CURR OPIN ALLERGY CL, V3, P313, DOI 10.1097/01.all.0000083958.99396.53; Lieberman P, 2007, ANN ALLERG ASTHMA IM, V98, P519, DOI 10.1016/S1081-1206(10)60729-6; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126, P477, DOI 10.1016/j.jaci.2010.06.022; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; Limb SL, 2007, J ALLERGY CLIN IMMUN, V120, P1378, DOI 10.1016/j.jaci.2007.09.022; Lin RY, 2000, ANN EMERG MED, V36, P462, DOI 10.1067/mem.2000.109445; Loibl M, 2009, ALLERGY, V64, P1560, DOI 10.1111/j.1398-9995.2009.02103.x; Malling Hans-Jorgen, 2005, Ugeskr Laeger, V167, P664; Manivannan V, 2009, ANN ALLERG ASTHMA IM, V103, P395, DOI 10.1016/S1081-1206(10)60358-4; Matsuo H, 2009, J DERMATOL SCI, V53, P241, DOI 10.1016/j.jdermsci.2008.09.004; McLean-Tooke APC, 2003, BMJ-BRIT MED J, V327, P1332, DOI 10.1136/bmj.327.7427.1332; Mehr S, 2009, CLIN EXP ALLERGY, V39, P1390, DOI 10.1111/j.1365-2222.2009.03276.x; Metcalfe DD, 2009, J ALLERGY CLIN IMMUN, V123, P687, DOI 10.1016/j.jaci.2009.02.003; Mirakian R, 2009, CLIN EXP ALLERGY, V39, P43, DOI 10.1111/j.1365-2222.2008.03155.x; Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046; Mueller UR, 2007, CURR OPIN ALLERGY CL, V7, P337, DOI 10.1097/ACI.0b013e328259c328; Muller UR, 2010, CHEM IMMUNOL ALLERGY, V95, P141, DOI 10.1159/000315948; MULLNER M, 2004, COCHRANE DB SYST REV, V3; Muraro A, 2007, ALLERGY, V62, P857, DOI 10.1111/j.1398-9995.2007.01421.x; Narisety SD, 2009, J ALLERGY CLIN IMMUN, V124, P610, DOI 10.1016/j.jaci.2009.06.025; National Institutes of Health National Heart Lung and Blood Institute National Asthma Education and Prevention Program, 2007, NIH PUBLICATION; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042; Nurmatov U, 2008, J ALLERGY CLIN IMMUN, V122, P353, DOI 10.1016/j.jaci.2008.05.028; Oswalt ML, 2007, IMMUNOL ALLERGY CLIN, V27, P177, DOI 10.1016/j.iac.2007.03.004; Ott H, 2008, ALLERGY, V63, P1521, DOI 10.1111/j.1398-9995.2008.01748.x; Pieretti MM, 2009, J ALLERGY CLIN IMMUN, V124, P337, DOI 10.1016/j.jaci.2009.05.032; Polimeno L, 2010, FOODBORNE PATHOG DIS, V7, P809, DOI 10.1089/fpd.2009.0484; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Pumphrey RSH, 2003, J ALLERGY CLIN IMMUN, V112, P451, DOI 10.1067/mai.2003.1614; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Rawas-Qalaji M, 2009, ANN ALLERG ASTHMA IM, V102, P500, DOI 10.1016/S1081-1206(10)60124-X; Rezvani M, 2007, IMMUNOL ALLERGY CLIN, V27, P295, DOI 10.1016/j.iac.2007.03.010; Ridella Maricel, 2009, Inflammation & Allergy Drug Targets, V8, P11; Ring J, 2010, CHEM IMMUNOL ALLERGY, V95, P201, DOI 10.1159/000315953; Robson-Ansley P, 2010, CURR OPIN ALLERGY CL, V10, P312, DOI 10.1097/ACI.0b013e32833b9bb0; Rowe BH, 2008, COCHRANE DB SYST REV, V4; Rudders SA, 2010, ANN ALLERG ASTHMA IM, V105, P85, DOI 10.1016/j.anai.2010.05.004; Rueff F, 2009, J ALLERGY CLIN IMMUN, V124, P1047, DOI 10.1016/j.jaci.2009.08.027; RUNGE JW, 1992, ANN EMERG MED, V21, P237, DOI 10.1016/S0196-0644(05)80881-9; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sanchez-Borges M, 2005, ANN ALLERG ASTHMA IM, V94, P216, DOI 10.1016/S1081-1206(10)61298-7; Sanchez-Borges M, 2007, J ALLERGY CLIN IMMUN, V120, P714, DOI 10.1016/j.jaci.2007.04.017; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; Scranton SE, 2009, J ALLERGY CLIN IMMUN, V123, P493, DOI 10.1016/j.jaci.2008.10.026; Sheikh A, 2007, ALLERGY, V62, P830, DOI 10.1111/j.1398-9995.2007.01435.x; Sheikh A, 2009, ALLERGY, V64, P204, DOI 10.1111/j.1398-9995.2008.01926.x; Sheikh A, 2008, J ROY SOC MED, V101, P139, DOI 10.1258/jrsm.2008.070306; Shek LPC, 2006, CURR OPIN ALLERGY CL, V6, P197, DOI 10.1097/01.all.0000225160.52650.17; Shek LPC, 2004, CURR OPIN ALLERGY CL, V4, P325, DOI 10.1097/01.all.0000136761.51195.01; Shekelle PG, 1999, BRIT MED J, V318, P593, DOI 10.1136/bmj.318.7183.593; Shen YW, 2009, FORENSIC SCI INT, V186, P1, DOI 10.1016/j.forsciint.2008.12.007; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, P537, DOI 10.1016/j.jaci.2007.06.025; Simons FER, 2010, CURR OPIN ALLERGY CL, V10, P384, DOI 10.1097/ACI.0b013e32833c2038; Simons FER, 2010, ANN ALLERG ASTHMA IM, V104, P405, DOI 10.1016/j.anai.2010.01.023; Simons FER, 2010, J ALLERGY CLIN IMMUN, V125, pS161, DOI 10.1016/j.jaci.2009.12.981; Simons FER, 2010, J ALLERGY CLIN IMMUN, V125, P419, DOI 10.1016/j.jaci.2009.10.056; Simons FER, 2009, J ALLERGY CLIN IMMUN, V124, P625, DOI 10.1016/j.jaci.2009.08.025; Simons FER, 2009, ANN ALLERG ASTHMA IM, V102, P403, DOI 10.1016/S1081-1206(10)60512-1; Simons FER, 2009, J ALLERGY CLIN IMMUN, V124, P301, DOI 10.1016/j.jaci.2009.03.050; Simons FER, 2005, ANN ALLERG ASTHMA IM, V94, P534, DOI 10.1016/S1081-1206(10)61129-5; Simons FER, 2004, NEW ENGL J MED, V351, P2203, DOI 10.1056/NEJMra033121; Simons KJ, 2010, CURR OPIN ALLERGY CL, V10, P354, DOI 10.1097/ACI.0b013e32833bc670; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Smit DV, 2005, J EMERG MED, V28, P381, DOI 10.1016/j.jemermed.2004.11.028; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; Soar J, 2008, RESUSCITATION, V77, P157, DOI 10.1016/j.resuscitation.2008.02.001; Summers CW, 2008, J ALLERGY CLIN IMMUN, V121, P632, DOI 10.1016/j.jaci.2007.12.003; Svensson L, 2010, NEW ENGL J MED, V363, P434, DOI 10.1056/NEJMoa0908991; Tankersley MS, 2008, CURR OPIN ALLERGY CL, V8, P354, DOI 10.1097/ACI.0b013e3283073b48; TenBrook JA, 2004, J ALLERGY CLIN IMMUN, V113, P977, DOI 10.1016/j.jaci.2004.02.043; Thomas M, 2005, EMERG MED J, V22, P272, DOI 10.1136/emj.2005.023507; Thong B. Y. H., 2005, SMJ Singapore Medical Journal, V46, P529; Thong BYH, 2004, ANN ALLERG ASTHMA IM, V92, P619, DOI 10.1016/S1081-1206(10)61427-5; Tole JW, 2007, IMMUNOL ALLERGY CLIN, V27, P309, DOI 10.1016/j.iac.2007.03.011; Triggiani M, 2008, CLIN EXP IMMUNOL, V153, P7, DOI 10.1111/j.1365-2249.2008.03714.x; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Warrier P, 2009, ANN ALLERG ASTHMA IM, V102, P257, DOI 10.1016/S1081-1206(10)60091-9; Yilmaz R, 2009, AM J FOREN MED PATH, V30, P346, DOI 10.1097/PAF.0b013e3181c0e7bb; Zuraw BL, 2008, NEW ENGL J MED, V359, P1027, DOI 10.1056/NEJMcp0803977	150	55	55	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3								10.1097/WOX.0b013e318211496c	http://dx.doi.org/10.1097/WOX.0b013e318211496c			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG		Green Published, gold			2022-12-18	WOS:000288018400005
J	Santiago, HC; Bennuru, S; Boyd, A; Eberhard, M; Nutman, TB				Santiago, Helton C.; Bennuru, Sasisekhar; Boyd, Alexis; Eberhard, Mark; Nutman, Thomas B.			Structural and immunologic cross-reactivity among filarial and mite tropomyosin: Implications for the hygiene hypothesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; antibody cross-reactivity; Dermatophagoides pteronyssinus; filariasis; hygiene hypothesis; tropomyosin	FC-GAMMA-RIIB; IMMUNOGLOBULIN-E; HELMINTH INFECTIONS; ASCARIS-LUMBRICOIDES; ANTIBODY-RESPONSES; BLOCKING ANTIBODY; IGE BINDING; SERUM-IGE; T-CELLS; B-CELLS	Background: The hygiene hypothesis suggests that parasitic infection modulates host immune responses and decreases atopy. Other data suggest parasitic infections may induce allergic responsiveness. Objective: To assess the structural and immunologic relationships between the known Dermatophagoides pteronyssinus (Der p 10) tropomyosin allergen and filarial tropomyosin of Onchocerca volvulus (OvTrop). Methods: The molecular, structural, and immunologic relationships between OvTrop and Der p 10 were compared. Levels of OvTrop-specific and Der p 10-specific IgE, IgG, and IgG(4) in sera of filaria-infected and filarial-uninfected D pteronyssinus-atopic individuals were compared, as were the responses in nonhuman primates infected with the filarial parasite Loa loa. Cross-reactivity was compared by antigen-mediated depletion assays and functionality by passive basophil sensitization. Results: Filarial and mite tropomyosins were very similar, with 72% identity at the amino acid level, and overlapping predicted 3-dimensional structures. The prevalence of IgE and IgG to Der p 10 was increased in filaria-infected individuals compared with uninfected subjects. There was a strong correlation between serum levels of Ov- and Der p 10-tropomyosin-specific IgE, IgG, and IgG4 (P < .0001; r > 0.79). Preincubation of sera from anti-Der p 10-positive subjects with OvTrop completely depleted IgE, IgG, and IgG4 anti-Der p 10. Basophils sensitized with sera from individuals allergic to Der p 10 released histamine similarly when triggered with OvTrop or Der p 10. Primates experimentally infected with L loa developed IgE that cross-reacted with Der p 10. Conclusion: Filarial infection induces strong cross-reactive antitropomyosin antibody responses that may affect sensitization and regulation of allergic reactivity. (J Allergy Clin Immunol 2011;127:479-86.)	[Santiago, Helton C.; Bennuru, Sasisekhar; Boyd, Alexis; Nutman, Thomas B.] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; [Boyd, Alexis] George Washington Univ, Washington, DC USA; [Eberhard, Mark] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); George Washington University; Centers for Disease Control & Prevention - USA	Nutman, TB (corresponding author), NIAID, Parasit Dis Lab, NIH, 4 Ctr Dr,Bldg 4,Room B105, Bethesda, MD 20892 USA.	tnutman@niaid.nih.gov	Santiago, Helton/F-8704-2012	Santiago, Helton/0000-0002-5695-8256	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000512] Funding Source: NIH RePORTER	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Intramural Research Program, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.	Acevedo N, 2009, ALLERGY, V64, P1635, DOI 10.1111/j.1398-9995.2009.02084.x; Altschul SF, 2005, FEBS J, V272, P5101, DOI 10.1111/j.1742-4658.2005.04945.x; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aoyama H, 2007, AM J TROP MED HYG, V76, P972; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; CALVERT J, J ALLERGY CLIN IMMUN, V125, pE1; Calvert J, 2010, J ALLERGY CLIN IMMUN, V125, P100, DOI 10.1016/j.jaci.2009.09.010; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Daeron M, 2008, IMMUNOL REV, V224, P11, DOI 10.1111/j.1600-065X.2008.00666.x; Fernandes J, 2003, CLIN EXP ALLERGY, V33, P956, DOI 10.1046/j.1365-2222.2003.01722.x; Flicker S, 2003, INT ARCH ALLERGY IMM, V132, P13, DOI 10.1159/000073260; Flicker S, 2002, EUR J IMMUNOL, V32, P2156, DOI 10.1002/1521-4141(200208)32:8<2156::AID-IMMU2156>3.0.CO;2-A; Flores M, 2009, J IMMUNOL, V183, P7129, DOI 10.4049/jimmunol.0901169; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GRIEVE RB, 1985, TROP MED PARASITOL, V36, P225; Hagel I, 2007, ACTA TROP, V103, P231, DOI 10.1016/j.actatropica.2007.06.010; Hartmann S, 2006, VACCINE, V24, P3581, DOI 10.1016/j.vaccine.2006.01.064; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; JARRETT E, 1974, NATURE, V251, P613, DOI 10.1038/251613a0; Jenkins JA, 2007, J ALLERGY CLIN IMMUN, V120, P1399, DOI 10.1016/j.jaci.2007.08.019; Jenkins RE, 1998, P NATL ACAD SCI USA, V95, P7550, DOI 10.1073/pnas.95.13.7550; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Kondo Yasuto, 2009, Allergology International, V58, P485, DOI 10.2332/allergolint.09-RAI-0136; Leonardi-Bee J, 2006, AM J RESP CRIT CARE, V174, P514, DOI 10.1164/rccm.200603-331OC; Liu AH, 2006, J ALLERGY CLIN IMMUN, V117, P1063, DOI 10.1016/j.jaci.2006.03.027; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; Metenou S, 2010, J IMMUNOL, V184, P5375, DOI 10.4049/jimmunol.0904067; Mitre E, 2005, INFECT IMMUN, V73, P4106, DOI 10.1128/IAI.73.7.4106-4111.2005; Mitre E, 2004, J IMMUNOL, V172, P2439, DOI 10.4049/jimmunol.172.4.2439; Mitre E, 2008, J INFECT DIS, V197, P94, DOI 10.1086/524301; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; ORR TSC, 1969, LIFE SCI PT 1 PHYSI, V8, P1073, DOI 10.1016/0024-3205(69)90459-7; OTTESEN EA, 1985, J IMMUNOL, V134, P2707; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Rodrigues LC, 2008, CLIN EXP ALLERGY, V38, P1769, DOI 10.1111/j.1365-2222.2008.03027.x; Santos ABR, 2008, J ALLERGY CLIN IMMUN, V121, P1040, DOI 10.1016/j.jaci.2007.12.1147; Sereda MJ, 2008, TRENDS PARASITOL, V24, P272, DOI 10.1016/j.pt.2008.03.006; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Summers RW, 2005, GASTROENTEROLOGY, V128, P825, DOI 10.1053/j.gastro.2005.01.005; Tezuka H, 2002, INFECT IMMUN, V70, P1235, DOI 10.1128/IAI.70.3.1235-1244.2002; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Vercelli D, 2010, CURR OPIN ALLERGY CL, V10, P145, DOI 10.1097/ACI.0b013e32833653d7; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Warner JO, 2007, EARLY HUM DEV, V83, P777, DOI 10.1016/j.earlhumdev.2007.09.005; Wordemann M, 2008, TROP MED INT HEALTH, V13, P180, DOI 10.1111/j.1365-3156.2007.01988.x; Yazdanbakhsh M, 2005, CURR OPIN ALLERGY CL, V5, P386, DOI 10.1097/01.all.0000182541.52971.eb; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	50	55	56	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					479	486		10.1016/j.jaci.2010.11.007	http://dx.doi.org/10.1016/j.jaci.2010.11.007			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21185070	Green Accepted			2022-12-18	WOS:000286808000023
J	Ueta, M; Sotozono, C; Nakano, M; Taniguchi, T; Yagi, T; Tokuda, Y; Fuwa, M; Inatomi, T; Yokoi, N; Tashiro, K; Kinoshita, S				Ueta, Mayumi; Sotozono, Chie; Nakano, Masakazu; Taniguchi, Takazumi; Yagi, Tomohito; Tokuda, Yuichi; Fuwa, Masahiro; Inatomi, Tsutomu; Yokoi, Norihiko; Tashiro, Kei; Kinoshita, Shigeru			Association between prostaglandin E receptor 3 polymorphisms and Stevens-Johnson syndrome identified by means of a genome-wide association study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Prostaglandin E receptor 3; Stevens-Johnson syndrome; toxic epidermal necrolysis; genome-wide association study; single nucleotide polymorphism	TOXIC EPIDERMAL NECROLYSIS; ERYTHEMA MULTIFORME; OCULAR SURFACE; JAPANESE POPULATION; GENE POLYMORPHISMS; EPITHELIAL-CELLS; INNATE IMMUNITY; MANIFESTATIONS; ALLOPURINOL; MARKER	Background: Stevens-Johnson syndrome (SJS) and its severe variant, toxic epidermal necrolysis (TEN), are acute inflammatory vesiculobullous reactions of the skin and mucosa. They often affect the ocular surface and can result in permanent visual dysfunction. Objectives: We sought to discover genetic markers for SJS/TEN susceptibility. Methods: We performed a genome-wide association study with 60 patients and 300 control subjects. We applied stringent filter and visual assessments for selecting single nucleotide polymorphisms (SNPs) and a high false discovery rate threshold. We fine-mapped the region where a candidate SNP was found and confirmed the results by means of sequencing. We evaluated the function of agonist-activated prostaglandin E receptor 3 (EP3), the gene for which contained several SNPs, in regulating cytokine production in human conjunctival epithelial (CE) cells. The expression levels of EP3 in the CE cells from patients and control subjects were also compared. Results: We identified 3 SNPs that passed the false discovery rate threshold. One (rs17131450) was close to the EP3 gene. Therefore we analyzed the EP3 region in detail and identified 5 other SNPs. We confirmed the association between SJS/TEN and all 6 SNPs. Activated EP3 was expressed in control CE cells, and it suppressed polyI:C-stimulated cytokine production, suggesting that EP3 might help prevent ocular surface inflammation. Concordantly, the EP3 levels were much lower in the CE cells of the patients than in those of the control subjects. Conclusion: We demonstrated, using both genetic and functional analyses, that EP3 could be a key player in the pathogenesis of SJS/TEN accompanied by ocular complications. (J Allergy Clin Immunol 2010;126:1218-25.)	[Kinoshita, Shigeru] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, Kyoto 6020841, Japan; [Nakano, Masakazu; Taniguchi, Takazumi; Yagi, Tomohito; Tokuda, Yuichi; Fuwa, Masahiro; Tashiro, Kei] Kyoto Prefectural Univ Med, Dept Genom Med Sci, Kyoto 6020841, Japan; [Ueta, Mayumi] Doshisha Univ, Res Ctr Inflammat & Regenerat Med, Fac Life & Med Sci, Kyoto 602, Japan	Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; Doshisha University	Kinoshita, S (corresponding author), Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, Kawaramachi, Kyoto 6020841, Japan.	shigeruk@koto.kpu-m.ac.jp			Japanese Ministry of Health, Labour and Welfare; Japanese Ministry of Education, Culture, Sports, Science and Technology; Kyoto Foundation for the Promotion of Medical Science; Kyoto Prefectural University of Medicine; Grants-in-Aid for Scientific Research [22790324] Funding Source: KAKEN	Japanese Ministry of Health, Labour and Welfare(Ministry of Health, Labour and Welfare, Japan); Japanese Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Kyoto Foundation for the Promotion of Medical Science(Kyoto Foundation for the Promotion of Medical Science); Kyoto Prefectural University of Medicine; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported in part by grants-in-aid for scientific research from the Japanese Ministry of Health, Labour and Welfare; the Japanese Ministry of Education, Culture, Sports, Science and Technology; a research grant from the Kyoto Foundation for the Promotion of Medical Science; and the Intramural Research Fund of Kyoto Prefectural University of Medicine.	Araki Y, 2009, AM J OPHTHALMOL, V147, P1004, DOI 10.1016/j.ajo.2008.12.040; Auquier-Dunant A, 2002, ARCH DERMATOL, V138, P1019, DOI 10.1001/archderm.138.8.1019; BASTUJIGARIN S, 1993, ARCH DERMATOL, V129, P92, DOI 10.1001/archderm.129.1.92; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Dainichi T, 2007, DERMATOLOGY, V215, P86, DOI 10.1159/000102045; Forman R, 2002, DRUG SAFETY, V25, P965, DOI 10.2165/00002018-200225130-00006; Halevy S, 2008, J AM ACAD DERMATOL, V58, P25, DOI 10.1016/j.jaad.2007.08.036; Honda T, 2009, J ALLERGY CLIN IMMUN, V124, P809, DOI 10.1016/j.jaci.2009.04.029; Hung SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/pnas.0409500102; Kojima K, 2008, BRIT J OPHTHALMOL, V92, P411, DOI 10.1136/bjo.2007.128322; Leaute-Labreze C, 2000, ARCH DIS CHILD, V83, P347, DOI 10.1136/adc.83.4.347; Levi N, 2009, PEDIATRICS, V123, pE297, DOI 10.1542/peds.2008-1923; Lonjou C, 2006, PHARMACOGENOMICS J, V6, P265, DOI 10.1038/sj.tpj.6500356; Lonjou C, 2008, PHARMACOGENET GENOM, V18, P99, DOI 10.1097/FPC.0b013e3282f3ef9c; Matsuoka T, 2007, THESCIENTIFICWORLDJO, V7, P1329, DOI 10.1100/tsw.2007.182; MONDINO BJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1453; Nakano M, 2009, P NATL ACAD SCI USA, V106, P12838, DOI 10.1073/pnas.0906397106; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Narumiya S, 2009, J MOL MED, V87, P1015, DOI 10.1007/s00109-009-0500-1; Power WJ, 1996, OPHTHALMOLOGY, V103, P1406, DOI 10.1016/S0161-6420(96)30491-0; POWER WJ, 1995, OPHTHALMOLOGY, V102, P1669; ROUJEAU JC, 1986, TISSUE ANTIGENS, V28, P251; ROUJEAU JC, 1987, ARCH DERMATOL, V123, P1171, DOI 10.1001/archderm.123.9.1171; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; Sotozono C, 2007, OPHTHALMOLOGY, V114, P1294, DOI 10.1016/j.ophtha.2006.10.029; Sotozono C, 2009, OPHTHALMOLOGY, V116, P685, DOI 10.1016/j.ophtha.2008.12.048; Ueta M, 2008, BRIT J OPHTHALMOL, V92, P989, DOI 10.1136/bjo.2007.136796; Ueta M, 2005, BIOCHEM BIOPH RES CO, V331, P285, DOI 10.1016/j.bbrc.2005.02.196; Ueta M, 2008, CORNEA, V27, pS31, DOI 10.1097/ICO.0b013e31817f2a7f; Ueta M, 2008, MOL VIS, V14, P550; Ueta M, 2008, INVEST OPHTH VIS SCI, V49, P1809, DOI 10.1167/iovs.07-1401; Ueta M, 2007, J ALLERGY CLIN IMMUN, V120, P1457, DOI 10.1016/j.jaci.2007.07.048; Ueta M, 2007, BRIT J OPHTHALMOL, V91, P962, DOI 10.1136/bjo.2006.113449; Ueta M, 2007, AM J OPHTHALMOL, V143, P367, DOI 10.1016/j.ajo.2006.09.029; Ueta M, 2010, BRAIN RES BULL, V81, P219, DOI 10.1016/j.brainresbull.2009.10.001; Ueta M, 2009, J ALLERGY CLIN IMMUN, V123, P466, DOI 10.1016/j.jaci.2008.09.044; Wolf R, 2005, CLIN DERMATOL, V23, P171, DOI 10.1016/j.clindermatol.2004.06.012; Yamaguchi-Kabata Y, 2008, AM J HUM GENET, V83, P445, DOI 10.1016/j.ajhg.2008.08.019; Yamane Yumiko, 2007, Allergol Int, V56, P419, DOI 10.2332/allergolint.O-07-483; YETIV JZ, 1980, SOUTH MED J, V73, P599, DOI 10.1097/00007611-198005000-00015	40	55	57	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1218	U234		10.1016/j.jaci.2010.08.007	http://dx.doi.org/10.1016/j.jaci.2010.08.007			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	20947153				2022-12-18	WOS:000284947800021
J	Reed, CE				Reed, Charles E.			Asthma in the elderly: Diagnosis and management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; elderly; diagnosis; management; environmental exposures; innate immunity; microbial colonization	ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; RESOLUTION COMPUTED-TOMOGRAPHY; OBSTRUCTIVE PULMONARY-DISEASE; PROTEASE-ACTIVATED RECEPTORS; LATENT ADENOVIRAL INFECTION; FUNGAL SENSITIZATION; LUNG INFLAMMATION; BRONCHIAL-ASTHMA; UP-REGULATION; ENDOTOXIN	The National Asthma Education and Prevention Program's "Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma'' apply to all ages. This review discusses additional specific points for elderly patients. These patients are very heterogeneous. Their asthma can have begun at any time and can vary greatly in severity. It is frequently associated not only with any of the diseases that affect older persons but also with comorbid lung diseases. Many patients have irreversible airway obstruction, which is due to severe airway remodeling, chronic obstructive pulmonary disease, or bronchiectasis. Diagnosis should include chest radiography and computed tomographic scanning to diagnose other lung diseases if FEV1 remains low after treatment. Asthma pathogenesis includes not only IgE-mediated allergy but also innate immune inflammation from endotoxin and trypsin-like proteases, and therefore evaluation and control of environmental exposures is an important part of management. Pharmacologic treatment, too, is adjusted to achieve and maintain control and is basically the same for all ages, except that elderly patients have reduced response to bronchodilators and increased side effects from beta adrenergic agonists and glucocorticoids. Many elderly patients have difficulty inhaling aerosols, and therefore nebulizers might be a better delivery system. Oral medications have the benefit of greater ease of administration and greater efficacy on the peripheral airways. Leukotriene antagonists and low-dose theophylline are often helpful additives to aerosol glucocorticoids. Oral glucocorticoids might be indicated for severe asthma. (J Allergy Clin Immunol 2010;126:681-7.)	[Reed, Charles E.] Mayo Clin & Mayo Grad Sch Med, Dept Med, Rochester, MN USA	Mayo Clinic	Reed, CE (corresponding author), 9193 Bald Eagle Rd,POB 158, Boulder Jct, WI 54512 USA.	cereed@centurytel.net						[Anonymous], 2007, J ALLERGY CLIN IMM S, V120, pS94; Barnes PJ, 2008, CHEST, V134, P1278, DOI 10.1378/chest.08-1385; Barnes PJ, 2003, AM J RESP CRIT CARE, V167, P813, DOI 10.1164/rccm.200210-1142PP; Bauer BA, 1997, CHEST, V111, P303, DOI 10.1378/chest.111.2.303; BIAN B, 2010, CURR DRUG SAF; Bos IST, 2007, EUR RESPIR J, V30, P653, DOI 10.1183/09031936.00004907; Brown DW, 2005, J ASTHMA, V42, P597, DOI 10.1080/02770900500216234; BURROWS B, 1991, J ALLERGY CLIN IMMUN, V88, P870, DOI 10.1016/0091-6749(91)90243-H; Busse PJ, 2007, CLIN EXP ALLERGY, V37, P1392, DOI 10.1111/j.1365-2222.2007.02775.x; CAMPBELL DA, 1992, MED J AUSTRALIA, V156, P860, DOI 10.5694/j.1326-5377.1992.tb137000.x; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; Chakrabarti A, 2009, LARYNGOSCOPE, V119, P1809, DOI 10.1002/lary.20520; Denning DW, 2009, AM J RESP CRIT CARE, V179, P11, DOI 10.1164/rccm.200805-737OC; Gore RB, 2010, CURR OPIN PULM MED, V16, P36, DOI 10.1097/MCP.0b013e328333900a; Gough L, 2001, CLIN EXP ALLERGY, V31, P1594, DOI 10.1046/j.1365-2222.2001.01207.x; Gupta S, 2009, CHEST, V136, P1521, DOI 10.1378/chest.09-0174; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; Hogg JC, 2001, AM J RESP CRIT CARE, V164, pS71, DOI 10.1164/ajrccm.164.supplement_2.2106063; HUNT LW, 1993, JAMA-J AM MED ASSOC, V269, P1947, DOI 10.1001/jama.269.15.1947; Kanazawa H, 2006, CURR OPIN PULM MED, V12, P60, DOI 10.1097/01.mcp.0000198066.73328.3a; Kauffman Henk F, 2006, Clin Mol Allergy, V4, P5, DOI 10.1186/1476-7961-4-5; Keicho N, 1999, AM J PHYSIOL-LUNG C, V277, pL523, DOI 10.1152/ajplung.1999.277.3.L523; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797, DOI 10.1067/mai.2001.119025; Laennec RTH., 1962, TREATISE DIS CHEST, P78; Lee HM, 2007, ANN OTO RHINOL LARYN, V116, P554, DOI 10.1177/000348940711600712; Macek V, 1999, Can Respir J, V6, P37; McHugh MK, 2009, J ASTHMA, V46, P759, DOI 10.3109/02770900903067895; NADEL JA, 1991, AM REV RESPIR DIS, V144, pS48, DOI 10.1164/ajrccm/144.3_pt_2.S48; Nelson H, 2010, J ALLERGY CLIN IMMUN, V125, P390, DOI 10.1016/j.jaci.2009.11.036; PAGANIN F, 1992, AM REV RESPIR DIS, V146, P1084, DOI 10.1164/ajrccm/146.4.1084; Paganin F, 1997, EUR RESPIR J, V10, P2446, DOI 10.1183/09031936.97.10112446; Park JW, 1997, J INVEST ALLERG CLIN, V7, P186; Pasqualotto AC, 2009, RESPIROLOGY, V14, P1121, DOI 10.1111/j.1440-1843.2009.01640.x; Ponikau JU, 2006, CLIN REV ALLERG IMMU, V30, P187, DOI 10.1385/CRIAI:30:3:187; Redecke V, 2004, J IMMUNOL, V172, P2739, DOI 10.4049/jimmunol.172.5.2739; Reed CE, 2004, J ALLERGY CLIN IMMUN, V114, P997, DOI 10.1016/j.jaci.2004.07.060; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Reed CE, 1999, J ALLERGY CLIN IMMUN, V103, P539, DOI 10.1016/S0091-6749(99)70221-6; Reed CE, 2007, CURR ALLERGY ASTHM R, V7, P368, DOI 10.1007/s11882-007-0056-5; Salo PM, 2008, J ALLERGY CLIN IMMUN, V121, P678, DOI 10.1016/j.jaci.2007.12.1164; Sebastian A, 2006, J ENVIRON MONITOR, V8, P519, DOI 10.1039/b600706f; Sharma G, 2006, CLIN INTERV AGING, V1, P253, DOI 10.2147/ciia.2006.1.3.253; Shpacovitch V, 2008, J LEUKOCYTE BIOL, V83, P1309, DOI 10.1189/jlb.0108001; SILVERSTEIN MD, 1994, NEW ENGL J MED, V331, P1537, DOI 10.1056/NEJM199412083312301; Stevens DA, 2000, NEW ENGL J MED, V342, P756, DOI 10.1056/NEJM200003163421102; Thorne PS, 2005, AM J RESP CRIT CARE, V172, P1371, DOI 10.1164/rccm.200505-758OC; Tsuda Y, 2009, RESPIROLOGY, V14, P529, DOI 10.1111/j.1440-1843.2009.01533.x; ULRIK CS, 1992, J ASTHMA, V29, P29, DOI 10.3109/02770909209110638; Vignola AM, 2000, J ALLERGY CLIN IMMUN, V105, P1041, DOI 10.1067/mai.2000.107195; Ward GW, 1999, J ALLERGY CLIN IMMUN, V104, P541, DOI 10.1016/S0091-6749(99)70321-0; Weatherall M, 2010, THORAX, V65, P39, DOI 10.1136/thx.2009.116608; WEISS K B, 1990, Journal of the American Medical Association, V263, P2323, DOI 10.1001/jama.263.17.2323; WRIGHT SC, 1994, THORAX, V49, P141, DOI 10.1136/thx.49.2.141; Yamada K, 2002, J ALLERGY CLIN IMMUN, V109, P35, DOI 10.1067/mai.2002.120525; Yamada K, 2000, J ALLERGY CLIN IMMUN, V106, P844, DOI 10.1067/mai.2000.110473; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	56	55	57	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					681	687		10.1016/j.jaci.2010.05.035	http://dx.doi.org/10.1016/j.jaci.2010.05.035			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20673985				2022-12-18	WOS:000282510000001
J	Al-Samri, MT; Benedetti, A; Prefontaine, D; Olivenstein, R; Lemiere, C; Nair, P; Martin, JG; Hamid, Q				Al-Samri, Mohammed T.; Benedetti, Andrea; Prefontaine, David; Olivenstein, Ron; Lemiere, Catherine; Nair, Parameswaran; Martin, James G.; Hamid, Qutayba			Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: A prospective study using multiple samples	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							COUNTS; SUBTYPES		[Al-Samri, Mohammed T.; Prefontaine, David; Martin, James G.; Hamid, Qutayba] McGill Univ, Fac Med, Meakins Christie Labs, Montreal, PQ, Canada; [Benedetti, Andrea; Olivenstein, Ron] McGill Univ, Montreal Chest Hosp Res Inst, Ctr Hlth, Montreal, PQ, Canada; [Lemiere, Catherine] Univ Montreal, Hop Sacre Coeur Montreal, Montreal, PQ, Canada; [Nair, Parameswaran] St Josephs Healthcare, Firestone Inst Resp Hlth, Hamilton, ON, Canada; [Nair, Parameswaran] McMaster Univ, Hamilton, ON, Canada	McGill University; McGill University; Universite de Montreal; McMaster University; McMaster University	Al-Samri, MT (corresponding author), McGill Univ, Fac Med, Meakins Christie Labs, Montreal, PQ, Canada.	qutayba.hamid@mcgill.ca		Martin, James/0000-0001-7574-5363; Alsamri, Mohammed/0000-0003-2475-7967				Belda J, 2000, AM J RESP CRIT CARE, V161, P475, DOI 10.1164/ajrccm.161.2.9903097; D'silva L, 2007, RESP MED, V101, P2217, DOI 10.1016/j.rmed.2007.05.010; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Shannon J, 2008, CHEST, V133, P420, DOI 10.1378/chest.07-1881; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110	9	55	55	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1161	1163		10.1016/j.jaci.2010.02.005	http://dx.doi.org/10.1016/j.jaci.2010.02.005			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20392486	Bronze			2022-12-18	WOS:000277686700030
J	Verbanck, S; Schuermans, D; Vincken, W				Verbanck, Sylvia; Schuermans, Daniel; Vincken, Walter			Inflammation and airway function in the lung periphery of patients with stable asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Small airways; exhaled nitric oxide; stable asthma; inflammation	EXHALED NITRIC-OXIDE; VENTILATION HETEROGENEITY; ALVEOLAR; HEALTHY; INVOLVEMENT; ADULTS	Background: An important role for exhaled nitric oxide (NO) measurement could be in the distinction between proximal and peripheral lung contributions to inflammation, with a particular interest for the alveolar lung zone and its implication on airway function. Objective: We aimed to isolate the acinar lung zone contribution to both inflammation and airway function to seek a relationship between them. Methods: In 30 patients with asthma with an asthma control test score exceeding 20, indices of conductive and acinar ventilation heterogeneity (Scond, Sacin) were obtained from a multiple breath washout. NO production in the conductive airways (J'aw(NO)), alveolar NO concentration (CA(NO)), and the standard exhaled NO at 50 mL/s (FENO50) were obtained from exhaled NO. Results: Scond was consistently abnormal in all patients with stable asthma, but without any correlation to inflammation abnormality in that compartment (J'aw(NO)). Sacin was particularly abnormal in the asthma subgroup receiving >500 mu g budesonide equivalent, and a correlation was found between Sacin and CAN (r = 0.61; P = .015); in this subgroup, a weak association was found between Scond and J'aw(NO) or FENO50 (r = 0.50; P = .059 for both). Conclusion: The persistent functional abnormality of small conductive airways in patients with stable asthma is largely independent of inflammation as measured by exhaled NO. In the alveolar compartment, a functional correlate of alveolar NO was found in a subgroup of patients with stable asthma on moderate-to-high maintenance doses of inhaled steroids. These patients in particular could benefit from novel therapies specifically aimed at improving airway functionality at the level of the acinar entrance and beyond. (J Allergy Clin Immunol 2010;125:611-6.)	[Verbanck, Sylvia; Schuermans, Daniel; Vincken, Walter] Univ Hosp UZ Brussel, Div Resp, B-1090 Brussels, Belgium		Verbanck, S (corresponding author), Univ Hosp UZ Brussel, Div Resp, Laarbeeklaan 101, B-1090 Brussels, Belgium.	sylvia.verbanck@uzbrussel.be	Verbanck, Sylvia/L-7849-2016	Verbanck, Sylvia/0000-0003-0231-2756	Fund for Scientific Research Flanders; European Space Agency	Fund for Scientific Research Flanders(FWO); European Space Agency(European Space AgencyEuropean Commission)	Supported by the Fund for Scientific Research Flanders and the NO Microgravity Application Project of the European Space Agency.; Disclosure of potential conflict of interest: S. Verbanck has received research support from the Fund for Scientific Research and the European Space Agency. The rest of the authors have declared that they have no conflict of interest.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Battaglia S, 2005, THORAX, V60, P639, DOI 10.1136/thx.2004.035279; Berry M, 2005, EUR RESPIR J, V25, P986, DOI 10.1183/09031936.05.00132404; Brindicci C, 2007, CHEST, V132, P581, DOI 10.1378/chest.06-3046; Brindicci C, 2007, CHEST, V131, P1353, DOI 10.1378/chest.06-2531; Bush Andrew, 2008, Allergol Int, V57, P11, DOI 10.2332/allergolint.R-07-155; Cohen J, 2008, EUR RESPIR J, V31, P1213, DOI 10.1183/09031936.00082407; Condorelli P, 2007, J APPL PHYSIOL, V102, P417, DOI 10.1152/japplphysiol.00533.2006; Downie SR, 2007, THORAX, V62, P684, DOI 10.1136/thx.2006.069682; Fritscher LG, 2009, RESP MED, V103, P296, DOI 10.1016/j.rmed.2008.08.007; Gelb AF, 2004, AM J RESP CRIT CARE, V170, P737, DOI 10.1164/rccm.200403-408OC; George SC, 2004, J APPL PHYSIOL, V96, P831, DOI 10.1152/japplphysiol.00950.2003; *GLOB IN ASTHM, 2002, NHLBI PUB; Haight RR, 2006, LUNG, V184, P113, DOI 10.1007/s00408-005-2570-3; Hogman M, 2009, CLIN PHYSIOL FUNCT I, V29, P18, DOI 10.1111/j.1475-097X.2008.00831.x; Kerckx Y, 2008, J APPL PHYSIOL, V104, P918, DOI 10.1152/japplphysiol.01032.2007; Kharitonov SA, 2003, EUR RESPIR J, V21, P433, DOI 10.1183/09031936.03.00066903a; Lehtimaki L, 2001, EUR RESPIR J, V18, P635, DOI 10.1183/09031936.01.00000201; Malinovschi A, 2009, J APPL PHYSIOL, V106, P513, DOI 10.1152/japplphysiol.91148.2008; Menzies D, 2007, J ALLERGY CLIN IMMUN, V119, P328, DOI 10.1016/j.jaci.2006.10.014; Michils A, 2008, EUR RESPIR J, V31, P539, DOI 10.1183/09031936.00020407; Olin AC, 2007, CHEST, V131, P1852, DOI 10.1378/chest.06-2928; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Shaw DE, 2007, AM J RESP CRIT CARE, V176, P231, DOI 10.1164/rccm.200610-1427OC; Stick S, 2009, AM J RESP CRIT CARE, V179, P87, DOI 10.1164/rccm.200810-1604ED; Suresh V, 2008, J APPL PHYSIOL, V104, P1743, DOI 10.1152/japplphysiol.01355.2007; Taylor DR, 2009, AM J RESP CRIT CARE, V179, P88, DOI 10.1164/rccm.200810-1605ED; Travers J, 2007, AM J RESP CRIT CARE, V176, P238, DOI 10.1164/rccm.200609-1346OC; van Veen IH, 2006, EUR RESPIR J, V27, P951, DOI 10.1183/09031936.06.00087905; Verbanck S, 1999, AM J RESP CRIT CARE, V159, P1545, DOI 10.1164/ajrccm.159.5.9809017; Verbanck S, 2004, AM J RESP CRIT CARE, V170, P414, DOI 10.1164/rccm.200401-037OC; VERBANCK S, 1990, J APPL PHYSIOL, V69, P2269, DOI 10.1152/jappl.1990.69.6.2269; Verbanck S, 2003, J APPL PHYSIOL, V94, P1380, DOI 10.1152/japplphysiol.00588.2002; Verbanck S, 2008, J APPL PHYSIOL, V104, P925, DOI 10.1152/japplphysiol.01019.2007; Verbanck S, 2006, J ALLERGY CLIN IMMUN, V118, P340, DOI 10.1016/j.jaci.2006.04.056; Verbanck S, 2009, J APPL PHYSIOL, V106, P1494, DOI 10.1152/japplphysiol.91641.2008	36	55	56	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					611	616		10.1016/j.jaci.2009.10.053	http://dx.doi.org/10.1016/j.jaci.2009.10.053			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20132975				2022-12-18	WOS:000275883200016
J	Jackson, DJ; Virnig, CM; Gangnon, RE; Evans, MD; Roberg, KA; Anderson, EL; Burton, RM; Salazar, LP; DaSilva, DF; Shanovich, KM; Tisler, CJ; Gern, JE; Lemanske, RF				Jackson, Daniel J.; Virnig, Christine M.; Gangnon, Ronald E.; Evans, Michael D.; Roberg, Kathy A.; Anderson, Elizabeth L.; Burton, Ryan M.; Salazar, Lisa P.; DaSilva, Douglas F.; Shanovich, Kathleen M.; Tisler, Christopher J.; Gern, James E.; Lemanske, Robert F., Jr.			Fractional exhaled nitric oxide measurements are most closely associated with allergic sensitization in school-age children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fractional exhaled nitric oxide (FeNO); asthma; allergic sensitization; atopic dermatitis; lung junction; children; seasonality; atopy	RANDOMIZED CONTROLLED-TRIAL; RESPIRATORY SYMPTOMS; PRESCHOOL-CHILDREN; RESPONSE PROFILES; CHILDHOOD ASTHMA; LUNG-FUNCTION; YOUNG-ADULTS; ATOPY; POPULATION; DISTINGUISHES	Background: Factors affecting fractional exhaled nitric oxide (FeNO) in early childhood are incompletely understood. Objective: To examine the relationships between FeNO and allergic sensitization, total IgE, atopic dermatitis, rhinitis, asthma, and lung function (spirometry) in children. Methods: Children at high risk of asthma and other allergic diseases because of parental history were enrolled at birth and followed prospectively. FeNO was measured by an online technique at ages 6 and 8 years. Relationships among FeNO, various atopic characteristics, and asthma were evaluated. Results: Reproducible FeNO measurements were obtained in 64% (135/210) of 6-year-old and 93% (180/194) of 8-year-old children. There was seasonal variability in FeNO. Children with aeroallergen sensitization at ages 6 and 8 years had increased levels of FeNO compared with those not sensitized (geometric mean; 6 years, 10.9 vs 6.7 parts per billion [ppb], P < .0001; 8 years, 14.6 vs 7.1 ppb, P < .0001). FeNO was higher in children with asthma than in those without asthma at 8 years but not 6 years of age (6 years, 9.2 vs 8.3 ppb, P = .48; 8 years, 11.5 vs 9.2 ppb, P = .03). At 8 years of age, this difference was no longer significant in a multivariate model that included aeroallergen sensitization (P = .33). There were no correlations between FeNO and spirometric indices at 6 or 8 years of age. Conclusion: These findings underscore the importance of evaluating allergen sensitization status when FeNO is used as a potential biomarker in the diagnosis and/or monitoring of atopic diseases, particularly asthma. (J Allergy Clin Immunol 2009;124:949-53.)	[Jackson, Daniel J.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53792 USA; [Jackson, Daniel J.; Virnig, Christine M.; Burton, Ryan M.; Lemanske, Robert F., Jr.] Univ Wisconsin, Dept Med, Madison, WI 53792 USA; [Gangnon, Ronald E.; Evans, Michael D.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53792 USA; [Gangnon, Ronald E.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jackson, DJ (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, 600 Highland Ave,K4-910,CSC Box 9988, Madison, WI 53792 USA.	djj@medicine.wisc.edu		Evans, Michael/0000-0001-7449-3993; Gangnon, Ronald/0000-0003-2587-6714	National Institutes of Health [R01 HL61879, P01 HL70831, T32 AI007635, M01 RR03186]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD061879] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR003186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061879, P01HL070831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061879] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Supported by National Institutes of Health grants R01 HL61879, P01 HL70831, T32 AI007635 and M01 RR03186.	*AM LUNG ASS MED S, 1994, AM REV RESPIR DIS, V152, P1107; Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; Barreto M, 2005, PEDIAT ALLERG IMM-UK, V16, P52, DOI 10.1111/j.1399-3038.2005.00220.x; Brussee JE, 2005, EUR RESPIR J, V25, P455, DOI 10.1183/09031936.05.00079604; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; Buchvald F, 2001, AM J RESP CRIT CARE, V163, P699, DOI 10.1164/ajrccm.163.3.2004233; DE MG, 2005, ALLERGY, V60, P1499; Eigen H, 2001, AM J RESP CRIT CARE, V163, P619, DOI 10.1164/ajrccm.163.3.2002054; Franklin PJ, 2003, THORAX, V58, P1048, DOI 10.1136/thorax.58.12.1048; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jentzsch Nulma S., 2006, J. Pediatr. (Rio J.), V82, P193, DOI [10.2223/JPED.1472, 10.1590/S0021-75572006000300007]; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Malmberg LP, 2003, THORAX, V58, P494, DOI 10.1136/thorax.58.6.494; Moeller A, 2008, J ALLERGY CLIN IMMUN, V121, P705, DOI 10.1016/j.jaci.2007.11.008; Napier E, 2005, PEDIATR PULM, V40, P97, DOI 10.1002/ppul.20249; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Nordvall SL, 2005, ALLERGY, V60, P469, DOI 10.1111/j.1398-9995.2005.00735.x; Paul EF, 2002, SOCIETY, V39, P7, DOI 10.1007/s12115-002-1000-x; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; Pijnenburg MW, 2005, AM J RESP CRIT CARE, V172, P831, DOI 10.1164/rccm.200503-458OC; Shaw DE, 2007, AM J RESP CRIT CARE, V176, P231, DOI 10.1164/rccm.200610-1427OC; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Spanier AJ, 2008, PEDIATR PULM, V43, P576, DOI 10.1002/ppul.20816; Steerenberg PA, 2003, THORAX, V58, P242, DOI 10.1136/thorax.58.3.242; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; van Asch CJJ, 2008, ANN ALLERG ASTHMA IM, V100, P59, DOI 10.1016/S1081-1206(10)60406-1; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012	31	55	58	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					949	953		10.1016/j.jaci.2009.07.024	http://dx.doi.org/10.1016/j.jaci.2009.07.024			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19748661	Green Accepted, Bronze			2022-12-18	WOS:000272108000011
J	Philip, G; Hustad, CM; Malice, MP; Noonan, G; Ezekowitz, A; Reiss, TF; Knorr, B				Philip, George; Hustad, Carolyn M.; Malice, Marie-Pierre; Noonan, Gertrude; Ezekowitz, Alan; Reiss, Theodore F.; Knorr, Barbara			Analysis of behavior-related adverse experiences in clinical trials of montelukast	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Montelukast; placebo; clinical trial; behavior; psychiatric; adverse experiences; asthma; allergic rhinitis	1966 BIRTH COHORT; UNITED-STATES; MAJOR DEPRESSION; ASTHMA; RECEPTOR; ANXIETY; ATOPY; LEUKOTRIENES; ASSOCIATION; POPULATION	Background: Frequencies of behavior-related adverse experiences (BRAEs) in controlled clinical studies of leukotriene modifier drugs have not been summarized. Objective: We sought to compare the frequency of BRAEs in patients receiving montelukast or placebo in a retrospective analysis of Merck clinical trial data. Methods: An adverse experience database was constructed to include all double-blind, placebo-controlled trials of montelukast meeting prespecified criteria. BRAEs (described using the Medical Dictionary for Regulatory Activities controlled vocabulary dictionary) were prespecified to include any term in the Psychiatric Disorders System Organ Class, selected terms related to general disorders, and terms related to akathisia. Frequencies of BRAEs (overall, leading to study discontinuation, and/or serious) were summarized. Analyses estimated the odds ratios (ORs) for montelukast versus placebo based on the frequency of patients with BRAEs in each study. Results: In total 35 adult and 11 pediatric placebo-controlled trials were included; 11,673 patients received montelukast, 8,827 received placebo, and 4,724 received active control. The frequency of patients with 1 or more BRAEs was 2.73% and 2.27% in the montelukast and placebo groups, respectively; the OR for montelukast versus placebo was 1.12 (95% CI, 0.93-1.36). The frequency of patients with a BRAE leading to study discontinuation was 0.07% and 0.11% in the montelukast and placebo groups, respectively (OR, 0.52; 95% CI, 0.17-1.51). The frequency of patients with a BRAE considered serious was 0.03% in both treatment groups. Conclusion: Reports of BRAEs were infrequent in clinical trials of montelukast. Those leading to study discontinuation or considered serious were rare. Frequencies were similar regardless of treatment group. (J Allergy Clin Immunol 2009;124:699-706.)	[Philip, George] Merck & Co Inc, Merck Res Labs, N Wales, PA 19454 USA; [Malice, Marie-Pierre] Merck & Co Inc, Brussels, Belgium; [Noonan, Gertrude; Ezekowitz, Alan; Reiss, Theodore F.; Knorr, Barbara] Merck & Co Inc, Rahway, NJ 07065 USA	Merck & Company; Merck & Company; Merck & Company	Philip, G (corresponding author), Merck & Co Inc, Merck Res Labs, 351 N Sumneytown Pike,UG3D-66, N Wales, PA 19454 USA.	george_philip@merck.com			Merck Co. Inc.	Merck Co. Inc.(Merck & Company)	The studies referenced in this article were sponsored by Merck & Co. Inc.	*ASTRAZENECA LP, 2008, PULMICORT FLEXHALER; BELL IR, 1991, PSYCHOTHER PSYCHOSOM, V55, P24, DOI 10.1159/000288404; Blackman JA, 2007, J DEV BEHAV PEDIATR, V28, P92, DOI 10.1097/01.DBP.0000267557.80834.e5; Brunlof Gertrud, 2008, BMC Clin Pharmacol, V8, P1, DOI 10.1186/1472-6904-8-1; Chun TH, 2008, CHEST, V134, P1176, DOI 10.1378/chest.08-1528; Ciana P, 2006, EMBO J, V25, P4615, DOI 10.1038/sj.emboj.7601341; Fang SH, 2006, NEUROSCIENCE, V140, P969, DOI 10.1016/j.neuroscience.2006.02.051; *GLAXOSMITHKLINE, 2008, FLOVENT DISKUS 50 MC; *GLAXOSMITHKLINE, 2009, ADVAIR DISKUS 100 50; Goodwin RD, 2006, PSYCHOSOM MED, V68, P94, DOI 10.1097/01.psy.0000195797.78162.f4; Holbrook JT, 2008, J ALLERGY CLIN IMMUN, V122, P828, DOI 10.1016/j.jaci.2008.07.012; Hurwitz EL, 1999, AM J EPIDEMIOL, V150, P1107, DOI 10.1093/oxfordjournals.aje.a009936; *I SAF MED PRACT, QUARTERWATCH 2008 QU; JONES TR, 1995, CAN J PHYSIOL PHARM, V73, P191, DOI 10.1139/y95-028; Katon W, 2007, J ADOLESCENT HEALTH, V41, P455, DOI 10.1016/j.jadohealth.2007.05.023; Kewalramani Anupama, 2008, Int J Child Health Hum Dev, V1, P115; Lecca D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003579; Lynch KR, 1999, NATURE, V399, P789; *MERCK CO INC, 2009, SINGULAIR MONT SOD P; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; Postolache TT, 2007, THESCIENTIFICWORLDJO, V7, P1968, DOI 10.1100/tsw.2007.286; Scott KM, 2007, GEN HOSP PSYCHIAT, V29, P123, DOI 10.1016/j.genhosppsych.2006.12.006; Strauss A, 2005, CLIN THER, V27, P355, DOI 10.1016/S0149-2918(05)00053-6; Strine TW, 2008, PSYCHIAT SERV, V59, P1383, DOI 10.1176/appi.ps.59.12.1383; Timonen M, 2003, J ALLERGY CLIN IMMUN, V111, P1249, DOI 10.1067/mai.2003.1546; Timonen M, 2003, MOL PSYCHIATR, V8, P738, DOI 10.1038/sj.mp.4001274; Timonen M, 2002, BIOL PSYCHIAT, V52, P349, DOI 10.1016/S0006-3223(01)01364-6; *US FDA, 2008, UPD SAF REV FOLL MAR; US Food and Drug Administration, POT SIGN SER RISKS N; US Food and Drug Administration, UPD INF LEUK INH MON; US Food and Drug Administration, 2008, EARL COMM ONG SAF RE; US Food and Drug Administration, 2007, GUID DRUG SAF INF FD; Uz T, 2002, RESTOR NEUROL NEUROS, V20, P15; Uz T, 2008, NEUROSCI LETT, V436, P269, DOI 10.1016/j.neulet.2008.03.041; Uz Tolga, 2008, Open Neuropsychopharmacol J, V1, P1, DOI 10.2174/1876523800801010001; Van Lieshout RJ, 2009, PSYCHOSOM MED, V71, P187, DOI 10.1097/PSY.0b013e3181907012; ZELEN M, 1971, BIOMETRIKA, V58, P129, DOI 10.1093/biomet/58.1.129	37	55	63	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					699	706		10.1016/j.jaci.2009.08.011	http://dx.doi.org/10.1016/j.jaci.2009.08.011			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19815116				2022-12-18	WOS:000270802800012
J	Tantisira, KG; Drazen, JM				Tantisira, Kelan G.; Drazen, Jeffrey M.			Genetics and pharmacogenetics of the leukotriene pathway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Leukotrienes; single nucleotide polymorphism; asthma; 5-lipoxygenase; zileuton; montelukast; pharmacogenetics	ALOX5 PROMOTER GENOTYPE; ASPIRIN INTOLERANCE; ASTHMA; 5-LIPOXYGENASE; MONTELUKAST; POLYMORPHISMS; RECEPTOR; ASSOCIATION; RESPONSES; MODERATE	Leukotrienes are now established contributors to the inflammatory process in asthma, and leukotriene modifiers are mainstays in the therapy of asthma. This review focuses on published association studies implicating the role of leukotriene pathway genes in asthma pathogenesis and treatment response, specifically focusing on those genetic variants associated with asthma affection status, the development of aspirin-exacerbated respiratory disease, and pharmacogenetic response. Although published studies have been limited by small sample sizes and a lack of independent replication, multiple loci within multiple leukotriene pathway genes have now been associated in more than 1 study related to asthma or asthma treatment response. Those specific variants include 2 variants in the 5-lipoxygenase gene (ALOX5) that are both associated with response to 5-lipoxygenase inhibition and to leukotriene receptor antagonists, variants in genes encoding the 2 established cysteinyl leukotriene receptor antagonists (CYSLTR1 and CYSLTR2) that are both associated with asthma susceptibility in at least 2 independent populations, and a leukotriene C-4 synthase promoter polymorphism (LTC4s) that has been associated with asthma affection status and asthma-exacerbated respiratory disease. Despite these successes, genetic investigations into this pathway remain in their formative stages. Future studies aimed at providing a broader scope of investigation through increased sample sizes and through genome-wide approaches are needed. (J Allergy Clin Immunol 2009; 124:422-7.)	[Tantisira, Kelan G.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Tantisira, Kelan G.; Drazen, Jeffrey M.] Brigham & Womens Hosp, Div Pulm, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Tantisira, KG (corresponding author), Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	rekgt@channing.harvard.edu	Drazen, Jeffrey M/E-5841-2012	Drazen, Jeffrey/0000-0003-2715-9890	National Institutes of Health [U01:HL65899, K23:HG3983, R01:HL92197]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092197, U01HL065899] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K23HG003983] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	Supported by the National Institutes of Health (U01:HL65899, K23:HG3983, and R01:HL92197).	Choi JH, 2004, HUM GENET, V114, P337, DOI 10.1007/s00439-004-1082-1; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Drazen JM, 2000, BRIT MED BULL, V56, P1054, DOI 10.1258/0007142001903535; Holloway JW, 2008, ALLERGY, V63, P1046, DOI 10.1111/j.1398-9995.2008.01667.x; Hong X, 2009, EUR RESPIR J, V33, P42, DOI 10.1183/09031936.00057708; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; Kalayci O, 2006, ALLERGY, V61, P97, DOI 10.1111/j.1398-9995.2006.00979.x; Kawagishi Y, 2002, J ALLERGY CLIN IMMUN, V109, P936, DOI 10.1067/mai.2002.124466; Kedda MA, 2004, J ALLERGY CLIN IMMUN, V113, P889, DOI 10.1016/j.jaci.2004.02.008; Kim SH, 2006, CLIN EXP ALLERGY, V36, P433, DOI 10.1111/j.1365-2222.2006.02457.x; Klotsman M, 2007, PHARMACOGENET GENOM, V17, P189, DOI 10.1097/FPC.0b013e3280120043; Lima JJ, 2006, AM J RESP CRIT CARE, V173, P379, DOI 10.1164/rccm.200509-1412OC; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Mougey EB, 2009, PHARMACOGENET GENOM, V19, P129, DOI 10.1097/FPC.0b013e32831bd98c; Niemi M, 2007, PHARMACOGENOMICS, V8, P787, DOI 10.2217/14622416.8.7.787; Park JS, 2005, PHARMACOGENET GENOM, V15, P483, DOI 10.1097/01.fpc.0000166456.84905.a0; Pillai SG, 2004, PHARMACOGENETICS, V14, P627, DOI 10.1097/00008571-200409000-00007; SETTIPANE GA, 1975, J ALLERGY CLIN IMMUN, V56, P215, DOI 10.1016/0091-6749(75)90092-5; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Tantisira KG, 2009, PHARMACOGENET GENOM, V19, P244, DOI 10.1097/FPC.0b013e328326e0b1; Telleria JJ, 2008, RESP MED, V102, P857, DOI 10.1016/j.rmed.2008.01.011; Thompson MD, 2007, PHARMACOGENET GENOM, V17, P539, DOI 10.1097/FPC.0b013e328012d0bf; Werz O, 2006, PHARMACOL THERAPEUT, V112, P701, DOI 10.1016/j.pharmthera.2006.05.009	23	55	58	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					422	427		10.1016/j.jaci.2009.06.035	http://dx.doi.org/10.1016/j.jaci.2009.06.035			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19665766	Green Accepted			2022-12-18	WOS:000274315900004
J	Arellano, FM; Arana, A; Wentworth, CE; Fernandez-Vidaurre, C; Schlienger, RG; Conde, E				Arellano, Felix M.; Arana, Alejandro; Wentworth, Charles E.; Fernandez-Vidaurre, Carlos; Schlienger, Raymond G.; Conde, Eulogio			Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Lymphoma; skin lymphoma; topical corticosteroids; atopic dermatitis; risk	NON-HODGKINS-LYMPHOMA; MEDICATION USE; RISK; STEROIDS; CANCER; CLASSIFICATION; COHORT; STATES; SKIN	Background: Atopic dermatitis (AD) has been associated with an increased risk of lymphoma. Objectives: To assess the risk of lymphoma associated with AD and use of topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) in a database allowing medical record validation. Methods: We conducted a nested-case control study using the United Kingdom-based The Health Improvement Network (THIN) database. We excluded patients with established risk factors for lymphoma. Cases of lymphoma were identified and classified after review of the medical records and hospital discharge files. Results: In the study population of 3,500,194 individuals, we identified 2738 cases of lymphoma (1722 non-Hodgkin lymphoma [NHL], 466 Hodgkin disease, 550 indeterminate cases; overall, 188 had cutaneous involvement) and 10,949 matched controls. AD was associated with an increased lymphoma risk (odds ratio [OR], 1.83; 95% CI, 1.41-2.36). In patients with AD referred to a dermatologist, the OR further increased (OR, 3.72; 95% CI, 1.40-9.87). We did not find any cases of lymphoma in To users; however, the number of patients exposed to TCI was insufficient to study any possible association between lymphoma and these drugs. TCS use was associated with an increased lymphoma risk (OR, 1.46; 95% CI, 1.33-1.61). The risk increase was dependent on TCS potency (OR for high-potency TCS, 1.80; 95% CI, 1.54-2.11). The increased risk involved both Hodgkin disease and NHL, especially NHL with skin involvement (OR for high-potency TCS, 26.24; 95% CI, 13.49-51.07). Conclusion: Our results show an association between lymphoma-especially skin lymphoma-and use of TCS. The risk increased with duration of exposure and potency of TCS. Q Allergy Clin Immunol 2009;123:1111-6.)	[Arellano, Felix M.; Wentworth, Charles E.] Risk MR LLC, Bridgewater, NJ 08807 USA; [Arellano, Felix M.; Arana, Alejandro] Risk MR Pharmacovigilance Serv SL, Zaragoza, Spain; [Fernandez-Vidaurre, Carlos] Novartis Pharmaceut, E Hanover, NJ USA; [Schlienger, Raymond G.] Novartis Pharmaceut, Basel, Switzerland; [Conde, Eulogio] Univ Cantabria, E-39005 Santander, Spain; [Conde, Eulogio] Hosp Marques Valdecilla, Dept Hematol, Santander, Spain	Novartis; Novartis; Universidad de Cantabria; Hospital Universitario Marques de Valdecilla (HUMV)	Arellano, FM (corresponding author), Risk MR LLC, 726 Route 202 S,Suites 320-361, Bridgewater, NJ 08807 USA.	arellano@riskmr.com		ARANA, Alejandro/0000-0002-1593-3124	Novartis; Schering-Plough; Sepracor	Novartis(Novartis); Schering-Plough(Merck & CompanySchering Plough Corporation); Sepracor	Disclosure of potential conflict of interest: F. M. Arellano receives grant support from Novartis, Schering-Plough, and Sepracor. A. Arana receives grant support from Novartis and Schering-Plough. C. E. Wentworth receives grant support from Novartis. C. Fernandez-Vidaurre and R. Schlienger are employed by Novartis. The rest of the authors have declared that they have no conflict of interest.	Arellano FM, 2007, J INVEST DERMATOL, V127, P808, DOI 10.1038/sj.jid.5700622; Askling J, 2005, ANN RHEUM DIS, V64, P1765, DOI 10.1136/ard.2005.036459; Beiderbeck AB, 2003, CANCER CAUSE CONTROL, V14, P639, DOI 10.1023/A:1025698109991; Bernatsky S, 2007, RHEUMATOLOGY, V46, P690, DOI 10.1093/rheumatology/kel396; BERNSTEIN L, 1992, CANCER RES, V52, pS5510; CARTWRIGHT RA, 1988, LEUKEMIA RES, V12, P81, DOI 10.1016/S0145-2126(98)80012-X; CHAHIN F, SALIVARY GLAND TUMOR; Chang ET, 2005, AM J EPIDEMIOL, V162, P965, DOI 10.1093/aje/kwi311; *CUT LYMPH FDN, TREATM CTCL; DREWS CD, 1990, INT J EPIDEMIOL, V19, P1107, DOI 10.1093/ije/19.4.1107; Duvic M, 2001, Dermatol Online J, V7, P3; EKSTROMSMEDBY K, 2006, CANCER EPIDEM BIOMAR, V15, P2069; EPSTEIN EH, 1972, MEDICINE, V15, P61; Faye Albert, 2005, Paediatr Drugs, V7, P55, DOI 10.2165/00148581-200507010-00005; Guitart J, 2007, ARCH DERMATOL, V143, P921, DOI 10.1001/archderm.143.7.921; Hagstromer L, 2005, ARCH DERMATOL, V141, P1123, DOI 10.1001/archderm.141.9.1123; Harris NL, 1999, J CLIN ONCOL, V17, P3835, DOI 10.1200/JCO.1999.17.12.3835; Kato I, 2002, CANCER CAUSE CONTROL, V13, P965, DOI 10.1023/A:1021953224822; OBRYANTEAR CG, 1987, CLIN EXP DERMATOL, V12, P69, DOI 10.1111/j.1365-2230.1987.tb01863.x; Opelz G, 2004, AM J TRANSPLANT, V4, P222, DOI 10.1046/j.1600-6143.2003.00325.x; Ormerod AD, 2005, BRIT J DERMATOL, V153, P701, DOI 10.1111/j.1365-2133.2005.06899.x; Soderberg KC, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-51; Sorensen HT, 2004, JNCI-J NATL CANCER I, V96, P709, DOI 10.1093/jnci/djh118; Swinnen L J, 2001, J Natl Cancer Inst Monogr, P38; Wang H, 2006, BRIT J DERMATOL, V154, P205, DOI 10.1111/j.1365-2133.2005.07077.x; Willemze R, 2005, BLOOD, V105, P3768, DOI 10.1182/blood-2004-09-3502; Zhang YW, 2004, CANCER CAUSE CONTROL, V15, P419, DOI 10.1023/B:CACO.0000027506.55846.5d	27	55	57	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1111	1116		10.1016/j.jaci.2009.02.028	http://dx.doi.org/10.1016/j.jaci.2009.02.028			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19361841				2022-12-18	WOS:000266309400020
J	Janke, M; Poth, J; Wimmenauer, V; Giese, T; Coch, C; Barchet, W; Schlee, M; Hartmann, G				Janke, Markus; Poth, Jens; Wimmenauer, Vera; Giese, Thomas; Coch, Christoph; Barchet, Winfried; Schlee, Martin; Hartmann, Gunther			Selective and direct activation of human neutrophils but not eosinophils by Toll-like receptor 8	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Toll-like receptor; immunostimulatory RNA; neutrophil; granulocyte; immunotherapy; small molecule; 3M001; 3M002; 3M007; R-848	IMMUNE-RESPONSES; INNATE IMMUNITY; TLR AGONISTS; HLA-DR; EXPRESSION; CELLS; MONOCYTES; BLOOD; RNA; TOLL-LIKE-RECEPTOR-7	Background: Granulocytes represent the largest fraction of immune cells in peripheral blood and are directly exposed to circulating Toll-like receptor (TLR) ligands. Although highly relevant for TLR-based therapies, because of the technical challenge, activation of the granulocyte subsets of neutrophils and eosinophils by TLR ligands is less well studied than activation of other immune cell subsets. Objective: The aim of this work was to study direct versus indirect neutrophil and eosinophil activation by TLR7 and TLR8 ligands. Methods: We used a new whole-blood assay, single cell-based cytokine detection, and highly purified primary human neutrophils and eosinophils to separate direct and indirect effects on these blood cell subsets. Results: We found indirect but not direct activation of neutrophils but not eosinophils in whole blood by using unmodified immunostimulatory RNA (isRNA; TLR7/8 ligand). In contrast, direct activation and stimulation of the respiratory burst and degranulation was seen with nuclease-stable isRNA and with the small-molecule TLR8 agonist 3M002 but not 3M001 (TLR7). Neutrophils expressed TLR8 but none of the other 2 RNA-detecting TLRs (TLR3 and TLR7). Conclusions: Together, these results demonstrate that neutrophils are directly and fully activated through TLR8 but not TLR7. Furthermore, the results predict that the clinical utility of small-molecule TLR8 ligands or nuclease-stable RNA ligands for TLR8 might be limited because of neutrophil-mediated toxicity and that no such limitation applies for unmodified isRNA, which is known to induce desired T(H)1 activities in other immune cell subsets. (J Allergy Clin Immunol 2009;123:1026-33.)	[Janke, Markus; Poth, Jens; Wimmenauer, Vera; Coch, Christoph; Barchet, Winfried; Schlee, Martin; Hartmann, Gunther] Univ Bonn, Inst Clin Chem & Pharmacol, Univ Hosp, D-53105 Bonn, Germany; [Giese, Thomas] Univ Heidelberg, Inst Immunol, D-6900 Heidelberg, Germany	University of Bonn; Ruprecht Karls University Heidelberg	Hartmann, G (corresponding author), Univ Bonn, Inst Clin Chem & Pharmacol, Univ Hosp, Sigmund Freud Str 25, D-53105 Bonn, Germany.	gunther.hartmann@uni-bonn.de	Coch, Christoph/AAW-5336-2021; Schlee, Martin/AAL-1238-2021; Hartmann, Gunther/P-7492-2017	Hartmann, Gunther/0000-0003-1021-2018; Schlee, Martin/0000-0003-3671-7639; Barchet, Winfried/0000-0002-6745-6606; Poth, Jens/0000-0003-2534-5382	BMBF Biofuture [0311896, SFB 704, SFB 670, KFO115, KFO177]; Institute for Molecular Medicine and Experimental Immunology, University of Bonn [HBFG-109-517]	BMBF Biofuture(Federal Ministry of Education & Research (BMBF)); Institute for Molecular Medicine and Experimental Immunology, University of Bonn	Supported by grants BMBF Biofuture 0311896, SFB 704, SFB 670, KFO115, and KFO177 to G. Hartmann. Parts of this work were done in the Flow Cytometry Core Facility at the Institute for Molecular Medicine and Experimental Immunology, University of Bonn, which is supported in part by grant HBFG-109-517.	Bekeredjian-Ding I, 2006, J IMMUNOL, V176, P7438, DOI 10.4049/jimmunol.176.12.7438; BENTWOOD BJ, 1980, J IMMUNOL, V124, P855; Butcher SK, 2001, J LEUKOCYTE BIOL, V70, P881; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; DRANSFIELD I, 1994, J IMMUNOL, V153, P1254; Francois S, 2005, J IMMUNOL, V174, P3633, DOI 10.4049/jimmunol.174.6.3633; Gorden KB, 2005, J IMMUNOL, V174, P1259, DOI 10.4049/jimmunol.174.3.1259; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; HANSEL TT, 1992, J IMMUNOL, V149, P2130; Hattermann K, 2007, FASEB J, V21, P1575, DOI 10.1096/fj.06-7457com; Hayashi F, 2003, BLOOD, V102, P2660, DOI 10.1182/blood-2003-04-1078; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Hornung Veit, 2008, V183, P71; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Krieg AM, 2007, IMMUNOL REV, V220, P251, DOI 10.1111/j.1600-065X.2007.00572.x; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; LIVINGSTON DH, 1989, J SURG RES, V46, P322, DOI 10.1016/0022-4804(89)90195-9; LLOYD AR, 1992, IMMUNOL TODAY, V13, P169, DOI 10.1016/0167-5699(92)90121-M; LUCEY DR, 1989, P NATL ACAD SCI USA, V86, P1348, DOI 10.1073/pnas.86.4.1348; MENEGAZZI R, 1992, J LEUKOCYTE BIOL, V52, P619, DOI 10.1002/jlb.52.6.619; Nagase H, 2003, J IMMUNOL, V171, P3977, DOI 10.4049/jimmunol.171.8.3977; OLOFSSON TB, 1991, ACTA ONCOL, V30, P889, DOI 10.3109/02841869109088241; PALMBLAD J, 1984, J IMMUNOL, V132, P3041; Pockros PJ, 2007, J HEPATOL, V47, P174, DOI 10.1016/j.jhep.2007.02.025; Radsak MP, 2003, BLOOD, V101, P2810, DOI 10.1182/blood-2002-07-2261; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Sabroe I, 2003, J IMMUNOL, V170, P5268, DOI 10.4049/jimmunol.170.10.5268; Sabroe I, 2002, J IMMUNOL, V168, P4701, DOI 10.4049/jimmunol.168.9.4701; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; Sendo F, 1996, Hum Cell, V9, P215; VANFURTH R, 1973, J EXP MED, V138, P1314, DOI 10.1084/jem.138.6.1314; Ward AC, 2000, LEUKEMIA, V14, P973, DOI 10.1038/sj.leu.2401808	37	55	55	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1026	1033		10.1016/j.jaci.2009.02.015	http://dx.doi.org/10.1016/j.jaci.2009.02.015			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19361845				2022-12-18	WOS:000266309400007
J	Carroll, KN; Wu, PS; Gebretsadik, T; Griffin, MR; Dupont, WD; Mitchel, EF; Hartert, TV				Carroll, Kecia N.; Wu, Pingsheng; Gebretsadik, Tebeb; Griffin, Marie R.; Dupont, William D.; Mitchel, Edward F.; Hartert, Tina V.			Season of infant bronchiolitis and estimates of subsequent risk and burden of early childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RESPIRATORY-SYNCYTIAL-VIRUS; RHINOVIRUS ILLNESSES; INFECTION; CHILDREN; LIFE; AGE		[Carroll, Kecia N.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA; [Wu, Pingsheng] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; [Wu, Pingsheng] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA; [Griffin, Marie R.; Dupont, William D.; Mitchel, Edward F.] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA; [Wu, Pingsheng; Gebretsadik, Tebeb; Dupont, William D.] Vanderbilt Univ, Sch Med, Div Gen Pediat, Nashville, TN 37212 USA; [Griffin, Marie R.] Vanderbilt Univ, Sch Med, Div Gen Internal Med, Nashville, TN 37212 USA; [Hartert, Tina V.] Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37212 USA; [Griffin, Marie R.; Hartert, Tina V.] Vanderbilt Univ, Sch Med, Ctr Educ & Res Therapeut, Nashville, TN 37212 USA; [Hartert, Tina V.] Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Nashville, TN 37212 USA; [Griffin, Marie R.] Vet Affairs Tennessee Valley Hlth Care Syst, Mid S Geriatr Res Educ & Clin Ctr, Nashville, TN USA; [Griffin, Marie R.] Vet Affairs Tennessee Valley Hlth Care Syst, Clin Res Ctr Excellence, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Carroll, KN (corresponding author), Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA.	tina.hartert@vanderbilt.edu	Dupont, William D./I-4430-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL086048, U01HL072471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI077930, R01AI050884, K01AI070808] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL086048-01, F32 HL086048, U01 HL072471, U01 HL 072471, U01 HL072471-02, U01 HL072471-04, U01 HL072471-03, U01 HL072471-01, F32 HL086048-02, F32 HL 086048, U01 HL072471-05, L40 HL086298] Funding Source: Medline; NIAID NIH HHS [K01 AI070808, K24 AI077930, R01 AI050884-03, R01 AI050884, K24 AI 077930, R01 AI050884-02, K24 AI077930-01, K01 AI070808-01A1, K01 AI070808-02, R01 AI050884-05, R01 AI 50884, K24 AI077930-02, R01 AI050884-04, R01 AI050884-01A2] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; GWALTNEY JM, 1984, T AM CLIN CLIMAT ASS, V96, P159; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Wakefield DB, 2006, PEDIATR PULM, V41, P962, DOI 10.1002/ppul.20476; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232, DOI 10.1093/oxfordjournals.aje.a115243; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	10	55	55	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					964	966		10.1016/j.jaci.2008.12.011	http://dx.doi.org/10.1016/j.jaci.2008.12.011			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19181372	Green Accepted			2022-12-18	WOS:000265058600030
J	Hajek, AR; Lindley, AR; Favoreto, S; Carter, R; Schleimer, RP; Kuperman, DA				Hajek, Amanda R.; Lindley, Alexa R.; Favoreto, Silvio, Jr.; Carter, Roderick; Schleimer, Robert P.; Kuperman, Douglas A.			12/15-lipoxygenase deficiency protects mice from allergic airways inflammation and increases secretory IgA levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; inflammation; lipoxygenase; IL-13; IgA; B cells; airway; lung	DENDRITIC CELLS; MUCUS PRODUCTION; RECEPTOR; 5-LIPOXYGENASE; ACTIVATION; EXPRESSION; COMPONENT; MOUSE; PATHWAY; DISEASE	Background: Induction of 15-lipoxygenase-1 (15-LO-1) has been observed in the airways of subjects with asthma, although its physiologic role in the airways has remained largely undefined. Objectives: We sought to test the hypothesis that the mouse 15-LO-1 ortholog 12/15-LO contributes to the development of allergic airways inflammation. Methods: Two models were used to evaluate wild-type and 12/15-LO-deficient mice. The systemic model involved intraperitoneal injections of allergen, and the mucosal model involved allergen exposures occurring exclusively in the airways. The systemic and mucosal-specific contributions of 12/15-LO to allergic sensitization and airways inflammation were determined by comparing the results obtained in the 2 models. Results: In the mucosal model 12/15-LO knockout mice were protected from the development of allergic sensitization and airways inflammation, as evidenced by circulating levels of allergen-specific IgE, lgG1, and IgG2a; the profile of inflammatory cells in bronchoalveolar lavage fluid; and the expression of cytokines and mediators in lung tissue. In the systemic model 12/15-LO knockout mice were not protected. This suggested the presence of a lung-restricted protective role for 12/15-LO deficiency that was potentially accounted for by increased activation of mucosal B cells and increased production of the known mucosal-specific protective mediator secretory IgA. Conclusions: Induction of 15-LO-1 in asthma might contribute to allergic sensitization and airways inflammation, potentially by causing suppression of secretory IgA.	[Hajek, Amanda R.; Lindley, Alexa R.; Favoreto, Silvio, Jr.; Carter, Roderick; Schleimer, Robert P.; Kuperman, Douglas A.] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Dept Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Kuperman, DA (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Dept Med, 240 E Huron,Room M-317, Chicago, IL 60611 USA.	d-kuperman@northwestern.edu			NHLBI NIH HHS [R01 HL078860, R01 HL078860-03] Funding Source: Medline; NIAID NIH HHS [R01 AI072570-02, R01 AI072570, R01 AI076315] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072570, R01AI076315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balzar S, 2006, INT ARCH ALLERGY IMM, V140, P96, DOI 10.1159/000092252; Bennett WA, 1999, J SOC GYNECOL INVEST, V6, P311, DOI 10.1016/S1071-5576(99)00037-4; BRANDTZAEG P, 1984, NATURE, V311, P71, DOI 10.1038/311071a0; Brown CD, 2001, INFLAMM RES, V50, P321, DOI 10.1007/PL00000251; Chu H. W., 2002, Clinical and Experimental Allergy, V32, P1558, DOI 10.1046/j.1365-2222.2002.01477.x; Conrad DJ, 1999, CLIN REV ALLERG IMMU, V17, P71, DOI 10.1007/BF02737598; Emerson MR, 2004, BRAIN RES, V1021, P140, DOI 10.1016/j.brainres.2004.06.045; Erlandsson L, 2001, J EXP MED, V194, P557, DOI 10.1084/jem.194.5.557; Eutamene H, 2005, EUR RESPIR J, V25, P789, DOI 10.1183/09031936.05.00064704; Fedyk ER, 1996, P NATL ACAD SCI USA, V93, P10978, DOI 10.1073/pnas.93.20.10978; Heystek HC, 2002, J IMMUNOL, V168, P102, DOI 10.4049/jimmunol.168.1.102; Jisaka M, 2005, BIOCHEM BIOPH RES CO, V338, P136, DOI 10.1016/j.bbrc.2005.08.029; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kim ND, 2007, THESCIENTIFICWORLDJO, V7, P1307, DOI 10.1100/tsw.2007.181; Krause S, 2006, MOL IMMUNOL, V43, P1799, DOI 10.1016/j.molimm.2005.11.001; KROP I, 1996, J IMMUNOL, V157, P49; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Kuperman DA, 2005, J IMMUNOL, V175, P3746, DOI 10.4049/jimmunol.175.6.3746; Kuperman DA, 2005, J ALLERGY CLIN IMMUN, V116, P305, DOI 10.1016/j.jaci.2005.03.024; Li QX, 2004, J BIOL CHEM, V279, P11570, DOI 10.1074/jbc.M311773200; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Macpherson AJ, 2008, MUCOSAL IMMUNOL, V1, P11, DOI 10.1038/mi.2007.6; McCusker CT, 2007, J IMMUNOL, V179, P2556, DOI 10.4049/jimmunol.179.4.2556; Middleton MK, 2006, J EXP MED, V203, P2529, DOI 10.1084/jem.20061444; Motegi Y, 1998, J IMMUNOL, V161, P4340; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Otten MA, 2006, IMMUNOBIOLOGY, V211, P503, DOI 10.1016/j.imbio.2006.05.016; Pilette Charles, 2004, Proc Am Thorac Soc, V1, P125, DOI 10.1513/pats.2306032; Schwarze J, 1998, AM J RESP CRIT CARE, V158, P519, DOI 10.1164/ajrccm.158.2.9801014; Spanbroek R, 2001, P NATL ACAD SCI USA, V98, P5152, DOI 10.1073/pnas.091076998; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; van Leyen K, 2006, STROKE, V37, P3014, DOI 10.1161/01.STR.0000249004.25444.a5	32	55	61	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					633	639		10.1016/j.jaci.2008.06.021	http://dx.doi.org/10.1016/j.jaci.2008.06.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18692885	Green Accepted, Bronze			2022-12-18	WOS:000259234000029
J	Haynes, BF; Shattock, RJ				Haynes, Barton F.; Shattock, Robin J.			Critical issues in mucosal immunity for HIV-1 vaccine development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						HIV-1; vaccine; mucosal; gastrointestinal tract; T cells; antibody; innate; adaptive; immunity	IMMUNODEFICIENCY-VIRUS-INFECTION; CD4(+) T-CELLS; ANTIBODY POLYSPECIFICITY; ENVELOPE GLYCOPROTEIN; SEXUAL TRANSMISSION; DENDRITIC CELLS; NEUTRALIZATION; BINDING; IGA; ACTIVATION	Development of a safe and effective vaccine for HIV-1 infection is a critical global priority. However, the nature of host-virus interactions that lead to early immunosuppression and CD4 depletion, HIV-1 diversity, and the inability of the immune system to eliminate the latently infected CD4 pool of cells has to date thwarted successful vaccine development. Moreover, both the initial antibody-inducing vaccine (protein envelope gp120) and cell-mediated vaccine (recombinant adenovirus containing HIV-1 genes) strategies have failed in efficacy trials, and the latter cell-mediated vaccine appeared to have caused enhanced HIV-1 acquisition. Thus basic and translational research to understand why current vaccines have failed and elucidation of new mechanisms of virus control at mucosal surfaces is essential for eventual successful development of a preventive HIV-1 vaccine.	[Haynes, Barton F.] Duke Univ, Human Vaccine Inst, Sch Med, Dept Immunol, Durham, NC 27710 USA; [Haynes, Barton F.] Duke Univ, Human Vaccine Inst, Sch Med, Dept Med, Durham, NC 27710 USA; [Shattock, Robin J.] St Georges Univ, Dept Cellular & Mol Med, London, England	Duke University; Duke University; St Georges University London	Haynes, BF (corresponding author), Duke Univ, Human Vaccine Inst, Sch Med, Dept Med, 106 Res Dr,Med Sci Res Bldg 2,Rm 4087, Durham, NC 27710 USA.	hayne002@mc.duke.edu			NIAID NIH HHS [U19 AI067854, U19 AI067854-05, AI-0678501] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI067854] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alam SM, 2008, J VIROL, V82, P115, DOI 10.1128/JVI.00927-07; Alam SM, 2007, J IMMUNOL, V178, P4424, DOI 10.4049/jimmunol.178.7.4424; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; BRENCHLEY JM, 2008, NATURE, V1, P49; Burton DR, 2005, P NATL ACAD SCI USA, V102, P14943, DOI 10.1073/pnas.0505126102; Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182; Cerutti A, 1998, J IMMUNOL, V160, P2145; Chase A, 2006, TRENDS PHARMACOL SCI, V27, P4, DOI 10.1016/j.tips.2005.11.005; Chen P, 2007, J VIROL, V81, P12582, DOI 10.1128/JVI.00381-07; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; Crooks ET, 2007, VIROLOGY, V366, P245, DOI 10.1016/j.virol.2007.04.033; Devito C, 2000, J IMMUNOL, V165, P5170, DOI 10.4049/jimmunol.165.9.5170; EMAU P, 2006, AIDS RES THER, V28, P29; Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005; Fischer W, 2007, NAT MED, V13, P100, DOI 10.1038/nm1461; Furci L, 2007, BLOOD, V109, P2928, DOI 10.1182/blood-2006-05-024489; Ganesh L, 2004, J VIROL, V78, P11980, DOI 10.1128/JVI.78.21.11980-11987.2004; Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130; Gao F, 2007, CURR HIV RES, V5, P572, DOI 10.2174/157016207782418498; Gao Feng, 2004, Expert Rev Vaccines, V3, pS161, DOI 10.1586/14760584.3.4.S161; Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441; Haynes BF, 2006, EXPERT REV VACCINES, V5, P578; Haynes Barton F., 2005, Human Antibodies, V14, P59; Haynes BF, 2006, NAT MED, V12, P1351, DOI 10.1038/nm1206-1351; Haynes BF, 2005, SCIENCE, V308, P1906, DOI 10.1126/science.1111781; He B, 2006, J IMMUNOL, V176, P3931, DOI 10.4049/jimmunol.176.7.3931; Herbeuval JP, 2007, CLIN IMMUNOL, V123, P121, DOI 10.1016/j.clim.2006.09.016; Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106; Huber LC, 2007, APOPTOSIS, V12, P363, DOI 10.1007/s10495-006-0622-7; Huber M, 2006, PLOS MED, V3, P2078, DOI 10.1371/journal.pmed.0030441; Johnston MI, 2007, NEW ENGL J MED, V356, P2073, DOI 10.1056/NEJMra066267; JUSTIN SBW, 2007, AIDS VACCINE DEV CHA, P17; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; Klausner RD, 2003, SCIENCE, V300, P2036, DOI 10.1126/science.1086916; Koff WC, 2006, NAT IMMUNOL, V7, P19, DOI 10.1038/ni1296; Korber B, 2000, SCIENCE, V289, P1140; Korber B T, 1995, AIDS, V9 Suppl A, pS5; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188; Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226; Letvin NL, 2006, NAT REV IMMUNOL, V6, P930, DOI 10.1038/nri1959; Liao HX, 2006, VIROLOGY, V353, P268, DOI 10.1016/j.virol.2006.04.043; Lopes-Carvalho T, 2005, CURR OPIN IMMUNOL, V17, P244, DOI 10.1016/j.coi.2005.04.009; Lore K, 2005, J EXP MED, V201, P2023, DOI 10.1084/jem.20042413; Macpherson AJ, 2008, MUCOSAL IMMUNOL, V1, P11, DOI 10.1038/mi.2007.6; Margolis L, 2006, NAT REV MICROBIOL, V4, P312, DOI 10.1038/nrmicro1387; Mascola JR, 2002, VACCINE, V20, P1922, DOI 10.1016/S0264-410X(02)00068-3; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; MCNEELY TB, 1995, J CLIN INVEST, V96, P456, DOI 10.1172/JCI118056; Miller CJ, 2003, MICROBES INFECT, V5, P59, DOI 10.1016/S1286-4579(02)00056-4; Montefiori D, 2007, PLOS MED, V4, P1867, DOI 10.1371/journal.pmed.0040348; Morris L, 1998, J EXP MED, V188, P233, DOI 10.1084/jem.188.2.233; Nickle DC, 2007, PLOS COMPUT BIOL, V3, P754, DOI 10.1371/journal.pcbi.0030075; O'Leary JG, 2006, NAT IMMUNOL, V7, P507, DOI 10.1038/ni1332; OUTLAW MC, 1990, J GEN VIROL, V71, P69, DOI 10.1099/0022-1317-71-1-69; Peeters M, 2003, AIDS, V17, P2547, DOI 10.1097/00002030-200312050-00002; Pilcher CD, 2004, J INFECT DIS, V189, P1785, DOI 10.1086/386333; Pilcher CD, 2004, J CLIN INVEST, V113, P937, DOI [10.1172/JCI200421540, 10.1172/JCI21540]; Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748; Pope M, 2003, NAT MED, V9, P847, DOI 10.1038/nm0703-847; Reynolds MR, 2005, J VIROL, V79, P9228, DOI 10.1128/JVI.79.14.9228-9235.2005; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; Scanlan CN, 2007, J MOL BIOL, V372, P16, DOI 10.1016/j.jmb.2007.06.027; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Sekaly RP, 2008, J EXP MED, V205, P7, DOI 10.1084/jem.20072681; Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729; Shattock RJ, 2008, PLOS MED, V5, P537, DOI 10.1371/journal.pmed.0050081; Shen Y, 2002, SCIENCE, V295, P2255, DOI 10.1126/science.1068819; SHIRAI A, 1992, J CLIN INVEST, V89, P561, DOI 10.1172/JCI115621; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; Stebbing Justin, 2003, AIDS Rev, V5, P205; Sun LL, 2005, J VIROL, V79, P14318, DOI 10.1128/JVI.79.22.14318-14329.2005; Sun ZYJ, 2008, IMMUNITY, V28, P52, DOI 10.1016/j.immuni.2007.11.018; Telenti A, 2006, NAT REV MICROBIOL, V4, P865, DOI 10.1038/nrmicro1532; van Montfort T, 2007, J IMMUNOL, V178, P3177, DOI 10.4049/jimmunol.178.5.3177; von Bubnoff Andreas, 2008, IAVI Rep, V12, P8; Weaver EA, 2006, J VIROL, V80, P6745, DOI 10.1128/JVI.02484-05; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Weiler AM, 2008, J VIROL, V82, P4154, DOI 10.1128/JVI.01947-07; Weinhold K J, 1991, Biotechnol Ther, V2, P147; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; 2005, PLOS MED, V2, pE25	85	55	59	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					3	9		10.1016/j.jaci.2008.03.036	http://dx.doi.org/10.1016/j.jaci.2008.03.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18468671	Green Accepted			2022-12-18	WOS:000257605100001
J	Yang, YW; Haitchi, HM; Cakebread, J; Sammut, D; Harvey, A; Powell, RM; Holloway, JW; Howarth, P; Holgate, ST; Davies, DE				Yang, Youwen; Haitchi, Hans Michael; Cakebread, Julie; Sammut, David; Harvey, Anna; Powell, Robert M.; Holloway, John W.; Howarth, Peter; Holgate, Stephen T.; Davies, Donna E.			Epigenetic mechanisms silence a disintegrin and metalloprotease 33 expression in bronchial epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						promoter; CpG island; methylation; expression; ADAM33; epithelial-mesenchymal transition	DNA METHYLATION; CPG-ISLANDS; TUMOR-SUPPRESSOR; LUNG-FUNCTION; GENE; ADAM33; PROMOTER; ASTHMA; HYPERRESPONSIVENESS; METHYLTRANSFERASE	Background: A disintegrin and metalloprotease 33 (ADAM33) polymorphism is strongly associated with asthma and bronchial hyperresponsiveness. Although considered to be a mesenchymal cell-specific gene, recent reports have suggested epithelial expression of ADAM33 in patients with severe asthma. Objectives: Because dysregulated expression of ADAM33 can contribute to disease pathogenesis, we characterized the mechanism or mechanisms that control its transcription and investigated ADAM33 expression in bronchial biopsy specimens and brushings from healthy and asthmatic subjects. Methods: The ADAM33 promoter and CpG island methylation were analyzed by using bioinformatics, luciferase reporters, and bisulfite sequencing of genomic DNA. Epithelial-mesenchymal transition was induced by using TGF-beta 1. ADAM33 mRNA was scrutinized in bronchial biopsy specimens and brushings by using reverse transcriptase-quantitative polymerase chain reaction, melt-curve analysis, and direct sequencing. Results: The predicted ADAM33 promoter (-550 to +87) had promoter transcriptional activity. Bisulfite sequencing showed that the predicted promoter CpG island (-362 to +80) was hypermethylated in epithelial cells but hypomethylated in ADAM33-expressing fibroblasts. Treatment of epithelial cells with 5-aza-deoxycytidine caused demethylation of the CpG island and induced ADAM33 expression. In contrast, phenotypic transformation of epithelial cells through a TGF-beta-induced epithelial-mesenchymal transition was insufficient to induce ADAM33 expression. ADAM33 mRNA was confirmed in bronchial biopsy specimens, but no validated signal was detected in bronchial brushings from healthy or asthmatic subjects. Conclusion: The ADAM33 gene contains a regulatory CpG island within its promoter, the methylation status of which tightly controls its expression in a cell type-specific manner. ADAM33 repression is a stable feature of airway epithelial cells, irrespective of disease.	[Yang, Youwen; Haitchi, Hans Michael; Cakebread, Julie; Sammut, David; Harvey, Anna; Powell, Robert M.; Holloway, John W.; Howarth, Peter; Holgate, Stephen T.; Davies, Donna E.] Univ Southampton, Sch Med, Div Infect Inflammat & Repair, Brooke Labs, Southampton SO9 5NH, Hants, England	University of Southampton	Davies, DE (corresponding author), Southampton Gen Hosp, Level F S Block 810, Southampton SO16 6YD, Hants, England.	donnad@soton.ac.uk	Davies, Donna E/H-2993-2012; Sammut, David/AAM-9164-2021; Holloway, John W/B-5424-2009	Holloway, John W/0000-0001-9998-0464; Yang, Youwen/0000-0002-6402-8032; Haitchi, Hans Michael/0000-0001-8603-302X; Davies, Donna/0000-0002-5117-2991; Howarth, Peter/0000-0003-0619-7927; Cakebread, Julie/0000-0001-5937-6705	Medical Research Council [G0400473] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0400473] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; Douet V, 2007, BIOCHEM BIOPH RES CO, V354, P66, DOI 10.1016/j.bbrc.2006.12.151; Dunn JR, 2006, BRIT J CANCER, V94, P1186, DOI 10.1038/sj.bjc.6603006; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Foley SC, 2007, J ALLERGY CLIN IMMUN, V119, P863, DOI 10.1016/j.jaci.2006.12.665; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005; Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721; Haitchi HM, 2005, AM J RESP CRIT CARE, V171, P958, DOI 10.1164/rccm.200409-1251OC; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; Ioshikhes IP, 2000, NAT GENET, V26, P61, DOI 10.1038/79189; Kasai H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-56; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Lee JY, 2006, AM J RESP CRIT CARE, V173, P729, DOI 10.1164/rccm.200409-1175OC; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Powell RM, 2004, AM J RESP CELL MOL, V31, P13, DOI 10.1165/rcmb.2003-0330OC; Razin A, 2005, PROG MOLEC, V38, P151; Roach HI, 2005, ARTHRITIS RHEUM-US, V52, P3110, DOI 10.1002/art.21300; Roder K, 2002, J BIOL CHEM, V277, P30543, DOI 10.1074/jbc.M111891200; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Saper CB, 2005, J COMP NEUROL, V493, P477, DOI 10.1002/cne.20839; Simpson A, 2005, AM J RESP CRIT CARE, V172, P55, DOI 10.1164/rccm.200412-1708OC; Takada H, 2005, ONCOGENE, V24, P8051, DOI 10.1038/sj.onc.1208952; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Umland SP, 2003, AM J RESP CELL MOL, V29, P571, DOI 10.1165/rcmb.2003-0028OC; van Diemen CC, 2005, AM J RESP CRIT CARE, V172, P329, DOI 10.1164/rccm.200411-1486OC; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Willis Brigham C, 2006, Proc Am Thorac Soc, V3, P377, DOI 10.1513/pats.200601-004TK; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287	37	55	59	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1393	1399		10.1016/j.jaci.2008.02.031	http://dx.doi.org/10.1016/j.jaci.2008.02.031			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18423563				2022-12-18	WOS:000256771700014
J	Love, TM; Moffett, HF; Novina, CD				Love, Tara M.; Moffett, Howell F.; Novina, Carl D.			Not miR-ly small RNAs: Big potential for microRNAs in therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RNA interference; small interfering RNA; microRNA; antagomiR	SHORT INTERFERING RNA; CELL-PENETRATING PEPTIDES; IN-VIVO; OVARIAN-CARCINOMA; BURKITT-LYMPHOMA; CATIONIC LIPIDS; SYNTHETIC SIRNA; GENE-EXPRESSION; DOWN-REGULATION; PROTECTS MICE	RNA interference (RNAi) describes a set of natural processes in which genes are silenced by small RNAs. RNAi has been widely used as an experimental tool that has recently become the focus of drug development efforts to treat a variety of diseases and disorders. Like all molecular therapies, in vivo delivery is the major hurdle to realizing therapeutic RNAi. Several strategies have been developed that increase small RNA half-life in the blood, facilitate transduction across biological membranes, and mediate cell-specific delivery. Importantly, these strategies permit targeting of mRNAs as well as microRNAs (miRNAs), a class of small RNAs encoded in the genome. miRNAs are required for multiple developmental and cellular processes. Dysfunction of miRNAs can result in a host of pathologies, suggesting that miRNAs are potential targets of therapy. Recent studies of miRNA function in immune-specific pathways indicate that specific miRNAs might be exploited as therapeutic targets to treat immune disorders, including autoimmunity, allergy, and hematopoietic cancers.	[Love, Tara M.; Moffett, Howell F.; Novina, Carl D.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Love, Tara M.; Moffett, Howell F.; Novina, Carl D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; [Novina, Carl D.] Harvard & Massachusetts Inst Technol, Broad Inst, Cambridge, MA USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Love, TM (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.	carl_novina@dfci.harvard.edu		Moffett, Howell/0000-0002-7799-1688				Aigner A, 2006, J BIOTECHNOL, V124, P12, DOI 10.1016/j.jbiotec.2005.12.003; Batist G, 2001, J CLIN ONCOL, V19, P1444, DOI 10.1200/JCO.2001.19.5.1444; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Choi WY, 2007, SCIENCE, V318, P271, DOI 10.1126/science.1147535; Corey DR, 2007, NAT CHEM BIOL, V3, P8, DOI 10.1038/nchembio0107-8; Dass CR, 2002, J PHARM PHARMACOL, V54, P593, DOI 10.1211/0022357021778817; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Gabizon AA, 2001, CANCER INVEST, V19, P424, DOI 10.1081/CNV-100103136; Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791; Halder J, 2006, CLIN CANCER RES, V12, P4916, DOI 10.1158/1078-0432.CCR-06-0021; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Herman RE, 2007, J BIOL CHEM, V282, P9813, DOI 10.1074/jbc.M610722200; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Hosen N, 2007, P NATL ACAD SCI USA, V104, P11008, DOI 10.1073/pnas.0704271104; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Jackson AL, 2006, RNA, V12, P1197, DOI 10.1261/rna.30706; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Judge AD, 2006, MOL THER, V13, P494, DOI 10.1016/j.ymthe.2005.11.002; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Kim DH, 2005, NAT BIOTECHNOL, V23, P222, DOI 10.1038/nbt1051; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901; Kurreck J, 2003, EUR J BIOCHEM, V270, P1628, DOI 10.1046/j.1432-1033.2003.03555.x; Landen CN, 2006, CANCER BIOL THER, V5, P1708, DOI 10.4161/cbt.5.12.3468; Lee YS, 2005, J BIOL CHEM, V280, P16635, DOI 10.1074/jbc.M412247200; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li QJ, 2007, CELL, V129, P147, DOI 10.1016/j.cell.2007.03.008; Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372; Lu C, 2005, J CLIN ONCOL, V23, P3495, DOI 10.1200/JCO.2005.00.802; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lundberg P, 2007, FASEB J, V21, P2664, DOI 10.1096/fj.06-6502com; Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014; Ma Z, 2005, BIOCHEM BIOPH RES CO, V330, P755, DOI 10.1016/j.bbrc.2005.03.041; Mae M, 2006, CURR OPIN PHARMACOL, V6, P509, DOI 10.1016/j.coph.2006.04.004; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Moffett HF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-221; Monticelli S, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r71; Morrissey DV, 2005, HEPATOLOGY, V41, P1349, DOI 10.1002/hep.20702; Neilson JR, 2007, GENE DEV, V21, P578, DOI 10.1101/gad.1522907; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263; Patil SD, 2005, AAPS J, V7, pE61, DOI 10.1208/aapsj070109; Peek AS, 2007, CURR OPIN MOL THER, V9, P110; Pei Y, 2006, NAT METHODS, V3, P670, DOI 10.1038/NMETH911; Reynolds A, 2006, RNA, V12, P988, DOI 10.1261/rna.2340906; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Santel A, 2006, GENE THER, V13, P1222, DOI 10.1038/sj.gt.3302777; Schubert S, 2004, CURR DRUG TARGETS, V5, P667, DOI 10.2174/1389450043345092; Siolas D, 2005, NAT BIOTECHNOL, V23, P227, DOI 10.1038/nbt1052; Sioud M, 2003, BIOCHEM BIOPH RES CO, V312, P1220, DOI 10.1016/j.bbrc.2003.11.057; Sioud M, 2005, J MOL BIOL, V348, P1079, DOI 10.1016/j.jmb.2005.03.013; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Sonkoly E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000610; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Tam W, 2002, J VIROL, V76, P4275, DOI 10.1128/JVI.76.9.4275-4286.2002; Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; Thanik VD, 2007, GENE THER, V14, P1305, DOI 10.1038/sj.gt.3302986; Tomanin R, 2004, CURR GENE THER, V4, P357; Tsuda N, 2006, CLIN CANCER RES, V12, P6557, DOI 10.1158/1078-0432.CCR-06-0588; Wen WH, 2007, HEPATOLOGY, V46, P84, DOI 10.1002/hep.21663; Whelan JW, 2005, DRUG DISCOV TODAY, V10, P1014, DOI 10.1016/S1359-6446(05)03547-6; Zehn D, 2006, IMMUNITY, V25, P261, DOI 10.1016/j.immuni.2006.06.009; Zhang BH, 2007, J CELL PHYSIOL, V210, P279, DOI 10.1002/jcp.20869; Zhang CL, 2006, J CONTROL RELEASE, V112, P229, DOI 10.1016/j.jconrel.2006.01.022	86	55	63	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					309	319		10.1016/j.jaci.2007.12.1167	http://dx.doi.org/10.1016/j.jaci.2007.12.1167			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18269923				2022-12-18	WOS:000253337800003
J	Novak, N; Bieber, T				Novak, Natalija; Bieber, Thomas			Dendritic cells as regulators of immunity and tolerance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; immunity; tolerance; skin; mucosa	ATOPIC-DERMATITIS; TISSUE; LUNG; EXPRESS; SIGNALS; ANTIGEN; INNATE	Dendritic cells (DCs) are antigen sampling sentinels of the peripheral tissue and specialists for antigen capture, processing, and presentation to T cells as well as T-cell priming. By virtue of their mission as antigen samplers, they populate the body surfaces that line the border of our organism with the environment such as the skin and the mucosa of the respiratory and the gastrointestinal tract. Although all DCs share some classic features, their individual organ-specific phenotype and function are ascertained by a complex, dynamic network of coregulatory factors provided by their microenvironment. DC subtypes might initiate novel inflammatory immune responses as well as accelerate or break down ongoing inflammatory immune reactions in the skin, the gut, and the respiratory tract. On the basis of the recognition of self-signals or nonself-signals in the presence or absence of danger signals, the interplay of DC antigen uptake and presentation leads into immunosilencing or immunoactivating properties, which designate the outcome of tolerance or defensive immunity within the skin, the gut, or the respiratory tree.	[Novak, Natalija; Bieber, Thomas] Univ Bonn, Dept Dermatol, D-53105 Bonn, Germany	University of Bonn	Novak, N (corresponding author), Univ Bonn, Dept Dermatol, Sigmund Freud Str 25, D-53105 Bonn, Germany.	Natalija.Novak@ukb.uni-bonn.de						Akbari O, 2005, CURR ALLERGY ASTHM R, V5, P56, DOI 10.1007/s11882-005-0055-3; Bilsborough J, 2004, GASTROENTEROLOGY, V127, P300, DOI 10.1053/j.gastro.2004.01.028; Bonasio R, 2006, CURR OPIN IMMUNOL, V18, P503, DOI 10.1016/j.coi.2006.05.011; Cao W, 2007, CURR OPIN IMMUNOL, V19, P24, DOI 10.1016/j.coi.2006.11.004; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; de Heer HJ, 2005, SEMIN IMMUNOL, V17, P295, DOI 10.1016/j.smim.2005.05.002; Dudda JC, 2004, TRENDS IMMUNOL, V25, P417, DOI 10.1016/j.it.2004.05.008; Flacher V, 2006, J IMMUNOL, V177, P7959, DOI 10.4049/jimmunol.177.11.7959; Ginhoux F, 2006, NAT IMMUNOL, V7, P265, DOI 10.1038/ni1307; Hammad H, 2006, J ALLERGY CLIN IMMUN, V118, P331, DOI 10.1016/j.jaci.2006.03.041; Holt PG, 2004, CURR OPIN ALLERGY CL, V4, P39, DOI 10.1097/01.all.0000113677.18759.dc; Iwasaki A, 2007, ANNU REV IMMUNOL, V25, P381, DOI 10.1146/annurev.immunol.25.022106.141634; Johansson C, 2005, SEMIN IMMUNOL, V17, P284, DOI 10.1016/j.smim.2005.05.010; Kaplan DH, 2005, IMMUNITY, V23, P611, DOI 10.1016/j.immuni.2005.10.008; Kohl J, 2006, IMMUNOL RES, V34, P157, DOI 10.1385/IR:34:2:157; Matzinger P, 2007, NAT IMMUNOL, V8, P11, DOI 10.1038/ni0107-11; Niedergang F, 2005, TRENDS MICROBIOL, V13, P485, DOI 10.1016/j.tim.2005.08.001; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; Novak N, 2005, J AM ACAD DERMATOL, V53, pS171, DOI 10.1016/j.jaad.2005.04.060; Novak N, 2004, J ALLERGY CLIN IMMUN, V114, P364, DOI 10.1016/j.jaci.2004.05.038; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Shortman K, 2007, NAT REV IMMUNOL, V7, P19, DOI 10.1038/nri1996; Takabayshi K, 2006, IMMUNITY, V24, P475, DOI 10.1016/j.immuni.2006.02.008; Valladeau J, 2005, SEMIN IMMUNOL, V17, P273, DOI 10.1016/j.smim.2005.05.009; von Bubnoff D, 2004, J INVEST DERMATOL, V123, P298, DOI 10.1111/j.0022-202X.2004.23217.x	27	55	60	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2		2			S370	S374		10.1016/j.jaci.2007.06.001	http://dx.doi.org/10.1016/j.jaci.2007.06.001			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266IB	18241684				2022-12-18	WOS:000253426600003
J	Bonadonna, P; Zanotti, R; Caruso, B; Castellani, L; Perbellini, O; Colarossi, S; Chilosi, M; Dania, A; Schiaploli, M; Pizzolo, G; Senna, G; Passalacqua, G				Bonadonna, Patrizia; Zanotti, Roberta; Caruso, Beatrice; Castellani, Luca; Perbellini, Oinar; Colarossi, Sabrina; Chilosi, Marco; Dania, Annarita; Schiaploli, Michele; Pizzolo, Giovanni; Senna, Gianenrico; Passalacqua, Gioianni			Allergen specific immunotherapy is safe and effective inpatients with systemic mastocytosis and Hymenoptera, allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							VENOM IMMUNOTHERAPY; ANAPHYLAXIS; DIAGNOSIS		[Bonadonna, Patrizia; Caruso, Beatrice; Dania, Annarita; Senna, Gianenrico] Verona Gen Hosp, Allergy Unit, Verona, Italy; [Zanotti, Roberta; Perbellini, Oinar; Pizzolo, Giovanni] Univ Verona, Dept Clin & Expt Med, Sect Hematol, I-37100 Verona, Italy; [Chilosi, Marco] Univ Verona, Dept Pathol, I-37100 Verona, Italy; [Castellani, Luca] Santa Maria Carmine Hosp, Dept Dermatol, Rovereto, Italy; [Colarossi, Sabrina] Univ Bologna, Dept Hematol Oncol, I-40126 Bologna, Italy; [Passalacqua, Gioianni] Univ Genoa, Dipartimento Med Interna, I-16126 Genoa, Italy	University of Verona; University of Verona; University of Bologna; University of Genoa	Bonadonna, P (corresponding author), Verona Gen Hosp, Allergy Unit, Verona, Italy.	passalacqua@unige.it	Schiappoli, Michele/M-5590-2019; Schiappoli, Michele/J-5054-2012; Senna, Gianenrico/AAC-5201-2022; CHILOSI, MARCO/ABB-8028-2021; CARUSO, Beatrice/C-7528-2017	Schiappoli, Michele/0000-0002-4718-5984; Schiappoli, Michele/0000-0002-4718-5984; Senna, Gianenrico/0000-0003-4172-3216; CARUSO, Beatrice/0000-0003-2291-4025; PERBELLINI, Omar/0000-0002-8278-8916				Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; Dubois AEJ, 2004, CURR OPIN ALLERGY CL, V4, P291, DOI 10.1097/01.all.0000136756.20701.f8; Elberink JNGO, 1997, J ALLERGY CLIN IMMUN, V99, P153, DOI 10.1016/S0091-6749(97)70314-2; Fricker M, 1997, J ALLERGY CLIN IMMUN, V100, P11, DOI 10.1016/S0091-6749(97)70188-X; Haeberli G, 2003, CLIN EXP ALLERGY, V33, P1216, DOI 10.1046/j.1365-2222.2003.01755.x; KORS JW, 1993, J INTERN MED, V233, P255, DOI 10.1111/j.1365-2796.1993.tb00984.x; RUEFF F, PATIENTS STILL REACT; Valent P, 2003, BRIT J HAEMATOL, V122, P695, DOI 10.1046/j.1365-2141.2003.04575.x	9	55	55	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					256	257		10.1016/j.jaci.2007.10.014	http://dx.doi.org/10.1016/j.jaci.2007.10.014			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18206512				2022-12-18	WOS:000252372000041
J	Williams, LK; McPhee, RA; Ownby, DR; Peterson, EL; James, M; Zoratti, EM; Johnson, CC				Williams, L. Keoki; McPhee, Roderick A.; Ownby, Dennis R.; Peterson, Edward L.; James, Melissa; Zoratti, Edward M.; Johnson, Christine C.			Gene-environment interactions with CD14 C-260T and their relationship to total serum IgE levels in adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic hypersensitivity; cat; CD14; dog; domestic animals; endotoxin; endotoxin receptor; IgE; single nucleotide polymorphism	HOUSE-DUST ENDOTOXIN; AIRBORNE ENDOTOXIN; IMMUNOGLOBULIN-E; SOLUBLE CD14; ALLERGIC SENSITIZATION; YOUNG-CHILDREN; DOG OWNERSHIP; RECEPTOR CD14; PLASMA-LEVELS; EXPOSURE	Background: Both endotoxin exposure and a single nucleotide polymorphism in one of its receptors, CD14 C-260T, have been separately associated with total serum IgE levels. Furred pets might also influence IgE levels through their effects on endotoxin levels. However, how these factors interact to influence total IgE levels is not well known, especially in adults. Objective: We sought to investigate the interactive relationship between endotoxin levels, pet exposure, and CD14 C-260T genotype on total serum IgE levels in adults. Methods: Mothers enrolled in an ongoing cohort study were genotyped for the CD14 C-260T polymorphism. Exposure to pets was assessed by using questionnaires and dust allergen levels collected in the home. Endotoxin exposure was estimated by using dust collected from mothers' bedroom floors. The primary outcome measure was total serum IgE level. Results: CD14 C-260T genotype was assessed in 517 (85.2%) of the 607 women enrolled in the study. The CD14 C-260T genotype was significantly associated with total IgE levels; however, this relationship appeared to be modified by the level of endotoxin exposure. Similar interactions between CD14 C-260T and pet exposure were not seen, regardless of the measure of pet exposure used. Conclusions: The CD14 C-260T genotype and endotoxin exposure together appear to influence total serum IgE levels in adults. The absence of a similar gene-environment interaction for pet exposure suggests separate mechanisms of action. Clinical implications: A common polymorphism in the endotoxin receptor, CD14 C-260T, and dust endotoxin levels in the home might interact to influence total serum IgE levels into adulthood.	Henry Ford Hlth Syst, Ctr Hlth Serv Res, Detroit, MI 48202 USA; Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, Detroit, MI USA; Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI USA; Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; University System of Georgia; Augusta University	Williams, LK (corresponding author), Henry Ford Hlth Syst, Ctr Hlth Serv Res, 1 Ford Pl,3A,CHSR, Detroit, MI 48202 USA.	kwillia5@hfhs.org		Johnson, Christine Cole/0000-0002-6864-6604	NIAID NIH HHS [AI61774, AI50681, AI51598, AI50594] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050681, R01AI061774, R01AI051598, R56AI050681] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amar J, 2004, J HYPERTENS, V22, P1523, DOI 10.1097/01.hjh.0000133724.16947.a3; AMINO N, 1978, OBSTET GYNECOL, V52, P415; Arias MA, 2000, J IMMUNOL, V164, P3480, DOI 10.4049/jimmunol.164.7.3480; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Choudhry S, 2005, AM J RESP CRIT CARE, V172, P173, DOI 10.1164/rccm.200409-1232OC; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Gao PS, 1999, CLIN GENET, V56, P164; Gehring U, 2004, INDOOR AIR, V14, P284, DOI 10.1111/j.1600-0668.2004.00244.x; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Joseph CLM, 2006, J ALLERGY CLIN IMMUN, V117, P233, DOI 10.1016/j.jaci.2005.11.004; Koenig W, 2002, J AM COLL CARDIOL, V40, P34, DOI 10.1016/S0735-1097(02)01937-X; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P1056, DOI 10.1016/j.jaci.2005.02.006; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; Liu AH, 2003, J ALLERGY CLIN IMMUN, V111, P471, DOI 10.1067/mai.2003.172; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Morange PE, 2004, EUR J HUM GENET, V12, P1041, DOI 10.1038/sj.ejhg.5201277; Noguchi E, 1997, AM J RESP CRIT CARE, V156, P1390, DOI 10.1164/ajrccm.156.5.9702084; O'Donnell AR, 2004, AM J RESP CRIT CARE, V169, P615, DOI 10.1164/rccm.200302-278OC; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Park JH, 2001, ENVIRON HEALTH PERSP, V109, P859, DOI 10.2307/3454831; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills JA, 2005, J ALLERGY CLIN IMMUN, V116, P384, DOI 10.1016/j.jaci.2005.05.012; Portengen L, 2005, J ALLERGY CLIN IMMUN, V115, P797, DOI 10.1016/j.jaci.2004.11.046; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; SCHATZ M, 2003, MIDDLETONS ALLERGY P, P1303; Sohy C, 2005, ALLERGY, V60, P541, DOI 10.1111/j.1398-9995.2005.00742.x; Tulic MK, 2004, LANCET, V363, P1689, DOI 10.1016/S0140-6736(04)16253-3; Vercelli D, 2002, J ALLERGY CLIN IMMUN, V109, P14, DOI 10.1067/mai.2002.121015; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Wickens K, 2003, INDOOR AIR, V13, P128, DOI 10.1034/j.1600-0668.2003.00187.x; XU J, 1995, AM J HUM GENET, V57, P425	43	55	56	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					851	857		10.1016/j.jaci.2006.07.007	http://dx.doi.org/10.1016/j.jaci.2006.07.007			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030237	Bronze			2022-12-18	WOS:000241434200011
J	Chen, CL; Wang, SD; Zeng, ZY; Lin, KJ; Kao, ST; Tani, T; Yu, CK; Wang, JY				Chen, Chih-Lung; Wang, Shulhn-Der; Zeng, Zhao-Ying; Lin, Kuo-Juei; Kao, Shung-Te; Tani, Thoru; Yu, Chun-Keung; Wang, Jiu-Yao			Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergeninduced airway inflammation and eosinophilia in a murine model of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						serine protease inhibitor; allergy; airway inflammation; eosinophils	URINARY TRYPSIN-INHIBITOR; MAST-CELL TRYPTASE; MITE ALLERGENS; EPITHELIAL-CELLS; ACTIVATION; RELEASE; LIPOPOLYSACCHARIDE; INDUCE; RATS; SENSITIZATION	Background: Serine proteases such as mast cell tryptase and certain allergens are important in the pathogenesis of allergic inflammation of asthma. Objective: We sought to investigate the effects of serine protease inhibitors nafamostat mesilate (FUT), gabexate mesilate (FOY), and ulinastatin (UTI) on airway inflammation in a mouse model of allergic asthma. Methods: BALB/c mice were sensitized to Dermatophagoides pteronyssinus (Der p) and intratracheally challenged with Der p (0.5 mg/mL). Therapeutic doses of FUT (0.0625 mg/kg), FOY (20 mg/kg), and UTI (10,000 U/kg) were intra-peritoneally injected into 3 corresponding sensitized mice during the sensitization phase (protocol 1) or 24 hours after allergen challenge (protocol 2). Results: Both FUT-treated and FOY-treated sensitized mice had reduced mast cells activation, airway hyperresponsiveness, attenuated eosinophils infiltrations, and decreased Der p-induced IL-4 and TNF-alpha, but increased IL-12 cytokine production in bronchoalveolar lavage fluid compared with nontreated mice. Furthermore, FUT treatment downregulated the expression of IL-1 beta, TNF-alpha, IL-6, eotaxin, inducible NO synthase, CD86, and nuclear factor-kappa B activation, but enhanced the expression of IL-12 and IL-10 in Der p-stimulated alveolar macrophages. UTI-treated mice have no significant change of the aforementioned measurements compared with nontreated sensitized mice. Conclusion: Nafamostat mesilate and FOY exerting the therapeutic effect in allergen-induced airway inflammation was a result not only of their inhibitory action in the early phase of mast cells activation but also of immunoregulatory function in the late phase of allergic inflammation. Such properties of FUT and FOY might be a potential therapeutic approach for asthma. Clinical implications: The clinical used of serine protease inhibitors FUT and FOY may also have implications for treating airway inflammation of asthma.	Natl Cheng Kung Univ, Coll Med, Dept Pediat, Tainan 70101, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 70101, Taiwan; Ind Technol Res Inst, Div Biomat & Tissue Engn, Hsinchu, Taiwan; China Med Univ, Inst Chinese Med Sci, Taichung, Taiwan; China Med Univ, Inst Chinese & Western Med Sci, Taichung, Taiwan; Shiga Univ Med Sci, Dept Surg, Shiga, Japan	National Cheng Kung University; National Cheng Kung University; Industrial Technology Research Institute - Taiwan; China Medical University Taiwan; China Medical University Taiwan; Shiga University of Medical Science	Wang, JY (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pediat, 138,Sheng Li Rd, Tainan 70101, Taiwan.	a122@mail.ncku.edu.tw						Asokananthan N, 2002, J IMMUNOL, V169, P4572, DOI 10.4049/jimmunol.169.8.4572; Berger P, 2001, J APPL PHYSIOL, V91, P1372, DOI 10.1152/jappl.2001.91.3.1372; Chen CL, 2003, J IMMUNOL, V170, P528, DOI 10.4049/jimmunol.170.1.528; CLARK JM, 1995, AM J RESP CRIT CARE, V152, P2076, DOI 10.1164/ajrccm.152.6.8520778; Erba F, 2001, BIOCHEM PHARMACOL, V61, P271, DOI 10.1016/S0006-2952(00)00550-5; Flores I, 2003, INT ARCH ALLERGY IMM, V130, P12, DOI 10.1159/000068375; Fundueanu G, 2004, BIOMATERIALS, V25, P159, DOI 10.1016/S0142-9612(03)00477-0; He S, 1998, J PHARMACOL EXP THER, V286, P289; Hewitt CRA, 1998, ALLERGY, V53, P60, DOI 10.1111/j.1398-9995.1998.tb05000.x; Hirano T, 1996, J SURG RES, V61, P301, DOI 10.1006/jsre.1996.0120; INO Y, 1989, INT ARCH ALLER A IMM, V89, P321, DOI 10.1159/000234970; Inoue KI, 2005, MOL PHARMACOL, V67, P673, DOI 10.1124/mol.104.005967; Ito K, 2005, INJURY, V36, P387, DOI 10.1016/j.injury.2004.06.018; Katsuno G, 2005, J PHARMACOL SCI, V98, P463, DOI 10.1254/jphs.SC0050130; Kauffman HF, 2003, CURR ALLERGY ASTHM R, V3, P430, DOI 10.1007/s11882-003-0080-z; King C, 1998, J IMMUNOL, V161, P3645; Komori M, 2003, SHOCK, V20, P189, DOI 10.1097/01.shk.0000074483.07619.4b; Miike S, 2003, J ALLERGY CLIN IMMUN, V111, P704, DOI 10.1067/mai.2003.1332; Mori S, 2003, J PHARMACOL SCI, V92, P420; Nakatsuka M, 2000, LIFE SCI, V67, P1243, DOI 10.1016/S0024-3205(00)00716-5; Reed CE, 2004, J ALLERGY CLIN IMMUN, V114, P997, DOI 10.1016/j.jaci.2004.07.060; SCHWARTZ LB, 1990, J ALLERGY CLIN IMMUN, V86, P594, DOI 10.1016/S0091-6749(05)80222-2; Sendo T, 2003, BRIT J PHARMACOL, V138, P959, DOI 10.1038/sj.bjp.0705121; Shen HD, 1999, INT ARCH ALLERGY IMM, V119, P259, DOI 10.1159/000024202; Sun G, 2001, J IMMUNOL, V167, P1014, DOI 10.4049/jimmunol.167.2.1014; Takahashi H, 2003, CLIN NEPHROL, V59, P458; TAM EK, 1990, AM J RESP CELL MOL, V3, P27, DOI 10.1165/ajrcmb/3.1.27; WALLS AF, 1995, INT ARCH ALLERGY IMM, V107, P372, DOI 10.1159/000237039; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002; Wright CD, 1999, BIOCHEM PHARMACOL, V58, P1989, DOI 10.1016/S0006-2952(99)00304-4; Yasui K, 2003, EUR RESPIR J, V22, P739, DOI 10.1183/09031936.03.00015703; Yu CK, 2003, J IMMUNOL, V171, P3808, DOI 10.4049/jimmunol.171.7.3808; Yuksel M, 2003, J PHARMACOL EXP THER, V305, P298, DOI 10.1124/jpet.102.041988	33	55	58	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					105	112		10.1016/j.jaci.2006.02.047	http://dx.doi.org/10.1016/j.jaci.2006.02.047			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815145	Bronze			2022-12-18	WOS:000239184800013
J	Ho, MHK; Heine, RG; Wong, W; Hill, DJ				Ho, Marco H. K.; Heine, Raif G.; Wong, Wilfred; Hill, David J.			Diagnostic accuracy of skin prick testing in children with tree nut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Royal Childrens Hosp, Dept Allergy, Melbourne, Vic, Australia; Murdoch Childrens Res Inst, Melbourne, Vic, Australia; Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; Univ Hong Kong, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China	Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; University of Melbourne; University of Hong Kong	Ho, MHK (corresponding author), Royal Childrens Hosp, Dept Allergy, Melbourne, Vic, Australia.			Heine, Ralf Gunter/0000-0002-3343-0379; Ho, Marco/0000-0003-1802-2120				Akkerdaas JH, 2003, INT ARCH ALLERGY IMM, V132, P132, DOI 10.1159/000073714; Clark AT, 2003, CLIN EXP ALLERGY, V33, P1041, DOI 10.1046/j.1365-2745.2003.01624.x; Fleischer DM, 2005, J ALLERGY CLIN IMMUN, V116, P1087, DOI 10.1016/j.jaci.2005.09.002; Illi S, 1998, ALLERGY, V53, P353, DOI 10.1111/j.1398-9995.1998.tb03905.x; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; SKASSABROCIEK W, 1987, J ALLERGY CLIN IMMUN, V80, P711, DOI 10.1016/0091-6749(87)90292-2; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x	9	55	55	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1506	1508		10.1016/j.jaci.2006.03.029	http://dx.doi.org/10.1016/j.jaci.2006.03.029			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751023				2022-12-18	WOS:000238332300050
J	Maintz, L; Benfadal, S; Allam, JP; Hagemann, T; Fimmers, R; Novak, N				Maintz, Laura; Benfadal, Said; Allam, Jean-Pierre; Hagemann, Tobias; Fimmers, Rolf; Novak, Natalija			Evidence for a reduced histamine degradation capacity in a subgroup of patients with atopic eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic eczema; histamine; diaminoxidase; food intolerance; allergy	INTESTINAL DIAMINE OXIDASE; N-METHYLTRANSFERASE PHARMACOGENETICS; FOOD-INDUCED HISTAMINOSIS; WINE PROVOCATION TEST; PLASMA HISTAMINE; INFUSED HISTAMINE; CROHNS-DISEASE; COLONIC-MUCOSA; FREE DIET; DERMATITIS	Background: A diminished histamine degradation based on a reduced diaminoxidase activity is suspected as a reason for non-IgE-mediated food intolerance caused by histamine. Atopic eczema (AE) is often complicated by relapses triggered by IgE-mediated allergy to different kinds of food. However, in a subgroup of patients with AE, allergy testing proves negative, although these patients report a coherence of food intake and worsening of AE and describe symptoms that are very similar to histamine intolerance (HIT). Objectives: It was the aim of our study to evaluate symptoms of HIT in combination with diaminoxidase levels in a total of 360 individuals consisting of patients with AE (n = 162) in comparison with patients with HIT (n = 124) without AE and healthy control volunteers (n = 85). Methods: Histamine plasma level was determined with an ELISA and diaminoxidase serum activity with the help of radio extraction assays using [3H]-labeled putrescine-dihydrochloride as a substrate. Detailed clinical evaluations of characteristic features of AE and HIT were performed. Results: Reduced diaminoxidase serum levels leading to occurrence of HIT symptoms like chronic headache, dysmenorrhea, flushing, gastrointestinal symptoms, and intolerance of histamine-rich food and alcohol were significantly more common in patients with AE than in controls. Reduction of both symptoms of HIT and Severity Scoring of Atopic Dermatitis could be achieved by a. histamine-free diet in the subgroup of patients with AE and low diaminoxidase serum levels. Conclusion: Higher histamine plasma levels combined with a reduced histamine degradation capacity might influence the clinical course of a subgroup of patients with AE. Clinical implications: As HIT emerges in a subgroup of patients with AE, a detailed anamnestic evaluation of food intolerance and HIT symptoms complemented by an allergological screening for food allergy, a diet diary, and, in confirmed suspicion of HIT, measurement of diaminoxidase activity and a histamine-free diet should be undertaken.	Univ Bonn, Dept Dermatol, D-53105 Bonn, Germany; Univ Bonn, Dept Med Biometry Informat & Epidemiol, D-53105 Bonn, Germany	University of Bonn; University of Bonn	Novak, N (corresponding author), Univ Bonn, Dept Dermatol, Sigmund Freud Str 25, D-53105 Bonn, Germany.	Novak@ukb.uni-bonn.de						AGRO AF, 1969, FEBS LETT, V4, P31, DOI 10.1016/0014-5793(69)80188-2; BIEGANSKI T, 1983, BIOCHIM BIOPHYS ACTA, V756, P196, DOI 10.1016/0304-4165(83)90092-2; BIEGANSKI T, 1982, AGENTS ACTIONS, V12, P41, DOI 10.1007/BF01965104; BIEGANSKI T, 1980, ARCH IMMUNOL THER EX, V28, P901; BIEGANSKI T, 1980, AGENTS ACTIONS, V10, P108, DOI 10.1007/BF02024190; BIEGANSKI T, 1983, Acta Physiologica Polonica, V34, P139; Bodmer S, 1999, INFLAMM RES, V48, P296, DOI 10.1007/s000110050463; Bos JD, 1998, EXP DERMATOL, V7, P132, DOI 10.1111/j.1600-0625.1998.tb00313.x; BROWN DD, 1959, J BIOL CHEM, V234, P2948; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; DIEPGEN TL, 1989, ACTA DERM-VENEREOL, P50; Elmore BO, 2002, J BIOL INORG CHEM, V7, P565, DOI 10.1007/s00775-001-0331-1; Hamid Q, 2004, J ALLERGY CLIN IMMUN, V113, P1006, DOI 10.1016/S0091-6749(04)01072-3; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; HERMAN JJ, 1979, SCIENCE, V206, P77, DOI 10.1126/science.113872; Ignesti G, 2003, J ENZYM INHIB MED CH, V18, P463, DOI 10.1080/14756360310001605543; IND PW, 1982, AGENTS ACTIONS, V12, P12, DOI 10.1007/BF01965099; IONESCU G, 1989, ALLERGY, V44, P298, DOI 10.1111/j.1398-9995.1989.tb01074.x; IONESCU G, 1988, ALLERGY, V43, P318, DOI 10.1111/j.1398-9995.1988.tb00907.x; Jarisch R, 1996, INT ARCH ALLERGY IMM, V110, P7, DOI 10.1159/000237304; Jarisch R, 2004, HISTAMIN INTOLERANZ, V2; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; KIEHL R, 1989, Z HAUTKRANKHEITEN, V64, P1121; Klocker J, 2005, INFLAMM RES, V54, pS54, DOI 10.1007/s00011-004-0425-7; Kuefner MA, 2004, INFLAMM RES, V53, pS31, DOI 10.1007/s00011-003-0314-5; Kuefner MA, 2002, INFLAMM RES, V51, pS87; Kufner MA, 2001, INFLAMM RES, V50, pS96; MU D, 1994, J BIOL CHEM, V269, P9926; NOVOTNY WF, 1994, J BIOL CHEM, V269, P9921; Peters GJ, 2003, CANCER CHEMOTH PHARM, V52, P1, DOI 10.1007/s00280-003-0617-9; Petersen J, 2005, INFLAMM RES, V54, pS58, DOI 10.1007/s00011-004-0426-6; Petersen J, 2002, INFLAMM RES, V51, pS91; POLLOCK I, 1991, AGENTS ACTIONS, V32, P359, DOI 10.1007/BF01980899; Preuss CV, 1998, MOL PHARMACOL, V53, P708, DOI 10.1124/mol.53.4.708; Raithel M, 1998, ANN NY ACAD SCI, V859, P258, DOI 10.1111/j.1749-6632.1998.tb11141.x; Raithel M, 1999, INFLAMM RES, V48, pS75; RAITHEL M, 1995, INT ARCH ALLERGY IMM, V108, P127, DOI 10.1159/000237129; RING J, 1983, CLIN ALLERGY, V13, P545, DOI 10.1111/j.1365-2222.1983.tb02636.x; RING J, 1979, INT ARCH ALLER A IMM, V58, P322, DOI 10.1159/000232208; RING J, 1989, ACTA DERM-VENEREOL, P70; RING J, 1991, Journal of Dermatological Science, V2, P413, DOI 10.1016/0923-1811(91)90005-I; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Santos MHS, 1996, INT J FOOD MICROBIOL, V29, P213, DOI 10.1016/0168-1605(95)00032-1; SATTLER J, 1987, AGENTS ACTIONS, V20, P270, DOI 10.1007/BF02074688; SATTLER J, 1988, AGENTS ACTIONS, V23, P361, DOI 10.1007/BF02142588; SATTLER J, 1985, AGENTS ACTIONS, V16, P91, DOI 10.1007/BF01983109; SATTLER J, 1989, AGENTS ACTIONS, V27, P212, DOI 10.1007/BF02222242; Sattler J., 1990, J NEURAL TRANSM-SUPP, V32, P291; SCHMIDT WU, 1990, AGENTS ACTIONS, V30, P267, DOI 10.1007/BF01969057; Schwelberger H G, 1995, Inflamm Res, V44 Suppl 1, pS94, DOI 10.1007/BF01674413; Schwelberger HG, 1997, BBA-PROTEIN STRUCT M, V1340, P152, DOI 10.1016/S0167-4838(97)00039-3; Schwelberger HG, 1998, INFLAMM RES, V47, pS60; Steinbrecher I, 2005, ALLERGOLOGIE, V28, P85; TUFVESSON G, 1969, J CLIN LAB INVEST, V24, P163; WANTKE F, 1994, ALLERGY PROC, V15, P27, DOI 10.2500/108854194778816599; WANTKE F, 1993, HAUTARZT, V44, P512; WANTKE F, 1993, CLIN EXP ALLERGY, V23, P982, DOI 10.1111/j.1365-2222.1993.tb00287.x; Wantke F, 2001, UROL INT, V67, P59, DOI 10.1159/000050946; Wantke F, 1996, INT ARCH ALLERGY IMM, V110, P397, DOI 10.1159/000237333; Wohrl S, 2004, ALLERGY ASTHMA PROC, V25, P305; WOLLIN A, 1983, CAN J PHYSIOL PHARM, V61, P349, DOI 10.1139/y83-053; Yan L, 2000, PHARMACOGENETICS, V10, P261, DOI 10.1097/00008571-200004000-00007; Zimatkin SM, 1999, ALCOHOL ALCOHOLISM, V34, P141, DOI 10.1093/alcalc/34.2.141; 1993, DERMATOLOGY, V183, P23	67	55	58	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1106	1112		10.1016/j.jaci.2005.11.041	http://dx.doi.org/10.1016/j.jaci.2005.11.041			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675339				2022-12-18	WOS:000237436300019
J	Lemanske, RF				Lemanske, RF			Viral infections and asthma inception	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						respiratory syncytial virus; rhinovirus; asthma; cytokine; virus	RESPIRATORY SYNCYTIAL VIRUS; INTERFERON-GAMMA PRODUCTION; CHILDHOOD ASTHMA; IFN-GAMMA; BRONCHIOLITIS; DISEASE; AGE; ASSOCIATION; INFANTS; RATS	Respiratory tract infections caused by viruses have been implicated in the pathogenesis of asthma. Of these respiratory pathogens, viruses have been demonstrated to be associated with asthma epidemiologically in at least 3 ways (Fig 1). First, during infancy, certain viruses have been implicated in the inception of the asthmatic phenotype. Genetic susceptibility, particularly genes coding for atopic phenotypic characteristics, might differentiate, at least in part, those children who are destined to have persistent wheezing, asthma, or both later in childhood. Second, repeated exposure to infectious viruses in daycare centers or in households with multiple older siblings increases the number of respiratory infections, but in doing so, it might paradoxically reduce the long-term risk of allergies and asthma through either pre-existing or newly formed alterations in cytokine response profiles. Third, in patients with established asthma, particularly children, viral upper respiratory tract infections play a significant role in producing acute exacerbations of airway obstruction that might result in frequent outpatient visits or in hospitalizations. This review will highlight available data on respiratory syncytial virus infections and their relationship to asthma inception in childhood.	Univ Wisconsin, Sch Med, Dept Pediat, Div Pediat Allergy Immunol & Rheumatol, Madison, WI USA; Univ Wisconsin, Sch Med, Dept Med, Div Pediat Allergy Immunol & Rheumatol, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Lemanske, RF (corresponding author), Univ Wisconsin Hosp, Dept Pediat, 600 Highland Ave K4-916, Madison, WI 53792 USA.	rfl@medicine.wisc.edu			NIAID NIH HHS [1P01 AI 50500] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050500] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aberle JH, 1999, AM J RESP CRIT CARE, V160, P1263, DOI 10.1164/ajrccm.160.4.9812025; Bont L, 2000, AM J RESP CRIT CARE, V161, P1518, DOI 10.1164/ajrccm.161.5.9904078; Castro-Rodriguez JA, 1999, AM J RESP CRIT CARE, V159, P1891, DOI 10.1164/ajrccm.159.6.9811035; Choi EH, 2002, J INFECT DIS, V186, P1207, DOI 10.1086/344310; Culley FJ, 2002, J EXP MED, V196, P1381, DOI 10.1084/jem.20020943; Hoebee B, 2004, J INFECT DIS, V189, P239, DOI 10.1086/380908; Hoebee B, 2003, J INFECT DIS, V187, P2, DOI 10.1086/345859; Hoffjan S, 2004, J ALLERGY CLIN IMMUN, V113, P511, DOI 10.1016/j.jaci.2003.10.044; Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023; Hull J, 2003, J INFECT DIS, V188, P904, DOI 10.1086/377587; Johnson TR, 2003, J IMMUNOL, V170, P2037, DOI 10.4049/jimmunol.170.4.2037; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Kumar A, 1997, AM J RESP CRIT CARE, V155, P130, DOI 10.1164/ajrccm.155.1.9001301; Lahti M, 2002, PEDIATR RES, V51, P696, DOI [10.1203/00006450-200206000-00006, 10.1023/01.PDR.0000015911.65104.93]; Legg JP, 2003, AM J RESP CRIT CARE, V168, P633, DOI 10.1164/rccm.200210-1148OC; Makela MJ, 2003, J ALLERGY CLIN IMMUN, V112, P861, DOI 10.1067/mai.2003.1768; Openshaw PJM, 2003, PEDIATR INFECT DIS J, V22, pS58, DOI 10.1097/00006454-200302001-00009; Renzi PM, 1999, AM J RESP CRIT CARE, V159, P1417, DOI 10.1164/ajrccm.159.5.9805080; Rosenthal LA, 2004, AM J RESP CELL MOL, V30, P702, DOI 10.1165/rcmb.2003-0181OC; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Sorkness RL, 1999, AM J RESP CRIT CARE, V160, P705, DOI 10.1164/ajrccm.160.2.9810002; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Tekkanat KK, 2001, J IMMUNOL, V166, P3542, DOI 10.4049/jimmunol.166.5.3542; van Schaik SM, 1999, J ALLERGY CLIN IMMUN, V103, P630, DOI 10.1016/S0091-6749(99)70235-6; Williams JV, 2004, NEW ENGL J MED, V350, P443, DOI 10.1056/NEJMoa025472	25	55	58	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1023	1026		10.1016/j.jaci.2004.08.031	http://dx.doi.org/10.1016/j.jaci.2004.08.031			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536404				2022-12-18	WOS:000225047800004
J	Zhang, K; Kepley, CL; Terada, T; Zhu, DC; Perez, H; Saxon, A				Zhang, K; Kepley, CL; Terada, T; Zhu, DC; Perez, H; Saxon, A			Inhibition of allergen-specific IgE reactivity by a human Ig Fc gamma-Fc epsilon bifunctional fusion protein	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; IgE; Fc epsilon RI; anaphylaxis; fusion protein; immunotherapy; degranulution; mast cells; basophils; transgenic mouse	MAST-CELLS; MULTIPLE-SCLEROSIS; DISEASE; BASOPHILS; ASTHMA	Background: Coaggregating FcepsilonRI with FcgammaRII receptors holds great potential for treatment of IgE-mediated disease by inhibiting FcepsilonRI signaling. We have previously shown that an Fcgamma-Fcepsilon fusion protein, human IgG-IgE Fc fusion protein (GE2), could inhibit FeepsilonRI-mediated mediator releases in vitro and in vivo. Objective: We sought to test whether GE2 was capable of blocking mediator release from FcepsilonRI cells sensitized with IgE in vivo or in vitro before exposure to GE2, a critical feature for GE2 to be clinically applicable. Methods: GE2 was tested for its ability to inhibit Fel d 1-induced mediator release from human blood basophils from subjects with cat allergy, human lung-derived mast cells, human FcepsilonRIalpha transgenic mice sensitized with human cat allergic serum, and rhesus; monkeys naturally allergic to the dust mite Dermatophagoides farinae. Results: Basophils from subjects with cat allergy and lung mast cells degranulate when challenged with Fel d 1 and anti-IgE, respectively. GE2 itself did not induce mediator release but strongly blocked this Fel d 1- and anti-IgE-driven mediator release. GE2 was able to block Fel d 1-driven passive cutaneous anaphylaxis at skin sites sensitized with human serum from subjects with cat allergy in human FcepsilonRIalpha transgenic mice, but by itself, GE2 did not induce a passive cutaneous anaphyiaxis reaction. Finally, GE2 markedly inhibited skin test reactivity to D farinae in monkeys naturally allergic to this allergen, with complete inhibition being observed at 125 ng. Conclusion: GE2 is able to successfully compete for FcepsilonRs and FcgammaRs on cells presensitized in vitro and in vivo and lead to inhibition of IgE-mediated reactivity through coaggregation of FcepsilonRI with FcgammaRII.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol & Allergy,Hart & Louis Lyon Lab, Los Angeles, CA 90095 USA; Univ Puerto Rico, Caribbean Primate Res Ctr, San Juan, PR 00936 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Puerto Rico; University of Puerto Rico Mayaguez	Saxon, A (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Clin Immunol Allergy, 52-175 CHS, Los Angeles, CA 90095 USA.	asaxon@mednet.ucla.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053257, P30AI028697] Funding Source: NIH RePORTER; NIAID NIH HHS [AI53257, AI11521, AI28697] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexander Clare, 2002, Current Drug Targets - Inflammation and Allergy, V1, P353, DOI 10.2174/1568010023344562; Barnes PJ, 2003, CYTOKINE GROWTH F R, V14, P511, DOI 10.1016/S1359-6101(03)00058-3; Benoist C, 2002, NATURE, V420, P875, DOI 10.1038/nature01324; BRENNER T, 1994, J NEUROL SCI, V122, P210, DOI 10.1016/0022-510X(94)90300-X; Chen RY, 2001, J CLIN INVEST, V108, P1151, DOI 10.1172/jci11494; Dombrowicz D, 1996, J IMMUNOL, V157, P1645; Dombrowicz D, 1998, IMMUNITY, V8, P517, DOI 10.1016/S1074-7613(00)80556-7; Hamelmann E, 2003, CURR OPIN ALLERGY CL, V3, P501, DOI 10.1097/01.all.0000104455.09202.52; Hussain Iftikhar, 2003, Current Drug Targets - Inflammation and Allergy, V2, P199, DOI 10.2174/1568010033484151; Kambe N, 2001, BLOOD, V97, P2045, DOI 10.1182/blood.V97.7.2045; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Kepley CL, 2003, CLIN IMMUNOL, V108, P89, DOI 10.1016/S1521-6616(03)00155-4; KEPLEY CL, 1995, J IMMUNOL, V154, P6548; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; PRESCOTT SL, 2000, CURR DRUG TARGETS IN, V1, P65; Rosenwasser LJ, 2003, J ALLERGY CLIN IMMUN, V112, P563, DOI 10.1067/mai.2003.1709; ROZNIECKI JJ, 1995, ANN NEUROL, V37, P63, DOI 10.1002/ana.410370112; Schelegle ES, 2001, AM J PATHOL, V158, P333, DOI 10.1016/S0002-9440(10)63973-9; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; Steinman L, 2001, NAT IMMUNOL, V2, P762, DOI 10.1038/ni0901-762; Yamada T, 2003, J BIOL CHEM, V278, P32818, DOI 10.1074/jbc.M304590200; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	22	55	57	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					321	327		10.1016/j.jaci.2004.03.058	http://dx.doi.org/10.1016/j.jaci.2004.03.058			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316510	Bronze			2022-12-18	WOS:000223405600017
J	Agrawal, DK; Ariyarathna, K; Kelbe, PW				Agrawal, DK; Ariyarathna, K; Kelbe, PW			(S)-albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						albuterol; asthma; bronchial smooth muscle cells; enantiomers; G-proteins; inflammation; levalbuterol; P13 kinase; pro-constriction; (S)-albuterol	PROTEIN-KINASE-B; FACTOR-KAPPA-B; RACEMIC ALBUTEROL; BETA-AGONISTS; BETA(2)-ADRENERGIC RECEPTOR; HEALTHY-VOLUNTEERS; INHALED ALBUTEROL; HUMAN EOSINOPHILS; S-SALBUTAMOL; RS-ALBUTEROL	Background: Pro-constrictory and proinflammatory properties of (S)-albuterol have been widely reported both under in vivo and in vitro conditions. However, underlying mechanisms are unclear. Objective: We examined and compared the cellular effects of albuterol enantiomers on key intracellular molecules involved in constrictory and inflammatory pathways in human bronchial smooth muscle cells (hBSMCs). Methods: Primary hBSMCs were grown in culture and treated with various concentrations of albuterol enantiomers for various periods. Methacholine was used to stimulate cells. The expression and activity of G(s) and G(i) proteins, the intracellular free calcium concentration ([Ca2+](i)), the activity of phosphatidylinositol 3'-OH-kinase (PI3) kinase, and the transcriptional nuclear factor kappaB (NF-kappaB) level were examined. Results: There was a significant increase in the expression and activity of G(ialpha-1) protein and a decrease in the expression of G(s) protein in hBSMCs after 8 hours of treatment with (S)albuterol. These effects of (S)-albuterol were observed in a dose-dependent manner. Nonreceptor-mediated activation of adenylate cyclase by forskolin was attenuated with (S)albuterol. Treatment of the cells for 24 hours with (S)-albuterol significantly increased [Ca2+](i) on stimulation with methacholine. Interestingly, the effect of (R)-albuterol was opposite to that of (S)-albuterol. The effect of the racemic albuterol in some cases was similar to that of (S)-albuterol. (S)-Albuterol significantly activated both PI3 kinase and NF-kappaB in hBSMCs. Conclusion: These studies demonstrated an (S)albuterol-induced increase in the expression and activity of pro-constrictory pathways involving G(ialpha-1) protein and [Ca2+](i) and a decrease in the activity of the bronchodilatory pathway involving G(s) proteins in hBSMCs. Additionally, (S)-albuterol activated proinflammatory pathways involving PI3 kinase and NF-kappaB. Because (S)-albuterol metabolizes at least 10-fold slower than (R)-albuterol and has a longer elimination half-life, these cellular effects of (S)-albuterol might explain the detrimental effect seen with chronic administration of racemic albuterol in the treatment of airway diseases, such as bronchial asthma.	Creighton Univ, Sch Med, Ctr Allergy Asthma & Immunol, Omaha, NE 68178 USA; Sepracor Inc, Marlborough, MA USA	Creighton University; Dainippon Sumitomo Pharmaceutical Company; Sunovion Pharmaceuticals Inc.	Agrawal, DK (corresponding author), Creighton Univ, Sch Med, Ctr Allergy Asthma & Immunol, CRISS I Room 131,2500 Calif Plaza, Omaha, NE 68178 USA.		Agrawal, Devendra/GLR-3925-2022	Agrawal, Devendra/0000-0001-5445-0013				AGRAWAL DK, 2000, AM J RESP CRIT CARE, V161, pA191; Ahrens R, 2001, J ALLERGY CLIN IMMUN, V108, P681; Arcaro A, 1998, J BIOL CHEM, V273, P33082, DOI 10.1074/jbc.273.49.33082; Baramki D, 2002, J ALLERGY CLIN IMMUN, V109, P449, DOI 10.1067/mai.2002.122159; Barnes PJ, 1997, INT J BIOCHEM CELL B, V29, P867, DOI 10.1016/S1357-2725(96)00159-8; Billington CK, 1999, AM J RESP CELL MOL, V21, P597, DOI 10.1165/ajrcmb.21.5.3759; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; Cho SH, 2001, INT ARCH ALLERGY IMM, V124, P478, DOI 10.1159/000053783; COCKCROFT DW, 1995, J ALLERGY CLIN IMMUN, V96, P44, DOI 10.1016/S0091-6749(95)70031-5; Cockcroft DW, 1996, THORAX, V51, P1051, DOI 10.1136/thx.51.10.1051; Coffer PJ, 1998, BLOOD, V91, P2547, DOI 10.1182/blood.V91.7.2547.2547_2547_2557; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Dhand R, 1999, AM J RESP CRIT CARE, V160, P1136, DOI 10.1164/ajrccm.160.4.9812074; Dutta EJ, 2002, MED CLIN N AM, V86, P991, DOI 10.1016/S0025-7125(02)00031-7; Frieri M, 2000, J ALLERGY CLIN IMMUN, V105, pS292, DOI 10.1016/S0091-6749(00)91286-7; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gumbhir-Shah K, 1998, J CLIN PHARMACOL, V38, P1096; Handley D, 1999, J ALLERGY CLIN IMMUN, V104, pS69, DOI 10.1016/S0091-6749(99)70276-9; Handley D A, 2000, Curr Opin Pulm Med, V6, P43, DOI 10.1097/00063198-200001000-00009; HOSHIKO K, 1993, JPN J PHARMACOL, V63, P159, DOI 10.1254/jjp.63.159; Johansson F, 1996, CLIN REV ALLERG IMMU, V14, P57, DOI 10.1007/BF02772203; Johnson M, 1998, AM J RESP CRIT CARE, V158, pS146, DOI 10.1164/ajrccm.158.supplement_2.13tac110; Jouriles NJ, 2002, ACAD EMERG MED, V9, P1338, DOI 10.1111/j.1553-2712.2002.tb01598.x; Leff AR, 1997, PULM PHARMACOL THER, V10, P97, DOI 10.1006/pupt.1997.0082; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Lotvall J, 2001, J ALLERGY CLIN IMMUN, V108, P726; MAZZONI L, 1994, PULM PHARMACOL, V7, P367, DOI 10.1006/pulp.1994.1043; McGraw DW, 1997, J BIOL CHEM, V272, P7338, DOI 10.1074/jbc.272.11.7338; Milgrom H, 2001, J ALLERGY CLIN IMMUN, V108, P938, DOI 10.1067/mai.2001.120134; Milligan G, 1997, TRENDS PHARMACOL SCI, V18, P468, DOI 10.1016/S0165-6147(97)90685-4; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Mitra S, 1998, MOL PHARMACOL, V53, P347, DOI 10.1124/mol.53.3.347; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V102, P943, DOI 10.1016/S0091-6749(98)70332-X; NELSON HS, 1995, NEW ENGL J MED, V333, P499, DOI 10.1056/NEJM199508243330807; Penn RB, 1996, CLIN REV ALLERG IMMU, V14, P37, DOI 10.1007/BF02772201; PerrinFayolle M, 1996, CLIN REV ALLERG IMMU, V14, P139, DOI 10.1007/BF02772208; Prasad SVN, 2001, J BIOL CHEM, V276, P18953, DOI 10.1074/jbc.M102376200; Ramsay CM, 1999, EUR J CLIN PHARMACOL, V55, P353, DOI 10.1007/s002280050640; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Schmekel B, 1999, EUR RESPIR J, V13, P1230, DOI 10.1034/j.1399-3003.1999.13f04.x; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; Templeton AGB, 1998, PULM PHARMACOL THER, V11, P1, DOI 10.1006/pupt.1998.0110; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Truitt T, 2003, CHEST, V123, P128, DOI 10.1378/chest.123.1.128; Volcheck GW, 1998, J ALLERGY CLIN IMMUN, V101, pS35; Yamaguchi H, 1996, CLIN REV ALLERG IMMU, V14, P47, DOI 10.1007/BF02772202; Yu JH, 1998, J BIOL CHEM, V273, P30199, DOI 10.1074/jbc.273.46.30199; ZHANG X, 1998, AM J PHYSIOL, V74, pL32	50	55	56	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					503	510		10.1016/j.jaci.2003.12.039	http://dx.doi.org/10.1016/j.jaci.2003.12.039			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007354				2022-12-18	WOS:000220144200024
J	Depta, JPH; Altznauer, F; Gamerdinger, K; Burkhart, C; Weltzien, HU; Pichler, WJ				Depta, JPH; Altznauer, F; Gamerdinger, K; Burkhart, C; Weltzien, HU; Pichler, WJ			Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T-cell receptor; drug-reactive T cells; drug-hypersensitivity; cross-reactivity; sulfonamides	RECOGNITION; CLONES; SULFAMETHOXAZOLE; ACTIVATION; HYBRIDOMA; NICKEL; TCR; LIDOCAINE; PEPTIDE; CHAIN	Background: Immune-mediated adverse reactions to drugs are often due to T-cell reactivity, and cross-reactivity is an important problem in pharmacotherapy. Objective: We investigated whether chemical inert drugs can stimulate T cells through their T-cell receptor (TCR) and analyzed the cross-reactivities to related compounds. Methods: We transfected human TCRs isolated from two drug-reactive T-cell clones (TCCs) by PCR into a TCR-negative mouse T-cell hybridoma. The TCCs were isolated from a patient with drug hypersensitivity to the antibacterial sulfonamide sulfamethoxazole (SMX). Results: The transfectants; reacted to SMX only in the presence of antigen-presenting cells (APCs). Glutaraldehyde-fixed APCs, however, were sufficient to elicit T-cell stimulation, indicating a processing-independent direct interaction of the drug with the TCR and MHC molecule. The transfected hybridomas secreted IL-2 in a drug dose-dependent manner, whereas the degree of reactivity was dependent on the level of TCR expression. One transfectant reacted not only to SMX but also to related sulfonamide compounds. Interestingly, high TCR expression increased cross-reactivity to other structurally related compounds. In addition, SMX-specific TCR cross-reacted only with sulfonamides bearing a sulfanilamide core structure but not with sulfonamides such as celecoxib, furosemide, or glibenclamide. Conclusions: These results demonstrate that the T-cell reactivity to drugs is solely determined by the TCR. Moreover,. these results show that cross-reactivity of structurally similar compounds correlates with the density of the TCR. Stably transfected T-cell hybridomas may represent a powerful screening tool for cross-reactivity of newly generated sulfonamide-containing compounds such as celecoxib.	Univ Bern, Inselspital, Div Allergol, Clin Rheumatol & Clin Immunol Allergol, CH-3010 Bern, Switzerland; Max Planck Inst Immunobiol, D-7800 Freiburg, Germany	University of Bern; University Hospital of Bern; Max Planck Society	Pichler, WJ (corresponding author), Univ Bern, Inselspital, Div Allergol, Clin Rheumatol & Clin Immunol Allergol, CH-3010 Bern, Switzerland.			Pichler, Werner J./0000-0002-8117-359X				Altznauer F, 2003, J ALLERGY CLIN IMMUN, V112, P1185, DOI 10.1016/j.jaci.2003.09.045; BLANK U, 1993, EUR J IMMUNOL, V23, P3057, DOI 10.1002/eji.1830231203; Britschgi M, 2001, J CLIN INVEST, V107, P1433, DOI 10.1172/JCI12118; Burkhart C., 2002, Clinical and Experimental Allergy, V32, P1635, DOI 10.1046/j.1365-2222.2002.01513.x; CASORATI G, 1993, EUR J IMMUNOL, V23, P586, DOI 10.1002/eji.1830230246; Depta JPH, 2003, CURR OPIN ALLERGY CL, V3, P261, DOI 10.1097/01.all.0000083951.99396.30; FERNANDEZ M, 1995, EUR J IMMUNOL, V25, P2486, DOI 10.1002/eji.1830250912; Gamerdinger K, 2003, J EXP MED, V197, P1345, DOI 10.1084/jem.20030121; GENEVEE C, 1992, EUR J IMMUNOL, V22, P1261, DOI 10.1002/eji.1830220522; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GRABSTEIN K, 1986, J EXP MED, V163, P1405, DOI 10.1084/jem.163.6.1405; Kim DT, 1996, J IMMUNOL, V156, P2737; Landsteiner K, 1935, J EXP MED, V61, P643, DOI 10.1084/jem.61.5.643; Lefranc MP, 2001, T CELL RECEPTOR FACT; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1989, EUR J IMMUNOL, V19, P2269, DOI 10.1002/eji.1830191214; Pichler WJ, 2002, CURR OPIN ALLERGY CL, V2, P301, DOI 10.1097/00130832-200208000-00003; SCHNEIDER CH, 1966, HELV CHIM ACTA, V49, P1695, DOI 10.1002/hlca.19660490532; Schnyder B, 1997, J CLIN INVEST, V100, P136, DOI 10.1172/JCI119505; Schnyder B, 2000, J IMMUNOL, V164, P6647, DOI 10.4049/jimmunol.164.12.6647; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Vollmer J, 1999, J IMMUNOL, V163, P2723; Vollmer J, 1999, J INVEST DERMATOL, V113, P175, DOI 10.1046/j.1523-1747.1999.00646.x; von Greyerz S, 1999, J IMMUNOL, V162, P595; von Greyerz S, 2001, INT IMMUNOL, V13, P877, DOI 10.1093/intimm/13.7.877; von Greyerz S, 1999, INT ARCH ALLERGY IMM, V119, P173, DOI 10.1159/000024192; WEI S, 1994, IMMUNOGENETICS, V40, P27, DOI 10.1007/BF00163961; Whitehurst CE, 1996, J IMMUNOL, V156, P1020; Zanni MP, 1998, J CLIN INVEST, V102, P1591, DOI 10.1172/JCI3544; Zanni MP, 1999, J INVEST DERMATOL, V112, P197, DOI 10.1046/j.1523-1747.1999.00484.x; Zanni MP, 1997, J IMMUNOL, V158, P1139; Zanni MP, 1998, INT IMMUNOL, V10, P507, DOI 10.1093/intimm/10.4.507; Zhao Z., 2002, Clinical and Experimental Allergy, V32, P1644, DOI 10.1046/j.1365-2222.2002.01492.x	33	55	58	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					519	527		10.1016/j.jaci.2003.11.030	http://dx.doi.org/10.1016/j.jaci.2003.11.030			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007356				2022-12-18	WOS:000220144200026
J	Nakano, Y; Morita, S; Kawamoto, A; Suda, T; Chida, K; Nakamura, H				Nakano, Y; Morita, S; Kawamoto, A; Suda, T; Chida, K; Nakamura, H			Elevated complement C3a in plasma from patients with severe acute asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; innate immunity; complement; C3a; eosinophil cationic protein	BRONCHOALVEOLAR LAVAGE FLUID; ANAPHYLATOXIN C3A; PROTEIN-LEVELS; C5A; INFLAMMATION; EXACERBATION; EOSINOPHILS; LYMPHOCYTES; RECEPTOR; SPUTUM	Background: Complement component C3a, an anaphylatoxin, provokes acute inflammatory responses, including smooth muscle contraction, mucus hypersecretion, increase in vascular permeability, and recruitment of inflammatory cells. Thus C3a may be related to airway inflammation and bronchoconstriction in acute asthma exacerbation. Objective: We sought to determine whether plasma C3a is elevated in patients presenting for emergency treatment of acute asthma exacerbations and to correlate C3a concentrations with response to therapy. Methods: Plasma C3a and serum eosinophil cationic protein were measured in 52 patients with acute asthma with peak expiratory flow of: less than or equal to50% the predicted value. Control subjects were 42 patients with stable chronic asthma. Patients with severe acute asthma were classified into 2 groups (admitted and discharged), according to how effective inhaled bronchodilators and systemic corticosteroids were in the first 2 hours of treatment. Results: Concentrations of C3a in plasma from subjects in the admitted group (median, 256 ng/mL; range, 94 to 454) were significantly higher than those in the discharged group (197 ng/mL; 72 to 300) or those in patients with stable chronic asthma (166 ng/mL; 89 to 254; P < .0001). Elevated plasma C3a concentrations in admitted asthmatic patients decreased significantly by 7 days after admission (P = .0005). No significant difference was evident in serum eosinophil cationic protein concentration between the admitted group (33.1 mug/L; 6.3 to 143) and the discharged group (32.7 mug/L; 14.6 to 160; P = .99). Conclusions: Concentrations of C3a, which can induce airway inflammation and bronchoconstriction, were associated with differences in response to emergency treatment of severe asthma exacerbation.	Hamamatsu Rosai Hosp, Dept Internal Med, Hamamatsu, Shizuoka, Japan; Hamamatsu Univ Sch Med, Dept Internal Med 2, Hamamatsu, Shizuoka 43131, Japan	Hamamatsu University School of Medicine	Nakano, Y (corresponding author), Seirei Mikatabara Hosp, 3453 Mikatabara Cho, Hamamatsu, Shizuoka 4338558, Japan.							*AM THOR SOC, 1987, AM REV RESPIR DIS, V136, P1202; Atmar RL, 1998, ARCH INTERN MED, V158, P2453, DOI 10.1001/archinte.158.22.2453; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; Clark HW, 2000, MICROBES INFECT, V2, P273, DOI 10.1016/S1286-4579(00)00301-4; COOPER NR, 1999, INFLAMMATION BASIC P, P281; de la Fuente PT, 1998, AM J RESP CRIT CARE, V157, P1127, DOI 10.1164/ajrccm.157.4.9610008; Di Lorenzo G, 2002, INT ARCH ALLERGY IMM, V127, P308, DOI 10.1159/000057748; DRAZEN JM, 1992, AM REV RESPIR DIS, V146, P104, DOI 10.1164/ajrccm/146.1.104; Drouin SM, 2001, J IMMUNOL, V166, P2025, DOI 10.4049/jimmunol.166.3.2025; EMBER JA, 1998, HUMAN COMPLEMENT SYS, P241; FLEISS JL, 1980, BIOMETRICS, V36, P343, DOI 10.2307/2529990; GERARD NP, 1997, ASTHMA, P639; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; Jousilahti P, 2002, ANN ALLERG ASTHMA IM, V89, P381, DOI 10.1016/S1081-1206(10)62039-X; Krug N, 2001, AM J RESP CRIT CARE, V164, P1841, DOI 10.1164/ajrccm.164.10.2010096; Lee MH, 1997, ANN ALLERG ASTHMA IM, V79, P363, DOI 10.1016/S1081-1206(10)63029-3; Lilly CM, 1999, J ALLERGY CLIN IMMUN, V104, P786, DOI 10.1016/S0091-6749(99)70288-5; Martin U, 1997, J EXP MED, V186, P199, DOI 10.1084/jem.186.2.199; MOUSLI M, 1992, J IMMUNOL, V148, P2456; Nakano Y, 2003, ANN ALLERG ASTHMA IM, V90, P331, DOI 10.1016/S1081-1206(10)61802-9; National cholesterol education program National heart lung and blood institute National institutes of health, 2002, 3 REP NAT CHOL ED PR; Onodera H, 1991, Arerugi, V40, P1272; Oshikawa K, 2001, AM J RESP CRIT CARE, V164, P277, DOI 10.1164/ajrccm.164.2.2008120; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Rodrigo G, 1998, CHEST, V114, P1016, DOI 10.1378/chest.114.4.1016; TAKAFUJI S, 1994, INT ARCH ALLERGY IMM, V104, P27, DOI 10.1159/000236743; Teran LM, 1997, CLIN EXP ALLERGY, V27, P396; TSUKIOKA K, 1996, ARERUGI, V45, P4442	28	55	56	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					525	530		10.1067/mai.2003.1710	http://dx.doi.org/10.1067/mai.2003.1710			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679811				2022-12-18	WOS:000185231200011
J	Groneberg, DA; Welker, P; Fischer, TC; Dinh, QT; Grutzkau, A; Peiser, C; Wahn, U; Henz, BM; Fischer, A				Groneberg, DA; Welker, P; Fischer, TC; Dinh, QT; Grutzkau, A; Peiser, C; Wahn, U; Henz, BM; Fischer, A			Downregulation of vasoactive intestinal polypeptide receptor expression in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; atopic dermatitis; VIP; neuropeptide; cytokine receptors	CYCLASE-ACTIVATING POLYPEPTIDE; MAST-CELLS; MESSENGER-RNA; HUMAN SKIN; FUNCTIONAL-CHARACTERIZATION; PEPTIDE RECEPTOR; VIP; INFLAMMATION; KERATINOCYTE; LOCALIZATION	Background: Receptors for vasoactive intestinal polypeptide (VIP) have recently been suggested to play a key role in immunomodulation with genetically modified mice. However, it is not known whether changes in receptor gene regulation are involved in the pathogenesis of human immune disorders. Objective: We studied the expression of VPAC(2) in acute lesions of the human immune disease atopic dermatitis. Methods: By using nonradioactive in situ hybridization, quantitative inummohistochemistry, RT-PCR, and gene array studies, the expression status of VPAC(2) was assessed in atopic dermatitis and control tissues and in the human mast cell line HMC-1. Results: In situ hybridization and inummohistochemistry demonstrated VPAC2 mRNA and protein expression in human mast cells surrounded by VIP positive nerve fibers. Gene array experiments and RT-PCR studies showed high levels of VPAC2, mRNA expression in mast cells that were increased compared to other receptors such as VPAC(1) or VIP in the human mast cell line HMC-1. Stimulation of HMC-1 cells led to a downregulation of VPAC(2). Similarly, quantitative inummohistochemistry for VPAC(2) in acute atopic dermatitis lesions showed a significantly decreased VPAC(2) immunoreactivity in mast cells. Conclusion: The downregulation of VPAC(2) in human mast cells in acute lesions of atopic dermatitis suggests a role of this G-protein-coupled receptor in the pathophysioIogy of the disease.	Humboldt Univ, Charite Sch Med, Dept Pediat Pneumol & Immunol, Clin Res Unit Allergol, D-13353 Berlin, Germany; Humboldt Univ, Charite Sch Med, Dept Dermatol, D-13353 Berlin, Germany; Humboldt Univ, Charite Sch Med, Inst Anat, D-13353 Berlin, Germany; Humboldt Univ, Charite Sch Med, Dept Med, D-13353 Berlin, Germany; Res Ctr, Dept Med, Borstel, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Forschungszentrum Borstel	Fischer, A (corresponding author), Humboldt Univ, Charite Sch Med, Dept Pediat Pneumol & Immunol, Clin Res Unit Allergol, Augustenburger Pl 1, D-13353 Berlin, Germany.		Groneberg, David/A-5132-2018	Groneberg, David/0000-0001-8551-6556; Peiser, Christian/0000-0003-1230-8697				Bauer O, 2000, NEWS PHYSIOL SCI, V15, P213, DOI 10.1152/physiologyonline.2000.15.5.213; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; CUTZ E, 1978, NATURE, V275, P661, DOI 10.1038/275661a0; Damsgaard TE, 1997, ARCH DERMATOL RES, V289, P256, DOI 10.1007/s004030050189; Delgado M, 2001, NAT MED, V7, P563, DOI 10.1038/87887; Dickinson T, 1999, TRENDS PHARMACOL SCI, V20, P324, DOI 10.1016/S0165-6147(99)01340-1; Ermert L, 2000, AM J PATHOL, V156, P1275, DOI 10.1016/S0002-9440(10)64998-X; Fischer A, 1996, J CLIN INVEST, V98, P2284, DOI 10.1172/JCI119039; Fischer TC, 2002, J CUTAN PATHOL, V29, P65, DOI 10.1034/j.1600-0560.2002.290201.x; Fischer TC, 2001, J INVEST DERMATOL, V117, P754, DOI 10.1046/j.0022-202x.2001.01449.x; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; Goetzl EJ, 2001, P NATL ACAD SCI USA, V98, P13854, DOI 10.1073/pnas.241503798; GOZES I, 1989, MOL NEUROBIOL, V3, P201, DOI 10.1007/BF02740606; Grabbe J, 1996, J INVEST DERMATOL, V107, P419, DOI 10.1111/1523-1747.ep12363402; Granoth R, 2000, FEBS LETT, V475, P71, DOI 10.1016/S0014-5793(00)01629-X; Groneberg DA, 2001, LAB INVEST, V81, P749, DOI 10.1038/labinvest.3780283; Groneberg DA, 2001, AM J PATHOL, V158, P707, DOI 10.1016/S0002-9440(10)64013-8; Grutzkau A, 2000, BIOCHEM BIOPH RES CO, V278, P14, DOI 10.1006/bbrc.2000.3764; INAGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679, DOI 10.1073/pnas.91.7.2679; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; Kakurai M, 2001, J INVEST DERMATOL, V116, P743, DOI 10.1046/j.1523-1747.2001.01306.x; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; LEWIS RA, 1981, NATURE, V293, P103, DOI 10.1038/293103a0; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; NAKAZAWA M, 1989, BLOOD, V73, P2003; PINCELLI C, 1990, BRIT J DERMATOL, V122, P745, DOI 10.1111/j.1365-2133.1990.tb06261.x; PINCELLI C, 1991, ARCH DERMATOL RES, V283, P230, DOI 10.1007/BF01106107; Raouf A, 2002, BONE, V30, P463, DOI 10.1016/S8756-3282(01)00699-8; RUDZKI E, 1991, ALLERGY, V46, P125, DOI 10.1111/j.1398-9995.1991.tb00555.x; Rukwied R, 2000, BRIT J DERMATOL, V142, P1114, DOI 10.1046/j.1365-2133.2000.03535.x; Said S I, 1970, Nature, V225, P863, DOI 10.1038/225863a0; SREEDHARAN SP, 1995, P NATL ACAD SCI USA, V92, P2939, DOI 10.1073/pnas.92.7.2939; SVOBODA M, 1994, BIOCHEM BIOPH RES CO, V205, P1617, DOI 10.1006/bbrc.1994.2852; Trautmann A, 2001, J ALLERGY CLIN IMMUN, V108, P839, DOI 10.1067/mai.2001.118796; USDIN TB, 1994, ENDOCRINOLOGY, V135, P2662, DOI 10.1210/en.135.6.2662; Voice JK, 2001, FASEB J, V15, P2489, DOI 10.1096/fj.01-0671com; WALLENGREN J, 1986, ACTA DERM-VENEREOL, V66, P23; Wei Y, 1996, J NEUROENDOCRINOL, V8, P811, DOI 10.1046/j.1365-2826.1996.05191.x; Welker P, 2000, IMMUNOLOGY, V99, P418, DOI 10.1046/j.1365-2567.2000.00984.x	40	55	58	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1099	1105		10.1067/mai.2003.1477	http://dx.doi.org/10.1067/mai.2003.1477			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743576				2022-12-18	WOS:000182904500026
J	Linneberg, A; Nielsen, NH; Menne, T; Madsen, F; Jorgensen, T				Linneberg, A; Nielsen, NH; Menne, T; Madsen, F; Jorgensen, T			Smoking might be a risk factor for contact allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic contact dermatitis; contact allergy; delayed hypersensitivity; nickel; patch tests; smoking; tobacco	UNSELECTED DANISH POPULATION; GLOSTRUP ALLERGY; EUROPEAN MULTICENTER; TRUE TEST; SENSITIZATION; DENMARK; DERMATITIS	Background: Contact allergy is a major public health problem in industrialized countries. Hitherto, known risk factors for contact allergy have mainly included increased exposure to allergens. There are no published data on the relation between smoking and contact allergy. Objective: To investigate the association between smoking and contact allergy. Methods: The study population comprised a cross-sectional, general population-based sample of 15- to 69-year-old persons living in Copenhagen, Denmark. A total of 1056 persons (73.6% of the invited) were given a patch test (TRUE test). Contact allergy was defined as a positive patch test result to at least I of 23 allergens. Nickel contact allergy was defined as a positive patch test reaction to nickel. Allergic nickel contact dermatitis was defined as a history of eczema on exposure to metallic objects and a positive patch test reaction to nickel. A detailed smoking history was obtained in a questionnaire. Results: Contact allergy (adjusted odds ratio, 1.8; 95% CI, 1.2 to 2-9), nickel contact allergy (adjusted odds ratio, 2.7; 95% Cl, 1.4 to 5.2), and allergic nickel contact dermatitis (adjusted odds ratio, 3.0, 95% CI, 1.5 to 6.2) were significantly associated with a smoking history of more than 15 pack-years. Moreover, these associations showed a significant dose-response relation, and they were independent of sex, age, and exposure to nickel, as reflected by a history of ear piercing. Conclusions: These data raise the hypothesis that smoking increases the risk of contact allergy. Further epidemiologic studies and investigations into the possible mechanisms are warranted.	Glostrup Univ Hosp, Ctr Prevent Med, DK-2600 Glostrup, Denmark; Univ Copenhagen, Gentofte Hosp, Dept Dermatol, Copenhagen, Denmark; Frederiksberg Univ Hosp, Dept Internal Med B, DK-2000 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital	Linneberg, A (corresponding author), Glostrup Univ Hosp, Ctr Prevent Med, 57 Nor Ringvej Entrance 8,7th Floor, DK-2600 Glostrup, Denmark.		Jørgensen, Torben/Z-1335-2018	Linneberg, Allan/0000-0002-0994-0184; Jorgensen, Torben/0000-0001-9453-2830; Madsen, Flemming/0000-0002-9911-0175				Agner T, 2002, CONTACT DERMATITIS, V47, P21, DOI 10.1034/j.1600-0536.2002.470105.x; Berndt U, 2000, CONTACT DERMATITIS, V43, P327, DOI 10.1034/j.1600-0536.2000.043006327.x; EDMAN B, 1988, ACTA DERM-VENEREOL, V68, P402; KREILGARD B, 1989, CONTACT DERMATITIS, V21, P23, DOI 10.1111/j.1600-0536.1989.tb04680.x; LACHAPELLE JM, 1988, CONTACT DERMATITIS, V19, P91, DOI 10.1111/j.1600-0536.1988.tb05504.x; Leow YH, 1998, CLIN DERMATOL, V16, P579, DOI 10.1016/S0738-081X(98)00042-X; NIELSEN NH, 1993, CONTACT DERMATITIS, V29, P16; NIELSEN NH, 1992, ACTA DERM-VENEREOL, V72, P456; Nielsen NH, 1996, BRIT J DERMATOL, V134, P669, DOI 10.1111/j.1365-2133.1996.tb06967.x; NIELSEN NH, 1993, ALLERGY, V48, P319, DOI 10.1111/j.1398-9995.1993.tb02400.x; Nielsen NH, 2001, ACTA DERM-VENEREOL, V81, P31, DOI 10.1080/000155501750208155; Schafer T, 2001, ALLERGY, V56, P1192, DOI 10.1034/j.1398-9995.2001.00086.x; Schnuch A, 1997, CONTACT DERMATITIS, V37, P200, DOI 10.1111/j.1600-0536.1997.tb02435.x; SHEHADE S A, 1991, Contact Dermatitis, V24, P119, DOI 10.1111/j.1600-0536.1991.tb01663.x; Sigurgeirsson B, 1991, AM J CONTACT DERMATI, V2, P235; Sopori ML, 1998, J NEUROIMMUNOL, V83, P148, DOI 10.1016/S0165-5728(97)00231-2; Sprince NL, 1996, AM J IND MED, V30, P421, DOI 10.1002/(SICI)1097-0274(199610)30:4<421::AID-AJIM7>3.0.CO;2-Y; WILKINSON DS, 1970, ACTA DERM-VENEREOL, V50, P287; WILKINSON JD, 1990, CONTACT DERMATITIS, V22, P218, DOI 10.1111/j.1600-0536.1990.tb01570.x	19	55	56	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					980	984		10.1067/mai.2003.1394	http://dx.doi.org/10.1067/mai.2003.1394			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743561				2022-12-18	WOS:000182904500011
J	Leduc, V; Moneret-Vautrin, DA; Guerin, L; Morisset, M; Kanny, G				Leduc, V; Moneret-Vautrin, DA; Guerin, L; Morisset, M; Kanny, G			Anaphylaxis to wheat isolates: Immunochemical study of a case proved by means of double-blind, placebo-controlled food challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FUNCTIONAL-PROPERTIES; DEAMIDATION; PROTEINS; GLUTEN		Lab Allerbio, Varennes En Argonne, France; Hop Cent, Serv Allergol, F-54035 Nancy, France	CHU de Nancy	Leduc, V (corresponding author), Lab Allerbio, Varennes En Argonne, France.		Kanny, Gisèle/AHA-8910-2022; Morisset, Martine/A-3084-2017	Morisset, Martine/0000-0002-4028-703X				BOLLECKER S, 1990, SCI ALIMENT, V10, P343; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; Davis PJ, 2001, ALLERGY, V56, P56, DOI 10.1034/j.1398-9995.2001.00918.x; Hefle S L, 1999, Adv Exp Med Biol, V459, P107; Hefle SL, 2001, CURR OPIN ALLERGY CL, V1, P269, DOI 10.1097/00130832-200106000-00012; KATO A, 1987, J AGR FOOD CHEM, V35, P285, DOI 10.1021/jf00074a029; Marchal R, 2002, J AGR FOOD CHEM, V50, P177, DOI 10.1021/jf0105539; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Moneret-Vautrin DA, 1999, J ALLERGY CLIN IMMUN, V104, P883, DOI 10.1016/S0091-6749(99)70303-9; Moneret-Vautrin DA, 2001, B ACAD NAT MED PARIS, V185, P943, DOI 10.1016/S0001-4079(19)34505-4; Pecquet C, 2002, CONTACT DERMATITIS, V46, P123, DOI 10.1034/j.1600-0536.2002.460220.x; van de Wal Y, 1998, J IMMUNOL, V161, P1585; WU CH, 1976, J AGR FOOD CHEM, V24, P504, DOI 10.1021/jf60205a057	13	55	55	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					897	899		10.1067/mai.2003.1345	http://dx.doi.org/10.1067/mai.2003.1345			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704375				2022-12-18	WOS:000182258500035
J	Smart, JM; Horak, E; Kemp, AS; Robertson, CF; Tang, MLK				Smart, JM; Horak, E; Kemp, AS; Robertson, CF; Tang, MLK			Polyclonal and allergen-induced cytokine responses in adults with asthma: Resolution of asthma is associated with normalization of IFN-gamma responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokines; adult asthma; IFN-gamma; IL-4; IL-5; IL-13; allergens; mitogen; house dust mite	BLOOD MONONUCLEAR-CELLS; REDUCED INTERFERON-GAMMA; NATURAL-HISTORY; GENE-EXPRESSION; CPG OLIGODEOXYNUCLEOTIDES; ATOPIC-DERMATITIS; CHILDHOOD ASTHMA; MESSENGER-RNA; CHILDREN; INTERLEUKIN-4	Background: Atopic disease is associated with skewing of immune responses away from a T(H)1 toward a T(H)2 profile. Previous studies have implicated this cytokine imbalance in the development of disease. However, it is not known whether normalization of this imbalance is conversely associated with disease resolution. Objective: To further delineate the role of reduced T(H)1 and increased T(H)2 cytokine production in the pathogenesis of atopic disease and to determine whether disease resolution is associated with alteration of cytokine profiles, we investigated cytokine responses in a cohort of adult patients with asthma followed from childhood. Methods: A cohort of wheezy children and control subjects aged 7 to 10 years were recruited from 1964 to 1967. Subjects were reevaluated every 7 years to monitor the outcome of childhood asthma. At the 42-year follow-up, 89 subjects from this cohort were evaluated for mitogen and house dust mite (HDM)-induced T(H)1 (IFN-gamma) and T(H)2 (IL-4, IL-5, and IL-13) cytokine responses. Cytokine responses were compared in patients with ongoing asthma, patients with resolved asthma, and control subjects. Results: Patients with severe ongoing asthma had significantly reduced HDM-induced IFN-gamma production compared with that of control subjects and patients with resolved asthma. In contrast, HDM-induced IFN-gamma production in patients with resolved asthma was equivalent to that seen in control subjects. Patients with ongoing and resolved asthma produced significantly higher levels of IL-5 in response to HDM compared with that seen in control subjects, with levels being equivalent in patients with active and resolved asthma. HDM-induced IL-13 production was significantly increased in the patients with resolved asthma when compared with that seen in the control subjects. PHA-induced cytokine responses did not parallel HDM-induced responses. Conclusion: Patients with persistent and severe atopic asthma have a reduced HDM-induced T(H)1 response, whereas those with resolved asthma do not. This suggests that reduced HDM-induced IFN-gamma production might be an important factor contributing to ongoing severe asthma and that normalization of allergen-induced Till responses might be important for disease resolution. The finding that all subjects with a history of asthma displayed increased HDM-induced T(H)2 (IL-5 and IL-43) cytokine responses, irrespective of the presence or absence of asthma, suggests that increased T(H)2 responses reflect the presence of the atopic state per se rather than being specifically linked to asthma.	Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Immunol, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Resp Med, Parkville, Vic 3052, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Tang, MLK (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Immunol, Flemington Rd, Parkville, Vic 3052, Australia.			Tang, Mimi/0000-0002-3839-5293				ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BHALLA R, 1982, SERUM IGE LEVELS NE; Braun CM, 1997, J ALLERGY CLIN IMMUN, V100, P400, DOI 10.1016/S0091-6749(97)70255-0; BRONNIMANN S, 1986, CHEST, V90, P480, DOI 10.1378/chest.90.4.480; BYRON KA, 1992, IMMUNOLOGY, V77, P624; CESARIO TC, 1986, J INTERFERON RES, V6, P337, DOI 10.1089/jir.1986.6.337; Chang JH, 1996, J ALLERGY CLIN IMMUN, V98, P922, DOI 10.1016/S0091-6749(96)80008-X; Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623; COOPER DM, 1977, CHEST, V71, P361, DOI 10.1378/chest.71.3.361; CORRIGAN CJ, 1995, AM J RESP CELL MOL, V12, P567, DOI 10.1165/ajrcmb.12.5.7742019; Crocker IC, 1998, ANN ALLERG ASTHMA IM, V80, P509, DOI 10.1016/S1081-1206(10)63075-X; DOI S, 1994, CLIN EXP ALLERGY, V24, P854, DOI 10.1111/j.1365-2222.1994.tb01808.x; FERGUSON AC, 1988, J ALLERGY CLIN IMMUN, V82, P19, DOI 10.1016/0091-6749(88)90045-0; FRIBERG S, 1989, J ALLERGY CLIN IMMUN, V84, P183, DOI 10.1016/0091-6749(89)90323-0; Fushimi T, 1998, TOHOKU J EXP MED, V185, P157, DOI 10.1620/tjem.185.157; Gabrielsson S, 1998, SCAND J IMMUNOL, V48, P429; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Leonard C, 1997, AM J RESP CELL MOL, V17, P368, DOI 10.1165/ajrcmb.17.3.2797; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; Li Y, 1998, J IMMUNOL, V161, P7007; Mackie AE, 2000, CLIN PHARMACOKINET, V39, P23, DOI 10.2165/00003088-200039001-00004; MAZON A, 1994, ANN ALLERGY, V72, P455; NOMA T, 1995, PEDIATR RES, V38, P187, DOI 10.1203/00006450-199508000-00009; Nurse B, 1997, J ALLERGY CLIN IMMUN, V100, P662, DOI 10.1016/S0091-6749(97)70171-4; OKAYAMA H, 1994, J ALLERGY CLIN IMMUN, V93, P1006, DOI 10.1016/S0091-6749(94)70049-4; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P39; RADFORD PJ, 1992, CHEST, V101, P624, DOI 10.1378/chest.101.3.624; REINHOLD U, 1991, CLIN EXP IMMUNOL, V86, P444; Robertson CF, 1998, MED J AUSTRALIA, V168, P434, DOI 10.5694/j.1326-5377.1998.tb139022.x; Rowland TL, 1998, IMMUNOPHARMACOLOGY, V40, P11, DOI 10.1016/S0162-3109(98)00010-1; Smart JM, 2002, CLIN EXP ALLERGY, V32, P796, DOI 10.1046/j.1365-2222.2002.01391.x; Smart JM, 2001, PEDIATR ALLERGY IMMU, V12, P181, DOI 10.1034/j.1399-3038.2001.012004181.x; STEWART GA, 1987, INT ARCH ALLER A IMM, V83, P384, DOI 10.1159/000234373; Sur S, 1999, J IMMUNOL, V162, P6284; Tang CB, 1996, AM J RESP CRIT CARE, V154, P1615, DOI 10.1164/ajrccm.154.6.8970344; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; TANG MLK, 1995, CLIN EXP ALLERGY, V25, P515, DOI 10.1111/j.1365-2222.1995.tb01088.x; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; WILLIAMS HE, 1977, AUST PAEDIATR J, V13, P88; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	44	55	63	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					450	456		10.1067/mai.2002.127283	http://dx.doi.org/10.1067/mai.2002.127283			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209093	Bronze			2022-12-18	WOS:000177936900016
